PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Coleman, ML; Densham, RM; Croft, DR; Olson, MF				Coleman, ML; Densham, RM; Croft, DR; Olson, MF			Stability of p21(Waf1)/(Cip1) CDK inhibitor protein is responsive to RhoA- mediated regulation of the actin cytoskeleton	ONCOGENE			English	Article						signal transduction; cellular; molecular and tumour biology; guanine nucleotide binding proteins and effectors	CELL-CYCLE PROGRESSION; HMG-COA REDUCTASE; SIGNALING PATHWAYS; C-JUN; MORPHOGENESIS CHECKPOINT; RETINOBLASTOMA PROTEIN; INDUCED PROLIFERATION; KINASE-ACTIVITY; GROWTH-FACTORS; G1 PHASE	The proto-oncogene Ras GTPase stimulates transcription of p21(Waf1/Cip1) (p21), which is repressed by the RhoA GTPase. We previously showed that Ras also elevates p21 protein levels by reducing its proteasome-mediated degradation. Therefore, we investigated whether RhoA also influenced p21 protein degradation. Pulse-chase analysis of p21 protein stability revealed that inhibitors of Rho function, which disrupt filamentous actin (F-actin), drastically slowed p21 degradation. Direct F-actin disruption mimicked Rho inhibition to stabilize p21. We found that Rho inhibition, or F-actin disruption, activated the JNK stress-activated protein kinase, and that interfering with JNK signalling, but not p38, abrogated p21 stabilization by Rho inhibition or F-actin-disrupting drugs. In addition, Ras-transformation led to increased constitutive JNK activity that contributed to the elevated p21 protein levels. These data suggest that p21 stability is influenced by a mechanism that monitors F-actin downstream of Rho, and which acts through a pathway involving activation of JNK. These results may have significant implications for therapies that target Rho-signalling pathways to induce p21-mediated cell-cycle arrest.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Wellcome Trust Ctr Human Genet, Oxford, England	Beatson Institute; University of Oxford; Wellcome Centre for Human Genetics	Olson, MF (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	m.olson@beatson.gla.ac.uk	Coleman, Mathew L/C-1676-2014; Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011; Densham, Ruth/AAO-1971-2020	Coleman, Mathew L/0000-0001-6020-9023; Olson, Michael/0000-0003-3428-3507; Densham, Ruth/0000-0003-4490-2842	NCI NIH HHS [R01 CA030721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bergo MO, 2004, J CLIN INVEST, V113, P539, DOI 10.1172/JCI200418829; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; Denoyelle C, 2003, CELL SIGNAL, V15, P327, DOI 10.1016/S0898-6568(02)00124-9; Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Escote X, 2004, NAT CELL BIOL, V6, P997, DOI 10.1038/ncb1174; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Han SW, 2005, CANCER LETT, V219, P71, DOI 10.1016/j.canlet.2004.07.040; Harrison JC, 2001, NAT CELL BIOL, V3, P417, DOI 10.1038/35070104; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang S, 2002, EXP CELL RES, V275, P255, DOI 10.1006/excr.2002.5504; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Lew DJ, 2003, CURR OPIN CELL BIOL, V15, P648, DOI 10.1016/j.ceb.2003.09.001; Liberto M, 2002, ONCOGENE, V21, P1590, DOI 10.1038/sj.onc.1205242; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reshetnikova G, 2000, EXP CELL RES, V259, P35, DOI 10.1006/excr.2000.4966; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	56	31	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2708	2716		10.1038/sj.onc.1209322	http://dx.doi.org/10.1038/sj.onc.1209322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407839				2022-12-25	WOS:000237272900002
J	Asante-Appiah, E; Patel, S; Desponts, C; Taylor, JM; Lau, C; Dufresne, C; Therien, M; Friesen, R; Becker, JW; Leblanc, Y; Kennedy, BP; Scapin, G				Asante-Appiah, E; Patel, S; Desponts, C; Taylor, JM; Lau, C; Dufresne, C; Therien, M; Friesen, R; Becker, JW; Leblanc, Y; Kennedy, BP; Scapin, G			Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURES; INSULIN SENSITIVITY; 1B; REFINEMENT; POTENT; DEPHOSPHORYLATION; DISCOVERY; SUBSTRATE; RECEPTOR; REVEALS	PTP-1B represents an attractive target for the treatment of type 2 diabetes and obesity. Given the role that protein phosphatases play in the regulation of many biologically relevant processes, inhibitors against PTP-1B must be not only potent, but also selective. It has been extremely difficult to synthesize inhibitors that are selective over the highly homologous TCPTP. We have successfully exploited the conservative Leu(119) to Val substitution between the two enzymes to synthesize a PTP-1B inhibitor that is an order of magnitude more selective over TCPTP. Structural analyses of PTP1B/inhibitor complexes show a conformation-assisted inhibition mechanism as the basis for selectivity. Such an inhibitory mechanism may be applicable to other homologous enzymes.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ H9R 4P8, Canada; Merck & Co Inc, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Asante-Appiah, E (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.	ernest_asanteappiah@merck.com						AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Asante-Appiah E, 2002, BIOCHEMISTRY-US, V41, P9043, DOI 10.1021/bi0259554; Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Erlanson DA, 2003, J AM CHEM SOC, V125, P5602, DOI 10.1021/ja034440c; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HOWARD AJ, 2001, CRYSTALLOGRAPHIC COM, V7, P150; Huang Z, 1999, J BIOMOL SCREEN, V4, P327, DOI 10.1177/108705719900400608; Iversen LF, 2002, J BIOL CHEM, V277, P19982, DOI 10.1074/jbc.M200567200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lau CK, 2004, BIOORG MED CHEM LETT, V14, P1043, DOI 10.1016/j.bmcl.2003.11.076; Liu G, 2003, J MED CHEM, V46, P2093, DOI 10.1021/jm0205696; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Romsicki Y, 2004, J BIOL CHEM, V279, P12868, DOI 10.1074/jbc.M309600200; Romsicki Y, 2003, ARCH BIOCHEM BIOPHYS, V414, P40, DOI 10.1016/S0003-9861(03)00178-4; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Scapin G, 2003, BIOCHEMISTRY-US, V42, P11451, DOI 10.1021/bi035098j; Seely BL, 1996, DIABETES, V45, P1379, DOI 10.2337/diabetes.45.10.1379; Sun JP, 2003, J BIOL CHEM, V278, P12406, DOI 10.1074/jbc.M212491200; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; Xin ZL, 2003, BIOORG MED CHEM LETT, V13, P1887, DOI 10.1016/S0960-894X(03)00302-0; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	39	38	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8010	8015		10.1074/jbc.M511827200	http://dx.doi.org/10.1074/jbc.M511827200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407290	hybrid			2022-12-25	WOS:000236031000037
J	Surjit, M; Oberoi, R; Kumar, R; Lal, SK				Surjit, M; Oberoi, R; Kumar, R; Lal, SK			Enhanced alpha(1) microglobulin secretion from hepatitis E virus ORF3-expressing human hepatoma cells is mediated by the tumor susceptibility gene 101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORF3 PROTEIN; UBIQUITIN LIGASE; VP40 PROTEIN; ESCRT-I; TSG101; ALPHA(1)-MICROGLOBULIN; INTERACTS; COMPLEX; DOMAIN; INTERNALIZATION	Viruses are known to exploit the host cell machinery for their benefit during different stages of their life cycle within the infected host. One of the major challenges for a virus during the early stages of infection is to escape recognition by the host immune system. Viruses have adopted many novel strategies to evade the host immune response or to create an immune suppressed environment. An earlier study in our laboratory has demonstrated that the ORF3 protein of the hepatitis E virus expedites the secretion of alpha(1) microglobulin, an immunosuppressant molecule. Based on this observation, we proposed that enhanced secretion of alpha(1) microglobulin may help maintain an immunosuppressed milieu around the infected hepatocyte (Tyagi, S., Surjit, M., Roy, A. K., Jameel, S., and Lal, S. K. ( 2004) J. Biol. Chem. 279, 29308 - 29319). In the present study, we discovered that the ability of the ORF3 protein to expedite alpha(1) microglobulin secretion is attributed to the PSAP motif present at the C terminus of the former. The ORF3 protein was able to associate with the tumor susceptibility gene 101 (TSG101) through the PSAP motif. Further, a PSAP motif-mutated ORF3 protein was unable to associate with TSG101 and also lost its ability to enhance the secretion of alpha(1) microglobulin. In addition, the ORF3 protein was found to associate simultaneously with TSG101 and alpha(1) microglobulin because all three of them were co-precipitated as a ternary complex. Finally, a dominant negative mutant of the VPS4 protein was shown to block the enhanced alpha(1) microglobulin secretion in ORF3-expressing hepatocytes. These results suggest a mechanism by which the ORF3 protein exploits the endosomal sorting machinery to enhance the secretion of an immunosuppressant molecule (alpha(1) microglobulin) from the cultured hepatocytes.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Lal, SK (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, Aruna Asaf Ali Rd, New Delhi 110067, India.	sunillal@icgeb.res.in						Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P172, DOI 10.1016/S0167-4838(00)00157-6; Amara A, 2003, J CELL BIOL, V162, P371, DOI 10.1083/jcb.200307062; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; BEGGARD T, 1998, J HISTOCHEM CYTOCHEM, V46, P887; Beyer A, 2003, GENE, V305, P47, DOI 10.1016/S0378-1119(02)01205-2; Goff A, 2003, J VIROL, V77, P9173, DOI 10.1128/JVI.77.17.9173-9182.2003; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Jameel S, 1996, J VIROL, V70, P207, DOI 10.1128/JVI.70.1.207-216.1996; James P, 1996, GENETICS, V144, P1425; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; Licata JM, 2003, J VIROL, V77, P1812, DOI 10.1128/JVI.77.3.1812-1819.2003; LOGDBERG L, 1981, SCAND J IMMUNOL, V13, P383, DOI 10.1111/j.1365-3083.1981.tb00148.x; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003; MENDEZ E, 1986, P NATL ACAD SCI USA, V83, P1472, DOI 10.1073/pnas.83.5.1472; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2003, J CELL BIOL, V162, P425, DOI 10.1083/jcb.200302138; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Stuchell MD, 2004, J BIOL CHEM, V279, P36059, DOI 10.1074/jbc.M405226200; Timmins J, 2003, J MOL BIOL, V326, P493, DOI 10.1016/S0022-2836(02)01406-7; Tyagi S, 2004, J BIOL CHEM, V279, P29308, DOI 10.1074/jbc.M402017200; Tyagi S, 2002, J BIOL CHEM, V277, P22759, DOI 10.1074/jbc.M200185200; Tyagi S, 2001, J VIROL, V75, P2493, DOI 10.1128/JVI.75.5.2493-2498.2001; Wester L, 1997, PROTEIN EXPRES PURIF, V11, P95, DOI 10.1006/prep.1997.0760; Zafrullah M, 1997, J VIROL, V71, P9045, DOI 10.1128/JVI.71.12.9045-9053.1997	29	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8135	8142		10.1074/jbc.M509568200	http://dx.doi.org/10.1074/jbc.M509568200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407257	hybrid			2022-12-25	WOS:000236031000051
J	Allen, JM; Bateman, JF; Hansen, U; Wilson, R; Bruckner, P; Owens, RT; Sasaki, T; Timpl, R; Fitzgerald, J				Allen, JM; Bateman, JF; Hansen, U; Wilson, R; Bruckner, P; Owens, RT; Sasaki, T; Timpl, R; Fitzgerald, J			WARP is a novel multimeric component of the chondrocyte pericellular matrix that interacts with perlecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; SITE-DIRECTED MUTAGENESIS; FIBROBLAST-GROWTH-FACTOR; BASEMENT-MEMBRANE; PROTEIN CORE; CARTILAGE MATRIX; DOMAIN I; CELL-ADHESION; COLLAGEN; BINDS	WARP is a novel member of the von Willebrand factor A domain superfamily of extracellular matrix proteins that is expressed by chondrocytes. WARP is restricted to the presumptive articular cartilage zone prior to joint cavitation and to the articular cartilage and fibrocartilaginous elements in the joint, spine, and sternum during mouse embryonic development. In mature articular cartilage, WARP is highly specific for the chondrocyte pericellular microenvironment and co-localizes with perlecan, a prominent component of the chondrocyte pericellular region. WARP is present in the guanidine-soluble fraction of cartilage matrix extracts as a disulfide-bonded multimer, indicating that WARP is a strongly interacting component of the cartilage matrix. To investigate how WARP is integrated with the pericellular environment, we studied WARP binding to mouse perlecan using solid phase and surface plasmon resonance analysis. WARP interacts with domain III-2 of the perlecan core protein and the heparan sulfate chains of the perlecan domain I with K-D values in the low nanomolar range. We conclude that WARP forms macromolecular structures that interact with perlecan to contribute to the assembly and/or maintenance of "permanent" cartilage structures during development and in mature cartilages.	Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Parkville, Vic 3052, Australia; Univ Hosp Muenster, Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany; LifeCell Corp, Branchburg, NJ 08876 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; University of Munster; Max Planck Society	Fitzgerald, J (corresponding author), Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Matrix Biol Res Unit, Flemington Rd, Parkville, Vic 3052, Australia.	j.fitzgerald@mcri.edu.au	Wilson, Richard/H-8429-2012; Bruckner, Peter/F-4817-2019	Wilson, Richard/0000-0003-0152-4394; Bruckner, Peter/0000-0002-5566-5611; Bateman, John/0000-0001-8542-0730				BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; Bengtsson E, 2002, J BIOL CHEM, V277, P15061, DOI 10.1074/jbc.M108285200; Bix G, 2004, J CELL BIOL, V166, P97, DOI 10.1083/jcb.200401150; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Braissant O, 1998, BIOCHEMICA, V1, P10; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Costell M, 1996, FEBS LETT, V396, P127, DOI 10.1016/0014-5793(96)01082-4; Costell M, 1997, EUR J BIOCHEM, V243, P115, DOI 10.1111/j.1432-1033.1997.t01-1-00115.x; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Fitzgerald J, 2003, FEBS LETT, V552, P91, DOI 10.1016/S0014-5793(03)00968-2; Fitzgerald J, 2002, FEBS LETT, V517, P61, DOI 10.1016/S0014-5793(02)02579-6; Frank S, 2002, J BIOL CHEM, V277, P19071, DOI 10.1074/jbc.M202146200; French MM, 2002, J BONE MINER RES, V17, P48, DOI 10.1359/jbmr.2002.17.1.48; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Govindraj P, 2002, J BIOL CHEM, V277, P19461, DOI 10.1074/jbc.M200786200; HAUDENSCHILD DR, 1995, J BIOL CHEM, V270, P23150, DOI 10.1074/jbc.270.39.23150; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; Hohenester E, 2002, MATRIX BIOL, V21, P115, DOI 10.1016/S0945-053X(01)00191-3; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Melrose J, 2003, J HISTOCHEM CYTOCHEM, V51, P1331, DOI 10.1177/002215540305101010; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Mongiat M, 2003, J BIOL CHEM, V278, P17491, DOI 10.1074/jbc.M210529200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; Poole CA, 1997, J ANAT, V191, P1, DOI 10.1046/j.1469-7580.1997.19110001.x; Sasaki T, 1998, FEBS LETT, V435, P169, DOI 10.1016/S0014-5793(98)01063-1; SCHULZE B, 1995, EUR J BIOCHEM, V231, P551, DOI 10.1111/j.1432-1033.1995.tb20731.x; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; SUNDARRAJ N, 1995, J CELL SCI, V108, P2663; Tiedemann K, 2005, J BIOL CHEM, V280, P11404, DOI 10.1074/jbc.M409882200; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; Veit G, 2006, J BIOL CHEM, V281, P3494, DOI 10.1074/jbc.M509333200; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433	44	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7341	7349		10.1074/jbc.M513746200	http://dx.doi.org/10.1074/jbc.M513746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407285	hybrid			2022-12-25	WOS:000236030900053
J	Hansch, R; Lang, C; Riebeseel, E; Lindigkeit, R; Gessler, A; Rennenberg, H; Mendel, RR				Hansch, R; Lang, C; Riebeseel, E; Lindigkeit, R; Gessler, A; Rennenberg, H; Mendel, RR			Plant sulfite oxidase as novel producer of H2O2 - Combination of enzyme catalysis with a subsequent non-enzymatic reaction step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; SULFUR-DIOXIDE; ARABIDOPSIS-THALIANA; PROSTHETIC GROUPS; OXYGEN-EXCHANGE; PURIFICATION; METABOLISM; OXIDATION; IDENTIFICATION; LOCALIZATION	Sulfite oxidase (EC 1.8.3.1) from the plant Arabidopsis thaliana is the smallest eukaryotic molybdenum enzyme consisting of a molybdenum cofactor-binding domain but lacking the heme domain that is known from vertebrate sulfite oxidase. While vertebrate sulfite oxidase is a mitochondrial enzyme with cytochrome c as the physiological electron acceptor, plant sulfite oxidase is localized in peroxisomes and does not react with cytochrome c. Here we describe results that identified oxygen as the terminal electron acceptor for plant sulfite oxidase and hydrogen peroxide as the product of this reaction in addition to sulfate. The latter finding might explain the peroxisomal localization of plant sulfite oxidase. O-18 labeling experiments and the use of catalase provided evidence that plant sulfite oxidase combines its catalytic reaction with a subsequent non-enzymatic step where its reaction product hydrogen peroxide oxidizes another molecule of sulfite. In vitro, for each catalytic cycle plant SO will bring about the oxidation of two molecules of sulfite by one molecule of oxygen. In the plant, sulfite oxidase could be responsible for removing sulfite as a toxic metabolite, which might represent a means to protect the cell against excess of sulfite derived from SO2 gas in the atmosphere ( acid rain) or during the decomposition of sulfur-containing amino acids. Finally we present a model for the metabolic interaction between sulfite and catalase in the peroxisome.	Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Dept Pharmaceut Biol, D-38023 Braunschweig, Germany; Univ Freiburg, Dept Tree Physiol, D-79085 Freiburg, Germany	Braunschweig University of Technology; Braunschweig University of Technology; University of Freiburg	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	r.mendel@tu-bs.de	Rennenberg, Heinz/A-2083-2013; Gessler, Arthur/C-7121-2008	Gessler, Arthur/0000-0002-1910-9589; Hansch, Robert/0000-0003-1310-8419; Rennenberg, Heinz/0000-0001-6224-2927				Clegg SM, 2001, ATMOS CHEM PHYS, V1, P73, DOI 10.5194/acp-1-73-2001; COHEN HJ, 1971, J BIOL CHEM, V246, P367; COHEN HJ, 1972, J BIOL CHEM, V247, P7759; COHEN HJ, 1971, J BIOL CHEM, V246, P359; Eilers T, 2001, J BIOL CHEM, V276, P46989, DOI 10.1074/jbc.M108078200; FREDERICK SE, 1969, J CELL BIOL, V43, P343, DOI 10.1083/jcb.43.2.343; Garrett RM, 1998, P NATL ACAD SCI USA, V95, P6394, DOI 10.1073/pnas.95.11.6394; GARSED SG, 1977, NEW PHYTOL, V78, P111, DOI 10.1111/j.1469-8137.1977.tb01549.x; Heber U, 1998, INT REV CYTOL, V177, P255; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; Horner DA, 2003, INORG CHEM, V42, P1884, DOI 10.1021/ic020692n; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; Karpinski S, 1999, SCIENCE, V284, P654, DOI 10.1126/science.284.5414.654; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Laloi C, 2004, CURR OPIN PLANT BIOL, V7, P323, DOI 10.1016/j.pbi.2004.03.005; Leustek Thomas, 2002, Arabidopsis Book, V1, pe0017, DOI 10.1199/tab.0017; Lindigkeit R, 1997, EUR J BIOCHEM, V245, P626, DOI 10.1111/j.1432-1033.1997.00626.x; MACLEOD RM, 1961, J BIOL CHEM, V236, P1841; MCARDLE JV, 1983, J PHYS CHEM-US, V87, P5425, DOI 10.1021/j150644a024; Mills GA, 1940, J AM CHEM SOC, V62, P2833, DOI 10.1021/ja01867a058; MISZALSKI Z, 1992, Z NATURFORSCH C, V47, P360; Nag S, 2000, PLANT SCI, V157, P157, DOI 10.1016/S0168-9452(00)00281-8; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; Neill S, 2002, CURR OPIN PLANT BIOL, V5, P388, DOI 10.1016/S1369-5266(02)00282-0; Nowak K, 2004, PLANT CELL PHYSIOL, V45, P1889, DOI 10.1093/pcp/pch212; Rost M, 1998, J BIOLUM CHEMILUM, V13, P355, DOI 10.1002/(SICI)1099-1271(199811/12)13:6<355::AID-BIO502>3.0.CO;2-L; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.104.046755; Schrader N, 2003, STRUCTURE, V11, P1251, DOI 10.1016/j.str.2003.09.001; Seinfeld J.H, 1998, WILEY INT, V40, P1326, DOI [10.1080/00139157.1999.10544295, DOI 10.1080/00139157.1999.10544295]; vanderKooij TAW, 1997, NEW PHYTOL, V135, P101, DOI 10.1046/j.1469-8137.1997.00619.x; Veljovic-Jovanovic S, 1998, PLANT CELL PHYSIOL, V39, P1203, DOI 10.1093/oxfordjournals.pcp.a029321; Veljovic-Jovanovic SD, 2001, PLANT PHYSIOL, V127, P426, DOI 10.1104/pp.010141; Wilson HL, 2004, J BIOL CHEM, V279, P15105, DOI 10.1074/jbc.M314288200; Winner W. E., 1985, Sulfur dioxide and vegetation. Physiology, ecology, and policy issues.	34	99	109	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6884	6888		10.1074/jbc.M513054200	http://dx.doi.org/10.1074/jbc.M513054200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407262	hybrid			2022-12-25	WOS:000236030800086
J	Tang, L; Breinig, S; Stith, L; Mischel, A; Tannir, J; Kokona, B; Fairman, R; Jaffe, EK				Tang, L; Breinig, S; Stith, L; Mischel, A; Tannir, J; Kokona, B; Fairman, R; Jaffe, EK			Single amino acid mutations alter the distribution of human porphobilinogen synthase quaternary structure isoforms (morpheeins)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DEHYDRATASE; PORPHYRIA; MECHANISM; PATIENT; FORMS; GENE	Porphobilinogen synthase (PBGS) is an obligate oligomer that can exist in functionally distinct quaternary states of different stoichiometries, which are called morpheeins. The morpheein concept describes an ensemble of quaternary structure isoforms wherein different structures of the monomer dictate different multiplicities of the oligomer ( Jaffe, E. K. ( 2005) Trends Biochem. Sci. 30, 490 497). Human PBGS assembles into long-lived morpheeins and has been shown to be capable of forming either a high activity octamer or a low activity hexamer (Breinig, S., Kervinen, J., Stith, L., Wasson, A. S., Fairman, R., Wlodawer, A., Zdanov, A., and Jaffe, E. K. ( 2003) Nat. Struct. Biol. 10, 757 - 763). All PBGS monomers contain an alpha beta-barrel domain and an N-terminal arm domain. The N-terminal arm structure varies among PBGS morpheeins, and the spatial relationship between the arm and the barrel dictates the different quaternary assemblies. We have analyzed the structures of human PBGS morpheeins for key interactions that would be predicted to affect the oligomeric assembly. Examples of individual mutations that shift assembly of human PBGS away from the native octamer are R240A and W19A. The alternate morpheeins of human PBGS variants R240A and W19A are chromatographically separable from each other and kinetically distinct; their structure and dynamics have been characterized by native gel electrophoresis, dynamic light scattering, and analytical ultracentrifugation. R240A assembles into a metastable hexamer, which can undergo a reversible conversion to the octamer in the presence of substrate. The metastable nature of the R240A hexamer supports the hypothesis that octameric and hexameric morpheeins of PBGS are very close in energy. W19A assembles into a mixture of dimers, which appear to be stable.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Haverford Coll, Dept Biol, Haverford, PA 19041 USA	Fox Chase Cancer Center; Haverford College	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Eileen.Jaffe@fccc.edu			NCI NIH HHS [CA006927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akagi R, 2000, HEPATOLOGY, V31, P704, DOI 10.1002/hep.510310321; Akagi R, 2000, BLOOD, V96, P3618, DOI 10.1182/blood.V96.10.3618.h8003618_3618_3623; AKAGI R, 2006, MOL GENET METAB; Arkin M, 2001, ANAL BIOCHEM, V299, P98, DOI 10.1006/abio.2001.5396; Breinig S, 2003, NAT STRUCT BIOL, V10, P757, DOI 10.1038/nsb963; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Jaffe EK, 2004, BIOORG CHEM, V32, P316, DOI 10.1016/j.bioorg.2004.05.010; Jaffe EK, 2003, CHEM BIOL, V10, P25, DOI 10.1016/S1074-5521(02)00296-X; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; Jaffe EK, 2000, J BIOL CHEM, V275, P2619, DOI 10.1074/jbc.275.4.2619; Jaffe EK, 2005, TRENDS BIOCHEM SCI, V30, P490, DOI 10.1016/j.tibs.2005.07.003; JAFFE EK, 1990, BIOORG CHEM, V18, P381, DOI 10.1016/0045-2068(90)90022-W; JORDAN PM, 1985, BIOCHEM J, V227, P1015, DOI 10.1042/bj2271015; Kervinen J, 2001, BIOCHEMISTRY-US, V40, P8227, DOI 10.1021/bi010656k; Laue TM, 1992, BIOCH POLYM SCI, P90; Maruno M, 2001, BLOOD, V97, P2972, DOI 10.1182/blood.V97.10.2972; MILLSDAVIES NL, 2000, THESIS U SOUTHAMPTON; SASSA S, 1992, T ASSOC AM PHYSICIAN, V105, P250; Sassa S, 2000, J INTERN MED, V247, P169, DOI 10.1046/j.1365-2796.2000.00618.x; Tang L, 2005, J BIOL CHEM, V280, P15786, DOI 10.1074/jbc.M500218200; van Holde K.E., 1998, PRINCIPLES PHYS BIOC, Vsecond; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X	22	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6682	6690		10.1074/jbc.M511134200	http://dx.doi.org/10.1074/jbc.M511134200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377642	hybrid			2022-12-25	WOS:000236030800065
J	Arima, J; Uesugi, Y; Uraji, M; Yatsuhiro, S; Tsuboi, S; Iwabuchi, M; Hatanaka, T				Arima, J; Uesugi, Y; Uraji, M; Yatsuhiro, S; Tsuboi, S; Iwabuchi, M; Hatanaka, T			Modulation of Streptomyces leucine aminopeptidase by calcium - Identification and functional analysis of key residues in activation and stabilization by calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMERCIAL PREPARATION PRONASE; AEROMONAS-PROTEOLYTICA AMINOPEPTIDASE; GRISEUS AMINOPEPTIDASE; K-1 STRAIN; CRYSTALLOGRAPHIC CHARACTERIZATION; SEPTATUS TH-2; BINDING; ENZYMES; ACID; PURIFICATION	Streptomyces griseus leucine aminopeptidase (SGAP), which has two zinc atoms in its active site, is clinically important as a model for understanding the structure and mechanism of action of other metallopeptidases. SGAP is a calcium-activated and calcium-stabilized enzyme, and its activation by calcium correlates with substrate specificity. In our previous study, we found a non-calcium-modulated leucine aminopeptidase secreted by Streptomyces septatus, the primary structure of which showed 71% identity with SGAP. In this study, we constructed chimeras of SGAP and S. septatus aminopeptidase by using an in vivo DNA shuffling system and several mutant enzymes by site-directed mutagenesis to identify the key residues in this modulation by calcium. We identified the key residues Asp-173 and Asp-174 of SGAP associated with both SGAP activation and stabilization by calcium. We also showed that the known calcium-binding site, which is composed of Asp-3, Ile-4, Asp-262, and Asp-266 of SGAP, only contributes to SGAP stabilization by calcium. Furthermore, we identified an important residue, Glu-196, that functions in cooperation with Asp-173, Asp-174, and calcium to increase the catalytic activity of SGAP.	Res Inst Biol Sci, Okayama 7161241, Japan; Shujitsu Univ, Sch Pharm, Dept Biol Pharm, Okayama 7038516, Japan		Hatanaka, T (corresponding author), Res Inst Biol Sci, 7549-1 Kibichuo Cho, Okayama 7161241, Japan.	hatanaka@bio-ribs.com						ALLAIN CC, 1974, CLIN CHEM, V20, P470; Arima J, 2005, APPL ENVIRON MICROB, V71, P7229, DOI 10.1128/AEM.71.11.7229-7235.2005; Arima J, 2004, BIOCHEM BIOPH RES CO, V317, P531, DOI 10.1016/j.bbrc.2004.03.082; ARIMA J, 2006, IN PRESS APPL MICROB; BENMEIR D, 1993, EUR J BIOCHEM, V212, P107, DOI 10.1111/j.1432-1033.1993.tb17639.x; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; BURLEY SK, 1992, J MOL BIOL, V224, P113, DOI 10.1016/0022-2836(92)90580-D; Bzymek KP, 2004, J BIOL CHEM, V279, P31018, DOI 10.1074/jbc.M404035200; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; De Paola CC, 1999, BIOCHEMISTRY-US, V38, P9048, DOI 10.1021/bi9900572; Desmarais WT, 2002, STRUCTURE, V10, P1063, DOI 10.1016/S0969-2126(02)00810-9; Fundoiano-Hershcovitz Y, 2004, FEBS LETT, V571, P192, DOI 10.1016/j.febslet.2004.07.001; Gilboa R, 2001, PROTEINS, V44, P490, DOI 10.1002/prot.1115; Gilboa R, 2000, ACTA CRYSTALLOGR D, V56, P551, DOI 10.1107/S0907444900002420; Greenblatt HM, 1997, J MOL BIOL, V265, P620, DOI 10.1006/jmbi.1996.0729; Kato J, 2002, J BACTERIOL, V184, P6016, DOI 10.1128/JB.184.21.6016-6025.2002; KLOTZ IM, 1981, BIOCHEMISTRY-US, V10, P3065; Lee BI, 2003, J BIOL INORG CHEM, V8, P341, DOI 10.1007/s00775-002-0421-8; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; Maras B, 1996, EUR J BIOCHEM, V236, P843, DOI 10.1111/j.1432-1033.1996.00843.x; MASSEY V, 1967, J BIOL CHEM, V242, P1259; Mishima N, 1997, BIOTECHNOL PROGR, V13, P864, DOI 10.1021/bp970084o; Mori K, 2005, APPL ENVIRON MICROB, V71, P754, DOI 10.1128/AEM.71.2.754-760.2005; Mukaihara T, 1997, GENETICS, V145, P563; Papir G, 1998, EUR J BIOCHEM, V258, P313, DOI 10.1046/j.1432-1327.1998.2580313.x; Park TJ, 2002, BBA-PROTEINS PROTEOM, V1599, P36, DOI 10.1016/S1570-9639(02)00379-5; POST LE, 1980, J BIOL CHEM, V255, P4660; Prescott J M, 1976, Methods Enzymol, V45, P530; SANDERINK GJ, 1988, J CLIN CHEM CLIN BIO, V26, P795; SPUNGIN A, 1989, EUR J BIOCHEM, V183, P471, DOI 10.1111/j.1432-1033.1989.tb14952.x; Stamper C, 2001, BIOCHEMISTRY-US, V40, P7035, DOI 10.1021/bi0100891; Stamper CC, 2004, BIOCHEMISTRY-US, V43, P9620, DOI 10.1021/bi049126p; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Taylor A, 1996, AMINOPEPTIDASES, P1; VOSBECK KD, 1973, J BIOL CHEM, V248, P6029; VOSBECK KD, 1975, J BIOL CHEM, V250, P3981; VOSBECK KD, 1978, J BIOL CHEM, V253, P257; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5885	5894		10.1074/jbc.M509025200	http://dx.doi.org/10.1074/jbc.M509025200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407307	hybrid			2022-12-25	WOS:000235568900069
J	Sun, HY; Liu, XD; Xiong, QJ; Shikano, S; Li, M				Sun, HY; Liu, XD; Xiong, QJ; Shikano, S; Li, M			Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; INTERVAL PROLONGATION; SURFACE EXPRESSION; MEMBRANE-RECEPTORS; MOLECULAR-BASIS; CELL-SURFACE; DRUG; RELEVANCE; DISEASE; SIGNALS	A high percentage of drugs and drug candidates has been found to cause cardiotoxicity by reducing potassium conductance, more commonly known as QT prolongation. However, some compounds do not show direct block of ionic flow, suggesting that other mechanisms may also lead to reduction of potassium currents. Using the functional recovery after chemobleaching (FRAC) assay, we have examined a collection of drugs and drug-like compounds for potential perturbation of cardiac potassium channel trafficking. Here we report that a significant number of inhibitory compounds displayed effects on channel expression on the cell surface. Further investigation of celastrol (3-hydroxy-24-nor-2-oxo-1 (10),3,5,7-friedelatetraen-29-oic acid), a cell-permeable dienonephenolic triterpene compound, revealed its potent inhibitory activity on both Kir2.1 and hERG potassium channels, causal to QT prolongation. In addition to acute block of ion conduction, celastrol also alters the rate of ion channel transport and causes a reduction of channel density on the cell surface. In contrast, celastrol has no effects on trafficking of either CD4 or CD8 membrane proteins. Furthermore, the potency for reducing surface expression is similar to 5-10-fold more effective than that for either direct acute inhibition or reported cytoprotectivity via activation of the heat shock transcription factor 1. Because the reduction of potassium channel activity is a common form of drug-induced cardiotoxicity, the potent inhibition of cell surface expression by celastrol underscores a need to evaluate drug candidates for their chronic effects on biogenesis of potassium channels. Our results suggest that chronic exposure to certain drugs may be an important aspect of acquired QT prolongation.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Li, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, BRB311,733 N Broadway, Baltimore, MD 21205 USA.	minli@jhmi.edu	Liu, Xiaodong/B-1839-2008; Liu, Xiaodong/N-3373-2019	Liu, Xiaodong/0000-0002-3171-9611; Liu, Xiaodong/0000-0002-3171-9611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070959] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 70959] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allison AC, 2001, PROG NEURO-PSYCHOPH, V25, P1341, DOI 10.1016/S0278-5846(01)00192-0; Ashcroft F.M., 2000, ION CHANNELS DIS, P67; Clancy CE, 2001, CARDIOVASC RES, V50, P301, DOI 10.1016/S0008-6363(00)00293-5; Cleren C, 2005, J NEUROCHEM, V94, P995, DOI 10.1111/j.1471-4159.2005.03253.x; Coblitz B, 2005, J BIOL CHEM, V280, P36263, DOI 10.1074/jbc.M507559200; Cordes JS, 2005, BRIT J PHARMACOL, V145, P15, DOI 10.1038/sj.bjp.0706140; Curran ME, 1998, CURR OPIN BIOTECH, V9, P565, DOI 10.1016/S0958-1669(98)80133-X; De Ponti F, 2000, EUR J CLIN PHARMACOL, V56, P1, DOI 10.1007/s002280050714; Ford John W, 2002, Prog Drug Res, V58, P133; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; Kuryshev YA, 2005, J PHARMACOL EXP THER, V312, P316, DOI 10.1124/jpet.104.073692; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mu D, 2003, CANCER CELL, V3, P297, DOI 10.1016/S1535-6108(03)00054-0; Muhlbauer E, 2003, EUR J PHARMACOL, V459, P121, DOI 10.1016/S0014-2999(02)02855-8; NGASSAPA O, 1994, J NAT PROD, V57, P1, DOI 10.1021/np50103a001; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Redfern WS, 2003, CARDIOVASC RES, V58, P32, DOI 10.1016/S0008-6363(02)00846-5; Roden DM, 2002, ANNU REV PHYSIOL, V64, P431, DOI 10.1146/annurev.physiol.64.083101.145105; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; Sallette J, 2005, NEURON, V46, P595, DOI 10.1016/j.neuron.2005.03.029; Sanguinetti MC, 2005, TRENDS PHARMACOL SCI, V26, P119, DOI 10.1016/j.tips.2005.01.003; Shah M, 2005, CIRCULATION, V112, P2517, DOI 10.1161/CIRCULATIONAHA.104.494476; Shikano S, 2005, NAT CELL BIOL, V7, P985, DOI 10.1038/ncb1297; Shikano S, 2003, P NATL ACAD SCI USA, V100, P5783, DOI 10.1073/pnas.1031748100; Sun HY, 2004, P NATL ACAD SCI USA, V101, P16964, DOI 10.1073/pnas.0404178101; Taglialatela M, 1998, MOL PHARMACOL, V54, P113, DOI 10.1124/mol.54.1.113; Terstappen GC, 1999, ANAL BIOCHEM, V272, P149, DOI 10.1006/abio.1999.4179; Thomas D, 2003, BRIT J PHARMACOL, V139, P567, DOI 10.1038/sj.bjp.0705283; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; XU J, 2004, TARGETS, V3, P32; ZHOU BN, 1991, MEM I OSWALDO CRUZ, V86, P219, DOI 10.1590/S0074-02761991000600049; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	36	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5877	5884		10.1074/jbc.M600072200	http://dx.doi.org/10.1074/jbc.M600072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407206	hybrid			2022-12-25	WOS:000235568900068
J	Bunch, TA; Helsten, TL; Kendall, TL; Shirahatti, N; Mahadevan, D; Shattil, SJ; Brower, DL				Bunch, TA; Helsten, TL; Kendall, TL; Shirahatti, N; Mahadevan, D; Shattil, SJ; Brower, DL			Amino acid changes in Drosophila alpha PS2 beta PS integrins that affect ligand affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; PSI DOMAIN; SUBUNIT; TIGGRIN; COMPLEX; BINDING; ALPHA-V-BETA-3; ADHESIVENESS	We developed a ligand-mimetic antibody Fab fragment specific for Drosophila alpha PS2 beta PS integrins to probe the ligand binding affinities of these invertebrate receptors. TWOW-1 was constructed by inserting a fragment of the extracellular matrix protein Tiggrin into the H-CDR3 of the alpha v beta 3 ligand-mimetic antibody WOW-1. The specificity of alpha PS2 beta PS binding to TWOW-1 was demonstrated by numerous tests used for other integrin-ligand interactions. Binding was decreased in the presence of EDTA or RGD peptides and by mutation of the TWOW-1 RGD sequence or the beta PS metal ion-dependent adhesion site ( MIDAS) motif. TWOW-1 binding was increased by mutations in the alpha PS2 membrane-proximal cytoplasmic GFFNR sequence or by exposure to Mn2+. Although Mn2+ is sometimes assumed to promote maximal integrin activity, TWOW-1 binding in Mn2+ could be increased further by the beta PS2 GFFNR -> GFANA mutation. A mutation in the beta PS I domain ( beta PS-b58; V409D) greatly increased ligand binding affinity, explaining the increased cell spreading mediated by alpha PS2 beta PS-b58. Further mutagenesis of this residue suggested that Val-409 normally stabilizes the closed head conformation. Mutations that potentially reduce interaction of the integrin beta subunit plexin-semaphorin-integrin ( PSI) and stalk domains have been shown to have activating properties. We found that complete deletion of the beta PS PSI domain enhanced TWOW-1 binding. Moreover the PSI domain is dispensable for at least some other integrin functions because beta PS-Delta PSI displayed an enhanced ability to mediate cell spreading. These studies establish a means to evaluate mechanisms and consequences of integrin affinity modulation in a tractable model genetic system.	Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Univ Arizona, Arizona Canc Ctr, Dept Biochem, Tucson, AZ 85724 USA; Univ Arizona, Arizona Canc Ctr, Dept Med, Tucson, AZ 85724 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona; University of California System; University of California San Diego	Bunch, TA (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Rm 0977,1515 N Campbell Ave, Tucson, AZ 85724 USA.	tbunch@u.arizona.edu			NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042474] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA023074] Funding Source: Medline; NHLBI NIH HHS [R01HL56595] Funding Source: Medline; NIGMS NIH HHS [R0GM42474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Alahari SK, 2002, INT REV CYTOL, V220, P145; Baker SE, 2002, GENETICS, V162, P285; Barton SJ, 2004, BIOCHEM J, V380, P401, DOI 10.1042/BJ20031973; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Brower DL, 2003, CURR OPIN CELL BIOL, V15, P607, DOI 10.1016/S0955-0674(03)00102-9; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; Bunch TA, 2004, EXP CELL RES, V294, P118, DOI 10.1016/j.yexcr.2003.11.002; BUNCH TA, 1992, DEVELOPMENT, V116, P239; Bunch TA, 1998, DEVELOPMENT, V125, P1679; Burke RD, 1999, INT REV CYTOL, V191, P257, DOI 10.1016/S0074-7696(08)60161-8; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; Graner MW, 1998, J BIOL CHEM, V273, P18235, DOI 10.1074/jbc.273.29.18235; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jannuzi AL, 2004, MOL BIOL CELL, V15, P3829, DOI 10.1091/mbc.E04-02-0085; Jannuzi AL, 2002, MOL BIOL CELL, V13, P1352, DOI 10.1091/mbc.01-08-0429; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Liu SC, 2000, J CELL SCI, V113, P3563; Lu CF, 1997, J IMMUNOL, V159, P268; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TAUB R, 1989, J BIOL CHEM, V264, P259; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xie C, 2004, P NATL ACAD SCI USA, V101, P15422, DOI 10.1073/pnas.0406680101; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, J THROMB HAEMOST, V1, P1642, DOI 10.1046/j.1538-7836.2003.00277.x; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zang Q, 2001, J BIOL CHEM, V276, P6922, DOI 10.1074/jbc.M005868200; ZAVORTINK M, 1993, CELL ADHES COMMUN, V1, P251, DOI 10.3109/15419069309097258	47	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5050	5057		10.1074/jbc.M508550200	http://dx.doi.org/10.1074/jbc.M508550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371365	hybrid			2022-12-25	WOS:000235426200059
J	Miura, A; Yamagata, K; Kakei, M; Hatakeyama, H; Takahashi, N; Fukui, K; Nammo, T; Yoneda, K; Inoue, Y; Sladek, FM; Magnuson, MA; Kasai, H; Miyagawa, J; Gonzalez, FJ; Shimomura, I				Miura, A; Yamagata, K; Kakei, M; Hatakeyama, H; Takahashi, N; Fukui, K; Nammo, T; Yoneda, K; Inoue, Y; Sladek, FM; Magnuson, MA; Kasai, H; Miyagawa, J; Gonzalez, FJ; Shimomura, I			Hepatocyte nuclear factor-4 alpha is essential for glucosestimulated insulin secretion by pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HNF-4; SENSITIVE K+ CHANNELS; GLUCOSE-METABOLISM; GENE-EXPRESSION; ATP CHANNELS; YOUNG MODY1; ALPHA-GENE; MUTATIONS; RECEPTOR; MOUSE	Mutations in the hepatocyte nuclear factor (HNF)-4 alpha gene cause a form of maturity-onset diabetes of the young (MODY1) that is characterized by impairment of glucose- stimulated insulin secretion by pancreatic beta-cells. HNF-4 alpha, a transcription factor belonging to the nuclear receptor superfamily, is expressed in pancreatic islets as well as in the liver, kidney, and intestine. However, the role of HNF-4 alpha in pancreatic beta-cell is unclear. To clarify the role of HNF-4 alpha in beta-cells, we generated beta-cell-specific HNF-4 alpha knock-out (beta HNF-4 alpha KO) mice using the Cre-LoxP system. The beta HNF-4 alpha KO mice exhibited impairment of glucose- stimulated insulin secretion, which is a characteristic of MODY1. Pancreatic islet morphology, beta-cell mass, and insulin content were normal in the HNF-4 alpha mutant mice. Insulin secretion by beta HNF-4 alpha KO islets and the intracellular calcium response were impaired after stimulation by glucose or sulfonylurea but were normal after stimulation with KCl or arginine. Both NAD(P)H generation and ATP content at high glucose concentrations were normal in the beta HNF-4 alpha KO mice. Expression levels of Kir6.2 and SUR1 proteins in the beta HNF-4 alpha KO mice were unchanged as compared with control mice. Patch clamp experiments revealed that the current density was significantly increased in beta HNF-4 alpha KO mice compared with control mice. These results are suggestive of the dysfunction of K-ATP channel activity in the pancreatic beta-cells of HNF-4 alpha-deficient mice. Because the K-ATP channel is important for proper insulin secretion in beta-cells, altered K-ATP channel activity could be related to the impaired insulin secretion in the beta HNF-4 alpha KO mice.	Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan; Akita Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Geriatr Med, Akita 0108543, Japan; Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies, Okazaki, Aichi 4448787, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; NCI, Lab Metab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Osaka University; Akita University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST); University of California System; University of California Riverside; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yamagata, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Metab Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kazu@imed2.med.osaka-u.ac.jp	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Inoue, Yusuke/O-6207-2018	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Inoue, Yusuke/0000-0002-9710-7482; Kasai, Haruo/0000-0003-2327-9027; YONEDA, KAZUE/0000-0001-7142-2743	NATIONAL CANCER INSTITUTE [Z01BC005561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053892] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK053892] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2001, NUCL RECEPTORS GENET; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; BYRNE MM, 1995, DIABETES, V44, P699, DOI 10.2337/diabetes.44.6.699; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Fukui K, 2005, CELL METAB, V2, P373, DOI 10.1016/j.cmet.2005.11.003; Gonzalez FJ, 1997, BIOCHIMIE, V79, P139, DOI 10.1016/S0300-9084(97)81506-4; Gupta RK, 2005, J CLIN INVEST, V115, P1006, DOI 10.1172/JCI22365; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Herman WH, 1997, DIABETES, V46, P1749, DOI 10.2337/diabetes.46.11.1749; Ihara A, 2005, BIOCHEM BIOPH RES CO, V329, P984, DOI 10.1016/j.bbrc.2005.02.072; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; KREYMANN B, 1987, LANCET, V2, P1300; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Love-Gregory LD, 2004, DIABETES, V53, P1134, DOI 10.2337/diabetes.53.4.1134; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; NAKAZAKI M, 1995, DIABETES, V44, P878, DOI 10.2337/diabetes.44.8.878; Noda M, 2002, J BIOL CHEM, V277, P41817, DOI 10.1074/jbc.M207690200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Vaxillaire M, 2004, DIABETES, V53, P2719, DOI 10.2337/diabetes.53.10.2719; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Weedon MN, 2004, DIABETES, V53, P3002, DOI 10.2337/diabetes.53.11.3002; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yamagata K, 2002, DIABETES, V51, P114, DOI 10.2337/diabetes.51.1.114; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yang Q, 2000, DIABETOLOGIA, V43, P520, DOI 10.1007/s001250051338	45	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5246	5257		10.1074/jbc.M507496200	http://dx.doi.org/10.1074/jbc.M507496200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377800	hybrid			2022-12-25	WOS:000235426200079
J	Wu, SF; Yoshiko, Y; De Luca, F				Wu, SF; Yoshiko, Y; De Luca, F			Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONGITUDINAL BONE-GROWTH; CHONDROCYTE MATURATION; INORGANIC-PHOSPHATE; TRANSGENIC MICE; MESSENGER-RNA; RAT; APOPTOSIS; MOUSE; EXPRESSION; PROTEIN	During embryogenesis, the expression of mammalian stanniocalcin (STC1) in the appendicular skeleton suggests its involvement in the regulation of longitudinal bone growth. Such a role is further supported by the presence of dwarfism in mice overexpressing STC1. Yet, the STC 1 inhibitory effect on growth may be related to both postnatal metabolic abnormalities and prenatal defective bone formation. In our study, we used an organ culture system to evaluate the effects of STC on growth plate chondrogenesis, which is the primary determinant of longitudinal bone growth. Fetal rat metatarsal bones were cultured in the presence of recombinant human STC (rhSTC). After 3 days, rhSTC suppressed metatarsal growth, growth plate chondrocyte proliferation and hypertrophy/differentiation, and extracellular matrix synthesis. In addition, rhSTC increased the number of apoptotic chondrocytes in the growth plate. In cultured chondrocytes, rhSTC increased phosphate uptake, reduced chondrocyte proliferation and matrix synthesis, and induced apoptosis. All these effects were reversed by culturing chondrocytes with rhSTC and phosphonoformic acid, an inhibitor of phosphate transport. The rhSTC-mediated inhibition of metatarsal growth and growth plate chondrocyte proliferation and hypertrophy/differentiation was abolished by culturing metatarsals with rhSTC and phosphonoformic acid. Taken together, our findings indicate that STC1 inhibits longitudinal bone growth directly at the growth plate. Such growth inhibition, likely mediated by an increased chondrocyte phosphate uptake, results from suppressed chondrocyte proliferation, hypertrophy/differentiation, and matrix synthesis and by increased apoptosis. Last, the expression of both STC1 and its binding site in the growth plate would support an autocrine/paracrine role for this growth factor in the regulation of growth plate chondrogenesis.	Drexel Univ, Sect Endocrinol & Diabet, St Christophers Hosp Children, Dept Pediat,Coll Med, Philadelphia, PA 19134 USA; Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral Growth & Dev Biol, Minami Ku, Hiroshima 7348553, Japan	Drexel University; Hiroshima University	De Luca, F (corresponding author), Drexel Univ, Sect Endocrinol & Diabet, St Christophers Hosp Children, Dept Pediat,Coll Med, Erie Ave & Front St, Philadelphia, PA 19134 USA.	francesco.deluca@drexel.edu						AHARINEJAD S, 1995, ANAT REC, V242, P111, DOI 10.1002/ar.1092420115; APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; BAGI C, 1989, CALCIFIED TISSUE INT, V45, P342, DOI 10.1007/BF02556004; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; De Niu P, 2000, MOL CELL ENDOCRINOL, V162, P131, DOI 10.1016/S0303-7207(00)00199-4; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; FARNUM CE, 1987, ANAT REC, V219, P221, DOI 10.1002/ar.1092190303; Filvaroff EH, 2002, ENDOCRINOLOGY, V143, P3681, DOI 10.1210/en.2001-211424; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Hoshi K, 1999, BONE, V25, P639, DOI 10.1016/S8756-3282(99)00223-9; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1; Jiang WQ, 2000, J ENDOCRINOL, V165, P457, DOI 10.1677/joe.0.1650457; LU M, 1994, AM J PHYSIOL, V36, pR1356; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; Magne D, 2003, J BONE MINER RES, V18, P1430, DOI 10.1359/jbmr.2003.18.8.1430; Mansfield K, 1999, J CELL PHYSIOL, V179, P276, DOI 10.1002/(SICI)1097-4652(199906)179:3<276::AID-JCP5>3.0.CO;2-#; Mansfield K, 2001, BONE, V28, P1, DOI 10.1016/S8756-3282(00)00409-9; MCCUDDEN CR, 2002, J BIOL CHEM, V47, P4549; Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756-3282(00)00346-X; Naski MC, 1998, DEVELOPMENT, V125, P4977; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; Rajpurohit R, 1999, J CELL PHYSIOL, V179, P287, DOI 10.1002/(SICI)1097-4652(199906)179:3<287::AID-JCP6>3.0.CO;2-T; Sabbagh Y, 2005, P NATL ACAD SCI USA, V102, P9637, DOI 10.1073/pnas.0502249102; Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Stannius H, 1839, ARCH ANAT PHYSIOL, V6, P97; Stasko SE, 2001, J ENDOCRINOL, V171, P237, DOI 10.1677/joe.0.1710237; Varghese R, 1998, ENDOCRINOLOGY, V139, P4714, DOI 10.1210/en.139.11.4714; Varghese R, 2002, ENDOCRINOLOGY, V143, P868, DOI 10.1210/en.143.3.868; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; WAGNER GF, 1995, P NATL ACAD SCI USA, V92, P1871, DOI 10.1073/pnas.92.6.1871; WAGNER GF, 1986, GEN COMP ENDOCR, V63, P481, DOI 10.1016/0016-6480(86)90149-8; Wagner GF, 1997, J BONE MINER RES, V12, P165, DOI 10.1359/jbmr.1997.12.2.165; WAGNER GF, 1991, MOL CELL ENDOCRINOL, V79, P129, DOI 10.1016/0303-7207(91)90103-Y; Wong CKC, 1998, J ENDOCRINOL, V158, P183, DOI 10.1677/joe.0.1580183; Worthington RA, 1999, ELECTROPHORESIS, V20, P2071, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2071::AID-ELPS2071>3.0.CO;2-#; Wu LNY, 2002, J CELL BIOCHEM, V86, P475, DOI 10.1002/jcb.10240; Wu SF, 2004, J CHILD NEUROL, V19, P26, DOI 10.1177/088307380401900105011; Wu SF, 2004, J BIOL CHEM, V279, P4642, DOI 10.1074/jbc.M305518200; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yoshiko Y, 1999, ENDOCRINOLOGY, V140, P1869, DOI 10.1210/en.140.4.1869; Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003-0130; Yoshiko Y, 2002, J HISTOCHEM CYTOCHEM, V50, P483, DOI 10.1177/002215540205000405; Zhang KZ, 1998, AM J PATHOL, V153, P439, DOI 10.1016/S0002-9440(10)65587-3; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897	47	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5120	5127		10.1074/jbc.M506667200	http://dx.doi.org/10.1074/jbc.M506667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377640	hybrid			2022-12-25	WOS:000235426200066
J	Charalampopoulos, I; Alexaki, VI; Lazaridis, I; Dermitzaki, E; Avlonitis, N; Tsatsanis, C; Calogeropoulou, T; Margioris, AN; Castanas, E; Gravanis, A				Charalampopoulos, I; Alexaki, VI; Lazaridis, I; Dermitzaki, E; Avlonitis, N; Tsatsanis, C; Calogeropoulou, T; Margioris, AN; Castanas, E; Gravanis, A			G protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone	FASEB JOURNAL			English	Article						apoptosis; neurosteroid; steroid membrane receptors	IN-VITRO MODEL; TESTOSTERONE RECEPTORS; ALZHEIMERS-DISEASE; CORTISOL-LEVELS; SULFATE DHEAS; ESTROGEN; CELLS; NEURONS; DIFFERENTIATION; ACTIVATION	The neurosteroid dehydroepiandrosterone (DHEA) at 1 nM protects NMDA-/GABA(A)-receptor negative neural crest-derived PC12 cells from apoptosis. We now report that membrane-impermeable DHEA-BSA conjugate replaces unconjugated DHEA in protecting serum-deprived PC12 cells from apoptosis (IC50=1.5 nM). Protection involves phosphorylation of the prosurvival factor Src and induction of the anti-apoptotic protein Bcl-2 and is sensitive to pertussis toxin. Binding assays of [H-3] DHEA on isolated PC12 cell membranes revealed saturation within 30 min and binding of DHEA with a K-d of 0.9 nM. A similar binding activity was detectable in isolated membranes from rat hippocampus and from normal human adrenal chromaffin cells. The presence of DHEA-specific membrane binding sites was confirmed by flow cytometry and confocal laser microscopy of DHEA-BSA-FITC stained cells. In contrast to estrogens and progestins, glucocorticoids and androgens displaced DHEA from its membrane binding sites but with a 10-fold lower affinity than DHEA (IC50= 9.3 and 13.6 nM, respectively). These agents acted as pure antagonists, blocking the antiapoptotic effect of DHEA as well as the induction of Bcl-2 proteins and Src kinase activation. In conclusion, our findings suggest that neural crest-derived cells possess specific DHEA membrane binding sites coupled to G proteins. Binding to these sites confers neuroprotection.	Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71003, Greece; Univ Crete, Sch Med, Dept Expt Endocrinol, Iraklion 71003, Greece; Univ Crete, Sch Med, Dept Clin Chem, Iraklion 71003, Greece; Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, GR-15258 Athens, Greece	University of Crete; University of Crete; University of Crete; National Hellenic Research Foundation	Gravanis, A (corresponding author), Univ Crete, Sch Med, Dept Pharmacol, POB 2208, Iraklion 71003, Greece.	gravanis@med.uoc.gr	Alexaki, Vasileia Ismini/K-5527-2019; Castanas, Elias/E-7007-2010; Avlonitis, Nicolaos/T-6053-2019; Tsatsanis, Christos/AAM-9362-2020; Charalampopoulos, Ioannis/I-6319-2012; Avlonitis, Nicolaos/A-5161-2009	Castanas, Elias/0000-0002-8370-1835; Tsatsanis, Christos/0000-0003-1214-4151; Charalampopoulos, Ioannis/0000-0003-3415-7332; Lazaridis, Iakovos/0000-0002-4578-2347; Alexaki, Vasileia Ismini/0000-0003-3935-8985				Alexaki VI, 2004, FASEB J, V18, P1594, DOI 10.1096/fj.04-1495fje; Baulieu EE, 1998, P NATL ACAD SCI USA, V95, P4089, DOI 10.1073/pnas.95.8.4089; BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Charalampopoulos I, 2005, ENDOCRINOLOGY, V146, P3309, DOI 10.1210/en.2005-0263; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; Dermitzaki E, 2002, J BIOL CHEM, V277, P12280, DOI 10.1074/jbc.M111236200; Falkenstein E, 1996, BIOCHEM BIOPH RES CO, V229, P86, DOI 10.1006/bbrc.1996.1761; GAETJENS E, 1980, J STEROID BIOCHEM, V13, P1001, DOI 10.1016/0022-4731(80)90177-6; Gametchu B, 1999, STEROIDS, V64, P107, DOI 10.1016/S0039-128X(98)00097-X; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HALES TG, 1994, J NEUROSCI, V14, P5429; Hatzoglou A, 2005, J CLIN ENDOCR METAB, V90, P893, DOI 10.1210/jc.2004-0801; HATZOGLOU A, 1994, CLIN CHIM ACTA, V227, P97, DOI 10.1016/0009-8981(94)90139-2; Kampa M, 2002, FASEB J, V16, P1429, DOI 10.1096/fj.02-0131fje; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; Liu DM, 2002, J BIOL CHEM, V277, P21379, DOI 10.1074/jbc.M200491200; Liu DM, 2004, STEROIDS, V69, P279, DOI 10.1016/j.steroids.2004.02.004; LUSTIG RH, 1994, J NEUROSCI, V14, P3945; LUSTIG RH, 1994, MOL CELL NEUROSCI, V5, P587, DOI 10.1006/mcne.1994.1072; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marder K, 1996, NEUROLOGY, V47, P155, DOI 10.1212/WNL.47.1.155; MIGNON CJ, 1957, J CLIN ENDOCR METAB, V17, P1051; Mizota K, 2005, BRIT J PHARMACOL, V145, P545, DOI 10.1038/sj.bjp.0706213; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Saito Y, 2003, MOL BRAIN RES, V110, P159, DOI 10.1016/S0169-328X(02)00548-X; SAPOLSKY RM, 1986, ENDOCR REV, V7, P284, DOI 10.1210/edrv-7-3-284; SAPOLSKY RM, 1986, J NEUROSCI, V6, P2240; Swaab DF, 2005, AGEING RES REV, V4, P141, DOI 10.1016/j.arr.2005.03.003; SWAAB DF, 1994, J NEUROENDOCRINOL, V6, P681, DOI 10.1111/j.1365-2826.1994.tb00635.x; Umegaki H, 2000, BRAIN RES, V881, P241, DOI 10.1016/S0006-8993(00)02847-X; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Widstrom RL, 2004, SEMIN REPROD MED, V22, P289, DOI 10.1055/s-2004-861546; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2237, DOI 10.1073/pnas.0436133100	41	56	62	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					577	+		10.1096/fj.05-5078fje	http://dx.doi.org/10.1096/fj.05-5078fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407456				2022-12-25	WOS:000235996000023
J	Yu, J; Lei, L; Liang, YX; Hinh, L; Hickey, RP; Huang, Y; Liu, DG; Yeh, JL; Rebar, E; Case, C; Spratt, K; Sessa, WC; Giordano, FJ				Yu, J; Lei, L; Liang, YX; Hinh, L; Hickey, RP; Huang, Y; Liu, DG; Yeh, JL; Rebar, E; Case, C; Spratt, K; Sessa, WC; Giordano, FJ			An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice	FASEB JOURNAL			English	Article						vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; DNA RECOGNITION; MOUSE MODEL; ANGIOGENESIS; INDUCTION; ISOFORMS; CELLS; SELECTION; ISCHEMIA; SEQUENCE	Advances in understanding the relationship between protein structure and DNA binding specificity have made it possible to engineer zinc finger protein (ZFP) transcription factors to specifically activate or repress virtually any gene. To evaluate the potential clinical utility of this approach for peripheral vascular disease, we investigated the ability of an engineered vascular endothelial growth factor (VEGFa)-activating ZFP (MVZ+ 426b) to induce angiogenesis and rescue hindlimb ischemia in a murine model. Hindlimb ischemia was surgically induced in advanced-age C57/BL6 mice. Adenovirus ( Ad) encoding either MVZ+ 426b or the fluorescent marker dsRed was delivered to the adducter muscle of the ischemic hindlimb, and the effects on blood flow, limb salvage, and vascularization were assessed. Ad-MVZ+426b induced expression of VEGFa at the mRNA and protein levels and stimulated a significant increase in vessel counts in the ischemic limb. This was accompanied by significantly increased blood flow and limb salvage as measured serially for 4 wk. These data demonstrate that activation of the endogenous VEGFa gene by an engineered ZFP can induce angiogenesis in a clinically relevant model and further document the feasibility of designing ZFPs to therapeutically regulate gene expression in vivo.	Yale Univ, Sch Med, Dept Pharmacol, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Sangamo Biosci, Richmond, CA USA	Yale University; Yale University; Sangamo Therapeutics, Inc.	Giordano, FJ (corresponding author), BCMM 436C,295 Congress Ave, New Haven, CT 06443 USA.	Frank.Giordano@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NHLBI NIH HHS [R01HL-63770, R01HL-64001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063770, R01HL064001] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Giordano FJ, 1997, CIRCULATION, V96, P400; Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Huang Y, 2004, FASEB J, V18, P1138, DOI 10.1096/fj.04-1510fje; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Kato Y, 2001, BIOCHEM BIOPH RES CO, V287, P422, DOI 10.1006/bbrc.2001.5622; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; KLUG A, 1987, COLD SPRING HARB SYM, V52, P473, DOI 10.1101/SQB.1987.052.01.054; Lee CW, 2004, J AM COLL CARDIOL, V43, P474, DOI 10.1016/j.jacc.2003.09.033; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Oh H, 2002, P NATL ACAD SCI USA, V99, P383, DOI 10.1073/pnas.012074399; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Robinson CJ, 2001, J CELL SCI, V114, P853; Tuomisto TT, 2004, ATHEROSCLEROSIS, V174, P111, DOI 10.1016/j.atherosclerosis.2004.01.015; Urnov FD, 2002, BIOCHEM PHARMACOL, V64, P919, DOI 10.1016/S0006-2952(02)01150-4; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183	27	40	58	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					479	+		10.1096/fj.04-3670fje	http://dx.doi.org/10.1096/fj.04-3670fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423874				2022-12-25	WOS:000235996000009
J	Shalev, DE; Rotem, S; Fish, A; Mor, A				Shalev, DE; Rotem, S; Fish, A; Mor, A			Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K-4-S4-(1-13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDE; ESCHERICHIA-COLI; MACROMOLECULAR-SYNTHESIS; SELECTIVE CYTOTOXICITY; AQUEOUS-SOLUTIONS; NMR-SPECTROSCOPY; LACTOFERRICIN-B; S4 DERIVATIVES; HOST-DEFENSE; IN-VITRO	Acyl conjugation to antimicrobial peptides is known to enhance antimicrobial properties. Here, we investigated the consequences of aminolauryl (NC12) conjugation to the dermaseptin derivative K-4-S4-(1-13) (P) on binding properties to bilayer models mimicking bacterial plasma membrane, which is often cited as the ultimate site of action. Isothermal titration calorimetry revealed that acylation was responsible for enhancing the binding affinity of NC12-P compared with P (K = 13 x 10(5) and 1.5 x 10(5) M-1, respectively). Surface plasmon resonance measurements confirmed the isothermal titration calorimetry results (K-app = 12.6 x 10(5) and 1.53 x 10(5) M-1, respectively) and further indicated that enhanced adhesion affinity (K-adhesion = 3 x 10(5) and 1.5 x 10(5) M-1, respectively) was coupled to enhanced tendency to insert within the bilayer (K-insertion = 4.5 and 1.5, respectively). To gain insight into the molecular basis for these observations, we investigated the three-dimensional structures in the presence of dodecylphosphocholine using NMR. The ensemble of NMR-calculated structures ( backbone root mean square deviation <0.6 angstrom) showed that the acyl moiety was responsible for a significant molecular reorganization, possibly affecting the electrostatic potential distribution in NC12-P relative to that of P. The combined data present compelling evidence in support of the hypothesis that N-acylation affects antimicrobial properties by modifying the secondary structure of the peptide in a manner that facilitates contact with the membrane and consequently increases its disruption.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Lab Antimicrobial Peptides Invest, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel	Technion Israel Institute of Technology; Hebrew University of Jerusalem	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Lab Antimicrobial Peptides Invest, IL-32000 Haifa, Israel.	amor@tx.technion.ac.il	Shalev, Deborah E/AAY-2873-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR-01081] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ammar B, 1998, BIOCHEM BIOPH RES CO, V247, P870, DOI 10.1006/bbrc.1998.8879; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Balaban N, 2004, ANTIMICROB AGENTS CH, V48, P2544, DOI 10.1128/AAC.48.7.2544-2550.2004; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; Blazyk J, 2001, J BIOL CHEM, V276, P27899, DOI 10.1074/jbc.M102865200; Blondelle SE, 2000, BIOPOLYMERS, V55, P74, DOI 10.1002/1097-0282(2000)55:1&lt;74::AID-BIP70&gt;3.0.CO;2-S; Brul S, 1999, INT J FOOD MICROBIOL, V50, P1, DOI 10.1016/S0168-1605(99)00072-0; Chapple DS, 1998, INFECT IMMUN, V66, P2434, DOI 10.1128/IAI.66.6.2434-2440.1998; Chen J, 2000, BIOPOLYMERS, V55, P88, DOI 10.1002/1097-0282(2000)55:1<88::AID-BIP80>3.3.CO;2-B; Chicharro C, 2001, ANTIMICROB AGENTS CH, V45, P2441, DOI 10.1128/AAC.45.9.2441-2449.2001; Dathe M, 2004, BIOCHEMISTRY-US, V43, P9140, DOI 10.1021/bi035948v; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; Efron L, 2002, J BIOL CHEM, V277, P24067, DOI 10.1074/jbc.M202089200; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; Epand R, 2003, BIOPOLYMERS, V71, P2, DOI 10.1002/bip.10372; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Gaidukov L, 2003, BIOCHEMISTRY-US, V42, P12866, DOI 10.1021/bi034514x; Ge YG, 1999, DIAGN MICR INFEC DIS, V35, P45, DOI 10.1016/S0732-8893(99)00056-5; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hariton-Gazal E, 2002, BIOCHEMISTRY-US, V41, P9208, DOI 10.1021/bi0201466; Haukland HH, 2001, FEBS LETT, V508, P389, DOI 10.1016/S0014-5793(01)03100-3; HAYNIE SL, 1995, ANTIMICROB AGENTS CH, V39, P301, DOI 10.1128/AAC.39.2.301; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; Hobta A, 2001, CELL BIOCHEM FUNCT, V19, P291, DOI 10.1002/cbf.929; HONIG B, 1993, J PHYS CHEM-US, V97, P1101, DOI 10.1021/j100108a002; Huang H W, 1999, Novartis Found Symp, V225, P188; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kustanovich I, 2002, J BIOL CHEM, V277, P16941, DOI 10.1074/jbc.M111071200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee WJ, 1998, INFECT IMMUN, V66, P1421, DOI 10.1128/IAI.66.4.1421-1426.1998; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Levy O, 2000, BLOOD, V96, P2664; Lockwood NA, 2004, BIOCHEM J, V378, P93, DOI 10.1042/BJ20031393; Mak P, 2003, INT J ANTIMICROB AG, V21, P13, DOI 10.1016/S0924-8579(02)00245-5; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; Mor A, 2000, DRUG DEVELOP RES, V50, P440, DOI 10.1002/1098-2299(200007/08)50:3/4<440::AID-DDR27>3.3.CO;2-W; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; Navon-Venezia S, 2002, ANTIMICROB AGENTS CH, V46, P689, DOI 10.1128/AAC.46.3.689-694.2002; NILGES M, 1991, COMPUTATIONAL ASPECT; Okumura K, 2004, CANCER LETT, V212, P185, DOI 10.1016/j.canlet.2004.04.006; Papo N, 2003, BIOCHEMISTRY-US, V42, P9346, DOI 10.1021/bi027212o; Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peggion C, 2003, J PEPT SCI, V9, P679, DOI 10.1002/psc.500; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Radzishevsky IS, 2005, ANTIMICROB AGENTS CH, V49, P2412, DOI 10.1128/AAC.49.6.2412-2420.2005; Sal-Man N, 2002, BIOCHEMISTRY-US, V41, P11921, DOI 10.1021/bi0260482; Salzet M, 2002, TRENDS IMMUNOL, V23, P283, DOI 10.1016/S1471-4906(02)02236-6; Scott MG, 2000, J IMMUNOL, V165, P3358, DOI 10.4049/jimmunol.165.6.3358; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Shalev DE, 2002, BIOCHEMISTRY-US, V41, P7312, DOI 10.1021/bi016013m; Stark M, 2002, ANTIMICROB AGENTS CH, V46, P3585, DOI 10.1128/AAC.46.11.3585-3590.2002; Tossi A, 1997, EUR J BIOCHEM, V250, P549, DOI 10.1111/j.1432-1033.1997.0549a.x; Ulvatne H, 2004, FEMS MICROBIOL LETT, V237, P377, DOI 10.1016/j.femsle.2004.07.001; Welling MM, 2000, EUR J NUCL MED, V27, P292, DOI 10.1007/s002590050036; Wenk MR, 1998, BIOCHEMISTRY-US, V37, P3909, DOI 10.1021/bi972615n; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13; Yaron S, 2003, PEPTIDES, V24, P1815, DOI 10.1016/j.peptides.2003.09.016; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	66	35	38	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9432	9438		10.1074/jbc.M513051200	http://dx.doi.org/10.1074/jbc.M513051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16407175	hybrid			2022-12-25	WOS:000236404700053
J	Carissimi, C; Saieva, L; Baccon, J; Chiarella, P; Maiolica, A; Sawyer, A; Rappsilber, J; Pellizzoni, L				Carissimi, C; Saieva, L; Baccon, J; Chiarella, P; Maiolica, A; Sawyer, A; Rappsilber, J; Pellizzoni, L			Gemin8 is a novel component of the survival motor neuron complex and functions in small nuclear ribonucleoprotein assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; REPEAT PROTEIN-COMPONENT; BINDS SM PROTEINS; SNRNP PROTEINS; COILED BODIES; GENE-PRODUCT; IDENTIFICATION; SIP1; GEMS; LOCALIZATION	The survival motor neuron (SMN) protein is the product of the spinal muscular atrophy disease gene. SMN and Gemin2 - 7 proteins form a large macromolecular complex that localizes in the cytoplasm as well as in the nucleoplasm and in nuclear Gems. The SMN complex interacts with several additional proteins and likely functions in multiple cellular pathways. In the cytoplasm, a subset of SMN complexes containing unrip and Sm proteins mediates the assembly of spliceosomal small nuclear ribonucleoproteins (snRNPs). Here, by mass spectrometry analysis of SMN complexes purified from HeLa cells, we identified a novel protein that is evolutionarily conserved in metazoans, and we named it Gemin8. Co-immunoprecipitation and immunolocalization experiments demonstrated that Gemin8 is associated with the SMN complex and is localized in the cytoplasm and in the nucleus, where it is highly concentrated in Gems. Gemin8 interacts directly with the Gemin6-Gemin7 heterodimer and, together with unrip, these proteins form a heteromeric subunit of the SMN complex. Gemin8 is also associated with Sm proteins, and Gemin8-containing SMN complexes are competent to carry out snRNP assembly. Importantly, RNA interference experiments indicate that Gemin8 knock-down impairs snRNP assembly, and Gemin8 expression is down-regulated in cells with low levels of SMN. These results demonstrate that Gemin8 is a novel integral component of the SMN complex and extend the repertoire of cellular proteins involved in the pathway of snRNP biogenesis.	CNR, Inst Cell Biol, Dulbecco Telethon Inst, I-00016 Monterotondo, Rome, Italy; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; EMBL Monoclonal Antibody Core Facil, I-00016 Monterotondo, Rome, Italy; FIRC Inst Mol Oncol Fdn, I-20139 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Pennsylvania; European Molecular Biology Laboratory (EMBL); IFOM - FIRC Institute of Molecular Oncology	Pellizzoni, L (corresponding author), CNR, Inst Cell Biol, Dulbecco Telethon Inst, Via E Ramarini 32, I-00016 Monterotondo, Rome, Italy.	livio.pellizzoni@ibc.cnr.it	carissimi, claudia/AAU-7414-2021; Rappsilber, Juri/ABF-3328-2020; Rappsilber, Juri/B-7265-2015	carissimi, claudia/0000-0002-9885-2855; Rappsilber, Juri/0000-0001-5999-1310; Pellizzoni, Livio/0000-0002-9168-5628; Sawyer, Alan/0000-0001-5942-4498	Telethon [TCP02011] Funding Source: Medline	Telethon(Fondazione Telethon)		Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Carissimi C, 2005, FEBS LETT, V579, P2348, DOI 10.1016/j.febslet.2005.03.034; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; De Masi F, 2005, PROTEOMICS, V5, P4070, DOI 10.1002/pmic.200401279; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Gall JG, 2003, NAT REV MOL CELL BIO, V4, P975, DOI 10.1038/nrm1262; Golembe TJ, 2005, MOL CELL BIOL, V25, P602, DOI 10.1128/MCB.25.2.602-611.2005; Grimmler M, 2005, HUM MOL GENET, V14, P3099, DOI 10.1093/hmg/ddi343; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; Hane B, 1999, AM J MED GENET, V85, P271; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Hebert MD, 2002, DEV CELL, V3, P329, DOI 10.1016/S1534-5807(02)00222-8; Helmken C, 2003, HUM GENET, V114, P11, DOI 10.1007/s00439-003-1025-2; IONASESCU VV, 1995, MUSCLE NERVE, V18, P267, DOI 10.1002/mus.880180302; Jablonka S, 2001, HUM MOL GENET, V10, P497, DOI 10.1093/hmg/10.5.497; Jurica MS, 2003, MOL CELL, V12, P5, DOI 10.1016/S1097-2765(03)00270-3; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Kiss T, 2004, J CELL SCI, V117, P5949, DOI 10.1242/jcs.01487; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Ma YL, 2005, STRUCTURE, V13, P883, DOI 10.1016/j.str.2005.03.014; Martinez F, 2001, AM J MED GENET, V102, P200, DOI 10.1002/ajmg.1416; Massenet S, 2002, MOL CELL BIOL, V22, P6533, DOI 10.1128/MCB.22.18.6533-6541.2002; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2002, EMBO J, V21, P5853, DOI 10.1093/emboj/cdf585; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Narayanan U, 2002, HUM MOL GENET, V11, P1785, DOI 10.1093/hmg/11.15.1785; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Pillai RS, 2003, GENE DEV, V17, P2321, DOI 10.1101/gad.274403; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Wang J, 2001, J BIOL CHEM, V276, P9599, DOI 10.1074/jbc.M009162200; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yong J, 2004, MOL CELL BIOL, V24, P2747, DOI 10.1128/MCB.24.7.2747-2756.2004; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010; Yong JS, 2002, EMBO J, V21, P1188, DOI 10.1093/emboj/21.5.1188; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858	48	84	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8126	8134		10.1074/jbc.M512243200	http://dx.doi.org/10.1074/jbc.M512243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434402	hybrid			2022-12-25	WOS:000236031000050
J	Dai, EB; Viswanathan, K; Sun, YM; Li, X; Liu, LY; Togonu-Bickersteth, B; Richardson, J; Macaulay, C; Nash, P; Turner, P; Nazarian, SH; Moyer, R; McFadden, G; Lucas, AR				Dai, EB; Viswanathan, K; Sun, YM; Li, X; Liu, LY; Togonu-Bickersteth, B; Richardson, J; Macaulay, C; Nash, P; Turner, P; Nazarian, SH; Moyer, R; McFadden, G; Lucas, AR			Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; NEOINTIMA FORMATION; SERINE PROTEINASE; GLYCOSAMINOGLYCAN BINDING; INHIBITORY SPECIFICITY; FIBRINOLYTIC SYSTEM; DIFFERENT ROLES; GENE-TRANSFER; VIRUS SERP2; UROKINASE	The thrombolytic serine protease cascade is intricately involved in activation of innate immune responses. The urokinase-type plasminogen activator and receptor form complexes that aid inflammatory cell invasion at sites of arterial injury. Plasminogen activator inhibitor-1 is a mammalian serpin that binds and regulates the urokinase receptor complex. Serp-1, a myxomaviral serpin, also targets the urokinase receptor, displaying profound anti-inflammatory and anti-atherogenic activity in a wide range of animal models. Serp-1 reactive center site mutations, mimicking known mammalian and viral serpins, were constructed in order to define sequences responsible for regulation of inflammation. Thrombosis, inflammation, and plaque growth were assessed after treatment with Serp-1, Serp-1 chimeras, plasminogen activator inhibitor-1, or unrelated viral serpins in plasminogen activator inhibitor or urokinase receptor-deficient mouse aortic transplants. Altering the P1-P1' Arg-Asn sequence compromised Serp-1 protease-inhibitory activity and anti-inflammatory activity in animal models; P1-P1' Ala-Ala mutants were inactive, P1 Met increased remodeling, and P1' Thr increased thrombosis. Substitution of Serp-1 P2-P7 with Ala(6) allowed for inhibition of urokinase but lost plasmin inhibition, unexpectedly inducing a diametrically opposed, proinflammatory response with mononuclear cell activation, thrombosis, and aneurysm formation (p<0.03). Other serpins did not reproduce Serp-1 activity; plasminogen activator inhibitor-1 increased thrombosis (p<0.0001), and unrelated viral serpin, CrmA, increased inflammation. Deficiency of urokinase receptor in mouse transplants blocked Serp-1 and chimera activity, in some cases increasing inflammation. In summary, 1) Serp-1 anti-inflammatory activity is highly dependent upon the reactive center loop sequence, and 2) plasmin inhibition is central to anti-inflammatory activity.	Univ Western Ontario, Robarts Res Inst, Vasc Biol Res Grp, London, ON N6A 2K8, Canada; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Viron Therapeut Inc, Res & Dev, London, ON N6G 4X8, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 2K8, Canada	Western University (University of Western Ontario); State University System of Florida; University of Florida; Western University (University of Western Ontario)	Lucas, AR (corresponding author), Univ Western Ontario, Robarts Res Inst, Vasc Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 2K8, Canada.	arl@robarts.ca		Macaulay, Colin/0000-0003-0118-7674; Turner, Peter/0000-0002-7706-4593; McFadden, Grant/0000-0002-2556-3526				AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; Alessi MC, 2004, ARCH MAL COEUR VAISS, V97, P673; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Barbour KW, 2002, MOL BIOL EVOL, V19, P718, DOI 10.1093/oxfordjournals.molbev.a004130; Bot I, 2003, CIRC RES, V93, P464, DOI 10.1161/01.RES.0000090993.01633.D4; BRAUTBOUCHER F, 1995, J IMMUNOL METHODS, V178, P41, DOI 10.1016/0022-1759(94)00239-S; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; CARMELIET P, 1995, FASEB J, V9, P934, DOI 10.1096/fasebj.9.10.7615162; Chavakis T, 2002, BIOCHEM SOC T, V30, P168, DOI 10.1042/BST0300168; Chen VC, 2000, J BIOL CHEM, V275, P38457, DOI 10.1074/jbc.M005605200; Christov A, 2000, PHOTOCHEM PHOTOBIOL, V72, P242, DOI 10.1562/0031-8655(2000)072<0242:ODOTAP>2.0.CO;2; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Dai E, 2003, J BIOL CHEM, V278, P18563, DOI 10.1074/jbc.M209683200; DALY LE, 1991, INTERPRETATION USES, P139; FALKENBERG M, 1990, THROMB HAEMOSTASIS, V72, P933; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gu JM, 2005, J CELL PHYSIOL, V204, P73, DOI 10.1002/jcp.20262; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Krettek A, 2003, ARTERIOSCL THROM VAS, V23, P582, DOI 10.1161/01.ATV.0000064372.78561.A5; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; LOMAS DA, 1993, J BIOL CHEM, V268, P516; Lucas A, 2004, J IMMUNOL, V173, P4765, DOI 10.4049/jimmunol.173.8.4765; Lucas A, 1996, CIRCULATION, V94, P2890, DOI 10.1161/01.CIR.94.11.2890; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Matsuno H, 2002, THROMB HAEMOSTASIS, V87, P98; Matsuno H, 2002, J CARDIOVASC PHARM, V39, P278, DOI 10.1097/00005344-200202000-00015; Matsuno H, 1999, THROMB HAEMOSTASIS, V81, P601; Miller LW, 2000, CIRCULATION, V101, P1598, DOI 10.1161/01.CIR.101.13.1598; Mitchell JW, 2002, J BIOL CHEM, V277, P19823, DOI 10.1074/jbc.M200630200; Moreno PR, 1996, CIRCULATION, V94, P3090, DOI 10.1161/01.CIR.94.12.3090; Nash P, 2000, FEBS LETT, V475, P1, DOI 10.1016/S0014-5793(00)01620-3; Nash P, 1998, J BIOL CHEM, V273, P20982, DOI 10.1074/jbc.273.33.20982; Nathaniel R, 2004, J GEN VIROL, V85, P1267, DOI 10.1099/vir.0.79905-0; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Patston PA, 2004, METHODS, V32, P93, DOI 10.1016/S1046-2023(03)00201-9; Ploplis VA, 2001, ANN NY ACAD SCI, V936, P466; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Schechter NM, 2004, METHODS, V32, P159, DOI 10.1016/S1046-2023(03)00207-X; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stein CM, 1998, J AM COLL CARDIOL, V32, P117, DOI 10.1016/S0735-1097(98)00210-1; Turner PC, 1999, J VIROL, V73, P6394, DOI 10.1128/JVI.73.8.6394-6404.1999; Wiman J, 2000, HEMATOL ONCOL CLIN N, V14, P325, DOI 10.1016/S0889-8588(05)70136-2; Zalai CV, 2002, FUND CL CAR, V45, P447; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	50	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8041	8050		10.1074/jbc.M509454200	http://dx.doi.org/10.1074/jbc.M509454200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407226	hybrid			2022-12-25	WOS:000236031000041
J	Montana, ES; Littleton, JT				Montana, ES; Littleton, JT			Expression profiling of a hypercontraction-induced myopathy in Drosophila suggests a compensatory cytoskeletal remodeling response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LONG-TERM POTENTIATION; IMMEDIATE-EARLY GENE; CARDIAC-HYPERTROPHY; MESSENGER-RNA; MEMORY CONSOLIDATION; SYNAPTIC PLASTICITY; MUSCLE ATTACHMENTS; SKELETAL-MUSCLE; CDNA MICROARRAY	Mutations that alter muscle contraction lead to a large array of diseases, including muscular dystrophies and cardiomyopathies. Although the molecular lesions underlying many hereditary muscle diseases are known, the downstream pathways that contribute to disease pathogenesis and compensatory muscle remodeling are poorly defined. We have recently identified and characterized mutations in Myosin Heavy Chain (Mhc) that lead to hypercontraction and subsequent degeneration of flight muscles in Drosophila. To characterize the genomic response to hypercontraction-induced myopathy, we performed expression analysis using Affymetrix high density oligonucleotide microarrays in Drosophila Mhc hypercontraction alleles. The altered transcriptional profile of dystrophic Mhc muscles suggests an actin-dependent remodeling of the muscle cytoskeleton. Specifically, a subset of the highly up-regulated transcripts is involved in actin regulation and structural support for the contractile machinery. In addition, we identified previously uncharacterized proteins with putative actin-interaction domains that are up-regulated in Mhc mutants and differentially expressed in muscles. Several of the up-regulated proteins, including the dystrophin-related protein, MSP-300, and the homolog of the neuronal activity-regulated protein, ARC, localize to specific subcellular muscle structures that may provide key structural sites for cytoskeletal remodeling in dystrophic muscles. Defining the genome-wide transcriptional response to muscle hypercontraction in Drosophila has revealed candidate loci that may participate in the pathogenesis of muscular dystrophy and in compensatory muscle repair pathways through modulation of the actin cytoskeleton.	MIT, Picower Inst Learning & Memory, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Northwell Health; Massachusetts Institute of Technology (MIT)	Littleton, JT (corresponding author), MIT, Picower Inst Learning & Memory, Dept Biol, 46-3243, Cambridge, MA 02139 USA.	troy@mit.edu		Littleton, J. Troy/0000-0001-5576-2887	NINDS NIH HHS [R01 NS043244, R01 NS043244-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043244] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aronow BJ, 2001, PHYSIOL GENOMICS, V6, P19, DOI 10.1152/physiolgenomics.2001.6.1.19; Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4; Baum B, 2000, CURR BIOL, V10, P964, DOI 10.1016/S0960-9822(00)00640-0; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Campanaro S, 2002, HUM MOL GENET, V11, P3283, DOI 10.1093/hmg/11.26.3283; Chamberlain JS, 2000, J CELL BIOL, V151, pF43, DOI 10.1083/jcb.151.6.F43; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHOH RD, 2000, MUSCLE NERVE, V10, P1456; Ferrus A, 2000, TRENDS CARDIOVAS MED, V10, P293, DOI 10.1016/S1050-1738(01)00063-9; FOSNAUGH JS, 1995, J NEUROCHEM, V64, P2377; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; Guan Z, 2005, NEURON, V48, P91, DOI 10.1016/j.neuron.2005.08.036; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Hakeda S, 2000, J CELL BIOL, V148, P101, DOI 10.1083/jcb.148.1.101; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Kronert WA, 1999, J CELL BIOL, V144, P989, DOI 10.1083/jcb.144.5.989; Kuelzer F, 1999, J NEUROBIOL, V41, P482, DOI 10.1002/(SICI)1097-4695(199912)41:4<482::AID-NEU4>3.0.CO;2-X; Labuhn M, 1997, GERONTOLOGY, V43, P261; LAKEY A, 1993, EMBO J, V12, P2863, DOI 10.1002/j.1460-2075.1993.tb05948.x; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Lim DS, 2001, J AM COLL CARDIOL, V38, P1175, DOI 10.1016/S0735-1097(01)01509-1; Lowes BD, 2002, NEW ENGL J MED, V346, P1357, DOI 10.1056/NEJMoa012630; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; MALENKA RC, 1991, MOL NEUROBIOL, V5, P289, DOI 10.1007/BF02935552; Martonosi AN, 2003, ACTA BIOCHIM POL, V50, P1; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montana ES, 2004, J CELL BIOL, V164, P1045, DOI 10.1083/jcb.200308158; Nedivi E, 1996, P NATL ACAD SCI USA, V93, P2048, DOI 10.1073/pnas.93.5.2048; Noguchi S, 2003, HUM MOL GENET, V12, P595, DOI 10.1093/hmg/ddg065; Piper HM, 2004, CARDIOVASC RES, V61, P365, DOI 10.1016/j.cardiores.2003.12.012; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Raghavan S, 2000, CURR BIOL, V10, P269, DOI 10.1016/S0960-9822(00)00364-X; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; RosenbergHasson Y, 1996, MECH DEVELOP, V60, P83, DOI 10.1016/S0925-4773(96)00602-8; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Semsarian C, 2002, J CLIN INVEST, V109, P1013, DOI 10.1172/JCI200214677; Shinozaki K, 1997, BIOCHEM BIOPH RES CO, V240, P766, DOI 10.1006/bbrc.1997.7660; Steward O, 2002, NEURON, V36, P338, DOI 10.1016/S0896-6273(02)01006-1; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; Steward O, 2002, NEUROBIOL LEARN MEM, V78, P508, DOI 10.1006/nlme.2002.4102; Stronach BE, 1996, J CELL BIOL, V134, P1179, DOI 10.1083/jcb.134.5.1179; Stronach BE, 1999, MOL BIOL CELL, V10, P2329, DOI 10.1091/mbc.10.7.2329; TOBIN SL, 1990, DEV GENET, V11, P15, DOI 10.1002/dvg.1020110104; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Straaten M, 1999, J MOL BIOL, V285, P1549, DOI 10.1006/jmbi.1998.2386; Vigoreaux JO, 2001, BIOESSAYS, V23, P1047, DOI 10.1002/bies.1150; VOLK T, 1992, DEVELOPMENT, V116, P721; Wallace CS, 1998, J NEUROSCI, V18, P26; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang QP, 2002, GENOMICS, V80, P473, DOI 10.1006/geno.2002.6859	59	23	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8100	8109		10.1074/jbc.M512468200	http://dx.doi.org/10.1074/jbc.M512468200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415344	hybrid			2022-12-25	WOS:000236031000047
J	Eisner, G; Moser, M; Schafer, U; Beck, K; Muller, M				Eisner, G; Moser, M; Schafer, U; Beck, K; Muller, M			Alternate recruitment of signal recognition particle and trigger factor to the signal sequence of a growing nascent polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; MANNITOL PERMEASE; MEMBRANE-PROTEINS; DEPENDENT TRANSLOCATION; TARGETING PATHWAY; IN-VITRO; SRP; BINDING; SECA; COMPLEX	Different from cytoplasmic membrane proteins, presecretory proteins of bacteria usually do not require the signal recognition particle for targeting to the Sec translocon. Nevertheless signal sequences of presecretory proteins have been found in close proximity to signal recognition particle immediately after they have emerged from the ribosome. We show here that at the ribosome, the molecular environment of a signal sequence depends on the nature of downstream sequence elements that can cause an alternate recruitment of signal recognition particle and the ribosome-associated chaperone Trigger factor to a growing nascent chain. While signal recognition particle and Trigger factor might remain bound to the same ribosome, both ligands are clearly able to displace each other from a nascent chain. The data also imply that a signal sequence owes its molecular environment to the fact that it remains closely apposed to the ribosomal exit site during growth of a nascent secretory protein.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Freiburg	Muller, M (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	matthias.mueller@biochemie.uni-freiburg.de						Aboulwafa M, 2003, MOL MICROBIOL, V48, P131, DOI 10.1046/j.1365-2958.2003.03394.x; Agashe VR, 2004, CELL, V117, P199, DOI 10.1016/S0092-8674(04)00299-5; Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Beha D, 2003, J BIOL CHEM, V278, P22161, DOI 10.1074/jbc.M300929200; Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; Buskiewicz I, 2004, P NATL ACAD SCI USA, V101, P7902, DOI 10.1073/pnas.0402231101; CAMMACK KA, 1965, BIOCHEM J, V96, P671, DOI 10.1042/bj0960671; Chevalier N, 2004, J MOL MICROB BIOTECH, V8, P7, DOI 10.1159/000082076; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Ezraty B, 2004, EMBO J, V23, P1868, DOI 10.1038/sj.emboj.7600172; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; GRISAFI PL, 1989, J BACTERIOL, V171, P2719, DOI 10.1128/jb.171.5.2719-2727.1989; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Karamyshev AL, 2005, J BIOL CHEM, V280, P37930, DOI 10.1074/jbc.M509100200; Kim J, 2001, FEBS LETT, V505, P245, DOI 10.1016/S0014-5793(01)02784-3; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; MANEEWANNAKUL S, 1994, PLASMID, V31, P300, DOI 10.1006/plas.1994.1032; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Patzelt H, 2002, BIOL CHEM, V383, P1611, DOI 10.1515/BC.2002.182; Peterson JH, 2003, J BIOL CHEM, V278, P46155, DOI 10.1074/jbc.M309082200; Pool MR, 2005, MOL MEMBR BIOL, V22, P3, DOI 10.1080/09687860400026348; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Raine A, 2004, BIOCHIMIE, V86, P495, DOI 10.1016/j.biochi.2004.05.004; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Vervoort EB, 2005, J MOL BIOL, V346, P733, DOI 10.1016/j.jmb.2004.12.011; WERNER PK, 1992, J BIOL CHEM, V267, P24523	49	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7172	7179		10.1074/jbc.M511388200	http://dx.doi.org/10.1074/jbc.M511388200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421097	hybrid			2022-12-25	WOS:000236030900032
J	Richie-Jannetta, R; Busch, JL; Higgins, KA; Corbin, JD; Francis, SH				Richie-Jannetta, R; Busch, JL; Higgins, KA; Corbin, JD; Francis, SH			Isolated regulatory domains of cGMP-dependent protein kinase I alpha and I beta retain dimerization and native cGMP-binding properties and undergo isoform-specific conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; SITES; ISOZYME; AUTOINHIBITION; SEQUENCE; CLONING; CAMP	Molecular mechanisms that provide for cGMP activation of cGMP-dependent protein kinase (PKG) are unknown. PKGs are dimeric; each monomer contains a regulatory ( R) and catalytic ( C) domain. In this study, isolated recombinant R domains of PKGI alpha(Delta 349-670) and PKGI beta- (Delta 364-685) containing the dimerization and autoinhibitory subdomains and two allosteric cGMP-binding sites were expressed in Sf9 cells. Both R domains were dimers with elongated conformations ( Stokes radii of 44 and 51 A, respectively, and frictional coefficients of 1.6 and 1.8, respectively). Exchange dissociation kinetics and K-D values for cGMP were similar for each holoenzyme and its isolated R domain, indicating that under these conditions the C domain does not appreciably alter cGMP-binding functions of the R domain. As determined by gel filtration chromatography, cGMP binding caused elongation of the PKGI alpha-isolated R domain and contraction of the PKGI alpha-isolated R domain. Cyclic GMP-bound forms of the isoforms have similar physical dimensions that may reflect a common conformation of active isoforms. Elongation of the PKGI beta holoenzyme associated with cGMP binding and PKG activation cannot be explained solely by conformational change in its R domain, but elongation of the PKGI alpha R domain may partially account for the elongation of wild type PKGI alpha associated with cGMP binding. The cGMP-induced conformational changes in the respective R domains are likely to be critical for kinase activation.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Francis, SH (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Light Hall Rm 702, Nashville, TN 37232 USA.	Sharron.francis@vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058277, R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40029, DK 58277] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; Busch JL, 2002, J BIOL CHEM, V277, P34048, DOI 10.1074/jbc.M202761200; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; Dostmann WRG, 1996, FEBS LETT, V398, P206, DOI 10.1016/S0014-5793(96)01242-2; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 2002, FRONT BIOSCI-LANDMRK, V7, pD580, DOI 10.2741/francis; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; FRANCIS SH, 1993, CYCLIC GMP SYNTHESIS, P115; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kotera J, 2003, BIOCHEM J, V372, P419, DOI 10.1042/BJ20030107; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; Richie-Jannetta R, 2003, J BIOL CHEM, V278, P50070, DOI 10.1074/jbc.M306796200; Ruth P, 1997, J BIOL CHEM, V272, P10522; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Wall ME, 2003, P NATL ACAD SCI USA, V100, P2380, DOI 10.1073/pnas.0534892100; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	30	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6977	6984		10.1074/jbc.M510886200	http://dx.doi.org/10.1074/jbc.M510886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407222	hybrid			2022-12-25	WOS:000236030900010
J	Gerard, F; Cline, K				Gerard, F; Cline, K			Efficient twin arginine translocation (Tat) pathway transport of a precursor protein covalently anchored to its initial cpTatC binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANES; SIGNAL PEPTIDE; ESCHERICHIA-COLI; SEC; CHLOROPLASTS; SYSTEM; COMPLEX; REQUIREMENTS; SPECIFICITY; INTEGRATION	The thylakoid twin arginine protein translocation ( Tat) system operates by a cyclical mechanism in which precursors bind to a cpTatC-Hcf106 receptor complex, which then recruits Tha4 to form the translocase. After translocation, the translocase disassembles. Here, we fine-mapped initial interactions between precursors and the components of the receptor complex. Precursors with (Tmd) Phe substitutions in the signal peptide and early mature domain were bound to thylakoids and photo-cross-linked to components. cpTatC and Hcf106 were found to interact with different regions of the signal peptide. cpTatC cross-linked strongly to residues in the immediate vicinity of the twin arginine motif. Hcf106 cross-linked less strongly to residues in the hydrophobic core and the early mature domain. To determine whether precursors must leave their initial sites of interaction during translocation, crosslinked precursors were subjected to protein transport conditions. tOE17 cross-linked to cpTatC was efficiently translocated, indicating that the mature domain of the precursor can be translocated while the signal peptide remains anchored to the receptor complex.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, 1109 Fifield Hall,Box 110690, Gainesville, FL 32611 USA.	kcline@ufl.edu	Cline, Kenneth/J-6238-2013		NIGMS NIH HHS [R01 GM48179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048179, R29GM048179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alder NN, 2003, FEBS LETT, V540, P96, DOI 10.1016/S0014-5793(03)00231-X; Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Ma XY, 2000, J BIOL CHEM, V275, P10016, DOI 10.1074/jbc.275.14.10016; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; MOULD RM, 1991, J BIOL CHEM, V266, P17286; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Sargent F, 2002, ARCH MICROBIOL, V178, P77, DOI 10.1007/s00203-002-0434-2; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Theg SM, 2005, TRENDS PLANT SCI, V10, P153, DOI 10.1016/j.tplants.2005.02.001; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	31	86	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6130	6135		10.1074/jbc.M512733200	http://dx.doi.org/10.1074/jbc.M512733200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407185	hybrid			2022-12-25	WOS:000236030800004
J	Grant, JE; Guo, LW; Vestling, MM; Martemyanov, KA; Arshavsky, VY; Ruoho, AE				Grant, JE; Guo, LW; Vestling, MM; Martemyanov, KA; Arshavsky, VY; Ruoho, AE			The N terminus of GTP gamma S-activated transducin alpha-subunit interacts with the C terminus of the cGMP phosphodiesterase gamma-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; LIPID MODIFICATIONS; INHIBITORY SUBUNIT; AMINO-TERMINUS; BINDING-SITES; 2.0 ANGSTROM; BETA-GAMMA; PHOTORECEPTORS	Dynamic regulation of G-protein signaling in the phototransduction cascade ensures the high temporal resolution of vision. In a key step, the activated alpha-subunit of transducin (G alpha(t)-GTP) activates the cGMP phosphodiesterase (PDE) by binding the inhibitory gamma-subunit (PDE gamma). Significant progress in understanding the interaction between G alpha(t) and PDE gamma was achieved by solving the crystal structure of the PDE gamma C-terminal peptide bound to G alpha(t) in the transition state for GTP hydrolysis (Slep, K. C., Kercher, M. A., He, W., Cowan, C. W., Wensel, T. G., and Sigler, P. B. ( 2001) Nature 409, 1071 1077). However, some of the structural elements of each molecule were absent in the crystal structure. We have probed the binding surface between the PDE gamma C terminus and activated G alpha(t) bound to guanosine 5'-O-(3-thio)-triphosphate (GTP gamma S) using a series of full-length PDE gamma photoprobes generated by intein-mediated expressed protein ligation. For each of seven PDE gamma photoprobe species, expressed protein ligation allowed one benzoyl-L-phenylalaine substitution at selected hydrophobic C-terminal positions, and the addition of a biotin affinity tag at the extreme C terminus. We have detected photocross-linking from several PDE gamma C-terminal positions to the G alpha(t)-GTP gamma S N terminus, particularly from PDE gamma residue 73. The overall percentage of cross-linking to the G alpha(t)-GTP gamma S N terminus was analyzed using a far Western method for examining G alpha(t)-GTP gamma S proteolytic digestion patterns. Furthermore, mass spectrometric analysis of cross-links to G alpha(t) from a benzoyl-phenylalanine replacement at PDE gamma position 86 localized the region of photoinsertion to G alpha(t) N-terminal residues G alpha(t)-(22 - 26). This novel G alpha(t)/PDE gamma interaction suggests that the transducin N terminus plays an active role in signal transduction.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School	Ruoho, AE (corresponding author), 1300 Univ Ave, Madison, WI 53706 USA.	aeruoho@facstaff.wisc.edu			NEI NIH HHS [EY12859] Funding Source: Medline; NIGMS NIH HHS [GM33138] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012859] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033138] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cowan CW, 2000, METHOD ENZYMOL, V315, P524; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Granovsky AE, 2001, BIOCHEMISTRY-US, V40, P13209, DOI 10.1021/bi011127j; Guo LW, 2005, J BIOL CHEM, V280, P12585, DOI 10.1074/jbc.M410380200; Hashimoto Y, 2004, J BIOCHEM, V135, P319, DOI 10.1093/jb/mvh039; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; KUHN H, 1980, NATURE, V283, P749; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; Martemyanov KA, 2004, METHOD ENZYMOL, V390, P196; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Medkova M, 2002, BIOCHEMISTRY-US, V41, P9962, DOI 10.1021/bi0255726; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NEUBERT TA, 1995, METHOD ENZYMOL, V250, P487; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Preininger AM, 2003, BIOCHEMISTRY-US, V42, P7931, DOI 10.1021/bi0345438; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; TING TD, 1993, METH NEUROSCI, V15, P180	40	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6194	6202		10.1074/jbc.M509511200	http://dx.doi.org/10.1074/jbc.M509511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407279	hybrid			2022-12-25	WOS:000236030800011
J	Schrodt, S; Koch, J; Tampe, R				Schrodt, S; Koch, J; Tampe, R			Membrane topology of the transporter associated with antigen processing (TAP1) within an assembled functional peptide-loading complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ABC TRANSPORTERS; STRUCTURE PREDICTION; RAT-BRAIN; BINDING; PROTEIN; MECHANISM; SUBUNITS; MSBA; HOMOLOG	The transporter associated with antigen processing (TAP) translocates antigenic peptides from the cytosol into the endoplasmic reticular lumen for subsequent loading onto major histocompatibility complex (MHC) class I molecules. These peptide-MHC complexes are inspected at the cell surface by cytotoxic T-lymphocytes. Assembly of the functional peptide transport and loading complex depends on intra- and intermolecular packing of transmembrane helices (TMs). Here, we have examined the membrane topology of human TAP1 within an assembled and functional transport complex by cysteine-scanning mutagenesis. The accessibility of single cysteine residues facing the cytosol or endoplasmic reticular lumen was probed by aminimally invasive approach using membrane-impermeable, thiol-specific fluorophores in semipermeabilized "living" cells. TAP1 contains ten transmembrane segments, which place the N and C termini in the cytosol. The transmembrane domain consists of a translocation core of six TMs, a building block conserved among most ATP-binding cassette transporters, and a unique additional N-terminal domain of four TMs, essential for tapasin binding and assembly of the peptide-loading complex. This study provides a first map of the structural organization of the TAP machinery within the macromolecular MHCI peptide-loading complex.	Univ Frankfurt, Bioctr, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Univ Frankfurt, Bioctr, Inst Biochem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Beismann-Driemeyer S, 2004, ANGEW CHEM INT EDIT, V43, P4014, DOI 10.1002/anie.200300642; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen M, 2004, J BIOL CHEM, V279, P46073, DOI 10.1074/jbc.M404042200; Gileadi U, 1997, J BIOL CHEM, V272, P11103; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Heintke S, 2003, FEBS LETT, V533, P42, DOI 10.1016/S0014-5793(02)03746-8; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Koch J, 2005, FEBS LETT, V579, P4413, DOI 10.1016/j.febslet.2005.07.006; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lankat-Buttgereit B, 1999, FEBS LETT, V464, P108, DOI 10.1016/S0014-5793(99)01676-2; Lehner PJ, 2004, CURR OPIN IMMUNOL, V16, P82, DOI 10.1016/j.coi.2003.11.012; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; STOFFEL W, 1993, FEBS LETT, V333, P119, DOI 10.1016/0014-5793(93)80387-A; TAMPE R, 1997, UNUSUAL SECRETORY PA, P115; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	33	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6455	6462		10.1074/jbc.M509784200	http://dx.doi.org/10.1074/jbc.M509784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407277	hybrid			2022-12-25	WOS:000236030800040
J	Muroi, M; Tanamoto, K				Muroi, M; Tanamoto, K			Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; BACTERIAL LIPOPOLYSACCHARIDE; MOLECULAR-MECHANISMS; CELL-SURFACE; ACTIVATION; RESPONSIVENESS; RECOGNITION; ENDOTOXIN; COMPLEX	A cell surface receptor complex consisting of CD14, Toll-like receptor (TLR4), and MD-2 recognizes lipid A, the active moiety of lipopolysaccharide (LPS). Escherichia coli-type lipid A, a typical lipid A molecule, potently activates both human and mouse macrophage cells, whereas the lipid A precursor, lipid IVa, activates mouse macrophages but is inactive and acts as an LPS antagonist in human macrophages. This animal species-specific activity of lipid IVa involves the species differences in MD-2 structure. We explored the structural region of MD-2 that determines the agonistic and antagonistic activities of lipid IVa to induce nuclear factor-kappa B activation. By expressing human/mouse chimeric MD-2 together with mouse CD14 and TLR4 in human embryonic kidney 293 cells, we found that amino acid regions 57 - 79 and 108 - 135 of MD- 2 determine the species-specific activity of lipid IVa. We also showed that the replacement of Thr(57), Val(61), and Glu(122) of mouse MD-2 with corresponding human MD- 2 sequence or alanines impaired the agonistic activity of lipid IVa, and antagonistic activity became evident. These mutations did not affect the activation of nuclear factor-kappa B, TLR4 oligomerization, and inducible phosphorylation of I kappa B alpha in response to E. coli-type lipid A. These results indicate that amino acid residues 57, 61, and 122 of mouse MD- 2 are critical to determine the agonist-antagonist activity of lipid IVa and suggest that these amino acid residues may be involved in the discrimination of lipid A structure.	Natl Inst Hlth Sci, Div Microbiol, Setagaya Ku, Tokyo 1588501, Japan	National Institute of Health Sciences - Japan	Tanamoto, K (corresponding author), Natl Inst Hlth Sci, Div Microbiol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	tanamoto@nihs.go.jp						Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; DASILVA CJ, 2002, J BIOL CHEM, V277, P1845, DOI [DOI 10.1074/JBC.M109910200, 10.1074/jbc.M109910200]; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; LUDERITZ O, 1982, CURR TOP MEMBR TRANS, V17, P79; MANEEK M, 2002, BIOCHEM BIOPH RES CO, V292, P880; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Miyake K, 2004, TRENDS MICROBIOL, V12, P186, DOI 10.1016/j.tim.2004.02.009; Muroi M, 2002, INFECT IMMUN, V70, P6043, DOI 10.1128/IAI.70.11.6043-6047.2002; Muroi M, 2002, J BIOL CHEM, V277, P42372, DOI 10.1074/jbc.M205966200; Muroi M, 2002, INFECT IMMUN, V70, P3546, DOI 10.1128/IAI.70.7.3546-3550.2002; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Tanamoto K, 2000, J IMMUNOL, V164, P3149, DOI 10.4049/jimmunol.164.6.3149; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	28	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5484	5491		10.1074/jbc.M509193200	http://dx.doi.org/10.1074/jbc.M509193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407172	hybrid			2022-12-25	WOS:000235568900021
J	Gong, J; Zhu, J; Goodman, OB; Pestell, RG; Schlegel, PN; Nanus, DM; Shen, R				Gong, J; Zhu, J; Goodman, OB; Pestell, RG; Schlegel, PN; Nanus, DM; Shen, R			Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells	ONCOGENE			English	Article						bombesin; neuropeptides; p300; androgen receptor; acetylation; androgen-independent prostate cancer	FOCAL ADHESION KINASE; CREB-BINDING PROTEIN; GROWTH-FACTOR; PHOSPHORYLATION; EXPRESSION; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION; COREGULATORS; RECRUITMENT	Androgen receptor signaling in prostate cancer cells is augmented by the androgen receptor (AR) coactivator p300, which transactivates and acetylates the AR in the presence of dihydrotestosterone (DHT). As prostate cancer (PC) cells progress to androgen independence, AR signaling remains intact, indicating that other factors stimulate AR activities in the absence of androgen. We previously reported that neuropeptide growth factors could transactivate the AR in the presence of very low concentrations of DHT. Here, we examine the involvement of p300 in neuropeptide activation of AR signaling. Transfection of increasing concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase in AR transactivation, suggesting that p300 acts as a coactivator in neuropeptide-mediated AR transactivation. P300 is endowed with histone acetyltransferase ( HAT) activity. Therefore, we examine the effect of bombesin on p300 HAT activity. At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (P < 0.01). Incubation with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity. To explore the potential signaling pathways involved in bombesin-induced p300 HAT activity, we examined Src and PKC delta pathways that mediate bombesin signaling. Inhibitors of Src kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCd inhibitors or PKCd siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src kinase and PKCd kinase are involved in the regulation of p300 HAT activity. As AR is acetylated in the presence of 100 nM DHT, we next examined whether bombesin-induced p300 HAT activity would result in enhanced AR acetylation. Bombesin-induced AR acetylation at the same motif KLKK observed in DHT-induced acetylation. Elimination of p300 using p300 siRNA reduced AR acetylation, demonstrating that AR acetylation was mediated by p300. AR acetylation results in AR transactivation and the expression of the AR-regulated gene prostate-specific antigen (PSA). Therefore, we examined bombesin-induced AR transactivation and PSA expression in the presence and absence of p300 siRNA and found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression. Together these results demonstrate that bombesin, via Src and PKCd signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes.	Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; Georgetown University	Shen, R (corresponding author), Cornell Univ, Weill Med Coll, Dept Urol, Rm E-300,Box 23,1300 York Ave, New York, NY 10021 USA.	rshen@med.cornell.edu		Goodman, Oscar/0000-0002-0882-3621	NCI NIH HHS [R01 CA80240, R01CA93596-01, P30CA51008-14, R01CA107382, R01CA86072] Funding Source: Medline; NIDDK NIH HHS [R01 DK060908-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA080240, R01CA107382, R01CA093596, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1998, PROSTATE, P52; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; BOLOGNA M, 1989, CANCER, V63, P1714; Borre M, 2000, CLIN CANCER RES, V6, P1882; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chan HM, 2001, J CELL SCI, V114, P2363; Chim CS, 2004, CANCER GENET CYTOGEN, V150, P164, DOI 10.1016/j.cancergencyto.2003.09.006; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; CULIG Z, 1994, CANCER RES, V54, P5474; Dai J, 2002, CLIN CANCER RES, V8, P2399; Darne C, 1998, EUR J BIOCHEM, V256, P541, DOI 10.1046/j.1432-1327.1998.2560541.x; Debes JD, 2005, CANCER RES, V65, P5965, DOI 10.1158/0008-5472.CAN-04-2837; Debes JD, 2002, CANCER RES, V62, P5632; Debes JD, 2003, CANCER RES, V63, P7638; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Fu MF, 2004, J BIOL CHEM, V279, P29436, DOI 10.1074/jbc.M313466200; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kasper S, 1999, J MOL ENDOCRINOL, V22, P313, DOI 10.1677/jme.0.0220313; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Levine L, 2003, CANCER RES, V63, P3495; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9; Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2000, CANCER RES, V60, P6590; Sumitomo M, 2001, CANCER RES, V61, P3294; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang C, 2004, METH MOL B, V241, P207; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	49	58	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2011	2021		10.1038/sj.onc.1209231	http://dx.doi.org/10.1038/sj.onc.1209231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434977				2022-12-25	WOS:000236359700004
J	Chang, YF; Carman, GM				Chang, YF; Carman, GM			Casein kinase II phosphorylation of the yeast phospholipid synthesis transcription factor Opi1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN OPI1P; SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; MYO-INOSITOL-1-PHOSPHATE SYNTHASE; COORDINATE REGULATION; FUNCTIONAL-ANALYSIS; NEGATIVE REGULATOR; GENETIC-REGULATION; STRUCTURAL GENE; SHUTTLE VECTORS	The transcription factor Opi1p regulates phospholipid synthesis in the yeast Saccharomyces cerevisiae by repressing the expression of several UAS(INO)-containing genes (e.g. INO1). Opi1p repressor activity is most active in inositol-supplemented cells. Regulation of Opi1p repressor activity is mediated by multiple phosphorylations catalyzed by protein kinases A and C. In this work, we showed that Opi1p was also phosphorylated by casein kinase II. Using purified maltose-binding protein-Opi1p as a substrate, casein kinase II activity was dose-and time-dependent and dependent on the concentrations of maltose-binding protein-Opi1p (K-m = 25 mu g/ml) and ATP (K-m = 7 mu M). Of three mutations (S10A, S38A, and S239A) in putative phosphorylation sites, only the S10A mutation affected Opi1p phosphorylation. That Ser(10) was a specific target of casein kinase II was confirmed by the loss of a phosphopeptide in the S10A mutant protein. The S10A mutation did not affect phosphorylation of Opi1p by either protein kinase A or protein kinase C. Likewise, phosphorylation of Opi1p by casein kinase II was not affected by mutations in protein kinase A (S31A and S251A) and protein kinase C (S26A) phosphorylation sites. Expression of the OPI1(S10A) allele in an opi1 Delta mutant attenuated (2-fold) the repressive effect of Opi1p on INO1 expression, and this effect was only observed when cells were grown in the absence of inositol. These data supported the conclusion that casein kinase II phosphorylation at Ser10 played a role in stimulating the repression of INO1 when Opi1p was not in its most active state (i.e. in inositol-dprived cells).	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [R01 GM050679, GM50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 2005, BIOCHEM SOC T, V33, P1150, DOI 10.1042/BST0331150; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CHESTER N, 1995, J BIOL CHEM, V270, P7501, DOI 10.1074/jbc.270.13.7501; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARLOW F, 1988, ANTIBODIES LAB MANUA; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jesch SA, 2005, J BIOL CHEM, V280, P9106, DOI 10.1074/jbc.M411770200; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESTER RL, 1993, ADV LIPID RES, V26, P253; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MORASH SC, 1994, J BIOL CHEM, V269, P28769; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; REED JC, 1994, J BIOL CHEM, V269, P18192; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SIKORSKI RS, 1989, GENETICS, V122, P19; Sreenivas A, 2003, J BIOL CHEM, V278, P20673, DOI 10.1074/jbc.M300132200; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; WHITE MJ, 1991, ADV MICROB PHYSIOL, V32, P1, DOI 10.1016/S0065-2911(08)60004-1; WHITE MJ, 1991, J BIOL CHEM, V266, P863; WU WI, 1993, J BIOL CHEM, V268, P13830; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777	74	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4754	4761		10.1074/jbc.M513064200	http://dx.doi.org/10.1074/jbc.M513064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16407309	Green Accepted, hybrid			2022-12-25	WOS:000235426200025
J	Ostheimer, GJ; Rojas, M; Hadjivassiliou, H; Barkan, A				Ostheimer, GJ; Rojas, M; Hadjivassiliou, H; Barkan, A			Formation of the CRS2-CAF2 group II intron splicing complex is mediated by a 22-amino acid motif in the COOH-terminal region of CAF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; YHBY	CRS2-associated factors 1 and 2 (CAF1 and CAF2) are closely related proteins that function in concert with chloroplast RNA splicing 2 (CRS2) to promote the splicing of specific sets of group II introns in maize chloroplasts. The CRS2-CAF complexes bind tightly to their cognate group II introns in vivo, with the CAF subunit determining the intron specificity of the complex. In this work we show that the CRS2-CAF complexes are stable in the absence of their intron targets and that CRS2 binds a 22 amino acid motif in the COOH-terminal region of CAF2 that is conserved in CAF1. Yeast two-hybrid assays and co-fractionation studies using recombinant proteins show that this motif is both necessary and sufficient to bind CRS2. The 22-amino acid motif is predicted to form an amphipathic helix whose hydrophobic surface is conserved between CAF1 and CAF2. We propose that this surface binds the hydrophobic patch on the surface of CRS2 previously shown to be necessary for the interaction between CRS2 and CAF2.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Dept Biol, Eugene, OR 97403 USA	University of Oregon; University of Oregon; University of Oregon	Barkan, A (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	abarkan@molbio.uoregon.edu						Barkan A., 2004, MOL BIOL BIOTECHNOLO, P281, DOI DOI 10.1007/978-1-4020-3166-3_; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; Dai LX, 2003, RNA, V9, P14, DOI 10.1261/rna.2126203; Dai LX, 2002, NUCLEIC ACIDS RES, V30, P1091, DOI 10.1093/nar/30.5.1091; Jenkins BD, 2001, EMBO J, V20, P872, DOI 10.1093/emboj/20.4.872; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Lambowitz AM, 2004, ANNU REV GENET, V38, P1, DOI 10.1146/annurev.genet.38.072902.091600; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; Liu DJ, 2004, J BIOMOL NMR, V29, P391, DOI 10.1023/B:JNMR.0000032524.62229.93; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Ostersetzer O, 2005, PLANT CELL, V17, P241, DOI 10.1105/tpc.104.027516; Ostheimer GJ, 2005, J MOL BIOL, V345, P51, DOI 10.1016/j.jmb.2004.10.032; Ostheimer GJ, 2003, EMBO J, V22, P3919, DOI 10.1093/emboj/cdg372; Ostheimer GJ, 2002, STRUCTURE, V10, P1593, DOI 10.1016/S0969-2126(02)00886-9; Qin PZ, 1998, CURR OPIN STRUC BIOL, V8, P301, DOI 10.1016/S0959-440X(98)80062-6; Till B, 2001, RNA, V7, P1227, DOI 10.1017/S1355838201010445; Toro N, 2003, ENVIRON MICROBIOL, V5, P143, DOI 10.1046/j.1462-2920.2003.00398.x; Vogel J, 1999, NUCLEIC ACIDS RES, V27, P3866, DOI 10.1093/nar/27.19.3866; Willis MA, 2002, PROTEINS, V49, P423, DOI 10.1002/prot.10225	21	29	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4732	4738		10.1074/jbc.M508921200	http://dx.doi.org/10.1074/jbc.M508921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16379013				2022-12-25	WOS:000235426200022
J	Tinhofer, I; Biedermann, R; Krismer, M; Crazzolara, R; Greil, R				Tinhofer, I; Biedermann, R; Krismer, M; Crazzolara, R; Greil, R			A role of TRAIL in killing osteoblasts by myeloma cells	FASEB JOURNAL			English	Article							MALIGNANT PLASMA-CELLS; FAS-LIGAND GENE; MULTIPLE-MYELOMA; BONE-DISEASE; INDUCED APOPTOSIS; UP-REGULATION; TNF FAMILY; KAPPA-B; RECEPTOR; EXPRESSION	In multiple myeloma (MM), neoplastic plasma cells accumulate in the bone marrow where their survival, proliferation, and apoptosis are controlled at multiple levels by interaction with the bone marrow microenvironment. Myeloma cells actively control these interactions by activating stromal and endothelial cells for production of survival factors, such as interleukin-6, and suppressing other cell types such as erythroblasts, normal B cell progenitors, and T-cells. In the present study, we identified primary osteoblasts as additional potential targets for myeloma cell-mediated suppression which was partly dependent on the death receptor ligand TRAIL. Besides killing of osteoblasts, myeloma cell lines sensitized osteoblasts to cell death mediated by recombinant TRAIL, whereas primary osteoblasts protected myeloma cells from TRAIL-mediated apoptosis that was mediated by osteoprotegerin (OPG). Besides increase of osteoclastogenesis and osteoclast activity, suppression of bone-forming cells by myeloma cells might contribute to bone loss in MM patients. In addition, clinical development of recombinant TRAIL as anti-myeloma therapy should include evaluation of potential side effects on viability of normal bone cells.	Salzburg Gen Hosp, Med Dept Hematol Oncol Hemostaseol Rheumatol & In, Lab Immunol & Mol Canc Res, Salzburg, Austria; Private Paracelsus Med Univ, Salzburg, Austria; Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Orthoped Surg, A-6020 Innsbruck, Austria; Univ Innsbruck Hosp, Dept Pediat, A-6020 Innsbruck, Austria	Paracelsus Private Medical University; University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Tinhofer, I (corresponding author), Univ Hosp, Med Dept Hematol Oncol Hemostaseol Rheumatol & In, Lab Immunol & Mol Canc Res, Salzburg, Austria.	i.tinhofer@salk.at	Greil, Richard F/C-7673-2017; Biedermann, Rainer/AAF-2636-2020	Greil, Richard F/0000-0002-4462-3694; Tinhofer, Ingeborg/0000-0002-0512-549X				Atkins GJ, 2002, BONE, V31, P448, DOI 10.1016/S8756-3282(02)00858-X; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Drexler HG, 2000, LEUKEMIA RES, V24, P681, DOI 10.1016/S0145-2126(99)00195-2; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Formigli L, 2000, J CELL PHYSIOL, V182, P41, DOI 10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hjorth-Hansen H, 1999, J BONE MINER RES, V14, P256, DOI 10.1359/jbmr.1999.14.2.256; Kagawa S, 2001, CANCER RES, V61, P3330; Katavic V, 2003, J IMMUNOL, V170, P1540, DOI 10.4049/jimmunol.170.3.1540; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; Meyer MA, 2004, NEW ENGL J MED, V350, P1464; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Roodman GD, 1997, CANCER, V80, P1557, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1557::AID-CNCR5>3.3.CO;2-K; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shipman CM, 2003, CANCER RES, V63, P912; Silvestris F, 2004, BRIT J HAEMATOL, V126, P475, DOI 10.1111/j.1365-2141.2004.05084.x; Silvestris F, 2003, BRIT J HAEMATOL, V122, P39, DOI 10.1046/j.1365-2141.2003.04374.x; Silvestris F, 2002, BLOOD, V99, P1305, DOI 10.1182/blood.V99.4.1305; Silvestris F, 2001, BLOOD, V97, P1155, DOI 10.1182/blood.V97.5.1155; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; SOBEL ES, 1993, INT IMMUNOL, V5, P1275, DOI 10.1093/intimm/5.10.1275; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Ursini-Siegel J, 2002, J IMMUNOL, V169, P5505, DOI 10.4049/jimmunol.169.10.5505; Villunger A, 1997, BLOOD, V90, P12; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	36	37	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					759	+		10.1096/fj.05-4329fje	http://dx.doi.org/10.1096/fj.05-4329fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16436464				2022-12-25	WOS:000235996000004
J	De Toni, F; Racaud-Sultan, C; Chicanne, G; Mansat-De Mas, V; Cariven, C; Mesange, F; Salles, JP; Demur, C; Allouche, M; Payrastre, B; Manenti, S; Ysebaert, L				De Toni, F.; Racaud-Sultan, C.; Chicanne, G.; Mansat-De Mas, V.; Cariven, C.; Mesange, F.; Salles, J-P; Demur, C.; Allouche, M.; Payrastre, B.; Manenti, S.; Ysebaert, L.			A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia	ONCOGENE			English	Article						leukemia; chemoresistance; adhesion; Wnt; GSK3 beta	GLYCOGEN-SYNTHASE KINASE-3-BETA; NF-KAPPA-B; FRIZZLED-RELATED PROTEIN-1; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-NECROSIS-FACTOR; BETA-CATENIN; STEM-CELLS; DRUG-RESISTANCE; CANCER CELLS; ACTIVATION	Relapses following chemotherapy are a major hindrance to patients' survival in acute myeloid leukemia (AML). To investigate the role of the hematopoietic niche in the chemoresistance of leukemic cells, we examined two pathways: one mediated by adhesion molecules/integrins, and the other by soluble factors of the morphogen Wnt pathway. In our study, both the adhesion of leukemic blasts to fibronectin and the addition of Wnt antagonists induced, independently, resistance of AML cells to daunorubicin in a cell survival assay. Using pharmacological inhibitors and siRNA, we showed that both resistance pathways required the activity of the glycogen synthase kinase 3 beta (GSK3 beta). Moreover, the AML cell protection downstream of GSK3 beta was mediated by NF-kappa B. A link between the adhesion and the Wnt pathway was found, as adhesion of U937 on human osteoblasts, a component of the hematopoietic niche, triggered the secretion of the Wnt antagonist sFRP-1 and supported resistance to daunorubicin. The osteoblast-conditioned medium could also confer chemoresistance to U937 cells cultured in suspension, and this cell protective effect was abrogated after depletion of sFRP-1. In the context of this potential double in vivo resistance, modulators of the common signal GSK3 beta and of its target NF-kappa B could represent important novel therapeutic tools.	CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, F-31024 Toulouse 3, France; CHU Purpan, INSERM, Hematol Lab, Unite 563, F-31024 Toulouse 3, France; CHU Purpan, INSERM, IFR 30, Unite 563,Dept Lipoprot & Mediateurs Lipid, F-31024 Toulouse 3, France; CHU Purpan, INSERM, Serv Hematol Clin, Unite 563, F-31024 Toulouse 3, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Racaud-Sultan, C (corresponding author), CHU Purpan, INSERM, U563,CPTP, Dept Oncogenesis & Hematopoiet Cells,Hosp Purpan, Pl Baylac, F-31024 Toulouse 3, France.	claire.racaud@toulouse.inserm.fr	manenti, stephane/P-1518-2014; Ysebaert, Loic/H-1554-2016; SALLES, Jean Pierre/K-2998-2014; De Mas, Véronique/P-2414-2014	manenti, stephane/0000-0002-4793-3196; Ysebaert, Loic/0000-0001-8478-5623; Chicanne, Gaetan/0000-0002-7081-2595; Racaud-Sultan, Claire/0000-0002-6549-1088; , Bernard/0000-0002-8693-0190				Bendall LJ, 1998, LEUKEMIA, V12, P1375, DOI 10.1038/sj.leu.2401136; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chung EJ, 2002, BLOOD, V100, P982, DOI 10.1182/blood.V100.3.982; Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078-0432.CCR-04-2624; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Han XZ, 2004, J BIOL CHEM, V279, P2832, DOI 10.1074/jbc.M308102200; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hwang SG, 2002, LEUKEMIA RES, V26, P863, DOI 10.1016/S0145-2126(02)00018-8; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; Lee JL, 2004, J BIOL CHEM, V279, P14602, DOI 10.1074/jbc.M309008200; Liao XB, 2003, MOL CANCER THER, V2, P1215; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097-4644(19991001)75:1<22::AID-JCB3>3.0.CO;2-6; Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4	39	107	115	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3113	3122		10.1038/sj.onc.1209346	http://dx.doi.org/10.1038/sj.onc.1209346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407823				2022-12-25	WOS:000237951000003
J	Surjit, M; Liu, BP; Chow, VTK; Lal, SK				Surjit, M; Liu, BP; Chow, VTK; Lal, SK			The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS K-BZIP; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; LYTIC REPLICATION; SARS CORONAVIRUS; G(1); P53; ARREST; GROWTH; INDUCTION	Deregulation of the cell cycle is a common strategy employed by many DNA and RNA viruses to trap and exploit the host cell machinery toward their own benefit. In many coronaviruses, the nucleocapsid protein (N protein) has been shown to inhibit cell cycle progression although the mechanism behind this is poorly understood. The N protein of severe acute respiratory syndrome-coronavirus (SARS-CoV) bears signature motifs for binding to cyclin and phosphorylation by cyclin-dependent kinase (CDK) and has recently been reported by us to get phosphorylated by the cyclin-CDK complex (Surjit, M., Kumar, R., Mishra, R. N., Reddy, M. K., Chow, V. T., and Lal, S. K. (2005) J. Virol. 79, 11476-11486). In the present study, we prove that the N protein of SARS-CoV can inhibit S phase progression in mammalian cell lines. N protein expression was found to directly inhibit the activity of the cyclin-CDK complex, resulting in hypophosphorylation of retinoblastoma protein with a concomitant down-regulation in E2F1-mediated transactivation. Coexpression of E2F1 under such conditions could restore the expression of S phase genes. Analysis of RXL and CDK phosphorylation mutant N protein identified the mechanism of inhibition of CDK4 and CDK2 activity to be different. Whereas N protein could directly bind to cyclin D and inhibit the activity of CDK4-cyclin D complex; inhibition of CDK2 activity appeared to be achieved in two different ways: indirectly by down-regulation of protein levels of CDK2, cyclin E, and cyclin A and by direct binding of N protein to CDK2-cyclin complex. Down-regulation of E2F1 targets was also observed in SARS-CoV-infected VeroE6 cells. These data suggest that the S phase inhibitory activity of the N protein may have major significance during viral pathogenesis.	Int Ctr Genet Engn & Biotechnol, Virol Grp, New Delhi 110067, India; Natl Univ Singapore, Fac Med, Dept Microbiol, Human Genome Lab, Singapore 117597, Singapore	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; National University of Singapore	Lal, SK (corresponding author), Int Ctr Genet Engn & Biotechnol, Virol Grp, Aruna Asaf Ali Rd, New Delhi 110067, India.	sunillal@icgeb.res.in		Chow, Vincent/0000-0003-2634-6213				Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; Chen CJ, 2004, J VIROL, V78, P10410, DOI 10.1128/JVI.78.19.10410-10419.2004; Flemington EK, 2001, J VIROL, V75, P4475, DOI 10.1128/JVI.75.10.4475-4481.2001; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hobbs WE, 1999, J VIROL, V73, P8245, DOI 10.1128/JVI.73.10.8245-8255.1999; Ikeda K, 1998, J HISTOCHEM CYTOCHEM, V46, P397, DOI 10.1177/002215549804600314; Izumiya Y, 2003, J VIROL, V77, P9652, DOI 10.1128/JVI.77.17.9652-9661.2003; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kramer MF, 2003, J VIROL, V77, P9533, DOI 10.1128/JVI.77.17.9533-9541.2003; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Kudoh A, 2003, J VIROL, V77, P851, DOI 10.1128/JVI.77.2.851-861.2003; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Lu MS, 1999, J VIROL, V73, P676, DOI 10.1128/JVI.73.1.676-683.1999; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Munir S, 2003, J VIROL, V77, P4899, DOI 10.1128/JVI.77.8.4899-4910.2003; Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Polson AG, 2001, J VIROL, V75, P3175, DOI 10.1128/JVI.75.7.3175-3184.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 2000, CANCER RES, V60, P3489; Song BW, 2001, VIROLOGY, V290, P320, DOI 10.1006/viro.2001.1175; Surjit M, 2005, J VIROL, V79, P11476, DOI 10.1128/JVI.79.17.11476-11486.2005; Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wiebusch L, 1999, J VIROL, V73, P9274, DOI 10.1128/JVI.73.11.9274-9283.1999; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	35	140	146	6	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10669	10681		10.1074/jbc.M509233200	http://dx.doi.org/10.1074/jbc.M509233200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16431923	hybrid, Green Published			2022-12-25	WOS:000236822200005
J	Wang, S; Raven, JF; Baltzis, D; Kazemi, S; Brunet, DV; Hatzoglou, M; Tremblay, ML; Koromilas, AE				Wang, S; Raven, JF; Baltzis, D; Kazemi, S; Brunet, DV; Hatzoglou, M; Tremblay, ML; Koromilas, AE			The catalytic activity of the eukaryotic initiation factor-2 alpha kinase PKR is required to negatively regulate Stat1 and Stat3 via activation of the T-cell protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOMATITIS-VIRUS INFECTION; TARGETED DISRUPTION; GENE-EXPRESSION; INNATE IMMUNITY; MICE; PHOSPHORYLATION; SPECIFICITY; RESISTANCE; APOPTOSIS; PATHWAY	Tyrosine phosphorylation of the transcription factors Stat1 and Stat3 is required for them to dimerize, translocate to the nucleus, and induce gene transcription. Nuclear Stat1 and Stat3 are dephosphorylated and deactivated by the T-cell protein-tyrosine phosphatase (TC-PTP), which facilitates the return of both proteins to the cytoplasm. The protein kinase PKR plays an important role in translational control through the modulation of eukaryotic initiation factor-2 alpha phosphorylation. Previous data have implicated PKR in cell signaling via regulation of Stat1 and Stat3, but the molecular mechanisms underlying these events have remained elusive. Using PKR-/- mouse embryonic fibroblasts and a conditionally active form of human PKR, we demonstrate herein that tyrosine ( but not serine) phosphorylation of either Stat1 or Stat3 is impaired in cells with activated kinase. This reduction in Stat1 and Stat3 tyrosine phosphorylation by active PKR proceeds through TC-PTP, which is a substrate of the eukaryotic initiation factor-2 alpha kinase both in vitro and in vivo. TC-PTP phosphorylation alone is insufficient to increase its in vivo phosphatase activity unless accompanied by the inhibition of protein synthesis as a result of PKR activation. These data reveal a novel function of PKR as a negative regulator of Stat1 and Stat3 with important implications in cell signaling.	McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Sir Mortimer B Davis Jewish Gen Hosp, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; Case Western Reserve University	Koromilas, AE (corresponding author), McGill Univ, Lady Davis Inst Med Res, Rm 508,3755 Cote St Catherine St, Montreal, PQ H3T 1E2, Canada.	antonis.koromilas@mcgill.ca						Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baltzis D, 2004, J VIROL, V78, P12747, DOI 10.1128/JVI.78.23.12747-12761.2004; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bukczynska P, 2004, BIOCHEM J, V380, P939, DOI 10.1042/BJ20031780; Deb A, 2001, EMBO J, V20, P2487, DOI 10.1093/emboj/20.10.2487; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; Kazemi S, 2004, MOL CELL BIOL, V24, P3415, DOI 10.1128/MCB.24.8.3415-3429.2004; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lam MHC, 2001, J BIOL CHEM, V276, P37700, DOI 10.1074/jbc.M105128200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; McBride Kevin M, 2003, Sci STKE, V2003, pRE13; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meyer T, 2004, EUR J BIOCHEM, V271, P4606, DOI 10.1111/j.1432-1033.2004.04423.x; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wong AHT, 2001, J BIOL CHEM, V276, P13727, DOI 10.1074/jbc.M011240200; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	44	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9439	9449		10.1074/jbc.M504977200	http://dx.doi.org/10.1074/jbc.M504977200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431927	hybrid			2022-12-25	WOS:000236404700054
J	Peloponese, JM; Jeang, KT				Peloponese, JM; Jeang, KT			Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 tax oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR AP-1; I TAX; SIGNALING PATHWAY; GROWTH-FACTOR; HUMAN CANCER; C-FOS; PHOSPHATIDYLINOSITOL 3'-KINASE; TRANSGENIC MICE; TRANSFORMATION	Human T-cell leukemia virus type 1 is an oncogenic retrovirus etiologically causal of adult T-cell leukemia. The virus encodes a Tax oncoprotein, which functions in transcriptional regulation, cell cycle control, and transformation. Because adult T-cell leukemia is a highly virulent cancer that is resistant to numerous chemotherapeutic treatments, to understand better this disease it is important to comprehend how human T-cell leukemia virus type 1 promotes cellular growth and survival. Most of the existing data point to Tax activation of NF-kappa B as important for cellular proliferation and transformation. We show here that Tax, in the absence of NF-kappa B signaling, can activate activator protein-1 to promote cellular proliferation and survival. Tax is shown to activate activator protein-1 through the phosphatidylinositol 3-kinase/Akt pathway.	NIAID, Mol Virol Sect, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kjeang@niaid.nih.gov	Jeang, Kuan-Teh/A-2424-2008	Peloponese, Jean-Marie/0000-0002-9677-9703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Asquith B, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-75; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Breslin EM, 2005, BRIT J PHARMACOL, V144, P791, DOI 10.1038/sj.bjp.0706061; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dong ZG, 1999, ANTICANCER RES, V19, P3743; Fraedrich K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-54; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Fujii MI, 2000, AIDS RES HUM RETROV, V16, P1603, DOI 10.1089/08892220050193029; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kane LP, 2003, IMMUNOL REV, V192, P7, DOI 10.1034/j.1600-065X.2003.00008.x; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kannagi Mari, 2004, Expert Rev Anticancer Ther, V4, P369, DOI 10.1586/14737140.4.3.369; Katabami M, 2005, J BIOL CHEM, V280, P16728, DOI 10.1074/jbc.M413892200; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kim R, 2003, ANTI-CANCER DRUG, V14, P3, DOI 10.1097/00001813-200301000-00002; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Lazo A, 1996, J MED PRIMATOL, V25, P257, DOI 10.1111/j.1600-0684.1996.tb00208.x; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; Majone F, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-45; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; Martelli AM, 2005, HISTOL HISTOPATHOL, V20, P239, DOI 10.14670/HH-20.239; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Matsuoka M, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-27; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Mori N, 2000, BLOOD, V95, P3915; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Ozes ON, 1999, NATURE, V401, P82; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Pim D, 2005, ONCOGENE, V24, P7830, DOI 10.1038/sj.onc.1208935; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Xu X, 1996, J INVEST MED, V44, P113; Xu X, 1996, ONCOGENE, V13, P135; Yakova Maria, 2005, Retrovirology, V2, P4, DOI 10.1186/1742-4690-2-4; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	80	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8927	8938		10.1074/jbc.M510598200	http://dx.doi.org/10.1074/jbc.M510598200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16436385	Green Published, hybrid			2022-12-25	WOS:000236247100073
J	Chen, HY; Challa, AK; Varki, A				Chen, HY; Challa, AK; Varki, A			9-O-acetylation of exogenously added ganglioside GD3 - The GD3 molecule induces its own O-acetylation machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; DE-ORTHO-ACETYLATION; HAMSTER OVARY CELLS; PLASMA-MEMBRANE; RAT-LIVER; MONOCLONAL-ANTIBODY; SKIN FIBROBLASTS; GOLGI-APPARATUS; CULTURED-CELLS; SIALIC ACIDS	Sialic acids are sometimes 9-O-acetylated in a developmentally regulated and cell-type-specific manner. Cells naturally expressing the disialoganglioside GD3 often O-acetylate the terminal sialic acid residue, giving 9-O-acetyl-GD3 (9AcGD3), a marker of neural differentiation and malignant transformation. We also reported that Chinese hamster ovary cells transfected with GD3 synthase can spontaneously O-acetylate some of the newly synthesized GD3. It is unclear whether such phenomena result from induction of the 9-O-acetylation machinery and whether induction is caused by the GD3 synthase protein or by the GD3 molecule itself. We now show that exogenously added GD3 rapidly incorporates into the plasma membrane of Chinese hamster ovary cells, and 9AcGD3 is detected after similar to 6 h. The incorporated GD3 and newly synthesized 9AcGD3 have a half-life of similar to 24 h. This phenomenon is also seen in other cell types, such as human diploid fibroblasts. Inhibitors of gene transcription, protein translation, or endoplasmic reticulum-to-Golgi transport each prevent induction of 9-O-acetylation, without affecting GD3 incorporation. Inhibition of the initial clathrin-independent internalization of incorporated GD3 also blocks induction of 9-O-acetylation. Thus, new synthesis of one or more components of the 9-O-acetylation machinery is induced by incorporation and internalization of GD3. Prepriming with structurally related gangliosides fails to accelerate the onset of 9-O-acetylation of subsequently added GD3, indicating a requirement for specific recognition of GD3. To our knowledge, this is the first example wherein a newly expressed or exogenously introduced ganglioside induces de novo synthesis of an enzymatic machinery to modify itself, and the first evidence for a mechanism of induction of sialic acid O-acetylation.	Univ Calif San Diego, CMM E, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, CMM E, Glycobiol Res & Training Ctr, Dept Med, Rm 1065,Mail Code 0687, La Jolla, CA 92093 USA.	a1varki@ucsd.edu	Challa, Anil Kumar/AAQ-3306-2021; Challa, Anil Kumar/A-5819-2009	Challa, Anil Kumar/0000-0002-3633-3304	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; BERNHARD H, 1989, INT J CANCER, V44, P155, DOI 10.1002/ijc.2910440127; CALLIES R, 1977, EUR J BIOCHEM, V80, P425, DOI 10.1111/j.1432-1033.1977.tb11897.x; Chen HY, 2002, J EXP MED, V196, P1529, DOI 10.1084/jem.20021915; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DIAZ S, 1989, J BIOL CHEM, V264, P19416; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; Fox DA, 2001, IMMUNOL INVEST, V30, P67, DOI 10.1081/IMM-100104017; GU XB, 1995, J NEUROCHEM, V64, P2295; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; HEIDENHEIM M, 1995, BRIT J DERMATOL, V133, P392, DOI 10.1111/j.1365-2133.1995.tb02666.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; Iwersen M, 1998, GLYCOCONJUGATE J, V15, P895, DOI 10.1023/A:1006911100081; Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600-0854.2002.30701.x; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Kanamori A, 1997, P NATL ACAD SCI USA, V94, P2897, DOI 10.1073/pnas.94.7.2897; Kolter T, 2002, J BIOL CHEM, V277, P25859, DOI 10.1074/jbc.R200001200; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; LEVINE JM, 1984, J NEUROSCI, V4, P820; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Mobius W, 1999, J HISTOCHEM CYTOCHEM, V47, P1005; Negreiros EMA, 2003, J NEUROBIOL, V57, P31, DOI 10.1002/neu.10248; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; PRETI A, 1980, J NEUROCHEM, V35, P281, DOI 10.1111/j.1471-4159.1980.tb06263.x; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; REIVINEN J, 1992, KIDNEY INT, V42, P624, DOI 10.1038/ki.1992.327; REIVINEN J, 1994, INT IMMUNOL, V6, P1409, DOI 10.1093/intimm/6.9.1409; Riboni L, 2000, METHOD ENZYMOL, V311, P656; SAITO M, 1992, J NEUROCHEM, V58, P83, DOI 10.1111/j.1471-4159.1992.tb09280.x; Satake H, 2003, J BIOL CHEM, V278, P7942, DOI 10.1074/jbc.M210565200; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; Schwarzmann G, 2001, SEMIN CELL DEV BIOL, V12, P163, DOI 10.1006/scdb.2000.0233; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P3041; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Shi WX, 1996, J BIOL CHEM, V271, P15130, DOI 10.1074/jbc.271.25.15130; Simon BM, 2002, CELL DEATH DIFFER, V9, P758, DOI 10.1038/sj.cdd.4401027; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SONDERFELD S, 1985, EUR J BIOCHEM, V149, P247, DOI 10.1111/j.1432-1033.1985.tb08919.x; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TETTAMANTI G, 1972, BRAIN RES, V47, P515, DOI 10.1016/0006-8993(72)90661-0; TRINCHERA M, 1990, J BIOCHEM-TOKYO, V107, P619, DOI 10.1093/oxfordjournals.jbchem.a123096; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; Vyas AA, 2001, BIOCHIMIE, V83, P677, DOI 10.1016/S0300-9084(01)01308-6; Vyas KA, 2001, BIOL CHEM, V382, P241, DOI 10.1515/BC.2001.031; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	59	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7825	7833		10.1074/jbc.M512379200	http://dx.doi.org/10.1074/jbc.M512379200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434401	hybrid			2022-12-25	WOS:000236031000016
J	Dutkiewicz, R; Marszalek, J; Schillke, B; Craig, EA; Lill, R; Muhlenhoff, U				Dutkiewicz, R; Marszalek, J; Schillke, B; Craig, EA; Lill, R; Muhlenhoff, U			The Hsp70 chaperone Ssq1p is dispensable for iron-sulfur cluster formation on the scaffold protein Isu1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL HSP70; 4FE-4S CLUSTERS; 2FE-2S CLUSTER; ISCU; YEAST; BIOSYNTHESIS; BIOGENESIS; MATURATION; SYSTEM; NIFU	The specialized yeast mitochondrial chaperone system, composed of the Hsp70 Ssq1p, its co-chaperone J-protein Jac1p, and the nucleotide release factor Mge1p, perform a critical function in the biogenesis of iron-sulfur (Fe/S) proteins. Using a spectroscopic assay, we have analyzed the potential role of the chaperones in Fe/S cluster assembly on the scaffold protein Isu1p in vitro in the presence of the cysteine desulfurase Nfs1p. In the absence of chaperones, the kinetics of Fe/S cluster formation on Isu1p were compatible with a chemical reconstitution pathway with Nfs1p functioning as a sulfide donor. Addition of Ssq1p improved the rates of Fe/S cluster assembly 3-fold. However, this stimulatory effect of Ssq1p required neither ATP nor Jac1p and could be fully attributed to the activation of the Nfs1p desulfurase activity by Ssq1p. Furthermore, chaperone-stimulated Fe/S cluster assembly did not involve the specific interaction between Isu1p and Ssq1p, since the effect was observed with Isu1p mutant proteins defective in this interaction, suggesting that nonspecific binding of Ssq1p to Nfs1p helped to prevent its unfolding. Consistent with this idea, these Isu1p mutants were capable of binding an Fe/S cluster in vivo but failed to restore the growth and Fe/S cluster assembly defects of a Isu1p/ Isu2p-deficient yeast strain. Taken together, these data suggest that Ssq1p/Jac1p/Mge1p are not important for Fe/S cluster synthesis on Isu1p. Hence, consistent with previous in vivo data, these chaperones likely function in steps subsequent to the de novo synthesis of the Fe/S cluster on Isu1p.	Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Philipps University Marburg; Fahrenheit Universities; University of Gdansk; University of Wisconsin System; University of Wisconsin Madison	Muhlenhoff, U (corresponding author), Univ Marburg, Inst Zytobiol & Zytopathol, Robert Koch Str 6, D-35033 Marburg, Germany.	muehlenh@mailer.uni-marburg.de	Dutkiewicz, Rafal/F-5956-2011; Marszalek, Jaroslaw/F-5824-2011; Dutkiewicz, Rafal/ABE-6979-2020	Dutkiewicz, Rafal/0000-0003-4150-0450; Lill, Roland/0000-0002-8345-6518; Marszalek, Jaroslaw/0000-0002-6978-1189	NIGMS NIH HHS [R01GM27870] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Bonomi F, 2005, J BIOL CHEM, V280, P29513, DOI 10.1074/jbc.M504344200; Craig EA, 2002, CELL MOL LIFE SCI, V59, P1658, DOI 10.1007/PL00012493; Cupp-Vickery JR, 2004, J MOL BIOL, V342, P1265, DOI 10.1016/j.jmb.2004.07.025; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Ding HG, 2004, BIOCHEM J, V379, P433, DOI 10.1042/BJ20031702; Dos Santos PC, 2004, J BIOL CHEM, V279, P19705, DOI 10.1074/jbc.M400278200; Dutkiewicz R, 2004, J BIOL CHEM, V279, P29167, DOI 10.1074/jbc.M402947200; Dutkiewicz R, 2003, J BIOL CHEM, V278, P29719, DOI 10.1074/jbc.M303527200; Frazzon J, 2002, BIOCHEM SOC T, V30, P680, DOI 10.1042/BST0300680; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Gerber J, 2004, MOL CELL BIOL, V24, P4848, DOI 10.1128/MCB.24.11.4848-4857.2004; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoff KG, 2003, J BIOL CHEM, V278, P37582, DOI 10.1074/jbc.M305292200; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; Johnson DC, 2005, BIOCHEM SOC T, V33, P90, DOI 10.1042/BST0330090; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Knieszner H, 2005, J BIOL CHEM, V280, P28966, DOI 10.1074/jbc.M503031200; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lill R, 2005, TRENDS BIOCHEM SCI, V30, P133, DOI 10.1016/j.tibs.2005.01.006; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Muhlenhoff U, 2004, J BIOL CHEM, V279, P36906, DOI 10.1074/jbc.M406516200; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Papenbrock J, 2000, EUR J BIOCHEM, V267, P145, DOI 10.1046/j.1432-1327.2000.00980.x; Ramelot TA, 2004, J MOL BIOL, V344, P567, DOI 10.1016/j.jmb.2004.08.038; Sambrook J, 2001, MOL CLONING LAB MANU; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Schmidt S, 2001, J MOL BIOL, V313, P13, DOI 10.1006/jmbi.2001.5013; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2004, J BIOL CHEM, V279, P53924, DOI 10.1074/jbc.M410117200; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Smith AD, 2005, BIOCHEMISTRY-US, V44, P12955, DOI 10.1021/bi051257i; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Sutton VR, 2004, J BACTERIOL, V186, P8018, DOI 10.1128/JB.186.23.8018-8025.2004; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu SP, 2005, BIOCHEMISTRY-US, V44, P4284, DOI 10.1021/bi0483007; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	56	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7801	7808		10.1074/jbc.M513301200	http://dx.doi.org/10.1074/jbc.M513301200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431909	hybrid			2022-12-25	WOS:000236031000013
J	Hsieh, TS; Plank, JL				Hsieh, TS; Plank, JL			Reverse gyrase functions as a DNA renaturase - Annealing of complementary single-stranded circles and positive supercoiling of a bubble substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I; DROSOPHILA-MELANOGASTER; MECHANISM; HYPERTHERMOPHILE; ENERGETICS; SITE	Reverse gyrase is a hyperthermophile-specific enzyme that can positively supercoil DNA concomitant with ATP hydrolysis. However, the DNA supercoiling activity is inefficient and requires an excess amount of enzyme relative to DNA. We report here several activities that reverse gyrase can efficiently mediate with a substoichiometric amount of enzyme. In the presence of a nucleotide cofactor, reverse gyrase can readily relax negative supercoils, but not the positive ones, from a plasmid DNA substrate. Reverse gyrase can completely relax positively supercoiled DNA, provided that the DNA substrate contains a single-stranded bubble. Reverse gyrase efficiently anneals complementary single-stranded circles. A substoichiometric amount of reverse gyrase can insert positive supercoils into DNA with a single-stranded bubble, in contrast to plasmid DNA substrate. We have designed a novel method based on phage-mid DNA vectors to prepare a circular DNA substrate containing a single-stranded bubble with defined length and sequence. With these bubble DNA substrates, we demonstrated that efficient positive supercoiling by reverse gyrase requires a bubble size larger than 20 nucleotides. The activities of annealing single-stranded DNA circles and positive supercoiling of bubble substrate demonstrate that reverse gyrase can function as a DNA renaturase. These biochemical activities also suggest that reverse gyrase can have an important biological function in sensing and eliminating unpaired regions in the genome of a hyperthermophilic organism.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hsieh@biochem.duke.edu	Plank, Jody/B-4827-2009; Wu, Wan-lin/G-8937-2012; Hsieh, Tao-shih/G-9305-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; Atomi H, 2004, J BACTERIOL, V186, P4829, DOI 10.1128/JB.186.14.4829-4833.2004; BAUER WR, 1995, J MOL BIOL, V253, P438, DOI 10.1006/jmbi.1995.0565; BENHAM CJ, 1992, J MOL BIOL, V225, P835, DOI 10.1016/0022-2836(92)90404-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P5328, DOI 10.1073/pnas.74.12.5328; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; DUGUET M, 1993, NUCLEIC ACIDS RES, V21, P463, DOI 10.1093/nar/21.3.463; Forterre P, 2002, TRENDS GENET, V18, P236, DOI 10.1016/S0168-9525(02)02650-1; Hsieh TS, 2005, J BIOL CHEM, V280, P20467, DOI 10.1074/jbc.M502739200; HSIEH TS, 1975, BIOCHEMISTRY-US, V14, P527, DOI 10.1021/bi00674a011; HSIEH TS, 1992, NUCLEIC ACIDS RES, V20, P6177, DOI 10.1093/nar/20.23.6177; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIRKEGAARD K, 1978, NUCLEIC ACIDS RES, V5, P3811, DOI 10.1093/nar/5.10.3811; Krah R, 1996, P NATL ACAD SCI USA, V93, P106, DOI 10.1073/pnas.93.1.106; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Plank JL, 2005, J BIOL CHEM, V280, P3564, DOI 10.1074/jbc.M411337200; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831	24	40	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5640	5647		10.1074/jbc.M513252200	http://dx.doi.org/10.1074/jbc.M513252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407212	hybrid			2022-12-25	WOS:000235568900040
J	Pentia, DC; Hosier, S; Cote, RH				Pentia, DC; Hosier, S; Cote, RH			The glutamic acid-rich protein-2 (GARP2) is a high affinity rod photoreceptor phosphodiesterase (PDE6)-binding protein that modulates its catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CGMP-GATED CHANNEL; OUTER SEGMENTS; BINDING-SITES; DARK NOISE; VISUAL TRANSDUCTION; RETINAL CONES; BETA-SUBUNIT; ADAPTATION; PHOTOTRANSDUCTION	The glutamic acid-rich protein-2 (GARP2) is a splice variant of the beta-subunit of the cGMP-gated ion channel of rod photoreceptors. GARP2 is believed to interact with several membrane-associated phototransduction proteins in rod photoreceptors. In this study, we demonstrated that GARP2 is a high affinity PDE6-binding protein and that PDE6 co-purifies with GARP2 during several stages of chromatographic purification. We found that hydrophobic interaction chromatography succeeds in quantitatively separating GARP2 from the PDE6 holoenzyme. Furthermore, the 17-kDa prenyl-binding protein, abundant in retinal cells, selectively released PDE6 ( but not GARP2) from rod outer segment membranes, demonstrating the specificity of the interaction between GARP2 and PDE6. Purified GARP2 was able to suppress 80% of the basal activity of the nonactivated, membrane-bound PDE6 holoenzyme at concentrations equivalent to its endogenous concentration in rod outer segment membranes. However, GARP2 was unable to reverse the transducin activation of PDE6 ( in contrast to a previous study) nor did it significantly alter catalysis of the fully activated PDE6 catalytic dimer. The high binding affinity of GARP2 for PDE6 and its ability to regulate PDE6 activity in its dark-adapted state suggest a novel role for GARP2 as a regulator of spontaneous activation of rod PDE6, thereby serving to lower rod photoreceptor "dark noise" and allowing these sensory cells to operate at the single photon detection limit.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.	rick.cote@unh.edu	Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	NEI NIH HHS [R01 EY005798, R01 EY005798-18A1, EY 05798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; BAEHR W, 1979, J BIOL CHEM, V254, P1669; Batra-Safferling R, 2006, J BIOL CHEM, V281, P1449, DOI 10.1074/jbc.M505012200; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Calvert PD, 2002, J GEN PHYSIOL, V119, P129, DOI 10.1085/jgp.119.2.129; Colville CA, 1996, J BIOL CHEM, V271, P32968, DOI 10.1074/jbc.271.51.32968; Cook TA, 2000, BIOCHEMISTRY-US, V39, P13516, DOI 10.1021/bi001070l; COTE RH, 1993, J BIOL CHEM, V268, P17190; Cote RH, 2000, METHOD ENZYMOL, V315, P646; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; ERICKSON MA, 1992, SCIENCE, V257, P1255, DOI 10.1126/science.1519062; FLORIO SK, 1996, J BIOL CHEM, V271, P1; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Gallagher S., 1998, CURRENT PROTOCOLS PR; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; Holcman D, 2005, J GEN PHYSIOL, V125, P641, DOI 10.1085/jgp.200509277; Huang DM, 2004, J BIOL CHEM, V279, P48143, DOI 10.1074/jbc.M404338200; HURWITZ RL, 1984, J BIOL CHEM, V259, P8612; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Krispel CM, 2003, J NEUROSCI, V23, P6965, DOI 10.1523/JNEUROSCI.23-18-06965.2003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Norton AW, 2005, J BIOL CHEM, V280, P1248, DOI 10.1074/jbc.M410475200; Pentia Dana C., 2005, V307, P125; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; Rieke F, 1996, BIOPHYS J, V71, P2553, DOI 10.1016/S0006-3495(96)79448-1; Rieke F, 2000, NEURON, V26, P181, DOI 10.1016/S0896-6273(00)81148-4; Rodieck R.W., 1998, 1 STEPS SEEING; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; Zhang XJ, 2005, FRONT BIOSCI-LANDMRK, V10, P1191, DOI 10.2741/1612	40	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5500	5505		10.1074/jbc.M507488200	http://dx.doi.org/10.1074/jbc.M507488200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407240	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000235568900023
J	Reboul, E; Klein, A; Bietrix, F; Gleize, B; Malezet-Desmoulins, C; Schneider, M; Margotat, A; Lagrost, L; Collet, X; Borel, P				Reboul, E; Klein, A; Bietrix, F; Gleize, B; Malezet-Desmoulins, C; Schneider, M; Margotat, A; Lagrost, L; Collet, X; Borel, P			Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TOCOPHEROL; GAMMA-TOCOPHEROL; LIPOPROTEIN METABOLISM; CHOLESTEROL ABSORPTION; INTESTINAL-ABSORPTION; CACO-2 CELLS; HUMANS; HDL; DIETARY; EXPRESSION	Although cellular uptake of vitamin E was initially described as a passive process, recent studies in the liver and brain have shown that SR-BI (scavenger receptor class B type I) is involved in this phenomenon. As SR-BI is expressed at high levels in the intestine, the present study addressed the involvement of SR-BI in vitamin E trafficking across enterocytes. Apical uptake and efflux of the main dietary forms of vitamin E were examined using Caco-2 TC-7 cell monolayers as a model of human intestinal epithelium. (R,R,R)-gamma-tocopherol bioavailability was compared between wild-type mice and mice overexpressing SR-BI in the intestine. The effect of vitamin E on enterocyte SR-BI mRNA levels was measured by real-time quantitative reverse transcription-PCR. Concentration-dependent curves for vitamin E uptake were similar for (R,R,R)-alpha-, (R,R,R)-gamma-, and DL-alpha-tocopherol. (R,R,R)-alpha-tocopherol transport was dependent on incubation temperature, with a 60% reduction in absorption at 4 C compared with 37 degrees C (p < 0.05). Vitamin E flux in enterocytes was directed from the apical to the basal side, with a relative 10-fold reduction in the transfer process when measured in the opposite direction (p < 0.05). Co-incubation with cholesterol, gamma-tocopherol, or lutein significantly impaired alpha-tocopherol absorption. Anti-human SR-BI antibodies and BLT1 (a chemical inhibitor of lipid transport via SR-BI) blocked up to 80% of vitamin E uptake and up to 30% of apical vitamin E efflux (p < 0.05), and similar results were obtained for (R,R,R)-alpha-tocopherol. SR-BI mRNA levels were not significantly modified after a 24-h incubation of Caco-2 cells with vitamin E. Finally, (R,R,R)-gamma-tocopherol bioavailability was 2.7-fold higher in mice overexpressing SR-BI than in wild-type mice (p < 0.05). The present data show for the first time that vitamin E intestinal absorption is, at least in part, mediated by SR-BI.	Univ Aix Marseille, INRA 1260, INSERM, UMR 476,Fac Med Marseille, F-13385 Marseille 5, France; Inst Physiopathol Humaine Marseille, F-13385 Marseille, France; INSERM, U498, F-21079 Dijon, France; Hop Purpan, INSERM, U563, F-31024 Toulouse, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Borel, P (corresponding author), Univ Aix Marseille, INRA 1260, INSERM, UMR 476,Fac Med Marseille, 27 Bd Jean Moulin, F-13385 Marseille 5, France.	Patrick.Borel@medecine.univ-mrs.fr	Collet, Xavier/M-6938-2017; Borel, Patrick/A-4057-2015; Reboul, Emmanuelle/K-6637-2017	Borel, Patrick/0000-0001-9977-3238; Reboul, Emmanuelle/0000-0002-4576-1992				ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; ARTURSSON P, 1995, EPITHELIA CELL CULTU, P111; Balazs Z, 2004, J NEUROCHEM, V89, P939, DOI 10.1111/j.1471-4159.2004.02373.x; BERNIER JJ, 1988, ALIMENTS TUBE DIGEST; BIETRIX F, 2006, J BIOL CHEM; Borel P, 2001, AM J PHYSIOL-GASTR L, V280, pG95, DOI 10.1152/ajpgi.2001.280.1.G95; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Burnichon V, 2003, TOXICOL LETT, V143, P155, DOI 10.1016/S0378-4274(03)00171-1; Cai L, 2004, J LIPID RES, V45, P253, DOI 10.1194/jlr.M300303-JLR200; CHANTRET I, 1994, J CELL SCI, V107, P213; CHEESEMAN KH, 1995, FREE RADICAL BIO MED, V19, P591, DOI 10.1016/0891-5849(95)00083-A; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Hageman SH, 1999, LIPIDS, V34, P627, DOI 10.1007/s11745-999-0407-3; Huang HY, 2003, J NUTR, V133, P3137, DOI 10.1093/jn/133.10.3137; Jourdheuil-Rahmani D, 2002, BIOCHEM BIOPH RES CO, V292, P390, DOI 10.1006/bbrc.2002.6664; Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899; KIYOSE C, 1995, LIPIDS, V30, P1015, DOI 10.1007/BF02536286; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Kramer W, 2005, J BIOL CHEM, V280, P1306, DOI 10.1074/jbc.M406309200; Levy E, 2004, J CELL SCI, V117, P327, DOI 10.1242/jcs.00856; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554; Salvini S, 2002, BRIT J NUTR, V87, P211, DOI 10.1079/BJN2001507; STAGGERS JE, 1990, BIOCHEMISTRY-US, V29, P2028, DOI 10.1021/bi00460a011; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; Traber MG, 2004, AM J CLIN NUTR, V80, P3; TRABER MG, 1992, J LIPID RES, V33, P1171; van Bennekum A, 2005, BIOCHEMISTRY-US, V44, P4517, DOI 10.1021/bi0484320; Violi F, 2004, ANN NY ACAD SCI, V1031, P292, DOI 10.1196/annals.1331.029; Wagner KH, 2004, ANN NUTR METAB, V48, P169, DOI 10.1159/000079555	34	189	195	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4739	4745		10.1074/jbc.M509042200	http://dx.doi.org/10.1074/jbc.M509042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380385	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000235426200023
J	Dorschner, RA; Lopez-Garcia, B; Peschel, A; Kraus, D; Morikawa, K; Nizet, V; Gallo, RL				Dorschner, RA; Lopez-Garcia, B; Peschel, A; Kraus, D; Morikawa, K; Nizet, V; Gallo, RL			The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides	FASEB JOURNAL			English	Article						leukocyte recruitment; cathelicidin; AMP activity; dermatitis	STAPHYLOCOCCUS-AUREUS; SIGMA-FACTOR; ADAPTIVE RESPONSE; INNATE IMMUNITY; SKIN; EXPRESSION; VIRULENCE; MICE; BETA-DEFENSIN-1; NEUTROPHILS	Antimicrobial peptides (AMPs) have been shown in animal and human systems to be effective natural antibiotics. However, it is unclear how they convey protection; they often appear inactive when assayed under culture conditions applied to synthetic antibiotics. This inactivation has been associated with loss of function in physiological concentrations of NaCl or serum. In this study we show that the balance of host ionic conditions dictate microbial sensitivity to AMPs. Carbonate is identified as the critical ionic factor present in mammalian tissues that imparts the ability of AMPs such as cathelicidins and defensins to kill at physiological NaCl concentrations. After adapting to carbonate-containing solutions, global changes occur in Staphylococcus aureus and Escherichia coli structure and gene expression despite no change in growth rate. Our findings show that changes in cell wall thickness and Sigma factor B expression correspond to the increased susceptibility to the AMP LL-37. These observations provide new insight into the factors involved in enabling function of innate immune effector molecules, and suggest that discovery of new antimicrobials should specifically target pathogens as they exist in the host and not the distinctly different phenotype of bacteria grown in culture broth.-Dorschner, R. A., Lopez-Garcia, B., Peschel, A., Kraus, D., Morikawa, K., Nizet, V., Gallo, R. L. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides.	Univ Calif San Diego, Dept Med, Div Dermatol, San Diego, CA 92103 USA; VA San Dieg Healthcare Ctr, San Diego, CA USA; Univ Calif San Diego, Dept Pediat, Div Infect Dis, San Diego, CA 92103 USA; Univ Tubingen, Cellular & Mol Microbiol Div, Med Microbiol & Hyg Dept, Tubingen, Germany; Univ Tsukuba, Inst Basic Med Sci, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 305, Japan	University of California System; University of California San Diego; University of California System; University of California San Diego; Eberhard Karls University of Tubingen; University of Tsukuba	Gallo, RL (corresponding author), Mail Code 9111B,3350 La Jolla Viallage Dr, La Jolla, CA 92161 USA.	rgallo@vapop.ucsd.edu	Gallo, Richard L/A-8931-2009; Nizet, Victor/AAF-3190-2019	Gallo, Richard L/0000-0002-1401-7861; Morikawa, Kazuya/0000-0002-1503-7151; Nizet, Victor/0000-0003-3847-0422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI052453, R01AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NIAID NIH HHS [AI052453] Funding Source: Medline; NIAMS NIH HHS [AR45676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AOYAMA T, 1990, FEBS LETT, V263, P1, DOI 10.1016/0014-5793(90)80691-B; BORREGAARD N, 1984, J CLIN INVEST, V74, P455, DOI 10.1172/JCI111442; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Dorschner RA, 2003, PEDIATR RES, V53, P566, DOI 10.1203/01.PDR.0000057205.64451.B7; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GALLO RL, 2005, ANTIMICROBIAL PEPTID; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Heuner K, 2002, INFECT IMMUN, V70, P1604, DOI 10.1128/IAI.70.3.1604-1608.2002; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Jonsson IM, 2004, INFECT IMMUN, V72, P6106, DOI 10.1128/IAI.72.10.6106-6111.2004; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; MCKAY W, 1987, ANESTH ANALG, V66, P572; Morikawa K, 2001, BIOCHEM BIOPH RES CO, V288, P385, DOI 10.1006/bbrc.2001.5774; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ouellette AJ, 1999, INFECT IMMUN, V67, P6643; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Sahu SN, 2003, MOL CELL BIOCHEM, V253, P167, DOI 10.1023/A:1026028930203; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000; TURNBERG L A, 1970, Journal of Clinical Investigation, V49, P548, DOI 10.1172/JCI106265; Wang YQ, 1998, J BIOL CHEM, V273, P33115, DOI 10.1074/jbc.273.50.33115; Wu SW, 1996, J BACTERIOL, V178, P6036, DOI 10.1128/jb.178.20.6036-6042.1996; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zasloff M, 2002, NEW ENGL J MED, V347, P1199, DOI 10.1056/NEJMe020106; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	34	150	155	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					35	42		10.1096/fj.05-4406com	http://dx.doi.org/10.1096/fj.05-4406com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394265				2022-12-25	WOS:000235996000042
J	Semba, S; Trapasso, F; Fabbri, M; McCorkell, KA; Volinia, S; Druck, T; Iliopoulos, D; Pekarsky, Y; Ishii, H; Garrison, PN; Barnes, LD; Croce, CM; Huebner, K				Semba, S.; Trapasso, F.; Fabbri, M.; McCorkell, K. A.; Volinia, S.; Druck, T.; Iliopoulos, D.; Pekarsky, Y.; Ishii, H.; Garrison, P. N.; Barnes, L. D.; Croce, C. M.; Huebner, K.			Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential	ONCOGENE			English	Article						Fhit; tyrosine 114 (Y114); Akt; survivin; lung cancer; apoptosis	FRAGILE HISTIDINE-TRIAD; EXPRESSION INDUCES APOPTOSIS; TUMOR-SUPPRESSOR; GENE; TUMORIGENICITY; CARCINOMA; KINASE; HYPERMETHYLATION; RESTORATION; COMPLEXES	The Fhit tumor suppressor binds and hydrolyses diadenosine polyphosphates and the Fhit - substrate complex has been proposed as a proapoptotic effector, as determined by infection of susceptible cancer cells with adenoviruses carrying wild- type fragile histidine triad ( FHIT) or catalytic site mutants. The highly conserved Fhit tyrosine 114 ( Y114), within the unstructured loop C- terminal of the catalytic site, can be phosphorylated by Src family tyrosine kinases, although endogenous phospho- Fhit is rarely detected. To explore the importance of Y114 and identify Fhit- mediated signaling events, wild- type and Y114 mutant FHIT- expressing adenoviruses were introduced into two human lung cancer cell lines. Caspase-dependent apoptosis was effectively induced only by wildtype but not Y114 mutant Fhit proteins. By expression proling of FHIT versus mutant FHIT- infected cells, we found that survivin, an Inhibitor of Apoptosis Protein ( IAP) family member, was significantly decreased by wildtype Fhit. In addition, Fhit inhibited activity of Akt, a key effector in the phosphatidylinositol 3- OH kinase ( PI3K) pathway; loss of endogenous Fhit expression caused increased Akt activity in vitro and in vivo, and overexpression of constitutively active Akt inhibited Fhit-induced apoptosis. The results indicate that the Fhit Y114 residue plays a critical role in Fhit- induced apoptosis, occurring through inactivation of the PI3K- Akt- survivin signal pathway.	Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Magna Graecia Univ Catanzaro, Med Sch Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; Univ Ferrara, Telethon Facil, Data Min Anal DNA Microarrays, I-44100 Ferrara, Italy; Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat Mol Hematopoiesis, Minami Kawachi, Tochigi 32904, Japan; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78285 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Magna Graecia University of Catanzaro; University of Ferrara; Jichi Medical University; University of Texas System; University of Texas Health San Antonio	Huebner, K (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Room 455C Wiseman Hall,410 W 12th Ave, Columbus, OH 43210 USA.	kay.huebner@osumc.edu	Young, Richard A/F-6495-2012; Volinia, Stefano/A-3029-2010; Iliopoulos, Dimitrios/AAE-9106-2019; Volinia, Stefano/AAA-9264-2019	Young, Richard A/0000-0001-8855-8647; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007780] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07780] Funding Source: Medline; Telethon [GTF03012] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Brenner C, 1997, PROTEIN ENG, V10, P1461, DOI 10.1093/protein/10.12.1461; Croce CM, 1999, J CLIN ONCOL, V17, P1618, DOI 10.1200/JCO.1999.17.5.1618; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Fujishita T, 2004, BRIT J CANCER, V91, P1571, DOI 10.1038/sj.bjc.6602182; Garrison PN, 2005, BIOCHEMISTRY-US, V44, P6286, DOI 10.1021/bi047670s; Hao XP, 2000, CANCER RES, V60, P18; Hu BC, 2005, J CELL PHYSIOL, V202, P518, DOI 10.1002/jcp.20139; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kuroki T, 2003, CANCER RES, V63, P3724; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mori M, 2000, CANCER RES, V60, P1177; Nishizaki M, 2004, CANCER RES, V64, P5745, DOI 10.1158/0008-5472.CAN-04-0195; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Ottey M, 2004, BRIT J CANCER, V91, P1669, DOI 10.1038/sj.bjc.6602058; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2004, P NATL ACAD SCI USA, V101, P3775, DOI 10.1073/pnas.0400481101; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Semba S, 2002, CLIN CANCER RES, V8, P3824; Sevignani C, 2003, CANCER RES, V63, P1183; Shi YF, 2000, BIOCHEM J, V352, P443, DOI 10.1042/0264-6021:3520443; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	44	54	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2860	2872		10.1038/sj.onc.1209323	http://dx.doi.org/10.1038/sj.onc.1209323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407838				2022-12-25	WOS:000237448200004
J	Yanyan, JY; Peter, O; Davies, KE; Platt, N				Yanyan, JY; Peter, O; Davies, KE; Platt, N			Identification and characterization of murine SCARA5, a novel class A scavenger receptor that is expressed by populations of epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONONUCLEAR PHAGOCYTE SYSTEM; SURFACE EXPRESSION; ESCHERICHIA-COLI; IMMUNE-SYSTEM; IMMUNOHISTOCHEMICAL LOCALIZATION; PATTERN-RECOGNITION; POLYANIONIC LIGANDS; CYTOKINE RESPONSES; MOLECULAR-CLONING; APOPTOTIC CELLS	Epithelia are positioned at a critical interface to prevent invasion by microorganisms from the environment. Pattern recognition receptors are important components of innate immunity because of their ability to interact with specific microbe-associated structures and initiate immune responses. Several distinct groups of receptors have been recognized. One of these, the scavenger receptors, has been classified into at least eight separate classes. The class A scavenger receptors are characterized by the presence of a collagen-like domain and include macrophage scavenger receptor type A (SR-A1 I/II, SCARA1) and MARCO (SCARA2). These receptors are known to make important contributions to host defense. Here, we identify a novel murine scavenger receptor, SCARA5, which has a structure typical of this class. The cDNA encodes 491 amino acids, which predict a type II protein that contains C-terminal intracellular, transmembrane, extracellular spacer, collagenous, and N-terminal scavenger receptor cysteine rich domains. Expression in Chinese hamster ovary cells confirmed that the receptor assembles as a homotrimer and is expressed at the plasma membrane. SCARA5-transfected cells bound Escherichia coli and Staphylococcus aureus, but not zymosan, in a polyanionic-inhibitable manner. Unlike other class A scavenger receptors, the receptor was unable to endocytose acetylated or oxidized low density lipoprotein. Quantitative RTPCR and in situ hybridization demonstrate SCARA5 has a tissue and cellular distribution unique among class A scavenger receptors. Because of the restriction of SCARA5 transcripts to populations of epithelial cells, we propose that this receptor may play important roles in the innate immune activities of these cells.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England	University of Oxford; University of Southampton	Platt, N (corresponding author), Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England.	N.Platt@soton.ac.uk	Oliver, Peter/F-1453-2010; Jiang, Yanyan/AAE-2495-2020; Eckhardt, Erik/G-1567-2010; Yan, Yong-Bin/A-4282-2008	Jiang, Yanyan/0000-0001-6014-811X; Yan, Yong-Bin/0000-0002-8565-3558	MRC [MC_U137761449] Funding Source: UKRI; Medical Research Council [MC_U137761449, G0800158] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ACTON S, 1993, J BIOL CHEM, V268, P3530; Akira S, 2004, SEMIN IMMUNOL, V16, P1, DOI 10.1016/j.smim.2003.10.001; Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; ASHKENAS J, 1993, J LIPID RES, V34, P983; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; DOI T, 1993, J BIOL CHEM, V268, P2126; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; Eckmann Lars, 1995, Trends in Microbiology, V3, P118, DOI 10.1016/S0966-842X(00)88894-0; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; Elshourbagy MA, 2000, EUR J BIOCHEM, V267, P919, DOI 10.1046/j.1432-1327.2000.01077.x; Eskola V, 1998, MOL CELL ENDOCRINOL, V139, P143, DOI 10.1016/S0303-7207(98)00063-X; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Godaly G, 2001, J LEUKOCYTE BIOL, V69, P899; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Hertz CJ, 2003, J IMMUNOL, V171, P6820, DOI 10.4049/jimmunol.171.12.6820; HOLNESS CL, 1993, J BIOL CHEM, V268, P9661; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hoshino K, 1999, J IMMUNOL, V162, P3749; HUGHES DA, 1995, EUR J IMMUNOL, V25, P466, DOI 10.1002/eji.1830250224; HUME DA, 1984, ANAT REC, V210, P503, DOI 10.1002/ar.1092100311; HUME DA, 1984, P NATL ACAD SCI-BIOL, V81, P4174, DOI 10.1073/pnas.81.13.4174; Isaacs AM, 2003, J NEUROSCI, V23, P1631; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kodama T, 1996, CURR OPIN LIPIDOL, V7, P287, DOI 10.1097/00041433-199610000-00005; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Levy E, 2004, J CELL SCI, V117, P327, DOI 10.1242/jcs.00856; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; Morimoto K, 1999, BIOL PHARM BULL, V22, P1022; Nakagawa A, 2005, MOL REPROD DEV, V71, P166, DOI 10.1002/mrd.20278; Nakamura K, 2001, BBA-GENE STRUCT EXPR, V1522, P53, DOI 10.1016/S0167-4781(01)00284-6; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; Pearson AM, 1996, CURR OPIN IMMUNOL, V8, P20, DOI 10.1016/S0952-7915(96)80100-2; Peiser L, 2000, INFECT IMMUN, V68, P1953, DOI 10.1128/IAI.68.4.1953-1963.2000; Platt N, 1998, CHEM BIOL, V5, pR193, DOI 10.1016/S1074-5521(98)90156-9; Platt N, 2002, INT REV CYTOL, V212, P1; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schilling JD, 2003, P NATL ACAD SCI USA, V100, P4203, DOI 10.1073/pnas.0736473100; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Svanborg C, 1996, ANN NY ACAD SCI, V797, P177, DOI 10.1111/j.1749-6632.1996.tb52959.x; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Tian G, 2004, J BIOL CHEM, V279, P39303, DOI 10.1074/jbc.M405219200; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	58	57	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11834	11845		10.1074/jbc.M507599200	http://dx.doi.org/10.1074/jbc.M507599200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	035GH	16407294	hybrid			2022-12-25	WOS:000236988100050
J	Kimoto, H; Fujii, Y; Hirano, S; Yokota, Y; Taketo, A				Kimoto, H; Fujii, Y; Hirano, S; Yokota, Y; Taketo, A			Genetic and biochemical properties of streptococcal NAD-glycohydrolase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; COMPLETE GENOME SEQUENCE; STREPTOLYSIN-O; III SECRETION; HEMOLYTIC STREPTOCOCCI; M3 STRAIN; GROUP-C; PYOGENES; TOXINS; PATHOGENESIS	The gene encoding streptolysin O (slo), a cytolysin of hemolytic streptococci, is transcribed polycistronically from the promoter of the preceding NAD-glycohydrolase (NADase) gene (nga). Between nga and slo, a putative open reading frame (orf1) is located whose function has been totally unknown. Present investigation demonstrated that the orf1 encodes a protein designated as streptococcal NADase inhibitor (SNI). From its nucleotide sequence, SNI was inferred to comprise 161 amino acid residues and the deduced molecular weight was 18,800. This protein was detectable only within cells. Coexpression of SNI was essential for production of streptococcal NADase, and NADase precursor existed as an inactive complex with SNI, in recombinant Escherichia coli. Monomeric NADase and SNI rapidly formed in vitro a stable heterodimer complex in the ratio 1:1, resulting in complete suppression of the hydrolase activity. Unlike other bacterial NADase inhibitors, SNI was thermostable. This protein, coexpressed and complexed with NADase, may protect the producer cocci from exhaustion of NAD.	Univ Fukui, Fac Med, Dept Mol Genet, Fukui 9101193, Japan; Univ Fukui, Fac Med, Dept Mol Biol & Chem, Fukui 9101193, Japan; Univ Fukui, Fac Med, Dept Pediat, Fukui 9101193, Japan; Fukui Univ Technol, Dept Environm & Biotechnol Frontier Engn, Fukui 9108505, Japan	University of Fukui; University of Fukui; University of Fukui	Kimoto, H (corresponding author), Univ Fukui, Fac Med, Dept Mol Genet, 23-3 Shimoaizuki, Fukui 9101193, Japan.	hisashi@fmsrsa.fukui-med.ac.jp		Fujii, Yutaka/0000-0001-6357-3795				ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; Alouf JE, 2000, INT J MED MICROBIOL, V290, P351; Banks DJ, 2004, J INFECT DIS, V190, P727, DOI 10.1086/422697; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; Billington SJ, 2000, FEMS MICROBIOL LETT, V182, P197, DOI 10.1016/S0378-1097(99)00536-4; Blocker A, 2000, CELL MICROBIOL, V2, P387, DOI 10.1046/j.1462-5822.2000.00068.x; Buttner D, 2002, TRENDS MICROBIOL, V10, P186, DOI 10.1016/S0966-842X(02)02331-4; CARLSON AS, 1956, J EXP MED, V104, P577, DOI 10.1084/jem.104.4.577; CARLSON AS, 1957, J EXP MED, V106, P15, DOI 10.1084/jem.106.1.15; Cheng LW, 2000, TRENDS MICROBIOL, V8, P214, DOI 10.1016/S0966-842X(99)01665-0; CHRISTENSEN LR, 1945, J GEN PHYSIOL, V28, P363, DOI 10.1085/jgp.28.4.363; Coye LH, 2004, MOL MICROBIOL, V54, P89, DOI 10.1111/j.1365-2958.2004.04262.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Everse K E, 1980, Methods Enzymol, V66, P137; FEHRENBA.FJ, 1971, Z NATURFORSCH PT B, VB 26, P1336, DOI 10.1515/znb-1971-1224; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Gerlach D, 1996, FEMS MICROBIOL LETT, V136, P71; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hashikawa S, 2004, J CLIN MICROBIOL, V42, P186, DOI 10.1128/JCM.42.1.186-192.2004; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOLM SE, 1967, ACTA PATHOL MIC SC, V69, P277; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kimoto H, 2005, BBA-GENE STRUCT EXPR, V1681, P134, DOI 10.1016/j.bbaexp.2004.10.011; Kimoto H, 1997, J BIOCHEM, V122, P237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; Mitaku S, 2002, BIOINFORMATICS, V18, P608, DOI 10.1093/bioinformatics/18.4.608; Nakagawa I, 2003, GENOME RES, V13, P1042, DOI 10.1101/gr.1096703; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Palmer M, 2001, TOXICON, V39, P1681, DOI 10.1016/S0041-0101(01)00155-6; Sachse S, 2002, FEMS IMMUNOL MED MIC, V34, P159, DOI 10.1016/S0928-8244(02)00373-5; Savic DJ, 2002, INFECT IMMUN, V70, P2730, DOI 10.1128/IAI.70.5.2730-2733.2002; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; SWARTZ MN, 1956, SCIENCE, V123, P50, DOI 10.1126/science.123.3185.50; TAKETA K, 1986, J IMMUNOL METHODS, V95, P71; TIESLER E, 1982, ZBL BAKT-INT J MED M, V253, P81; Yamamoto I, 2001, BIOSCI BIOTECH BIOCH, V65, P2682, DOI 10.1271/bbb.65.2682	39	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9181	9189		10.1074/jbc.M506879200	http://dx.doi.org/10.1074/jbc.M506879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16380378	hybrid			2022-12-25	WOS:000236404700024
J	Beahm, DL; Oshima, A; Gaietta, GM; Hand, GM; Smock, AE; Zucker, SN; Toloue, MM; Chandrasekhar, A; Nicholson, BJ; Sosinsky, GE				Beahm, DL; Oshima, A; Gaietta, GM; Hand, GM; Smock, AE; Zucker, SN; Toloue, MM; Chandrasekhar, A; Nicholson, BJ; Sosinsky, GE			Mutation of a conserved threonine in the third transmembrane helix of alpha- and beta-connexins creates a dominant-negative closed gap junction channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; MOLECULAR-CLONING; GENE-MUTATIONS; MEMBRANE; LIVER; PORE; PHENOTYPE; UNDERLIES; OLIGOMERIZATION; IDENTIFICATION	Single site mutations in connexins have provided insights about the influence specific amino acids have on gap junction synthesis, assembly, trafficking, and functionality. We have discovered a single point mutation that eliminates functionality without interfering with gap junction formation. The mutation occurs at a threonine residue located near the cytoplasmic end of the third transmembrane helix. This threonine is strictly conserved among members of the alpha- and beta-connexin subgroups but not the gamma-subgroup. In HeLa cells, connexin43 and connexin26 mutants are synthesized, traffic to the plasma membrane, and make gap junctions with the same overall appearance as wild type. We have isolated connexin26T135A gap junctions both from HeLa cells and baculovirus-infected insect Sf9 cells. By using cryoelectron microscopy and correlation averaging, difference images revealed a small but significant size change within the pore region and a slight rearrangement of the subunits between mutant and wild-type connexons expressed in Sf9 cells. Purified, detergent-solubilized mutant connexons contain both hexameric and partially disassembled structures, although wild-type connexons are almost all hexameric, suggesting that the three-dimensional mutant connexon is unstable. Mammalian cells expressing gap junction plaques composed of either connexin43T154A or connexin26T135A showed an absence of dye coupling. When expressed in Xenopus oocytes, these mutants, as well as a cysteine substitution mutant of connexin50 (connexin50T157C), failed to produce electrical coupling in homotypic and heteromeric pairings with wild type in a dominant-negative effect. This mutant may be useful as a tool for knocking down or knocking out connexin function in vitro or in vivo.	Univ Calif San Diego, Dept Neurosci, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	University of California System; University of California San Diego; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Sosinsky, GE (corresponding author), Univ Calif San Diego, Dept Neurosci, Natl Ctr Microscopy & Imaging Res, 1070 Basic Sci Bldg,MC 0608,9500 Gilman Dr, La Jolla, CA 92093 USA.	gsosinsky@ucsd.edu	Oshima, Atsunori/F-8346-2010	Nicholson, Bruce/0000-0003-1649-7173; Oshima, Atsunori/0000-0003-1174-1368	NATIONAL CANCER INSTITUTE [R01CA048049] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050, P41RR002250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072881, R01GM065937] Funding Source: NIH RePORTER; NCI NIH HHS [CA048049] Funding Source: Medline; NCRR NIH HHS [P41RR02250, RR04050] Funding Source: Medline; NIGMS NIH HHS [GM065937, GM072881, R01 GM065937, GM048773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams CK, 2000, CURR TOP MEMBR, V49, P423; Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Andreadis ST, 2001, FASEB J, V15, P898, DOI 10.1096/fj.00-0324com; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Beltramello M, 2005, NAT CELL BIOL, V7, P63, DOI 10.1038/ncb1205; BONE LJ, 1995, NEUROLOGY, V45, P1863, DOI 10.1212/WNL.45.10.1863; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; Bukauskas FF, 2004, BBA-BIOMEMBRANES, V1662, P42, DOI 10.1016/j.bbamem.2004.01.008; CROWTHER RA, 1971, J MOL BIOL, V184, P81; Cryns K, 2004, J MED GENET, V41, P147, DOI 10.1136/jmg.2003.013896; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; Falk MM, 2000, J CELL SCI, V113, P4109; Fleishman SJ, 2004, MOL CELL, V15, P879, DOI 10.1016/j.molcel.2004.08.016; Frei K, 2004, AUDIOL NEURO-OTOL, V9, P47, DOI 10.1159/000074186; Fuse Y, 1999, NEUROREPORT, V10, P1853, DOI 10.1097/00001756-199906230-00010; Gabriel HD, 1998, J CELL BIOL, V140, P1453, DOI 10.1083/jcb.140.6.1453; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Gourdie RG, 2000, CURR TOP MEMBR, V49, P581; Hand GM, 2002, J MOL BIOL, V315, P587, DOI 10.1006/jmbi.2001.5262; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunter AW, 2003, CELL COMMUN ADHES, V10, P211, DOI 10.1080/714040429; JONGSMA HJ, 1991, BIOPHYSICS GAP JUNCT, P163; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kronengold J, 2003, J GEN PHYSIOL, V122, P389, DOI 10.1085/jgp.200308861; Krutovskikh V, 2000, MUTAT RES-REV MUTAT, V462, P197, DOI 10.1016/S1383-5742(00)00037-5; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; Kumari SS, 2001, BIOCHEM BIOPH RES CO, V280, P440, DOI 10.1006/bbrc.2000.4121; Lagree V, 2003, J CELL SCI, V116, P3189, DOI 10.1242/jcs.00604; LAL R, 1995, AM J PHYSIOL-CELL PH, V268, pC968, DOI 10.1152/ajpcell.1995.268.4.C968; Lauf U, 2002, P NATL ACAD SCI USA, V99, P10446, DOI 10.1073/pnas.162055899; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; Martin BR, 2005, NAT BIOTECHNOL, V23, P1308, DOI 10.1038/nbt1136; Maza J, 2005, J BIOL CHEM, V280, P21115, DOI 10.1074/jbc.M412612200; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A; Nelles E, 1996, P NATL ACAD SCI USA, V93, P9565, DOI 10.1073/pnas.93.18.9565; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; PATEL PI, 1994, TRENDS GENET, V10, P128, DOI 10.1016/0168-9525(94)90214-3; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Ressot C, 1996, HUM GENET, V98, P172, DOI 10.1007/s004390050183; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Scherer SS, 1999, NOVART FDN SYMP, V219, P175; Schonherr R, 2002, NEURON, V35, P935, DOI 10.1016/S0896-6273(02)00869-3; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; Skerrett IM, 2004, FASEB J, V18, P860, DOI 10.1096/fj.03-0763fje; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; Sorour E, 1998, HUM MUTAT, pS242; SOSINSKY GE, 1990, BIOPHYS J, V58, P1213, DOI 10.1016/S0006-3495(90)82462-0; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Tsien RY, 2005, FEBS LETT, V579, P927, DOI 10.1016/j.febslet.2004.11.025; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; UNWIN N, 1986, NATURE, V323, P12, DOI 10.1038/323012a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; Weber PA, 2004, BIOPHYS J, V87, P958, DOI 10.1529/biophysj.103.036350; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4	71	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7994	8009		10.1074/jbc.M506533200	http://dx.doi.org/10.1074/jbc.M506533200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407179	hybrid			2022-12-25	WOS:000236031000036
J	Zheng, PS; Reis, M; Sparling, C; Lee, DY; La Pierre, DP; Wong, CKA; Deng, ZQ; Kahai, S; Wen, JP; Yang, BB				Zheng, PS; Reis, M; Sparling, C; Lee, DY; La Pierre, DP; Wong, CKA; Deng, ZQ; Kahai, S; Wen, JP; Yang, BB			Versican G3 domain promotes blood coagulation through suppressing the activity of tissue factor pathway inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; PG-M/VERSICAN; PROTEOGLYCAN; BINDING; ATHEROSCLEROSIS; PROLIFERATION; EXPRESSION; ADHESION; MATRIX	We have detected versican, a member of the large chondroitin sulfate proteoglycans, and its degraded C-terminal G3 fragments in human plasma and observed that the versican G3 domain promoted blood coagulation. Silencing G3 expression with small interfering RNA reduced the effect of G3 on coagulation. Plasma coagulation assays suggest that G3 enhances coagulation irrespective of its actions on platelets and white blood cells. To examine how versican affected blood coagulation, we used normal human plasma and different types of coagulation factor-deficient plasmas. The experiments indicated that versican enhanced coagulation through the extrinsic pathway, and that Factor VII was the target molecule. FVII activity assays showed that G3 activated FVII in the presence of plasma but not with purified FVII directly. Yeast two-hybrid, immunoprecipitation, and gel co-migration assays showed that G3 interacted with the tissue factor pathway inhibitor-1 (TFPI-1). TFPI-1 activity assays suggested that G3 inhibited TFPI-1 activity, allowing FVIIa and FXa to facilitate the coagulation process. G3-induced blood coagulation was further confirmed with a mouse model in a real-time manner. Taken together, these results indicate that versican may represent a new target for the development of therapies against atherosclerosis.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	burton.yang@sw.ca						Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen LW, 2003, BIOCHEMISTRY-US, V42, P8332, DOI 10.1021/bi034335f; FAIR DS, 1987, J BIOL CHEM, V262, P11692; Kenagy RD, 2002, ARTERIOSCL THROM VAS, V22, P400, DOI 10.1161/hq0302.105376; KOCH AE, 1990, AM J PATHOL, V137, P1199; Kolodgie FD, 2002, ARTERIOSCL THROM VAS, V22, P1642, DOI 10.1161/01.ATV.0000034021.92658.4C; Lee V, 2002, J BIOL CHEM, V277, P22279, DOI 10.1074/jbc.M110227200; Lemire JM, 2002, J CELL PHYSIOL, V190, P38, DOI 10.1002/jcp.10043; Lijnen HR, 2001, THROMB HAEMOSTASIS, V86, P324; Lin H, 1996, J HEART LUNG TRANSPL, V15, P1233; Little PJ, 2002, ARTERIOSCL THROM VAS, V22, P55, DOI 10.1161/hq0102.101100; Matsuura R, 1996, J PATHOL, V180, P311, DOI 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B; McGee M, 2003, ARTERIOSCL THROM VAS, V23, P1921, DOI 10.1161/01.ATV.0000090673.96120.67; Merrilees MJ, 2001, CORONARY ARTERY DIS, V12, P7, DOI 10.1097/00019501-200102000-00002; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Sheng W, 2005, MOL BIOL CELL, V16, P1330, DOI 10.1091/mbc.e04-04-0295; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; SRINIVASAN SR, 1995, BBA-MOL BASIS DIS, V1272, P61, DOI 10.1016/0925-4439(95)00068-F; Strassel C, 2003, BIOCHEMISTRY-US, V42, P4452, DOI 10.1021/bi026213d; Vandendries ER, 2004, THROMB HAEMOSTASIS, V92, P459, DOI 10.1160/TH04-05-0306; Vijayagopal P, 1996, ATHEROSCLEROSIS, V127, P195, DOI 10.1016/S0021-9150(96)05954-0; Wight TN, 1997, AM J PATHOL, V151, P963; Wight TN, 2004, CIRC RES, V94, P1158, DOI 10.1161/01.RES.0000126921.29919.51; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zheng PS, 2004, J CELL SCI, V117, P5887, DOI 10.1242/jcs.01516; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje	33	17	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8175	8182		10.1074/jbc.M509182200	http://dx.doi.org/10.1074/jbc.M509182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431924	hybrid			2022-12-25	WOS:000236031000056
J	Li, JZ; Lee, B; Lee, AS				Li, JZ; Lee, B; Lee, AS			Endoplasmic reticulum stress-induced apoptosis - Multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH PROGRAM; BH3-ONLY PROTEINS; GENE; BAX; CASPASE-12; INDUCTION; EXPRESSION; CHOP; ER; TRANSLOCATION	Endoplasmic reticulum ( ER) stress-induced apoptosis has been implicated in the development of multiple diseases. However, the in vivo signaling pathways are still not fully understood. In this report, through the use of genetically deficient mouse embryo fibroblasts (MEFs) and their matched wild-type controls, we have demonstrated that the mitochondrial apoptotic pathway mediated by Apaf-1 is an integral part of ER stress-induced apoptosis and that ER stress activates different caspases through Apaf-1-dependent and - independent mechanisms. In search of the molecular link between ER stress and the mitochondrial apoptotic pathway, we have discovered that in MEFs, ER stress selectively activates BH3-only proteins PUMA and NOXA at the transcript level through the tumor suppressor gene p53. In p53(-/-) MEFs, ER stress-induced apoptosis is partially suppressed. The p53-independent apoptotic pathway may be mediated by C/EBP homologous protein ( CHOP) and caspase-12, as their activation is intact in p53(-/-) MEFs. In multiple MEF lines, p53 is primarily nuclear and its level is elevated upon ER stress. To establish the role of NOXA and PUMA in ER stress-induced apoptosis, we have shown that, in MEFs deficient in NOXA or PUMA, ER stress-induced apoptosis is reduced. Reversibly, overexpression of NOXA or PUMA induces apoptosis as evidenced by the activation of BAK and caspase-7. Our results provide new evidence that, in MEFs, in addition to PUMA, p53 and NOXA are novel components of the ER stress-induced apoptotic pathway, and both contribute to ER stress-induced apoptosis.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 1441 Eastlake Ave, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [CA 027607, CA 111700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607, R01CA027607, R01CA111700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Ho AT, 2004, EMBO J, V23, P460, DOI 10.1038/sj.emboj.7600039; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Hong M, 2004, J BIOL CHEM, V279, P11354, DOI 10.1074/jbc.M309804200; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kalai M, 2003, J CELL BIOL, V162, P457, DOI 10.1083/jcb.200303157; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Lamkanfi M, 2004, CELL DEATH DIFFER, V11, P365, DOI 10.1038/sj.cdd.4401364; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; Perkins CL, 2000, CANCER RES, V60, P1645; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rao RV, 2004, J BIOL CHEM, V279, P177, DOI 10.1074/jbc.M304490200; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RAO RV, 2005, IN PRESS CELL DEATH; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	51	402	419	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7260	7270		10.1074/jbc.M509868200	http://dx.doi.org/10.1074/jbc.M509868200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407291	hybrid			2022-12-25	WOS:000236030900044
J	Yoon, SO; Lee, TS; Kim, SJ; Jang, MH; Kang, YJ; Park, JH; Kim, KS; Lee, HS; Ryu, CJ; Gonzales, NR; Kashmiri, SVS; Lim, SM; Choi, CW; Hong, HJ				Yoon, SO; Lee, TS; Kim, SJ; Jang, MH; Kang, YJ; Park, JH; Kim, KS; Lee, HS; Ryu, CJ; Gonzales, NR; Kashmiri, SVS; Lim, SM; Choi, CW; Hong, HJ			Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND-GENERATION MONOCLONAL-ANTIBODIES; METASTATIC COLON-CARCINOMA; HEPATITIS-B-VIRUS; RADIOIMMUNOTHERAPY TRIAL; ANTICARCINOMA ANTIBODY; PHASE-I; IMMUNOGENICITY; CC49; BINDING; B72.3	The tumor-associated glycoprotein (TAG)-72 is expressed in the majority of human adenocarcinomas but is rarely expressed in most normal tissues, which makes it a potential target for the diagnosis and therapy of a variety of human cancers. Here we describe the construction, affinity maturation, and biological characterization of an anti-TAG-72 humanized antibody with minimum potential immunogenicity. The humanized antibody was constructed by grafting only the specificity-determining residues (SDRs) within the complementarity-determining regions (CDRs) onto homologous human immunoglobulin germ line segments while retaining two mouse heavy chain framework residues that support the conformation of the CDRs. The resulting humanized antibody ( AKA) showed only about 2-fold lower affinity compared with the original murine monoclonal antibody CC49 and 27-fold lower reactivity to patient serum compared with the humanized antibody HuCC49 that was constructed by CDR grafting. The affinity of AKA was improved by random mutagenesis of the heavy chain CDR3 (HCDR3). The highest affinity variant (3E8) showed 22-fold higher affinity compared with AKA and retained the original epitope specificity. Mutational analysis of the HCDR3 residues revealed that the replacement of Asn(97) by isoleucine or valine was critical for the affinity maturation. The 3E8 labeled with I-125 or I-131 showed efficient tumor targeting or therapeutic effects, respectively, in athymic mice with human colon carcinoma xenografts, suggesting that 3E8 may be beneficial for the diagnosis and therapy of tumors expressing TAG-72.	Korea Inst Radiol & Med Sci, Dept Nucl Med, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Cyclotron Applicat, Seoul 139706, South Korea; Aprogen Inc, Korea Res Inst Biosci & Biotechnol, Lab Antibody Engn, Taejon 305333, South Korea; NCI, Tumor Immunol & Biol Lab, NIH, Bethesda, MD 20892 USA	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Choi, CW (corresponding author), Korea Inst Radiol & Med Sci, Dept Nucl Med, 215-4 Gongneung, Seoul 139706, South Korea.	cwchoi@kcch.re.kr; hjhong@kribb.re.kr	LEE, TAE SUP/K-9638-2019; Cheon, Gi Jeong/G-6064-2018	Cheon, Gi Jeong/0000-0002-1360-5186; Kang, Young Jun/0000-0001-9778-1963				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; Bell SJ, 2000, ALIMENT PHARM THER, V14, P501; BUCHSBAUM D, 1995, CANCER RES, V55, pS5881; COLCHER D, 1990, J NUCL MED, V31, P1133; COLCHER D, 1988, CANCER RES, V48, P4597; Coligan JKA, 1991, CURRENT PROTOCOLS IM; De Pascalis R, 2003, CLIN CANCER RES, V9, P5521; DIVGI CR, 1994, NUCL MED BIOL, V21, P9, DOI 10.1016/0969-8051(94)90124-4; Divgi CR, 1995, CLIN CANCER RES, V1, P1503; DIVGI CR, 1995, J NUCL MED, V36, P586; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GLASER SM, 1992, J IMMUNOL, V149, P2607; Gonzales NR, 2003, MOL IMMUNOL, V40, P337, DOI 10.1016/S0161-5890(03)00166-4; Gonzales NR, 2002, J IMMUNOL METHODS, V268, P197, DOI 10.1016/S0022-1759(02)00205-3; Hong HJ, 2004, VIROLOGY, V318, P134, DOI 10.1016/j.virol.2003.09.014; Hwang WYK, 2005, METHODS, V36, P3, DOI 10.1016/j.ymeth.2005.01.001; Iwahashi M, 1999, MOL IMMUNOL, V36, P1079, DOI 10.1016/S0161-5890(99)00094-2; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kabat E.A., 1991, NIH PUBLICATION, V91-3242, P103; KASHMIRI SVS, 1995, HYBRIDOMA, V14, P461, DOI 10.1089/hyb.1995.14.461; Kim SJ, 2004, VIROLOGY, V318, P598, DOI 10.1016/j.virol.2003.10.014; KJELDSEN T, 1988, CANCER RES, V48, P2214; KUROKI M, 1990, CANCER RES, V50, P4872; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; Mulligan T, 1995, CLIN CANCER RES, V1, P1447; MURARO R, 1988, CANCER RES, V48, P4588; O'Donoghue JA, 2002, CANCER BIOTHER RADIO, V17, P435, DOI 10.1089/108497802760363222; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; PADLAN EA, 1995, FASEB J, V9, P133, DOI 10.1096/fasebj.9.1.7821752; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Park SS, 1996, HYBRIDOMA, V15, P435, DOI 10.1089/hyb.1996.15.435; Peterson JA, 1997, CANCER RES, V57, P1103; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; Radosevic K, 2003, J IMMUNOL METHODS, V272, P219, DOI 10.1016/S0022-1759(02)00208-9; Reichert JM, 2001, NAT BIOTECHNOL, V19, P819, DOI 10.1038/nbt0901-819; Ryu Chun Jeih, 1996, Human Antibodies and Hybridomas, V7, P113; SECCAMANI E, 1989, NUCL MED BIOL, V16, P167, DOI 10.1016/0883-2897(89)90191-8; STEPHENS S, 1995, IMMUNOLOGY, V85, P668; Tamura M, 2000, J IMMUNOL, V164, P1432, DOI 10.4049/jimmunol.164.3.1432; Tangri S, 2002, CURR MED CHEM, V9, P2191, DOI 10.2174/0929867023368647; THOR A, 1986, CANCER RES, V46, P3118; THOR A, 1987, INT J GYNECOL PATHOL, V6, P235, DOI 10.1097/00004347-198709000-00005; WINTER G, 1993, IMMUNOL TODAY, V14, P243, DOI 10.1016/0167-5699(93)90039-N	45	40	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6985	6992		10.1074/jbc.M511165200	http://dx.doi.org/10.1074/jbc.M511165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407221	hybrid			2022-12-25	WOS:000236030900011
J	Zachariae, U; Kluhspies, T; De, S; Engelhardt, H; Zeth, K				Zachariae, U; Kluhspies, T; De, S; Engelhardt, H; Zeth, K			High resolution crystal structures and molecular dynamics studies reveal substrate binding in the porin Omp32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE PORIN; OUTER-MEMBRANE PROTEINS; COMAMONAS-ACIDOVORANS; ESCHERICHIA-COLI; ELECTROSTATIC PROPERTIES; SALMONELLA-TYPHIMURIUM; SUGAR-TRANSPORT; ION PERMEATION; CHANNEL; TRANSLOCATION	The porin Omp32 is the major outer membrane protein of the bacterium Delftia acidovorans. The crystal structures of the strongly anion-selective porin alone and in complex with the substrate malate were solved at 1.5 and 1.45 angstrom resolution, respectively, and revealed a malate-binding motif adjacent to the channel constriction zone. Binding is mediated by interaction with a cluster of two arginine residues and two threonines. This binding site is specific for Omp32 and reflects the physiological adaptation of the organism to organic acids. Structural studies are combined with a 7-ns unbiased molecular dynamics simulation of the trimeric channel in a model membrane. Molecular dynamics trajectories show how malate ions are efficiently captured from the surrounding bulk solution by the electrostatic potential of the channel, translocated to the binding site region, and immobilized in the constriction zone. In accordance with these results, conductance measurements with Omp32 inserted in planar lipid membranes revealed binding of malate. The anion-selective channel Omp32 is the first reported example of a porin with a 16-stranded beta-barrel and proven substrate specificity. This finding suggests a new view on the correlation of porin structure with substrate binding in specific channels.	Max Planck Inst Biochem, Dept Mol Struct Biol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Membrane Biochem, D-82152 Martinsried, Germany; Dinabandhu Mahavidyalaya, Dept Phys, Bongaon 743235, W Bengal, India	Max Planck Society; Max Planck Society	Engelhardt, H (corresponding author), Max Planck Inst Biochem, Dept Mol Struct Biol, Klopferspitz 18, D-82152 Martinsried, Germany.	engelhar@biochem.mpg.de		Zachariae, Ulrich/0000-0003-3287-8494				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldermann C, 1998, J BACTERIOL, V180, P3741, DOI 10.1128/JB.180.15.3741-3749.1998; BEREZKHOVSKII AM, 2005, BIOPHYS J, V88, P17; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Ceccarelli M, 2004, BIOPHYS J, V87, P58, DOI 10.1529/biophysj.103.037283; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Danelon C, 2003, BIOPHYS CHEM, V104, P591, DOI 10.1016/S0301-4622(03)00062-0; Domene C, 2003, ADV PROTEIN CHEM, V66, P159; Dutzler R, 2002, STRUCTURE, V10, P1273, DOI 10.1016/S0969-2126(02)00811-0; Dutzler R, 1999, STRUCT FOLD DES, V7, P425, DOI 10.1016/S0969-2126(99)80055-0; ENGELHARDT H, 1990, J STRUCT BIOL, V105, P92, DOI 10.1016/1047-8477(90)90103-J; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Forst D, 1998, NAT STRUCT BIOL, V5, P37, DOI 10.1038/nsb0198-37; Godde C, 1999, FEMS MICROBIOL LETT, V173, P365; Grizot S, 2004, MOL MICROBIOL, V51, P1027, DOI 10.1111/j.1365-2958.2003.03903.x; Hirsch A, 1997, FEBS LETT, V404, P208, DOI 10.1016/S0014-5793(97)00131-2; HOROWITZ H, 1990, J CLIN MICROBIOL, V28, P143, DOI 10.1128/JCM.28.1.143-145.1990; Im W, 2002, J MOL BIOL, V322, P851, DOI 10.1016/S0022-2836(02)00778-7; Im W, 2002, J MOL BIOL, V319, P1177, DOI 10.1016/S0022-2836(02)00380-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordy M, 1996, J MOL BIOL, V259, P666, DOI 10.1006/jmbi.1996.0348; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Kosztin I, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.238102; KREUSCH A, 1994, J MOL BIOL, V243, P891, DOI 10.1006/jmbi.1994.1690; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Mathes A, 1998, BIOPHYS J, V75, P1255, DOI 10.1016/S0006-3495(98)74045-7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meyer JEW, 1997, J MOL BIOL, V266, P761, DOI 10.1006/jmbi.1996.0823; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Nestorovich EM, 2002, P NATL ACAD SCI USA, V99, P9789, DOI 10.1073/pnas.152206799; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Prinz T, 2000, FEMS MICROBIOL LETT, V183, P49, DOI 10.1111/j.1574-6968.2000.tb08932.x; Robertson KM, 2002, FEBS LETT, V528, P53, DOI 10.1016/S0014-5793(02)03173-3; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schirmer T, 1998, J STRUCT BIOL, V121, P101, DOI 10.1006/jsbi.1997.3946; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schulz GE, 2003, ADV PROTEIN CHEM, V63, P47; Suenaga A, 1998, BIOSCIENCE REP, V18, P39, DOI 10.1023/A:1022292801256; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; van den Berg B, 2004, SCIENCE, V304, P1506, DOI 10.1126/science.1097524; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; Willems A., 1992, PROKARYOTES HDB BIOL, P2583; Winterhalter M, 1999, COLLOID SURFACE A, V149, P547, DOI 10.1016/S0927-7757(98)00290-8; WOOLF TB, 1994, P NATL ACAD SCI USA, V91, P11631, DOI 10.1073/pnas.91.24.11631; Woolf TB, 1996, PROTEINS, V24, P92; Ye JQ, 2004, EMBO J, V23, P3187, DOI 10.1038/sj.emboj.7600330; Zachariae U, 2003, BIOPHYS J, V85, P954, DOI 10.1016/S0006-3495(03)74534-2; Zachariae U, 2002, PROTEIN SCI, V11, P1309, DOI 10.1110/ps.4910102; Zeth K, 2000, STRUCTURE, V8, P981, DOI 10.1016/S0969-2126(00)00189-1	53	25	25	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7413	7420		10.1074/jbc.M510939200	http://dx.doi.org/10.1074/jbc.M510939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16434398	hybrid, Green Submitted			2022-12-25	WOS:000236030900062
J	Mohri, T; Fujio, Y; Maeda, M; Ito, T; Iwakura, T; Oshima, Y; Uozumi, Y; Segawa, M; Yamamoto, H; Kishimoto, T; Azuma, J				Mohri, T; Fujio, Y; Maeda, M; Ito, T; Iwakura, T; Oshima, Y; Uozumi, Y; Segawa, M; Yamamoto, H; Kishimoto, T; Azuma, J			Leukemia inhibitory factor induces endothelial differentiation in cardiac stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; PROGENITOR CELLS; GROWTH-FACTOR; HEART-FAILURE; JAK-STAT; EXPRESSION; MYOCYTES; CARDIOMYOCYTES; ACTIVATION; GP130	The importance of interleukin 6 (IL-6)-related cytokines in cardiac homeostasis has been studied extensively; however, little is known about their biological significance in cardiac stem cells. Here we describe that leukemia inhibitory factor (LIF), a member of IL-6-related cytokines, activated STAT3 and ERK1/2 in cardiac Sca-1+ stem cells. LIF stimulation resulted in the induction of endothelial cell-specific genes, including VE-cadherin, Flk-1, and CD31, whereas neither smooth muscle nor cardiac muscle marker genes such as GATA4, GATA6, Nkx-2.5, and calponin were up-regulated. Immunocytochemical examination showed that about 25% of total cells were positively stained with anti-CD31 antibody 14 days after LIF stimulation. Immunofluorescent microscopic analyses identified the Sca-1+ cells that were also positively stained with anti-von Willebrand factor antibody, indicating the differentiating process of Sca-1+ cells into the endothelial cells. IL-6, which did not activate STAT3 and ERK1/2, failed to induce the differentiation of cardiac stem cells into the endothelial cells. In cardiac stem cells, the transduction with dominant negative STAT3 abrogated the LIF-induced endothelial differentiation. And the inhibition of ERK1/2 with the MEK1/2 inhibitor U0126 also prevented the differentiation of Sca-1+ cells into endothelial cells. Thus, both STAT3 and ERK1/2 are required for LIF-mediated endothelial differentiation in cardiac stem cells. Collectively, it is proposed that LIF regulates the commitment of cardiac stem cells into the endothelial cell lineage, contributing to neovascularization in the process of tissue remodeling and/or regeneration.	Osaka Univ, Dept Clin Evaluat Med & Therapeut, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Immune Regulat, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Fujio, Y (corresponding author), Osaka Univ, Dept Clin Evaluat Med & Therapeut, 1-6 Yamadaoka, Osaka 5650871, Japan.	fujio@phs.osaka-u.ac.jp	Fujio, Yasushi/H-3421-2017; Kishimoto, Tadamitsu/C-8470-2009	Fujio, Yasushi/0000-0003-0828-2930; 				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 2004, FEBS LETT, V573, P202, DOI 10.1016/j.febslet.2004.07.082; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Funamoto M, 2000, J MOL CELL CARDIOL, V32, P1275, DOI 10.1006/jmcc.2000.1161; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Gorski DH, 2000, CIRC RES, V87, P865, DOI 10.1161/01.RES.87.10.865; Hilfiker-Kleiner D, 2004, CIRC RES, V95, P187, DOI 10.1161/01.RES.0000134921.50377.61; Hishinuma S, 1999, BIOCHEM BIOPH RES CO, V264, P436, DOI 10.1006/bbrc.1999.1535; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; Jougasaki M, 2003, EUR J HEART FAIL, V5, P137, DOI 10.1016/S1388-9842(02)00236-2; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Kurdi M, 2005, MOL CELL BIOCHEM, V269, P95, DOI 10.1007/s11010-005-3085-1; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Oshima Y, 2005, CARDIOVASC RES, V65, P428, DOI 10.1016/j.cardiores.2004.10.021; Osugi T, 2002, J BIOL CHEM, V277, P6676, DOI 10.1074/jbc.M108246200; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Podewski EK, 2003, CIRCULATION, V107, P798, DOI 10.1161/01.CIR.0000057545.82749.FF; Rossig L, 2005, J EXP MED, V201, P1825, DOI 10.1084/jem.20042097; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Suganami E, 2004, DIABETES, V53, P2443, DOI 10.2337/diabetes.53.9.2443; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; WARE CB, 1995, DEVELOPMENT, V121, P1283; Zou YZ, 2003, CIRCULATION, V108, P748, DOI 10.1161/01.CIR.0000081773.76337.44	35	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6442	6447		10.1074/jbc.M508969200	http://dx.doi.org/10.1074/jbc.M508969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407199	hybrid			2022-12-25	WOS:000236030800038
J	Xifro, X; Falluel-Morel, A; Minano, A; Aubert, N; Fado, R; Malagelada, C; Vaudry, D; Vaudry, H; Gonzalez, B; Rodriguez-Alvarez, J				Xifro, X; Falluel-Morel, A; Minano, A; Aubert, N; Fado, R; Malagelada, C; Vaudry, D; Vaudry, H; Gonzalez, B; Rodriguez-Alvarez, J			N-methyl-D-aspartate blocks activation of JNK and mitochondrial apoptotic pathway induced by potassium deprivation in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; TERMINAL KINASE; CASPASE ACTIVATION; NEURON APOPTOSIS; BAX; JUN; DEATH; PROTEIN; PROMOTES; BCL-2	During the postnatal development of cerebellum, lack of excitatory innervation from the mossy fibers results in cerebellar granule cell (CGC) apoptosis during the migration of the cells toward the internal granule cell layer. Accordingly, CGCs die by apoptosis when cultured in physiological KCl concentrations (5 mM; K5), and they survive in the presence of depolarizing conditions such as high KCl concentration (25 mM; K25) or N-methyl-D-aspartate ( NMDA). We have recently shown that NMDA is able to exert a long lasting neuroprotective effect when added to immature ( 2 days in vitro) CGC cultures by inhibition of caspase-3 activity. Here we show that NMDA- and K25-mediated neuroprotection is associated with an increase in the levels of Bcl-2, an inhibition of K5-mediated increase in Bax, and the inhibition of the release of apoptogenic factors from mitochondria such as Smac/DIABLO and cytochrome c. Moreover, we have shown that similar effects are observed when c-Jun N-terminal kinases (JNKs) are inhibited and that treatment of CGC cultures with NMDA blocks K5-mediated JNK activation. These results allow us to postulate that the inhibition of JNK-mediated release of apoptogenic factors from mitochondria is involved in the NMDA protection from K5-mediated apoptosis of CGCs.	Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, CNRS,UA,INSERM,U413, F-76821 Mont St Aignan, France	Autonomous University of Barcelona; Autonomous University of Barcelona; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Rodriguez-Alvarez, J (corresponding author), Univ Autonoma Barcelona, Inst Neurociencies, Edifici M,Campus Bellaterra, E-08193 Barcelona, Spain.	jose.rodriguez@uab.es	Miñano-Molina, Alfredo J/C-9863-2011; Malagelada, Cristina/A-6101-2012; Malagelada, Cristina/X-6065-2019; Xifro, Xavier/ABH-2365-2020; Gonzalez, Bruno/E-6103-2016; Andrés, Fadó Fadó/L-8585-2014; VAUDRY, David/M-1454-2018; Rodriguez-Alvarez, Jose/F-8403-2011	Miñano-Molina, Alfredo J/0000-0002-7761-5682; Malagelada, Cristina/0000-0001-7185-436X; Malagelada, Cristina/0000-0001-7185-436X; Xifro, Xavier/0000-0002-7417-9475; Gonzalez, Bruno/0000-0002-7176-1320; Andrés, Fadó Fadó/0000-0002-3293-2342; VAUDRY, David/0000-0003-3567-7452; Rodriguez-Alvarez, Jose/0000-0001-8582-8082; Anthony, FALLUEL-MOREL/0000-0002-4081-6704				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Alavez S, 2003, NEUROCHEM INT, V43, P581, DOI 10.1016/S0197-0186(03)00079-2; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BALAZS R, 1988, DEV BRAIN RES, V40, P269, DOI 10.1016/0165-3806(88)90139-3; BURGOYNE RD, 1993, J NEUROCYTOL, V22, P689, DOI 10.1007/BF01181314; Caballero-Benitez A, 2003, J NEUROSCI RES, V71, P383, DOI 10.1002/jnr.10493; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fonfria E, 2002, EUR J NEUROSCI, V16, P2013, DOI 10.1046/j.1460-9568.2002.02269.x; GALLO V, 1987, J NEUROSCI, V7, P2203; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Harris CA, 2001, J BIOL CHEM, V276, P37754; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Ikemoto H, 2000, CELL DEATH DIFFER, V7, P511, DOI 10.1038/sj.cdd.4400682; Inamura N, 2001, BRAIN RES, V904, P270, DOI 10.1016/S0006-8993(01)02472-6; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MORAN J, 1989, BRAIN RES, V486, P15, DOI 10.1016/0006-8993(89)91272-9; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wadia JS, 1998, J NEUROSCI, V18, P932; Watson A, 1998, J NEUROSCI, V18, P751; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wigdal SS, 2002, J NEUROCHEM, V82, P1029, DOI 10.1046/j.1471-4159.2002.01049.x; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xifro X, 2005, EUR J NEUROSCI, V21, P827, DOI 10.1111/j.1460-9568.2005.03935.x; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6801	6812		10.1074/jbc.M504571200	http://dx.doi.org/10.1074/jbc.M504571200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16380382	hybrid			2022-12-25	WOS:000236030800079
J	Garcia-Manyes, S; Bucior, I; Ros, R; Anselmetti, D; Sanz, F; Burger, MM; Fernandez-Busquets, X				Garcia-Manyes, S; Bucior, I; Ros, R; Anselmetti, D; Sanz, F; Burger, MM; Fernandez-Busquets, X			Proteoglycan mechanics studied by single-molecule force spectroscopy of allotypic cell adhesion glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE MICROCIONA-PROLIFERA; HEPARAN-SULFATE PROTEOGLYCANS; CARBOHYDRATE-CARBOHYDRATE INTERACTIONS; MARINE SPONGE; AGGREGATION FACTOR; CIRCULAR PROTEOGLYCANS; EXTRACELLULAR-MATRIX; SELF-RECOGNITION; MICROSCOPY; BINDING	Early Metazoans had to evolve the first cell adhesion system addressed to maintaining stable interactions between cells constituting different individuals. As the oldest extant multicellular animals, sponges are good candidates to have remnants of the molecules responsible for that crucial innovation. Sponge cells associate in a species-specific process through multivalent calcium-dependent interactions of carbohydrate structures on an extracellular membrane-bound proteoglycan termed aggregation factor. Single-molecule force spectroscopy studies of the mechanics of aggregation factor self-binding indicate the existence of intermolecular carbohydrate adhesion domains. A 200-kDa aggregation factor glycan (g200) involved in cell adhesion exhibits interindividual differences in size and epitope content which suggest the existence of allelic variants. We have purified two of these g200 distinct forms from two individuals of the same sponge species. Comparison of allotypic versus isotypic g200 binding forces reveals significant differences. Surface plasmon resonance measurements show that g200 self-adhesion is much stronger than its binding to other unrelated glycans such as chondroitin sulfate. This adhesive specificity through multiple carbohydrate binding domains is a type of cooperative interaction that can contribute to explain some functions of modular proteoglycans in general. From our results it can be deduced that the binding strength/surface area between two aggregation factor molecules is comparable with that of focal contacts in vertebrate cells, indicating that strong carbohydrate-based cell adhesions evolved at the very start of Metazoan history.	Univ Barcelona, Res Ctr Bioelect & Nanobiosci, E-08028 Barcelona, Spain; Univ Barcelona, Dept Quim Fis, E-08028 Barcelona, Spain; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Bielefeld, Dept Expt Biophys & Appl Nanosci, Fac Phys, D-33615 Bielefeld, Germany	University of Barcelona; University of Barcelona; Friedrich Miescher Institute for Biomedical Research; Marine Biological Laboratory - Woods Hole; University of Bielefeld	Fernandez-Busquets, X (corresponding author), Univ Barcelona, Res Ctr Bioelect & Nanobiosci, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	xfernandez_busquets@ub.edu	Fernàndez-Busquets, Xavier/K-1323-2014; Ros, Robert/G-2154-2012; Ros, Robert/X-3030-2019; Anselmetti, Dario/F-1664-2011	Fernàndez-Busquets, Xavier/0000-0002-4622-9631; Ros, Robert/0000-0001-9271-4091; Anselmetti, Dario/0000-0002-8720-4369; Garcia-Manyes, Sergi/0000-0001-5140-2606				Abu-Lail NI, 2003, J MICROSC-OXFORD, V212, P217, DOI 10.1111/j.1365-2818.2003.01261.x; ALBERTS B, 1989, MOL BIOL CELL, P805; Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054; Bucior I, 2004, GLYCOCONJUGATE J, V21, P111, DOI 10.1023/B:GLYC.0000044843.72595.7d; Bucior I, 2004, CURR OPIN STRUC BIOL, V14, P631, DOI 10.1016/j.sbi.2004.08.006; Bucior I, 2004, J CELL BIOL, V165, P529, DOI 10.1083/jcb.200309005; Carrion-Vazquez M, 2000, PROG BIOPHYS MOL BIO, V74, P63, DOI 10.1016/S0079-6107(00)00017-1; CASSARO CMF, 1977, J BIOL CHEM, V252, P2254; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; de la Fuente JM, 2004, GLYCOCONJUGATE J, V21, P149, DOI 10.1023/B:GLYC.0000044846.80014.cb; Dicko A, 2003, BBA-BIOMEMBRANES, V1613, P87, DOI 10.1016/S0005-2736(03)00141-X; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; EGGENS I, 1989, J BIOL CHEM, V264, P9476; Fernandez-Busquets X, 2003, CELL MOL LIFE SCI, V60, P88, DOI 10.1007/s000180300006; Fernandez-Busquets X, 1999, MICROSC RES TECHNIQ, V44, P204, DOI 10.1002/(SICI)1097-0029(19990215)44:4<204::AID-JEMT2>3.0.CO;2-I; Fernandez-Busquets X, 2002, DEV COMP IMMUNOL, V26, P313, DOI 10.1016/S0145-305X(01)00079-9; Fernandez-Busquets X, 1998, J BIOL CHEM, V273, P29545, DOI 10.1074/jbc.273.45.29545; FernandezBusquets X, 1997, J BIOL CHEM, V272, P27839, DOI 10.1074/jbc.272.44.27839; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Fritz J, 1997, J STRUCT BIOL, V119, P165, DOI 10.1006/jsbi.1997.3887; Grandbois M, 1999, SCIENCE, V283, P1727, DOI 10.1126/science.283.5408.1727; Guerardel Y, 2004, J BIOL CHEM, V279, P15591, DOI 10.1074/jbc.M308928200; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Haseley SR, 2001, P NATL ACAD SCI USA, V98, P9419, DOI 10.1073/pnas.151111298; HEGNER M, 1993, SURF SCI, V291, P39, DOI 10.1016/0039-6028(93)91474-4; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HUMPHREYS S, 1977, J SUPRAMOL STR CELL, V7, P339, DOI 10.1002/jss.400070307; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Jarchow J, 2000, J STRUCT BIOL, V132, P95, DOI 10.1006/jsbi.2000.4309; Jarchow J, 1998, CELL ADHES COMMUN, V6, P405, DOI 10.3109/15419069809109149; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; KUHNS WJ, 1995, J CELL BIOCHEM, V57, P71, DOI 10.1002/jcb.240570109; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; Misevic GN, 2004, J BIOL CHEM, V279, P15579, DOI 10.1074/jbc.M308927200; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; Muller WEG, 2003, INTEGR COMP BIOL, V43, P281, DOI 10.1093/icb/43.2.281; Oberhauser AF, 2002, J MOL BIOL, V319, P433, DOI 10.1016/S0022-2836(02)00306-6; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; *PHARM BIOS AB, 1994, BIAAPPLICATIONS HDB; Pincet F, 2001, BIOPHYS J, V80, P1354, DOI 10.1016/S0006-3495(01)76108-5; Popescu O, 1997, NATURE, V386, P231, DOI 10.1038/386231b0; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Rauch U, 2001, CELL MOL LIFE SCI, V58, P1842, DOI 10.1007/PL00000822; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Roseman S, 2001, J BIOL CHEM, V276, P41527, DOI 10.1074/jbc.R100053200; Sanderson RD, 2001, SEMIN CELL DEV BIOL, V12, P89, DOI 10.1006/scdb.2000.0241; Schwartz NB, 2000, FRONT BIOSCI, V5, pD649; Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242; Seog J, 2002, MACROMOLECULES, V35, P5601, DOI 10.1021/ma0121621; Smith BL, 1999, NATURE, V399, P761, DOI 10.1038/21607; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; Spillmann D., 2000, CARBOHYDRATES CHEM B, P1061; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; Tromas C, 2001, ANGEW CHEM INT EDIT, V40, P3052, DOI 10.1002/1521-3773(20010817)40:16<3052::AID-ANIE3052>3.0.CO;2-Q; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Yamaguchi Y, 2001, SEMIN CELL DEV BIOL, V12, P99, DOI 10.1006/scdb.2000.0238; Zhang XH, 2002, BIOPHYS J, V83, P2270, DOI 10.1016/S0006-3495(02)73987-8	64	30	30	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5992	5999		10.1074/jbc.M507878200	http://dx.doi.org/10.1074/jbc.M507878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373355	Green Published, hybrid			2022-12-25	WOS:000235568900080
J	Edwin, F; Singh, R; Endersby, R; Baker, SJ; Patel, TB				Edwin, F; Singh, R; Endersby, R; Baker, SJ; Patel, TB			The tumor suppressor PTEN is necessary for human sprouty 2-mediated inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE-ACTIVITY; DROSOPHILA-SPROUTY; KINASE PATHWAY; C-TERMINUS; GROWTH; ACTIVATION; PROTEIN; MIGRATION; PHOSPHORYLATION; ARREST	Sprouty family proteins are novel regulators of growth factor actions. Human Sprouty 2 (hSPRY2) inhibits the proliferation of a number of different cell types. However, the mechanisms involved in the anti-proliferative actions of hSPRY2 remain to be elucidated. Here we have demonstrated that hSPRY2 increases the amount of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) and decreases its phosphorylation. The resultant increase in PTEN activity is reflected in decreased activation of Akt by epidermal growth factor and serum. Consistent with increased PTEN activity, in hSPRY2-expressing cells, the progression of cells from the G(1) to S phase is decreased. By using PTEN null primary mouse embryonic fibroblasts and their isogenic controls as well as small interfering RNA against PTEN, we demonstrated that PTEN is necessary for hSPRY2 to inhibit Akt activation by epidermal growth factor as well as cell proliferation. Overall, we concluded that hSPRY2 mediates its anti-proliferative actions by altering PTEN content and activity.	Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	Loyola University Chicago; St Jude Children's Research Hospital	Patel, TB (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, 2160 S 1st Ave, Maywood, IL 60153 USA.	tpatel7@lumc.edu	Endersby, Raelene/A-2969-2013; Baker, Suzanne J/N-8167-2018	Endersby, Raelene/0000-0003-3554-2769; 	NCI NIH HHS [CA096832] Funding Source: Medline; NHLBI NIH HHS [HL59679] Funding Source: Medline; NIGMS NIH HHS [GM073181] Funding Source: Medline; NINDS NIH HHS [NS44172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA096832] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Furnari FB, 1998, CANCER RES, V58, P5002; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim MA, 2004, ONCOGENE, V23, P9348, DOI 10.1038/sj.onc.1208147; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Minowada G, 1999, DEVELOPMENT, V126, P4465; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; Poppleton HM, 2004, BIOCHEM BIOPH RES CO, V323, P98, DOI 10.1016/j.bbrc.2004.08.070; Reich A, 1999, DEVELOPMENT, V126, P4139; Rozen S, 2000, Methods Mol Biol, V132, P365; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Weng LP, 1999, CANCER RES, V59, P5808; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhang CX, 2005, ARTERIOSCL THROM VAS, V25, P533, DOI 10.1161/01.ATV.0000155461.50450.5a	49	84	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4816	4822		10.1074/jbc.M508300200	http://dx.doi.org/10.1074/jbc.M508300200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371366	hybrid			2022-12-25	WOS:000235426200032
J	Ishii, S; Yano, T; Hayashi, H				Ishii, S; Yano, T; Hayashi, H			Expression and characterization of the peptidase domain of Streptococcus pneumoniae ComA, a bifunctional ATP-binding cassette transporter involved in quorum sensing pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; GENETIC-TRANSFORMATION; BACTERIA; ENDOPEPTIDASE; FAMILY	ComA, a member of the bacteriocin ATP-binding cassette transporters, is postulated to be responsible for both the processing of the propeptide ComC and secretion of the mature competence-stimulating peptide, which regulates the competence and subsequent genetic transformation in Streptococcus pneumoniae. A recombinant N-terminal peptidase domain of ComA, designated PEP, was expressed as a soluble protein in Escherichia coli, purified to homogeneity, and characterized. Gel-filtration analysis revealed that PEP functions as a monomer. The purified PEP exhibited an efficient proteolytic activity for the substrate ComC, which was cleaved after the double glycine site. The stability of PEP was examined by circular dichroism analyses. A convenient method for analyzing the proteolytic activity of PEP was developed, and the kinetic parameters for ComC were determined (k(cat) = 1.5 +/- 0.083 min(-1) and K-m = 62 +/- 9.0 mu M). Replacements of Cys(17) of PEP with Ser or Ala and His(96) with Ala resulted in complete loss of activity, indicating that both Cys(17) and His(96) are essential for the catalysis. Together with information from a protease data base, the N-terminal domain of ComA was concluded to belong to the same clan as the papain-like cysteine proteases. Mutant substrates, in which each of the double glycines was replaced with Ala, were cleaved very poorly by PEP. The mechanism of this strict substrate specificity is discussed on the basis of the sequence alignment with other cysteine proteases.	Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan	Osaka Medical College	Hayashi, H (corresponding author), Osaka Med Coll, Dept Biochem, 2-7 Daigakumachi, Osaka 5698686, Japan.	hayashi@art.osaka-med.ac.jp						Cvitkovitch DG, 2003, J CLIN INVEST, V112, P1626, DOI 10.1172/JCI200320430; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Gabrilovac J, 2004, IMMUNOL LETT, V91, P39, DOI 10.1016/j.imlet.2003.10.006; Guarne A, 1998, EMBO J, V17, P7469, DOI 10.1093/emboj/17.24.7469; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kleerebezem M, 2001, PEPTIDES, V22, P1579, DOI 10.1016/S0196-9781(01)00493-4; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Lazazzera BA, 2000, CURR OPIN MICROBIOL, V3, P177, DOI 10.1016/S1369-5274(00)00072-2; Luo P, 2004, MOL MICROBIOL, V54, P172, DOI 10.1111/j.1365-2958.2004.04254.x; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; OHARA BP, 1995, BIOCHEMISTRY-US, V34, P13190, DOI 10.1021/bi00040a034; Rawlings ND, 1999, NUCLEIC ACIDS RES, V27, P325, DOI 10.1093/nar/27.1.325; Umetsu H, 2004, BIOSCI BIOTECH BIOCH, V68, P945, DOI 10.1271/bbb.68.945; Woessner JF, 2004, HDB PROTEOLYTIC ENZY; Wu KH, 2004, J BIOL CHEM, V279, P901, DOI 10.1074/jbc.M308296200; ZOLLER H, 1993, HDB ENZYME INHIBITOR	19	31	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4726	4731		10.1074/jbc.M512516200	http://dx.doi.org/10.1074/jbc.M512516200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377622	hybrid			2022-12-25	WOS:000235426200021
J	Kreft, SG; Wang, L; Hochstrasser, M				Kreft, SG; Wang, L; Hochstrasser, M			Membrane topology of the yeast endoplasmic reticulum-localized ubiquitin ligase Doa10 and comparison with its human ortholog TEB4 (MARCH-VI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; PROTEIN-QUALITY CONTROL; HIDDEN MARKOV MODEL; I HEAVY-CHAINS; SACCHAROMYCES-CEREVISIAE; PREDICTION; DOMAIN; MEMBER	Quality control machinery in the endoplasmic reticulum (ER) helps ensure that only properly folded and assembled proteins accumulate in the ER or continue along the secretory pathway. Aberrant proteins are retrotranslocated to the cytosol and degraded by the proteasome, a process called ER-associated degradation. Doa10, a transmembrane protein of the ER/nuclear envelope, is one of the primary ubiquitin ligases (E3s) participating in ER-associated degradation in Saccharomyces cerevisiae. Here we report the membrane organization of the 1319-residue Doa10 polypeptide. The topology was determined by fusing a dual-topology reporter after 16 different Doa10 fragments. Our results indicate that Doa10 contains 14 transmembrane helices (TMs). Based on protease digestion of yeast microsomes, both the N-terminal RING-CH domain and the Cterminus face the cytosol. Notably, the experimentally derived topology was not predicted correctly by any of the generally available TM prediction algorithms. Bioinformatic analysis and in silico mutagenesis guided the topological studies through problematic regions. The conserved TD domain in Doa10 includes three TMs. These TMs might function in cofactor binding or substrate recognition, or they might be part of a retrotranslocation channel. The Derlins were previously proposed to provide such channels, but we show that the two yeast Derlins are not required for degradation of Doa10 membrane substrates, as was found before for the Sec61 translocon. Finally, we provide evidence that the likely human Doa10 ortholog, TEB4 (MARCH-VI), adopts a topology similar to that of Doa10.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Hochstrasser, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	mark.hochstrasser@yale.edu		Hochstrasser, Mark/0000-0002-1131-5484	NIGMS NIH HHS [GM46904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046904, R01GM046904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dodd RB, 2004, J BIOL CHEM, V279, P53840, DOI 10.1074/jbc.M409662200; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; Hassink G, 2005, BIOCHEM J, V388, P647, DOI 10.1042/BJ20041241; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hitt R, 2004, FEMS YEAST RES, V4, P721, DOI 10.1016/j.femsyr.2004.02.003; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huyer G, 2004, J BIOL CHEM, V279, P38369, DOI 10.1074/jbc.M402468200; Kahsay RY, 2005, BIOINFORMATICS, V21, P1853, DOI 10.1093/bioinformatics/bti303; Kall L, 2005, BIOINFORMATICS, V21, pI251, DOI 10.1093/bioinformatics/bti1014; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RAVID T, 2006, IN PRESS EMBO J, V25; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sengstag C, 2000, METHOD ENZYMOL, V327, P175, DOI 10.1016/S0076-6879(00)27275-3; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; Wang QQ, 2003, EMBO J, V22, P3792, DOI 10.1093/emboj/cdg378; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656	36	112	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4646	4653		10.1074/jbc.M512215200	http://dx.doi.org/10.1074/jbc.M512215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373356	hybrid, Green Submitted			2022-12-25	WOS:000235426200012
J	Yamamura, Y; Lee, WL; Inoue, K; Ida, H; Ito, Y				Yamamura, Y; Lee, WL; Inoue, K; Ida, H; Ito, Y			RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; BCL-2 FAMILY-MEMBER; FUNCTIONAL COOPERATION; OXIDATIVE STRESS; BIM; EXPRESSION; GROWTH; GENE; PROTEINS; PROMOTER	The transcription factor RUNX3, which mediates apoptosis and cell growth inhibition in gastric epithelial cells, is a candidate tumor suppressor that is frequently lost in gastric cancer cells. Here, we found that restoration of RUNX3 expression in the cell line not expressing RUNX3 induced apoptosis and that it physically interacted with the Forkhead transcription factor FoxO3a/FKHRL1, known to be an important regulator of apoptosis and the cell cycle. Active unphosphorylated FoxO3a/FKHRL1 was expressed in the gastric cancer cell lines. RUNX3-induced apoptosis depended on the expression of Bim, a proapoptotic BH3-only protein, and both RUNX3 and FoxO3a/FKHRL1 were required for induction of Bim expression. Furthermore, we showed that interaction of RUNX3 and FoxO3a/FKHRL1 was also indispensable for Bim expression and apoptosis in mouse embryonic fibroblasts. In the Bim promoter, RUNX3 bound to two conserved RUNX-binding elements (RBE1 and RBE2), with RBE1 being immediately downstream of a FoxO-binding element. The physical interaction of RUNX3 and FoxO3a/FKHRL1 on the Bim promoter activated transcription of Bim. These findings show that RUNX3 cooperates with FoxO3a/FKHRL1 to participate in the induction of apoptosis by activating Bim and may play an important role in tumor suppression in gastric cancer.	Natl Univ Singapore, Natl Univ Med Inst, Oncol Res Inst, Clin Res Ctr, Singapore 117592, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117592, Singapore; Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117592, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Ito, Y (corresponding author), Natl Univ Singapore, Natl Univ Med Inst, Oncol Res Inst, Clin Res Ctr, Block MD11,Level 5,10 Med Dr, Singapore 117592, Singapore.	itoy@imcb.a-star.edu.sg						Abrams MT, 2004, J BIOL CHEM, V279, P55809, DOI 10.1074/jbc.M411767200; Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Barnes GL, 2003, CANCER RES, V63, P2631; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Kim SG, 2001, ONCOGENE, V20, P1254, DOI 10.1038/sj.onc.1204203; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Oki E, 2005, INT J CANCER, V117, P376, DOI 10.1002/ijc.21170; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; Sato T, 2005, IMMUNITY, V22, P317, DOI 10.1016/j.immuni.2005.01.012; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi MJ, 1998, J IMMUNOL, V161, P6751; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Viard-Leveugle I, 2003, J BIOL CHEM, V278, P16183, DOI 10.1074/jbc.M212188200; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	44	111	123	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5267	5276		10.1074/jbc.M512151200	http://dx.doi.org/10.1074/jbc.M512151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373335	hybrid			2022-12-25	WOS:000235426200081
J	Jin, LM; Foss, CE; Zhao, XY; Mills, TM; Wang, MH; McCluskey, LP; Yaddanapud, GSS; Falck, JR; Imig, JD; Webb, RC				Jin, LM; Foss, CE; Zhao, XY; Mills, TM; Wang, MH; McCluskey, LP; Yaddanapud, GSS; Falck, JR; Imig, JD; Webb, RC			Cytochrome P450 epoxygenases provide a novel mechanism for penile erection	FASEB JOURNAL			English	Article						erectile dysfunction; epoxyeicosatrienoic acids; corpus cavernosum; smooth muscle	NITRIC-OXIDE SYNTHASE; FLOW-INDUCED DILATION; HYPERPOLARIZING FACTOR; ARACHIDONIC-ACID; CALCIUM DOBESILATE; DEPENDENT HYPERPOLARIZATION; EPOXYEICOSATRIENOIC ACIDS; GENE-TRANSFER; DYSFUNCTION; RELAXATION	Erectile dysfunction (ED) is estimated to affect more than 30 million American men and 152 million men worldwide. Therapeutic agents targeting the nitric oxide/cyclic GMP signaling pathway have successfully treated patients with ED; however, the efficacies of these treatments are significantly lower in specific populations such as patients with diabetes. The goal of this study was to discover and identify new endothelium-derived relaxing factors involved in the regulation of erectile function, providing alternative therapeutic targets for treatment of ED. Immunoblotting results showed that protein expressions of epoxygenases from cytochrome P450 (CYP) 2B, 2C and 2J subfamilies, as well as NADPH CYP reductase were present in rat corpora cavernosa, which was confirmed by immunohistochemical analysis. Furthermore, CYP2C was localized in cavernosal endothelial cells using double immunolabeling. CYP epoxygenase activity was analyzed by reverse-phase high-pressure liquid chromatography; and the results showed that 11,12- epoxyeicosatrienoic acid (EET) was the major product metabolized by CYP epoxygenases in rat corpora cavernosa. Inhibition of EETs function by injection of an EETs antagonist into rat penis significantly decreased intracavernosal pressure-induced by electrical stimulation of the major pelvic ganglion in vivo. In conclusion, our results suggest that EETs, produced by CYP epoxygenases, in penile endothelial cells serve as vasodilators. Inhibition of this pathway attenuated erectile function, suggesting that EETs are required for normal erection.	Johns Hopkins Univ, Dept Urol, Baltimore, MD 21287 USA; Med Coll Georgia, Dept Physiol, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Surg, Urol Sect, Augusta, GA 30912 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Johns Hopkins University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jin, LM (corresponding author), Johns Hopkins Univ, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA.	ljin8@jhmi.edu	Falck, John R/B-3030-2011	Falck, John R/0000-0002-9219-7845; McCluskey, Lynnette/0000-0003-1765-6068; Imig, John/0000-0002-9668-2899	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071138, P01HL074167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-74167, HL-71138] Funding Source: Medline; NIDDK NIH HHS [DK38226] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angulo J, 2003, BIOCHEM BIOPH RES CO, V312, P1202, DOI 10.1016/j.bbrc.2003.11.034; Angulo J, 2003, BRIT J PHARMACOL, V139, P854, DOI 10.1038/sj.bjp.0705293; Archer SL, 2003, CIRCULATION, V107, P769, DOI 10.1161/01.CIR.0000047278.28407.C2; Bauersachs J, 1996, CIRCULATION, V94, P3341, DOI 10.1161/01.CIR.94.12.3341; Bivalacqua TJ, 2003, J UROLOGY, V169, P1911, DOI 10.1097/01.ju.0000051881.14239.4a; Brandes RP, 2000, P NATL ACAD SCI USA, V97, P9747, DOI 10.1073/pnas.97.17.9747; Burnett AL, 2004, INT J IMPOT RES, V16, pS15, DOI 10.1038/sj.ijir.3901209; Burnett AL, 2002, J ANDROL, V23, P92, DOI 10.1002/j.1939-4640.2002.tb02601.x; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA J, 1981, BIOCHEM BIOPH RES CO, V101, P1357, DOI 10.1016/0006-291X(81)91597-7; Champion HC, 1999, P NATL ACAD SCI USA, V96, P11648, DOI 10.1073/pnas.96.20.11648; Chitaley K, 2001, NAT MED, V7, P119, DOI 10.1038/83258; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; de Tejada IS, 2002, DIABETES CARE, V25, P2159; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; DUBE S, 2004, AM J PHYSIOL-HEART C, V280, pH2581; Fisslthaler B, 2001, HYPERTENSION, V38, P1427, DOI 10.1161/hy1201.096532; Gauthier KM, 2002, CIRC RES, V90, P1028, DOI 10.1161/01.RES.0000018162.87285.F8; Goldstein I, 2003, DIABETES CARE, V26, P777, DOI 10.2337/diacare.26.3.777; Gonzalez-Cadavid NF, 2004, EXP GERONTOL, V39, P1705, DOI 10.1016/j.exger.2004.06.022; Gonzalgo ML, 2003, J UROLOGY, V170, P503, DOI 10.1097/01.ju.0000071478.69480.fd; Huang A, 2005, CIRC RES, V96, P376, DOI 10.1161/01.RES.0000155332.17783.26; Huang A, 2004, CIRC RES, V94, P245, DOI 10.1161/01.RES.0000111525.96232.46; Huang A, 2001, AM J PHYSIOL-HEART C, V280, pH2462, DOI 10.1152/ajpheart.2001.280.6.H2462; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; Lin CS, 2002, BJU INT, V89, P955, DOI 10.1046/j.1464-410X.2002.02792.x; McKinlay JB, 2000, INT J IMPOT RES, V12, pS6, DOI 10.1038/sj.ijir.3900567; Miura H, 2001, CIRCULATION, V103, P1992; Mizusawa H, 2001, BRIT J PHARMACOL, V132, P1333, DOI 10.1038/sj.bjp.0703938; Nishikawa Y, 2000, AM J PHYSIOL-HEART C, V279, pH459, DOI 10.1152/ajpheart.2000.279.2.H459; Podlasek CA, 2001, J UROLOGY, V166, P746, DOI 10.1016/S0022-5347(05)66054-5; Popp R, 1998, CIRC RES, V82, P696, DOI 10.1161/01.RES.82.6.696; Price DE, 1998, DIABETIC MED, V15, P821, DOI 10.1002/(SICI)1096-9136(199810)15:10<821::AID-DIA697>3.0.CO;2-P; Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Rota R, 2004, EUR J PHARMACOL, V495, P217, DOI 10.1016/j.ejphar.2004.05.019; Ruiz E, 1997, BRIT J PHARMACOL, V121, P711, DOI 10.1038/sj.bjp.0701184; Shimokawa H, 1996, J CARDIOVASC PHARM, V28, P703, DOI 10.1097/00005344-199611000-00014; Stanarius A, 2001, UROL RES, V29, P168, DOI 10.1007/s002400100181; Udosen IT, 2003, AM J PHYSIOL-HEART C, V285, pH2054, DOI 10.1152/ajpheart.00075.2003; Urakami-Harasawa L, 1997, J CLIN INVEST, V100, P2793, DOI 10.1172/JCI119826; Vickers MA, 2002, INT J IMPOT RES, V14, P466, DOI 10.1038/sj.ijir.3900910; Wang H, 2003, J PHARMACOL EXP THER, V307, P753, DOI 10.1124/jpet.103.052787; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966	44	18	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					539	+		10.1096/fj.05-4341fje	http://dx.doi.org/10.1096/fj.05-4341fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16415108				2022-12-25	WOS:000235996000016
J	Zhang, JP; Wang, Y; Chu, YW; Su, LP; Gong, YP; Zhang, RH; Xiong, SD				Zhang, JP; Wang, Y; Chu, YW; Su, LP; Gong, YP; Zhang, RH; Xiong, SD			Agrin is involved in lymphocytes activation that is mediated by alpha-dystroglycan	FASEB JOURNAL			English	Article						agrin; alpha-dystroglycan; immunological synapse; lymphocyte activation	IMMUNOLOGICAL SYNAPSE FORMATION; T-CELL-ACTIVATION; DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; TORPEDO ELECTRIC ORGAN; BETA-DYSTROGLYCAN; ACETYLCHOLINE-RECEPTORS; EXTRACELLULAR-MATRIX; MUTANT MICE; COSTIMULATION; IDENTIFICATION	It is well established that agrin, an extracellular matrix protein, plays a crucial role in the formation of neuromuscular junctions. Recent evidence indicates that agrin also contributes to immunological synapse formation. However, little is known about how agrin induces the activation of lymphocytes and whose receptors mediate its regulatory effects on these cells. In the present study, agrin was detected in lymphocytes. Up-regulation of agrin expression was involved in lymphocyte activation whereas down-regulation of its expression led to inhibition of both antigen-specific and nonspecific lymphocyte activation, indicating an intrinsic role for agrin in the activation of lymphocytes. Unexpectedly, unlike that found in muscle cells where there is coexpression of muscle-specific kinase (MuSK) and alpha-dystroglycan receptors for agrin, only alpha-dystroglycan could be detected in lymphocytes. Confocal examination showed that alpha-dystroglycan colocalized with agrin in forming the immunological synapse. Down-regulation of alpha-dystroglycan expression inhibited lymphocyte activation even in the presence of agrin. However, agrin involved in down-regulation of alpha-dystroglycan receptors did not increase the inhibitory effect on lymphocytes activation. The anti-alpha-dystroglycan antibody also induced lymphocytes activation. Taken together, these findings strongly indicate that agrin and alpha-dystroglycan mediate lymphocyte activation. Furthermore, agrin-involved lymphocyte activation is mediated by alpha-dystroglycan.-Zhang, J., Wang, Y., Chu, Y., Su, L., Gong, Y., Zhang, R., Xiong, S. Agrin is involved in lymphocytes activation that is mediated by alpha-dystroglycan.	Fudan Univ, Shanghai Med Coll, Dept Immunol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Coll, Key Lab Mol Med, Minist Educ, Shanghai 200032, Peoples R China; Shanghai Univ E Inst, Div Immunol, Shanghai, Peoples R China	Fudan University; Fudan University	Xiong, SD (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Immunol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	sdxiongfd@126.com						Andres PG, 2004, J IMMUNOL, V172, P5880, DOI 10.4049/jimmunol.172.10.5880; Bezakova G, 2003, NAT REV MOL CELL BIO, V4, P295, DOI 10.1038/nrm1074; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; Bromley SK, 2002, IMMUNOLOGY, V106, P289, DOI 10.1046/j.1365-2567.2002.01441.x; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Friedl P, 2004, TRENDS CELL BIOL, V14, P557, DOI 10.1016/j.tcb.2004.09.005; Friedl P, 2002, IMMUNOL REV, V186, P83, DOI 10.1034/j.1600-065X.2002.18608.x; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Gingras J, 2002, J CELL BIOL, V158, P1109, DOI 10.1083/jcb.200203012; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hailman E, 2002, IMMUNITY, V16, P839, DOI 10.1016/S1074-7613(02)00326-6; Herbst R, 2002, DEVELOPMENT, V129, P5449, DOI 10.1242/dev.00112; Huppa JB, 2003, NAT REV IMMUNOL, V3, P973, DOI 10.1038/nri1245; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Ilsley JL, 2001, CELL SIGNAL, V13, P625, DOI 10.1016/S0898-6568(01)00188-7; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jacobson C, 1998, J NEUROSCI, V18, P6340; James M, 2000, J CELL SCI, V113, P1717; Kahl J, 2003, J NEUROSCI, V23, P392, DOI 10.1523/JNEUROSCI.23-02-00392.2003; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Kiefer F, 2002, TRANSPL IMMUNOL, V9, P69, DOI 10.1016/S0966-3274(02)00009-6; Krogsgaard M, 2003, SEMIN IMMUNOL, V15, P307, DOI 10.1016/j.smim.2003.09.002; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Maldonado RA, 2004, NATURE, V431, P527, DOI 10.1038/nature02916; Miceli MC, 2001, SEMIN IMMUNOL, V13, P115, DOI 10.1006/smim.2000.0303; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Phillips WD, 1995, CLIN EXP PHARMACOL P, V22, P961, DOI 10.1111/j.1440-1681.1995.tb02333.x; Richie LI, 2002, IMMUNITY, V16, P595, DOI 10.1016/S1074-7613(02)00299-6; Salgado FJ, 2003, J BIOL CHEM, V278, P24849, DOI 10.1074/jbc.M212978200; Sambrook J., MOL CLONING LAB MANU; Samstag Y, 2003, J LEUKOCYTE BIOL, V73, P30, DOI 10.1189/jlb.0602272; Schwartz JCD, 2002, NAT IMMUNOL, V3, P427, DOI 10.1038/ni0502-427; Sciandra F, 2001, EUR J BIOCHEM, V268, P4590, DOI 10.1046/j.1432-1327.2001.02386.x; Shaw AS, 2001, NAT IMMUNOL, V2, P575, DOI 10.1038/89712; Tseng SY, 2002, CURR OPIN CELL BIOL, V14, P575, DOI 10.1016/S0955-0674(02)00370-8; WALLACE BG, 1989, J NEUROSCI, V9, P1294; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wetzel SA, 2002, J IMMUNOL, V169, P6092, DOI 10.4049/jimmunol.169.11.6092; Wulfing C, 2002, NAT IMMUNOL, V3, P42, DOI 10.1038/ni741	49	31	35	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					50	58		10.1096/fj.04-3303com	http://dx.doi.org/10.1096/fj.04-3303com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394267				2022-12-25	WOS:000235996000044
J	Frame, FM; Rogoff, HA; Pickering, MT; Cress, WD; Kowalik, TF				Frame, F. M.; Rogoff, H. A.; Pickering, M. T.; Cress, W. D.; Kowalik, T. F.			E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts	ONCOGENE			English	Article						E2F1; DNA damage; cell cycle checkpoint; apoptosis	NIJMEGEN BREAKAGE SYNDROME; DNA-DAMAGE CHECKPOINT; TRANSCRIPTION FACTOR; MRE11 COMPLEX; NUCLEAR FOCI; HISTONE H2AX; S-PHASE; ATAXIA-TELANGIECTASIA; TUMOR SUPPRESSION; GROWTH CONTROL	Deregulation of the Rb/E2F pathway in human fibroblasts results in an E2F1-mediated apoptosis dependent on Atm, Nbs1, Chk2 and p53. Here, we show that E2F1 expression results in MRN foci formation, which is independent of the Nbs1 interacting region and the DNA-binding domain of E2F1. E2F1-induced MRN foci are similar to irradiation-induced foci (IRIF) that result from double-strand DNA breaks because they correlate with 53BP1 and gamma H2AX foci, do not form in NBS cells, do form in AT cells and do not correlate with cell cycle entry. In fact, we find that in human fibroblasts deregulated E2F1 causes a G1 arrest, blocking serum-induced cell cycle progression, in part through an Nbs1/53BP1/p53/p21(WAF1/CIP1) checkpoint pathway. This checkpoint protects against apoptosis because depletion of 53BP1 or p21(WAF1/CIP1) increases both the rate and extent of apoptosis. Nbs1 and p53 contribute to both checkpoint and apoptosis pathways. These results suggest that E2F1-induced foci generate a cell cycle checkpoint that, with sustained E2F1 activity, eventually yields to apoptosis. Uncontrolled proliferation due to Rb/E2F deregulation as well as inactivation of both checkpoint and apoptosis programs would then be required for transformation of normal cells to tumor cells.	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA; Univ Massachusetts, Program Immunol & Virol, Worcester, MA USA; H Lee Moffitt Comprehens Canc Ctr, Mol Oncol Program, Tampa, FL USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; H Lee Moffitt Cancer Center & Research Institute	Kowalik, TF (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, 55 Lake Ave N, Worcester, MA 01655 USA.	timothy.kowalik@umassmed.edu		Frame, Fiona/0000-0002-2377-1110	NCI NIH HHS [CA90489, CA86038] Funding Source: Medline; NIAID NIH HHS [5T32 AI09749] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090489, R01CA086038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Castillo JP, 2000, J VIROL, V74, P8028, DOI 10.1128/JVI.74.17.8028-8037.2000; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lindstrom MS, 2003, ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Lombard DB, 2000, CANCER RES, V60, P2331; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; PICKERING MT, 2005, ONOCOGENE; Powers JT, 2004, MOL CANCER RES, V2, P203; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200	49	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3258	3266		10.1038/sj.onc.1209352	http://dx.doi.org/10.1038/sj.onc.1209352			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434972				2022-12-25	WOS:000237951200004
J	Ragona, L; Catalano, M; Luppi, M; Cicero, D; Eliseo, T; Foote, J; Fogolari, F; Zetta, L; Molinari, H				Ragona, L; Catalano, M; Luppi, M; Cicero, D; Eliseo, T; Foote, J; Fogolari, F; Zetta, L; Molinari, H			NMR dynamic studies suggest that allosteric activation regulates ligand binding in chicken liver bile acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT EXPORT PUMP; MOLECULAR-DYNAMICS; CONFORMATIONAL EXCHANGE; BETA-LACTOGLOBULIN; BACKBONE DYNAMICS; ESCHERICHIA-COLI; RELAXATION; N-15; SYSTEM; SPECTROSCOPY	Apo chicken liver bile acid-binding protein has been structurally characterized by NMR. The dynamic behavior of the protein in its apo- and holo-forms, complexed with chenodeoxycholate, has been determined via N-15 relaxation and steady state heteronuclear N-15(H-1) nuclear Overhauser effect measurements. The dynamic parameters were obtained at two pH values (5.6 and 7.0) for the apoprotein and at pH 7.0 for the holoprotein, using the model free approach. Relaxation studies, performed at three different magnetic fields, revealed a substantial conformational flexibility on the microsecond to millisecond time scales, mainly localized in the C-terminal face of the beta-barrel. The observed dynamics are primarily caused by the protonation/deprotonation of a buried histidine residue, His(98), located on this flexible face. A network of polar buried side chains, defining a spine going from the E to J strand, is likely to provide the long range connectivity needed to communicate motion from His(98) to the EF loop region. NMR data are accompanied by molecular dynamics simulations, suggesting that His(98) protonation equilibrium is the triggering event for the modulation of a functionally important motion, i.e. the opening/closing at the protein open end, whereas ligand binding stabilizes one of the preexisting conformations ( the open form). The results presented here, complemented with an analysis of proteins belonging to the intracellular lipid-binding protein family, are consistent with a model of allosteric activation governing the binding mechanism. The functional role of this mechanism is thoroughly discussed within the framework of the mechanism for the enterohepatic circulation of bile acids.	Univ Verona, Dept Sci & Tecnol, I-37134 Verona, Italy; CNR, ISMAC, Lab NMR, I-20133 Milan, Italy; Univ Roma Tor Vergata, Dipartimento Sci & Tecnol Chim, I-00133 Rome, Italy; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-43100 Udine, Italy	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto per lo Studio delle Macromolecole (ISMAC-CNR); University of Rome Tor Vergata; Fred Hutchinson Cancer Center; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Molinari, H (corresponding author), Univ Verona, Dept Sci & Tecnol, Strada Grazie 15, I-37134 Verona, Italy.	molinari@sci.univr.it	molinari, henriette/ABE-9775-2021; Molinari, Henriette/A-1695-2008; Cicero, Daniel/AAV-5203-2021; Ragona, Laura/AAB-9691-2020	Molinari, Henriette/0000-0002-3678-130X; Ragona, Laura/0000-0003-3893-7117; Fogolari, Federico/0000-0001-9862-250X				ABRAGAM A, 1961, PRINCIPLES NUCLEAR M, P315; ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; Bakowies D, 2002, J MOL BIOL, V315, P713, DOI 10.1006/jmbi.2001.5202; Ballatori N, 2000, AM J PHYSIOL-GASTR L, V278, pG57, DOI 10.1152/ajpgi.2000.278.1.G57; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Cicero DO, 2003, INT J BIOL MACROMOL, V33, P193, DOI 10.1016/j.ijbiomac.2003.08.010; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Eberini I, 2004, PROTEINS, V54, P744, DOI 10.1002/prot.10643; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fogolari F, 2005, PROTEINS, V59, P91, DOI 10.1002/prot.20384; Fogolari F, 2001, J COMPUT CHEM, V22, P1830, DOI 10.1002/jcc.1134; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hass MAS, 2004, J AM CHEM SOC, V126, P753, DOI 10.1021/ja030366m; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kramer W, 1997, EUR J BIOCHEM, V249, P456, DOI 10.1111/j.1432-1033.1997.00456.x; Kramer W, 1998, BIOCHEM J, V333, P335, DOI 10.1042/bj3330335; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kurz M, 2003, PROTEINS, V50, P312, DOI 10.1002/prot.10289; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LIPARI G, 1981, BIOCHEMISTRY-US, V20, P6250, DOI 10.1021/bi00524a053; Lucke C, 2000, EUR J BIOCHEM, V267, P2929, DOI 10.1046/j.1432-1327.2000.01307.x; Lucke C, 1996, STRUCTURE, V4, P785, DOI 10.1016/S0969-2126(96)00086-X; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Marin JJG, 2003, BBA-BIOMEMBRANES, V1611, P249, DOI 10.1016/S0005-2736(03)00080-4; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; Nichesola D, 2004, BIOCHEMISTRY-US, V43, P14072, DOI 10.1021/bi0489661; Pawley NH, 2001, J BIOMOL NMR, V20, P149, DOI 10.1023/A:1011249816560; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; Phan IQH, 1996, J BIOMOL NMR, V8, P369, DOI 10.1007/BF00228140; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; Prost E, 2002, J MAGN RESON, V159, P76, DOI 10.1016/S1090-7807(02)00003-4; Ragona L, 2003, J BIOL CHEM, V278, P38840, DOI 10.1074/jbc.M306269200; SCHARSCHMIDT BF, 1987, ANNU REV PHYSIOL, V49, P69; Small DM, 1997, J CLIN INVEST, V99, P1807, DOI 10.1172/JCI119345; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Tochtrop GP, 2004, J AM CHEM SOC, V126, P11024, DOI 10.1021/ja047589c; Tochtrop GP, 2003, BIOCHEMISTRY-US, V42, P11561, DOI 10.1021/bi0346502; Tochtrop GP, 2002, P NATL ACAD SCI USA, V99, P1847, DOI 10.1073/pnas.012379199; Trauner M, 2003, PHYSIOL REV, V83, P633, DOI 10.1152/physrev.00027.2002; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; Vasile F, 2003, J BIOMOL NMR, V25, P157, DOI 10.1023/A:1022277727303; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; WADE RC, 1994, NAT STRUCT BIOL, V1, P65, DOI 10.1038/nsb0194-65	55	50	51	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9697	9709		10.1074/jbc.M513003200	http://dx.doi.org/10.1074/jbc.M513003200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16439356	hybrid			2022-12-25	WOS:000236404700082
J	Zhang, YM; Wang, H; Li, JR; Dong, L; Xu, P; Chen, WZ; Neve, RL; Volpe, JJ; Rosenberg, PA				Zhang, YM; Wang, H; Li, JR; Dong, L; Xu, P; Chen, WZ; Neve, RL; Volpe, JJ; Rosenberg, PA			Intracellular zinc release and ERK phosphorylation are required upstream of 12-lipoxygenase activation in peroxynitrite toxicity to mature rat oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ACTIVE MULTIPLE-SCLEROSIS; INDUCED CELL-DEATH; INDUCED NEURONAL APOPTOSIS; SIGNAL-REGULATED KINASE; GLUTATHIONE DEPLETION; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID	Peroxynitrite toxicity has been implicated in the pathogenesis of white matter injury. The mechanisms of peroxynitrite toxicity to oligodendrocytes (OLs), the major cell type of the white matter, are unknown. Using primary cultures of mature OLs that express myelin basic protein, we found that 3-morpholinosydnonimine, a peroxynitrite generator, caused toxicity to OLs. N, N, N', N'-tetrakis (2-pyridylmethyl) ethylenediamine, a zinc chelator, completely blocked peroxynitrite-induced toxicity. Use of FluoZin-3, a specific fluorescence zinc indicator, demonstrated the liberation of zinc from intracellular stores by peroxynitrite. Peroxynitrite caused the sequential activation of extracellular signal-regulated kinase 42/44 (ERK42/44), 12-lipoxygenase, and generation of reactive oxygen species, which were all dependent upon the intracellular release of zinc. The same cell death pathway was also activated when exogenous zinc was used. These results suggest that in addition to preventing the formation of peroxynitrite, useful strategies in preventing disease progression in pathologies in which peroxynitrite toxicity plays a critical role might include maintaining intracellular zinc homeostasis, blocking phosphorylation of ERK42/44, inhibiting activation of 12-lipoxygenase, and eliminating the accumulation of reactive oxygen species.	Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Program Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; McLean Hosp, Belmont, MA 02478 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; McLean Hospital	Rosenberg, PA (corresponding author), 300 Longwood Ave, Boston, MA 02115 USA.	paul.rosenberg@childrens.harvard.edu	Li, Jianrong/C-4126-2011	Li, Jianrong/0000-0002-8232-9322; Rosenberg, Paul/0000-0002-5185-1118	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS038475] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18655] Funding Source: Medline; NINDS NIH HHS [NS 38475] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Armstrong C, 2001, BRAIN RES, V892, P51, DOI 10.1016/S0006-8993(00)03195-4; Arnett HA, 2002, J IMMUNOL, V168, P427, DOI 10.4049/jimmunol.168.1.427; Back SA, 1999, J NEUROSCI METH, V91, P47, DOI 10.1016/S0165-0270(99)00062-X; Back SA, 1998, J NEUROSCI, V18, P6241; Baud O, 2004, EUR J NEUROSCI, V20, P1713, DOI 10.1111/j.1460-9568.2004.03616.x; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bhat NR, 1996, J NEUROCHEM, V66, P1986; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brenner T, 1997, J IMMUNOL, V158, P2940; Calabrese V, 2003, NEUROCHEM RES, V28, P1321, DOI 10.1023/A:1024984013069; Calabrese V, 2002, J NEUROSCI RES, V70, P580, DOI 10.1002/jnr.10408; Canals S, 2003, J BIOL CHEM, V278, P21542, DOI 10.1074/jbc.M213174200; Cross AH, 2000, J NEUROIMMUNOL, V107, P21, DOI 10.1016/S0165-5728(00)00242-3; Crow JP, 1997, J NEUROCHEM, V69, P1945; Cuzzocrea S, 1998, BRIT J PHARMACOL, V123, P525, DOI 10.1038/sj.bjp.0701612; Dikalov SI, 2001, FREE RADICAL BIO MED, V30, P187, DOI 10.1016/S0891-5849(00)00456-1; Ding XZ, 2001, INT J CANCER, V94, P630, DOI 10.1002/ijc.1527.abs; Du S, 2002, J NEUROSCI, V22, P7408; Fragoso G, 2004, J NEUROCHEM, V90, P392, DOI 10.1111/j.1471-4159.2004.02488.x; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Gee KR, 2002, J AM CHEM SOC, V124, P776, DOI 10.1021/ja011774y; Guidarelli A, 2000, BRIT J PHARMACOL, V129, P1539, DOI 10.1038/sj.bjp.0703275; Guidarelli A, 2002, BIOCHEM J, V366, P307, DOI 10.1042/BJ20020284; Hill KE, 2004, J NEUROIMMUNOL, V151, P171, DOI 10.1016/j.jneuroim.2004.02.005; HONN KV, 1994, EXP CELL RES, V210, P1, DOI 10.1006/excr.1994.1001; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; Khanna S, 2003, J BIOL CHEM, V278, P43508, DOI 10.1074/jbc.M307075200; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Lebeau A, 2004, CELL DEATH DIFFER, V11, P875, DOI 10.1038/sj.cdd.4401395; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Li JR, 2003, J NEUROSCI, V23, P5816; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lindahl M, 1996, INFLAMMATION, V20, P599, DOI 10.1007/BF01488798; Liu JSH, 2001, AM J PATHOL, V158, P2057, DOI 10.1016/S0002-9440(10)64677-9; MANCINI JA, 1992, MOL PHARMACOL, V41, P267; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; MITROVIC B, 1995, NEUROSCIENCE, V65, P531, DOI 10.1016/0306-4522(94)00491-M; Moskowitz SI, 2001, BRAIN RES, V913, P207, DOI 10.1016/S0006-8993(01)02756-1; Nabeyrat E, 2003, AM J PHYSIOL-LUNG C, V284, pL1112, DOI 10.1152/ajplung.00178.2002; NAKADATE T, 1985, J PHARM PHARMACOL, V37, P71, DOI 10.1111/j.2042-7158.1985.tb04938.x; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Pal S, 2004, PFLUG ARCH EUR J PHY, V448, P296, DOI 10.1007/s00424-004-1256-7; Palomba L, 2000, FREE RADICAL BIO MED, V29, P783, DOI 10.1016/S0891-5849(00)00381-6; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Sahrbacher UC, 1998, EUR J IMMUNOL, V28, P1332, DOI 10.1002/(SICI)1521-4141(199804)28:04<1332::AID-IMMU1332>3.3.CO;2-7; Scott GS, 2002, P NATL ACAD SCI USA, V99, P16303, DOI 10.1073/pnas.212645999; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; SEGER R, 1994, J BIOL CHEM, V269, P25699; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Sharpe MA, 2002, BIOCHEM J, V366, P97, DOI 10.1042/bj20020154; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Sloane JA, 1999, NEUROBIOL AGING, V20, P395, DOI 10.1016/S0197-4580(99)00066-4; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Szekeres CK, 2000, J BIOL CHEM, V275, P38831, DOI 10.1074/jbc.M002673200; Thome U, 2003, FREE RADICAL BIO MED, V35, P662, DOI 10.1016/S0891-5849(03)00392-7; Tommasini I, 2002, MOL PHARMACOL, V61, P870, DOI 10.1124/mol.61.4.870; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Upmacis RK, 2004, AM J PHYSIOL-CELL PH, V286, pC1271, DOI 10.1152/ajpcell.00143.2003; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang H, 2004, EUR J NEUROSCI, V20, P2049, DOI 10.1111/j.1460-9568.2004.03650.x; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004; Zhang YM, 2002, EUR J NEUROSCI, V16, P1015, DOI 10.1046/j.1460-9568.2002.02169.x	78	54	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9460	9470		10.1074/jbc.M510650200	http://dx.doi.org/10.1074/jbc.M510650200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431921	hybrid			2022-12-25	WOS:000236404700056
J	Ledford, AS; Weinberg, RB; Cook, VR; Hantgan, RR; Shelness, GS				Ledford, AS; Weinberg, RB; Cook, VR; Hantgan, RR; Shelness, GS			Self-association and lipid binding properties of the lipoprotein initiating domain of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; N-TERMINAL 17-PERCENT; INTERFACIAL PROPERTIES; SUBCELLULAR-LOCALIZATION; A-IV; SECRETION; MODEL; LIPOVITELLIN; SOLUBILIZATION; BIOSYNTHESIS	The amino-terminal 20.1% of apolipoprotein B (apoB20.1; residues 1-912) is sufficient to initiate and direct the formation of nascent apoB-containing lipoprotein particles. To investigate the mechanism of initial lipid acquisition by apoB, we examined the lipid binding and interfacial properties of a carboxyl-terminal His6-tagged form of apoB20.1 (apoB20.1H). ApoB20.1H was expressed in Sf9 cells and purified by nickel affinity chromatography. ApoB20.1H was produced in a folded state as characterized by formation of intramolecular disulfide bonds and resistance to chemical reduction. Dynamic light scattering in physiological buffer indicated that purified apoB20.1H formed multimers, which were readily dissociable upon the addition of nonionic detergent (0.1% Triton X-100). ApoB20.1H was incapable of binding dimyristoylphosphatidylcholine multilamellar vesicles, unless its multimeric structure was first disrupted by guanidine hydrochloride. However, apoB20.1H multimers spontaneously dissociated and bound to the interface of naked and phospholipid-coated triolein droplets. These data reveal that the initiating domain of apoB contains solvent-accessible hydrophobic sequences, which, in the absence of a hydrophobic lipid interface or detergent, engage in self-association. The high affinity of apoB20.1H for neutral lipid is consistent with the membrane binding and desorption model of apoB-containing lipoprotein assembly.	Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Shelness, GS (corresponding author), Wake Forest Univ, Sch Med, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	gshelnes@wfubmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R23HL030897, P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL030897-23, HL49373, HL30897, R01 HL030897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Burch WL, 2000, J BIOL CHEM, V275, P16267, DOI 10.1074/jbc.M000446200; Chu B., 1983, MEASUREMENT SUSPENDE, P81; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; DeLozier JA, 2001, J LIPID RES, V42, P399; GIBBONS GF, 1990, BIOCHEM J, V268, P1; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Gusarova V, 2003, J BIOL CHEM, V278, P48051, DOI 10.1074/jbc.M306898200; HAMILTON JA, 1983, J BIOL CHEM, V258, P2821; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; Hamilton RL, 1998, J LIPID RES, V39, P1543; HANTGAN RR, 1993, BIOCHEMISTRY-US, V32, P3935, DOI 10.1021/bi00066a013; Harazono A, 2005, GLYCOBIOLOGY, V15, P447, DOI 10.1093/glycob/cwi033; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Herscovitz H, 2001, J LIPID RES, V42, P51; Hockey KJ, 2001, J LIPID RES, V42, P211; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 2005, CURR OPIN LIPIDOL, V16, P281, DOI 10.1097/01.mol.0000169347.53568.5a; Ingram MF, 1997, J BIOL CHEM, V272, P10279; Jiang ZG, 2005, BIOCHEMISTRY-US, V44, P1163, DOI 10.1021/bi048286y; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Manchekar M, 2004, J BIOL CHEM, V279, P39757, DOI 10.1074/jbc.M406302200; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; Richardson PE, 2005, BIOPHYS J, V88, P2789, DOI 10.1529/biophysj.104.046235; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; Shelness GS, 2005, CURR OPIN LIPIDOL, V16, P325, DOI 10.1097/01.mol.0000169353.12772.eb; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Thompson JR, 2002, BIOCHEMISTRY-US, V41, P9398, DOI 10.1021/bi025674w; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Wang LB, 2004, J LIPID RES, V45, P1704, DOI 10.1194/jlr.M400106-JLR200; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; Weinberg RB, 2000, J LIPID RES, V41, P1419; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96	50	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8871	8876		10.1074/jbc.M507657200	http://dx.doi.org/10.1074/jbc.M507657200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407215	hybrid			2022-12-25	WOS:000236247100067
J	Toruner, M; Fernandez-Zapico, M; Sha, JJ; Pham, L; Urrutia, R; Egan, LJ				Toruner, M; Fernandez-Zapico, M; Sha, JJ; Pham, L; Urrutia, R; Egan, LJ			Antianoikis effect of nuclear factor-kappa B through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; APOPTOSIS-INDUCING LIGAND; IKK-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CANCER-CELLS; TNF-ALPHA; ACTIVATION; SURVIVAL	Epithelial cells undergo a form of apoptosis termed anoikis when they lose extracellular attachments. We evaluated the role of transcription factor NF-kappa B in the regulation of anoikis susceptibility of intestinal epithelial cells. Culture of rat intestinal epithelial cells in suspension induced NF-kappa B activation, which blocked the anoikis of those cells, as assessed by internucleosomal DNA fragmentation and caspase-3 cleavage. Activation of NF-kappa B after the loss of extracellular attachments required focal adhesion kinase tyrosine 397 phosphorylation. This triggered a signaling cascade through phosphatidylinositol 3-kinase and AKT, to induce DNA binding of the RelA/p65 NF-kappa B polypeptide. NF-kappa B activated in this manner induced the up-regulated expression of a distinct program of genes that included osteoprotegerin, BCL-2, and IAP-1 ( inhibitor of apoptosis protein-1). Chromatin immunoprecipitation experiments revealed that NF-kappa B directly regulated the promoters of these 3 genes. Knock-down of the expression of osteoprotegerin, BCL-2, or inhibitor of apoptosis protein-1 by RNA interference showed that these factors inhibit anoikis, and genetic reconstitution of their expression alone or in combination restored normal levels of anoikis to NF-kappa B-inactive intestinal epithelial cells. Together, these findings have identified the molecular components of a previously unrecognized antianoikis pathway in intestinal epithelial cells.	Mayo Clin & Mayo Fdn, Gastroenterol Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Program Mol Med, Rochester, MN 55905 USA; Natl Univ Ireland, Dept Pharmacol & Therapeut, Galway, Ireland	Mayo Clinic; Mayo Clinic; Ollscoil na Gaillimhe-University of Galway	Egan, LJ (corresponding author), Univ Coll Hosp, Inst Clin Sci, Dept Pharmacol & Therapeut, Galway, Ireland.		Törüner, Murat/AAQ-1826-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060792] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60792] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLACOSA A, 1993, ONCOGENE, V8, P745; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; DEL PL, 1997, SCIENCE, V278, P687; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Dufour G, 2004, J BIOL CHEM, V279, P44113, DOI 10.1074/jbc.M405323200; Egan LJ, 2004, P NATL ACAD SCI USA, V101, P2452, DOI 10.1073/pnas.0306734101; Egan LJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1028, DOI 10.1152/ajpcell.00167.2003; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; EGAN LJ, 2003, AM J PHYSIOL, V25, pC25; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grossmann J, 1998, AM J PATHOL, V153, P53, DOI 10.1016/S0002-9440(10)65545-9; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; HALL PA, 1994, J CELL SCI, V107, P3569; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jobin C, 1997, J IMMUNOL, V158, P226; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LEIST M, 1994, J IMMUNOL, V153, P1778; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pritzker LB, 2004, MOL BIOL CELL, V15, P2834, DOI 10.1091/mbc.E04-01-0059; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Scaife CL, 2002, CANCER RES, V62, P6870; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Vidal K, 2004, AM J PHYSIOL-GASTR L, V287, pG836, DOI 10.1152/ajpgi.00428.2003; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	58	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8686	8696		10.1074/jbc.M512178200	http://dx.doi.org/10.1074/jbc.M512178200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407217	hybrid			2022-12-25	WOS:000236247100046
J	Aisenbrey, C; Kinder, R; Goormaghtigh, E; Ruysschaert, JM; Bechinger, B				Aisenbrey, C; Kinder, R; Goormaghtigh, E; Ruysschaert, JM; Bechinger, B			Interactions involved in the realignment of membrane-associated helices - An investigation using oriented solid-state NMR and attenuated total reflection Fourier transform infrared spectroscopies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC TRANSMEMBRANE SEGMENTS; AMINO-ACID-COMPOSITION; KNOWLEDGE-BASED SCALE; PROTEIN STRUCTURE; PEPTIDE ANTIBIOTICS; LINEAR DICHROISM; ORIENTATION; PREDICTION; ALIGNMENT; TOPOLOGY	A series of histidine-containing peptides (LAH(4)X(6)) was designed to investigate the membrane interactions of selected side chains. To this purpose, their pH-dependent transitions from in-plane to transmembrane orientations were investigated by attenuated total reflection Fourier transform infrared and oriented solid-state NMR spectroscopies. Peptides of the same family have previously been shown to exhibit antibiotic and DNA transfection activities. Solution NMR spectroscopy indicates that these peptides form amphipathic helical structures in membrane environments, and the technique was also used to characterize the pK values of all histidines in the presence of detergent micelles. Whereas one face of the amphipathic helix is clearly hydrophobic, the opposite side is flanked by four histidines surrounding six leucine, alanine, glycine, tryptophan, or tyrosine residues, respectively. This diversity in peptide composition causes pronounced shifts in the midpoint pH of the in-plane to transmembrane helical transition, which is completely abolished for the peptides carrying the most hydrophilic amino acid residues. These properties open up a conceptually new approach to study in a quantitative manner the hydrophobic as well as specific interactions of amino acids in membranes. Notably, the resulting scale for whole residue transitions from the bilayer interface to the hydrophobic membrane interior is obtained from extended helical sequences in lipid bilayers.	Univ Strasbourg, CNRS, Inst Fac Chim, L3 UMR7177, F-67070 Strasbourg, France; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Libre Bruxelles, Ctr Struct Biol & Bioinformat, Lab Struct & Funct Biol Membranes, B-1050 Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society; Universite Libre de Bruxelles	Bechinger, B (corresponding author), Univ Strasbourg, CNRS, Inst Fac Chim, L3 UMR7177, 4 Rue Blaise Pascal, F-67070 Strasbourg, France.	bechinger@chimie.u-strasbg.fr		Goormaghtigh, Erik/0000-0002-2071-2262				AISENBREY C, 2003, THESIS U L PASTEUR S; ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; Bechinger B, 1996, J MOL BIOL, V263, P768, DOI 10.1006/jmbi.1996.0614; Bechinger B, 2004, BBA-BIOMEMBRANES, V1666, P190, DOI 10.1016/j.bbamem.2004.08.008; BECHINGER B, 1991, J MAGN RESON, V95, P585, DOI 10.1016/0022-2364(91)90173-Q; Bechinger B, 1999, BIOPHYS J, V76, P552, DOI 10.1016/S0006-3495(99)77223-1; Bechinger B, 2001, FEBS LETT, V504, P161, DOI 10.1016/S0014-5793(01)02741-7; Bechinger B, 2001, BIOPHYS J, V81, P2251, DOI 10.1016/S0006-3495(01)75872-9; Bechinger B., 2003, CONCEPT MAGN RESON A, V18A, P130; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; Chatelier RC, 1996, BIOPHYS J, V71, P2367, DOI 10.1016/S0006-3495(96)79430-4; Chen CP, 2002, PROTEIN SCI, V11, P2774, DOI 10.1110/ps.0214502; CHEN CP, 2002, APPL BIOINFORM, V1, P1; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; DEGLIESPOSTI M, 1990, EUR J BIOCHEM, V190, P207, DOI 10.1111/j.1432-1033.1990.tb15566.x; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Gardiennet C, 2005, CHEM COMMUN, P180, DOI 10.1039/b413415j; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Gromiha MM, 1996, INT J PEPT PROT RES, V48, P452; Harzer U, 2000, BIOCHEMISTRY-US, V39, P13106, DOI 10.1021/bi000770n; Henry B, 2002, J AM CHEM SOC, V124, P2025, DOI 10.1021/ja011638t; Hessa T, 2005, SCIENCE, V307, P1427, DOI 10.1126/science.1109176; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; Ikeda Masami, 2002, In Silico Biology, V2, P19; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; Ivanov D, 2004, BIOPHYS J, V87, P1307, DOI 10.1529/biophysj.104.041863; Jayasinghe S, 2001, J MOL BIOL, V312, P927, DOI 10.1006/jmbi.2001.5008; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kall L, 2002, FEBS LETT, V532, P415, DOI 10.1016/S0014-5793(02)03730-4; Kichler A, 2003, M S-MED SCI, V19, P1046, DOI 10.1051/medsci/200319111046; Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lopes SCDN, 2004, J AM CHEM SOC, V126, P5396, DOI 10.1021/ja031782+; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Moller S, 2000, BIOINFORMATICS, V16, P1159, DOI 10.1093/bioinformatics/16.12.1159; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; Pilpel Y, 1999, J MOL BIOL, V294, P921, DOI 10.1006/jmbi.1999.3257; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PROMPONAS VJ, 1999, IN SILICO BIOL, V1, P159; Punta M, 2003, PROTEINS, V50, P114, DOI 10.1002/prot.10247; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Vogt B, 2000, BIOPHYS J, V79, P2644, DOI 10.1016/S0006-3495(00)76503-9; Vogt TCB, 1999, J BIOL CHEM, V274, P29115, DOI 10.1074/jbc.274.41.29115; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1981, EUR J BIOCHEM, V120, P275; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; WHITE SH, 1994, MEMBRANE PROTEIN STR, P3; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zakharov SD, 1998, P NATL ACAD SCI USA, V95, P4282, DOI 10.1073/pnas.95.8.4282; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2362, DOI 10.1021/bi00007a032; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2348, DOI 10.1021/bi00007a031	62	40	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7708	7716		10.1074/jbc.M513151200	http://dx.doi.org/10.1074/jbc.M513151200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407268	hybrid			2022-12-25	WOS:000236031000003
J	Goumon, Y; Muller, A; Glattard, E; Marban, C; Gasnier, C; Strub, JM; Chasserot-Golaz, S; Rohr, O; Stefano, GB; Welters, ID; Van Dorsselaer, A; Schoentgen, F; Aunis, D; Metz-Boutigue, MH				Goumon, Y; Muller, A; Glattard, E; Marban, C; Gasnier, C; Strub, JM; Chasserot-Golaz, S; Rohr, O; Stefano, GB; Welters, ID; Van Dorsselaer, A; Schoentgen, F; Aunis, D; Metz-Boutigue, MH			Identification of morphine-6-glucuronide in chromaffin cell secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; BOVINE BRAIN CYTOSOL; ENDOGENOUS MORPHINE; MORPHINE-6-BETA-GLUCURONIDE ANALGESIA; UDP-GLUCURONOSYLTRANSFERASE; NOMENCLATURE UPDATE; TISSUE DISTRIBUTION; HEALTHY-VOLUNTEERS; GENE SUPERFAMILY; LIGAND-BINDING	We report for the first time that morphine-6-glucuronide, a highly analgesic morphine-derived molecule, is present in adrenal chromaffin granules and secreted from chromaffin cells upon stimulation. We also demonstrate that phosphatidylethanolamine-binding protein (alternatively named Raf-1 kinase inhibitor protein or RKIP) acts as an endogenous morphine-6-glucuronide-binding protein. An UDP-glucuronosyltransferase 2B-like enzyme, described to transform morphine into morphine-6-glucuronide, has been immunodetected in the chromaffin granule matrix, and morphine-6-glucuronide de novo synthesis has been characterized, demonstrating the possible involvement of intragranular UDP-glucuronosyltransferase 2B-like enzyme in morphine-6-glucuronide metabolism. Once secreted into the circulation, morphine-6-glucuronide may mediate several systemic actions (e.g. on immune cells) based on its affinity for mu-opioid receptors. These activities could be facilitated by phosphatidylethanolamine-binding protein (PEBP), acting as a molecular shield and preventing morphine-6-glucuronide from rapid clearance. Taken together, our data represent an important observation on the role of morphine-6-glucuronide as a new endocrine factor.	INSERM, U Physiopathol Syst Nerveux 575, F-67084 Strasbourg, France; CNRS, Ctr Biophys Mol, UPR 4301, F-45071 Orleans, France; Univ Giessen, Dept Anesthesiol Intens Care & Pain Med, D-35385 Giessen, Germany; SUNY Coll Old Westbury, Neurosci Res Inst, New York, NY 11568 USA; CNRS, UPR 2356, Lab Neurotransmiss & Secret Neuroendocrine, F-67084 Strasbourg, France; CNRS, UMR 7168 LC2, Lab Spectrometrie Mass Bioorgan, F-67087 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Justus Liebig University Giessen; State University of New York (SUNY) System; SUNY Old Westbury; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Goumon, Y (corresponding author), INSERM, U Physiopathol Syst Nerveux 575, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	goumon@neurochem.u-strasbg.fr	Stefano, George Bogdan/ABD-9152-2021; Dominique, Aunis/W-1419-2019; Chasserot-Golaz, Sylvette/K-7625-2017	Stefano, George Bogdan/0000-0002-8146-0740; Welters, Ingeborg/0000-0002-3408-8798; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; ROHR, Olivier/0000-0001-8992-2025; , Elise/0000-0002-4501-9675; Strub, Jean-Marc/0000-0001-6224-3428; Goumon, Yannick/0000-0003-4336-3437				AMANN T, 1995, HETEROCYCLES, V40, P425; Armstrong SC, 2003, PSYCHOSOMATICS, V44, P515, DOI 10.1176/appi.psy.44.6.515; Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2; Barbier O, 2000, BIOCHEMISTRY-US, V39, P11540, DOI 10.1021/bi000779p; BERNIER I, 1986, BIOCHIM BIOPHYS ACTA, V871, P19, DOI 10.1016/0167-4838(86)90128-7; Boettcher C, 2005, P NATL ACAD SCI USA, V102, P8495, DOI 10.1073/pnas.0503244102; Cadet P, 2004, FRONT BIOSCI-LANDMRK, V9, P3176, DOI 10.2741/1471; Duplan H, 2000, EXP NEUROL, V163, P331, DOI 10.1006/exnr.1999.7352; EPPLE A, 1994, LIFE SCI, V54, P695, DOI 10.1016/0024-3205(94)90157-0; Fimiani C, 1999, CANCER LETT, V146, P45, DOI 10.1016/S0304-3835(99)00227-X; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; FRANCES B, 1990, PROG CLIN BIOL RES, V328, P477; Frayne J, 1999, CELL TISSUE RES, V298, P415, DOI 10.1007/s004419900113; Gasnier C, 2004, PROTEOMICS, V4, P1789, DOI 10.1002/pmic.200300693; GOLDSTEIN A, 1985, P NATL ACAD SCI USA, V82, P5203, DOI 10.1073/pnas.82.15.5203; Goumon Y, 2000, J BIOL CHEM, V275, P38355, DOI 10.1074/jbc.M007557200; Goumon Y, 2000, MOL BRAIN RES, V77, P267, DOI 10.1016/S0169-328X(00)00056-5; Goumon Y, 2000, J IMMUNOL, V165, P339, DOI 10.4049/jimmunol.165.1.339; Goumon Y, 2004, J BIOL CHEM, V279, P13054, DOI 10.1074/jbc.M308533200; Goumon Y, 2000, MOL BRAIN RES, V81, P177, DOI 10.1016/S0169-328X(00)00141-8; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; Herbert RB, 2000, NAT PROD REP, V17, P317, DOI 10.1039/a809409h; LEOW KP, 1993, THER DRUG MONIT, V15, P440, DOI 10.1097/00007691-199310000-00014; LEUNG MK, 1995, EXP PARASITOL, V81, P208, DOI 10.1006/expr.1995.1110; Levesque E, 2001, BIOCHEMISTRY-US, V40, P3869, DOI 10.1021/bi002607y; Lotsch J, 2001, CLIN PHARMACOKINET, V40, P485; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; Mackenzie PI, 2005, PHARMACOGENET GENOM, V15, P677, DOI 10.1097/01.fpc.0000173483.13689.56; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MAKMAN MH, 1995, EUR J PHARMACOL, V273, pR5, DOI 10.1016/0014-2999(95)00002-3; Marban C, 2005, NUCLEIC ACIDS RES, V33, P2318, DOI 10.1093/nar/gki529; Massotte D, 1998, ESSAYS BIOCHEM, V33, P65, DOI 10.1042/bse0330065; Meijerink WJHJ, 1999, SHOCK, V12, P165, DOI 10.1097/00024382-199909000-00001; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; OLSEN GD, 1975, CLIN PHARMACOL THER, V17, P31; Poeaknapo C, 2004, P NATL ACAD SCI USA, V101, P14091, DOI 10.1073/pnas.0405430101; Romberg R, 2004, ANESTHESIOLOGY, V100, P120, DOI 10.1097/00000542-200401000-00021; Romberg R, 2003, ANESTHESIOLOGY, V99, P788, DOI 10.1097/00000542-200310000-00008; ROSSI GC, 1995, FEBS LETT, V369, P192, DOI 10.1016/0014-5793(95)00757-Z; Rossi GC, 1996, NEUROSCI LETT, V216, P1; Rossi GC, 1997, J PHARMACOL EXP THER, V281, P109; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706; Seematter G, 2004, CURR OPIN CLIN NUTR, V7, P169, DOI 10.1097/00075197-200403000-00011; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; Sol JC, 2004, EXP NEUROL, V186, P198, DOI 10.1016/j.expneurol.2003.10.018; Sonetti D, 1999, BRAIN RES, V835, P137, DOI 10.1016/S0006-8993(99)01534-6; Stefano GB, 2000, TRENDS NEUROSCI, V23, P436, DOI 10.1016/S0166-2236(00)01611-8; STEFANO GB, 1994, ADV NEUROIMMUNOL, V4, P57, DOI 10.1016/S0960-5428(05)80001-4; Stone AN, 2003, DRUG METAB DISPOS, V31, P1086, DOI 10.1124/dmd.31.9.1086; Turgeon D, 2001, ENDOCRINOLOGY, V142, P778, DOI 10.1210/en.142.2.778; Yamada Hideyuki, 2003, J Toxicol Sci, V28, P395, DOI 10.2131/jts.28.395; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhu W, 2005, MED SCI MONITOR, V11, pBR397; Zhu W, 2005, J IMMUNOL, V175, P7357, DOI 10.4049/jimmunol.175.11.7357; Zhu W, 2001, MOL BRAIN RES, V88, P155, DOI 10.1016/S0169-328X(01)00048-1	56	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8082	8089		10.1074/jbc.M502298200	http://dx.doi.org/10.1074/jbc.M502298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434406	Green Published, hybrid			2022-12-25	WOS:000236031000045
J	Braathen, R; Sandvik, A; Berntzen, G; Hammerschmidt, S; Fleckenstein, B; Sandlie, I; Brandtzaeg, P; Johansen, FE; Lauvrak, V				Braathen, R; Sandvik, A; Berntzen, G; Hammerschmidt, S; Fleckenstein, B; Sandlie, I; Brandtzaeg, P; Johansen, FE; Lauvrak, V			Identification of a polymeric Ig receptor binding phage-displayed peptide that exploits epithelial transcytosis without dimeric IgA competition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; HUMAN SECRETORY COMPONENT; IMMUNOGLOBULIN RECEPTOR; STREPTOCOCCUS-PNEUMONIAE; CYCLIC-PEPTIDES; GENE-TRANSFER; J-CHAIN; TRANSPORT; MUCOSAL; CELLS	The polymeric Ig receptor (pIgR), also called membrane secretory component (SC), mediates epithelial transcytosis of polymeric immunoglobulins (pIgs). J Chain-containing polymeric IgA (pIgA) and pentameric IgM bind pIgR at the basolateral epithelial surface. After transcytosis, the extracellular portion of the pIgR is cleaved at the apical side, either complexed with pIgs as bound SC or unoccupied as free SC. This transport pathway may be exploited to target bioactive molecules to the mucosal surface. To identify small peptide motifs with specific affinity to human pIgR, we used purified free SC and selection from randomized, cysteine-flanked 6- and 9-mer phage-display libraries. One of the selected phages, called C9A, displaying the peptide CVVWMGFQQVC, showed binding both to human free SC and SC complexed with pIgs. However, the pneumococcal surface protein SpsA ( Streptococcus pneumoniae secretory IgA-binding protein), which binds human SC at a site distinct from the pIg binding site, competed with the C9A phage for binding to SC. The C9A phage showed greatly increased transport through polarized Madin-Darby canine kidney cells transfected with human pIgR. This transport was not affected by pIgA nor did it inhibit pIgR-mediated pIgA transcytosis. A free peptide of identical amino acid sequence as that displayed by the C9A phage inhibited phage interaction with SC. This implied that the C9A peptide sequence may be exploited for pIgR-mediated epithelial transport without interfering with secretory immunity.	Univ Oslo, Rikshosp Univ Hosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; Univ Oslo, Rikshosp Univ Hosp, Inst Immunol, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; University of Wurzburg; University of Oslo; National Hospital Norway	Braathen, R (corresponding author), Univ Oslo, Rikshosp Univ Hosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway.	ranveig.braathen@medisin.uio.no	Hammerschmidt, Sven/G-2598-2010	Hammerschmidt, Sven/0000-0002-6382-6681				BERNTZEN G, 2006, IN PRESS PROTEIN ENG; Braathen R, 2002, J BIOL CHEM, V277, P42755, DOI 10.1074/jbc.M205502200; Brandtzaeg P, 1999, IMMUNOL REV, V171, P45, DOI 10.1111/j.1600-065X.1999.tb01342.x; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; BRANDTZAEG P, 1974, SCAND J IMMUNOL, V3, P579, DOI 10.1111/j.1365-3083.1974.tb01291.x; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Crottet P, 1998, J IMMUNOL, V161, P5445; Eckman EA, 1999, AM J RESP CELL MOL, V21, P246, DOI 10.1165/ajrcmb.21.2.3687; Elm C, 2004, J BIOL CHEM, V279, P6296, DOI 10.1074/jbc.M310528200; Ferkol T, 2003, AM J RESP CRIT CARE, V167, P1374, DOI 10.1164/rccm.200209-1119OC; FERKOL T, 1993, J CLIN INVEST, V92, P2394, DOI 10.1172/JCI116845; FERKOL T, 1995, J CLIN INVEST, V95, P493, DOI 10.1172/JCI117690; Ferkol T, 2000, AM J RESP CRIT CARE, V161, P944, DOI 10.1164/ajrccm.161.3.9907018; Gan YJ, 1997, J VIROL, V71, P519, DOI 10.1128/JVI.71.1.519-526.1997; Hamburger AE, 2004, STRUCTURE, V12, P1925, DOI 10.1016/j.str.2004.09.006; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hammerschmidt S, 2000, MOL MICROBIOL, V36, P726, DOI 10.1046/j.1365-2958.2000.01897.x; Johansen FE, 1999, EUR J IMMUNOL, V29, P1701, DOI 10.1002/(SICI)1521-4141(199905)29:05<1701::AID-IMMU1701>3.0.CO;2-Z; Johansen FE, 2004, TRENDS IMMUNOL, V25, P150, DOI 10.1016/j.it.2004.01.001; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Lauvrak V, 2004, SCAND J IMMUNOL, V59, P373, DOI 10.1111/j.1365-3083.2004.01400.x; Lin CT, 1997, AM J PATHOL, V150, P1745; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; LUO R, 2004, EMBO J; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; Mostov K, 1999, MUCOSAL IMMUNOLOGY, P133; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; Natvig IB, 1997, J IMMUNOL, V159, P4330; Norderhaug IN, 1999, CRIT REV IMMUNOL, V19, P481; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; Roe M, 1999, J IMMUNOL, V162, P6046; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; White KD, 2002, J EXP MED, V196, P551, DOI 10.1084/jem.20020581; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4	36	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7075	7081		10.1074/jbc.M508509200	http://dx.doi.org/10.1074/jbc.M508509200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423833	hybrid			2022-12-25	WOS:000236030900021
J	Bush, LA; Nelson, RW; Di Cera, E				Bush, LA; Nelson, RW; Di Cera, E			Murine thrombin lacks Na+ activation but retains high catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOVALENT CATION SPECIFICITY; HEPARIN-COFACTOR-II; SERINE PROTEASES; BINDING-SITE; CRYSTAL-STRUCTURE; FACTOR XA; ANTICOAGULANT THROMBIN; PROTHROMBINASE COMPLEX; SUBSTRATE-SPECIFICITY; ALLOSTERIC REGULATION	Human thrombin utilizes Na+ as a driving force for the cleavage of substrates mediating its procoagulant, prothrombotic, and signaling functions. Murine thrombin has Asp-222 in the Na+ binding site of the human enzyme replaced by Lys. The charge reversal substitution abrogates Na+ activation, which is partially restored with the K222D mutation, and ensures high activity even in the absence of Na+. This property makes the murine enzyme more resistant to the effect of mutations that destabilize Na+ binding and shift thrombin to its anticoagulant slow form. Compared with the human enzyme, murine thrombin cleaves fibrinogen and protein C with similar k(cat)/K-m values but activates PAR1 and PAR4 with k(cat)/K-m values 4- and 26-fold higher, respectively. The significantly higher specificity constant toward PAR4 accounts for the dominant role of this receptor in platelet activation in the mouse. Murine thrombin can also cleave substrates carrying Phe at P1, which potentially broadens the repertoire of molecular targets available to the enzyme in vivo.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	enrico@wustl.edu		Nelson, Ryan/0000-0003-2327-9481	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073813, R01HL049413, R29HL049413, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49413, HL 58141, HL 73813] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARNES WM, 2003, PCR PRIMER LAB MANUA, P441; Bobofchak KM, 2005, J BIOL CHEM, V280, P25644, DOI 10.1074/jbc.M503499200; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; Butenas S, 1997, THROMB HAEMOSTASIS, V78, P1193; Cantwell AM, 2000, J BIOL CHEM, V275, P39827, DOI 10.1074/jbc.C000751200; CHEN ZG, 1995, ARCH BIOCHEM BIOPHYS, V322, P198, DOI 10.1006/abbi.1995.1452; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; De Simone G, 2003, BIOCHEMISTRY-US, V42, P9013, DOI 10.1021/bi020512l; DEGEN SJF, 1995, THROMB HAEMOSTASIS, V73, P203; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; Di Cera E, 2006, J BIOL CHEM, V281, P1305, DOI 10.1074/jbc.R500023200; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gosalia DN, 2005, PROTEOMICS, V5, P1292, DOI 10.1002/pmic.200401011; Gruber A, 2002, J BIOL CHEM, V277, P27581, DOI 10.1074/jbc.C200237200; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Henriksen RA, 1998, BLOOD, V91, P2026, DOI 10.1182/blood.V91.6.2026.2026_2026_2031; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KEZDY FJ, 1965, BIOCHEMISTRY-US, V4, P2302, DOI 10.1021/bi00887a007; Krem MM, 2003, BIOPHYS CHEM, V100, P315, DOI 10.1016/S0301-4622(02)00289-2; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; Laughlin LT, 1997, ARCH BIOCHEM BIOPHYS, V348, P262, DOI 10.1006/abbi.1997.0448; Lee SL, 1997, BIOCHEMISTRY-US, V36, P13180, DOI 10.1021/bi970912m; LORAND L, 1962, ARCH BIOCHEM BIOPHYS, V96, P147, DOI 10.1016/0003-9861(62)90463-0; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; Malikayil JA, 1997, BIOCHEMISTRY-US, V36, P1034, DOI 10.1021/bi9622231; Mann KG, 2003, CHEST, V124, p4S, DOI 10.1378/chest.124.3_suppl.4S; MARTIN CJ, 1959, J BIOL CHEM, V234, P1718; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; Monnaie D, 2000, BIOCHEMISTRY-US, V39, P5349, DOI 10.1021/bi9926781; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; Pineda AO, 2004, BIOPHYS CHEM, V112, P253, DOI 10.1016/j.bpc.2004.07.027; Pineda AO, 2004, J BIOL CHEM, V279, P39824, DOI 10.1074/jbc.M407272200; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Prasad S, 2004, J BIOL CHEM, V279, P10103, DOI 10.1074/jbc.M312614200; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rezaie AR, 2004, J BIOL CHEM, V279, P48262, DOI 10.1074/jbc.M409964200; Riester D, 2005, P NATL ACAD SCI USA, V102, P8597, DOI 10.1073/pnas.0501983102; Roy DB, 2001, PROTEINS, V43, P315, DOI 10.1002/prot.1042; Schmidt AE, 2005, J MOL BIOL, V350, P78, DOI 10.1016/j.jmb.2005.04.052; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; Sun WY, 2001, THROMB HAEMOSTASIS, V85, P651, DOI 10.1055/s-0037-1615648; Vindigni A, 2000, PROTEIN SCI, V9, P619; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Wilbanks SM, 1998, BIOCHEMISTRY-US, V37, P7456, DOI 10.1021/bi973046m; Zhang B, 2004, J THROMB HAEMOST, V2, P1564, DOI 10.1111/j.1538-7836.2004.00857.x	62	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7183	7188		10.1074/jbc.M512082200	http://dx.doi.org/10.1074/jbc.M512082200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16428384	hybrid			2022-12-25	WOS:000236030900034
J	Edosada, CY; Quan, C; Wiesmann, C; Tran, T; Sutherlin, D; Reynolds, M; Elliott, JM; Raab, H; Fairbrother, W; Wolf, BB				Edosada, CY; Quan, C; Wiesmann, C; Tran, T; Sutherlin, D; Reynolds, M; Elliott, JM; Raab, H; Fairbrother, W; Wolf, BB			Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD26/DIPEPTIDYL PEPTIDASE-IV; SERINE-PROTEASE; CRYSTAL-STRUCTURE; STROMAL FIBROBLASTS; MOLECULAR-CLONING; TUMOR-GROWTH; DPP-IV; REVEALS; LOCALIZATION; PURIFICATION	Fibroblast activation protein (FAP) is a transmembrane serine peptidase that belongs to the prolyl peptidase family. FAP has been implicated in cancer; however, its specific role remains elusive because inhibitors that distinguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed. To identify peptide motifs for FAP-selective inhibitor design, we used P-2-Pro(1) and acetyl (Ac)-P-2-Pro(1) dipeptide substrate libraries, where P-2 was varied and substrate hydrolysis occurs between Pro(1) and a fluorescent leaving group. With the P-2-Pro(1) library, FAP preferred Ile, Pro, or Arg at the P-2 residue; however, DPP-4 showed broad reactivity against this library, precluding selectivity. By contrast, with the Ac-P-2-Pro(1) library, FAP cleaved only Ac-Gly-Pro, whereas DPP-4 showed little reactivity with all substrates. FAP also cleaved formyl-, benzyloxycarbonyl-, biotinyl-, and peptidyl-Gly-Pro substrates, which DPP-4 cleaved poorly, suggesting an N-acyl-Gly- Pro motif for inhibitor design. Therefore, we synthesized and tested the compound Ac-Gly-prolineboronic acid, which inhibited FAP with a K-i of 23 +/- 3 nM. This was similar to 9- to similar to 5400-fold lower than the Ki values for other prolyl peptidases, including DPP-4, DPP-7, DPP-8, DPP-9, prolyl oligopeptidase, and acylpeptide hydrolase. These results identify Ac-Gly-BoroPro as a FAP-selective inhibitor and suggest that N-acyl-Gly- Pro-based inhibitors will allow testing of FAP as a therapeutic target.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Med Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Wolf, BB (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS42, San Francisco, CA 94080 USA.	bbwolf@gene.com		Wiesmann, Christian/0000-0002-4092-9880				Abbott CA, 2000, EUR J BIOCHEM, V267, P6140, DOI 10.1046/j.1432-1327.2000.01617.x; Adams S, 2004, CANCER RES, V64, P5471, DOI 10.1158/0008-5472.CAN-04-0447; Aertgeerts K, 2005, J BIOL CHEM, V280, P19441, DOI 10.1074/jbc.C500092200; Aertgeerts K, 2004, PROTEIN SCI, V13, P145, DOI 10.1110/ps.03352504; Ajami K, 2004, BBA-GENE STRUCT EXPR, V1679, P18, DOI 10.1016/j.bbaexp.2004.03.010; Augustyns K, 2005, CURR MED CHEM, V12, P971, DOI 10.2174/0929867053507298; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Cheng JD, 2005, MOL CANCER THER, V4, P351; Cheng JD, 2002, CANCER RES, V62, P4767; CHENG JD, 2004, AM ASS CANC RES 95 A; COPELAND RA, 2000, ENZYMES PRACTICAL IN, P136; Coutts SJ, 1996, J MED CHEM, V39, P2087, DOI 10.1021/jm950732f; Dembitsky VM, 2004, MINI-REV MED CHEM, V4, P1001, DOI 10.2174/1389557043403125; Dolznig H., 2005, CANC IMMUN, V5, P1; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Engel M, 2003, P NATL ACAD SCI USA, V100, P5063, DOI 10.1073/pnas.0230620100; FIELDS GB, 1988, P NATL ACAD SCI USA, V85, P1384, DOI 10.1073/pnas.85.5.1384; FLENTKE GR, 1991, P NATL ACAD SCI USA, V88, P1556, DOI 10.1073/pnas.88.4.1556; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Ghersi G, 2002, J BIOL CHEM, V277, P29231, DOI 10.1074/jbc.M202770200; Gibson FS, 2002, ORG PROCESS RES DEV, V6, P814, DOI 10.1021/op025587b; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Hiramatsu H, 2004, BIOL CHEM, V385, P561, DOI 10.1515/BC.2004.068; Hu Y, 2005, BIOORG MED CHEM LETT, V15, P4239, DOI 10.1016/j.bmcl.2005.06.075; Huang Y, 2004, CANCER RES, V64, P2712, DOI 10.1158/0008-5472.CAN-03-3184; Huber MA, 2004, J INVEST DERMATOL, V123; Jones B, 2003, BLOOD, V102, P1641, DOI 10.1182/blood-2003-01-0208; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lankas GR, 2005, DIABETES, V54, P2988, DOI 10.2337/diabetes.54.10.2988; Lee KN, 2004, BLOOD, V103, P3783, DOI 10.1182/blood-2003-12-4240; Leiting B, 2003, BIOCHEM J, V371, P525, DOI 10.1042/BJ20021643; Levy MT, 1999, HEPATOLOGY, V29, P1768, DOI 10.1002/hep.510290631; MALY D, 1920, J ORG CHEM, V67, P910; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Mogridge Jeremy, 2004, Methods Mol Biol, V261, P113; NICKLIN MJH, 1984, BIOCHEM J, V223, P245, DOI 10.1042/bj2230245; Niedermeyer J, 1997, INT J CANCER, V71, P383, DOI 10.1002/(SICI)1097-0215(19970502)71:3<383::AID-IJC14>3.0.CO;2-H; ODYA CE, 1978, J BIOL CHEM, V253, P5927; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Polgar L, 2002, CELL MOL LIFE SCI, V59, P349, DOI 10.1007/s00018-002-8427-5; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; RETTIG WJ, 1993, CANCER RES, V53, P3327; Rosenblum JS, 2003, CURR OPIN CHEM BIOL, V7, P496, DOI 10.1016/S1367-5931(03)00084-X; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Shreder KR, 2005, BIOORG MED CHEM LETT, V15, P4256, DOI 10.1016/j.bmcl.2005.06.076; Thoma R, 2003, STRUCTURE, V11, P947, DOI 10.1016/S0969-2126(03)00160-6; Underwood R, 1999, J BIOL CHEM, V274, P34053, DOI 10.1074/jbc.274.48.34053; Zhu L, 2003, J BIOL CHEM, V278, P22418, DOI 10.1074/jbc.M212355200	51	89	120	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7437	7444		10.1074/jbc.M511112200	http://dx.doi.org/10.1074/jbc.M511112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410248	hybrid			2022-12-25	WOS:000236030900065
J	Meyer, A; Eskandari, S; Grallath, S; Rentsch, D				Meyer, A; Eskandari, S; Grallath, S; Rentsch, D			AtGAT1, a high affinity transporter for gamma-aminobutyric acid in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; SUBSTRATE-SPECIFICITY; DIFFERENTIAL EXPRESSION; 4-AMINOBUTYRATE GABA; PROLINE TRANSPORTER; GENE-EXPRESSION; PERMEASE; METABOLISM; IDENTIFICATION; SENESCENCE	Functional characterization of Arabidopsis thaliana GAT1 in heterologous expression systems, i.e. Saccharomyces cerevisiae and Xenopus laevis oocytes, revealed that AtGAT1 (At1g08230) codes for an H+-driven, high affinity gamma-aminobutyric acid ( GABA) transporter. In addition to GABA, other omega-aminofatty acids and butylamine are recognized. In contrast to the most closely related proteins of the proline transporter family, proline and glycine betaine are not transported by AtGAT1. AtGAT1 does not share sequence similarity with any of the non-plant GABA transporters described so far, and analyses of substrate selectivity and kinetic properties showed that AtGAT1-mediated transport is similar but distinct from that of mammalian, bacterial, and S. cerevisiae GABA transporters. Consistent with a role in GABA uptake into cells, transient expression of AtGAT1/green fluorescent protein fusion proteins in tobacco protoplasts revealed localization at the plasma membrane. In planta, AtGAT1 expression was highest in flowers and under conditions of elevated GABA concentrations such as wounding or senescence.	Univ Bern, Inst Plant Sci, CH-3013 Bern, Switzerland; Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA	University of Bern; California State University System; California State Polytechnic University Pomona	Rentsch, D (corresponding author), Univ Bern, Inst Plant Sci, Altenbergrain 21, CH-3013 Bern, Switzerland.	doris.rentsch@ips.unibe.ch		Rentsch, Doris/0000-0003-4313-7683	NIGMS NIH HHS [S06 GM053933, S06 GM 53933, S06 GM053933-090006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM053933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Bouche N, 2004, TRENDS PLANT SCI, V9, P110, DOI 10.1016/j.tplants.2004.01.006; Bouche N, 2003, TRENDS CELL BIOL, V13, P607, DOI 10.1016/j.tcb.2003.10.001; Bouche N, 2003, P NATL ACAD SCI USA, V100, P6843, DOI 10.1073/pnas.1037532100; Brechtel CE, 1998, BIOCHEM J, V333, P565, DOI 10.1042/bj3330565; Breitkreuz KE, 1999, FEBS LETT, V450, P280, DOI 10.1016/S0014-5793(99)00516-5; Breitkreuz KE, 2003, J BIOL CHEM, V278, P41552, DOI 10.1074/jbc.M305717200; Buchanan-Wollaston V, 2005, PLANT J, V42, P567, DOI 10.1111/j.1365-313X.2005.02399.x; BURKE D, 2000, METHODS YEAST GENETI, P172; Chen LS, 2001, PLANT PHYSIOL, V125, P1813, DOI 10.1104/pp.125.4.1813; Chen NH, 2004, PFLUG ARCH EUR J PHY, V447, P519, DOI 10.1007/s00424-003-1064-5; CHUNG ID, 1992, PLANT PHYSIOL, V99, P659, DOI 10.1104/pp.99.2.659; Coleman ST, 2001, J BIOL CHEM, V276, P244, DOI 10.1074/jbc.M007103200; Diaz C, 2005, PLANT PHYSIOL, V138, P898, DOI 10.1104/pp.105.060764; Dietrich D, 2004, PLANT J, V40, P488, DOI 10.1111/j.1365-313X.2004.02224.x; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; Doring F, 1998, J CLIN INVEST, V101, P2761, DOI 10.1172/JCI1909; Doring F, 1998, J BIOL CHEM, V273, P23211, DOI 10.1074/jbc.273.36.23211; Fang G, 2000, J BACTERIOL, V182, P2530, DOI 10.1128/JB.182.9.2530-2535.2000; Fischer WN, 1998, TRENDS PLANT SCI, V3, P188, DOI 10.1016/S1360-1385(98)01231-X; Fischer WN, 2002, PLANT J, V29, P717, DOI 10.1046/j.1365-313X.2002.01248.x; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Forster IC, 1999, AM J PHYSIOL-RENAL, V276, pF644, DOI 10.1152/ajprenal.1999.276.4.F644; Grallath S, 2005, PLANT PHYSIOL, V137, P117, DOI 10.1104/pp.104.055079; Hosie AHF, 2002, J BACTERIOL, V184, P4071, DOI 10.1128/JB.184.15.4071-4080.2002; Igarashi Y, 2000, PLANT CELL PHYSIOL, V41, P750, DOI 10.1093/pcp/41.6.750; Jack DL, 2000, MICROBIOL-SGM, V146, P1797, DOI 10.1099/00221287-146-8-1797; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; Kragler A, 2005, EUR J PHARMACOL, V519, P43, DOI 10.1016/j.ejphar.2005.06.053; Kumar S, 1997, MYCOL RES, V101, P403, DOI 10.1017/S0953756296002742; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LIU QR, 1993, J BIOL CHEM, V268, P2106; Moretti MB, 2002, BRIT J CANCER, V87, P471, DOI 10.1038/sj.bjc.6600481; Moretti MB, 1996, CELL MOL BIOL, V42, P519; Noh YS, 1999, PLANT MOL BIOL, V41, P181, DOI 10.1023/A:1006342412688; Owens DF, 2002, NAT REV NEUROSCI, V3, P715, DOI 10.1038/nrn919; Palanivelu R, 2003, CELL, V114, P47, DOI 10.1016/S0092-8674(03)00479-3; Pruzinska A, 2005, PLANT PHYSIOL, V139, P52, DOI 10.1104/pp.105.065870; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; Rubinstein B, 2000, PLANT MOL BIOL, V44, P303, DOI 10.1023/A:1026540524990; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Schwacke R, 1999, PLANT CELL, V11, P377, DOI 10.1105/tpc.11.3.377; Schwacke R, 2003, PLANT PHYSIOL, V131, P16, DOI 10.1104/pp.011577; Serraj R, 1998, PHYSIOL PLANTARUM, V102, P79, DOI 10.1034/j.1399-3054.1998.1020111.x; SERVAITES JC, 1979, PLANT PHYSIOL, V64, P546, DOI 10.1104/pp.64.4.546; SHAIBE E, 1985, J BACTERIOL, V163, P933, DOI 10.1128/JB.163.3.933-937.1985; Shelp BJ, 1999, TRENDS PLANT SCI, V4, P446, DOI 10.1016/S1360-1385(99)01486-7; Solomon PS, 2002, PLANTA, V214, P414, DOI 10.1007/s004250100632; STEWARD FC, 1949, SCIENCE, V110, P439; Strain HH, 1971, METHOD ENZYMOL, V23, P452, DOI DOI 10.1016/S0076-6879(71)23118-9; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; Temple CS, 1998, J BIOL CHEM, V273, P20, DOI 10.1074/jbc.273.1.20; Theis S, 2002, MOL PHARMACOL, V61, P214, DOI 10.1124/mol.61.1.214; Tilsner J, 2005, PLANTA, V221, P328, DOI 10.1007/s00425-004-1446-8; Ueda A, 2001, PLANT CELL PHYSIOL, V42, P1282, DOI 10.1093/pcp/pce166; van Dongen JT, 2003, PLANT PHYSIOL, V131, P1529, DOI 10.1104/pp.102.017202; Waditee R, 2002, J BIOL CHEM, V277, P18373, DOI 10.1074/jbc.M112012200; WALLACE W, 1984, PLANT PHYSIOL, V75, P170, DOI 10.1104/pp.75.1.170; Whitlow RD, 2003, J BIOL CHEM, V278, P17716, DOI 10.1074/jbc.M207582200; Wipf D, 2002, TRENDS BIOCHEM SCI, V27, P139, DOI 10.1016/S0968-0004(01)02054-0; Yohannes E, 2004, J BACTERIOL, V186, P192, DOI 10.1128/JB.186.1.192-199.2004; Young GB, 1999, BBA-BIOMEMBRANES, V1415, P306, DOI 10.1016/S0005-2736(98)00196-5; Zheng XQ, 2005, J EXP BOT, V56, P1615, DOI 10.1093/jxb/eri156	68	94	98	5	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7197	7204		10.1074/jbc.M510766200	http://dx.doi.org/10.1074/jbc.M510766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407306	Green Accepted, hybrid			2022-12-25	WOS:000236030900036
J	Stefanic, S; Palm, D; Svard, SG; Hehl, AB				Stefanic, S; Palm, D; Svard, SG; Hehl, AB			Organelle proteomics reveals cargo maturation mechanisms associated with Golgi-like encystation vesicles in the early-diverged protozoan Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYST WALL; ENDOPLASMIC-RETICULUM; PRIMITIVE EUKARYOTE; SECRETORY APPARATUS; PROTEIN TRAFFICKING; ENTAMOEBA-INVADENS; QUALITY-CONTROL; INTESTINALIS; GENE; IDENTIFICATION	During encystation Giardia trophozoites secrete a fibrillar extracellular matrix of glycans and cyst wall proteins on the cell surface. The cyst wall material is accumulated in encystation-specific vesicles (ESVs), specialized Golgi-like compartments generated de novo, after export from the endoplasmic reticulum (ER) and before secretion. These large post-ER vesicles neither have the morphological characteristics of Golgi cisternae nor sorting functions, but may represent an evolutionary early form of the Golgi-like maturation compartment. Because little is known about the genesis and maturation of ESVs, we used a limited proteomics approach to discover novel proteins that are specific for developing ESVs or associated peripherally with these organelles. Unexpectedly, we identified cytoplasmic and luminal factors of the ER quality control system on two-dimensional electrophoresis gels, i.e. several proteasome subunits and HSP70-BiP. We show that BiP is exported to ESVs and retrieved via its C-terminal KDEL signal from ESVs. In contrast, cytoplasmic proteasome complexes undergo a developmentally regulated re-localization to ESVs during encystation. This suggests that maturation of bulk exported cyst wall material in the Golgi-like ESVs involves both continuous activity of ER-associated quality control mechanisms and retrograde Golgi to ER transport.	Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Uppsala Univ, BMC, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden	University of Zurich; Karolinska Institutet; Uppsala University	Hehl, AB (corresponding author), Univ Zurich, Inst Parasitol, Winterthurerstr 266A, CH-8057 Zurich, Switzerland.	Adrian.Hehl@access.unizh.ch	Stefanic, Sasa/AAF-3063-2020	Stefanic, Sasa/0000-0001-7367-1831; Hehl, Adrian/0000-0002-2110-4445; Svard, Staffan/0000-0002-7392-1746				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; ARROYOBEGOVICH A, 1980, J PARASITOL, V66, P735, DOI 10.2307/3280662; Benedetti C, 2000, BIOCHEM BIOPH RES CO, V278, P530, DOI 10.1006/bbrc.2000.3838; Davids BJ, 2004, MOL BIOCHEM PARASIT, V136, P173, DOI 10.1016/j.molbiopara.2004.03.011; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Emmerlich V, 2001, PARASITOL RES, V87, P112, DOI 10.1007/s004360000332; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Ferguson DJP, 2003, INT J PARASITOL, V33, P1329, DOI 10.1016/S0020-7519(03)00185-1; Frisardi M, 2000, INFECT IMMUN, V68, P4217, DOI 10.1128/IAI.68.7.4217-4224.2000; Gaechter V, 2005, INT J PARASITOL, V35, P1359, DOI 10.1016/j.ijpara.2005.06.007; Gerwig GJ, 2002, GLYCOBIOLOGY, V12, P499, DOI 10.1093/glycob/cwf059; GILLIN FD, 1989, EXP PARASITOL, V69, P164, DOI 10.1016/0014-4894(89)90185-9; Gonzalez J, 1999, EUR J BIOCHEM, V264, P897, DOI 10.1046/j.1432-1327.1999.00682.x; GUPTA RS, 1994, P NATL ACAD SCI USA, V91, P2895, DOI 10.1073/pnas.91.8.2895; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Hehl AB, 2004, MOL MICROBIOL, V53, P19, DOI 10.1111/j.1365-2958.2004.04115.x; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Lanfredi-Rangel A, 2003, J STRUCT BIOL, V143, P153, DOI 10.1016/S1047-8477(03)00123-0; Lujan HD, 1996, BIOL CELL, V86, P11, DOI 10.1016/0248-4900(96)89519-0; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 2003, CELL MICROBIOL, V5, P427, DOI 10.1046/j.1462-5822.2003.00284.x; Marti M, 2003, TRENDS PARASITOL, V19, P440, DOI 10.1016/S1471-4922(03)00201-0; Marti M, 2003, J BIOL CHEM, V278, P24837, DOI 10.1074/jbc.M302082200; Marti M, 2003, MOL BIOL CELL, V14, P1433, DOI 10.1091/mbc.E02-08-0467; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Petri WA, 2002, CURR OPIN MICROBIOL, V5, P443, DOI 10.1016/S1369-5274(02)00335-1; RAJAS F, 1993, BIOCHEM J, V295, P447, DOI 10.1042/bj2950447; Regoes A, 2005, J BIOL CHEM, V280, P30557, DOI 10.1074/jbc.M500787200; Reiner DS, 2001, CELL MICROBIOL, V3, P459, DOI 10.1046/j.1462-5822.2001.00129.x; Roger AJ, 1999, J MOL EVOL, V48, P750, DOI 10.1007/PL00006519; Slavin I, 2002, MOL BIOCHEM PARASIT, V122, P95, DOI 10.1016/S0166-6851(02)00065-8; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Soltys BJ, 1996, J CELL SCI, V109, P1909; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Van Horssen AM, 1998, J NEUROCHEM, V71, P402; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Weiland MEL, 2005, INT J PARASITOL, V35, P617, DOI 10.1016/j.ijpara.2004.12.009	42	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7595	7604		10.1074/jbc.M510940200	http://dx.doi.org/10.1074/jbc.M510940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407213	hybrid			2022-12-25	WOS:000236030900081
J	Teran, W; Krell, T; Ramos, JL; Gallegos, MT				Teran, W; Krell, T; Ramos, JL; Gallegos, MT			Effector-repressor interactions, binding of a single effector molecule to the operator-bound TtgR homodimer mediates derepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG EFFLUX PUMPS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURES; RESISTANCE; INHIBITORS; REGULATOR; RECOGNITION; TOLERANCE; MECHANISM; DRUGS	The RND family transporter TtgABC and its cognate repressor TtgR from Pseudomonas putida DOT-T1E were both shown to possess multidrug recognition properties. Structurally unrelated molecules such as chloramphenicol, butyl paraben, 1,3-dihydroxynaphthalene, and several flavonoids are substrates of TtgABC and activate pump expression by binding to the TtgR-operator complex. Isothermal titration calorimetry was employed to determine the thermodynamic parameters for the binding of these molecules to TtgR. Dissociation constants were in the range from 1 to 150 mu M, the binding stoichiometry was one effector molecule per dimer of TtgR, and the process was driven by favorable enthalpy changes. Although TtgR exhibits a large multidrug binding profile, the plant-derived compounds phloretin and quercetin were shown to bind with the highest affinity (K-D of around 1 mu M), in contrast to other effectors ( chloramphenicol and aromatic solvents) for which exhibited a more reduced affinity. Structure-function studies of effectors indicate that the presence of aromatic rings as well as hydroxyl groups are determinants for TtgR binding. The binding of TtgR to its operator DNA does not alter the protein effector profile nor the effector binding stoichiometry. Moreover, we demonstrate here for the first time that the binding of a single effector molecule to the DNA-bound TtgR homodimer induces the dissociation of the repressor-operator complex. This provides important insight into the molecular mechanism of effector-mediated derepression.	CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, E-18008 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ)	Gallegos, MT (corresponding author), CSIC, Dept Biochem & Mol & Cellular Biol Plants, Estac Expt Zaidin, Apartado de Correos 419, E-18008 Granada, Spain.	maritrini.gallegos@eez.csic.es	Krell, Tino/G-7296-2015; Teran, Wilson/AAG-3072-2019; Gallegos, María-Trinidad M.T./K-6501-2014	Krell, Tino/0000-0002-9040-3166; Gallegos, María-Trinidad M.T./0000-0001-7633-8807; Teran, Wilson/0000-0002-7597-5190; Ramos, Juan L./0000-0002-8731-7435				Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMSTERDAM D, 1991, ANTIBIOTICS LAB MED, P53; Borges-Waimsley MI, 2005, J MOL BIOL, V349, P387, DOI 10.1016/j.jmb.2005.03.045; Brooun A, 1999, J BACTERIOL, V181, P5131, DOI 10.1128/JB.181.16.5131-5133.1999; Burse A, 2004, MOL PLANT MICROBE IN, V17, P43, DOI 10.1094/MPMI.2004.17.1.43; Dastidar SG, 2001, IN VIVO, V15, P519; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Duque E, 2001, MOL MICROBIOL, V39, P1100, DOI 10.1046/j.1365-2958.2001.02310.x; Espinosa-Urgel Manuel, 2002, Microbiology (Reading), V148, P341, DOI 10.1099/00221287-148-2-341; Gonzalez-Pasayo R, 2000, MOL PLANT MICROBE IN, V13, P572, DOI 10.1094/MPMI.2000.13.5.572; Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665; Guazzaroni MAE, 2005, J BIOL CHEM, V280, P20887, DOI 10.1074/jbc.M500783200; HAGMAN KE, 1995, MICROBIOL-SGM, V141, P611, DOI 10.1099/13500872-141-3-611; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; KISKER C, 1995, J MOL BIOL, V247, P260, DOI 10.1006/jmbi.1994.0138; Kuiper I, 2001, MOL PLANT MICROBE IN, V14, P1197, DOI 10.1094/MPMI.2001.14.10.1197; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee EH, 1999, MOL MICROBIOL, V33, P839, DOI 10.1046/j.1365-2958.1999.01530.x; Levy SB, 2002, J APPL MICROBIOL, V92, p65S, DOI 10.1046/j.1365-2672.92.5s1.4.x; Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247; Lomovskaya O, 2001, ANTIMICROB AGENTS CH, V45, P105, DOI 10.1128/AAC.45.1.105-116.2001; Markham PN, 1996, J BACTERIOL, V178, P1473, DOI 10.1128/jb.178.5.1473-1475.1996; Molina L, 2000, SOIL BIOL BIOCHEM, V32, P315, DOI 10.1016/S0038-0717(99)00156-X; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Neyfakh AA, 2001, J MOL MICROB BIOTECH, V3, P151; Neyfakh AA, 1997, TRENDS MICROBIOL, V5, P309, DOI 10.1016/S0966-842X(97)01064-0; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Palumbo JD, 1998, J BACTERIOL, V180, P3107, DOI 10.1128/JB.180.12.3107-3113.1998; Peng WT, 2001, GENE, V270, P245, DOI 10.1016/S0378-1119(01)00468-1; Plaper A, 2003, BIOCHEM BIOPH RES CO, V306, P530, DOI 10.1016/S0006-291X(03)01006-4; Poole K, 2004, CLIN MICROBIOL INFEC, V10, P12, DOI 10.1111/j.1469-0691.2004.00763.x; Poole K, 2002, J APPL MICROBIOL, V92, p55S, DOI 10.1046/j.1365-2672.92.5s1.8.x; Poole K, 2001, CURR OPIN MICROBIOL, V4, P500, DOI 10.1016/S1369-5274(00)00242-3; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Ramos JL, 2005, MICROBIOL MOL BIOL R, V69, P326, DOI 10.1128/MMBR.69.2.326-356.2005; Ramos JL, 2002, ANNU REV MICROBIOL, V56, P743, DOI 10.1146/annurev.micro.56.012302.161038; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; Rauha JP, 2000, INT J FOOD MICROBIOL, V56, P3, DOI 10.1016/S0168-1605(00)00218-X; Renau TE, 1999, J MED CHEM, V42, P4928, DOI 10.1021/jm9904598; Rojas A, 2001, J BACTERIOL, V183, P3967, DOI 10.1128/JB.183.13.3967-3973.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; Schumacher MA, 2003, RES MICROBIOL, V154, P69, DOI 10.1016/S0923-2508(02)00013-X; Schweizer Herbert P, 2003, Genet Mol Res, V2, P48; SPAINK HP, 1987, PLANT MOL BIOL, V9, P27, DOI 10.1007/BF00017984; Tegos G, 2002, ANTIMICROB AGENTS CH, V46, P3133, DOI 10.1128/AAC.46.10.3133-3141.2002; Teran W, 2003, ANTIMICROB AGENTS CH, V47, P3067, DOI 10.1128/AAC.47.10.3067-3072.2003; TERAN W, 2005, THESIS U GRANADA GRA; vanVeen HW, 1997, BIOL CHEM, V378, P769; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhang L, 2000, ANTIMICROB AGENTS CH, V44, P287, DOI 10.1128/AAC.44.2.287-293.2000; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	58	60	62	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7102	7109		10.1074/jbc.M511095200	http://dx.doi.org/10.1074/jbc.M511095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407274	hybrid			2022-12-25	WOS:000236030900024
J	Islam, A; Adamik, B; Hawari, FI; Ma, G; Rouhani, FN; Zhang, J; Levine, SJ				Islam, A; Adamik, B; Hawari, FI; Ma, G; Rouhani, FN; Zhang, J; Levine, SJ			Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCYL-SPECIFIC AMINOPEPTIDASE; NECROSIS-FACTOR-ALPHA; FACTOR-BINDING-PROTEIN; CELL-DERIVED EXOSOMES; MOLECULAR-CLONING; MULTIVESICULAR BODY; RECEPTOR; ACTIVATION; DISTINCT; NEFA	Extracellular tumor necrosis factor (TNF) receptors function as TNF-binding proteins that modulate TNF activity. In human vascular endothelial cells ( HUVEC), extracellular TNFR1 ( type I TNF receptor, TNFRSF1A) is generated by two mechanisms, proteolytic cleavage of soluble TNFR1 ectodomains and the release of full-length 55-kDa TNFR1 in the membranes of exosome-like vesicles. TNFR1 release from HUVEC is known to involve the association between ARTS-1 ( aminopeptidase regulator of TNFR1 shedding), an integral membrane aminopeptidase, and TNFR1. The goal of this study was to identify ARTS-1 binding partners that modulate TNFR1 release to the extracellular space. A yeast two-hybrid screen of a human placenta cDNA library showed that NUCB2( nucleobindin 2), via its helix-loop-helix domains, binds the ARTS-1 extracellular domain. The association between endogenous ARTS-1 and NUCB2 in HUVEC was demonstrated by co-immunoprecipitation experiments, which showed the formation of a calcium-dependent NUCB2 . ARTS-1 complex that associated with a subset of total cellular TNFR1. Confocal microscopy experiments demonstrated that this association involved a distinct population of NUCB2-containing intracytoplasmic vesicles. RNA interference was utilized to specifically knock down NUCB2 and ARTS-1 expression, which demonstrated that both are required for the constitutive release of a full-length 55-kDa TNFR1 within exosome-like vesicles as well as the inducible proteolytic cleavage of soluble TNFR1 ectodomains. We propose that calcium-dependent NUCB2 . ARTS-1 complexes, which associate with TNFR1 prior to its commitment to pathways that result in either the constitutive release of TNFR1 exosome-like vesicles or the inducible proteolytic cleavage of TNFR1 ectodomains, play an important role in mediating TNFR1 release to the extracellular compartment.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, SJ (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 6D03,MSC 1590, Bethesda, MD 20892 USA.	levines@nhlbi.nih.gov	Adamik, Barbara/H-8696-2016	Adamik, Barbara/0000-0002-0541-841X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002544, ZIAHL002544] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BARNIKOLWATANABE S, 1994, BIOL CHEM H-S, V375, P497, DOI 10.1515/bchm3.1994.375.8.497; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; de Gassart A, 2003, BLOOD, V102, P4336, DOI 10.1182/blood-2003-03-0871; Denzer K, 2000, J CELL SCI, V113, P3365; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.1831413100; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; Hattori A, 2001, J BIOCHEM-TOKYO, V130, P235, DOI 10.1093/oxfordjournals.jbchem.a002977; Hattori A, 2000, J BIOCHEM-TOKYO, V128, P755, DOI 10.1093/oxfordjournals.jbchem.a022812; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; HOE MH, 1992, J BIOL CHEM, V267, P4916; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kroll KA, 1999, BIOCHEM BIOPH RES CO, V260, P1, DOI 10.1006/bbrc.1999.0867; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Miyashita H, 2002, BLOOD, V99, P3241, DOI 10.1182/blood.V99.9.3241; Morel-Huaux VM, 2002, EUR J CELL BIOL, V81, P87, DOI 10.1078/0171-9335-00224; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Moss ML, 2004, BIOCHEMISTRY-US, V43, P7227, DOI 10.1021/bi049677f; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; Olsen NJ, 2004, NEW ENGL J MED, V350, P2167, DOI 10.1056/NEJMra032906; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schomburg L, 2000, EUR J BIOCHEM, V267, P3198, DOI 10.1046/j.1432-1327.2000.01348.x; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Taniguchi N, 2000, J BIOL CHEM, V275, P31674, DOI 10.1074/jbc.M005103200; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; WALLACH D, TUMOR NECROSIS FACTO; Wang J, 2003, J BIOL CHEM, V278, P21751, DOI 10.1074/jbc.M212662200; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Yamamoto N, 2002, HUM MUTAT, V19, P251, DOI 10.1002/humu.10047; Yamazaki T, 2004, BLOOD, V104, P2345, DOI 10.1182/blood-2003-12-4260; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860	52	69	70	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6860	6873		10.1074/jbc.M509397200	http://dx.doi.org/10.1074/jbc.M509397200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407280	hybrid			2022-12-25	WOS:000236030800084
J	Munteanu, A; Taddei, M; Tamburini, I; Bergamini, E; Azzi, A; Zingg, JM				Munteanu, A; Taddei, M; Tamburini, I; Bergamini, E; Azzi, A; Zingg, JM			Antagonistic effects of oxidized low density lipoprotein and alpha-tocopherol on CD36 scavenger receptor expression in monocytes - Involvement of protein kinase B and peroxisome proliferator-activated receptor-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; INHIBITS MACROPHAGE APOPTOSIS; ELEMENT-BINDING PROTEIN-1; CHAIN FATTY-ACIDS; NF-KAPPA-B; VITAMIN-E; PPAR-GAMMA; GENE-EXPRESSION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY	Vitamin E deficiency increases expression of the CD36 scavenger receptor, suggesting specific molecular mechanisms and signaling pathways modulated by alpha-tocopherol. We show here that alpha-tocopherol down-regulated CD36 expression ( mRNA and protein) in oxidized low density lipoprotein (oxLDL)-stimulated THP-1 monocytes, but not in unstimulated cells. Furthermore, alpha-tocopherol treatment of monocytes led to reduction of fluorescent oxLDL-3,3'-dioctadecyloxacarbocyanine perchlorate binding and uptake. Protein kinase C (PKC) appears not to be involved because neither activation of PKC by phorbol 12-myristate 13-acetate nor inhibition by PKC412 was affected by alpha-tocopherol. However, alpha-tocopherol could partially prevent CD36 induction after stimulation with a specific agonist of peroxisome proliferator-activated receptor-gamma (PPAR gamma; troglitazone), indicating that this pathway is susceptible to alpha-tocopherol action. Phosphorylation of protein kinase B (PKB) at Ser(473) was increased by oxLDL, and alpha-tocopherol could prevent this event. Expression of PKB stimulated the CD36 promoter as well as a PPAR gamma element-driven reporter gene, whereas an inactive PKB mutant had no effect. Moreover, coexpression of PPAR gamma and PKB led to additive induction of CD36 expression. Altogether, our results support the existence of PKB/PPAR gamma signaling pathways that mediate CD36 expression in response to oxLDL. The activation of CD36 expression by PKB suggests that both lipid biosynthesis and fatty acid uptake are stimulated by PKB.	Univ Bern, Inst Biochem & Mol Med, CH-3012 Bern, Switzerland; Univ Pisa, Ctr Ric Biol & Patol Invecchiamento, I-56126 Pisa, Italy	University of Bern; University of Pisa	Zingg, JM (corresponding author), Univ Bern, Inst Biochem & Mol Med, Buhlstr 28, CH-3012 Bern, Switzerland.	zin34@swissonline.ch	Zingg, Jean-Marc/H-6960-2019; Vlad, Adelina/C-6288-2012	Vlad, Adelina/0000-0002-2282-6802				Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Akazawa A, 2002, JPN J PHARMACOL, V89, P417, DOI 10.1254/jjp.89.417; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Antoniades C, 2003, HERZ, V28, P628, DOI 10.1007/s00059-003-2417-8; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Brigelius-Flohe R, 2002, AM J CLIN NUTR, V76, P703, DOI 10.1093/ajcn/76.4.703; Campbell SE, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-25; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Chabowski A, 2004, AM J PHYSIOL-ENDOC M, V287, pE781, DOI 10.1152/ajpendo.00573.2003; Chan SS, 2001, FREE RADICAL RES, V35, P843, DOI 10.1080/10715760100301341; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Chien MW, 2003, J LIPID RES, V44, P1667, DOI 10.1194/jlr.M300006-JLR200; d'Abramo C, 2005, BIOCHEM J, V391, P693, DOI 10.1042/BJ20050560; Devaraj S, 2001, J LIPID RES, V42, P521; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Feng JW, 2000, J LIPID RES, V41, P688; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Frank GD, 2000, ENDOCRINOLOGY, V141, P3120, DOI 10.1210/en.141.9.3120; Fu MG, 2001, CIRC RES, V89, P1058, DOI 10.1161/hh2301.099642; Fu YC, 2000, J LIPID RES, V41, P2017; Ghanim H, 2001, J CLIN ENDOCR METAB, V86, P1306, DOI 10.1210/jc.86.3.1306; Goti D, 2000, J NEUROCHEM, V74, P1374, DOI 10.1046/j.1471-4159.2000.0741374.x; Guthmann F, 1999, AM J PHYSIOL-LUNG C, V277, pL191, DOI 10.1152/ajplung.1999.277.1.L191; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HAMMER A, 1995, ARTERIOSCL THROM VAS, V15, P704, DOI 10.1161/01.ATV.15.5.704; Han JH, 1999, J LIPID RES, V40, P830; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Han S, 2002, IMMUNOLOGY, V106, P53, DOI 10.1046/j.1365-2567.2002.01404.x; Hathcock JN, 2005, AM J CLIN NUTR, V81, P736, DOI 10.1093/ajcn/81.4.736; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hayden JM, 2002, J LIPID RES, V43, P26; Hodis HN, 2002, CIRCULATION, V106, P1453, DOI 10.1161/01.CIR.0000029092.99946.08; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Huh HY, 1996, BLOOD, V87, P2020; Hundal RS, 2003, J BIOL CHEM, V278, P24399, DOI 10.1074/jbc.M209179200; Hundal RS, 2001, J LIPID RES, V42, P1483; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Iynedjian PB, 2000, BIOCHEM J, V351, P621, DOI 10.1042/0264-6021:3510621; Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953; JIALAL I, 1995, ARTERIOSCL THROM VAS, V15, P190, DOI 10.1161/01.ATV.15.2.190; Jostarndt K, 2004, BIOCHEM PHARMACOL, V67, P841, DOI 10.1016/j.bcp.2003.09.041; Kelly DP, 2001, CIRC RES, V89, P935, DOI 10.1161/res.89.11.935; Kempna P, 2004, J BIOL CHEM, V279, P50700, DOI 10.1074/jbc.M410800200; Kempna P, 2003, FREE RADICAL BIO MED, V34, P1458, DOI 10.1016/S0891-5849(03)00173-4; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Lamharzi N, 2004, DIABETES, V53, P3217, DOI 10.2337/diabetes.53.12.3217; Landes N, 2003, BIOCHEM PHARMACOL, V65, P269, DOI 10.1016/S0006-2952(02)01520-4; Maziere C, 2001, FREE RADICAL BIO MED, V31, P1334, DOI 10.1016/S0891-5849(01)00649-9; Mikita T, 2001, J BIOL CHEM, V276, P45729, DOI 10.1074/jbc.M106114200; Morganelli PM, 1997, ARTERIOSCL THROM VAS, V17, P3248, DOI 10.1161/01.ATV.17.11.3248; Munteanu A, 2004, J CELL MOL MED, V8, P59, DOI 10.1111/j.1582-4934.2004.tb00260.x; Munteanu A, 2004, BIOCHEM BIOPH RES CO, V318, P311, DOI 10.1016/j.bbrc.2004.04.028; Munteanu A, 2005, FREE RADICAL BIO MED, V38, P1047, DOI 10.1016/j.freeradbiomed.2004.12.030; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; Ni J, 2005, CANCER RES, V65, P9807, DOI 10.1158/0008-5472.CAN-05-1334; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; Noguchi N, 2003, FREE RADICAL BIO MED, V34, P1614, DOI 10.1016/S0891-5849(03)00216-8; Noushmehr H, 2005, DIABETES, V54, P472, DOI 10.2337/diabetes.54.2.472; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Oudit GY, 2004, J MOL CELL CARDIOL, V37, P449, DOI 10.1016/j.yjmcc.2004.05.015; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P590, DOI 10.1161/01.ATV.13.4.590; Ribaux PG, 2003, BIOCHEM J, V376, P697, DOI 10.1042/BJ20031287; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; Ricciarelli R, 2004, FREE RADICAL BIO MED, V36, P1018, DOI 10.1016/j.freeradbiomed.2004.01.007; Ricciarelli R, 2001, FASEB J, V15, P2314, DOI 10.1096/fj.01-0258rev; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Shah S, 2004, EXP BIOL MED, V229, P745, DOI 10.1177/153537020422900806; Sugano R, 2001, ATHEROSCLEROSIS, V158, P351, DOI 10.1016/S0021-9150(01)00456-7; Sylvester PW, 2005, FRONT BIOSCI, V10, P699, DOI 10.2741/1565; Sylvester PW, 2002, ASIA PAC J CLIN NUTR, V11, pS452, DOI 10.1046/j.1440-6047.11.s.7.9.x; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Teupser D, 1999, ATHEROSCLEROSIS, V144, P109, DOI 10.1016/S0021-9150(99)00040-4; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsukamoto Kayo, 2002, J Atheroscler Thromb, V9, P57; Venugopal SK, 2004, ATHEROSCLEROSIS, V175, P213, DOI 10.1016/j.atherosclerosis.2004.03.012; Viana M, 2005, FREE RADICAL RES, V39, P973, DOI 10.1080/10715760500073758; Vicca S, 2000, BIOCHEM BIOPH RES CO, V273, P948, DOI 10.1006/bbrc.2000.3017; Villacorta L, 2003, CIRC RES, V92, P104, DOI 10.1161/01.RES.0000049103.38175.1B; Wang XS, 1999, ANAL BIOCHEM, V267, P271, DOI 10.1006/abio.1998.3023; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Zingg JM, 2000, BIOFACTORS, V11, P189, DOI 10.1002/biof.5520110305; Zingg JM, 2004, CURR MED CHEM, V11, P1113, DOI 10.2174/0929867043365332; Zingg JM, 2002, ARTERIOSCL THROM VAS, V22, P412, DOI 10.1161/hq0302.104517	100	78	80	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6489	6497		10.1074/jbc.M508799200	http://dx.doi.org/10.1074/jbc.M508799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407258	hybrid			2022-12-25	WOS:000236030800044
J	Piscitelli, CL; Angel, BE; Bailey, BW; Hargrave, P; Dratz, EA; Lawrence, CM				Piscitelli, CL; Angel, BE; Bailey, BW; Hargrave, P; Dratz, EA; Lawrence, CM			Equilibrium between metarhodopsin-I and metarhodopsin-II is dependent on the conformation of the third cytoplasmic loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; INITIAL RATE ANALYSIS; TRANSDUCIN ACTIVATION; CRYSTAL-STRUCTURE; STRUCTURAL FEATURES; INTRINSIC DISORDER; EXCITED RHODOPSIN; BOVINE RHODOPSIN; PHAGE-DISPLAY; ALPHA-SUBUNIT	Rhodopsin is a G-protein-coupled receptor ( GPCR) that is the light detector in the rod cells of the eye. Rhodopsin is the best understood member of the large GPCR superfamily and is the only GPCR for which atomic resolution structures have been determined. However, these structures are for the inactive, dark-adapted form. Characterization of the conformational changes in rhodopsin caused by light-induced activation is of wide importance, because the metarhodopsin-II photoproduct is analogous to the agonist-occupied conformation of other GPCRs, and metarhodopsin-I may be similar to antagonist-occupied GPCR conformations. In this work we characterize the interaction of antibody K42-41L with the metarhodopsin photoproducts. K42-41L is shown to inhibit formation of metarhodopsin-II while it stabilizes the metarhodopsin-I state. Thus, K42-41L recognizes an epitope accessible in dark-adapted rhodopsin and metarhodopsin-I that is lost upon formation of metarhodopsin-II. Previous work has shown that the peptide TGALQERSK is able to mimic the K42-41L epitope, and we have now determined the structure of the K42-41L-peptide complex. The structure demonstrates a central role for elements of the rhodopsin C3 loop, particularly Gln(238) and Glu(239), in the interaction with K42-41L. Geometric constraints taken from the antibody-bound peptide were used to model the epitope on the rhodopsin surface. The resulting model suggests that K42-41L locks the C3 loop into an extended conformation that is intermediate between two compact conformations seen in crystal structures of dark-adapted rhodopsin. Together, the structural and functional data strongly suggest that the equilibrium between metarhodopsin-I and metarhodopsin-II is dependent upon the conformation of the C3 loop. The biological implications of this model and its possible relations to dimeric and multimeric complexes of rhodopsin are discussed.	Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; NCI, NIH, Rockville, MD 20852 USA; Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida	Lawrence, CM (corresponding author), Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA.	lawrence@chemistry.montana.edu	Bailey, Brian/B-1732-2009; Lawrence, C. Martin/AAH-3420-2020	Lawrence, C. Martin/0000-0002-5398-466X	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062547] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ADAMUS G, 1988, Peptide Research, V1, P42; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; Bailey BW, 2003, PROTEIN SCI, V12, P2453, DOI 10.1110/ps.03233703; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; Burritt JB, 1996, ANAL BIOCHEM, V238, P1, DOI 10.1006/abio.1996.0241; Burritt JB, 2000, EUR J HAEMATOL, V65, P407, DOI 10.1034/j.1600-0609.2000.065006407.x; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; Collis AVJ, 2003, J MOL BIOL, V325, P337, DOI 10.1016/S0022-2836(02)01222-6; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Echols N, 2003, NUCLEIC ACIDS RES, V31, P478, DOI 10.1093/nar/gkg104; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321; Ishiguro M, 2004, CHEMBIOCHEM, V5, P298, DOI 10.1002/cbic.200300668; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Jesaitis AJ, 1999, PROTEIN SCI, V8, P760; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Koenig BW, 2002, J MOL BIOL, V322, P441, DOI 10.1016/S0022-2836(02)00745-3; KONIG B, 1989, FEBS LETT, V257, P163, DOI 10.1016/0014-5793(89)81811-3; Krebs WG, 2000, NUCLEIC ACIDS RES, V28, P1665, DOI 10.1093/nar/28.8.1665; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mumey BM, 2003, J COMPUT BIOL, V10, P555, DOI 10.1089/10665270360688183; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; Nikiforovich GV, 2003, BIOCHEMISTRY-US, V42, P9110, DOI 10.1021/bi034586o; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t	72	12	12	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6813	6825		10.1074/jbc.M510175200	http://dx.doi.org/10.1074/jbc.M510175200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407202	hybrid			2022-12-25	WOS:000236030800080
J	Senga, T; Sivaprasad, U; Zhu, WG; Park, JH; Arias, EE; Walter, JC; Dutta, A				Senga, T; Sivaprasad, U; Zhu, WG; Park, JH; Arias, EE; Walter, JC; Dutta, A			PCNA is a cofactor for Cdt1 degradation by CUL4/DDB1-mediated N-terminal ubiquitination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; LICENSING FACTOR; GEMININ BINDING; IN-VIVO; S-PHASE; INHIBITION; P21; REREPLICATION	Cdt1, a protein essential in G(1) for licensing of origins for DNA replication, is inhibited in S-phase, both by binding to geminin and degradation by proteasomes. Cdt1 is also degraded after DNA damage to stop licensing of new origins until after DNA repair. Phosphorylation of Cdt1 by cyclin-dependent kinases promotes its binding to SCF-Skp2 E3 ubiquitin ligase, but the Cdk2/Skp2-mediated pathway is not essential for the degradation of Cdt1. Here we show that the N terminus of Cdt1 contains a second degradation signal that is active after DNA damage and in S-phase and is dependent on the interaction of Cdt1 with proliferating cell nuclear antigen ( PCNA) through a PCNA binding motif. The degradation involves N-terminal ubiquitination and requires Cul4 and Ddb1 proteins, components of an E3 ubiquitin ligase implicated in protein degradation after DNA damage. Therefore PCNA, the matchmaker for many proteins involved in DNA and chromatin metabolism, also serves to promote the targeted degradation of associated proteins in S-phase or after DNA damage.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Seoul Natl Univ, Sch Biol Sci, Inst Mol Biol & Genet, Seoul 151742, South Korea	University of Virginia; Harvard University; Harvard Medical School; Seoul National University (SNU)	Dutta, A (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733,1300 Jefferson Pk Ave,Jordan 1240, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Walter, Johannes/0000-0002-4186-7570; Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA060499, R01-CA60499, R01 CA060499-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arias EE, 2006, NAT CELL BIOL, V8, P84, DOI 10.1038/ncb1346; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Takeda DY, 2005, J BIOL CHEM, V280, P23416, DOI 10.1074/jbc.M501208200; Ukomadu C, 2003, J BIOL CHEM, V278, P43586, DOI 10.1074/jbc.M307194200; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	31	200	207	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6246	6252		10.1074/jbc.M512705200	http://dx.doi.org/10.1074/jbc.M512705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407252	hybrid			2022-12-25	WOS:000236030800017
J	Sunderhaus, S; Dudkina, NV; Jansch, L; Klodmann, J; Heinemeyer, J; Perales, M; Zabaleta, E; Boekema, EJ; Braun, HP				Sunderhaus, S; Dudkina, NV; Jansch, L; Klodmann, J; Heinemeyer, J; Perales, M; Zabaleta, E; Boekema, EJ; Braun, HP			Carbonic anhydrase subunits form a matrix-exposed domain attached to the membrane arm of mitochondrial complex I in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE REDUCTASE; CHLAMYDOMONAS-REINHARDTII; RESPIRATORY-CHAIN; POLYACRYLAMIDE GELS; BLUE DYES; PURIFICATION; ARABIDOPSIS; COMPONENTS; QUANTIFICATION; SUPERCOMPLEXES	Complex I of Arabidopsis includes five structurally related subunits representing gamma-type carbonic anhydrases termed CA1, CA2, CA3, CAL1, and CAL2. The position of these subunits within complex I was investigated. Direct analysis of isolated subcomplexes of complex I by liquid chromatography linked to tandem mass spectrometry allowed the assignment of the CA subunits to the membrane arm of complex I. Carbonate extraction experiments revealed that CA2 is an integral membrane protein that is protected upon protease treatment of isolated mitoplasts, indicating a location on the matrix-exposed side of the complex. A structural characterization by single particle electron microscopy of complex I from the green alga Polytomella and a previous analysis from Arabidopsis indicate a plant-specific spherical extra-domain of about 60 angstrom in diameter, which is attached to the central part of the membrane arm of complex I on its matrix face. This spherical domain is proposed to contain a heterotrimer of three CA subunits, which are anchored with their C termini to the hydrophobic arm of complex I. Functional implications of the complex I-integrated CA subunits are discussed.	Leibniz Univ Hannover, Inst Angew Genet, D-30419 Hannover, Germany; Univ Groningen, Dept Biophys Chem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany; Univ Nacl Mar del Plata, Fac Ciencias Exactas & Nat, Inst Invest Biol, RA-7600 Mar Del Plata, Argentina	Leibniz University Hannover; University of Groningen; Gesellschaft fur Biotechnologische Forschung mbH; National University of Mar del Plata	Braun, HP (corresponding author), Leibniz Univ Hannover, Inst Angew Genet, Herrenhauser Str 2, D-30419 Hannover, Germany.	braun@genetik.uni-hannover.de	Klodmann, Jennifer/B-2131-2013; perales, mariano/L-5412-2014; Braun, Hans-Peter/E-7149-2011	perales, mariano/0000-0002-7351-8439; Braun, Hans-Peter/0000-0002-4459-9727; Senkler, Jennifer/0000-0002-1377-3841; zabaleta, eduardo/0000-0001-5767-141X				Abdrakhmanova A, 2004, BBA-BIOENERGETICS, V1658, P148, DOI 10.1016/j.bbabio.2004.04.019; Atteia A, 2003, PLANT MOL BIOL, V53, P175, DOI 10.1023/B:PLAN.0000009274.19340.36; Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; Cardol P, 2004, BBA-BIOENERGETICS, V1658, P212, DOI 10.1016/j.bbabio.2004.06.001; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Dudkina NV, 2005, FEBS LETT, V579, P5769, DOI 10.1016/j.febslet.2005.09.065; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Friedrich T, 2004, BBA-BIOENERGETICS, V1608, P1, DOI 10.1016/j.bbabio.2003.10.002; Heazlewood JL, 2003, BBA-BIOENERGETICS, V1604, P159, DOI 10.1016/S0005-2728(03)00045-8; Heinemeyer J, 2004, PHYTOCHEMISTRY, V65, P1683, DOI 10.1016/j.phytochem.2004.04.022; HEINEMEYER J, 2005, IN PRESS PLANT PROTE; HERZ U, 1994, J BIOL CHEM, V269, P2263; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Iverson TM, 2000, BIOCHEMISTRY-US, V39, P9222, DOI 10.1021/bi000204s; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; LETERME S, 1993, PLANT PHYSIOL, V102, P435, DOI 10.1104/pp.102.2.435; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Moroney JV, 2001, PLANT CELL ENVIRON, V24, P141, DOI 10.1111/j.1365-3040.2001.00669.x; NEUHOFF V, 1985, ELECTROPHORESIS, V6, P427, DOI 10.1002/elps.1150060905; NEUHOFF V, 1990, ELECTROPHORESIS, V11, P101, DOI 10.1002/elps.1150110202; Parisi G, 2004, PLANT MOL BIOL, V55, P193, DOI 10.1007/s11103-004-0149-7; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Perales M, 2005, J MOL BIOL, V350, P263, DOI 10.1016/j.jmb.2005.04.062; Perales M, 2004, PLANT MOL BIOL, V56, P947, DOI 10.1007/s11103-004-6324-z; RASMUSSON AG, 1994, PHYSIOL PLANTARUM, V90, P607, DOI 10.1111/j.1399-3054.1994.tb08821.x; Rasmusson AG, 1998, BBA-BIOENERGETICS, V1364, P101, DOI 10.1016/S0005-2728(98)00021-8; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUNDERHAUS S, 2005, IN PRESS MITOCHONDRI; TROST P, 1995, EUR J BIOCHEM, V234, P452, DOI 10.1111/j.1432-1033.1995.452_b.x; van Lis R, 2003, PLANT PHYSIOL, V132, P318, DOI 10.1104/pp.102.018325; van Lis R, 2005, BBA-BIOENERGETICS, V1708, P23, DOI 10.1016/j.bbabio.2004.12.010; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; Werhahn W, 2001, PLANT PHYSIOL, V125, P943, DOI 10.1104/pp.125.2.943; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131	37	139	151	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6482	6488		10.1074/jbc.M511542200	http://dx.doi.org/10.1074/jbc.M511542200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407270	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000236030800043
J	Casas, J; Gijon, MA; Vigo, AG; Crespo, MS; Balsinde, J; Balboa, MA				Casas, J; Gijon, MA; Vigo, AG; Crespo, MS; Balsinde, J; Balboa, MA			Overexpression of cytosolic group IVA phospholipase A(2) protects cells from Ca2+-dependent death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; U937 CELLS; C2 DOMAIN; MITOCHONDRIAL-MEMBRANE; HUMAN CYTOMEGALOVIRUS; PLASMA-MEMBRANE; FATTY-ACIDS; APOPTOSIS	The calcium ionophore ionomycin induces apoptosis-like events in the human embryonic kidney cell line at early times. Plasma membrane blebbing, mitochondrial depolarization, externalization of phosphatidylserine, and nuclear permeability changes can all be observed within 15 min of treatment. However, there is no activation of caspases or chromatin condensation. Expression of a fusion protein containing the enhanced green fluorescent protein (EGFP) and human cytosolic Group IVA phospholipase A(2)alpha (EGFP-cPLA(2)alpha) in these cells prevents ionomycin-induced phosphatidylserine externalization and death. Cells expressing the cPLA(2)alpha mutant D43N, which does not bind calcium, retain their susceptibility to ionomycin-induced cell death. Both nonexpressing and EGFP-D43N-cPLA(2)alpha-expressing human embryonic kidney cells can be spared from ionomycin-induced cell death by pretreating them with exogenous arachidonic acid. Moreover, during calcium overload, mitochondrial depolarization is significantly lower in the EGFP-cPLA(2)alpha-expressing cells than in cells expressing normal amounts of cPLA(2)alpha. These results suggest that early cell death events promoted by an overload of calcium can be prevented by the presence of high levels of arachidonic acid.	Univ Valladolid, Inst Biol & Genet Mol, CSIC, Sch Med, Valladolid 47003, Spain; Inst Mol Biol & Genet, Spanish Res Council, Valladolid 47003, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM)	Balboa, MA (corresponding author), Univ Valladolid, Inst Biol & Genet Mol, CSIC, Sch Med, Calle Sanz & Fores S-N, Valladolid 47003, Spain.	Miguel.Gijon@uchsc.edu; jbalsinde@ibgm.uva.es; mbalboa@ibgm.uva.es	Balboa, María A./V-9493-2018; Casas, Javier/K-7190-2015; Balsinde, Jesús/C-7833-2018	Balboa, María A./0000-0002-2130-5298; Casas, Javier/0000-0002-6413-8127; Balsinde, Jesús/0000-0002-4157-6714				Allal C, 2004, J VIROL, V78, P7717, DOI 10.1128/JVI.78.14.7717-7726.2004; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Balboa MA, 2002, J BIOL CHEM, V277, P40384, DOI 10.1074/jbc.M206155200; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 2004, TRENDS IMMUNOL, V25, P116, DOI 10.1016/j.it.2004.01.006; BRATTON DL, 1992, J IMMUNOL, V148, P514; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; Doug M, 2003, CARCINOGENESIS, V24, P307, DOI 10.1093/carcin/24.2.307; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Fortunato EA, 2000, TRENDS MICROBIOL, V8, P111, DOI 10.1016/S0966-842X(00)01699-1; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Girod A, 2002, J GEN VIROL, V83, P973, DOI 10.1099/0022-1317-83-5-973; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kronke M, 2002, FEBS LETT, V531, P18, DOI 10.1016/S0014-5793(02)03407-5; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Penzo D, 2004, J BIOL CHEM, V279, P25219, DOI 10.1074/jbc.M310381200; Perez R, 2004, J BIOL CHEM, V279, P40385, DOI 10.1074/jbc.M402562200; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Roehrig S, 2003, ANAL BIOCHEM, V318, P244, DOI 10.1016/S0003-2697(03)00242-2; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; TAIT JF, 1989, J BIOL CHEM, V264, P7944; Takadera T, 1997, EUR J BIOCHEM, V249, P8, DOI 10.1111/j.1432-1033.1997.00008.x; Tommasini I, 2002, CELL DEATH DIFFER, V9, P1368, DOI 10.1038/sj.cdd.4401123; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Wojtczak L, 1999, J BIOENERG BIOMEMBR, V31, P447, DOI 10.1023/A:1005444322823; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200	47	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6106	6116		10.1074/jbc.M505230200	http://dx.doi.org/10.1074/jbc.M505230200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407173	Green Submitted, hybrid			2022-12-25	WOS:000235568900092
J	Ida, M; Shuo, T; Hirano, K; Tokita, Y; Nakanishi, K; Matsui, F; Aono, S; Fujita, H; Fujiwara, Y; Kaji, T; Oohira, A				Ida, M; Shuo, T; Hirano, K; Tokita, Y; Nakanishi, K; Matsui, F; Aono, S; Fujita, H; Fujiwara, Y; Kaji, T; Oohira, A			Identification and functions of chondroitin sulfate in the milieu of neural stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH FACTOR-2; TYROSINE-PHOSPHATASE-BETA; CENTRAL-NERVOUS-SYSTEM; EMBRYONIC PIG BRAIN; HEPARAN-SULFATE; DERMATAN SULFATE; NEUROGLYCAN-C; NEURONAL DIFFERENTIATION; MOLECULAR-INTERACTIONS; PROTEOGLYCAN	The behavior of cells is generally considered to be regulated by environmental factors, but the molecules in the milieu of neural stem cells have been little studied. We found by immunohistochemistry that chondroitin sulfate (CS) existed in the surroundings of nestin-positive cells or neural stem/progenitor cells in the rat ventricular zone of the telencephalon at embryonic day 14. Brain-specific chondroitin sulfate proteoglycans (CSPGs), including neurocan, phosphacan/receptor-type protein-tyrosine phosphatase beta, and neuroglycan C, were detected in the ventricular zone. Neurospheres formed by cells from the fetal telencephalon also expressed these CSPGs and NG2 proteoglycan. To examine the structural features and functions of CS polysaccharides in the milieu of neural stem cells, we isolated and purified CS from embryonic day 14 telencephalons. The CS preparation consisted of two fractions differing in size and extent of sulfation: small CS polysaccharides with low sulfation and large CS polysaccharides with high sulfation. Interestingly, both CS polysaccharides and commercial preparations of dermatan sulfate CS-B and an E-type of highly sulfated CS promoted the fibroblast growth factor-2-mediated proliferation of neural stem/progenitor cells. None of these CS preparations promoted the epidermal growth factor-mediated neural stem cell proliferation. These results suggest that these CSPGs are involved in the proliferation of neural stem cells as a group of cell microenvironmental factors.	Aichi Human Serv Ctr, Dept Perinatol, Inst Dev Res, Aichi 4800392, Japan; Nagoya Univ, Dept Neurochem, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Environm Hlth, Kanazawa, Ishikawa 9201181, Japan; Seikagaku Corp, Kanagawa 2390831, Japan	Nagoya University; Hokuriku University; Seikagaku Corporation	Oohira, A (corresponding author), Aichi Human Serv Ctr, Dept Perinatol & Neuroglycosci, Inst Dev Res, Aichi 4800392, Japan.	oohira@inst-hsc.jp	Fujiwara, Yasuyuki/AAB-8775-2020	Fujiwara, Yasuyuki/0000-0003-0028-0658; Ida-Eto, Michiru/0000-0002-2469-4006				Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Aono S, 2006, J NEUROSCI RES, V83, P110, DOI 10.1002/jnr.20698; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Brakebusch C, 2002, MOL CELL BIOL, V22, P7417, DOI 10.1128/MCB.22.21.7417-7427.2002; Campos LS, 2004, J NEUROSCI RES, V78, P761, DOI 10.1002/jnr.20333; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Engel M, 1996, J COMP NEUROL, V366, P34; Ford-Perriss M, 2003, DEV DYNAM, V227, P170, DOI 10.1002/dvdy.10298; Fukuda T, 1997, J COMP NEUROL, V382, P141; Gabay L, 2003, NEURON, V40, P485, DOI 10.1016/S0896-6273(03)00637-8; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Hagihara K, 2000, DEV DYNAM, V219, P353, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1059>3.0.CO;2-#; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; Kabos P, 2004, BIOCHEM BIOPH RES CO, V318, P955, DOI 10.1016/j.bbrc.2004.04.114; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Li WW, 1998, J NEUROSCI, V18, P8853; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MATSUI F, 1994, NEUROCHEM INT, V25, P425, DOI 10.1016/0197-0186(94)90018-3; Matsuno Y, 2004, J PHARMACEUT BIOMED, V36, P9, DOI 10.1016/j.jpba.2004.05.020; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; Muroyama Y, 2004, BIOCHEM BIOPH RES CO, V313, P915, DOI 10.1016/j.bbrc.2003.12.023; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; OOHIRA A, 1986, J NEUROCHEM, V47, P588; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Popp S, 2003, DEV DYNAM, V227, P143, DOI 10.1002/dvdy.10282; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Shuo T, 2003, GLYCOCONJUGATE J, V20, P267, DOI 10.1023/B:GLYC.0000025821.22618.33; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; TEKOTTE H, 1994, J NEUROCHEM, V62, P1126; Villena J, 2004, J CELL PHYSIOL, V198, P169, DOI 10.1002/jcp.10422; Yamauchi S, 2002, J BIOL CHEM, V277, P20583, DOI 10.1074/jbc.M200909200; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	53	105	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5982	5991		10.1074/jbc.M507130200	http://dx.doi.org/10.1074/jbc.M507130200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373347	hybrid			2022-12-25	WOS:000235568900079
J	Palma, AS; Feizi, T; Zhang, YB; Stoll, MS; Lawson, AM; Diaz-Rodriguez, E; Campanero-Rhodes, MA; Costa, J; Gordon, S; Brown, GD; Chai, WG				Palma, AS; Feizi, T; Zhang, YB; Stoll, MS; Lawson, AM; Diaz-Rodriguez, E; Campanero-Rhodes, MA; Costa, J; Gordon, S; Brown, GD; Chai, WG			Ligands for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; C-TYPE LECTIN; CARBOHYDRATE MICROARRAYS; E-SELECTIN; RECOGNITION; CELLS; TECHNOLOGY; BINDING; IDENTIFICATION; SPECIFICITY	Dectin- 1 is a C- type lectin- like receptor on leukocytes that mediates phagocytosis and inflammatory mediator production in innate immunity to fungal pathogens. Dectin- 1 lacks residues involved in calcium ligation that mediates carbohydrate- binding by classical C- type lectins; nevertheless, it binds zymosan, a particulate beta- glucan-rich extract of Saccharomyces cerevisiae, and binding is inhibited by polysaccharides rich in beta 1,3- or both beta 1,3- and beta 1,6- linked glucose. The oligosaccharide ligands on glucans recognized by Dectin-1 have not yet been delineated precisely. It is also not known whether Dectin- 1 can interact with other types of carbohydrates. We have investigated this, since Dectin- 1 shows glucan- independent binding to a subset of T- lymphocytes and is involved in triggering their proliferation. Here we assign oligosaccharide ligands for Dectin- 1 using the neoglycolipid- based oligosaccharide microarray technology, a unique approach for constructing microarrays of lipid-linked oligosaccharide probes from desired sources. We generate " designer" microarrays from three glucan polysaccharides, a neutral soluble glucan isolated from S. cerevisiae and two bacterial glucans, curdlan from Alcaligenes faecalis and pustulan from Umbilicaria papullosa, and use these in conjunction with 187 diverse, sequence- defined, predominantly mammalian- type, oligosaccharide probes. Among these, Dectin- 1 binding is detected exclusively to 1,3- linked glucose oligomers, the minimum length required for detectable binding being a 10- or 11- mer. Thus, the ligands assigned so far are exogenous rather than endogenous. We further show that Dectin- 1 ligands, 11 - 13 gluco- oligomers, in clustered form ( displayed on liposomes), mimic the macromolecular beta- glucans and compete with zymosan binding and triggering of tumor necrosis factor-alpha secretion by a Dectin- 1- expressing macrophage cell line.	Imperial Coll London, Fac Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Lab Glicobiol, P-2781901 Oeiras, Portugal; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	Imperial College London; Universidade Nova de Lisboa; University of Oxford; University of Cape Town	Feizi, T (corresponding author), Imperial Coll London, Fac Med, Glycosci Lab, Northwick Pk & St Marks Campus,Watford Rd, Harrow HA1 3UJ, Middx, England.	t.feizi@imperial.ac.uk	Costa, Júlia C/B-7131-2008; brown, gordon/B-4249-2012; Campanero-Rhodes, María Asunción/M-3158-2014; Palma, Angelina S/D-2052-2013	Costa, Júlia C/0000-0001-7782-6319; Campanero-Rhodes, María Asunción/0000-0002-3373-0064; Palma, Angelina S/0000-0001-5797-6555; brown, gordon/0000-0002-0287-5383; Feizi, Ten/0000-0001-6495-0329	MRC [G9601454] Funding Source: UKRI; Engineering and Physical Sciences Research Council [GR/S79268/02] Funding Source: researchfish; Medical Research Council [G9601454] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adachi Y, 2004, INFECT IMMUN, V72, P4159, DOI 10.1128/IAI.72.7.4159-4171.2004; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; BLACK WAP, 1951, J APPL CHEM, V1, P505, DOI 10.1002/jctb.5010011112; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4; Chai WG, 2003, METHOD ENZYMOL, V362, P160; Chai WG, 1997, GLYCOBIOLOGY, V7, P861, DOI 10.1093/glycob/7.6.861; CHAI WG, 1992, EUR J BIOCHEM, V203, P257, DOI 10.1111/j.1432-1033.1992.tb19855.x; CHANDA NB, 1957, J CHEM SOC, P1951, DOI 10.1039/jr9570001951; DELACRUZ J, 1995, J BACTERIOL, V177, P1864, DOI 10.1128/jb.177.7.1864-1871.1995; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Feizi T, 2004, NAT REV MOL CELL BIO, V5, P582, DOI 10.1038/nrm1428; Feizi T, 2003, CURR OPIN STRUC BIOL, V13, P637, DOI 10.1016/j.sbi.2003.09.002; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; Fukui S, 2002, NAT BIOTECHNOL, V20, P1011, DOI 10.1038/nbt735; Galustian C, 2004, INT IMMUNOL, V16, P853, DOI 10.1093/intimm/dxh089; Galustian C, 1997, BIOCHEMISTRY-US, V36, P5260, DOI 10.1021/bi962887a; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Grunebach F, 2002, EXP HEMATOL, V30, P1309, DOI 10.1016/S0301-472X(02)00928-1; Haworth W. N., 1937, J CHEM SOC, P748; HER GR, 1987, J CARBOHYD CHEM, V6, P129, DOI 10.1080/07328308708058864; Herre J, 2004, CRIT REV IMMUNOL, V24, P193, DOI 10.1615/CritRevImmunol.v24.i3.30; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Hong F, 2003, CANCER RES, V63, P9023; JAMAS S, 1991, ACS SYM SER, V469, P44; Lindberg B., 1975, ADV CARBOHYD CHEM BI, V31, P185; McCleary B V, 1986, Adv Carbohydr Chem Biochem, V44, P147; Ratner DM, 2004, CHEMBIOCHEM, V5, P1375, DOI 10.1002/cbic.200400106; Reddy ST, 2004, J BIOL CHEM, V279, P38658, DOI 10.1074/jbc.M407474200; Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Shin I, 2005, CHEM-EUR J, V11, P2894, DOI 10.1002/chem.200401030; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; Stoll MS, 2000, EUR J BIOCHEM, V267, P1795, DOI 10.1046/j.1432-1327.2000.01178.x; STOLL MS, 1997, PREPARATION NEOGLYCO, V9, P329; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Willment JA, 2005, EUR J IMMUNOL, V35, P1539, DOI 10.1002/eji.200425725; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	49	272	292	0	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5771	5779		10.1074/jbc.M511461200	http://dx.doi.org/10.1074/jbc.M511461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371356	hybrid			2022-12-25	WOS:000235568900055
J	Sirokmany, G; Szidonya, L; Kaldi, K; Gaborik, Z; Ligeti, E; Geiszt, M				Sirokmany, G; Szidonya, L; Kaldi, K; Gaborik, Z; Ligeti, E; Geiszt, M			Sec14 homology domain targets p50RhoGAP to endosomes and provides a link between Rab and Rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; ENDOCYTOSIS; RECEPTORS; DYNAMICS; GOLGI; GAPS	Sec14 protein was first identified in Saccharomyces cerevisiae, where it serves as a phosphatidylinositol transfer protein that is essential for the transport of secretory proteins from the Golgi complex. A protein domain homologous to Sec14 was identified in several mammalian proteins that regulates Rho GTPases, including exchange factors and GTPase activating proteins. P50RhoGAP, the first identified GTPase activating protein for Rho GTPases, is composed of a Sec14-like domain and a Rho-GTPase activating protein (GAP) domain. The biological function of its Sec14-like domain is still unknown. Here we show that p50RhoGAP is present on endosomal membranes, where it colocalizes with internalized transferrin receptor. We demonstrate that the Sec14-like domain of P50RhoGAP is responsible for the endosomal targeting of the protein. We also show that overexpression of p50RhoGAP or its Sec14-like domain inhibits transferrin uptake. Furthermore, both P50RhoGAP and its Sec14-like domain show colocalization with small GTPases Rab11 and Rab5. We measured bioluminescence resonance energy transfer between p50RhoGAP and Rab11, indicating that these proteins form molecular complex in vivo on endosomal membranes. The interaction was mediated by the Sec 14-like domain of p50RhoGAP. Our results indicate that Sec14-like domain, which was previously considered as a phospholipid binding module, may have a role in the mediation of protein-protein interactions. We suggest that p50RhoGAP provides a link between Rab and Rho GTPases in the regulation of receptor-mediated endocytosis.	Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary	Semmelweis University	Geiszt, M (corresponding author), Semmelweis Univ, Dept Physiol, POB 259, H-1444 Budapest, Hungary.	geiszt@puskin.sote.u	Káldi, Krisztina/X-4080-2019; Szidonya, Laszlo/A-2271-2010	Kaldi, Krisztina/0000-0002-5724-0182	FOGARTY INTERNATIONAL CENTER [R03TW006421] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 006421-01A1] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016/j.tem.2004.06.009; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Kostenko EV, 2005, J BIOL CHEM, V280, P2807, DOI 10.1074/jbc.M411139200; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Moskwa P, 2005, J BIOL CHEM, V280, P6716, DOI 10.1074/jbc.M412563200; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Qualmann B, 2003, BIOCHEM J, V371, P233, DOI 10.1042/bj20030139; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Ueda S, 2004, CELL SIGNAL, V16, P899, DOI 10.1016/j.cellsig.2004.01.007; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wang L, 2005, P NATL ACAD SCI USA, V102, P13484, DOI 10.1073/pnas.0504420102; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	39	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6096	6105		10.1074/jbc.M510619200	http://dx.doi.org/10.1074/jbc.M510619200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380373	hybrid			2022-12-25	WOS:000235568900091
J	Takada, Y; Gillenwater, A; Ichikawa, H; Aggarwal, BB				Takada, Y; Gillenwater, A; Ichikawa, H; Aggarwal, BB			Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; TUMOR-NECROSIS-FACTOR; ALPHA KINASE; CELL-DEATH; INFLAMMATORY STIMULI; ABROGATES ACTIVATION; P65 PHOSPHORYLATION; FACTOR (NF)-KAPPA-B; EXPRESSION LEVELS; GENETIC DELETION	Because of its ability to suppress tumor cell proliferation, angiogenesis, and inflammation, the histone deacetylase inhibitor suberoylanilide hydroxamic acid ( SAHA) is currently in clinical trials. How SAHA mediates its effects is poorly understood. We found that in several human cancer cell lines, SAHA potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents and inhibited TNF-induced invasion and receptor activator of NF-kappa B ligand-induced osteoclastogenesis, all of which are known to require NF-kappa B activation. These observations corresponded with the down-regulation of the expression of anti-apoptotic (IAP1, IAP2, X chromosome- linked IAP, Bcl-2, Bcl-x(L), TRAF1, FLIP, and survivin), proliferative ( cyclin D1, cyclooxygenase 2, and c-Myc), and angiogenic (ICAM-1, matrix metalloproteinase-9, and vascular endothelial growth factor) gene products. Because several of these genes are regulated by NF-kappa B, we postulated that SAHA mediates its effects by modulating NF-kappa B and found that SAHA suppressed NF-kappa B activation induced by TNF, IL-1 beta, okadaic acid, doxorubicin, lipopolysaccharide, H2O2, phorbol myristate acetate, and cigarette smoke; the suppression was not cell type-specific because both inducible and constitutive NF-kappa B activation was inhibited. We also found that SAHA had no effect on direct binding of NF-kappa B to the DNA but inhibited sequentially the TNF-induced activation of I kappa B alpha kinase, I kappa B alpha phosphorylation, I kappa B alpha ubiquitination, I kappa B alpha degradation, p65 phosphorylation, and p65 nuclear translocation. Furthermore, SAHA inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NF-kappa B-inducing kinase, I kappa B alpha kinase, and the p65 subunit of NF-kappa B. Overall, our results indicated that NF-kappa B and NF-kappa B-regulated gene expression inhibited by SAHA can enhance apoptosis and inhibit invasion and osteoclastogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013	Gillenwater, Ann/0000-0002-0935-0037	NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 91844, P50 CA 97007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bottero V, 2001, CANCER RES, V61, P7785; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Facchetti F, 2004, APOPTOSIS, V9, P573, DOI 10.1023/B:APPT.0000038036.31271.50; Gao N, 2004, MOL PHARMACOL, V66, P956, DOI 10.1124/mol.104.002014; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Kim MS, 2003, CANCER RES, V63, P7291; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kutko MC, 2003, CLIN CANCER RES, V9, P5749; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Munster PN, 2001, CANCER RES, V61, P8492; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Nakayama H, 2001, CANCER, V92, P3037, DOI 10.1002/1097-0142(20011215)92:12<3037::AID-CNCR10171>3.0.CO;2-#; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Nimmanapalli R, 2003, BLOOD, V101, P3236, DOI 10.1182/blood-2002-08-2675; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood-2002-08-2622; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Ruefli AA, 2002, INT J CANCER, V99, P292, DOI 10.1002/ijc.10327; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Samanta AK, 2004, J BIOL CHEM, V279, P7576, DOI 10.1074/jbc.M311659200; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shishodia S, 2004, CANCER RES, V64, P5004, DOI 10.1158/0008-5472.CAN-04-0206; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Webb Y, 1999, J BIOL CHEM, V274, P14280, DOI 10.1074/jbc.274.20.14280; Xu YX, 2005, INT J MOL MED, V15, P169; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200; Yu CR, 2003, CANCER RES, V63, P2118; Yu ZT, 2002, J AM SOC NEPHROL, V13, P2009, DOI 10.1097/01.ASN.0000024253.59665.F1	69	108	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5612	5622		10.1074/jbc.M507213200	http://dx.doi.org/10.1074/jbc.M507213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377638	hybrid			2022-12-25	WOS:000235568900037
J	Kajaste-Rudnitski, A; Mashimo, T; Frenkiel, MP; Guenet, JL; Lucas, M; Despres, P				Kajaste-Rudnitski, A; Mashimo, T; Frenkiel, MP; Guenet, JL; Lucas, M; Despres, P			The 2 ',5 '-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2'-5'-OLIGOADENYLATE SYNTHETASE; ALPHA/BETA-INTERFERON; GENE; ACTIVATION; FLAVIVIRUS; PROTEIN; FAMILY; SUSCEPTIBILITY; ENCEPHALITIS; RESISTANCE	The 2',5'-oligoadenylate synthetase (OAS) proteins associated with endoribonuclease RNase L are components of the interferon-regulated OAS/RNase L system, which is an RNA decay pathway known to play an important role in the innate antiviral immunity. A large body of evidence suggests a critical role for the 1b isoform of the mouse Oas gene (Oas1b) in resistance to West Nile virus (WNV) infection in vivo. WNV is a positive, single-stranded RNA virus responsible for severe encephalitis in a large range of animal species and humans. To investigate the molecular basis for the sensitivity of WNV to the Oas1b antiviral pathway, we established a stable mouse fibroblastic cell clone that up-regulates Oas1b protein expression under the control of the Tet-Off expression system. We showed that murine cells respond to Oas1b expression by efficiently inhibiting WNV replication. The antiviral action of Oas1b was essentially restricted to the early stages in virus life cycle. We found that the inability of WNV to productively infect the Oas1b-expressing cells was attributable to a dramatic reduction in positive-stranded viral RNA level. Thus, Oas1b represents an antiviral pathway that exerts its inhibitory effect on WNV replication by preventing viral RNA accumulation inside infected cells.	Inst Pasteur, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Despres, P (corresponding author), Inst Pasteur, 25 Rue Dr Roux, F-75724 Paris 15, France.	pdespres@pasteur.fr		Kajaste-Rudnitski, Anna/0000-0003-1549-2426				Best SM, 2005, J VIROL, V79, P12828, DOI 10.1128/JVI.79.20.12828-12839.2005; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Ceccaldi PE, 2004, FEMS MICROBIOL LETT, V233, P1, DOI 10.1016/j.femsle.2004.01.035; Despres P, 2005, J INFECT DIS, V191, P207, DOI 10.1086/426824; Diamond MS, 2003, VIRAL IMMUNOL, V16, P259, DOI 10.1089/088282403322396082; Eskildsen S, 2002, CELL MOL LIFE SCI, V59, P1212, DOI 10.1007/s00018-002-8499-2; Fredericksen BL, 2004, J VIROL, V78, P7737, DOI 10.1128/JVI.78.14.7737-7747.2004; Guo JT, 2005, J VIROL, V79, P1343, DOI 10.1128/JVI.79.3.1343-1350.2005; Hartmann R, 2003, MOL CELL, V12, P1173, DOI 10.1016/S1097-2765(03)00433-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kakuta S, 2002, J INTERF CYTOK RES, V22, P981, DOI 10.1089/10799900260286696; Liu WJ, 2005, J VIROL, V79, P1934, DOI 10.1128/JVI.79.3.1934-1942.2005; Lucas M, 2003, IMMUNOL CELL BIOL, V81, P230, DOI 10.1046/j.1440-1711.2003.01166.x; Lucas M, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-9; Mashimo T, 2003, GENOMICS, V82, P537, DOI 10.1016/S0888-7543(03)00176-9; Mashimo T, 2002, P NATL ACAD SCI USA, V99, P11311, DOI 10.1073/pnas.172195399; Pantelic L, 2005, J VIROL, V79, P1753, DOI 10.1128/JVI.79.3.1753-1764.2005; Perelygin AA, 2002, P NATL ACAD SCI USA, V99, P9322, DOI 10.1073/pnas.142287799; Rogozin IB, 2003, J MOL BIOL, V326, P1449, DOI 10.1016/S0022-2836(03)00055-X; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Samuel CE, 2002, P NATL ACAD SCI USA, V99, P11555, DOI 10.1073/pnas.202448899; Samuel MA, 2005, J VIROL, V79, P13350, DOI 10.1128/JVI.79.21.13350-13361.2005; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Silvonek AL, 2004, J MIDWIFERY WOM HEAL, V49, P464, DOI 10.1016/j.jmwh.2004.04.026; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Taguchi T, 2004, J GEN VIROL, V85, P959, DOI 10.1099/vir.0.19513-0; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Wang T, 2004, CURR OPIN IMMUNOL, V16, P519, DOI 10.1016/j.coi.2004.05.008; Yakub I, 2005, J INFECT DIS, V192, P1741, DOI 10.1086/497340	31	88	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4624	4637		10.1074/jbc.M508649200	http://dx.doi.org/10.1074/jbc.M508649200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371364	hybrid			2022-12-25	WOS:000235426200010
J	Rey, O; Papazyan, R; Waldron, RT; Young, SH; Lippincott-Schwartz, J; Jacamo, R; Rozengurt, E				Rey, O; Papazyan, R; Waldron, RT; Young, SH; Lippincott-Schwartz, J; Jacamo, R; Rozengurt, E			The nuclear import of protein kinase D3 requires its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR ACTIVATION; PLECKSTRIN HOMOLOGY DOMAIN; CYSTEINE-RICH MOTIFS; INTRACELLULAR REDISTRIBUTION; MOLECULAR-CLONING; TYROSINE KINASE; PHORBOL ESTERS; EXPORT SIGNALS; C FAMILY; TRANSLOCATION	The protein kinase D (PKD) family consists of three serine/threonine protein kinases termed PKD, PKD2, and PKD3, which are similar in overall structure and primary amino acid sequence. However, each isozyme displays a distinctive intracellular localization. Taking advantage of the structural homology and opposite nuclear localization of PKD2 and PKD3, we generated an extensive set of chimeric proteins between both isozymes to determine which PKD3 domain(s) mediates its nuclear localization. We found that the C-terminal region of PKD3, which contains its catalytic domain, is necessary but not sufficient for its nuclear localization. Real time imaging of a photoactivatable green fluorescent protein fused to PKD3 revealed that point mutations that render PKD3 catalytically inactive completely prevented its nuclear import despite its interaction with importin alpha and beta. We also found that activation loop phosphorylation of PKD3 did not require its nuclear localization, and it was not sufficient to promote the nuclear import of PKD3. These results identify a novel function for the kinase activity of PKD3 in promoting its nuclear entry and suggest that the catalytic activity of PKD3 may regulate its nuclear import through autophosphorylation and/or interaction with another protein(s).	Univ Calif Los Angeles, Dept Med, Unit Signal Transduct & Gastrointestinal Canc, Div Digest Dis,CURE Digest Dis Res Ctr,David Geff, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rey, O (corresponding author), Univ Calif Los Angeles, Dept Med, Unit Signal Transduct & Gastrointestinal Canc, Div Digest Dis,CURE Digest Dis Res Ctr,David Geff, 900 Vet Ave,Warren Hall Rm 11-115, Los Angeles, CA 90095 USA.	orey@mednet.ucla.edu	Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002; Rey, Osvaldo/0000-0003-1575-9864	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001609] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K01CA097956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER; NCI NIH HHS [K01CA097956] Funding Source: Medline; NIDDK NIH HHS [DK 55003, DK 56930, 5 P30 DK41301] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Jacamo R, 2003, J VIROL, V77, P10383, DOI 10.1128/JVI.77.19.10383-10393.2003; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lippincott-Schwartz J, 2003, NAT CELL BIOL, pS7, DOI 10.1038/ncb1032; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Patterson GH, 2004, METHODS, V32, P445, DOI 10.1016/j.ymeth.2003.10.006; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Perander M, 2001, J BIOL CHEM, V276, P13015, DOI 10.1074/jbc.M010356200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2005, J BIOL CHEM, V280, P22875, DOI 10.1074/jbc.M503455200; Rey O, 2004, J BIOL CHEM, V279, P34361, DOI 10.1074/jbc.M403265200; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2003, J BIOL CHEM, V278, P23773, DOI 10.1074/jbc.M300226200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YAMAKASI L, 1992, NUCL TRAFFICKING	46	18	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5149	5157		10.1074/jbc.M508014200	http://dx.doi.org/10.1074/jbc.M508014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380377	hybrid			2022-12-25	WOS:000235426200069
J	Yamaguchi, H; Tateno, M; Yamasaki, K				Yamaguchi, H; Tateno, M; Yamasaki, K			Solution structure and DNA-binding mode of the matrix attachment region-binding domain of the transcription factor SATB1 that regulates the T-cell maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU DOMAIN; PROTEIN STRUCTURES; HOMEODOMAIN; RECOGNITION; SEQUENCE; OCT-1; DISTAMYCIN; EXPRESSION; PROGRAM; QUALITY	SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell. SATB1 binds to the nuclear matrix attachment regions of DNA, where it recruits histone deacetylase and represses transcription through a local chromatin remodeling. Here we determined the solution structure of the matrix attachment region-binding domain, possessing similarity to the CUT DNA-binding domain, of human SATB1 by NMR spectroscopy. The structure consists of five alpha-helices, in which the N-terminal four are arranged similarly to the four-helix structure of the CUT domain of hepatocyte nuclear factor 6 alpha. By an NMR chemical shift perturbation analysis and by surface plasmon resonance analyses of SATB1 mutant proteins, an interface for DNA binding was revealed to be located at the third helix and the surrounding regions. Surface plasmon resonance experiments using groove-specific binding drugs and methylated DNAs indicated that the domain recognizes DNA from the major groove side. These observations suggested that SATB1 possesses a DNA-binding mode similar to that of the POU-specific DNA-binding domain, which is known to share structural similarity to the four-helix CUT domain.	Natl Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, Tsukuba, Ibaraki 3058566, Japan; Tottori Univ, Fac Engn, Dept Mat Sci, Tottori 6808552, Japan; Univ Tsukuba, Inst Phys, Tsukuba, Ibaraki 3058571, Japan; Univ Tsukuba, Ctr Computat Sci, Tsukuba, Ibaraki 3058571, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Tottori University; University of Tsukuba; University of Tsukuba	Yamasaki, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	k-yamasaki@aist.go.jp	Yamaguchi, Hiroshi/A-2068-2016; Yamasaki, Kazuhiko/L-7108-2018	Yamaguchi, Hiroshi/0000-0001-9148-7990; Yamasaki, Kazuhiko/0000-0003-0320-9697				Alvarez JD, 2000, GENE DEV, V14, P521; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BAX A, 1994, CURR OPIN STRUC BIOL, V4, P738, DOI 10.1016/S0959-440X(94)90173-2; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chi YI, 2002, MOL CELL, V10, P1129, DOI 10.1016/S1097-2765(02)00704-9; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LUCK G, 1974, NUCLEIC ACIDS RES, V1, P503, DOI 10.1093/nar/1.3.503; MONDRAGON A, 1989, J MOL BIOL, V205, P180; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NORDEN B, 1977, CHEM PHYS LETT, V50, P508, DOI 10.1016/0009-2614(77)80379-5; Reay P, 2004, PROTEINS, V56, P40, DOI 10.1002/prot.20054; Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200; Sheng WY, 2004, J BIOL CHEM, V279, P33928, DOI 10.1074/jbc.M403805200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Truscott M, 2004, J BIOL CHEM, V279, P49787, DOI 10.1074/jbc.M409484200; Wen J, 2005, BLOOD, V105, P3330, DOI 10.1182/blood-2004-08-2988; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P44; Yamasaki K, 2004, PLANT CELL, V16, P3448, DOI 10.1105/tpc.104.026112; Yamasaki K, 2004, J MOL BIOL, V337, P49, DOI 10.1016/j.jmb.2004.01.015; Yamasaki T, 1998, P JPN ACAD B-PHYS, V74, P210, DOI 10.2183/pjab.74.210; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084	37	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5319	5327		10.1074/jbc.M510933200	http://dx.doi.org/10.1074/jbc.M510933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371359	hybrid			2022-12-25	WOS:000235426200086
J	D'Argenio, G; Valenti, M; Scaglione, G; Cosenza, V; Sorrentini, I; Di Marzo, V				D'Argenio, G; Valenti, M; Scaglione, G; Cosenza, V; Sorrentini, I; Di Marzo, V			Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation	FASEB JOURNAL			English	Article						cannabinoid; endocannabinoid; regulation; inflammatory bowel diseases	ENDOCANNABINOID SYSTEM; VANILLOID RECEPTOR; INDUCED COLITIS; CANNABINOIDS; VR1; INHIBITORS; PROTECTS; LIGAND; BINDS; MODEL	Direct stimulation of cannabinoid CB1 receptors exerts a protective function in animal models of inflammatory bowel diseases (IBDs). However, it is not known whether endocannabinoids are up-regulated during IBDs in animals or humans, nor whether pharmacological elevation of endocannabinoid levels can be exploited therapeutically in these disorders. In this study we addressed these questions. Colon inflammation was induced in mice and rats with 2,4-dinitrobenzene- and 2,4,6-trinitrobenzene sulfonic acids (DNBS and TNBS), respectively. DNBS-treated mice were treated chronically (for 3 or 7 days) with inhibitors of anandamide enzymatic hydrolysis (N-arachidonoyl-serotonin, AA-5-HT) or reuptake (VDM11), 10 or 5 mg/kg, s.c., or with 5-amino-salicilic acid (5-ASA, 1.4 mg/kg, i.r.). Endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG) were quantified in mouse colon, or in rat colon mucosa and submucosa, and in bioptic samples from the colon of patients with untreated ulcerative colitis, by liquid chromatography-mass spectrometry. A strong elevation of anandamide, but not 2-AG, levels was found in the colon of DNBS-treated mice, in the colon submucosa of TNBS-treated rats, and in the biopsies of patients with ulcerative colitis. VDM-11 significantly elevated anandamide levels in the colon of DNBS-treated mice and concomitantly abolished inflammation, whereas AA-5-HT did not affect endocannabinoid levels and was significantly less efficacious at attenuating colitis. 5-ASA also increased anandamide levels and abolished colitis. Thus, anandamide is elevated in the inflamed colon of patients with ulcerative colitis, as well as in animal models of IBDs, to control inflammation, and elevation of its levels with inhibitors of its cellular reuptake might be used in the treatment of IBDs.	CNR, Ist Chim Biomol, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy; Univ Naples Federico II, Naples, Italy; AO Rummo, Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Naples Federico II	Di Marzo, V (corresponding author), CNR, Ist Chim Biomol, Endocannabinoid Res Grp, Via Campi Flegrei 34, I-80078 Pozzuoli, NA, Italy.	vdimarzo@icmib.na.cnr.it	Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070				Anavi-Goffer S, 2003, EUR J PHARMACOL, V458, P61, DOI 10.1016/S0014-2999(02)02653-5; Bisogno T, 1998, BIOCHEM BIOPH RES CO, V248, P515, DOI 10.1006/bbrc.1998.8874; Capasso R, 2005, GASTROENTEROLOGY, V129, P941, DOI 10.1053/j.gastro.2005.06.018; Coutts AA, 2004, CURR OPIN PHARMACOL, V4, P572, DOI 10.1016/j.coph.2004.05.007; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 2002, PROSTAG LEUKOTR ESS, V66, P377, DOI 10.1054/plef.2001.0349; Di Marzo V, 1998, BBA-LIPID LIPID MET, V1392, P153, DOI 10.1016/S0005-2760(98)00042-3; Fegley D, 2005, J PHARMACOL EXP THER, V313, P352, DOI 10.1124/jpet.104.078980; GOSO C, 1993, EUR J PHARMACOL, V249, P185, DOI 10.1016/0014-2999(93)90431-G; GUAGNINI F, IN PRESS GUT; Hanauer SB, 2004, GASTROENTEROLOGY, V126, P1582, DOI 10.1053/j.gastro.2004.02.071; Izzo AA, 2003, GASTROENTEROLOGY, V125, P765, DOI 10.1016/S0016-5085(03)00892-8; Izzo AA, 2001, BRIT J PHARMACOL, V134, P563, DOI 10.1038/sj.bjp.0704293; Kankuri E, 2001, INFLAMMATION, V25, P301, DOI 10.1023/A:1012860509440; Kihara N, 2003, GUT, V52, P713, DOI 10.1136/gut.52.5.713; Kozak KR, 2002, PROSTAG LEUKOTR ESS, V66, P211, DOI 10.1054/plef.2001.0359; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; Kunos G, 2004, NAT MED, V10, P678, DOI 10.1038/nm0704-678; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Mascolo N, 2002, FASEB J, V16, P1973, DOI 10.1096/fj.02-0338fje; Massa F, 2004, J CLIN INVEST, V113, P1202, DOI 10.1172/JCI200419465; Mathison R, 2004, BRIT J PHARMACOL, V142, P1247, DOI 10.1038/sj.bjp.0705889; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; Pinto L, 2002, GASTROENTEROLOGY, V123, P227, DOI 10.1053/gast.2002.34242; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P1008, DOI 10.1056/NEJM199110033251406; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; Sands BE, 2000, GASTROENTEROLOGY, V118, pS68, DOI 10.1016/S0016-5085(00)70007-2; SARTOR RB, 1991, INFLAMM BOWEL DIS, P337; Shanahan F, 2001, GASTROENTEROLOGY, V120, P622, DOI 10.1053/gast.2001.22122; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; VALENTI M, 2005, 2005 S CANN BURL VER, P158; Vigna SR, 2003, GASTROENTEROLOGY, V125, P973, DOI 10.1016/S0016-5085(03)01134-X; Ward SM, 2003, J COMP NEUROL, V465, P121, DOI 10.1002/cne.10801; Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026	39	184	186	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					568	+		10.1096/fj.05-4943fje	http://dx.doi.org/10.1096/fj.05-4943fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403786				2022-12-25	WOS:000235996000027
J	Gerard, M; Debyser, Z; Desender, L; Kahle, PJ; Baert, J; Baekelandt, V; Engelborghs, Y				Gerard, M; Debyser, Z; Desender, L; Kahle, PJ; Baert, J; Baekelandt, V; Engelborghs, Y			The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy	FASEB JOURNAL			English	Article						Parkinson's disease; peptidyl-prolyl cis-trans isomerase; immunophilin; amyloid fibrils	FAMILIAL PARKINSONS-DISEASE; IN-VITRO; LEWY BODIES; IMMUNOSUPPRESSANT FK506; RYANODINE RECEPTOR; UNFOLDED PROTEINS; PROLYL ISOMERASE; FIBRIL FORMATION; AMYLOID FIBRILS; IMMUNOPHILINS	Aggregation of alpha-synuclein (alpha-SYN) plays a key role in Parkinson's disease (PD). We have used fluorescence correlation spectroscopy (FCS) to study alpha-SYN aggregation in vitro and discovered that this process is clearly accelerated by addition of FK506 binding proteins (FKBPs). This effect was observed both with E. coli SlyD FKBP and with human FKBP12 and was counteracted by FK506, a specific inhibitor of FKBP. The alpha-SYN aggregates formed in the presence of FKBP12 showed fibrillar morphology. The rotamase activity of FKBP apparently accelerates the folding and subsequent aggregation of alpha-SYN. Since FK506 and other nonimmunosuppressive FKBP inhibitors are known to display neuroregenerative and neuroprotective properties in disease models, the observed inhibition of rotamase activity and alpha-SYN aggregation, may explain their mode of action. Our results open perspectives for the treatment of PD with immunophilin ligands that inhibit a specific member of the FKBP family.	Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium; Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Heverlee, Belgium; Univ Munich, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Katholieke Univ Leuven, Histol Lab, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven; University of Munich; KU Leuven	Baekelandt, V (corresponding author), Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, Kapucijnenvoer 33, B-3000 Louvain, Belgium.	Veerle.baekelandt@med.kuleuven.be	Gerard, Melanie/B-6898-2019	Gerard, Melanie/0000-0003-0585-6978				Antony T, 2003, J BIOL CHEM, V278, P3235, DOI 10.1074/jbc.M208249200; Avramut M, 2003, CURR TOP MED CHEM, V3, P1376, DOI 10.2174/1568026033451871; Avramut M, 2002, PHYSIOL BEHAV, V77, P463, DOI 10.1016/S0031-9384(02)00934-4; Avramut M, 2001, DEV BRAIN RES, V132, P151, DOI 10.1016/S0165-3806(01)00307-8; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Chartier-Harlin MC, 2004, LANCET, V364, P1167, DOI 10.1016/S0140-6736(04)17103-1; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Galat A, 2003, CURR TOP MED CHEM, V3, P1315, DOI 10.2174/1568026033451862; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; Gold BG, 1999, J PHARMACOL EXP THER, V289, P1202; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hoyer W, 2004, BIOCHEMISTRY-US, V43, P16233, DOI 10.1021/bi048453u; Ibanez P, 2004, LANCET, V364, P1169, DOI 10.1016/S0140-6736(04)17104-3; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Lakso M, 2003, J NEUROCHEM, V86, P165, DOI 10.1046/j.1471-4159.2003.01809.x; Lauwers E, 2003, BRAIN PATHOL, V13, P364; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Lo BC, 2002, P NATL ACAD SCI USA, V99, P10813; Lu PJ, 1999, NATURE, V399, P784; Maertens G, 2005, FASEB J, V19, P1039, DOI 10.1096/fj.04-3373fje; Magde D, 1977, Mol Biol Biochem Biophys, V24, P43; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; OHAMA E, 1976, ACTA NEUROPATHOL, V34, P311, DOI 10.1007/BF00696560; PARK ST, 1992, J BIOL CHEM, V267, P3316; PARSONS WH, 1993, ANN NY ACAD SCI, V685, P22, DOI 10.1111/j.1749-6632.1993.tb35847.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Vercammen J, 2002, J BIOL CHEM, V277, P38045, DOI 10.1074/jbc.M205842200; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; XIN HB, 1995, BIOCHEM BIOPH RES CO, V214, P263, DOI 10.1006/bbrc.1995.2283; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	49	48	52	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					524	+		10.1096/fj.05-5126fje	http://dx.doi.org/10.1096/fj.05-5126fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16410343				2022-12-25	WOS:000235996000020
J	Knight, KR; Uda, Y; Findlay, MW; Brown, DL; Cronin, KJ; Jamieson, E; Tai, T; Keramidaris, E; Penington, AJ; Rophael, J; Harrison, LC; Morrison, WA				Knight, KR; Uda, Y; Findlay, MW; Brown, DL; Cronin, KJ; Jamieson, E; Tai, T; Keramidaris, E; Penington, AJ; Rophael, J; Harrison, LC; Morrison, WA			RETRACTED: Vascularized tissue-engineered chambers promote survival and function of transplanted islets and improve glycemic control (Retracted Article. See vol 22, pg 3747, 2008)	FASEB JOURNAL			English	Article; Retracted Publication						streptozotocin; diabetes; islet transplantation; vascularized chambers; renal capsule	TYPE-1 DIABETES-MELLITUS; EXTRACELLULAR-MATRIX; GRAFT-SURVIVAL; MOUSE; ALGINATE; GROWTH; MODEL; MICROENCAPSULATION; GENERATION; MEMBRANE	We have developed a chamber model of islet engraftment that optimizes islet survival by rapidly restoring islet-extracellular matrix relationships and vascularization. Our aim was to assess the ability of syngeneic adult islets seeded into blood vessel-containing chambers to correct streptozotocin-induced diabetes in mice. Approximately 350 syngeneic islets suspended in Matrigel (R) extracellular matrix were inserted into chambers based on either the splenic or groin (epigastric) vascular beds, or, in the standard approach, injected under the renal capsule. Blood glucose was monitored weekly for 7 weeks, and an intraperitoneal glucose tolerance test performed at 6 weeks in the presence of the islet grafts. Relative to untreated diabetic animals, glycemic control significantly improved in all islet transplant groups, strongly correlating with islet counts in the graft (P < 0.01), and with best results in the splenic chamber group. Glycemic control deteriorated after chambers were surgically removed at week 8. Immunohistochemistry revealed islets with abundant insulin content in grafts from all groups, but with significantly more islets in splenic chamber grafts than the other treatment groups (P < 0.05). It is concluded that hyperglycemia in experimental type 1 diabetes can be effectively treated by islets seeded into a vascularized chamber functioning as a "pancreatic organoid".	Univ Melbourne, Dept Surg, Fitzroy, Vic 3065, Australia; Univ Michigan, Div Plast Surg, Ann Arbor, MI 48109 USA; Mater Misericordiae Univ Hosp, Dept Plast & Reconstruct Surg, Dublin 7, Ireland; St Vincents Inst, Fitzroy, Vic, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Melbourne, Vic, Australia	University of Melbourne; University of Michigan System; University of Michigan; Mater Misericordiae University Hospital; University College Dublin; St. Vincent's Institute of Medical Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Knight, KR (corresponding author), OBrien Inst Microsurg, 42 Fitzroy St, Fitzroy, Vic 3065, Australia.	Kenneth.Knight@svhm.org.au		Brown, David/0000-0002-5889-9886				Bhargava R, 2004, DIABETES, V53, P1311, DOI 10.2337/diabetes.53.5.1311; Bottino R, 2004, DIABETES, V53, P2559, DOI 10.2337/diabetes.53.10.2559; BROWN DL, 2005, IN PRESS CELL T 0928; Cassell OCS, 2001, ANN NY ACAD SCI, V944, P429; Cronin KJ, 2004, PLAST RECONSTR SURG, V113, P260, DOI 10.1097/01.PRS.0000095942.71618.9D; CUTHBERTSON RA, 1986, AUST J EXP BIOL MED, V64, P175, DOI 10.1038/icb.1986.19; DeVos P, 1997, DIABETOLOGIA, V40, P262; Dickson BC, 2003, TRANSPLANTATION, V75, P599, DOI 10.1097/01.TP.0000048226.28357.0D; Duvivier-Kali VF, 2001, DIABETES, V50, P1698, DOI 10.2337/diabetes.50.8.1698; FOLKMAN J, 1973, J EXP MED, V138, P745, DOI 10.1084/jem.138.4.745; Gray DWR, 2001, WORLD J SURG, V25, P497, DOI 10.1007/s002680020343; HILLER WFA, 1991, DIABETES, V40, P134, DOI 10.2337/diabetes.40.1.134; Hirshberg B, 2002, J CLIN ENDOCR METAB, V87, P5424, DOI 10.1210/jc.2002-020684; Hofer SOP, 2005, BRIT J PLAST SURG, V58, P1104, DOI 10.1016/j.bjps.2005.04.033; Jiang FX, 1999, DIABETES, V48, P722, DOI 10.2337/diabetes.48.4.722; Juang JH, 2000, TRANSPLANT P, V32, P1076, DOI 10.1016/S0041-1345(00)01131-3; Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062; Kin T, 2003, AM J TRANSPLANT, V3, P281, DOI 10.1034/j.1600-6143.2003.00049.x; Li XY, 2004, J BIOL CHEM, V279, P765, DOI 10.1074/jbc.M307907200; Matarazzo M, 2002, CELL TRANSPLANT, V11, P103; MELLGREN A, 1986, DIABETOLOGIA, V29, P670, DOI 10.1007/BF00869269; Messina A, 2005, FASEB J, V19, P1570, DOI 10.1096/fj.04-3241fje; Mian RW, 2000, TISSUE ENG, V6, P595, DOI 10.1089/10763270050199541; Nagata N, 2001, CELL TRANSPLANT, V10, P447; Niklason LE, 2001, JAMA-J AM MED ASSOC, V285, P573, DOI 10.1001/jama.285.5.573; Rother KI, 2004, J CLIN INVEST, V114, P877, DOI 10.1172/JC1200423235; Ryan EA, 2002, DIABETES, V51, P2148, DOI 10.2337/diabetes.51.7.2148; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Tanaka Y, 2000, BRIT J PLAST SURG, V53, P51, DOI 10.1054/bjps.1999.3186; Thomas HE, 1999, J IMMUNOL, V163, P1562	30	25	25	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					565	+		10.1096/fj.05-4879fje	http://dx.doi.org/10.1096/fj.05-4879fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16436466	Green Published			2022-12-25	WOS:000235996000005
J	Kunzelmann, K; Scheidt, K; Scharf, B; Ousingsawat, J; Schreiber, R; Wainwright, B; McMorran, B				Kunzelmann, K; Scheidt, K; Scharf, B; Ousingsawat, J; Schreiber, R; Wainwright, B; McMorran, B			Flagellin of Pseudomonas aeruginosa inhibits Na+ transport in airway epithelia	FASEB JOURNAL			English	Article						EnaC; flagella; cystic fibrosis; infection	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS PATIENTS; SODIUM-CHANNEL ENAC; MOUSE TRACHEA; ION-TRANSPORT; CELLS; ATP; RELEASE; CFTR; LUNG	Pseudomonas aeruginosa causes severe life-threatening airway infections that are a frequent cause for hospitalization of cystic fibrosis (CF) patients. These Gram-negative pathogens possess flagella that contain the protein flagellin as a major structural component. Flagellin binds to the host cell glycolipid asialoGM1 (ASGM1), which appears enriched in luminal membranes of respiratory epithelial cells. We demonstrate that in mouse airways, luminal exposure to flagellin leads to inhibition of Na+ absorption by the epithelial Na+ channel ENaC, but does not directly induce a secretory response. Inhibition of ENaC was observed in tracheas of wild-type mice and was attenuated in mice homozygous for the frequent cystic fibrosis conductance regulator (CFTR) mutation G551D. Similar to flagellin, anti-ASGM1 antibody also inhibited ENaC. The inhibitory effects of flagellin on ENaC were attenuated by blockers of the purinergic signaling pathway, although an increase in the intracellular Ca2+ concentration by recombinant or purified flagellin or whole flagella was not observed. Because an inhibitor of the mitogen-activated protein kinase (MAPK) pathway also attenuated the effects of flagellin on Na+ absorption, we conclude that flagellin exclusively inhibits ENaC, probably due to release of ATP and activation of purinergic receptors of the P2Y subtype. Stimulation of these receptors activates the MAPK pathway, thereby leading to inhibition of ENaC. Thus, P. aeruginosa reduces Na+ absorption, which could enhance local mucociliary clearance, a mechanism that seem to be attenuated in CF.	Univ Regensburg, Inst Physiol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Genet, D-93053 Regensburg, Germany; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4067, Australia	University of Regensburg; University of Regensburg; University of Queensland	Kunzelmann, K (corresponding author), Univ Regensburg, Inst Physiol, Univ Str 31, D-93053 Regensburg, Germany.	uqkkunze@mailbox.uq.edu.au	Schreiber, Robert/Q-7550-2019	Kunzelmann, Karl/0000-0002-4583-7037; Wainwright, Brandon/0000-0003-0406-2092				Adamo R, 2004, AM J RESP CELL MOL, V30, P627, DOI 10.1165/rcmb.2003-0260OC; Bryan R, 1998, AM J RESP CELL MOL, V19, P269, DOI 10.1165/ajrcmb.19.2.2889; Castrop H, 2004, J CLIN INVEST, V114, P634, DOI 10.1172/JCI200421851; Crane JK, 2002, AM J PHYSIOL-GASTR L, V283, pG74, DOI 10.1152/ajpgi.00484.2001; Dagenais A, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-2; deBentzmann S, 1996, EUR RESPIR J, V9, P2145, DOI 10.1183/09031936.96.09102145; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Delaney SJ, 1996, EMBO J, V15, P955, DOI 10.1002/j.1460-2075.1996.tb00432.x; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Evans DJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1284, DOI 10.1152/ajpcell.1998.275.5.C1284; Falin R, 2005, AM J PHYSIOL-CELL PH, V288, pC1003, DOI 10.1152/ajpcell.00213.2004; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; FUKUDA H, 1994, NEUROCHEM INT, V25, P567, DOI 10.1016/0197-0186(94)90155-4; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; GRAHAM A, 1993, EXP LUNG RES, V19, P77, DOI 10.3109/01902149309071082; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; Jacob T, 2002, INFECT IMMUN, V70, P6399, DOI 10.1128/IAI.70.11.6399-6408.2002; Konig J, 2002, BBA-BIOMEMBRANES, V1565, P17, DOI 10.1016/S0005-2736(02)00502-3; KOSLOWSKY T, 1994, PFLUG ARCH EUR J PHY, V428, P597, DOI 10.1007/BF00374583; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; Kunzelmann K, 2004, FASEB J, V18, P142, DOI 10.1096/fj.04-2314fje; Kunzelmann K, 2004, J BIOL CHEM, V279, P48760, DOI 10.1074/jbc.M409747200; Kunzelmann K, 2002, PFLUG ARCH EUR J PHY, V444, P220, DOI 10.1007/s00424-002-0796-y; Kunzelmann Karl, 2003, Am J Respir Med, V2, P299; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Ma HP, 2002, J BIOL CHEM, V277, P7641, DOI 10.1074/jbc.C100737200; McMorran BJ, 2001, AM J PHYSIOL-LUNG C, V281, pL740, DOI 10.1152/ajplung.2001.281.3.L740; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Oceandy D, 2002, HUM MOL GENET, V11, P1059, DOI 10.1093/hmg/11.9.1059; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Pittet JF, 1996, AM J PHYSIOL-LUNG C, V270, pL232, DOI 10.1152/ajplung.1996.270.2.L232; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ramos HC, 2004, TRENDS MICROBIOL, V12, P509, DOI 10.1016/j.tim.2004.09.002; RAMPHAL R, 1989, INFECT IMMUN, V57, P3066, DOI 10.1128/IAI.57.10.3066-3071.1989; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; Reddy MM, 1996, SCIENCE, V271, P1876, DOI 10.1126/science.271.5257.1876; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; Rochelle LG, 2000, AM J PHYSIOL-LUNG C, V279, pL14, DOI 10.1152/ajplung.2000.279.1.L14; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schreiber R, 2005, CELL PHYSIOL BIOCHEM, V16, P99, DOI 10.1159/000087736; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Soong G, 2004, J CLIN INVEST, V113, P1482, DOI 10.1172/JCI200420773; STUTTS MJ, 1986, AM REV RESPIR DIS, V134, P17; Ullrich S, 2003, PFLUG ARCH EUR J PHY, V447, P23, DOI 10.1007/s00424-003-1136-6; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wolfgang MC, 2004, P NATL ACAD SCI USA, V101, P6664, DOI 10.1073/pnas.0307553101; Yue G, 2002, J BIOL CHEM, V277, P11965, DOI 10.1074/jbc.M108951200; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668	59	27	27	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					545	+		10.1096/fj.05-4454fje	http://dx.doi.org/10.1096/fj.05-4454fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16410345				2022-12-25	WOS:000235996000018
J	Miyazaki, I; Asanuma, M; Diaz-Corrales, FJ; Fukuda, M; Kitaichi, K; Miyoshi, K; Ogawa, N				Miyazaki, I; Asanuma, M; Diaz-Corrales, FJ; Fukuda, M; Kitaichi, K; Miyoshi, K; Ogawa, N			Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone formation-related molecules	FASEB JOURNAL			English	Article						dopamine quinone; quinone reductase; tyrosinase	PARKINSONS-DISEASE; RAT-BRAIN; OXIDATIVE STRESS; TYROSINE-HYDROXYLASE; SUBSTANTIA-NIGRA; CYTOTOXICITY; CELLS; METHYLAMPHETAMINE; CATECHOLAMINES; VULNERABILITY	Recently, the neurotoxicity of dopamine (DA) quinone formation by auto-oxidation of DA has focused on dopaminergic neuron-specific oxidative stress. In the present study, we examined DA quinone formation in methamphetamine (METH)-induced dopaminergic neuronal cell death using METH-treated dopaminergic cultured CATH. a cells and METH-injected mouse brain. In CATH. a cells, METH treatment dose-dependently increased the levels of quinoprotein (protein-bound quinone) and the expression of quinone reductase in parallel with neurotoxicity. A similar increase in quinoprotein levels was seen in the striatum of METH (4 mg/kg X4, i.p., 2 h interval)-injected BALB/c mice, coinciding with reduction of DA transporters. Furthermore, pretreatment of CATH. a cells with quinone reductase inducer, butylated hydroxyanisole, significantly and dose-dependently blocked METH-induced elevation of quinoprotein, and ameliorated METH-induced cell death. We also showed the protective effect of tyrosinase, which rapidly oxidizes DA and DA quinone to form stable melanin, against METH-induced dopaminergic neurotoxicity in vitro and in vivo using tyrosinase null mice. Our results indicate that DA quinone formation plays an important role, as a dopaminergic neuron-specific neurotoxic factor, in METH-induced neurotoxicity, which is regulated by quinone formation-related molecules.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, Okayama, Japan; Nagoya Univ, Grad Sch Med, Dept Med Technol, Nagoya, Aichi, Japan	Okayama University; Nagoya University	Asanuma, M (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Brain Sci, Okayama, Japan.	asachan@cc.okayama-u.ac.jp	soler, martha maricel m gomez/L-6025-2014; Diaz-Corrales, Francisco/L-7559-2014	soler, martha maricel m gomez/0000-0002-4412-8108; Diaz-Corrales, Francisco/0000-0002-5752-0205				ASANUMA M, 1995, MOL BRAIN RES, V33, P29, DOI 10.1016/0169-328X(95)00102-X; Asanuma M, 2004, ACTA MED OKAYAMA, V58, P221; Asanuma M, 2003, NEUROSCI LETT, V352, P13, DOI 10.1016/j.neulet.2003.08.015; Asanuma M, 2003, NEUROTOX RES, V5, P165, DOI 10.1007/BF03033137; AXT KJ, 1990, BRAIN RES, V515, P269, DOI 10.1016/0006-8993(90)90606-C; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Cavelier G, 2001, PROTEINS, V43, P420, DOI 10.1002/prot.1055.abs; Choi HJ, 2005, NEUROCHEM INT, V46, P329, DOI 10.1016/j.neuint.2004.10.009; Choi HJ, 2003, J NEUROCHEM, V86, P143, DOI 10.1046/j.1471-4159.2003.01808.x; Clement MW, 2002, J NEUROCHEM, V81, P414, DOI 10.1046/j.1471-4159.2002.00802.x; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; FORNSTEDT B, 1986, NEUROPHARMACOLOGY, V25, P451, DOI 10.1016/0028-3908(86)90242-X; Fumagalli F, 1999, J NEUROSCI, V19, P2424; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Haque ME, 2003, NEUROSCI RES, V47, P31, DOI 10.1016/S0168-0102(03)00166-4; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; Higashi Y, 2000, J NEUROCHEM, V75, P1771, DOI 10.1046/j.1471-4159.2000.0751771.x; HOTCHKISS AJ, 1980, J PHARMACOL EXP THER, V214, P257; Joseph P, 2000, BIOCHEM PHARMACOL, V60, P207, DOI 10.1016/S0006-2952(00)00321-X; Kita T, 2003, J PHARMACOL SCI, V92, P178; Kitaichi K, 2003, EUR J PHARMACOL, V464, P39, DOI 10.1016/S0014-2999(03)01321-9; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; Lai CT, 1997, BIOCHEM PHARMACOL, V53, P363, DOI 10.1016/S0006-2952(96)00731-9; LaVoie MJ, 1999, J NEUROCHEM, V73, P2546, DOI 10.1046/j.1471-4159.1999.0732546.x; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; MAREK GJ, 1990, BRAIN RES, V513, P274, DOI 10.1016/0006-8993(90)90467-P; MIRANDA M, 1984, GEN PHARMACOL-VASC S, V15, P541, DOI 10.1016/0306-3623(84)90212-X; MIRANDA M, 1983, GEN PHARMACOL, V14, P231, DOI 10.1016/0306-3623(83)90002-2; Miyazaki I, 1999, NEUROCHEM RES, V24, P857, DOI 10.1023/A:1020953913490; Miyazaki I, 2005, CLIN NEUROPHARMACOL, V28, P155, DOI 10.1097/01.wnf.0000175523.33334.24; Munday R, 1998, CHEM-BIOL INTERACT, V108, P155, DOI 10.1016/S0009-2797(97)00105-1; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; PAZ MA, 1991, J BIOL CHEM, V266, P689; RICAURTE GA, 1980, BRAIN RES, V193, P153, DOI 10.1016/0006-8993(80)90952-X; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; SEIDEN LS, 1984, PHARMACOL BIOCHEM BE, V21, P29, DOI 10.1016/0091-3057(84)90125-4; Tief K, 1997, PIGM CELL RES, V10, P153; Tief K, 1996, EUR J BIOCHEM, V241, P12, DOI 10.1111/j.1432-1033.1996.0012t.x; Tief K, 1996, DEV DYNAM, V205, P445, DOI 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; TSE DCS, 1976, J MED CHEM, V19, P37, DOI 10.1021/jm00223a008; Uhl GR, 1998, ANN NEUROL, V43, P555, DOI 10.1002/ana.410430503; WAGNER GC, 1980, BRAIN RES, V181, P151, DOI 10.1016/0006-8993(80)91265-2; WAGNER GC, 1983, BRAIN RES, V270, P285, DOI 10.1016/0006-8993(83)90602-9; Whitehead RE, 2001, J NEUROCHEM, V76, P1242, DOI 10.1046/j.1471-4159.2001.00125.x; Wrona M Z, 1997, NIDA Res Monogr, V173, P146; Yuan J, 2001, J NEUROCHEM, V77, P1338, DOI 10.1046/j.1471-4159.2001.00339.x	48	95	97	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					571	+		10.1096/fj.05-4996fje	http://dx.doi.org/10.1096/fj.05-4996fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403784	Green Submitted			2022-12-25	WOS:000235996000028
J	Rolls, A; Cahalon, L; Bakalash, S; Avidan, H; Lider, O; Schwartz, M				Rolls, A; Cahalon, L; Bakalash, S; Avidan, H; Lider, O; Schwartz, M			A sulfated disaccharide derived from chondroitin sulfate proteoglycan protects against inflammation-associated neurodegeneration	FASEB JOURNAL			English	Article						encephalomyelitis; experimental autoimmune uveitis; immunosuppression	CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HIGH-DOSE METHYLPREDNISOLONE; NF-KAPPA-B; MULTIPLE-SCLEROSIS; T-CELLS; TNF-ALPHA; THERAPEUTIC VACCINATION	Chondroitin sulfate proteoglycan (CSPG), a matrix protein that occurs naturally in the central nervous system (CNS), is considered to be a major inhibitor of axonal regeneration and is known to participate in activation of the inflammatory response. The degradation of CSPG by a specific enzyme, chondroitinase ABC, promotes repair. We postulated that a disaccharidic degradation product of this glycoprotein (CSPG-DS), generated following such degradation, participates in the modulation of the inflammatory responses and can, therefore, promote recovery in immune-induced neuropathologies of the CNS, such as experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune uveitis (EAU). In these pathologies, the dramatic increase in T cells infiltrating the CNS is far in excess of the numbers needed for regular maintenance. Here, we show that CSPG-DS markedly alleviated the clinical symptoms of EAE and protected against the neuronal loss in EAU. The last effect was associated with a reduction in the numbers of infiltrating T cells and marked microglia activation. This is further supported by our in vitro results indicating that CSPG-DS attenuated T cell motility and decreased secretion of the cytokines interferon-gamma and tumor necrosis factor-alpha. Mechanistically, these effects are associated with an increase in SOCS-3 levels and a decrease in NF-kappa B. Our results point to a potential therapeutic modality, in which a compound derived from an endogenous CNS-resident molecule, known for its destructive role in CNS recovery, might be helpful in overcoming inflammation-induced neurodegenerative conditions.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	michal.schwartz@weizmann.ac.il		Rolls, Asya/0000-0001-5862-4287				ABDELBASSET E, 1995, J NEUROSCI RES, V41, P222, DOI 10.1002/jnr.490410210; Ariel A, 1998, J IMMUNOL, V161, P2465; Asher R A, 2001, Prog Brain Res, V132, P611; Bakalash S, 2003, INVEST OPHTH VIS SCI, V44, P3374, DOI 10.1167/iovs.03-0080; Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chau CH, 2004, FASEB J, V18, P194, DOI 10.1096/fj.03-0196fje; Chavarria A, 2004, AUTOIMMUN REV, V3, P251, DOI 10.1016/j.autrev.2003.09.006; Chitnis T, 2003, IMMUNOL RES, V28, P223, DOI 10.1385/IR:28:3:223; Combs CK, 2001, J NEUROSCI, V21, P1179; Cooney RN, 2002, SHOCK, V17, P83, DOI 10.1097/00024382-200202000-00001; DeWitt DA, 1996, EXP NEUROL, V142, P103, DOI 10.1006/exnr.1996.0182; Dick AD, 2004, PROG RETIN EYE RES, V23, P617, DOI 10.1016/j.preteyeres.2004.06.005; Diem R, 2003, J NEUROSCI, V23, P6993, DOI 10.1523/JNEUROSCI.23-18-06993.2003; DSOUZA R, 2004, COMP CHONDROITINASE; Eng LF, 1996, NEUROCHEM RES, V21, P511, DOI 10.1007/BF02527717; Fang IM, 2004, EXP EYE RES, V78, P1043, DOI 10.1016/j.exer.2004.02.006; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; Fukuda T, 1997, J COMP NEUROL, V382, P141; Furlan R, 2001, J IMMUNOL, V167, P1821, DOI 10.4049/jimmunol.167.3.1821; Furlan Roberto, 2004, Methods Mol Med, V98, P171; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grimpe B, 2002, PROG BRAIN RES, V137, P333; Haghighi SS, 2000, SPINAL CORD, V38, P733, DOI 10.1038/sj.sc.3101074; Hall GL, 1999, J NEUROIMMUNOL, V98, P105, DOI 10.1016/S0165-5728(99)00069-7; HASCALL VC, 1970, J BIOL CHEM, V245, P4920; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI200112837; Hausler KG, 2002, EUR J NEUROSCI, V16, P2113, DOI 10.1046/j.1460-9568.2002.02287.x; Hemmer B, 1996, J NEUROSCI RES, V45, P852; Inoue S, 2001, INT REV CYTOL, V210, P121; Kantele JM, 2000, J IMMUNOL, V164, P5035, DOI 10.4049/jimmunol.164.10.5035; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Knepper PA, 1996, INVEST OPHTH VIS SCI, V37, P1360; Kotter MR, 2001, GLIA, V35, P204, DOI 10.1002/glia.1085; Laakko T, 2003, J BIOL CHEM, V278, P31621, DOI 10.1074/jbc.M304700200; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Leussink VI, 2001, ARCH NEUROL-CHICAGO, V58, P91, DOI 10.1001/archneur.58.1.91; Link J, 1994, Acta Neurol Scand Suppl, V158, P1; LUBLIN FD, 1985, SPRINGER SEMIN IMMUN, V8, P197; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; Matsui Fumiko, 2004, Congenital Anomalies, V44, P181, DOI 10.1111/j.1741-4520.2004.00038.x; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; Nussenblatt RB, 1996, J AUTOIMMUN, V9, P575, DOI 10.1006/jaut.1996.0077; OLSSON T, 1995, IMMUNOL REV, V144, P245, DOI 10.1111/j.1600-065X.1995.tb00072.x; Pashenkov M, 2003, J NEUROIMMUNOL, V135, P154, DOI 10.1016/S0165-5728(02)00441-1; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Pelletier AJ, 2000, BLOOD, V96, P2682; Pender MP, 2002, INTERN MED J, V32, P554, DOI 10.1046/j.1445-5994.2002.00269.x; POWRIE F, 1993, EUR J IMMUNOL, V23, P3043, DOI 10.1002/eji.1830231147; Prat A, 2005, CURR OPIN NEUROL, V18, P225, DOI 10.1097/01.wco.0000169737.99040.31; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; Qian T, 2000, MED HYPOTHESES, V55, P452, DOI 10.1054/mehy.2000.1165; Raivich G, 2004, BRAIN RES REV, V46, P261, DOI 10.1016/j.brainresrev.2004.06.006; Rohowsky-Kochan C, 2000, MULT SCLER, V6, P69, DOI 10.1177/135245850000600203; Rolls A, 2004, EUR J NEUROSCI, V20, P1973, DOI 10.1111/j.1460-9568.2004.03676.x; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755; Schmidt J, 2000, BRAIN, V123, P1431, DOI 10.1093/brain/123.7.1431; Schwartz M, 2005, ACTA NEUROCHIR SUPPL, V93, P147; Segal BA, 2003, CURR ALLERGY ASTHM R, V3, P86, DOI 10.1007/s11882-003-0017-6; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sobel RA, 2001, J NEUROPATH EXP NEUR, V60, P1198, DOI 10.1093/jnen/60.12.1198; Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041; Steinsapir KD, 2000, RESTOR NEUROL NEUROS, V17, P157; Tanihara H, 2002, CORNEA, V21, pS62, DOI 10.1097/01.ico.0000263121.45898.d2; Thurau SR, 2003, AUTOIMMUN REV, V2, P171, DOI 10.1016/S1568-9972(03)00011-9; Wildbaum G, 2003, IMMUNITY, V19, P679, DOI 10.1016/S1074-7613(03)00291-7; WILLIAMS KC, 1994, CLIN NEUROSCI, V2, P229; Yang PZ, 2000, CHINESE MED J-PEKING, V113, P643; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Zanin-Zhorov A, 2005, J IMMUNOL, V174, P3227, DOI 10.4049/jimmunol.174.6.3227	78	69	77	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					547	+		10.1096/fj.05-4540fje	http://dx.doi.org/10.1096/fj.05-4540fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16396993				2022-12-25	WOS:000235996000035
J	Albini, A; Dell'Eva, R; Vene, R; Ferrari, N; Buhler, DR; Noonan, DM; Fassina, G				Albini, A; Dell'Eva, R; Vene, R; Ferrari, N; Buhler, DR; Noonan, DM; Fassina, G			Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappa B and Akt as targets	FASEB JOURNAL			English	Article						angioprevention; chemoprevention; endothelial cells; NF-kappa B; Akt	HUMULUS-LUPULUS; PRENYLATED FLAVONOIDS; UP-REGULATION; TUMOR-GROWTH; IN-VIVO; ANGIOGENESIS; INHIBITION; ACTIVATION; CELLS; PRENYLFLAVONOIDS	Xanthohumol (XN), the principal flavonoid of the hop plant (Humulus lupulus L.) and a constituent of beer, has been suggested to have potential cancer chemopreventive activities. We have observed that most cancer chemopreventive agents show antiangiogenic properties in vitro and in vivo, a concept we termed "angioprevention." Here we show for the first time that XN can inhibit growth of a vascular tumor in vivo. Histopathology and in vivo angiogenesis assays indicated that tumor angiogenesis inhibition was involved. Further, we show the mechanisms for its inhibition of angiogenesis in vivo and related endothelial cell activities in vitro. XN repressed both the NF-kappa B and Akt pathways in endothelial cells, indicating that components of these pathways are major targets in the molecular mechanism of XN. Moreover, using in vitro analyses, we show that XN interferes with several points in the angiogenic process, including inhibition of endothelial cell invasion and migration, growth, and formation of a network of tubular-like structures. Our results suggest that XN can be added to the expanding list of antiangiogenic chemopreventive drugs whose potential in cancer prevention and therapy should be evaluated.	Univ Insubria, Dipartimento Sci Clin & Biol, Fac Med & Chirurg, I-21100 Varese, Italy; Ist Nazl Ric Canc, Mol Oncol Lab, I-16132 Genoa, Italy; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Ist Nazl Ric Canc, Tumor Progress Unit, I-16132 Genoa, Italy; CNR, Sez Genova, Ist Bioimmagini & Fisiol Mol, Genoa, Italy	University of Insubria; University of Genoa; IRCCS AOU San Martino IST; Oregon State University; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR)	Noonan, DM (corresponding author), Univ Insubria, Dipartimento Sci Clin & Biol, Fac Med & Chirurg, Via Ottorino Rossi 9, I-21100 Varese, Italy.	douglas.noonan@uninsubria.it	Albini, Adriana/J-3701-2018; Ferrari, Nicoletta/AAG-6049-2019; Noonan, Douglas/A-8620-2010	Ferrari, Nicoletta/0000-0002-6027-1035; Albini, Adriana/0000-0002-9624-5103; Noonan, Douglas/0000-0001-8058-0719	NIEHS NIH HHS [ES000210] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; Albini A, 2001, CANCER RES, V61, P8171; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1987, CANCER RES, V47, P3239; ANTO RJ, 1995, CANCER LETT, V97, P33, DOI 10.1016/0304-3835(95)03945-S; Barcelos LS, 2005, J LEUKOCYTE BIOL, V78, P352, DOI 10.1189/jlb.1104682; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bjorndahl M, 2005, P NATL ACAD SCI USA, V102, P15593, DOI 10.1073/pnas.0507865102; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Cai T, 1999, LAB INVEST, V79, P1151; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; DEVINCENZO R, 1995, ANTI-CANCER DRUG DES, V10, P481; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Fassina G, 2004, CLIN CANCER RES, V10, P4865, DOI 10.1158/1078-0432.CCR-03-0672; Ferrari N, 2005, CLIN CANCER RES, V11, P4610, DOI 10.1158/1078-0432.CCR-04-2210; Ferrari N, 2003, CLIN CANCER RES, V9, P6020; Garbisa S, 1999, NAT MED, V5, P1216, DOI 10.1038/15145; Garbisa S, 2001, CANCER-AM CANCER SOC, V91, P822, DOI 10.1002/1097-0142(20010215)91:4<822::AID-CNCR1070>3.0.CO;2-G; Gerhauser C, 2005, EUR J CANCER, V41, P1941, DOI 10.1016/j.ejca.2005.04.012; Gerhauser C, 2002, MOL CANCER THER, V1, P959; Goto K, 2005, CANCER LETT, V219, P215, DOI 10.1016/j.canlet.2004.07.034; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Henderson MC, 2000, XENOBIOTICA, V30, P235, DOI 10.1080/004982500237631; Lambert JD, 2005, AM J CLIN NUTR, V81, p284S, DOI 10.1093/ajcn/81.1.284S; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Miranda CL, 2000, DRUG METAB DISPOS, V28, P1297; Miranda CL, 1999, FOOD CHEM TOXICOL, V37, P271, DOI 10.1016/S0278-6915(99)00019-8; Miranda CL, 2000, CANCER LETT, V149, P21, DOI 10.1016/S0304-3835(99)00328-6; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Pan L, 2005, MOL NUTR FOOD RES, V49, P837, DOI 10.1002/mnfr.200500065; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Stevens JF, 1999, J CHROMATOGR A, V832, P97, DOI 10.1016/S0021-9673(98)01001-2; Stevens JF, 1997, PHYTOCHEMISTRY, V44, P1575, DOI 10.1016/S0031-9422(96)00744-3; Tosetti F, 2003, MOL PHARMACOL, V63, P565, DOI 10.1124/mol.63.3.565; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; Vanhoecke B, 2005, INT J CANCER, V117, P889, DOI 10.1002/ijc.21249; Zhao F, 2003, BIOL PHARM BULL, V26, P61, DOI 10.1248/bpb.26.61	42	156	172	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					527	+		10.1096/fj.05-5128fje	http://dx.doi.org/10.1096/fj.05-5128fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16403733				2022-12-25	WOS:000234405500014
J	Mei, FC; Young, TW; Liu, JS; Cheng, XD				Mei, FC; Young, TW; Liu, JS; Cheng, XD			RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells	FASEB JOURNAL			English	Article						ovarian cancer; oncogene; DNA methylation	SIGNALING PATHWAY; DNA METHYLATION; GENE-MUTATIONS; CANCER; METHYLTRANSFERASE; EXPRESSION; PROTEIN; TUMORS; MODEL; PROTOONCOGENE	Opioid binding protein/cell adhesion molecule-like gene (OPCML), a recently identified tumor-suppressor, is frequently inactivated by allele loss and CpG island promoter methylation in epithelial ovarian cancer. Since elevated activation of the RAS signaling pathway, including overexpression of HER-2/neu and mutations of RAS and BRAF, is common in human ovarian carcinoma, we examined the cellular effect of oncogenic RAS on the expression status of OPCML in a genetically defined human ovarian cancer model. Our study revealed that RAS(V12)-mediated oncogenic transformation was accompanied by a concomitant loss of OPCML expression. Methylation-sensitive PCR analysis showed that the OPCML promoter was hypermethylated in RAS-transformed human ovarian epithelial cells (T29H) and that treatment with the DNA methyltransferase inhibitor 5'-aza-2'-deoxycytidine promoted demethylation of the OPCML promoter and restored OPCML expression in T29H cells. Furthermore, suppression of oncogenic RAS activity by stable siRNA specific for HRAS(V12) led to the demethylation and re-expression of OPCML in T29H cells, demonstrating that oncogenic RAS activity is directly responsible for the observed OPCML promoter hypermethylation and epigenetic gene silencing of OPCML. Taken together, our study suggests that elevation of the RAS signaling pathway may play an important role in epigenetic inactivation of OPCML in human epithelial ovarian cancer.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, Galveston, TX 77555 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol,Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu			NIGMS NIH HHS [GM060170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcock RA, 2002, ONCOGENE, V21, P7883, DOI 10.1038/sj.onc.1205948; Baylin Stephen B., 2000, P293; BOS JL, 1989, CANCER RES, V49, P4682; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; Deng C, 1998, BIOL CHEM, V379, P1113, DOI 10.1515/bchm.1998.379.8-9.1113; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Gemignani ML, 2003, GYNECOL ONCOL, V90, P378, DOI 10.1016/S0090-8258(03)00264-6; Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; ICHIKAWA Y, 1994, CANCER RES, V54, P33; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MOK SCH, 1993, CANCER RES, V53, P1489; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Patton SE, 1998, CANCER RES, V58, P2253; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; PRUITT K, 2005, J BIOL CHEM; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Young T, 2005, ONCOGENE, V24, P6174, DOI 10.1038/sj.onc.1208753; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222	30	32	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2005	19	14					497	+		10.1096/fj.05-4586fje	http://dx.doi.org/10.1096/fj.05-4586fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16384911				2022-12-25	WOS:000234405500016
J	Richardson, DS; Lai, AZ; Mulligan, LM				Richardson, D. S.; Lai, A. Z.; Mulligan, L. M.			RET ligand-induced internalization and its consequences for downstream signaling	ONCOGENE			English	Article						RET; receptor mediated endocytosis; Akt; MAP kinase	CLATHRIN-MEDIATED ENDOCYTOSIS; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DYNAMIN BINDS; SH3 DOMAINS; MAP KINASE; ACTIVATION; CELLS; TRANSDUCTION	RET is a receptor tyrosine kinase (RTK) with roles in cell growth, differentiation and survival. Ligand-induced activation of RET results in stimulation of multiple signal transduction pathways, including the MAP kinase/Erk and PI3 kinase/Akt pathways. However, the mechanisms governing receptor internalization and signal downregulation have not been explored. As other RTKs are internalized through the clathrin-coated pit pathway in a ligand-dependant manner, we have investigated whether RET is internalized through a similar process. Using a highly sensitive fluorescence resonance energy transfer (FRET)-based assay, we have shown that RET is internalized from the plasma membrane in a ligand-dependant manner that requires RET kinase activity as well as the GTPase activity of the clathrin-coated vesicle scission protein dynamin 2. Further, we have demonstrated that RET colocalizes with Rab5a, a marker of clathrin-coated vesicles and early endosomes, after internalization. Finally, we demonstrated that RET internalization is required for complete activation of Erk1/2, but not for activation of Akt signaling. Our data suggest that ligand-induced internalization of RET not only plays an overall role in downregulation and termination of signaling, but also functions to traffic RET to subcellular locations where it can fully activate certain downstream signaling pathways.	Queens Univ, Canc Res Inst, Dept Pathol & Mol Med, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Mulligan, LM (corresponding author), Queens Univ, Canc Res Inst, Dept Pathol & Mol Med, Div Canc Biol & Genet, Rm 329 Botterell Hall, Kingston, ON K7L 3N6, Canada.	mulligal@post.queensu.ca	Richardson, Douglas/K-9922-2016	Richardson, Douglas/0000-0002-3189-2190				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grimes ML, 1996, J NEUROSCI, V16, P7950; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuetz G, 2004, J CELL BIOL, V167, P945, DOI 10.1083/jcb.200404108; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; van Rheenen J, 2004, BIOPHYS J, V86, P2517, DOI 10.1016/S0006-3495(04)74307-6; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Zaccolo M, 2000, IUBMB LIFE, V49, P375	38	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3206	3211		10.1038/sj.onc.1209349	http://dx.doi.org/10.1038/sj.onc.1209349			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16418724				2022-12-25	WOS:000237951000011
J	Warbrick, E				Warbrick, E.			A functional analysis of PCNA-binding peptides derived from protein sequence, interaction screening and rational design	ONCOGENE			English	Article						PCNA; peptides; interaction; screening	CELL NUCLEAR ANTIGEN; DNA-POLYMERASE-DELTA; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REPLICATION; P21; INHIBITOR; PHOSPHORYLATION; GADD45; MOTIF	Proliferating cell nuclear antigen ( PCNA) has no intrinsic enzymatic function, but functions as a sliding platform to mediate protein interactions with the DNA strand. Many proteins interact with PCNA through a small conserved motif with consensus QxxLxxFF. This work uses Schizosaccharomyces pombe and human cells to analyse the function of PCNA- binding peptides. Interacting peptides were identified using two- hybrid screening; one ( pep102) binds directly to a physiologically relevant site on PCNA. The EGFP- pep102 overexpression phenotype is consistent with competitive blocking of PCNA - protein interactions. Various PCNA- binding peptides were all shown to inhibit PCNA function by competitive binding in both human and S. pombe cells as EGFP fusion proteins. The action of a p21( WAF1/ Cip1)- derived peptide was complicated by the presence of additional functional domains and possible post- translational modi. cation. The activity of pep102 was hampered by low expression in both model systems. The peptide derived from rational design ( con1) was stable, highly active in inhibiting PCNA function both S. pombe and human cells and showed a high affinity for PCNA both in vitro and in vivo. These results validate the use of functional screening in yeast to identify peptide aptamers that are functional in mammalian cells; such aptamers provide excellent leads for small molecule antiproliferative therapies.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Warbrick, E (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	e.warbrick@dundee.ac.uk	Warbrick, Emma/C-6424-2008		Cancer Research UK [A6613] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adams PD, 1996, MOL CELL BIOL, V16, P6623; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN IT, 1995, ONCOGENE, V11, P1931; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kamb A, 2001, CURR OPIN CHEM BIOL, V5, P74, DOI 10.1016/S1367-5931(00)00160-5; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kontopidis G, 2005, P NATL ACAD SCI USA, V102, P1871, DOI 10.1073/pnas.0406540102; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Mattock H, 2001, EXP CELL RES, V265, P242, DOI 10.1006/excr.2001.5181; Mattock H, 2001, EXP CELL RES, V265, P234, DOI 10.1006/excr.2001.5160; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; SAZER S, 1990, J CELL SCI, V97, P509; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; Xu H, 2001, BIOCHEMISTRY-US, V40, P4512, DOI 10.1021/bi010103+; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; Zheleva DI, 2002, J PEPT RES, V60, P257, DOI 10.1034/j.1399-3011.2002.21014.x; Zheleva DI, 2000, BIOCHEMISTRY-US, V39, P7388, DOI 10.1021/bi992498r	39	32	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2850	2859		10.1038/sj.onc.1209320	http://dx.doi.org/10.1038/sj.onc.1209320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407840	Green Accepted, Bronze			2022-12-25	WOS:000237448200003
J	Guo, K; Lukacik, P; Papagrigoriou, E; Meier, M; Lee, WH; Adamski, J; Oppermann, U				Guo, K; Lukacik, P; Papagrigoriou, E; Meier, M; Lee, WH; Adamski, J; Oppermann, U			Characterization of human DHRS6, an orphan short chain dehydrogenase/reductase enzyme - A novel, cytosolic type 2 R-beta-hydroxybutyrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; (R)-3-HYDROXYBUTYRATE DEHYDROGENASE; ALCOHOL-DEHYDROGENASE; KETONE-BODY; HUMAN HEART; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-HYDROXYBUTYRATE DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; RAT-LIVER; FAMILY	Human DHRS6 is a previously uncharacterized member of the short chain dehydrogenases/reductase family and displays significant homologies to bacterial hydroxybutyrate dehydrogenases. Substrate screening reveals sole NAD(+)-dependent conversion of (R)-hydroxybutyrate to acetoacetate with K-m values of about 10 mM, consistent with plasma levels of circulating ketone bodies in situations of starvation or ketoacidosis. The structure of human DHRS6 was determined at a resolution of 1.8 angstrom in complex with NAD(H) and reveals a tetrameric organization with a short chain dehydrogenases/ reductase-typical folding pattern. A highly conserved triad of Arg residues ("triple R" motif consisting of Arg(144), Arg(188), and Arg(205)) was found to bind a sulfate molecule at the active site. Docking analysis of R-beta-hydroxybutyrate into the active site reveals an experimentally consistent model of substrate carboxylate binding and catalytically competent orientation. GFP reporter gene analysis reveals a cytosolic localization upon transfection into mammalian cells. These data establish DHRS6 as a novel, cytosolic type 2 ( R)hydroxybutyrate dehydrogenase, distinct from its well characterized mitochondrial type 1 counterpart. The properties determined for DHRS6 suggest a possible physiological role in cytosolic ketone body utilization, either as a secondary system for energy supply in starvation or to generate precursors for lipid and sterol synthesis.	Univ Oxford, Struct Genom Consortium, Oxford OX3 7LD, England; GSF, Natl Res Ctr, Inst Expt Genet, D-85764 Neuherberg, Germany	University of Oxford; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Oppermann, U (corresponding author), Univ Oxford, Struct Genom Consortium, Oxford OX3 7LD, England.	Udo.Oppermann@sgc.ox.ac.uk	Lukacik, Petra/AAY-3775-2021; Lee, Wen Hwa/GZA-8183-2022; Lee, Wen Hwa/G-1250-2013	Lukacik, Petra/0000-0002-3179-7273; Lee, Wen Hwa/0000-0002-4098-5225; Lee, Wen Hwa/0000-0002-4098-5225; Adamski, Jerzy/0000-0001-9259-0199	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aneja P, 1999, J BACTERIOL, V181, P849, DOI 10.1128/JB.181.3.849-857.1999; Benach J, 1999, J MOL BIOL, V289, P335, DOI 10.1006/jmbi.1999.2765; Breitkreuz KE, 2003, J BIOL CHEM, V278, P41552, DOI 10.1074/jbc.M305717200; Chelius D, 2000, BIOCHEMISTRY-US, V39, P9687, DOI 10.1021/bi000274z; CHURCHILL P, 1992, BIOCHEMISTRY-US, V31, P3793, DOI 10.1021/bi00130a009; DALTON LA, 1993, BIOCHEM J, V296, P563, DOI 10.1042/bj2960563; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Green D, 1996, BIOCHEMISTRY-US, V35, P8158, DOI 10.1021/bi952807n; Hawes JW, 2000, METHOD ENZYMOL, V324, P218; Hawes JW, 1997, ADV EXP MED BIOL, V414, P395; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; KOUNDAKJIAN PP, 1970, BIOCHEM J, V119, P49, DOI 10.1042/bj1190049; LeBlanc PJ, 2000, J EXP ZOOL, V286, P434, DOI 10.1002/(SICI)1097-010X(20000301)286:4<434::AID-JEZ11>3.3.CO;2-X; MARKS AR, 1992, J BIOL CHEM, V267, P15459; Ohnuki M, 2005, BBA-GENE STRUCT EXPR, V1729, P147, DOI 10.1016/j.bbaexp.2005.05.006; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; Powell AJ, 2000, J MOL BIOL, V303, P311, DOI 10.1006/jmbi.2000.4139; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Totrov M, 1997, PROTEINS, P215	25	52	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10291	10297		10.1074/jbc.M511346200	http://dx.doi.org/10.1074/jbc.M511346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16380372	hybrid			2022-12-25	WOS:000236594300057
J	Milano, SK; Kim, YM; Stefano, FP; Benovic, JL; Brenner, C				Milano, SK; Kim, YM; Stefano, FP; Benovic, JL; Brenner, C			Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hexakisphosphate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; CLATHRIN ADAPTER AP-2; BETA-ARRESTIN; VISUAL ARRESTIN; CRYSTAL-STRUCTURE; BETA(2)-ADRENERGIC RECEPTOR; PROTEIN; ENDOCYTOSIS; ACTIVATION; COMPLEX	Interactions between arrestins and phosphoinositides have been reported to regulate multiple membrane-associated signaling and trafficking events including clathrin-mediated endocytosis and light adaptation in Drosophila. Arrestins have been proposed to have nuclear and cytosolic functions as well, although the ligand dependence of these functions has not been investigated. Here we characterize the structural, molecular, and cellular interactions between arrestin-2 and inositol hexakisphosphate ( inositol 1,2,3,4,5,6-hexakisphosphate (IP6)). The crystal structure of the arrestin-2.IP6 complex was solved to 2.9 angstrom with crystal lattice contacts suggesting two sites on a protein monomer mediating IP6 binding. Mutagenesis coupled to isothermal titration calorimetry and tritiated IP6 binding assays confirmed two-site binding with a low affinity IP6-binding site in the N-domain and a high affinity site in the C-domain. Native gel electrophoresis, gel filtration, and analytical ultracentrifugation demonstrated the ability of IP6 to promote arrestin-2 oligomerization via the two crystallographically defined ligand-binding locations. In addition, analysis in mammalian cells revealed that arrestin-2 not only undergoes homo-oligomerization, but it can also hetero-oligomerize with arrestin-3 in a manner that depends on IP6-binding sites. Mutation of either IP6-binding site in arrestin-2 disrupted oligomerization while interactions with known binding partners including clathrin, AP-2, and ERK2 were maintained. Subcellular localization studies showed that arrestin-2 oligomers are primarily cytoplasmic, whereas arrestin-2 monomers displayed increased nuclear localization. Thus, by promoting cytosolic oligomerization, IP6 binding is proposed to be a negative regulator of interactions of arrestin with plasma membrane and nuclear signaling proteins.	Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Dartmouth Med Sch, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Med Sch, Dept Biochem, Lebanon, NH 03756 USA	Jefferson University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Dartmouth College; Dartmouth College	Brenner, C (corresponding author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA.	benovic@mail.jci.tju.edu; charles.brenner@dartmouth.edu	Brenner, Charles/D-6339-2014; Kim, You-Me/I-5553-2013	Brenner, Charles/0000-0002-4955-3226; Kim, You-Me/0000-0001-8780-704X	NCRR NIH HHS [1S10 RR019431] Funding Source: Medline; NIGMS NIH HHS [GM47417, GM068857] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047417, R01GM068857, R37GM047417] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK KA, 1991, J BIOL CHEM, V266, P4442; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DELANO WL, 2002, PYMOL VERSION 0 97; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Frederick JP, 2005, P NATL ACAD SCI USA, V102, P8454, DOI 10.1073/pnas.0503706102; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Imamoto Y, 2003, BIOPHYS J, V85, P1186, DOI 10.1016/S0006-3495(03)74554-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JH, 2004, J BIOL CHEM, V279, P9912, DOI 10.1074/jbc.M310824200; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Milano SK, 2002, BIOCHEMISTRY-US, V41, P3321, DOI 10.1021/bi015905j; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCZEWSKI K, 1991, FEBS LETT, V295, P195, DOI 10.1016/0014-5793(91)81416-6; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Storez H, 2005, J BIOL CHEM, V280, P40210, DOI 10.1074/jbc.M508001200; Verbsky J, 2005, P NATL ACAD SCI USA, V102, P8448, DOI 10.1073/pnas.0503656102; Verbsky JW, 2005, J BIOL CHEM, V280, P1911, DOI 10.1074/jbc.M411528200; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200	43	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9812	9823		10.1074/jbc.M512703200	http://dx.doi.org/10.1074/jbc.M512703200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16439357	hybrid			2022-12-25	WOS:000236404700094
J	Hopfer, U; Hopfer, H; Jablonski, K; Stahl, RAK; Wolf, G				Hopfer, U; Hopfer, H; Jablonski, K; Stahl, RAK; Wolf, G			The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLASES PHD1; DEPENDENT CELL-DEATH; SMOOTH-MUSCLE-CELLS; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; UBIQUITIN LIGASE; ANGIOTENSIN-II; BETA-SUBUNIT; DNA-BINDING	Hypoxia-inducible factor-1 (HIF-1), a transcriptional complex composed of an oxygen-sensitive alpha- and a beta-subunit, plays a pivotal role in cellular adaptation to low oxygen availability. Under normoxia, the alpha-subunit of HIF-1 is hydroxylated by a family of prolyl hydroxylases (PHDs) and consequently targeted for proteasomal degradation. Three different PHDs have been identified, but the difference among their in vivo roles remain unclear. PHD3 is strikingly expressed by hypoxia, displays high substrate specificity, and has been identified in other signaling pathways. PHD3 may therefore hydroxylate divergent substrates and/or connect divergent cellular responses with HIF. We identified a novel WD-repeat protein, recently designated Morg1 ( MAPK organizer 1), by screening a cDNA library with yeast two-hybrid assays. The interaction between PHD3 and Morg1 was confirmed in vitro and in vivo. We found seven WD-repeat domains by cloning the full-length cDNA of Morg1. By confocal microscopy both proteins co-localize within the cytoplasm and the nucleus and display a similar tissue expression pattern in Northern blots. Binding occurs at a conserved region predicted to the top surface of one propeller blade. Finally, HIF-mediated reporter gene activity is decreased by Morg1 and reduced to basal levels when Morg1 is co-expressed with PHD3. Suppression of Morg1 or PHD3 by stealth RNA leads to a marked increase of HIF-1 activity. These results indicate that Morg1 specifically interacts with PHD3 most likely by acting as a molecular scaffold. This interaction may provide a molecular framework between HIF regulation and other signaling pathways.	Univ Hamburg, Dept Med, D-20246 Hamburg, Germany; Univ Hamburg, Dept Pathol, D-20246 Hamburg, Germany; Univ Jena, Dept Med, D-07747 Jena, Germany	University of Hamburg; University of Hamburg; Friedrich Schiller University of Jena	Hopfer, U (corresponding author), Ctr innovat Med, Dept Med, Falkenried 88,5 St, D-20251 Hamburg, Germany.	u.hopfer@uke.uni-hamburg.de	Hopfer, Helmut/T-5954-2019	Hopfer, Helmut/0000-0003-1755-2170				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503; Butzmann U, 2002, J AM SOC NEPHROL, V13, p495A; Cheng HL, 2004, MOL CELL BIOL, V24, P2932, DOI 10.1128/MCB.24.7.2932-2943.2004; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erez N, 2002, ONCOGENE, V21, P6713, DOI 10.1038/sj.onc.1205867; Freeman RS, 2003, MOL CELLS, V16, P1; FUTEY LM, 1995, J BIOL CHEM, V270, P523, DOI 10.1074/jbc.270.2.523; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Harendza S, 2000, J BIOL CHEM, V275, P19552, DOI 10.1074/jbc.M001322200; Hewitson KS, 2003, BIOCHEM SOC T, V31, P510, DOI 10.1042/BST0310510; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hopfer H, 2003, FASEB J, V17, P860, DOI 10.1096/fj.02-0746com; Hopfer U, 2005, FASEB J, V19, P1232, DOI 10.1096/fj.04-3019com; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janda L, 1996, J BACTERIOL, V178, P1487, DOI 10.1128/jb.178.5.1487-1489.1996; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Madden SL, 1996, CANCER RES, V56, P5384; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Menzies K, 2004, BIOCHEM BIOPH RES CO, V317, P801, DOI 10.1016/j.bbrc.2004.03.115; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Straub JA, 2003, J NEUROCHEM, V85, P318, DOI 10.1046/j.1471-4159.2003.01688.x; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tuckerman JR, 2004, FEBS LETT, V576, P145, DOI 10.1016/j.febslet.2004.09.005; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Vodermaier HC, 2004, CURR BIOL, V14, pR787, DOI 10.1016/j.cub.2004.09.020; Vodermaier HC, 2001, CURR BIOL, V11, pR834, DOI 10.1016/S0960-9822(01)00498-5; Vomastek T, 2004, P NATL ACAD SCI USA, V101, P6981, DOI 10.1073/pnas.0305894101; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warnecke C, 2003, FASEB J, V17, P1186, DOI 10.1096/fj.02-1062fje; Wax SD, 1996, LAB INVEST, V74, P797; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Wilson DK, 2005, J BIOL CHEM, V280, P13944, DOI 10.1074/jbc.M412919200; Wolf C, 2001, FEBS LETT, V488, P154, DOI 10.1016/S0014-5793(00)02403-0; Wolf G, 2004, AM J NEPHROL, V24, P415, DOI 10.1159/000080086; Wolf G, 2002, LAB INVEST, V82, P1305, DOI 10.1097/01.LAB.0000029207.92039.2F; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu LH, 2000, PROTEIN SCI, V9, P2470, DOI 10.1110/ps.9.12.2470; Zahner G, 2002, J BIOL CHEM, V277, P9763, DOI 10.1074/jbc.M106307200	76	52	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8645	8655		10.1074/jbc.M513751200	http://dx.doi.org/10.1074/jbc.M513751200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407229	hybrid			2022-12-25	WOS:000236247100042
J	Buchse, T; Prietzsch, H; Sasse, T; Korbel, S; Stigge, G; Bogdanow, S; Brock, J; Bittorf, T				Buchse, T; Prietzsch, H; Sasse, T; Korbel, S; Stigge, G; Bogdanow, S; Brock, J; Bittorf, T			Profiling of early gene expression induced by erythropoietin receptor structural variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; MESSENGER-RNA; EPO RECEPTOR; PROTHYMOSIN-ALPHA; GROWTH-HORMONE; DIFFERENTIATION; ACTIVATION; STAT5; JAK2	The development of erythroid progenitor cells is triggered via the expression of the erythropoietin receptor ( EPOR) and its activation by erythropoietin. The function of the resulting receptor complex depends critically on the presence of activated JAK2, and the complex contains a large number of signaling molecules recruited to eight phosphorylated tyrosine residues. Studies using mutant receptor forms have demonstrated that truncated receptors lacking all tyrosines are able to support red blood cell development with low efficiency, whereas add-back mutants containing either Tyr(343) or Tyr(479) reconstitute EPOR signaling and erythropoiesis in vivo. To study the contribution of tyrosines to receptor function, we analyzed the activation of essential signaling pathways and early gene induction promoted by different receptor structural variants using human epidermal growth factor receptor/murine EPOR hybrids. In our experiments, receptors lacking all tyrosine residues or the JAK2-binding site did not induce mitogenic and anti-apoptotic signaling, whereas add-back mutant receptors containing single tyrosine residues (Try(343) and Tyr(479)) supported the activation of these functions efficiently. Profiling of early gene expression using cDNA array hybridization revealed that ( i) the high redundancy in the activation of signaling pathways is continued at the level of transcription; (ii) the expression of many genes targeted by the wild-type receptor is not supported by add-back mutants; and (iii) a small set of genes are exclusively induced by add-back receptors. We report the identification of several early genes that have not been implicated in the EPOR-dependent response so far.	Univ Rostock, Fac Med, Inst Med Biochem & Mol Biol, D-18057 Rostock, Germany	University of Rostock	Bittorf, T (corresponding author), Univ Rostock, Fac Med, Inst Med Biochem & Mol Biol, Schillingallee 70, D-18057 Rostock, Germany.	thomas.bittorf@med.uni-rostock.de						Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Berridge MV, 2000, ANTIOXID REDOX SIGN, V2, P231, DOI 10.1089/ars.2000.2.2-231; BITTORF T, 1994, CELL SIGNAL, V6, P305, DOI 10.1016/0898-6568(94)90035-3; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Karetsou Z, 2004, FEBS LETT, V577, P496, DOI 10.1016/j.febslet.2004.09.091; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Korbel S, 2005, PROTEOMICS, V5, P91, DOI 10.1002/pmic.200400883; KRANTZ SB, 1991, BLOOD, V77, P419; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Li K, 2003, BLOOD, V102, P3147, DOI 10.1182/blood-2003-01-0078; Li K, 2003, J BIOL CHEM, V278, P40702, DOI 10.1074/jbc.M307182200; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Miller CP, 2002, BLOOD, V99, P898, DOI 10.1182/blood.V99.3.898; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; REN HY, 1994, J BIOL CHEM, V269, P19633; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Sarna MK, 2003, ONCOGENE, V22, P3221, DOI 10.1038/sj.onc.1206381; Segade F, 1999, INT J BIOCHEM CELL B, V31, P1243, DOI 10.1016/S1357-2725(99)00094-1; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Shimizu R, 1996, BIOCHEM BIOPH RES CO, V222, P1, DOI 10.1006/bbrc.1996.0688; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; Vareli K, 2004, BIOL CELL, V96, P421, DOI 10.1016/j.biolcel.2004.04.002; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yang CH, 2004, EXP CELL RES, V298, P197, DOI 10.1016/j.yexcr.2004.04.008; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; Yoon DH, 2003, EXP HEMATOL, V31, P1310, DOI 10.1016/j.exphem.2003.08.009; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156	52	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7697	7707		10.1074/jbc.M508481200	http://dx.doi.org/10.1074/jbc.M508481200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16380376	hybrid			2022-12-25	WOS:000236031000002
J	Meyer, MZ; Deliot, N; Chasserot-Golaz, S; Premont, RT; Bader, MF; Vitale, N				Meyer, MZ; Deliot, N; Chasserot-Golaz, S; Premont, RT; Bader, MF; Vitale, N			Regulation of neuroendocrine exocytosis by the ARF6 GTPase-activating protein GIT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CHROMAFFIN CELLS; SECRETORY GRANULES; PHOSPHOLIPASE D1; EXCHANGE FACTOR; FAMILY; COMPLEX; ACTIN; REQUIRES; FUSION	Neuroendocrine cells release hormones and neuropeptides by exocytosis, a highly regulated process in which secretory granules fuse with the plasma membrane to release their contents in response to a calcium trigger. Using chromaffin and PC12 cells, we have recently described that the granule-associated GTPase ARF6 plays a crucial role in exocytosis by activating phospholipase D1 at the plasma membrane and, presumably, promoting the fusion reaction between the two membrane bilayers. ARF6 is activated by the nucleotide exchange factor ARNO following docking of granules to the plasma membrane. We show here that GIT1, a GTPase-activating protein stimulating GTP hydrolysis on ARF6, is the second molecular partner that turns over the GDP/GTP cycle of ARF6 during cell stimulation. Western blot and immunofluorescence experiments indicated that GIT1 is cytosolic in resting cells but is recruited to the plasma membrane in stimulated cells, where it colocalizes with ARF6 at the granule docking sites. Over-expression of wild-type GIT1 inhibits growth hormone secretion from PC12 cells; this inhibitory effect was not observed in cells expressing a GIT1 mutant impaired in its ARF-GTPase-activating protein ( GAP) activity or in cells expressing other ARF6-GAPs. Conversely reduction of GIT1 by RNA interference increased the exocytotic activity. Using a real time assay for individual chromaffin cells, we found that microinjection of GIT1 strongly reduced the number of exocytotic events. These results provide the first evidence that GIT1 plays a function in calcium-regulated exocytosis in neuroendocrine cells. We propose that GIT1 represents part of the pathway that inactivates ARF6-dependent reactions and thereby negatively regulates and/or terminates exocytotic release.	Univ Strasbourg 1, UMR 7168 CNRS, Dept Neurotransmiss & Neuroendocrine Sect, Inst Neurosci Cellulaires & Integrat, F-67084 Strasbourg, France; Duke Univ, Med Ctr, Dept Med Gastroenterol, Durham, NC 27710 USA	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Duke University	Vitale, N (corresponding author), Univ Strasbourg 1, UMR 7168 CNRS, Dept Neurotransmiss & Neuroendocrine Sect, Inst Neurosci Cellulaires & Integrat, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	vitalen@neurochem.u-strasbg.fr	Chasserot-Golaz, Sylvette/K-7625-2017; Vitale, Nicolas/G-5967-2014; Bader, Marie-France/O-2098-2016	Vitale, Nicolas/0000-0002-4752-4907; deliot, nadine/0000-0002-1258-7377; Chasserot-Golaz, Sylvette/0000-0002-7437-2558; Premont, Richard/0000-0002-8053-5026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059989] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa Y, 2003, J CELL BIOL, V162, P647, DOI 10.1083/jcb.200212142; Albertinazzi C, 2003, MOL BIOL CELL, V14, P1295, DOI 10.1091/mbc.E02-07-0406; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Elhamdani A, 2001, NEURON, V31, P819, DOI 10.1016/S0896-6273(01)00418-4; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; Gasman S, 1999, J CELL SCI, V112, P4763; Gensse M, 2000, FEBS LETT, V480, P184, DOI 10.1016/S0014-5793(00)01926-8; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Humeau Y, 2001, P NATL ACAD SCI USA, V98, P15300, DOI 10.1073/pnas.261358698; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Premont RT, 2004, CELL SIGNAL, V16, P1001, DOI 10.1016/j.cellsig.2004.02.002; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Schweitzer JK, 2002, J BIOL CHEM, V277, P27210, DOI 10.1074/jbc.M201569200; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Zhang HY, 2003, J CELL BIOL, V161, P131, DOI 10.1083/jcb.200211002	30	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7919	7926		10.1074/jbc.M600081200	http://dx.doi.org/10.1074/jbc.M600081200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16439353	hybrid			2022-12-25	WOS:000236031000027
J	Race, PR; Lakey, JH; Banfield, MJ				Race, PR; Lakey, JH; Banfield, MJ			Insertion of the enteropathogenic Escherichia coli Tir virulence protein into membranes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PORE-FORMING PROTEIN; EQUINATOXIN-II; SEA-ANEMONE; HOST-CELLS; MAMMALIAN-CELLS; ACTINIA-EQUINA; SECRETION; RECEPTOR; INTIMIN	Insertion of the enteropathogenic Escherichia coli Tir protein into the plasma membrane of intestinal epithelial cells is a crucial event in infection because it provides a receptor for intimate bacterial adherence. This interaction with the bacterial outer membrane protein intimin is also essential in generating a number of signaling activities associated with virulence. Tir can be modified at various sites by phosphorylation and functionally interacts with multiple host proteins. To investigate the mechanism of membrane insertion and to establish a model system in which the multiple interactions/ functions of Tir can be uncoupled and independently characterized, we used intrinsic tryptophan fluorescence, surface plasmon resonance, and protease digestion assays to show that Tir can insert directly into phospholipid vesicles in a composition-dependent manner to generate the topology reported in vivo. This is the first time that Tir has been shown to insert into membranes in a simple model system in the absence of chemical modification or other factors. These data are consistent with the protein interacting with lipids through two sites. The major site is localized to the transmembrane/ intimin-binding domain region and includes Trp(235), which is shown to be an effective reporter of interaction. The minor site is located within the C-terminal domain. Together, these data support a model in which Tir is released into the cytoplasm by the type III translocon and then independently inserts into the plasma membrane from a cytoplasmic location. A thorough understanding of this mechanism will be crucial to understand the subtleties of enteropathogenic E. coli pathogenesis.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Banfield, MJ (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	M.J.Banfield@ncl.ac.uk	Banfield, Mark/C-7453-2013	Banfield, Mark/0000-0001-8921-3835				Abe A, 1999, MOL MICROBIOL, V33, P1162, DOI 10.1046/j.1365-2958.1999.01558.x; Barlic A, 2004, J BIOL CHEM, V279, P34209, DOI 10.1074/jbc.M313817200; Berne S, 2005, BIOCHEMISTRY-US, V44, P11137, DOI 10.1021/bi051013y; Campellone KG, 2004, J CELL BIOL, V164, P407, DOI 10.1083/jcb.200306032; Chen HD, 2005, FEMS MICROBIOL REV, V29, P83, DOI 10.1016/j.femsre.2004.07.002; Colomer-Pallas A, 2004, BBA-BIOMEMBRANES, V1660, P16, DOI 10.1016/j.bbamem.2003.10.006; Cooper MA, 2000, ANAL BIOCHEM, V277, P196, DOI 10.1006/abio.1999.4389; Daghastanli KRP, 2004, COLLOID SURFACE B, V36, P127, DOI 10.1016/j.colsurfb.2004.03.015; de Grado M, 1999, CELL MICROBIOL, V1, P7, DOI 10.1046/j.1462-5822.1999.00001.x; Dean P, 2005, CURR OPIN MICROBIOL, V8, P28, DOI 10.1016/j.mib.2004.12.010; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Hawrani A, 2003, J BIOL CHEM, V278, P25839, DOI 10.1074/jbc.M212409200; Hayward RD, 2005, MOL MICROBIOL, V56, P590, DOI 10.1111/j.1365-2958.2005.04568.x; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Jakes KS, 1998, P NATL ACAD SCI USA, V95, P4321, DOI 10.1073/pnas.95.8.4321; Kenny B, 1999, MOL MICROBIOL, V31, P1229, DOI 10.1046/j.1365-2958.1999.01265.x; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; McGhie EJ, 2002, MOL MICROBIOL, V44, P1309, DOI 10.1046/j.1365-2958.2002.02958.x; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Nougayrede JP, 2003, CELL MICROBIOL, V5, P359, DOI 10.1046/j.1462-5822.2003.00281.x; Page AL, 2002, MOL MICROBIOL, V46, P1, DOI 10.1046/j.1365-2958.2002.03138.x; Parker MW, 2005, PROG BIOPHYS MOL BIO, V88, P91, DOI 10.1016/j.pbiomolbio.2004.01.009; Ray S, 2004, MOL MEMBR BIOL, V21, P93, DOI 10.1080/09687680310001625800; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Slatin SL, 2002, P NATL ACAD SCI USA, V99, P1286, DOI 10.1073/pnas.022480199; Thomas NA, 2005, MOL MICROBIOL, V57, P1762, DOI 10.1111/j.1365-2958.2005.04802.x; Touze T, 2004, MOL MICROBIOL, V51, P73, DOI 10.1046/j.1365-2958.2003.03830.x; Vallance BA, 2000, P NATL ACAD SCI USA, V97, P8799, DOI 10.1073/pnas.97.16.8799; van der Goot FG, 2004, J BIOL CHEM, V279, P47792, DOI 10.1074/jbc.M406824200; Virtanen JA, 1998, P NATL ACAD SCI USA, V95, P4964, DOI 10.1073/pnas.95.9.4964; Yu L, 2000, NATURE, V405, P1073, DOI 10.1038/35016618	37	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7842	7849		10.1074/jbc.M513532200	http://dx.doi.org/10.1074/jbc.M513532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436373	hybrid			2022-12-25	WOS:000236031000018
J	Zhang, XX; Hu, YF; Guo, XR; Lescop, E; Li, Y; Xia, B; Jin, CW				Zhang, XX; Hu, YF; Guo, XR; Lescop, E; Li, Y; Xia, B; Jin, CW			The Bacillus subtilis YkuV is a thiol: Disulfide oxidoreductase revealed by its redox structures and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; THIOREDOXIN-LIKE-PROTEIN; COMPLETE GENOME SEQUENCE; NMR SOLUTION STRUCTURE; MODEL-FREE APPROACH; ESCHERICHIA-COLI; ROTATIONAL DIFFUSION; BACKBONE DYNAMICS; RESOLUTION; SUBSTRATE	The Bacillus subtilis YkuV responds to environmental oxidative stress and plays an important role for the bacteria to adapt to the environment. Bioinformatic analysis suggests that YkuV is a homolog of membrane-anchored proteins and belongs to the thioredoxin-like protein superfamily containing the typical Cys-Xaa-Xaa-Cys active motif. However, the biological function of this protein remains unknown thus far. In order to elucidate the biological function, we have determined the solution structures of both the oxidized and reduced forms of B. subtilis YkuV by NMR spectroscopy and performed biochemical studies. Our results demonstrated that the reduced YkuV has a low midpoint redox potential, allowing it to reduce a variety of protein substrates. The overall structures of both oxidized and reduced forms are similar, with a typical thioredoxin-like fold. However, significant conformational changes in the Cys-Xaa- Xaa-Cys active motif of the tertiary structures are observed between the two forms. In addition, the backbone dynamics provide further insights in understanding the strong redox potential of the reduced YkuV. Furthermore, we demonstrated that YkuV is able to reduce different protein substrates in vitro. Together, our results clearly established that YkuV may function as a general thiol: disulfide oxidoreductase, which acts as an alternative for thioredoxin or thioredoxin reductase to maintain the reducing environment in the cell cytoplasm.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	Lescop, Ewen/AAA-8700-2019; zhang, xinxin/E-8629-2012	Lescop, Ewen/0000-0002-2623-9365				BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Bloomfield KL, 2003, GENE, V319, P107, DOI 10.1016/S0378-1119(03)00799-6; Capitani G, 2001, J MOL BIOL, V311, P1037, DOI 10.1006/jmbi.2001.4913; CERVANTES C, 1994, FEMS MICROBIOL REV, V15, P355, DOI 10.1016/0168-6445(94)90069-8; CHAE HZ, 1995, FASEB J, V9, pA1478; Copley SD, 2004, BIOCHEMISTRY-US, V43, P13981, DOI 10.1021/bi048947r; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Crow A, 2004, J BIOL CHEM, V279, P23654, DOI 10.1074/jbc.M402823200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; Erlendsson LS, 2003, J BIOL CHEM, V278, P17852, DOI 10.1074/jbc.M300103200; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Friemann R, 2003, FEBS LETT, V554, P301, DOI 10.1016/S0014-5793(03)01173-6; Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HUTCHISON RS, 1995, METHOD ENZYMOL, V252, P220; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Messens J, 2004, J MOL BIOL, V339, P527, DOI 10.1016/j.jmb.2004.04.016; Mittard V, 1997, EUR J BIOCHEM, V243, P374, DOI 10.1111/j.1432-1033.1997.0374a.x; Moszer I, 1998, FEBS LETT, V430, P28, DOI 10.1016/S0014-5793(98)00620-6; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; Neira JL, 2001, BIOCHEMISTRY-US, V40, P15246, DOI 10.1021/bi011186x; Nicastro G, 2000, EUR J BIOCHEM, V267, P403, DOI 10.1046/j.1432-1327.2000.01015.x; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peng K, 2004, J BIOMOL NMR, V29, P459, DOI 10.1023/B:JNMR.0000032555.97201.bb; Petersohn A, 2001, J BACTERIOL, V183, P5617, DOI 10.1128/JB.183.19.5617-5631.2001; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Qi Y, 2005, PROTEINS, V58, P376, DOI 10.1002/prot.20329; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Rey MW, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r77; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Scharf C, 1998, J BACTERIOL, V180, P1869, DOI 10.1128/JB.180.7.1869-1877.1998; Schirra HJ, 1998, BIOCHEMISTRY-US, V37, P6263, DOI 10.1021/bi980136y; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X; Smits WK, 2005, J BACTERIOL, V187, P3921, DOI 10.1128/JB.187.12.3921-3930.2005; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zhang XX, 2005, J BIOMOL NMR, V32, P258, DOI 10.1007/s10858-005-7195-6	71	12	13	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8296	8304		10.1074/jbc.M512015200	http://dx.doi.org/10.1074/jbc.M512015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418167	hybrid			2022-12-25	WOS:000236031000069
J	Serrano-Heras, G; Salas, M; Bravo, A				Serrano-Heras, G; Salas, M; Bravo, A			A uracil-DNA glycosylase inhibitor encoded by a non-uracil containing viral DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE PHI-29 DNA; PYRUVATE-DEHYDROGENASE COMPLEX; COLI EXONUCLEASE-III; DOUBLE-STRANDED DNA; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEIN MIMICRY; N-GLYCOSIDASE; E2 SUBUNIT	Uracil-DNA glycosylase (UDG) is an enzyme involved in the base excision repair pathway. It specifically removes uracil from both single-stranded and double-stranded DNA. The genome of the Bacillus subtilis phage phi 29 is a linear double-stranded DNA with a terminal protein covalently linked at each 5'-end. Replication of phi 29 DNA starts by a protein-priming mechanism and generates intermediates that have long stretches of single-stranded DNA. By using in vivo chemical cross-linking and affinity chromatography techniques, we found that UDG is a cellular target for the early viral protein p56. Addition of purified protein p56 to B. subtilis extracts inhibited the endogenous UDG activity. Moreover, extracts from phi 29-infected cells were deficient in UDG activity. We suggested that inhibition of the cellular UDG is a defense mechanism developed by phi 29 to prevent the action of the base excision repair pathway if uracil residues arise in their replicative intermediates. Protein p56 is the first example of a UDG inhibitor encoded by a non-uracil-containing viral DNA.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Bravo, A (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, Inst Biol Mol Eladio Vinuela, E-28049 Madrid, Spain.	abravo@cbm.uam.es	Bravo, Alicia/Y-5060-2019; Salas, Margarita/J-9873-2014; Garcia, Pedro/L-2808-2017	Bravo, Alicia/0000-0002-4410-3584; Salas, Margarita/0000-0001-5939-3441; Garcia, Pedro/0000-0001-6717-8717; Serrano-Heras, Gemma/0000-0001-9368-4832				BARTHELEMY I, 1986, J VIROL, V60, P874, DOI 10.1128/JVI.60.3.874-879.1986; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; Bravo A, 1997, J MOL BIOL, V269, P102, DOI 10.1006/jmbi.1997.1032; Bravo A, 2000, EMBO J, V19, P5575, DOI 10.1093/emboj/19.20.5575; Bravo A, 2005, FEMS MICROBIOL REV, V29, P25, DOI 10.1016/j.femsre.2004.06.003; BRAVO A, 1990, NUCLEIC ACIDS RES, V18, P2881, DOI 10.1093/nar/18.10.2881; Chen RX, 2002, J GEN VIROL, V83, P2339, DOI 10.1099/0022-1317-83-10-2339; CONE R, 1980, J BIOL CHEM, V255, P354; Dianov GL, 2003, MUTAT RES-FUND MOL M, V531, P157, DOI 10.1016/j.mrfmmm.2003.09.003; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Gao HC, 2002, J BACTERIOL, V184, P2780, DOI 10.1128/JB.184.10.2780-2788.2002; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; INCIARTE MR, 1980, J VIROL, V34, P187, DOI 10.1128/JVI.34.1.187-199.1980; JIMENEZ F, 1977, EUR J BIOCHEM, V73, P57, DOI 10.1111/j.1432-1033.1977.tb11291.x; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Marenstein DR, 2004, DNA REPAIR, V3, P527, DOI 10.1016/j.dnarep.2004.01.010; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; MELLADO RP, 1976, EUR J BIOCHEM, V65, P213, DOI 10.1111/j.1432-1033.1976.tb10408.x; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MORENO F, 1974, VIROLOGY, V62, P1, DOI 10.1016/0042-6822(74)90298-0; Neveling U, 1998, BBA-PROTEIN STRUCT M, V1385, P367, DOI 10.1016/S0167-4838(98)00080-6; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; Parsons LM, 2005, PROTEIN SCI, V14, P1684, DOI 10.1110/ps.041275705; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Putnam CD, 1999, J MOL BIOL, V287, P331, DOI 10.1006/jmbi.1999.2605; Rojo F, 1998, PROG NUCLEIC ACID RE, V60, P29, DOI 10.1016/S0079-6603(08)60888-0; Salas M, 1999, GENET ENG P, V21, P159; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serrano-Heras G, 2003, J BIOL CHEM, V278, P40771, DOI 10.1074/jbc.M306935200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; Shida T, 1999, BIOSCI BIOTECH BIOCH, V63, P1528, DOI 10.1271/bbb.63.1528; SOGO JM, 1982, VIROLOGY, V116, P1, DOI 10.1016/0042-6822(82)90398-1; SOGO MJ, 1984, NUCLEIC ACIDS RES, V12, P1943, DOI 10.1093/nar/12.4.1943; Stein A, 2000, J BACTERIOL, V182, P2119, DOI 10.1128/JB.182.8.2119-2124.2000; STEINER M, 1993, J BACTERIOL, V175, P1038, DOI 10.1128/JB.175.4.1038-1042.1993; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; Walter T, 1999, J BIOL CHEM, V274, P7901, DOI 10.1074/jbc.274.12.7901; Wang JB, 2005, VIROLOGY, V332, P45, DOI 10.1016/j.virol.2004.10.049; WANG Z, 1989, J BIOL CHEM, V264, P1163; WARNER HR, 1980, J VIROL, V33, P535, DOI 10.1128/JVI.33.1.535-538.1980; YASBIN RE, 1980, GENE, V12, P155, DOI 10.1016/0378-1119(80)90026-8	48	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7068	7074		10.1074/jbc.M511152200	http://dx.doi.org/10.1074/jbc.M511152200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421108	Green Published, hybrid			2022-12-25	WOS:000236030900020
J	Hoffmann, A; Merz, F; Rutkowska, A; Zachmann-Brand, B; Deuerling, E; Bukau, B				Hoffmann, A; Merz, F; Rutkowska, A; Zachmann-Brand, B; Deuerling, E; Bukau, B			Trigger factor forms a protective shield for nascent polypeptides at the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEWLY SYNTHESIZED PROTEINS; ESCHERICHIA-COLI; IN-VIVO; MOLECULAR CHAPERONES; CRYSTAL-STRUCTURE; DNAK; BINDING; DOMAIN; ISOMERASE; COMPLEX	In prokaryotes, the ribosome-associated Trigger Factor is the first chaperone newly synthesized polypeptides encounter when they emerge from the ribosomal exit tunnel. The effects that Trigger Factor exerts on nascent polypeptides, however, remain unclear. Here we analyzed the potential of the Trigger Factor to shield nascent polypeptides at the ribosome. A set of arrested nascent polypeptides differing in origin, size, and folding status were synthesized in an Escherichia coli-based in vitro transcription/translation system and tested for sensitivity to degradation by the unspecific protease proteinase K. In the absence of Trigger Factor, nascent polypeptides exposed outside the ribosomal exit tunnel were rapidly degraded unless they were folded into a compact domain. The presence of Trigger Factor, as well as a Trigger Factor fragment lacking its peptidyl-prolyl isomerase domain, counteracted degradation of all unfolded nascent polypeptides tested. This protective function was specific for ribosome-tethered Trigger Factor, since neither non-ribosomal Trigger Factor nor the DnaK system, which cooperates with Trigger Factor in the folding process in vivo, revealed a comparable efficiency in protection. Furthermore, shielding by Trigger Factor was not restricted to short stretches of nascent chains but was evident for large, non-native nascent polypeptides exposing up to 41 kDa outside the ribosome. We suggest that Trigger Factor supports productive de novo folding by shielding nascent polypeptides on the ribosome thereby preventing untimely degradation or aggregation processes. This protected environment provided by Trigger Factor might be particularly important for large multidomain proteins to fold productively into their native states.	Univ Heidelberg, Zentrum Mol Biol Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Deuerling, E (corresponding author), Univ Heidelberg, Zentrum Mol Biol Heidelberg, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	e.deuerling@zmbh.uni-heidelberg.de; bukau@zmbh.uni-heidelberg.de		Bukau, Bernd/0000-0003-0521-7199				Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Baram D, 2005, FEBS LETT, V579, P948, DOI 10.1016/j.febslet.2004.11.063; Blanco FJ, 1999, J MOL BIOL, V285, P741, DOI 10.1006/jmbi.1998.2333; BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Evans MS, 2005, NAT METHODS, V2, P757, DOI 10.1038/NMETH790; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; Maier R, 2001, J MOL BIOL, V314, P1181, DOI 10.1006/jmbi.2000.5192; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; MULLER M, 1986, CURR TOP MICROBIOL, V125, P33; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	31	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6539	6545		10.1074/jbc.M512345200	http://dx.doi.org/10.1074/jbc.M512345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407311	Green Submitted, hybrid			2022-12-25	WOS:000236030800049
J	Sarg, B; Helliger, W; Talasz, H; Forg, B; Lindner, HH				Sarg, B; Helliger, W; Talasz, H; Forg, B; Lindner, HH			Histone H1 phosphorylation occurs site-specifically during interphase and mitosis - Identification of a novel phosphorylation site on histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; INTERACTION LIQUID-CHROMATOGRAPHY; TRANSFORMED MOUSE FIBROBLASTS; C-TERMINAL DOMAIN; CELL-CYCLE; CHROMATIN-STRUCTURE; IN-VIVO; H3 PHOSPHORYLATION; LINKER HISTONES; TETRAHYMENA	H1 histones, isolated from logarithmically growing and mitotically enriched human lymphoblastic T-cells (CCRF-CEM), were fractionated by reversed phase and hydrophilic interaction liquid chromatography, subjected to enzymatic digestion, and analyzed by amino acid sequencing and mass spectrometry. During interphase the four H1 subtypes present in these cells differ in their maximum phosphorylation levels: histone H1.5 is tri-, H1.4 di-, and H1.3 and H1.2, only monophosphorylated. The phosphorylation is site-specific and occurs exclusively on serine residues of SP(K/A) K motifs. The phosphorylation sites of histone H1.5 from mitotically enriched cells were also examined. In contrast to the situation in interphase, at mitosis there were additional phosphorylations, exclusively at threonine residues. Whereas the tetraphosphorylated H1.5 arises from the triphosphosphorylated form by phosphorylation of one of two TPKK motifs in the C-terminal domain, namely Thr(137) and Thr(154), the pentaphosphorylated H1.5 was the result of phosphorylation of one of the tetraphosphorylated forms at a novel nonconsensus motif at Thr(10) in the N-terminal tail. Despite the fact that histone H1.5 has five (S/T) P(K/A) K motifs, all of these motifs were never found to be phosphorylated simultaneously. Our data suggest that phosphorylation of human H1 variants occurs nonrandomly during both interphase and mitosis and that distinct serine- or threonine-specific kinases are involved in different cell cycle phases. The order of increased phosphorylation and the position of modification might be necessary for regulated chromatin decondensation, thus facilitating processes of replication and transcription as well as of mitotic chromosome condensation.	Innsbruck Med Univ, Bioctr, Div Clin Biochem, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Lindner, HH (corresponding author), Innsbruck Med Univ, Bioctr, Div Clin Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	herbert.lindner@i-med.ac.at						AJIRO K, 1985, J BIOL CHEM, V260, P5379; AJIRO K, 1983, J BIOL CHEM, V258, P4534; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Chadee DN, 2002, ONCOGENE, V21, P8397, DOI 10.1038/sj.onc.1206029; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; GURLEY LR, 1995, J BIOL CHEM, V270, P27653, DOI 10.1074/jbc.270.46.27653; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; JERZMANOWSKI A, 1992, J BIOL CHEM, V267, P8514; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LENNOX RW, 1984, HISTONE GENES, V3, P3; Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8; Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8; Lindner Herbert, 2004, Methods Mol Biol, V251, P75; Mizzen CA, 1999, J BIOL CHEM, V274, P14533, DOI 10.1074/jbc.274.21.14533; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Ota T, 2002, CANCER RES, V62, P5168; Paulson JR, 1996, J CELL SCI, V109, P1437; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Roque A, 2004, NUCLEIC ACIDS RES, V32, P6111, DOI 10.1093/nar/gkh945; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sarg B, 2004, J BIOL CHEM, V279, P53458, DOI 10.1074/jbc.M409099200; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Swank RA, 1997, BIOCHEMISTRY-US, V36, P13761, DOI 10.1021/bi9714363; Talasz H, 1996, BIOCHEMISTRY-US, V35, P1761, DOI 10.1021/bi951914e; Van Holde K.A., 1988, CHROMATIN, P69; VANHOLDE K, 1995, ELEMENTS CHROMATIN S, V9, P1; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028	42	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6573	6580		10.1074/jbc.M508957200	http://dx.doi.org/10.1074/jbc.M508957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377619	hybrid			2022-12-25	WOS:000236030800053
J	Lai, AL; Park, H; White, JM; Tamm, LK				Lai, AL; Park, H; White, JM; Tamm, LK			Fusion peptide of influenza hemagglutinin requires a fixed angle boomerang structure for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; LIPID-BILAYERS; VIRUS HEMAGGLUTININ; SECONDARY STRUCTURE; HEMIFUSION; MECHANISM; MUTANTS; SPECTROSCOPY; PROTEINS; PROGRAM	The fusion peptide of influenza hemagglutinin is crucial for cell entry of this virus. Previous studies showed that this peptide adopts a boomerang- shaped structure in lipid model membranes at the pH of membrane fusion. To examine the role of the boomerang in fusion, we changed several residues proposed to stabilize the kink in this structure and measured fusion. Among these, mutants E11A and W14A expressed hemagglutinins with hemifusion and no fusion activities, and F9A and N12A had no effect on fusion, respectively. Binding enthalpies and free energies of mutant peptides to model membranes and their ability to perturb lipid bilayer structures correlated well with the fusion activities of the parent full-length molecules. The structure of W14A determined by NMR and site- directed spin labeling features a flexible kink that points out of the membrane, in sharp contrast to the more ordered boomerang of the wild- type, which points into the membrane. A specific fixed angle boomerang structure is thus required to support membrane fusion.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Tamm, LK (corresponding author), Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	lkt2e@virginia.edu	Lai, Alex/G-8668-2014		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030557, R01AI022470] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI 30557, R01 AI 22470, R37 AI030557, R01 AI022470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; Gray C, 1996, BIOPHYS J, V70, P2275, DOI 10.1016/S0006-3495(96)79793-X; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Han X, 1999, BIOCHEMISTRY-US, V38, P15052, DOI 10.1021/bi991232h; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Han X, 2000, J MOL BIOL, V304, P953, DOI 10.1006/jmbi.2000.4251; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Lai AL, 2005, PROTEIN-LIPID INTERACTIONS: FROM MEMBRANE DOMAINS TO CELLULAR NETWORKS, P279; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Li YL, 2005, J VIROL, V79, P12065, DOI 10.1128/JVI.79.18.12065-12076.2005; Li YL, 2003, BIOCHEMISTRY-US, V42, P7245, DOI 10.1021/bi0341760; Luginbuhl P, 1996, J BIOMOL NMR, V8, P136; Qiao H, 1999, MOL BIOL CELL, V10, P2759, DOI 10.1091/mbc.10.8.2759; SCHOCH C, 1993, J BIOL CHEM, V268, P9267; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; Tamm LK, 2003, BBA-BIOMEMBRANES, V1614, P14, DOI 10.1016/S0005-2736(03)00159-7; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Zaitseva E, 2005, J CELL BIOL, V169, P167, DOI 10.1083/jcb.200412059	25	112	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5760	5770		10.1074/jbc.M512280200	http://dx.doi.org/10.1074/jbc.M512280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407195	hybrid			2022-12-25	WOS:000235568900054
J	Zoraghi, R; Corbin, JD; Francis, SH				Zoraghi, R; Corbin, JD; Francis, SH			Phosphodiesterase-5 Gln(817) is critical for cGMP, vardenafil, or sildenafil affinity - Its orientation impacts cGMP but not cAMP affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; INHIBITOR SELECTIVITY; BINDING; SPECIFICITY; MECHANISM; COMPLEX; PDE5; PROTEIN	The side group of an invariant Gln in cGMP- and cAMP-specific phosphodiesterases (PDE) is held in different orientations by bonds with other amino acids and purportedly discriminates between guanine and adenine in cGMP and cAMP. In cGMP- specific PDE5, Gln(775) constrains the orientation of the invariant Gln(817) side chain, which forms bidentate bonds with 5'-GMP, vardenafil, sildenafil, and 3-isobutyl-1-methylxanthine ( IBMX) ( Sung, B. J., Hwang, K. Y., Jeon, Y. H., Lee, J. I., Heo, Y. S., Kim, J. H., Moon, J., Yoon, J. M., Hyun, Y. L., Kim, E., Eum, S. J., Park, S. Y., Lee, J. O., Lee, T. G., Ro, S., and Cho, J. M. ( 2003) Nature 425, 98 - 102; Huai, Q., Liu, Y., Francis, S. H., Corbin, J. D., and Ke, H. ( 2004) J. Biol. Chem. 279, 13095 - 13101; Zhang, K. Y., Card, G. L., Suzuki, Y., Artis, D. R., Fong, D., Gillette, S., Hsieh, D., Neiman, J., West, B. L., Zhang, C., Milburn, M. V., Kim, S. H., Schlessinger, J., and Bollag, G. ( 2004) Mol. Cell 15, 279 - 286). PDE5(Q817A) and PDE5(Q775A) were generated to test the hypotheses that Gln(817) is critical for cyclic nucleotide or inhibitor affinity and that Gln(775) immobilizes the Gln(817) side chain to provide cGMP/cAMP selectivity. Allosteric cGMP binding and the molecular mass of the mutant proteins were unchanged compared with PDE5(WT). For PDE5(Q817A), K-m for cGMP or cAMP was weakened 60- or 2-fold, respectively. For PDE5(Q775A), K-m for cGMP was weakened similar to 20-fold but was unchanged for cAMP. For PDE5Q817A, vardenafil, sildenafil, and IBMX inhibitory potencies were weakened 610-, 48-, and 60- fold, respectively, indicating that Gln817 is a major determinant of potency, especially for vardenafil, and that binding of vardenafil and sildenafil differs substantially. Sildenafil and vardenafil affinity were not significantly affected in PDE5Q775A. It is concluded that Gln(817) is a positive determinant for PDE5 affinity for cGMP and several inhibitors; Gln(775), which perhaps restricts rotation of Gln(817) side chain, is critical for cGMP affinity but has no measurable effect on affinity for cAMP, sildenafil, or vardenafil.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Francis, SH (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Light Hall Rm 702, Nashville, TN 37232 USA.	Sharron.francis@vanderbilt.edu			NIDDK NIH HHS [DK 58277, DK 40299] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058277, R01DK040299] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PR, 1984, J MED CHEM, V27, P1648, DOI 10.1021/jm00378a021; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Blount MA, 2004, MOL PHARMACOL, V66, P144, DOI 10.1124/mol.66.1.144; Conti M, 2004, NAT STRUCT MOL BIOL, V11, P809, DOI 10.1038/nsmb0904-809; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; Francis SH, 2003, INT J IMPOT RES, V15, P369, DOI 10.1038/sj.ijir.3901040; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Huai Q, 2004, P NATL ACAD SCI USA, V101, P9624, DOI 10.1073/pnas.0401120101; Huai Q, 2004, J BIOL CHEM, V279, P13095, DOI 10.1074/jbc.M311556200; Huai Q, 2003, BIOCHEMISTRY-US, V42, P13220, DOI 10.1021/bi034653e; Huai Q, 2003, STRUCTURE, V11, P865, DOI 10.1016/S0969-2126(03)00123-0; Lee ME, 2002, FEBS LETT, V530, P53, DOI 10.1016/S0014-5793(02)03396-3; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; Scapin G, 2004, BIOCHEMISTRY-US, V43, P6091, DOI 10.1021/bi049868i; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sung BJ, 2003, NATURE, V425, P98, DOI 10.1038/nature01914; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Zhang KYJ, 2004, MOL CELL, V15, P279, DOI 10.1016/j.molcel.2004.07.005; ZORAGHI R, 2005, IN PRESS INT J IMPOT	26	41	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5553	5558		10.1074/jbc.M510372200	http://dx.doi.org/10.1074/jbc.M510372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407275	hybrid			2022-12-25	WOS:000235568900030
J	Bai, JX; Cederbaum, AI				Bai, JX; Cederbaum, AI			Overexpression of CYP2E1 in mitochondria sensitizes HepG2 cells to the toxicity caused by depletion of glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED OVEREXPRESSION; CYTOCHROME-P450 2E1; PERMEABILITY TRANSITION; CHRONIC ETHANOL; RAT-LIVER; COMPARTMENT PROTECTS; LIPID-PEROXIDATION; HEPATIC GLUTATHIONE; FISH-OIL; APOPTOSIS	Induction of CYP2E1 by ethanol is one mechanism by which ethanol causes oxidative stress and alcohol liver disease. Although CYP2E1 is predominantly found in the endoplasmic reticulum, it is also located in rat hepatic mitochondria. In the current study, chronic alcohol consumption induced rat hepatic mitochondrial CYP2E1. To study the role of mitochondrial targeted CYP2E1 in generating oxidative stress and causing damage to mitochondria, HepG2 lines overexpressing CYP2E1 in mitochondria (mE10 and mE27 cells) were established by transfecting a plasmid containing human CYP2E1 cDNA lacking the hydrophobic endoplasmic reticulum targeting signal sequence into HepG2 cells followed by G418 selection. A 40-kDa catalytically active NH2-terminally truncated form of CYP2E1 (mtCYP2E1) was detected in the mitochondrial compartment in these cells by Western blot analysis. Cell death caused by depletion of GSH by buthionine sulfoximine (BSO) was increased in mE10 and mE27 cells as compared with cells transfected with empty vector (pCI-neo). Antioxidants were able to abolish the loss of cell viability. Increased levels of reactive oxygen species and mitochondrial 3-nitrotyrosine and 4-hydroxynonenal protein adducts and decreased mitochondrial aconitase activity and mitochondrial membrane potential were observed in mE10 and mE27 cells treated with BSO. The mitochondrial membrane stabilizer, cyclosporine A, was also able to protect these cells from BSO toxicity. These results revealed that CYP2E1 in the mitochondrial compartment could induce oxidative stress in the mitochondria, damage mitochondria membrane potential, and cause a loss of cell viability. The accumulation of CYP2E1 in hepatic mitochondria induced by ethanol consumption might play an important role in alcohol liver disease.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	arthur.cederbaum@mssm.edu			NIAAA NIH HHS [AA 03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA003312] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Bai JX, 2001, J BIOL CHEM, V276, P4315, DOI 10.1074/jbc.M008895200; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Eliasson E, 1996, MOL PHARMACOL, V50, P573; Fang C, 1998, HEPATOLOGY, V27, P1304, DOI 10.1002/hep.510270516; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; Hall AG, 1999, ADV EXP MED BIOL, V457, P199; Hirokawa M, 1998, ALCOHOL CLIN EXP RES, V22, p111S, DOI 10.1111/acer.1998.22.s3_part1.111s; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Iimuro Y, 2000, HEPATOLOGY, V31, P391, DOI 10.1002/hep.510310219; INGELMANSUNDBERG M, 1993, ALCOHOL, V10, P447, DOI 10.1016/0741-8329(93)90063-T; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Lemasters JJ, 1997, BIOSCIENCE REP, V17, P281, DOI 10.1023/A:1027332611839; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Mari M, 2002, J PHARMACOL EXP THER, V301, P111, DOI 10.1124/jpet.301.1.111; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; MORTON S, 1985, BIOCHEM PHARMACOL, V34, P1559, DOI 10.1016/0006-2952(85)90699-9; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; Neve EPA, 2000, J BIOL CHEM, V275, P17130, DOI 10.1074/jbc.M000957200; Neve EPA, 2003, BIOCHEMISTRY-US, V42, P14566, DOI 10.1021/bi035193s; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; Neve EPA, 2001, J BIOL CHEM, V276, P11317, DOI 10.1074/jbc.M008640200; Oh SI, 1998, J NUTR, V128, P758, DOI 10.1093/jn/128.4.758; Pahan K, 1997, FREE RADICAL BIO MED, V23, P963, DOI 10.1016/S0891-5849(97)00017-8; Perez MJ, 2003, HEPATOLOGY, V38, P1146, DOI 10.1053/jhep.2003.50479; Raza H, 2004, DIABETES, V53, P185, DOI 10.2337/diabetes.53.1.185; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Robin MA, 2001, J BIOL CHEM, V276, P24680, DOI 10.1074/jbc.M100363200; RONIS MJJ, 1991, EUR J BIOCHEM, V198, P383, DOI 10.1111/j.1432-1033.1991.tb16026.x; SADRZADEH SMH, 1994, J PHARMACOL EXP THER, V269, P632; SPEISKY H, 1985, BIOCHEM J, V225, P565, DOI 10.1042/bj2250565; Tada-Oikawa S, 1998, BIOCHEM BIOPH RES CO, V247, P693, DOI 10.1006/bbrc.1998.8869; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Wu DF, 2001, ALCOHOL CLIN EXP RES, V25, P619, DOI 10.1097/00000374-200104000-00021; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	50	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5128	5136		10.1074/jbc.M510484200	http://dx.doi.org/10.1074/jbc.M510484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380384	hybrid			2022-12-25	WOS:000235426200067
J	Kang, HW; Park, JY; Jeong, SW; Kim, JA; Moon, HJ; Perez-Reyes, E; Lee, JH				Kang, HW; Park, JY; Jeong, SW; Kim, JA; Moon, HJ; Perez-Reyes, E; Lee, JH			A molecular determinant of nickel inhibition in Ca(v)3.2 T-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; SENSORY NEURONS; SCORPION TOXIN; AMINO-ACIDS; BLOCK; SELECTIVITY; BINDING; FAMILY; CELLS; GENE	Molecular cloning studies have revealed that heterogeneity of T-type Ca2+ currents in native tissues arises from the three isoforms of Ca(v)3 channels: Ca(v)3.1, Ca(v)3.2, and Ca(v)3.3. From pharmacological analysis of the recombinant T-type channels, low concentrations ( < 50 mu M) of nickel were found to selectively block the Ca(v)3.2 over the other isoforms. To date, however, the structural element(s) responsible for the nickel block on the Ca(v)3.2 T-type Ca2+ channel remain unknown. Thus, we constructed chimeric channels between the nickel-sensitive Ca(v)3.2 and the nickel-insensitive Ca(v)3.1 to localize the region interacting with nickel. Systematic assaying of serial chimeras suggests that the region preceding domain I S4 of Ca(v)3.2 contributes to nickel block. Point mutations of potential nickel-interacting sites revealed that H191Q in the S3-S4 loop of domain I significantly attenuated the nickel block of Ca(v)3.2, mimicking the nickel-insensitive blocking potency of Ca(v)3.1. These findings indicate that His-191 in the S3-S4 loop is a critical residue conferring nickel block to Ca(v)3.2 and reveal a novel role for the S3-S4 loop to control ion permeation through T-type Ca2+ channels.	Sogang Univ, Dept Life Sci, Mapo Gu, Seoul 121742, South Korea; Sogang Univ, Interdisciplinary Program Biotechnol, Seoul 121742, South Korea; Yonsei Univ, Coll Med, Inst Basic Med Sci, Dept Physiol, Kangwon Do, South Korea; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	Sogang University; Sogang University; Yonsei University; Yonsei University Health System; University of Virginia	Lee, JH (corresponding author), Sogang Univ, Dept Life Sci, Mapo Gu, Shinsu Dong 1, Seoul 121742, South Korea.	jhleem@sogang.ac.kr			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038691] Funding Source: NIH RePORTER; NINDS NIH HHS [NS038691] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBRACCHIO MP, 1982, BIOL TRACE ELEM RES, V4, P289, DOI 10.1007/BF02786543; Bal W, 1998, CHEM RES TOXICOL, V11, P1014, DOI 10.1021/tx980051y; Bourinet E, 2005, EMBO J, V24, P315, DOI 10.1038/sj.emboj.7600515; Brueggemann LI, 2005, AM J PHYSIOL-HEART C, V288, pH923, DOI 10.1152/ajpheart.01126.2003; Chakrabarti SK, 2001, TOXICOL APPL PHARM, V170, P153, DOI 10.1006/taap.2000.9097; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Chen HJ, 2000, PFLUG ARCH EUR J PHY, V439, P423, DOI 10.1007/s004240050959; Chen XL, 1999, AM J PHYSIOL-RENAL, V276, pF674, DOI 10.1152/ajprenal.1999.276.5.F674; Chuang RSI, 1998, NAT NEUROSCI, V1, P668, DOI 10.1038/3669; Clozel JP, 1999, P ASSOC AM PHYSICIAN, V111, P429, DOI 10.1111/paa.1999.111.5.429; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Durell SR, 2004, BIOPHYS J, V87, P2116, DOI 10.1529/biophysj.104.040618; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; GORDON SE, 1995, NEURON, V14, P177; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Jeong SW, 2003, NEUROREPORT, V14, P1537, DOI 10.1097/00001756-200308060-00028; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Lee JH, 1999, J NEUROSCI, V19, P1912; Martinez ML, 1999, J MOL CELL CARDIOL, V31, P1617, DOI 10.1006/jmcc.1999.0998; Park JY, 2003, EXP MOL MED, V35, P285, DOI 10.1038/emm.2003.39; Park JY, 2004, J BIOL CHEM, V279, P21707, DOI 10.1074/jbc.M400684200; Peng SQ, 2002, MOL PHARMACOL, V62, P1418, DOI 10.1124/mol.62.6.1418; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sillen L.G., 1971, STABILITY CONSTANTS; Talavera K, 2001, J BIOL CHEM, V276, P45628, DOI 10.1074/jbc.M103047200; Todorovic SM, 1998, J NEUROPHYSIOL, V79, P240, DOI 10.1152/jn.1998.79.1.240; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; Van Horn JD, 2003, J BIOL INORG CHEM, V8, P601, DOI 10.1007/s00775-003-0454-7; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059	33	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4823	4830		10.1074/jbc.M510197200	http://dx.doi.org/10.1074/jbc.M510197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377633	hybrid			2022-12-25	WOS:000235426200033
J	Dastur, A; Beaudenon, S; Kelley, M; Krug, RM; Huibregtse, JM				Dastur, A; Beaudenon, S; Kelley, M; Krug, RM; Huibregtse, JM			Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN PROTEIN LIGASE; FAMILY; E2; INSIGHTS; COMPLEX; TARGETS	ISG15 is an interferon (IFN)-alpha/beta-induced ubiquitin-like protein that is conjugated to cellular proteins during innate immune responses to viral and bacterial infections. A recent proteomics study identified 158 human proteins targeted for ISG15 conjugation, including the ISG15 E1 and E2 enzymes (Ube1L and UbcH8, respectively) and a HECT E3 enzyme, Herc5. Like the genes encoding Ube1L and UbcH8, expression of Herc5 was also induced by IFN-beta, suggesting that Herc5 might be a component of the ISG15 conjugation system. Consistent with this, small interfering RNAs targeting Herc5 had a dramatic effect on overall ISG15 conjugation in human cells, abrogating conjugation to the vast majority of ISG15 target proteins in vivo. In addition, co-transfection of plasmids expressing ISG15, Ube1L, UbcH8, and Herc5 resulted in robust ISG15 conjugation in non-IFN-treated cells, while the active-site cysteine mutant of Herc5 or a mutant lacking the RCC1 repeat region did not support ISG15 conjugation. These results demonstrate that Herc5 is required for conjugation of ISG15 to a broad spectrum of target proteins in human cells.	Univ Texas, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Huibregtse, JM (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	huibreg@mail.utexas.edu			NATIONAL CANCER INSTITUTE [R01CA072943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011772, R01AI011772] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA072943-11, R01 CA072943, CA72943] Funding Source: Medline; NIAID NIH HHS [AI11772] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Biron C.A., 2001, FIELDS VIROLOGY, P321; Denison C, 2005, MOL CELL PROTEOMICS, V4, P246, DOI 10.1074/mcp.M400154-MCP200; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hochrainer K, 2005, GENOMICS, V85, P153, DOI 10.1016/j.ygeno.2004.10.006; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Liu MJ, 2003, J BIOL CHEM, V278, P1594, DOI 10.1074/jbc.M208123200; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V266, P115, DOI 10.1006/bbrc.1999.1777; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Nyman TA, 2000, EUR J BIOCHEM, V267, P4011, DOI 10.1046/j.1432-1327.2000.01433.x; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Salvat C, 2004, J BIOL CHEM, V279, P18935, DOI 10.1074/jbc.M312201200; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Xu LX, 2003, EXP CELL RES, V288, P84, DOI 10.1016/S0014-4827(03)00187-3; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102	24	192	200	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4334	4338		10.1074/jbc.M512830200	http://dx.doi.org/10.1074/jbc.M512830200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16407192	hybrid			2022-12-25	WOS:000235275300068
J	Garbuzova-Davis, S; Gografe, SJ; Sanberg, CD; Willing, AE; Saporta, S; Cameron, DF; Desjarlais, T; Daily, J; Kuzmin-Nichols, N; Chamizo, W; Klasko, SK; Sanberg, PR				Garbuzova-Davis, S; Gografe, SJ; Sanberg, CD; Willing, AE; Saporta, S; Cameron, DF; Desjarlais, T; Daily, J; Kuzmin-Nichols, N; Chamizo, W; Klasko, SK; Sanberg, PR			Maternal transplantation of human umbilical cord blood cells provides prenatal therapy in Sanfilippo type B mouse model	FASEB JOURNAL			English	Article						transmigration; Naglu enzyme; CD34 and CD117 antigens	BONE-MARROW; FETAL CELLS; DIAGNOSIS; DISEASE; TROPHOBLAST; IMMUNOLOGY; PLACENTA; MURINE; FETUS	Numerous data support passage of maternal cells into the fetus during pregnancy in both human and animal models. However, functional benefits of maternal microchimerism in utero are unknown. The current study attempted to take advantage of this route for prenatal delivery of alpha-N-acetylglucosaminidase (Naglu) enzyme into the enzyme-deficient mouse model of Sanfilippo syndrome type B (MPS III B). Enzymatically sufficient mononuclear cells from human umbilical cord blood (MNC hUCB) were intravenously administered into heterozygote females modeling MPS III B on the 5th day of pregnancy during blastocyst implantation. The major findings were 1) administered MNC hUCB cells transmigrated and diffused into the embryos (E12.5); 2) some transmigrated cells expressed CD34 and CD117 antigens; 3) transmigrated cells were found in both the maternal and embryonic parts of placentas; 4) transmigrated cells corrected Naglu enzyme activity in all embryos; 5) administered MNC hUCB cells were extensively distributed in the organs and the blood of heterozygote mothers at one week after transplantation. Results indicate that prenatal delivery of Naglu enzyme by MNC hUCB cell administration into mothers of enzyme-deficient embryos is possible and may present a significant opportunity for new biotechnologies to treat many inherited disorders.	Univ S Florida, Dept Neurosurg, Coll Med, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; Univ S Florida, Dept Physiol & Biophys, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Anat, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Dept Pathol, Coll Med, Tampa, FL 33612 USA; Univ S Florida, Div Comparat Med, Coll Med, Tampa, FL 33612 USA; Univ Technol Ctr II, Saneron CCEL Therapeut Inc, Tampa, FL USA; All Childrens Hosp, St Petersburg, Russia	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Garbuzova-Davis, S (corresponding author), Univ S Florida, Dept Neurosurg, Coll Med, Ctr Excellence Aging & Brain Repair, 12901 Bruce B Downs Blvd MDC 78, Tampa, FL 33612 USA.	sgarbuzo@hsc.usf.edu	Garbuzova-Davis, Svitlana/Q-3687-2019; Willing, Alison/AAP-7759-2021; Willing, Alison/I-4946-2012					Adamson SL, 2002, DEV BIOL, V250, P358, DOI 10.1006/dbio.2002.0773; Ando T, 2003, J CLIN ENDOCR METAB, V88, P2965, DOI 10.1210/jc.2002-021903; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BROXMEYER HE, 1989, P NATL ACAD SCI USA, V86, P3828, DOI 10.1073/pnas.86.10.3828; BULMER JN, 1988, PLACENTA, V9, P237, DOI 10.1016/0143-4004(88)90031-8; BURTON GJ, 1987, SCANNING MICROSCOPY, V1, P1811; CEUTERICK C, 1980, NEUROPADIATRIE, V11, P176, DOI 10.1055/s-2008-1071387; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; Garbuzova-Davis S, 2005, STEM CELLS DEV, V14, P384, DOI 10.1089/scd.2005.14.384; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Georgiades P, 2002, PLACENTA, V23, P3, DOI 10.1053/plac.2001.0738; Gluckman E, 2005, SEMIN HEMATOL, V42, P85, DOI 10.1053/j.seminhematol.2005.01.006; Gografe SI, 2003, COMPARATIVE MED, V53, P622; HALL JM, 1995, BLOOD, V86, P2829; HE W, 1994, PRENATAL DIAG, V14, P17, DOI 10.1002/pd.1970140104; Hoogerbrugge P M, 1991, Bone Marrow Transplant, V7 Suppl 2, P71; Hopwood JJ, 2005, PRENATAL DIAG, V25, P148, DOI 10.1002/pd.1094; Johnson KL, 2001, ARTHRITIS RHEUM-US, V44, P1848, DOI 10.1002/1529-0131(200108)44:8<1848::AID-ART323>3.0.CO;2-L; JONES CJP, 1990, PLACENTA, V11, P395, DOI 10.1016/S0143-4004(05)80215-2; Kaufman M. H., 2001, ATLAS MOUSE DEV; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Khosrotehrani K, 2004, JAMA-J AM MED ASSOC, V292, P75, DOI 10.1001/jama.292.1.75; Kleijer WJ, 1996, PRENATAL DIAG, V16, P829, DOI 10.1002/(SICI)1097-0223(199609)16:9<829::AID-PD953>3.0.CO;2-H; Li HH, 1999, P NATL ACAD SCI USA, V96, P14505, DOI 10.1073/pnas.96.25.14505; Lo YMD, 1996, BLOOD, V88, P4390; Lo YMD, 1998, BRIT J HAEMATOL, V100, P605; Marleau AM, 2003, LAB INVEST, V83, P673, DOI 10.1097/01.LAB.0000067500.85003.32; MARSH J, 1985, CLIN GENET, V27, P258; Mellor AL, 2000, ANNU REV IMMUNOL, V18, P367, DOI 10.1146/annurev.immunol.18.1.367; Mikami Tetsuya, 2002, Medical Electron Microscopy, V35, P96, DOI 10.1007/s007950200012; MUNTENER M, 1977, ACTA ANAT, V98, P241; Nayar B, 2002, INT J GYNECOL OBSTET, V79, P31, DOI 10.1016/S0020-7292(02)00187-X; NEUFELD EF, 1995, METABOLIC MOL BASES, V2, P2465; NOWAKOWSKI RW, 1989, PEDIATR RES, V26, P462, DOI 10.1203/00006450-198911000-00020; OBRIEN JS, 1972, P NATL ACAD SCI USA, V69, P1720, DOI 10.1073/pnas.69.7.1720; Peters C, 1998, BLOOD, V91, P2601, DOI 10.1182/blood.V91.7.2601.2601_2601_2608; Petit T, 1997, BRIT J HAEMATOL, V98, P767, DOI 10.1046/j.1365-2141.1997.2603076.x; PIJNENBORG R, 1981, PLACENTA, V2, P71, DOI 10.1016/S0143-4004(81)80042-2; SHAPIRO EG, 1995, J INHERIT METAB DIS, V18, P413, DOI 10.1007/BF00710053; SIMPSON JL, 1993, JAMA-J AM MED ASSOC, V270, P2357, DOI 10.1001/jama.270.19.2357; Staba SL, 2004, NEW ENGL J MED, V350, P1960, DOI 10.1056/NEJMoa032613; Thomson BG, 2000, BLOOD, V96, P2703; Todaro AM, 2000, BLOOD PURIFICAT, V18, P144, DOI 10.1159/000014438; Trundley A, 2004, TISSUE ANTIGENS, V63, P1, DOI 10.1111/j.1399-0039.2004.00170.x; van Nieuwenhoven ALV, 2003, HUM REPROD UPDATE, V9, P347, DOI 10.1093/humupd/dmg026; Wan WH, 2002, IMMUNOLOGY, V107, P261, DOI 10.1046/j.1365-2567.2002.01499.x; Ward JM, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P103; Weber B, 1996, HUM MOL GENET, V5, P771, DOI 10.1093/hmg/5.6.771; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056; Zhao HG, 1996, P NATL ACAD SCI USA, V93, P6101, DOI 10.1073/pnas.93.12.6101; ZILLIACUS R, 1975, SCAND J HAEMATOL, V15, P333	51	15	17	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					485	+		10.1096/fj.05-4684fje	http://dx.doi.org/10.1096/fj.05-4684fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16401642				2022-12-25	WOS:000235996000031
J	Gonzalez-Herrera, IG; Prado-Lourenco, L; Pileur, F; Conte, C; Morin, A; Cabon, F; Prats, H; Vagner, S; Bayard, F; Audigier, S; Prats, AC				Gonzalez-Herrera, IG; Prado-Lourenco, L; Pileur, F; Conte, C; Morin, A; Cabon, F; Prats, H; Vagner, S; Bayard, F; Audigier, S; Prats, AC			Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism	FASEB JOURNAL			English	Article						translation control; transgenic mouse; growth factor; hormone; spermatogenesis	FIBROBLAST-GROWTH-FACTOR; RIBOSOME ENTRY SITE; FIBROBLAST-GROWTH-FACTOR-2 MESSENGER-RNA; HEPARAN-SULFATE PROTEOGLYCANS; CELL-CELL INTERACTIONS; ALTERNATIVE TRANSLATION; SERTOLI-CELLS; TRANSGENIC MICE; 3'-UNTRANSLATED REGION; GENE-EXPRESSION	Spermatogenesis is a complex process involving cell proliferation, differentiation, and apoptosis. Fibroblast growth factor 2 (FGF-2) is involved in testicular function, but its role in spermatogenesis has not been fully documented. The control of FGF-2 expression particularly occurs at the translational level, by an internal ribosome entry site (IRES)-dependent mechanism driving the use of alternative initiation codons. To study IRES activity regulation in vivo, we have developed transgenic mice expressing a bicistronic construct coding for two luciferase genes. Here, we show that the FGF-2 IRES is age-dependently activated in mouse testis, whereas EMCV and c-myc IRESs are not. Real-time PCR confirms that this regulation is translational. By using immunohistological techniques, we demonstrate that FGF-2 IRES stimulation occurs in adult, but not in immature, type-A spermatogonias. This is correlated with activation of endogenous FGF-2 expression in spermatogonia; whereas FGF-2 mRNA transcription is known to decrease in adult testis. Interestingly, the FGF-2 IRES activation is triggered by testosterone and is partially inhibited by siRNA directed against the androgen receptor. Two-dimensional analysis of proteins bound to the FGF-2 mRNA 5'UTR after UV cross-linking reveals that testosterone treatment correlates with the binding of several proteins. These data suggest a paracrine loop where IRES- dependent FGF-2 expression, stimulated by Sertoli cells in response to testosterone produced by Leydig cells, would in turn activate Leydig function and testosterone production. In addition, nuclear FGF-2 isoforms could be involved in an intracrine function of FGF-2 in the start of spermatogenesis, mitosis, or meiosis initiation. This report demonstrates that mRNA translation regulation by an IRES- dependent mechanism participates in a physiological process.	Hop Rangueil, Inst Louis Bugnard, INSERM U589, IFR31, F-31432 Toulouse 4, France; Univ Toulouse 3, F-31062 Toulouse, France; MilleGen, Prologue Biotech, Labege, France; Lab Oncogenese Differenciat & Transduct Signal, Villejuif, France; Ctr Hosp Univ Rangueil, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Prats, AC (corresponding author), Hop Rangueil, Inst Louis Bugnard, INSERM U589, IFR31, Bat L3,Ave Jean Poulhes,BP 84225, F-31432 Toulouse 4, France.	pratsac@toulouse.inserm.fr	Vagner, Stephan/G-3664-2013; Cabon, Florence/B-3284-2013; Prats, Anne-Catherine/E-5051-2016	Cabon, Florence/0000-0002-6149-082X; Prats, Anne-Catherine/0000-0002-5282-3776; vagner, stephan/0000-0003-1452-7164; Prats, Herve/0000-0002-4861-2167				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnal S, 2005, J BIOL CHEM, V280, P4144, DOI 10.1074/jbc.M411492200; Bonnal S, 2003, J BIOL CHEM, V278, P39330, DOI 10.1074/jbc.M305580200; Brucato S, 2002, EUR J BIOCHEM, V269, P502, DOI 10.1046/j.0014-2956.2001.02672.x; Chang CS, 2004, P NATL ACAD SCI USA, V101, P6876, DOI 10.1073/pnas.0307306101; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Grootegoed JA, 2000, BEST PRACT RES CL EN, V14, P331, DOI 10.1053/beem.2000.0083; HALL SH, 1991, ENDOCRINOLOGY, V129, P1243, DOI 10.1210/endo-129-3-1243; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; Hofmann MC, 2005, STEM CELLS, V23, P200, DOI 10.1634/stemcells.2003-0036; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; KOIKE S, 1994, GROWTH REGULAT, V4, P77; LAHR G, 1992, FEBS LETT, V302, P43, DOI 10.1016/0014-5793(92)80280-T; Laslett AL, 1997, J STEROID BIOCHEM, V60, P171, DOI 10.1016/S0960-0760(96)00180-X; LASLETT AL, 1995, J STEROID BIOCHEM, V54, P245, DOI 10.1016/0960-0760(95)00138-P; Loir M, 1999, MOL REPROD DEV, V53, P434, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;434::AID-MRD9&gt;3.0.CO;2-L; Mainwaring WIP, 1979, BIOCHEM SOC T, V7, P556, DOI 10.1042/bst0070556; MAYERHOFER A, 1991, ENDOCRINOLOGY, V129, P921, DOI 10.1210/endo-129-2-921; McLachlan RI, 2000, BEST PRACT RES CL EN, V14, P345, DOI 10.1053/beem.2000.0084; Miura P, 2005, J BIOL CHEM, V280, P32997, DOI 10.1074/jbc.M503994200; Monesi V., 1978, Current Topics in Developmental Biology, V12, P11, DOI 10.1016/S0070-2153(08)60592-X; MULLANEY BP, 1991, BAILLIERE CLIN ENDOC, V5, P771, DOI 10.1016/S0950-351X(10)80014-X; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Pyronnet S, 2001, GENE DEV, V15, P2083, DOI 10.1101/gad.889201; Qin XL, 2004, J BIOL CHEM, V279, P13721, DOI 10.1074/jbc.M312854200; Roser JF, 2001, ANIM REPROD SCI, V68, P139, DOI 10.1016/S0378-4320(01)00151-8; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SORDOILLET C, 1992, MOL CELL ENDOCRINOL, V89, P163, DOI 10.1016/0303-7207(92)90222-R; Steger K, 1998, HISTOCHEM CELL BIOL, V110, P57, DOI 10.1007/s004180050265; STEINBERGER A, 1979, IN VITRO CELL DEV B, V15, P23; SUZUKI K, 1991, P SOC EXP BIOL MED, V198, P728; Suzuki M, 1996, GENES CELLS, V1, P1077, DOI 10.1046/j.1365-2443.1996.d01-228.x; Teshima-Kondo S, 2004, FASEB J, V18, P1583, DOI 10.1096/fj.03-1118fje; Touriol C, 1999, J BIOL CHEM, V274, P21402, DOI 10.1074/jbc.274.30.21402; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; UETANI N, 1994, CELL BIOL INT, V18, P85, DOI 10.1006/cbir.1994.1046; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Van den Berghe L, 2000, MOL ENDOCRINOL, V14, P1709, DOI 10.1210/me.14.11.1709; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; vanDisselEmiliani FMF, 1996, ENDOCRINOLOGY, V137, P647, DOI 10.1210/en.137.2.647; Wagener A, 2000, ANIM REPROD SCI, V64, P65, DOI 10.1016/S0378-4320(00)00191-3	53	37	40	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					476	+		10.1096/fj.04-3314fje	http://dx.doi.org/10.1096/fj.04-3314fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423876	Green Submitted			2022-12-25	WOS:000235996000008
J	De Jaco, A; Comoletti, D; Kovarik, Z; Gaietta, G; Radic, Z; Lockridge, O; Ellisman, MH; Taylor, P				De Jaco, A; Comoletti, D; Kovarik, Z; Gaietta, G; Radic, Z; Lockridge, O; Ellisman, MH; Taylor, P			A mutation linked with autism reveals a common mechanism of endoplasmic reticulum retention for the alpha,beta-hydrolase fold protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN ACETYLCHOLINESTERASE; HUMAN BUTYRYLCHOLINESTERASE; MASS-SPECTROMETRY; DISULFIDE BONDS; C-TERMINUS; BCHE GENE; NEUROLIGINS; TORPEDO; CHOLINESTERASE; EXPRESSION	A mutation linked to autistic spectrum disorders encodes an Arg to Cys replacement in the C-terminal portion of the extracellular domain of neuroligin-3. The solvent-exposed Cys causes virtually complete retention of the protein in the endoplasmic reticulum when the protein is expressed in transfected cells. An identical Cys substitution was reported for butyrylcholinesterase through genotyping patients with post-succinylcholine apnea. Neuroligin, butyrylcholinesterase, and acetylcholinesterase are members of the alpha,beta-hydrolase fold family of proteins sharing sequence similarity and common tertiary structures. Although these proteins have distinct oligomeric assemblies and cellular dispositions, homologous Arg residues in neuroligin-3 (Arg-451), in butyrylcholinesterase (Arg-386), and in acetylcholinesterase (Arg-395) are conserved in all studied mammalian species. To examine whether an homologous Arg to Cys mutation affects related proteins similarly despite their differing capacities to oligomerize, we inserted homologous mutations in the acetylcholinesterase and butyrylcholinesterase cDNAs. Using confocal fluorescence microscopy and analysis of oligosaccharide processing, we find that the homologous Arg to Cys mutation also results in endoplasmic reticulum retention of the two cholinesterases. Small quantities of mutated acetylcholinesterase exported from the cell retain activity but show a greater K-m, a much smaller k(cat), and altered substrate inhibition. The nascent proteins associate with chaperones during processing, but the mutation presumably restricts processing through the endoplasmic reticulum and Golgi apparatus, because of local protein misfolding and inability to oligomerize. The mutation may alter the capacity of these proteins to dissociate from their chaperone prior to oligomerization and processing for export.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; Univ Nebraska, Med Ctr, Eppley Inst, Omaha, NE 68198 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Nebraska System; University of Nebraska Medical Center	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	pwtaylor@ucsd.edu		DE JACO, Antonella/0000-0002-9394-0207	NIEHS NIH HHS [P42-ES 10337] Funding Source: Medline; NIGMS NIH HHS [R37-GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blong RM, 1997, BIOCHEM J, V327, P747, DOI 10.1042/bj3270747; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Chan AOK, 2005, CLIN CHIM ACTA, V351, P155, DOI 10.1016/j.cccn.2004.09.004; Chih B, 2004, HUM MOL GENET, V13, P1471, DOI 10.1093/hmg/ddh158; Chubykin AA, 2005, J BIOL CHEM, V280, P22365, DOI 10.1074/jbc.M410723200; Comoletti D, 2003, J BIOL CHEM, V278, P50497, DOI 10.1074/jbc.M306803200; Comoletti D, 2004, J NEUROSCI, V24, P4889, DOI 10.1523/JNEUROSCI.0468-04.2004; CYGLER M, 1993, PROTEIN SCI, V2, P366; Darvesh S, 2003, NAT REV NEUROSCI, V4, P131, DOI 10.1038/nrn1035; Dean C, 2003, NAT NEUROSCI, V6, P708, DOI 10.1038/nn1074; DOLGINOVA EA, 1992, BIOCHEMISTRY-US, V31, P12248, DOI 10.1021/bi00163a039; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FUTERMAN AH, 1985, BIOCHEM J, V226, P369, DOI 10.1042/bj2260369; Giacobini E., 2003, BUTYRYLCHOLINESTERAS, V1st; Graf ER, 2004, CELL, V119, P1013, DOI 10.1016/j.cell.2004.11.035; Haas R, 1996, BIOCHEM J, V314, P817, DOI 10.1042/bj3140817; Hoffman RC, 2004, BIOCHEMISTRY-US, V43, P1496, DOI 10.1021/bi035278t; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Jennings LL, 2003, BIOCHEMISTRY-US, V42, P11083, DOI 10.1021/bi034756x; KEREM A, 1993, J BIOL CHEM, V268, P180; LI Y, 1991, J BIOL CHEM, V266, P23083; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; Marchot P, 1996, PROTEIN SCI, V5, P672; Massoulie J, 1998, J PHYSIOLOGY-PARIS, V92, P183, DOI 10.1016/S0928-4257(98)80007-7; MASSOULIE J, 2000, CHOLINESTERASES CHOL, P81; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; Nicolet Y, 2003, J BIOL CHEM, V278, P41141, DOI 10.1074/jbc.M210241200; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Scholl FG, 2003, TRENDS NEUROSCI, V26, P618, DOI 10.1016/j.tins.2003.09.004; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; Shi JX, 2001, J BIOL CHEM, V276, P42196, DOI 10.1074/jbc.M106896200; Silman I, 2005, CURR OPIN PHARMACOL, V5, P293, DOI 10.1016/j.coph.2005.01.014; SILMAN I, 1987, EUR J BIOCHEM, V170, P11, DOI 10.1111/j.1432-1033.1987.tb13662.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Souza RLR, 2005, MOL GENET METAB, V84, P349, DOI 10.1016/j.ymgme.2004.12.005; TAYLOR P, 2000, CHOLINESTERASES CHOL, P63; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsigelny I, 2000, PROTEIN SCI, V9, P180; Varoqueaux F, 2004, EUR J CELL BIOL, V83, P449, DOI 10.1078/0171-9335-00410; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Yan J, 2005, MOL PSYCHIATR, V10, P329, DOI 10.1038/sj.mp.4001629; Yen T, 2003, CLIN CHEM, V49, P1297, DOI 10.1373/49.8.1297	53	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9667	9676		10.1074/jbc.M510262200	http://dx.doi.org/10.1074/jbc.M510262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16434405	hybrid			2022-12-25	WOS:000236404700079
J	Leivonen, SK; Ala-aho, R; Koli, K; Grenman, R; Peltonen, J; Kahari, VM				Leivonen, SK; Ala-aho, R; Koli, K; Grenman, R; Peltonen, J; Kahari, VM			Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells	ONCOGENE			English	Article						TGF-beta; Smad; matrix metalloproteinase; collagenase; squamous cell carcinoma	GROWTH-FACTOR-BETA; HUMAN GINGIVAL FIBROBLASTS; TGF-BETA; IN-VITRO; MATRIX METALLOPROTEINASE-13; MEDIATED TRANSCRIPTION; SUPPRESSES METASTASIS; HUMAN KERATINOCYTES; GENE-EXPRESSION; KINASE PATHWAY	Squamous cell carcinoma ( SCC) cells of the head and neck specifically express collagenase-3 ( matrix metalloproteinase-13 ( MMP-13)), the expression of which correlates with their invasion capacity. Transforming growth factor-beta ( TGF-beta) enhances MMP-13 and collagenase-1( MMP-1) expression and invasion of SCC cells via p38 mitogen-activated protein kinase. Here, we have examined the role of Smad signaling in regulating MMP-13 expression and in invasion of head and neck SCC cells. Treatment with TGF-beta resulted in activation of Smad2 and Smad3 in SCC cells, but had no effect on their proliferation or viability. Basal activation of Smad3 and p38 was noted in SCC cells without exogenous TGF-beta stimulation, and adenoviral delivery of Smad7 and dominant-negative Smad3 inhibited p38 activation in these cells. Adenoviral overexpression of Smad3 augmented the upregulatory effect of TGF-beta on MMP-13 expression by SCC cells. Disruption of Smad signaling by adenoviral expression of kinase-defective TGF-b type I receptor ( activin-receptor-like kinase-5),Smad7, and dominant-negative Smad3 potently suppressed the basal and TGF-beta-induced expression of MMP-13 and MMP-1 in SCC cells, and inhibited their basal and TGF-beta-induced invasion through Matrigel and type I collagen. Adenoviral overexpression of Smad7 in cutaneous and oral SCC cells significantly inhibited their implantation in skin of SCID mice and growth of xenografts in vivo, as compared to LacZ adenovirus-transduced control cells. Together, these results show that Smad signaling plays an important role in promoting the invasive phenotype of human head and neck SCC cells by upregulating their collagenase expression.	Univ Turku, Dept Dermatol, Dept Med Biochem & Mol Biol, FI-20521 Turku, Finland; Univ Turku, MediCity Res Lab, FI-20521 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FI-20521 Turku, Finland; Univ Helsinki, Dept Virol, Helsinki, Finland; Univ Helsinki, Dept Pathol, Haartman Inst, Helsinki, Finland; Univ Helsinki, Helsinki Univ Hosp, Helsinki, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland	University of Turku; University of Turku; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Turku; University of Oulu	Kahari, VM (corresponding author), Univ Turku, Dept Dermatol, Dept Med Biochem & Mol Biol, POB 52, FI-20521 Turku, Finland.	veli-matti.kahari@utu.fi	Leivonen, Suvi-Katri/AAK-3096-2021; Peltonen, Juha/O-7159-2019; Kahari, Veli-Matti/E-5144-2011	Peltonen, Juha/0000-0002-5732-4167; Kahari, Veli-Matti/0000-0003-2421-9368; Leivonen, Suvi-Katri/0000-0003-3224-0757				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-aho R, 2004, ONCOGENE, V23, P5111, DOI 10.1038/sj.onc.1207678; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hu PPC, 1998, ENDOCR REV, V19, P349, DOI 10.1210/er.19.3.349; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LANSDORF CD, 1999, HUMAN CELL CULTURE, V2; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Li AG, 2004, CANCER RES, V64, P7836, DOI 10.1158/0008-5472.CAN-04-1331; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodeck U, 1999, CANCER RES, V59, P547; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian F, 2003, CANCER RES, V63, P8284; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Ungefroren H, 2003, J BIOL CHEM, V278, P11041, DOI 10.1074/jbc.M300035200; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	61	77	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2588	2600		10.1038/sj.onc.1209291	http://dx.doi.org/10.1038/sj.onc.1209291			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16407850				2022-12-25	WOS:000237099400003
J	Lavieu, G; Scarlatti, F; Sala, G; Carpentier, S; Levade, T; Ghidoni, R; Botti, J; Codogno, P				Lavieu, G; Scarlatti, F; Sala, G; Carpentier, S; Levade, T; Ghidoni, R; Botti, J; Codogno, P			Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATING ENZYME; ISOLATED RAT HEPATOCYTES; TUMOR-SUPPRESSOR; DAP KINASE; SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID METABOLISM; PHOSPHATIDIC-ACID; UP-REGULATION; DEATH; APOPTOSIS	The sphingolipid ceramide induces macroautophagy ( here called autophagy) and cell death with autophagic features in cancer cells. Here we show that overexpression of sphingosine kinase 1 ( SK1), an enzyme responsible for the production of sphingosine 1- phosphate ( S1P), in MCF- 7 cells stimulates autophagy by increasing the formation of LC3- positive autophagosomes and the rate of proteolysis sensitive to the autophagy inhibitor 3- methyladenine. Autophagy was blocked in the presence of dimethylsphingosine, an inhibitor of SK activity, and in cells expressing a catalytically inactive form of SK1. In SK1(wt)- overexpressing cells, however, autophagy was not sensitive to fumonisin B1, an inhibitor of ceramide synthase. In contrast to ceramide- induced autophagy, SK1( S1P)- induced autophagy is characterized by ( i) the inhibition of mammalian target of rapamycin signaling independently of the Akt/ protein kinase B signaling arm and ( ii) the lack of robust accumulation of the autophagy protein Beclin 1. In addition, nutrient starvation induced both the stimulation of autophagy and SK activity. Knocking down the expression of the autophagy protein Atg7 or that of SK1 by siRNA abolished starvation- induced autophagy and increased cell death with apoptotic hallmarks. In conclusion, these results show that SK1( S1P)- induced autophagy protects cells from death with apoptotic features during nutrient starvation.	Inst Andre Lwoff, INSERM, U504, F-94807 Villejuif, France; Univ Paris Sud, Fac Pharm, INSERM, U756, F-92296 Chatenay Malabry, France; San Paolo Med Sch, Biochem & Mol Biol Lab, I-20142 Milan, Italy; CHU Rangueil, Inst Louis Bugnard, INSERM, U466, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Codogno, P (corresponding author), Fac Pharm Chatenay Malabry, INSERM, U756, F-92296 Chatenay Malabry, France.	codogno@vjf.inserm.fr	Codogno, Patrice/G-1384-2013; Levade, Thierry/O-8948-2014	Codogno, Patrice/0000-0002-5492-3180; GHIDONI, RICCARDO/0000-0002-6300-5867; lavieu, gregory/0000-0001-9852-4977				Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445; AMES BN, 1960, J BIOL CHEM, V235, P769; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gijsbers S, 2001, BBA-MOL CELL BIOL L, V1532, P37, DOI 10.1016/S1388-1981(01)00111-1; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Golstein P, 2005, CELL DEATH DIFFER, V12, P1490, DOI 10.1038/sj.cdd.4401607; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lanterman MM, 1998, BIOCHEM J, V332, P525, DOI 10.1042/bj3320525; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Levade T, 2002, NEUROCHEM RES, V27, P601, DOI 10.1023/A:1020215815013; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liang XH, 2001, CANCER RES, V61, P3443; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Martinet W, 2002, ARTERIOSCL THROM VAS, V22, P2023, DOI 10.1161/01.ATV.0000041843.44312.12; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2004, METHOD ENZYMOL, V390, P17; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reiss U, 2004, J BIOL CHEM, V279, P1281, DOI 10.1074/jbc.M309646200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shohat G, 2002, EUR CYTOKINE NETW, V13, P398; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Tiesong SS, 2005, J BIOL CHEM, V280, P34644, DOI 10.1074/jbc.M506466200; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Vessey DA, 2005, ANAL BIOCHEM, V337, P136, DOI 10.1016/j.ab.2004.10.032; Yamamoto M, 2002, EUR J BIOCHEM, V269, P139, DOI 10.1046/j.0014-2956.2002.00029.x; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	79	211	217	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8518	8527		10.1074/jbc.M506182200	http://dx.doi.org/10.1074/jbc.M506182200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16415355	hybrid			2022-12-25	WOS:000236247100027
J	Bisbis, B; Delmas, F; Joubes, J; Sicard, A; Hernould, M; Inze, D; Mouras, A; Chevalier, C				Bisbis, B; Delmas, F; Joubes, J; Sicard, A; Hernould, M; Inze, D; Mouras, A; Chevalier, C			Cyclin-dependent kinase (CDK) inhibitors regulate the CDK-cyclin complex activities in endoreduplicating cells of developing tomato fruit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA-RELATED PROTEIN; MOLECULAR CHARACTERIZATION; REDUCES ENDOREDUPLICATION; IN-VIVO; ARABIDOPSIS; SIZE; MAIZE; ICK1; DIFFERENTIATION; EXPRESSION	The jelly-like locular ( gel) tissue of tomato fruit is made up of large thin-walled and highly vacuolized cells. The development of the gel tissue is characterized by the arrest of mitotic activities, the inhibition of cyclin-dependent kinase A ( CDKA) activity, and numerous rounds of nuclear DNA endoreduplication. To decipher the molecular determinants controlling these developmental events, we investigated the putative involvement of CDK inhibitors (p27(Kip)-related proteins, or KRPs) during the endoreduplication process. Two cDNAs, LeKRP1 and LeKRP2, encoding tomato CDK inhibitors were isolated. The LeKRP1 and LeKRP2 transcript expression was shown to be enhanced in the differentiating cells of the gel undergoing endoreduplication. At the translational level, LeKRP1 was shown to accumulate in the gel tissue and to participate in the inhibition of the CDK-cyclin kinase activities occurring in endoreduplicating cells of the gel tissue. We here propose that LeKRP1 participates in the control of both the cell cycle and the endoreduplication cycle.	Univ Bordeaux 1, Inst Natl Rech Agron, Inst Biol Vegetale Mol, Unite Mixte Rech Physiol & Biotechnol Vegetales 6, F-33883 Villenave Dornon, France; Univ Bordeaux 2, F-33883 Villenave Dornon, France; State Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium	INRAE; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Flanders Institute for Biotechnology (VIB); Ghent University	Chevalier, C (corresponding author), Univ Bordeaux 1, Inst Natl Rech Agron, Inst Biol Vegetale Mol, Unite Mixte Rech Physiol & Biotechnol Vegetales 6, F-33883 Villenave Dornon, France.	chevalie@bordeaux.inra.fr	Sicard, Adrien/E-6246-2013; Hernould, Michel/AAD-5355-2019; Inzé, Dirk/AAW-6381-2021; Chevalier, Christian/AAL-4578-2020; Delmas, Frederic/C-3685-2011	Inzé, Dirk/0000-0002-3217-8407; Joubes, Jerome/0000-0001-5385-450X; Delmas, Frederic/0000-0002-2599-6778; Sicard, Adrien/0000-0002-4104-6844; Hernould, Michel/0000-0003-0676-6173				AZZI L, 1992, EUR J BIOCHEM, V203, P353, DOI 10.1111/j.1432-1033.1992.tb16557.x; Boniotti MB, 2001, PLANT J, V28, P341, DOI 10.1046/j.1365-313X.2001.01160.x; Boudolf V, 2004, PLANT CELL, V16, P2683, DOI 10.1105/tpc.104.024398; Cebolla A, 1999, EMBO J, V18, P4476, DOI 10.1093/emboj/18.16.4476; De Veylder L, 2002, EMBO J, V21, P1360, DOI 10.1093/emboj/21.6.1360; De Veylder L, 2001, PLANT CELL, V13, P1653, DOI 10.2307/3871392; Dewitte W, 2003, ANNU REV PLANT BIOL, V54, P235, DOI 10.1146/annurev.arplant.54.031902.134836; GILLASPY G, 1993, PLANT CELL, V5, P1439, DOI 10.1105/tpc.5.10.1439; Gonzalez N, 2004, PLANT MOL BIOL, V56, P849, DOI 10.1007/s11103-004-5110-2; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; Grafi G, 1998, EXP CELL RES, V244, P372, DOI 10.1006/excr.1998.4213; Gutierrez C, 2002, CURR OPIN PLANT BIOL, V5, P480, DOI 10.1016/S1369-5266(02)00301-1; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Healy JMS, 2001, J BIOL CHEM, V276, P7041, DOI 10.1074/jbc.M009074200; Himanen K, 2002, PLANT CELL, V14, P2339, DOI 10.1105/tpc.004960; Jasinski S, 2002, PLANT PHYSIOL, V130, P1871, DOI 10.1104/pp.008573; Jasinski S, 2002, J CELL SCI, V115, P973; Joubes J, 2000, PLANT MOL BIOL, V43, P735, DOI 10.1023/A:1006446417196; Joubes J, 2000, PLANTA, V211, P430, DOI 10.1007/s004250000306; Joubes J, 2001, PLANT PHYSIOL, V126, P1403, DOI 10.1104/pp.126.4.1403; Joubes J, 1999, PLANT PHYSIOL, V121, P857, DOI 10.1104/pp.121.3.857; Kondorosi E, 2000, CURR OPIN PLANT BIOL, V3, P488, DOI 10.1016/S1369-5266(00)00118-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leiva-Neto JT, 2004, PLANT CELL, V16, P1854, DOI 10.1105/tpc.022178; Lui H, 2000, PLANT J, V21, P379, DOI 10.1046/j.1365-313x.2000.00688.x; MAGYAR Z, 1993, PLANT J, V4, P151, DOI 10.1046/j.1365-313X.1993.04010151.x; Martin-Castellanos C, 1996, Prog Cell Cycle Res, V2, P29; Meijer M, 2000, PLANT MOL BIOL, V43, P621, DOI 10.1023/A:1006482115915; MELARAGNO JE, 1993, PLANT CELL, V5, P1661, DOI 10.1105/tpc.5.11.1661; Menges M, 2002, PLANT J, V30, P203, DOI 10.1046/j.1365-313X.2002.01274.x; Nakagami H, 1999, PLANT J, V18, P243, DOI 10.1046/j.1365-313X.1999.00449.x; Nakagami H, 2002, PLANT CELL, V14, P1847, DOI 10.1105/tpc.002550; Park JA, 2005, PLANT J, V42, P153, DOI 10.1111/j.1365-313X.2005.02361.x; Schnittger A, 2003, PLANT CELL, V15, P303, DOI 10.1105/tpc.008342; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P4180, DOI 10.1073/pnas.96.7.4180; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; Verkest A, 2005, PLANT CELL, V17, P1723, DOI 10.1105/tpc.105.032383; Vilhar B, 2002, PLANT PHYSIOL, V129, P23, DOI 10.1104/pp.001826; Vinardell JM, 2003, PLANT CELL, V15, P2093, DOI 10.1105/tpc.014373; Wang H, 1998, PLANT J, V15, P501, DOI 10.1046/j.1365-313X.1998.00231.x; Wang H, 1997, NATURE, V386, P451, DOI 10.1038/386451a0; Weinl C, 2005, PLANT CELL, V17, P1704, DOI 10.1105/tpc.104.030486; Zhou YM, 2003, PLANT J, V35, P476, DOI 10.1046/j.1365-313X.2003.01821.x; Zhou YM, 2003, PLANTA, V216, P604, DOI 10.1007/s00425-002-0935-x	45	52	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7374	7383		10.1074/jbc.M506587200	http://dx.doi.org/10.1074/jbc.M506587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407228	hybrid, Green Published			2022-12-25	WOS:000236030900057
J	Calkins, CC; Setzer, SV; Jennings, JM; Summers, S; Tsunoda, K; Amagai, M; Kowalczyk, AP				Calkins, CC; Setzer, SV; Jennings, JM; Summers, S; Tsunoda, K; Amagai, M; Kowalczyk, AP			Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; CELL-ADHESION; VULGARIS-IGG; ADHERENS JUNCTIONS; DISEASE; ANTIGEN; DSG3; KERATINOCYTES; PLAKOGLOBIN; ANTIBODIES	Desmosomes are adhesive intercellular junctions prominent in the skin and heart. Loss of desmosome function is associated with severe congenital and acquired disorders characterized by tissue fragility. Pemphigus vulgaris (PV) is an autoimmune disorder in which antibodies are directed against the desmosomal adhesion molecule Dsg3, resulting in severe mucosal erosions and epidermal blistering. To define the mechanisms by which Dsg3 autoantibodies disrupt keratinocyte adhesion, the fate of PV IgG and various desmosomal components was monitored in primary human keratinocytes exposed to PV patient IgG. PV IgG initially bound to keratinocyte cell surfaces and colocalized with desmosomal markers. Within 6 h after PV IgG binding to Dsg3, electron microscopy revealed that desmosomes were dramatically disrupted and keratinocyte adhesion was severely compromised. Immunofluorescence analysis indicated that PV IgG and Dsg3 were rapidly internalized from the cell surface in a complex with plakoglobin but not desmoplakin. Dsg3 internalization was associated with retraction of keratin filaments from cell-cell borders. Furthermore, the internalized PV IgG-Dsg3 complex colocalized with markers for both endosomes and lysosomes, suggesting that Dsg3 was targeted for degradation. Consistent with this possibility, biotinylation experiments demonstrated that soluble Dsg3 cell surface pools were rapidly depleted followed by loss of detergent-insoluble Dsg3. These findings demonstrate that Dsg3 endocytosis, keratin filament retraction, and the loss of keratinocyte cell-cell adhesion are coordinated responses to PV IgG.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, Tokyo 1608582, Japan	Emory University; Emory University; Keio University	Kowalczyk, AP (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	akowalc@emory.edu	tsunoda, kazuyuki/GLR-8745-2022; Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052	NIAMS NIH HHS [R21 AR 050779, T32 AR 007587, R01 AR 048266] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050779, T32AR007587, R01AR048266] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1995, J INVEST DERMATOL, V105, P243, DOI 10.1111/1523-1747.ep12317587; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Angst BD, 2001, J CELL SCI, V114, P629; Anhalt GJ, 2004, J AM ACAD DERMATOL, V51, pS20, DOI 10.1016/j.jaad.2004.01.011; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Cheng X, 2004, J DERMATOL, V31, P171, DOI 10.1111/j.1346-8138.2004.tb00654.x; Chidgey M, 2002, HISTOL HISTOPATHOL, V17, P1179, DOI 10.14670/HH-17.1179; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Gloushankova NA, 2003, CELL TISSUE RES, V314, P399, DOI 10.1007/s00441-003-0812-3; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; IWATSUKI K, 1989, J AM ACAD DERMATOL, V20, P578, DOI 10.1016/S0190-9622(89)70066-9; Iwatsuki K, 1999, BRIT J DERMATOL, V140, P35; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kitajima Y, 2002, CLIN EXP DERMATOL, V27, P684, DOI 10.1046/j.1365-2230.2002.01116.x; Koch AW, 2004, CELL MOL LIFE SCI, V61, P1884, DOI 10.1007/s00018-004-4006-2; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KOWALCZYK AP, 1995, J INVEST DERMATOL, V105, P147, DOI 10.1111/1523-1747.ep12316680; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MILNER Y, 1989, J CELL PHYSIOL, V139, P441, DOI 10.1002/jcp.1041390229; Muller E, 2000, J INVEST DERMATOL, V115, P332, DOI 10.1046/j.1523-1747.2000.00abs-2.x; Nguyen VT, 2004, J BIOL CHEM, V279, P2135, DOI 10.1074/jbc.M309000200; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Palka HL, 1997, J CELL SCI, V110, P2359; PATEL HP, 1984, J INVEST DERMATOL, V83, P409, DOI 10.1111/1523-1747.ep12273480; Payne AS, 2004, CURR OPIN CELL BIOL, V16, P536, DOI 10.1016/j.ceb.2004.07.006; Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Sato M, 2000, LAB INVEST, V80, P1583, DOI 10.1038/labinvest.3780168; Shimizu A, 2004, J INVEST DERMATOL, V122, P1145, DOI 10.1111/j.0022-202X.2004.22426.x; Stanley JR, 2001, J INVEST DERMATOL, V116, P489, DOI 10.1046/j.1523-1747.2001.01307.x; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; Vincent PA, 2004, AM J PHYSIOL-CELL PH, V286, pC987, DOI 10.1152/ajpcell.00522.2003; Waschke J, 2005, J CLIN INVEST, V115, P3157, DOI 10.1172/JCI23475; Windoffer R, 2002, J CELL SCI, V115, P1717; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yin TF, 2004, SEMIN CELL DEV BIOL, V15, P665, DOI 10.1016/j.semcdb.2004.09.005	48	169	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7623	7634		10.1074/jbc.M512447200	http://dx.doi.org/10.1074/jbc.M512447200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16377623	hybrid			2022-12-25	WOS:000236030900084
J	Khersonsky, O; Tawfik, DS				Khersonsky, O; Tawfik, DS			The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PON1; RESIDUES; MUTAGENESIS; STABILITY; EVOLUTION	Serum paraoxonases (PONs) are calcium-dependent lactonases that catalyze the hydrolysis and formation of a variety of lactones, with a clear preference for lipophilic lactones. However, the lactonase mechanism of mammalian PON1, a high density lipoprotein-associated enzyme that is the most studied family member, remains unclear, and other family members have not been examined at all. We present a kinetic and site-directed mutagenesis study aimed at deciphering the lactonase mechanism of PON1 and PON3. The pH-rate profile determined for the lactonase activity of PON1 indicated an apparent pK(a) of similar to 7.4. We thus explored the role of all amino acids in the PON1 active site that are not directly ligated to the catalytic calcium and that possess an imidazolyl or carboxyl side chain (His(115), His(134), His(184), His(285), Asp(183), and Asp(269)). Extensive site-directed mutagenesis studies in which each amino acid candidate was replaced with all other 19 amino acids were conducted to identify the residue(s) that mediate the lactonase activity of PONs. The results indicate that the lactonase activity of PON1 and PON3 and the esterase activity of PON1 are mediated by the His(115)-His(134) dyad. Notably, the phosphotriesterase activity of PON1, which is a promiscuous activity of this enzyme, is mediated by other residues. To our knowledge, this is one of few examples of a histidine dyad in enzyme active sites and the first example of a hydrolytic enzyme with such a dyad.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tawfik, DS (corresponding author), Weizmann Inst Sci, Dept Biol Chem, Ullman Bldg, IL-76100 Rehovot, Israel.	tawfik@weizmann.ac.il						Adams TB, 1998, FOOD CHEM TOXICOL, V36, P249, DOI 10.1016/S0278-6915(97)00163-4; Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; Copeland R. A., 2004, ENZYMES PRACTICAL IN; Draganov DI, 2005, J LIPID RES, V46, P1239, DOI 10.1194/jlr.M400511-JLR200; Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1; Edwards SH, 2002, BIOCHEMISTRY-US, V41, P15468, DOI 10.1021/bi020485z; FERSHT A, 1999, STRUCTURE MECH PROTE, P423; Gaidukov L, 2005, BIOCHEMISTRY-US, V44, P11843, DOI 10.1021/bi050862i; Gutteridge A, 2005, TRENDS BIOCHEM SCI, V30, P622, DOI 10.1016/j.tibs.2005.09.006; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P1253, DOI 10.1038/nsmb1204-1253a; Hartleib J, 2001, BBA-PROTEIN STRUCT M, V1546, P312, DOI 10.1016/S0167-4838(01)00153-4; Josse D, 1999, BIOCHEMISTRY-US, V38, P2816, DOI 10.1021/bi982281h; JOSSE D, 2001, J APPL TOXICOL S1, V21, P7, DOI DOI 10.1002/JAT.789; Khersonsky O, 2006, CHEMBIOCHEM, V7, P49, DOI 10.1002/cbic.200500334; Khersonsky O, 2005, BIOCHEMISTRY-US, V44, P6371, DOI 10.1021/bi047440d; Kuo CL, 1998, DRUG METAB DISPOS, V26, P653; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P379, DOI 10.1016/S0009-2797(99)00049-6; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; Peracchi A, 2001, TRENDS BIOCHEM SCI, V26, P497, DOI 10.1016/S0968-0004(01)01911-9; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; Rosenblat M, 2006, J BIOL CHEM, V281, P7657, DOI 10.1074/jbc.M512595200; Scharff EI, 2001, STRUCTURE, V9, P493, DOI 10.1016/S0969-2126(01)00610-4; Sekar K, 1997, BIOCHEMISTRY-US, V36, P3104, DOI 10.1021/bi961576x; Teiber JF, 2003, BIOCHEM PHARMACOL, V66, P887, DOI 10.1016/S0006-2952(03)00401-5; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; Yeung DT, 2005, FEBS J, V272, P2225, DOI 10.1111/j.1742-4658.2005.04646.x; Yeung DT, 2004, BBA-PROTEINS PROTEOM, V1702, P67, DOI 10.1016/j.bbapap.2004.08.002	31	137	141	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7649	7656		10.1074/jbc.M512594200	http://dx.doi.org/10.1074/jbc.M512594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407305	hybrid			2022-12-25	WOS:000236030900086
J	Mendiratta, G; Eriksson, PR; Shen, CH; Clark, DJ				Mendiratta, G; Eriksson, PR; Shen, CH; Clark, DJ			The DNA-binding domain of the yeast Spt10p activator includes a zinc finger that is homologous to foamy virus integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ACTIVATION; CHROMATIN-STRUCTURE; SPT21 GENES; PROTEIN; ACETYLATION; MUTATIONS; IDENTIFICATION; RECOGNITION; HISTONE-H3	The yeast SPT10 gene encodes a putative histone acetyltransferase that binds specifically to pairs of upstream activating sequence (UAS) elements found only in the histone gene promoters. Here, we demonstrate that the DNA-binding domain of Spt10p is located between residues 283 and 396 and includes a His(2)-Cys(2) zinc finger. The binding of Spt10p to the histone UAS is zinc-dependent and is disabled by a zinc finger mutation (C388S). The isolated DNA-binding domain binds to single histone UAS elements with high affinity. In contrast, full-length Spt10p binds with high affinity only to pairs of UAS elements with very strong positive cooperativity and is unable to bind to a single UAS element. This implies the presence of a "blocking" domain in full-length Spt10p, which forces it to search for a pair of UAS elements. Chromatin immunoprecipitation experiments indicate that, unlike wild-type Spt10p, the C388S protein does not bind to the promoter of the gene encoding histone H2A (HTA1) in vivo. The C388S mutant has a phenotype similar to that of the spt10 Delta mutant: poor growth and global aberrations in gene expression. Thus, the C388S mutation disables the DNA-binding function of Spt10p in vitro and in vivo. The zinc finger of Spt10p is homologous to that of foamy virus integrase, perhaps suggesting that this integrase is also a sequence-specific DNA-binding protein.	NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; CUNY Coll Staten Isl, Dept Biol, Staten Isl, NY 10314 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); City University of New York (CUNY) System; College of Staten Island (CUNY)	Clark, DJ (corresponding author), NICHD, Lab Mol Growth Regulat, NIH, Bldg 6A,Rm 2A14,6 Ctr Dr, Bethesda, MD 20892 USA.	clarkda@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM067730] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIGMS NIH HHS [1R15 GM 67730-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; COOK WJ, 1994, J BIOL CHEM, V269, P9374; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Delelis O, 2004, CURR OPIN MICROBIOL, V7, P400, DOI 10.1016/j.mib.2004.06.009; Dimova D, 1999, MOL CELL, V4, P75, DOI 10.1016/S1097-2765(00)80189-6; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; Eriksson PR, 2005, MOL CELL BIOL, V25, P9127, DOI 10.1128/MCB.25.20.9127-9137.2005; FASSLER JS, 1988, GENETICS, V118, P203; FREEMAN KB, 1992, MOL CELL BIOL, V12, P5455, DOI 10.1128/MCB.12.12.5455; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Green A, 1998, BIOCHEM J, V333, P85, DOI 10.1042/bj3330085; HAZUDA DJ, 1994, J BIOL CHEM, V269, P3999; Hess D, 2004, MOL CELL BIOL, V24, P135, DOI 10.1128/MCB.24.1.135-143.2004; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; NATSOULIS G, 1991, NEW BIOL, V3, P1249; NATSOULIS G, 1994, GENETICS, V136, P93; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; Ozdemir A, 2005, J BIOL CHEM, V280, P25949, DOI 10.1074/jbc.C500181200; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Shen CH, 2002, MOL CELL BIOL, V22, P6406, DOI 10.1128/MCB.22.18.6406-6416.2002; SHERWOOD PW, 1991, GENETICS, V128, P729; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Trobridge G, 2004, J VIROL, V78, P2327, DOI 10.1128/JVI.78.5.2327-2335.2004; VANHOLDE KF, 1988, SPRINGER SERIES MOL, P118; Winston F, 1998, COLD SPRING HARB SYM, V63, P553, DOI 10.1101/sqb.1998.63.553; Xu F, 2005, CELL, V121, P375, DOI 10.1016/j.cell.2005.03.011; Yamaguchi Y, 2001, J BIOCHEM, V129, P185, DOI 10.1093/oxfordjournals.jbchem.a002842; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	30	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7040	7048		10.1074/jbc.M511416200	http://dx.doi.org/10.1074/jbc.M511416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415340	hybrid			2022-12-25	WOS:000236030900017
J	Nilsson, EC; Long, YC; Martinsson, S; Glund, S; Garcia-Roves, P; Svensson, LT; Andersson, L; Zierath, JR; Mahlapuu, M				Nilsson, EC; Long, YC; Martinsson, S; Glund, S; Garcia-Roves, P; Svensson, LT; Andersson, L; Zierath, JR; Mahlapuu, M			Opposite transcriptional regulation in skeletal muscle of AMP-activated protein kinase gamma 3 R225Q transgenic versus knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; PROTEIN-KINASE; NITRIC-OXIDE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; ENZYME-ACTIVITIES; LIPID-METABOLISM; CARRIER PIGS; BETA; STIMULATION	AMP-activated protein kinase (AMPK) is an evolutionarily conserved heterotrimer important for metabolic sensing in all eukaryotes. The muscle-specific isoform of the regulatory gamma-subunit of the kinase, AMPK gamma 3, has an important role in glucose uptake, glycogen synthesis, and fat oxidation in white skeletal muscle, as previously demonstrated by physiological characterization of AMPK gamma 3 mutant (R225Q) transgenic (TgPrkag3(225Q)) and gamma 3 knock-out (Prkag3(-/-)) mice. We determined AMPK gamma 3-dependent regulation of gene expression by analyzing global transcription profiles in glycolytic skeletal muscle from gamma 3 mutant transgenic and knock-out mice using oligonucleotide microarray technology. Evidence is provided for coordinated and reciprocal regulation of multiple key components in glucose and fat metabolism, as well as skeletal muscle ergogenics in TgPrkag3(225Q) and Prkag3(-/-) mice. The differential gene expression profile was consistent with the physiological differences between the models, providing a molecular mechanism for the observed phenotype. The striking pattern of opposing transcriptional changes between TgPrkag3(225Q) and Prkag3(-/-) mice identifies differentially expressed targets being truly regulated by AMPK and is consistent with the view that R225Q is an activating mutation, in terms of its downstream effects. Additionally, we identified a wide array of novel targets and regulatory pathways for AMPK in skeletal muscle.	Arexis AB, Biotech Ctr, SE-41346 Gothenburg, Sweden; Karolinska Inst, Dept Mol Med & Surg, SE-17177 Stockholm, Sweden; Uppsala Univ, Dept Med Biochem & Microbiol, SE-75124 Uppsala, Sweden	Karolinska Institutet; Uppsala University	Mahlapuu, M (corresponding author), Arexis AB, Biotech Ctr, Arvid Wallgrens Backe 20, SE-41346 Gothenburg, Sweden.	margit.mahlapuu@arexis.com	Roves, Pablo Garcia/A-7113-2015; Garcia-Roves, Pablo M./X-4585-2018	Svensson, Thomas/0000-0002-9190-2979; Zierath, Juleen/0000-0001-6891-7497; Mahlapuu, Margit/0000-0001-8740-8874; Garcia-Roves, Pablo M./0000-0002-8371-2067				*APPL BIOS, 1997, US B APPL BIOS; Arad M, 2002, J CLIN INVEST, V109, P357, DOI 10.1172/JCI200214571; Barnes BR, 2005, DIABETES, V54, P3484, DOI 10.2337/diabetes.54.12.3484; Barnes BR, 2005, FASEB J, V19, P773, DOI 10.1096/fj.04-3221com; Barnes BR, 2004, J BIOL CHEM, V279, P38441, DOI 10.1074/jbc.M405533200; BENNETT C, 1995, AM J MED GENET, V60, P1, DOI 10.1002/ajmg.1320600102; BLANCO CE, 1988, HISTOCHEM J, V20, P230, DOI 10.1007/BF01747468; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Bonen A, 1999, AM J PHYSIOL-ENDOC M, V276, pE642, DOI 10.1152/ajpendo.1999.276.4.E642; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Brutsaert TD, 2003, AM J CLIN NUTR, V77, P441, DOI 10.1093/ajcn/77.2.441; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Ciobanu D, 2001, GENETICS, V159, P1151; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; ESTRADE M, 1994, COMP BIOCHEM PHYS B, V108, P295, DOI 10.1016/0305-0491(94)90080-9; ESTRADE M, 1993, COMP BIOCHEM PHYS B, V104, P321, DOI 10.1016/0305-0491(93)90375-F; Fryer LGD, 2000, DIABETES, V49, P1978, DOI 10.2337/diabetes.49.12.1978; Gollob MH, 2003, BIOCHEM SOC T, V31, P228, DOI 10.1042/bst0310228; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hedegaard J, 2004, PROTEOMICS, V4, P2448, DOI 10.1002/pmic.200300761; Hirschfield W, 2000, AM J PHYSIOL-REG I, V278, pR95, DOI 10.1152/ajpregu.2000.278.1.R95; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lanone S, 2001, CRIT CARE MED, V29, P1720, DOI 10.1097/00003246-200109000-00011; Lebret B, 1999, J ANIM SCI, V77, P1482; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; Long YC, 2005, DIABETOLOGIA, V48, P2354, DOI 10.1007/s00125-005-1962-5; Mahlapuu M, 2004, AM J PHYSIOL-ENDOC M, V286, pE194, DOI 10.1152/ajpendo.00147.2003; Marechal G, 1999, CELL MOL LIFE SCI, V55, P1088, DOI 10.1007/s000180050359; MCLANE JA, 1981, AM J PHYSIOL, V241, pC47, DOI 10.1152/ajpcell.1981.241.1.C47; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Reid MB, 1998, ACTA PHYSIOL SCAND, V162, P401, DOI 10.1046/j.1365-201X.1998.0303f.x; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Skurat AV, 1996, ARCH BIOCHEM BIOPHYS, V328, P283, DOI 10.1006/abbi.1996.0174; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Taha C, 1997, AM J PHYSIOL-ENDOC M, V273, pE68, DOI 10.1152/ajpendo.1997.273.1.E68; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Wojtaszewski JFP, 2002, DIABETES, V51, P284, DOI 10.2337/diabetes.51.2.284; Wojtaszewski JFP, 2003, AM J PHYSIOL-ENDOC M, V284, pE813, DOI 10.1152/ajpendo.00436.2002; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	57	43	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7244	7252		10.1074/jbc.M510461200	http://dx.doi.org/10.1074/jbc.M510461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410251	hybrid, Green Published			2022-12-25	WOS:000236030900042
J	Sha, Q; Redman, CM; Lee, S				Sha, Q; Redman, CM; Lee, S			Endothelin-3-converting enzyme activity of the KEL1 and KEL6 phenotypes of the Kell blood group system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND METALLOPROTEASE; MOLECULAR-CLONING; PROTEIN; IDENTIFICATION; ANTIGEN	The Kell blood group protein is a metalloendopeptidase that preferentially cleaves a Trp(21)-Ile(22) bond of big endothelin-3 producing bioactive endothelin-3. Kell is a polymorphic protein, and 25 different phenotypes, because of point mutations resulting in single amino acid substitutions, have been described. It was recently reported that a recombinant form of KEL1 ( K, K1) phenotype, expressed in K562 and HEK293 cells, had no endothelin-3-converting activity, in contrast to the common KEL2 (k, K2) phenotype. We demonstrate that KEL1 red blood cells and also a soluble recombinant form of KEL1 protein (s-Kell KEL1) have similar enzymatic activity as the common Kell phenotype. In addition we show that KEL6 red blood cells, which are more prevalent in persons of African heritage than in Caucasians also have endothelin-3-converting enzyme activity and that the recombinant soluble form of KEL6 protein (s-Kell KEL6) has similar Km values as the wild-type.	New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	New York Blood Center	Lee, S (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, 310 E 67th St, New York, NY 10021 USA.	solee@nybloodcenter.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075716, P50HL054459] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 075716, HL 54459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Carbonnet F, 1997, BRIT J HAEMATOL, V96, P857, DOI 10.1046/j.1365-2141.1997.d01-2110.x; Claperon A, 2005, J BIOL CHEM, V280, P21272, DOI 10.1074/jbc.M500100200; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; Lee S, 1997, VOX SANG, V73, P1, DOI 10.1046/j.1423-0410.1997.7310001.x; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; Lee S, 2003, BLOOD, V102, P3028, DOI 10.1182/blood-2003-05-1564; Lee S, 2001, J BIOL CHEM, V276, P27281, DOI 10.1074/jbc.M103433200; LEE S, 1995, TRANSFUSION, V35, P822, DOI 10.1046/j.1537-2995.1995.351096026362.x; Lee S, 2000, TRANSFUS MED REV, V14, P93, DOI 10.1016/S0887-7963(00)80001-2; LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912; Russo D, 1998, J BIOL CHEM, V273, P13950, DOI 10.1074/jbc.273.22.13950; SHIPP MA, 1988, P NATL ACAD SCI USA, V85, P4819, DOI 10.1073/pnas.85.13.4819; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; Turner AJ, 2000, ADV EXP MED BIOL, V477, P229; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	21	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7180	7182		10.1074/jbc.M507776200	http://dx.doi.org/10.1074/jbc.M507776200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423827	hybrid			2022-12-25	WOS:000236030900033
J	Balestrieri, B; Hsu, VW; Gilbert, H; Leslie, CC; Han, WK; Bonventre, JV; Arm, JP				Balestrieri, B; Hsu, VW; Gilbert, H; Leslie, CC; Han, WK; Bonventre, JV; Arm, JP			Group V secretory phospholipase A(2) translocates to the phagosome after zymosan stimulation of mouse peritoneal macrophages and regulates phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; TARGETED GENE DISRUPTION; LEUKOTRIENE C-4 SYNTHASE; ARACHIDONIC-ACID RELEASE; LOW-MOLECULAR-WEIGHT; VASCULAR-PERMEABILITY; PROSTAGLANDIN PRODUCTION; RECOMBINANT EXPRESSION; KLEBSIELLA-PNEUMONIAE; P388D(1) MACROPHAGES	We have previously reported that group V secretory phospholipase A(2) (sPLA(2)) amplifies the action of cytosolic phospholipase A2 (cPLA(2)) alpha in regulating eicosanoid biosynthesis by mouse peritoneal macrophages stimulated with zymosan (Satake, Y., Diaz, B. L., Balestrieri, B., Lam, B. K., Kanaoka, Y., Grusby, M. J., and Arm, J. P. ( 2004) J. Biol. Chem. 279, 16488 - 16494). To further understand the role of group V sPLA2, we studied its localization in resting mouse peritoneal macrophages before and after stimulation with zymosan and the effect of deletion of the gene encoding group V sPLA2 on phagocytosis of zymosan. We report that group V sPLA2 is present in the Golgi apparatus and recycling endosome in the juxtanuclear region of resting peritoneal macrophages. Upon ingestion of zymosan by mouse peritoneal macrophages, group V sPLA(2) is recruited to the phagosome. There it co-localizes with cPLA(2) alpha, 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C-4 synthase. Using immunostaining for the cysteinyl leukotrienes in carbodiimide-fixed cells, we show, for the first time, that the phagosome is a site of cysteinyl leukotriene formation. Furthermore, peritoneal macrophages from group V sPLA(2)-null mice demonstrated a> 50% attenuation in phagocytosis of zymosan particles, which was restored by adenoviral expression of group V sPLA(2) but not group IIA sPLA(2). These data demonstrate that group V sPLA(2) contributes to the innate immune response both through regulation of eicosanoid generation in response to a phagocytic stimulus and also as a component of the phagocytic machinery.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Partners Asthma Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Jewish Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Arm, JP (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Res Bldg,Rm 638B,1 Jimmy Fund Way, Boston, MA 02115 USA.	jarm@rics.bwh.harvard.edu	Balestrieri, Barbara/Y-2547-2018	Balestrieri, Barbara/0000-0002-0323-3278	NHLBI NIH HHS [R01 HL061378, P01 HL034303, R01 HL068864, HL070946, HL36110, HL34303] Funding Source: Medline; NIAID NIH HHS [AI07306] Funding Source: Medline; NIDDK NIH HHS [R01 DK039773, DK38452, P01 DK038452, DK74099, DK39773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110, R01HL070946, R01HL061378, R01HL068864, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452, R37DK039773, R21DK074099, R01DK039773, R33DK074099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aderem A, 2002, CELL, V110, P5, DOI 10.1016/S0092-8674(02)00819-X; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Bailie MB, 1996, J IMMUNOL, V157, P5221; Balboa MA, 2003, J BIOL CHEM, V278, P48059, DOI 10.1074/jbc.M305904200; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1999, J BIOL CHEM, V274, P25967, DOI 10.1074/jbc.274.37.25967; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200; Bao SZ, 2004, J BIOL CHEM, V279, P38194, DOI 10.1074/jbc.M406489200; Bingham CO, 1999, J BIOL CHEM, V274, P31476, DOI 10.1074/jbc.274.44.31476; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DeLeo FR, 1999, J IMMUNOL, V163, P6732; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598; Lam BK, 1996, EUR J BIOCHEM, V238, P606, DOI 10.1111/j.1432-1033.1996.0606w.x; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Mancuso P, 1998, INFECT IMMUN, V66, P5140, DOI 10.1128/IAI.66.11.5140-5146.1998; Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001; Mancuso P, 2000, AM J RESP CELL MOL, V23, P727, DOI 10.1165/ajrcmb.23.6.4246; Massoumi R, 2002, J CELL SCI, V115, P3509; MOUNIER CM, 2004, J BIOL CHEM, P19200; Munoz NM, 2003, J BIOL CHEM, V278, P38813, DOI 10.1074/jbc.M302476200; OMANN GM, 1995, J IMMUNOL, V155, P5375; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4279, DOI 10.1073/pnas.77.7.4279; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Rubin BB, 2005, J BIOL CHEM, V280, P7519, DOI 10.1074/jbc.M407438200; Saegusa S, 2001, EUR J PHARMACOL, V413, P163, DOI 10.1016/S0014-2999(01)00773-7; Satake Y, 2004, J BIOL CHEM, V279, P16488, DOI 10.1074/jbc.M313748200; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Soberman RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Touret N, 2005, CELL, V123, P157, DOI 10.1016/j.cell.2005.08.018; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	60	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6691	6698		10.1074/jbc.M508314200	http://dx.doi.org/10.1074/jbc.M508314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407308	Green Accepted, hybrid			2022-12-25	WOS:000236030800066
J	Kim, MW; Kim, EJ; Kim, JY; Park, JS; Oh, DB; Shimma, Y; Chiba, Y; Jigami, Y; Rhee, SK; Kang, HA				Kim, MW; Kim, EJ; Kim, JY; Park, JS; Oh, DB; Shimma, Y; Chiba, Y; Jigami, Y; Rhee, SK; Kang, HA			Functional characterization of the Hansenula polymorpha HOC1, OCH1, and OCR1 genes as members of the yeast OCH1 mannosyltransferase family involved in protein glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER CHAIN ELONGATION; N-LINKED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; ALPHA-1,6-MANNOSYLTRANSFERASE; ENCODES; MNN1; SECRETION; MUTANTS; CLONING; MANNAN	The alpha-1,6-mannosyltransferaseencoded by Saccharomyces cerevisiae OCH1 (ScOCH1) is responsible for the outer chain initiation of N-linked oligosaccharides. To identify the genes involved in the first step of outer chain biosynthesis in the methylotrophic yeast Hansenula polymorpha, we undertook the functional analysis of three H. polymorpha genes, HpHOC1, HpOCH1, and HpOCR1, that belong to the OCH1 family containing seven members with significant sequence identities to ScOCH1. The deletions of these H. polymorpha genes individually resulted in several phenotypes suggestive of cell wall defects. Whereas the deletion of HpHOC1 (Hphoc1 Delta) did not generate any detectable changes in N-glycosylation, the null mutant strains of HpOCH1 (Hpoch1 Delta) and HpOCR1 (Hpocr1 Delta) displayed a remarkable reduction in hypermannosylation. Although the apparent phenotypes of Hpocr1 Delta were most similar to those of S. cerevisiae och1 mutants, the detailed structural analysis of N-glycans revealed that the major defect of Hpocr1 Delta is not in the initiation step but rather in the subsequent step of outer chain elongation by alpha-1,2-mannose addition. Most interestingly, Hpocr1 Delta showed a severe defect in the O-linked glycosylation of extracellular chitinase, representing HpOCR1 as a novel member of the OCH1 family implicated in both N- and O-linked glycosylation. In contrast, addition of the first alpha-1,6-mannose residue onto the core oligosaccharide Man(8)GlcNAc(2) was completely blocked in Hpoch1 Delta despite the comparable growth of its wild type under normal growth conditions. The complementation of the S. cerevisiae och1 null mutation by the expression of HpOCH1 and the lack of in vitro alpha-1,6-mannosyltransferase activity in Hpoch1 Delta provided supportive evidence that HpOCH1 is the functional orthologue of ScOCH1. The engineered Hpoch1 Delta strain with the targeted expression of Aspergillus saitoi alpha-1,2-mannosidase in the endoplasmic reticulum was shown to produce human-compatible high mannose-type Man(5)GlcNAc(2) oligosaccharide as a major N-glycan.	Korea Res Inst Biosci & Biotechnol, Metab Engn Lab, Taejon 305600, South Korea; Chungnam Natl Univ, Dept Microbiol, Taejon 305764, South Korea; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; National Institute of Advanced Industrial Science & Technology (AIST)	Kang, HA (corresponding author), Korea Res Inst Biosci & Biotechnol, Metab Engn Lab, Oun Dong 52, Taejon 305600, South Korea.	hyunkang@kribb.re.kr	Chiba, Yasunori/L-7993-2018	Chiba, Yasunori/0000-0002-6401-5071; Kim, Jeong-Yoon/0000-0001-5873-2069; Oh, Doo-Byoung/0000-0002-4432-0941				Agaphonov MO, 2005, YEAST, V22, P1037, DOI 10.1002/yea.1297; Barnay-Verdier S, 2004, MICROBIOL-SGM, V150, P2185, DOI 10.1099/mic.0.26887-0; Blandin G, 2000, FEBS LETT, V487, P76, DOI 10.1016/S0014-5793(00)02284-5; Chiba Y, 1998, J BIOL CHEM, V273, P26298, DOI 10.1074/jbc.273.41.26298; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DEAN N, 1995, P NATL ACAD SCI USA, V15, P3209; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; Gellissen Gerd, 2001, Yeast, V18, pi, DOI 10.1002/1097-0061(200102)18:3<::AID-YEA695>3.0.CO;2-9; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; INOUE T, 1995, BBA-PROTEIN STRUCT M, V1253, P141, DOI 10.1016/0167-4838(95)00195-6; Jungmann J, 1998, EMBO J, V17, P423, DOI 10.1093/emboj/17.2.423; Kang HA, 1998, YEAST, V14, P371, DOI 10.1002/(SICI)1097-0061(19980315)14:4<371::AID-YEA231>3.3.CO;2-T; Kang HA, 2002, HANSENULA POLYMORPHA: BIOLOGY AND APPLICATIONS, P124; Kang HA, 2005, PRODUCTION RECOMBINA, P111, DOI [10.1002/3527603670.ch6, DOI 10.1002/3527603670.CH6]; Kim MW, 2004, GLYCOBIOLOGY, V14, P243, DOI 10.1093/glycob/cwh030; Kim SY, 2001, YEAST, V18, P455, DOI 10.1002/yea.699; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Lussier M, 1999, BBA-GEN SUBJECTS, V1426, P323, DOI 10.1016/S0304-4165(98)00133-0; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; MURAKAMI K, 1997, Patent No. 1997000261; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Nakayama K, 1997, FEBS LETT, V412, P547, DOI 10.1016/S0014-5793(97)00634-0; Neiman AM, 1997, GENETICS, V145, P637; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Ramezani-Rad M, 2003, FEMS YEAST RES, V4, P207, DOI 10.1016/S1567-1356(03)00125-9; Rodriguez L, 1996, YEAST, V12, P815, DOI 10.1002/(SICI)1097-0061(199607)12:9<815::AID-YEA916>3.0.CO;2-H; Seok OK, 2004, J MICROBIOL BIOTECHN, V14, P1239; Stolz J, 2002, J BIOL CHEM, V277, P44801, DOI 10.1074/jbc.M208023200; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yoko-o T, 2001, FEBS LETT, V489, P75, DOI 10.1016/S0014-5793(01)02082-8	36	59	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6261	6272		10.1074/jbc.M508507200	http://dx.doi.org/10.1074/jbc.M508507200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407250	hybrid			2022-12-25	WOS:000236030800019
J	Murat, D; Bance, P; Callebaut, I; Dassa, E				Murat, D; Bance, P; Callebaut, I; Dassa, E			ATP hydrolysis is essential for the function of the Uup ATP-binding cassette ATPase in precise excision of transposons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; ESCHERICHIA-COLI; ABC TRANSPORTER; P-GLYCOPROTEIN; ACTIVE-SITE; AGROBACTERIUM-TUMEFACIENS; SALMONELLA-TYPHIMURIUM; HISTIDINE PERMEASE; MALTOSE TRANSPORT; CRYSTAL-STRUCTURE	In Escherichia coli K-12, the RecA- and transposase-independent precise excision of transposons is thought to be mediated by the slippage of the DNA polymerase between the two short direct repeats that flank the transposon. Inactivation of the uup gene, encoding an ATP-binding cassette (ABC) ATPase, led to an important increase in the frequency of precise excision of transposons Tn10 and Tn5 and a defective growth of bacteriophage Mu. To provide insight into the mechanism of Uup in transposon excision, we purified this protein, and we demonstrated that it is a cytosolic ABC protein. Purified recombinant Uup binds and hydrolyzes ATP and undergoes a large conformational change in the presence of this nucleotide. This change affects a carboxyl-terminal domain of the protein that displays predicted structural homology with the so-called little finger domain of Y family DNA polymerases. In these enzymes, this domain is involved in DNA binding and in the processivity of replication. We show that Uup binds to DNA and that this binding is in part dependent on its carboxyl-terminal domain. Analysis of Walker motif B mutants suggests that ATP hydrolysis at the two ABC domains is strictly coordinated and is essential for the function of Uup in vivo.	Inst Pasteur, Dept Microbiol Fondamentale & Med, Unite Membranes Bacteriennes, CNRS,URA2172, F-75724 Paris 15, France; UP6, Inst Mineral & Phys Milieux Condenses, Dept Biol Struct, CNRS,UMR C7590, F-75252 Paris 05, France; UP7, Inst Mineral & Phys Milieux Condenses, Dept Biol Struct, CNRS,UMR C7590, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paris Cite	Dassa, E (corresponding author), Inst Pasteur, Dept Microbiol Fondamentale & Med, Unite Membranes Bacteriennes, CNRS,URA2172, Site Fernbach,25 Rue Docteur Roux, F-75724 Paris 15, France.	elidassa@pasteur.fr		Dorothee, MURAT/0000-0001-5809-9267				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Belin P, 2004, PROTEIN ENG DES SEL, V17, P491, DOI 10.1093/protein/gzh054; Bellier A, 2004, J BACTERIOL, V186, P3238, DOI 10.1128/JB.186.10.3238-3248.2004; Boyd D, 2000, J BACTERIOL, V182, P842, DOI 10.1128/JB.182.3.842-847.2000; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Chaveroche MK, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e97; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Dassa E, 2001, RES MICROBIOL, V152, P211, DOI 10.1016/S0923-2508(01)01194-9; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; FOSTER TJ, 1981, CELL, V23, P215, DOI 10.1016/0092-8674(81)90286-5; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HOPKINS JD, 1983, J BACTERIOL, V153, P384, DOI 10.1128/JB.153.1.384-389.1983; Jha S, 2003, BIOCHEMISTRY-US, V42, P10822, DOI 10.1021/bi0345900; Karcher A, 2005, STRUCTURE, V13, P649, DOI 10.1016/j.str.2005.02.008; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kerr ID, 2004, BIOCHEM BIOPH RES CO, V315, P166, DOI 10.1016/j.bbrc.2004.01.044; KORONAKIS E, 1995, MOL MICROBIOL, V16, P87, DOI 10.1111/j.1365-2958.1995.tb02394.x; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUHNAU S, 1991, J BACTERIOL, V173, P2180; KURTZ HD, 1994, FEMS MICROBIOL LETT, V116, P175, DOI 10.1111/j.1574-6968.1994.tb06697.x; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Liu ZY, 2001, J BACTERIOL, V183, P3310, DOI 10.1128/JB.183.11.3310-3317.2001; Llama-Palacios A, 2002, APPL ENVIRON MICROB, V68, P1624, DOI 10.1128/AEM.68.4.1624-1630.2002; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Lovett ST, 2004, MOL MICROBIOL, V52, P1243, DOI 10.1111/j.1365-2958.2004.04076.x; LUNDBLAD V, 1984, P NATL ACAD SCI-BIOL, V81, P824, DOI 10.1073/pnas.81.3.824; Lundblad V, 1982, Basic Life Sci, V20, P245; LUNDBLAD V, 1985, GENETICS, V109, P3; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; Miller J. H., 1972, EXPT MOL GENETICS, P439; MORBACH S, 1993, J BIOL CHEM, V268, P18617; Mourez M, 1998, MOL MICROBIOL, V30, P353, DOI 10.1046/j.1365-2958.1998.01070.x; Nagel R, 2000, MUTAT RES-DNA REPAIR, V459, P275, DOI 10.1016/S0921-8777(00)00008-2; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Reddy M, 1997, J BACTERIOL, V179, P2892, DOI 10.1128/jb.179.9.2892-2899.1997; Reddy M, 2000, J BACTERIOL, V182, P1978, DOI 10.1128/JB.182.7.1978-1986.2000; Roux A, 2005, J BACTERIOL, V187, P1001, DOI 10.1128/JB.187.3.1001-1013.2005; SCHNEIDER E, 1995, PROTEIN EXPRES PURIF, V6, P10, DOI 10.1006/prep.1995.1002; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Tyzack JK, 2000, J BIOL CHEM, V275, P34131, DOI 10.1074/jbc.M002868200; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; van Belkum A, 1999, CELL MOL LIFE SCI, V56, P729, DOI 10.1007/s000180050019; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Verdon G, 2002, ACTA CRYSTALLOGR D, V58, P362, DOI 10.1107/S0907444901020765; WANG JT, 1994, J BIOL CHEM, V269, P10771; WINANS SC, 1988, J BACTERIOL, V170, P4047, DOI 10.1128/jb.170.9.4047-4054.1988; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	60	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6850	6859		10.1074/jbc.M509926200	http://dx.doi.org/10.1074/jbc.M509926200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407313	hybrid			2022-12-25	WOS:000236030800083
J	Piccirella, S; Czegle, I; Lizak, B; Margittai, E; Senesi, S; Papp, E; Csala, M; Fulceri, R; Csermely, P; Mandl, J; Benedetti, A; Banhegyi, G				Piccirella, S; Czegle, I; Lizak, B; Margittai, E; Senesi, S; Papp, E; Csala, M; Fulceri, R; Csermely, P; Mandl, J; Benedetti, A; Banhegyi, G			Uncoupled redox systems in the lumen of the endoplasmic reticulum - Pyridine nucleotides stay reduced in an oxidative environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; MICROSOMAL HEXOSE-6-PHOSPHATE DEHYDROGENASE; FUNCTIONAL-RELATIONSHIP; LIVER-MICROSOMES; PROTEIN; GLUTATHIONE; REDUCTASE; DISULFIDE; TRANSPORT; DEHYDROASCORBATE	The redox state of the intraluminal pyridine nucleotide pool was investigated in rat liver microsomal vesicles. The vesicles showed cortisone reductase activity in the absence of added reductants, which was dependent on the integrity of the membrane. The intraluminal pyridine nucleotide pool could be oxidized by the addition of cortisone or metyrapone but not of glutathione. On the other hand, intraluminal pyridine nucleotides were slightly reduced by cortisol or glucose 6-phosphate, although glutathione was completely ineffective. Redox state of microsomal protein thiols/disulfides was not altered either by manipulations affecting the redox state of pyridine nucleotides or by the addition of NAD(P)(+) or NAD(P)H. The uncoupling of the thiol/disulfide and NAD(P)(+)/NAD(P)H redox couples was not because of their subcompartmentation, because enzymes responsible for the intraluminal oxidoreduction of pyridine nucleotides were distributed equally in smooth and rough microsomal subfractions. Instead, the phenomenon can be explained by the negligible representation of glutathione reductase in the endoplasmic reticulum lumen. The results demonstrated the separate existence of two redox systems in the endoplasmic reticulum lumen, which explains the contemporary functioning of oxidative folding and of powerful reductive reactions.	Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1444 Budapest, Hungary; Hungarian Acad Sci, Endoplasm Reticulum Res Grp, H-1444 Budapest, Hungary; Univ Siena, Dept Pathophysiol Expt Med & Publ Hlth, I-53100 Siena, Italy; Santa Maria Scotte Hosp, Unit Dev Biomed Res, I-53100 Siena, Italy	Semmelweis University; Hungarian Academy of Sciences; University of Siena	Banhegyi, G (corresponding author), Semmelweis Univ, Dept Med Chem, PO 260, H-1444 Budapest, Hungary.	banhegyi@puskin.sote.hu	Bánhegyi, Gábor/A-1476-2014; Csermely, Peter/J-2067-2017; Czegle, Ibolya/Y-3365-2019; Csala, Miklos/H-5369-2011	Csermely, Peter/0000-0001-9234-0659; Csala, Miklos/0000-0002-3829-4361; Czegle, Ibolya/0000-0001-7240-4678				Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Banhegyi G, 2004, J BIOL CHEM, V279, P27017, DOI 10.1074/jbc.M404159200; Bannenberg G, 2003, CHEM-BIOL INTERACT, V143, P449, DOI 10.1016/S0009-2797(02)00183-7; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; BENEDETTI A, 1988, J BIOL CHEM, V263, P3466; BENEDETTI A, 2005, NATO SCI SERIES LIFE, V363; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BUBLITZ C, 1988, BIOCHIM BIOPHYS ACTA, V965, P90, DOI 10.1016/0304-4165(88)90155-9; BUBLITZ C, 1987, BIOCHEM J, V245, P263, DOI 10.1042/bj2450263; BUBLITZ C, 1987, ARCH BIOCHEM BIOPHYS, V259, P22, DOI 10.1016/0003-9861(87)90465-6; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Csala M, 2004, BIOCHEM PHARMACOL, V68, P1353, DOI 10.1016/j.bcp.2004.05.055; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; Hewitt KN, 2005, ENDOCRINOLOGY, V146, P2539, DOI 10.1210/en.2005-0117; HINO Y, 1982, J BIOCHEM, V92, P547, DOI 10.1093/oxfordjournals.jbchem.a133963; HINO Y, 1987, EUR J BIOCHEM, V165, P195, DOI 10.1111/j.1432-1033.1987.tb11211.x; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KEHRER JP, 1994, FREE RADICAL BIO MED, V17, P65, DOI 10.1016/0891-5849(94)90008-6; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; KULKARNI AP, 1982, BIOCHEM PHARMACOL, V31, P1131, DOI 10.1016/0006-2952(82)90353-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWRY OH, 1957, J BIOL CHEM, V224, P1047; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; Marcolongo P, 1996, BIOCHEM BIOPH RES CO, V219, P916, DOI 10.1006/bbrc.1996.0333; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Ogg D, 2005, J BIOL CHEM, V280, P3789, DOI 10.1074/jbc.M412463200; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Papp E, 2005, BIOCHEM BIOPH RES CO, V338, P938, DOI 10.1016/j.bbrc.2005.10.027; SAWADA H, 1981, J BIOCHEM-TOKYO, V90, P1077, DOI 10.1093/oxfordjournals.jbchem.a133559; SAWADA H, 1980, J BIOCHEM-TOKYO, V87, P985, DOI 10.1093/oxfordjournals.jbchem.a132829; Senesi S, 2005, BIOCHEM J, V389, P57, DOI 10.1042/BJ20050213; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; Szarka A, 2002, J BIOENERG BIOMEMBR, V34, P317, DOI 10.1023/A:1020212720330; TAKAHASHI T, 1978, BIOCHIM BIOPHYS ACTA, V524, P262, DOI 10.1016/0005-2744(78)90163-8; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200	50	73	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4671	4677		10.1074/jbc.M509406200	http://dx.doi.org/10.1074/jbc.M509406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373343	hybrid			2022-12-25	WOS:000235426200015
J	Bouakaz, L; Bouakaz, E; Murgola, EJ; Ehrenberg, M; Sanyal, S				Bouakaz, L; Bouakaz, E; Murgola, EJ; Ehrenberg, M; Sanyal, S			The role of ribosomal protein L11 in class I release factor-mediated translation termination and translational accuracy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-CHAIN TERMINATION; ESCHERICHIA-COLI RIBOSOME; CONSERVED GTPASE CENTER; RECYCLING FACTOR RRF; FACTOR RF3; CODON RECOGNITION; MESSENGER-RNAS; EF-G; COMPLEX; SUBUNIT	It has been suggested from in vivo and cryoelectron micrographic studies that the large ribosomal subunit protein L11 and its N-terminal domain play an important role in peptide release by, in particular, the class I release factor RF1. In this work, we have studied in vitro the role of L11 in translation termination with ribosomes from a wild type strain (WT-L11), an L11 knocked-out strain (Delta L11), and an L11 N terminus truncated strain (Cter-L11). Our data show 4-6fold reductions in termination efficiency (k(cat)/K-m) of RF1, but not of RF2, on Delta L11 and Cter-L11 ribosomes compared with wild type. There is, at the same time, no effect of these L11 alterations on the maximal rate of ester bond cleavage by either RF1 or RF2. The rates of dissociation of RF2 but not of RF1 from the ribosome after peptide release are somewhat reduced by the L11 changes irrespective of the presence of RF3, and they cause a 2-fold decrease in the missense error. Our results suggest that the L11 modifications increase nonsense suppression at UAG codons because of the reduced termination efficiency of RF1 and that they decrease nonsense suppression at UGA codons because of a decreased missense error level.	Uppsala Univ, Inst Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Uppsala University; University of Texas System; UTMD Anderson Cancer Center	Sanyal, S (corresponding author), Uppsala Univ, Inst Cell & Mol Biol, BMC,Box 596, S-75124 Uppsala, Sweden.	Suparna.sanyal@icm.uu.se			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021499] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21499, GM70768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; ARMSTRONG IL, 1978, J MOL BIOL, V120, P155, DOI 10.1016/0022-2836(78)90062-1; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNEL C, 1993, BIOCHIMIE, V75, P1167, DOI 10.1016/0300-9084(93)90016-L; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; Freistroffer DV, 2000, P NATL ACAD SCI USA, V97, P2046, DOI 10.1073/pnas.030541097; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Jemiolo DK, 1995, P NATL ACAD SCI USA, V92, P12309, DOI 10.1073/pnas.92.26.12309; KAZEMIE M, 1975, EUR J BIOCHEM, V58, P501, DOI 10.1111/j.1432-1033.1975.tb02398.x; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; McCaughan KK, 1998, BIOL CHEM, V379, P857, DOI 10.1515/bchm.1998.379.7.857; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOFFAT JG, 1991, BIOCHIMIE, V73, P1113, DOI 10.1016/0300-9084(91)90154-S; Mora L, 2003, MOL MICROBIOL, V50, P1467, DOI 10.1046/j.1365-2958.2003.03799.x; Pavlov MY, 1996, ARCH BIOCHEM BIOPHYS, V328, P9, DOI 10.1006/abbi.1996.0136; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)80125-E; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; SENO T, 1968, BIOCHIM BIOPHYS ACTA, V169, P80, DOI 10.1016/0005-2787(68)90010-5; STOFFLER G, 1980, J BIOL CHEM, V255, P517; TATE WP, 1983, J BIOL CHEM, V258, P2816; TATE WP, 1975, J MOL BIOL, V93, P375, DOI 10.1016/0022-2836(75)90284-3; TATE WP, 1984, J BIOL CHEM, V259, P7317; TATE WP, 1986, J BIOL CHEM, V261, P2289; Tenson T, 2003, J MOL BIOL, V330, P1005, DOI 10.1016/S0022-2836(03)00662-4; Van Dyke N, 2003, J MOL BIOL, V330, P9, DOI 10.1016/S0022-2836(03)00537-0; Van Dyke N, 2002, J MOL BIOL, V319, P329, DOI 10.1016/S0022-2836(02)00304-2; WOLLENZIEN P, 1991, BIOCHEMISTRY-US, V30, P1788, DOI 10.1021/bi00221a009; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6	39	22	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4548	4556		10.1074/jbc.M510433200	http://dx.doi.org/10.1074/jbc.M510433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16371360	hybrid			2022-12-25	WOS:000235275300091
J	Hasturk, H; Kantarci, A; Ohira, T; Arita, M; Ebrahimi, N; Chiang, N; Petasis, NA; Levy, BD; Serhan, CN; Van Dyke, TE				Hasturk, H.; Kantarci, A.; Ohira, T.; Arita, M.; Ebrahimi, N.; Chiang, N.; Petasis, N. A.; Levy, B. D.; Serhan, C. N.; Van Dyke, T. E.			RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis	FASEB JOURNAL			English	Article									[Ohira, T.; Arita, M.; Chiang, N.; Levy, B. D.; Serhan, C. N.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; [Ohira, T.; Arita, M.; Chiang, N.; Levy, B. D.; Serhan, C. N.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Hasturk, H.; Kantarci, A.; Ebrahimi, N.; Van Dyke, T. E.] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02215 USA; [Petasis, N. A.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; [Levy, B. D.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; University of Southern California; Harvard University; Brigham & Women's Hospital	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu; tvandyke@bu.edu	Chiang, Nan/ABA-4924-2021; Petasis, Nicos/B-3162-2009	Chiang, Nan/0000-0003-1963-1585; Petasis, Nicos/0000-0002-8864-4446; Arita, Makoto/0000-0001-9902-0463	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00533] Funding Source: Medline; NIDCR NIH HHS [DE-016191] Funding Source: Medline; NIGMS NIH HHS [GM-38765] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))			0	297	319	1	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					401	403		10.1096/fj.05-4724fje	http://dx.doi.org/10.1096/fj.05-4724fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16373400				2022-12-25	WOS:000207915000035
J	Niculescu, MD; Craciunescu, CN; Zeisel, SH				Niculescu, MD; Craciunescu, CN; Zeisel, SH			Dietary choline deficiency alters global and gene-specific DNA methylation in the developing hippocampus of mouse fetal brains	FASEB JOURNAL			English	Article						Cdkn3; Kap; Cdkn2b; p15(INK4b); Calb2; calretinin; fetal brain; DNA methylation; choline deficiency; hippocampus	DEPENDENT KINASE INHIBITORS; SPATIAL MEMORY; AVAILABILITY ALTERS; RAT-BRAIN; SUPPLEMENTATION; LOCALIZATION; EXPRESSION; APOPTOSIS; CELLS; INACTIVATION	The availability of choline during critical periods of fetal development alters hippocampal development and affects memory function throughout life. Choline deficiency during fetal development reduces proliferation and migration of neuronal precursor cells in the mouse fetal hippocampus and these changes are associated with modifications in the protein levels of some cell cycle regulators and early differentiation markers. We fed C57 BL/6 mouse dams diets deficient or normal in choline content from days 12 to 17 of pregnancy, and then collected fetal brains on embryonic day 17. Using laser-capture micro-dissection we harvested cells from the ventricular and subventricular zones of Ammon's horn and from the prime germinal zone of the dentate gyrus (hippocampus). In the ventricular and subventricular zones from the choline-deficient group, we observed increased protein levels for kinase-associated phosphatase (Kap) and for p15(INK4b) (two cell cycle inhibitors). In the dentate gyrus, we observed increased levels of calretinin (an early marker of neuronal differentiation). In fetal brain from mothers fed a choline-deficient diet, DNA global methylation was decreased in the ventricular and subventricular zones of Ammon's horn. We also observed decreased gene-specific DNA methylation of the gene (Cdkn3) that encodes for Kap, correlating with increased expression of this protein. This was not the case for p15INK4b or calretinin (Cdkn2b and Calb2, respectively). These data suggest that choline deficiency-induced changes in gene methylation could mediate the expression of a cell cycle regulator and thereby alter brain development.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA.	steven_zeisel@unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055865, P30DK056350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126, R21ES012997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525, P01 AG009525] Funding Source: Medline; NIDDK NIH HHS [P30 DK056350, DK56350, R01 DK055865, DK55865] Funding Source: Medline; NIEHS NIH HHS [ES10126, R21 ES012997, P30 ES010126, ES012997] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1998, NEUROCHEM RES, V23, P751, DOI 10.1023/A:1022411510636; Albright CD, 2001, DEV NEUROSCI-BASEL, V23, P100, DOI 10.1159/000048701; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; Brandner C, 2002, BRAIN RES, V928, P85, DOI 10.1016/S0006-8993(01)03363-7; Brandt MD, 2003, MOL CELL NEUROSCI, V24, P603, DOI 10.1016/S1044-7431(03)00207-0; Cooney CA, 2002, J NUTR, V132, p2393S; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Davies TG, 2002, PHARMACOL THERAPEUT, V93, P125, DOI 10.1016/S0163-7258(02)00182-1; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466; Hamilton DW, 2005, CANCER LETT, V227, P75, DOI 10.1016/j.canlet.2004.11.044; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Holmes GL, 2002, EPILEPSY RES, V48, P3, DOI 10.1016/S0920-1211(01)00321-7; Institute of Medicine, 1998, DIET REF INT THIAM R, P390, DOI [DOI 10.17226/6015, 10.17226/6015]; Jacobowitz D, 1997, CHEMOARCHITECTONIC A; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Niculescu MD, 2005, MOL BRAIN RES, V134, P309, DOI 10.1016/j.molbrainres.2004.11.001; Niculescu MD, 2004, J NEUROCHEM, V89, P1252, DOI 10.1111/j.1471-4159.2004.02414.x; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; RODIER PM, 1980, DEV MED CHILD NEUROL, V22, P525; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Xu XL, 2001, CANCER RES, V61, P7943; Yang XY, 2000, BIOSCIENCE REP, V20, P1, DOI 10.1023/A:1005556715479; Yen CLE, 2002, J NUTR, V132, P1840, DOI 10.1093/jn/132.7.1840; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	36	232	244	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					43	49		10.1096/fj.05-4707com	http://dx.doi.org/10.1096/fj.05-4707com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394266	Green Accepted, Green Submitted			2022-12-25	WOS:000235996000043
J	Clement, G; Braunschweig, R; Pasquier, N; Bosman, FT; Benhattar, J				Clement, G.; Braunschweig, R.; Pasquier, N.; Bosman, F. T.; Benhattar, J.			Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus	ONCOGENE			English	Article						Barrett's esophagus; Wnt pathway; DNA methylation; APC; SFRP	BETA-CATENIN EXPRESSION; FREQUENT UP-REGULATION; PRIMARY GASTRIC-CANCER; APC GENE; HUMAN MESOTHELIOMA; COLORECTAL-CANCER; DNA METHYLATION; COLON-CANCER; E-CADHERIN; ADENOCARCINOMA	Aberrant activation of the Wnt signaling pathway has been reported during neoplastic progression in Barrett's esophagus (BE). However, mutations in APC and CTNNB1 genes were rarely observed. In this study, expression pattern of Wnt ligands, Frizzled receptors and APC, as well as the methylation status of the APC, SFRP1 and SFRP2 promoter genes were investigated in normal esophageal mucosa and in preneoplastic and neoplastic lesions of BE patients. Promoter methylation of APC was found in all BE samples and in 95% of esophageal adenocarcinomas (EAC). Full methylation of APC correlated with lack of expression. In EAC, nuclear translocation of ss-catenin was observed regardless of the expression of APC. WNT2 expression was higher in dysplasia and EAC than in BE, with 20/26 (77%) of the EAC showing high expression of WNT2. SFRP1 methylation occurred in all BE samples and in 96% of EAC, while SFRP2 was methylated in 73% of the normal squamous esophageal mucosa samples. In conclusion, (1) alterations of key regulators of the Wnt signaling are frequent in the pathogenesis of BE; (2) the APC and SFRP1 genes are inactivated by promoter methylation in BE; (3) the WNT2 gene is upregulated along the progression from low-grade dysplasia to EAC.	CHU Vaudois, Inst Pathol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Benhattar, J (corresponding author), CHU Vaudois, Inst Pathol, Bugnon 25, CH-1011 Lausanne, Switzerland.	Jean.Benhattar@chuv.hospvd.ch						Baisse B, 2000, BIOTECHNIQUES, V28, P856; Benhattar Jean, 2004, Methods Mol Biol, V287, P181; Bian YS, 2000, AM J CLIN PATHOL, V114, P583, DOI 10.1309/3QLC-5MF1-JYXU-A5XX; Bian YS, 2001, BIOTECHNIQUES, V30, P66, DOI 10.2144/01301st02; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BLASBAND A, 1992, ONCOGENE, V7, P153; Blot WJ, 1999, SEMIN ONCOL, V26, P2; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Clement G, 2004, CANCER RES, V64, P6867, DOI 10.1158/0008-5472.CAN-03-2503; Clement G, 2005, J CLIN PATHOL, V58, P155, DOI 10.1136/jcp.2004.021147; Falk GW, 2002, GASTROENTEROLOGY, V122, P1569, DOI 10.1053/gast.2002.33427; Flejou JF, 2005, GUT, V54, pI6, DOI 10.1136/gut.2004.041525; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; Guillou L, 2001, HUM PATHOL, V32, P105, DOI 10.1053/hupa.2001.21130; He B, 2005, CANCER RES, V65, P743; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Howng SL, 2002, CANCER LETT, V183, P95, DOI 10.1016/S0304-3835(02)00085-X; Jenkins GJS, 2002, BRIT J SURG, V89, P824, DOI 10.1046/j.1365-2168.2002.02107.x; Katoh M, 2001, INT J ONCOL, V19, P1003; Katoh M, 2003, INT J MOL MED, V12, P811; Katoh M, 2001, INT J MOL MED, V8, P657; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kitadai Y, 1998, CLIN CANCER RES, V4, P2195; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Koppert LB, 2004, BRIT J CANCER, V90, P892, DOI 10.1038/sj.bjc.6601589; Le Floch N, 2004, FASEB J, V18, P144, DOI 10.1096/fj.04-2373fje; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; Metzger R, 2004, ONKOLOGIE, V27, P200, DOI 10.1159/000076913; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Osterheld MC, 2002, AM J CLIN PATHOL, V117, P451; Pham K, 2003, J CLIN PATHOL-MOL PA, V56, P280, DOI 10.1136/mp.56.5.280; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Saitoh T, 2002, INT J MOL MED, V9, P515; Seery JP, 1999, ACTA ONCOL, V38, P945, DOI 10.1080/028418699432635; Shih IM, 2000, CANCER RES, V60, P1671; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647	51	95	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3084	3092		10.1038/sj.onc.1209338	http://dx.doi.org/10.1038/sj.onc.1209338			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407829				2022-12-25	WOS:000237950800014
J	Kelly, AE; Kranitz, H; Dotsch, V; Mullins, RD				Kelly, AE; Kranitz, H; Dotsch, V; Mullins, RD			Actin binding to the central domain of WASP/Scar proteins plays a critical role in the activation of the arp2/3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WASP-FAMILY PROTEINS; CONFORMATIONAL-CHANGES; STRUCTURAL BASIS; N-WASP; MOTILITY; THYMOSIN-BETA-4; IDENTIFICATION; NUCLEOTIDE; NUCLEATION; SIGNALS	The Arp2/3 complex nucleates and cross-links actin filaments at the leading edge of motile cells, and its activity is stimulated by C-terminal regions of WASP/Scar proteins, called VCA domains. VCA domains contain a verprolin homology sequence (V) that binds monomeric actin and central (C) and acidic sequences (A) that bind the Arp2/3 complex. Here we show that the C domain binds to monomeric actin with higher affinity (K-d = 10 mu M) than to the Arp2/3 complex (K-d > 200 mu M). Nuclear magnetic resonance spectroscopy reveals that actin binds to the N-terminal half of the C domain and that both the V and C domains can bind actin independently and simultaneously, indicating that they interact with different sites. Mutation of conserved hydrophobic residues in the actin-binding interface of the C domain disrupts activation of the Arp2/3 complex but does not alter affinity for the complex. By chemical cross-linking the C domain interacts with the p40 subunit of the Arp2/3 complex and, by fluorescence polarization anisotropy, the binding of actin and the Arp2/3 complex are mutually exclusive. Our results indicate that both actin and Arp2/3 binding are important for C domain function but that the C domain does not form a static bridge between the two. We propose a model for activation of the Arp2/3 complex in which the C domain first primes the complex by inducing a necessary conformational change and then initiates nucleus assembly by bringing an actin monomer into proximity of the primed complex.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Goethe Univ Frankfurt, Inst Biophys Chem, D-60439 Frankfurt, Germany; Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, D-60439 Frankfurt, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Goethe University Frankfurt; Goethe University Frankfurt	Mullins, RD (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	dyche@mullinslab.ucsf.edu	Kelly, Alexander/AAZ-8425-2021; Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X; KELLY, ALEXANDER/0000-0002-3395-6012	NIGMS NIH HHS [R01 GM061010, R01 GM 61010, R01 GM061010-06] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Beltzner CC, 2004, J MOL BIOL, V336, P551, DOI 10.1016/j.jmb.2003.12.017; Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; Chereau D, 2005, P NATL ACAD SCI USA, V102, P16644, DOI 10.1073/pnas.0507021102; DAYEL MJ, 2004, PLOS BIOL; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; EGILE C, 2005, PLOS BIOL; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Goley ED, 2004, MOL CELL, V16, P269, DOI 10.1016/j.molcel.2004.09.018; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Hufner K, 2001, J BIOL CHEM, V276, P35761, DOI 10.1074/jbc.M106520200; Irobi E, 2004, EMBO J, V23, P3599, DOI 10.1038/sj.emboj.7600372; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Kelly AE, 2002, J AM CHEM SOC, V124, P12013, DOI 10.1021/ja026121b; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Martin AC, 2005, J CELL BIOL, V168, P315, DOI 10.1083/jcb.200408177; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Pan F, 2004, J BIOL CHEM, V279, P54629, DOI 10.1074/jbc.M402357200; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Riek R, 2002, J AM CHEM SOC, V124, P12144, DOI 10.1021/ja026763z; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Zalevsky J, 2001, CURR BIOL, V11, P1903, DOI 10.1016/S0960-9822(01)00603-0	39	54	57	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10589	10597		10.1074/jbc.M507470200	http://dx.doi.org/10.1074/jbc.M507470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16403731	Green Accepted, hybrid			2022-12-25	WOS:000236594300091
J	Lim, JH; Kim, MS; Kim, HE; Yano, T; Oshima, Y; Aggarwal, K; Goldman, WE; Silverman, N; Kurata, S; Oh, BH				Lim, JH; Kim, MS; Kim, HE; Yano, T; Oshima, Y; Aggarwal, K; Goldman, WE; Silverman, N; Kurata, S; Oh, BH			Structural basis for preferential recognition of diaminopimelic acid-type peptidoglycan by a subset of peptidoglycan recognition proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; DROSOPHILA-IMD-PATHWAY; PATTERN-RECOGNITION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; INNATE IMMUNITY; ANTIBACTERIAL DEFENSE; TOLL PATHWAY; I-ALPHA; RECEPTOR	Drosophila peptidoglycan recognition protein (PGRP)-LCx and - LCa are receptors that preferentially recognize meso-diaminopimelic acid (DAP)-type peptidoglycan (PGN) present in Gram-negative bacteria over lysine-type PGN of Gram-positive bacteria and initiate the IMD signaling pathway, whereas PGRP-LE plays a synergistic role in this process of innate immune defense. How these receptors can distinguish the two types of PGN remains unclear. Here the structure of the PGRP domain of Drosophila PGRP-LE in complex with tracheal cytotoxin (TCT), the monomeric DAP-type PGN, reveals a buried ionic interaction between the unique carboxyl group of DAP and a previously unrecognized arginine residue. This arginine is conserved in the known DAP-type PGN-interacting PGRPs and contributes significantly to the affinity of the protein for the ligand. Unexpectedly, TCT induces infinite head-to-tail dimerization of PGRP-LE, in which the disaccharide moiety, but not the peptide stem, of TCT is positioned at the dimer interface. A sequence comparison suggests that TCT induces heterodimerization of the ectodomains of PGRP-LCx and - LCa in a closely analogous manner to prime the IMD signaling pathway, except that the heterodimer formation is nonperpetuating.	Pohang Univ Sci & Technol, Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Div Mol & Life Sci, Pohang 790784, Kyungbuk, South Korea; Tohoku Univ, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01605 USA; Washington Univ, Sch Med, Dept Microbiol, St Louis, MO 63110 USA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Tohoku University; University of Massachusetts System; University of Massachusetts Worcester; Washington University (WUSTL)	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea.	bhoh@postech.ac.kr	Oh, Byung-Ha/C-2061-2011; Yano, Tamaki/AHB-5620-2022	Yano, Tamaki/0000-0002-5576-1128; Goldman, William/0000-0002-1551-6718; Silverman, Neal/0000-0002-4259-456X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang CI, 2004, PLOS BIOL, V2, P1293, DOI 10.1371/journal.pbio.0020277; Chang CI, 2005, P NATL ACAD SCI USA, V102, P10279, DOI 10.1073/pnas.0504547102; Cho JH, 2005, BLOOD, V106, P2551, DOI 10.1182/blood-2005-02-0530; Choe KM, 2005, P NATL ACAD SCI USA, V102, P1122, DOI 10.1073/pnas.0404952102; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; ENGEL H, 1991, J BACTERIOL, V173, P6773, DOI 10.1128/jb.173.21.6773-6782.1991; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Guan RJ, 2004, J BIOL CHEM, V279, P31873, DOI 10.1074/jbc.M404920200; Hedengren M, 1999, MOL CELL, V4, P827, DOI 10.1016/S1097-2765(00)80392-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko T, 2005, CELL MICROBIOL, V7, P461, DOI 10.1111/j.1462-5822.2005.00504.x; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kumar S, 2005, J BIOL CHEM, V280, P37005, DOI 10.1074/jbc.M506385200; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2005, P NATL ACAD SCI USA, V102, P6455, DOI 10.1073/pnas.0407559102; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JT, 2001, J BACTERIOL, V183, P3842, DOI 10.1128/JB.183.13.3842-3847.2001; Pili-Floury S, 2004, J BIOL CHEM, V279, P12848, DOI 10.1074/jbc.M313324200; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Reiser JB, 2004, J MOL BIOL, V340, P909, DOI 10.1016/j.jmb.2004.04.077; Rutschmann S, 2002, J IMMUNOL, V168, P1542, DOI 10.4049/jimmunol.168.4.1542; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Stenbak CR, 2004, J IMMUNOL, V173, P7339, DOI 10.4049/jimmunol.173.12.7339; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Werner T, 2003, J BIOL CHEM, V278, P26319, DOI 10.1074/jbc.C300184200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	46	137	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8286	8295		10.1074/jbc.M513030200	http://dx.doi.org/10.1074/jbc.M513030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428381	hybrid			2022-12-25	WOS:000236031000068
J	Vigetti, D; Ori, M; Viola, M; Genasetti, A; Karousou, E; Rizzi, M; Pallotti, F; Nardi, I; Hascall, VC; De Luca, G; Passi, A				Vigetti, D; Ori, M; Viola, M; Genasetti, A; Karousou, E; Rizzi, M; Pallotti, F; Nardi, I; Hascall, VC; De Luca, G; Passi, A			Molecular cloning and characterization of UDP-glucose dehydrogenase from the amphibian Xenopus laevis and its involvement in hyaluronan synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GROUP-A STREPTOCOCCI; N-ACETYLGALACTOSAMINE; EXTRACELLULAR-MATRIX; EARLY EMBRYOGENESIS; GROWTH-FACTOR; GENE; EXPRESSION; CELLS; MOUSE	UDP-glucose dehydrogenase (UGDH) supplies the cell with UDP-glucuronic acid (UDP-GlcUA), a precursor of glycosaminoglycan and proteoglycan synthesis. Here we reported the cloning and the characterization of the UGDH from the amphibian Xenopus laevis that is one of the model organisms for developmental biology. We found that X. laevis UGDH (xUGDH) maintained a very high degree of similarity with other known UGDH sequences both at the genomic and the protein levels. Also its kinetic parameters are similar to those of UGDH from other species. During X. laevis development, UDGH is always expressed but clearly increases its mRNA levels at the tail bud stage (i.e. 30 h post-fertilization). This result fits well with our previous observation that hyaluronan, a glycosaminoglycan that is synthesized using UDP-GlcUA and UDP-N-acetylglucosamine, is abundantly detected at this developmental stage. The expression of UGDH was found to be related to hyaluronan synthesis. In human smooth muscle cells the overexpression of xUGDH or endogenous abrogation of UGDH modulated hyaluronan synthesis specifically. Our findings were confirmed by in vivo experiments where the silencing of xUGDH in X. laevis embryos decreased glycosaminoglycan synthesis causing severe embryonic malformations because of a defective gastrulation process.	Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, I-21100 Varese, Italy; Univ Pisa, Dipartimento Fisiol & Biochim, Lab Biol Cellulare & Sviluppo, I-56010 Pisa, Italy; Cleveland Clin Fdn, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthopaed Res Ctr ND20, Cleveland, OH 44195 USA	University of Insubria; University of Pisa; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Passi, A (corresponding author), Univ Insubria, Dipartimento Sci Biomed Sperimentali & Clin, Via JH Dunant 5, I-21100 Varese, Italy.	alberto.passi@uninsubria.it	Rizzi, Manuela/AAE-9202-2021; Vigetti, Davide/C-9861-2010; Viola, Manuela/B-7120-2011; passi, alberto g/A-1752-2018; Ori, Michela/G-6835-2017; Ori, Michela/N-3452-2019; Ori, Michela/M-8003-2013	Rizzi, Manuela/0000-0002-6174-7111; Vigetti, Davide/0000-0002-6339-8453; Viola, Manuela/0000-0002-0634-6390; passi, alberto g/0000-0003-3328-3089; Ori, Michela/0000-0002-6777-0208; Pallotti, Francesco/0000-0001-9946-8516				Anderson RB, 1998, DEV BIOL, V202, P235, DOI 10.1006/dbio.1998.9006; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; Bakkers J, 2004, DEVELOPMENT, V131, P525, DOI 10.1242/dev.00954; BALDUINI C, 1973, BIOCHEM J, V133, P243, DOI 10.1042/bj1330243; BDOLAH A, 1968, BIOCHIM BIOPHYS ACTA, V159, P176, DOI 10.1016/0005-2744(68)90256-8; Beck CW, 2001, GENOME BIOL, V2; Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Bontemps Y, 2000, BIOCHEM BIOPH RES CO, V275, P981, DOI 10.1006/bbrc.2000.3389; Burset M, 2000, NUCLEIC ACIDS RES, V28, P4364, DOI 10.1093/nar/28.21.4364; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Campbell RE, 1997, J BIOL CHEM, V272, P3416, DOI 10.1074/jbc.272.6.3416; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P7012, DOI 10.1021/bi000181h; DALESSANDRO G, 1977, BIOCHEM J, V162, P281, DOI 10.1042/bj1620281; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; Dutton G.F., 1980, GLUCURONIDATION DRUG; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; Galli A, 2003, DEVELOPMENT, V130, P4919, DOI 10.1242/dev.00706; Garcia-Garcia MJ, 2003, CELL, V114, P727, DOI 10.1016/S0092-8674(03)00715-3; Ge X, 2004, EUR J BIOCHEM, V271, P14, DOI 10.1046/j.1432-1033.2003.03876.x; Grangeasse C, 2003, J BIOL CHEM, V278, P39323, DOI 10.1074/jbc.M305134200; GRUNZ H, 1990, CELL DIFFER DEV, V32, P117, DOI 10.1016/0922-3371(90)90105-6; Hacker U, 1997, DEVELOPMENT, V124, P3565; HADDON CM, 1991, DEVELOPMENT, V112, P541; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; Hickery MS, 2003, J BIOL CHEM, V278, P53063, DOI 10.1074/jbc.M209632200; Hoflich J, 2004, J BIOL CHEM, V279, P30440, DOI 10.1074/jbc.M402429200; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14224, DOI 10.1073/pnas.172522499; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Johansson H, 2002, BBA-GENE STRUCT EXPR, V1576, P53, DOI 10.1016/S0167-4781(02)00292-0; Kakizaki I, 2004, J BIOL CHEM, V279, P33281, DOI 10.1074/jbc.M405918200; Karousou EG, 2004, ELECTROPHORESIS, V25, P2919, DOI 10.1002/elps.200406034; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; Latinkic BV, 2003, DEVELOPMENT, V130, P2429, DOI 10.1242/dev.00449; Lehmann R, 2000, ELECTROPHORESIS, V21, P3010, DOI 10.1002/1522-2683(20000801)21:14<3010::AID-ELPS3010>3.0.CO;2-C; Lind T, 1999, GLYCOBIOLOGY, V9, P595, DOI 10.1093/glycob/9.6.595; Magee C, 2001, BIOCHEM J, V360, P667, DOI 10.1042/0264-6021:3600667; Mijakovic I, 2003, EMBO J, V22, P4709, DOI 10.1093/emboj/cdg458; MOLZ RJ, 1971, BIOCHIM BIOPHYS ACTA, V250, P6, DOI 10.1016/0005-2744(71)90114-8; Mullegger J, 2002, MOL REPROD DEV, V61, P312, DOI 10.1002/mrd.10097; Nardini M, 2004, GENE EXPR PATTERNS, V4, P303, DOI 10.1016/j.modgep.2003.10.006; Oppenheimer N. J., 1992, ENZYMES, P453; PEROZICH J, 1995, ADV EXP MED BIOL, V372, P79; Pitsillides AA, 2003, CELL BIOCHEM FUNCT, V21, P235, DOI 10.1002/cbf.1079; Princivalle M, 2002, INT J DEV BIOL, V46, P267; RODEN L, 1980, BIOCH GLYCOPROTEINS; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sander V, 2001, MECH DEVELOP, V102, P251, DOI 10.1016/S0925-4773(01)00302-1; SCHILLER JG, 1973, BIOCHIM BIOPHYS ACTA, V293, P1, DOI 10.1016/0005-2744(73)90369-0; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Somasekhar T, 1997, DEV BRAIN RES, V99, P208, DOI 10.1016/S0165-3806(97)00011-4; Sommer BJ, 2004, J BIOL CHEM, V279, P23590, DOI 10.1074/jbc.M401928200; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Torrado Mario, 2005, J Mol Cell Cardiol, V38, P353, DOI 10.1016/j.yjmcc.2004.11.034; Vigetti D, 2000, ARCH BIOCHEM BIOPHYS, V379, P90, DOI 10.1006/abbi.2000.1863; Vigetti D, 2003, MATRIX BIOL, V22, P511, DOI 10.1016/S0945-053X(03)00082-9; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; Ye L, 1997, CIRC RES, V81, P289, DOI 10.1161/01.RES.81.3.289	64	92	93	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8254	8263		10.1074/jbc.M508516200	http://dx.doi.org/10.1074/jbc.M508516200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418163	Green Published, hybrid			2022-12-25	WOS:000236031000065
J	Sabina, J; Soll, D				Sabina, J; Soll, D			The RNA-binding PUA domain of archaeal tRNA-guanine transglycosylase is not required for archaeosine formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOACYL-TRANSFER-RNA; GLUTAMINYL-TRANSFER-RNA; COLI YADB GENE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; POSTTRANSCRIPTIONAL MODIFICATION; QUEUOSINE MODIFICATION; S-ADENOSYLMETHIONINE; QSTAR NUCLEOSIDE; ANTICODON LOOP	Bacterial tRNA-guanine transglycosylase (TGT) replaces the G in position 34 of tRNA with preQ(1), the precursor to the modified nucleoside queuosine. Archaeal TGT, in contrast, substitutes preQ(0) for the G in position 15 of tRNA as the first step in archaeosine formation. The archaeal enzyme is about 60% larger than the bacterial protein; a carboxyl-terminal extension of 230 amino acids contains the PUA domain known to contact the four 3'-terminal nucleotides of tRNA. Here we show that the C-terminal extension of the enzyme is not required for the selection of G15 as the site of base exchange; truncated forms of Pyrococcus furiosus TGT retain their specificity for guanine exchange at position 15. Deletion of the PUA domain causes a 4-fold drop in the observed k(cat) (2.8 x 10(-3) s(-1)) and results in a 75-fold increased K-m for tRNA(Asp) (1.2 x 10(-5) M) compared with full-length TGT. Mutations in tRNAAsp altering or abolishing interactions with the PUA domain can compete with wildtype tRNA(Asp) for binding to full-length and truncated TGT enzymes. Whereas the C-terminal domains do not appear to play a role in selection of the modification site, their relevance for enzyme function and their role in vivo remains to be discovered.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu			NIGMS NIH HHS [GM 022854] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022854, R01GM022854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; Arluison V, 1999, J MOL BIOL, V289, P491, DOI 10.1006/jmbi.1999.2789; Bai Y, 2000, J BIOL CHEM, V275, P28731, DOI 10.1074/jbc.M002174200; BARON C, 1991, J BIOL CHEM, V266, P20375; Blaise M, 2004, NUCLEIC ACIDS RES, V32, P2768, DOI 10.1093/nar/gkh608; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campanacci V, 2004, J MOL BIOL, V337, P273, DOI 10.1016/j.jmb.2004.01.027; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; Dirheimer G., 1995, P93; Dubois DY, 2004, P NATL ACAD SCI USA, V101, P7530, DOI 10.1073/pnas.0401634101; Garcia GA, 2005, BIOORG CHEM, V33, P229, DOI 10.1016/j.bioorg.2005.01.001; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; Grosjean H, 2004, TRENDS BIOCHEM SCI, V29, P519, DOI 10.1016/j.tibs.2004.08.005; Grosjean H, 2004, TRENDS BIOCHEM SCI, V29, P165, DOI 10.1016/j.tibs.2004.02.009; Gu XR, 1998, BIOCHEMISTRY-US, V37, P339, DOI 10.1021/bi971590p; GUPTA R, 1984, J BIOL CHEM, V259, P9461; HAUMONT E, 1987, EUR J BIOCHEM, V168, P219, DOI 10.1111/j.1432-1033.1987.tb13408.x; Huang LX, 1998, BIOCHEMISTRY-US, V37, P344, DOI 10.1021/bi971874+; Ishitani R, 2002, J MOL BIOL, V318, P665, DOI 10.1016/S0022-2836(02)00090-6; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; Iwata-Reuyl D, 2003, BIOORG CHEM, V31, P24, DOI 10.1016/S0045-2068(02)00513-8; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; Korencic D, 2004, J BIOL CHEM, V279, P48780, DOI 10.1074/jbc.M408753200; Kung FL, 1998, FEBS LETT, V431, P427, DOI 10.1016/S0014-5793(98)00801-1; Lauhon CT, 2004, J BIOL CHEM, V279, P23022, DOI 10.1074/jbc.M401757200; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mathews I, 2005, PROTEINS, V59, P869, DOI 10.1002/prot.20419; McCloskey JA, 2001, NUCLEIC ACIDS RES, V29, P4699, DOI 10.1093/nar/29.22.4699; MEIER F, 1985, EMBO J, V4, P823, DOI 10.1002/j.1460-2075.1985.tb03704.x; Morris RC, 2001, MOL GENET METAB, V74, P147, DOI 10.1006/mgme.2001.3216; Morris RC, 1999, J BIOMOL STRUCT DYN, V16, P757, DOI 10.1080/07391102.1999.10508291; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; NOGUCHI S, 1982, J BIOL CHEM, V257, P6544; Nonekowski ST, 2002, J BIOL CHEM, V277, P7178, DOI 10.1074/jbc.M111077200; Nonekowski ST, 2001, RNA, V7, P1432; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P2931, DOI 10.1093/nar/4.8.2931; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P415, DOI 10.1093/nar/4.2.415; OKADA N, 1979, J BIOL CHEM, V254, P3061; Raczniak G, 2001, J BIOL CHEM, V276, P45862, DOI 10.1074/jbc.M109494200; Reader JS, 2004, J BIOL CHEM, V279, P6280, DOI 10.1074/jbc.M310858200; Rinehart J, 2004, J BIOL CHEM, V279, P1161, DOI 10.1074/jbc.M310100200; Romier C, 1997, FEBS LETT, V416, P93, DOI 10.1016/S0014-5793(97)01175-7; Salazar JC, 2004, P NATL ACAD SCI USA, V101, P7536, DOI 10.1073/pnas.0401982101; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Van Lanen SG, 2005, P NATL ACAD SCI USA, V102, P4264, DOI 10.1073/pnas.0408056102; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Waters E, 2003, P NATL ACAD SCI USA, V100, P12984, DOI 10.1073/pnas.1735403100; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Xie W, 2003, NAT STRUCT BIOL, V10, P781, DOI 10.1038/nsb976; YARUS M, 1970, ANAL BIOCHEM, V35, P450, DOI 10.1016/0003-2697(70)90207-1	55	20	22	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6993	7001		10.1074/jbc.M512841200	http://dx.doi.org/10.1074/jbc.M512841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407303	hybrid			2022-12-25	WOS:000236030900012
J	Watanabe, S; Ikebe, R; Ikebe, M				Watanabe, S; Ikebe, R; Ikebe, M			Drosophila myosin VIIA is a high duty ratio motor with a unique kinetic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							USHER-SYNDROME 1B; UNCONVENTIONAL MYOSINS; FLUORESCENT-PROBE; MOLECULAR MOTOR; LARGE STEP; ACTIN; GENE; DEAFNESS; DOMAIN; SUBFRAGMENT-1	Mutations of myosin VIIA cause deafness in various species from human and mice to Zebrafish and Drosophila. We analyzed the kinetic mechanism of the ATPase cycle of Drosophila myosin VIIA by using a single-headed construct with the entire neck domain. The steady-state ATPase activity (0.06 s(-1)) was markedly activated by actin to yield V-max and K-ATPase of 1.72 s(-1) and 3.2 mu M, respectively. The most intriguing finding is that the ATP hydrolysis predominantly takes place in the actin-bound form (actin-attached hydrolysis) for the actomyosin VIIA ATPase reaction. The ATP hydrolysis rate was much faster for the actin-attached form than the dissociated form, in contrast to other myosins reported so far. Both the ATP hydrolysis step and the phosphate release step were significantly faster than the entire ATPase cycle rate, thus not rate-determining. The rate of ADP dissociation from actomyosin VIIA was 1.86 s(-1), which was comparable with the overall ATPase cycle rate, thus assigned to be a rate-determining step. The results suggest that Drosophila myosin VIIA spends the majority of the ATPase cycle in an actomyosin . ADP form, a strong actin binding state. The duty ratio calculated from our kinetic model was similar to 0.9. Therefore, myosin VIIA is classified to be a high duty ratio motor. The present results suggested that myosin VIIA can be a processive motor to serve cargo trafficking in cells once it forms a dimer structure.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	Mitsuo.Ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, R01AR048898, R01AR048526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC006103] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 41653, AR 048526, AR 048898] Funding Source: Medline; NIDCD NIH HHS [DC 006103] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Chen ZY, 1996, GENOMICS, V36, P440, DOI 10.1006/geno.1996.0489; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Friedman TB, 1999, AM J MED GENET, V89, P147, DOI 10.1002/(SICI)1096-8628(19990924)89:3<147::AID-AJMG5>3.0.CO;2-6; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Hasson T, 1999, CURR BIOL, V9, pR838, DOI 10.1016/S0960-9822(00)80040-8; Henn A, 2005, J BIOL CHEM, V280, P39665, DOI 10.1074/jbc.M507667200; Hodge T, 2000, J CELL SCI, V113, P3353; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; Knight PJ, 2005, J BIOL CHEM, V280, P34702, DOI 10.1074/jbc.M504887200; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Kovacs M, 2005, J BIOL CHEM, V280, P15071, DOI 10.1074/jbc.M500616200; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Liu XR, 1999, J NEUROSCI, V19, P6267; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; Rock RS, 2001, P NATL ACAD SCI USA, V98, P13655, DOI 10.1073/pnas.191512398; Rosenfeld SS, 2003, J BIOL CHEM, V278, P27449, DOI 10.1074/jbc.M302555200; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Self T, 1998, DEVELOPMENT, V125, P557; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Soni LE, 2005, CELL MOTIL CYTOSKEL, V62, P13, DOI 10.1002/cm.20080; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; Titus MA, 1999, CURR BIOL, V9, P1297, DOI 10.1016/S0960-9822(00)80051-2; Todi SV, 2005, CURR BIOL, V15, P862, DOI 10.1016/j.cub.2005.03.050; Todorov PT, 2001, BIOCHEM J, V354, P267, DOI 10.1042/0264-6021:3540267; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Watanabe TM, 2004, P NATL ACAD SCI USA, V101, P9630, DOI 10.1073/pnas.0402914101; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yang Y, 2005, J BIOL CHEM, V280, P32061, DOI 10.1074/jbc.M506765200	48	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7151	7160		10.1074/jbc.M511592200	http://dx.doi.org/10.1074/jbc.M511592200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415346	hybrid			2022-12-25	WOS:000236030900030
J	Ikeda, H; Omoteyama, K; Yoshida, K; Nishi, S; Sakai, M				Ikeda, H; Omoteyama, K; Yoshida, K; Nishi, S; Sakai, M			CCAAT enhancer-binding protein alpha suppresses the rat placental glutathione S-transferase gene in normal liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GENE; CHEMICAL HEPATOCARCINOGENESIS; SILENCER ELEMENT; RESPONSIVE ELEMENTS; FUNCTIONAL-ANALYSIS; GST-P; CELLS; TRANSCRIPTION; EXPRESSION; FAMILY	The rat placental glutathione S-transferase (GST-P), an isozyme of glutathione S-transferase, is not expressed in normal liver but is highly induced at an early stage of chemical hepatocarcinogenesis and in hepatomas. Recently, we reported that the NF-E2 p45-related factor 2 (Nrf2)/MafK heterodimer binds to GST-P enhancer 1 (GPE1), a strong enhancer of the GST-P gene, and activates this gene in preneoplastic lesions and hepatomas. In addition to the positive regulation during hepatocarcinogenesis, negative regulatory mechanisms might work to repress GST-P in normal liver, but this remains to be clarified. In this work, we identify the CCAAT enhancer-binding protein alpha(C/EBP alpha) as a negative regulator that binds to GPE1 and suppresses GST-P expression in normal liver. C/EBP alpha binds to part of the GPE1 sequence, and the binding of Nrf2/MafK and C/EBP alpha to GPE1 is mutually exclusive. In a transient-transfection analysis, C/EBP alpha activated GPE1 in F9 embryonal carcinoma cells but strongly inhibited GPE1 activity in hepatoma cells. The expression of C/EBP alpha was specifically suppressed in GST-P-positive preneoplastic foci in the livers of carcinogen-treated rats. A chromatin immunoprecipitation analysis showed that C/EBP alpha bound to GPE1 in the normal liver in vivo but did not bind in preneoplastic hepatocytes. Introduction of the C/EBP alpha gene fused with the estrogen receptor ligand-binding domain into hepatoma cells, and subsequent activation by beta-estradiol led to the suppression of endogenous GST-P expression. These results indicate that C/EBP alpha is a negative regulator of GST-P gene expression in normal liver.	Hokkaido Univ, Sch Med, Dept Hlth Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Hokkaido Univ, Grad Sch Med, Dept Biochem, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Sakai, M (corresponding author), Hokkaido Univ, Sch Med, Dept Hlth Sci, Kita Ku, N12,W5, Sapporo, Hokkaido 0600812, Japan.	m_sakai@med.hokudai.ac.jp	Sakai, Masaharu/A-4773-2012					BAMMLER TK, 1994, BIOCHEM J, V298, P385, DOI 10.1042/bj2980385; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARBER E, 1984, CAN J BIOCHEM CELL B, V62, P486, DOI 10.1139/o84-066; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HATAYAMA I, 1993, CARCINOGENESIS, V14, P537, DOI 10.1093/carcin/14.3.537; Ikeda H, 2004, BIOCHEM J, V380, P515, DOI 10.1042/BJ20031948; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KITAHARA A, 1984, CANCER RES, V44, P2698; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; MOORE MA, 1987, CARCINOGENESIS, V8, P483, DOI 10.1093/carcin/8.3.483; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osada S, 1997, J BIOCHEM, V121, P355; Osada S, 1996, J BIOL CHEM, V271, P3891; Osada S, 1995, J BIOL CHEM, V270, P31288, DOI 10.1074/jbc.270.52.31288; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; SAKAI M, 1990, PROG CLIN BIOL RES, V344, P123; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; SAKAI M, 1995, CANCER RES, V55, P5370; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO K, 1989, ADV CANCER RES, V52, P205; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; Satoh K, 2002, CARCINOGENESIS, V23, P1193, DOI 10.1093/carcin/23.7.1193; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; SUGIOKA Y, 1985, CANCER RES, V45, P365; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; SUZUKI T, 1995, CANCER RES, V55, P2651; Tanabe A, 2002, BIOL PHARM BULL, V25, P970, DOI 10.1248/bpb.25.970; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; XU X, 1994, J BIOL CHEM, V269, P30268	46	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6734	6741		10.1074/jbc.M513014200	http://dx.doi.org/10.1074/jbc.M513014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407263	hybrid			2022-12-25	WOS:000236030800071
J	Kuwae, A; Matsuzawa, T; Ishikawa, N; Abe, H; Nonaka, T; Fukuda, H; Imajoh-Ohmi, S; Abe, A				Kuwae, A; Matsuzawa, T; Ishikawa, N; Abe, H; Nonaka, T; Fukuda, H; Imajoh-Ohmi, S; Abe, A			BopC is a novel type III effector secreted by Bordetella bronchiseptica and has a critical role in type III-dependent necrotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LEGIONELLA-PNEUMOPHILA; TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; PROTEIN FAMILIES; PRODOM DATABASE; RNA-POLYMERASE; VIRULENCE; SHIGELLA	In Bordetella bronchiseptica, the functional type III secretion system (TTSS) is required for the induction of necrotic cell death in infected mammalian cells. To identify the factor(s) involved in necrotic cell death, type III-secreted proteins from B. bronchiseptica were analyzed using matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry and electrospray ionization tandem mass spectrometry. We identified a 69-kDa secreted protein designated BopC. The gene encoding BopC is located outside of the TTSS locus and is also highly conserved in both Bordetella parapertussis and Bordetella pertussis. The results of a lactate dehydrogenase release assay and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling assay demonstrated that BopC is required for necrotic cell death. It has been reported that tyrosine-phosphorylated proteins (PY) of host cells are dephosphorylated during B. bronchiseptica infection in a TTSS-dependent manner. We found that BopC is also involved in PY dephosphorylation in infected host cells. It appears that the necrotic cell death triggered by BopC occurs prior to the PY reduction in host cells, because Bordetella-induced cell death was not affected even in the presence of a dephosphorylation inhibitor. Furthermore, a translocation assay showed that the signal sequence for both secretion into culture supernatant and translocation into the host cell is located in 48 amino acid residues of the BopC N terminus. This report reveals for the first time that a novel type III effector, BopC, is required for the induction of necrotic cell death during Bordetella infection.	Kitasato Univ, Kitasato Inst Life Sci, Lab Bacterial Infect, Minato Ku, Tokyo 1088641, Japan; Kitasato Inst, Minato Ku, Tokyo 1088642, Japan; Osaka Univ, Grad Sch Med, Div Appl Bacteriol, Osaka 5650871, Japan; Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, Tokyo 1568585, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Lab Ctr Prote Res,Minato Ku, Tokyo 1088639, Japan	Kitasato University; Osaka University; Tokyo Institute of Psychiatry; Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Kuwae, A (corresponding author), Kitasato Univ, Kitasato Inst Life Sci, Lab Bacterial Infect, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	kuwae@lisci.kitasato-u.ac.jp	Abe, Akio/AAQ-2464-2020; Nonaka, Takashi/L-8572-2017	Nonaka, Takashi/0000-0002-0830-9403				Anderson DM, 1999, P NATL ACAD SCI USA, V96, P12839, DOI 10.1073/pnas.96.22.12839; ATTWOOD TK, 1994, PROTEIN ENG, V7, P841, DOI 10.1093/protein/7.7.841; Attwood TK, 2002, NUCLEIC ACIDS RES, V30, P239, DOI 10.1093/nar/30.1.239; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOUCHER PE, 1995, J BACTERIOL, V177, P6486, DOI 10.1128/jb.177.22.6486-6491.1995; Boucher PE, 1997, J BACTERIOL, V179, P1755, DOI 10.1128/jb.179.5.1755-1763.1997; Charpentier X, 2004, J BACTERIOL, V186, P5486, DOI 10.1128/JB.186.16.5486-5495.2004; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; Corpet F, 1999, NUCLEIC ACIDS RES, V27, P263, DOI 10.1093/nar/27.1.263; Cotter PA, 1997, MOL MICROBIOL, V24, P671, DOI 10.1046/j.1365-2958.1997.3821741.x; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; Creasey EA, 2003, MICROBIOL-SGM, V149, P3639, DOI 10.1099/mic.0.26735-0; Creasey EA, 2003, MOL MICROBIOL, V47, P209, DOI 10.1046/j.1365-2958.2003.03290.x; deTejada GM, 1996, MOL MICROBIOL, V22, P895, DOI 10.1046/j.1365-2958.1996.01538.x; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Elliott SJ, 2001, INFECT IMMUN, V69, P4027, DOI 10.1128/IAI.69.6.4027-4033.2001; Feldman MF, 2003, FEMS MICROBIOL LETT, V219, P151, DOI 10.1016/S0378-1097(03)00042-9; Foley JE, 2002, PREV VET MED, V54, P141, DOI 10.1016/S0167-5877(02)00022-3; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; GOODNOW RA, 1980, MICROBIOL REV, V44, P722, DOI 10.1128/MMBR.44.4.722-738.1980; Gruenheid S, 2004, MOL MICROBIOL, V51, P1233, DOI 10.1046/j.1365-2958.2003.03911.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; HEININGER U, 1994, PEDIATR INFECT DIS J, V13, P306, DOI 10.1097/00006454-199404000-00011; Henikoff JG, 2000, NUCLEIC ACIDS RES, V28, P228, DOI 10.1093/nar/28.1.228; Henikoff S, 1999, BIOINFORMATICS, V15, P471, DOI 10.1093/bioinformatics/15.6.471; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kaper JB, 2004, NAT REV MICROBIOL, V2, P123, DOI 10.1038/nrmicro818; Karimova G, 1996, MOL MICROBIOL, V20, P489, DOI 10.1046/j.1365-2958.1996.5231057.x; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kuwae A, 2001, J BIOL CHEM, V276, P32230, DOI 10.1074/jbc.M103831200; Kuwae A, 2003, CELL MICROBIOL, V5, P973, DOI 10.1046/j.1462-5822.2003.00341.x; LEVINE MM, 1985, J INFECT DIS, V152, P550, DOI 10.1093/infdis/152.3.550; Lord JM, 2005, CURR BIOL, V15, pR169, DOI 10.1016/j.cub.2005.02.043; Magyar T, 2002, VACCINE, V20, P1797, DOI 10.1016/S0264-410X(02)00023-3; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; Nagai H, 2001, EMBO J, V20, P5962, DOI 10.1093/emboj/20.21.5962; Niebuhr K, 2002, EMBO J, V21, P5069, DOI 10.1093/emboj/cdf522; Nogawa H, 2004, J BACTERIOL, V186, P3806, DOI 10.1128/JB.186.12.3806-3813.2004; Nonaka T, 2003, MICROBIOL-SGM, V149, P2513, DOI 10.1099/mic.0.26341-0; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Ogino T, 2004, J VIROL, V78, P11766, DOI 10.1128/JVI.78.21.11766-11777.2004; Olsson J, 2004, J BACTERIOL, V186, P4110, DOI 10.1128/JB.186.13.4110-4123.2004; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pfeifer CG, 1999, INFECT IMMUN, V67, P5690, DOI 10.1128/IAI.67.11.5690-5698.1999; Rossier O, 1999, P NATL ACAD SCI USA, V96, P9368, DOI 10.1073/pnas.96.16.9368; Roy CR, 1997, INFECT IMMUN, V65, P571, DOI 10.1128/IAI.65.2.571-578.1997; SASAKAWA C, 1988, J BACTERIOL, V170, P2480, DOI 10.1128/jb.170.6.2480-2484.1988; Sekiya K, 2001, P NATL ACAD SCI USA, V98, P11638, DOI 10.1073/pnas.191378598; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; Stockbauer KE, 2003, CELL MICROBIOL, V5, P123, DOI 10.1046/j.1462-5822.2003.00260.x; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Toyotome T, 2001, J BIOL CHEM, V276, P32071, DOI 10.1074/jbc.M101882200; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; Van Nhieu GT, 1999, CURR OPIN MICROBIOL, V2, P51; VanderZee A, 1997, J BACTERIOL, V179, P6609, DOI 10.1128/jb.179.21.6609-6617.1997; Yeh Sylvia H, 2003, Expert Rev Vaccines, V2, P113, DOI 10.1586/14760584.2.1.113; YODA H, 1982, Experimental Animals (Tokyo), V31, P113; Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319; Yuk MH, 2000, MOL MICROBIOL, V35, P991, DOI 10.1046/j.1365-2958.2000.01785.x; Yuk MH, 1998, MOL MICROBIOL, V28, P945, DOI 10.1046/j.1365-2958.1998.00850.x	65	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6589	6600		10.1074/jbc.M512711200	http://dx.doi.org/10.1074/jbc.M512711200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407269	hybrid			2022-12-25	WOS:000236030800055
J	Mattioli, I; Geng, H; Sebald, A; Hodel, M; Bucher, C; Kracht, M; Schmitz, ML				Mattioli, I; Geng, H; Sebald, A; Hodel, M; Bucher, C; Kracht, M; Schmitz, ML			Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-RELATED KINASES; LIVER DEGENERATION; REGULATORY SUBUNIT; GENE-EXPRESSION; PHORBOL ESTER; ACTIVATION; ALPHA; BETA; BINDING; TBK1	Here we identify IKK epsilon as a novel NF-kappa B p65 kinase that mediates inducible phosphorylation of Ser(468) and Ser(536) in response to T cell costimulation. In addition, the kinase activity of IKK epsilon contributes to the control of p65 nuclear uptake. Serines 468 and 536 are evolutionarily conserved, and the surrounding amino acids display sequence homology. Down-regulation of IKK epsilon levels by small interfering RNA does not affect inducible phosphorylation of Ser(536) but largely prevents Ser(468) phosphorylation induced by T cell costimulation. Ser(536)-phosphorylated p65 is found predominantly in the cytosol. In contrast, the Ser(468) phosphorylated form of this transcription factor occurs mainly in the nucleus, suggesting a function for transactivation. Reconstitution of p65(-/-) cells with either wild type p65 or point-mutated p65 variants showed that inducible phosphorylation of Ser(468) serves to enhance p65-dependent transactivation. These results also provide a mechanistic link that helps to explain the relevance of IKK epsilon for the expression of a subset of NF-kappa B target genes without affecting cytosolic I kappa B degradation.	Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	Justus Liebig University Giessen; Hannover Medical School; University of Bern	Schmitz, ML (corresponding author), Univ Giessen, Fac Med, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	lienhard.schmitz@biochemie.med.uni-giessen.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X				Bae JS, 2003, BIOCHEM BIOPH RES CO, V305, P1094, DOI 10.1016/S0006-291X(03)00869-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Ben-Neriah Y, 2004, EMBO REP, V5, P668, DOI 10.1038/sj.embor.7400187; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Frelin C, 2003, ONCOGENE, V22, P8187, DOI 10.1038/sj.onc.1206963; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hehner SP, 2000, J IMMUNOL, V164, P3829, DOI 10.4049/jimmunol.164.7.3829; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Mattioli I, 2004, BLOOD, V104, P3302, DOI 10.1182/blood-2004-04-1536; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Tanahashi M, 2001, HUM IMMUNOL, V62, P771, DOI 10.1016/S0198-8859(01)00276-2; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wang NZ, 2005, GENE, V353, P118, DOI 10.1016/j.gene.2005.04.013; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zheng L, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh110; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	47	103	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6175	6183		10.1074/jbc.M508045200	http://dx.doi.org/10.1074/jbc.M508045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407239	hybrid			2022-12-25	WOS:000236030800009
J	Samino, Y; Lopez, D; Guil, S; Saveanu, L; van Endert, PM; Del Val, M				Samino, Y; Lopez, D; Guil, S; Saveanu, L; van Endert, PM; Del Val, M			A long N-terminal-extended nested set of abundant and antigenic major histocompatibility complex class I natural Ligands from HIV envelope protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; EPITOPE PRECURSOR PEPTIDES; ENDOPLASMIC-RETICULUM; 3-DIMENSIONAL STRUCTURE; ENDOGENOUS PEPTIDES; T-LYMPHOCYTES; CELL-LINE; MOLECULES; AMINOPEPTIDASE; BINDING	Viral antigens complexed with major histocompatibility complex (MHC) class Imolecules are recognized by cytotoxic T lymphocytes on infected cells. Assays with synthetic peptides identify optimal MHC class I ligands often used for vaccines. However, when natural peptides are analyzed, more complex mixtures including long peptides bulging in the middle of the binding site or with carboxyl extensions are found, reflecting lack of exposure to carboxypeptidases in the antigen processing pathway. In contrast, precursor peptides are exposed to extensive cytosolic aminopeptidase activity, and fewer than 1% survive, only to be further trimmed in the endoplasmic reticulum. We show here a striking example of a nested set of at least three highly antigenic and similarly abundant natural MHC class I ligands, 15, 10, and 9 amino acids in length, derived from a single human immunodeficiency virus gp160 epitope. Antigen processing, thus, gives rise to a rich pool of possible ligands from which MHC class I molecules can choose. The natural peptide set includes a 15-residue-long peptide with unprecedented 6 N-terminal residues that most likely extend out of the MHC class I binding groove. This 15-mer is the longest natural peptide known recognized by cytotoxic T lymphocytes and is surprisingly protected from aminopeptidase trimming in living cells.	Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain; Univ Paris 05, INSERM, U580, F-75015 Paris, France	Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Del Val, M (corresponding author), Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.	mdval@isciii.es	López, Daniel/I-2632-2014; van Endert, Peter/R-4606-2017; Saveanu, Loredana/K-6821-2017; SAVEANU, Loredana/Q-1241-2019; Del Val, Margarita/E-4769-2010	López, Daniel/0000-0003-0268-5878; van Endert, Peter/0000-0003-3782-0750; SAVEANU, Loredana/0000-0003-3138-7968; Del Val, Margarita/0000-0001-6769-4279				ABASTADO JP, 1987, J EXP MED, V166, P327, DOI 10.1084/jem.166.2.327; Achour A, 2002, IMMUNITY, V17, P757, DOI 10.1016/S1074-7613(02)00478-8; Balendiran GK, 1997, P NATL ACAD SCI USA, V94, P6880, DOI 10.1073/pnas.94.13.6880; BERGMANN CC, 1994, J IMMUNOL, V152, P5603; Brouwenstijn N, 2001, IMMUNITY, V15, P95, DOI 10.1016/S1074-7613(01)00174-1; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; CHAKRABARTI S, 1986, NATURE, V320, P535, DOI 10.1038/320535a0; CHEN Y, 1994, J IMMUNOL, V152, P2874; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CRUMPACKER DB, 1992, J IMMUNOL, V148, P3004; Daniel S, 1997, J IMMUNOL, V159, P2350; DEL VM, 1991, CELL, V66, P1145; DELVAL M, 1988, J VIROL, V62, P3965, DOI 10.1128/JVI.62.11.3965-3972.1988; Flyer DC, 2002, INFECT IMMUN, V70, P2926, DOI 10.1128/IAI.70.6.2926-2932.2002; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fruci D, 2001, IMMUNITY, V15, P467, DOI 10.1016/S1074-7613(01)00203-5; FRUMENTO G, 1993, CELL IMMUNOL, V152, P623, DOI 10.1006/cimm.1993.1318; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HENGEL H, 1995, J IMMUNOL, V154, P4557; Herr W, 1999, P NATL ACAD SCI USA, V96, P12033, DOI 10.1073/pnas.96.21.12033; KORBER BTM, 2005, LAUR060036 LOS AL NA; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KOZLOWSKI S, 1993, J IMMUNOL, V151, P4033; Lauvau G, 1999, J EXP MED, V190, P1227, DOI 10.1084/jem.190.9.1227; Lopez D, 2000, J IMMUNOL, V164, P5070, DOI 10.4049/jimmunol.164.10.5070; Lucchiari-Hartz M, 2000, J EXP MED, V191, P239, DOI 10.1084/jem.191.2.239; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; OZATO K, 1980, J IMMUNOL, V125, P2473; PARKER KC, 1994, J IMMUNOL, V152, P163; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Probst-Kepper M, 2001, J EXP MED, V193, P1189, DOI 10.1084/jem.193.10.1189; Probst-Kepper M, 2004, J IMMUNOL, V173, P5610, DOI 10.4049/jimmunol.173.9.5610; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Samino Y, 2004, J BIOL CHEM, V279, P1151, DOI 10.1074/jbc.M305343200; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saveanu L, 2005, NAT IMMUNOL, V6, P689, DOI 10.1038/ni1208; Serwold T, 1999, J IMMUNOL, V162, P4712; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Speir JA, 2001, IMMUNITY, V14, P81, DOI 10.1016/S1074-7613(01)00091-7; TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105; Tanioka T, 2003, J BIOL CHEM, V278, P32275, DOI 10.1074/jbc.M305076200; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860	51	31	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6358	6365		10.1074/jbc.M512263200	http://dx.doi.org/10.1074/jbc.M512263200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407287	Green Published, hybrid			2022-12-25	WOS:000236030800029
J	Xie, ZL; Dong, YZ; Zhang, M; Cui, MZ; Cohen, RA; Riek, U; Neumann, D; Schlattner, U; Zou, MH				Xie, ZL; Dong, YZ; Zhang, M; Cui, MZ; Cohen, RA; Riek, U; Neumann, D; Schlattner, U; Zou, MH			Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ACETYL-COA CARBOXYLASE; TUMOR-SUPPRESSOR; UPSTREAM KINASE; NITRIC-OXIDE; LKB1; GLUCOSE; PHOSPHORYLATION; BETA; STIMULATION	We previously reported the phosphoinositide 3-kinase-dependent activation of the 5'-AMP-activated kinase ( AMPK) by peroxynitrite (ONOO-) and hypoxia-reoxygenation in cultured endothelial cells. Here we show the molecular mechanism of activation of this pathway. Exposure of bovine aortic endothelial cells to ONOO- significantly increased the phosphorylation of both Thr(172) of AMPK and Ser(1179) of endothelial nitric-oxide synthase, a known downstream enzyme of AMPK. In addition, activation of AMPK by ONOO- was accompanied by increased phosphorylation of protein kinase C zeta (PKC zeta) ( Thr(410/403)) and translocation of cytosolic PKC zeta into the membrane. Further, inhibition of PKC zeta abrogated ONOO--induced AMPK-Thr(172) phosphorylation as that of endothelial nitric-oxide synthase. Furthermore, overexpression of a constitutively active PKC zeta mutant enhanced the phosphorylation of AMPK-Thr(172), suggesting that PKC zeta is upstream of AMPK activation. In contrast, ONOO- activated PKC zeta in LKB1-deficient HeLa-S3 but affected neither AMPK-Thr(172) nor AMPK activity. These data suggest that LKB1 is required for PKC zeta-enhanced AMPK activation. In vitro, recombinant PKC zeta phosphorylated LKB1 at Ser(428), resulting in phosphorylation of AMPK at Thr(172). Further, direct mutation of Ser(428) of LKB1 into alanine, like the kinase-inactive LKB1 mutant, abolished ONOO--induced AMPK activation. In several cell types originating from human, rat, and mouse, inhibition of PKC zeta significantly attenuated the phosphorylation of both LKB1-Ser(428) and AMPK-Thr(172) that were enhanced by ONOO-. Taken together, we conclude that PKC zeta can regulate AMPK activity by increasing the Ser(428) phosphorylation of LKB1, resulting in association of LKB1 with AMPK and consequent AMPK Thr(172) phosphorylation by LKB1.	Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Endocrinol & Diabet, Oklahoma City, OK 73104 USA; Univ Tennessee, Coll Vet Med, Dept Pathol, Knoxville, TN 37996 USA; Boston Univ, Sch Med, Vasc Biol Unit, Boston, MA 02118 USA; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; Boston University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zou, MH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Div Endocrinol & Diabet, 941 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	ming-hui-zou@ouhsc.edu	Schlattner, Uwe/D-1267-2009	Schlattner, Uwe/0000-0003-1159-5911; Neumann, Dietbert/0000-0002-4316-684X; Cui, Mei-Zhen/0000-0003-4745-6999; /0000-0002-1070-6408	NHLBI NIH HHS [HL68758, HL080499, HL079584, HL07439] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079584, R01HL080499, T32HL007439, P01HL068758] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beauloye C, 2002, FEBS LETT, V531, P324, DOI 10.1016/S0014-5793(02)03552-4; Boudeau J, 2003, FEBS LETT, V546, P159, DOI 10.1016/S0014-5793(03)00642-2; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Carling D, 2005, BIOCHIMIE, V87, P87, DOI 10.1016/j.biochi.2004.10.017; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; DAVIS B, 2006, IN PRESS DIABETES; Dyck JRB, 1996, J BIOL CHEM, V271, P17798, DOI 10.1074/jbc.271.30.17798; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Fleming I, 2003, THROMB HAEMOSTASIS, V90, P863, DOI 10.1160/TH03-04-0228; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Green Jeremy B A, 2004, Cell Cycle, V3, P12; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; HUTBER CA, 1996, AM J PHYSIOL, V272, pE262; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Puceat M, 1996, MOL CELL BIOCHEM, V157, P65; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shizukuda Y, 2002, AM J PHYSIOL-HEART C, V282, pH320, DOI 10.1152/ajpheart.2002.282.1.H320; Tan MQ, 2003, J BIOL CHEM, V278, P2824, DOI 10.1074/jbc.M211523200; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xie ZL, 2004, J BIOL CHEM, V279, P39513, DOI 10.1074/jbc.M405844200; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	56	156	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6366	6375		10.1074/jbc.M511178200	http://dx.doi.org/10.1074/jbc.M511178200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407220	hybrid			2022-12-25	WOS:000236030800030
J	Clohessy, JG; Zhuang, JG; de Boer, J; Gil-Gomez, G; Brady, HJM				Clohessy, JG; Zhuang, JG; de Boer, J; Gil-Gomez, G; Brady, HJM			Mcl-1 interacts with truncated bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; BH3-ONLY PROTEINS; IMMUNOHISTOCHEMICAL ANALYSIS; MITOCHONDRIAL-MEMBRANE; CONFORMATIONAL-CHANGE; DEATH RECEPTORS; BH3 DOMAINS; CELL-DEATH; T-CELLS; BAX	Engagement of death receptors such as tumor necrosis factor-R1 and Fas brings about the cleavage of cytosolic Bid to truncated Bid (tBid), which translocates to mitochondria to activate Bax/Bak, resulting in the release of cytochrome c. The mechanism underlying the activation, however, is not fully understood. Here, we have identified the anti-apoptotic Bcl-2 family member Mcl-1 as a potent tBid-binding partner. Site-directed mutagenesis reveals that the Bcl-2 homology (BH) 3 domain of tBid is essential for binding to Mcl-1, whereas all threeBHdomains (BH1, BH2, and BH3) of Mcl-1 are required for interaction with tBid. In vitro studies using isolated mitochondria and recombinant proteins demonstrate that Mcl-1 strongly inhibits tBid-induced cytochrome c release. In addition to its ability to interact directly with Bax and Bak, tBid also binds Mcl-1 and displaces Bak from the Mcl-1-Bak complex. Importantly, overexpression of Mcl-1 confers resistance to the induction of apoptosis by both TRAIL and tumor necrosis factor-alpha in HeLa cells, whereas targeting Mcl-1 by RNA interference sensitizes HeLa cells to TRAIL-induced apoptosis. Therefore, our study demonstrates a novel regulation of tBid by Mcl-1 through protein-protein interaction in apoptotic signaling from death receptors to mitochondria.	Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; UCL, Great Ormond St Hosp Children, London WC1N 1EH, England; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-03003 Barcelona, Spain	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Pompeu Fabra University	Brady, HJM (corresponding author), Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	h.brady@ich.ucl.ac.uk	de Boer, Jasper/B-5067-2013; Gil-Gomez, G/H-6307-2014	de Boer, Jasper/0000-0002-3220-8776; Gil-Gomez, G/0000-0002-9790-7308; Clohessy, John/0000-0001-5186-9775; Zhuang, Jianguo/0000-0003-3245-0789; Brady, Hugh/0000-0002-3152-067X				Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Edwards SW, 2004, BIOCHEM SOC T, V32, P489, DOI 10.1042/BST0320489; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Okita H, 1998, BBA-GENE STRUCT EXPR, V1398, P335, DOI 10.1016/S0167-4781(98)00059-1; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Rinkenberger JL, 2000, GENE DEV, V14, P23; Schulze-Bergkamen H, 2004, HEPATOLOGY, V39, P645, DOI 10.1002/hep.20138; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Seol DW, 2001, CANCER RES, V61, P1138; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	46	149	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5750	5759		10.1074/jbc.M505688200	http://dx.doi.org/10.1074/jbc.M505688200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380381	hybrid			2022-12-25	WOS:000235568900053
J	Phillips-Mason, PJ; Gates, TJ; Major, DL; Sacks, DB; Brady-Kalnay, SM				Phillips-Mason, PJ; Gates, TJ; Major, DL; Sacks, DB; Brady-Kalnay, SM			The receptor protein-tyrosine phosphatase PTP mu interacts with IQGAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; HOMOPHILIC BINDING-SITE; RASGAP-RELATED PROTEIN; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; NEURITE OUTGROWTH; RPTP-MU; BETA-CATENIN; PKC-DELTA; IN-VIVO	The receptor protein-tyrosine phosphatase PTP mu is a member of the Ig superfamily of cell adhesion molecules. The extracellular domain of PTP mu contains motifs commonly found in cell adhesion molecules. The intracellular domain of PTP mu contains two conserved catalytic domains, only the membrane-proximal domain has catalytic activity. The unique features of PTP mu make it an attractive molecule to transduce signals upon cell-cell contact. PTP mu has been shown to regulate cadherin-mediated cell adhesion, neurite outgrowth, and axon guidance. Protein kinase C is a component of the PTP mu signaling pathway utilized to regulate these events. To aid in the further characterization of PTP mu signaling pathways, we used a series of GST-PTP mu fusion proteins, including catalytically inactive and substrate trapping mutants, to identify PTP mu-interacting proteins. We identified IQGAP1, a known regulator of the Rho GTPases, Cdc42 and Rac1, as a novel PTP mu-interacting protein. We show that this interaction is due to direct binding. In addition, we demonstrate that amino acid residues 765-958 of PTP mu, which include the juxtamembrane domain and 35 residues of the first phosphatase domain, mediate the binding to IQGAP1. Furthermore, we demonstrate that constitutively active Cdc42, and to a lesser extent Rac1, enhances the interaction of PTP mu and IQGAP1. These data indicate PTP mu may regulate Rho-GTPase-dependent functions of IQGAP1 and suggest that IQGAP1 is a component of the PTP mu signaling pathway. In support of this, we show that a peptide that competes IQGAP1 binding to Rho GTPases blocks PTP mu-mediated neurite outgrowth.	Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Brady-Kalnay, SM (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	susann.brady-kalnay@case.edu		Sacks, David/0000-0003-3100-0735	NATIONAL CANCER INSTITUTE [R01CA093645] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY011373, R01EY012251] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA93645] Funding Source: Medline; NEI NIH HHS [R01-EY12251, P0-EY11373, R01 EY012251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Blanchetot C, 2005, METHODS, V35, P44, DOI 10.1016/j.ymeth.2004.07.007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Burden-Gulley SM, 2002, J NEUROSCI, V22, P3615; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Cismasiu VB, 2004, J BIOL CHEM, V279, P26922, DOI 10.1074/jbc.M313115200; Ensslen SE, 2004, MOL CELL NEUROSCI, V25, P558, DOI 10.1016/j.mcn.2003.12.003; Ensslen-Craig SE, 2005, MOL CELL NEUROSCI, V28, P177, DOI 10.1016/j.mcn.2004.08.011; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fukada M, 2005, METHODS, V35, P54, DOI 10.1016/j.ymeth.2004.07.008; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Grohmanova K, 2004, J BIOL CHEM, V279, P48495, DOI 10.1074/jbc.M408113200; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; Li ZG, 2005, J BIOL CHEM, V280, P13871, DOI 10.1074/jbc.M413482200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lui WY, 2005, J CELL PHYSIOL, V202, P49, DOI 10.1002/jcp.20098; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mataraza JM, 2003, BIOCHEM BIOPH RES CO, V305, P315, DOI 10.1016/S0006-291X(03)00759-9; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosdahl JA, 2003, J NEUROBIOL, V56, P199, DOI 10.1002/neu.10231; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VIELMETTER J, 1990, EXP BRAIN RES, V81, P283; WALTER J, 1987, DEVELOPMENT, V101, P909; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	66	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4903	4910		10.1074/jbc.M506414200	http://dx.doi.org/10.1074/jbc.M506414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380380	hybrid			2022-12-25	WOS:000235426200041
J	Tanemura, K; Chui, DH; Fukuda, T; Murayama, M; Park, JM; Akagi, T; Tatebayashi, Y; Miyasaka, T; Kimura, T; Hashikawa, T; Nakano, Y; Kudo, T; Takeda, M; Takashima, A				Tanemura, K; Chui, DH; Fukuda, T; Murayama, M; Park, JM; Akagi, T; Tatebayashi, Y; Miyasaka, T; Kimura, T; Hashikawa, T; Nakano, Y; Kudo, T; Takeda, M; Takashima, A			Formation of Tau inclusions in knock-in mice with familial Alzheimer disease (FAD) mutation of presenilin 1 (PS1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; FRONTOTEMPORAL DEMENTIA; AMYLOID DEPOSITION; CELL-LINES; A-BETA; NEURODEGENERATION; ACCUMULATION; ACTIVATION; PROTEIN	Mutations in the presenilin 1 ( PS1) gene are responsible for the early onset of familial Alzheimer disease ( FAD). Accumulating evidence shows that PS1 is involved in gamma-secretase activity and that FAD-associated mutations of PS1 commonly accelerate A beta(1-42) production, which causes Alzheimer disease ( AD). Recent studies suggest, however, that PS1 is involved not only in A beta production but also in other processes that lead to neurodegeneration. To better understand the causes of neurodegeneration linked to the PS1 mutation, we analyzed the development of tau pathology, another key feature of AD, in PS1 knock-in mice. Hippocampal samples taken from FAD mutant ( I213T) PS1 knock-in mice contained hyperphosphorylated tau that reacted with various phosphodependent tau antibodies and with Alz50, which recognizes the conformational change of PHF tau. Some neurons exhibited Congo red birefringence and Thioflavin T reactivity, both of which are histological criteria for neurofibrillary tangles ( NFTs). Biochemical analysis of the samples revealed SDS-insoluble tau, which under electron microscopy examination, resembled tau fibrils. These results indicate that our mutant PS1 knock-in mice exhibited NFT-like tau pathology in the absence of A beta deposition, suggesting that PS1 mutations contribute to the onset of AD not only by enhancing A beta(1-42) production but by also accelerating the formation and accumulation of filamentous tau.	RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Med, Dept Psychiat & Behav Sci & Environm Med, Suita, Osaka 5650871, Japan	RIKEN; RIKEN; Osaka University	Takashima, A (corresponding author), RIKEN, Brain Sci Inst, Lab Alzheimers Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kenneth@brain.riken.jp						Amtul Z, 2002, NEUROBIOL DIS, V9, P269, DOI 10.1006/nbdi.2001.0473; Baki L, 2004, EMBO J, V23, P2586, DOI 10.1038/sj.emboj.7600251; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Chang PT, 2000, BRAIN RES PROTOC, V6, P6, DOI 10.1016/S1385-299X(00)00031-3; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dermaut B, 2004, ANN NEUROL, V55, P617, DOI 10.1002/ana.20083; Evin G, 2002, NEUROREPORT, V13, P719, DOI 10.1097/00001756-200204160-00036; Gomez-Isla T, 1999, BRAIN, V122, P1709, DOI 10.1093/brain/122.9.1709; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; IQBAL K, 1991, NEUROBIOL AGING, V12, P357, DOI 10.1016/0197-4580(91)90022-C; Kang DE, 2005, J BIOL CHEM, V280, P31537, DOI 10.1074/jbc.M500833200; Klein AM, 1999, ANN NY ACAD SCI, V893, P314, DOI 10.1111/j.1749-6632.1999.tb07845.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Morelli L, 1999, CELL TISSUE RES, V298, P225, DOI 10.1007/s004419900109; Murayama O, 1997, NEUROSCI LETT, V229, P61, DOI 10.1016/S0304-3940(97)00417-5; Nakano Y, 1999, EUR J NEUROSCI, V11, P2577, DOI 10.1046/j.1460-9568.1999.00698.x; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Siman R, 2000, J NEUROSCI, V20, P8717; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; St George-Hyslop PH, 2005, CR BIOL, V328, P119, DOI 10.1016/j.crvi.2004.10.013; Sun XY, 2002, NEUROBIOL AGING, V23, P195, DOI 10.1016/S0197-4580(01)00265-2; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tanemura K, 2002, J NEUROSCI, V22, P133, DOI 10.1523/JNEUROSCI.22-01-00133.2002; Tang-Wai D, 2002, DEMENT GERIATR COGN, V14, P13, DOI 10.1159/000058328; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; Yoshiyama Y, 2001, Curr Neurol Neurosci Rep, V1, P413, DOI 10.1007/s11910-001-0100-0; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2	33	43	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5037	5041		10.1074/jbc.M509145200	http://dx.doi.org/10.1074/jbc.M509145200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377636	hybrid			2022-12-25	WOS:000235426200057
J	Ulrichts, H; Udvardy, MS; Lenting, PJ; Pareyn, I; Vandeputte, N; Vanhoorelbeke, K; Deckmyn, H				Ulrichts, H; Udvardy, MS; Lenting, PJ; Pareyn, I; Vandeputte, N; Vanhoorelbeke, K; Deckmyn, H			Shielding of the A1 domain by the D ' D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR DOMAIN; MONOCLONAL-ANTIBODY; FACTOR-VIII; BINDING DOMAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ALPHA-CHAIN; AMINO-ACIDS; COLLAGEN; COMPLEX	Soluble von Willebrand factor (VWF) has a low affinity for platelet glycoprotein (GP) Ib alpha and needs immobilization and/or high shear stress to enable binding of its A1 domain to the receptor. The previously described anti-VWF monoclonal antibody 1C1E7 enhances VWF/GPIb alpha binding and recognizes an epitope in the amino acids 764-1035 region in the N-terminal D'D3 domains. In this study we demonstrated that the D'D3 region negatively modulates the VWF/GPIb-IX-V interaction; (i) deletion of the D'D3 region in VWF augmented binding to GPIb alpha, suggesting an inhibitory role for this region, (ii) the isolated D'D3 region inhibited the GPIb alpha interaction of a VWF deletion mutant lacking this region, indicating that intramolecular interactions limit the accessibility of the A1 domain, (iii) using a panel of anti-VWF monoclonal antibodies, we next showed that the D'D3 region is in close proximity with the A1 domain in soluble VWF but not when VWF was immobilized; (iv) destroying the epitope of 1C1E7 resulted in a mutant VWF with an increased affinity for GPIb alpha. Our results support a model of domain translocation in VWF that allows interaction with GPIb alpha. The suggested shielding interaction of the A1 domain by the D'D3 region then becomes disrupted by VWF immobilization.	Katholieke Univ Leuven, Lab Thrombosis Res, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium; Univ Debrecen, Fac Med, Dept Clin Biochem & Mol Pathol, H-4012 Debrecen, Hungary; Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3584 CX Utrecht, Netherlands	KU Leuven; University of Debrecen; Utrecht University	Deckmyn, H (corresponding author), Katholieke Univ Leuven, Lab Thrombosis Res, Interdisciplinary Res Ctr, Campus Kortrijk,E Sabbelaan 53, B-8500 Kortrijk, Belgium.	Hans.Deckmyn@kuleuven-kortrijk.br	Lenting, Peter/AAH-5663-2019; Deckmyn, Hans/L-9434-2015; Deckmyn, Hans/N-8932-2019; Lenting, Peter/F-8269-2013	Lenting, Peter/0000-0002-7937-3429; Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; Lenting, Peter/0000-0002-7937-3429; Udvardy, Miklos Laszlo/0000-0002-0021-1225; Vanhoorelbeke, Karen/0000-0003-2288-8277				ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; Bendetowicz AV, 1999, J BIOL CHEM, V274, P12300, DOI 10.1074/jbc.274.18.12300; Depraetere H, 1998, BLOOD, V91, P3792; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Esch JSA, 1997, BLOOD, V90, P4425, DOI 10.1182/blood.V90.11.4425.4425_4425_4437; ESCH SA, 2005, BRIT J HAEMATOL, V128, P82; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; GOUDEMAND J, 1977, PATHOL BIOL, V25, P241; GRALNICK HR, 1992, P NATL ACAD SCI USA, V89, P7880, DOI 10.1073/pnas.89.17.7880; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; LANKHOF H, 1995, BLOOD, V86, P1035, DOI 10.1182/blood.V86.3.1035.bloodjournal8631035; Lenting PJ, 2004, J BIOL CHEM, V279, P12102, DOI 10.1074/jbc.M310436200; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; Meyer D, 2001, BEST PRACT RES CL HA, V14, P349, DOI 10.1053/beha.2001.0137; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; MOHRI H, 1988, J BIOL CHEM, V263, P17901; Nakayama T, 2002, J BIOL CHEM, V277, P22063, DOI 10.1074/jbc.M201327200; Novak L, 2002, BLOOD, V99, P2070, DOI 10.1182/blood.V99.6.2070; Obert B, 1999, BLOOD, V93, P1959, DOI 10.1182/blood.V93.6.1959.406k01_1959_1968; PIETU G, 1989, BIOCHEM BIOPH RES CO, V163, P618, DOI 10.1016/0006-291X(89)92182-7; READ MS, 1989, BLOOD, V74, P1031; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; RUGGERI ZM, 1981, BLOOD, V57, P1140; Sblattero D, 1998, IMMUNOTECHNOLOGY, V3, P271, DOI 10.1016/S1380-2933(97)10004-5; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; STAELENS S, 2005, IN PRESS MOL IMMUNOL; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; TORNAI I, 1993, J CLIN INVEST, V91, P273, DOI 10.1172/JCI116181; Ulrichts H, 2005, J THROMB HAEMOST, V3, P552, DOI 10.1111/j.1538-7836.2005.01209.x; Ulrichts H, 2004, J THROMB HAEMOST, V2, P1622, DOI 10.1111/j.1538-7836.2004.00865.x; Ulrichts H, 2003, ARTERIOSCL THROM VAS, V23, P1302, DOI 10.1161/01.ATV.0000079510.23517.43; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; Vanhoorelbeke K, 2003, J BIOL CHEM, V278, P37815, DOI 10.1074/jbc.M304289200; Vanhoorelbeke K, 2000, THROMB HAEMOSTASIS, V83, P107; VERMYLEN J, 1973, NATURE, V244, P167, DOI 10.1038/244167a0; VICENTE V, 1990, J BIOL CHEM, V265, P274	43	101	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4699	4707		10.1074/jbc.M513314200	http://dx.doi.org/10.1074/jbc.M513314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373331	Green Published, hybrid			2022-12-25	WOS:000235426200018
J	Woollhead, AM; Baines, DL				Woollhead, AM; Baines, DL			Forskolin-induced cell shrinkage and apical translocation of functional enhanced green fluorescent protein-human alpha ENaC in H441 lung epithelial cell monolayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; SODIUM-CHANNEL; LIQUID CLEARANCE; GUINEA-PIGS; II CELLS; CAMP; EXPRESSION; TRANSPORT; ABSORPTION; MEMBRANE	Elevation of intracellular cAMP increases fluid re-absorption in the lung by raising amiloride-sensitive Na+ transport through the apically localized epithelial, amiloride-sensitive Na+ channel (ENaC). However, the signaling pathways mediating this response are still not fully understood. We show that inhibition of protein-tyrosine kinase (PTK) with Genistein and protein kinase A (PKA) with KT5720, decreased forskolin-stimulated amiloride-sensitive short circuit current (I-sc) across H441 adult human lung epithelial cell monolayers. KT5720 also decreased basal Isc. Stable expression of green fluorescent protein (GFP)-labeled human alpha ENaC in H441 cells was used to investigate dynamic changes in the cellular localization of this protein in response to forskolin. Reverse transcription-PCR and immunoblotting analysis revealed two clones expressing a truncated (alpha C3-5) and full-length (alpha C3-3) EGFP-h alpha ENaC protein. Only the alpha C3-3 clone displayed dome formation and exhibited a 50% increase in basal and forskolin-stimulated amiloride-sensitive I-sc indicating that the full-length protein was required for functional activity. Apical surface biotinylation and real-time confocal microscopy demonstrated that EGFP-h alpha ENaC (alpha C3-3) translocated to the apical membrane in response to forskolin in a Brefeldin A-sensitive manner. This effect was completely inhibited by Genistein but only partially inhibited by KT5720. Forskolin also induced a reduction in the height of cells within alpha C3-3 monolayers, indicative of cell shrinkage. This effect was inhibited by KT5720 but not by Genistein or Brefeldin A. These data show that forskolin activates PKA-sensitive cell shrinkage in adult human H441 lung epithelial cell monolayers, which induces a PTK-sensitive translocation of EGFP-h alpha ENaC subunits to the apical membrane and increases amiloride-sensitive Na+ transport.	St Georges Univ London, Div Basic Med Sci, Ion Channels & Cell Signaling Ctr, London SW17 0RE, England	St Georges University London	Baines, DL (corresponding author), St Georges Univ London, Div Basic Med Sci, Ion Channels & Cell Signaling Ctr, Cranmer Terrace, London SW17 0RE, England.	d.baines@sgul.ac.uk		Baines, Deborah/0000-0001-7229-0244	Wellcome Trust [068674/Z/02/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blazer-Yost BL, 2004, AM J PHYSIOL-CELL PH, V287, pC1569, DOI 10.1152/ajpcell.00226.2004; Blazer-Yost BL, 2001, AM J PHYSIOL-CELL PH, V281, pC624, DOI 10.1152/ajpcell.2001.281.2.C624; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; BONNY O, 1997, J AM SOC NEPHROL, V8, pM572; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chraibi A, 2001, CELL PHYSIOL BIOCHEM, V11, P115, DOI 10.1159/000047799; Finley N, 1998, J CLIN INVEST, V101, P972, DOI 10.1172/JCI1478; GOODMAN BE, 1989, AM J PHYSIOL, V257, pL86, DOI 10.1152/ajplung.1989.257.2.L86; Helve O, 2004, PEDIATRICS, V113, P1267, DOI 10.1542/peds.113.5.1267; Hosoi K, 2002, JPN J PHYSIOL, V52, P561, DOI 10.2170/jjphysiol.52.561; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Ito Y, 1997, PFLUG ARCH EUR J PHY, V434, P492, DOI 10.1007/s004240050425; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Koh G, 2005, ARCH BIOCHEM BIOPHYS, V438, P70, DOI 10.1016/j.abb.2005.03.018; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Marunaka Y, 2000, J KOREAN MED SCI, V15, pS42, DOI 10.3346/jkms.2000.15.S.S42; Moran O, 2005, FEBS LETT, V579, P3979, DOI 10.1016/j.febslet.2005.06.026; Niisato N, 1997, PFLUG ARCH EUR J PHY, V434, P227, DOI 10.1007/s004240050389; Niisato N, 1999, AM J PHYSIOL-LUNG C, V277, pL727, DOI 10.1152/ajplung.1999.277.4.L727; Norlin A, 1999, J PHYSIOL-LONDON, V519, P261, DOI 10.1111/j.1469-7793.1999.0261o.x; OBRODOVICH H, 1991, AM J PHYSIOL, V261, P555; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Ramminger SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL411, DOI 10.1152/ajplung.00407.2003; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SAUMON G, 1987, PFLUG ARCH EUR J PHY, V410, P464, DOI 10.1007/BF00586526; Shlyonsky V, 2005, J BIOL CHEM, V280, P24181, DOI 10.1074/jbc.M413823200; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Thomas CP, 2004, AM J PHYSIOL-LUNG C, V287, pL843, DOI 10.1152/ajplung.00340.2003; WALTERS DV, 1990, J APPL PHYSIOL, V68, P2054, DOI 10.1152/jappl.1990.68.5.2054; WALTERS DV, 1978, PEDIATR RES, V12, P239, DOI 10.1203/00006450-197803000-00017; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Woollhead AM, 2005, J PHYSIOL-LONDON, V566, P781, DOI 10.1113/jphysiol.2005.088674	35	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5158	5168		10.1074/jbc.M509947200	http://dx.doi.org/10.1074/jbc.M509947200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373340	hybrid			2022-12-25	WOS:000235426200070
J	Pullar, CE; Grahn, JC; Liu, W; Isseroff, RR				Pullar, CE; Grahn, JC; Liu, W; Isseroff, RR			beta 2-Adrenergic receptor activation delays wound healing	FASEB JOURNAL			English	Article						wound re-epithelialization; ERK activation; keratinocyte migration; focal adhesions	HUMAN EPIDERMAL-KERATINOCYTES; BETA-ADRENERGIC STIMULATION; PROTEIN PHOSPHATASE 2A; CELL-MIGRATION; BETA(2)-ADRENERGIC RECEPTOR; HUMAN SKIN; EXTRACELLULAR-MATRIX; KINASE ACTIVATION; FOCAL ADHESIONS; GROWTH	Keratinocytes migrate directionally into the wound bed to initiate re-epithelialization, necessary for wound closure and restoration of barrier function. They solely express the beta 2-adrenergic receptor (beta 2-AR) subtype of beta-ARs and can also synthesize beta-AR agonists generating a hormonal mediator network in the skin. Emerging studies from our laboratory demonstrate that beta-AR agonists decrease keratinocyte migration via a protein phosphatase (PP) 2A-dependent mechanism. Here we have extended our investigations to observe the effects of beta 2-AR activation on keratinocyte polarization, migration, and ERK phosphorylation at the wound edge, cytoskeletal organization, phospho-ERK intracellular localization, proliferation, human skin wound re-epithelialization, wound-induced ERK phosphorylation, and murine skin wound healing. We demonstrate that in keratinocytes, beta 2-AR activation is antimotogenic and anti-mitogenic with both mechanisms being PP2A dependent. beta 2-AR activation dramatically alters the organization of the actin cytoskeleton and prevents localization of phospho-ERK to the lamellipodial edge and its colocalization with vinculin. Finally, we demonstrate a beta 2-AR-mediated delay in re-epithelialization and decrease in wound-induced epidermal ERK phosphorylation in human skin wounds and a delay in re-epithelialization in murine tail-clip wounds. Our work uncovers novel keratinocyte biology and a previously unrecognized role for the adrenergic hormonal mediator network in the wound repair process. Pullar, C. E., Grahn, J. C., Liu, W., Isseroff, R. R. beta 2-Adrenergic receptor activation delays wound healing.	Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA	University of California System; University of California Davis	Pullar, CE (corresponding author), Univ Calif Davis, Dept Dermatol, TB 192,1 Shields Ave, Davis, CA 95616 USA.	cepullar@ucdavis.edu	Isseroff, Roslyn Rivkah/AAD-8478-2021	Isseroff, Roslyn Rivkah/0000-0001-7813-0858	NIAMS NIH HHS [AR 44518, AR 48827] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044518, K01AR048827] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; Chen J, 2002, J INVEST DERMATOL, V119, P1261, DOI 10.1046/j.1523-1747.2002.19611.x; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Cupp Craig L, 2002, Facial Plast Surg, V18, P53, DOI 10.1055/s-2002-19827; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; Denda M, 2003, J INVEST DERMATOL, V121, P142, DOI 10.1046/j.1523-1747.2003.12310.x; Denda M, 2000, AM J PHYSIOL-REG I, V278, pR367, DOI 10.1152/ajpregu.2000.278.2.R367; Detillion CE, 2004, PSYCHONEUROENDOCRINO, V29, P1004, DOI 10.1016/j.psyneuen.2003.10.003; DONALDSON DJ, 1984, COMP BIOCHEM PHYS C, V78, P267, DOI 10.1016/0742-8413(84)90081-1; EEDY DJ, 1990, BRIT J DERMATOL, V122, P477, DOI 10.1111/j.1365-2133.1990.tb14724.x; Frank DE, 2004, J CELL SCI, V117, P1351, DOI 10.1242/jcs.01003; GABBIANI G, 1978, J CELL BIOL, V76, P561, DOI 10.1083/jcb.76.3.561; Gillbro JM, 2004, J INVEST DERMATOL, V123, P346, DOI 10.1111/j.0022-202X.2004.23210.x; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; HAAS AF, 1990, J INVEST DERMATOL, V94, P822, DOI 10.1111/1523-1747.ep12874679; Haruta Y, 1997, Eur J Ophthalmol, V7, P334; ISSEROFF RR, 1987, J LIPID RES, V28, P1342; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kawada M, 1999, BBA-MOL CELL RES, V1452, P209, DOI 10.1016/S0167-4889(99)00126-3; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kratz G, 1998, MICROSC RES TECHNIQ, V42, P345, DOI 10.1002/(SICI)1097-0029(19980901)42:5<345::AID-JEMT5>3.0.CO;2-O; KUBLER MD, 1993, J INVEST DERMATOL, V100, P785, DOI 10.1111/1523-1747.ep12476492; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LIU GS, 1990, J OCUL PHARMACOL, V6, P101, DOI 10.1089/jop.1990.6.101; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MCSWIGAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P7670, DOI 10.1073/pnas.78.12.7670; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Nankova BB, 1999, ACTA PHYSIOL SCAND, V167, P1; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Providence KM, 2004, J CELL PHYSIOL, V200, P297, DOI 10.1002/jcp.20016; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; REIDY JJ, 1994, BRIT J OPHTHALMOL, V78, P377, DOI 10.1136/bjo.78.5.377; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHALLREUTER KU, 1993, ARCH DERMATOL RES, V285, P216, DOI 10.1007/BF00372012; SCHALLREUTER KU, 1995, J INVEST DERMATOL, V104, P953, DOI 10.1111/1523-1747.ep12606218; Schallreuter KU, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P37, DOI 10.1038/jidsymp.1997.9; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; STEINKRAUS V, 1992, J INVEST DERMATOL, V98, P475, DOI 10.1111/1523-1747.ep12499860; Steinkraus V, 1996, ARCH DERMATOL RES, V288, P549, DOI 10.1007/BF02505253; Tseraidis G S, 1972, Vestn Dermatol Venerol, V46, P40; Turchi L, 2002, J INVEST DERMATOL, V119, P56, DOI 10.1046/j.1523-1747.2002.01805.x; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	60	81	86	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					76	86		10.1096/fj.05-4188com	http://dx.doi.org/10.1096/fj.05-4188com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394270				2022-12-25	WOS:000235996000047
J	Razzaque, MS; Sitara, D; Taguchi, T; St-Arnaud, R; Lanske, B				Razzaque, MS; Sitara, D; Taguchi, T; St-Arnaud, R; Lanske, B			Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process	FASEB JOURNAL			English	Article						rescue; klotho; phosphate	FAMILIAL TUMORAL CALCINOSIS; OXIDATIVE STRESS; HUMAN EPIDERMIS; MUTATION; APOPTOSIS; HYPERPHOSPHATEMIA; EXPRESSION; DEFICIENT; PHOSPHATE; ABLATION	Fibroblast growth factor 23 null mice (Fgf-23(-/-)) have a short lifespan and show numerous biochemical and morphological features consistent with premature aging-like phenotypes, including kyphosis, severe muscle wasting, hypogonadism, osteopenia, emphysema, uncoordinated movement, T cell dysregulation, and atrophy of the intestinal villi, skin, thymus, and spleen. Furthermore, increased vitamin D activities in homozygous mutants are associated with severe atherosclerosis and widespread soft tissue calcifications; ablation of vitamin D activity from Fgf-23(-/-) mice, by genetically deleting the 1 alpha(OH)ase gene, eliminates atherosclerosis and ectopic calcifications and significantly rescues premature aging-like features of Fgf-23(-/-) mice, resulting in prolonged survival of Fgf-23(-/-)/ 1 alpha(OH)ase(-/-) double mutants. Our results indicate a novel role of Fgf-23 in developing premature aging-like features through regulating vitamin D homeostasis. Finally, our data support a new model of interactions among Fgf-23, vitamin D, and klotho, a gene described as being associated with premature aging process.	Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol, Nagasaki 852, Japan; Shriners Hosp Children, Genet Unit, Montreal, PQ, Canada	Harvard University; Harvard School of Dental Medicine; Nagasaki University; McGill University	Lanske, B (corresponding author), Harvard Univ, Sch Dent Med, Dept Dev Biol, Res & Educ Bldg,Room 303,188 Longwood Ave, Boston, MA 02115 USA.	beate_lanske@hsdm.harvard.edu	Razzaque, Mohammed S./K-4282-2019; RAZZAQUE, MOHAMMED/M-6017-2019	SITARA, DESPINA/0000-0002-4836-5039; Lanske, Beate/0000-0003-4638-804X	NIDDK NIH HHS [R01 DK073944-01A2, R01 DK073944] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073944] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai XY, 2004, ENDOCRINOLOGY, V145, P5269, DOI 10.1210/en.2004-0233; Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Delmas D, 2005, MOL NUTR FOOD RES, V49, P377, DOI 10.1002/mnfr.200400098; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Edwards MG, 2003, PHYSIOL GENOMICS, V13, P119, DOI 10.1152/physiolgenomics.00172.2002; EVERS BM, 1994, SURG CLIN N AM, V74, P23; Gilhar A, 2004, BRIT J DERMATOL, V150, P56, DOI 10.1111/j.1365-2133.2004.05715.x; Gilhar A, 2004, J GERONTOL A-BIOL, V59, P411; Ichikawa S, 2005, J CLIN ENDOCR METAB, V90, P2420, DOI 10.1210/jc.2004-2302; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Judge S, 2005, FASEB J, V19, P419, DOI 10.1096/fj.04-2622fje; Kawai T, 2000, J IMMUNOL, V164, P2102, DOI 10.4049/jimmunol.164.4.2102; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Larsson T, 2005, J CLIN ENDOCR METAB, V90, P2424, DOI 10.1210/jc.2004-2238; MARTIN CJ, 1977, AM REV RESPIR DIS, V115, P981; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; QUARLESLD, 2003, AM J PHYSL ENDOCRINO, V285, pE1; Radak Z, 2004, FASEB J, V18, P749, DOI 10.1096/fj.03-0509fje; Rauser CL, 2003, EXP GERONTOL, V38, P27, DOI 10.1016/S0531-5565(02)00148-1; Razzaque MS, 2005, NEPHROL DIAL TRANSPL, V20, P2032, DOI 10.1093/ndt/gfh991; Razzaque MS, 1997, J PATHOL, V183, P24; Razzaque MS, 2003, INVEST OPHTH VIS SCI, V44, P1616, DOI 10.1167/iovs.02-0644; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Sitara D, 2004, MATRIX BIOL, V23, P421, DOI 10.1016/j.matbio.2004.09.007; Taub DD, 2005, IMMUNOL REV, V205, P72, DOI 10.1111/j.0105-2896.2005.00275.x; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Yamamoto K, 2002, EUR HEART J, V23, P277; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696	35	264	274	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					720	+		10.1096/fj.05-5432fje	http://dx.doi.org/10.1096/fj.05-5432fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16436465	Green Accepted			2022-12-25	WOS:000235996000007
J	Schmidt, MHH; Husnjak, K; Szymkiewicz, I; Haglund, K; Dikic, I				Schmidt, M. H. H.; Husnjak, K.; Szymkiewicz, I.; Haglund, K.; Dikic, I.			Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule beta Pix	ONCOGENE			English	Article						Cbl; Cdc42; beta Pix; ubiquitylation; degradation	RECEPTOR TYROSINE KINASES; NUCLEOTIDE EXCHANGE FACTOR; P21-ACTIVATED KINASES; BINDING PARTNERS; C-CBL; ENDOCYTOSIS; PROTEINS; FAMILY; DEGRADATION; MECHANISMS	The Pix/Cool proteins are involved in the regulation of cell morphology by binding to small Rho GTPases and kinases of the Pak family. Recently, it has been shown that ss Pix/Cool-1 associates with the ubiquitin ligase Cbl, which appears to be a critical step in Cdc42- mediated inhibition of epidermal-growth-factor-receptor(EGFR) ubiquitylation and downregulation. Here we show that the SH3 domain of ss Pix specifically interacts with a proline arginine motif (PxxxPR) present within the ubiquitin ligase Cbl and Pak1 kinase. Owing to targeting of the same sequence, Cbl and Pak1 compete for binding to ss Pix. In this complex, Cbl mediates ubiquitylation and subsequent degradation of ss Pix. Our findings reveal a double feedback loop in which the Cdc42/ss Pix complex blocks Cbl's ability to downregulate EGFR, while Cbl in turn promotes degradation of ss Pix in order to escape this inhibition. Such a relationship provides a mechanism to tune-tune the kinetics of RTK endocytosis and degradation depending on the pool of active Cdc42 and the duration of EGFR signaling.	Univ Frankfurt, Univ Hosp, Inst Biochem 2, Frankfurt, Germany; Rudjer Boskovic Inst, Div Mol Med, Mol Oncol Lab, Zagreb, Croatia	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Rudjer Boskovic Institute	Dikic, I (corresponding author), Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany.	ivan.dikic@biochem2.de	Haglund, Kaisa/B-3927-2017; Schmidt, Mirko H. H./ABI-6650-2020; Husnjak, Koraljka/C-3717-2015; Dikic, Ivan/O-4650-2015; Pilecka, Iwona/AAT-9114-2021	Haglund, Kaisa/0000-0002-7946-3299; Schmidt, Mirko H. H./0000-0001-7411-8835; Husnjak, Koraljka/0000-0003-0573-6239; Dikic, Ivan/0000-0001-8156-9511; Pilecka, Iwona/0000-0002-5057-346X				Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lee J, 2005, EXP CELL RES, V307, P315, DOI 10.1016/j.yexcr.2005.03.028; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3	26	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3071	3078		10.1038/sj.onc.1209329	http://dx.doi.org/10.1038/sj.onc.1209329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407834				2022-12-25	WOS:000237950800012
J	Su, LT; Agapito, MA; Li, MJ; Sinomson, WTN; Huttenlocher, A; Habas, R; Yue, LX; Runnels, LW				Su, LT; Agapito, MA; Li, MJ; Sinomson, WTN; Huttenlocher, A; Habas, R; Yue, LX; Runnels, LW			TRPM7 regulates cell adhesion by controlling the calcium-dependent protease calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE RETRACTION; POLYVALENT CATIONS; NEURONAL DEATH; MIC CHANNELS; GROWTH CONE; ACTIVATION; KINASE; RHO; MOTILITY; TRANSFORMATION	m-Calpain is a protease implicated in the control of cell adhesion through focal adhesion disassembly. The mechanism by which the enzyme is spatially and temporally controlled is not well understood, particularly because the dependence of calpain on calcium exceeds the submicromolar concentrations normally observed in cells. Here we show that the channel kinase TRPM7 localizes to peripheral adhesion complexes with m-calpain, where it regulates cell adhesion by controlling the activity of the protease. Our research revealed that overexpression of TRPM7 in cells caused cell rounding with a concomitant loss of cell adhesion that is dependent upon the channel of the protein but not its kinase activities. Knockdown of m-calpain blocked TRPM7-induced cell rounding and cell detachment. Silencing of TRPM7 by RNA interference, however, strengthened cell adhesion and increased the number of peripheral adhesion complexes in the cells. Together, our results suggest that the ion channel TRPM7 regulates cell adhesion through m-calpain by mediating the local influx of calcium into peripheral adhesion complexes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT 06030 USA; Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Connecticut; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Rutgers State University New Brunswick; Rutgers State University Medical Center	Runnels, LW (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	runnellw@umdnj.edu		Runnels, Loren/0000-0002-2537-7360	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL078960-02, R01 HL078960] Funding Source: Medline; NIGMS NIH HHS [T32 GM008692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8; Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Elizondo MR, 2005, CURR BIOL, V15, P667, DOI 10.1016/j.cub.2005.02.050; Fleig Andrea, 2004, Novartis Found Symp, V258, P248; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hanano T, 2004, J PHARMACOL SCI, V95, P403, DOI 10.1254/jphs.FP0040273; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Inserte J, 2005, CIRC RES, V97, P465, DOI 10.1161/01.RES.0000181170.87738.f3; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jiang JM, 2005, J GEN PHYSIOL, V126, P137, DOI 10.1085/jgp.200409185; Kerschbaum HH, 2003, BIOPHYS J, V84, P2293, DOI 10.1016/S0006-3495(03)75035-8; Kozak JA, 2005, J GEN PHYSIOL, V126, P499, DOI 10.1085/jgp.200509324; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Liu XL, 2001, AM J PHYSIOL-RENAL, V281, pF728, DOI 10.1152/ajprenal.2001.281.4.F728; Mamoune A, 2003, CANCER RES, V63, P4632; Marzocco S, 2004, SHOCK, V21, P38, DOI 10.1097/01.shk.0000095056.62263.b2; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; Mehendale HM, 2005, TRENDS PHARMACOL SCI, V26, P232, DOI 10.1016/j.tips.2005.03.008; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nagy Z, 2004, ADV EXP MED BIOL, V541, P39; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; Nilius Bernd, 2004, Novartis Found Symp, V258, P140; Ortiz-Urda S, 2005, SCIENCE, V307, P1773, DOI 10.1126/science.1106209; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; PERRIN BJ, 2005, MOL BIOL CELL; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Schmitz C, 2005, J BIOL CHEM, V280, P37763, DOI 10.1074/jbc.M509175200; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; SONG DK, 1994, J NEUROSCI RES, V39, P474, DOI 10.1002/jnr.490390414; Spira ME, 2003, J COMP NEUROL, V457, P293, DOI 10.1002/cne.10569; Starling A, 2003, J MOL NEUROSCI, V21, P233, DOI 10.1385/JMN:21:3:233; Tamada Y, 2002, COMP BIOCHEM PHYS B, V131, P221, DOI 10.1016/S1096-4959(01)00489-4; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Wells A, 2005, INT REV CYTOL, V245, P1, DOI 10.1016/S0074-7696(05)45001-9; Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Zatz M, 2005, NEW ENGL J MED, V352, P2413, DOI 10.1056/NEJMra043361	67	185	193	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11260	11270		10.1074/jbc.M512885200	http://dx.doi.org/10.1074/jbc.M512885200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16436382	Green Accepted, hybrid			2022-12-25	WOS:000236822200069
J	Uruno, T; Remmert, K; Hammer, JA				Uruno, T; Remmert, K; Hammer, JA			CARMIL is a potent capping protein antagonist - Identification of a conserved CARMIL domain that inhibits the activity of capping protein and uncaps capped actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARBED-END; ARP2/3 COMPLEX; ACANTHAMOEBA-CASTELLANII; ENA/VASP PROTEINS; FAMILY PROTEINS; MYOSIN-I; POLYMERIZATION; MOTILITY; BINDING; DICTYOSTELIUM	Acanthamoeba CARMIL was previously shown to co-purify with capping protein (CP) and to bind pure CP. Here we show that this interaction inhibits the barbed end-capping activity of CP. Even more strikingly, this interaction drives the uncapping of actin filaments previously capped with CP. These activities are CP-specific; CARMIL does not inhibit the capping activities of either gelsolin or CapG and does not uncap gelsolin-capped filaments. Although full-length (FL) CARMIL (residues 1-1121) possesses both anti-CP activities, C-terminal fragments like glutathione S-transferase (GST)-P (940-1121) that contain the CARMIL CP binding site are at least 10 times more active. We localized the full activities of GST-P to its C-terminal 51 residues (1071-1121). This sequence contains a stretch of 25 residues that is highly conserved in CARMIL proteins from protozoa, flies, worms, and vertebrates (CARMIL Homology domain 3; CAH3). Point mutations showed that the majority of the most highly conserved residues within CAH3 are critical for the anti-CP activity of GST-AP (862-1121). Finally, we found that GST-AP binds CP similar to 20-fold more tightly than does FL-CARMIL. This observation together with the elevated activities of C-terminal fragments relative to FL-CARMIL suggests that FL-CARMIL might exist primarily in an autoinhibited state. Consistent with this idea, proteolytic cleavage of FL-CARMIL with thrombin generated an similar to 14-kDa C-terminal fragment that expresses full anti-CP activities. We propose that, after some type of physiological activation event, FL-CARMIL could function in vivo as a potent CP antagonist. Given the pivotal role that CP plays in determining the global actin phenotype of cells, our results suggest that CARMIL may play an important role in the physiological regulation of actin assembly.	NHLBI, Cell Biol Lab, Sect Mol Cell Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hammer, JA (corresponding author), NHLBI, Cell Biol Lab, Sect Mol Cell Biol, NIH, Bldg 50,Rm 2523,9000 Rockville Pike, Bethesda, MD 20892 USA.	hammerj@nhlbi.nih.gov	Uruno, Takehito/AAF-7998-2019	Uruno, Takehito/0000-0002-2812-9645	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000514, Z01HL000514] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Barzik M, 2005, J BIOL CHEM, V280, P28653, DOI 10.1074/jbc.M503957200; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; BHATTACHARYA N, 2004, 44 ANN M AM SOC CELL; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; DABIRI GA, 1992, J BIOL CHEM, V267, P16545; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Evangelista M, 2003, J CELL SCI, V116, P2603, DOI 10.1242/jcs.00611; GORDON DJ, 1976, J BIOL CHEM, V251, P4778; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hopmann R, 1996, J CELL BIOL, V133, P1293, DOI 10.1083/jcb.133.6.1293; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; KAISER DA, 1986, J CELL BIOL, V102, P221, DOI 10.1083/jcb.102.1.221; Kelleher JF, 1998, METHOD ENZYMOL, V298, P42, DOI 10.1016/S0076-6879(98)98007-7; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lee WL, 1999, J BIOL CHEM, V274, P35159, DOI 10.1074/jbc.274.49.35159; Matsuzaka Y, 2004, GENE, V343, P291, DOI 10.1016/j.gene.2004.09.004; Mejillano MR, 2004, CELL, V118, P363, DOI 10.1016/j.cell.2004.07.019; Mullins RD, 2000, METHOD ENZYMOL, V325, P214; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; Remmert K, 2004, J BIOL CHEM, V279, P3068, DOI 10.1074/jbc.M308829200; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Takenawa T, 2001, J CELL SCI, V114, P1801; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wear MA, 2004, TRENDS BIOCHEM SCI, V29, P418, DOI 10.1016/j.tibs.2004.06.003; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; Xu P, 1997, P NATL ACAD SCI USA, V94, P3685, DOI 10.1073/pnas.94.8.3685; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; Yang CS, 2005, DEV CELL, V9, P209, DOI 10.1016/j.devcel.2005.06.008; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	48	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10635	10650		10.1074/jbc.M513186200	http://dx.doi.org/10.1074/jbc.M513186200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16434392	hybrid			2022-12-25	WOS:000236594300096
J	Hales, TG; Dunlop, JI; Deeb, TZ; Carland, JE; Kelley, SP; Lambert, JJ; Peters, JA				Hales, TG; Dunlop, JI; Deeb, TZ; Carland, JE; Kelley, SP; Lambert, JJ; Peters, JA			Common determinants of single channel conductance within the large cytoplasmic loop of 5-hydroxytryptamine type 3 and alpha(4)beta(2) nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-HT3 RECEPTORS; ANGSTROM RESOLUTION; ION SELECTIVITY; AMINO-ACIDS; EXPRESSION; SUBUNIT	Homomeric 5-hydroxytryptamine type 3A receptors (5-HT(3A)Rs) have a single channel conductance (gamma) below the resolution of single channel recording (966 +/- 75 fS, estimated by variance analysis). By contrast, heteromeric 5-HT3A/B and nicotinic acetylcholine receptors (nAChRs) have picosiemen range gamma values. In this study, single channel recordings revealed that replacement of cytoplasmic membrane-associated (MA) helix arginine 432 (-4'), 436 (0'), and 440 (4') residues by 5-HT3B (-4'Gln, 0'Asp, and 4'Ala) residues increases gamma to 36.5 +/- 1.0 pS. The 0' residue makes the most substantial contribution to gamma of the 5-HT3AR. Replacement of 0' Arg by aspartate, glutamate (alpha(7)nAChR subunit MA 0'), or glutamine (beta(2) subunit MA 0') increases gamma to the resolvable range (>6 pS). By contrast, replacement of 0' Arg by phenylalanine (alpha(4) subunit MA 0') reduced gamma to 416 +/- 107 fS. In reciprocal experiments with alpha(4)beta(2) nAChRs (gamma=31.3 +/- 0.8 pS), replacement of MA 0' residues by arginine in alpha(4)beta(2)(Q443R) and alpha(4)(F588R) beta(2) reduced gamma slightly. By contrast, the gamma of double mutant alpha 4(F588R)beta(2)(Q443R) was halved. The MA -4' and 4' residues also influenced gamma of 5-HT(3A)Rs. Replacement of nAChR alpha(4) or beta(2) MA 4' residues by arginine made current density negligible. By contrast, replacement of both -4' residues by arginine produced functional nAChRs with substantially reduced gamma (11.4 +/- 0.5 pS). Homology models of the 5-HT3A and alpha(4)beta(2) nAChRs against Torpedo nAChR revealed MA -4', 0', and 4' residues within five intracellular portals. This locus may be a common determinant of ion conduction throughout the Cys loop receptor family.	George Washington Univ, Dept Physiol & Pharmacol, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA; Univ Dundee, Inst Neurosci, Div Pathol & neurosci, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland	George Washington University; George Washington University; University of Dundee	Hales, TG (corresponding author), George Washington Univ, Dept Physiol & Pharmacol, Med Ctr, 2300 Eye St NW, Washington, DC 20037 USA.	phmtgh@gwumc.edu		Carland, Jane/0000-0002-1456-876X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander SPH, 2004, BRIT J PHARMACOL, V141, pS1; Boyd GW, 2002, MOL CELL NEUROSCI, V21, P38, DOI 10.1006/mcne.2002.1160; Brown AM, 1998, J PHYSIOL-LONDON, V507, P653, DOI 10.1111/j.1469-7793.1998.653bs.x; Buisson B, 1996, J NEUROSCI, V16, P7880; Cooper ST, 1999, J BIOL CHEM, V274, P27145, DOI 10.1074/jbc.274.38.27145; Davies PA, 2001, J PHYSIOL-LONDON, V537, P101, DOI 10.1111/j.1469-7793.2001.0101k.x; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; Fucile S, 2002, P NATL ACAD SCI USA, V99, P3956, DOI 10.1073/pnas.052699599; HILLE B, 1992, IONIC CHANNELS EXCIT, P274; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Keramidas A, 2004, PROG BIOPHYS MOL BIO, V86, P161, DOI 10.1016/j.pbiomolbio.2003.09.002; Kuryatov A, 1997, J NEUROSCI, V17, P9035; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Peters JA, 2005, TRENDS PHARMACOL SCI, V26, P587, DOI 10.1016/j.tips.2005.09.011; Reeves DC, 2005, J NEUROSCI, V25, P9358, DOI 10.1523/JNEUROSCI.1045-05.2005; Unwin N, 2003, FEBS LETT, V555, P91, DOI 10.1016/S0014-5793(03)01084-6; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031	21	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8062	8071		10.1074/jbc.M513222200	http://dx.doi.org/10.1074/jbc.M513222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407231	hybrid, Green Accepted			2022-12-25	WOS:000236031000043
J	Liu, XH; Alexander, C; Serrano, J; Borg, E; Dawson, DC				Liu, XH; Alexander, C; Serrano, J; Borg, E; Dawson, DC			Variable reactivity of an engineered cysteine at position 338 in cystic fibrosis transmembrane conductance regulator reflects different chemical states of the thiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; SULFHYDRYL-SPECIFIC REAGENTS; METAL-BINDING SITES; DISULFIDE INTERCHANGE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; LINING RESIDUES; S-NITROSOTHIOLS; ANION-BINDING; COPPER	In a previous study of T338C CFTR ( cystic fibrosis transmembrane conductance regulator) we found that protons and thiol-directed reagents modified channel properties in a manner consistent with the hypothesis that this residue lies within the conduction path, but the observed reactivity was not consistent with the presence of a single thiolate species in the pore. Here we report results consistent with the notion that the thiol moiety can exist in at least three chemical states, the simple thiol, and two altered states. One of the altered states displays reactivity toward thiols like dithiothreitol and 2-mercaptoethanol as well as mixed disulfides ( methanethiosulfonate reagents: MTSET+, MTSES-) and an alkylating agent ( iodoacetamide). The other altered state is unreactive. The phenotype associated with the reactive, altered state could be replicated by exposing oocytes expressing T338C CFTR to CuCl2, but not by glutathionylation or nitrosylation of the thiol or by oxidation with hydrogen peroxide. The results are consistent with the hypothesis that substituting a cysteine at 338 can create an adventitious metal binding site. Metal liganding alters thiol reactivity and may, in some cases, catalyze oxidation of the thiol to an unreactive form such as a sulfinic or sulfonic acid.	Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA	Oregon Health & Science University	Dawson, DC (corresponding author), L334,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	dawsonda@ohsu.edu			NIDDK NIH HHS [DK45880, DK60312, DK070755] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK045880, K01DK070755, F32DK060312, R01DK045880] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Baty JW, 2002, PROTEOMICS, V2, P1261, DOI 10.1002/1615-9861(200209)2:9<1261::AID-PROT1261>3.0.CO;2-Q; BELTRAMINI M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P24, DOI 10.1016/0167-4838(92)90420-I; BERNHARD WR, 1986, BIOCHEMISTRY-US, V25, P1975, DOI 10.1021/bi00356a021; Chan KM, 2000, J GEN PHYSIOL, V116, P163, DOI 10.1085/jgp.116.2.163; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; Cheung M, 1996, BIOPHYS J, V70, P2688, DOI 10.1016/S0006-3495(96)79838-7; Chiou SJ, 2003, P NATL ACAD SCI USA, V100, P3695, DOI 10.1073/pnas.0637221100; Cross JV, 2004, BIOCHEM J, V381, P675, DOI 10.1042/BJ20040591; DAWSON DC, 2003, CFTR CHLORIDE CHANNE, P1; FELIX K, 1988, BIOCHEM J, V252, P577, DOI 10.1042/bj2520577; Filomeni G, 2002, BIOCHEM PHARMACOL, V64, P1057, DOI 10.1016/S0006-2952(02)01176-0; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; FORMICKA G, 1992, FEBS LETT, V309, P92, DOI 10.1016/0014-5793(92)80747-5; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Giles NM, 2003, CHEM BIOL, V10, P677, DOI 10.1016/S1074-5521(03)00174-1; Gong XD, 2003, J PHYSIOL-LONDON, V549, P375, DOI 10.1113/jphysiol.2002.038216; Gong XD, 2003, J PHYSIOL-LONDON, V549, P387, DOI 10.1113/jphysiol.2002.038232; Grapperhaus CA, 1998, INORG CHEM, V37, P4052, DOI 10.1021/ic971599f; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; Gruss M, 2004, MOL PHARMACOL, V66, P530; Hammes BS, 2001, INORG CHEM, V40, P919, DOI 10.1021/ic001178p; HE MM, 1995, BIOCHEMISTRY-US, V34, P15667, DOI 10.1021/bi00048a010; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Huynh PD, 1997, J GEN PHYSIOL, V110, P229, DOI 10.1085/jgp.110.3.229; JONES JG, 1975, BIOCHEMISTRY-US, V14, P2396, DOI 10.1021/bi00682a020; KAEGI JH, 1961, J BIOL CHEM, V236, P2435; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KAWABATA T, 1986, ACTA MED OKAYAMA, V40, P163; Kenyon G L, 1977, Methods Enzymol, V47, P407; Kiley PJ, 2004, PLOS BIOL, V2, P1714, DOI 10.1371/journal.pbio.0020400; Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7; Krezel A, 2001, J INORG BIOCHEM, V84, P77, DOI 10.1016/S0162-0134(00)00212-9; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; Leichert LI, 2004, PLOS BIOL, V2, P1723, DOI 10.1371/journal.pbio.0020333; Li Y, 2005, BIOPHYS J, V88, P3936, DOI 10.1529/biophysj.104.055012; Liebeskind LS, 2002, PURE APPL CHEM, V74, P115, DOI 10.1351/pac200274010115; LIU X, 2002, PED PULM S, V24, pA37; Liu XH, 2004, BIOPHYS J, V86, p284A; Liu XH, 2004, BIOPHYS J, V87, P3826, DOI 10.1529/biophysj.104.050534; Liu XH, 2001, J GEN PHYSIOL, V118, P433, DOI 10.1085/jgp.118.4.433; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Luo DY, 2005, J PHARM SCI-US, V94, P304, DOI 10.1002/jps.20253; Mallis RJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P60, DOI 10.1006/abbi.2000.2048; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; McGuirl MA, 1997, J BIOL INORG CHEM, V2, P336, DOI 10.1007/s007750050140; Means G.E., 1971, CHEM MODIFICATION PR; MENSE M, 2002, PEDIATR PULM, V24, pA58; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; Morera FJ, 2003, J MEMBRANE BIOL, V192, P65, DOI 10.1007/s00232-002-1064-y; NOMIZU T, 1993, MOL REPROD DEV, V36, P419, DOI 10.1002/mrd.1080360403; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Rabenstein DL, 1996, J ORG CHEM, V61, P7391, DOI 10.1021/jo960917+; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Sharonova IN, 1998, EUR J NEUROSCI, V10, P522, DOI 10.1046/j.1460-9568.1998.00057.x; Smith SS, 2001, J GEN PHYSIOL, V118, P407, DOI 10.1085/jgp.118.4.407; Smith SS, 1999, J GEN PHYSIOL, V114, P799, DOI 10.1085/jgp.114.6.799; Sohn J, 2003, BIOCHEMISTRY-US, V42, P10060, DOI 10.1021/bi0345081; SPEAR N, 1994, ARCH BIOCHEM BIOPHYS, V312, P198, DOI 10.1006/abbi.1994.1299; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STROTHKAMP KG, 1981, BIOCHEMISTRY-US, V20, P7488, DOI 10.1021/bi00529a025; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Thomas C, 2004, PFLUG ARCH EUR J PHY, V448, P431; Van Horn JD, 2003, J BIOL INORG CHEM, V8, P601, DOI 10.1007/s00775-003-0454-7; VASAK M, 1981, BIOCHEMISTRY-US, V20, P2852, DOI 10.1021/bi00513a022; WANG G, 2003, BIOPHYS J, V82, pL59; Warthen CR, 2001, J BIOL INORG CHEM, V6, P82, DOI 10.1007/s007750000171; Webster SM, 2004, NATURE, V428, P864, DOI 10.1038/nature02468; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627; Zhang H, 1997, BIOCHEMISTRY-US, V36, P15856, DOI 10.1021/bi972357u; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101; Zhang ZR, 2005, J BIOL CHEM, V280, P458, DOI 10.1074/jbc.M409626200	82	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8275	8285		10.1074/jbc.M512458200	http://dx.doi.org/10.1074/jbc.M512458200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436375	hybrid			2022-12-25	WOS:000236031000067
J	Aachmann, FL; Svanem, BIG; Guntert, P; Petersen, SB; Valla, S; Wimmer, R				Aachmann, FL; Svanem, BIG; Guntert, P; Petersen, SB; Valla, S; Wimmer, R			NMR structure of the R-module - A parallel beta-roll subunit from an Azotobacter vinelandii mannuronan C-5 epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; PSEUDOMONAS-AERUGINOSA; ALGINIC ACID; C-5-EPIMERASE GENE; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; ABC-TRANSPORTERS; CHEMICAL-SHIFT; PROTEIN; SEQUENCE	In the bacterium Azotobacter vinelandii, a family of seven secreted and calcium-dependent mannuronan C-5 epimerases ( AlgE1 - 7) has been identified. These epimerases are responsible for the epimerization of beta-D-mannuronic acid to alpha-L-guluronic acid in alginate polymers. The epimerases consist of two types of structural modules, designated A ( one or two copies) and R ( one to seven copies). The structure of the catalytically active A-module from the smallest epimerase AlgE4 ( consisting of AR) has been solved recently. This paper describes the NMR structure of the R-module from AlgE4 and its titration with a substrate analogue and paramagnetic thulium ions. The R-module folds into a right-handed parallel beta-roll. The overall shape of the R-module is an elongated molecule with a positively charged patch that interacts with the substrate. Titration of the R-module with thulium indicated possible calcium binding sites in the loops formed by the nonarepeat sequences in the N-terminal part of the molecule and the importance of calcium binding for the stability of the R-module. Structure calculations showed that calcium ions can be incorporated in these loops without structural violations and changes. Based on the structure and the electrostatic surface potential of both the A- and R-module from AlgE4, a model for the appearance of the whole protein is proposed.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; Univ Aalborg, Dept Life Sci, DK-9000 Aalborg, Denmark; RIKEN Genom Sci Ctr, Tatsuo Miyazawa Mem Program, Yokohama, Kanagawa 2300045, Japan; Univ Aalborg, Inst Phys & Nanotechnol, DK-9000 Aalborg, Denmark	Norwegian University of Science & Technology (NTNU); Aalborg University; RIKEN; Aalborg University	Valla, S (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.	svein.valla@biotech.ntnu.no; rw@bio.aau.dk	Wimmer, Reinhard/A-7901-2012; Petersen, Steffen B/F-8280-2010; Aachmann, Finn/G-4136-2015; Petersen, Steffen b/E-8727-2015; Wimmer, Reinhard/M-2346-2019; Güntert, Peter/L-5577-2013	Wimmer, Reinhard/0000-0001-6942-5056; Aachmann, Finn/0000-0003-1613-4663; Petersen, Steffen b/0000-0002-0739-2751; Güntert, Peter/0000-0002-2911-7574				Aachmann FL, 2005, J BIOMOL NMR, V31, P259, DOI 10.1007/s10858-004-7911-7; Aghajari N, 2003, PROTEINS, V50, P636, DOI 10.1002/prot.10264; Amada K, 2000, BBA-PROTEIN STRUCT M, V1478, P201, DOI 10.1016/S0167-4838(00)00046-7; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Bertini I, 2001, J AM CHEM SOC, V123, P4181, DOI 10.1021/ja0028626; Billeter M, 1995, J BIOMOL NMR, V5, P1; Bjerkan TM, 2004, J BIOL CHEM, V279, P28920, DOI 10.1074/jbc.M313293200; BJERKAN TM, 2003, THESIS NORWEGIAN U S; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; COTE GL, 1988, CARBOHYD RES, V181, P143, DOI 10.1016/0008-6215(88)84030-8; Donati I, 2005, BIOMACROMOLECULES, V6, P1031, DOI 10.1021/bm049306e; Douthit SA, 2005, J BACTERIOL, V187, P4573, DOI 10.1128/JB.187.13.4573-4583.2005; Duong F, 1996, MOL MICROBIOL, V21, P459, DOI 10.1111/j.1365-2958.1996.tb02555.x; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; Ertesvag H, 1999, J BACTERIOL, V181, P3033; Ertesvag H, 1999, METAB ENG, V1, P262, DOI 10.1006/mben.1999.0130; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FELMLEE T, 1988, P NATL ACAD SCI USA, V85, P5269, DOI 10.1073/pnas.85.14.5269; FELMLEE T, 1985, J BACTERIOL, V163, P88, DOI 10.1128/JB.163.1.88-93.1985; FETT WF, 1986, APPL ENVIRON MICROB, V52, P466, DOI 10.1128/AEM.52.3.466-473.1986; Fischer F. G., 1955, Z PHYSL CHEM, V302, P186; FREI E, 1962, NATURE, V196, P130, DOI 10.1038/196130a0; Gimmestad M, 2003, J BACTERIOL, V185, P3515, DOI 10.1128/JB.185.12.3515-3523.2003; GORIN PAJ, 1966, CAN J CHEMISTRY, V44, P993, DOI 10.1139/v66-147; GOVAN JRW, 1981, J GEN MICROBIOL, V125, P217; GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P531, DOI 10.1016/0022-2836(91)90755-U; Hamada K, 1996, J BIOCHEM, V119, P844, DOI 10.1093/oxfordjournals.jbchem.a021320; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; HAUG A, 1971, CARBOHYD RES, V17, P297, DOI 10.1016/S0008-6215(00)82537-9; HELLEBUST JA, 1972, CAN J BOTANY, V50, P177, DOI 10.1139/b72-023; HIRST EL, 1964, J CHEM SOC, P1493, DOI 10.1039/jr9640001493; Hoidal HK, 2000, ENVIRON MICROBIOL, V2, P27, DOI 10.1046/j.1462-2920.2000.00074.x; Hui D, 2000, J BIOL CHEM, V275, P2713, DOI 10.1074/jbc.275.4.2713; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 2000, COMPUT PHYS COMMUN, V124, P139, DOI 10.1016/S0010-4655(99)00436-1; Kwon HJ, 2002, J BIOSCI BIOENG, V93, P157, DOI 10.1263/jbb.93.157; LARSEN B, 1971, CARBOHYD RES, V20, P225, DOI 10.1016/S0008-6215(00)81375-0; LETOFFE S, 1992, J BACTERIOL, V174, P4920; Lilie H, 2000, FEBS LETT, V470, P173, DOI 10.1016/S0014-5793(00)01308-9; Mustafi SM, 2004, BIOCHEMISTRY-US, V43, P9320, DOI 10.1021/bi049657d; Omori K, 2003, J BIOSCI BIOENG, V95, P1; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; SADOFF HL, 1975, BACTERIOL REV, V39, P516, DOI 10.1128/MMBR.39.4.516-539.1975; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SHERBROCKCOX V, 1984, CARBOHYD RES, V135, P147, DOI 10.1016/0008-6215(84)85012-0; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; Sletmoen M, 2004, BIOMACROMOLECULES, V5, P1288, DOI 10.1021/bm0345211; Smidsrod O., 1996, CARBOHYDR EUR, V14, P6; STOKKE BT, 1991, MACROMOLECULES, V24, P6637; Valla S, 2001, BIOCHIMIE, V83, P819, DOI 10.1016/S0300-9084(01)01313-X; Walling AE, 1997, J PHYS CHEM A, V101, P7299, DOI 10.1021/jp971783m; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3	59	29	29	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7350	7356		10.1074/jbc.M510069200	http://dx.doi.org/10.1074/jbc.M510069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407237	hybrid			2022-12-25	WOS:000236030900054
J	Allan, RK; Mok, D; Ward, BK; Ratajczak, T				Allan, RK; Mok, D; Ward, BK; Ratajczak, T			Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90 - Evidence that coumarin antibiotics disrupt Hsp90 dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; STEROID-RECEPTOR COMPLEXES; GLUCOCORTICOID-RECEPTOR; MOLECULAR CHAPERONE; MUTATIONAL ANALYSIS; ANDROGEN RECEPTOR; PROSTATE-CANCER; BINDING SITE; ATP-BINDING	The C-terminal domain of Hsp90 displays independent chaperone activity, mediates dimerization, and contains the MEEVD motif essential for interaction with tetratricopeptide repeat-containing immunophilin cochaperones assembled in mature steroid receptor complexes. An alpha-helical region, upstream of the MEEVD peptide, helps form the dimerization interface and includes a hydrophobic microdomain that contributes to the Hsp90 interaction with the immunophilin cochaperones and corresponds to the binding site for novobiocin, a coumarin-related Hsp90 inhibitor. Mutation of selected residues within the hydrophobic microdomain significantly impacted the chaperone function of a recombinant C-terminal Hsp90 fragment and novobiocin inhibited wild-type chaperone activity. Prior incubation of the Hsp90 fragment with novobiocin led to a direct blockade of immunophilin cochaperone binding. However, the drug had little influence on the pre-formed Hsp90-immunophilin complex, suggesting that bound cochaperones mask the novobiocin-binding site. We observed a differential effect of the drug on Hsp90-immunophilin interaction, suggesting that the immunophilins make distinct contacts within the C-terminal domain to specifically modulate Hsp90 function. Novobiocin also precluded the interaction of full-length Hsp90 with the p50(cdc37) cochaperone, which targets the N-terminal nucleotide-binding domain, and is prevalent in Hsp90 complexes with protein kinase substrates. Novobiocin therefore acts locally and allosterically to induce conformational changes within multiple regions of the Hsp90 protein. We provide evidence that coumermycin A1, a coumarin structurally related to novobiocin, interferes with dimerization of the Hsp90 C-terminal domain. Coumarin-based inhibitors then may antagonize Hsp90 function by inducing a conformation favoring separation of the C-terminal domains and release of substrate.	Western Australian Inst Med Res, Mol Endocrinol Lab, Nedlands, WA 6009, Australia; Med Res Ctr, Nedlands, WA 6009, Australia; Univ Western Australia, Nedlands, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia; Queen Elizabeth II Med Ctr, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Ratajczak, T (corresponding author), Western Australian Inst Med Res, Mol Endocrinol Lab, Nedlands, WA 6009, Australia.	tomr@cyllene.uwa.edu.au	Mok, Danny/A-5328-2011					Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BINART N, 1995, BIOCHEM J, V311, P797, DOI 10.1042/bj3110797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchanan G, 2001, CLIN CANCER RES, V7, P1273; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung-Flynn J, 2005, MOL ENDOCRINOL, V19, P1654, DOI 10.1210/me.2005-0071; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Daikoku T, 2005, MOL ENDOCRINOL, V19, P683, DOI 10.1210/me.2004-0332; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Denny WB, 2005, ENDOCRINOLOGY, V146, P3194, DOI 10.1210/en.2005-0027; Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200; Harris SF, 2004, STRUCTURE, V12, P1087, DOI 10.1016/j.str.2004.03.020; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Itoh H, 1999, BIOCHEM J, V343, P697, DOI 10.1042/0264-6021:3430697; Jibard N, 1999, EXP CELL RES, V247, P461, DOI 10.1006/excr.1998.4375; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Marcu MG, 2000, JNCI-J NATL CANCER I, V92, P242, DOI 10.1093/jnci/92.3.242; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Meng X, 1996, J CELL SCI, V109, P1677; Munster PN, 2002, CANCER RES, V62, P3132; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Ratajczak T, 2003, CURR TOP MED CHEM, V3, P1348, DOI 10.2174/1568026033451934; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; Riggs DL, 2004, CRIT REV BIOCHEM MOL, V39, P279, DOI 10.1080/10409230490892513; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Rosenhagen MC, 2003, MOL ENDOCRINOL, V17, P1991, DOI 10.1210/me.2003-0141; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SHUE GL, 1994, J BIOL CHEM, V269, P2707; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith DF, 2004, CELL STRESS CHAPERON, V9, P109, DOI 10.1379/CSC-31.1; Soga S, 1999, CANCER RES, V59, P2931; Solit DB, 2002, CLIN CANCER RES, V8, P986; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Tranguch S, 2005, P NATL ACAD SCI USA, V102, P14326, DOI 10.1073/pnas.0505775102; Ward BK, 2002, J BIOL CHEM, V277, P40799, DOI 10.1074/jbc.M207097200; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Wei H, 2005, J BIOL CHEM, V280, P37041, DOI 10.1074/jbc.M506520200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; Yamada S, 2003, EUR J BIOCHEM, V270, P146, DOI 10.1046/j.1432-1033.2003.03375.x; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Yu XM, 2005, J AM CHEM SOC, V127, P12778, DOI 10.1021/ja0535864; Yun BG, 2004, BIOCHEMISTRY-US, V43, P8217, DOI 10.1021/bi0497998	72	122	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7161	7171		10.1074/jbc.M512406200	http://dx.doi.org/10.1074/jbc.M512406200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421106	hybrid			2022-12-25	WOS:000236030900031
J	Joo, NS; Irokawa, T; Robbins, RC; Wine, JJ				Joo, NS; Irokawa, T; Robbins, RC; Wine, JJ			Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; SINGLE SUBMUCOSAL GLANDS; EPITHELIAL NA+ CHANNELS; NEUTROPHIL ELASTASE; MUCUS SECRETION; SODIUM-CHANNEL; ION-TRANSPORT; EXPRESSION; CELLS; CFTR	Human airways and glands express the anion channel cystic fibrosis transmembrane conductance regulator, CFTR, and the epithelial Na+ channel, ENaC. Cystic fibrosis (CF) airway glands fail to secrete mucus in response to vasoactive intestinal peptide or forskolin; the failure was attributed to loss of CFTR-mediated anion and fluid secretion. Alternatively, CF glands might secrete acinar fluid via CFTR-independent pathways, but the exit of mucus from the glands could be blocked by hyperabsorption of fluid in the gland ducts. This could occur because CFTR loss can disinhibit ENaC, and ENaC activity can drive absorption. To test these two hypotheses, we measured single gland mucus secretion optically and applied ENaC inhibitors to determine whether they augmented secretion. Human CF glands were pretreated with benzamil and then stimulated with forskolin in the continued presence of benzamil. Benzamil did not rescue the lack of secretion to forskolin ( 50 glands, 6 CF subjects) nor did it increase the rate of cholinergically mediated mucus secretion from CF glands. Finally, neither benzamil nor amiloride increased forskolin-stimulated mucus secretion from porcine submucosal glands ( 75 glands, 7 pigs). One possible explanation for these results is that ENaC within the gland ducts was not active in our experiments. Consistent with that possibility, we discovered that human airway glands express Kunitz-type and non-Kunitz serine protease inhibitors, which might prevent proteolytic activation of ENaC. Our results suggest that CF glands do not display excessive, ENaC-mediated fluid absorption, leaving defective, anion-mediated fluid secretion as the most likely mechanism for defective mucus secretion from CF glands.	Stanford Univ, Cyst Fibrosis Res Lab, Stanford, CA 94305 USA; Stanford Univ, Cardiothorac Surg & Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Joo, NS (corresponding author), Stanford Univ, Cyst Fibrosis Res Lab, Rm 516,Bldg 420,Main Quad, Stanford, CA 94305 USA.	nsjoo@psych.stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 51817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballard ST, 2004, J PHYSIOL-LONDON, V556, P1, DOI 10.1113/jphysiol.2003.052779; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; Caldwell RA, 2005, AM J PHYSIOL-LUNG C, V288, pL813, DOI 10.1152/ajplung.00435.2004; Caldwell RA, 2004, AM J PHYSIOL-CELL PH, V286, pC190, DOI 10.1152/ajpcell.00342.2003; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; Gaillard D, 2000, AM J PHYSIOL-LUNG C, V278, pL177, DOI 10.1152/ajplung.2000.278.1.L177; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Hirsh AJ, 2004, J PHARMACOL EXP THER, V311, P929, DOI 10.1124/jpet.104.071886; Irokawa T, 2004, AM J PHYSIOL-LUNG C, V287, pL784, DOI 10.1152/ajplung.00124.2004; Itoh M, 2000, EUR J BIOCHEM, V267, P3351, DOI 10.1046/j.1432-1327.2000.01368.x; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Joo NS, 2004, J BIOL CHEM, V279, P38854, DOI 10.1074/jbc.M407077200; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; Joo NS, 2002, J BIOL CHEM, V277, P28167, DOI 10.1074/jbc.M202712200; Kirchhofer D, 2003, J BIOL CHEM, V278, P36341, DOI 10.1074/jbc.M304643200; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kreda SM, 2005, MOL BIOL CELL, V16, P2154, DOI 10.1091/mbc.E04-11-1010; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Phillips JE, 2002, J APPL PHYSIOL, V93, P873, DOI 10.1152/japplphysiol.00174.2002; Reddy MM, 2003, PFLUG ARCH EUR J PHY, V445, P499, DOI 10.1007/s00424-002-0959-x; Salinas D, 2004, FASEB J, V18, P431, DOI 10.1096/fj.04-2879fje; Singh M, 1997, AM J PHYSIOL-LUNG C, V272, pL690, DOI 10.1152/ajplung.1997.272.4.L690; SONG Y, 2006, IN PRESS AM J PHYSL; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Wine Jeffrey J, 2004, Proc Am Thorac Soc, V1, P47, DOI 10.1513/pats.2306015; YAMAYA M, 1991, AM J PHYSIOL, V261, pL485, DOI 10.1152/ajplung.1991.261.6.L485	29	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7392	7398		10.1074/jbc.M512766200	http://dx.doi.org/10.1074/jbc.M512766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410244	hybrid			2022-12-25	WOS:000236030900059
J	Qiao, M; Shapiro, P; Fosbrink, M; Rus, H; Kumar, R; Passaniti, A				Qiao, M; Shapiro, P; Fosbrink, M; Rus, H; Kumar, R; Passaniti, A			Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SKELETAL GENE-EXPRESSION; TGF-BETA SUPERFAMILY; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; BONE SIALOPROTEIN; MAMMALIAN-CELLS; DNA-BINDING; CBFA1; GROWTH	RUNX2 is a member of the runt family of DNA-binding transcription factors. RUNX2 mediates endothelial cell migration and invasion during tumor angiogenesis and is expressed in metastatic breast and prostate tumors. Our published studies showed that RUNX2 DNA-binding activity is low during growth arrest, but elevated in proliferating endothelial cells. To investigate its role in cell proliferation and cell cycle regulation, RUNX2 was depleted in human bone marrow endothelial cells using RNA interference. Specific RUNX2 depletion inhibited DNA-binding activity as measured by electrophoretic mobility shift assay resulting in inhibition of cell proliferation. Cells were synchronized at the G(1)/S boundary with excess thymidine or in mitosis ( M phase) with nocodazole. Endogenous or ectopic RUNX2 activity was maximal at late G(2) and during M phase. Inhibition of RUNX2 expression by RNA interference delayed entry into and exit out of the G(2)/M phases of the cell cycle. RUNX2 was coimmunoprecipitated with cyclin B1 in mitotic cells, which further supported a role for RUNX2 in cell cycle progression. Moreover, in vitro kinase assays using recombinant cdc2 kinase showed that RUNX2 was phosphorylated at Ser(451). The cdc2 inhibitor roscovitine dose dependently inhibited in vivo RUNX2 DNA-binding activity during mitosis and the RUNX2 mutant S451A exhibited lower DNA-binding activity and reduced stimulation of anchorage-independent growth relative to wild type RUNX2. These results suggest for the first time that RUNX2 phosphorylation by cdc2 may facilitate cell cycle progression possibly through regulation of G(2) and M phases, thus promoting endothelial cell proliferation required for tumor angiogenesis.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; Univ Texas, MD Anderson Canc Ctr, Dept Cellular & Mol Oncol, Houston, TX 77030 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Marlene & Stewart Greenbaum Canc Ctr Progrom Onco, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Marlene & Stewart Greenbaum Canc Ctr Progrom Onco, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Passaniti, A (corresponding author), 655 W Baltimore St, Baltimore, MD 21201 USA.	apass001@umaryland.edu	Rus, Horea/AAF-2583-2020		NATIONAL CANCER INSTITUTE [R21CA095350] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA 95350-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anglin Ian, 2004, Cancer Treat Res, V119, P189; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Barnes GL, 2004, CANCER RES, V64, P4506, DOI 10.1158/0008-5472.CAN-03-3851; Barnes GL, 2003, CANCER RES, V63, P2631; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Gonczy P, 2002, CURR BIOL, V12, pR242, DOI 10.1016/S0960-9822(02)00781-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hart SM, 2002, HAEMATOLOGICA, V87, P1307; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; John PCL, 2001, PROTOPLASMA, V216, P119, DOI 10.1007/BF02673865; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KREK W, 1995, METHOD ENZYMOL, V254, P114; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Lian JB, 2003, CONNECT TISSUE RES, V44, P141, DOI 10.1080/03008200390152232; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Miyazono K, 2004, ONCOGENE, V23, P4232, DOI 10.1038/sj.onc.1207131; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Oettgen P, 2001, CIRC RES, V89, P380, DOI 10.1161/hh1701.095958; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Pratap J, 2003, CANCER RES, V63, P5357; Qiao M, 2004, J BIOL CHEM, V279, P42709, DOI 10.1074/jbc.M404480200; Riminucci M, 2003, CALCIFIED TISSUE INT, V73, P281, DOI 10.1007/s00223-002-2134-y; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; Sato Y, 2000, PHARMACOL THERAPEUT, V87, P51, DOI 10.1016/S0163-7258(00)00067-X; Shekhar MPV, 2000, CANCER RES, V60, P439; Stein GS, 2003, CONNECT TISSUE RES, V44, P149, DOI 10.1080/03008900390152241; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Steinman RA, 2002, ONCOGENE, V21, P3403, DOI 10.1038/sj.onc.1205325; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Sun LX, 2001, CANCER RES, V61, P4994; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Yang J, 2001, CANCER RES, V61, P5652; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200	75	93	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7118	7128		10.1074/jbc.M508162200	http://dx.doi.org/10.1074/jbc.M508162200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407259	hybrid			2022-12-25	WOS:000236030900026
J	Vadolas, J; Nefedov, M; Wardan, H; Mansooriderakshan, S; Voullaire, L; Jamsai, D; Williams, R; Ioannou, PA				Vadolas, J; Nefedov, M; Wardan, H; Mansooriderakshan, S; Voullaire, L; Jamsai, D; Williams, R; Ioannou, PA			Humanized beta-thalassemia mouse model containing the common IVSI-110 splicing mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ARTIFICIAL CHROMOSOMES; TRANSGENIC KNOCKOUT MICE; GLOBIN LOCUS; DEVELOPMENTAL REGULATION; PREMESSENGER RNA; GENE-EXPRESSION; HEMOGLOBIN; RECOMBINATION; OLIGONUCLEOTIDES; RESTORATION	Splicing mutations are common causes of beta-thalassemia. Some splicing mutations permit normal splicing as well as aberrant splicing, which can give a reduced level of normal beta-globin synthesis causing mild disease (thalassemia intermedia). For other mutations, normal splicing is reduced to low levels, and patients are transfusion dependent when homozygous for the disease. The development of therapies for beta-thalassemia will require suitable mouse models for preclinical studies. In this study, we report the generation of a humanized mouse model carrying the common IVSI-110 splicing mutation on a BAC including the human beta-globin ((hu)beta-globin) locus. We examined heterozygous murine beta-globin knock-out mice ((mu)beta(th-3/+)) carrying either the IVSI-110 or the normal (hu)beta-globin locus. Our results show a 90% decrease in (hu)beta-globin chain synthesis in the IVSI-110 mouse model compared with the mouse model carrying the normal (hu)beta-globin locus. This notable difference is attributed to aberrant splicing. The humanized IVSI-110 mouse model accurately recapitulates the splicing defect found in comparable beta-thalassemia patients. This mouse model is available as a platform for testing strategies for the restoration of normal splicing.	Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Res Grp, Melbourne, Vic 3052, Australia; Cyprus Inst Neurol & Genet, CY-1683 Nicosia, Cyprus	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Vadolas, J (corresponding author), Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Cell & Gene Therapy Res Grp, Melbourne, Vic 3052, Australia.	jim.vadolas@mcri.edu.au		Vadolas, Jim/0000-0002-3072-3512				Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Cartegni L, 2003, NAT STRUCT BIOL, V10, P120, DOI 10.1038/nsb887; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chang JC, 1998, P NATL ACAD SCI USA, V95, P14886, DOI 10.1073/pnas.95.25.14886; Danckwardt S, 2002, BLOOD, V99, P1811, DOI 10.1182/blood.V99.5.1811; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Fabry ME, 2000, BLOOD CELL MOL DIS, V26, P331, DOI 10.1006/bcmd.2000.0313; Gaensler KML, 2003, P NATL ACAD SCI USA, V100, P3374, DOI 10.1073/pnas.0634132100; Huang Y, 2000, BLOOD CELL MOL DIS, V26, P598, DOI 10.1006/bcmd.2000.0339; IOANNOU P, 1995, COLLOQ INSE, V234, P143; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Jamsai D, 2005, GENOMICS, V85, P453, DOI 10.1016/j.ygeno.2004.11.016; Jamsai D, 2003, GENOMICS, V82, P68, DOI 10.1016/S0888-7543(03)00100-9; Jamsai D, 2003, MOL BIOTECHNOL, V23, P29, DOI 10.1385/MB:23:1:29; Lacerra G, 2000, P NATL ACAD SCI USA, V97, P9591, DOI 10.1073/pnas.97.17.9591; Lewis J, 1998, BLOOD, V91, P2152, DOI 10.1182/blood.V91.6.2152.2152_2152_2156; Muyrers JPP, 1999, NUCLEIC ACIDS RES, V27, P1555, DOI 10.1093/nar/27.6.1555; Narayanan K, 1999, GENE THER, V6, P442, DOI 10.1038/sj.gt.3300901; Navas PA, 2002, HUM MOL GENET, V11, P893, DOI 10.1093/hmg/11.8.893; Nefedov M, 2000, Nucleic Acids Res, V28, pE79, DOI 10.1093/nar/28.17.e79; Olivieri NF, 1998, HUM MOL GENET, V7, P1655, DOI 10.1093/hmg/7.10.1655; ORFORD MR, 2003, METH MOL B, V240, P243; Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876; Porcu S, 1997, BLOOD, V90, P4602, DOI 10.1182/blood.V90.11.4602.4602_4602_4609; Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873; Sarsero JP, 2004, MAMM GENOME, V15, P370, DOI 10.1007/s00335-004-3019-3; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Skordis LA, 2003, P NATL ACAD SCI USA, V100, P4114, DOI 10.1073/pnas.0633863100; SPRITZ RA, 1981, P NATL ACAD SCI-BIOL, V78, P2455, DOI 10.1073/pnas.78.4.2455; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; Swaminathan S, 2001, GENESIS, V29, P14, DOI 10.1002/1526-968X(200101)29:1<14::AID-GENE1001>3.0.CO;2-X; Vadolas J, 2005, BBA-GENE STRUCT EXPR, V1728, P150, DOI 10.1016/j.bbaexp.2005.02.008; Vadolas J, 2002, BLOOD, V100, P4209, DOI 10.1182/blood-2001-12-0365; Zhang Y, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-42	35	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7399	7405		10.1074/jbc.M512931200	http://dx.doi.org/10.1074/jbc.M512931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421096	hybrid			2022-12-25	WOS:000236030900060
J	Vaughan, DJ; Millman, EE; Godines, V; Friedman, J; Tran, TM; Dai, WP; Knoll, BJ; Clark, RB; Moore, RH				Vaughan, DJ; Millman, EE; Godines, V; Friedman, J; Tran, TM; Dai, WP; Knoll, BJ; Clark, RB; Moore, RH			Role of the G protein-coupled receptor kinase site serine cluster in beta(2)-adrenergic receptor internalization, desensitization, and beta-arrestin translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; ADRENERGIC-RECEPTOR; VISUAL ARRESTIN; BETA-2-ADRENERGIC RECEPTOR; AGONIST STIMULATION; CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; WILD-TYPE; PHOSPHORYLATION; BINDING	There is considerable evidence for the role of carboxyl-terminal serines 355, 356, and 364 in G protein-coupled receptor kinase (GRK)-mediated phosphorylation and desensitization of beta(2)-adrenergic receptors (beta(2)ARs). In this study we used receptors in which these serines were changed to alanines (SA3) or to aspartic acids (SD3) to determine the role of these sites in beta-arrestin-dependent beta(2)AR internalization and desensitization. Coupling efficiencies for epinephrine activation of adenylyl cyclase were similar in wild-type and mutant receptors, demonstrating that the SD3 mutant did not drive constitutive GRK desensitization. Treatment of wild-type and mutant receptors with 0.3 nM isoproterenol for 5 min induced similar to 2-fold increases in the EC50 for agonist activation of adenylyl cyclase, consistent with protein kinase A (PKA) site-mediated desensitization. When exposed to 1 mu M isoproterenol to trigger GRK site-mediated desensitization, only wild-type receptors showed significant further desensitization. Using a phospho site-specific antibody, we determined that there is no requirement for these GRK sites in PKA-mediated phosphorylation at high agonist concentration. The rates of agonist-induced internalization of the SD3 and SA3 mutants were 44 and 13%, respectively, relative to that of wild-type receptors, but the SD3 mutant recruited enhanced green fluorescent protein (EGFP)-beta-arrestin 2 to the plasma membrane, whereas the SA3 mutant did not. EGFP-beta-Arrestin2 overexpression triggered a significant increase in the extent of SD3 mutant desensitization but had no effect on the desensitization of wild-type receptors or the SA3 mutant. Expression of a phosphorylation-independent beta-arrestin 1 mutant (R169E) significantly rescued the internalization defect of the SA3 mutant but inhibited the phosphorylation of serines 355 and 356 in wild-type receptors. Our data demonstrate that (i) the lack of GRK sites does not impair PKA site phosphorylation, (ii) the SD3 mutation inhibits GRK-mediated desensitization although it supports some agonist-induced beta-arrestin binding and receptor internalization, and (iii) serines 355, 356, and 364 play a pivotal role in the GRK-mediated desensitization, beta-arrestin binding, and internalization of beta(2)ARs.	Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Houston, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA	Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Houston System; University of Houston	Moore, RH (corresponding author), Baylor Coll Med, Dept Pediat, 6621 Fannin,CCC1040, Houston, TX 77030 USA.	rmoore@bcm.tmc.edu	Vaughan, David/AAZ-3873-2020		NHLBI NIH HHS [HL 64934] Funding Source: Medline; NIGMS NIH HHS [GM 031208] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Jala VR, 2005, J BIOL CHEM, V280, P4880, DOI 10.1074/jbc.M409821200; January B, 1998, BRIT J PHARMACOL, V123, P701, DOI 10.1038/sj.bjp.0701658; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Millman EE, 2004, BRIT J PHARMACOL, V141, P277, DOI 10.1038/sj.bjp.0705504; Moore RH, 2004, J CELL SCI, V117, P3107, DOI 10.1242/jcs.01168; MOORE RH, 1995, J CELL SCI, V108, P2983; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; Raman D, 2003, J NEUROCHEM, V84, P1040, DOI 10.1046/j.1471-4159.2003.01598.x; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Seibold A, 2000, MOL PHARMACOL, V58, P1162, DOI 10.1124/mol.58.5.1162; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; Trester-Zedlitz M, 2005, BIOCHEMISTRY-US, V44, P6133, DOI 10.1021/bi0475469; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; VON ZM, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	46	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7684	7692		10.1074/jbc.M500328200	http://dx.doi.org/10.1074/jbc.M500328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407241	hybrid			2022-12-25	WOS:000236030900089
J	Martinez-Martinez, S; Rodriguez, A; Lopez-Maderuelo, MD; Ortega-Perez, I; Vazquez, J; Redondo, JM				Martinez-Martinez, S; Rodriguez, A; Lopez-Maderuelo, MD; Ortega-Perez, I; Vazquez, J; Redondo, JM			Blockade of NFAT activation by the second calcineurin binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NFAT1; T-CELLS; CYCLOSPORINE-A; NUCLEAR FACTOR; SELECTIVE-INHIBITION; MUSCLE-CELLS; DOMAIN; PROTEINS; CALCIUM; SIGNAL	Activation of NFAT transcription factors requires their dephosphorylation by the phosphatase calcineurin (CN). NFATs contain two CN binding motifs: PxIxIT and CnBP-B/CNBR2 ( which we call LxVP). Here we carry out a detailed comparative analysis of the CN binding activity displayed by the PxIxIT and LxVP sites from different NFATs. Dose-response CN binding experiments with GST fusion proteins of NFATc1 and NFATc2 showed that NFATc1 binds CN in vitro more efficiently than does NFATc2. This difference in binding appears to be caused by the different CN binding potencies of the corresponding LxVP sites; thus while the LxVPc2 peptide fused to GST did not bind CN, GST-LxVPc1 bound it more efficiently than did GST-PxIxITc1 or GST-PxIxITc2. Furthermore, an NFATc2 chimera protein containing the LxVP motif from NFATc1 interacted with CN much more potently than did wild-type NFATc2. Free peptides spanning the LxVP motifs from NFATc1, c3 or c4 displaced CN from GST-NFATc1 and GST-NFATc2 more efficiently than any PxIxIT peptide. PxIxITc2 and LxVPc1 peptides were each able to cross-compete GST-LxVPc1-CN and GST-PxIx-ITc2-CN binding. In contrast with PxIxITc2, the LxVP peptide not only blocked CN-NFAT binding but also inhibited CN phosphatase activity in vitro. Furthermore, exogenous LxVPc1 blocked NFATc2 phosphorylation and nuclear translocation in vivo. These results suggest a model in which the different CN binding characteristics of the PxIxIT and LxVP sites enable different NFAT members to influence each others activities in cells where they are co-expressed.	CNIC, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Fac Ciencias, E-28049 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Redondo, JM (corresponding author), CNIC, Melchor Femandez Almagro 3, Madrid 28029, Spain.	jmredondo@cbm.uam.es	Marquez, Antonio A. Rodriguez/L-2422-2013; Redondo, Juan Miguel/H-6351-2015; Vazquez, Jesus/B-7697-2015	Marquez, Antonio A. Rodriguez/0000-0003-2455-6583; Redondo, Juan Miguel/0000-0001-5779-9122; Vazquez, Jesus/0000-0003-1461-5092				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Bandyopadhyay A, 2000, BIOCHEM J, V352, P61, DOI 10.1042/0264-6021:3520061; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Chow CW, 1999, MOL CELL BIOL, V19, P2300; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lambrechts D, 2004, CELL, V118, P532, DOI 10.1016/j.cell.2004.08.022; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; Liu J, 1999, J IMMUNOL, V162, P4755; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu J, 2001, J IMMUNOL, V167, P2677, DOI 10.4049/jimmunol.167.5.2677; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; Molkentin JD, 2001, CIRC RES, V88, P1220, DOI 10.1161/hh1201.093159; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rodriguez A, 2005, J BIOL CHEM, V280, P9980, DOI 10.1074/jbc.C400401200; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; Serfling E, 2004, INT J BIOCHEM CELL B, V36, P1166, DOI 10.1016/j.biocel.2003.07.002; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	44	62	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6227	6235		10.1074/jbc.M513885200	http://dx.doi.org/10.1074/jbc.M513885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407284	hybrid			2022-12-25	WOS:000236030800015
J	Yoo, EJ; Chung, JJ; Choe, SS; Kim, KH; Kim, JB				Yoo, EJ; Chung, JJ; Choe, SS; Kim, KH; Kim, JB			Down-regulation of histone deacetylases stimulates adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-RECEPTOR-GAMMA; SUBEROYLANILIDE HYDROXAMIC ACID; SODIUM-BUTYRATE; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTIONAL ACTIVITY; COACTIVATORS P300; BINDING-PROTEIN; PPAR-GAMMA; C/EBP-BETA; ACETYLATION	Specific cell type differentiation is driven by programmed regulation of gene expression, which is the result of coordinated modulation of the transcription machinery and chromatin-remodeling factors. We present evidence here that the down-regulation of histone deacetylases is an important process during adipocyte differentiation. In 3T3-L1 cells, histone hyperacetylation was selectively induced at the promoter regions of adipogenic genes during adipocyte differentiation. Interestingly, this was accompanied by a dramatic decrease in the expression level of several histone deacetylases including HDAC1, - 2, and - 5 and a reduction in overall histone deacetylase enzyme activity. Inhibition of histone deacetylase activity using sodium butyrate resulted in stimulation of adipogenic gene expression and adipocyte differentiation. Consistently, HDAC1 knock-down promoted adipogenesis whereas HDAC1 overexpression attenuated adipocyte differentiation in 3T3-L1 cells. Together, these results suggest that the regulation of not only adipogenic transcription factors, but also chromatin-modifying enzymes is crucial for the execution of bona fide adipogenesis.	Seoul Natl Univ, Dept Biol Sci, Res Ctr Funct Cellul, Seoul 151742, South Korea	Seoul National University (SNU)	Kim, JB (corresponding author), Seoul Natl Univ, Dept Biol Sci, Res Ctr Funct Cellul, San 56-1, Seoul 151742, South Korea.	jaebkim@snu.ac.kr	Song, Minsun/I-5701-2015	Chung, Jun-Jae/0000-0002-3053-5693; KIM, Jae Bum/0000-0003-2337-6935				Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Lee YS, 2003, NUCLEIC ACIDS RES, V31, P7165, DOI 10.1093/nar/gkg934; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; Mal A, 2003, P NATL ACAD SCI USA, V100, P1735, DOI 10.1073/pnas.0437843100; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; Mariadason JM, 2000, CANCER RES, V60, P4561; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rahmani M, 2003, CANCER RES, V63, P8420; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Rosen ED, 2000, GENE DEV, V14, P1293; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Seo JB, 2003, MOL ENDOCRINOL, V17, P1522, DOI 10.1210/me.2003-0028; Seo JB, 2004, MOL CELL BIOL, V24, P3430, DOI 10.1128/MCB.24.8.3430-3444.2004; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; TOSCANI A, 1990, J BIOL CHEM, V265, P5722; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wallberg AE, 2003, MOL CELL, V12, P1137, DOI 10.1016/S1097-2765(03)00391-5; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000	56	137	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6608	6615		10.1074/jbc.M508982200	http://dx.doi.org/10.1074/jbc.M508982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407282	hybrid			2022-12-25	WOS:000236030800057
J	Huang, LS; Sun, G; Cobessi, D; Wang, AC; Shen, JT; Tung, EY; Anderson, VE; Berry, EA				Huang, LS; Sun, G; Cobessi, D; Wang, AC; Shen, JT; Tung, EY; Anderson, VE; Berry, EA			3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by Complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES QUINOL; FUMARATE REDUCTASE; SUCCINATE-DEHYDROGENASE; HUNTINGTONS-DISEASE; PROTEIN; IDENTIFICATION; MUTATIONS; MECHANISM; RESIDUES; MODELS	We report three new structures of mitochondrial respiratory Complex II (succinate ubiquinone oxidoreductase, E.C. 1.3.5.1) at up to 2.1 angstrom resolution, with various inhibitors. The structures define the conformation of the bound inhibitors and suggest the residues involved in substrate binding and catalysis at the dicarboxylate site. In particular they support the role of Arg(297) as a general base catalyst accepting a proton in the dehydrogenation of succinate. The dicarboxylate ligand in oxaloacetate-containing crystals appears to be the same as that reported for Shewanella flavocytochrome c treated with fumarate. The plant and fungal toxin 3-nitropropionic acid, an irreversible inactivator of succinate dehydrogenase, forms a covalent adduct with the side chain of Arg(297). The modification eliminates a trypsin cleavage site in the flavoprotein, and tandem mass spectroscopic analysis of the new fragment shows the mass of Arg(297) to be increased by 83 Da and to have the potential of losing 44 Da, consistent with decarboxylation, during fragmentation.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Case Western Reserve University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Anderson, VE (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	vea@cwru.edu; EABerry@LBL.gov	Anderson, Vernon/W-2673-2019; wang, andy/GRJ-8724-2022	Huang, Li-Shar/0000-0003-1427-2544; Anderson, Vernon Emmett/0000-0002-1699-7621	NIA NIH HHS [P01 AG015885, P01 AG 15885] Funding Source: Medline; NIDDK NIH HHS [R01 DK044842, DK 44842] Funding Source: Medline; NIGMS NIH HHS [R01 GM 62563, R01 GM062563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; ACKRELL BAC, 1975, J BIOL CHEM, V250, P7114; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; ALSTON TA, 1977, P NATL ACAD SCI USA, V74, P3767, DOI 10.1073/pnas.74.9.3767; ANDERSON RC, 1993, APPL ENVIRON MICROB, V59, P3056, DOI 10.1128/AEM.59.9.3056-3061.1993; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; BEAL MF, 1993, J NEUROSCI, V13, P4181; BELIKOVA YO, 1988, BIOCHIM BIOPHYS ACTA, V936, P1, DOI 10.1016/0005-2728(88)90245-9; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9; Borlongan CV, 1997, BRAIN RES PROTOC, V1, P253, DOI 10.1016/S1385-299X(96)00037-2; Brambrink AM, 2004, ACT NEUR S, V89, P63; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; COLES CJ, 1979, J BIOL CHEM, V254, P5161; DERVARTANIAN D. V., 1965, BIOCHIM BIOPHYS ACTA, V105, P424; Doherty MK, 2000, BIOCHEMISTRY-US, V39, P10695, DOI 10.1021/bi000871l; GILBERT HF, 1975, BIOCHEMISTRY-US, V14, P5194, DOI 10.1021/bi00694a027; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Huang LS, 2005, ACTA CRYSTALLOGR D, V61, P380, DOI 10.1107/S0907444905000181; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOTLYAR AB, 1984, BIOCHIM BIOPHYS ACTA, V784, P24, DOI 10.1016/0167-4838(84)90168-7; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2003, FEBS LETT, V555, P21, DOI 10.1016/S0014-5793(03)01100-1; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Liu X, 1992, Biomed Environ Sci, V5, P161; MING L, 1995, J TOXICOL-CLIN TOXIC, V33, P363, DOI 10.3109/15563659509028924; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; PANCHENKO MV, 1991, FEBS LETT, V286, P76, DOI 10.1016/0014-5793(91)80944-X; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Senoo-Matsuda N, 2003, J BIOL CHEM, V278, P22031, DOI 10.1074/jbc.M211377200; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Sun G, 2003, J MASS SPECTROM, V38, P531, DOI 10.1002/jms.467; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; TOI K, 1967, J BIOL CHEM, V242, P1036; Urbanska EM, 2000, POL J PHARMACOL, V52, P55; Walker FA, 2004, CHEM REV, V104, P589, DOI 10.1021/cr020634j; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	47	221	233	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5965	5972		10.1074/jbc.M511270200	http://dx.doi.org/10.1074/jbc.M511270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371358	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000235568900077
J	Khoshnoodi, J; Sigmundsson, K; Cartailler, JP; Bondar, O; Sundaramoorthy, M; Hudson, BG				Khoshnoodi, J; Sigmundsson, K; Cartailler, JP; Bondar, O; Sundaramoorthy, M; Hudson, BG			Mechanism of chain selection in the assembly of collagen IV - A prominent role for the alpha 2 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; GROWTH IN-VIVO; NONCOLLAGENOUS DOMAIN; CRYSTAL-STRUCTURE; MASS-TRANSPORT; TRIPLE-HELIX; NC1 DOMAINS; CROSS-LINK; PROCOLLAGEN; IDENTIFICATION	Collagens comprise a large superfamily of extracellular matrix proteins that play diverse roles in tissue function. The mechanism by which newly synthesized collagen chains recognize each other and assemble into specific triple-helical molecules is a fundamental question that remains unanswered. Emerging evidence suggests a role for the non-collagenous domain (NC1) located at the C-terminal end of each chain. In this study, we have investigated the molecular mechanism underlying chain selection in the assembly of collagen IV. Using surface plasmon resonance, we have determined the kinetics of interaction and assembly of the alpha 1(IV) and alpha 2(IV) NC1 domains. We show that the differential affinity of alpha 2(IV) NC1 domain for dimer formation underlies the driving force in the mechanism of chain discrimination. Given its characteristic domain recognition and affinity for the alpha 1(IV) NC1 domain, we conclude that the alpha 2(IV) chain plays a regulatory role in directing chain composition in the assembly of (alpha 1)(2)alpha 2 triple-helical molecule. Detailed crystal structure analysis of the [(alpha 1)(2)alpha 2](2) NC1 hexamer and sequence alignments of the NC1 domains of all six alpha-chains from mammalian species revealed the residues involved in the molecular recognition of NC1 domains. We further identified a hypervariable region of 15 residues and a beta-hairpin structural motif of 13 residues as two prominent regions that mediate chain selection in the assembly of collagen IV. To our knowledge, this report is the first to combine kinetics and structural data to describe molecular basis for chain selection in the assembly of a collagen molecule.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Novo Nordisk AS, DK-2760 Malov, Denmark	Vanderbilt University; Novo Nordisk	Khoshnoodi, J (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, S-3223 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	Jamshid.Khoshnoodi@vanderbilt.edu	Cartailler, Jean-Philippe/D-2543-2010	Cartailler, Jean-Philippe/0000-0002-0312-2391; Hudson, Billy/0000-0002-5420-4100	NCI NIH HHS [CA 68485] Funding Source: Medline; NIDDK NIH HHS [R37 DK 18381, P01 DK 065123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK065123, R37DK018381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HUDSON BG, 1994, CONTRIB NEPHROL, V107, P163; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Hulmes DJS, 2002, J STRUCT BIOL, V137, P2, DOI 10.1006/jsbi.2002.4450; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McLaughlin SH, 1999, J BIOL CHEM, V274, P7570, DOI 10.1074/jbc.274.11.7570; Myers JK, 2001, BIOCHEMISTRY-US, V40, P8479, DOI 10.1021/bi0027884; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myszka DG, 1997, BIOPHYS CHEM, V64, P127, DOI 10.1016/S0301-4622(96)02230-2; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; Press W. H., 1999, NUMERICAL RECIPES C; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Rogers KS, 1997, BIOCHEM MOL MED, V61, P114, DOI 10.1006/bmme.1997.2596; Roth JM, 2005, AM J PATHOL, V166, P901, DOI 10.1016/S0002-9440(10)62310-3; Sigmundsson K, 2002, BIOCHEMISTRY-US, V41, P8263, DOI 10.1021/bi020099h; Soder S, 2004, BIOCHEM BIOPH RES CO, V325, P276, DOI 10.1016/j.bbrc.2004.10.034; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; Vanacore RM, 2005, J BIOL CHEM, V280, P29300, DOI 10.1074/jbc.M502752200; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575	32	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6058	6069		10.1074/jbc.M506555200	http://dx.doi.org/10.1074/jbc.M506555200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373348	hybrid			2022-12-25	WOS:000235568900087
J	Mishra, S; Saleh, A; Espino, PS; Davie, JR; Murphy, LJ				Mishra, S; Saleh, A; Espino, PS; Davie, JR; Murphy, LJ			Phosphorylation of histones by tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; BINDING PROTEIN; ACTIVATION; APOPTOSIS; PATHWAY; KINASE; GTP; H3	Tissue transglutaminase 2 (TG2) has recently been shown to have intrinsic serine/threonine kinase activity. Since histones are known to be cross-linked by TG2, we investigated whether histones are also substrates for TG2 kinase activity. TG2 was able to phosphorylate H1, H2A, H2B, H3, and H4 histones in vitro. Using peptide substrates and phosphospecific antibodies we demonstrated that TG2 phosphorylated Ser(10) in H3 and that this phosphorylation was reduced by acetylation, whereas phosphorylation of Ser10 by TG2 enhanced acetylation. Furthermore we demonstrated that exogenous TG2 phosphorylated H1 and H3 in nucleosome preparations. We examined the abundance of TG2 in DNA-associated proteins from MCF-7 cells treated with phorbol ester (TPA) and 17 beta-estradiol (E2). TG2 abundance was significantly reduced in E2-treated cells and enhanced in TPA-treated cells. In summary we have demonstrated that TG2 is able to phosphorylate purified histone proteins, and H3 and H1 in chromatin preparations, and it is associated with chromatin in breast cancer cells. These studies suggest a novel role for TG2 in the regulation of chromatin structure and function.	Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba; University of Manitoba	Murphy, LJ (corresponding author), Univ Manitoba, John Buhler Res Ctr, Rm 843,715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	ljmurph@cc.umanitoba.ca	Espino, Paula/A-9459-2008; Mishra, Suresh/W-1633-2019	Davie, James/0000-0002-0420-6888; Mishra, Suresh/0000-0002-0364-1538				Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Ballestar E, 2001, BIOCHEMISTRY-US, V40, P1922, DOI 10.1021/bi001575b; BODE AM, 2005, SCI STKE, V281, pRE4; Bonelli G, 1996, EXP CELL RES, V228, P292, DOI 10.1006/excr.1996.0329; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Dunn KL, 2005, ONCOGENE, V24, P3492, DOI 10.1038/sj.onc.1208521; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Enomoto R, 2004, NEUROCHEM INT, V44, P459, DOI 10.1016/S0197-0186(03)00175-X; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Han JA, 2000, MOL CELLS, V10, P612, DOI 10.1007/s100590000020; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Ientile R, 2003, J NEUROSCI RES, V74, P52, DOI 10.1002/jnr.10702; Johnson KA, 2005, J BIOL CHEM, V280, P15004, DOI 10.1074/jbc.M500962200; Kim JH, 2002, BIOCHEM BIOPH RES CO, V293, P1453, DOI 10.1016/S0006-291X(02)00393-5; Kweon SM, 2004, J BIOCHEM MOL BIOL, V37, P185; Lai TS, 1998, J BIOL CHEM, V273, P1776, DOI 10.1074/jbc.273.3.1776; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nicholas B, 2003, BIOCHEM J, V371, P413, DOI 10.1042/BJ20021949; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Peng XJ, 1999, FEBS LETT, V446, P35, DOI 10.1016/S0014-5793(99)00018-6; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; Robitaille K, 2004, CELL DEATH DIFFER, V11, P542, DOI 10.1038/sj.cdd.4401392; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; Sato N, 2003, J PROTEIN CHEM, V22, P303, DOI 10.1023/A:1025032906494; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Song LW, 2003, CHINESE MED J-PEKING, V116, P742; Takeuchi Y, 1998, Z NATURFORSCH C, V53, P352; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; Zhang Y, 2004, J BIOL CHEM, V279, P21866, DOI 10.1074/jbc.M400099200	38	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5532	5538		10.1074/jbc.M506864200	http://dx.doi.org/10.1074/jbc.M506864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407273	hybrid			2022-12-25	WOS:000235568900027
J	Sugahara, KN; Hirata, T; Hayasaka, H; Stern, R; Murai, T; Miyasaka, M				Sugahara, KN; Hirata, T; Hayasaka, H; Stern, R; Murai, T; Miyasaka, M			Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; UP-REGULATION; URINE MARKER; OLIGOSACCHARIDES; GROWTH; SERUM; ACID; HYALURONIDASE-2; PURIFICATION; ACTIVATION	Hyaluronan (HA) is an extracellular matrix glycosaminoglycan that interacts with cell-surface receptors, including CD44. Although HA usually exists as a high molecular mass polymer, HA of a much lower molecular mass that shows a variety of biological activities can be detected under certain pathological conditions, particularly in tumors. We previously reported that low molecular weight HAs (LMW-HAs) of a certain size range induce the proteolytic cleavage of CD44 from the surface of tumor cells and promote tumor cell migration in a CD44-dependent manner. Here, we show that MIA PaCa-2, a human pancreatic carcinoma cell line, secreted hyaluronidases abundantly and generated readily detectable levels of LMW-HAs ranging from similar to 10- to 40-mers. This occurred in the absence of any exogenous stimulation. The tumor-derived HA oligosaccharides were able to enhance CD44 cleavage and tumor cell motility. Inhibition of the CD44-HA interaction resulted in the complete abrogation of these cellular events. These results are consistent with the concept that tumor cells generate HA oligosaccharides that bind to tumor cell CD44 through the expression of their own constitutive hyaluronidases. This enhances their own CD44 cleavage and cell motility, which would subsequently promote tumor progression. Such an autocrine/paracrine-like process may represent a novel activation mechanism that would facilitate and promote the malignant potential of tumor cells.	Osaka Univ, Grad Sch Med, Dept Microbiol & Immunol, Lab Immunodynam, Suita, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, 21st Century COE Program, Suita, Osaka 5650871, Japan; Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA	Osaka University; Osaka University; University of California System; University of California San Francisco	Miyasaka, M (corresponding author), Osaka Univ, Grad Sch Med C8, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mmiyasak@orgctl.med.osaka-u.ac.jp	Miyasaka, Masayuki/AAM-6343-2020	Hirata, Takako/0000-0002-1740-6168				AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; DAHL IMS, 1988, CANCER-AM CANCER SOC, V62, P326, DOI 10.1002/1097-0142(19880715)62:2<326::AID-CNCR2820620217>3.0.CO;2-Y; Fieber C, 2004, J CELL SCI, V117, P359, DOI 10.1242/jcs.00831; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Fujisaki T, 1999, CANCER RES, V59, P4427; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; GUO YJ, 1994, CANCER RES, V54, P422; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; KUMAR S, 1989, INT J CANCER, V44, P445, DOI 10.1002/ijc.2910440311; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lokeshwar VB, 2000, J UROLOGY, V163, P348, DOI 10.1016/S0022-5347(05)68050-0; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Novak U, 1999, CANCER RES, V59, P6246; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Pham HT, 1997, CANCER RES, V57, P778; Ropponen K, 1998, CANCER RES, V58, P342; Shi M, 2001, J IMMUNOL, V167, P123, DOI 10.4049/jimmunol.167.1.123; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; STERN M, 1992, MATRIX, V12, P397, DOI 10.1016/S0934-8832(11)80036-3; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Sugahara KN, 2004, TRENDS GLYCOSCI GLYC, V16, P187, DOI 10.4052/tigg.16.187; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Toole BP, 2000, J CLIN INVEST, V106, P335, DOI 10.1172/JCI10706; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Zeng CX, 1998, INT J CANCER, V77, P396	52	100	105	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5861	5868		10.1074/jbc.M506740200	http://dx.doi.org/10.1074/jbc.M506740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407205	hybrid			2022-12-25	WOS:000235568900066
J	Civas, A; Genin, P; Morin, P; Lin, RT; Hiscott, J				Civas, A; Genin, P; Morin, P; Lin, RT; Hiscott, J			Promoter organization of the interferon-A genes differentially affects virus-induced expression and responsiveness to TBK1 and IKK epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED RNA; NF-KAPPA-B; TRANSCRIPTION FACTOR; RIG-I; REGULATORY FACTOR-3; ANTIVIRAL RESPONSES; POSITIVE FEEDBACK; CRYSTAL-STRUCTURE; ALPHA PRODUCTION; ADAPTER PROTEIN	Virus-induced expression of interferon (IFN)-A genes is regulated by two members of the IFN regulatory factor (IRF) family, IRF-3 and IRF-7, which are activated by phosphorylation during viral infection by the IKK-related serine/threonine kinases TBK1 and I kappa B kinase epsilon (IKK epsilon). In this study, we demonstrate that three IRF- binding sites located in the virus-responsive element mediate the transcriptional activation of the IFN-A4 promoter by IRF-3. The precise arrangement of these IRF elements is required for synergistic activation of the IFN-A4 promoter following Newcastle disease virus infection or activation by TBK1 or IKK epsilon. The ordered assembly of IRF- 3 multimers on the promoter also determines cooperative recruitment of IRF-3 and CREB-binding protein and differential virus-induced expression of IFN-A4 gene promoter compared with IFN-A11. Naturally occurring nucleotide substitutions disrupt two of the IRF elements in the IFN-A11 gene promoter, leading to a dramatic decrease in IRF-3 and CREB-binding protein recruitment and in IRF-3-dependent transcription. Transcription of the IFN-A4 promoter by IRF- 7 is mediated by two IRF elements; promoter mutants that carry a reversed IRF element retain the ability to respond to IKK epsilon or TBK1 expression in the presence of IRF- 7 but lose the capacity to respond to virus or kinase-induced IRF-3. Interestingly, IKK epsilon or TBK1 stimulates the IRF-7-mediated transcription of IFN-A11, although at a lesser extent compared with IFN-A4. Our data indicate that virus-induced expression of IFN-A genes is dictated by the organization of IRF elements within the IFN-A promoters and that the differential IFN-A gene expression, based on the IRF- 3 responsiveness, is partially compensated in the presence of IRF-7 when both factors are activated by IKK epsilon or TBK1.	Univ Paris 05, CNRS, UPR 2228, Lab Regulat Transcript & Malad Genet, F-75270 Paris 06, France; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Civas, A (corresponding author), Univ Paris 05, CNRS, UPR 2228, Lab Regulat Transcript & Malad Genet, 45 Rue St Peres, F-75270 Paris 06, France.	ahmet.civas@univ-paris5.fr	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503; Genin, Pierre/0000-0002-7502-3851				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; AU WC, 1993, J BIOL CHEM, V268, P24032; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Barchet W, 2002, J EXP MED, V195, P507, DOI 10.1084/jem.20011666; Braganca J, 1997, J BIOL CHEM, V272, P22154, DOI 10.1074/jbc.272.35.22154; CIVAS A, 1991, NUCLEIC ACIDS RES, V19, P4497, DOI 10.1093/nar/19.16.4497; Civas A, 2002, BIOCHIMIE, V84, P643, DOI 10.1016/S0300-9084(02)01431-1; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Colonna M, 2002, CURR OPIN IMMUNOL, V14, P373, DOI 10.1016/S0952-7915(02)00349-7; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; Dalod M, 2003, J EXP MED, V197, P885, DOI 10.1084/jem.20021522; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Harlow E., 1988, ANTIBODIES LAB MANUA; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; HOSSHOMFELD A, 1989, VIROLOGY, V173, P539, DOI 10.1016/0042-6822(89)90566-7; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P805, DOI 10.1093/nar/13.3.805; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Morin P, 2002, J MOL BIOL, V316, P1009, DOI 10.1006/jmbi.2001.5401; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Ning SB, 2005, J BIOL CHEM, V280, P12262, DOI 10.1074/jbc.M404260200; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yang HM, 2003, J BIOL CHEM, V278, P15495, DOI 10.1074/jbc.M212940200; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; ZWARTHOFF EC, 1985, NUCLEIC ACIDS RES, V13, P791, DOI 10.1093/nar/13.3.791	65	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4856	4866		10.1074/jbc.M506812200	http://dx.doi.org/10.1074/jbc.M506812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380379	hybrid			2022-12-25	WOS:000235426200036
J	Sawai, H; Okada, Y; Funahashi, H; Matsuo, Y; Takahashi, H; Takeyama, H; Manabe, T				Sawai, H.; Okada, Y.; Funahashi, H.; Matsuo, Y.; Takahashi, H.; Takeyama, H.; Manabe, T.			Integrin-linked kinase activity is associated with interleukin-1a-induced progressive behavior of pancreatic cancer and poor patient survival	ONCOGENE			English	Article						integrins; integrin-linked kinase; interleukin; pancreatic cancer	EXPRESSION; APOPTOSIS; ILK; BETA-1-INTEGRIN; ADENOCARCINOMA; ACTIVATION; INHIBITION; GROWTH; PHOSPHORYLATION; MIGRATION	Cancer cell adhesion and invasion into extracellular matrix are regulated by integrin-linked kinase ( ILK) activity in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner. In this study, we demonstrated that ILK and beta(1)-integrin play important roles in interleukin (IL)-1 alpha-induced enhancement of adhesion and invasion of pancreatic cancer cells through p38 mitogen-activated protein kinase ( MAPK) signaling pathway and activator protein-1 (AP-1) activation. Alteration of ILK kinase activity controlled IL-1 alpha-induced p38 MAPK phosphorylation and its downstream AP-1 activation with subsequent regulation of pancreatic cancer cell adhesion and invasion. Overexpressed ILK enhances the IL-1 alpha-induced p38 MAPK phosphorylation more strongly through glycogen synthase kinase 3 (GSK-3) activation, and subsequently induces AP-1 activation, which promotes aggressive capabilities of pancreatic cancer cells. In contrast, knockdown of ILK kinase activity inhibits the IL-1 alpha-induced activation of MAPK/AP-1 pathway via inhibition of GSK-3 phosphorylation. In immunohistochemical analysis, statistically significant association between strong expression of ILK and poor prognosis of pancreatic cancer patients were observed, and strong expression of ILK in cancerous tissues can be a significant prognostic indicator of pancreatic cancer patients. Our results suggest that ILK is involved with aggressive capability in pancreatic cancer and that these regulations can be helpful to understand biological processes for a better translational treatment for pancreatic cancer patients.	Nagoya City Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Sawai, H (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.	cb8h-swi@asahi-net.or.jp	Sawai, Hirozumi/AAZ-1639-2020	Sawai, Hirozumi/0000-0002-2534-5959				Ahmed N, 2005, BRIT J CANCER, V92, P1475, DOI 10.1038/sj.bjc.6602495; Ahmed N, 2004, CLIN CANCER RES, V10, P2415, DOI 10.1158/1078-0432.CCR-03-0042; Buda A, 2003, GUT, V52, P729, DOI 10.1136/gut.52.5.729; Chen P, 2004, INT J CANCER, V111, P881, DOI 10.1002/ijc.20340; Chua YJ, 2005, J CLIN ONCOL, V23, P4532, DOI 10.1200/JCO.2005.17.954; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427; Feng H, 2004, ONCOGENE, V23, P7310, DOI 10.1038/sj.onc.1208041; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Marotta A, 2001, ONCOGENE, V20, P6250, DOI 10.1038/sj.onc.1204791; Mayoral R, 2005, CARCINOGENESIS, V26, P753, DOI 10.1093/carcin/bgi022; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Nho RS, 2005, J BIOL CHEM, V280, P26630, DOI 10.1074/jbc.M411798200; Park S, 2004, J CELL BIOCHEM, V91, P973, DOI 10.1002/jcb.10768; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Sawai H, 2003, DIGEST DIS SCI, V48, P1241, DOI 10.1023/A:1024276821731; Sawai H, 2003, ONCOLOGY-BASEL, V65, P167, DOI 10.1159/000072343; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Stocken DD, 2005, BRIT J CANCER, V92, P1372, DOI 10.1038/sj.bjc.6602513; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; van Golen CM, 2003, ONCOGENE, V22, P2664, DOI 10.1038/sj.onc.1206362; Vellon L, 2005, ONCOGENE, V24, P3759, DOI 10.1038/sj.onc.1208452; Vogelmann R, 1999, INT J CANCER, V80, P791, DOI 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025	40	51	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3237	3246		10.1038/sj.onc.1209356	http://dx.doi.org/10.1038/sj.onc.1209356			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407822				2022-12-25	WOS:000237951200002
J	Wojcik, EJ; Sharifpoor, S; Miller, NA; Wright, TG; Watering, R; Tremblay, E; Swan, K; Mueller, CR; Elliott, BE				Wojcik, EJ; Sharifpoor, S; Miller, NA; Wright, TG; Watering, R; Tremblay, E; Swan, K; Mueller, CR; Elliott, BE			A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells	ONCOGENE			English	Article						HGF expression; Src; Stat3; breast carcinoma cells	HEPATOCYTE GROWTH-FACTOR; FACTOR GENE PROMOTER; FACTOR SCATTER FACTOR; FACTOR EXPRESSION; BREAST-CARCINOMA; DNA-BINDING; SIGNAL TRANSDUCERS; MET/HGF RECEPTOR; MET RECEPTOR; CANCER	In the normal breast, hepatocyte growth factor (HGF) is primarily expressed by stromal cells, and stimulates in a paracrine manner epithelial cells expressing the HGF receptor ( Met). In invasive human breast carcinomas, HGF and Met are frequently overexpressed, possibly establishing an autocrine HGF/Met loop that promotes tumour cell invasion. However, the mechanisms leading to autocrine HGF expression in carcinoma cells are not known. We previously demonstrated a cooperative effect between c-Src and Stat3 in the activation of HGF transcription in mammary carcinoma cells. The present report defines a novel Stat3 consensus site at nt - 95 in the HGF promoter that is highly conserved in human and mouse, and is required for c-Src and Stat3 to activate HGF transcription in breast epithelial cells. DNA - protein binding studies demonstrated high affinity binding of a Stat3-containing complex to the nt -95 site. Endogenous Stat3 binding to this region of the HGF promoter in carcinoma cells expressing HGF was demonstrated using a chromatin immunoprecipitation assay. In addition, coexpression of Stat3 and activated c-Src caused increased expression of endogenous HGF mRNA and protein and marked cell scattering in breast epithelial cells. Our results delineate a novel c-Src/Stat3-dependent mechanism that regulates HGF promoter activity, and is linked to transformation of mammary epithelial cells.	Queens Univ, Inst Canc Res, Dept Pathol & Lab Med, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Elliott, BE (corresponding author), Queens Univ, Inst Canc Res, Dept Pathol & Lab Med, Div Canc Biol & Genet, 10 Stuart St, Kingston, ON K7L 3N6, Canada.	elliottb@post.queensu.ca						Andermarcher E, 1996, DEV GENET, V18, P254, DOI 10.1002/(SICI)1520-6408(1996)18:3<254::AID-DVG6>3.0.CO;2-8; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Bell AW, 1998, J BIOL CHEM, V273, P6900, DOI 10.1074/jbc.273.12.6900; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; BUSSOLINO F, 1992, J CELL BIOL, V119, P929; BYERS S, 1994, BREAST CANCER RES TR, V31, P203, DOI 10.1007/BF00666154; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Gallego MI, 2003, ONCOGENE, V22, P8498, DOI 10.1038/sj.onc.1207063; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jiang JG, 2000, ONCOGENE, V19, P2786, DOI 10.1038/sj.onc.1203581; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; Jiang JG, 2001, J BIOL CHEM, V276, P25049, DOI 10.1074/jbc.M101611200; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Klosek SK, 2004, ONCOL REP, V12, P293; LIU YH, 1994, J BIOL CHEM, V269, P4152; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Paz K, 2004, ONCOGENE, V23, P8455, DOI 10.1038/sj.onc.1207803; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Siegfried JM, 1997, CANCER RES, V57, P433; Tomida M, 2004, ONCOGENE, V23, P679, DOI 10.1038/sj.onc.1207190; Trovato M, 2004, EUR J HISTOCHEM, V48, P291; Tuck AB, 1996, AM J PATHOL, V148, P225; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; WANG Y, 1994, AM J PATHOL, V144, P675; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yang J, 2005, CANCER RES, V65, P939; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004	50	47	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2773	2784		10.1038/sj.onc.1209306	http://dx.doi.org/10.1038/sj.onc.1209306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407846				2022-12-25	WOS:000237272900008
J	Chen, CG; Li, JG; Chen, Y; Huang, P; Wang, YL; Liu-Chen, LY				Chen, CG; Li, JG; Chen, Y; Huang, P; Wang, YL; Liu-Chen, LY			GEC1 interacts with the kappa opioid receptor and enhances expression of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; MEMBRANE-TRANSPORT MODULATOR; CELL-SURFACE EXPRESSION; HAMSTER OVARY CELLS; RAT SPINAL-CORD; GABA(A) RECEPTOR; DOWN-REGULATION; U50,488H-INDUCED INTERNALIZATION; DEPENDENT MECHANISM; PROTEIN GABARAP	We identified a truncated form (38-117) of GEC1 that interacts with the C-tail of the human kappa opioid receptor (hKOR) by yeast two-hybrid screening. GEC1-(38-117) did not interact with the C-tail of the mu or delta opioid receptors. GEC1, a 117-amino acid protein (Pellerin, I., Vuillermoz, C., Jouvenot, M., Ordener, C., Royez, M., and Adessi, G. L. (1993) Mol. Cell Endocrinol. 90, R17-R21), is highly homologous to GABARAP, GATE-16, and Apg8/aut7, all members of the microtubule associated protein (MAP) family. In pull-down assays, GST-GEC1 interacted directly with the hKOR C-tail, full-length hKOR, and tubulin. When expressed in Chinese hamster ovary (CHO) cells, GEC1 co-immunoprecipitated with FLAG-hKOR. Expression of GEC1 greatly increased total and cell-surface KOR but not mu or delta opioid receptors. GEC1 expression slightly reduced U50,488H-promoted down-regulation, without affecting ligand binding affinity, receptor-G protein coupling, or U50,488H-induced desensitization and internalization. HA-GEC1 expressed in CHO cells was localized in the Golgi apparatus and endoplasmic reticulum (ER). When cells were pulsed with [S-35]Met/Cys, GEC1 expression enhanced the level of the mature form (55-kDa band) of FLAG-hKOR at 4, 8, and 22 h after pulse without affecting the precursors (39- and 45-kDa bands), indicating that GEC1 facilitates trafficking of FLAG-hKOR from the ER/Golgi to plasma membranes. GEC1 interacted with N-ethylmaleimide-sensitive factor (NSF) in pull-down assays and co-immunoprecipitated with NSF in rat brain extracts. The interaction with NSF may contribute to GEC1 effects. This is the first report on biological functions of GEC1 and the first demonstration that a GPCR interacts with a protein of the MAP family. The interaction is important for trafficking of the receptor in the biosynthesis pathway.	Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Ctr Substance Abuse Res, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liu-Chen, LY (corresponding author), Temple Univ, Sch Med, Dept Pharmacol, 3420 N Broad St, Philadelphia, PA 19140 USA.	lliuche@temple.edu			NIDA NIH HHS [DA17302, DA04745] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA004745, R01DA004745] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ango F, 2002, MOL CELL NEUROSCI, V20, P323, DOI 10.1006/mcne.2002.1100; Bermak J C, 2001, Mol Interv, V1, P282; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Chang PC, 2000, BRAIN RES, V861, P168, DOI 10.1016/S0006-8993(99)02461-0; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; DYKSTRA LA, 1987, J PHARMACOL EXP THER, V242, P413; Elazar Z, 2003, BBA-MOL CELL RES, V1641, P145, DOI 10.1016/S0167-4889(03)00086-7; Everitt AB, 2004, J BIOL CHEM, V279, P21701, DOI 10.1074/jbc.M312806200; Green F, 2002, FEBS LETT, V518, P101, DOI 10.1016/S0014-5793(02)02655-8; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Harris JA, 2004, NEUROSCIENCE, V124, P879, DOI 10.1016/j.neuroscience.2003.12.042; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Hemelaar J, 2003, J BIOL CHEM, V278, P51841, DOI 10.1074/jbc.M308762200; Huang P, 2004, J BIOL CHEM, V279, P25002, DOI 10.1074/jbc.M313366200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Knight D, 2002, J BIOL CHEM, V277, P5556, DOI 10.1074/jbc.M109753200; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; Leil TA, 2004, J NEUROSCI, V24, P11429, DOI 10.1523/JNEUROSCI.3355-04.2004; Li J, 2002, MOL PHARMACOL, V61, P73, DOI 10.1124/mol.61.1.73; Li JG, 2003, J PHARMACOL EXP THER, V305, P531, DOI 10.1124/jpet.102.045559; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Li JG, 2000, MOL PHARMACOL, V58, P795, DOI 10.1124/mol.58.4.795; LIUCHEN LY, 1993, MOL PHARMACOL, V44, P749; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malyala A, 2004, NEUROCHEM RES, V29, P1189, DOI 10.1023/B:NERE.0000023606.13670.1d; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Mansuy V, 2004, BIOCHEM BIOPH RES CO, V325, P639, DOI 10.1016/j.bbrc.2004.10.072; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Nemos C, 2003, MOL BRAIN RES, V119, P216, DOI 10.1016/j.molbrainres.2003.09.011; Noel J, 1999, NEURON, V23, P365, DOI 10.1016/S0896-6273(00)80786-2; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; PELLERIN I, 1993, MOL CELL ENDOCRINOL, V90, pR17, DOI 10.1016/0303-7207(93)90161-C; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Vernier-Magnin S, 2001, BIOCHEM BIOPH RES CO, V284, P118, DOI 10.1006/bbrc.2001.4908; VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Wang Y, 2005, J PHARMACOL EXP THER, V312, P220, DOI 10.1124/jpet.104.073668; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; Xin YR, 2001, GENOMICS, V74, P408, DOI 10.1006/geno.2001.6555; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28; ZHU JM, 1995, LIFE SCI, V56, pPL201, DOI 10.1016/0024-3205(94)00507-O	59	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7983	7993		10.1074/jbc.M509805200	http://dx.doi.org/10.1074/jbc.M509805200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431922	hybrid			2022-12-25	WOS:000236031000035
J	Okochi, M; Fukumori, A; Jiang, JW; Itoh, N; Kimura, R; Steiner, H; Haass, C; Tagami, S; Takeda, M				Okochi, M; Fukumori, A; Jiang, JW; Itoh, N; Kimura, R; Steiner, H; Haass, C; Tagami, S; Takeda, M			Secretion of the Notch-1 A beta-like peptide during Notch signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; REGULATED INTRAMEMBRANE PROTEOLYSIS; DISEASE GAMMA-SECRETASE; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; PRESENILIN-1 MUTATIONS; TRANSMEMBRANE DOMAIN; DROSOPHILA NOTCH; CLEAVAGE; RECEPTOR	The canonical pathway of Notch signaling is mediated by regulated intramembrane proteolysis ( RIP). In the pathway, ligand binding results in sequential proteolysis of the Notch receptor, and presenilin (PS)-dependent intramembrane proteolysis at the interface between the membrane and cytosol liberates the Notch-1 intracellular domain (NICD), a transcription modifier. Because the degradation of the Notch-1 transmembrane domain is thought to require an additional cleavage near the middle of the transmembrane domain, extracellular small peptides (Notch-1 A beta-like peptide (N beta)) should be produced. Here we showed that N beta species are indeed secreted during the process of Notch signaling. We identified mainly two distinct molecular species of novel N beta, N beta 21 and C-terminally elongated N beta 25, which were produced in an similar to 5: 1 ratio. This process is reminiscent of the production of Alzheimer disease-associated A beta. PS pathogenic mutants increased the production of the longer species of A beta(A beta 42) from beta-amyloid protein precursor. We revealed that several Alzheimer disease mutants also cause a parallel increase in the secretion of the longer form of N beta. Strikingly, chemicals that modify the A beta 42 level caused parallel changes in the N beta 25 level. These results demonstrated that the characteristics of C-terminal elongation of N beta and A beta are almost identical. In addition, because many other type 1 membrane-bound receptors release intracellular domains by PS-dependent intramembrane proteolysis, we suspect that the release of A beta- or N beta-like peptides is a common feature of the proteolysis during RIP signaling. We anticipate that this study will open the door to searches for markers of RIP signaling and surrogate markers for A beta 42 production.	Osaka Univ, Grad Sch Med, Dept Psychiat & Behav Prote, Dept Post Genom & Dis, Osaka 5650871, Japan; Shionogi & Co Ltd, Discovery Res Labs, Shiga 5203423, Japan; Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimer & Parkinsons Dis Res, D-80336 Munich, Germany	Osaka University; Shionogi & Company Limited; University of Munich	Okochi, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Psychiat & Behav Prote, Dept Post Genom & Dis, D3,2-2 Yamadaoka, Osaka 5650871, Japan.	mokochi@psy.med.osaka-u.ac.jp		Okochi, Masayasu/0000-0002-2318-7651				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NYE JS, 1994, DEVELOPMENT, V120, P2421; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Okochi M, 1997, FEBS LETT, V418, P162, DOI 10.1016/S0014-5793(97)01378-1; Okochi M, 2000, J BIOL CHEM, V275, P40925, DOI 10.1074/jbc.M005254200; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Sagi SA, 2003, J BIOL CHEM, V278, P31825, DOI 10.1074/jbc.M303588200; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yoshiike Y, 2003, J BIOL CHEM, V278, P23648, DOI 10.1074/jbc.M212785200; Zhang JM, 2002, J BIOL CHEM, V277, P15069, DOI 10.1074/jbc.M105375200	46	90	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7890	7898		10.1074/jbc.M513250200	http://dx.doi.org/10.1074/jbc.M513250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434391	hybrid			2022-12-25	WOS:000236031000024
J	Riuzzi, F; Sorci, G; Donato, R				Riuzzi, F; Sorci, G; Donato, R			The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness - Functional inactivation of rage in L6 myoblasts results in tumor formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FIBROBLAST-GROWTH-FACTOR; SKELETAL-MUSCLE DIFFERENTIATION; MYOGENIC DIFFERENTIATION; MYOTUBE FORMATION; GENE-EXPRESSION; CELL-SURVIVAL; RESERVE-CELLS; ALPHA-7-BETA-1 INTEGRIN; MUSCULAR-DYSTROPHIES	We reported that RAGE ( receptor for advanced glycation end products), amultiligand receptor of the immunoglobulin superfamily expressed in myoblasts, when activated by its ligand amphoterin (HMGB1), stimulates rat L6 myoblast differentiation via a Cdc42-Rac-MKK6-p38 mitogen-activated protein kinase pathway, and that RAGE expression in skeletal muscle tissue is developmentally regulated. We show here that inhibition of RAGE function via overexpression of a signaling deficient RAGE mutant (RAGE Delta cyto) results in increased myoblast proliferation, migration, and invasiveness, and decreased apoptosis and adhesiveness, whereas myoblasts overexpressing RAGE behave the opposite, compared with mock-transfected myoblasts. These effects are accompanied by a decreased induction of the proliferation inhibitor, p21(Waf1), and increased induction of cyclin D1 and extent of Rb, ERK1/2, and JNK phosphorylation in L6/RAGE Delta cyto myoblasts, the opposite occurring in L6/RAGE myoblasts. Neutralization of culture medium amphoterin negates effects of RAGE activation, suggesting that amphoterin is the RAGE ligand involved in RAGE-dependent effects in myoblasts. Finally, mice injected with L6/RAGE Delta cyto myoblasts develop tumors as opposed to mice injected with L6/RAGE or L6/mock myoblasts that do not. Thus, the amphoterin/RAGE pair stimulates myoblast differentiation by the combined effect of stimulation of differentiation and inhibition of proliferation, and deregulation of RAGE expression in myoblasts might contribute to their neoplastic transformation.	Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, I-06122 Perugia, Italy; Univ Perugia, Ist Interuniv Miol, I-06122 Perugia, Italy	University of Perugia; University of Perugia	Donato, R (corresponding author), Univ Perugia, Dept Expt Med & Biochem Sci, Sect Anat, Via Giochetto,Casella Postale 81 Succursale 3, I-06122 Perugia, Italy.	donato@unipg.it	Donato, Rosario/I-3943-2019; li, tao/B-2402-2008	Riuzzi, Francesca/0000-0001-7908-3379; Sorci, Guglielmo/0000-0002-1973-9679				Ahmadzadeh M, 1999, J IMMUNOL, V163, P3053; Allen DL, 2003, AM J PHYSIOL-CELL PH, V284, pC805, DOI 10.1152/ajpcell.00215.2002; Allikian MJ, 2004, J CELL SCI, V117, P3821, DOI 10.1242/jcs.01234; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Bour BA, 2000, GENE DEV, V14, P1498; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Carnac G, 2000, CURR BIOL, V10, P543, DOI 10.1016/S0960-9822(00)00471-1; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dee K, 2002, CELL DEATH DIFFER, V9, P209, DOI 10.1038/sj/cdd/4400930; Fazeli S, 1996, J CELL BIOL, V135, P241, DOI 10.1083/jcb.135.1.241; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Friday BB, 2001, J CELL SCI, V114, P303; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Hodges BL, 1997, J CELL SCI, V110, P2873; Huttunen HJ, 2004, J INTERN MED, V255, P351, DOI 10.1111/j.1365-2796.2003.01301.x; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ito H, 2004, BIOCHEM BIOPH RES CO, V318, P594, DOI 10.1016/j.bbrc.2004.04.070; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Lee J, 2002, BIOCHEM BIOPH RES CO, V298, P765, DOI 10.1016/S0006-291X(02)02562-7; Li YQ, 2000, CELL SIGNAL, V12, P751, DOI 10.1016/S0898-6568(00)00120-0; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ostrovsky O, 2003, J BIOL CHEM, V278, P21221, DOI 10.1074/jbc.M211357200; Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Sorci G, 2004, MOL CELL BIOL, V24, P4880, DOI 10.1128/MCB.24.11.4880-4894.2004; Sorci G, 2004, J CELL PHYSIOL, V199, P274, DOI 10.1002/jcp.10462; Sorci G, 2003, MOL CELL BIOL, V23, P4870, DOI 10.1128/MCB.23.14.4870-4881.2003; Spence HJ, 2002, BIOESSAYS, V24, P542, DOI 10.1002/bies.10098; Tietze L, 1999, EXP MOL PATHOL, V66, P131, DOI 10.1006/exmp.1999.2252; Tortorella LL, 2001, J BIOL CHEM, V276, P13709, DOI 10.1074/jbc.M100091200; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yonekura H, 2003, BIOCHEM J, V370, P1097, DOI 10.1042/BJ20021371; Yoshida N, 1998, J CELL SCI, V111, P769; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	57	98	107	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8242	8253		10.1074/jbc.M509436200	http://dx.doi.org/10.1074/jbc.M509436200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407300	hybrid			2022-12-25	WOS:000236031000064
J	Amici, C; Rossi, A; Costanzo, A; Ciafre, S; Marinari, B; Balsamo, M; Levrero, M; Santoro, MG				Amici, C; Rossi, A; Costanzo, A; Ciafre, S; Marinari, B; Balsamo, M; Levrero, M; Santoro, MG			Herpes simplex virus disrupts NF-kappa B regulation by blocking its recruitment on the I kappa B alpha promoter and directing the factor on viral genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPENTENONE PROSTAGLANDINS; TYPE-1; REPLICATION; ACTIVATION; CELLS; INHIBITION; INFECTION; KINASE; PROTEINS; HISTONES	Herpes simplex viruses (HSVs) are able to hijack the host-cell I kappa B kinase (IKK)/NF-kappa B pathway, which regulates critical cell functions from apoptosis to inflammatory responses; however, the molecular mechanisms involved and the outcome of the signaling dysregulation on the host-virus interaction are mostly unknown. Here we show that in human keratinocytes HSV-1 attains a sophisticated control of the IKK/NF-kappa B pathway, inducing two distinct temporally controlled waves of IKK activity and disrupting the NF-kappa B autoregulatory mechanism. Using chromatin immunoprecipitation we demonstrate that dysregulation of the NF-kappa B-response is mediated by a virus-induced block of NF-kappa B recruitment to the promoter of the I kappa B alpha gene, encoding the main NF-kappa B-inhibitor. We also show that HSV-1 redirects NF-kappa B recruitment to the promoter of ICP0, an immediate-early viral gene with a key role in promoting virus replication. The results reveal a new level of control of cellular functions by invading viruses and suggest that persistent NF-kappa B activation in HSV-1-infected cells, rather than being a host response to the virus, may play a positive role in promoting efficient viral replication.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; Univ Roma La Sapienza, Dept Internal Med, I-00185 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Santoro, MG (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	santoro@bio.uniroma2.it	Costanzo, Antonio/D-3896-2012; ciafrè, stefania g.l./B-5158-2015; Costanzo, Antonio/GZG-2433-2022; Levrero, Massimo/G-5680-2016	ciafrè, stefania g.l./0000-0002-2629-8787; Costanzo, Antonio/0000-0001-9697-2557; Santoro, Maria Gabriella/0000-0003-1432-4949; Levrero, Massimo/0000-0002-4978-0875; ROSSI, ANTONIO/0000-0003-0383-3828				Amici C, 2004, AIDS, V18, P1271, DOI 10.1097/00002030-200406180-00005; Amici C, 2001, J BIOL CHEM, V276, P28759, DOI 10.1074/jbc.M103408200; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; D'Addario M, 2000, J MOL BIOL, V298, P765, DOI 10.1006/jmbi.2000.3717; Davido DJ, 1998, J GEN VIROL, V79, P2093, DOI 10.1099/0022-1317-79-9-2093; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goodkin ML, 2003, J VIROL, V77, P7261, DOI 10.1128/JVI.77.13.7261-7280.2003; Gregory D, 2004, J VIROL, V78, P13582, DOI 10.1128/JVI.78.24.13582-13590.2004; Herrera FJ, 2004, J VIROL, V78, P9689, DOI 10.1128/JVI.78.18.9689-9696.2004; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kent JR, 2004, J VIROL, V78, P10178, DOI 10.1128/JVI.78.18.10178-10186.2004; Kubat NJ, 2004, J VIROL, V78, P1139, DOI 10.1128/JVI.78.3.1139-1149.2004; Kubat NJ, 2004, J VIROL, V78, P12508, DOI 10.1128/JVI.78.22.12508-12518.2004; LEINBACH SS, 1980, J GEN VIROL, V51, P45, DOI 10.1099/0022-1317-51-1-45; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; MUGGERIDGE MI, 1986, J VIROL, V59, P764, DOI 10.1128/JVI.59.3.764-767.1986; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; RONG BL, 1992, VIROLOGY, V189, P750, DOI 10.1016/0042-6822(92)90599-K; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Sugano N, 1997, J EXP MED, V186, P731, DOI 10.1084/jem.186.5.731; Taddeo B, 2004, J VIROL, V78, P11615, DOI 10.1128/JVI.78.21.11615-11621.2004; Taddeo B, 2002, P NATL ACAD SCI USA, V99, P17031, DOI 10.1073/pnas.252588599; Taddeo B, 2003, P NATL ACAD SCI USA, V100, P12408, DOI 10.1073/pnas.2034952100	35	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7110	7117		10.1074/jbc.M512366200	http://dx.doi.org/10.1074/jbc.M512366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407234	hybrid			2022-12-25	WOS:000236030900025
J	Cantini, F; Savino, S; Scarselli, M; Masignani, V; Pizza, M; Romagnoli, G; Swennen, E; Veggi, D; Banci, L; Rappuoli, R				Cantini, F; Savino, S; Scarselli, M; Masignani, V; Pizza, M; Romagnoli, G; Swennen, E; Veggi, D; Banci, L; Rappuoli, R			Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-B; OUTER-MEMBRANE PROTEIN; ELICITS BACTERICIDAL ANTIBODIES; MENINGOCOCCAL VACCINES; CRYSTAL-STRUCTURE; NMR RELAXATION; TRANSFERRIN; IMMUNOGENICITY; IDENTIFICATION; COMPLEXES	GNA1870, a 28-kDa surface-exposed lipoprotein of Neisseria meningitidis recently discovered by reverse vaccinology, is one of the most potent antigens of Meningococcus and a promising candidate for a universal vaccine against a devastating disease. Previous studies of epitope mapping and genetic characterization identified residues critical for bactericidal response within the C-terminal domain of the molecule. To elucidate the conformation of protective epitopes, we used NMR spectroscopy to obtain the solution structure of the immunodominant 18-kDa C-terminal portion of GNA1870. The structure consists of an eight-stranded antiparallel beta-barrel overlaid by a short alpha-helix with an unstructured N-terminal end. Residues previously shown to be important for antibody recognition were mapped on loops facing the same ridge of the molecule. The sequence similarity of GNA1870 with members of the bacterial transferrin receptor family allows one to predict the folding of this class of well known bacterial antigens, providing the basis for the rational engineering of high affinity B cell epitopes.	Univ Florence, Ctr Risonanze Magnet CERM, I-50019 Sesto Fiorentino, Italy; CHIRON Vaccines Res Ctr, I-53100 Siena, Italy	University of Florence; Novartis	Rappuoli, R (corresponding author), IRIS Res Ctr, Chiron Srl Via Fiorentina 1, I-53100 Siena, Italy.	rino_rappuoli@chiron.com	Cantini, Francesca/O-1220-2015	Cantini, Francesca/0000-0003-0526-6732; BANCI, LUCIA/0000-0003-0562-5774				AlaAldeen DAA, 1996, VACCINE, V14, P49, DOI 10.1016/0264-410X(95)00136-O; Banci L, 1998, J AM CHEM SOC, V120, P12903, DOI 10.1021/ja981791w; BAX A, 1994, METHOD ENZYMOL, V239, P79; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BRANHAM SE, 1953, BACTERIOL REV, V17, P175, DOI 10.1128/MMBR.17.3.175-188.1953; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; Decanniere K, 2001, J MOL BIOL, V313, P473, DOI 10.1006/jmbi.2001.5075; DEMORAES JC, 1992, LANCET, V340, P1074; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FRASCH CE, 1989, CLIN MICROBIOL REV S, V2, P134; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Giuliani MM, 2005, INFECT IMMUN, V73, P1151, DOI 10.1128/IAI.73.2.1151-1160.2005; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Holm L, 1998, PROTEINS, V33, P88, DOI 10.1002/(SICI)1097-0134(19981001)33:1<88::AID-PROT8>3.0.CO;2-H; Kahler CM, 2001, INFECT IMMUN, V69, P1687, DOI 10.1128/IAI.69.3.1687-1696.2001; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; LISSOLO L, 1995, INFECT IMMUN, V63, P884, DOI 10.1128/IAI.63.3.884-890.1995; Martin D, 1997, J EXP MED, V185, P1173, DOI 10.1084/jem.185.7.1173; Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911; Myers LE, 1998, INFECT IMMUN, V66, P4183; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pearl F, 2005, NUCLEIC ACIDS RES, V33, pD247, DOI 10.1093/nar/gki024; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Perkins BA, 1998, J INFECT DIS, V177, P683, DOI 10.1086/514232; Prince SM, 2002, P NATL ACAD SCI USA, V99, P3417, DOI 10.1073/pnas.062630899; Renauld-Mongenie G, 2004, J BACTERIOL, V186, P850, DOI 10.1128/JB.186.3.850-857.2004; Retzer MD, 1999, MOL MICROBIOL, V32, P111, DOI 10.1046/j.1365-2958.1999.01331.x; ROSENQVIST E, 1995, INFECT IMMUN, V63, P4642, DOI 10.1128/IAI.63.12.4642-4652.1995; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Takagi K, 2001, EUR J BIOCHEM, V268, P470, DOI 10.1046/j.1432-1033.2001.01912.x; Tappero JW, 1999, JAMA-J AM MED ASSOC, V281, P1520, DOI 10.1001/jama.281.16.1520; Vandeputte-Rutten L, 2003, J BIOL CHEM, V278, P24825, DOI 10.1074/jbc.M302803200; VEDROS NA, 1987, EVOLUTION MENINGOCOC; Webb DC, 1999, INFECT IMMUN, V67, P2138, DOI 10.1128/IAI.67.5.2138-2144.1999; Welsch JA, 2004, J IMMUNOL, V172, P5606, DOI 10.4049/jimmunol.172.9.5606	44	38	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7220	7227		10.1074/jbc.M508595200	http://dx.doi.org/10.1074/jbc.M508595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407174	hybrid			2022-12-25	WOS:000236030900039
J	Choi, SY; Kim, MJ; Kang, CM; Bae, S; Cho, CK; Soh, JW; Kim, JH; Kang, S; Chung, HY; Lee, YS; Lee, SJ				Choi, SY; Kim, MJ; Kang, CM; Bae, S; Cho, CK; Soh, JW; Kim, JH; Kang, S; Chung, HY; Lee, YS; Lee, SJ			Activation of Bak and Bax through c-Abl-protein kinase C delta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-INDUCED APOPTOSIS; CYTOCHROME-C; PKC-DELTA; TYROSINE PHOSPHORYLATION; IN-VITRO; DEATH; TRANSLOCATION; MITOCHONDRIA; RELEASE; GROWTH	Intracellular signaling molecules and apoptotic factors seem to play an important role in determining the radiation response of tumor cells. However, the basis for the link between signaling pathway and apoptotic cell death machinery after ionizing irradiation remains still largely unclear. In this study, we showed that c-Abl-PKC delta-Rac1- p38 MAPK signaling is required for the conformational changes of Bak and Bax during ionizing radiation-induced apoptotic cell death in human non-small cell lung cancer cells. Ionizing radiation induced conformational changes and subsequent oligomerizations of Bak and Bax, dissipation of mitochondrial membrane potential, and cytochrome c release from mitochondria. Small interference ( siRNA) targeting of Bak and Bax effectively protected cells from radiation-induced mitochondrial membrane potential loss and apoptotic cell death. p38 MAPK was found to be selectively activated in response to radiation treatment. Inhibition of p38 MAPK completely suppressed radiation-induced Bak and Bax activations, dissipation of mitochondrial membrane potential, and cell death. Moreover, expression of a dominant negative form of protein kinase C delta (PKC delta) or siRNA targeting of PKC delta attenuated p38 MAPK activation and conformational changes of Bak and Bax. In addition, ectopic expression of RacN17, a dominant negative form of Rac1, markedly inhibited p38 MAPK activation but did not affect PKC delta activation. Upon stimulation of cells with radiation, PKC delta was phosphorylated dramatically on tyrosine. c-Abl-PKC delta complex formation was also increased in response to radiation. Moreover, siRNA targeting of c-Abl attenuated radiation-induced PKC delta and p38 MAPK activations, and Bak and Bax modulations. These data support a notion that activation of the c-Abl-PKC delta-Rac1- p38 MAPK pathway in response to ionizing radiation signals conformational changes of Bak and Bax, resulting in mitochondrial activation-mediated apoptotic cell death in human non-small cell lung cancer cells.	Korea Inst Radiol & Med Sci, Lab Radiat Expt Therapeut, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Radiat Cytogenet & Epidemiol, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Inha Univ, Dept Chem, Coll Nat Sci, Inchon 402751, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Inha University; Korea University; Hanyang University	Lee, SJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Expt Therapeut, Seoul 139706, South Korea.	sjlee@kcch.re.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brachat A, 2000, ONCOGENE, V19, P5073, DOI 10.1038/sj.onc.1203882; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Choi JA, 2004, ONCOGENE, V23, P9, DOI 10.1038/sj.onc.1206982; Deacon K, 2003, MOL BIOL CELL, V14, P2071, DOI 10.1091/mbc.e02-10-0653; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Eom YW, 2001, BIOCHEM BIOPH RES CO, V284, P126, DOI 10.1006/bbrc.2001.4937; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; Garcia-Fernandez LF, 2002, ONCOGENE, V21, P7533, DOI 10.1038/sj.onc.1205972; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HarmsRingdahl M, 1996, MUTAT RES-REV GENET, V366, P171, DOI 10.1016/S0165-1110(96)90038-X; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lee YJ, 2005, ONCOGENE, V24, P3715, DOI 10.1038/sj.onc.1208440; Lee YJ, 2005, J BIOL CHEM, V280, P18108, DOI 10.1074/jbc.M501131200; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Maher P, 2001, J NEUROSCI, V21, P2929, DOI 10.1523/JNEUROSCI.21-09-02929.2001; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Maloney JA, 1998, AM J PHYSIOL-CELL PH, V274, pC974, DOI 10.1152/ajpcell.1998.274.4.C974; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Marshall CJ, 1998, CURR OPIN GENET DEV, V8, P11, DOI 10.1016/S0959-437X(98)80055-5; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Sodhi A, 2005, CELL SIGNAL, V17, P377, DOI 10.1016/j.cellsig.2004.08.004; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Ting HC, 2002, IMMUNOL LETT, V82, P205, DOI 10.1016/S0165-2478(02)00044-5; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; YANG J, 1997, SCIENCE, V275, P1132; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zheng YH, 2005, ONCOGENE, V24, P3339, DOI 10.1038/sj.onc.1208484; Zhivotovsky B, 1999, EXP CELL RES, V248, P10, DOI 10.1006/excr.1999.4452	58	72	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7049	7059		10.1074/jbc.M512000200	http://dx.doi.org/10.1074/jbc.M512000200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410245	hybrid			2022-12-25	WOS:000236030900018
J	Rabah, N; Gauthier, D; Wilkes, BC; Gauthier, DJ; Lazure, C				Rabah, N; Gauthier, D; Wilkes, BC; Gauthier, DJ; Lazure, C			Single amino acid substitution in the PC1/3 propeptide can induce significant modifications of its inhibitory profile toward its cognate enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITORS; PRO-PROTEIN CONVERTASES; PROPROTEIN CONVERTASES; PROHORMONE CONVERTASES; CRYSTAL-STRUCTURE; INTRAMOLECULAR CHAPERONE; POTENT INHIBITORS; INSECT CELLS; HUMAN FURIN; IN-VITRO	The proprotein convertase PC1/3 is synthesized as a large precursor that undergoes proteolytic processing of the signal peptide, the propeptide and ultimately the COOH-terminal tail, to generate the mature form. The propeptide is essential for protease folding, and, although cleaved by an autocatalytic process, it remains associated with the mature form acting as an auto-inhibitor of PC1/3. To further assess the role of certain residues in its interaction with its cognate enzyme, we performed an alanine scan on two PC1/3 propeptide potential cleavable sites ((RRSRR54)-R-50 and (KR62)-K-61) and an acidic region (DDD67)-D-65 conserved among species. Upon incubation with PC1/3, the ensuing peptides exhibit equal inhibitory potency, lower potency, or higher potency than the wild-type propeptide. The K-i values calculated varied between 0.15 and 16.5 nM. All but one mutant exhibited a tight binding behavior. To examine the specificity of mutants, we studied their reactivity toward furin, a closely related convertase. The mutation of certain residues also affects the inhibition behavior toward furin yielding propeptides exhibiting K-i ranging from 0.2 to 24 nM. Mutant propeptides exhibited against each enzyme either different mode of inhibition, enhanced selectivity in the order of 40-fold for one enzyme, or high potency with no discrimination. Hence, we demonstrate through single amino acid substitution that it is feasible to modify the inhibitory behavior of propeptides toward convertases in such away as to increase or decrease their potency, modify their inhibitory mechanisms, as well as increase their selectivity.	Univ Montreal, Inst Rech Clin Montreal, Neuropeptides Struct & Metab Res Lab, Neuropeptides Struct & Metab Res Unit, Montreal, PQ H2W 1R7, Canada; Clin Res Inst Montreal, Chem Biol & Peptide Res Unit, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Lazure, C (corresponding author), Univ Montreal, Inst Rech Clin Montreal, Neuropeptides Struct & Metab Res Lab, Neuropeptides Struct & Metab Res Unit, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	lazurec@ircm.qc.ca						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Basak A, 2003, BIOCHEM J, V373, P231, DOI 10.1042/BJ20030120; Basak A, 1999, PEPTIDES: FRONTIERS OF PEPTIDES SCIENCE, P676; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bhattacharjya S, 2000, BIOCHEMISTRY-US, V39, P2868, DOI 10.1021/bi9923961; Bissonnette L, 2004, BIOCHEM J, V379, P757, DOI 10.1042/BJ20031902; Boudreault A, 1998, PROTEIN EXPRES PURIF, V14, P353, DOI 10.1006/prep.1998.0964; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BRENNAN SO, 1994, FEBS LETT, V347, P80, DOI 10.1016/0014-5793(94)00511-7; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Chapman RL, 1997, J BIOL CHEM, V272, P8808, DOI 10.1074/jbc.272.13.8808; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; EGGELKRAUTGOTTA.R, 2004, CURR MED CHEM, V11, P2651; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; Fugere M, 2002, CURR PHARM DESIGN, V8, P549, DOI 10.2174/1381612023395736; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Holyoak T, 2004, BIOCHEMISTRY-US, V43, P2412, DOI 10.1021/bi035849h; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; Lesage G, 2001, FEBS LETT, V508, P332, DOI 10.1016/S0014-5793(01)03096-4; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; Powner D, 1998, MOL CELL BIOL, V18, P400, DOI 10.1128/MCB.18.1.400; Rabah N, 2004, PROTEIN EXPRES PURIF, V37, P377, DOI 10.1016/j.pep.2004.06.014; Rockwell NC, 2004, TRENDS BIOCHEM SCI, V29, P80, DOI 10.1016/j.tibs.2003.12.006; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Sauter NK, 1998, NAT STRUCT BIOL, V5, P945, DOI 10.1038/2919; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Takagi H, 2003, APPL MICROBIOL BIOT, V63, P1, DOI 10.1007/s00253-003-1352-1; Tangrea MA, 2002, J MOL BIOL, V320, P801, DOI 10.1016/S0022-2836(02)00543-0; Tangrea MA, 2001, BIOCHEMISTRY-US, V40, P5488, DOI 10.1021/bi0026472; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Villemure M, 2003, BIOCHEMISTRY-US, V42, P9659, DOI 10.1021/bi034418w; Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	56	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7556	7567		10.1074/jbc.M510607200	http://dx.doi.org/10.1074/jbc.M510607200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407210	hybrid			2022-12-25	WOS:000236030900077
J	Struewing, IT; Toborek, A; Mao, CD				Struewing, IT; Toborek, A; Mao, CD			Mitochondrial and nuclear forms of Wnt13 are generated via alternative promoters, alternative RNA splicing, and alternative translation start sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; ENDOPLASMIC-RETICULUM; CELL POLARIZATION; FAMILY PROTEINS; PORCUPINE; MECHANISMS; DROSOPHILA; POLARITY; GENE	Wnt proteins play a key role in cell survival, cell proliferation, and cell fate during development. In endothelial cells, we identified the expression of Wnt13A, Wnt13B, and Wnt13C mRNAs, which are generated by alternative promoters and alternative RNA splicing. Wnt13A and Wnt13B proteins differ only in their N-terminal sequences. Wnt13A, a typical Wnt, is N-glycosylated and localized in the endoplasmic reticulum, with only a small fraction being secreted. Wnt13B proteins appear as a protein doublet, L-Wnt13B and S-Wnt13B, which are neither N-glycosylated nor secreted. Wnt13B proteins localized mainly to mitochondria, as demonstrated using detection in mitochondria enriched fractions and colocalization with Mitotracker and HSP60. A nuclear localization was also observed in 20% of Wnt13B-expressing cells. Both the N-terminal hydrophobic stretch ( residues 1 - 17) and alpha-helix ( residues 26 - 50) were the main determinants for Wnt13B mitochondrial targeting. Serial deletions of Wnt13B N-terminal sequences abolished its association with mitochondria and favored instead a nuclear localization. The production of S-Wnt13B was independent of the mitochondrial targeting but dependent on an alternative translation start corresponding to Met(74) in L-Wnt13B. The same translation start is used in Wnt13C mRNA to encode a protein undistinguishable from S-Wnt13B. S-Wnt13B when expressed alone localized to the nucleus like Wnt13C, whereas L-Wnt13B localized to mitochondria. Wnt13 nuclear forms increased the beta-catenin/T-cell factor activity in HEK293 cells and increased apoptosis in bovine aortic endothelial cells. Altogether our results demonstrate that, in addition to alternative promoters and RNA splicing, an alternative translation start in Wnt13B and Wnt13C mRNAs increases the complexity of both human wnt13 expression and functions.	Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky	Mao, CD (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, 900 Limestone St, Lexington, KY 40536 USA.	cdmao2@uky.edu			NHLBI NIH HHS [HL 68698, R01 HL068698-04] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068698] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Goldstein B, 2000, DEV DYNAM, V218, P23, DOI 10.1002/(SICI)1097-0177(200005)218:1<23::AID-DVDY3>3.0.CO;2-Z; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Jasoni C, 1999, DEV DYNAM, V215, P215, DOI 10.1002/(SICI)1097-0177(199907)215:3<215::AID-AJA4>3.0.CO;2-W; Julius MA, 1999, ONCOGENE, V18, P149, DOI 10.1038/sj.onc.1202268; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Katoh M, 2000, BIOCHEM BIOPH RES CO, V275, P209, DOI 10.1006/bbrc.2000.3252; Katoh M, 2001, BIOCHEM BIOPH RES CO, V289, P1093, DOI 10.1006/bbrc.2001.6076; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kubo F, 2003, DEVELOPMENT, V130, P587, DOI 10.1242/dev.00244; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Liu H, 2003, DEV DYNAM, V227, P323, DOI 10.1002/dvdy.10315; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; Lynn BD, 2001, J NEUROSCI RES, V65, P6, DOI 10.1002/jnr.1122; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Nakagawa S, 2003, DEV BIOL, V260, P414, DOI 10.1016/S0012-1606(03)00320-8; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Voos W, 2002, BBA-MOL CELL RES, V1592, P51, DOI 10.1016/S0167-4889(02)00264-1; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200	47	22	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7282	7293		10.1074/jbc.M511182200	http://dx.doi.org/10.1074/jbc.M511182200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407296	hybrid			2022-12-25	WOS:000236030900046
J	Lu, XH; Gilbert, L; He, XF; Rubin, J; Nanes, MS				Lu, XH; Gilbert, L; He, XF; Rubin, J; Nanes, MS			Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELL-DIFFERENTIATION; ESTROGEN DEFICIENCY; FACTOR-ALPHA; EXTRACELLULAR-MATRIX; BONE-FORMATION; EXPRESSION; P38; APOPTOSIS; RUNX2; GENE	Osteoblast ( OB) differentiation is suppressed by tumor necrosis factor-alpha (TNF-alpha), an inflammatory stimulus that is elevated in arthritis and menopause. Because OB differentiation requires the expression of the transcription factor osterix (Osx), we investigated TNF effects on Osx. TNF inhibited Osx mRNA in pre-osteoblastic cells without affecting Osx mRNA half-life. Inhibition was independent of new protein synthesis. Analysis of the Osx promoter revealed two transcription start sites that direct the expression of an abundant mRNA(Osx1) and an alternatively spliced mRNA(Osx2). Promoter fragments driving the expression of luciferase were constructed to identify TNF regulatory sequences. Two independent promoters were identified upstream of each transcription start site. TNF potently inhibited transcription of both promoters. Deletion and mutational analysis identified a TNF-responsive region proximal to the Osx2 start site that retained responsiveness when inserted upstream of a heterologous promoter. The TNF response region was a major binding site for nuclear proteins, although TNF did not change binding at the site. The roles of MAPK and NF kappa B were investigated as signal mediators of TNF. Inhibitors of MEK1 and ERK1, but not of JNK or p38 kinase, abrogated TNF inhibition of Osx mRNA and promoter activity. TNF action was not prevented by blockade of NF kappa B nuclear entry. The forced expression of high levels of NF kappa B uncovered a proximal promoter enhancer; however, this site was not activated by TNF. The inhibitory effect of TNF on Osx expression may decrease OB differentiation in arthritis and osteoporosis.	Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab & Lipids, Decatur, GA 30033 USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Nanes, MS (corresponding author), Vet Affairs Med Ctr, Mail Code 111,1670 Clairmont Rd, Decatur, GA 30033 USA.	mnanes@emory.edu			NIAMS NIH HHS [AR046452] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046452] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Bingham CO, 2002, J RHEUMATOL, V29, P3; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Farmer PK, 2000, AM J PHYSIOL-ENDOC M, V279, pE213, DOI 10.1152/ajpendo.2000.279.1.E213; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; Gao YG, 2004, GENE, V341, P101, DOI 10.1016/j.gene.2004.05.026; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; GILBERT LC, 2004, AM J PHYSIOL, V288, pE1011; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785; Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002-220863; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; LIAN JB, 2001, OSTEOPOROSIS, V1, P21; Lu XH, 2004, J CELL BIOCHEM, V92, P833, DOI 10.1002/jcb.20143; Milona M, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-43; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378-1119(03)00841-2; Noth U, 2003, EXP CELL RES, V291, P201, DOI 10.1016/S0014-4827(03)00386-0; Osyczka AM, 2005, ENDOCRINOLOGY, V146, P3428, DOI 10.1210/en.2005-0303; Pacifici R, 1999, CALCIFIED TISSUE INT, V65, P345, DOI 10.1007/s002239900710; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698; Tai GP, 2004, TISSUE ENG, V10, P1456, DOI 10.1089/1076327042500300; Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101	34	116	122	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6297	6306		10.1074/jbc.M507804200	http://dx.doi.org/10.1074/jbc.M507804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16410254	hybrid			2022-12-25	WOS:000236030800023
J	Wilkinson, BM; Purswani, J; Stirling, CJ				Wilkinson, BM; Purswani, J; Stirling, CJ			Yeast GTB1 encodes a subunit of glucosidase II required for glycoprotein processing in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC LIVER-DISEASE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; HETERODIMERIC STRUCTURE; PROTEIN TRANSLOCATION; MEMBRANE-PROTEIN; DISTINCT DOMAINS; GENE DELETION; RAT-LIVER; MUTATIONS	Glucosidase II is essential for sequential removal of two glucose residues from N-linked glycans during glycoprotein biogenesis in the endoplasmic reticulum. The enzyme is a heterodimer whose alpha-subunit contains the glycosyl hydrolase active site. The function of the beta-subunit has yet to be defined, but mutations in the human gene have been linked to an autosomal dominant form of polycystic liver disease. Here we report the identification and characterization of a Saccharomyces cerevisiae gene, GTB1, encoding a polypeptide with 21% sequence similarity to the beta-subunit of human glucosidase II. The Gtb1 protein was shown to be a soluble glycoprotein ( 96 102 kDa) localized to the endoplasmic reticulum lumen where it was present in a complex together with the yeast alpha-subunit homologue Gls2p. Surprisingly, we found that Delta gtb1 mutant cells were specifically defective in the processing of monoglucosylated glycans. Thus, although Gls2p is sufficient for cleavage of the penultimate glucose residue, Gtb1p is essential for cleavage of the final glucose. Our data demonstrate that Gtb1p is required for normal glycoprotein biogenesis and reveal that the final two glucose-trimming steps in N-glycan processing are mechanistically distinct.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Stirling, CJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	colin.stirling@manchester.ac.uk	Purswani, Jessica/M-8038-2018; , Jessica/T-7459-2019	Purswani, Jessica/0000-0001-7846-9368; , Jessica/0000-0001-7846-9368	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO JM, 1993, EUR J BIOCHEM, V215, P37, DOI 10.1111/j.1432-1033.1993.tb18004.x; Arendt CW, 2000, GLYCOBIOLOGY, V10, P487, DOI 10.1093/glycob/10.5.487; Brachmann CB, 1998, YEAST, V14, P115; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; Deprez P, 2005, MOL CELL, V19, P183, DOI 10.1016/j.molcel.2005.05.029; Drenth JPH, 2004, GASTROENTEROLOGY, V126, P1819, DOI 10.1053/j.gastro.2004.02.023; Drenth JPH, 2004, HEPATOLOGY, V39, P924, DOI 10.1002/hep.20141; Drenth JPH, 2003, NAT GENET, V33, P345, DOI 10.1038/ng1104; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Levinson JN, 2002, YEAST, V19, P1243, DOI 10.1002/yea.908; Li AR, 2003, AM J HUM GENET, V72, P691, DOI 10.1086/368295; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Munro S, 2001, CURR BIOL, V11, pR499, DOI 10.1016/S0960-9822(01)00302-5; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; Pelletier MF, 2000, GLYCOBIOLOGY, V10, P815, DOI 10.1093/glycob/10.8.815; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHAILUBHAI K, 1991, J BIOL CHEM, V266, P16587; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; Treml K, 2000, GLYCOBIOLOGY, V10, P493, DOI 10.1093/glycob/10.5.493; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 2001, BIOCHEMISTRY-US, V40, P10717, DOI 10.1021/bi010629u; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; Wilkinson BM, 2000, J BIOL CHEM, V275, P521, DOI 10.1074/jbc.275.1.521; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xu XH, 2004, FEBS LETT, V570, P155, DOI 10.1016/j.febslet.2004.06.039; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	43	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6325	6333		10.1074/jbc.M510455200	http://dx.doi.org/10.1074/jbc.M510455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373354	hybrid			2022-12-25	WOS:000236030800026
J	Choudhary, S; Doherty, KM; Handy, CJ; Sayer, JM; Yagi, H; Jerina, DM; Brosh, RM				Choudhary, S; Doherty, KM; Handy, CJ; Sayer, JM; Yagi, H; Jerina, DM; Brosh, RM			Inhibition of Werner syndrome helicase activity by benzo[a]pyrene diol epoxide adducts can be overcome by replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7,8-DIOL 9,10-EPOXIDE ADDUCTS; CODON 61 SEQUENCE; DNA DUPLEX; SYNDROME CELLS; SOLUTION CONFORMATION; HOMOLOGOUS RECOMBINATION; MODIFIED DEOXYGUANOSINE; TRANSLESION SYNTHESIS; RECQ HELICASES; WRN HELICASE	RecQ helicases are believed to function in repairing replication forks stalled by DNA damage and may also play a role in the intra-S-phase checkpoint, which delays the replication of damaged DNA, thus permitting repair to occur. Since little is known regarding the effects of DNA damage on RecQ helicases, and because the replication and recombination defects in Werner syndrome cells may reflect abnormal processing of damaged DNA associated with the replication fork, we examined the effects of specific bulky, covalent adducts at N-6 of deoxyadenosine (dA) or N-2 of deoxyguanosine (dG) on Werner (WRN) syndrome helicase activity. The adducts are derived from the optically active 7,8-diol 9,10-epoxide (DE) metabolites of the carcinogen benzo[a]pyrene (BaP). The results demonstrate that WRN helicase activity is inhibited in a strand-specific manner by BaP DE-dG adducts only when on the translocating strand. These adducts either occupy the minor groove without significant perturbation of DNA structure (trans adducts) or cause base displacement at the adduct site (cis adducts). In contrast, helicase activity is only mildly affected by intercalating BaP DE-dA adducts that locally perturb DNA double helical structure. This differs from our previous observation that intercalating dA adducts derived from benzo[c]phenanthrene (BcPh) DEs inhibit WRN activity in a strand-and stereospecific manner. Partial unwinding of the DNA helix at BaP DE-dA adduct sites may make such adducted DNAs more susceptible to the action of helicase than DNA containing the corresponding BcPh DE-dA adducts, which cause little or no destabilization of duplex DNA. The single-stranded DNA binding protein RPA, an auxiliary factor for WRN helicase, enabled the DNA unwinding enzyme to overcome inhibition by either the trans-R or cis-R BaP DE-dG adduct, suggesting that WRN and RPA may function together to unwind duplex DNA harboring specific covalent adducts that otherwise block WRN helicase acting alone.	NIDDK, Bioorgan Chem Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; NIA, Lab Mol Gerontol, NIH, Dept Hlth & Human Serv, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Brosh, RM (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.	broshr@grc.nia.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000741, ZIAAG000741] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Blank A, 2004, DNA REPAIR, V3, P629, DOI 10.1016/j.dnarep.2004.02.003; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Buterin T, 2000, CANCER RES, V60, P1849; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Choudhary S, 2004, J BIOL CHEM, V279, P34603, DOI 10.1074/jbc.M401901200; Committee on Biologic Effects of Atmospheric Pollutants, 1972, PART POL ORG MATT; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cosman M, 1996, BIOCHEMISTRY-US, V35, P9850, DOI 10.1021/bi9605346; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P4145, DOI 10.1021/bi00067a001; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Cui S, 2004, NUCLEIC ACIDS RES, V32, P2158, DOI 10.1093/nar/gkh540; Custer L, 1999, BIOCHEMISTRY-US, V38, P569, DOI 10.1021/bi9813330; Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Driscoll HC, 2003, J BIOL CHEM, V278, P41126, DOI 10.1074/jbc.M304798200; FOUNTAIN MA, 1995, BIOCHEMISTRY-US, V34, P3152, DOI 10.1021/bi00010a004; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Garcia PL, 2004, NUCLEIC ACIDS RES, V32, P3771, DOI 10.1093/nar/gkh709; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Graziewicz MA, 2004, NUCLEIC ACIDS RES, V32, P397, DOI 10.1093/nar/gkh213; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Hussain SP, 2001, CANCER RES, V61, P6350; Jerina D M, 1991, Adv Exp Med Biol, V283, P533; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; Khan QA, 2003, P NATL ACAD SCI USA, V100, P12498, DOI 10.1073/pnas.2032456100; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Kroth H, 2000, J ORG CHEM, V65, P5558, DOI 10.1021/jo000522x; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Mao B, 1999, BIOCHEMISTRY-US, V38, P10831, DOI 10.1021/bi991212f; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Perlow RA, 2003, J MOL BIOL, V327, P797, DOI 10.1016/S0022-2836(03)00187-6; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Pilcher AS, 1998, J AM CHEM SOC, V120, P3520, DOI 10.1021/ja980176p; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Rodriguez-Lopez AM, 2002, AGING CELL, V1, P30, DOI 10.1046/j.1474-9728.2002.00002.x; Ruan Q, 2002, CHEM RES TOXICOL, V15, P249, DOI 10.1021/tx010157k; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Sayer JM, 1999, POLYCYCL AROMAT COMP, V17, P95, DOI 10.1080/10406639908020605; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; THAKKER DR, 1977, CHEM-BIOL INTERACT, V16, P281, DOI 10.1016/0009-2797(77)90108-9; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Villani G, 2000, J BIOL CHEM, V275, P33185, DOI 10.1074/jbc.R000011200; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Volk DE, 2003, BIOCHEMISTRY-US, V42, P1410, DOI 10.1021/bi026745u; YEH HJC, 1995, BIOCHEMISTRY-US, V34, P13570, DOI 10.1021/bi00041a037; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	69	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6000	6009		10.1074/jbc.M510122200	http://dx.doi.org/10.1074/jbc.M510122200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380375	hybrid			2022-12-25	WOS:000235568900081
J	Sanchez-Magraner, L; Cortajarena, AL; Goni, FM; Ostolaza, H				Sanchez-Magraner, L; Cortajarena, AL; Goni, FM; Ostolaza, H			Membrane insertion of Escherichia coli alpha-hemolysin is independent from membrane lysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TOXIN; PHOSPHOLIPID MONOLAYERS; SELF-AGGREGATION; LIPID MONOLAYERS; BINDING; ADSORPTION; PURIFICATION; INTERFACES; MECHANISM; VESICLES	Escherichia coli alpha-hemolysin ( HlyA) is a protein exotoxin that binds and lyses eukaryotic cell and model membranes in the presence of calcium. Previous studies have been able to distinguish between reversible toxin binding to the membrane and irreversible insertion into the lipid matrix. Membrane lysis occurs as the combined effect of protein insertion plus a transient perturbation of the membrane bilayer structure. In the past, insertion and bilayer perturbation have not been experimentally dissected. This has now been achieved by studying HlyA penetration into lipid monolayers at the air-water interface, in which three-dimensional effects ( of the kind required to break down the bilayer permeability barrier) cannot occur. The study of native HlyA, together with the nonlytic precursor pro-HlyA, and of different mutants demonstrates that although some nonlytic variants ( e. g. pro-HlyA) exhibit very low levels of insertion, others ( e. g. the nonlytic mutant HlyA H859N) insert even more strongly than the lytic wild type. These results show that insertion does not necessarily lead to membrane lysis, i.e. that insertion and lysis are not "coupled" phenomena. Millimolar levels of Ca2+, which are essential for the lytic activity, cause an extra degree of insertion but only in the case of the lytic forms of HlyA.	Univ Basque Country, Consejo Super Invest Cient, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Ostolaza, H (corresponding author), Univ Basque Country, Consejo Super Invest Cient, Unidad Biofis, Aptdo 644, E-48080 Bilbao, Spain.	gbzoseth@lg.ehu.es	Goni, Felix M/M-5425-2015; Cortajarena, Aitziber L/J-6202-2012	Goni, Felix M/0000-0001-6270-9216; Cortajarena, Aitziber L/0000-0002-5331-114X; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Adamson A.W., 1997, PHYS CHEM SURFACES, P390; Bakas L, 1998, BBA-BIOMEMBRANES, V1368, P225, DOI 10.1016/S0005-2736(97)00181-8; Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Barlic A, 2004, J BIOL CHEM, V279, P34209, DOI 10.1074/jbc.M313817200; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BHAKOO M, 1982, BIOCHEMISTRY-US, V21, P6879, DOI 10.1021/bi00269a039; Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X; Cornec M, 1999, J COLLOID INTERF SCI, V214, P129, DOI 10.1006/jcis.1999.6230; Cortajarena AL, 2003, FEBS LETT, V546, P271, DOI 10.1016/S0014-5793(03)00595-7; Cortajarena AL, 2003, J BIOL CHEM, V278, P19159, DOI 10.1074/jbc.M208552200; Cortajarena AL, 2002, J BIOL CHEM, V277, P23223, DOI 10.1074/jbc.M202028200; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FIDELIO GD, 1982, BIOCHEM J, V203, P717, DOI 10.1042/bj2030717; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; GRAHAM DE, 1980, J COLLOID INTERF SCI, V76, P227, DOI 10.1016/0021-9797(80)90289-1; Herlax V, 2003, CHEM PHYS LIPIDS, V122, P185, DOI 10.1016/S0009-3084(02)00191-3; Holland IB, 2005, MOL MEMBR BIOL, V22, P29, DOI 10.1080/09687860500042013; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; KSENZHEK O S, 1978, Molekulyarnaya Biologiya (Moscow), V12, P1057; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5; MagetDana R, 1997, BIOPHYS J, V73, P2527, DOI 10.1016/S0006-3495(97)78281-X; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; Netz RR, 1996, J PHYS II, V6, P1023, DOI 10.1051/jp2:1996114; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; OSTOLAZA H, 1995, FEBS LETT, V371, P303, DOI 10.1016/0014-5793(95)00927-2; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; OSTOLAZA H, 1991, FEBS LETT, V280, P195, DOI 10.1016/0014-5793(91)80291-A; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Soloaga A, 1998, BIOCHEMISTRY-US, V37, P6387, DOI 10.1021/bi9730994; Soloaga A, 1999, MOL MICROBIOL, V31, P1013, DOI 10.1046/j.1365-2958.1999.01225.x; Soloaga A, 1996, EUR J BIOCHEM, V238, P418, DOI 10.1111/j.1432-1033.1996.0418z.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Wang SX, 1998, BIOCHEM J, V335, P225, DOI 10.1042/bj3350225; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Xia XF, 2001, BBA-BIOMEMBRANES, V1515, P1, DOI 10.1016/S0005-2736(01)00348-0	41	28	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5461	5467		10.1074/jbc.M512897200	http://dx.doi.org/10.1074/jbc.M512897200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377616	hybrid			2022-12-25	WOS:000235568900018
J	Um, M; Lodish, HF				Um, M; Lodish, HF			Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BCL-X-L; TRANSCRIPTION FACTOR; IN-VITRO; TYROSINE PHOSPHORYLATION; STAT5A(-/-)5B(-/-) MICE; INDUCED APOPTOSIS; PROTECTS NEURONS; GENE-EXPRESSION; MAP KINASE	The hematopoietic cytokine erythropoietin (Epo) prevents neuronal death during ischemic events in the brain and in neurodegenerative diseases, presumably through its antiapoptotic effects. To explore the role of different signaling pathways in Epo-mediated antiapoptotic effects in differentiated human neuroblastoma SH-SY5Y cells, we employed a prolactin receptor (PrlR)/ erythropoietin receptor (EpoR) chimera system, in which binding of prolactin (Prl) to the extracellular domain activates EpoR signaling in the cytosol. On induction of apoptosis by staurosporine, Prl supports survival of the SH-SY5Y cells expressing the wild-type PrlR/ EpoR chimera. In these cells Prl treatment strongly activates the STAT5, AKT, and MAPK signaling pathways and induces weak activation of the p65 NF-kappa B factor. Selective mutation of the eight tyrosine residues of the EpoR cytoplasmic domain results in impaired or absent activation of either STAT5 ( mutation of Tyr(343)) or AKT ( mutation of Tyr(479)) or both ( mutation of all eight tyrosine residues). Most interestingly, Prl treatment does not prevent apoptosis in cells expressing mutant PrlR/ EpoR chimeras in which either the STAT5 or the AKT signaling pathways are not activated. In contrast, ERK 1/2 is fully activated by all mutant PrlR/ EpoR chimeras, comparable with the level seen with the wild-type PrlR/ EpoR chimera, implying that activation of the MAPK signaling pathway per se is not sufficient for antiapoptotic activity. Therefore, the antiapoptotic effects of Epo in neuronal cells require the combinatorial activation of multiple signaling pathways, including STAT5, AKT, and potentially MAPK as well, in a manner similar to that observed in hematopoietic cells.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr,Ste 601, Cambridge, MA 02142 USA.	lodish@wi.mit.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrassy M, 2002, CLIN NEPHROL, V58, P179; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Boudot C, 1999, J BIOL CHEM, V274, P33966, DOI 10.1074/jbc.274.48.33966; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carvalho G, 2005, ONCOGENE, V24, P737, DOI 10.1038/sj.onc.1208205; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Chun SJ, 2003, J CELL BIOL, V163, P397, DOI 10.1083/jcb.200304154; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Diaz Z, 2005, J NEUROCHEM, V93, P392, DOI 10.1111/j.1471-4159.2005.03038.x; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Fiordaliso F, 2005, P NATL ACAD SCI USA, V102, P2046, DOI 10.1073/pnas.0409329102; Gaffen SL, 1999, BLOOD, V94, P74, DOI 10.1182/blood.V94.1.74.413k36_74_86; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Ghaffari S, 2003, P NATL ACAD SCI USA, V100, P6523, DOI 10.1073/pnas.0731871100; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Haq R, 2002, J BIOL CHEM, V277, P17359, DOI 10.1074/jbc.M201842200; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; Henry MK, 2001, BLOOD, V98, P834, DOI 10.1182/blood.V98.3.834; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; KORNER M, 1994, J NEUROCHEM, V62, P1716; Lee SM, 2004, BIOCHEM BIOPH RES CO, V320, P1087, DOI 10.1016/j.bbrc.2004.06.060; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Marszalek JR, 2004, J BIOL CHEM, V279, P23882, DOI 10.1074/jbc.M313460200; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Nakamura T, 2002, J BIOL CHEM, V277, P6254, DOI 10.1074/jbc.M109878200; Nakata S, 2004, J BIOL CHEM, V279, P55578, DOI 10.1074/jbc.M408238200; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Ozes ON, 1999, NATURE, V401, P82; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Posmantur R, 1997, J NEUROCHEM, V68, P2328; REN HY, 1994, J BIOL CHEM, V269, P19633; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Suzuki N, 2002, BLOOD, V100, P2279, DOI 10.1182/blood-2002-01-0124; Tang T, 1999, BIOCHEM J, V343, P615, DOI 10.1042/0264-6021:3430615; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	77	89	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5648	5656		10.1074/jbc.M510943200	http://dx.doi.org/10.1074/jbc.M510943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407271	hybrid			2022-12-25	WOS:000235568900041
J	Zhao, YH; White, MA; Muralidhara, BK; Sun, L; Halpert, JR; Stout, CD				Zhao, YH; White, MA; Muralidhara, BK; Sun, L; Halpert, JR; Stout, CD			Structure of microsomal cytochrome P4502B4 complexed with the antifungal drug bifonazole - Insight into p450 conformational plasticity and membrane interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; DENSITY MODIFICATION; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; DIFFRACTION DATA; CRYSTALLOGRAPHY; MONOOXYGENASES; ASSOCIATION; DIVERSITY; MECHANISM	To better understand ligand-induced structural transitions in cytochrome P450 2B4, protein-ligand interactions were investigated using a bulky inhibitor. Bifonazole, a broad spectrum antifungal agent, inhibits monooxygenase activity and induces a type II binding spectrum in 2B4dH(H226Y), a modified enzyme previously crystallized in the presence of 4-(4-chlorophenyl)imidazole (CPI). Isothermal titration calorimetry and tryptophan fluorescence quenching indicate no significant burial of protein apolar surface nor altered accessibility of Trp-121 upon bifonazole binding, in contrast to recent results with CPI. A 2.3 angstrom crystal structure of 2B4-bifonazole reveals a novel open conformation with ligand bound in the active site, which is significantly different from either the U-shaped cleft of ligand-free 2B4 or the small active site pocket of 2B4-CPI. The O-shaped active site cleft of 2B4-bifonazole is widely open in the middle but narrow at the top. A bifonazole molecule occupies the bottom of the active site cleft, where helix I is bent similar to 15 degrees to accommodate the bulky ligand. The structure also defines unanticipated interactions between helix C residues and bifonazole, suggesting an important role of helix C in azole recognition by mammalian P450s. Comparison of the ligand-free 2B4 structure, the 2B4-CPI structure, and the 2B4-bifonazole structure identifies structurally plastic regions that undergo correlated conformational changes in response to ligand binding. The most plastic regions are putative membrane-binding motifs involved in substrate access or substrate binding. The results allow us to model the membrane-associated state of P450 and provide insight into how lipophilic substrates access the buried active site.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Scripps Research Institute	Zhao, YH (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA.	yozhao@utmb.edu	White, Mark Andrew/B-1723-2012	White, Mark Andrew/0000-0003-1057-4203	NIEHS NIH HHS [ES 06676, ES 03619] Funding Source: Medline; NIGMS NIH HHS [GM 61545] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES003619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061545] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; BOSSCHE HV, 1995, PHARMACOL THERAPEUT, V67, P79; Bracey MH, 2004, FEBS LETT, V567, P159, DOI 10.1016/j.febslet.2004.04.084; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COON MJ, 1973, ANN NY ACAD SCI, V212, P449, DOI 10.1111/j.1749-6632.1973.tb47613.x; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; GOTOH O, 1992, J BIOL CHEM, V267, P83; Hernandez-Guzman FG, 2003, J BIOL CHEM, V278, P22989, DOI 10.1074/jbc.M211497200; Im YJ, 2005, NATURE, V437, P154, DOI 10.1038/nature03923; Johnson EF, 2005, BIOCHEM BIOPH RES CO, V338, P331, DOI 10.1016/j.bbrc.2005.08.190; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Li HY, 2004, CURR TOP MED CHEM, V4, P1789, DOI 10.2174/1568026043387205; Matsuura K, 2005, J BIOL CHEM, V280, P9088, DOI 10.1074/jbc.M413042200; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mueller Ernest J., 1995, P83; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poulos TL, 2005, DRUG METAB DISPOS, V33, P10, DOI 10.1124/dmd.104.002071; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Tanaka T, 2004, CHEM PHARM BULL, V52, P830, DOI 10.1248/cpb.52.830; Tanaka T, 2004, CHEM PHARM BULL, V52, P836, DOI 10.1248/cpb.52.836; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; van Tiel CM, 2002, FEBS LETT, V531, P69, DOI 10.1016/S0014-5793(02)03403-8; Wade RC, 2004, J INORG BIOCHEM, V98, P1175, DOI 10.1016/j.jinorgbio.2004.02.007; Waterman MR, 2005, BIOCHEM BIOPH RES CO, V338, P418, DOI 10.1016/j.bbrc.2005.08.118; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200	47	143	148	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5973	5981		10.1074/jbc.M511464200	http://dx.doi.org/10.1074/jbc.M511464200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373351	hybrid, Green Submitted			2022-12-25	WOS:000235568900078
J	Luo, W; Wang, X; Kageshita, T; Wakasugi, S; Karpf, AR; Ferrone, S				Luo, W.; Wang, X.; Kageshita, T.; Wakasugi, S.; Karpf, A. R.; Ferrone, S.			Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells	ONCOGENE			English	Article						HMW-MAA expression; melanoma cell lines and lesions; promoter DNA methylation; 5-aza 2 '-deoxycytidine	CHONDROITIN SULFATE PROTEOGLYCAN; ACRAL LENTIGINOUS MELANOMA; MONOCLONAL-ANTIBODY MK2-23; CPG ISLANDS; TUMOR; 5-AZA-2'-DEOXYCYTIDINE; LESIONS; CANCER; ACTIVATION; INDUCTION	The human high molecular weight- melanoma associated antigen ( HMW- MAA) is a membrane- bound chondroitin sulfate proteoglycan that is variably expressed in a high percentage of melanoma cell lines and tumors. Since the mechanism( s) regulating HMW- MAA expression has( ve) not been defined, in this study, we have examined whether promoter DNA methylation regulates the level of HMW-MAA expression. In melanoma cell lines, the level of HMW- MAA mRNA and protein expression is coordinately regulated, implicating a transcriptional control mechanism. Consistent with a role for regulation by DNA methylation, we have found that a dense CpG island flanks the human HMW- MAA gene transcriptional start site. Methylation- specific PCR and sodium bisulfite DNA sequencing analyses indicate that the HMW- MAA promoter is heavily methylated in melanoma cell lines, melanoma lesions and normal lymphocytes that do not express HMW- MAA; in contrast, the HMW- MAA promoter is not methylated in melanoma cell lines and tumors that express this antigen. In addition, HMW-MAA expression is markedly induced in HMW- MAA-negative melanoma cell lines by incubation with the DNA methyltransferase inhibitor 5- aza- 2'- deoxycytidine. In summary, our results establish DNA methylation as a key regulator of HMW- MAA expression by human melanoma cells. This information represents a useful background to optimize immunotherapeutic strategies targeting HMW- MAA.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Kumamoto Univ, Grad Sch Med Sci, Dept Dermatol, Kumamoto, Japan	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Kumamoto University	Ferrone, S (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Immunol, Elm & Carlton St, Buffalo, NY 14263 USA.	soldano.ferrone@roswellpark.org		Karpf, Adam/0000-0002-0866-0666	NCI NIH HHS [P01 CA89480, R01 CA105500, R01 CA116674-01A1, R01 CA116674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA105500, P01CA089480, R01CA116674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bestor TH, 2003, ANN NY ACAD SCI, V983, P22, DOI 10.1111/j.1749-6632.2003.tb05959.x; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Chekenya M, 1999, INT J DEV NEUROSCI, V17, P421, DOI 10.1016/S0736-5748(99)00019-2; Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Hafner C, 2005, INT J CANCER, V114, P426, DOI 10.1002/ijc.20769; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAGESHITA T, 1991, CANCER RES, V51, P1726; KAGESHITA T, 1993, CANCER RES, V53, P2830; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; KUSAMA M, 1989, J IMMUNOL, V143, P3844; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504; MITTELMAN A, 1992, P NATL ACAD SCI USA, V89, P466, DOI 10.1073/pnas.89.2.466; MITTELMAN A, 1994, CANCER RES, V54, P415; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102; TEMPONI M, 1992, CANCER RES, V52, P2497; WEBER J, 1994, CANCER RES, V54, P1766; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174	35	30	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2873	2884		10.1038/sj.onc.1209319	http://dx.doi.org/10.1038/sj.onc.1209319			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407841				2022-12-25	WOS:000237448200005
J	Vidi, PA; Kanwischer, M; Baginsky, S; Austin, JR; Csucs, G; Dormann, P; Kessler, F; Brehelin, C				Vidi, PA; Kanwischer, M; Baginsky, S; Austin, JR; Csucs, G; Dormann, P; Kessler, F; Brehelin, C			Tocopherol cyclase (VTE1) localization and vitamin E accumulation in chloroplast plastoglobule lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; ALLENE OXIDE SYNTHASE; 9-CIS-EPOXYCAROTENOID DIOXYGENASE GENE; CHROMOPLAST-SPECIFIC PROTEINS; CAROTENOID-ASSOCIATED PROTEIN; MOLECULAR CHARACTERIZATION; PLASTOQUINONE SYNTHESIS; ARABIDOPSIS MUTANT; ALPHA-TOCOPHEROL; IMPORT RECEPTOR	Chloroplasts contain lipoprotein particles termed plastoglobules. Plastoglobules are generally believed to have little function beyond lipid storage. Here we report on the identification of plastoglobule proteins using mass spectrometry methods in Arabidopsis thaliana. We demonstrate specific plastoglobule association of members of the plastid lipid-associated proteins/fibrillin family as well as known metabolic enzymes, including the tocopherol cyclase (VTE1), a key enzyme of tocopherol ( vitamin E) synthesis. Moreover, comparative analysis of chloroplast membrane fractions shows that plastoglobules are a site of vitamin E accumulation in chloroplasts. Thus, in addition to their lipid storage function, we propose that plastoglobules are metabolically active, taking part in tocopherol synthesis and likely other pathways.	Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, CH-2007 Neuchatel, Switzerland; Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany; Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Univ Chicago, Chicago, IL 60637 USA; Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	University of Neuchatel; Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Chicago; Swiss Federal Institutes of Technology Domain; ETH Zurich	Kessler, F (corresponding author), Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, Emile Argand 11, CH-2007 Neuchatel, Switzerland.	felix.kessler@unine.ch	Kessler, Felix Henrique/AAO-1722-2020	Kanwischer, Marion/0000-0002-2317-0112; Baginsky, Sacha/0000-0002-5440-3898; Kessler, Felix/0000-0001-6409-5043; Brehelin, Claire/0000-0002-1889-9582; Vidi, Pierre-Alexandre/0000-0002-9117-8896				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Bailey JL, 1963, BIOCHIM BIOPHYS ACTA, V78, P163; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bondada BR, 2003, TREE PHYSIOL, V23, P553, DOI 10.1093/treephys/23.8.553; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; Chen HC, 1998, PLANT J, V14, P317, DOI 10.1046/j.1365-313X.1998.00127.x; Chen XJ, 2002, PLANT CELL, V14, P641, DOI 10.1105/tpc.010336; Cheng ZG, 2003, PLANT CELL, V15, P2343, DOI 10.1105/tpc.013656; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; DERUERE J, 1994, BIOCHEM BIOPH RES CO, V199, P1144, DOI 10.1006/bbrc.1994.1350; DERUERE J, 1994, PLANT CELL, V6, P119, DOI 10.1105/tpc.6.1.119; Eymery F, 1999, PLANT PHYSIOL BIOCH, V37, P305, DOI 10.1016/S0981-9428(99)80029-1; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Froehlich JE, 2001, PLANT PHYSIOL, V125, P306, DOI 10.1104/pp.125.1.306; Ghosh S, 2001, PLANT PHYSIOL BIOCH, V39, P777, DOI 10.1016/S0981-9428(01)01296-7; Gillet B, 1998, PLANT J, V16, P257, DOI 10.1046/j.1365-313x.1998.00292.x; GREENWOOD AD, 1963, BIOCHIM BIOPHYS ACTA, V78, P148, DOI 10.1016/0006-3002(63)91620-2; Guiamet JJ, 1999, PLANT CELL PHYSIOL, V40, P986, DOI 10.1093/oxfordjournals.pcp.a029632; Havaux M, 2003, PLANT PHYSIOL, V132, P300, DOI 10.1104/pp.102.017178; Havaux M, 2005, PLANT CELL, V17, P3451, DOI 10.1105/tpc.105.037036; Hernandez-Pinzon I, 1999, PLANTA, V208, P588, DOI 10.1007/s004250050597; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Kanwischer M, 2005, PLANT PHYSIOL, V137, P713, DOI 10.1104/pp.104.054908; Kaup MT, 2002, PLANT PHYSIOL, V129, P1616, DOI 10.1104/pp.003087; Kessler F, 1999, PLANTA, V208, P107, DOI 10.1007/s004250050540; Kim HU, 2001, PLANT PHYSIOL, V126, P330, DOI 10.1104/pp.126.1.330; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Laizet Y., 2004, J GENOME SCI TECHNOL, V3, P19, DOI DOI 10.1166/GL.2004.038; Langenkamper G, 2001, J EXP BOT, V52, P1545, DOI 10.1093/jexbot/52.360.1545; Laudert D, 1998, PLANT J, V15, P675, DOI 10.1046/j.1365-313x.1998.00245.x; Laudert D, 1996, PLANT MOL BIOL, V31, P323, DOI 10.1007/BF00021793; LICHTENT.HK, 1967, PLANTA, V72, P1; LICHTENTHALER HK, 1968, ENDEAVOUR, V27, P144; LICHTENTHALER HK, 1966, Z NATURFORSCH PT B, VB 21, P690; Locy RD, 1996, PLANT PHYSIOL, V110, P321, DOI 10.1104/pp.110.1.321; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; Michelis R, 2000, PLANT MOL BIOL, V44, P487, DOI 10.1023/A:1026528319769; Monte E, 1999, PLANT J, V19, P399, DOI 10.1046/j.1365-313X.1999.00537.x; NEWMAN LA, 1989, PLANT PHYSIOL, V91, P455, DOI 10.1104/pp.91.2.455; Otegui MS, 2001, PLANT CELL, V13, P2033, DOI 10.1105/tpc.13.9.2033; Porfirova S, 2002, P NATL ACAD SCI USA, V99, P12495, DOI 10.1073/pnas.182330899; PozuetaRomero J, 1997, PLANT PHYSIOL, V115, P1185, DOI 10.1104/pp.115.3.1185; Provencher LM, 2001, PLANT CELL, V13, P1127, DOI 10.1105/tpc.13.5.1127; Pruvot G, 1996, PHYSIOL PLANTARUM, V97, P123, DOI 10.1111/j.1399-3054.1996.tb00488.x; Qin XQ, 2002, PLANT PHYSIOL, V128, P544, DOI 10.1104/pp.010663; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Rey P, 2000, PLANT J, V21, P483, DOI 10.1046/j.1365-313x.2000.00699.x; Sattler SE, 2003, PLANT PHYSIOL, V132, P2184, DOI 10.1104/pp.103.024257; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; Shabanowitz J, 2000, MASS SPECTROMETRY IN BIOLOGY & MEDICINE, P163; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shintani D, 1998, SCIENCE, V282, P2098, DOI 10.1126/science.282.5396.2098; SOLL J, 1985, ARCH BIOCHEM BIOPHYS, V238, P290, DOI 10.1016/0003-9861(85)90167-5; SOLL J, 1987, METHOD ENZYMOL, V148, P383; SOLL J, 1980, FEBS LETT, V112, P243, DOI 10.1016/0014-5793(80)80189-X; SPREY B, 1966, Z NATURFORSCH PT B, VB 21, P697; STEINMULLER D, 1985, PLANTA, V163, P201, DOI 10.1007/BF00393507; Tan BC, 2003, PLANT J, V35, P44, DOI 10.1046/j.1365-313X.2003.01786.x; TEVINI M, 1985, PLANTA, V163, P91, DOI 10.1007/BF00395902; THOMPSON JN, 1979, J LIQ CHROMATOGR, V2, P327, DOI 10.1080/01483917908060067; THOMSON WW, 1966, BOT GAZ, V127, P133, DOI 10.1086/336354; Ting JTL, 1998, PLANT J, V16, P541, DOI 10.1046/j.1365-313x.1998.00325.x; Van Eenennaam AL, 2003, PLANT CELL, V15, P3007, DOI 10.1105/tpc.015875; Vishnevetsky M, 1996, PLANT J, V10, P1111, DOI 10.1046/j.1365-313X.1996.10061111.x; Vishnevetsky M, 1999, PLANT J, V20, P423, DOI 10.1046/j.1365-313x.1999.00615.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wu SSH, 1997, P NATL ACAD SCI USA, V94, P12711, DOI 10.1073/pnas.94.23.12711	73	229	258	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11225	11234		10.1074/jbc.M511939200	http://dx.doi.org/10.1074/jbc.M511939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16414959	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000236822200066
J	Fujioka, A; Terai, K; Itoh, RE; Aoki, K; Nakamura, T; Kuroda, S; Nishida, E; Matsuda, M				Fujioka, A; Terai, K; Itoh, RE; Aoki, K; Nakamura, T; Kuroda, S; Nishida, E; Matsuda, M			Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPATIOTEMPORAL CONTROL; SIGNAL-TRANSDUCTION; NUCLEAR EXPORT; KINASE CASCADE; PROTEIN; RAS; EGF; ERK; PHOSPHORYLATION; MECHANISMS	To comprehend the Ras/ERK MAPK cascade, which comprises Ras, Raf, MEK, and ERK, several kinetic simulation models have been developed. However, a large number of parameters that are essential for the development of these models are still missing and need to be set arbitrarily. Here, we aimed at collecting these missing parameters using fluorescent probes. First, the levels of the signaling molecules were quantitated. Second, to monitor both the activation and nuclear translocation of ERK, we developed probes based on the principle of fluorescence resonance energy transfer. Third, the dissociation constants of Ras.Raf, Raf.MEK, and MEK.ERK complexes were estimated using a fluorescent tag that can be highlighted very rapidly. Finally, the same fluorescent tag was used to measure the nucleocytoplasmic shuttling rates of ERK and MEK. Using these parameters, we developed a kinetic simulation model consisting of the minimum essential members of the Ras/ERK MAPK cascade. This simple model reproduced essential features of the observed activation and nuclear translocation of ERK. In this model, the concentration of Raf significantly affected the levels of phospho-MEK and phospho-ERK upon stimulation. This prediction was confirmed experimentally by decreasing the level of Raf using the small interfering RNA technique. This observation verified the usefulness of the parameters collected in this study.	Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Informat Sci & Technol, Undergrad Program Bioinformat & Syst Biol, Bunkyo Ku, Tokyo 1130033, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Osaka University; University of Tokyo; Kyoto University	Matsuda, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Signal Transduct, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	matsudam@biken.osaka-u.ac.jp	Aoki, Kazuhiro/I-5483-2019; Aoki, Kazuhiro/B-5777-2013; 寺井, 健太/AFQ-7663-2022	Aoki, Kazuhiro/0000-0001-7263-1555; Aoki, Kazuhiro/0000-0001-7263-1555; 寺井, 健太/0000-0001-7638-3720; Matsuda, Michiyuki/0000-0002-5876-9969; Itoh, Reina/0000-0001-6385-7886				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Ando R, 2004, SCIENCE, V306, P1370, DOI 10.1126/science.1102506; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bhalla US, 2004, BIOPHYS J, V87, P745, DOI 10.1529/biophysj.104.040501; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Brightman FA, 2000, FEBS LETT, V482, P169, DOI 10.1016/S0014-5793(00)02037-8; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Day RN, 2005, MOL ENDOCRINOL, V19, P1675, DOI 10.1210/me.2005-0028; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Hailey DW, 2002, METHOD ENZYMOL, V351, P34; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Riddick G, 2005, J CELL BIOL, V168, P1027, DOI 10.1083/jcb.200409024; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Terai K, 2005, EMBO REP, V6, P251, DOI 10.1038/sj.embor.7400349; Torii S, 2004, J BIOCHEM, V136, P557, DOI 10.1093/jb/mvh159; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Yamada S, 2004, BIOCHEM BIOPH RES CO, V314, P1113, DOI 10.1016/j.bbrc.2004.01.009; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	44	242	248	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8917	8926		10.1074/jbc.M509344200	http://dx.doi.org/10.1074/jbc.M509344200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16418172	hybrid			2022-12-25	WOS:000236247100072
J	Maliga, Z; Xing, J; Cheung, H; Juszczak, LJ; Friedman, JM; Rosenfeld, SS				Maliga, Z; Xing, J; Cheung, H; Juszczak, LJ; Friedman, JM; Rosenfeld, SS			A pathway of structural changes produced by monastrol binding to eg5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC KINESIN EG5; MOTOR PROTEIN; BIPOLAR KINESIN; CROSS-LINKS; INHIBITOR; KSP; CONFORMATIONS; MICROTUBULES; SPECTROSCOPY; MECHANISM	Monastrol is a small molecule inhibitor that is specific for Eg5, a member of the kinesin 5 family of mitotic motors. Crystallographic models of Eg5 in the presence and absence of monastrol revealed that drug binding produces a variety of structural changes in the motor, including in loop L5 and the neck linker. What is not clear from static crystallographic models, however, is the sequence of structural changes produced by drug binding. Furthermore, because crystallographic structures can be influenced by the packing forces in the crystal, it also remains unclear whether these drug-induced changes occur in solution, at physiologically active concentrations of monastrol or of other drugs that target this site. We have addressed these issues by using a series of spectroscopic probes to monitor the structural consequences of drug binding. Our results demonstrated that the crystallographic model of an Eg5-ADP-monastrol ternary complex is consistent with several solution-based spectroscopic probes. Furthermore, the kinetics of these spectroscopic signal changes allowed us to determine the temporal sequence of drug-induced structural transitions. These results suggested that L5 may be an element in the pathway that links the state of the nucleotide-binding site to the neck linker in kinesin motors.	Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA; Columbia Univ, Neurol Inst, New York, NY 10032 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Harvard Univ, Program Biophys, Boston, MA 02115 USA	Columbia University; Columbia University; Yeshiva University; Albert Einstein College of Medicine; University of Alabama System; University of Alabama Birmingham; Harvard University	Rosenfeld, SS (corresponding author), 710 W 168th St,Rm 204, New York, NY 10032 USA.	sr2327@columbia.edu						Asbury CL, 2005, CURR OPIN CELL BIOL, V17, P89, DOI 10.1016/j.ceb.2004.12.002; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Brier S, 2004, BIOCHEMISTRY-US, V43, P13072, DOI 10.1021/bi049264e; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; COLE DG, 1994, J BIOL CHEM, V269, P22913; Cox CD, 2005, BIOORG MED CHEM LETT, V15, P2041, DOI 10.1016/j.bmcl.2005.02.055; DeBonis S, 2003, BIOCHEMISTRY-US, V42, P338, DOI 10.1021/bi026716j; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; HEIDECKER M, 1995, BIOCHEMISTRY-US, V34, P11017, DOI 10.1021/bi00035a007; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Juszczak LJ, 1998, J RAMAN SPECTROSC, V29, P963, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<963::AID-JRS332>3.0.CO;2-4; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; KINOSITA K, 1982, BIOPHYS J, V37, P461, DOI 10.1016/S0006-3495(82)84692-4; Luo LS, 2004, BIOCHEMISTRY-US, V43, P15258, DOI 10.1021/bi048282t; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; MIURA T, 1989, J RAMAN SPECTROSC, V20, P667, DOI 10.1002/jrs.1250201007; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; Rosenfeld SS, 2005, J BIOL CHEM, V280, P35684, DOI 10.1074/jbc.M506561200; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Scholey JM, 2003, ANNU REV CELL DEV BI, V19, P423, DOI 10.1146/annurev.cellbio.19.111401.091318; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Wordeman L, 2005, CURR OPIN CELL BIOL, V17, P82, DOI 10.1016/j.ceb.2004.12.003; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	33	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7977	7982		10.1074/jbc.M511955200	http://dx.doi.org/10.1074/jbc.M511955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434397	hybrid			2022-12-25	WOS:000236031000034
J	Qin, CL; Huang, BZ; Wygant, JN; McIntyre, BW; McDonald, CH; Cook, RG; Butler, WT				Qin, CL; Huang, BZ; Wygant, JN; McIntyre, BW; McDonald, CH; Cook, RG; Butler, WT			A chondroitin sulfate chain attached to the bone dentin matrix protein 1 NH2-terminal fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PHOSPHOPROTEIN; SIBLING PROTEINS; IN-VIVO; SIALOPROTEIN; EXPRESSION; GENE; IDENTIFICATION; SEQUENCE; BIOMINERALIZATION; PROTEOGLYCANS	Dentin matrix protein 1 (DMP1) is an acidic noncollagenous protein shown by gene ablations to be critical for the proper mineralization of bone and dentin. In the extracellular matrix of these tissues DMP1 is present as fragments representing the NH2-terminal (37 kDa) and COOH-terminal (57 kDa) portions of the cDNA-deduced amino acid sequence. During our separation of bone noncollagenous proteins, we observed a high molecular weight, DMP1-related component (designated DMP1-PG). We purified DMP1-PG with a monoclonal anti-DMP1 antibody affinity column. Amino acid analysis and Edman degradation of tryptic peptides proved that the core protein for DMP1-PG is the 37-kDa fragment of DMP1. Chondroitinase treatments demonstrated that the slower migration rate of DMP1-PG is due to the presence of glycosaminoglycan. Quantitative disaccharide analysis indicated that the glycosaminoglycan is made predominantly of chondroitin 4-sulfate. Further analysis on tryptic peptides led us to conclude that a single glycosaminoglycan chain is linked to the core protein via Ser(74), located in the Ser(74)-Gly(75) dipeptide, an amino acid sequence specific for the attachment of glycosaminoglycans. Our findings show that in addition to its existence as a phosphoprotein, the NH2-terminal fragment from DMP1 occurs as a proteoglycan. Amino acid sequence alignment analysis showed that the Ser(74)-Gly(75) dipeptide and its flanking regions are highly conserved among a wide range of species from caiman to the Homo sapiens, indicating that this glycosaminoglycan attachment domain has survived an extremely long period of evolution pressure, suggesting that the glycosaminoglycan may be critical for the basic biological functions of DMP1.	Univ Texas, Hlth Sci Ctr, Dept Endodont, Dent Branch, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Prot Chem Core Lab, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Qin, CL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Endodont, Dent Branch, MD Anderson Blvd,DBB,Ste 307, Houston, TX 77030 USA.	Chunlin.Qin@uth.tmc.edu			NIDCR NIH HHS [DE 005092] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE005092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE005092] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baba O, 2004, EUR J ORAL SCI, V112, P163, DOI 10.1111/j.0909-8836.2004.00110.x; Baba O, 2004, MATRIX BIOL, V23, P371, DOI 10.1016/j.matbio.2004.07.008; BUTLER WT, 1987, METHOD ENZYMOL, V145, P290; Fedarko NS, 2004, FASEB J, V18, P734, DOI 10.1096/fj.03-0966fje; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Gluhak-Heinrich J, 2003, J BONE MINER RES, V18, P807, DOI 10.1359/jbmr.2003.18.5.807; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; Hirst KL, 1997, J DENT RES, V76, P754, DOI 10.1177/00220345970760030701; Jain A, 2002, J BIOL CHEM, V277, P13700, DOI 10.1074/jbc.M110757200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kulkarni GV, 2000, ARCH ORAL BIOL, V45, P475, DOI 10.1016/S0003-9969(00)00010-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Ogbureke KUE, 2005, KIDNEY INT, V68, P155, DOI 10.1111/j.1523-1755.2005.00389.x; Ogbureke KUE, 2004, J DENT RES, V83, P664, DOI 10.1177/154405910408300902; Prydz K, 2000, J CELL SCI, V113, P193; Qin CL, 2001, EUR J ORAL SCI, V109, P133, DOI 10.1034/j.1600-0722.2001.00001.x; Qin CL, 2003, J BIOL CHEM, V278, P34700, DOI 10.1074/jbc.M305315200; Qin CL, 2003, EUR J ORAL SCI, V111, P235, DOI 10.1034/j.1600-0722.2003.00043.x; Qin CL, 2001, J BIOL CHEM, V276, P904, DOI 10.1074/jbc.M006271200; RODEN L, 1985, FED PROC, V44, P373; ROUGHLEY PJ, 2003, PROTEOLYCANS LUNG DI, P4; Tartaix PH, 2004, J BIOL CHEM, V279, P18115, DOI 10.1074/jbc.M314114200; Toyosawa S, 1999, GENE, V234, P307, DOI 10.1016/S0378-1119(99)00195-X; Toyosawa S, 2000, J MOL EVOL, V50, P31, DOI 10.1007/s002399910004; Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017; Yamakoshi Y, 2005, J BIOL CHEM, V280, P1552, DOI 10.1074/jbc.M409606200; Ye L, 2005, J BIOL CHEM, V280, P6197, DOI 10.1074/jbc.M412911200; Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200	33	64	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8034	8040		10.1074/jbc.M512964200	http://dx.doi.org/10.1074/jbc.M512964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421105	hybrid			2022-12-25	WOS:000236031000040
J	Yao, CJ; Karabasil, MR; Purwanti, N; Li, XF; Akamatsu, T; Kanamori, N; Hosoi, K				Yao, CJ; Karabasil, MR; Purwanti, N; Li, XF; Akamatsu, T; Kanamori, N; Hosoi, K			Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1 beta in the submandibular gland of mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-1-BETA CONVERTING-ENZYME; PAROTID ACINAR-CELLS; MURINE MACROPHAGES; GENE FAMILY; INACTIVE PRECURSOR; MOUSE; PRORENIN; CLONING; CDNA; IDENTIFICATION	By using Western blot analysis, high levels of 17.5- and 20-kDa interleukin-1 beta(IL-1 beta) proteins were detected in the submandibular gland(SMG) of mice. Despite this fact, the amount of pro-IL-1 beta protein, a precursor of IL-1 beta, with a molecular size of 35 kDa in this tissue was below the detectable level, although strong expression of pro-IL-1 beta mRNA was observed. A large amount of 17.5- kDa IL-1 beta also appeared in the saliva of mice injected with lipopolysaccharide, suggesting that this IL-1 beta is a secretory form produced by the SMG. The protein for IL-1 beta-converting enzyme, a processing enzyme for pro-IL-1 beta, was expressed only at a low level in the SMG as compared with its level in various epithelial tissues or lipopolysaccharide-stimulated macrophages. On the other hand, mK1, mK9, mK13, and mK22, members of the kallikrein family, were detected strongly in the SMG but not in other tissues. By incubation with mK13, but not with mK1, mK9, or mK22, the 35-kDa pro-IL-1 beta was cleaved into two major products with molecular masses of 17.5 and 22 kDa, and production was inhibited by phenylmethylsulfonyl fluoride, a serine protease inhibitor, but not by IL-1 beta-converting enzyme inhibitors. A peptide segment corresponding to amino acid residues 107-121 of mouse pro-IL-1 beta ((WDDDDNLLVCDVPIR)-W-107) was cleaved by incubation with mK13, generating two peptides, (WDDDDNL)-W-107 and (LVCDVPIR)-L-114. Therefore, kallikrein mK13 would appear to hydrolyze pro-IL-1 beta between its Leu(113) and Leu(114) residues. The results of immunohistochemistry and an autonomic therapy experiment showed that IL-1 beta and kallikrein mK13 were co-localized in the secretory granules of granular convoluted tubular cells. Our present results thus suggest kallikrein mK13 is a plausible candidate for the processing enzyme for pro-IL-1 beta in the SMG of mice.	Univ Tokushima, Grad Sch, Dept Mol Oral Physiol, Tokushima 7708504, Japan	Tokushima University	Hosoi, K (corresponding author), Univ Tokushima, Grad Sch, Dept Mol Oral Physiol, 3-18-15 Kuramoto Cho, Tokushima 7708504, Japan.	hosoi@dent.tokushima-u.ac.jp		Hosoi, Kazuo/0000-0001-5165-5056				ADUCCI P, 2004, HDB PROTEOLYTIC ENZY, P1847; Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; Berg T, 1992, Agents Actions Suppl, V38 ( Pt 1), P19; BEUSCHER HU, 1990, J IMMUNOL, V144, P2179; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BLACK RA, 1989, J BIOL CHEM, V264, P5323; BLACK RA, 1988, J BIOL CHEM, V263, P9437; Brough D, 2003, J IMMUNOL, V170, P3029, DOI 10.4049/jimmunol.170.6.3029; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DAVID GP, 2002, J IMMUNOL, V168, P3024; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Fantuzzi G, 1997, J IMMUNOL, V158, P1818; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HAZUDA DJ, 1990, J BIOL CHEM, V265, P6318; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOSOI K, 1978, CAN J PHYSIOL PHARM, V56, P634, DOI 10.1139/y78-101; HOSOI K, 1983, ARCH ORAL BIOL, V28, P5, DOI 10.1016/0003-9969(83)90020-1; HOSOI K, 1983, BIOCHIM BIOPHYS ACTA, V756, P163, DOI 10.1016/0304-4165(83)90088-0; HOSOI K, 1994, J BIOCHEM-TOKYO, V115, P137, DOI 10.1093/oxfordjournals.jbchem.a124288; HOSOI K, 2004, HDB PROTEOLYTIC ENZY, P1599; Kikkawa Y, 1998, BBA-PROTEIN STRUCT M, V1382, P55, DOI 10.1016/S0167-4838(97)00144-1; KIM WS, 1990, J BIOL CHEM, V265, P5930; KIM WS, 1991, J BIOL CHEM, V266, P19283; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; Kurabuchi S, 1999, HISTOCHEM J, V31, P19, DOI 10.1023/A:1003506302065; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; MILLER BE, 1995, J IMMUNOL, V154, P1331; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; Tanda N, 1998, AM J PHYSIOL-GASTR L, V274, pG147, DOI 10.1152/ajpgi.1998.274.1.G147; TAYLOR JM, 1970, P NATL ACAD SCI USA, V67, P164, DOI 10.1073/pnas.67.1.164; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Yamakawa M, 2000, J HISTOCHEM CYTOCHEM, V48, P1033, DOI 10.1177/002215540004800802; Yao CJ, 2005, IMMUNOLOGY, V116, P213, DOI 10.1111/j.1365-2567.2005.02212.x; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; Yousef GM, 2000, BIOCHEM BIOPH RES CO, V276, P125, DOI 10.1006/bbrc.2000.3448; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	43	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7968	7976		10.1074/jbc.M507705200	http://dx.doi.org/10.1074/jbc.M507705200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16423834	hybrid			2022-12-25	WOS:000236031000033
J	Arnold, JN; Wallis, R; Willis, AC; Harvey, DJ; Royle, L; Dwek, RA; Rudd, PM; Sim, RB				Arnold, JN; Wallis, R; Willis, AC; Harvey, DJ; Royle, L; Dwek, RA; Rudd, PM; Sim, RB			Interaction of mannan binding lectin with alpha(2) macroglobulin via exposed oligomannose glycans - A conserved feature of the thiol ester protein family?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C1S-LIKE SERINE-PROTEASE; COMPLEMENT COMPONENT C3; ALPHA-2-MACROGLOBULIN; COMPLEXES; PATHWAY; GLYCOSYLATION; ACTIVATION; MBL; ASSOCIATION; INHIBITORS	The serum collectin mannan-binding lectin (MBL) binds to oligomannose and GlcNAc-terminating glycans present on microorganisms. Using a commercial affinity chromatography resin containing immobilized MBL we screened human and mouse serum for endogenous MBL-binding targets. We isolated the serum protease inhibitor alpha(2) macroglobulin (alpha 2M), a heavily glycosylated thiol ester protein (TEP) composed of four identical 180-kDa subunits, each of which has eight N-linked glycosylation sites. alpha 2M has previously been reported to interact with MBL; however, the interaction was not characterized. We investigated the mechanism of formation of complexes between alpha 2M and MBL and concluded that they form by the direct binding of oligomannose glycans Man(5-7) occupying Asn-846 on alpha 2M to the lectin domains ( carbohydrate recognition domains) of MBL. The oligomannose glycans are accessible for lectin binding on both active alpha 2M ( thiol ester intact) and protease-cleaved alpha 2M( thiol ester cleaved). We demonstrate that MBL is able to interact with alpha 2M in the fluid phase, but the interaction does not inhibit the binding of MBL to mannan-coated surfaces. In addition to alpha 2M, two other members of the TEP family, C3 and C4, which also contain oligomannose glycans, were captured from human serum using the MBL resin. MBL binding may be a conserved feature of the TEPs, dating from their ancestral origins. We suggest that the inhibition of proteases on the surface of microorganisms by an ancestral alpha 2M-like TEP may generate "arrays" of oligomannose glycans to which MBL or other lectins can bind. Binding would lead to opsonization or activation of enzyme systems such as complement.	Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England; Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HH, Leics, England	University of Oxford; University of Oxford; University of Leicester	Sim, RB (corresponding author), Univ Oxford, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.	bob.sim@bioch.ox.ac.uk	Sim, Bob/A-1354-2008; Arnold, James/ABE-3900-2021; Harvey, David/A-5579-2013	Sim, Bob/0000-0002-2855-7455; Arnold, James/0000-0002-6949-0613; Wallis, Russell/0000-0002-8705-5295; Harvey, David/0000-0003-0544-771X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ambrus G, 2003, J IMMUNOL, V170, P1374, DOI 10.4049/jimmunol.170.3.1374; ARAKAWA H, 1989, J BIOL CHEM, V264, P2350; Arnold JN, 2005, J BIOL CHEM, V280, P29080, DOI 10.1074/jbc.M504528200; Arnold JN, 2004, J IMMUNOL, V173, P6831, DOI 10.4049/jimmunol.173.11.6831; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Chen CB, 2001, J BIOL CHEM, V276, P25894, DOI 10.1074/jbc.M103539200; CHU CT, 1991, BIOCHEMISTRY-US, V30, P1551, DOI 10.1021/bi00220a016; Crispin MDM, 2004, FEBS LETT, V566, P270, DOI 10.1016/j.febslet.2004.04.045; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Dodds AW, 2002, IMMUNOBIOLOGY, V205, P340, DOI 10.1078/0171-2985-00137; GONIAS SL, 1983, J BIOL CHEM, V258, P4682; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; Hajela K, 2002, IMMUNOBIOLOGY, V205, P467, DOI 10.1078/0171-2985-00147; HARPEL PC, 1983, ANN NY ACAD SCI, V421, P1, DOI 10.1111/j.1749-6632.1983.tb18088.x; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Holmskov U, 1996, FEBS LETT, V393, P314, DOI 10.1016/0014-5793(96)00915-5; HOWARD JB, 1983, ANN NY ACAD SCI, V421, P160, DOI 10.1111/j.1749-6632.1983.tb18106.x; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Kolodziej SJ, 2002, J BIOL CHEM, V277, P28031, DOI 10.1074/jbc.M202714200; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Lahteenmaki K, 2001, FEBS LETT, V504, P69, DOI 10.1016/S0014-5793(01)02775-2; MALHOTRA R, 1995, NAT MED, V1, P237, DOI 10.1038/nm0395-237; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Nyberg P, 2004, J BIOL CHEM, V279, P52820, DOI 10.1074/jbc.C400485200; Petersen SV, 2000, MOL IMMUNOL, V37, P803, DOI 10.1016/S0161-5890(01)00004-9; Presanis JS, 2004, MOL IMMUNOL, V40, P921, DOI 10.1016/j.molimm.2003.10.013; Qazi U, 2000, J STRUCT BIOL, V131, P19, DOI 10.1006/jsbi.2000.4269; Qazi U, 1999, J BIOL CHEM, V274, P8137, DOI 10.1074/jbc.274.12.8137; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; Ritchie GE, 2002, CHEM REV, V102, P305, DOI 10.1021/cr990294a; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SIM RB, 1981, BIOCHEM J, V193, P129, DOI 10.1042/bj1930129; SIM RB, 1979, BIOCHEM J, V179, P449, DOI 10.1042/bj1790449a; SOLIS D, 1994, J BIOL CHEM, V269, P11555; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; SOTTRUPJENSEN L, 1985, P NATL ACAD SCI USA, V82, P9, DOI 10.1073/pnas.82.1.9; STORGAARD P, 1995, SCAND J IMMUNOL, V42, P373, DOI 10.1111/j.1365-3083.1995.tb03670.x; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; TERAI I, 1995, INT IMMUNOL, V7, P1579, DOI 10.1093/intimm/7.10.1579; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; Vorup-Jensen T, 2000, J IMMUNOL, V165, P2093, DOI 10.4049/jimmunol.165.4.2093; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Wong NKH, 1999, MOL IMMUNOL, V36, P853, DOI 10.1016/S0161-5890(99)00106-6	53	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6955	6963		10.1074/jbc.M511432200	http://dx.doi.org/10.1074/jbc.M511432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407218	hybrid			2022-12-25	WOS:000236030900007
J	Kim, EA; Noh, YT; Ryu, MJ; Kim, HT; Lee, SE; Kim, CH; Lee, C; Kim, YH; Choi, CY				Kim, EA; Noh, YT; Ryu, MJ; Kim, HT; Lee, SE; Kim, CH; Lee, C; Kim, YH; Choi, CY			Phosphorylation and transactivation of Pax6 by homeodomain-interacting protein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED-DOMAIN; PROTEIN-KINASE; TRANSCRIPTIONAL REGULATION; GENE-TRANSCRIPTION; P300 COACTIVATOR; CRYSTALLIN GENES; EYE DEVELOPMENT; NEURONAL FATE; MOUSE; P53	Pax6 is a transcriptional activator that contains two DNA binding domains and a potent transcription activation domain in the C terminus, which regulates organogenesis of the eye, nose, pancreas, and central nervous system. Homeodomain-interacting protein kinase 2 (HIPK2) interacts with transcription factors, including homeoproteins, and regulates activities of transcription factors. Here we show that HIPK2 phosphorylates the activation domain of Pax6, which augments Pax6 transactivation by enhancing its interaction with p300. Mass spectrometric analysis identified three Pax6 phosphorylation sites as threonines 281, 304, and 373. The substitutions of these threonines with alanines decreased Pax6 transactivation, whereas substitutions to glutamic acids increased transactivation in mimicry of phosphorylation. Furthermore, the knock-down of either endogenous or exogenous HIPK2 expression with HIPK2 shRNA markedly inhibited Pax6 phosphorylation and its transactivating function on proglucagon promoter in cultured cells. These results strongly indicate that HIPK2 is an upstream protein kinase for Pax6 and suggest that it modulates Pax6-mediated transcriptional regulation.	Digital Biotech, Ansan 425839, South Korea; Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea; Korea Inst Sci & Technol, Div Life Sci, Seoul 136791, South Korea; Chungnam Natl Univ, Dept Biol, Taejon 305764, South Korea; Univ Hawaii, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA	Sungkyunkwan University (SKKU); Korea Institute of Science & Technology (KIST); Chungnam National University; University of Hawaii System	Kim, YH (corresponding author), Digital Biotech, 1227 Shingildong, Ansan 425839, South Korea.	youngho@digitalbiotech.com; choicy@skku.ac.kr	Lee, Sung-Eun/E-3786-2015	Lee, Sung-Eun/0000-0001-7690-9956; Kim, Cheol-Hee/0000-0002-3019-0699				Andersen FG, 1999, FEBS LETT, V445, P315, DOI 10.1016/S0014-5793(99)00144-1; Ashery-Padan R, 2004, DEV BIOL, V269, P479, DOI 10.1016/j.ydbio.2004.01.040; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chan HM, 2001, J CELL SCI, V114, P2363; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 2005, J BIOL CHEM, V280, P21427, DOI 10.1074/jbc.M500496200; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Chow RL, 1999, DEVELOPMENT, V126, P4213; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Favor J, 2001, GENETICS, V159, P1689; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Grzeskowiak R, 2000, J BIOL CHEM, V275, P30037, DOI 10.1074/jbc.M000984200; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Hanson I, 1999, HUM MOL GENET, V8, P165, DOI 10.1093/hmg/8.2.165; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jun S, 1996, DEVELOPMENT, V122, P2639; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Li XX, 2005, J BIOL CHEM, V280, P24245, DOI 10.1074/jbc.M414637200; Li YH, 2005, DIABETES, V54, P482, DOI 10.2337/diabetes.54.2.482; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Mishra R, 2002, J BIOL CHEM, V277, P49488, DOI 10.1074/jbc.M206478200; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Onuma Y, 2002, P NATL ACAD SCI USA, V99, P2020, DOI 10.1073/pnas.022626999; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; Raska CS, 2002, ANAL CHEM, V74, P3429, DOI 10.1021/ac0111199; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; Simpson TI, 2002, BIOESSAYS, V24, P1041, DOI 10.1002/bies.10174; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Singh S, 2000, J BIOL CHEM, V275, P17306, DOI 10.1074/jbc.M000359200; Sisodiya SM, 2001, NAT GENET, V28, P214, DOI 10.1038/90042; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tabb DL, 2003, ANAL CHEM, V75, P1155, DOI 10.1021/ac026122m; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Tholey A, 1999, J MASS SPECTROM, V34, P117, DOI 10.1002/(SICI)1096-9888(199902)34:2<117::AID-JMS769>3.0.CO;2-V; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; Wawersik S, 2000, HUM MOL GENET, V9, P917, DOI 10.1093/hmg/9.6.917; Yang Y, 2004, J MOL BIOL, V344, P351, DOI 10.1016/j.jmb.2004.07.102	51	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7489	7497		10.1074/jbc.M507227200	http://dx.doi.org/10.1074/jbc.M507227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407227	hybrid			2022-12-25	WOS:000236030900071
J	Kuwasako, K; Cao, YN; Chu, CP; Iwatsubo, S; Eto, T; Kitamura, K				Kuwasako, K; Cao, YN; Chu, CP; Iwatsubo, S; Eto, T; Kitamura, K			Functions of the cytoplasmic tails of the human receptor activity-modifying protein components of calcitonin gene-related peptide and adrenomedullin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST BINDING; UBIQUITINATION; ENDOCYTOSIS; MOTIF; INTERNALIZATION; IDENTIFICATION; TRAFFICKING; SUFFICIENT; TRANSPORT; TERMINUS	Receptor activity-modifying proteins (RAMPs) enable calcitonin receptor-like receptor (CRLR) to function as a calcitonin gene-related peptide receptor (CRLR/RAMP1) or an adrenomedullin ( AM) receptor (CRLR/RAMP2 or - 3). Here we investigated the functions of the cytoplasmic C-terminal tails (C-tails) of human RAMP1, - 2, and - 3 (hRAMP1, - 2, and - 3) by cotransfecting their C-terminal deletion or progressive truncation mutants into HEK-293 cells stably expressing hCRLR. Deletion of the C-tail from hRAMP1 had little effect on the surface expression, function, or intracellular trafficking of the mutant heterodimers. By contrast, deletion of the C-tail from hRAMP2 disrupted transport of hCRLR to the cell surface, resulting in significant reductions in I-125-hAM binding and evoked cAMP accumulation. The transfection efficiency for the hRAMP2 mutant was comparable with that for wildtype hRAMP2; moreover, immunocytochemical analysis showed that the mutant hRAMP2 remained within the endoplasmic reticulum. FACS analysis revealed that deleting the C-tail from hRAMP3 markedly enhances AM-evoked internalization of the mutant heterodimers, although there was no change in agonist affinity. Truncating the C-tails by removing the six C-terminal amino acids of hRAMP2 and - 3 or exchanging their C-tails with one another had no effect on surface expression, agonist affinity, or internalization of hCRLR, which suggests that the highly conserved Ser-Lys sequence within hRAMP C-tails is involved in cellular trafficking of the two AM receptors. Notably, deleting the respective C-tails from hRAMPs had no effect on lysosomal sorting of hCRLR. Thus, the respective C-tails of hRAMP2 and - 3 differentially affect hCRLR surface delivery and internalization.	Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan; Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med 3, Miyazaki 8891692, Japan	University of Miyazaki; University of Miyazaki	Kuwasako, K (corresponding author), Miyazaki Univ, Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan.	kuwasako@fc.miyazaki-med.ac.jp	Kuwasako, Kenji/H-8065-2016					Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Bomberger JM, 2005, J BIOL CHEM, V280, P23926, DOI 10.1074/jbc.M501751200; Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200; Cao YN, 2005, BIOCHEM BIOPH RES CO, V332, P866, DOI 10.1016/j.bbrc.2005.05.034; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Eto T, 2001, PEPTIDES, V22, P1693, DOI 10.1016/S0196-9781(01)00513-7; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fitzsimmons TJ, 2003, J BIOL CHEM, V278, P14313, DOI 10.1074/jbc.M211946200; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Gage RM, 2005, J BIOL CHEM, V280, P3305, DOI 10.1074/jbc.M406934200; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hay DL, 2006, PHARMACOL THERAPEUT, V109, P173, DOI 10.1016/j.pharmthera.2005.06.015; Heydorn A, 2004, J BIOL CHEM, V279, P54291, DOI 10.1074/jbc.M406169200; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hilaire S, 2001, J BIOL CHEM, V276, P42182, DOI 10.1074/jbc.M107323200; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Kuwasako K, 2004, PEPTIDES, V25, P2003, DOI 10.1016/j.peptides.2004.06.002; Kuwasako K, 2004, MOL PHARMACOL, V65, P207, DOI 10.1124/mol.65.1.207; Kuwasako K, 2003, J BIOL CHEM, V278, P22623, DOI 10.1074/jbc.M302571200; Kuwasako K, 2002, FEBS LETT, V519, P113, DOI 10.1016/S0014-5793(02)02721-7; Kuwasako K, 2001, J BIOL CHEM, V276, P49459, DOI 10.1074/jbc.M108369200; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Muff R, 2003, HYPERTENS RES, V26, pS3, DOI 10.1291/hypres.26.S3; Nagoshi Y, 2004, BIOCHEM BIOPH RES CO, V314, P1057, DOI 10.1016/j.bbrc.2004.01.004; Nagoshi Y, 2002, EUR J PHARMACOL, V450, P237, DOI 10.1016/S0014-2999(02)02184-2; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Xu JH, 1999, J BIOL CHEM, V274, P19095, DOI 10.1074/jbc.274.27.19095	44	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7205	7213		10.1074/jbc.M511147200	http://dx.doi.org/10.1074/jbc.M511147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410241	hybrid			2022-12-25	WOS:000236030900037
J	Ishihara, Y; Shimamoto, N				Ishihara, Y; Shimamoto, N			Involvement of endonuclease G in nucleosomal DNA fragmentation under sustained endogenous oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; PEROXIDE-INDUCED APOPTOSIS; CASPASE-ACTIVATED DNASE; PROGRAMMED CELL-DEATH; HYDROGEN-PEROXIDE; HEPATOCYTE APOPTOSIS; DEOXYRIBONUCLEASE-II; REDOX REGULATION; PRIMARY CULTURES; FREE-RADICALS	We have previously shown that inhibition of catalase and glutathione peroxidase activities by 3-amino-1,2,4-triazole (ATZ) and mercaptosuccinic acid (MS), respectively, in rat primary hepatocytes caused sustained endogenous oxidative stress and apoptotic cell death without caspase-3 activation. In this study, we investigated the mechanism of this apoptotic cell death in terms of nucleosomal DNA fragmentation. Treatment with ATZ + MS time-dependently increased the number of deoxynucleotidyl transferase-mediated nickend-labeling (TUNEL)-positive nuclei from 12 h, resulting in clear DNA laddering at 24 h. The deoxyribonuclease ( DNase) inhibitor, aurintricarboxylic acid (ATA), completely inhibited nucleosomal DNA fragmentation but the pan-caspase inhibitor, z-VAD-fmk was without effects; furthermore, the cleavage of inhibitor of caspase-activated DNase was not detected, indicating the involvement of DNase(s) other than caspase-activated DNase. Considering that endonuclease G (EndoG) reportedly acts in a caspase-independent manner, we cloned rat EndoG cDNA for the first time. Recombinant EndoG alone digested plasmid DNA and induced nucleosomal DNA fragmentation in isolated hepatocyte nuclei. Recombinant EndoG activity was inhibited by ATA but not by hydrogen peroxide, even at 10 mM. ATZ + MS stimulation elicited decreases in mitochondrial membrane potential and EndoG translocation from mitochondria to nuclei. By applying RNA interference, the mRNA levels of EndoG were almost completely suppressed and the amount of EndoG protein was decreased to approximately half the level of untreated cells. Under these conditions, decreases in TUNEL-positive nuclei were significantly suppressed. These results indicate that EndoG is responsible, at least in part, for nucleosomal DNA fragmentation under endogenous oxidative stress conditions induced by ATZ + MS.	Tokushima Bunri Univ, Fac Pharmaceut Sci, Kagawa 7692193, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5328686, Japan	Tokushima Bunri University; Osaka University	Shimamoto, N (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Kagawa Campus,1314-1 Shido, Kagawa 7692193, Japan.	n-shimamoto@kph.bunri-u.ac.jp	Ishihara, Yasuhiro/U-6511-2017	Ishihara, Yasuhiro/0000-0001-9751-7660				Adachi T, 2005, HEPATOLOGY, V41, P1272, DOI 10.1002/hep.20719; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Djordjevic VB, 2004, INT REV CYTOL, V237, P57, DOI 10.1016/S0074-7696(04)37002-6; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Galli F, 2005, CONTRIB NEPHROL, V149, P240, DOI 10.1159/000085686; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HAROSH I, 1991, EUR J BIOCHEM, V202, P479, DOI 10.1111/j.1432-1033.1991.tb16397.x; Ishihara Y, 2005, FREE RADICAL RES, V39, P163, DOI 10.1080/10715760500043231; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; Kanno S, 2000, BIOL PHARM BULL, V23, P37; Katoh S, 1999, BIOCHEM J, V338, P465, DOI 10.1042/0264-6021:3380465; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kim HA, 2002, BIOCHEM BIOPH RES CO, V295, P937, DOI 10.1016/S0006-291X(02)00789-1; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Lee SJ, 2005, BRIT J PHARMACOL, V145, P469, DOI 10.1038/sj.bjp.0706206; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liao J, 2005, MED HYPOTHESES, V65, P23, DOI 10.1016/j.mehy.2005.01.028; LUTTER LC, 1979, NUCLEIC ACIDS RES, V6, P41, DOI 10.1093/nar/6.1.41; MASLANSKY CJ, 1982, IN VITRO CELL DEV B, V18, P683; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; MIYAZAKI M, 1985, EXP CELL RES, V159, P176, DOI 10.1016/S0014-4827(85)80047-1; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Prats E, 1997, DNA CELL BIOL, V16, P1111, DOI 10.1089/dna.1997.16.1111; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samali A, 1999, BIOCHEM BIOPH RES CO, V255, P6, DOI 10.1006/bbrc.1998.0139; Schafer P, 2004, J MOL BIOL, V338, P217, DOI 10.1016/j.jmb.2004.02.069; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shiba D, 1999, FREE RADICAL BIO MED, V27, P1019, DOI 10.1016/S0891-5849(99)00150-1; Shih CM, 2004, J CELL BIOCHEM, V91, P384, DOI 10.1002/jcb.10761; Shiokawa D, 2001, BIOCHEMISTRY-US, V40, P143, DOI 10.1021/bi001041a; Shiokawa D, 1998, BIOCHEM J, V332, P713, DOI 10.1042/bj3320713; Sloviter RS, 2002, TRENDS PHARMACOL SCI, V23, P19, DOI 10.1016/S0165-6147(00)01867-8; STAAL FJT, 1995, METHOD ENZYMOL, V252, P168; Stefan C, 1997, CHEM RES TOXICOL, V10, P636, DOI 10.1021/tx970006a; Steinbeck MJ, 1998, J CELL PHYSIOL, V176, P574, DOI 10.1002/(SICI)1097-4652(199809)176:3<574::AID-JCP14>3.0.CO;2-#; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki YJ, 2003, ANTIOXID REDOX SIGN, V5, P741, DOI 10.1089/152308603770380043; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447; TIRANTI V, 1995, GENOMICS, V25, P559, DOI 10.1016/0888-7543(95)80058-T; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Xu Y, 1997, AM J PHYSIOL-GASTR L, V273, pG795, DOI 10.1152/ajpgi.1997.273.4.G795; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; YASUDA T, 1992, BIOCHIM BIOPHYS ACTA, V1119, P185, DOI 10.1016/0167-4838(92)90390-Y; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zheng YH, 2005, ONCOGENE, V24, P3339, DOI 10.1038/sj.onc.1208484; Zhou X, 2000, J IMMUNOL, V165, P1252, DOI 10.4049/jimmunol.165.3.1252	69	56	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6726	6733		10.1074/jbc.M510382200	http://dx.doi.org/10.1074/jbc.M510382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407272	hybrid			2022-12-25	WOS:000236030800070
J	Zhang, X; Emerald, BS; Mukhina, S; Mohankumar, KM; Kraemer, A; Yap, AS; Gluckman, PD; Lee, KO; Lobie, PE				Zhang, X; Emerald, BS; Mukhina, S; Mohankumar, KM; Kraemer, A; Yap, AS; Gluckman, PD; Lee, KO; Lobie, PE			HOXA1 is required for E-cadherin-dependent anchorage-independent survival of human mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; HUMAN BREAST-CANCER; EPITHELIAL-CELLS; CYTOSKELETAL ORGANIZATION; ADHESIVE CONTACTS; GENE-EXPRESSION; HOMEOBOX GENES; BETA-CATENIN; P-CADHERIN; APOPTOSIS	Forced expression of HOXA1 is sufficient to stimulate oncogenic transformation of immortalized human mammary epithelial cells and subsequent tumor formation. We report here that the expression and transcriptional activity of HOXA1 are increased in mammary carcinoma cells at full confluence. This confluence-dependent expression of HOXA1 was abrogated by incubation of cells with EGTA to produce loss of intercellular contact and rescued by extracellular addition of Ca2+. Increased HOXA1 expression at full confluence was prevented by an E-cadherin function-blocking antibody and attachment of non-confluent cells to a substrate by homophilic ligation of E-cadherin increased HOXA1 expression. E-cadherin-directed signaling increased HOXA1 expression through Rac1. Increased HOXA1 expression consequent to E-cadherin-activated signaling decreased apoptotic cell death and was required for E-cadherin-dependent anchorage-independent proliferation of human mammary carcinoma cells. HOXA1 is therefore a downstream effector of E-cadherin-directed signaling required for anchorage-independent proliferation of mammary carcinoma cells.	Univ Auckland, Liggins Inst, Auckland 1001, New Zealand; Natl Univ Singapore, Dept Med, Singapore 117609, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Univ Queensland, Inst Mol Biosci, Div Mol Cell Biol, St Lucia, Qld 4072, Australia; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1001, New Zealand	University of Auckland; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of Queensland; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland 1001, New Zealand.	p.lobie@auckland.ac.nz	Lee, Kok-Onn/E-9874-2011; David, Starling Emerald Bright/R-6034-2019; Kumarasamypet Murugesan, Mohankumar/F-4231-2012; Yap, Alpha S./J-1554-2014	Lee, Kok-Onn/0000-0002-3040-1185; David, Starling Emerald Bright/0000-0001-6875-2258; Yap, Alpha S./0000-0002-1038-8956; KM, Mohankumar/0000-0001-9407-1800				Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Boersma C J, 1999, Mol Cell Biol Res Commun, V1, P117, DOI 10.1006/mcbr.1999.0115; Boussadia O, 2002, MECH DEVELOP, V115, P53, DOI 10.1016/S0925-4773(02)00090-4; BRACKE ME, 1994, CANCER RES, V54, P4607; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; CHARIOT A, 1995, BIOCHEM BIOPH RES CO, V215, P713, DOI 10.1006/bbrc.1995.2522; Charpin C, 1997, J PATHOL, V181, P294; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; Frankel A, 1997, CANCER RES, V57, P2388; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hashizume R, 1996, HISTOPATHOLOGY, V29, P139, DOI 10.1046/j.1365-2559.1996.d01-499.x; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Heiser D, 2004, EXP GERONTOL, V39, P1125, DOI 10.1016/j.exger.2004.04.011; Irving C, 2000, DEVELOPMENT, V127, P177; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li G, 2001, CANCER RES, V61, P3819; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; Maroulakou IG, 2003, ANTICANCER RES, V23, P2101; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Meniel V, 2003, J MAMMARY GLAND BIOL, V8, P435, DOI 10.1023/B:JOMG.0000017430.12210.37; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; MOLL R, 1993, AM J PATHOL, V143, P1731; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nakamura T, 2003, INT J MOL MED, V12, P693; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohsugi M, 1997, DEV BIOL, V185, P261, DOI 10.1006/dbio.1997.8560; OKA H, 1993, CANCER RES, V53, P1696; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; Peluso JJ, 2001, BIOL REPROD, V64, P1183, DOI 10.1095/biolreprod64.4.1183; Pujuguet P, 2003, MOL BIOL CELL, V14, P2181, DOI 10.1091/mbc.E02-07-0410; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; Rios-Doria J, 2005, PROSTATE, V63, P259, DOI 10.1002/pros.20179; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Srebrow A, 1998, J CELL BIOCHEM, V69, P377, DOI 10.1002/(SICI)1097-4644(19980615)69:4<377::AID-JCB1>3.0.CO;2-K; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317	63	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6471	6481		10.1074/jbc.M512666200	http://dx.doi.org/10.1074/jbc.M512666200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373333	hybrid			2022-12-25	WOS:000236030800042
J	Dabney-Smith, C; Mori, H; Cline, K				Dabney-Smith, C; Mori, H; Cline, K			Oligomers of Tha4 organize at the thylakoid Tat translocase during protein transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE SIGNAL PEPTIDE; ESCHERICHIA-COLI; ANTIMICROBIAL PEPTIDES; CRYSTAL-STRUCTURE; PHOTOSYSTEM-II; PATHWAY; MEMBRANE; SYSTEM; SEC; CHLOROPLASTS	The Tat ( twin arginine translocation) systems of thylakoids and bacteria transport fully folded protein substrates without breaching the permeability barrier of the membrane. Two components of the thylakoid system, cpTatC and Hcf106, compose a precursor-bound receptor complex. The third component, Tha4, assembles with the precursor-bound receptor complex for the translocation step and is thought to compose at least part of the protein-conducting channel. Here, we used two different cross-linking approaches to explore the organization of Tha4 in the translocase. These cross-linking techniques showed that transition to an active protein transport state resulted in an alignment of the Tha4 amphipathic helix and C-terminal tail domains to form Tha4 oligomers. Oligomerization required functional Tha4, a twin arginine signal peptide, and an active cpTatC-Hcf106 receptor complex. The spectrum of oligomers obtained was independent of the mature folded domain of the precursor. We propose a trapdoor mechanism for translocation whereby aligned oligomers of Tha4 amphipathic helices fold into the membrane to allow formfitting passage of precursor proteins.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA; Shujitsu Univ, Sch Pharm, Okayama 7038516, Japan	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, 1109 Fifield Hall,POB 110690, Gainesville, FL 32611 USA.	kcline@ufl.edu	Cline, Kenneth/J-6238-2013; Dabney-Smith, Carole/C-2432-2008	Dabney-Smith, Carole/0000-0003-1347-3870	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048179] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 48179] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alder NN, 2003, FEBS LETT, V540, P96, DOI 10.1016/S0014-5793(03)00231-X; Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; Calderone V, 2003, EMBO REP, V4, P900, DOI 10.1038/sj.embor.embor923; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Cline K, 2003, ADV PHOTOSYNTHESIS R, V13, P353; Dabney-Smith C, 2003, J BIOL CHEM, V278, P43027, DOI 10.1074/jbc.M307923200; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fincher V, 2003, EUR J BIOCHEM, V270, P4930, DOI 10.1046/j.1432-1033.2003.03894.x; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Gouffi K, 2004, J BIOL CHEM, V279, P11608, DOI 10.1074/jbc.M313187200; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Ifuku K, 2004, EMBO REP, V5, P362, DOI 10.1038/sj.embor.7400113; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Oates J, 2003, J MOL BIOL, V330, P277, DOI 10.1016/S0022-2836(03)00621-1; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; Pop OI, 2003, J BIOL CHEM, V278, P38428, DOI 10.1074/jbc.M306516200; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Reddy KVR, 2004, INT J ANTIMICROB AG, V24, P536, DOI 10.1016/j.ijantimicag.2004.09.005; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Teter SA, 1998, P NATL ACAD SCI USA, V95, P1590, DOI 10.1073/pnas.95.4.1590; Theg SM, 2005, TRENDS PLANT SCI, V10, P153, DOI 10.1016/j.tplants.2005.02.001; Tossi A, 2000, BIOPOLYMERS, V55, P4; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	45	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5476	5483		10.1074/jbc.M512453200	http://dx.doi.org/10.1074/jbc.M512453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407186	hybrid			2022-12-25	WOS:000235568900020
J	Ward, MW; Rehm, M; Duessmann, H; Kacmar, S; Concannon, CG; Prehn, JHM				Ward, MW; Rehm, M; Duessmann, H; Kacmar, S; Concannon, CG; Prehn, JHM			Real time single cell analysis of Bid cleavage and Bid translocation during caspase-dependent and neuronal caspase-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; CEREBELLAR GRANULE CELLS; ACUTE GLUTAMATE EXCITOTOXICITY; FOCAL CEREBRAL-ISCHEMIA; PERMEABILITY TRANSITION; BH3-ONLY PROTEINS; DNA FRAGMENTATION; BCL-2 FAMILY; DEATH	Bcl- 2 homology domain ( BH) 3- only proteins couple stress signals to evolutionarily conserved mitochondrial apoptotic pathways. Caspase 8- mediated cleavage of the BH3- only protein Bid into a truncated protein ( tBid) and subsequent translocation of tBid to mitochondria has been implicated in death receptor signaling. We utilized a recombinant fluorescence resonance energy transfer ( FRET) Bid probe to determine the kinetics of Bid cleavage and tBid translocation during death receptor- induced apoptosis in caspase 3- deficient MCF- 7 cells. Cells treated with tumor necrosis factor-alpha ( 200 ng/ ml) showed a rapid cleavage of the Bid- FRET probe occurring 75.4 +/- 12.6 min after onset of the tumor necrosis factor-alpha exposure. Cleavage of the Bid- FRET probe coincided with a translocation of tBid to the mitochondria and a collapse of the mitochondrial membrane potential ( Delta Psi m). We next investigated the role of Bid cleavage in a model of caspase- independent, glutamate- induced excitotoxic apoptosis. Rat cerebellar granule neurons were transfected with the Bid- FRET probe and exposed to glutamate for 5 min. In contrast to death receptor- induced apoptosis, neurons showed a translocation of full- length Bid to the mitochondria. This translocation occurred 5.6 +/- 1.7 h after the termination of the glutamate exposure and was also paralleled with a collapse of the Delta Psi m. Proteolytic cleavage of the FRET probe also occurred, however, only 25.2 +/- 3.5 min after its translocation to the mitochondria. Subfractionation experiments confirmed a translocation of full- length Bid from the cytosolic to the mitochondrial fraction during excitotoxic apoptosis. Our data demonstrate that both tBid and full- length Bid have the capacity to translocate to mitochondria during apoptosis.	Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; Royal Coll Surgeons Ireland, RCSI Neurosci Res Ctr, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland	Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	Prehn@rcsi.ie	Concannon, Caoimhin/B-2075-2010; Rehm, Markus/C-3398-2012; Prehn, Jochen HM/A-3928-2010	Rehm, Markus/0000-0001-6149-9261; Prehn, Jochen HM/0000-0003-3479-7794; Dussmann, Heiko/0000-0002-3582-8057; Ward, Manus/0000-0002-7085-9668				Armstrong RC, 1997, J NEUROSCI, V17, P553; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bouillet P, 2002, J CELL SCI, V115, P1567; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Budd SL, 1996, J NEUROCHEM, V67, P2282; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Castilho RF, 1999, J NEUROCHEM, V72, P1394, DOI 10.1046/j.1471-4159.1999.721394.x; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Gasull T, 2000, J BIOL CHEM, V275, P18350, DOI 10.1074/jbc.M910468199; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goonesinghe A, 2005, BIOCHEM J, V387, P109, DOI 10.1042/BJ20041389; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson MD, 1999, J NEUROSCI, V19, P2996; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Onuki R, 2002, P NATL ACAD SCI USA, V99, P14716, DOI 10.1073/pnas.232177599; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Rehm M, 2003, J CELL BIOL, V162, P1031, DOI 10.1083/jcb.200303123; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Villunger A, 2004, Cell Death Differ, V11, P790, DOI 10.1038/sj.cdd.4401460; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Ward MW, 2005, J NEUROCHEM, V92, P1081, DOI 10.1111/j.1471-4159.2004.02928.x; Ward MW, 2000, J NEUROSCI, V20, P7208; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	69	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5837	5844		10.1074/jbc.M511562200	http://dx.doi.org/10.1074/jbc.M511562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407197	hybrid, Green Published			2022-12-25	WOS:000235568900063
J	Vinall, RL; Tepper, CG; Shi, XB; Xue, LA; Gandour-Edwards, R; White, RWV				Vinall, RL; Tepper, CG; Shi, XB; Xue, LA; Gandour-Edwards, R; White, RWV			The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	ONCOGENE			English	Article						mutant p53; prostate cancer; relaxin	GAIN-OF-FUNCTION; REFRACTORY PROSTATE-CANCER; PROTEIN-COUPLED RECEPTORS; SUPPRESSOR GENE P53; MUTANT P53; FUNCTION PHENOTYPE; FACTOR-I; CELLS; EXPRESSION; CARCINOMA	Mutations in p53 occur at a rate of approximately 70% in hormone-refractory prostate cancer (CaP), suggesting that p53 mutations facilitate the progression of CaP to androgen-independent ( AI) growth. We have previously reported that transfection of p53 gain of function mutant alleles into LNCaP, an androgen-sensitive cell line, allows for AI growth of LNCaP in vitro. We herein confirm the in vivo relevance of those findings by demonstrating that the R273H p53 mutation ( p53(R273H)) facilitates AI growth in castrated nude mice. In addition, we demonstrate that H2 relaxin is responsible for facilitating p53(R273H)-mediated AI CaP. H2 relaxin is overexpressed in the LNCaP-R273H subline. Downregulation of H2 relaxin expression results in significant inhibition of AI growth, whereas addition of recombinant human H2 relaxin to parental LNCaP promotes AI growth. Inhibition of AI growth was also achieved by blocking expression of LGR7, the cognate receptor of H2 relaxin. Chromatin immunoprecipitation analysis was used to demonstrate that p53(R273H) binds directly to the relaxin promoter, further confirming a role for H2 relaxin signaling in p53(R273H)-mediated AI CaP. Lastly, we used a reporter gene assay to demonstrate that H2 relaxin can induce the expression of prostate-specific antigen via an androgen receptor-mediated pathway.	Univ Calif Davis, Med Ctr, Dept Urol, Sch Med & Canc Ctr, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med & Canc Ctr, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med & Canc Ctr, Dept Pathol, Sacramento, CA USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	White, RWV (corresponding author), Univ Calif Davis, Med Ctr, Dept Urol, Sch Med & Canc Ctr, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	ralph.devere-white@ucdmc.ucdavis.edu	Vinall, Ruth/L-7026-2019; Tepper, Clifford G/H-6527-2011		NATIONAL CANCER INSTITUTE [R01CA077612] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77612] Funding Source: Medline; PHS HHS [R0192069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amorino GP, 2004, CRIT REV EUKAR GENE, V14, P287, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.40; Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Culig Z, 2005, ENDOCR-RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a; CULIG Z, 1994, CANCER RES, V54, P5474; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; El-Hizawi S, 2002, CANCER RES, V62, P3264; Figueiredo KA, 2005, ANN NY ACAD SCI, V1041, P320, DOI 10.1196/annals.1282.051; Garibay-Tupas JL, 2000, J MOL ENDOCRINOL, V24, P241, DOI 10.1677/jme.0.0240241; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; IVELL R, 1989, MOL CELL ENDOCRINOL, V66, P251, DOI 10.1016/0303-7207(89)90037-3; Ivell R, 2002, TRENDS ENDOCRIN MET, V13, P343, DOI 10.1016/S1043-2760(02)00664-1; Kasamon KM, 2004, CURR OPIN UROL, V14, P185, DOI 10.1097/00042307-200405000-00008; Koul HK, 2004, ANN NY ACAD SCI, V1030, P243, DOI 10.1196/annals.1329.030; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Palejwala S, 2002, BIOL REPROD, V66, P1743, DOI 10.1095/biolreprod66.6.1743; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Raj GV, 2002, J UROLOGY, V167, P1458, DOI 10.1016/S0022-5347(05)65345-1; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Samuel CS, 2003, LAB INVEST, V83, P1055, DOI 10.1097/01.LAB.0000079784.81186.B9; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Shi XB, 2004, BJU INT, V94, P996, DOI 10.1111/j.1464-410X.2004.05093.x; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Shi XB, 2002, PROSTATE, V51, P59, DOI 10.1002/pros.10072; Silvertown JD, 2006, INT J CANCER, V118, P62, DOI 10.1002/ijc.21288; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; STEMMERMANN GN, 1994, J ENDOCRINOL, V140, P321, DOI 10.1677/joe.0.1400321; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; TASHIMA LS, 1994, J MOL ENDOCRINOL, V12, P351, DOI 10.1677/jme.0.0120351; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Zhang Q, 2002, J CELL BIOCHEM, V85, P536, DOI 10.1002/jcb.10150; AFFYMETRIX GENECHIP	55	35	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2082	2093		10.1038/sj.onc.1209246	http://dx.doi.org/10.1038/sj.onc.1209246			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434975				2022-12-25	WOS:000236359700011
J	ten Dam, GB; Kurup, S; van De Westerlo, EMA; Versteeg, EMM; Lindahl, U; Spillmann, D; van Kuppevelt, TH				ten Dam, GB; Kurup, S; van De Westerlo, EMA; Versteeg, EMM; Lindahl, U; Spillmann, D; van Kuppevelt, TH			3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; ANTITHROMBIN-BINDING-SITE; HERPES-SIMPLEX-VIRUS; GLOMERULAR-BASEMENT-MEMBRANE; GROWTH-FACTOR FGF; HEPARIN/HEPARAN SULFATE; SUBSTRATE-SPECIFICITY; NEONATAL LETHALITY; HUMAN CDNAS; DOMAIN	Antibodies against heparan sulfate (HS) are useful tools to study the structural diversity of HS. They demonstrate the large sequential variation within HS and show the distribution of HS oligosaccharide sequences within their natural environment. We analyzed the distribution and the structural characteristics of the oligosaccharide epitope recognized by anti-HS antibody HS4C3. Biosynthetic and synthetic heparin-related oligosaccharide libraries were used in affinity chromatography, immunoprecipitation, and enzyme-linked immunosorbent assay to identify this epitope as a 3-O-sulfated motif with antithrombin binding capacity. The antibody binds weakly to any N-sulfated, 2-O- and 6-O-sulfated hexa- to octasaccharide fragment but strongly to the corresponding oligosaccharide when there is a 3-O-sulfated glucosamine residue present in the sequence. This difference was highlighted by affinity interaction and immunohistochemistry at salt concentrations from 500 mM. At physiological salt conditions the antibody strongly recognized basal lamina of epithelia and endothelia. At 500 mM salt conditions, when 3-O sulfation is required for binding, antibody recognition was more restricted and selective. Antibody HS4C3 bound similar tissue structures as antithrombin in rat kidney. Furthermore, antithrombin and antibody HS4C3 could compete with one another for binding to heparin. Antibody HS4C3 was also able to inhibit the anti-coagulant activities of heparin and Arixtra as demonstrated using the activated partial thromboplastin time clotting and the anti-factor Xa assays. In summary, antibody HS4C3 selectively detects 3-O-sulfated HS structures and interferes with the coagulation activities of heparin by association with the antithrombin binding pentasaccharide sequence.	Radboud Univ, Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Biochem 280, NL-6500 HB Nijmegen, Netherlands; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Radboud University Nijmegen; Uppsala University	van Kuppevelt, TH (corresponding author), Radboud Univ, Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Biochem 280, POB 9101, NL-6500 HB Nijmegen, Netherlands.	a.vankuppevelt@ncmls.ru.nl	van Kuppevelt, A.H.M.S.M./L-4463-2015	Versteeg, Elly/0000-0001-7047-5173				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chen JH, 2003, GLYCOBIOLOGY, V13, P785, DOI 10.1093/glycob/cwg101; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Duncan MB, 2004, BBA-GEN SUBJECTS, V1671, P34, DOI 10.1016/j.bbagen.2003.12.010; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; Edge ASB, 2000, DIABETOLOGIA, V43, P1056, DOI 10.1007/s001250051489; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; Jemth P, 2003, J BIOL CHEM, V278, P24371, DOI 10.1074/jbc.M212155200; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2002, BBA-GEN SUBJECTS, V1573, P319, DOI 10.1016/S0304-4165(02)00399-9; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Smits NC, 2004, AM J RESP CELL MOL, V30, P166, DOI 10.1165/rcmb.2003-0198OC; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; ten Dam GB, 2004, J BIOL CHEM, V279, P38346, DOI 10.1074/jbc.M404166200; ten Dam GB, 2003, J HISTOCHEM CYTOCHEM, V51, P727; Tiwari V, 2004, J GEN VIROL, V85, P805, DOI 10.1099/vir.0.19641-0; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; van de Westerlo EMA, 2002, BLOOD, V99, P2427, DOI 10.1182/blood.V99.7.2427; van den Born J, 2005, J BIOL CHEM, V280, P20516, DOI 10.1074/jbc.M502065200; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VANDELEST CHA, 1994, ANAL BIOCHEM, V221, P356, DOI 10.1006/abio.1994.1425; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200	53	89	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4654	4662		10.1074/jbc.M506357200	http://dx.doi.org/10.1074/jbc.M506357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373349	hybrid, Green Published			2022-12-25	WOS:000235426200013
J	Gao, ZG; He, Q; Peng, BL; Chiao, PJ; Ye, JP				Gao, ZG; He, Q; Peng, BL; Chiao, PJ; Ye, JP			Regulation of nuclear translocation of HDAC3 by I kappa B alpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; FIBROBLAST-GROWTH-FACTOR; GENE-EXPRESSION; PPAR-GAMMA; TRANSCRIPTIONAL ACTIVITY; PROTEIN-KINASE; ADIPOCYTE DIFFERENTIATION; DEPENDENT REPRESSION; 3T3-L1 ADIPOCYTES; BINDING PROTEIN	dInhibition of peroxisome proliferator-activated receptor gamma (PPAR gamma) function by TNF-alpha contributes to glucose and fatty acid metabolic disorders in inflammation and cancer, although the molecular mechanism is not fully understood. In this study, we demonstrate that nuclear translocation of HDAC3 is regulated by TNF-alpha, and this event is required for inhibition of transcriptional activity of PPAR gamma by TNF-alpha. HDAC3 is associated with I kappa B alpha in the cytoplasm. After I kappa B alpha degradation in response to TNF-alpha, HDAC3 is subject to nuclear translocation, leading to an increase in HDAC3 activity in the nucleus. This event leads to subcellular redistribution of HDAC3. Knock-out of I kappa B alpha, but not p65 or p50, leads to disappearance of HDAC3 in the cytoplasm, which is associated with HDAC3 enrichment in the nucleus. These data suggest that inhibition of PPAR gamma by TNF-alpha is not associated with a reduction in the DNA binding activity of PPAR gamma. Rather, these results suggest that I kappa B alpha-dependent nuclear translocation of HDAC3 is responsible for PPAR gamma inhibition by TNF-alpha.	Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Texas System; UTMD Anderson Cancer Center	Ye, JP (corresponding author), Louisiana State Univ Syst, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	yej@pbrc.edu	Ye, Jianping/N-1998-2017	Ye, Jianping/0000-0003-3875-365X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068036, R56DK068036] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK068036, DK068036, R56 DK068036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GRAVES RA, 1992, MOL CELL BIOL, V12, P3313; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Krogsdam AM, 2002, BIOCHEM J, V363, P157, DOI 10.1042/0264-6021:3630157; Lazar MA, 2001, NAT MED, V7, P23, DOI 10.1038/83301; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; SUZAWA M, 2003, NAT CELL BIOL; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Viatour P, 2003, J BIOL CHEM, V278, P46541, DOI 10.1074/jbc.M306381200; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	61	118	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4540	4547		10.1074/jbc.M507784200	http://dx.doi.org/10.1074/jbc.M507784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16371367	Green Accepted, hybrid			2022-12-25	WOS:000235275300090
J	Malinge, S; Monni, R; Bernard, O; Penard-Lacronique, V				Malinge, S.; Monni, R.; Bernard, O.; Penard-Lacronique, V.			Activation of the NF-kappa B pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKK alpha	ONCOGENE			English	Article							BCR-ABL; TRANSCRIPTION FACTOR; MYELOPROLIFERATIVE DISEASE; TYROSINE PHOSPHORYLATION; LYMPHOBLASTIC-LEUKEMIA; CELL-RECEPTOR; BINDING-SITE; KINASE; EXPRESSION; INDUCE	Abnormal activation of tyrosine kinases and of signaling pathways they control plays a critical role in the neoplastic process of human hematopoietic malignancy. The nuclear factor-kappa B (NF-kappa B) pathway is one of the signalings activated by the TEL-Jak2 and TEL-Abl oncoproteins and required for their antiapoptotic activity. To define the signal relay responsible for this activation, we used mouse embryonic fibroblast (MEF) cells and observed that TEL-Jak2- and TEL-Abl-mediated NF-kappa B induction was abolished in cells lacking the I kappa B kinase (IKK)alpha but not in IKK beta(-/-) cells. Similar observations were performed with oncogenic forms of the FMS-like tyrosine kinase 3 (Flt-3) involved in the pathogenesis of one-third of acute myeloid leukemias. Rescue of TEL-Jak2-mediated NF-kappa B activation was obtained with a kinase-proficient form of IKK alpha in IKK alpha(-/-) MEF. Hematopoietic cells transformed by TEL-Jak2 and TEL-Abl showed sustained IKK alpha activity without promotion of NF-kappa B2/p100 processing, generally associated to IKK alpha functions. Furthermore, IAP1, IAP2 and XIAP, which are central regulators of the NF-kappa B-mediated survival pathway, were highly expressed in cells transformed by these oncoproteins. Our results indicate that these oncogenic tyrosine kinases preferentially use an IKK alpha-dependent mechanism to induce a persistent NF-kappa B activity and allow the production of antiapoptotic effectors that participate to their leukemogenic properties.	Hop Necker Enfants Malad, F-75743 Paris, France; INSERM, U528, Sect Rech, Inst Curie, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Penard-Lacronique, V (corresponding author), Hop Necker Enfants Malad, EMI 0210,Tour Pasteur,149 Rue Sevres, F-75743 Paris, France.	penard@necker.fr	Malinge, Sebastien/AAK-1158-2021; Penard-Lacronique, Virginie/R-1938-2019; Malinge, Sebastien/AAP-9452-2021; Penard-Lacronique, Virginie/E-5729-2016; Malinge, Sebastien/B-3507-2014; Bernard, Olivier A./E-5721-2016	Malinge, Sebastien/0000-0002-9533-7778; Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Malinge, Sebastien/0000-0002-9533-7778; Bernard, Olivier/0000-0002-0463-9747				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Feinman R, 1999, BLOOD, V93, P3044; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kashkar H, 2003, J EXP MED, V198, P341, DOI 10.1084/jem.20021279; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kirchner D, 2003, EXP HEMATOL, V31, P504, DOI 10.1016/S0301-472X(03)00069-9; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Million RP, 2004, MOL CELL BIOL, V24, P4685, DOI 10.1128/MCB.24.11.4685-4695.2004; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Minami Y, 2003, BLOOD, V102, P2969, DOI 10.1182/blood-2002-12-3813; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; OMAHONY AM, 2004, J BIOL CHEM, V12, P12; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Perrotti D, 2004, ONCOGENE, V23, P3222, DOI 10.1038/sj.onc.1207543; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Piccolella E, 2003, J IMMUNOL, V170, P2895, DOI 10.4049/jimmunol.170.6.2895; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Santos SCR, 2001, FEBS LETT, V497, P148; SAVAGE KJ, 2003, BLOOD, V106, P1392; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Ten RM, 1999, J IMMUNOL, V163, P3851; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805	67	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3589	3597		10.1038/sj.onc.1209390	http://dx.doi.org/10.1038/sj.onc.1209390			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434962				2022-12-25	WOS:000238448200011
J	Yue, J; Xiong, W; Ferrell, JE				Yue, J; Xiong, W; Ferrell, JE			B-Raf and C-Raf are required for Ras-stimulated p42 MAP kinase activation in Xenopus egg extracts	ONCOGENE			English	Article						B-Raf; C-Raf; Mos; Ras; p42; MAPK; MEK1	SPINDLE ASSEMBLY CHECKPOINT; MAMMALIAN SOMATIC-CELLS; PROTEIN-KINASE; OOCYTE MATURATION; A-RAF; MITOTIC PROGRESSION; SIGNALING PATHWAY; P34CDC2 KINASE; BRAF MUTATIONS; ONCOGENIC RAS	During mitosis, a select pool of MEK1 and p42/p44 MAPK becomes activated at the kinetochores and spindle poles, without substantial activation of the bulk of the cytoplasmic p42/p44 MAPK. Recently, we set out to identify the MAP kinase kinase kinase ( MAPKKK) responsible for this mitotic activation, using cyclin-treated Xenopus egg extracts as a model system, and presented evidence that Mos was the relevant MAPKKK. However, a second MAPKKK distinct from Mos was readily detectable as well. Here, we partially purify this second MAPKKK and identify it as B-Raf. No changes in the activity of B-Raf were detectable during progesterone-induced oocyte maturation, after egg fertilization, or during the early embryonic cell cycle, arguing against a role for B-Raf in the mitotic activation of MEK1 and p42 MAPK. Ras proteins can bring about activation of MEK1 and p42 MAPK in extracts, and Ras may contribute to signaling from the classical progesterone receptor during oocyte maturation and from receptor tyrosine kinases during early embryogenesis. We found that both B-Raf and C-Raf, but not Mos, are required for Ras-induced MEK1 and p42 MAPK activation. These data indicate that two upstream stimuli, active Ras and active Cdc2, utilize different MAPKKKs to activate MEK1 and p42 MAPK.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Yue, J (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR Room 3160,269 W Campus Dr, Stanford, CA 94305 USA.	jyue@stanford.edu	Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bagowski CP, 2001, J BIOL CHEM, V276, P1459, DOI 10.1074/jbc.M008050200; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Colanzi A, 2003, J CELL BIOL, V161, P27, DOI 10.1083/jcb.200208099; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; EYCHENE A, 1995, ONCOGENE, V10, P1159; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Ferrell JE, 1999, BIOESSAYS, V21, P866, DOI 10.1002/(SICI)1521-1878(199910)21:10<866::AID-BIES9>3.0.CO;2-1; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTORI S, 1992, J BIOL CHEM, V267, P20346; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Maller JL, 2003, SCIENCE, V300, P594, DOI 10.1126/science.1083725; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MURAKAMI MS, 2001, SCI STKE, pPE30; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Park JY, 2004, SCIENCE, V303, P682, DOI 10.1126/science.1092463; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; VANRENTERGHEM B, 1993, J BIOL CHEM, V268, P19935; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Yue JB, 2004, CURR BIOL, V14, P1581, DOI 10.1016/j.cub.2004.08.056; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	64	4	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2006	25	23					3307	3315		10.1038/sj.onc.1209354	http://dx.doi.org/10.1038/sj.onc.1209354			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434971				2022-12-25	WOS:000237951200009
J	Xu, L; Chen, S; Bergan, RC				Xu, L.; Chen, S.; Bergan, R. C.			MAPKAPK2 and HSP27 are downstream effectors of p38MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer	ONCOGENE			English	Article						transforming growth factor beta; prostate cancer; invasion; mitogen-activated protein kinase-activated protein kinase 2; heat-shock protein 27; matrix metalloproteinase-2	HEAT-SHOCK PROTEINS; MAP KINASE; SIGNAL-TRANSDUCTION; FOCAL ADHESION; SMOOTH-MUSCLE; EXPRESSION; HEAT-SHOCK-PROTEIN-27; PHOSPHORYLATION; INHIBITOR; MECHANISMS	Although cell invasion is a necessary early step in cancer metastasis, its regulation is not well understood. We have previously shown, in human prostate cancer, that transforming growth factor ss (TGF ss)-mediated increases in cell invasion are dependent upon activation of the serine/threonine kinase, p38 MAP kinase. In the current study, downstream effectors of p38 MAP kinase were sought by first screening for proteins phosphorylated after TGF ss treatment, only in the absence of chemical inhibitors of p38 MAP kinase. This led us to investigate mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), a known substrate of p38 MAP kinase, as well as heat-shock protein 27 (HSP27), a known substrate of MAPKAPK2, in both PC3 and PC3-M human prostate cells. After transient transfection, wildtype MAPKAPK2 and HSP27 both increased TGF ss-mediated matrix metalloproteinase type 2 (MMP-2) activity, as well as cell invasion, which in turn was inhibited by SB203580, an inhibitor of p38 MAP kinase. Conversely, dominant-negative MAPKAPK2 blocked phosphorylation of HSP27, whereas dominant-negative MAPKAPK2 or mutant, non-phosphorylateable, HSP27 each blocked TGF ss-mediated increases in MMP-2, as well as cell invasion. Similarly, knock down of MAPKAPK2, HSP27 or both together, by siRNA, also blocked TGF ss-mediated cell invasion. This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGF ss-mediated increases in MMP-2 and cell invasion in human prostate cancer.	Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Canc Ctr, Chicago, IL USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Bergan, RC (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Hematol Oncol, McGaw 2301,240 E Huron St, Chicago, IL 60611 USA.	r-bergan@northwestern.edu	xu, li/D-5310-2009	xu, li/0000-0002-2153-1471	NATIONAL CANCER INSTITUTE [P50CA090386] Funding Source: NIH RePORTER; NCI NIH HHS [CA90386] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldrian S, 2002, CELL STRESS CHAPERON, V7, P177, DOI 10.1379/1466-1268(2002)007<0177:OOHATM>2.0.CO;2; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; CARROLL PR, 2001, CANC PRINCIPLES PRAC, P1418; Cornford PA, 2000, CANCER RES, V60, P7099; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Guay J, 1997, J CELL SCI, V110, P357; Hansen RK, 2001, BIOCHEM BIOPH RES CO, V282, P186, DOI 10.1006/bbrc.2001.4548; Hatakeyama D, 2002, BBA-MOL CELL RES, V1589, P15, DOI 10.1016/S0167-4889(01)00183-5; Hayes SA, 2003, ONCOGENE, V22, P4841, DOI 10.1038/sj.onc.1206730; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Liu YQ, 2000, CLIN EXP METASTAS, V18, P203, DOI 10.1023/A:1006729106034; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Ruoslahti E, 1996, SCI AM, V275, P72, DOI 10.1038/scientificamerican0996-72; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Schwartz GN, 1998, ANTISENSE NUCLEIC A, V8, P329, DOI 10.1089/oli.1.1998.8.329; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	33	156	183	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2987	2998		10.1038/sj.onc.1209337	http://dx.doi.org/10.1038/sj.onc.1209337			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407830				2022-12-25	WOS:000237950800003
J	Jeong, MH; Bae, J; Kim, WH; Yoo, SM; Kim, JW; Song, PI; Choi, KH				Jeong, MH; Bae, J; Kim, WH; Yoo, SM; Kim, JW; Song, PI; Choi, KH			p19(ras) interacts with and activates p73 by involving the MDM2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSICAL INTERACTION; TRANSCRIPTIONAL ACTIVATION; P53-RELATED PROTEIN; VIRAL ONCOPROTEINS; BINDING-PROTEIN; CELL-CYCLE; C-MYC; P53; RAS; APOPTOSIS	p73 beta is a structural and functional homologue of p53, a tumor suppressor gene. In this study, we identified a novel p73 beta-binding protein, p19(ras), by the yeast two-hybrid screening method. Alternative splicing of the proto-oncogene H-ras pre-mRNA has led to two distinct transcripts, p19(ras) and p21(ras). In both endogenous and overexpressed systems, we confirmed that p19(ras) binds to full-length p73 beta in vivo and in vitro. Coexpression of p19(ras) with p73 beta stimulated the transcriptional activity of p73 beta. Ras proteins are known to be small membrane-localized guanine nucleotide-binding proteins. However, unlike other Ras proteins, p19(ras) is localized in the nucleus and the cytosol and its interaction with p73 beta occurred exclusively in the nucleus. Oncogenic MDM2 ( mouse double minutes 2) is a known repressor of p73 transcriptional activity. In this study, when p19(ras) was bound to MDM2, it further inhibited the association of MDM2 to the p73 beta protein. In addition, p19(ras) abolished MDM2-mediated transcriptional repression of p73 beta. Therefore, this study presents a novel pathway of Ras signaling that occurs in the nucleus, involving p19(ras) and p73 beta. Furthermore, a p19(ras)-mediated novel regulatory mechanism of p73 involving the MDM2 protein is described.	Chung Ang Univ, Coll Nat Sci, Dept Biol Sci, Mol Biol Lab, Seoul 156756, South Korea; Pochon CHA Univ, Grad Sch Life Sci & Biotechnol, Lab Mol Om Therapy, Seongnam 463836, South Korea; Norean Natl Inst Hlth, Korea Ctr Dis Control & Prevent, Seoul 122701, South Korea; Univ Colorado, Hlth Sci Ctr, Dept Dermatol, Aurora, CO 80045 USA	Chung Ang University; Pochon Cha University; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); University of Colorado System; University of Colorado Anschutz Medical Campus	Choi, KH (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Biol Sci, Mol Biol Lab, Seoul 156756, South Korea.	khchoi@cau.ac.kr		Kim, Won-Ho/0000-0002-4849-472X; bae, jeehyeon/0000-0003-1995-1378				Agami R, 1999, NATURE, V399, P809; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; CHEN CY, 1995, ONCOGENE, V11, P1487; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; Guil S, 2003, CANCER RES, V63, P5178; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang KH, 2002, FEBS LETT, V522, P161, DOI 10.1016/S0014-5793(02)02921-6; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kim KC, 2001, ONCOGENE, V20, P6689, DOI 10.1038/sj.onc.1204839; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOODIE SA, 1995, ONCOGENE, V11, P447; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; Scharnhorst V, 2000, J BIOL CHEM, V275, P10202, DOI 10.1074/jbc.275.14.10202; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Vikhanskaya F, 2001, CANCER RES, V61, P935; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wurzer G, 2001, J CELL BIOCHEM, P1; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061; Zwahlen D, 2000, INT J CANCER, V88, P66	47	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8707	8715		10.1074/jbc.M513853200	http://dx.doi.org/10.1074/jbc.M513853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16436381	hybrid			2022-12-25	WOS:000236247100048
J	Shojania, S; O'Neil, JD				Shojania, S; O'Neil, JD			HIV-1 Tat is a natively unfolded protein - The solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-MAGNETIC-RESONANCE; HUMAN COACTIVATOR CBP; UREA-DENATURED STATE; MODEL-FREE APPROACH; BACKBONE DYNAMICS; STRUCTURAL-CHARACTERIZATION; CHEMICAL-SHIFT; SECONDARY STRUCTURE; FOLDED PROTEINS	Tat ( transactivator of transcription) is a small RNA- binding protein that plays a central role in the regulation of human immunodeficiency virus type 1 replication and in approaches to treating latently infected cells. Its interactions with a wide variety of both intracellular and extracellular molecules is well documented. A molecular understanding of the multitude of Tat activities requires a determination of its structure and interactions with cellular and viral partners. To increase the dispersion of NMR signals and permit dynamics analysis by multinuclear NMR spectroscopy, we have prepared uniformly N-15- and N-15/C-13- labeled Tat-( 1 - 72) protein. The cysteine- rich protein is unambiguously reduced at pH 4.1, and NMR chemical shifts and coupling constants suggest that it exists in a random coil conformation. Line broadening and multiple peaks in the Cys- rich and core regions suggest that transient folding occurs in two of the five sequence domains. NMR relaxation parameters were measured and analyzed by spectral density and Lipari- Szabo approaches, both confirming the lack of structure throughout the length of the molecule. The absence of a fixed conformation and the observation of fast dynamics are consistent with the ability of Tat protein to interact with a wide variety of proteins and nucleic acid and support the concept of a natively unfolded protein.	Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	O'Neil, JD (corresponding author), Univ Manitoba, Dept Chem, Winnipeg, MB R3T 2N2, Canada.	joneil@cc.umanitoba.ca	O'Neil, Joe/R-2356-2019	O'Neil, Joe/0000-0002-5917-0392				ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; Alimonti JB, 2003, J GEN VIROL, V84, P1649, DOI 10.1099/vir.0.19110-0; Andrec M, 1999, J MAGN RESON, V139, P408, DOI 10.1006/jmre.1999.1839; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; Avraham HK, 2004, J IMMUNOL, V173, P6228, DOI 10.4049/jimmunol.173.10.6228; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bannwarth S, 2005, CURR HIV RES, V3, P61, DOI 10.2174/1570162052772924; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bhavesh NS, 2003, J BIOL CHEM, V278, P19980, DOI 10.1074/jbc.M301615200; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bourgeois CF, 2002, MOL CELL BIOL, V22, P1079, DOI 10.1128/MCB.22.4.1079-1093.2002; Buevich AV, 2001, J BIOMOL NMR, V20, P233, DOI 10.1023/A:1011243116136; Campbell GR, 2004, J BIOL CHEM, V279, P48197, DOI 10.1074/jbc.M406195200; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DERSE D, 1991, J VIROL, V65, P7012, DOI 10.1128/JVI.65.12.7012-7015.1991; Dyson HJ, 1998, NAT STRUCT BIOL, V5, P499, DOI 10.1038/739; Dyson HJ, 2005, METHOD ENZYMOL, V394, P299, DOI 10.1016/S0076-6879(05)94011-1; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Farrow NA, 1997, BIOCHEMISTRY-US, V36, P2390, DOI 10.1021/bi962548h; Fink AL, 2005, CURR OPIN STRUC BIOL, V15, P35, DOI 10.1016/j.sbi.2005.01.002; FRANK MK, 1995, PROTEIN SCI, V4, P2605, DOI 10.1002/pro.5560041218; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FREUND J, 1995, J MOL BIOL, V250, P672, DOI 10.1006/jmbi.1995.0407; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; Gillespie JR, 1997, J MOL BIOL, V268, P170, DOI 10.1006/jmbi.1997.0953; Greenbaum NL, 1996, STRUCTURE, V4, P5, DOI 10.1016/S0969-2126(96)00003-2; Gregoire C, 2001, BIOPOLYMERS, V62, P324, DOI 10.1002/bip.10000; Gregoire CJ, 1996, J BIOL CHEM, V271, P22641, DOI 10.1074/jbc.271.37.22641; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Gunasekaran K, 2003, TRENDS BIOCHEM SCI, V28, P81, DOI 10.1016/S0968-0004(03)00003-3; Guo XF, 2003, VIROLOGY, V307, P154, DOI 10.1016/S0042-6822(02)00068-5; Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007; Habazettl J, 1996, BIOCHEMISTRY-US, V35, P9335, DOI 10.1021/bi952524v; Hakansson S, 2003, BIOCHEMISTRY-US, V42, P8999, DOI 10.1021/bi020715+; HU Y, 1990, J CHEM PHYS, V93, P822, DOI 10.1063/1.459452; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lassen K, 2004, TRENDS MOL MED, V10, P525, DOI 10.1016/j.molmed.2004.09.006; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; Linding R, 2003, NUCLEIC ACIDS RES, V31, P3701, DOI 10.1093/nar/gkg519; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Metzger AU, 1997, BIOCHEM BIOPH RES CO, V241, P31, DOI 10.1006/bbrc.1997.7770; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Opi S, 2004, VACCINE, V22, P3105, DOI 10.1016/j.vaccine.2004.01.057; Otzen DE, 2004, BIOCHEMISTRY-US, V43, P12964, DOI 10.1021/bi048509k; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Peloponese JM, 2000, CR ACAD SCI III-VIE, V323, P883, DOI 10.1016/S0764-4469(00)01228-2; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; Peti W, 2001, J BIOMOL NMR, V19, P153, DOI 10.1023/A:1008307323283; Plattt GW, 2005, J MOL BIOL, V346, P279, DOI 10.1016/j.jmb.2004.11.035; Pocernich CB, 2005, BRAIN RES REV, V50, P14, DOI 10.1016/j.brainresrev.2005.04.002; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Pumfery A, 2003, CURR HIV RES, V1, P343, DOI 10.2174/1570162033485186; Redfield C, 2004, METHODS, V34, P121, DOI 10.1016/j.ymeth.2004.03.009; Schulte A, 2005, J BIOL CHEM, V280, P24968, DOI 10.1074/jbc.M501431200; SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127; Schwalbe H, 1997, BIOCHEMISTRY-US, V36, P8977, DOI 10.1021/bi970049q; Schwarzinger S, 2002, BIOCHEMISTRY-US, V41, P12681, DOI 10.1021/bi020381o; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Seewald MJ, 1998, J BIOMOL STRUCT DYN, V16, P683, DOI 10.1080/07391102.1998.10508280; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; Smith SM, 2003, J BIOL CHEM, V278, P44816, DOI 10.1074/jbc.M307546200; Spyracopoulos L, 1996, J BIOMOL NMR, V7, P283, DOI 10.1007/BF00200430; SZYPERSKI T, 1993, J BIOMOL NMR, V3, P151; Tafer H, 2004, BIOCHEMISTRY-US, V43, P860, DOI 10.1021/bi0356606; Teilum K, 2002, J MOL BIOL, V324, P349, DOI 10.1016/S0022-2836(02)01039-2; Thormann T, 2004, BIOCHEMISTRY-US, V43, P10364, DOI 10.1021/bi0495679; Ulrich DL, 2005, J MOL BIOL, V347, P297, DOI 10.1016/j.jmb.2005.01.039; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; Vendel AC, 2004, BIOCHEMISTRY-US, V43, P904, DOI 10.1021/bi035612l; Vendel AC, 2003, BIOCHEMISTRY-US, V42, P910, DOI 10.1021/bi0270034; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P6464, DOI 10.1021/ja00093a069; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i; Yao J, 1997, FEBS LETT, V419, P285, DOI 10.1016/S0014-5793(97)01474-9; ZHANG O, 1995, BIOCHEMISTRY-US, V34, P6784, DOI 10.1021/bi00020a025; Zhang OW, 1997, J BIOMOL NMR, V9, P181, DOI 10.1023/A:1018658305040; [No title captured]	104	103	107	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8347	8356		10.1074/jbc.M510748200	http://dx.doi.org/10.1074/jbc.M510748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16423825	hybrid, Green Submitted			2022-12-25	WOS:000236247100008
J	Luo, WB; Wang, YF; Hanck, T; Stricker, R; Reiser, G				Luo, WB; Wang, YF; Hanck, T; Stricker, R; Reiser, G			Jab1, a novel protease-activated receptor-2 (PAR-2)-interacting protein, is involved in PAR-2-induced activation of activator protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARRESTIN-DEPENDENT ENDOCYTOSIS; MODULATE AP-1 ACTIVITY; MAST-CELL TRYPTASE; COP9 SIGNALOSOME; INTRACELLULAR PRECURSOR; THROMBIN RECEPTOR; PROSTAGLANDIN E-2; DOWN-REGULATION; RAT ASTROCYTES; 26S PROTEASOME	Protease-activated receptor-2 (PAR-2), a G protein-coupled receptor for trypsin and tryptase, exerts important physiological and pathological functions in multiple systems. However, unlike PAR-1, the PAR-2-mediated intracellular signal transductions are hardly known. Here, using yeast two-hybrid screening with a human brain cDNA library, we identified an interacting partner of human PAR-2, the Jun activation domain-binding protein 1 (Jab1). The interaction was confirmed by glutathione S-transferase pull-down assays in vitro, and by co-immunoprecipitation assays in vivo. Jab1 was also shown to be colocalized with PAR-2 in both transfected HEK293 cells and in normal primary human astrocytes by double immunofluorescence staining. Further experiments demonstrated that multiple intracellular domains of PAR-2 are required for the interaction with Jab1. We then showed that agonist stimulation of PAR-2 disrupted the interaction, which could be prevented by the inhibitor of receptor endocytosis phenylarsine oxide, but not by the lysosomal protease inhibitor ZPAD. Importantly, we found that activation of PAR-2 induced the redistribution of Jab1 from the plasma membrane to the cytosol, but did not influence expression of Jab1. Furthermore, Jab1 mediated PAR-2-induced c-Jun activation, which was followed by increased activation of activator protein-1. Loss-of-function studies, using Jab1 small interfering RNA, demonstrated that Jab1 knockdown blocked PAR-2-induced activator protein-1 activation. Taken together, our data demonstrate that Jab1 is an important effector that mediates a novel signal transduction pathway for PAR-2-dependent gene expression.	Otto Von Guericke Univ, Inst Neurobiochem, Fak Med, D-39120 Magdeburg, Germany	Otto von Guericke University	Reiser, G (corresponding author), Otto Von Guericke Univ, Inst Neurobiochem, Fak Med, Leipziger Str 44, D-39120 Magdeburg, Germany.	georg.reiser@medizin.uni-magdeburg.de		wang, yingfei/0000-0002-8723-252X; Luo, Weibo/0000-0002-1992-0320				Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; Ascoli M, 2005, ENDOCRINOLOGY, V146, P3221, DOI 10.1210/en.2005-0590; Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Burger-Kentischer A, 2005, FEBS LETT, V579, P1693, DOI 10.1016/j.febslet.2005.01.080; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Cottrell GS, 2003, BIOCHEM SOC T, V31, P1191; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; FENG DM, 1995, J MED CHEM, V38, P4125, DOI 10.1021/jm00020a029; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Hanck T, 2004, J NEUROCHEM, V88, P326, DOI 10.1046/j.1471-4159.2003.02143.x; Hirano K, 2005, J PHARMACOL SCI, V97, P31, DOI 10.1254/jphs.FMJ04005X6; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Jin G, 2005, J CEREBR BLOOD F MET, V25, P302, DOI 10.1038/sj.jcbfm.9600021; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lundberg AH, 2000, PANCREAS, V21, P41, DOI 10.1097/00006676-200007000-00050; Luo WB, 2005, BRAIN RES, V1047, P159, DOI 10.1016/j.brainres.2005.04.040; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Noorbakhsh F, 2003, NAT REV NEUROSCI, V4, P981, DOI 10.1038/nrn1255; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Schwechheimer C, 2004, BBA-MOL CELL RES, V1695, P45, DOI 10.1016/j.bbamcr.2004.09.023; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; SmithSwintosky VL, 1997, J NEUROCHEM, V69, P1890; Sokolova E, 2005, AM J PHYSIOL-LUNG C, V288, pL793, DOI 10.1152/ajplung.00343.2004; Somasundaram P, 2005, J PATHOL, V205, P102, DOI 10.1002/path.1690; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Temkin V, 2002, J IMMUNOL, V169, P2662, DOI 10.4049/jimmunol.169.5.2662; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Wang H, 2003, J NEUROCHEM, V84, P1349, DOI 10.1046/j.1471-4159.2003.01637.x; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Yun JS, 2004, J BIOL CHEM, V279, P31296, DOI 10.1074/jbc.M401411200	50	27	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7927	7936		10.1074/jbc.M510784200	http://dx.doi.org/10.1074/jbc.M510784200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16410250	hybrid			2022-12-25	WOS:000236031000028
J	Wootton, LL; Michelangeli, F				Wootton, LL; Michelangeli, F			The effects of the phenylalanine 256 to valine mutation on the sensitivity of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) Ca2+ pump isoforms 1, 2, and 3 to thapsigargin and other inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; AMINO-ACID 256; TRANSPORT ATPASE; CYCLOPIAZONIC ACID; CALCIUM PUMPS; CA2+-ATPASE; EXPRESSION; RESISTANCE; MECHANISM; CURCUMIN	Three isoforms of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) are known to exist in mammalian cells. This study investigated the effects of thapsigargin and a variety of commonly used hydrophobic inhibitors on these SERCA isoforms (i.e. SERCA1b, SERCA2b, and SERCA3a), which were transiently expressed in COS-7 cells. In addition, the study assessed whether the introduction of the phenylalanine to valine mutation at position 256 (F256V), known to reduce the potency of thapsigargin inhibition in avian SERCA1, affects the other SERCA isoforms in a similar manner and whether this mutation also affects the inhibition by other inhibitors. This study has shown that the sensitivity to thapsigargin is different for the SERCA isoforms ( apparent K-i values being 0.21, 1.3, and 12 nM for SERCA1b, SERCA2b, and SERCA3a, respectively). The reduction in thapsigargin sensitivity caused by the F256V mutation was also different for the three isoforms, with SERCA2b only being modestly affected by this mutation. Although some of the other inhibitors investigated (i.e. cyclopiazonic acid and curcumin) showed some differences in their sensitivity toward the SERCA isoforms, most were little affected by the F256V mutation, indicating that they inhibit the Ca2+-ATPase by binding to sites on SERCA distinct from that of thapsigargin.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Michelangeli, F (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	F.Michelangeli@bham.ac.uk						BAPP B, 1992, BIOCHEM J, V288, P297; Bilmen JG, 2002, EUR J BIOCHEM, V269, P3678, DOI 10.1046/j.1432-1033.2002.03060.x; Bilmen JG, 2002, CELL SIGNAL, V14, P955, DOI 10.1016/S0898-6568(02)00042-6; Bilmen JG, 2001, EUR J BIOCHEM, V268, P6318, DOI 10.1046/j.0014-2956.2001.02589.x; BURK SE, 1989, J BIOL CHEM, V264, P18561; Dyer JL, 2002, CELL CALCIUM, V31, P45, DOI 10.1054/ceca.2001.0259; GERSHONI JM, 1985, ANAL BIOCHEM, V144, P32, DOI 10.1016/0003-2697(85)90080-6; GOEGER DE, 1988, BIOCHEM PHARMACOL, V37, P978, DOI 10.1016/0006-2952(88)90195-5; Hughes PJ, 2000, BIOCHEM BIOPH RES CO, V277, P568, DOI 10.1006/bbrc.2000.3710; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; KASS GEN, 1989, J BIOL CHEM, V264, P15192; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Logan-Smith MJ, 2002, BIOCHEMISTRY-US, V41, P2869, DOI 10.1021/bi011938n; Longland CL, 1998, CELL CALCIUM, V24, P27, DOI 10.1016/S0143-4160(98)90086-0; Lopez JJ, 2005, BIOCHEM J, V390, P243, DOI 10.1042/BJ20050168; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MICHELANGELI F, 1990, BIOCHEMISTRY-US, V29, P3091, DOI 10.1021/bi00464a028; MICHELANGELI F, 1990, BIOCHEM J, V267, P423, DOI 10.1042/bj2670423; MURAYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Somura F, 2001, CIRCULATION, V104, P658, DOI 10.1161/hc3101.093869; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; Xu C, 2004, J BIOL CHEM, V279, P17973, DOI 10.1074/jbc.M313263200; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; Zador E, 1996, BIOCHEM J, V320, P107, DOI 10.1042/bj3200107	33	60	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6970	6976		10.1074/jbc.M510978200	http://dx.doi.org/10.1074/jbc.M510978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410239	hybrid			2022-12-25	WOS:000236030900009
J	Lindzen, M; Gottschalk, KE; Fuzesi, M; Garty, H; Karlish, SJD				Lindzen, M; Gottschalk, KE; Fuzesi, M; Garty, H; Karlish, SJD			Structural interactions between FXYD proteins and Na+,K+-ATPase - alpha/beta/FXYD subunit stoichiometry and cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; ALPHA-SUBUNIT; FUNCTIONAL INTERACTION; NA+/K+-ATPASE; OLIGOMERIC STRUCTURE; RENAL NA,K-ATPASE; K-ATPASE; CHIF; EXPRESSION; AFFINITY	Interactions of rat FXYD4 (corticosteroid hormone-induced factor (CHIF)), FXYD2 (gamma), or FXYD1 (phospholemman (PLM)) proteins with rat alpha 1 subunits of Na+,K+-ATPase have been analyzed by co-immunoprecipitation and covalent cross-linking. In detergent-solubilized membranes from HeLa cells expressing both gamma and CHIF or CHIF and hemagglutinin A-tagged CHIF, mixed complexes of CHIF and gamma or CHIF and hemagglutinin A-tagged CHIF with alpha/beta subunits are undetectable. This implies that the alpha/beta/FXYD protomer is the major species in detergent solution. A lipid-soluble cysteine-cysteine bifunctional reagent, dibromobimane, cross-links CHIF to alpha in colonic membranes but not gamma or PLM to alpha in kidney or heart membranes, respectively. Sequence comparisons of the FXYD proteins suggested that Cys-49 in the trans-membrane segment of CHIF could be involved. In detergent-solubilized HeLa cell membranes, dibromobimane cross-links wild-type CHIF to alpha but not the C49F mutant, and also the corresponding F36C mutant but not wild-type gamma b, and F48C but not wild-type PLM. C140S, C338A, C804A, and C966S mutants of the alpha subunit have been expressed. Only the C140S mutant prevents cross-linking with CHIF. The data demonstrated the proximity of trans-membrane segments of CHIF, gamma, and PLM to M2 of alpha. Molecular modeling is consistent with location of the trans-membrane segment of all FXYD proteins between M2, M6, and M9 and the proximity of Cys-49 of CHIF or Phe-36 of gamma with Cys-140 of M2. Cross-linking also demonstrated CHIF-alpha and CHIF-beta proximities in extra-membrane regions, similar to the evidence for gamma-alpha and gamma-beta cross-links.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Steven.Karlish@weizmann.ac.il	Gottschalk, Kay/D-6503-2012	Gottschalk, Kay/0000-0002-7951-0972				Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Askari A, 2000, INT CONGR SER, V1207, P17; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen E, 2005, J BIOL CHEM, V280, P16610, DOI 10.1074/jbc.M414290200; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE, pRE1; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; Garty H, 2005, SEMIN NEPHROL, V25, P304, DOI 10.1016/j.semnephrol.2005.03.005; Garty H, 2003, ANN NY ACAD SCI, V986, P395, DOI 10.1111/j.1749-6632.2003.tb07220.x; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Garty H, 2006, ANNU REV PHYSIOL, V68, P431, DOI 10.1146/annurev.physiol.68.040104.131852; Geering K, 2003, ANN NY ACAD SCI, V986, P388, DOI 10.1111/j.1749-6632.2003.tb07219.x; Gottschalk KE, 2004, J MOL GRAPH MODEL, V23, P99, DOI 10.1016/j.jmgm.2004.02.002; Gottschalk KE, 2004, BIOPHYS J, V86, P3335, DOI 10.1529/biophysj.103.034546; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hayashi Y, 1997, ANN NY ACAD SCI, V834, P19, DOI 10.1111/j.1749-6632.1997.tb52222.x; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; Jones DH, 2005, J BIOL CHEM, V280, P19003, DOI 10.1074/jbc.M500697200; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KIM JS, 1995, ANAL BIOCHEM, V225, P174, DOI 10.1006/abio.1995.1131; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; Koster JC, 1997, ANN NY ACAD SCI, V834, P135, DOI 10.1111/j.1749-6632.1997.tb52240.x; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Laughery M, 2004, J BIOL CHEM, V279, P36339, DOI 10.1074/jbc.M402778200; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LINDZEN M, 2005, J GEN PHYSIOL, V126, pA51; MacLennan DH, 2003, ANN NY ACAD SCI, V986, P472, DOI 10.1111/j.1749-6632.2003.tb07231.x; Mahmmoud YA, 2005, J BIOL CHEM, V280, P27776, DOI 10.1074/jbc.M503150200; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; Martin DW, 2000, P NATL ACAD SCI USA, V97, P3195, DOI 10.1073/pnas.050558397; Martin DW, 2000, J BIOL CHEM, V275, P24512, DOI 10.1074/jbc.M003179200; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MIMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1145, P63, DOI 10.1016/0005-2736(93)90382-A; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Strugatsky D, 2005, BIOCHEMISTRY-US, V44, P15961, DOI 10.1021/bi051921v; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Wald H, 1996, AM J PHYSIOL-RENAL, V271, pF322, DOI 10.1152/ajprenal.1996.271.2.F322; Wald H, 1997, AM J PHYSIOL-RENAL, V272, pF617, DOI 10.1152/ajprenal.1997.272.5.F617; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; Wetzel RK, 2004, J BIOL CHEM, V279, P41750, DOI 10.1074/jbc.M405622200; Zouzoulas A, 2005, J MEMBRANE BIOL, V204, P49, DOI 10.1007/s00232-005-0746-7; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	58	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5947	5955		10.1074/jbc.M512063200	http://dx.doi.org/10.1074/jbc.M512063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373350	hybrid			2022-12-25	WOS:000235568900075
J	Constantinidou, C; Hobman, JL; Griffiths, L; Patel, MD; Penn, CW; Cole, JA; Overton, TW				Constantinidou, C; Hobman, JL; Griffiths, L; Patel, MD; Penn, CW; Cole, JA; Overton, TW			A reassessment of the FNR regulon and transcriptomic analysis of the effects of nitrate, nitrite, NarXL, and NarQP as Escherichia coli K12 adapts from aerobic to anaerobic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR GENETIC-ANALYSIS; OXIDE REDUCTASE GENE; COLI NIR PROMOTER; OPERON EXPRESSION; IN-VITRO; RESPONSIVE REGULATOR; DEPENDENT ACTIVATION; OXYGEN AVAILABILITY; ELECTRON-ACCEPTORS; PROTEIN	The transcription factor FNR, the regulator of fumarate and nitrate reduction, regulates major changes as Escherichia coli adapts from aerobic to anaerobic growth. In an anaerobic glycerol/ trimethylamine N-oxide/fumarate medium, the fnr mutant grew as well as the parental strain, E. coli K12 MG1655, enabling us to reveal the response to oxygen, nitrate, and nitrite in the absence of glucose repression or artifacts because of variations in growth rate. Hence, many of the discrepancies between previous microarray studies of the E. coli FNR regulon were resolved. The current microarray data confirmed 31 of the previously characterized FNR-regulated operons. Forty four operons not previously known to be included in the FNR regulon were activated by FNR, and a further 28 operons appeared to be repressed. For each of these operons, a match to the consensus FNR-binding site sequence was identified. The FNR regulon therefore minimally includes at least 103, and possibly as many as 115, operons. Comparison of transcripts in the parental strain and a narXL deletion mutant revealed that transcription of 51 operons is activated, directly or indirectly, by NarL, and a further 41 operons are repressed. The narP gene was also deleted from the narXL mutant to reveal the extent of regulation by phosphorylated NarP. Fourteen promoters were more active in the narP(+) strain than in the mutant, and a further 37 were strongly repressed. This is the first report that NarP might function as a global repressor as well as a transcription activator. The data also revealed possible new defense mechanisms against reactive nitrogen species.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Overton, TW (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	t.w.overton@bham.ac.uk	Overton, Tim W/F-3284-2011	Overton, Tim W/0000-0003-3050-2549; Hobman, Jon/0000-0003-0998-9444				Anderson LA, 2000, J BACTERIOL, V182, P7035, DOI 10.1128/JB.182.24.7035-7043.2000; Anjum MF, 2000, MICROBIOL-SGM, V146, P3157, DOI 10.1099/00221287-146-12-3157; APARICIO O, 2005, CURRENT PROTOCOLS MO; BEARSON SM, 2002, BMC MICROBIOL, V12, P2; BEAUMONT MD, 1993, J GEN MICROBIOL, V139, P2677, DOI 10.1099/00221287-139-11-2677; BELL AI, 1990, MOL MICROBIOL, V4, P1753, DOI 10.1111/j.1365-2958.1990.tb00553.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; BONNEFOY V, 1992, MOL MICROBIOL, V6, P3595; Boston T, 2003, J BACTERIOL, V185, P5310, DOI 10.1128/JB.185.17.5310-5313.2003; Browning DF, 2000, MOL MICROBIOL, V37, P1258, DOI 10.1046/j.1365-2958.2000.02087.x; Browning DF, 2005, MOL MICROBIOL, V57, P496, DOI 10.1111/j.1365-2958.2005.04701.x; Browning DF, 2004, MOL MICROBIOL, V53, P203, DOI 10.1111/j.1365-2958.2004.04104.x; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; Cook GM, 1997, J BACTERIOL, V179, P6525, DOI 10.1128/jb.179.20.6525-6530.1997; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Cunningham L, 1997, MICROBIOL-UK, V143, P3795, DOI 10.1099/00221287-143-12-3795; da Costa PN, 2003, FEMS MICROBIOL LETT, V218, P385, DOI 10.1016/S0378-1097(02)01186-2; DARIE S, 1994, J BACTERIOL, V176, P5270, DOI 10.1128/JB.176.17.5270-5276.1994; Darwin AJ, 1998, J BACTERIOL, V180, P4192, DOI 10.1128/JB.180.16.4192-4198.1998; Darwin AJ, 1996, MOL MICROBIOL, V20, P621, DOI 10.1046/j.1365-2958.1996.5491074.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; DRAPAL N, 1995, J BACTERIOL, V177, P5338, DOI 10.1128/jb.177.18.5338-5341.1995; Eichler K, 1996, J BACTERIOL, V178, P1248, DOI 10.1128/jb.178.5.1248-1257.1996; EIGLMEIER K, 1989, MOL MICROBIOL, V3, P869, DOI 10.1111/j.1365-2958.1989.tb00236.x; Filenko NA, 2005, BIOCHEM SOC T, V33, P195, DOI 10.1042/BST0330195; Flatley J, 2005, J BIOL CHEM, V280, P10065, DOI 10.1074/jbc.M410393200; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Golby P, 1998, J BACTERIOL, V180, P6586, DOI 10.1128/JB.180.24.6586-6596.1998; Govantes F, 2000, MOL MICROBIOL, V38, P1061, DOI 10.1046/j.1365-2958.2000.02215.x; Grainger DC, 2004, J BACTERIOL, V186, P6938, DOI 10.1128/JB.186.20.6938-6943.2004; GREEN J, 1994, MOL MICROBIOL, V12, P433, DOI 10.1111/j.1365-2958.1994.tb01032.x; Green J, 1996, MOL MICROBIOL, V19, P125, DOI 10.1046/j.1365-2958.1996.353884.x; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; GUNSALUS RP, 1994, RES MICROBIOL, V145, P437, DOI 10.1016/0923-2508(94)90092-2; Hasona A, 2001, ARCH MICROBIOL, V175, P178, DOI 10.1007/s002030100252; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; IUCHI S, 1990, J BACTERIOL, V172, P179, DOI 10.1128/JB.172.1.179-184.1990; JENNINGS MP, 1993, MOL MICROBIOL, V9, P155, DOI 10.1111/j.1365-2958.1993.tb01677.x; JONES HM, 1987, J BACTERIOL, V169, P3340, DOI 10.1128/jb.169.7.3340-3349.1987; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Jourlin C, 1996, J BACTERIOL, V178, P1219, DOI 10.1128/jb.178.4.1219-1223.1996; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Kim SJ, 1999, IUBMB LIFE, V48, P215, DOI 10.1080/713803496; LAMBDEN PR, 1976, J GEN MICROBIOL, V97, P145, DOI 10.1099/00221287-97-2-145; Lamberg KE, 2000, MOL MICROBIOL, V38, P817, DOI 10.1046/j.1365-2958.2000.02172.x; LI J, 1992, J BACTERIOL, V174, P4935, DOI 10.1128/JB.174.15.4935-4942.1992; Malpica R, 2004, P NATL ACAD SCI USA, V101, P13318, DOI 10.1073/pnas.0403064101; Marshall FA, 2001, MOL MICROBIOL, V39, P747, DOI 10.1046/j.1365-2958.2001.02262.x; McNicholas PM, 1998, MOL MICROBIOL, V27, P197, DOI 10.1046/j.1365-2958.1998.00675.x; Melville SB, 1996, P NATL ACAD SCI USA, V93, P1226, DOI 10.1073/pnas.93.3.1226; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7571; Messenger SL, 2003, FEMS MICROBIOL LETT, V228, P81, DOI 10.1016/S0378-1097(03)00726-2; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Notley L, 1996, J BACTERIOL, V178, P1465, DOI 10.1128/jb.178.5.1465-1468.1996; Notley-McRobb L, 2002, J BACTERIOL, V184, P806, DOI 10.1128/JB.184.3.806-811.2002; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POPE NR, 1982, J GEN MICROBIOL, V128, P219; Potter LC, 1999, BIOCHEM J, V344, P77, DOI 10.1042/0264-6021:3440077; RABIN RS, 1993, J BACTERIOL, V175, P3259, DOI 10.1128/jb.175.11.3259-3268.1993; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Rodionov DA, 2006, PLOS COMPUT BIOL, V2, P1568, DOI 10.1371/journal.pcbi.0020163; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; SAWERS RG, 1988, ARCH MICROBIOL, V149, P240, DOI 10.1007/BF00422011; Scott C, 2003, FEBS LETT, V541, P97, DOI 10.1016/S0014-5793(03)00312-0; Soballe B, 1997, FEBS LETT, V414, P373, DOI 10.1016/S0014-5793(97)01041-7; SPIRO S, 1987, J GEN MICROBIOL, V133, P3279; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; Stewart V, 2003, J BACTERIOL, V185, P5862, DOI 10.1128/JB.185.19.5862-5870.2003; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; TAKAHASHI K, 1994, FEBS LETT, V340, P59, DOI 10.1016/0014-5793(94)80173-8; Tyson K, 1997, ARCH MICROBIOL, V168, P240, DOI 10.1007/s002030050494; WALKER MS, 1991, MOL MICROBIOL, V5, P353, DOI 10.1111/j.1365-2958.1991.tb02116.x; Wang HN, 1999, J BACTERIOL, V181, P5303, DOI 10.1128/JB.181.17.5303-5308.1999; WONG KK, 1992, FEMS MICROBIOL LETT, V94, P15; Wu HC, 1998, MOL MICROBIOL, V27, P493, DOI 10.1046/j.1365-2958.1998.00699.x; Wyborn NR, 2004, MICROBIOL-SGM, V150, P1495, DOI 10.1099/mic.0.26877-0; Zheng DL, 2004, NUCLEIC ACIDS RES, V32, P5874, DOI 10.1093/nar/gkh908; Zientz E, 1999, J BACTERIOL, V181, P3716, DOI 10.1128/JB.181.12.3716-3720.1999; Zientz E, 1996, J BACTERIOL, V178, P7241, DOI 10.1128/jb.178.24.7241-7247.1996	88	217	223	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4802	4815		10.1074/jbc.M512312200	http://dx.doi.org/10.1074/jbc.M512312200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377617	hybrid			2022-12-25	WOS:000235426200031
J	Billington, RA; Bellomo, EA; Floriddia, EM; Erriquez, J; Distasi, C; Genazzani, AA				Billington, RA; Bellomo, EA; Floriddia, EM; Erriquez, J; Distasi, C; Genazzani, AA			A transport mechanism for NAADP in a rat basophilic cell line	FASEB JOURNAL			English	Article						pyridine nucleotides; calcium; RBL-2H3 cell line; cADPR	ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; PANCREATIC-ACINAR-CELLS; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR; MOBILIZES CA2+; BETA-CELLS; CALCIUM	NAADP is a second messenger that releases Ca2+ from intracellular stores. Surprisingly, it has been recently shown that extracellular application of NAADP is capable of inducing intracellular Ca2+ release. This is particularly important since the only mammalian enzymes known to catalyze the synthesis of this second messenger are located extracellularly. In the present manuscript, we have investigated whether mammalian cells possess a transport system capable of transporting this highly charged molecule into cells. Indeed, in RBL-2H3 cells, a rat basophilic cell line, and in SK-N-BE cells, a neuroblastoma cell line, [P-32]NAADP is efficiently transported inside cells. NAADP transport is Na+ and Ca2+ dependent, is partially blocked by dipyridamole, but is unaffected by nitrobenzylthioinosine. RBL-2H3 cells also transport [P-32] cADPR, but the differences in the pharmacological profile suggest that NAADP transport proceeds by a novel mechanism. Lastly, extracellular application of NAADP, but not NADP, induced a raise in intracellular Ca2+. This is the first demonstration that NAADP is transported into cells and highlights the possibility that, alongside a second messenger, NAADP might also act as an autocrine/paracrine signal.	DiSCAFF, I-28100 Novara, Italy; Univ Piemonte Orientale, DFB Ctr, I-28100 Novara, Italy	University of Eastern Piedmont Amedeo Avogadro	Billington, RA (corresponding author), DiSCAFF, Via Bovio 6, I-28100 Novara, Italy.	billington@pharm.unipmn.it	Billington, Richard/HGB-1970-2022; Genazzani, Armando/AAI-8280-2020; Distasi, Carla/AAE-1839-2021	Distasi, Carla/0000-0001-8815-3252; Floriddia, Elisa/0000-0003-2304-8114; Billington, Richard/0000-0001-7288-8916; Genazzani, Armando/0000-0003-1923-7430; erriquez, jessica/0000-0002-7152-0930; Bellomo, Elisa/0000-0003-4823-2209				Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Billington RA, 2000, BIOCHEM BIOPH RES CO, V276, P112, DOI 10.1006/bbrc.2000.3444; Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; Churamani D, 2004, BIOCHEM J, V380, P449, DOI 10.1042/BJ20031754; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; De Flora A, 1997, INT J BIOCHEM CELL B, V29, P1149, DOI 10.1016/S1357-2725(97)00062-9; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Galione A, 2005, MOL INTERV, V5, P73, DOI 10.1124/mi.5.2.4; Genazzani AA, 2002, CURR BIOL, V12, pR432, DOI 10.1016/S0960-9822(02)00918-1; Genazzani AA, 1996, J BIOL CHEM, V271, P11599, DOI 10.1074/jbc.271.20.11599; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; Guida L, 2004, J BIOL CHEM, V279, P22066, DOI 10.1074/jbc.M314137200; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Heidemann AC, 2005, J BIOL CHEM, V280, P35630, DOI 10.1074/jbc.M507338200; Hohenegger M, 1999, BRIT J PHARMACOL, V128, P1235, DOI 10.1038/sj.bjp.0702935; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lee HC, 1998, BBA-GEN SUBJECTS, V1425, P263, DOI 10.1016/S0304-4165(98)00079-8; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Patel S, 2000, J BIOL CHEM, V275, P36495, DOI 10.1074/jbc.C000458200; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Thomas JM, 2001, BIOCHEM J, V359, P451, DOI 10.1042/0264-6021:3590451; Thorn JA, 1996, GEN PHARMACOL, V27, P613, DOI 10.1016/0306-3623(95)02053-5; Yamasaki M, 2005, CURR BIOL, V15, P874, DOI 10.1016/j.cub.2005.04.033; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200	36	41	41	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					521	+		10.1096/fj.05-5058fje	http://dx.doi.org/10.1096/fj.05-5058fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403787				2022-12-25	WOS:000235996000029
J	Ledda-Columbano, GM; Molotzu, F; Pibiri, M; Cossu, C; Perra, A; Columbano, A				Ledda-Columbano, GM; Molotzu, F; Pibiri, M; Cossu, C; Perra, A; Columbano, A			Thyroid hormone induces cyclin D1 nuclear translocation and DNA synthesis in adult rat cardiomyocytes	FASEB JOURNAL			English	Article						T3; BrdU; cyclins	HEPATOCYTE PROLIFERATION; CELL-PROLIFERATION; IN-VIVO; RETINOBLASTOMA PROTEIN; EXPRESSION; HYPERTROPHY; HEART; PHOSPHORYLATION; RECEPTOR; GENES	Although mammalian cardiomyocytes lose their proliferative capacity after birth, there is evidence that postmitotic cardiomyocytes can proliferate provided that cyclin D1 accumulates in the nucleus. Here we show by Northern blot, Western analysis, and immunohistochemistry that 3,5,3'-triiodothyronine (T3) treatment of adult rats caused an increase of cyclin D1 mRNA and protein levels. The increased cyclin D1 protein content was associated with its translocation into the nucleus of cardiomyocytes. These changes were accompanied by the re-entry of cardiomyocytes into the cell cycle, as demonstrated by increased levels of cyclin A, PCNA, and incorporation of bromodeoxyuridine into DNA (labeling index was 30.2% in T3-treated rats vs. 2.2% in controls). Entry into the S phase was associated with an increased mitotic activity as demonstrated by positivity of cardiomyocyte nuclei to antibodies anti-phosphohistone-3, a specific marker of the mitotic phase (mitotic index was 3.01/1000 cardiomyocte nuclei in hyperthyroid rats vs. 0.04 in controls). No biochemical or histological signs of tissue damage were observed in the heart of T3-treated rats. These results demonstrated that T3 treatment is associated with a re-entry of cardiomyocytes into the cell cycle and so may be important for the development of future therapeutic strategies aimed at inducing proliferation of cardiomyocytes.-Ledda-Columbano, G. M., Molotzu, F., Pibiri, M., Cossu, C., Perra, A., Columbano, A. Thyroid hormone induces cyclin D1 nuclear translocation and DNA synthesis in adult rat cardiomyocytes.	Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, I-09124 Cagliari, Italy	University of Cagliari	Ledda-Columbano, GM (corresponding author), Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, Via Porcell 4, I-09124 Cagliari, Italy.	gmledda@unica.it	Columbano, Amedeo/C-7463-2011	Columbano, Amedeo/0000-0002-6956-9030; PIBIRI, MONICA/0000-0002-9660-9616				Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; ASTORRI E, 1977, J MOL CELL CARDIOL, V9, P763, DOI 10.1016/S0022-2828(77)80021-7; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Busk PK, 2002, CARDIOVASC RES, V56, P64, DOI 10.1016/S0008-6363(02)00510-2; Chaudhry HW, 2004, J BIOL CHEM, V279, P35858, DOI 10.1074/jbc.M404975200; De K, 2004, J ENDOCRINOL, V182, P303, DOI 10.1677/joe.0.1820303; DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Gonzalez-Sancho JM, 2002, MOL CARCINOGEN, V34, P25, DOI 10.1002/mc.10046; Hasmall S, 2001, ARCH TOXICOL, V75, P357, DOI 10.1007/s002040100246; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; JACKSON T, 1991, MOL CELL BIOCHEM, V104, P15; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Klein I, 2001, NEW ENGL J MED, V344, P501, DOI 10.1056/NEJM200102153440707; KLEIN I, 1986, J CLIN INVEST, V77, P1694, DOI 10.1172/JCI112488; KLEIN I, 1988, ENDOCRINOLOGY, V123, P203, DOI 10.1210/endo-123-1-203; Ledda-Columbano GM, 2005, J ENDOCRINOL, V185, P393, DOI 10.1677/joe.1.06110; Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018; Liao HS, 2001, CIRC RES, V88, P443; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; LINZBACH AJ, 1960, AM J CARDIOL, V5, P370, DOI 10.1016/0002-9149(60)90084-9; LORTET S, 1989, J CARDIOVASC PHARM, V14, P707, DOI 10.1097/00005344-198911000-00006; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; Natsume H, 2003, BIOCHEM BIOPH RES CO, V309, P408, DOI 10.1016/j.bbrc.2003.08.019; Ohmura T, 1996, LIFE SCI, V58, pPL211, DOI 10.1016/0024-3205(96)00039-2; Ojamaa K, 2000, ENDOCRINOLOGY, V141, P2139, DOI 10.1210/en.141.6.2139; OJAMAA K, 1992, AM J PHYSIOL, V263, pE534, DOI 10.1152/ajpendo.1992.263.3.E534; Pasumarthi KBS, 2005, CIRC RES, V96, P110, DOI 10.1161/01.RES.0000152326.91223.4F; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Sadoshima J, 1997, CIRC RES, V80, P228, DOI 10.1161/01.RES.80.2.228; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soonpaa MH, 1997, J CLIN INVEST, V99, P2644, DOI 10.1172/JCI119453; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; TAMALE-SALI E G, 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P19, DOI 10.3109/01443619209029911; Tamamori M, 1998, AM J PHYSIOL-HEART C, V275, pH2036, DOI 10.1152/ajpheart.1998.275.6.H2036; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; von Harsdorf R, 2004, LANCET, V363, P1306, DOI 10.1016/S0140-6736(04)16006-6; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	47	34	37	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					87	94		10.1096/fj.05-4202com	http://dx.doi.org/10.1096/fj.05-4202com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394271				2022-12-25	WOS:000235996000048
J	Kubota, N; Terauchi, Y; Kubota, T; Kumagai, H; Itoh, S; Satoh, H; Yano, W; Ogata, H; Tokuyama, K; Takamoto, I; Mineyama, T; Ishikawa, M; Moroi, M; Sugi, K; Yamauchi, T; Ueki, K; Tobe, K; Noda, T; Nagai, R; Kadowaki, T				Kubota, N; Terauchi, Y; Kubota, T; Kumagai, H; Itoh, S; Satoh, H; Yano, W; Ogata, H; Tokuyama, K; Takamoto, I; Mineyama, T; Ishikawa, M; Moroi, M; Sugi, K; Yamauchi, T; Ueki, K; Tobe, K; Noda, T; Nagai, R; Kadowaki, T			Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-RELATED PROTEIN; ACTIVATED RECEPTOR-GAMMA; NECROSIS-FACTOR-ALPHA; FATTY-ACID OXIDATION; OBESE ZUCKER RATS; PPAR-GAMMA; ADIPOSE-TISSUE; ADIPOCYTE; GLUCOSE; MICE	Thiazolidinediones have been shown to up-regulate adiponectin expression in white adipose tissue and plasma adiponectin levels, and these up-regulations have been proposed to be a major mechanism of the thiazolidinedione-induced amelioration of insulin resistance linked to obesity. To test this hypothesis, we generated adiponectin knock-out (adipo(-/-)) ob/ob mice with a C57B/6 background. After 14 days of 10 mg/kg pioglitazone, the insulin resistance and diabetes of ob/ob mice were significantly improved in association with significant up-regulation of serum adiponectin levels. Amelioration of insulin resistance in ob/ob mice was attributed to decreased glucose production and increased AMP-activated protein kinase in the liver but not to increased glucose uptake in skeletal muscle. In contrast, insulin resistance and diabetes were not improved in adipo(-/-) ob/ob mice. After 14 days of 30 mg/kg pioglitazone, insulin resistance and diabetes of ob/ob mice were again significantly ameliorated, which was attributed not only to decreased glucose production in the liver but also to increased glucose uptake in skeletal muscle. Interestingly, adipo(-/-) ob/ob mice also displayed significant amelioration of insulin resistance and diabetes, which was attributed to increased glucose uptake in skeletal muscle but not to decreased glucose production in the liver. The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo(-/-) ob/ob mice were unchanged after 10 mg/kg pioglitazone but were significantly reduced to a similar degree after 30 mg/kg pioglitazone. Moreover, the expressions of TNF alpha and resistin in adipose tissues of ob/ob and adipo(-/-) ob/ob mice were unchanged after 10 mg/kg pioglitazone but were decreased after 30 mg/kg pioglitazone. Thus, pioglitazone-induced amelioration of insulin resistance and diabetes may occur adiponectin dependently in the liver and adiponectin independently in skeletal muscle.	Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Natl Inst Hlth & Nutr, Div Appl Nutr, Tokyo 1628636, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3050006, Japan; Toho Univ, Ohashi Hosp, Div Cardiovasc Med, Tokyo 1538515, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1358550, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan	University of Tokyo; National Institute of Health & Nutrition - Japan; University of Tsukuba; Toho University; Japanese Foundation for Cancer Research; Tohoku University; University of Tokyo	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Terauchi, Yasuo/AAO-4347-2020; Kubota, Naoto/N-7892-2015	Yano, Wataru/0000-0002-6866-8520; Itoh, Shinsuke/0000-0001-9567-8188				Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; Chandran M, 2003, DIABETES CARE, V26, P2442, DOI 10.2337/diacare.26.8.2442; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hirose H, 2002, METABOLISM, V51, P314, DOI 10.1053/meta.2002.30506; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Mauvais-Jarvis F, 2000, DIABETES METAB, V26, P433; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P802; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Suzuki R, 2004, J BIOL CHEM, V279, P25039, DOI 10.1074/jbc.M311956200; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Wellen KE, 2004, ENDOCRINOLOGY, V145, P2214, DOI 10.1210/en.2003-1580; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968	41	261	278	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8748	8755		10.1074/jbc.M505649200	http://dx.doi.org/10.1074/jbc.M505649200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431926	hybrid			2022-12-25	WOS:000236247100053
J	Lu, J; Lin, WH; Chen, SY; Longnecker, R; Tsai, SC; Chen, CL; Tsai, CH				Lu, J; Lin, WH; Chen, SY; Longnecker, R; Tsai, SC; Chen, CL; Tsai, CH			Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CYTOPLASMIC DOMAINS; SH2 DOMAINS; SIGNAL-TRANSDUCTION; NASOPHARYNGEAL CARCINOMA; REGULATES REACTIVATION; ANTIGEN RECEPTOR; IN-VIVO; ACTIVATION; LMP2A; PHOSPHORYLATION	Although spleen tyrosine kinase (Syk) is known to be important in hematopoietic cell development, the roles of Syk in epithelial cells have not been well studied. Limited data suggest that Syk plays alternate roles in carcinogenesis under different circumstances. In breast cancer, Syk has been suggested to be a tumor suppressor. In contrast, Syk is essential for murine mammary tumor virus-mediated transformation. However, the roles of Syk in tumor migration are still largely unknown. Nasopharyngeal carcinoma, an unusually highly metastatic tumor, expresses Epstein-Barr virus LMP2A (latent membrane protein 2A) in most clinical specimens. Previously, we demonstrated LMP2A triggers epithelial cell migration. LMP2A contains an immunoreceptor tyrosine-based activation motif, which is important for Syk kinase activation in B cells. In this study, we explored whether Syk is important for LMP2A-mediated epithelial cell migration. We demonstrate that LMP2A expression can activate endogenous Syk activity. The activation requires the tyrosine residues in LMP2A ITAM but not YEEA motif, which is important for Syk activation by Lyn in B cells. LMP2A interacts with Syk as demonstrated by coimmunoprecipitation and confocal microscopy. Furthermore, LMP2A-induced cell migration is inhibited by a Syk inhibitor and short interfering RNA. Tyrosines 74 and 85 in the LMP2A immunoreceptor tyrosine-based activation motif are essential for both Syk activation and LMP2A-mediated cell migration, indicating the involvement of Syk in LMP2A-triggered cell migration. The LMP2A-Syk pathway may provide suitable drug targets for treatment of nasopharyngeal carcinoma.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10063, Taiwan; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Natl Taiwan Univ, Coll Med, Dept Pathol, Taipei 10063, Taiwan	National Taiwan University; Northwestern University; National Taiwan University	Tsai, CH (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Rm 714,Number 1,Sect 1,Jen Ai Rd, Taipei 10063, Taiwan.	chtsai@ha.mc.ntu.edu.tw			NATIONAL CANCER INSTITUTE [R01CA093444, R01CA062234, R01CA073507] Funding Source: NIH RePORTER; NCI NIH HHS [CA93444, CA62234, CA73507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BURG DL, 1994, J BIOL CHEM, V269, P28136; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Fabbro D, 2002, CURR OPIN DRUG DISC, V5, P701; Fabbro D, 2002, CURR OPIN PHARMACOL, V2, P374, DOI 10.1016/S1471-4892(02)00179-0; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTAFSON RO, 1989, CANCER HEAD NECK, P495; Harnett M, 1996, IMMUNOL TODAY, V17, P4, DOI 10.1016/0167-5699(96)80558-5; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Hsu JL, 2000, CRIT REV ONCOL HEMAT, V34, P27, DOI 10.1016/S1040-8428(00)00046-9; Inatome R, 2001, BIOCHEM BIOPH RES CO, V286, P195, DOI 10.1006/bbrc.2001.5355; Islam TC, 2000, J GENE MED, V2, P204; Islam TC, 2000, IMMUNOL REV, V178, P49, DOI 10.1034/j.1600-065X.2000.17811.x; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LENNETTE ET, 1995, EUR J CANCER, V31A, P1875, DOI 10.1016/0959-8049(95)00354-L; Longnecker R, 1996, TRENDS MICROBIOL, V4, P38; Longnecker R, 2000, ADV CANCER RES, V79, P175, DOI 10.1016/S0065-230X(00)79006-3; Lu J, 2000, J VIROL, V74, P7391, DOI 10.1128/JVI.74.16.7391-7399.2000; Lu J, 2003, CANCER RES, V63, P256; MILLER CL, 1994, INFECT AGENT DIS, V3, P128; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Renedo MA, 2001, EUR J IMMUNOL, V31, P1361, DOI 10.1002/1521-4141(200105)31:5<1361::AID-IMMU1361>3.0.CO;2-7; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 1999, J VIROL, V73, P4767, DOI 10.1128/JVI.73.6.4767-4775.1999; Scholle F, 2001, VIROLOGY, V291, P208, DOI 10.1006/viro.2001.1197; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Swanson-Mungerson MA, 2005, J VIROL, V79, P7355, DOI 10.1128/JVI.79.12.7355-7362.2005; Tsai CH, 1997, J BIOMED SCI, V4, P69, DOI 10.1007/BF02255596; Tsubata T, 2001, Int Rev Immunol, V20, P675, DOI 10.3109/08830180109045584; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Yanagi S, 2001, BLOOD, V98, P2869, DOI 10.1182/blood.V98.9.2869; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; Zhang J, 2000, J BIOL CHEM, V275, P35442, DOI 10.1074/jbc.M004549200; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	75	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8806	8814		10.1074/jbc.M507305200	http://dx.doi.org/10.1074/jbc.M507305200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16431925	hybrid			2022-12-25	WOS:000236247100060
J	Shen, YH; Zhang, L; Gan, YH; Wang, XW; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL				Shen, YH; Zhang, L; Gan, YH; Wang, XW; Wang, J; LeMaire, SA; Coselli, JS; Wang, XL			Up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) mediates p38 MAPK stress signal-induced inhibition of insulin signaling - A cross-talk between stress signaling and insulin signaling in resistin-treated human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; INFLAMMATORY CYTOKINES; METABOLIC SYNDROME; SKELETAL-MUSCLE; INDUCED PHOSPHORYLATION; DEPENDENT DILATATION; RECEPTOR SUBSTRATE-1; LEPTIN LEVELS; IN-VIVO; GLUCOSE	The key feature of metabolic syndrome, a cluster of metabolic and cardiovascular disorders, is systemic insulin resistance, which is associated with dysregulated endothelial nitric-oxide synthase ( eNOS). Stress signaling induced by inflammation can inhibit insulin signaling. However, molecular mechanisms for the cross-talk between stress signaling and insulin resistance are only partially understood. Resistin, an adipokine/ cytokine, is involved in inflammatory processes that could lead to insulin resistance status and vascular diseases. In the current study, we observed that resistin inhibited insulin signaling and eNOS activation in endothelial cells. Up-regulation of PTEN ( phosphatase and tensin homolog deleted on chromosome ten) expression by resistin may mediate the inhibitory effects. Activated stress signaling p38 MAPK, but not JNK, is involved in PTEN up-regulation. We further found that p38 target transcriptional factor activating transcription factor-2 (ATF-2) bound to ATF sites in the PTEN promoter. The phosphorylation/ activation of ATF-2 and its binding to PTEN promoter were increased by resistin treatment. In summary, up-regulation of PTEN is involved in the inhibitory effects of resistin on insulin signaling and eNOS activation in endothelial cells. Resistin induces PTEN expression by activating stress signaling p38 pathway, which may activate target transcription factor ATF-2, which in turn induces PTEN expression. Our findings suggest that resistin-mediated inhibition of insulin signaling and eNOS activation may contribute to cardiovascular diseases.	Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA	Baylor College of Medicine; Saint Lukes Episcopal Hospital; Texas Heart Institute	Shen, YH (corresponding author), Baylor Coll Med, Div Cardiothorac Surg, Michael E DeBakey Dept Surg, NAB 2010,1 Baylor Plaza, Houston, TX 77030 USA.	hyshen@bcm.tmc.edu; xlwang@bcm.tmc.edu	shen, ying/HHS-5635-2022	LeMaire, Scott/0000-0002-8736-4266	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071608, R01HL066053] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL066053, R01-HL071608] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Azuma K, 2003, OBES RES, V11, P997, DOI 10.1038/oby.2003.137; Banerjee RR, 2003, J MOL MED, V81, P218, DOI 10.1007/s00109-003-0428-9; Baron AD, 1999, AM J CARDIOL, V84, p25J; Begum N, 2003, FRONT BIOSCI-LANDMRK, V8, pS796, DOI 10.2741/1146; Bhagat K, 1997, CIRCULATION, V96, P3042, DOI 10.1161/01.CIR.96.9.3042; Bokarewa M, 2005, J IMMUNOL, V174, P5789, DOI 10.4049/jimmunol.174.9.5789; Bonora E, 1998, DIABETES, V47, P1643, DOI 10.2337/diabetes.47.10.1643; Calabro P, 2004, CIRCULATION, V110, P3335, DOI 10.1161/01.CIR.0000147825.97879.E7; Carlson CJ, 2003, DIABETES, V52, P634, DOI 10.2337/diabetes.52.3.634; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Fujinami A, 2004, CLIN CHIM ACTA, V339, P57, DOI 10.1016/j.cccn.2003.09.009; GAN Y, 2005, J BIOL CHEM; Graveleau C, 2005, J BIOL CHEM, V280, P31679, DOI 10.1074/jbc.M504008200; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Haffner S, 2003, CIRCULATION, V108, P1541, DOI 10.1161/01.CIR.0000088845.17586.EC; Hall JF, 2000, P NATL ACAD SCI USA, V97, P14022, DOI 10.1073/pnas.97.26.14022; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hingorani AD, 2000, CIRCULATION, V102, P994, DOI 10.1161/01.CIR.102.9.994; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hockings SC, 1998, P NATL ACAD SCI USA, V95, P1410, DOI 10.1073/pnas.95.4.1410; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JIANG G, 2002, FRONT BIOSCI, V7, P903; Kaser S, 2003, BIOCHEM BIOPH RES CO, V309, P286, DOI 10.1016/j.bbrc.2003.07.003; Kereiakes DJ, 2003, CIRCULATION, V108, P1552, DOI 10.1161/01.CIR.0000093203.00632.2B; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kitagawa Y, 2004, DIABETOLOGIA, V47, P1847, DOI 10.1007/s00125-004-1530-4; Koistinen HA, 2003, DIABETOLOGIA, V46, P1324, DOI 10.1007/s00125-003-1196-3; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Lu SC, 2002, FEBS LETT, V530, P158, DOI 10.1016/S0014-5793(02)03450-6; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Moon B, 2003, AM J PHYSIOL-ENDOC M, V285, pE106, DOI 10.1152/ajpendo.00457.2002; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Muse ED, 2004, J CLIN INVEST, V114, P232, DOI 10.1172/JCI200421270; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ohkawa F, 1995, CARDIOVASC RES, V30, P711, DOI 10.1016/S0008-6363(95)00101-8; Ort T, 2005, ENDOCRINOLOGY, V146, P2200, DOI 10.1210/en.2004-1421; Palanivel R, 2005, FEBS LETT, V579, P5049, DOI 10.1016/j.febslet.2005.08.011; Patel L, 2003, BIOCHEM BIOPH RES CO, V300, P472, DOI 10.1016/S0006-291X(02)02841-3; Patel SD, 2004, SCIENCE, V304, P1154, DOI 10.1126/science.1093466; Rangwala SM, 2004, DIABETES, V53, P1937, DOI 10.2337/diabetes.53.8.1937; Reaven Gerald M., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P387; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Reilly MP, 2004, J CLIN ENDOCR METAB, V89, P3872, DOI 10.1210/jc.2003-031676; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Reusch JEB, 2002, AM J CARDIOL, V90, p19G; Sato N, 2005, ENDOCRINOLOGY, V146, P273, DOI 10.1210/en.2004-0985; Satoh H, 2004, J CLIN INVEST, V114, P224, DOI 10.1172/JCI200420785; Silha JV, 2003, EUR J ENDOCRINOL, V149, P331, DOI 10.1530/eje.0.1490331; Silswal N, 2005, BIOCHEM BIOPH RES CO, V334, P1092, DOI 10.1016/j.bbrc.2005.06.202; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Verma S, 2003, CIRCULATION, V108, P736, DOI 10.1161/01.CIR.0000084503.91330.49; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wyatt AW, 2002, FASEB J, V16, P1584, DOI 10.1096/fasebj.16.12.1584; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhang JL, 2003, DIABETIC MED, V20, P828, DOI 10.1046/j.1464-5491.2003.01057.x; Zhao M, 1999, MOL CELL BIOL, V19, P21	77	113	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7727	7736		10.1074/jbc.M511105200	http://dx.doi.org/10.1074/jbc.M511105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418168	hybrid			2022-12-25	WOS:000236031000005
J	Bietrix, F; Yan, DG; Nauze, M; Rolland, C; Bertrand-Michel, J; Camera, C; Schaak, S; Barbaras, R; Groen, AK; Perret, B; Terce, F; Collet, X				Bietrix, F; Yan, DG; Nauze, M; Rolland, C; Bertrand-Michel, J; Camera, C; Schaak, S; Barbaras, R; Groen, AK; Perret, B; Terce, F; Collet, X			Accelerated lipid absorption in mice overexpressing intestinal SR-BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; HIGH-DENSITY-LIPOPROTEIN; BRUSH-BORDER MEMBRANE; SCAVENGER RECEPTOR; CHOLESTEROL ABSORPTION; DIETARY-CHOLESTEROL; TRANSGENIC MICE; INBRED STRAINS; IDENTIFICATION; TRANSPORT	Dietary cholesterol absorption contributes to a large part of the circulating cholesterol. However, the mechanism of sterol intestinal uptake is not clearly elucidated. Scavenger receptor class B type I (SR-BI), major component in the control of cholesterol homeostasis, is expressed in the intestine, but its role in this organ remains unclear. We have generated transgenic mice overexpressing SR-BI primarily in the intestine by using the mouse SR-BI gene under the control of intestinal specific "apoC-III enhancer coupled with apoA-IV promoter." We found SR-BI overexpression with respect to the natural protein along the intestine and at the top of the villosities. After a meal containing [C-14] cholesterol and [H-3] triolein, SR-BI transgenic mice presented a rise in intestinal absorption of both lipids that was not due to a defect in chylomicron clearance nor to a change in the bile flow or the bile acid content. Nevertheless, SR-BI transgenic mice showed a decrease of total cholesterol but an increase of triglyceride content in plasma without any change in the high density lipoprotein apoA-I level. Thus, we described for the first time a functional role in vivo for SR-BI in cholesterol but also in triglyceride intestinal absorption.	Acad Med Ctr, Ctr Liver, NL-1105 BK Amsterdam, Netherlands; Ctr Physiopathol Toulouse Purpan, INSERM, U563, Dept Lipoprot & Med Lipid, F-31024 Toulouse 3, France; Univ Toulouse 3, F-31024 Toulouse 3, France	University of Amsterdam; Academic Medical Center Amsterdam; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Collet, X (corresponding author), Hop Purpan, INSERM, U563, CPTP Bat C, F-31024 Toulouse, France.	xcollet@toulouse.inserm.fr	PERRET, Bertrand/Y-2326-2019; Tercé, François/M-5863-2018; Eckhardt, Erik/G-1567-2010; Collet, Xavier/M-6938-2017	Tercé, François/0000-0003-4488-2167; Bertrand, PERRET/0000-0001-7568-445X				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cai SF, 2001, J LIPID RES, V42, P902; Compassi S, 1995, BIOCHEMISTRY-US, V34, P16473, DOI 10.1021/bi00050a031; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Drover VA, 2005, J CLIN INVEST, V115, P1290, DOI 10.1172/JCI200521514; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Hansen GH, 2003, GUT, V52, P1424, DOI 10.1136/gut.52.10.1424; Hauser H, 1998, BIOCHEMISTRY-US, V37, P17843, DOI 10.1021/bi982404y; Hui DY, 2005, SEMIN CELL DEV BIOL, V16, P183, DOI 10.1016/j.semcdb.2005.01.003; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Kirby RJ, 2004, J LIPID RES, V45, P89, DOI 10.1194/jlr.M300148-JLR200; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Kramer W, 2003, BBA-MOL CELL BIOL L, V1633, P13, DOI 10.1016/S1388-1981(03)00068-4; Kruit JK, 2005, GASTROENTEROLOGY, V128, P147, DOI 10.1053/j.gastro.2004.10.006; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; Mardones P, 2001, J LIPID RES, V42, P170; MCGILL HC, 1979, AM J CLIN NUTR, V32, P2664, DOI 10.1093/ajcn/32.12.2664; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Out R, 2004, J BIOL CHEM, V279, P18401, DOI 10.1074/jbc.M401170200; Perez-Martinez P, 2004, J MOL ENDOCRINOL, V32, P237, DOI 10.1677/jme.0.0320237; Reboul E, 2006, J BIOL CHEM, V281, P4739, DOI 10.1074/jbc.M509042200; Ros E, 2000, ATHEROSCLEROSIS, V151, P357, DOI 10.1016/S0021-9150(00)00456-1; Schulthess G, 1996, J LIPID RES, V37, P2405; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; THURNHOFER H, 1990, BIOCHEMISTRY-US, V29, P2142, DOI 10.1021/bi00460a026; Torchia EC, 2001, ANAL BIOCHEM, V298, P293, DOI 10.1006/abio.2001.5379; TRABER MG, 1990, J LIPID RES, V31, P675; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; van Bennekum A, 2005, BIOCHEMISTRY-US, V44, P4517, DOI 10.1021/bi0484320; Vieu C, 1996, J LIPID RES, V37, P1153; Wang DQH, 2001, J LIPID RES, V42, P1820; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; WEISER MM, 1973, J BIOL CHEM, V248, P2536; Werder M, 2001, BIOCHEMISTRY-US, V40, P11643, DOI 10.1021/bi0109820; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	42	101	104	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7214	7219		10.1074/jbc.M508868200	http://dx.doi.org/10.1074/jbc.M508868200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421100	Green Submitted, Green Accepted, hybrid			2022-12-25	WOS:000236030900038
J	McDowell, LM; Frazier, BA; Studelska, DR; Giljum, K; Chen, JH; Liu, J; Yu, K; Ornitz, DM; Zhang, LJ				McDowell, LM; Frazier, BA; Studelska, DR; Giljum, K; Chen, JH; Liu, J; Yu, K; Ornitz, DM; Zhang, LJ			Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; LIGAND-BINDING SPECIFICITY; DERMATAN SULFATE; CHONDROITIN SULFATE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; RECEPTOR KINASE; MICE DEFICIENT; CELL-SURFACE	Most Apert syndrome patients harbor a single amino acid mutation (S252W) in fibroblast growth factor (FGF) receptor 2 (FGFR2), which leads to abnormal FGF/FGFR2 signaling. Here we show that specific combinations of FGFs and glycosaminoglycans activate both alternative splice forms of the mutant but not of the wild-type FGF receptors. More importantly, 2-O- and N-sulfated heparan sulfate, prepared by a combined chemical and enzymatic synthesis, antagonized the over-activated FGFR2b ( S252W) to basal levels at nanomolar concentrations. These studies demonstrated that specific glycosaminoglycans could be useful in treating ligand-dependent FGFR signaling-related diseases, such as Apert syndrome and cancer.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill	Zhang, LJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, Campus Box 8118, St Louis, MO 63110 USA.	ljzhang@wustl.edu		Ornitz, David/0000-0003-1592-7629	NIAID NIH HHS [R01 AI 50050] Funding Source: Medline; NICHD NIH HHS [R01 HD 39952] Funding Source: Medline; NIGMS NIH HHS [R01 GM 69968] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069968] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Bergefall K, 2005, J BIOL CHEM, V280, P32193, DOI 10.1074/jbc.M503645200; Chen JH, 2005, J BIOL CHEM, V280, P42817, DOI 10.1074/jbc.M504338200; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Garcia-Garcia MJ, 2003, CELL, V114, P727, DOI 10.1016/S0092-8674(03)00715-3; Grobe K, 2005, DEVELOPMENT, V132, P3777, DOI 10.1242/dev.01935; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Ibrahimi OA, 2005, PLAST RECONSTR SURG, V115, P264, DOI 10.1097/01.PRS.0000146703.08958.95; Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; Mohammadi M, 2005, CURR OPIN STRUC BIOL, V15, P506, DOI 10.1016/j.sbi.2005.09.002; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Oldridge M, 1999, AM J HUM GENET, V64, P446, DOI 10.1086/302245; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PARK WJ, 1995, AM J HUM GENET, V57, P321; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Robinson CJ, 2005, J BIOL CHEM, V280, P42274, DOI 10.1074/jbc.M505720200; Rusnati M, 2002, P NATL ACAD SCI USA, V99, P4367, DOI 10.1073/pnas.072651899; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shworak N W, 2001, Methods Mol Biol, V171, P79; Slaney SF, 1996, AM J HUM GENET, V58, P923; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Studelska DR, 2006, GLYCOBIOLOGY, V16, P65, DOI 10.1093/glycob/cwj037; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; von Gernet S, 2000, CLIN GENET, V57, P137, DOI 10.1034/j.1399-0004.2000.570208.x; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Wang YL, 2005, DEVELOPMENT, V132, P3537, DOI 10.1242/dev.01914; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yeh BK, 2002, MOL CELL BIOL, V22, P7184, DOI 10.1128/MCB.22.20.7184-7192.2002; Yu K, 2001, P NATL ACAD SCI USA, V98, P3641, DOI 10.1073/pnas.081082498; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536	60	40	43	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6924	6930		10.1074/jbc.M512932200	http://dx.doi.org/10.1074/jbc.M512932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16373332	hybrid			2022-12-25	WOS:000236030900004
J	Schonfeld, P; Reiser, G				Schonfeld, P; Reiser, G			Rotenone-like action of the branched-chain phytanic acid induces oxidative stress in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDOREDUCTASE COMPLEX-I; ELECTRON-TRANSPORT CHAIN; ALPHA-KETOGLUTARATE DEHYDROGENASE; OXYGEN SPECIES GENERATION; RAT-HEART MITOCHONDRIA; SUPEROXIDE-PRODUCTION; BRAIN MITOCHONDRIA; HYDROGEN-PEROXIDE; FATTY-ACIDS; RESPIRATORY-CHAIN	Phytanic acid (Phyt) increase is associated with the hereditary neurodegenerative Refsum disease. To elucidate the still unclear toxicity of Phyt, mitochondria from brain and heart of adult rats were exposed to free Phyt. Phyt at low micromolar concentrations (maximally: 100 nmol/mg of protein) enhances superoxide (O-2(radical anion))(2) generation. Phyt induces O-2(radical anion) in state 3 ( phosphorylating), as well as in state 4 ( resting). Phyt stimulates O-2(radical anion) generation when the respiratory chain is fed with electrons derived from oxidation of glutamate/ malate, pyruvate/ malate, or succinate in the presence of rotenone. With succinate alone, Phyt suppresses O-2(radical anion) generation caused by reverse electron transport from succinate to complex I. The enhanced O-2(radical anion) generation by Phyt in state 4 is in contrast to the mild uncoupling concept. In this concept uncoupling by nonesterified fatty acids should abolish O-2(radical anion) generation. Stimulation of O-2(radical anion) generation by Phyt is paralleled by inhibition of the electron transport within the respiratory chain or electron leakage from the respiratory chain. The interference of Phyt with the electron transport was demonstrated by inhibition of state 3- and p-trifluoromethoxyphenylhydrazone (FCCP)-dependent respiration, inactivation of the NADH-ubiquinone oxidoreductase complex in permeabilized mitochondria, decrease in reduction of the synthetic electron acceptor 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in state 4, and increase of the mitochondrial NAD(P) H level in FCCP-uncoupled mitochondria. Thus, we suggest that complex I is the main site of Phyt-stimulated O-2(radical anion) generation. Furthermore, inactivation of aconitase and oxidation of the mitochondrial glutathione pool show that enhanced O-2(radical anion) generation with chronic exposure to Phyt causes oxidative damage.	Univ Magdeburg, Fak Med, Inst Biochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Fak Med, Inst Neurobiochem, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Schonfeld, P (corresponding author), Univ Magdeburg, Fak Med, Inst Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	peter.schoenfeld@medizin.uni-magdeburg.de						Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; Brookes PS, 2005, FREE RADICAL BIO MED, V38, P12, DOI 10.1016/j.freeradbiomed.2004.10.016; CHANCE B, 1961, J BIOL CHEM, V236, P1534; Cocco T, 1999, FREE RADICAL BIO MED, V27, P51, DOI 10.1016/S0891-5849(99)00034-9; Dacremont G, 1995, J INHERIT METAB DIS, V18, P76, DOI 10.1007/BF00711430; Esposti MD, 2002, METHODS, V26, P335, DOI 10.1016/S1046-2023(02)00039-7; FRIEDMAN KJ, 1982, J MEMBRANE BIOL, V64, P1, DOI 10.1007/BF01870763; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gyulkhandanyan AV, 2004, J NEUROCHEM, V90, P405, DOI 10.1111/j.1471-4159.2004.02489.x; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Herrero A, 1997, J BIOENERG BIOMEMBR, V29, P241, DOI 10.1023/A:1022458010266; HINKLE PC, 1967, J BIOL CHEM, V242, P5169; Kahlert S, 2005, NEUROBIOL DIS, V18, P110, DOI 10.1016/j.nbd.2004.08.010; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lambert AJ, 2004, BIOCHEM J, V382, P511, DOI 10.1042/BJ20040485; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Loskovich MV, 2005, BIOCHEM J, V387, P677, DOI 10.1042/BJ20041703; Mannaerts GP, 2000, CELL BIOCHEM BIOPHYS, V32, P73, DOI 10.1385/CBB:32:1-3:73; Mukherji M, 2003, PROG LIPID RES, V42, P359, DOI 10.1016/S0163-7827(03)00016-X; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Nicholls D., 2002, BIOENERGETICS, V3; PATTON S, 1966, BIOCHIM BIOPHYS ACTA, V125, P22, DOI 10.1016/0005-2760(66)90140-8; REISER G, 2006, IN PRESS INT J DEV N; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; SCHALLER H, 1978, ACTA BIOL MED GER, V37, P31; Schonfeld P, 2004, BIOCHEM J, V383, P121, DOI 10.1042/BJ20040583; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Steinberg D., 1995, METABOLIC MOL BASES, P2351; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wanders RJA, 2003, BBA-MOL CELL BIOL L, V1631, P119, DOI 10.1016/S1388-1981(03)00003-9; WANDERS RJA, 2001, METABOLIC MOL BASES, P3303; Wierzbicki AS, 2002, J NEUROCHEM, V80, P727, DOI 10.1046/j.0022-3042.2002.00766.x; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	52	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7136	7142		10.1074/jbc.M513198200	http://dx.doi.org/10.1074/jbc.M513198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16410242	hybrid			2022-12-25	WOS:000236030900028
J	Li, SJ; Hong, XG; Shi, YY; Li, H; Wang, CC				Li, SJ; Hong, XG; Shi, YY; Li, H; Wang, CC			Annular arrangement and collaborative actions of four domains of protein-disulfide isomerase - A small angle X-ray scattering study in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; ALPHA-SYNUCLEIN; PROLYL 4-HYDROXYLASE; ESCHERICHIA-COLI; FOLDING CATALYST; FUNCTIONAL-PROPERTIES; CHAPERONE ACTIVITIES; SHAPE DETERMINATION; TERMINAL DOMAIN; BINDING SITE	We presented for the first time a small angle x-ray scattering study of intact protein-disulfide isomerase (PDI) in solution. The restored model revealed that PDI is a short and roughly elliptical cylinder with a molecular mass of 69 kDa and dimensions of 105 x 65 x 40 angstrom, and the four thioredoxin-fold domains in the order a-b-b'-a' are arranged in an annular fashion. Atomic force microscope imaging also supported the finding that PDI appears as an approximately flat elliptical cylinder. A PDI species with apparent molecular mass of 116 kDa measured by using size-exclusion chromatography, previously assumed to be a dimer, was determined to exist mainly as a monomer by using analytical ultracentrifugation. The C-terminal fragment 441 - 491 contributed to the anomalous molecular mass determination of PDI by size-exclusion chromatography. The annular model of PDI accounted for the cooperative properties of the four domains in both the isomerase and chaperone functions of PDI.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Biophys, Ctr Syst Biol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst High Energy Phys, Beijing 100039, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Wang, CC (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	chihwang@sun5.ibp.ac.cn	li, shengjian/B-4866-2013	Hong, Xinguo/0000-0001-8994-219X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; Chacon P, 1998, BIOPHYS J, V74, P2760, DOI 10.1016/S0006-3495(98)77984-6; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Choi JY, 2002, BIOTECHNOL APPL BIOC, V36, P33, DOI 10.1042/BA20020004; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fournet G., 1955, SMALL ANGLE SCATTERI, V24; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; Huang CJ, 2005, PROTEIN EXPRES PURIF, V42, P173, DOI 10.1016/j.pep.2005.02.014; Izumi Y, 2001, FEBS LETT, V495, P126, DOI 10.1016/S0014-5793(01)02375-4; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KELLER D, 1991, SURF SCI, V253, P353, DOI 10.1016/0039-6028(91)90606-S; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 2005, J BIOL CHEM, V280, P5227, DOI 10.1074/jbc.M412480200; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Martin SL, 2003, P NATL ACAD SCI USA, V100, P13815, DOI 10.1073/pnas.2336221100; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; Nielsen MS, 2001, J BIOL CHEM, V276, P22680, DOI 10.1074/jbc.M101181200; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; OHBA H, 1981, J BIOCHEM, V89, P889, DOI 10.1093/oxfordjournals.jbchem.a133272; Pan XM, 2001, PROTEINS, V43, P256, DOI 10.1002/prot.1036; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; PUIG A, 1994, J BIOL CHEM, V269, P7764; Puig A, 1997, J BIOL CHEM, V272, P32988, DOI 10.1074/jbc.272.52.32988; Sanchez-Puig N, 2005, PROTEIN SCI, V14, P1410, DOI 10.1110/ps.051368005; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Solovyov A, 2004, PROTEIN SCI, V13, P1902, DOI 10.1110/ps.04716104; Sun XX, 2000, BBA-PROTEIN STRUCT M, V1481, P45, DOI 10.1016/S0167-4838(00)00122-9; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TOJO H, 1994, J BIOTECHNOL, V33, P55, DOI 10.1016/0168-1656(94)90098-1; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	54	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6581	6588		10.1074/jbc.M508422200	http://dx.doi.org/10.1074/jbc.M508422200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407203	hybrid			2022-12-25	WOS:000236030800054
J	Matsubara, T; Shirai, Y; Miyasaka, K; Murakami, T; Yamaguchi, Y; Ueyama, T; Kai, M; Sakane, F; Kanoh, H; Hashimoto, T; Kamada, S; Kikkawa, U; Saito, N				Matsubara, T; Shirai, Y; Miyasaka, K; Murakami, T; Yamaguchi, Y; Ueyama, T; Kai, M; Sakane, F; Kanoh, H; Hashimoto, T; Kamada, S; Kikkawa, U; Saito, N			Nuclear transportation of diacylglycerol kinase gamma and its possible function in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAINS; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; CELL-CYCLE; HUMAN-PLATELETS; I-ALPHA; ACTIVATION	Diacylglycerol kinases (DGKs) convert diacylglycerol (DG) to phosphatidic acid, and both lipids are known to play important roles in lipid signal transduction. Thereby, DGKs are considered to be a one of the key players in lipid signaling, but its physiological function remains to be solved. In an effort to investigate one of nine subtypes, we found that DGK gamma came to be localized in the nucleus with time in all cell lines tested while seen only in the cytoplasm at the early stage of culture, indicating that DGK gamma is transported from the cytoplasm to the nucleus. The nuclear transportation of DGK gamma didn't necessarily need DGK activity, but its C1 domain was indispensable, suggesting that the C1 domain of DGK gamma acts as a nuclear transport signal. Furthermore, to address the function of DGK gamma in the nucleus, we produced stable cell lines of wild-type DGK gamma and mutants, including kinase negative, and investigated their cell size, growth rate, and cell cycle. The cells expressing the kinase-negative mutant of DGK gamma were larger in size and showed slower growth rate, and the S phase of the cells was extended. These findings implicate that nuclear DGK gamma regulates cell cycle.	Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Biosignal Res Ctr, Biochem Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Shirai, Y (corresponding author), Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Rokkodai Cho 1-1, Kobe, Hyogo 6578501, Japan.	shirai@kobe-u.ac.jp; naosaito@kobe-u.ac.jp	Shirai, Yasuhito/O-3255-2018; Kanoh, Hiroko/GOG-8672-2022; Kanoh, Hiroko/GWU-7640-2022; Sakane, Fumio/H-2693-2017	Kanoh, Hiroko/0000-0002-8765-1249; Sakane, Fumio/0000-0003-0857-0377				BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; Batista EL, 2005, J CELL BIOCHEM, V94, P774, DOI 10.1002/jcb.20356; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; Bregoli L, 2002, ADV ENZYME REGUL, V42, P213, DOI 10.1016/S0065-2571(01)00032-2; Bregoli L, 2001, J BIOL CHEM, V276, P23288, DOI 10.1074/jbc.M101501200; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; Deacon EM, 2002, J CELL SCI, V115, P983; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Divecha N, 1997, SEMIN CELL DEV BIOL, V8, P323, DOI 10.1006/scdb.1997.0154; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Flores I, 1999, J IMMUNOL, V163, P708; Gorlich D, 1995, COLD SPRING HARB SYM, V60, P695, DOI 10.1101/SQB.1995.060.01.075; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; Goto K, 1999, CHEM PHYS LIPIDS, V98, P109, DOI 10.1016/S0009-3084(99)00023-7; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Houssa B, 1997, J BIOL CHEM, V272, P10422; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jones DR, 2000, FEBS LETT, V476, P160, DOI 10.1016/S0014-5793(00)01702-6; KAI M, 1994, J BIOL CHEM, V269, P18492; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Luo B, 2004, CELL SIGNAL, V16, P891, DOI 10.1016/j.cellsig.2004.01.010; Moriyama T, 1999, J BIOCHEM, V125, P1077, DOI 10.1093/oxfordjournals.jbchem.a022389; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Shindo M, 2003, J BIOL CHEM, V278, P18448, DOI 10.1074/jbc.M300400200; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; Tsushima S, 2004, J BIOL CHEM, V279, P28603, DOI 10.1074/jbc.M314031200; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Yamada K, 2003, BIOCHEM BIOPH RES CO, V305, P101, DOI 10.1016/S0006-291X(03)00713-7; YORK JD, 1994, J BIOL CHEM, V269, P7847	45	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6152	6164		10.1074/jbc.M509873200	http://dx.doi.org/10.1074/jbc.M509873200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407189	hybrid			2022-12-25	WOS:000236030800007
J	Zhang, W; Anger, T; Su, JL; Hao, JM; Xu, XM; Zhu, M; Gach, A; Cui, L; Liao, RL; Mende, U				Zhang, W; Anger, T; Su, JL; Hao, JM; Xu, XM; Zhu, M; Gach, A; Cui, L; Liao, RL; Mende, U			Selective loss of fine tuning of G(q/11) signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT CARDIAC EXPRESSION; GTPASE-ACTIVATING PROTEINS; PRESSURE-OVERLOAD; HEART-FAILURE; 3RD-INTRACELLULAR LOOP; VENTRICULAR MYOCYTES; BLOOD-PRESSURE; REGULATOR; RNA; TRANSLOCATION	Alterations in cardiac G protein- mediated signaling, most prominently G(q/ 11) signaling, are centrally involved in hypertrophy and heart failure development. Several RGS proteins that can act as negative regulators of G protein signaling are expressed in the heart, but their functional roles are still poorly understood. RGS expression changes have been described in hypertrophic and failing hearts. In this study, we report a marked decrease in RGS2 ( but not other major cardiac RGS proteins ( RGS3 - RGS5)) that occurs prior to hypertrophy development in different models with enhanced G(q/11) signaling ( transgenic expression of activated G alpha(q)* and pressure overload due to aortic constriction). To assess functional consequences of selective down- regulation of endogenous RGS2, we identified targeting sequences for effective RGS2 RNA interference and used lipid- based transfection to achieve uptake of fluorescently labeled RGS2 small interfering RNA in > 90% of neonatal and adult ventricular myocytes. Endogenous RGS2 expression was dose- dependently suppressed ( up to 90%) with no major change in RGS3 RGS5. RGS2 knockdown increased phenylephrine- and endothelin-1- induced phospholipase C beta stimulation in both cell types and exacerbated the hypertrophic effect ( increase in cell size and radiolabeled protein) in neonatal myocytes, with no major change in G(q/11)- mediated ERK1/ 2, p38, or JNK activation. Taken together, this study demonstrates that endogenous RGS2 exerts functionally important inhibitory restraint on G(q/ 11)- mediated phospholipase C beta activation and hypertrophy in ventricular myocytes. Our findings point toward a potential pathophysiological role of loss of fine tuning due to selective RGS2 down- regulation in G(q/ 11)- mediated remodeling. Furthermore, this study shows the feasibility of effective RNA interference in cardiomyocytes using lipid- based small interfering RNA transfection.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Mende, U (corresponding author), Rhode Isl Hosp, SW Pavil 2nd Floor,593 Eddy St, Providence, RI 02903 USA.	UMende@Lifespan.org		Gach, Agnieszka/0000-0002-6590-5797; Anger, Thomas/0000-0001-9071-6405; Liao, Ronglih/0000-0002-9598-9020	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072174, P50HL052320, R01HL080127] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52320, HL 72174, R01 HL072174, R01 HL080127] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Anger T, 2004, J BIOL CHEM, V279, P3906, DOI 10.1074/jbc.M309496200; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; Dorn GW, 2004, ANN NY ACAD SCI, V1015, P225, DOI 10.1196/annals.1302.019; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Gross V, 2005, AM J PHYSIOL-REG I, V288, pR1134, DOI 10.1152/ajpregu.00246.2004; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Hao JM, 2005, CIRCULATION, V111, P1724; Hardt SE, 2004, CARDIOVASC RES, V63, P500, DOI 10.1016/j.cardiores.2004.03.015; Hepler JR, 2003, MOL PHARMACOL, V64, P547, DOI 10.1124/mol.64.3.547; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jalili T, 1999, AM J PHYSIOL-HEART C, V277, pH2298, DOI 10.1152/ajpheart.1999.277.6.H2298; Jin Y, 2004, J PEPT RES, V63, P141, DOI 10.1111/j.1399-3011.2003.00114.x; Kardestuncer T, 1998, FEBS LETT, V438, P285, DOI 10.1016/S0014-5793(98)01319-2; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; Liao RL, 2002, CIRCULATION, V106, P2125, DOI 10.1161/01.CIR.0000034049.61181.F3; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Mende U, 1999, CIRC RES, V85, P1085; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MENDE U, 2000, MOL CELL CARDIOL, V33, P1477; Mittmann C, 2002, CARDIOVASC RES, V55, P778, DOI 10.1016/S0008-6363(02)00459-5; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Owen VJ, 2001, EUR HEART J, V22, P1015, DOI 10.1053/euhj.2000.2578; Pasumarthi KBS, 1996, CIRC RES, V78, P126, DOI 10.1161/01.RES.78.1.126; Pedram A, 2005, J BIOL CHEM, V280, P26339, DOI 10.1074/jbc.M414409200; Peterson DJ, 1999, CARDIOVASC RES, V41, P575, DOI 10.1016/S0008-6363(98)00264-8; Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002; Riddle EL, 2005, CIRC RES, V96, P401, DOI 10.1161/01.RES.0000158287.49872.4e; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Seth M, 2004, P NATL ACAD SCI USA, V101, P16683, DOI 10.1073/pnas.0407537101; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sun XG, 2005, MOL PHARMACOL, V67, P631, DOI 10.1124/mol.104.007724; Tamirisa P, 1999, CIRCULATION, V99, P441, DOI 10.1161/01.CIR.99.3.441; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P161, DOI 10.1016/0022-2828(91)90103-S; Wang Q, 2004, METHOD ENZYMOL, V389, P244; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wang XH, 2004, J BIOL CHEM, V279, P133, DOI 10.1074/jbc.M310040200; Watanabe A, 2004, J MOL CELL CARDIOL, V37, P691, DOI 10.1016/j.yjmcc.2004.06.009; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200; Zhang SA, 1998, J MOL CELL CARDIOL, V30, P269, DOI 10.1006/jmcc.1997.0591	54	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5811	5820		10.1074/jbc.M507871200	http://dx.doi.org/10.1074/jbc.M507871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380388	hybrid			2022-12-25	WOS:000235568900060
J	Ai, XB; Do, AT; Kusche-Gullberg, M; Lindahl, U; Lu, K; Emerson, CP				Ai, XB; Do, AT; Kusche-Gullberg, M; Lindahl, U; Lu, K; Emerson, CP			Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BINDING; IDENTIFICATION; PROTEOGLYCAN; DIVERSITY; CANCER	The extracellular sulfatases (Sulfs) are an evolutionally conserved family of heparan sulfate (HS)-specific 6-O-endosulfatases. These enzymes remodel the 6-O-sulfation of cell surface HS chains to promote Wnt signaling and inhibit growth factor signaling for embryonic tissue patterning and control of tumor growth. In this study we demonstrate that the avian HS endosulfatases, QSulf1 and QSulf2, exhibit the same substrate specificity toward a subset of trisulfated disaccharides internal to HS chains. Further, we show that both QSulfs associate exclusively with cell membrane and are enzymatically active on the cell surface to desulfate both cell surface and cell matrix HS. Mutagenesis studies reveal that conserved amino acid regions in the hydrophilic domains of QSulf1 and QSulf2 have multiple functions, to anchor Sulf to the cell surface, bind to HS substrates, and to mediate HS 6-O-endosulfatase enzymatic activity. Results of our current studies establish the hydrophilic domain (HD) of Sulf enzymes as an essential multifunctional domain for their unique endosulfatase activities and also demonstrate the extracellular activity of Sulfs for desulfation of cell surface and cell matrix HS in the control of extracellular signaling for embryonic development and tumor progression.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Bergen, Div Physiol, Dept Biomed, N-5009 Bergen, Norway	Boston Biomedical Research Institute; Uppsala University; University of Bergen	Emerson, CP (corresponding author), Boston Biomed Res Inst, Watertown, MA 02472 USA.	emersonc@bbri.org	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695; Ai, Xingbin/0000-0002-2178-0080	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043891] Funding Source: NIH RePORTER; NINDS NIH HHS [F32 NS043891] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Braquart-Varnier C, 2004, MOL CELL NEUROSCI, V25, P612, DOI 10.1016/j.mcn.2003.11.013; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Goerges AL, 2003, J BIOL CHEM, V278, P19518, DOI 10.1074/jbc.M211208200; KRESSE H, 1980, P NATL ACAD SCI-BIOL, V77, P6822, DOI 10.1073/pnas.77.11.6822; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Rapraeger AC, 2002, METHOD CELL BIOL, V69, P83, DOI 10.1016/S0091-679X(02)69009-0; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101	23	122	124	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4969	4976		10.1074/jbc.M511902200	http://dx.doi.org/10.1074/jbc.M511902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377625	hybrid			2022-12-25	WOS:000235426200048
J	Sun, Q; Matta, H; Lu, G; Chaudhary, PM				Sun, Q; Matta, H; Lu, G; Chaudhary, PM			Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappa B activation	ONCOGENE			English	Article						vFLIP; KSHV; HHV-8; IL-8; K13; NF-kappa B	SARCOMA-ASSOCIATED HERPESVIRUS; ECTODERMAL DYSPLASIA RECEPTOR; PROTEIN-COUPLED RECEPTOR; KAPOSIS-SARCOMA; INTERLEUKIN-8 GENE; SIGNAL-TRANSDUCTION; SPINDLE CELLS; KINASE; APOPTOSIS; TRANSCRIPTION	Human herpesvirus 8 (HHV-8) encodes a viral FLICE inhibitory protein (vFLIP), called K13, with homology to the prodomain of caspase 8. K13 has been postulated to protect virally infected cells against death receptor-induced apoptosis. We report that K13 leads to constitutive upregulation of IL-8 secretion by transcriptional upregulation of its promoter. K13-induced IL-8 promoter activation is dependent on an intact NF-kappa B-binding site and is associated with increased binding of classical NF-kappa B pathway subunits p65, c-Rel and p50, respectively. IL-8 production is defective in K13 mutants defective in classical NF-kappa B activation and is blocked by genetic and pharmacological inhibitors of this pathway. In contrast, K13 failed to activate the JNK/AP-1 pathway and deletion of AP-1-binding site in the IL-8 promoter or use of a specific JNK inhibitor had only a partial effect on K13-induced IL-8 promoter activation. Collectively, above results demonstrate that K13 is a major mediator of IL-8 production and therapeutic agents targeting K13-induced NF-kappa B pathway may have a role in the treatment of conditions in which HHV-8-induced IL-8 production plays a pathogenic role.	Univ Pittsburgh, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Hillman Canc Ctr, Pittsburgh, PA USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Pittsburgh, Dept Med, Div Hematol Oncol, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Hu SM, 1997, J BIOL CHEM, V272, P9621; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Lane BR, 2002, J VIROL, V76, P11570, DOI 10.1128/JVI.76.22.11570-11583.2002; Lane BR, 2001, J VIROL, V75, P8195, DOI 10.1128/JVI.75.17.8195-8202.2001; Le XD, 2000, J INTERF CYTOK RES, V20, P935, DOI 10.1089/10799900050198372; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Masood R, 2001, CLIN CANCER RES, V7, P2693; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Moore PS, 2003, ANNU REV MICROBIOL, V57, P609, DOI 10.1146/annurev.micro.57.030502.090824; Mori N, 1998, CANCER RES, V58, P3993; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Roussel RR, 2000, ARCH BIOCHEM BIOPHYS, V377, P204, DOI 10.1006/abbi.2000.1770; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Singh RK, 1999, MELANOMA RES, V9, P383, DOI 10.1097/00008390-199908000-00007; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; Sinha SK, 2004, J BIOL CHEM, V279, P41873, DOI 10.1074/jbc.M407363200; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun QM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-9; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; UEDA T, 1994, J GASTROENTEROL, V29, P423, DOI 10.1007/BF02361238; Verma SC, 2003, FEMS MICROBIOL LETT, V222, P155, DOI 10.1016/S0378-1097(03)00261-1; Wang JF, 2004, BBA-MOL CELL RES, V1691, P129, DOI 10.1016/j.bbamcr.2004.01.002; WATANABE K, 1989, BIOCHEM BIOPH RES CO, V161, P1093, DOI 10.1016/0006-291X(89)91355-7; Wu GD, 1997, J BIOL CHEM, V272, P2396; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yokoe T, 1997, ANTICANCER RES, V17, P695	53	69	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2717	2726		10.1038/sj.onc.1209298	http://dx.doi.org/10.1038/sj.onc.1209298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16418726				2022-12-25	WOS:000237272900003
J	Dolznig, H; Grebien, F; Deiner, EM; Stangl, K; Kolbus, A; Habermann, B; Kerenyi, MA; Kieslinger, M; Moriggl, R; Beug, H; Mullner, E				Dolznig, H.; Grebien, F.; Deiner, E. M.; Stangl, K.; Kolbus, A.; Habermann, B.; Kerenyi, M. A.; Kieslinger, M.; Moriggl, R.; Beug, H.; Muellner, E. W.			Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR	ONCOGENE			English	Article						erythroid progenitor self-renewal; terminal erythropoiesis; Stat5; glucocorticoid receptor; erythropoietin receptor; Bcl-X-L	BCL-X-L; STEM-CELL; GLUCOCORTICOID-RECEPTOR; DNA-BINDING; C-KIT; ERYTHROPOIETIN; EXPRESSION; MECHANISMS; APOPTOSIS; BCL-X(L)	The balance between hematopoietic progenitor commitment and self- renewal versus differentiation is controlled by various transcriptional regulators cooperating with cytokine receptors. Disruption of this balance is increasingly recognized as important in the development of leukemia, by causing enhanced renewal and differentiation arrest. We studied regulation of renewal versus differentiation in primary murine erythroid progenitors that require cooperation of erythropoietin receptor ( EpoR), the receptor tyrosine kinase c- Kit and a transcriptional regulator ( glucocorticoid receptor; GR) for sustained renewal. However, mice defective for GR- ( GR(dim/ dim)), EpoR- ( EpoR(H)) or STAT5ab function ( Stat5ab (-/ -)) show no severe erythropoiesis defects in vivo. Using primary erythroblast cultures from these mutants, we present genetic evidence that functional GR, EpoR, and Stat5 are essential for erythroblast renewal in vitro. Cells from GRdim/ dim, Epo RH, and Stat5ab -/ - mice showed enhanced differentiation instead of renewal, causing accumulation of mature cells and gradual proliferation arrest. Stat5ab was additionally required for Epo- induced terminal differentiation: differentiating Stat5ab (-/ -) erythroblasts underwent apoptosis instead of erythrocyte maturation, due to absent induction of the antiapoptotic protein Bcl- X-L. This defect could be fully rescued by exogenous Bcl- X-L. These data suggest that signaling molecules driving leukemic proliferation may also be essential for prolonged self- renewal of normal erythroid progenitors.	Inst Mol Pathol, VBC, A-1030 Vienna, Austria; Med Univ Vienna, Div Mol Biol, Dept Med Biochem, Max F Perutz Labs, Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Beug, H (corresponding author), Inst Mol Pathol, VBC, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	beug@imp.univie; ernst.muellner@univie.ac.at	Moriggl, Richard/H-8118-2019; Grebien, Florian/H-9234-2019; Dolznig, Helmut/L-7005-2015; Habermann, Bianca/N-4886-2016	Moriggl, Richard/0000-0003-0918-9463; Grebien, Florian/0000-0003-4289-2281; Dolznig, Helmut/0000-0002-6063-3585; Habermann, Bianca/0000-0002-2457-7504	Austrian Science Fund FWF [F 2809, F 2807, F 2802, F 2801] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; BEUG H, 1995, ONCOGENE, V11, P59; BEUG H, 1996, BIOCHIM BIOPHYS ACTA, V1128, pM35; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; Carotta S, 2004, BLOOD, V104, P1873, DOI 10.1182/blood-2004-02-0570; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Dolznig H, 2004, METH MOLEC MED, V105, P323; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Doppler W, 2000, ADV EXP MED BIOL, V480, P139; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Kieslinger M, 2000, GENE DEV, V14, P232; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Li K, 2003, BLOOD, V102, P3147, DOI 10.1182/blood-2003-01-0078; MIKULITS W, 1995, NUCLEIC ACIDS RES, V23, P2342, DOI 10.1093/nar/23.12.2342; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Onnebo SMN, 2005, EXP HEMATOL, V33, P182, DOI 10.1016/j.exphem.2004.10.019; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; Schulte CE, 2002, EMBO J, V21, P4297, DOI 10.1093/emboj/cdf429; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; von Lindern M, 2004, CELL CYCLE, V3, P876; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; YU H, 2004, NAT REV CANCER, V4, P655; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156	48	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2890	2900		10.1038/sj.onc.1209308	http://dx.doi.org/10.1038/sj.onc.1209308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407844	Green Accepted			2022-12-25	WOS:000237448200007
J	Furuta, T; Hayward, RL; Meng, LH; Takemura, H; Aune, GJ; Bonner, WM; Aladjem, MI; Kohn, KW; Pommier, Y				Furuta, T.; Hayward, R. L.; Meng, L-H; Takemura, H.; Aune, G. J.; Bonner, W. M.; Aladjem, M. I.; Kohn, K. W.; Pommier, Y.			P21(CDKN1A) allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine	ONCOGENE			English	Article						UCN-01 (7-hydroxystaurosporine); p21; p53; gamma H2AX; camptothecin; cell cycle; DNA repair; DNA double-strand break	CELL-CYCLE ARREST; HISTONE H2AX PHOSPHORYLATION; HUMAN COLON-CARCINOMA; S-PHASE CHECKPOINT; DAMAGE CHECKPOINT; PROTEIN-KINASE; CLEAVAGE COMPLEXES; UP-REGULATION; CANCER CELLS; G(2) ARREST	This study provides evidence for the importance of p21(CDKN1A) for the repair of replication- mediated DNA double- strand breaks ( DSBs) induced by topoisomerase I. We report that defects of p21(CDKN1A) and p53 enhance camptothecin- induced histone H2AX phosphorylation ( gamma H2AX), a marker for DNA DSBs. In human colon carcinoma HCT116 cells with wild- type ( wt) p53, gamma H2AX reverses after camptothecin removal. By contrast, gamma H2AX increases after camptothecin removal in HCT116 cells deficient for p53 ( p53-/-) or p21(CDKN1A) ( p21-/-) as the cells reach the late- S and G2 phases. Since p21-/- cells exhibit similar S- phase arrest as wt cells in response to camptothecin and aphidicolin does not abrogate the enhanced gamma H2AX formation in p21-/- cells, we conclude that enhanced gamma H2AX formation in p21-/- cells is not due to re- replication. The cell cycle checkpoint abrogator and Chk1/ Chk2 inhibitor 7- hydroxystaurosporine ( UCN- 01) also increases camptothecin- induced gamma H2AX formation and inhibits camptothecin- induced p21(CDKN1A) upregulation in HCT116 wt cells. TUNEL ( terminal deoxynucleotidyl transferase ( TdT)- mediated dUTP- biotin nick end labeling) assays demonstrate that gamma H2AX formation in late S and G2 cells following CPT treatment corresponds to DNA breaks. However, these breaks are not related to apoptotic DNA fragmentation. We propose that p21(CDKN1A) prevents the collapse of replication forks damaged by stabilized topoisomerase I cleavage complexes.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 5060, Bethesda, MD 20892 USA.	pommier@nih.gov	Aune, Gregory/I-5895-2015; meng, linghua/Y-8110-2019; Aladjem, Mirit/G-2169-2010	Aune, Gregory/0000-0002-2750-6461; Aladjem, Mirit/0000-0002-1875-3110	NATIONAL CANCER INSTITUTE [ZIABC006150, Z01BC006150] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Antony S, 2004, NUCLEIC ACIDS RES, V32, P5685, DOI 10.1093/nar/gkh902; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; FAN SJ, 1995, CANCER RES, V55, P1649; Foiani M, 1998, BIOL CHEM, V379, P1019; Fujimori A, 1996, MOL PHARMACOL, V50, P1472; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Goldwasser F, 1996, CANCER RES, V56, P4430; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Guo CY, 1999, RADIAT RES, V151, P125, DOI 10.2307/3579762; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hayward RL, 2003, CLIN CANCER RES, V9, P2856; Hinz JM, 2003, CARCINOGENESIS, V24, P249, DOI 10.1093/carcin/24.2.249; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang X, 2004, CYTOM PART A, V58A, P99, DOI 10.1002/cyto.a.20018; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Larminat F, 2004, BIOL CELL, V96, P545, DOI 10.1016/j.biolcel.2004.06.001; Levesque AA, 2005, ONCOGENE, V24, P3786, DOI 10.1038/sj.onc.1208451; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Liu WM, 1998, INT J ONCOL, V12, P793; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Pommier Y, 2005, TRENDS PHARMACOL SCI, V26, P138, DOI 10.1016/j.tips.2005.01.008; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; POMMIER Y, 2006, PROG NUCL ACID RES M; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Raderschall E, 2002, J CELL SCI, V115, P153; Rao VA, 2005, MOL CELL BIOL, V25, P8925, DOI 10.1128/MCB.25.20.8925-8937.2005; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Senderowicz AM, 2002, ONCOLOGIST, V7, P12; Shao RG, 2004, ACTA PHARMACOL SIN, V25, P756; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shi Z, 2001, CANCER RES, V61, P1065; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TORNUSCIOLO DRZ, 1995, BIOTECHNIQUES, V19, P800; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wu JX, 2002, MOL PHARMACOL, V61, P742, DOI 10.1124/mol.61.4.742; Wyllie FS, 1996, ONCOGENE, V12, P1077; Yu Q, 2002, CANCER RES, V62, P5743; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	79	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2839	2849		10.1038/sj.onc.1209313	http://dx.doi.org/10.1038/sj.onc.1209313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407843				2022-12-25	WOS:000237448200002
J	Taylor, EJ; Gloster, TM; Turkenburg, JP; Vincent, F; Brzozowski, AM; Dupont, C; Shareck, F; Centeno, MSJ; Prates, JAM; Puchart, V; Ferreira, LMA; Fontes, CMGA; Biely, P; Davies, GJ				Taylor, EJ; Gloster, TM; Turkenburg, JP; Vincent, F; Brzozowski, AM; Dupont, C; Shareck, F; Centeno, MSJ; Prates, JAM; Puchart, V; Ferreira, LMA; Fontes, CMGA; Biely, P; Davies, GJ			Structure and activity of two metal ion-dependent acetylxylan esterases involved in plant cell wall degradation reveals a close similarity to peptidoglycan deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERULOYL ESTERASE; CLOSTRIDIUM-THERMOCELLUM; CRYSTAL-STRUCTURE; STREPTOMYCES-LIVIDANS; CARBOHYDRATE ESTERASE; SUBSTRATE-SPECIFICITY; TRICHODERMA-REESEI; XYLAN ESTERASE; CATALYTIC CORE; INSIGHTS	The enzymatic degradation of plant cell wall xylan requires the concerted action of a diverse enzymatic syndicate. Among these enzymes are xylan esterases, which hydrolyze the O-acetyl substituents, primarily at the O-2 position of the xylan backbone. All acetylxylan esterase structures described previously display a alpha/beta hydrolase fold with a "Ser-His-Asp" catalytic triad. Here we report the structures of two distinct acetylxylan esterases, those from Streptomyces lividans and Clostridium thermocellum, in native and complex forms, with x-ray data to between 1.6 and 1.0 angstrom resolution. We show, using a novel linked assay system with PNP-2-O-acetyl-xyloside and a beta-xylosidase, that the enzymes are sugar-specific and metal ion-dependent and possess a single metal center with a chemical preference for Co2+. Asp and His side chains complete the catalytic machinery. Different metal ion preferences for the two enzymes may reflect the surprising diversity with which the metal ion coordinates residues and ligands in the active center environment of the S. lividans and C. thermocellum enzymes. These "CE4" esterases involved in plant cell wall degradation are shown to be closely related to the de-N-acetylases involved in chitin and peptidoglycan degradation (Blair, D. E., Schuettelkopf, A. W., MacRae, J.I., and Aalten, D. M. (2005) Proc. Natl. Acad. Sci. U.S.A., 102, 15429-15434), which form the NodB deacetylase "superfamily."	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Quebec, Inst Armand Frappier, INRA, Laval, PQ H7V 1B7, Canada; Univ Tecn Lisboa, Fac Vet Med, Ctr Interdisciplinar Invest Sanidade Anim, P-1300477 Lisbon, Portugal; Slovak Acad Sci, Inst Chem, Bratislava 84538, Slovakia	University of York - UK; University of Quebec; Universidade de Lisboa; Slovak Academy of Sciences	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Puchart, Vladimir/AAD-6496-2019; Prates, José A M/K-9934-2013; Vincent, Florence/F-7137-2016; Biely, Peter/ABF-3465-2020; Davies, Gideon J/A-9042-2011	Prates, José A M/0000-0003-1032-5987; Biely, Peter/0000-0002-9915-7707; Davies, Gideon J/0000-0002-7343-776X; Puchart, Vladimir/0000-0002-6434-3462; Taylor, Edward/0000-0003-4024-0976; Ferreira, Luis/0000-0002-3543-9166; Turkenburg, Johan/0000-0001-6992-6838; Fontes, Carlos/0000-0002-1219-9753; vincent, Florence/0000-0002-8564-4184; Centeno, Maria S. Jose/0000-0002-8586-5542				Altaner C, 2003, J BIOTECHNOL, V105, P95, DOI 10.1016/S0168-1656(03)00187-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biely P, 2004, ANAL BIOCHEM, V332, P109, DOI 10.1016/j.ab.2004.04.022; Biely P, 2003, BBA-GEN SUBJECTS, V1622, P82, DOI 10.1016/S0304-4165(03)00130-2; Blair DE, 2005, P NATL ACAD SCI USA, V102, P15429, DOI 10.1073/pnas.0504339102; Blair DE, 2004, FEBS LETT, V570, P13, DOI 10.1016/j.febslet.2004.06.013; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Bornscheuer UT, 2002, FEMS MICROBIOL REV, V26, P73, DOI 10.1016/S0168-6445(01)00075-4; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Caufrier F, 2003, CARBOHYD RES, V338, P687, DOI 10.1016/S0008-6215(03)00002-8; Collins T, 2005, FEMS MICROBIOL REV, V29, P3, DOI 10.1016/j.femsre.2004.06.005; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Crepin VF, 2004, APPL MICROBIOL BIOT, V63, P647, DOI 10.1007/s00253-003-1476-3; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fernandes AC, 1999, BIOCHEM J, V342, P105, DOI 10.1042/0264-6021:3420105; Ghosh D, 2001, J BIOL CHEM, V276, P11159, DOI 10.1074/jbc.M008831200; Hakulinen N, 2000, J STRUCT BIOL, V132, P180, DOI 10.1006/jsbi.2000.4318; Hekmat O, 2003, BIOCHEM J, V374, P369, DOI 10.1042/BJ20030204; Henrissat B, 2001, PLANT MOL BIOL, V47, P55, DOI 10.1023/A:1010667012056; Hermoso JA, 2004, J MOL BIOL, V338, P495, DOI 10.1016/j.jmb.2004.03.003; Hernick M, 2005, ARCH BIOCHEM BIOPHYS, V433, P71, DOI 10.1016/j.abb.2004.08.006; Kleywegt GJ, 1997, J MOL BIOL, V272, P383, DOI 10.1006/jmbi.1997.1243; Kosugi A, 2002, APPL ENVIRON MICROB, V68, P6399, DOI 10.1128/AEM.68.12.6399-6402.2002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Mathew S, 2004, CRIT REV BIOTECHNOL, V24, P59, DOI 10.1080/07388550490491467; McAuley KE, 2004, ACTA CRYSTALLOGR D, V60, P878, DOI 10.1107/S0907444904004937; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Prates JAM, 2001, STRUCTURE, V9, P1183, DOI 10.1016/S0969-2126(01)00684-0; Psylinakis E, 2005, J BIOL CHEM, V280, P30856, DOI 10.1074/jbc.M407426200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schubot FD, 2001, BIOCHEMISTRY-US, V40, P12524, DOI 10.1021/bi011391c; SHARECK F, 1995, GENE, V153, P105, DOI 10.1016/0378-1119(94)00763-I; Tarbouriech N, 2005, ACTA CRYSTALLOGR D, V61, P194, DOI 10.1107/S0907444904029695; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Uson I, 1999, CURR OPIN STRUC BIOL, V9, P643, DOI 10.1016/S0959-440X(99)00020-2; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vincent F, 2003, J MOL BIOL, V330, P593, DOI 10.1016/S0022-2836(03)00632-6; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742	46	91	94	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10968	10975		10.1074/jbc.M513066200	http://dx.doi.org/10.1074/jbc.M513066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16431911	hybrid, Green Published			2022-12-25	WOS:000236822200037
J	Chen, L; Patel, RP; Teng, XJ; Bosworth, CA; Lancaster, JR; Matalon, S				Chen, L; Patel, RP; Teng, XJ; Bosworth, CA; Lancaster, JR; Matalon, S			Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitrosoglutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALVEOLAR EPITHELIAL-CELLS; DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; CHLORIDE CHANNELS; AIRWAY EPITHELIA; SODIUM-CHANNELS; CL-CHANNEL; CFTR; TRANSPORT; NITROSOTHIOLS	We investigated the mechanisms by which S-nitrosoglutathione (GSNO) alters cystic fibrosis transmembrane conductance regulator (CFTR) mediated chloride (Cl-) secretion across Calu-3 cells, an extensively used model of human airway gland serous cells. Confluent monolayers of Calu-3 cells, grown under an air-liquid interface, were mounted in Ussing chambers for the measurements of chloride short circuit current (I-sc) and trans-epithelial resistance (R-t). Addition of GSNO into the apical compartment of these chambers resulted in significant and sustained increase of I-sc with an IC50 of 3.2 +/- 1 mu M (mean +/- 1 S.E.; n = 6). Addition of either glibenclamide or pre-treatment of Calu-3 cells with the soluble guanylate cyclase inhibitor 1H-(1,2,4)-oxadiazolo[4,3-a]quinoxalin-1-one totally prevented the GSNO-induced increase of I-sc. Conversely, BAY 41-2272, a sGC stimulator, increased I-sc in a dose-response fashion. The GSNO increase of I-sc was reversed by addition of two phosphatases (PP2A1, PP2A2) into the apical compartment of Ussing chambers containing Calu-3 monolayers. Oxy-myoglobin (oxy-Mb, 300 mu M) added into the apical compartment of Ussing chambers either prior or after GSNO either completely prevented or immediately reversed the increase of I-sc. However, smaller concentrations of oxy-Mb (1-10 mu M), sufficient to scavenge NO in the medium (as assessed by direct measurement of NO in the Ussing chamber using an ISO-NO meter) decreased I-sc partially. Oxy-Mb did not reverse the increase of I-sc following addition of GSNO and cysteine (50 mu M). These findings indicate that GSNO stimulates Cl secretion via both cGMP-dependent and cGMP-independent mechanisms.	Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35205 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35205 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35205 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Matalon, S (corresponding author), Univ Alabama Birmingham, Dept Anesthesiol, 901 19th St S,BMR 2,Rm 224, Birmingham, AL 35205 USA.	sadis@uab.edu		Patel, Rakesh/0000-0002-1526-4303	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031197, R01HL075540, R01HL070146, R37HL031197, R01HL071189, R01HL074391] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL71189, HL31197, HL075540, HL70146, HL51173, HL074391] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; BERGER HA, 1993, J BIOL CHEM, V268, P2037; Chen L, 2004, AM J PHYSIOL-RENAL, V286, pF1202, DOI 10.1152/ajprenal.00352.2003; Cornwell TL, 2003, AM J PHYSIOL-CELL PH, V284, pC1516, DOI 10.1152/ajpcell.00268.2002; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; DEJONGE HR, 1976, NATURE, V262, P590, DOI 10.1038/262590a0; DuVall MD, 1998, AM J PHYSIOL-CELL PH, V274, pC1417, DOI 10.1152/ajpcell.1998.274.5.C1417; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Grasemann H, 1999, J PEDIATR-US, V135, P770, DOI 10.1016/S0022-3476(99)70101-0; Guo Y, 1998, AM J PHYSIOL-LUNG C, V274, pL369, DOI 10.1152/ajplung.1998.274.3.L369; Haddad IY, 1996, AM J PHYSIOL-LUNG C, V270, pL898, DOI 10.1152/ajplung.1996.270.6.L898; He H, 2003, AM J PHYSIOL-RENAL, V284, pF1235, DOI 10.1152/ajprenal.00192.2002; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Jilling T, 1999, AM J PHYSIOL-LUNG C, V277, pL89, DOI 10.1152/ajplung.1999.277.1.L89; KOTAMRAJU S, 2005, IN PRESS FREE RADIC; Lancaster JR, 1996, METHOD ENZYMOL, V268, P31; Lazrak A, 2002, AM J PHYSIOL-LUNG C, V282, pL650, DOI 10.1152/ajplung.00370.2001; Matalon S, 2003, AM J PHYSIOL-LUNG C, V285, pL1184, DOI 10.1152/ajplung.00281.2003; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; MATALON S, 2005, P AM THORACIC SOC, V2, P299; MCCRAY PB, 1993, AM J RESP CELL MOL, V9, P578, DOI 10.1165/ajrcmb/9.6.578; Muanprasat C, 2004, J GEN PHYSIOL, V124, P125, DOI 10.1085/jgp.200409059; Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; Stasch JP, 2001, NATURE, V410, P212, DOI 10.1038/35065611; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Thome U, 2003, FREE RADICAL BIO MED, V35, P662, DOI 10.1016/S0891-5849(03)00392-7; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Wang W, 2005, J GEN PHYSIOL, V125, P127, DOI 10.1085/jgp.200409115; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; Zaman K, 2004, BIOCHEM J, V380, P67, DOI 10.1042/BJ20031687; Zaman K, 2001, BIOCHEM BIOPH RES CO, V284, P65, DOI 10.1006/bbrc.2001.4935; Zhang YH, 2005, FREE RADICAL BIO MED, V38, P831, DOI 10.1016/j.freeradbiomed.2004.12.016; Zhang YH, 2004, P NATL ACAD SCI USA, V101, P7891, DOI 10.1073/pnas.0401167101	39	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9190	9199		10.1074/jbc.M513231200	http://dx.doi.org/10.1074/jbc.M513231200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16421103	hybrid			2022-12-25	WOS:000236404700025
J	Hirao, K; Natsuka, Y; Tamura, T; Wada, I; Morito, D; Natsuka, S; Romero, P; Sleno, B; Tremblay, LO; Herscovics, A; Nagata, K; Hosokawa, N				Hirao, K; Natsuka, Y; Tamura, T; Wada, I; Morito, D; Natsuka, S; Romero, P; Sleno, B; Tremblay, LO; Herscovics, A; Nagata, K; Hosokawa, N			EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; CLASS-I ALPHA-1,2-MANNOSIDASE; EARLY SECRETORY PATHWAY; SHORT-LIVED VARIANT; N-LINKED GLYCANS; QUALITY-CONTROL; SACCHAROMYCES-CEREVISIAE; ALPHA-MANNOSIDASE; MISFOLDED GLYCOPROTEINS; STRUCTURAL BASIS	Quality control in the endoplasmic reticulum ensures that only properly folded proteins are retained in the cell through mechanisms that recognize and discard misfolded or unassembled proteins in a process called endoplasmic reticulum-associated degradation (ERAD). We previously cloned EDEM ( ER degradation-enhancing alpha-mannosidase- like protein) and showed that it accelerates ERAD of misfolded glycoproteins. We now cloned mouse EDEM3, a soluble homolog of EDEM. EDEM3 consists of 931 amino acids and has all the signature motifs of Class I alpha-mannosidases ( glycosyl hydrolase family 47) in its N-terminal domain and a protease-associated motif in its C-terminal region. EDEM3 accelerates glycoprotein ERAD in transfected HEK293 cells, as shown by increased degradation of misfolded alpha 1-antitrypsin variant ( null ( Hong Kong)) and of TCR alpha. Overexpression of EDEM3 also greatly stimulates mannose trimming not only from misfolded alpha 1-AT null ( Hong Kong) but also from total glycoproteins, in contrast to EDEM, which has no apparent alpha 1,2-mannosidase activity. Furthermore, overexpression of the E147Q EDEM3 mutant, which has the mutation in one of the conserved acidic residues essential for enzyme activity of alpha 1,2-mannosidases, abolishes the stimulation of mannose trimming and greatly decreases the stimulation of ERAD by EDEM3. These results show that EDEM3 has alpha 1,2-mannosidase activity in vivo, suggesting that the mechanism whereby EDEM3 accelerates glycoprotein ERAD is different from that of EDEM.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068397, Japan; JST, CREST, Saitama 3320012, Japan; Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan; Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	Kyoto University; Japan Science & Technology Agency (JST); Fukushima Medical University; Osaka University; McGill University	Hosokawa, N (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Kyoto 6068397, Japan.	nobuko@frontier.kyoto-u.ac.jp	Natsuka, Shunji/L-9330-2018	Morito, Daisuke/0000-0003-2263-8200; Natsuka, Shunji/0000-0003-1726-8946; Tamura, Taku/0000-0001-6074-9273; Wada, Ikuo/0000-0001-5668-6994				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Carninci P, 2003, GENOME RES, V13, P1273, DOI 10.1101/gr.1119703; Chillaron J, 2000, BIOL CHEM, V381, P1155, DOI 10.1515/BC.2000.143; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ermonval M, 2001, GLYCOBIOLOGY, V11, P565, DOI 10.1093/glycob/11.7.565; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Frenkel Z, 2003, J BIOL CHEM, V278, P34119, DOI 10.1074/jbc.M305929200; HASE S, 1994, METHOD ENZYMOL, V230, P225; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Huyer G, 2004, J BIOL CHEM, V279, P38369, DOI 10.1074/jbc.M402468200; Jakob CA, 2001, EMBO REP, V2, P423; Kitzmuller C, 2003, BIOCHEM J, V376, P687, DOI 10.1042/BJ20030887; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; Lipari F, 1996, J BIOL CHEM, V271, P27615, DOI 10.1074/jbc.271.44.27615; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; Luo XM, 2001, TRENDS BIOCHEM SCI, V26, P147, DOI 10.1016/S0968-0004(00)01768-0; Mast SW, 2005, GLYCOBIOLOGY, V15, P421, DOI 10.1093/glycob/cwi014; McCracken AA, 2003, BIOESSAYS, V25, P868, DOI 10.1002/bies.10320; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Movsichoff F, 2005, MOL BIOL CELL, V16, P4714, DOI 10.1091/mbc.E05-03-0246; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Olivari S, 2005, J BIOL CHEM, V280, P2424, DOI 10.1074/jbc.C400534200; ROMERO PA, 1985, BIOCHEM J, V226, P733, DOI 10.1042/bj2260733; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Sitia R, 2003, NATURE, V426, P891, DOI 10.1038/nature02262; Sood R, 2001, GENOMICS, V73, P211, DOI 10.1006/geno.2001.6500; Tempel W, 2004, J BIOL CHEM, V279, P29774, DOI 10.1074/jbc.M403065200; Tokunaga F, 2000, J BIOL CHEM, V275, P40757, DOI 10.1074/jbc.M001073200; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Van Petegem F, 2001, J MOL BIOL, V312, P157, DOI 10.1006/jmbi.2001.4946; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	49	189	193	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9650	9658		10.1074/jbc.M512191200	http://dx.doi.org/10.1074/jbc.M512191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431915	hybrid			2022-12-25	WOS:000236404700077
J	Sommer, ME; Smith, WC; Farrens, DL				Sommer, ME; Smith, WC; Farrens, DL			Dynamics of arrestin-rhodopsin interactions - Acidic phospholipids enable binding of arrestin to purified rhodopsin in detergent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; PROTEIN-CONTAINING MEMBRANES; METARHODOPSIN-II; FUNCTIONAL-CHARACTERIZATION; PHOTORECEPTOR-MEMBRANES; VISUAL TRANSDUCTION; SIGNAL-TRANSDUCTION; COUPLED RECEPTOR; META-III; OPSIN	We report that acidic phospholipids can restore the binding of visual arrestin to purified rhodopsin solubilized in n-dodecyl-beta-D-maltopyranoside. We used this finding to investigate the interplay between arrestin binding and the status of the retinal chromophore ligand in the receptor binding pocket. Our results showed that arrestin can interact with the late photoproduct Meta III and convert it to a Meta II-like species. Interestingly in these mixed micelles, the release of retinal and arrestin was no longer directly coupled as it is in the native rod disk membrane. For example, up to similar to 50% of the retinal could be released even though arrestin remains bound to the receptor in a long lived complex. We anticipate that this new ability to study these proteins in a defined, purified system will facilitate further structural and dynamic studies of arrestin-rhodopsin interactions.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	Oregon Health & Science University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Farrens, DL (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.	farrensd@ohsu.edu	Smith, W. Clay/AAQ-1589-2021	Sommer, Martha E./0000-0003-0493-8584	NEI NIH HHS [EY06225, EY08571] Funding Source: Medline; NIDA NIH HHS [DA14896] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA014896] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alves ID, 2005, BIOPHYS J, V88, P198, DOI 10.1529/biophj.104.046722; ANDERSON RE, 1976, INVEST OPHTH VISUAL, V15, P232; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Aveldano MI, 1995, ARCH BIOCHEM BIOPHYS, V324, P331, DOI 10.1006/abbi.1995.0046; AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024; AVELDANO MI, 1983, J LIPID RES, V24, P620; BOWNDS D, 1965, NATURE, V205, P254, DOI 10.1038/205254a0; Bubis J, 1998, BIOL RES, V31, P59; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; Dryja TP, 2000, AM J OPHTHALMOL, V130, P547, DOI 10.1016/S0002-9394(00)00737-6; Dupuy C, 1997, LANGMUIR, V13, P3965, DOI 10.1021/la9604285; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2003, VISION RES, V43, P3003, DOI 10.1016/j.visres.2003.08.011; Hessel E, 2003, J BIOL CHEM, V278, P22853, DOI 10.1074/jbc.M302747200; Hessel E, 2001, J BIOL CHEM, V276, P2538, DOI 10.1074/jbc.M009061200; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Kiselev A, 1996, BIOCHEMISTRY-US, V35, P1848, DOI 10.1021/bi951399k; KOSOWER EM, 1986, J PHYS CHEM-US, V90, P5552, DOI 10.1021/j100280a014; Kragh-Hansen U, 1998, BIOPHYS J, V75, P2932, DOI 10.1016/S0006-3495(98)77735-5; KRAGHHANSEN U, 1993, BIOCHEMISTRY-US, V32, P1648, DOI 10.1021/bi00057a032; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lewis JW, 1997, VISION RES, V37, P1, DOI 10.1016/S0042-6989(96)00138-1; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Lichtenberg D, 2000, BBA-BIOMEMBRANES, V1508, P1, DOI 10.1016/S0304-4157(00)00004-6; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Mansoor SE, 2004, BIOCHEMISTRY-US, V43, P9426, DOI 10.1021/bi036259m; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Marsh D, 2004, BBA-BIOMEMBRANES, V1666, P118, DOI 10.1016/j.bbamem.2004.08.006; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Niu L, 2002, P NATL ACAD SCI USA, V99, P13409, DOI 10.1073/pnas.212518899; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pepe IM, 2001, PROG RETIN EYE RES, V20, P733, DOI 10.1016/S1350-9462(01)00013-1; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; RIM J, 1995, BIOCHEMISTRY-US, V34, P11938, DOI 10.1021/bi00037a035; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Seddon AM, 2004, BBA-BIOMEMBRANES, V1666, P105, DOI 10.1016/j.bbamem.2004.04.011; Sommer ME, 2005, J BIOL CHEM, V280, P6861, DOI 10.1074/jbc.M411341200; Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2004, BIOCHEMISTRY-US, V43, P9457, DOI 10.1021/bi049337u; Wang Y, 2002, J AM CHEM SOC, V124, P7690, DOI 10.1021/ja0200488; Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200	57	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9407	9417		10.1074/jbc.M510037200	http://dx.doi.org/10.1074/jbc.M510037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16428804	hybrid			2022-12-25	WOS:000236404700050
J	Xu, DG; Xie, DQ; Guo, H				Xu, DG; Xie, DQ; Guo, H			Catalytic mechanism of class B2 metallo-beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-FUNCTIONAL-THEORY; SCC-DFTB METHOD; BACILLUS-CEREUS; BACTEROIDES-FRAGILIS; ACTIVE-SITE; CRYSTAL-STRUCTURE; STENOTROPHOMONAS-MALTOPHILIA; COORDINATION GEOMETRY; ALKALINE-HYDROLYSIS; ANGSTROM RESOLUTION	The initial nucleophilic substitution step of biapenem hydrolysis catalyzed by a subclass B2 metallo-beta-lactamase (CphA from Aeromonas hydrophila) is investigated using hybrid quantum mechanical/ molecular mechanical methods and density functional theory. We focused on a recently proposed catalytic mechanism that involves a non-metal-binding water nucleophile in the active site of the monozinc CphA. Both theoretical models identified a single transition state featuring nearly concomitant nucleophilic addition and elimination steps, and the activation free energy from the potential of mean force calculations was estimated to be similar to 14 kcal/ mol. The theoretical results also identified the general base for activating the water nucleophile to be the metal-binding Asp-120 rather than His-118, as suggested earlier. The protonation of Asp-120 leads to cleavage of the O-delta 2-Zn coordination bond, whereas the negatively charged nitrogen leaving group resulting from the ring opening replaces Asp-120 as the fourth ligand of the sole zinc ion. The electrophilic catalysis by the metal ion provides sufficient stabilization for the leaving group to avoid a tetrahedral intermediate. The theoretical studies provided detailed insights into the catalytic strategy of this unique metallo-beta-lactamase.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Nanjing Univ, Inst Theoret & Computat Chem, Dept Chem, Nanjing 210093, Peoples R China	University of New Mexico; Nanjing University	Guo, H (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	hguo@unm.edu	Guo, H./J-2685-2014	Guo, H./0000-0001-9901-053X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P7208, DOI 10.1021/bi00370a066; Bounaga S, 1998, BIOCHEM J, V331, P703, DOI 10.1042/bj3310703; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1989, J MOL BIOL, V208, P159, DOI 10.1016/0022-2836(89)90093-4; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Coll M, 2000, J PHYS CHEM B, V104, P11389, DOI 10.1021/jp001989e; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Crawford PA, 2005, BIOCHEMISTRY-US, V44, P5168, DOI 10.1021/bi047463s; Cui Q, 2001, J PHYS CHEM B, V105, P569, DOI 10.1021/jp0029109; Dal Peraro M, 2004, J AM CHEM SOC, V126, P12661, DOI 10.1021/ja048071b; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; Diaz N, 2000, J AM CHEM SOC, V122, P4197, DOI 10.1021/ja994462s; Diaz N, 2002, CHEM-EUR J, V8, P859, DOI 10.1002/1521-3765(20020215)8:4<859::AID-CHEM859>3.0.CO;2-I; Elstner M, 1998, PHYS REV B, V58, P7260, DOI 10.1103/PhysRevB.58.7260; Elstner M, 2003, J COMPUT CHEM, V24, P565, DOI 10.1002/jcc.10201; Elstner M, 2001, J CHEM PHYS, V114, P5149, DOI 10.1063/1.1329889; Fabiane SM, 1998, BIOCHEMISTRY-US, V37, P12404, DOI 10.1021/bi980506i; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; FISCHER S, 1992, CHEM PHYS LETT, V194, P252, DOI 10.1016/0009-2614(92)85543-J; Fisher JF, 2005, CHEM REV, V105, P395, DOI 10.1021/cr030102i; Gao JL, 2002, ANNU REV PHYS CHEM, V53, P467, DOI 10.1146/annurev.physchem.53.091301.150114; Garau G, 2005, J MOL BIOL, V345, P785, DOI 10.1016/j.jmb.2004.10.070; Garrity JD, 2005, BIOCHEMISTRY-US, V44, P1078, DOI 10.1021/bi048385b; Garrity JD, 2004, J BIOL CHEM, V279, P920, DOI 10.1074/jbc.M309852200; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812; LIM HM, 1991, BIOCHEM J, V276, P401, DOI 10.1042/bj2760401; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Olsen L, 2003, J PHYS CHEM B, V107, P2366, DOI 10.1021/jp0275950; Orellano EG, 1998, BIOCHEMISTRY-US, V37, P10173, DOI 10.1021/bi980309j; Park H, 2005, J AM CHEM SOC, V127, P4232, DOI 10.1021/ja042607b; Prosperi-Meys C, 2001, CELL MOL LIFE SCI, V58, P2136, DOI 10.1007/PL00000843; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; RICCARDI D, IN PRESS J PHYS CH B; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; TORRIE GM, 1977, J COMPUT PHYS, V23, P187, DOI 10.1016/0021-9991(77)90121-8; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1998, J BIOL CHEM, V273, P22402, DOI 10.1074/jbc.273.35.22402; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Warshel A, 2003, ANNU REV BIOPH BIOM, V32, P425, DOI 10.1146/annurev.biophys.32.110601.141807; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; Xu DG, 2005, J MED CHEM, V48, P6679, DOI 10.1021/jm0505112; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	49	64	67	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8740	8747		10.1074/jbc.M512517200	http://dx.doi.org/10.1074/jbc.M512517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16423823	hybrid			2022-12-25	WOS:000236247100052
J	Park, JW; Je, BR; Piao, S; Inamura, S; Fujimoto, Y; Fukase, K; Kusumoto, S; Soderhall, K; Ha, NC; Lee, BL				Park, JW; Je, BR; Piao, S; Inamura, S; Fujimoto, Y; Fukase, K; Kusumoto, S; Soderhall, K; Ha, NC; Lee, BL			A synthetic peptidoglycan fragment as a competitive inhibitor of the melanization cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TENEBRIO-MOLITOR LARVAE; PROPHENOLOXIDASE-ACTIVATING SYSTEM; PATTERN-RECOGNITION PROTEIN; IMMUNE-RESPONSES; INNATE IMMUNITY; BOMBYX-MORI; BORDETELLA-PERTUSSIS; DIAMINOPIMELIC ACID; PRO-PHENOLOXIDASE; SERINE-PROTEASE	Melanin synthesis is essential for defense and development but must be tightly controlled because systemic hyperactivation of the prophenoloxidase and excessive melanin synthesis are deleterious to the hosts. The melanization cascade of the arthropods can be activated by bacterial lysine-peptidoglycan (PGN), diaminopimelic acid (DAP)-PGN, or fungal beta-1,3-glucan. The molecular mechanism of how DAP- or Lys-PGN induces melanin synthesis and which molecules are involved in distinguishing these PGNs are not known. The identification of PGN derivatives that can work as inhibitors of the melanization cascade and the characterization of PGN recognition molecules will provide important information to clarify how the melanization is regulated and controlled. Here, we report that a novel synthetic Lys-PGN fragment ((GlcNAc-Mur-NAc- L-Ala-D-isoGln-L-Lys-D-Ala)(2), T-4P(2)) functions as a competitive inhibitor of the natural PGN-induced melanization reaction. By using a T-4P(2)-coupled column, we purified the Tenebrio molitor PGN recognition protein (Tm-PGRP) without causing activation of the prophenoloxidase. The purified Tm-PGRP recognized both Lys- and DAP- PGN. In vitro reconstitution experiments showed that Tm-PGRP functions as a common recognition molecule of Lys- and DAP- PGN-dependent melanization cascades.	Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Pusan National University; Osaka University; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Natl Res Lab Def Prot, Pusan 609735, South Korea.	brlee@pusan.ac.kr	Fujimoto, Yukari/M-7282-2014	Fujimoto, Yukari/0000-0001-5320-3192				Ashida Masaaki, 1998, P135; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Cho JH, 2005, BLOOD, V106, P2551, DOI 10.1182/blood-2005-02-0530; COOKSON BT, 1989, INFECT IMMUN, V57, P2223, DOI 10.1128/IAI.57.7.2223-2229.1989; COOKSON BT, 1989, BIOCHEMISTRY-US, V28, P1744, DOI 10.1021/bi00430a048; DAQUINAG AC, 1995, P NATL ACAD SCI USA, V92, P2964, DOI 10.1073/pnas.92.7.2964; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Guan RJ, 2005, J MOL BIOL, V347, P683, DOI 10.1016/j.jmb.2005.01.070; GUPTA D, 1995, J IMMUNOL, V155, P2620; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Iketani M, 1999, INSECT BIOCHEM MOLEC, V29, P19, DOI 10.1016/S0965-1748(98)00099-X; Inamura S, 2006, ORG BIOMOL CHEM, V4, P232, DOI 10.1039/b511866b; Inamura S, 2001, TETRAHEDRON LETT, V42, P7613, DOI 10.1016/S0040-4039(01)01619-7; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kaneko T, 2004, IMMUNITY, V20, P637, DOI 10.1016/S1074-7613(04)00104-9; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kanost Michael R, 2004, Immunol Rev, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kumar S, 2005, J BIOL CHEM, V280, P37005, DOI 10.1074/jbc.M506385200; Lee HS, 1999, FEBS LETT, V444, P255, DOI 10.1016/S0014-5793(99)00067-8; Lee KM, 2000, EUR J BIOCHEM, V267, P3695, DOI 10.1046/j.1432-1327.2000.01402.x; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee MH, 2004, J BIOL CHEM, V279, P3218, DOI 10.1074/jbc.M309821200; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liang ZC, 1997, P NATL ACAD SCI USA, V94, P6682, DOI 10.1073/pnas.94.13.6682; Lien E, 2001, J BIOL CHEM, V276, P1873, DOI 10.1074/jbc.M009040200; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; Mellroth P, 2005, P NATL ACAD SCI USA, V102, P6455, DOI 10.1073/pnas.0407559102; Nappi AJ, 2001, ADV EXP MED BIOL, V484, P329; Nikulina M, 2004, J IMMUNOL, V173, P1925, DOI 10.4049/jimmunol.173.3.1925; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Parker LC, 2004, J IMMUNOL, V172, P4977, DOI 10.4049/jimmunol.172.8.4977; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Piao S, 2005, BBA-PROTEINS PROTEOM, V1752, P103, DOI 10.1016/j.bbapap.2005.05.008; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHLEIFER KH, 1983, ANNU REV MICROBIOL, V37, P143, DOI 10.1146/annurev.mi.37.100183.001043; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; YOSHIDA H, 1986, BIOCHEM BIOPH RES CO, V141, P1177, DOI 10.1016/S0006-291X(86)80168-1; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Zhang R, 2003, J BIOL CHEM, V278, P42072, DOI 10.1074/jbc.M307475200; Zhao MY, 2005, J BIOL CHEM, V280, P24744, DOI 10.1074/jbc.M504173200; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200	52	46	52	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7747	7755		10.1074/jbc.M510058200	http://dx.doi.org/10.1074/jbc.M510058200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421099	hybrid			2022-12-25	WOS:000236031000007
J	Song, K; Krebs, TL; Danielpour, D				Song, K; Krebs, TL; Danielpour, D			Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression - Mediation by stabilization of TGF-beta receptor type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC EPITHELIAL-CELLS; BREAST-CANCER CELLS; MALIGNANT-TRANSFORMATION; INDUCED APOPTOSIS; MESSENGER-RNA; EXPRESSION; ACTIVATION; PATHWAY; PROTEIN; GROWTH-FACTOR-BETA-1	Transforming growth factor beta (TGF-beta) signals through TGF-beta receptor serine/threonine kinases (T beta RI and T beta RII) and Smads, regulating cell growth and apoptosis. Although loss of TGF-beta receptor levels is strongly selected for during the progression of most cancers, tumor cells frequently escape from complete loss of TGF-beta receptors through unknown mechanisms. Here, we provide the first evidence that epidermal growth factor (EGF) signaling, which is generally enhanced in cancer, is permissive for regulation of gene expression and growth suppression by TGF-beta in LNCaP prostate adenocarcinoma cells. Our results support that these permissive effects occur through enhanced stability of T beta RII mRNA and reversal of TGF-beta-mediated T beta RII mRNA loss. Changes in stability of T beta RII mRNA occur soon after EGF or TGF-beta 1 addition ( optimal within 3 h) and are independent of de novo protein synthesis or transcription. Remarkably, such loss of T beta RII by TGF-beta can be mediated by a kinase-dead T beta RII (K277R), as well as by other forms of this receptor harboring mutations at prominent autophosphorylation sites. Moreover, Smad3 small interfering RNA, which blocks TGF-beta-induced AP-1 promoter activity, does not block changes in the expression of T beta RII by EGF or TGF-beta. We have also shown that changes in T beta RII levels by EGF are EGF receptor-kinase-dependent and are controlled by signals downstream of MEK1/2. Our findings provide invaluable insights on the role of the EGF receptor-kinase in enhancing TGF-beta responses during prostate carcinogenesis.	Case Western Reserve Univ, Case Comprehens Canc Ctr, Div Gen Med Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Danielpour, D (corresponding author), Case Canc Ctr Res Labs, Wolstein Res Bldg,Rm 3532,2103 Cornell Rd, Cleveland, OH 44106 USA.	dxd49@case.edu			NCI NIH HHS [R01CA102074, R01CA092102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102074, R01CA092102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Chang J, 1997, CANCER RES, V57, P2856; Chen XY, 2004, ONCOGENE, V23, P1854, DOI 10.1038/sj.onc.1207308; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; DANIELPOUR D, 1995, J IMMUNOL METHODS, V180, P265, DOI 10.1016/0022-1759(94)00322-N; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; DANIELPOUR D, 1991, J CELL PHYSIOL, V148, P235, DOI 10.1002/jcp.1041480208; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; Dore JJE, 2001, MOL BIOL CELL, V12, P675, DOI 10.1091/mbc.12.3.675; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Fombonne J, 2004, MOL BIOL CELL, V15, P4938, DOI 10.1091/mbc.E04-07-0601; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; Garamszegi N, 2001, MOL BIOL CELL, V12, P2881, DOI 10.1091/mbc.12.9.2881; Guo YP, 1999, CANCER RES, V59, P1366; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hsing AY, 1996, CANCER RES, V56, P5146; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ilio KY, 1995, J ANDROL, V16, P482; Jakowlew SB, 1997, ANTICANCER RES, V17, P1849; Jones HE, 1997, PROSTATE, V30, P219, DOI 10.1002/(SICI)1097-0045(19970301)30:4<219::AID-PROS1>3.0.CO;2-G; Juarranz MG, 2001, CELL SIGNAL, V13, P887, DOI 10.1016/S0898-6568(01)00199-1; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kim IY, 1998, EXP CELL RES, V241, P151, DOI 10.1006/excr.1998.4034; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kutz SM, 2001, J CELL SCI, V114, P3905; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LANDIS MD, 2005, ONCOGENE; Lee BI, 2001, CANCER RES, V61, P931; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; McCaffrey TA, 1999, J MOL CELL CARDIOL, V31, P1627, DOI 10.1006/jmcc.1999.0999; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; ROBERTS AB, 1983, FED PROC, V42, P2621; ROBERTS AB, 1990, HDB EXPT PHARM PEPTI, P414; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Song K, 2003, CANCER RES, V63, P4358; Stewart LMV, 2003, EXP CELL RES, V284, P303, DOI 10.1016/S0014(02)00037-X; Tang BW, 1999, CANCER RES, V59, P4834; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yamane K, 2003, ARTHRITIS RHEUM-US, V48, P1652, DOI 10.1002/art.11029; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521	70	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7765	7774		10.1074/jbc.M511781200	http://dx.doi.org/10.1074/jbc.M511781200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428382	hybrid			2022-12-25	WOS:000236031000009
J	Bachmann, RA; Kim, JH; Wu, AL; Park, IH; Chen, J				Bachmann, RA; Kim, JH; Wu, AL; Park, IH; Chen, J			A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; REPRESSOR PHAS-I; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; SEQUENCE REQUIREMENTS; BINDING PARTNER; EXPORT SIGNAL; PHOSPHORYLATION; DOMAIN; RAPTOR; MTOR	The mammalian target of rapamycin ( mTOR) regulates nutrient-dependent cell growth and proliferation through cytoplasmic targets, such as S6 kinase 1 (S6K1). Consistent with its main function in the cytoplasm, mTOR is predominantly cytoplasmic. However, previously we have found that mTOR shuttles between the nucleus and cytoplasm, and we have proposed that the nucleocytoplasmic shuttling of mTOR is required for the maximal activation of S6K1. The intrinsic signals directing mTOR nuclear transport and the underlying mechanisms are unknown. In this study we initially set out to identify nuclear export signals in mTOR. A systematic scan of the mTOR sequence revealed 16 peptides conforming to the canonical leucine-rich nuclear export signal, of which 3 were found by reporter assays to contain leptomycin B-sensitive and leucine-dependent nuclear export activity. Unexpectedly, mTOR proteins with those conserved leucines mutated to alanines were unable to enter the nucleus. Further investigation revealed that the L982A/ L984A and L1287A/L1289A mutations likely induced a global structural change in mTOR, whereas the L545A/L547A mutation directly impaired the nuclear import of the protein, potentially regulated by a nucleocytoplasmic shuttling signal. The loss of nuclear import was accompanied by the significantly reduced ability of the L545A/L547A mutant to activate S6K1 in cells. Most importantly, when nuclear import was restored in the L545A/L547A mutant by the addition of an exogenous nuclear import signal, signaling to S6K1 was rescued. Taken together, our observations suggest the existence of a nuclear shuttling signal in mTOR and provide definitive evidence for the requirement of mTOR nuclear import in its cytoplasmic signaling to S6K1.	Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, J (corresponding author), 601 S Goodwin Ave,B107, Urbana, IL 61801 USA.	jiechen@uiuc.edu		Chen, Jie/0000-0002-7887-3747	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058064, R55GM058064] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 48914] Funding Source: Medline; NIGMS NIH HHS [GM 58064] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; DRENAN RM, 2003, J BIOL CHEM, V24, P24; Dupont S, 1999, NATURE, V402, P681, DOI 10.1038/45272; Erbay E., 2005, Nutrients and cell signaling, P353; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Tirado OM, 2003, CANCER RES, V63, P6290; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Xu L, 2003, J BIOL CHEM, V278, P42569, DOI 10.1074/jbc.M307601200	47	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7357	7363		10.1074/jbc.M512218200	http://dx.doi.org/10.1074/jbc.M512218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407298	hybrid			2022-12-25	WOS:000236030900055
J	Ge, WT; Hu, HG; Ding, KF; Sun, LF; Zheng, S				Ge, WT; Hu, HG; Ding, KF; Sun, LF; Zheng, S			Protein interaction analysis of ST14 domains and their point and deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; SERINE-PROTEASE; MATRIPTASE; IDENTIFICATION; TMEFF1; HYBRIDIZATION; LOCALIZATION; INHIBITORS; ACTIVATOR	ST14 ( suppression of tumorigenicity 14) is a transmembrane serine protease that contains a serine protease catalytic (SP) domain, an SEA domain, two complement subcomponent C1r/s ( CUB) domains, and four low density lipoprotein receptor class A domains. Glutathione S-transferase fusion proteins with SP, CUB, and low density lipoprotein receptor domains and their corresponding mutants were generated to analyze protein interactions with these domains. Modified glutathione S-transferase pull-down assays demonstrated the interaction between the SP domain and hepatocyte growth factor activator inhibitor-1. With the same method, a CUB domain-interacting protein was isolated and turned out to be the transmembrane protein with epidermal growth factor-like and two follistatin-like domains 1 (TMEFF1). Quantitative real time PCR revealed that the expression of the TMEFF1 gene was dependent on the transfection of the ST14 gene in the RKO cell line. Our results also suggested that ST14 and TMEFF1 were co-expressed in the human breast cancer cell line MCF7, human placenta, kidney, and liver tissues. Interestingly, these two genes were co-upregulated in kidney tumors versus normal tissues, consistent with our results that showed the dependence of TMEFF1 expression on ST14 in RKO cells. Finally, homology modeling studies suggested that TMEFF1 might form a complex with ST14 by an interaction between epidermal growth factor and CUB domains.	Zhejiang Univ, Coll Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310009, Peoples R China; Zhejiang Univ, Coll Life Sci, Hangzhou 310029, Peoples R China	Zhejiang University; Zhejiang University	Zheng, S (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Inst Canc, Hangzhou 310009, Peoples R China.	zhengshu@zju.edu.cn	GE, Weiting/AAK-5197-2020	GE, Weiting/0000-0002-4769-0251				Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; Bhatt AS, 2003, BIOL CHEM, V384, P257, DOI 10.1515/BC.2003.029; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Cao J, 2001, CHINESE MED J-PEKING, V114, P726; Cao Jiang, 2005, Shi Yan Sheng Wu Xue Bao, V38, P183; Cao JN, 1997, J CANCER RES CLIN, V123, P447, DOI 10.1007/s004320050085; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; Gery S, 2003, ONCOGENE, V22, P2723, DOI 10.1038/sj.onc.1206351; Grimmond SM, 2003, GENOME RES, V13, P1350, DOI 10.1101/gr.983703; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kanemoto N, 2001, MOL BRAIN RES, V86, P48, DOI 10.1016/S0169-328X(00)00257-6; Kang JY, 2003, CANCER RES, V63, P1101; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Li WZ, 2002, PROTEIN ENG, V15, P643, DOI 10.1093/protein/15.8.643; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Orlinick JR, 1996, J BIOL CHEM, V271, P8627, DOI 10.1074/jbc.271.15.8627; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Sambrook J., 2001, MOL CLONING LAB MANU, P16; Satomi S, 2001, BIOCHEM BIOPH RES CO, V287, P995, DOI 10.1006/bbrc.2001.5686; SHI Y, 2004, ZHONGHUA BING LI SHE, V20, P1329; SHI YE, 1993, CANCER RES, V53, P1409; Shi Ying, 2005, Zhejiang Da Xue Xue Bao Yi Xue Ban, V34, P38; Sun Li-feng, 2004, Zhonghua Yi Xue Za Zhi, V84, P843; Szabo R, 2005, BIOCHEM J, V390, P231, DOI 10.1042/BJ20050299; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Yamasaki Y, 2003, J NUTR SCI VITAMINOL, V49, P27, DOI 10.3177/jnsv.49.27; Ye S, 2003, RHEUMATOLOGY, V42, P1155, DOI 10.1093/rheumatology/keg315; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125; Zheng S, 1997, Zhonghua Yi Xue Za Zhi, V77, P256	45	15	22	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7406	7412		10.1074/jbc.M510687200	http://dx.doi.org/10.1074/jbc.M510687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407223	hybrid			2022-12-25	WOS:000236030900061
J	McGrath, MJ; Cottle, DL; Nguyen, MA; Dyson, JM; Coghill, ID; Robinson, PA; Holdsworth, M; Cowling, BS; Hardeman, EC; Mitchell, CA; Brown, S				McGrath, MJ; Cottle, DL; Nguyen, MA; Dyson, JM; Coghill, ID; Robinson, PA; Holdsworth, M; Cowling, BS; Hardeman, EC; Mitchell, CA; Brown, S			Four and a half LIM protein 1 binds myosin-binding protein C and regulates myosin filament formation and sarcomere assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE HYPERTROPHY; CARDIAC MYOSIN; MYBP-C; ONLY PROTEIN; ALPHA-ACTININ; DILATED CARDIOMYOPATHY; X-PROTEIN; H-PROTEIN; DOMAIN; EXPRESSION	Four and a half LIM protein 1 (FHL1/SLIM1) is highly expressed in skeletal and cardiac muscle; however, the function of FHL1 remains unknown. Yeast two-hybrid screening identified slow type skeletal myosin-binding protein C as an FHL1 binding partner. Myosin-binding protein C is the major myosin-associated protein in striated muscle that enhances the lateral association and stabilization of myosin thick filaments and regulates actomyosin interactions. The interaction between FHL1 and myosin-binding protein C was confirmed using co-immunoprecipitation of recombinant and endogenous proteins. Recombinant FHL2 and FHL3 also bound myosin-binding protein C. FHL1 impaired co-sedimentation of myosin-binding protein C with reconstituted myosin filaments, suggesting FHL1 may compete with myosin for binding to myosin-binding protein C. In intact skeletal muscle and isolated myofibrils, FHL1 localized to the I-band, M-line, and sarcolemma, co-localizing with myosin-binding protein C at the sarcolemma in intact skeletal muscle. Furthermore, in isolated myofibrils FHL1 staining at the M-line appeared to extend partially into the C-zone of the A-band, where it co-localized with myosin-binding protein C. Overexpression of FHL1 in differentiating C2C12 cells induced "sac-like" myotube formation (myosac), associated with impaired Z-line and myosin thick filament assembly. This phenotype was rescued by co-expression of myosin-binding protein C. FHL1 knockdown using RNAi resulted in impaired myosin thick filament formation associated with reduced incorporation of myosin-binding protein C into the sarcomere. This study identified FHL1 as a novel regulator of myosin-binding protein C activity and indicates a role for FHL1 in sarcomere assembly.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Childrens Med Res Inst, Muscle Dev Unit, Westmead, NSW 2145, Australia	Monash University; Children's Medical Research Institute - Australia	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Wellington Rd, Clayton, Vic 3800, Australia.	christina.mitchell@med.monash.edu.au	Cottle, Denny/G-4278-2013; Hardeman, Edna C/F-8872-2012; Cowling, Belinda S/O-2730-2016; Cottle, Denny/AAN-1574-2020	Cowling, Belinda S/0000-0001-6915-2596; Cottle, Denny/0000-0001-5047-6515; Hardeman, Edna/0000-0003-1649-7712; McGrath, Meagan/0000-0002-9414-6558; Mitchell, Christina A/0000-0001-9372-3192				Alyonycheva TN, 1997, J BIOL CHEM, V272, P20866, DOI 10.1074/jbc.272.33.20866; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENNETT P, 1986, J MUSCLE RES CELL M, V7, P550, DOI 10.1007/BF01753571; Berthier C, 1997, BIOL CELL, V89, P413, DOI 10.1016/S0248-4900(97)89313-6; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Brown S, 1999, J MOL CELL CARDIOL, V31, P837, DOI 10.1006/jmcc.1998.0922; Carbo N, 2000, BRIT J CANCER, V83, P526, DOI 10.1054/bjoc.2000.1299; Carrier L, 2004, CARDIOVASC RES, V63, P293, DOI 10.1016/j.cardiores.2004.04.009; Carrier L, 1997, CIRC RES, V80, P427, DOI 10.1161/01.res.0000435859.24609.b3; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; Coghill ID, 2003, J BIOL CHEM, V278, P24139, DOI 10.1074/jbc.M213259200; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; DENNIS JE, 1984, J CELL BIOL, V98, P1514, DOI 10.1083/jcb.98.4.1514; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Flashman E, 2004, CIRC RES, V94, P1279, DOI 10.1161/01.RES.0000127175.21818.C2; Flick MJ, 2000, J CELL SCI, V113, P1553; Gaussin V, 2003, CIRCULATION, V108, P2926, DOI 10.1161/01.CIR.0000101922.18151.7B; Gilbert R, 1996, J CELL SCI, V109, P101; Gruen M, 1999, J MOL BIOL, V286, P933, DOI 10.1006/jmbi.1998.2522; Harris SP, 2002, CIRC RES, V90, P594, DOI 10.1161/01.RES.0000012222.70819.64; Hwang DM, 2000, GENOMICS, V66, P1, DOI 10.1006/geno.2000.6171; Hwang DM, 1997, CIRCULATION, V96, P4146; KANG SJ, 1995, J CELL BIOL, V130, P1127, DOI 10.1083/jcb.130.5.1127; KNIGHT PJ, 1982, METHOD ENZYMOL, V85, P9; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; KORETZ JF, 1979, BIOPHYS J, V27, P433, DOI 10.1016/S0006-3495(79)85227-3; LANE BP, 1977, J HISTOCHEM CYTOCHEM, V25, P69, DOI 10.1177/25.1.833423; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; Lim DS, 2001, J AM COLL CARDIOL, V38, P1175, DOI 10.1016/S0735-1097(01)01509-1; LIN ZX, 1987, J CELL BIOL, V105, P1365, DOI 10.1083/jcb.105.3.1365; LIN ZX, 1989, J CELL BIOL, V108, P1079, DOI 10.1083/jcb.108.3.1079; Littlefield R, 2002, BIOPHYS J, V82, P2548, DOI 10.1016/S0006-3495(02)75598-7; Loughna P. T., 2000, Molecular Cell Biology Research Communications, V3, P136, DOI 10.1006/mcbr.2000.0206; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Marian AJ, 2001, J MOL CELL CARDIOL, V33, P655, DOI 10.1006/jmcc.2001.1340; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; McGrath MJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1513, DOI 10.1152/ajpcell.00207.2003; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Mermelstein CD, 1996, J MUSCLE RES CELL M, V17, P199, DOI 10.1007/BF00124242; Miyamoto CA, 1999, J MUSCLE RES CELL M, V20, P703, DOI 10.1023/A:1005513312939; Mohapatra B, 2003, MOL GENET METAB, V80, P207, DOI 10.1016/S1096-7192(03)00142-2; MOOS C, 1975, J MOL BIOL, V97, P1, DOI 10.1016/S0022-2836(75)80017-9; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P245, DOI 10.1006/bbrc.1999.0179; MORGAN MJ, 1995, BIOCHEM BIOPH RES CO, V212, P840, DOI 10.1006/bbrc.1995.2045; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; OKAGAKI T, 1993, J CELL BIOL, V123, P619, DOI 10.1083/jcb.123.3.619; Palmer S, 2001, J CELL BIOL, V153, P985, DOI 10.1083/jcb.153.5.985; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669; Quinn LS, 2002, EXP CELL RES, V280, P55, DOI 10.1006/excr.2002.5624; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; Robinson PA, 2003, AM J PHYSIOL-CELL PH, V284, pC681, DOI 10.1152/ajpcell.00370.2002; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; SAITOH O, 1988, CELL TISSUE RES, V252, P263; Samson T, 2004, J BIOL CHEM, V279, P28641, DOI 10.1074/jbc.M312894200; Sato N, 2003, MOL BIOL CELL, V14, P3180, DOI 10.1091/mbc.E02-10-0685; Sebillon P, 2001, CR ACAD SCI III-VIE, V324, P251, DOI 10.1016/S0764-4469(00)01292-0; Seiler SH, 1996, MOL BIOL CELL, V7, P113, DOI 10.1091/mbc.7.1.113; STARR R, 1985, J MUSCLE RES CELL M, V6, P227, DOI 10.1007/BF00713063; STARR R, 1978, BIOCHEM J, V171, P813, DOI 10.1042/bj1710813; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; Welikson RE, 2002, J CELL SCI, V115, P3517; Winegrad S, 1999, CIRC RES, V84, P1117, DOI 10.1161/01.RES.84.10.1117; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yan JH, 2003, FEBS LETT, V553, P183, DOI 10.1016/S0014-5793(03)00978-5; Yang QL, 1999, CIRC RES, V85, P841, DOI 10.1161/01.RES.85.9.841; Yang QL, 1998, J CLIN INVEST, V102, P1292, DOI 10.1172/JCI3880; Yang YG, 2000, CELL STRUCT FUNCT, V25, P177, DOI 10.1247/csf.25.177; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	91	96	102	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7666	7683		10.1074/jbc.M512552200	http://dx.doi.org/10.1074/jbc.M512552200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407297	hybrid			2022-12-25	WOS:000236030900088
J	Mishra, P; Akhtar, MS; Bhakuni, V				Mishra, P; Akhtar, MS; Bhakuni, V			Unusual structural features of the bacteriophage-associated hyaluronate lyase (hylp2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; GENOME SEQUENCE; PYOGENES; GENE; MECHANISM; COMPLEX; ACID; HYALURONIDASES; DEGRADATION; PROTEINS	Hyaluronate lyases are a class of endoglycosaminidase enzymes, which are of considerable complexity and heterogeneity. Their primary function is to degrade hyaluronan and certain other glycosaminoglycans and facilitate the spread of disease. Among hyaluronate lyases, the bacteriophage-associated enzymes are unique as they have the lowest molecular mass, very low amino acid sequence homology with bacterial hyaluronate lyases, and exhibit absolute specificity for one type of glycosaminoglycan, i.e. hyaluronan. Despite such unique characteristics significant details on structural features of these lyases are not available. The Streptococcus pyogenes bacteriophage 10403 contains a gene, hylP2, which encodes for hyaluronate lyase (HylP2) in this organism. HylP2 was cloned, overexpressed, and purified to homogeneity. The recombinant HylP2 exists as a homotrimer of molecular mass about 110 kDa, under physiological conditions. Limited proteolysis and guanidine hydrochloride denaturation studies demonstrated that the N-terminal region of the protein is flexible, whereas the C-terminal portion has a compact conformation. The enzyme shows sequential unfolding, with the N-terminal unfolding first followed by the simultaneous unfolding and dissociation of the stabilized trimeric C-terminal domain. We isolated a functionally active C-terminal fragment (Ser(128) - Lys(337)) of the protein that was stabilized in a trimeric configuration. Comparative functional studies with full-length protein, N:C complex, and isolated C-terminal domain demonstrated that the active site of HylP2 is present in the C-terminal portion of the enzyme, and the N-terminal portion modulates the substrate specificity and enzymatic activity of the C-terminal domain.	Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bhakuni, V (corresponding author), Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India.	bhakuniv@rediffmail.com	Akhtar, Sohail/A-2300-2010; Mishra, Parul/AAY-2911-2020	Mishra, Parul/0000-0002-2989-7371				Akhtar MS, 2003, J BIOL CHEM, V278, P25509, DOI 10.1074/jbc.M301894200; Ali V, 1999, BIOCHEMISTRY-US, V38, P13635, DOI 10.1021/bi9907835; ANDREWS P, 1965, BIOCHEM J, V96, P569; Baker JR, 2002, BIOCHEM J, V365, P317, DOI 10.1042/BJ20020149; BENCHETRIT LC, 1978, J BACTERIOL, V134, P221, DOI 10.1128/JB.134.1.221-228.1978; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; Chaturvedi S, 2003, J BIOL CHEM, V278, P40793, DOI 10.1074/jbc.M306192200; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Harrington DJ, 2002, MICROBES INFECT, V4, P501, DOI 10.1016/S1286-4579(02)01565-4; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Hynes WL, 2000, FEMS MICROBIOL LETT, V184, P109, DOI 10.1016/S0378-1097(00)00029-X; Hynes WL, 2000, FEMS MICROBIOL LETT, V183, P201, DOI 10.1111/j.1574-6968.2000.tb08958.x; HYNES WL, 1989, INFECT IMMUN, V57, P533, DOI 10.1128/IAI.57.2.533-539.1989; HYNES WL, 1995, INFECT IMMUN, V63, P3015, DOI 10.1128/IAI.63.8.3015-3020.1995; KJEMS EBBE, 1958, ACTA PATHOL ET MICROBIOL SCAND, V42, P56; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; Lackowicz JR., 2006, PRINCIPLES FLUORESCE, V3, DOI 10.1007/978-0-387-46312-4; LINHARDT RJ, 1986, APPL BIOCHEM BIOTECH, V12, P135; LUI GY, 2004, FRONT BIOSCI, V9, P1794; Marciel AM, 1997, MICROB PATHOGENESIS, V22, P209, DOI 10.1006/mpat.1996.9999; MAXTED WR, 1952, NATURE, V170, P1020, DOI 10.1038/1701020b0; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; NIEMANN H, 1976, ACTA PATH MICRO IM B, V84, P145; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Pritchard DG, 2000, PROTEINS, V40, P126; Rigden DJ, 2003, J BIOL CHEM, V278, P50596, DOI 10.1074/jbc.M307596200; SHIMADA E, 1980, J BIOCHEM-TOKYO, V88, P557; Smith NL, 2005, P NATL ACAD SCI USA, V102, P17652, DOI 10.1073/pnas.0504782102; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; SONGLIN L, 2001, J BIOL CHEM, V276, P41407; Starr CR, 2006, INFECT IMMUN, V74, P40, DOI 10.1128/IAI.74.1.40-48.2006; STERN M, 1992, MOL BIOL EVOL, V9, P1179	34	13	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7143	7150		10.1074/jbc.M510991200	http://dx.doi.org/10.1074/jbc.M510991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415347	hybrid			2022-12-25	WOS:000236030900029
J	Rosenblat, M; Gaidukov, L; Khersonsky, O; Vaya, J; Oren, R; Tawfik, DS; Aviram, M				Rosenblat, M; Gaidukov, L; Khersonsky, O; Vaya, J; Oren, R; Tawfik, DS; Aviram, M			The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; PLATELET-ACTIVATING-FACTOR; LACTONASE ACTIVITY; LIPID PEROXIDES; TRANSGENIC MICE; HIGH-AFFINITY; ATHEROSCLEROSIS; CELLS; ANTIOXIDANTS; STRESS	High density lipoprotein (HDL)-associated paraoxonase-1 (PON1) anti-atherogenic properties in macrophages, i.e. inhibition of cell-mediated oxidation of low density lipoprotein (LDL) and stimulation of cholesterol efflux, were studied using recombinant variants of PON1 and apoA-I expressed in Escherichia coli and reconstituted HDL(rHDL) particles composed of phosphatidylcholine/free cholesterol (PC/FC) and apoA-I. PON1 lactonase activity is stimulated by apoA-I by similar to 7-fold relative to PC/FC particles. Wild-type (WT) PON1 bound to rHDL inhibited macrophage-mediated LDL oxidation and stimulated cholesterol efflux from the cells to 2.3- and 3.2-fold greater extents, respectively, compared with WT PON1 bound to PC/FC particles without apoA-I. We also tested PON1 catalytic histidine dyad mutants (H115Q and H134Q) that are properly folded and that bind HDL in a similar mode compared with WT PON1, but that exhibit almost no lactonase activity. These could not inhibit macrophage-mediated LDL oxidation or stimulate rHDL-mediated cholesterol efflux from the cells. Furthermore, whereas HDL-bound WT PON1 induced the formation of lysophosphatidylcholine (LPC) in macrophages, the His dyad mutants did not, suggesting that the above anti-atherogenic properties of HDL-associated PON1 involve LPC release. Indeed, enrichment of macrophages with increasing concentrations of LPC resulted in inhibition of the cells' capability to oxidize LDL and in stimulation of HDL-mediated cholesterol efflux from the macrophages in an LPC dose-dependent manner. Thus, we provide the first direct indication that the anti-atherogenic properties of PON1 are related to its lipolactonase activity and propose a model in which PON1 acts as a lipolactonase to break down oxidized lipids and to generate LPC.	Rambam Med Ctr, Lipid Res Lab, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Lipid Res Lab, IL-31096 Haifa, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Migal Galilee Technol Ctr, Lab Nat Med Cpds, IL-11016 Kiryat Shmona, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Weizmann Institute of Science	Aviram, M (corresponding author), Rambam Med Ctr, Lipid Res Lab, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel.	aviram@tx.technion.ac.il						Aharoni A, 2004, P NATL ACAD SCI USA, V101, P482, DOI 10.1073/pnas.2536901100; Ahmed Z, 2001, J BIOL CHEM, V276, P24473, DOI 10.1074/jbc.M010459200; AVIRAM M, 1983, BIOCHEM MED METAB B, V30, P111, DOI 10.1016/0006-2944(83)90013-3; Aviram M, 1999, MOL MED TODAY, V5, P381, DOI 10.1016/S1357-4310(99)01546-4; Aviram M, 2000, CIRCULATION, V101, P2510, DOI 10.1161/01.CIR.101.21.2510; Aviram M, 2004, FREE RADICAL BIO MED, V37, P1304, DOI 10.1016/j.freeradbiomed.2004.06.030; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; Bilenko MV, 2003, B EXP BIOL MED+, V135, P349, DOI 10.1023/A:1024656613633; Billeclke S, 2000, DRUG METAB DISPOS, V28, P1335; BLATTER MC, 1993, EUR J BIOCHEM, V211, P871, DOI 10.1111/j.1432-1033.1993.tb17620.x; Buege J A, 1978, Methods Enzymol, V52, P302; Connelly PW, 2005, FREE RADICAL BIO MED, V38, P164, DOI 10.1016/j.freeradbiomed.2004.10.010; Deakin S, 2005, ATHEROSCLEROSIS, V179, P17, DOI 10.1016/j.atherosclerosis.2004.08.039; Deakin S, 2002, J BIOL CHEM, V277, P4301, DOI 10.1074/jbc.M107440200; Draganov DI, 2005, J LIPID RES, V46, P1239, DOI 10.1194/jlr.M400511-JLR200; ELSAADANI M, 1989, J LIPID RES, V30, P627; Fuhrman B, 2005, ATHEROSCLEROSIS, V180, P55, DOI 10.1016/j.atherosclerosis.2004.12.009; Fuhrman B, 2002, ATHEROSCLEROSIS, V161, P307, DOI 10.1016/S0021-9150(01)00646-3; Gaidukov L, 2005, BIOCHEMISTRY-US, V44, P11843, DOI 10.1021/bi050862i; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P412, DOI 10.1038/nsmb767; Harel M, 2004, NAT STRUCT MOL BIOL, V11, P1253, DOI 10.1038/nsmb1204-1253a; James RW, 2004, FREE RADICAL BIO MED, V37, P1986, DOI 10.1016/j.freeradbiomed.2004.08.012; Khersonsky O, 2006, J BIOL CHEM, V281, P7649, DOI 10.1074/jbc.M512594200; Khersonsky O, 2006, CHEMBIOCHEM, V7, P49, DOI 10.1002/cbic.200500334; Khersonsky O, 2005, BIOCHEMISTRY-US, V44, P6371, DOI 10.1021/bi047440d; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mackness B, 2003, CIRCULATION, V107, P2775, DOI 10.1161/01.CIR.0000070954.00271.13; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; MATZ CE, 1982, J BIOL CHEM, V257, P4535; Navab M, 2000, J LIPID RES, V41, P1481; Navab M, 2000, J LIPID RES, V41, P1495; Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1325, DOI 10.1161/01.ATV.0000165694.39518.95; Navab M, 1996, ARTERIOSCL THROM VAS, V16, P831, DOI 10.1161/01.ATV.16.7.831; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; Oda MN, 2002, BIOCHEM BIOPH RES CO, V290, P921, DOI 10.1006/bbrc.2001.6295; Oda MN, 2001, BIOCHEMISTRY-US, V40, P1710, DOI 10.1021/bi001922h; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Rosenblat M, 2005, ATHEROSCLEROSIS, V179, P69, DOI 10.1016/j.atherosclerosis.2004.10.028; ROSENBLAT M, 2006, IN PRESS ATHEROSCLER; Rozenberg O, 2005, ATHEROSCLEROSIS, V181, P9, DOI 10.1016/j.atherosclerosis.2004.12.030; Rozenberg O, 2003, ARTERIOSCL THROM VAS, V23, P461, DOI 10.1161/01.ATV.0000060462.35946.B3; Rozenberg O, 2003, FREE RADICAL BIO MED, V34, P774, DOI 10.1016/S0891-5849(02)01429-6; Segrest JP, 2000, TRENDS CARDIOVAS MED, V10, P246, DOI 10.1016/S1050-1738(00)00078-5; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; Stadler N, 2004, ARTERIOSCL THROM VAS, V24, P949, DOI 10.1161/01.ATV.0000124892.90999.cb; Teiber JF, 2004, J LIPID RES, V45, P2260, DOI 10.1194/jlr.M400213-JLR200; Teiber JF, 2003, BIOCHEM PHARMACOL, V66, P887, DOI 10.1016/S0006-2952(03)00401-5; Tward A, 2002, CIRCULATION, V106, P484, DOI 10.1161/01.CIR.0000023623.87083.4F	55	185	191	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7657	7665		10.1074/jbc.M512595200	http://dx.doi.org/10.1074/jbc.M512595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407304	hybrid			2022-12-25	WOS:000236030900087
J	Yu, LQ; Bharadwaj, S; Brown, JM; Ma, YY; Du, W; Davis, MA; Michaely, P; Liu, PS; Willingham, MC; Rudel, LL				Yu, LQ; Bharadwaj, S; Brown, JM; Ma, YY; Du, W; Davis, MA; Michaely, P; Liu, PS; Willingham, MC; Rudel, LL			Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL-SENSING DOMAIN; POLARIZED HEPATIC CELLS; PICK C1 PROTEIN; ABSORPTION INHIBITOR; BILE CANALICULI; LIVING CELLS; EZETIMIBE; TRANSPORT; HOMEOSTASIS; MEMBRANE	Although NPC1L1 is required for intestinal cholesterol absorption, data demonstrating mechanisms by which this protein facilitates the process are few. In this study, a hepatoma cell line stably expressing human NPC1L1 was established, and cholesterol uptake was studied. A relationship between NPC1L1 intracellular trafficking and cholesterol uptake was apparent. At steady state, NPC1L1 proteins localized predominantly to the transferrin-positive endocytic recycling compartment, where free cholesterol also accumulated as revealed by filipin staining. Interestingly, acute cholesterol depletion induced with methyl-beta-cyclodextrin stimulated relocation of NPC1L1 to the plasma membrane, preferentially to a newly formed "apical-like" subdomain. This translocation was associated with a remarkable increase in cellular cholesterol uptake, which in turn was dose-dependently inhibited by ezetimibe, a novel cholesterol absorption inhibitor that specifically binds to NPC1L1. These findings define a cholesterol-regulated endocytic recycling of NPC1L1 as a novel mechanism regulating cellular cholesterol uptake.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Sect Lipid Sci, Winston Salem, NC 27157 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, LQ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Sect Lipid Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lyu@wfubmc.edu	Liu, Pingsheng/B-7124-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL043973, R00HL096166] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R00 HL096166, HL-43973] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORNIG H, 1974, ACTA HISTOCHEM, V50, P110; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHIU JH, 1990, HEPATOLOGY, V11, P834, DOI 10.1002/hep.1840110519; Davies JP, 2005, J BIOL CHEM, V280, P12710, DOI 10.1074/jbc.M409110200; Davies JP, 2000, GENOMICS, V65, P137, DOI 10.1006/geno.2000.6151; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Garcia-Calvo M, 2005, P NATL ACAD SCI USA, V102, P8132, DOI 10.1073/pnas.0500269102; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOTTARDI CJ, 1995, AM J PHYSIOL, V268, P285; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Iyer SPN, 2005, BBA-GEN SUBJECTS, V1722, P282, DOI 10.1016/j.bbagen.2004.12.021; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Kramer W, 2005, J BIOL CHEM, V280, P1306, DOI 10.1074/jbc.M406309200; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; OSHIO C, 1981, SCIENCE, V212, P1041, DOI 10.1126/science.7015506; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Smart EJ, 2004, P NATL ACAD SCI USA, V101, P3450, DOI 10.1073/pnas.0400441101; SORMUNEN R, 1993, LAB INVEST, V68, P652; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Sudhop T, 2002, CIRCULATION, V106, P1943, DOI 10.1161/01.CIR.0000034044.95911.DC; Tuma PL, 1999, J CELL BIOL, V145, P1089, DOI 10.1083/jcb.145.5.1089; Valasek MA, 2005, J BIOL CHEM, V280, P28103, DOI 10.1074/jbc.M504609200; van Heek M, 2001, BRIT J PHARMACOL, V134, P409, DOI 10.1038/sj.bjp.0704260; VanHeek M, 1997, J PHARMACOL EXP THER, V283, P157; Wustner D, 2002, J BIOL CHEM, V277, P30325, DOI 10.1074/jbc.M202626200; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898	40	156	174	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6616	6624		10.1074/jbc.M511123200	http://dx.doi.org/10.1074/jbc.M511123200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407187	hybrid			2022-12-25	WOS:000236030800058
J	Courtney, HS; Zhang, YM; Frank, MW; Rock, CO				Courtney, HS; Zhang, YM; Frank, MW; Rock, CO			Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE PROTEIN; CHOLESTEROL; PYOGENES; METABOLISM; MECHANISMS; DOMAIN; MICE	Serum opacity factor (SOF) is a virulence determinant of group A streptococci that opacifies mammalian sera. We analyzed the specificity and mechanism of the opacity reaction using a recombinant form of the amino-terminal opacification domain of SOF, rSOF. Our data indicate that rSOF is neither a protease nor a lipase, but rather it is the binding of rSOF to high density lipoprotein (HDL) that triggers the opacity reaction. rSOF did not opacify plasma from apoA-I-/- mice or purified low or very low density lipoproteins but readily opacified HDL. rSOF binding to HDL was characterized by two high affinity binding sites; it bound to apoA-I (K-d = 6 nM) and apoA-II (K-d = 30 nM), and both apoA-I and apoA-II blocked the binding of rSOF to HDL. Electron microscopic examination and biochemical analyses of HDL treated with rSOF revealed the formation of lipid droplets devoid of apolipoproteins. Thus, SOF interacts with HDL in human blood by binding to apoA-I and apoA-II and causing the release of HDL lipid cargo, which coalesces to form lipid droplets, resulting in opacification. The disruption of HDL may attenuate its anti-inflammatory functions and contribute to the pathogenesis of group A streptococcal infections.	Vet Affairs Med Ctr, Res Serv 151, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38104 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Courtney, HS (corresponding author), Vet Affairs Med Ctr, Res Serv 151, 1030 Jefferson Ave, Memphis, TN 38104 USA.	hcourtney@utmem.edu		Frank, Matthew/0000-0002-4914-1440	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Courtney HS, 2006, MOL MICROBIOL, V59, P936, DOI 10.1111/j.1365-2958.2005.04977.x; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Courtney HS, 2003, INFECT IMMUN, V71, P5097, DOI 10.1128/IAI.71.9.5097-5103.2003; Courtney HS, 2002, CURR MICROBIOL, V44, P236, DOI 10.1007/s00284-001-0037-1; Courtney HS, 2002, ANN MED, V34, P77, DOI 10.1080/07853890252953464; COURTNEY HS, 2004, BACTERIAL INVASION H, P239; Fielding P. E., 1996, BIOCH LIPIDS LIPOPRO, P495; Grunfeld C, 1999, J LIPID RES, V40, P245; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P7200, DOI 10.1021/bi00346a028; Jeng A, 2003, J BACTERIOL, V185, P1208, DOI 10.1128/JB.185.4.1208-1217.2003; Khovidhunkit W, 2004, J LIPID RES, V45, P1169, DOI 10.1194/jlr.R300019-JLR200; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Kreikemeyer B, 1999, FEMS MICROBIOL LETT, V178, P305, DOI 10.1016/S0378-1097(99)00373-0; KRUMWIEDE E, 1954, J EXP MED, V100, P629, DOI 10.1084/jem.100.6.629; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; O'Brien KL, 2002, CLIN INFECT DIS, V35, P268, DOI 10.1086/341409; Oehmcke S, 2004, INFECT IMMUN, V72, P4302, DOI 10.1128/IAI.72.7.4302-4308.2004; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; PARKER TS, 1995, INFECT IMMUN, V63, P253, DOI 10.1128/IAI.63.1.253-258.1995; Petrovic N, 2001, J LIPID RES, V42, P1706; RAKONJAC JV, 1995, INFECT IMMUN, V63, P622, DOI 10.1128/IAI.63.2.622-631.1995; ROWEN R, 1961, J EXP MED, V114, P807, DOI 10.1084/jem.114.5.807; ROWEN R, 1963, BIOCHIM BIOPHYS ACTA, V70, P396, DOI 10.1016/0926-6542(63)90058-1; RUSBRIDGE NM, 1990, FEBS LETT, V268, P133, DOI 10.1016/0014-5793(90)80991-Q; SARAVANI GA, 1990, FEMS MICROBIOL LETT, V68, P35; Wadham C, 2004, CIRCULATION, V109, P2116, DOI 10.1161/01.CIR.0000127419.45975.26; WARD HUGH K., 1938, AUSTRALIAN JOUR EXP BIOL AND MED SCI, V16, P181, DOI 10.1038/icb.1938.19; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; Wu AH, 2004, SHOCK, V21, P210, DOI 10.1097/01.shk.0000111661.09279.82; Zhang YQ, 2003, J BIOL CHEM, V278, P10417, DOI 10.1074/jbc.M211044200	34	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5515	5521		10.1074/jbc.M512538200	http://dx.doi.org/10.1074/jbc.M512538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407233	hybrid			2022-12-25	WOS:000235568900025
J	Le Moan, N; Clement, G; Le Maout, S; Tacnet, F; Toledano, MB				Le Moan, N; Clement, G; Le Maout, S; Tacnet, F; Toledano, MB			The Saccharomyces cerevisiae proteome of oxidized protein thiols - Contrasted functions for the thioredoxin and glutathione pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; CYSTEINE-SULFINIC ACID; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; COPPER CHAPERONE; RELAY SYSTEM; YAP1; CELL; PEROXIREDOXINS; IDENTIFICATION	Protein thiol oxidation subserves important biological functions and constitutes a sequel of reactive oxygen species toxicity. We developed two distinct thiol-labeling approaches to identify oxidized cytoplasmic protein thiols in Saccharomyces cerevisiae. In one approach, we used N-(6-(biotinamido)hexyl)-3'-(2'- pyridyldithio)propionamide to purify oxidized protein thiols, and in the other, we used N-[C-14] ethylmaleimide to quantify this oxidation. Both approaches showed a large number of the same proteins with oxidized thiols ( similar to 200), 64 of which were identified by mass spectrometry. We show that, irrespective of its mechanism, protein thiol oxidation is dependent upon molecular O-2. We also show that H2O2 does not cause de novo protein thiol oxidation, but rather increases the oxidation state of a select group of proteins. Furthermore, our study reveals contrasted differences in the oxidized proteome of cells upon inactivation of the thioredoxin or GSH pathway suggestive of very distinct thiol redox control functions, assigning an exclusive role for thioredoxin in H2O2 metabolism and the presumed thiol redox buffer function for GSH. Taken together, these results suggest the high selectivity of cytoplasmic protein thiol oxidation.	CEA Saclay, DBJC DSV, SBMS, LSOC, F-91191 Gif Sur Yvette, France; CEA Saclay, INRA, CEA,Lab Immunoallergie Alimentaire, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Toledano, MB (corresponding author), CEA Saclay, DBJC DSV, SBMS, LSOC, F-91191 Gif Sur Yvette, France.	Michel.Toledano@cea.fr	TACNET, Frédérique/B-3074-2009					Allen S, 2005, J MOL BIOL, V353, P937, DOI 10.1016/j.jmb.2005.08.049; Bardwell J, 2005, NAT BIOTECHNOL, V23, P42, DOI 10.1038/nbt0105-42; Baty JW, 2005, BIOCHEM J, V389, P785, DOI 10.1042/BJ20050337; Baty JW, 2002, PROTEOMICS, V2, P1261, DOI 10.1002/1615-9861(200209)2:9<1261::AID-PROT1261>3.0.CO;2-Q; Biteau B, 2003, NATURE, V425, P980, DOI 10.1038/nature02075; Brennan JP, 2004, J BIOL CHEM, V279, P41352, DOI 10.1074/jbc.M403827200; Carmel-Harel O, 2001, MOL MICROBIOL, V39, P595, DOI 10.1046/j.1365-2958.2001.02255.x; Cumming RC, 2005, FASEB J, V19, P2060, DOI 10.1096/fj.05-4195fje; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Ghezzi P, 2005, FREE RADICAL RES, V39, P573, DOI 10.1080/10715760500072172; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Jacob C, 2003, ANGEW CHEM INT EDIT, V42, P4742, DOI 10.1002/anie.200300573; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Leichert LI, 2004, PLOS BIOL, V2, P1723, DOI 10.1371/journal.pbio.0020333; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Linke K, 2003, ANTIOXID REDOX SIGN, V5, P425, DOI 10.1089/152308603768295168; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Moskovitz J, 2005, BBA-PROTEINS PROTEOM, V1703, P213, DOI 10.1016/j.bbapap.2004.09.003; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Poole LB, 2004, ANNU REV PHARMACOL, V44, P325, DOI 10.1146/annurev.pharmtox.44.101802.121735; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Saurin AT, 2004, P NATL ACAD SCI USA, V101, P17982, DOI 10.1073/pnas.0404762101; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Shackelford RE, 2005, ANTIOXID REDOX SIGN, V7, P940, DOI 10.1089/ars.2005.7.940; Shenton D, 2003, BIOCHEM J, V374, P513, DOI 10.1042/BJ20030414; SIKORSKI RS, 1989, GENETICS, V122, P19; Spector D, 2001, J BIOL CHEM, V276, P7011, DOI 10.1074/jbc.M009814200; Tanaka T, 2005, J BIOL CHEM, V280, P42078, DOI 10.1074/jbc.M508622200; Thomas JA, 2001, EXP GERONTOL, V36, P1519, DOI 10.1016/S0531-5565(01)00137-1; Tokatlidis K, 2005, CELL, V121, P965, DOI 10.1016/j.cell.2005.06.019; Toledano MB, 2004, TRENDS BIOCHEM SCI, V29, P351, DOI 10.1016/j.tibs.2004.05.005; Toledano MB, 2003, TOP CURR GENET, V1, P241; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Woo HA, 2003, J BIOL CHEM, V278, P47361, DOI 10.1074/jbc.C300428200	53	132	135	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10420	10430		10.1074/jbc.M513346200	http://dx.doi.org/10.1074/jbc.M513346200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16418165	hybrid			2022-12-25	WOS:000236594300071
J	Tu, XM; Kumar, P; Li, ZY; Wang, CC				Tu, XM; Kumar, P; Li, ZY; Wang, CC			An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM-FORM; CELL-CYCLE; RNA INTERFERENCE; MITOTIC SPINDLE; PROCYCLIC FORM; BUDDING YEAST; ALPHA-TUBULIN; MORPHOGENESIS; MICROTUBULES; SEGREGATION	The chromosomal passenger protein aurora kinases have been implicated in regulating chromosome segregation and cell division. Three aurora kinase homologues were identified (TbAUK1, - 2 and - 3) in the Trypanosome Genomic Data Base, and their expressions in the procyclic form of Trypanosoma brucei were knocked down individually by using the RNA interference technique. Only a knockdown of TbAUK1 arrested the cells in G(2)/M phase with each cell showing an extended posterior end, two kinetoplasts, and an enlarged nucleus, apparently the result of an inhibited kinetoplast multiplication and a failed mitosis. There is no mitotic spindle structure in the TbAUK1-depleted cell. The two kinetoplasts moved apart from each other but stopped just before cytokinesis, suggesting that cytokinesis was blocked in its early phase. Overexpression of TbAUK1 in the cells resulted in little change in cell growth. By immunofluorescence, TbAUK1 was primarily localized to the nucleus in interphase and to the mitotic spindle during apparent metaphase and anaphase. Thus, differing from other eukaryotes, TbAUK1 has an apparent triple function in coupling mitosis and kinetoplast replication with cytokinesis in T. brucei. T. brucei polo-like kinase, previously identified as the initiator of cytokinesis without apparent involvement in mitosis in the trypanosome, was either depleted or overexpressed in the TbAUK1-deficient cells. A dominant TbAUK1-depleted phenotype was demonstrated in both cases, suggesting that TbAUK1 plays an essential role in cytokinesis that cannot be affected by changes in the level of T. brucei polo-like kinase. To our knowledge, this is the first time that the function of an aurora B-like kinase is a prerequisite for polo-like kinase action in initiating cytokinesis. TbAUK1 is also the first identified protein that couples both mitosis and kinetoplast replication with cytokinesis in the trypanosome.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu	Tu, Xiaoming/G-5090-2018	Li, Ziyin/0000-0002-3960-9716	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786, R56AI021786] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-21786, R01 AI021786] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Baldauf SL, 2003, SCIENCE, V300, P1703, DOI 10.1126/science.1085544; Bapteste E, 2003, TRENDS GENET, V19, P696, DOI 10.1016/j.tig.2003.10.004; Bastin P, 2000, J CELL SCI, V113, P3321; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Chen HL, 2005, J BIOMED SCI, V12, P297, DOI 10.1007/s11373-005-0980-0; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; Desai A, 1998, J CELL BIOL, V141, P703, DOI 10.1083/jcb.141.3.703; Giet R, 1999, J CELL SCI, V112, P3591; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Kumar P, 2006, EUKARYOT CELL, V5, P92, DOI 10.1128/EC.5.1.92-102.2006; Kumar P, 2005, J BIOL CHEM, V280, P31783, DOI 10.1074/jbc.M504326200; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Liu XQ, 2004, J CELL SCI, V117, P3233, DOI 10.1242/jcs.01173; MATTHEWS KR, 1994, PARASITOL TODAY, V10, P473, DOI 10.1016/0169-4758(94)90159-7; McKean PG, 2003, CURR OPIN MICROBIOL, V6, P600, DOI 10.1016/j.mib.2003.10.010; Mishima M, 2003, CURR BIOL, V13, pR589, DOI 10.1016/S0960-9822(03)00521-9; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Ogbadoyi E, 2000, CHROMOSOMA, V108, P501, DOI 10.1007/s004120050402; Ploubidou A, 1999, J CELL SCI, V112, P4641; PLOUBIDOU A, 1991, NATURE, V352, P731; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tanaka TU, 2002, CURR OPIN CELL BIOL, V14, P365, DOI 10.1016/S0955-0674(02)00328-9; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tu XM, 2005, MOL BIOL CELL, V16, P97, DOI 10.1091/mbc.E04-05-0368; Tu XM, 2005, EUKARYOT CELL, V4, P755, DOI 10.1128/EC.4.4.755-764.2005; Tu XM, 2004, J BIOL CHEM, V279, P20519, DOI 10.1074/jbc.M312862200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; WEHLAND J, 1983, J CELL BIOL, V97, P1467, DOI 10.1083/jcb.97.5.1467; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODS A, 1989, J CELL SCI, V93, P491; Yan XM, 2005, GENES CELLS, V10, P617, DOI 10.1111/j.1365-2443.2005.00863.x; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	43	79	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9677	9687		10.1074/jbc.M511504200	http://dx.doi.org/10.1074/jbc.M511504200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16436376	hybrid			2022-12-25	WOS:000236404700080
J	Adrain, C; Duriez, PJ; Brumatti, G; Delivani, P; Martin, SJ				Adrain, C; Duriez, PJ; Brumatti, G; Delivani, P; Martin, SJ			The cytotoxic lymphocyte protease, Granzyme B, targets the cytoskeleton and perturbs microtubule polymerization dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENDED SUBSTRATE-SPECIFICITY; GRANULE EXOCYTOSIS; CYTOPLASMIC DYNEIN; MASS-SPECTROMETRY; INDUCED APOPTOSIS; T-LYMPHOCYTES; C-TERMINUS; TUBULIN; FAMILY; DEATH	Granzyme B, a serine protease derived from cytotoxic T lymphocyte (CTL) and Natural Killer (NK) cell granules, plays an important role in coordinating apoptosis of CTL and NK target cells. Here, we report that granzyme B targets the cytoskeleton by cleaving and removing the acidic C-terminal tail of alpha-tubulin. Consistent with this, Granzyme B markedly enhanced rates of microtubule polymerization in vitro, most likely by removal of an autoinhibitory domain within the tubulin C terminus. Moreover, delivery of Granzyme B into HeLa target cells promoted dramatic reorganization of the microtubule network in a caspase-independent manner. These data reveal that granzyme B directly attacks a major component of the cell cytoskeleton, which may contribute to the incapacitation of target cells during CTL/NK-mediated killing.	Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland	Trinity College Dublin	Martin, SJ (corresponding author), Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland.	martinsj@tcd.ie	Adrain, Colin/I-6259-2013	Adrain, Colin/0000-0001-7597-4393; Duriez, Patrick/0000-0003-1814-2552; Martin, Seamus/0000-0002-8539-3143				Adrain C, 2005, J BIOL CHEM, V280, P4663, DOI 10.1074/jbc.M410915200; Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Barry M, 2002, NAT REV IMMUNOL, V2, P401, DOI 10.1038/nri819; Bell JK, 2003, NAT STRUCT BIOL, V10, P527, DOI 10.1038/nsb944; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Catalfamo M, 2003, CURR OPIN IMMUNOL, V15, P522, DOI 10.1016/S0952-7915(03)00114-6; Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tim.2005.05.010; Edwards HM, 1999, J BIOL CHEM, V274, P30468, DOI 10.1074/jbc.274.43.30468; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Graubert TA, 1996, BLOOD, V87, P1232, DOI 10.1182/blood.V87.4.1232.bloodjournal8741232; Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Mahrus S, 2004, J BIOL CHEM, V279, P54275, DOI 10.1074/jbc.M411482200; MARTIN SJ, 1990, CELL TISSUE KINET, V23, P545, DOI 10.1111/j.1365-2184.1990.tb01345.x; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; Metkar SS, 2003, J CELL BIOL, V160, P875, DOI 10.1083/jcb.200210158; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Rugles SW, 2004, J BIOL CHEM, V279, P30751, DOI 10.1074/jbc.M400949200; SACKETT DL, 1985, J BIOL CHEM, V260, P43; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; Skiniotis G, 2004, EMBO J, V23, P989, DOI 10.1038/sj.emboj.7600118; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Trapani JA, 1999, IMMUNOL TODAY, V20, P351, DOI 10.1016/S0167-5699(99)01488-7; Trapani JA, 1998, J BIOL CHEM, V273, P27934, DOI 10.1074/jbc.273.43.27934; Verdier-Pinard P, 2003, BIOCHEMISTRY-US, V42, P12019, DOI 10.1021/bi0350147; Verdier-Pinard P, 2003, BIOCHEMISTRY-US, V42, P5349, DOI 10.1021/bi027293o; Wang ZH, 2000, BIOPHYS J, V78, P1955, DOI 10.1016/S0006-3495(00)76743-9; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200	37	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8118	8125		10.1074/jbc.M509361200	http://dx.doi.org/10.1074/jbc.M509361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415351	hybrid			2022-12-25	WOS:000236031000049
J	Zuo, Y; Qiang, L; Farmer, SR				Zuo, Y; Qiang, L; Farmer, SR			Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/ebp alpha gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; TRANSCRIPTION FACTORS; DIFFERENTIATION; PERILIPIN; PHOSPHORYLATION; FIBROBLASTS; INDUCTION; PATHWAY; LIGAND	Studies have shown that CCAAT/enhancer-binding protein beta (C/EBP beta) can stimulate adipogenesis in noncommitted fibroblasts by activating expression of peroxisome proliferator-activated receptor-gamma (PPAR gamma). Other investigations have established a role for C/EBP alpha as well as PPAR gamma in orchestrating the complex program of adipogenic gene expression during terminal preadipocyte differentiation. Consequently, it is important to identify factors regulating transcription of the C/ebp alpha gene. In this study, we demonstrated that inhibition of PPAR gamma activity by exposure of 3T3-L1 preadipocytes to a potent and selective PPAR gamma antagonist inhibits adipogenesis but also blocks the activation of C/EBP alpha expression at the onset of differentiation. Ectopic expression of C/EBP beta in Swiss 3T3 mouse fibroblasts (Swiss-LAP cells) induces PPAR gamma expression without any significant enhancement of C/EBP alpha expression. Treatment of Swiss-LAP cells with a PPAR gamma agonist induces adipogenesis, which includes activation of C/EBP alpha expression. To further establish a role for PPAR gamma in regulating C/EBP alpha expression, we expressed C/EBP beta in PPAR gamma-deficient mouse embryo fibroblasts (MEFs). The data show that C/EBP beta is capable of inducing PPAR gamma in Ppar gamma+/- MEFs, which leads to activation of adipogenesis, including C/EBP alpha expression following exposure to a PPAR gamma ligand. In contrast, C/EBP beta is not able to induce C/EBP alpha expression or adipogenesis in Ppar gamma-/- MEFs. Chromatin immunoprecipitation analysis reveals that C/EBP beta is bound to the minimal promoter of the C/ebp alpha gene in association with HDAC1 in unstimulated Swiss-LAP cells. Exposure of the cells to a PPAR gamma ligand dislodges HDAC1 from the proximal promoter of the C/ebp alpha gene, which involves degradation of HDAC1 in the 26 S proteasome. These data suggest that C/EBP beta activates a single unified pathway of adipogenesis involving its stimulation of PPAR gamma expression, which then activates C/EBP alpha expression by dislodging HDAC1 from the promoter for degradation in the proteasome.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@biochem.bumc.bu.edu	Qiang, Li/C-9560-2012	Farmer, Stephen/0000-0003-2483-2795; Qiang, Li/0000-0001-8322-1797	NIDDK NIH HHS [DK51586, DK58825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058825, R01DK058825, R01DK051586, R56DK051586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Dalen KT, 2004, DIABETES, V53, P1243, DOI 10.2337/diabetes.53.5.1243; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elberg G, 2000, J BIOL CHEM, V275, P27815; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; Linhart HG, 2001, P NATL ACAD SCI USA, V98, P12532, DOI 10.1073/pnas.211416898; Liu JQ, 2004, J BIOL CHEM, V279, P24493, DOI [10.1074/jbc.M402920200, 10.1074/jbc.M407050200]; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Nagai S, 2004, ENDOCRINOLOGY, V145, P2346, DOI 10.1210/en.2003-1180; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Yamamoto H, 2002, J CELL SCI, V115, P3601, DOI 10.1242/jcs.00044; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	30	153	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7960	7967		10.1074/jbc.M510682200	http://dx.doi.org/10.1074/jbc.M510682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431920	hybrid			2022-12-25	WOS:000236031000032
J	Horsefield, R; Yankovskaya, V; Sexton, G; Whittingham, W; Shiomi, K; Omura, S; Byrne, B; Cecchini, G; Iwata, S				Horsefield, R; Yankovskaya, V; Sexton, G; Whittingham, W; Shiomi, K; Omura, S; Byrne, B; Cecchini, G; Iwata, S			Structural and computational analysis of the quinone-binding site of complex II (succinate-ubiquinone oxidoreductase) - A mechanism of electron transfer and proton conduction during ubiquinone reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; COLI FUMARATE REDUCTASE; BACTERIAL REACTION CENTERS; CYTOCHROME BC(1) COMPLEX; SULFUR PROTEIN SUBUNIT; ESCHERICHIA-COLI; RESPIRATORY-CHAIN; WOLINELLA-SUCCINOGENES; ANGSTROM RESOLUTION; CONFERS RESISTANCE	The transfer of electrons and protons between membrane-bound respiratory complexes is facilitated by lipid-soluble redox-active quinone molecules ( Q). This work presents a structural analysis of the quinone- binding site (Q-site) identified in succinate: ubiquinone oxidoreductase (SQR) from Escherichia coli. SQR, often referred to as Complex II or succinate dehydrogenase, is a functional member of the Krebs cycle and the aerobic respiratory chain and couples the oxidation of succinate to fumarate with the reduction of quinone to quinol (QH(2)). The interaction between ubiquinone and the Q-site of the protein appears to be mediated solely by hydrogen bonding between the O1 carbonyl group of the quinone and the side chain of a conserved tyrosine residue. In this work, SQR was co-crystallized with the ubiquinone binding-site inhibitor Atpenin A5 (AA5) to confirm the binding position of the inhibitor and reveal additional structural details of the Q-site. The electron density for AA5 was located within the same hydrophobic pocket as ubiquinone at, however, a different position within the pocket. AA5 was bound deeper into the site prompting further assessment using protein-ligand docking experiments in silico. The initial interpretation of the Q-site was re-evaluated in the light of the new SQR-AA5 structure and protein-ligand docking data. Two binding positions, the Q1-site and Q(2)-site, are proposed for the E. coli SQR quinone- binding site to explain these data. At the Q(2)-site, the side chains of a serine and histidine residue are suitably positioned to provide hydrogen bonding partners to the O4 carbonyl and methoxy groups of ubiquinone, respectively. This allows us to propose a mechanism for the reduction of ubiquinone during the catalytic turnover of the enzyme.	Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Syngenta, Jealotts Hill Int Res Ctr, Bracknell RG42 6EY, Berks, England; Kitasato Univ, Sch Pharmaceut Sci, Tokyo 1088641, Japan; Kitasato Inst, Minato Ku, Tokyo 1088642, Japan	Imperial College London; University of California System; University of California San Francisco; Syngenta; Kitasato University	Cecchini, G (corresponding author), Vet Affairs Med Ctr, San Francisco, CA 94121 USA.	ceccini@itsa.ucsf.edu; s.iwata@imperial.ac.uk	Horsefield, Rob/B-1378-2010	Shiomi, Kazuro/0000-0003-1264-5116; Byrne, Bernadette/0000-0001-9598-9832	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061606] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BB/C505116/1] Funding Source: Medline; NIGMS NIH HHS [GM 61606] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; BROOMFIELD PLE, 1992, CURR GENET, V22, P117, DOI 10.1007/BF00351470; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; CRANE FL, 1966, PHYSIOL REV, V46, P662, DOI 10.1152/physrev.1966.46.4.662; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Dikanov SA, 2004, J BIOL CHEM, V279, P15814, DOI 10.1074/jbc.M313417200; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; GRIVENNIKOVA VG, 1982, BIOCHIM BIOPHYS ACTA, V682, P491, DOI 10.1016/0005-2728(82)90065-2; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Horsefield R, 2004, CURR PROTEIN PEPT SC, V5, P107, DOI 10.2174/1389203043486847; Horsefield R, 2003, ACTA CRYSTALLOGR D, V59, P600, DOI 10.1107/S0907444903002075; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; INGLEDEW WJ, 1977, BIOCHEM J, V164, P617, DOI 10.1042/bj1640617; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; Ishikita H, 2004, J AM CHEM SOC, V126, P8059, DOI 10.1021/ja038092q; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; KEON JPR, 1994, BIOCHEM SOC T, V22, P234, DOI 10.1042/bst0220234; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P1, DOI 10.1016/S0005-2728(01)00240-7; Lancaster CRD, 2000, P NATL ACAD SCI USA, V97, P13051, DOI 10.1073/pnas.220425797; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Matsson M, 2001, J BIOENERG BIOMEMBR, V33, P99, DOI 10.1023/A:1010744330092; Miyadera H, 2003, P NATL ACAD SCI USA, V100, P473, DOI 10.1073/pnas.0237315100; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; OMURA S, 1988, J ANTIBIOT, V41, P1769, DOI 10.7164/antibiotics.41.1769; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oyedotun KS, 2004, J BIOL CHEM, V279, P9424, DOI 10.1074/jbc.M311876200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Paddock ML, 2003, FEBS LETT, V555, P45, DOI 10.1016/S0014-5793(03)01149-9; PADDOCK ML, 1990, P NATL ACAD SCI USA, V87, P6803, DOI 10.1073/pnas.87.17.6803; Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033; Pedretti A, 2002, J MOL GRAPH MODEL, V21, P47, DOI 10.1016/S1093-3263(02)00123-7; RAMSAY RR, 1981, P NATL ACAD SCI-BIOL, V78, P825, DOI 10.1073/pnas.78.2.825; Rothery RA, 2005, FEBS J, V272, P313, DOI 10.1111/j.1742-4658.2004.04469.x; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Verdonk ML, 1999, J MOL BIOL, V289, P1093, DOI 10.1006/jmbi.1999.2809; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; WARNCKE K, 1994, BIOCHEMISTRY-US, V33, P7830, DOI 10.1021/bi00191a010; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020	53	214	229	2	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7309	7316		10.1074/jbc.M508173200	http://dx.doi.org/10.1074/jbc.M508173200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407191	hybrid			2022-12-25	WOS:000236030900049
J	Kim, C; Cha, JY; Yan, HG; Vakulenko, SB; Mobashery, S				Kim, C; Cha, JY; Yan, HG; Vakulenko, SB; Mobashery, S			Hydrolysis of ATP by aminoglycoside 3 '-phosphotransferases - An unexpected cost to bacteria for harboring an antibiotic resistance enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOLOGICAL COST; GENES; PURIFICATION; MECHANISM; FITNESS; PROTEIN	Aminoglycoside 3'-phosphotransferases (APH(3') s) are common bacterial resistance enzymes to aminoglycoside antibiotics. These enzymes transfer the gamma-phosphoryl group of ATP to the 3'-hydroxyl of the antibiotics, whereby the biological activity of the drugs is lost. Pre-steady-state and steady-state kinetics with two of these enzymes from Gram-negative bacteria, APH(3')-Ia and APH(3')IIa, were performed. It is demonstrated that these enzymes in both ternary and binary complexes facilitate an ATP hydrolase activity ( ATPase), which is competitive with the transfer of phosphate to the antibiotics. Because these enzymes are expressed constitutively in resistant bacteria, the turnover of ATP is continuous during the lifetime of the organism both in the absence and the presence of aminoglycosides. Concentrations of the enzyme in vivo were determined, and it was estimated that in a single generation of bacterial growth there exists the potential that this activity would consume as much as severalfold of the total existing ATP. Studies with bacteria harboring the aph(3')-Ia gene revealed that bacteria are able to absorb the cost of this ATP turnover, as ATP is recycled. However, the cost burden of this adventitious activity manifests a selection pressure against maintenance of the plasmids that harbor the aph(3')-Ia gene, such that similar to 50% of the plasmid is lost in 1500 bacterial generations in the absence of antibiotics. The implication is that, in the absence of selection, bacteria harboring an enzyme that catalyzes the consumption of key metabolites could experience the loss of the plasmid that encodes for the given enzyme.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	University of Notre Dame; Michigan State University	Mobashery, S (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	mobashery@nd.edu		Kim, Choon/0000-0003-0306-8935				Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3; Andersson DI, 2003, CURR OPIN MICROBIOL, V6, P452, DOI 10.1016/j.mib.2003.09.001; Bagel S, 1999, ANTIMICROB AGENTS CH, V43, P868, DOI 10.1128/AAC.43.4.868; Becker EC, 1997, J BACTERIOL, V179, P5947, DOI 10.1128/jb.179.18.5947-5950.1997; DiezGonzalez F, 1997, FEMS MICROBIOL LETT, V151, P71, DOI 10.1111/j.1574-6968.1997.tb10396.x; Gillespie SH, 1997, TRENDS MICROBIOL, V5, P337, DOI 10.1016/S0966-842X(97)01101-3; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; GOSS SR, 1988, FEBS LETT, V228, P245, DOI 10.1016/0014-5793(88)80008-5; GUIHARD G, 1993, J BIOL CHEM, V268, P17775; Kim C, 2005, BIOORG CHEM, V33, P149, DOI 10.1016/j.bioorg.2004.11.001; Kim C, 2004, BIOCHEMISTRY-US, V43, P2373, DOI 10.1021/bi036095+; Lasko DR, 1996, BIOTECHNOL BIOENG, V52, P364, DOI 10.1002/(SICI)1097-0290(19961105)52:3<364::AID-BIT2>3.0.CO;2-I; LENSKI RE, 1997, ANTIBIOTIC RESISTANC, P131; Louie TM, 2003, BIOCHEMISTRY-US, V42, P7509, DOI 10.1021/bi034092r; Magnet S, 2005, CHEM REV, V105, P477, DOI 10.1021/cr0301088; NANNINGA N, 1985, MOL CYTOLOGY ESCHERI, P161; Reisbig MD, 2003, J ANTIMICROB CHEMOTH, V51, P1141, DOI 10.1093/jac/dkg204; Rohwer JM, 1996, EUR J BIOCHEM, V235, P225, DOI 10.1111/j.1432-1033.1996.00225.x; Rozkov A, 1999, BIOTECHNOL BIOENG, V62, P730, DOI 10.1002/(SICI)1097-0290(19990320)62:6<730::AID-BIT12>3.0.CO;2-Q; Salyers AA, 1997, ANTIMICROB AGENTS CH, V41, P2321, DOI 10.1128/AAC.41.11.2321; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Seyer K, 2003, APPL ENVIRON MICROB, V69, P3231, DOI 10.1128/AEM.69.6.3231-3237.2003; SIREGAR JJ, 1995, BIOCHEMISTRY-US, V34, P12681, DOI 10.1021/bi00039a026; SIREGAR JJ, 1994, ANTIMICROB AGENTS CH, V38, P641, DOI 10.1128/AAC.38.4.641; Smith MA, 1998, CAN J MICROBIOL, V44, P351, DOI 10.1139/cjm-44-4-351; Vakulenko SB, 2003, CLIN MICROBIOL REV, V16, P430, DOI 10.1128/CMR.16.3.430-450.2003; Wright GD, 1999, CURR OPIN MICROBIOL, V2, P499, DOI 10.1016/S1369-5274(99)00007-7; Wright GD, 1998, ADV EXP MED BIOL, V456, P27	30	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6964	6969		10.1074/jbc.M513257200	http://dx.doi.org/10.1074/jbc.M513257200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407230	hybrid			2022-12-25	WOS:000236030900008
J	Ogden, SK; Casso, DJ; Ascano, M; Yore, MM; Kornberg, TB; Robbins, DJ				Ogden, SK; Casso, DJ; Ascano, M; Yore, MM; Kornberg, TB; Robbins, DJ			Smoothened regulates activator and repressor functions of hedgehog signaling via two distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN-RELATED PROTEIN; TARGET GENE-EXPRESSION; CUBITUS-INTERRUPTUS; KINASE-A; TRANSCRIPTIONAL ACTIVATOR; REQUIRES PHOSPHORYLATION; SUBCELLULAR-LOCALIZATION; IMAGINAL DISCS; DROSOPHILA; TRANSDUCTION	The secreted protein Hedgehog (Hh) plays an important role in metazoan development and as a survival factor for many human tumors. In both cases, Hh signaling proceeds through the activation of the seven-transmembrane protein Smoothened (Smo), which is thought to convert the Gli family of transcription factors from transcriptional repressors to transcriptional activators. Here, we provide evidence that Smo signals to the Hh signaling complex, which consists of the kinesin-related protein Costal2 (Cos2), the protein kinase Fused (Fu), and the Drosophila Gli homolog cubitus interruptus (Ci), in two distinct manners. We show that many of the commonly observed molecular events following Hh signaling are not transmitted in a linear fashion but instead are activated through two signals that bifurcate at Smo to independently affect activator and repressor pools of Ci.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Cincinnati, Med Ctr, Dept Mol Genet Grad Program, Cincinnati, OH 45267 USA	Dartmouth College; University of California System; University of California San Francisco; University System of Ohio; University of Cincinnati	Robbins, DJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, HB 7650 Remson, Hanover, NH 03755 USA.	David.J.Robbins@dartmouth.edu	Ogden, Stacey K/N-2528-2018; Ascano, Manuel/ABA-3586-2020; Ogden, Stacey K/P-9585-2019	Ascano, Manuel/0000-0002-9370-5493; Ogden, Stacey K/0000-0001-8991-3065	NCI NIH HHS [CA 82628, R01 CA082628] Funding Source: Medline; NIEHS NIH HHS [T32 ES007250, T32 ES 07250-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Apionishev S, 2005, NAT CELL BIOL, V7, P86, DOI 10.1038/ncb1210; Ascano M, 2004, MOL CELL BIOL, V24, P10397, DOI 10.1128/MCB.24.23.10397-10405.2004; Ascano M, 2002, MOL CELL BIOL, V22, P1555, DOI 10.1128/MCB.22.5.1555-1566.2002; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Fasken MB, 2000, J BIOL CHEM, V275, P1878, DOI 10.1074/jbc.275.3.1878; Hooper JE, 2003, DEVELOPMENT, V130, P3951, DOI 10.1242/dev.00594; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jia JH, 2003, GENE DEV, V17, P2709, DOI 10.1101/gad.1136603; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jia JH, 2004, NATURE, V432, P1045, DOI 10.1038/nature03179; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Nakano Y, 2004, MECH DEVELOP, V121, P507, DOI 10.1016/j.mod.2004.04.015; Ogden SK, 2004, BIOCHEM PHARMACOL, V67, P805, DOI 10.1016/j.bcp.2004.01.002; Ogden SK, 2003, CURR BIOL, V13, P1998, DOI 10.1016/j.cub.2003.10.004; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Price MA, 1999, DEVELOPMENT, V126, P4331; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Ruel L, 2003, NAT CELL BIOL, V5, P907, DOI 10.1038/ncb1052; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Stegman MA, 2004, J BIOL CHEM, V279, P7064, DOI 10.1074/jbc.M311794200; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 2000, DEVELOPMENT, V127, P3131; Wang QT, 1999, DEVELOPMENT, V126, P5097; Zhang C, 2004, P NATL ACAD SCI USA, V101, P17900, DOI 10.1073/pnas.0408093101; Zhang WS, 2005, DEV CELL, V8, P267, DOI 10.1016/j.devcel.2005.01.001; Zhu AJ, 2003, GENE DEV, V17, P1240, DOI 10.1101/gad.1080803	38	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7237	7243		10.1074/jbc.M510169200	http://dx.doi.org/10.1074/jbc.M510169200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423832	hybrid, Green Accepted			2022-12-25	WOS:000236030900041
J	Sawaya, MR; Cannon, GC; Heinhorst, S; Tanaka, S; Williams, EB; Yeates, TO; Kerfeld, CA				Sawaya, MR; Cannon, GC; Heinhorst, S; Tanaka, S; Williams, EB; Yeates, TO; Kerfeld, CA			The structure of beta-carbonic anhydrase from the carboxysomal shell reveals a distinct subclass with one active site for the price of two	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO2 CONCENTRATING MECHANISMS; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; CYANOBACTERIUM; MODELS; GENES	CsoSCA (formerly CsoS3) is a bacterial carbonic anhydrase localized in the shell of a cellular microcompartment called the carboxysome, where it converts HCO3- to CO2 for use in carbon fixation by ribulose-bisphosphate carboxylase/oxygenase (RuBisCO). CsoSCA lacks significant sequence similarity to any of the four known classes of carbonic anhydrase (alpha, beta, gamma, or delta), and so it was initially classified as belonging to a new class, epsilon. The crystal structure of CsoSCA from Halothiobacillus neapolitanus reveals that it is actually a representative member of a new subclass of beta-carbonic anhydrases, distinguished by a lack of active site pairing. Whereas a typical beta-carbonic anhydrase maintains a pair of active sites organized within a two-fold symmetric homodimer or pair of fused, homologous domains, the two domains in CsoSCA have diverged to the point that only one domain in the pair retains a viable active site. We suggest that this defunct and somewhat diminished domain has evolved a new function, specific to its carboxysomal environment. Despite the level of sequence divergence that separates CsoSCA from the other two subclasses of beta-carbonic anhydrases, there is a remarkable level of structural similarity among active site regions, which suggests a common catalytic mechanism for the interconversion of HCO3- and CO2. Crystal packing analysis suggests that CsoSCA exists within the carboxysome shell either as a homodimer or as extended filaments.	Univ Calif Los Angeles, DOE Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ So Mississippi, Dept Chem & Biochem, Hattiesburg, MS 39406 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Life Sci Core, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Southern Mississippi; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kerfeld, CA (corresponding author), Univ Calif Los Angeles, DOE Inst Genom & Proteom, Box 951570, Los Angeles, CA 90095 USA.	kerfeld@mbi.ucla.edu		Yeates, Todd/0000-0001-5709-9839; Sawaya, Michael/0000-0003-0874-9043				Badger MR, 2003, J EXP BOT, V54, P609, DOI 10.1093/jxb/erg076; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SH, 2000, ARCH MICROBIOL, V173, P278, DOI 10.1007/s002030000141; BEUDEKER RF, 1980, ARCH MICROBIOL, V124, P185, DOI 10.1007/BF00427725; Boggon TJ, 2000, STRUCTURE, V8, pR143, DOI 10.1016/S0969-2126(00)00168-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CANNON GC, 1983, ARCH MICROBIOL, V134, P52, DOI 10.1007/BF00429407; Cannon GC, 2002, FUNCT PLANT BIOL, V29, P175, DOI 10.1071/PP01200; Cannon GC, 2001, APPL ENVIRON MICROB, V67, P5351, DOI 10.1128/AEM.67.12.5351-5361.2001; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Covarrubias AS, 2005, J BIOL CHEM, V280, P18782, DOI 10.1074/jbc.M414348200; Cronk JD, 2001, PROTEIN SCI, V10, P911, DOI 10.1110/ps.46301; DeLano WL, 2002, PYMOL USERS MANUAL; Fabiola F, 2002, PROTEIN SCI, V11, P1415, DOI 10.1110/ps.4890102; Gao YQ, 2005, CELL, V123, P195, DOI 10.1016/j.cell.2005.10.001; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; HATCH MD, 1990, PLANT PHYSIOL, V93, P825, DOI 10.1104/pp.93.2.825; HOLTHUIJZEN YA, 1986, ARCH MICROBIOL, V144, P258, DOI 10.1007/BF00410959; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; Kerfeld CA, 2005, SCIENCE, V309, P936, DOI 10.1126/science.1113397; Kimber MS, 2000, EMBO J, V19, P1407, DOI 10.1093/emboj/19.7.1407; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Ludwig M, 2000, J PHYCOL, V36, P1109, DOI 10.1046/j.1529-8817.2000.00028.x; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ponstingl H, 2000, PROTEINS, V41, P47; PRICE GD, 1992, PLANT PHYSIOL, V100, P784, DOI 10.1104/pp.100.2.784; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; REINHOLD L, 1991, CAN J BOT, V69, P984, DOI 10.1139/b91-126; Sheldrick GM, 2001, NATO SCI SER I LIFE, V325, P72; SHIVELY JM, 1973, J BACTERIOL, V116, P1405, DOI 10.1128/JB.116.3.1405-1411.1973; So AKC, 2005, CAN J BOT, V83, P721, DOI 10.1139/B05-057; So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004; So AKC, 1998, PLANT MOL BIOL, V37, P205, DOI 10.1023/A:1005959200390; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240	40	128	135	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7546	7555		10.1074/jbc.M510464200	http://dx.doi.org/10.1074/jbc.M510464200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407248	hybrid, Green Submitted			2022-12-25	WOS:000236030900076
J	Stirling, PC; Cuellar, J; Alfaro, GA; El Khadali, F; Beh, CT; Valpuesta, JM; Melki, R; Leroux, MR				Stirling, PC; Cuellar, J; Alfaro, GA; El Khadali, F; Beh, CT; Valpuesta, JM; Melki, R; Leroux, MR			PhLP3 modulates CCT-mediated actin and tubulin folding via ternary complexes with substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSDUCIN-LIKE PROTEIN; CYTOSOLIC CHAPERONIN CCT; EUKARYOTIC CHAPERONIN; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; ATP HYDROLYSIS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE HYDROLYSIS; ELECTRON-MICROSCOPY; UNFOLDED PROTEINS	Many ATP-dependent molecular chaperones, including Hsp70, Hsp90, and the chaperonins GroEL/Hsp60, require cofactor proteins to regulate their ATPase activities and thus folding functions in vivo. One conspicuous exception has been the eukaryotic chaperonin CCT, for which no regulator of its ATPase activity, other than non-native substrate proteins, is known. We identify the evolutionarily conserved PhLP3 (phosducin-like protein 3) as a modulator of CCT function in vitro and in vivo. PhLP3 binds CCT, spanning the cylindrical chaperonin cavity and contacting at least two subunits. When present in a ternary complex with CCT and an actin or tubulin substrate, PhLP3 significantly diminishes the chaperonin ATPase activity, and accordingly, excess PhLP3 perturbs actin or tubulin folding in vitro. Most interestingly, however, the Saccharomyces cerevisiae PhLP3 homologue is required for proper actin and tubulin function. This cellular role of PhLP3 is most apparent in a strain that also lacks prefoldin, a chaperone that facilitates CCT-mediated actin and tubulin folding. We propose that the antagonistic actions of PhLP3 and prefoldin serve to modulate CCT activity and play a key role in establishing a functional cytoskeleton in vivo.	Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Simon Fraser University; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Leroux, MR (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	leroux@sfu.ca	Valpuesta, José M/T-1977-2017; Cuéllar, Jorge/GOH-3100-2022; Cuéllar, Jorge/S-4269-2017; Valpuesta, Jose M/AAA-6002-2019	Valpuesta, José M/0000-0001-7468-8053; Cuéllar, Jorge/0000-0002-7789-807X; Cuéllar, Jorge/0000-0002-7789-807X; Beh, Christopher/0000-0003-0201-6316; Stirling, Peter/0000-0003-2651-4539				Abruzzi KC, 2002, MOL CELL BIOL, V22, P138, DOI 10.1128/MCB.22.1.138-147.2002; Adams Alison, 1997, P139; Alvarez P, 1998, GENETICS, V149, P857; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Blaauw M, 2003, EMBO J, V22, P5047, DOI 10.1093/emboj/cdg508; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Cowan NJ, 1998, METHOD ENZYMOL, V290, P230, DOI 10.1016/S0076-6879(98)90022-2; Farr GW, 1997, CELL, V89, P927, DOI 10.1016/S0092-8674(00)80278-0; Flanary PL, 2000, J BIOL CHEM, V275, P18462, DOI 10.1074/jbc.M002163200; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gebauer M, 1998, J BIOL CHEM, V273, P29475, DOI 10.1074/jbc.273.45.29475; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoyt MA, 1997, GENETICS, V146, P849; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; KUZNETSOV SA, 1981, FEBS LETT, V135, P237, DOI 10.1016/0014-5793(81)80790-9; Lacefield S, 2003, GENETICS, V165, P531; Leroux MR, 2000, METH MOL B, V140, P195; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Llorca O, 2000, EMBO J, V19, P5971, DOI 10.1093/emboj/19.22.5971; Lopez-Fanarraga M, 2001, J STRUCT BIOL, V135, P219, DOI 10.1006/jsbi.2001.4386; Lukov GL, 2005, EMBO J, V24, P1965, DOI 10.1038/sj.emboj.7600673; Lundin VF, 2004, P NATL ACAD SCI USA, V101, P4367, DOI 10.1073/pnas.0306276101; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Martin-Benito J, 2004, P NATL ACAD SCI USA, V101, P17410, DOI 10.1073/pnas.0405070101; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; McLaughlin JN, 2002, P NATL ACAD SCI USA, V99, P7962, DOI 10.1073/pnas.112075699; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; MELKI R, 1990, BIOCHEMISTRY-US, V29, P8921, DOI 10.1021/bi00490a007; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Ogawa S, 2004, GENES CELLS, V9, P83, DOI 10.1111/j.1356-9597.2004.00708.x; Rommelaere H, 2001, J BIOL CHEM, V276, P41023, DOI 10.1074/jbc.M106591200; Scheres SHW, 2005, J MOL BIOL, V348, P139, DOI 10.1016/j.jmb.2005.02.031; Siegers K, 1999, EMBO J, V18, P75, DOI 10.1093/emboj/18.1.75; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Siligardi G, 2004, J BIOL CHEM, V279, P51989, DOI 10.1074/jbc.M410562200; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stirling PC, 2003, EMBO REP, V4, P565, DOI 10.1038/sj.embor.embor869; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930	49	56	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7012	7021		10.1074/jbc.M513235200	http://dx.doi.org/10.1074/jbc.M513235200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415341	hybrid			2022-12-25	WOS:000236030900014
J	Forsee, WT; Cartee, RT; Yother, J				Forsee, WT; Cartee, RT; Yother, J			Role of the carbohydrate binding site of the Streptococcus pneumoniae capsular polysaccharide type 3 synthase in the transition from oligosaccharide to polysaccharide synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN SYNTHASES; BIOSYNTHESIS; MECHANISM; GLYCOSYLTRANSFERASES; EQUISIMILIS; RECOGNITION; MODULES; ACID	The type 3 synthase catalyzes the formation of the Streptococcus pneumoniae type 3 capsular polysaccharide [- 3)-beta-D-GlcUA-(1, 4)-beta-D-Glc-(1-](n). Synthesis is comprised of two distinct catalytic phases separated by a transition step whereby an oligosaccharylphosphatidylglycerol primer becomes tightly bound to the carbohydrate acceptor recognition site of the synthase. Using the recombinant synthase in Escherichia coli membranes, we determined that a critical oligosaccharide length of similar to 8 monosaccharides was required for recognition of the growing chain by the synthase. Upon binding of the oligosaccharide- lipid to the carbohydrate recognition site, the polymerization reaction entered a highly processive phase to produce polymer of high molecular weight. The initial oligosaccharide-synthetic phase also appeared to be processive, the duration of which was enhanced by the concentration of UDP-GlcUA and diminished by an increase in temperature. The overall reaction approached a steady state equilibrium between the polymer- and oligosaccharide- forming phases that was shifted toward the former by higher UDP-GlcUA levels or lower temperatures and toward the latter by lower concentrations of UDP-GlcUA or higher temperatures. The transition step between the two enzymatic phases demonstrated cooperative kinetics, which is predicted to reflect a possible reorientation of the oligosaccharide- lipid in conjunction with the formation of a tight binding complex.	Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Yother, J (corresponding author), Univ Alabama Birmingham, Dept Microbiol, 845 19th St S BBRB 661-12, Birmingham, AL 35294 USA.	jyother@uab.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CAMPBELL JH, 1966, IMMUNOCHEMISTRY, V3, P195, DOI 10.1016/0019-2791(66)90184-4; Cartee RT, 2005, J BACTERIOL, V187, P4470, DOI 10.1128/JB.187.13.4470-4479.2005; Cartee RT, 2000, J BIOL CHEM, V275, P3907, DOI 10.1074/jbc.275.6.3907; Cartee RT, 2001, J BIOL CHEM, V276, P48831, DOI 10.1074/jbc.M106481200; Charnock SJ, 2001, PLANT PHYSIOL, V125, P527, DOI 10.1104/pp.125.2.527; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; Davies GJ, 2001, TRENDS GLYCOSCI GLYC, V13, P105, DOI 10.4052/tigg.13.105; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; Flint J, 2005, J BIOL CHEM, V280, P23718, DOI 10.1074/jbc.M501551200; Forsee WT, 2000, J BIOL CHEM, V275, P25972, DOI 10.1074/jbc.M002613200; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; Ramos A, 2001, APPL ENVIRON MICROB, V67, P33, DOI 10.1128/AEM.67.1.33-41.2001; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Tlapak-Simmons VL, 2005, J BIOL CHEM, V280, P13012, DOI 10.1074/jbc.M409788200; Tlapak-Simmons VL, 1999, J BIOL CHEM, V274, P4246, DOI 10.1074/jbc.274.7.4246; Tlapak-Simmons VL, 2004, BIOCHEMISTRY-US, V43, P9234, DOI 10.1021/bi049468v; TORRIANI A, 1962, J BIOL CHEM, V237, P3; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269	22	27	29	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6283	6289		10.1074/jbc.M511124200	http://dx.doi.org/10.1074/jbc.M511124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16410247	hybrid			2022-12-25	WOS:000236030800021
J	Xu, DR; Wang, SQ; Liu, W; Liu, JZ; Feng, X				Xu, DR; Wang, SQ; Liu, W; Liu, JZ; Feng, X			A novel receptor activator of NF-kappa B (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF FAMILY-MEMBER; ALPHA-INDUCED OSTEOCLASTOGENESIS; LYMPH-NODE ORGANOGENESIS; OSTEOPROTEGERIN-LIGAND; DIFFERENTIATION FACTOR; TERMINAL KINASE; BONE-RESORPTION; DENDRITIC-CELL; KEY REGULATOR	Receptor activator of NF-kappa B (RANK) ligand (RANKL) and its receptor RANK play an essential role in osteoclastogenesis and osteoclast function by activating several signaling pathways. However, several lines of evidence suggest that RANK also transmits an unidentified signaling pathway(s) essential for osteoclastogenesis. To identify the novel pathway(s), we carried out a detailed structure/function study of the RANK cytoplasmic domain. A series of studies using numerous deletion/point mutants elucidated a specific 4-amino acid motif ((IVVY538)-I-535) essential for osteoclastogenesis. This novel motif plays a crucial role in committing macrophages to the osteoclast lineage but is not implicated in osteoclast function or survival. Moreover, this motif does not activate the known RANK signaling pathways, indicating that it initiates a novel pathway(s). The identification of the novel motif not only provides critical insight into RANK signaling in osteoclastogenesis, but more importantly, the RANK motif and its downstream signaling pathways may represent specific therapeutic targets for various bone diseases, including postmenopausal osteoporosis.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Feng, X (corresponding author), Univ Alabama, Dept Pathol, 1670 Univ Blvd,VH G046B, Birmingham, AL 35294 USA.	xfeng@path.uab.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046031, R01AR047830] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 47830, P30AR46031] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Barnhart KN, 1999, BIOTECHNIQUES, V26, P624, DOI 10.2144/99264bm06; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Chung JY, 2002, J CELL SCI, V115, P679; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Doggrell SA, 2003, DRUG TODAY, V39, P633, DOI 10.1358/dot.2003.39.8.799409; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Eghbali-Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669; Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Jimi E, 1999, J IMMUNOL, V163, P434; Jin Y, 1998, BLOOD, V92, P2777, DOI 10.1182/blood.V92.8.2777.420k27_2777_2790; Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225; Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Liu W, 2004, J BIOL CHEM, V279, P54759, DOI 10.1074/jbc.M404687200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359-6101(03)00027-3; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yeh WC, 1999, IMMUNOL REV, V169, P283, DOI 10.1111/j.1600-065X.1999.tb01323.x; Zhang J, 2003, CANCER RES, V63, P7883	60	35	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4678	4690		10.1074/jbc.M510383200	http://dx.doi.org/10.1074/jbc.M510383200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373338	hybrid			2022-12-25	WOS:000235426200016
J	Matsumoto, G; Kim, S; Morimoto, RI				Matsumoto, G; Kim, S; Morimoto, RI			Huntingtin and mutant SOD1 form aggregate structures with distinct molecular properties in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; NEURONAL INTRANUCLEAR INCLUSIONS; TATA-BINDING PROTEIN; NEURODEGENERATIVE DISEASES; POLYGLUTAMINE AGGREGATION; EXPANDED POLYGLUTAMINE; SUPEROXIDE-DISMUTASE; CELLULAR TOXICITY; AMYLOID FORMATION; COACTIVATOR CBP	Expression of many proteins associated with neurodegenerative disease results in the appearance of misfolded species that readily adopt alternate folded states. In vivo, these appear as punctated subcellular structures typically referred to as aggregates or inclusion bodies. Whereas groupings of these distinct proteins into a common morphological class have been useful conceptually, there is some suggestion that aggregates are not homogeneous and can exhibit a range of biological properties. In this study, we use dynamic imaging analysis of living cells to compare the aggregation and growth properties of mutant huntingtin with polyglutamine expansions or mutant SOD1 (G85R/G93A) to examine the formation of aggregate structures and interactions with other cellular proteins. Using a dual conditional expression system for sequential expression of fluorescence- tagged proteins, we show that mutant huntingtin forms multiple intracellular cytoplasmic and nuclear structures composed of a dense core inaccessible to nascent polypeptides surrounded by a surface that stably sequesters certain transcription factors and interacts transiently with molecular chaperones. In contrast, mutant SOD1 (G85R/G93A) forms a distinct aggregate structure that is porous, through which nascent proteins diffuse. These results reveal that protein aggregates do not correspond to a single common class of subcellular structures, and rather that there may be a wide range of aggregate structures, perhaps each corresponding to the specific disease-associated protein with distinct consequences on the biochemical state of the cell.	Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Morimoto, RI (corresponding author), Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	r-morimoto@northwestern.edu		Matsumoto, Gen/0000-0002-9339-1682	NIGMS NIH HHS [R37 GM038109] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; Becker M, 2000, J CELL BIOL, V149, P255, DOI 10.1083/jcb.149.2.255; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chong JA, 2005, MOL CELL BIOL, V25, P2632, DOI 10.1128/MCB.25.7.2632-2643.2005; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hazeki N, 2002, BIOCHEM BIOPH RES CO, V294, P429, DOI 10.1016/S0006-291X(02)00498-9; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Hughes RE, 2001, NAT MED, V7, P419, DOI 10.1038/86486; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; Nagai Y, 1999, EXP NEUROL, V155, P195, DOI 10.1006/exnr.1998.6991; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; OKAMOTO K, 1991, NEUROSCI LETT, V129, P233, DOI 10.1016/0304-3940(91)90469-A; Patterson GH, 1998, YEAST, V14, P813, DOI 10.1002/(SICI)1097-0061(19980630)14:9<813::AID-YEA280>3.0.CO;2-2; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Qin ZH, 2004, J NEUROSCI, V24, P269, DOI 10.1523/JNEUROSCI.1409-03.2004; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reid SJ, 2004, MOL BRAIN RES, V125, P120, DOI 10.1016/j.molbrainres.2004.03.018; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schmidt T, 2002, ANN NEUROL, V51, P302, DOI 10.1002/ana.10101; Shimizu N, 2000, J NEURAL TRANSM-SUPP, P19; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	60	84	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4477	4485		10.1074/jbc.M509201200	http://dx.doi.org/10.1074/jbc.M509201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16371362				2022-12-25	WOS:000235275300083
J	Schulz, LL; Tyler, JK				Schulz, LL; Tyler, JK			The histone chaperone ASF1 localizes to active DNA replication forks to mediate efficient DNA replication	FASEB JOURNAL			English	Article						anti-silencing function 1; chromatin; knockdown; Drosophila	CHROMATIN ASSEMBLY FACTOR-1; TOUSLED-LIKE KINASES; S-PHASE; SACCHAROMYCES-CEREVISIAE; DAMAGE CHECKPOINT; IN-VIVO; DROSOPHILA; CELLS; YEAST; CAF-1	The packaging of the eukaryotic genome into chromatin is likely to regulate all processes that occur on the DNA template. The assembly and disassembly of chromatin structures from histone proteins and DNA are mediated by histone chaperones, including the histone H3/H4 chaperone anti-silencing function 1 (ASF1). To address the function of ASF1 in metazoan cells, we used RNA interference-mediated knockdown of Drosophila melanogaster ASF1 (dASF1). Cells lacking dASF1 accumulate in S phase of the cell cycle as determined by flow cytometry analysis of DNA content and quantitation of the proportion of cells with replication foci. In agreement, bromodeoxyuridine (BrdU) pulse-chase analysis demonstrates that the absence of ASF1 leads to delayed progression through S-phase. Furthermore, the absence of ASF1 leads to a reduced ability to incorporate the nucleoside analog BrdU, indicating that ASF1 is required for efficient DNA replication. We have also found that dASF1 colocalizes with DNA replication foci throughout S phase by immunofluorescence analysis and that these dASF1 foci are disrupted upon inhibition of DNA replication by treatment of cells with hydroxyurea. As such, these results demonstrate that dASF1 is present at active, but not stalled, replication forks. We propose that dASF1 has a direct role in modifying chromatin structure during DNA replication and that this function of dASF1 is important for the processivity of the replication machinery.	Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Biochem & Mol Genet, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Tyler, JK (corresponding author), Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Biochem & Mol Genet, Mail Stop 8101,POB 6511, Aurora, CO 80045 USA.	Jessica.tyler@uchsc.edu		Tyler, Jessica/0000-0001-9765-1659	NATIONAL CANCER INSTITUTE [R01CA095641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064475] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA095641, CA95641] Funding Source: Medline; NIGMS NIH HHS [R01 GM064475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins MW, 2004, J BIOL CHEM, V279, P52069, DOI 10.1074/jbc.M406113200; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Carrera P, 2003, GENE DEV, V17, P2578, DOI 10.1101/gad.276703; Claycomb JM, 2002, J CELL BIOL, V159, P225, DOI 10.1083/jcb.200207046; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Franco AA, 2005, GENE DEV, V19, P1365, DOI 10.1101/gad.1305005; Gerbi SA, 2002, CURR OPIN GENET DEV, V12, P243, DOI 10.1016/S0959-437X(02)00292-7; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Groth A, 2003, EMBO J, V22, P1676, DOI 10.1093/emboj/cdg151; Henderson DS, 2000, GENETICS, V154, P1721; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Myung K, 2003, P NATL ACAD SCI USA, V100, P6640, DOI 10.1073/pnas.1232239100; Nabatiyan A, 2004, MOL CELL BIOL, V24, P2853, DOI 10.1128/MCB.24.7.2853-2862.2004; Prado F, 2004, EMBO REP, V5, P497, DOI 10.1038/sj.embor.7400128; Ramey CJ, 2004, MOL CELL BIOL, V24, P10313, DOI 10.1128/MCB.24.23.10313-10327.2004; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Zabaronick SR, 2005, MOL CELL BIOL, V25, P652, DOI 10.1128/MCB.25.2.652-660.2005; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	30	61	63	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					488	+		10.1096/fj.05-5020fje	http://dx.doi.org/10.1096/fj.05-5020fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16396992				2022-12-25	WOS:000235996000036
J	Sotiriou, SN; Orlova, VV; Al-Fakhri, N; Ihanus, E; Economopoulou, M; Isermann, B; Bdeir, K; Nawroth, PP; Preissner, KT; Gahmberg, CG; Koschinsky, ML; Chavakis, T				Sotiriou, SN; Orlova, VV; Al-Fakhri, N; Ihanus, E; Economopoulou, M; Isermann, B; Bdeir, K; Nawroth, PP; Preissner, KT; Gahmberg, CG; Koschinsky, ML; Chavakis, T			Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin	FASEB JOURNAL			English	Article						plasminogen/angiostatin kringle 4; coronary arteries; prothrombotic tissue factor	NF-KAPPA-B; ANTIINFLAMMATORY FACTOR; TRANSCRIPTION FACTOR; TRANSGENIC MICE; LEUKOCYTE; APOLIPOPROTEIN(A); ATHEROGENESIS; MIGRATION; PATHWAY; BINDING	Lipoprotein(a) [Lp(a)], consisting of LDL and the unique constituent apolipoprotein(a) [apo(a)], which contains multiple repeats resembling plasminogen kringle 4, is considered a risk factor for the development of atherosclerotic disorders. However, the underlying mechanisms for the atherogenicity of Lp(a) are not completely understood. Here, we define a novel function of Lp(a) in promoting inflammatory cell recruitment that may contribute to its atherogenicity. Through its apo(a) moiety Lp(a) specifically interacts with the beta 2-integrin Mac-1, thereby promoting the adhesion of monocytes and their transendothelial migration in a Mac-1-dependent manner. Interestingly, the interaction between Mac-1 and Lp(a) was strengthened in the presence of proatherogenic homocysteine and was blocked by plasminogen/angiostatin kringle 4. Through its interaction with Mac-1, Lp(a) induced activation of the proinflammatory transcription factor NF kappa B, as well as the NF kappa B-related expression of prothrombotic tissue factor. In atherosclerotic coronary arteries Lp(a) was found to be localized in close proximity to Mac-1 on infiltrating mononuclear cells. Taken together, our data demonstrate that Lp(a), via its apo(a) moiety, is a ligand for the beta 2-integrin Mac-1, thereby facilitating inflammatory cell recruitment to atherosclerotic plaques. These observations suggest a novel mechanism for the atherogenic properties of Lp(a).	Natl Canc Inst, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; Heidelberg Univ, Dept Internal Med 1, Heidelberg, Germany; Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; Univ Helsinki, Fac Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Giessen, Inst Biochem, Giessen, Germany; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg; Philipps University Marburg; University of Helsinki; University of Pennsylvania; Justus Liebig University Giessen; Queens University - Canada	Chavakis, T (corresponding author), Natl Canc Inst, Expt Immunol Branch, NIH, 10 Ctr Dr,Rm 4B17, Bethesda, MD 20892 USA.	chavakist@mail.nih.gov	Gahmberg, Carl/AAE-1876-2019; Chavakis, Triantafyllos/ABE-8845-2020; Orlova, Valeria V/C-6065-2014	Orlova, Valeria V/0000-0002-1169-2802; Koschinsky, Marlys/0000-0002-2643-2288; Gahmberg, Carl/0000-0001-9892-9296	NATIONAL CANCER INSTITUTE [Z01BC010664, ZIABC010664] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen S, 1998, FASEB J, V12, P1765, DOI 10.1096/fasebj.12.15.1765; Angles-Cano E, 2001, ANN NY ACAD SCI, V936, P261; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Becker L, 2004, BIOCHEMISTRY-US, V43, P9978, DOI 10.1021/bi049536d; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; CALLOW MJ, 1995, J CLIN INVEST, V96, P1639, DOI 10.1172/JCI118203; Caplice NM, 2001, BLOOD, V98, P2980, DOI 10.1182/blood.V98.10.2980; Chavakis E, 2001, CIRCULATION, V103, P2102; Chavakis T, 2000, BLOOD, V96, P514; Chavakis T, 2005, BLOOD, V105, P1036, DOI 10.1182/blood-2004-01-0166; Chavakis T, 2004, J BIOL CHEM, V279, P55602, DOI 10.1074/jbc.M404676200; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chavakis T, 2003, THROMB HAEMOSTASIS, V89, P13; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; Falco C, 1998, THROMB HAEMOSTASIS, V79, P818, DOI 10.1055/s-0037-1615071; FAN ST, 1993, J IMMUNOL, V150, P2972; FAN ST, 1991, J CLIN INVEST, V87, P50, DOI 10.1172/JCI115000; Foody JM, 2000, ARTERIOSCL THROM VAS, V20, P493, DOI 10.1161/01.ATV.20.2.493; Gabel BR, 1998, BIOCHEMISTRY-US, V37, P7892, DOI 10.1021/bi973186w; Gahmberg CG, 1997, CURR OPIN CELL BIOL, V9, P643, DOI 10.1016/S0955-0674(97)80117-2; GERRITY RG, 1981, AM J PATHOL, V103, P181; Glader CA, 2002, J INTERN MED, V252, P27, DOI 10.1046/j.1365-2796.2002.00997.x; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Ingalls RR, 1997, J IMMUNOL, V159, P433; Kang C, 2002, ARTERIOSCL THROM VAS, V22, P1232, DOI 10.1161/01.ATV.0000021144.87870.C8; KEIPER T, 2006, IN PRESS FASEB J; Kim CH, 2004, J LEUKOCYTE BIOL, V75, P286, DOI 10.1189/jlb.0103038; Koschinsky ML, 2004, CURR OPIN LIPIDOL, V15, P167, DOI 10.1097/00041433-200404000-00009; Kronenberg F, 1999, CIRCULATION, V100, P1154, DOI 10.1161/01.CIR.100.11.1154; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LI R, 1993, J BIOL CHEM, V268, P17513; LIBBY P, 1991, LAB INVEST, V64, P5; Lishko VK, 2004, BLOOD, V104, P719, DOI 10.1182/blood-2003-09-3016; MAHER VMG, 1995, JAMA-J AM MED ASSOC, V274, P1771, DOI 10.1001/jama.274.22.1771; Marcovina Santica M, 2002, Semin Vasc Med, V2, P335, DOI 10.1055/s-2002-35404; Marcovina SM, 1996, CLIN CHEM, V42, P436; Marcovina SM, 2003, CURR OPIN LIPIDOL, V14, P361, DOI 10.1097/00041433-200308000-00004; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; NAGEH MF, 1997, ARTERIOSCLER THROMB, V80, P810; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Pluskota E, 2004, J BIOL CHEM, V279, P18063, DOI 10.1074/jbc.M310462200; Rand ML, 1998, ARTERIOSCL THROM VAS, V18, P1393, DOI 10.1161/01.ATV.18.9.1393; Rezzonico R, 2001, BLOOD, V97, P2932, DOI 10.1182/blood.V97.10.2932; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Santoso S, 2002, J EXP MED, V196, P679, DOI 10.1084/jem.20020267; Schmal H, 1998, J IMMUNOL, V161, P3685; Shi C, 2001, CIRC RES, V89, P859, DOI 10.1161/hh2201.099166; Spijkers PPEM, 2005, BLOOD, V105, P170, DOI 10.1182/blood-2004-02-0498; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; von Depka M, 2000, BLOOD, V96, P3364; Weisel JW, 2001, BIOCHEMISTRY-US, V40, P10424, DOI 10.1021/bi010556e	58	85	105	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					559	+		10.1096/fj.05-4857fje	http://dx.doi.org/10.1096/fj.05-4857fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16403785				2022-12-25	WOS:000235996000026
J	Dumay, A; Laulier, C; Bertrand, P; Saintigny, Y; Lebrun, F; Vayssiere, JL; Lopez, BS				Dumay, A.; Laulier, C.; Bertrand, P.; Saintigny, Y.; Lebrun, F.; Vayssiere, J-L; Lopez, B. S.			Bax and Bid, two proapoptotic Bcl-2 family members, inhibit homologous recombination, independently of apoptosis regulation	ONCOGENE			English	Article						homologous recombination; double-strand break repair; genetic instability; Bcl-2 family; BAX; BID; apoptosis	NUCLEOTIDE EXCISION-REPAIR; DEPENDENT PROTEIN-KINASE; DNA-DAMAGE RESPONSE; MAMMALIAN-CELLS; DIRECTED REPAIR; C-TERMINUS; RAD51; MITOCHONDRIA; SUPPRESSION; MUTAGENESIS	In order to analyse the relationships between regulation of apoptosis and homologous recombination (HR), we over-expressed proapoptotic Bax or only-BH3 Bid proteins or antiapoptotic Bcl-2 or Bcl-XL, in hamster CHO cells or in SV40-transformed human fibroblasts. We measured HR induced by gamma-rays, UVC or a specific double-strand cleavage targeted in the recombination substrate by the meganuclease I-SceI. We show here that the induction of both recombinant cells and recombinant colonies was impaired when expressing Bcl-2 family members, in hamster as well as in human cells. Moreover, the pro- as well as antiapoptotic Bcl-2 family members inhibited HR, independently of degradation of the RAD51 recombination protein and of their impact on apoptosis. These data reveal a mechanism of HR downregulation by potentially proapoptotic proteins, distinct from and parallel to degradation of recombination proteins, a situation that should also optimize the efficiency of programmed cell death.	CEA, CNRS, UMR 217, DSV,DRR, F-92265 Fontenay Aux Roses, France; Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78000 Versailles, France	CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, DSV,DRR, 18 Route Panorama,BP06, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Lopez, Bernard S/O-7308-2017; Saintigny, Yannick/C-2697-2008	Lopez, Bernard S/0000-0001-5088-0155; Saintigny, Yannick/0000-0002-3839-3562; BERTRAND, Pascale/0000-0002-9019-742X; dumay, anne/0000-0002-8188-4658				Ausubel F., 1999, CURRENT PROTOCOLS MO; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Cho SH, 2002, EXP CELL RES, V278, P158, DOI 10.1006/excr.2002.5572; Delsite RL, 2003, MUTAGENESIS, V18, P497, DOI 10.1093/mutage/geg027; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; FRIEDBERG EC, 1995, DNA REPAIR; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Heimlich G, 2004, BIOCHEM J, V378, P247, DOI 10.1042/BJ20031152; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kitao H, 2002, J BIOL CHEM, V277, P48944, DOI 10.1074/jbc.M208151200; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuo ML, 1999, MOL PHARMACOL, V55, P894; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu YF, 1997, CANCER RES, V57, P1650; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Radman M, 1975, Basic Life Sci, V5A, P355; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sambrook J, 1989, MOL CLONING; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Wiese C, 2002, CANCER RES, V62, P1279; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022	45	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3196	3205		10.1038/sj.onc.1209344	http://dx.doi.org/10.1038/sj.onc.1209344			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407825				2022-12-25	WOS:000237951000010
J	Khan, EM; Heidinger, JM; Levy, M; Lisanti, MP; Ravid, T; Goldkorn, T				Khan, Elaine M.; Heidinger, Jill M.; Levy, Michal; Lisanti, Michael P.; Ravid, Tommer; Goldkorn, Tzipora			Epidermal Growth Factor Receptor Exposed to Oxidative Stress Undergoes Src- and Caveolin-1-dependent Perinuclear Trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The epidermal growth factor (EGF) receptor (EGFR) has been found to be overexpressed in several types of cancer cells, and the regulation of its oncogenic potential has been widely studied. The paradigm for EGFR down-regulation involves the trafficking of activated receptor molecules from the plasma membrane, through clathrin-coated pits, and into the cell for lysosomal degradation. We have previously shown that oxidative stress generated by H2O2 results in aberrant phosphorylation of the EGFR. This leads to the loss of c-Cbl-mediated ubiquitination of the EGFR and, consequently, prevents its degradation. However, we have found that c-Cbl-mediated ubiquitination is required solely for degradation but not for internalization of the EGFR under oxidative stress. To further examine the fate of the EGFR under oxidative stress, we used confocal analysis to show that the receptor not only remains colocalized with caveolin-1 at the plasma membrane, but at longer time points, is also sorted to a perinuclear compartment via a clathrin-independent, caveolae-mediated pathway. Our findings indicate that although the EGFR associates with caveolin-1 constitutively, caveolin-1 is hyperphosphorylated only under oxidative stress, which is essential in transporting the EGFR to a perinuclear location, where it is not degraded and remains active. Thus, oxidative stress may have a role in tumorigenesis by not only activating the EGFR but also by promoting prolonged activation of the receptor both at the plasma membrane and within the cell.	[Goldkorn, Tzipora] Univ Calif Davis, Genome & Biomed Sci Facil, Dept Internal Med, Signal Transduct Lab,Sch Med, Davis, CA 95616 USA; [Lisanti, Michael P.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; [Lisanti, Michael P.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Lisanti, Michael P.] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; [Ravid, Tommer] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University of California System; University of California Davis; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yale University	Goldkorn, T (corresponding author), Univ Calif Davis, Genome & Biomed Sci Facil, Dept Internal Med, Signal Transduct Lab,Sch Med, Rm 6321,451 E Hlth Sci Dr, Davis, CA 95616 USA.	ttgoldkorn@ucdavis.edu	高, 雨莉/HGU-8187-2022; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	Tobacco-Related Disease Research Program [13FT-0126]; National Institutes of Health [HL-71871, HL-66189]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066189, R01HL071871] Funding Source: NIH RePORTER	Tobacco-Related Disease Research Program(University of California System); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Tobacco-Related Disease Research Program Grant 13FT-0126 (to E. M. K.) and National Institutes of Health Grants HL-71871 and HL-66189 (to T. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; de Melker AA, 2001, J CELL SCI, V114, P2167; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; ECCLES SA, 1994, INVAS METAST, V14, P337; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Huang FT, 2005, MOL BIOL CELL, V16, P1268, DOI 10.1091/mbc.E04-09-0832; Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030; Laude AJ, 2004, MOL MEMBR BIOL, V21, P193, DOI 10.1080/09687680410001700517; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Quest AFG, 2004, BIOCHEM CELL BIOL, V82, P129, DOI 10.1139/o03-071; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; Sanguinetti AR, 2003, CELL SIGNAL, V15, P289, DOI 10.1016/S0898-6568(02)00090-6; Shajahan AN, 2004, J BIOL CHEM, V279, P48055, DOI 10.1074/jbc.M405837200; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2	41	129	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14486	14493		10.1074/jbc.M509332200	http://dx.doi.org/10.1074/jbc.M509332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16407214	hybrid			2022-12-25	WOS:000207179300007
J	Kimura, T; Sakisaka, T; Baba, T; Yamada, T; Takai, Y				Kimura, T; Sakisaka, T; Baba, T; Yamada, T; Takai, Y			Involvement of the Ras-Ras-activated rab5 guanine nucleotide exchange factor RIN2-Rab5 pathway in the hepatocyte growth factor-induced endocytosis of E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; SMALL G-PROTEINS; CANINE KIDNEY-CELLS; ADHERENS JUNCTIONS; BINDING-PROTEIN; FACTOR RECEPTOR; MDCK CELLS; RHO; TRANSLOCATION; PURIFICATION	E-cadherin is a key cell-cell adhesion molecule at adherens junctions (AJs) and undergoes endocytosis when AJs are disrupted by the action of an extracellular signal, such as hepatocyte growth factor (HGF)/scatter factor. Rab5 small G protein has been implicated in the HGF-induced endocytosis of E-cadherin, but the molecular mechanism for the regulation of Rab5 activity remains unknown. We first studied this mechanism by using the cell-free assay system for the endocytosis of E-cadherin of the AJ-enriched fraction from rat livers. HGF induced activation of Ras small G protein, which then bound to RIN2, a Rab5 GDP/GTP exchange factor with the Vps9p-like guanine nucleotide exchange factor and Ras association domains, and activated it. Activated RIN2 then activated Rab5, eventually inducing the endocytosis of E-cadherin. We then studied whether RIN2 was involved in the HGF-induced endocytosis of E-cadherin in intact Madin-Darby canine kidney cells. RIN2 localized at the cell-cell adhesion sites, and its guanine nucleotide exchange factor activity was required for the HGF-induced endocytosis of E-cadherin in Madin-Darby canine kidney cells. These results indicate that RIN2 connects Ras to Rab5 in the HGF-induced endocytosis of E-cadherin.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp						Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; HORIUCHI H, 1995, METHOD ENZYMOL, V257, P9; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; Martinu L, 2002, J BIOL CHEM, V277, P50996, DOI 10.1074/jbc.M204869200; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Tanimura S, 1998, ONCOGENE, V17, P57, DOI 10.1038/sj.onc.1201905; TSUKITA S, 1989, J CELL BIOL, V108, P31, DOI 10.1083/jcb.108.1.31; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10598	10609		10.1074/jbc.M510531200	http://dx.doi.org/10.1074/jbc.M510531200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16423831	hybrid			2022-12-25	WOS:000236594300092
J	Gyulkhandanyan, AV; Lee, SC; Bikopoulos, G; Dai, FH; Wheeler, MB				Gyulkhandanyan, AV; Lee, SC; Bikopoulos, G; Dai, FH; Wheeler, MB			The Zn2+-transporting pathways in pancreatic beta-cells - A role for the L-type voltage-gated Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETORY GRANULES; MAMMALIAN ZINC TRANSPORTER; CALCIUM-CHANNELS; CORTICAL-NEURONS; K+ CHANNELS; MITOCHONDRIAL DYSFUNCTION; POTASSIUM CHANNELS; GLUCAGON-RELEASE; HEAVY-METALS; ALPHA-CELLS	In pancreatic beta-cells Zn2+ is crucial for insulin biosynthesis and exocytosis. Despite this, little is known about mechanisms of Zn2+ transport into beta-cells or the regulation and compartmentalization of Zn2+ within this cell type. Evidence suggests that Zn2+ in part enters neurons and myocytes through specific voltage-gated calcium channels (VGCC). Using a Zn2+-selective fluorescent dye with high affinity and quantum yield, FluoZin-3 AM and the plasma membrane potential dye DiBAC(4)(3) we applied fluorescent microscopy techniques for analysis of Zn2+-accumulating pathways in mouse islets, dispersed islet cells, and beta-cell lines (MIN6 and beta-TC6f7 cells). Because the stimulation of insulin secretion is associated with cell depolarization, Zn2+ (5-10 mu M) uptake was analyzed under basal (1 mM glucose) and stimulatory (10-20 mM glucose, tolbutamide, tetraethylammonium, and high K+) conditions. Under both basal and depolarized states, beta-cells were capable of Zn2+ uptake, and switching from basal to depolarizing conditions resulted in a marked increase in the rate of Zn2+ accumulation. Importantly, L-type VGCC (L-VGCC) blockers (verapamil, nitrendipine, and nifedipine) as well as nonspecific inhibitors of Ca2+ channels, Gd3+ and La3+, inhibited Zn2+ uptake in beta-cells under stimulatory conditions with little or no change in Zn2+ accumulation under low glucose conditions. To determine the mechanism of VGCC-independent Zn2+ uptake the expression of a number of ZIP family Zn2+ transporter mRNAs in islets and beta-cells was investigated. In conclusion, we demonstrate for the first time that, in part, Zn2+ transport into beta-cells takes place through the L-VGCC. Our investigation demonstrates direct Zn2+ accumulation in insulin-secreting cells by two pathways and suggests that the rate of Zn2+ transport across the plasma membrane is dependent upon the metabolic status of the cell.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle,Rm 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca		Wheeler, Michael B./0000-0002-7480-7267				Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Bancila V, 2004, J NEUROCHEM, V90, P1243, DOI 10.1111/j.1471-4159.2004.02587.x; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Brissova M, 2005, J HISTOCHEM CYTOCHEM, V53, P1087, DOI 10.1369/jhc.5C6684.2005; Chausmer AB, 1998, J AM COLL NUTR, V17, P109, DOI 10.1080/07315724.1998.10718735; Chimienti F, 2004, DIABETES, V53, P2330, DOI 10.2337/diabetes.53.9.2330; Colvin RA, 2003, EUR J PHARMACOL, V479, P171, DOI 10.1016/j.ejphar.2003.08.067; Colvin RA, 1998, NEUROSCI LETT, V247, P147, DOI 10.1016/S0304-3940(98)00302-4; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; Falkmer S, 1968, Diabetologia, V4, P239, DOI 10.1007/BF00430102; FIGLEWICZ DP, 1980, DIABETES, V29, P767, DOI 10.2337/diacare.20.10.767; FORMBY B, 1984, DIABETES, V33, P229, DOI 10.2337/diabetes.33.3.229; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; Franklin I, 2005, DIABETES, V54, P1808, DOI 10.2337/diabetes.54.6.1808; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; FREUND WD, 1994, BRAIN RES, V654, P257, DOI 10.1016/0006-8993(94)90487-1; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Gee KR, 2002, CELL CALCIUM, V31, P245, DOI 10.1016/S0143-4160(02)00053-2; GOLD G, 1984, EXPERIENTIA, V40, P1105, DOI 10.1007/BF01971458; Gromada J, 1997, J GEN PHYSIOL, V110, P217, DOI 10.1085/jgp.110.3.217; Guan ZX, 2003, J INORG BIOCHEM, V97, P199, DOI 10.1016/S0162-0134(03)00291-5; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; Henquin JC, 2004, DIABETES, V53, pS48, DOI 10.2337/diabetes.53.suppl_3.S48; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kim BJ, 2000, DIABETES, V49, P367, DOI 10.2337/diabetes.49.3.367; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; LUDVIGSEN C, 1979, DIABETES, V28, P570, DOI 10.2337/diab.28.6.570; Ma XS, 2005, MOL ENDOCRINOL, V19, P198, DOI 10.1210/me.2004-0059; MacDonald PE, 2003, DIABETOLOGIA, V46, P1046, DOI 10.1007/s00125-003-1159-8; Malaiyandi LM, 2005, J NEUROCHEM, V93, P1242, DOI 10.1111/j.1471-4159.2005.03116.x; Malaiyandi LM, 2004, GLIA, V45, P346, DOI 10.1002/glia.10332; Ohana E, 2004, J BIOL CHEM, V279, P4278, DOI 10.1074/jbc.M309229200; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PRASAD AS, 1995, NUTRITION, V11, P93; Qian WJ, 2003, ANAL CHEM, V75, P3468, DOI 10.1021/ac0341057; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; Segal D, 2004, BIOCHEM BIOPH RES CO, V323, P1145, DOI 10.1016/j.bbrc.2004.08.211; Sensi SL, 2000, EUR J NEUROSCI, V12, P3813, DOI 10.1046/j.1460-9568.2000.00277.x; Sensi SL, 2004, CURR MOL MED, V4, P87, DOI 10.2174/1566524043479211; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Straub SG, 2004, DIABETES, V53, P3179, DOI 10.2337/diabetes.53.12.3179; Taylor KM, 2003, BIOCHEM J, V375, P51, DOI 10.1042/BJ20030478; Truong-Tran AQ, 2001, BIOMETALS, V14, P315, DOI 10.1023/A:1012993017026; VEGA MT, 1994, PFLUG ARCH EUR J PHY, V429, P231, DOI 10.1007/BF00374317; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Yin HZ, 1995, NEUROREPORT, V6, P2553, DOI 10.1097/00001756-199512150-00025; YOKOH S, 1969, DIABETOLOGIA, V5, P137, DOI 10.1007/BF01213670; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	75	77	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9361	9372		10.1074/jbc.M508542200	http://dx.doi.org/10.1074/jbc.M508542200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16407176	hybrid			2022-12-25	WOS:000236404700045
J	Cougoule, C; Hoshino, S; Dart, A; Lim, J; Caron, E				Cougoule, C; Hoshino, S; Dart, A; Lim, J; Caron, E			Dissociation of recruitment and activation of the small G-protein Rac during Fc gamma receptor-mediated phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYK TYROSINE KINASE; DISTINCT MECHANISMS; PLASMA-MEMBRANE; FAMILY KINASES; RHO-GTPASES; VAV; CDC42; PHOSPHORYLATION; MACROPHAGES; INVOLVEMENT	Rho-family proteins play a central role in most actin-dependent processes, including the control and maintenance of cell shape, adhesion, motility, and phagocytosis. Activation of these GTP-binding proteins is tightly regulated spatially and temporally; however, very little is known of the mechanisms involved in their recruitment and activation in vivo. Because of its inducible, restricted signaling, phagocytosis offers an ideal physiological system to delineate the pathways linking surface receptors to actin remodeling via Rho GTPases. In this study, we investigated the involvement of early regulators of Fc gamma receptor signaling in Rac recruitment and activation. Using a combination of receptor mutagenesis, cellular, molecular, and pharmacological approaches, we show that Src family and Syk kinases control Rac and Vav function during phagocytosis. Importantly, both the immunoreceptor tyrosine-based activation motif within Fc gamma receptor cytoplasmic domain and Src kinase control the recruitment of Vav and Rac. However, Syk activity is dispensable for Vav and Rac recruitment. Moreover, we show that Rac and Cdc42 activities coordinate F-actin accumulation at nascent phagosomes. Our results provide new insights in the understanding of the spatiotemporal regulation of Rho-family GTPase function, and of Rac in particular, during phagocytosis. We believe they will contribute to a better understanding of more complex cellular processes, such as cell adhesion and migration.	Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Fac Life Sci, Div Cell & Mol Cell Biol, London SW7 2AZ, England	Imperial College London; Imperial College London	Caron, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, CMMI2, Flowers Bldg,Armstrong Rd, London SW7 2AZ, England.	e.caron@imperial.ac.uk	COUGOULE, Céline/ABB-4180-2021	Dart, Anna/0000-0002-2412-3502; Lim, Jenson/0000-0001-7417-356X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; August A, 1997, P NATL ACAD SCI USA, V94, P11227, DOI 10.1073/pnas.94.21.11227; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billker O, 2002, EMBO J, V21, P560, DOI 10.1093/emboj/21.4.560; Bonilla FA, 2000, P NATL ACAD SCI USA, V97, P1725, DOI 10.1073/pnas.040543597; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Carreno S, 2000, J BIOL CHEM, V275, P36223, DOI 10.1074/jbc.M003901200; Carreno S, 2002, J BIOL CHEM, V277, P21007, DOI 10.1074/jbc.M201212200; Castellano F, 2001, SEMIN IMMUNOL, V13, P347, DOI 10.1006/smim.2001.0331; Castellano F, 1999, CURR BIOL, V9, P351, DOI 10.1016/S0960-9822(99)80161-4; Castellano F, 2000, J CELL SCI, V113, P2955; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Coppolino MG, 2001, J CELL SCI, V114, P4307; Cougoule C, 2004, SEMIN CELL DEV BIOL, V15, P679, DOI 10.1016/j.semcdb.2004.09.001; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Crowley MT, 1997, J EXP MED, V186, P1027, DOI 10.1084/jem.186.7.1027; DARBY C, 1994, J IMMUNOL, V152, P5429; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dombroski D, 2005, J IMMUNOL, V174, P1385, DOI 10.4049/jimmunol.174.3.1385; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; Dransart E, 2005, J BIOL CHEM, V280, P4674, DOI 10.1074/jbc.M409741200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fitzer-Attas CJ, 2000, J EXP MED, V191, P669, DOI 10.1084/jem.191.4.669; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Groysman M, 2002, J BIOL CHEM, V277, P50121, DOI 10.1074/jbc.M204299200; Groysman M, 2000, FEBS LETT, V467, P75, DOI 10.1016/S0014-5793(00)01121-2; Guignot J, 2004, J CELL SCI, V117, P1033, DOI 10.1242/jcs.00949; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Huang ZY, 2004, J LEUKOCYTE BIOL, V76, P491, DOI 10.1189/jlb.1103562; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Ivetic A, 2004, IMMUNOLOGY, V112, P165, DOI 10.1111/j.1365-2567.2004.01882.x; Johmura S, 2003, IMMUNITY, V18, P777, DOI 10.1016/S1074-7613(03)00139-0; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Lowry MB, 1998, J EXP MED, V187, P161, DOI 10.1084/jem.187.2.161; Majeed M, 2001, J LEUKOCYTE BIOL, V70, P801; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; May RC, 2000, NAT CELL BIOL, V2, P246, DOI 10.1038/35008673; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; MITCHELL MA, 1994, BLOOD, V84, P1753; Niedergang F, 2003, J CELL BIOL, V161, P1143, DOI 10.1083/jcb.200210069; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Price LS, 2003, J BIOL CHEM, V278, P39413, DOI 10.1074/jbc.M302083200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schirmer J, 2004, BBA-GEN SUBJECTS, V1673, P66, DOI 10.1016/j.bbagen.2004.03.014; Schmitter T, 2004, J EXP MED, V199, P35, DOI 10.1084/jem.20030204; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; Simon M, 2005, J BIOL CHEM, V280, P4510, DOI 10.1074/jbc.M410326200; Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057; Suzuki T, 2000, J IMMUNOL, V165, P473, DOI 10.4049/jimmunol.165.1.473; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Wiedemann Agnes, 2005, P72, DOI 10.1007/978-0-387-28669-3_6; Yamada M, 2004, J BIOL CHEM, V279, P36228, DOI 10.1074/jbc.M403101200; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788	67	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8756	8764		10.1074/jbc.M513731200	http://dx.doi.org/10.1074/jbc.M513731200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16434390	hybrid			2022-12-25	WOS:000236247100054
J	Ruchalski, K; Mao, HP; Li, ZJ; Wang, ZY; Gillers, S; Wang, YH; Mosser, DD; Gabai, V; Schwartz, JH; Borkan, SC				Ruchalski, K; Mao, HP; Li, ZJ; Wang, ZY; Gillers, S; Wang, YH; Mosser, DD; Gabai, V; Schwartz, JH; Borkan, SC			Distinct hsp70 domains mediate apoptosis-inducing factor release and nuclear accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CYTOCHROME-C RELEASE; N-TERMINAL KINASE; MOLECULAR CHAPERONES; FACTOR AIF; INHIBITS APOPTOSIS; ATPASE ACTIVITY; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; SUBSTRATE-BINDING	Although hsp70 antagonizes apoptosis-inducing factor (AIF)mediated cell death, the relative importance of preventing its release from mitochondria versus sequestering leaked AIF in the cytosol remains controversial. To dissect these two protective mechanisms, hsp70 deletion mutants lacking either the chaperone function ( hsp70-Delta EEVD) or ATPase function (hsp70-Delta ATPase) were selectively overexpressed before exposing cells to a metabolic inhibitor, an insult sufficient to cause mitochondrial AIF release, nuclear AIF accumulation, and apoptosis. Compared with empty vector, overexpression of wild type human hsp70 inhibited bax activation and reduced mitochondrial AIF release after injury. In contrast, mutants lacking either the chaperone function (hsp70-Delta EEVD) or the ATP hydrolytic domain (hsp70-Delta ATPase) failed to prevent mitochondrial AIF release. Although hsp70-Delta EEVD did not inhibit bax activation or mitochondrial membrane injury after cell stress, this hsp70 mutant co-immunoprecipitated with leaked AIF in injured cells and decreased nuclear AIF accumulation. In contrast, hsp70-Delta ATPase did not interact with AIF either in intact cells or in a cell-free system and furthermore, failed to prevent nuclear AIF accumulation. These results demonstrate that mitochondrial protection against bax-mediated injury requires both intact chaperone and ATPase functions, whereas the ATPase domain is critical for sequestering AIF in the cytosol.	Zhongshan Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou, Peoples R China; Boston Univ, Boston Med Ctr, Dept Med, Renal Sect, Boston, MA 02118 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Sun Yat Sen University; Boston Medical Center; Boston University; Vanderbilt University; University of Guelph; Boston University	Borkan, SC (corresponding author), Evans Biomed Res Ctr, Renal Sect, Rm 546,650 Albany St, Boston, MA 02118 USA.	sborkan@bu.edu	Mosser, Dick D/A-7391-2008; Gabai, Vladimir L/I-1650-2013; Schwartz, John/AAO-8158-2021	Gabai, Vladimir L/0000-0003-4505-4718; Schwartz, John/0000-0002-1660-8681; Wang, Zhiyon/0000-0002-6471-266X; Mao, Haiping/0000-0002-3608-3851; Mosser, Richard/0000-0002-9183-2288; Borkan, Steven/0000-0003-3062-9486	NIDDK NIH HHS [DK-53387, DK-52898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053387, R01DK052898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonsson B, 2004, MOL CELL BIOCHEM, V256, P141, DOI 10.1023/B:MCBI.0000009865.70898.36; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Beissinger M, 1998, BIOL CHEM, V379, P245; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Borkan SC, 2002, ANNU REV PHYSIOL, V64, P503, DOI 10.1146/annurev.physiol.64.081501.155819; Caldarone CA, 2004, ANN THORAC SURG, V78, P948, DOI 10.1016/j.athoracsur.2004.04.031; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Carrello A, 2004, CELL STRESS CHAPERON, V9, P167, DOI 10.1379/CSC-26R.1; Chien CT, 2005, AM J TRANSPLANT, V5, P1194, DOI 10.1111/j.1600-6143.2005.00826.x; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deaciuc IV, 2004, ALCOHOL CLIN EXP RES, V28, P160, DOI 10.1111/j.1530-0277.2004.tb02981.x; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hou Q, 2005, AM J PHYSIOL-HEART C, V289, pH477, DOI 10.1152/ajpheart.00879.2004; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5; Kim GT, 2003, BIOCHEM BIOPH RES CO, V309, P619, DOI 10.1016/j.bbrc.2003.08.045; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Mallouk Y, 1999, INT J MOL MED, V4, P463; Mao HP, 2004, J BIOL CHEM, V279, P15472, DOI 10.1074/jbc.M313484200; Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Miernyk JA, 1996, PLANT PHYSIOL, V110, P419, DOI 10.1104/pp.110.2.419; Mikami KI, 2004, J GASTROEN HEPATOL, V19, P884, DOI 10.1111/j.1440-1746.2004.03401.x; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Mosser DD, 2004, ONCOGENE, V23, P2907, DOI 10.1038/sj.onc.1207529; Orrenius S, 2004, TOXICOL LETT, V149, P19, DOI 10.1016/j.toxlet.2003.12.017; Osipiuk J, 1999, ACTA CRYSTALLOGR D, V55, P1105, DOI 10.1107/S0907444999002103; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Peherstorfer E, 2002, AM J PHYSIOL-RENAL, V283, pF190, DOI 10.1152/ajprenal.00317.2001; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Price VR, 2002, J AM SOC NEPHROL, V13, P1152, DOI 10.1097/01.ASN.0000012609.22035.44; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ruchalski K, 2003, AM J PHYSIOL-CELL PH, V285, pC1483, DOI 10.1152/ajpcell.00049.2003; Schwartz JH, 1999, J AM SOC NEPHROL, V10, P2297; Shoskes DA, 1998, TRANSPLANTATION, V66, P147, DOI 10.1097/00007890-199807270-00001; SINHA D, 2003, AM J PHYSIOL-RENAL, V248, P488; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tafani M, 2001, CANCER RES, V61, P2459; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Volloch V, 1999, FEBS LETT, V461, P73, DOI 10.1016/S0014-5793(99)01428-3; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wang YH, 2002, CELL STRESS CHAPERON, V7, P137, DOI 10.1379/1466-1268(2002)007<0137:HEESIA>2.0.CO;2; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S; Yaglom JA, 1999, J BIOL CHEM, V274, P20223, DOI 10.1074/jbc.274.29.20223; Yaglom JA, 2003, J BIOL CHEM, V278, P50483, DOI 10.1074/jbc.M306903200; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	86	91	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7873	7880		10.1074/jbc.M513728200	http://dx.doi.org/10.1074/jbc.M513728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407317	hybrid			2022-12-25	WOS:000236031000022
J	Schiller, D; Ott, V; Kramer, R; Morbach, S				Schiller, D; Ott, V; Kramer, R; Morbach, S			Influence of membrane composition on osmosensing by the betaine carrier BetP from Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC-TRANSPORT-SYSTEM; COMPATIBLE SOLUTES; PROP; SECRETION; RESPONDS; BACTERIA; STRESS; SENSOR; STATE; K+	The glycine betaine carrier BetP from Corynebacterium glutamicum was recently shown to function as both an osmosensor and osmoregulator in proteoliposomes made from Escherichia coli phospholipids by sensing changes in the internal K+ concentration as a measure of hyperosmotic stress ( Rubenhagen, R., Morbach, S., and Kramer, R. ( 2001) EMBO J. 20, 5412 - 5420). Furthermore, evidence was provided that a stretch of 25 amino acids of the C-terminal domain of BetP is critically involved in K+ sensing. This K+-sensitive region has been further characterized. Glu(572) turned out to be important for osmosensing in E. coli cells and in proteoliposomes made from E. coli phospholipids. BetP mutants E572K, E572P, and E572A/ H573A/ R574A were unable to detect an increase in the internal K+ concentration in this membrane environment. However, these BetP variants regained their ability to detect osmotic stress in membranes with increased phosphatidylglycerol content, i.e. in intact C. glutamicum cells or in proteoliposomes mimicking the composition of the C. glutamicum membrane. Mutants E572P and Y550P were still insensitive to osmotic stress also in this membrane background. These results led to the following conclusions. (i) The K+ sensor in mutants E572Q, E572D, and E572K is only partially impaired. (ii) Restoration of activity regulation is not possible if the correct conformation or orientation of the C-terminal domain is compromised by a proline residue at position 572 or 550. (iii) Phosphatidylglycerol in the membrane of C. glutamicum seems to stabilize the inactive conformation of BetP C252T and other mutants.	Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Cologne; University of Wisconsin System; University of Wisconsin Madison	Morbach, S (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	s.morbach@uni-koeln.de						Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; Cantor RS, 1999, CHEM PHYS LIPIDS, V101, P45, DOI 10.1016/S0009-3084(99)00054-7; Culham DE, 2003, BIOCHEMISTRY-US, V42, P410, DOI 10.1021/bi0264364; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GUILLOUET S, 1995, APPL MICROBIOL BIOT, V43, P315, DOI 10.1007/s002530050409; HAARDT M, 1995, MOL GEN GENET, V246, P783, DOI 10.1007/BF00290728; HOISCHEN C, 1990, J BACTERIOL, V172, P3409, DOI 10.1128/jb.172.6.3409-3416.1990; Honore E, 2002, EMBO J, V21, P2968, DOI 10.1093/emboj/cdf288; Jakoby M, 1999, BIOTECHNOL TECH, V13, P437, DOI 10.1023/A:1008968419217; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; KRAMER R, 1994, FEMS MICROBIOL REV, V13, P75, DOI 10.1111/j.1574-6976.1994.tb00036.x; Morbach S, 2002, CHEMBIOCHEM, V3, P385, DOI 10.1002/1439-7633(20020503)3:5<384::AID-CBIC384>3.0.CO;2-H; Peter H, 1998, J BIOL CHEM, V273, P2567, DOI 10.1074/jbc.273.5.2567; Peter H, 1998, J BACTERIOL, V180, P6005, DOI 10.1128/JB.180.22.6005-6012.1998; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; POOLMAN B, 2004, BIOCHIM BIOPHYS ACTA, V1667, P88; PRASAD R, 1996, MANUAL MEMBRANE LIPI; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; RECORD MT, 1995, TRENDS BIOCHEM SCI, V23, P143; Rubenhagen R, 2000, J BIOL CHEM, V275, P735, DOI 10.1074/jbc.275.2.735; Rubenhagen R, 2001, EMBO J, V20, P5412, DOI 10.1093/emboj/20.19.5412; Schiller D, 2004, BIOCHEMISTRY-US, V43, P5583, DOI 10.1021/bi0359628; Schiller D, 2004, FEBS LETT, V563, P108, DOI 10.1016/S0014-5793(04)00279-0; Steger R, 2004, FEBS LETT, V573, P155, DOI 10.1016/j.febslet.2004.07.067; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; White GF, 2000, BBA-BIOMEMBRANES, V1468, P175, DOI 10.1016/S0005-2736(00)00255-8; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	30	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7737	7746		10.1074/jbc.M513052200	http://dx.doi.org/10.1074/jbc.M513052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421104	hybrid			2022-12-25	WOS:000236031000006
J	Ueno, S; Saito, S; Wada, T; Yamaguchi, K; Satoh, M; Arai, Y; Miyagi, T				Ueno, S; Saito, S; Wada, T; Yamaguchi, K; Satoh, M; Arai, Y; Miyagi, T			Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GANGLIOSIDE SIALIDASE; CANCER CELLS; EXPRESSION; NEU3; PROLIFERATION; GLYCOSYLATION; INVOLVEMENT; ACTIVATION; MALIGNANCY	Human plasma membrane-associated sialidase (NEU3), specifically hydrolyzing gangliosides, plays crucial roles in the regulation of cell surface functions. Here we demonstrate that NEU3 mRNA level are increased in renal cell carcinomas (RCCs) compared with adjacent non-tumor tissues, significantly correlating with elevation of interleukin-6 (IL-6), a pleiotropic cytokine that has been implicated in immune responses and pathogenesis of several cancers, including RCCs. In human RCC ACHN cells, IL-6 treatment enhanced NEU3 promoter luciferase activity 2.5-fold and the endogenous sialidase activity significantly. NEU3 transfection or IL-6 treatment resulted in both suppression of apoptosis and promotion of cell motility, and the combination had synergistic effects. NEU3 scarcely affected MAPK- or IL-6-induced STAT3 activation but promoted the phosphatidylinositol 3-kinase (PI3K)/Akt cascade in both IL-6-dependent and - independent ways. Consistent with these data, NEU3 markedly inhibited staurosporine-induced caspase-3 activity and enhanced IL-6-dependent inhibition, which was abolished by LY294002, a PI3K inhibitor. Furthermore, IL-6 promoted Rho activation, and the effect was potentiated by NEU3, leading to increased cell motility that was again affected by LY294002. NEU3 silencing by siRNA resulted in the opposite: decreased Akt phosphorylation and inhibition of Rho activation. Gycolipid analysis showed a decrease in ganglioside GM3 and increase in lactosylceramide after NEU3 transfection, with these lipids apparently affecting cell apoptosis and motility. The results indicate that NEU3 activated by IL-6 exerts IL-6-mediated signaling, largely via the PI3K/Akt cascade, in a positive feedback manner and contributes to expression of a malignant phenotype in RCCs. NEU3 thus may be a useful target for RCC diagnosis and therapy.	Miyagi Canc Ctr Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Tohoku Univ, Grad Sch Med, Dept Urol, Sendai, Miyagi 9808574, Japan	Miyagi Cancer Center; Japan Science & Technology Agency (JST); Tohoku University	Miyagi, T (corresponding author), Miyagi Canc Ctr Res Inst, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	miyagi-ta173@pref.miyagi.jp		Saito, Seiichi/0000-0001-8734-4591				Angelo LS, 2002, CANCER RES, V62, P932; ATLAS I, 1992, CANCER RES, V52, P3335; Badache A, 2001, CANCER RES, V61, P383; BLAY JY, 1992, CANCER RES, V52, P3317; Cantrell DA, 2001, J CELL SCI, V114, P1439; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Horiguchi A, 2002, KIDNEY INT, V61, P926, DOI 10.1046/j.1523-1755.2002.00206.x; Hsu JH, 2004, ONCOGENE, V23, P3368, DOI 10.1038/sj.onc.1207459; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; KISHIMOTO T, 1992, SCIENCE, V257, P88; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; MIKI S, 1989, FEBS LETT, V250, P607, DOI 10.1016/0014-5793(89)80805-1; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Nakamura T, 2001, ONCOGENE, V20, P7610, DOI 10.1038/sj.onc.1204975; Proshin S, 2002, NEUROCHEM RES, V27, P841, DOI 10.1023/A:1020269326825; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; Sasaki A, 2003, J BIOL CHEM, V278, P27896, DOI 10.1074/jbc.M212200200; TAKENAWA J, 1991, J NATL CANCER I, V83, P1668, DOI 10.1093/jnci/83.22.1668; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang XQ, 2002, J BIOL CHEM, V277, P40410, DOI 10.1074/jbc.M207117200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017	31	101	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7756	7764		10.1074/jbc.M509668200	http://dx.doi.org/10.1074/jbc.M509668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428383	hybrid			2022-12-25	WOS:000236031000008
J	Zhang, XQ; Ahlers, BA; Tucker, AL; Song, JL; Wang, JF; Moorman, JR; Mounsey, JP; Carl, LL; Rothblum, LI; Cheung, JY				Zhang, XQ; Ahlers, BA; Tucker, AL; Song, JL; Wang, JF; Moorman, JR; Mounsey, JP; Carl, LL; Rothblum, LI; Cheung, JY			Phospholemman inhibition of the cardiac Na+/Ca2(+) exchanger - Role of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADULT-RAT MYOCYTES; VENTRICULAR MYOCYTES; NA+-CA2+ EXCHANGER; POSTINFARCTION MYOCYTES; ALTERS CONTRACTILITY; <CA2+>(I) TRANSIENTS; DEPENDENT REGULATION; DOWN-REGULATION; NA/CA EXCHANGE	We have demonstrated previously that phospholemman (PLM), a 15-kDa integral sarcolemmal phosphoprotein, inhibits the cardiac Na+/Ca2+ exchanger (NCX1). In addition, protein kinase A phosphorylates serine 68, whereas protein kinase C phosphorylates both serine 63 and serine 68 of PLM. Using human embryonic kidney 293 cells that are devoid of both endogenous PLM and NCX1, we first demonstrated that the exogenous NCX1 current (I-NaCa) was increased by phorbol 12-myristate 13-acetate (PMA) but not by forskolin. When co-expressed with NCX1, PLM resulted in: (i) decreases in I-NaCa, (ii) attenuation of the increase in I-NaCa by PMA, and (iii) additional reduction in I-NaCa in cells treated with forskolin. Mutating serine 63 to alanine (S63A) preserved the sensitivity of PLM to forskolin in terms of suppression of I-NaCa, whereas mutating serine 68 to alanine (S68A) abolished the inhibitory effect of PLM on I-NaCa. Mutating serine 68 to glutamic acid (phosphomimetic) resulted in additional suppression of I-NaCa as compared with wildtype PLM. These results suggest that PLM phosphorylated at serine 68 inhibited I-NaCa. The physiological significance of inhibition of NCX1 by phosphorylated PLM was evaluated in PLM-knock-out (KO) mice. When compared with wild-type myocytes, I-NaCa was significant larger in PLM-KO myocytes. In addition, the PMA-induced increase in I-NaCa was significantly higher in PLM-KO myocytes. By contrast, forskolin had no effect on I-NaCa in wild-type myocytes. We conclude that PLM, when phosphorylated at serine 68, inhibits Na+/Ca2+ exchange in the heart.	Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Hershey, PA 17033 USA; Geisinger Med Ctr, Weis Ctr Res, Danville, PA 17822 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Div Cardiovasc, Charlottesville, VA 22908 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Geisinger Medical Center; University of Virginia	Cheung, JY (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, MC-H166, Hershey, PA 17033 USA.	jyc1@psu.edu	Moorman, J Randall/ABG-9946-2020		NHLBI NIH HHS [HL-69074, R01 HL074854, R01 HL058672, R01 HL069074, HL-74854, R01 HL070548, HL-70548, HL-58672] Funding Source: Medline; NIDDK NIH HHS [DK-46678] Funding Source: Medline; NIGMS NIH HHS [GM-64640, R01 GM064640, R01 GM069841, GM-69841] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069074, R01HL058672, R01HL070548, R01HL074854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064640, R01GM069841] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlers BA, 2005, J BIOL CHEM, V280, P19875, DOI 10.1074/jbc.M414703200; Ballard C, 1996, J MOL CELL CARDIOL, V28, P11, DOI 10.1006/jmcc.1996.0002; Bossuyt J, 2005, CIRC RES, V97, P558, DOI 10.1161/01.RES.0000181172.27931.c3; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Ginsburg KS, 2005, J MOL CELL CARDIOL, V39, P972, DOI 10.1016/j.yjmcc.2005.09.005; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; He LP, 2003, J PHYSIOL-LONDON, V548, P677, DOI 10.1113/jphysiol.2002.036426; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; LEVESQUE PC, 1995, CARDIOVASC RES, V29, P336, DOI 10.1016/0008-6363(96)88590-7; Lin X, 2006, AM J PHYSIOL-CELL PH, V290, pC601, DOI 10.1152/ajpcell.00452.2005; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; Mirza MA, 2004, AM J PHYSIOL-HEART C, V286, pH1322, DOI 10.1152/ajpheart.00997.2003; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; Perchenet L, 2000, PFLUG ARCH EUR J PHY, V439, P822, DOI 10.1007/s004240051010; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Rembold CM, 2005, J VASC RES, V42, P483, DOI 10.1159/000088102; Ruknudin A, 2000, J PHYSIOL-LONDON, V529, P599, DOI 10.1111/j.1469-7793.2000.00599.x; Schulze DH, 2003, J BIOL CHEM, V278, P28849, DOI 10.1074/jbc.M300754200; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Song JL, 2005, AM J PHYSIOL-HEART C, V288, pH2342, DOI 10.1152/ajpheart.01133.2004; Song JL, 2002, AM J PHYSIOL-HEART C, V283, pH576, DOI 10.1152/ajpheart.00197.2002; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tadros GM, 2002, AM J PHYSIOL-HEART C, V283, pH1616, DOI 10.1152/ajpheart.00186.2002; WAALAS SI, 1994, BIOCHEM J, V304, P635; Wei SK, 2003, CIRC RES, V92, P897, DOI 10.1161/01.RES.0000069701.19660.14; Zhang XQ, 1996, AM J PHYSIOL-CELL PH, V271, pC1800, DOI 10.1152/ajpcell.1996.271.6.C1800; Zhang XQ, 2006, J APPL PHYSIOL, V100, P212, DOI 10.1152/japplphysiol.00757.2005; Zhang XQ, 2003, AM J PHYSIOL-HEART C, V284, pH225, DOI 10.1152/ajpheart.00698.2002; Zhang XQ, 2001, AM J PHYSIOL-HEART C, V281, pH2079, DOI 10.1152/ajpheart.2001.281.5.H2079; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429	38	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7784	7792		10.1074/jbc.M512092200	http://dx.doi.org/10.1074/jbc.M512092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434394	hybrid, Green Accepted			2022-12-25	WOS:000236031000011
J	Gadd, ME; Broekemeier, KM; Crouser, ED; Kumar, J; Graff, G; Pfeiffer, DR				Gadd, ME; Broekemeier, KM; Crouser, ED; Kumar, J; Graff, G; Pfeiffer, DR			Mitochondrial iPLA(2) activity modulates the release of cytochrome c from mitochondria and influences the permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; PHOSPHOLIPASE A(2); CYCLOSPORINE-A; ENDONUCLEASE-G; PORE; INHIBITION; APOPTOSIS; ACTIVATION; INDUCTION; OXIDATION	The mitochondrial Ca2+-independent phospholipase A(2) is activated during energy-dependent Ca2+ accumulation under conditions where there is a sustained depression of the membrane potential. This activation is not dependent on induction of the mitochondrial permeability transition. Bromoenol lactone, which inhibits the phospholipase, is effective as an inhibitor of the transition, and this action can be overcome by low levels of exogenous free fatty acids. Apparently, activation of the Ca2+-independent phospholipase is a factor in the mechanisms by which depolarization and Ca2+ accumulation promote opening of the permeability transition pore. Sustained activity of the Ca2+-independent phospholipase A(2) promotes rupture of the outer mitochondrial membrane and spontaneous release of cytochrome c on a time scale similar to that of apoptosis occurring in cells. However, more swelling of the matrix space must occur to provoke release of a given cytochrome c fraction when the enzyme is active, compared with when it is inhibited. Through its effects on the permeability transition and release of intermembrane space proteins, the mitochondrial Ca2+-independent phospholipase A(2) may be an important factor governing cell death caused by necrosis or apoptosis.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Inst Mitochondrial Biol, Columbus, OH 43210 USA; Ohio No Univ, Dept Chem, Ada, OH 45018 USA; Alcon Labs Inc, Ft Worth, TX 76134 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Ohio Northern University; Novartis; Alcon	Pfeiffer, DR (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 1645 Neil Ave,310A Hamilton Hall, Columbus, OH 43210 USA.	pfeiffer.17@osu.edu	Crouser, Elliott/ABC-2602-2021; Crouser, Elliott/E-2933-2011		NHLBI NIH HHS [T32 HL 007946, K08 HL 04335] Funding Source: Medline; NIGMS NIH HHS [R21 GM 071396, R01 GM 66206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004335, T32HL007946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066206, R21GM071396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P486; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Broekemeier KM, 1998, BIOCHEMISTRY-US, V37, P13059, DOI 10.1021/bi980820c; Broekemeier KM, 2002, BIOCHEMISTRY-US, V41, P7771, DOI 10.1021/bi020157z; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; CHERNYAK BV, 1995, FEBS LETT, V365, P75, DOI 10.1016/0014-5793(95)00411-2; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crouser ED, 2003, ANAL BIOCHEM, V317, P67, DOI 10.1016/S0003-2697(03)00044-7; DANIELS SB, 1983, J BIOL CHEM, V258, P5046; Davies AM, 2003, NUCLEIC ACIDS RES, V31, P1364, DOI 10.1093/nar/gkg205; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Gadd ME, 2002, BIOPHYS J, V82, p111A; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; Johans M, 2005, J BIOL CHEM, V280, P12130, DOI 10.1074/jbc.M413454200; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LENTING HBM, 1988, BIOCHIM BIOPHYS ACTA, V961, P129, DOI 10.1016/0005-2760(88)90138-5; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; LIHUA H, 2002, FEBS LETT, V512, P1; Linder MD, 2002, J BIOL CHEM, V277, P937, DOI 10.1074/jbc.M107610200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; NG LT, 1993, BIOCHIM BIOPHYS ACTA, V1143, P29, DOI 10.1016/0005-2728(93)90212-X; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; Penzo D, 2004, J BIOL CHEM, V279, P25219, DOI 10.1074/jbc.M310381200; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; Picklo MJ, 1999, ANAL BIOCHEM, V276, P166, DOI 10.1006/abio.1999.4349; POWERS MF, 1994, J BIOL CHEM, V269, P10614; REED PW, 1972, J BIOL CHEM, V247, P6970; SCHLENK H, 1960, ANAL CHEM, V32, P1412, DOI 10.1021/ac60167a011; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WAITE M, 1971, BIOCHEMISTRY-US, V10, P2377, DOI 10.1021/bi00788a031; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023	52	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6931	6939		10.1074/jbc.M510845200	http://dx.doi.org/10.1074/jbc.M510845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407316	hybrid			2022-12-25	WOS:000236030900005
J	Maeda, N; Fukazawa, N; Hata, T				Maeda, N; Fukazawa, N; Hata, T			The binding of chondroitin sulfate to pleiotrophin/heparin-binding growth-associated molecule is regulated by chain length and oversulfated structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; OUTGROWTH-PROMOTING ACTIVITY; HB-GAM; NEURITE-OUTGROWTH; ZETA/RPTP-BETA; 6B4 PROTEOGLYCAN/PHOSPHACAN; EXTRACELLULAR VARIANT; FACTOR MIDKINE; HYBRID CHAINS; CELL-ADHESION	Pleiotrophin is an 18-kDa heparin-binding growth factor, which uses chondroitin sulfate (CS) proteoglycan, PTP zeta as a receptor. It has been suggested that the D-type structure (GlcA(2S)beta 1-3GalNAc(6S)) in CS contributes to the high affinity binding between PTP zeta and pleiotrophin. Here, we analyzed the interaction of shark cartilage CS-D with pleiotrophin using a surface plasmon resonance biosensor to reveal the importance of D-type structure. CS-D was partially digested with chondroitinase ABC, and fractionated using a Superdex 75pg column. The >= 18-mer CS fractions showed significant binding to pleiotrophin, and the longer fractions had stronger affinity for pleiotrophin than the shorter ones. The similar to 46-mer CS fraction bound to densely immobilized pleiotrophin with high affinity (K-D = similar to 30 nM), and the binding reactions fitted the bivalent analyte model. However, when the density of the immobilized pleiotrophin was lowered, the strength of affinity remarkably decreased (K-D = similar to 2.5 mu M), and the reactions no longer fitted the model and were considered to be monovalent binding. The 20 similar to 24-mer fractions showed low affinity binding to densely immobilized pleiotrophin (K-D = 3 similar to 20 mu M), which seemed to be monovalent. When similar to 22-mer CS oligosaccharides were fractionated by strong anion exchange HPLC, each fraction differed in affinity for pleiotrophin (K-D = 0.36 similar to > 10 mu M), and the affinity correlated with the amounts of D- and E- (GlcA beta 1-3GalNAc(4S, 6S)) type oversulfated structures. These results suggest that the binding of pleiotrophin to CS is regulated by multivalency with CS similar to 20 mer as a unit and by the amounts of oversulfated structures.	Tokyo Metropolitan Inst Neurosci, Dept Dev Neurosci, Tokyo 1838526, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Maeda, N (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Dev Neurosci, 2-6 Musashidai, Tokyo 1838526, Japan.	maedan@tmin.ac.jp						Bao XF, 2005, J BIOL CHEM, V280, P35318, DOI 10.1074/jbc.M507304200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bernard-Pierrot I, 1999, BIOCHEM BIOPH RES CO, V266, P437, DOI 10.1006/bbrc.1999.1835; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Fath M, 1999, FEBS LETT, V454, P105, DOI 10.1016/S0014-5793(99)00785-1; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kaneda N, 1996, BIOCHEM BIOPH RES CO, V220, P108, DOI 10.1006/bbrc.1996.0365; Kawachi H, 2001, P NATL ACAD SCI USA, V98, P6593, DOI 10.1073/pnas.041608698; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kojima S, 1997, J BIOL CHEM, V272, P9410; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Mahoney SA, 1996, BIOCHEM BIOPH RES CO, V224, P147, DOI 10.1006/bbrc.1996.0998; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAULO E, 1994, J BIOL CHEM, V269, P12999; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; Shimazaki Y, 2005, J NEUROSCI RES, V82, P172, DOI 10.1002/jnr.20639; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	33	40	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4894	4902		10.1074/jbc.M507750200	http://dx.doi.org/10.1074/jbc.M507750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373346	hybrid			2022-12-25	WOS:000235426200040
J	Qin, ZY; Itoh, S; Jeney, V; Ushio-Fukai, M; Fukai, T				Qin, Zhenyu; Itoh, Shinichi; Jeney, Viktoria; Ushio-Fukai, Masuko; Fukai, Tohru			Essential role for the Menkes ATPase in activation of extracellular superoxide dismutase: implication for vascular oxidative stress	FASEB JOURNAL			English	Article									[Qin, Zhenyu; Itoh, Shinichi; Jeney, Viktoria; Ushio-Fukai, Masuko; Fukai, Tohru] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA	Emory University	Fukai, T (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 101 Woodruff Circle,WMB 319, Atlanta, GA 30322 USA.	tfukai@emory.edu	Jeney, Viktória/AAF-5355-2019; Jeney, Viktoria/A-6779-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058000, R01HL070187] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58000, R01 HL70187] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	76	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					334	336		10.1096/fj.05-4564fje	http://dx.doi.org/10.1096/fj.05-4564fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371425				2022-12-25	WOS:000207915000012
J	Thomas, DM; Francescutti-Verbeem, DM; Kuhn, DM				Thomas, DM; Francescutti-Verbeem, DM; Kuhn, DM			Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage	FASEB JOURNAL			English	Article						microarray analysis; HIV TAT; lipopolysaccharide; neurodegeneration	HIV-ASSOCIATED DEMENTIA; PARKINSONS-DISEASE; INDUCED NEUROTOXICITY; MICROARRAY ANALYSIS; ALZHEIMERS-DISEASE; PROTEIN; METHAMPHETAMINE; BRAIN; INFLAMMATION; STRIATUM	Microglia are the resident antigen-presenting cells within the central nervous system (CNS), and they serve immune-like functions in protecting the brain against injury and invading pathogens. By contrast, activated microglia can secrete numerous reactants that damage neurons. The pathogenesis of various neurodegenerative diseases has been associated with microglial activation, but the signaling pathways that program a neuronally protective or destructive phenotype in microglia are not known. To increase the understanding of microglial activation, microarray analysis was used to profile the transcriptome of BV-2 microglial cells after activation. Microglia were activated by lipopolysaccharide, the HIV neurotoxic protein TAT, and dopamine quinone, each of which has been linked to dopamine neuronal damage. We identified 210 of 9882 genes whose expression was differentially regulated by all activators (116 increased and 94 decreased in expression). Gene ontology analysis assigned up-regulated genes to a number of specific biological processes and molecular functions, including immune response, inflammation, and cytokine/chemokine activity. Genes down-regulated in expression contribute to conditions that are permissive of microglial migration, lowered adhesion to matrix, lessened phagocytosis, and reduction in receptors that oppose chemotaxis and inflammation. These results elaborate a broad profile of microglial genes whose expression is altered by conditions associated with both neurodegenerative diseases and microglial activation.	John D Dingell VA Med Ctr, R&D Serv, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA	Wayne State University; Wayne State University	Kuhn, DM (corresponding author), John D Dingell VA Med Ctr, R&D Serv, 11R,4646 John R, Detroit, MI 48201 USA.	donald.kuhn@wayne.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA014692, R01DA017327, R01DA010756] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10756, DA014692, DA17327] Funding Source: Medline; NIEHS NIH HHS [P30ES006639] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aksenov MY, 2003, BRAIN RES, V987, P1, DOI 10.1016/S0006-8993(03)03194-9; Albright AV, 2004, J NEUROIMMUNOL, V157, P27, DOI 10.1016/j.jneuroim.2004.09.007; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Blalock EM, 2004, P NATL ACAD SCI USA, V101, P2173, DOI 10.1073/pnas.0308512100; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Chao CC, 1997, J PHARMACOL EXP THER, V281, P998; Chen ZG, 2005, J NEUROBIOL, V62, P207, DOI 10.1002/neu.20099; Dodds DC, 1997, J BIOL CHEM, V272, P21488, DOI 10.1074/jbc.272.34.21488; Duke DC, 2004, DEV NEUROSCI-BASEL, V26, P30, DOI 10.1159/000080709; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Gao HM, 2003, FASEB J, V17, P1957, DOI 10.1096/fj.03-0203fje; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Grunblatt E, 2004, J NEURAL TRANSM, V111, P1543, DOI 10.1007/s00702-004-0212-1; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kempermann G, 2003, SCIENCE, V302, P1689, DOI 10.1126/science.1092864; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Koutsilieri E, 2002, J NEURAL TRANSM, V109, P767, DOI 10.1007/s007020200063; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; LaVoie MJ, 2004, EXP NEUROL, V187, P47, DOI 10.1016/j.expneurol.2004.01.010; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Le WD, 2001, J NEUROSCI, V21, P8447, DOI 10.1523/JNEUROSCI.21-21-08447.2001; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Lopez-Rivera E, 2005, P NATL ACAD SCI USA, V102, P3685, DOI 10.1073/pnas.0408217102; Maguire-Zeiss KA, 2005, MOL BRAIN RES, V134, P18, DOI 10.1016/j.molbrainres.2004.09.014; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; Moran LB, 2004, NEUROGENETICS, V5, P95, DOI 10.1007/s10048-004-0172-5; Morner A, 2003, AIDS, V17, P1451, DOI 10.1097/01.aids.0000076269.76134.c7; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Ogata T, 2003, BRAIN RES, V981, P174, DOI 10.1016/S0006-8993(03)03028-2; Ouchi Y, 2005, ANN NEUROL, V57, P168, DOI 10.1002/ana.20338; PIANI D, 1994, J IMMUNOL, V152, P3578; Rowe DB, 1998, J NEUROSCI RES, V53, P551, DOI 10.1002/(SICI)1097-4547(19980901)53:5<551::AID-JNR5>3.3.CO;2-T; Speliotes EK, 1996, NEUROSCIENCE, V70, P67, DOI 10.1016/0306-4522(95)00301-X; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; TERPE HJ, 1994, HISTOCHEMISTRY, V101, P41, DOI 10.1007/BF00315830; Thomas DM, 2004, J NEUROCHEM, V88, P380, DOI 10.1046/j.1471-4159.2003.02182.x; Thomas DM, 2004, J PHARMACOL EXP THER, V311, P1, DOI 10.1124/jpet.104.070961; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Wang GJ, 2004, BRAIN, V127, P2452, DOI 10.1093/brain/awh269; Wang TG, 2005, FASEB J, V19, P1134, DOI 10.1096/fj.04-2457fje; Webster SD, 2000, J LEUKOCYTE BIOL, V67, P109, DOI 10.1002/jlb.67.1.109; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8	51	52	56	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					515	+		10.1096/fj.05-4873fje	http://dx.doi.org/10.1096/fj.05-4873fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16384912				2022-12-25	WOS:000234405500017
J	Huang, MC; Chen, HY; Huang, HC; Huang, J; Liang, JT; Shen, TL; Lin, NY; Ho, CC; Cho, IM; Hsu, SM				Huang, MC; Chen, HY; Huang, HC; Huang, J; Liang, JT; Shen, TL; Lin, NY; Ho, CC; Cho, IM; Hsu, SM			C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells	ONCOGENE			English	Article						C2GnT-M; colon cancer; apoptosis; migration; invasion	O-GLYCAN BIOSYNTHESIS; CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; TUMOR PROGRESSION; BRANCH FORMATION; PROSTATE-CANCER; GENE-TRANSFER; TN-EPITOPES; EXPRESSION	Changes in carbohydrates on the cell surface are associated with tumor malignancy. The mucin-type core 2 beta-1,6- N-acetylglucosaminyltransferase (C2GnT-M) is highly expressed in the gastrointestinal tract and catalyses the formation of core 2, core 4, and blood group I branches on O-glycans. In the present study, we evaluated the role of C2GnT-M in colorectal cancer. C2GnT-M downexpression was observed in 73.6% of the primary tumors from colorectal cancer patients (39 of 53) analysed by cancer pro. ling array. Consistently, the majority of colon cancer cell lines and primary colon tumors expressed lower levels of C2GnT-M than did normal colon tissues by RT-PCR. HCT116 cells stably transfected with C2GnT-M inhibited expression of the core 1 structure, Gal beta 1,3GalNAc alpha 1-Ser/Thr, on the cell surface. Moreover, C2GnT-M expression suppressed cell adhesion, motility, and invasion as well as colony formation ability. The growth of C2GnT-M-transfected HCT116 and SW480 cells was dramatically suppressed, and the cell death induced by C2GnT-M was demonstrated by an increase in the annexin V-positive cells. Interestingly, C2GnT-M inhibited cell adhesion to collagen IV and fibronectin, and decreased tyrosine phosphorylation of paxillin, indicating that the changes in cancer behavior may be partly mediated by integrin-signaling pathways. Tumor growth in vivo was also significantly suppressed by C2GnT-M in the xenografts of nude mice. These results demonstrate that C2GnT-M is frequently downregulated in colorectal cancer and suppresses colon cancer cell growth.	Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, Taipei, Taiwan; Anim Technol Inst Taiwan, Miaoli, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University	Huang, MC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, 1 Sec 1 Ren Ai Rd, Taipei, Taiwan.	mchuang@ha.mc.ntu.edu.tw	Shen, Tang-Long/C-7460-2011	Liang, Jin-Tung/0000-0002-0264-7735; HO, CHAO-CHI/0000-0002-8156-2413; HUANG, MIN-CHUAN/0000-0002-0704-3447; LIN, NENG-YU/0000-0003-0746-0483; Shen, Tang-Long/0000-0001-6264-3608				Baldus SE, 2000, CANCER-AM CANCER SOC, V88, P1536, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1536::AID-CNCR6>3.3.CO;2-N; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAO Y, 1995, CANCER-AM CANCER SOC, V76, P1700, DOI 10.1002/1097-0142(19951115)76:10<1700::AID-CNCR2820761005>3.0.CO;2-Z; Clement M, 2004, J CELL SCI, V117, P5059, DOI 10.1242/jcs.01350; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI200113737; Fukuda M, 1996, CANCER RES, V56, P2237; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hanisch FG, 1997, HISTOL HISTOPATHOL, V12, P263; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Huang MC, 2002, J BIOL CHEM, V277, P47786, DOI 10.1074/jbc.M208283200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inaba Y, 2003, INT J CANCER, V107, P949, DOI 10.1002/ijc.11513; Iwai T, 2005, P NATL ACAD SCI USA, V102, P4572, DOI 10.1073/pnas.0407983102; Khaldoyanidi SK, 2003, J BIOL CHEM, V278, P4127, DOI 10.1074/jbc.M209590200; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; LIOTTA LA, 1991, CANCER RES, V51, pS5054; OVADIA H, 1975, EUR J CANCER, V11, P413, DOI 10.1016/0014-2964(75)90072-9; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Quattrocchi CC, 2002, J BIOL CHEM, V277, P303, DOI 10.1074/jbc.M106996200; Schneider F, 2001, CANCER RES, V61, P4605; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; Shimodaira K, 1997, CANCER RES, V57, P5201; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Steiner MS, 2000, CANCER RES, V60, P4419; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VAVASSEUR F, 1995, GLYCOBIOLOGY, V5, P351, DOI 10.1093/glycob/5.3.351; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215	38	63	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2006	25	23					3267	3276		10.1038/sj.onc.1209350	http://dx.doi.org/10.1038/sj.onc.1209350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16418723				2022-12-25	WOS:000237951200005
J	Lannutti, BJ; Minear, J; Blake, N; Drachman, JG				Lannutti, B. J.; Minear, J.; Blake, N.; Drachman, J. G.			Increased megakaryocytopoiesis in Lyn-deficient mice	ONCOGENE			English	Article						megakaryocyte; Lyn; Mp1; MAPK; Akt	SRC-FAMILY KINASES; PROTEIN-TYROSINE KINASES; THROMBOPOIETIN-INDUCED PROLIFERATION; PRIMARY MURINE MEGAKARYOCYTES; SIGNAL-TRANSDUCTION; CELL-LINES; MAST-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SUSTAINED ACTIVATION; AUTOIMMUNE-DISEASE	Previous studies in cell lines have shown Lyn kinase to be a negative regulator of thrombopoietin (TPO)-induced proliferation. To further investigate the role of Lyn during megakaryocytopoiesis, Lyn-deficient mice (lyn(-/-)) were analyzed. We observed that lyn(-/-) mice have more bone marrow-derived GPIIB (CD41) and Mpl(+) cells when compared to their wild-type littermates. In addition, colony-forming unit-megakaryocytes (CFU-MK) are increased and TPO-induced expansion of primary marrow cells yielded a greater number of mature megakaryocytes (MKs) with increased nuclear ploidy. Histopathology of bone marrow and spleens from lyn(-/-) mice showed an increase in the number of MKs. Mechanistic studies revealed that TPO stimulation of MKs from lyn(-/-) mice did not affect phosphorylation of Janus kinase 2 (JAK2), signal transducer and activator of transcription ( STAT) 3, STAT5, or MAP kinase kinase (MEK). Lyn-deficient MKs supported greater TPO-mediated phosphorylation and kinase activity of both Erk1/2 (mitogen-activated protein kinase, MAPK) and Akt. In contrast, there was a reduction of tyrosine phosphorylation of the inositol phosphatase, SHIP. This is the first direct evidence using primary MKs from Lyn-deficient mice that confirms our prior data from cell lines that Lyn kinase is a negative regulator of TPO signaling.	Univ Washington, Puget Sound Blood Ctr, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA	Puget Sound Blood Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lannutti, BJ (corresponding author), Univ Washington, Puget Sound Blood Ctr, 921 Terry Ave, Seattle, WA 98195 USA.	brianl@psbc.org			NHLBI NIH HHS [R01HL65498] Funding Source: Medline; NIDDK NIH HHS [K01DK065129] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK065129] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200; Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Filippi MD, 2002, BLOOD, V99, P1174, DOI 10.1182/blood.V99.4.1174; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Gauld SB, 2004, ONCOGENE, V23, P8001, DOI 10.1038/sj.onc.1208075; Geddis AE, 2002, CYTOKINE GROWTH F R, V13, P61, DOI 10.1016/S1359-6101(01)00030-2; Geddis AE, 2001, J BIOL CHEM, V276, P34473, DOI 10.1074/jbc.M105178200; Hallek M, 1997, EXP HEMATOL, V25, P1367; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; Hernandez-Hansen V, 2004, J LEUKOCYTE BIOL, V75, P143, DOI 10.1189/jlb.0503224; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Horn S, 2004, LEUKEMIA, V18, P1839, DOI 10.1038/sj.leu.2403529; Kamata T, 2004, BLOOD, V103, P2568, DOI 10.1182/blood-2003-06-1803; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Lannutti BJ, 2005, BLOOD, V105, P3875, DOI 10.1182/blood-2004-10-3934; Lannutti BJ, 2004, BLOOD, V103, P3736, DOI 10.1182/blood-2003-10-3566; Lannutti BJ, 2003, EXP HEMATOL, V31, P1268, DOI 10.1016/j.exphem.2003.09.009; Maxwell MJ, 2004, J BIOL CHEM, V279, P32196, DOI 10.1074/jbc.M400746200; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Nishizumi H, 1997, J IMMUNOL, V158, P2350; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rojnuckarin P, 2001, J BIOL CHEM, V276, P41014, DOI 10.1074/jbc.M106508200; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Santini V, 2002, HAEMATOLOGICA, V87, P1242; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Stafford S, 2002, J IMMUNOL, V168, P1978, DOI 10.4049/jimmunol.168.4.1978; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Vara JAF, 2001, MOL BIOL CELL, V12, P2171, DOI 10.1091/mbc.12.7.2171; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831	50	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3316	3324		10.1038/sj.onc.1209351	http://dx.doi.org/10.1038/sj.onc.1209351			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16418722				2022-12-25	WOS:000237951200010
J	Uenoyama, Y; Seno, H; Fukuda, A; Sekikawa, A; Nanakin, A; Sawabu, T; Kawada, M; Kanda, N; Suzuki, K; Yada, N; Fukui, H; Chiba, T				Uenoyama, Y.; Seno, H.; Fukuda, A.; Sekikawa, A.; Nanakin, A.; Sawabu, T.; Kawada, M.; Kanda, N.; Suzuki, K.; Yada, N.; Fukui, H.; Chiba, T.			Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway	ONCOGENE			English	Article						colorectal tumor; fibroblast; cell density	EPIDERMAL-GROWTH-FACTOR; NF-KAPPA-B; PROSTAGLANDIN E-2; GENE-EXPRESSION; UP-REGULATION; CANCER CELLS; COLORECTAL ADENOMAS; SIGNALING PATHWAYS; C-JUN; ANGIOGENESIS	Cyclooxygenase-2 (COX-2) plays important roles in tumor development. Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma. However, the mechanism regulating such stromal expression of COX-2 remains unknown. In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells. COX-2 expression in NIH3T3 fibroblasts was upregulated when co-cultured with the 'dense' epithelial cells regardless of their character. Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when cocultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells. Furthermore, COX-2 expression was also reduced by the inhibition of transcription factor AP-1. Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Seno, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	seno@kuhp.kyoto-u.ac.jp		Seno, Hiroshi/0000-0002-8509-8128				BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Boman BM, 2004, AM J PATHOL, V165, P1489, DOI 10.1016/S0002-9440(10)63407-4; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fujita T, 1998, CANCER RES, V58, P4823; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Han C, 2004, J BIOL CHEM, V279, P44344, DOI 10.1074/jbc.M404852200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jobin C, 1997, J IMMUNOL, V158, P226; Kawada M, 2003, DIGESTION, V67, P20, DOI 10.1159/000069708; Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200; Kim HJ, 2004, J INVEST DERMATOL, V123, P547, DOI 10.1111/j.0022-202X.2004.23317.x; Ko SC, 2002, ONCOGENE, V21, P7175, DOI 10.1038/sj.onc.1205869; Kondoh N, 1999, CANCER RES, V59, P4990; Li QF, 2004, CANCER RES, V64, P7078, DOI 10.1158/0008-5472.CAN-04-1152; Liu WV, 2003, CANCER RES, V63, P3632; LU YP, 1994, CARCINOGENESIS, V15, P2363, DOI 10.1093/carcin/15.10.2363; Masferrer JL, 2000, CANCER RES, V60, P1306; Montano X, 2004, FEBS LETT, V571, P1, DOI 10.1016/j.febslet.2004.06.088; Nordsmark M, 1996, RADIOTHER ONCOL, V41, P31, DOI 10.1016/S0167-8140(96)91811-3; Oshima M, 2005, BIOCHEM BIOPH RES CO, V330, P928, DOI 10.1016/j.bbrc.2005.03.060; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park CH, 2005, J BIOCHEM MOL BIOL, V38, P474; Preston SL, 2003, CANCER RES, V63, P3819; Ricchi P, 2003, BRIT J CANCER, V88, P803, DOI 10.1038/sj.bjc.6600829; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Seno H, 2002, CANCER RES, V62, P506; Sheares KKK, 2004, AM J PHYSIOL-LUNG C, V287, pL919, DOI 10.1152/ajplung.00012.2004; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Slice LW, 2005, J BIOL CHEM, V280, P1582, DOI 10.1074/jbc.M408172200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sol VVD, 2005, J IMMUNOL, V174, P2825, DOI 10.4049/jimmunol.174.5.2825; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200; Tokuda Y, 2000, J CELL PHYSIOL, V182, P414, DOI 10.1002/(SICI)1097-4652(200003)182:3<414::AID-JCP12>3.0.CO;2-5; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu GF, 2003, AM J PHYSIOL-HEART C, V285, pH2420, DOI 10.1152/ajpheart.00187.2003; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang KX, 2004, MOL CANCER RES, V2, P242	47	6	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3277	3285		10.1038/sj.onc.1209359	http://dx.doi.org/10.1038/sj.onc.1209359			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407821	Green Submitted			2022-12-25	WOS:000237951200006
J	Yamasaki, E; Wada, A; Kumatori, A; Nakagawa, I; Funao, J; Nakayama, M; Hisatsune, J; Kimura, M; Moss, J; Hirayama, T				Yamasaki, E; Wada, A; Kumatori, A; Nakagawa, I; Funao, J; Nakayama, M; Hisatsune, J; Kimura, M; Moss, J; Hirayama, T			Helicobacter pylori vacuolating cytotoxin induces activation of the proapoptotic proteins Bax and Bak, leading to cytochrome C release and cell death, independent of vacuolation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; LIPID-BILAYERS; CANCER-CELLS; VACA TOXIN; APOPTOSIS; INDUCTION; EXPRESSION; INFECTION; PATHWAY; DOMAIN	Helicobacter pylori vacuolating cytotoxin, VacA, which causes vacuolation of gastric epithelial cells and other types of cultured cells, is known to stimulate apoptosis via a mitochondria-dependent pathway. In the present study, we examined the mechanisms of VacA-induced mitochondrial damage. Intracellular VacA localization was monitored by immunostaining and confocal microscopy; in AZ-521 cells in which cytochrome c release was stimulated, most of VacA was localized to vacuoles rather than mitochondria. VacA reduced the membrane potential of isolated mitochondria without inducing cytochrome c release, suggesting that it did not act directly to induce cytochrome c release from mitochondria and that in intact cells, VacA-induced cytochrome c release involved apoptosis-related factor(s), such as a proapoptotic Bcl-2 family protein. In agreement, flow cytometric analyses using antibodies specific for activated Bax revealed that intracellular Bax was activated by VacA in a concentration- and time-dependent manner. Using active form-specific antibodies, we also observed that the Bcl-2 family protein, Bak, was activated. By confocal microscopy, Bax and Bak were activated in AZ-521 cells in which cytochrome c release was induced by VacA. In addition, small interfering RNA-induced silencing of the bax gene resulted in reduction of VacA-stimulated cytochrome c release, consistent with a contribution of VacA-induced Bax activation to cytochrome c release. NH4Cl enhanced both VacA-induced vacuolation and Bax activation, whereas Bax activation was not inhibited by bafilomycin A1, which inhibited vacuolation caused by VacA. These results suggest that VacA acts through different signaling pathways to induce apoptosis via Bax activation, independent of vacuolation.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Japan Sci & Technol Corp, PRESTO, Saitama 3320012, Japan; Chiba Inst Technol, Fac Risk & Crisis Management, Dept Disaster Prevent Syst, Div Med Sci, Chiba 2880025, Japan; Osaka Univ, Grad Sch Dent, Dept Oral & Mol Microbiol, Suita, Osaka 5650871, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Dept Med Technol, Okayama 7008558, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Japan Science & Technology Agency (JST); Chiba Institute of Technology; Osaka University; Okayama University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Wada, A (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	a-wada@net.nagasaki-u.ac.jp			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Ashktorab H, 2004, GUT, V53, P805, DOI 10.1136/gut.2003.024372; Boncristiano M, 2003, J EXP MED, V198, P1887, DOI 10.1084/jem.20030621; Boquet P, 2003, TRENDS MICROBIOL, V11, P410, DOI 10.1016/S0966-842X(03)00211-7; Cho SJ, 2003, TOXICON, V42, P601, DOI 10.1016/j.toxicon.2003.08.003; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J INFECT DIS, V166, P1073, DOI 10.1093/infdis/166.5.1073; Cover TL, 2003, CANCER RES, V63, P951; COVER TL, 1992, HUM PATHOL, V23, P1004, DOI 10.1016/0046-8177(92)90261-Z; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; de Bernard M, 1998, INFECT IMMUN, V66, P6014, DOI 10.1128/IAI.66.12.6014-6016.1998; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Eaton KA, 1997, INFECT IMMUN, V65, P3462, DOI 10.1128/IAI.65.8.3462-3464.1997; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fujikawa A, 2003, NAT GENET, V33, P375, DOI 10.1038/ng1112; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Hofman V, 2001, LAB INVEST, V81, P375, DOI 10.1038/labinvest.3780245; Jones NL, 1999, INFECT IMMUN, V67, P4237, DOI 10.1128/IAI.67.8.4237-4242.1999; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; Li Y, 2004, MOL BIOL CELL, V15, P1946, DOI 10.1091/mbc.e03-08-0618; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Menaker RJ, 2004, INFECT IMMUN, V72, P2889, DOI 10.1128/IAI.72.5.2889-2898.2004; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Nakagawa I, 2001, CELL MICROBIOL, V3, P395, DOI 10.1046/j.1462-5822.2001.00122.x; Nakayama M, 2004, J BIOL CHEM, V279, P7024, DOI 10.1074/jbc.M308898200; NEITHERCUT WD, 1991, GUT, V32, P973, DOI 10.1136/gut.32.9.973; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; Papini E, 2001, TOXICON, V39, P1757, DOI 10.1016/S0041-0101(01)00162-3; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; Ray S, 2003, CANCER RES, V63, P4713; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Supajatura V, 2002, J IMMUNOL, V168, P2603, DOI 10.4049/jimmunol.168.6.2603; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Torres VJ, 2004, J BIOL CHEM, V279, P2324, DOI 10.1074/jbc.M310159200; Wang J, 2001, J IMMUNOL, V167, P926, DOI 10.4049/jimmunol.167.2.926; Willhite DC, 2004, CELL MICROBIOL, V6, P143, DOI 10.1046/j.1462-5822.2003.00347.x; Willhite DC, 2003, J BIOL CHEM, V278, P48204, DOI 10.1074/jbc.M304131200; Yahiro K, 2004, J BIOL CHEM, V279, P51013, DOI 10.1074/jbc.M406473200; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277; Yilmaz O, 2004, INFECT IMMUN, V72, P3743, DOI 10.1128/IAI.72.7.3743-3751.2004; Zhang H, 2004, WORLD J GASTROENTERO, V10, P227	51	114	122	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11250	11259		10.1074/jbc.M509404200	http://dx.doi.org/10.1074/jbc.M509404200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16436379	hybrid			2022-12-25	WOS:000236822200068
J	Moreira, PI; Custodio, J; Moreno, A; Oliveira, CR; Santos, MS				Moreira, PI; Custodio, J; Moreno, A; Oliveira, CR; Santos, MS			Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; STIMULATED GROWTH; OXIDATIVE STRESS; ATHYMIC MICE; ESTROGEN; RAT; INHIBITION; CELL; APOPTOSIS; HYDROXYTAMOXIFEN	This study evaluated the action of tamoxifen and estradiol on the function of isolated liver mitochondria. We observed that although tamoxifen and estradiol per se did not affect mitochondrial complexes II, III, or IV, complex I is affected, this effect being more drastic (except for state 4 of respiration) when mitochondria were coincubated with both drugs. Furthermore, using two respiratory chain inhibitors, rotenone and diphenyliodonium chloride, we identified the flavin mononucleotide site of complex I as the target of tamoxifen and/or estradiol action(s). Tamoxifen (25 mu M) per se induced a significant increase in hydrogen peroxide production and state 4 of respiration. Additionally, a significant decrease in respiratory control ratio, transmembrane, and depolarization potentials were observed. Estradiol per se decreased carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP)-stimulated respiration, state 3 of respiration, and respiratory control ratio and increased lag phase of repolarization. With the exception of state 4 of respiration whose increase induced by tamoxifen was reversed by the presence of estradiol, the effects of tamoxifen were highly exacerbated when estradiol was present. We observed that 10 mu M tamoxifen in the presence of estradiol affected mitochondria significantly by decreasing FCCP-stimulated respiration, state 3 of respiration, respiratory control ratio, and ADP depolarization and increasing the lag phase of repolarization. All of the deleterious effects induced by 25 mu M tamoxifen were highly exacerbated in the presence of estradiol. Furthermore, we observed that the effects of both compounds were independent of estrogen receptors because the pure estrogen antagonist ICI 182,780 did not interfere with tamoxifen and/or estradiol detrimental effects. Altogether, our data provide a mechanistic explanation for the multiple cytotoxic effects of tamoxifen including its capacity to destroy tamoxifen-resistant breast cancer cells in the presence of estradiol. This new piece of information provides a basis for the development of new and promising anticancer therapeutic strategies.	Univ Coimbra, Fac Sci & Technol, Dept Zool, P-3004517 Coimbra, Portugal; Univ Coimbra, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal; Univ Coimbra, Fac Pharm, Biochem Lab, P-3004517 Coimbra, Portugal; Univ Coimbra, Marine Res Inst, P-3004517 Coimbra, Portugal; Univ Coimbra, Fac Med, Inst Biochem, P-3004517 Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra	Santos, MS (corresponding author), Univ Coimbra, Fac Sci & Technol, Dept Zool, P-3004517 Coimbra, Portugal.	mssantos@cl.uc.pt	Moreira, Paula/B-3608-2009; Oliveira, Catarina R./F-3685-2010	Moreira, Paula/0000-0001-5177-6747; Custodio, Jose/0000-0001-5694-966X; Oliveira, Catarina/0000-0001-6942-4328; santos, maria sancha/0000-0002-6881-9392; Moreno, Antonio/0000-0003-3575-7604				Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Baum M, 2002, LANCET, V359, P2131; Bergan RC, 1999, CLIN CANCER RES, V5, P2366; CARACENI P, 1995, BBA-MOL CELL RES, V1268, P249, DOI 10.1016/0167-4889(95)00077-6; Cardoso CMP, 2001, TOXICOL APPL PHARM, V176, P145, DOI 10.1006/taap.2001.9265; Clarke M, 1998, LANCET, V351, P1451; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; CUSTODIO JBA, 1991, BIOCHEM BIOPH RES CO, V176, P1079, DOI 10.1016/0006-291X(91)90394-M; Custodio JBA, 1998, TOXICOL APPL PHARM, V152, P10, DOI 10.1006/taap.1998.8510; CUSTODIO JBA, 1994, BIOCHEM PHARMACOL, V47, P1989, DOI 10.1016/0006-2952(94)90073-6; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Felty Quentin, 2005, J Carcinog, V4, P1, DOI 10.1186/1477-3163-4-1; FROMSON JM, 1973, XENOBIOTICA, V3, P711, DOI 10.3109/00498257309151595; Gauduchon J, 2005, CLIN CANCER RES, V11, P2345, DOI 10.1158/1078-0432.CCR-04-1668; Gazotti P., 1979, LAB MANUAL TRANSPORT, P62; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; GOTTARDIS MM, 1989, CANCER RES, V49, P4090; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hagen T, 2004, BIOCHEM BIOPH RES CO, V322, P923, DOI 10.1016/j.bbrc.2004.07.204; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V240, P464, DOI 10.1006/bbrc.1997.7681; Hensley K, 1998, J NEUROCHEM, V71, P2549; HOWELL A, 1992, ANN ONCOL, V3, P611, DOI 10.1093/oxfordjournals.annonc.a058286; JENSEN BD, 1984, BIOPHYS J, V45, pA92; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; JORDAN VC, 1990, BREAST CANCER RES TR, V15, P125, DOI 10.1007/BF01806350; JORDAN VC, 1983, BREAST CANCER RES TR, V3, pS73, DOI 10.1007/BF01855131; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kennedy AM, 2005, ENDOCRINOLOGY, V146, P201, DOI 10.1210/en.2004-0486; KUSS E, 1967, H-S Z PHYSIOL CHEM, V348, P913, DOI 10.1515/bchm2.1967.348.1.913; LAURENCE J, 1990, BLOOD, V75, P696; LERNER LJ, 1996, ENDOCRINOLOGY, V138, P863; Lewis JS, 2004, BRIT J CANCER, V90, P944, DOI 10.1038/sj.bjc.6601627; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LIEN EA, 1991, CANCER RES, V51, P4837; Luxo C, 2001, TOXICOL IN VITRO, V15, P303, DOI 10.1016/S0887-2333(01)00024-8; McDonnell DP, 2000, J SOC GYNECOL INVEST, V7, pS10, DOI 10.1177/1071557600007001S05; Mishra DP, 2005, J BIOL CHEM, V280, P6181, DOI 10.1074/jbc.M405970200; Moats RK, 1998, BIOL REPROD, V58, P531, DOI 10.1095/biolreprod58.2.531; Moreira PI, 2005, NEUROPHARMACOLOGY, V48, P435, DOI 10.1016/j.neuropharm.2004.10.012; Moreira PI, 2004, BIOCHEM PHARMACOL, V68, P195, DOI 10.1016/j.bcp.2004.03.019; MURATSUGU M, 1977, BIOCHIM BIOPHYS ACTA, V464, P613, DOI 10.1016/0005-2736(77)90035-9; ODONNELL VB, 1994, MOL PHARMACOL, V46, P778; Osipo C, 2005, J STEROID BIOCHEM, V93, P249, DOI 10.1016/j.jsbmb.2004.12.005; PALMER G, 1968, J BIOL CHEM, V243, P844; Rowlands JC, 1998, PHARMACOL TOXICOL, V83, P214, DOI 10.1111/j.1600-0773.1998.tb01471.x; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Schafer JM, 2000, CLIN CANCER RES, V6, P4373; Trope C, 2000, EUR J CANCER, V36, pS59; Tsuchiya Y, 2005, CANCER LETT, V227, P115, DOI 10.1016/j.canlet.2004.10.007; Tuquet C, 2000, CELL BIOL TOXICOL, V16, P207, DOI 10.1023/A:1007695308257; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; WINGROVE DE, 1985, FED PROC, V44, P1082; Yang SH, 2004, P NATL ACAD SCI USA, V101, P4130, DOI 10.1073/pnas.0306948101; Zheng JB, 1999, EUR J PHARMACOL, V368, P95, DOI 10.1016/S0014-2999(99)00012-6	60	92	96	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10143	10152		10.1074/jbc.M510249200	http://dx.doi.org/10.1074/jbc.M510249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16410252	Green Published, hybrid			2022-12-25	WOS:000236594300040
J	Vanwildemeersch, M; Olsson, AK; Gottfridsson, E; Claesson-Welsh, L; Lindahl, U; Spillmann, D				Vanwildemeersch, M; Olsson, AK; Gottfridsson, E; Claesson-Welsh, L; Lindahl, U; Spillmann, D			The anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION; TUMOR VASCULARIZATION; FIBROBLAST-GROWTH; HIGH-AFFINITY; DOMAIN; ENDOSTATIN; PROLINE; PROTEIN; PLASMA; GLYCOSAMINOGLYCANS	The plasma protein histidine-rich glycoprotein ( HRGP), which has been identified as an angiogenesis inhibitor, binds to heparan sulfate (HS) in a Zn2+-dependent manner. We wished to test whether this interaction is mechanistically important in mediation of the anti-angiogenic effect of HRGP. Inhibition of angiogenesis by HRGP is exerted through its central His/Pro-rich domain, which is proteolytically released. A35-amino-acid residue synthetic peptide, HRGP330, derived from the His/Pro-rich domain retains the inhibitory effect on blood vessel formation in vitro and in vivo, an effect dependent on the presence of Zn2+. We now show that HRGP330 binds heparin/HS with the same capacity as full-length HRGP, and the binding is Zn2+-dependent. Peptides derived from the His/Pro-rich domain of HRGP downstream of HRGP330 fail to inhibit endothelial cell migration and display a significantly reduced heparin-binding capacity. An even shorter peptide, HRGP335, covering a 26-amino-acid sequence within HRGP330 retains full heparin/HS-binding capacity. Characterization of the HS interaction shows that there is a tissue-specific HS pattern recognized by HRGP335 and that the minimal length of heparin/HS required for binding to HRGP335 is an 8-mer oligosaccharide. Saturation of the HS binding sites in HRGP330 by pre-incubation with heparin abrogates the HRGP330-induced rearrangement of endothelial cell focal adhesions, suggesting that interaction with cell surface HS is needed for HRGP330 to exert its anti-angiogenic effect.	Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University	Spillmann, D (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Dorothe.Spillmann@imbim.uu.se						AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; DIXELIUS J, 2005, CANCER RES, V6, P2089; Donate F, 2004, CANCER RES, V64, P5812, DOI 10.1158/0008-5472.CAN-04-0440; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Guimond S, 2004, MOL CELL, V16, P159, DOI 10.1016/j.molcel.2004.10.008; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Jones AL, 2005, IMMUNOL CELL BIOL, V83, P106, DOI 10.1111/j.1440-1711.2005.01320.x; Jones AL, 2004, J BIOL CHEM, V279, P38267, DOI 10.1074/jbc.M406027200; Juarez JC, 2002, CANCER RES, V62, P5344; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kluszynski BA, 1997, J BIOL CHEM, V272, P13541, DOI 10.1074/jbc.272.21.13541; Kreuger J, 2003, METHOD ENZYMOL, V363, P327; Kreuger J, 1999, GLYCOBIOLOGY, V9, P723, DOI 10.1093/glycob/9.7.723; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; LANE DA, 1986, J BIOL CHEM, V261, P3980; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; LIJNEN HR, 1983, J BIOL CHEM, V258, P3803; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINKER A, 1973, CARBOHYD RES, V29, P41, DOI 10.1016/S0008-6215(00)82069-8; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MORGAN WT, 1985, BIOCHEMISTRY-US, V24, P1496, DOI 10.1021/bi00327a031; Olsson AK, 2004, CANCER RES, V64, P9012, DOI 10.1158/0008-5472.CAN-04-2172; Olsson AK, 2004, CANCER RES, V64, P599, DOI 10.1158/0008-5472.CAN-03-1941; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Wickstrom SA, 2003, J BIOL CHEM, V278, P37895, DOI 10.1074/jbc.M303569200; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	43	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10298	10304		10.1074/jbc.M508483200	http://dx.doi.org/10.1074/jbc.M508483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16436387	hybrid			2022-12-25	WOS:000236594300058
J	Sudhamsu, J; Crane, BR				Sudhamsu, J; Crane, BR			Structure and reactivity of a thermostable prokaryotic nitric-oxide synthase that forms a long-lived oxy-heme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIWAVELENGTH SPECTROSCOPIC DATA; FERROUS DIOXYGEN COMPLEX; LIGAND-PROTEIN INTERACTIONS; COMPLETE GENOME SEQUENCE; COMPOUND-I FORMATION; N-G-HYDROXYARGININE; CYTOCHROME P450CAM; EQUILIBRIUM-CONSTANTS; BACILLUS-SUBTILIS; L-ARGININE	In an effort to generate more stable reaction intermediates involved in substrate oxidation by nitric-oxide synthases (NOSs), we have cloned, expressed, and characterized a thermostable NOS homolog from the thermophilic bacterium Geobacillus stearothermophilus (gsNOS). As expected, gsNOS forms nitric oxide ( NO) from L-arginine via the stable intermediate N-hydroxy L-arginine ( NOHA). The addition of oxygen to ferrous gsNOS results in long-lived heme-oxy complexes in the presence (Soret peak 427 nm) and absence ( Soret peak 413 nm) of substrates L-arginine and NOHA. The substrate-induced red shift correlates with hydrogen bonding between substrate and heme-bound oxygen resulting in conversion to a ferric heme-superoxy species. In single turnover experiments with NOHA, NO forms only in the presence of H4B. The crystal structure of gsNOS at 3.2 angstrom of resolution reveals great similarity to other known bacterial NOS structures, with the exception of differences in the distal heme pocket, close to the oxygen binding site. In particular, a Lys-356 ( Bacillus subtilis NOS) to Arg-365 ( gsNOS) substitution alters the conformation of a conserved Asp carboxylate, resulting in movement of an Ile residue toward the heme. Thus, a more constrained heme pocket may slow ligand dissociation and increase the lifetime of heme-bound oxygen to seconds at 4 degrees C. Similarly, the ferric-heme NO complex is also stabilized in gsNOS. The slow kinetics of gsNOS offer promise for studying downstream intermediates involved in substrate oxidation.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Crane, BR (corresponding author), Cornell Univ, Dept Chem & Biol Chem, G 60 ST Olin, Ithaca, NY 14853 USA.	bc69@cornell.edu	Sudhamsu, Jawahar/A-8751-2012					AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Berka V, 2004, BIOCHEMISTRY-US, V43, P13137, DOI 10.1021/bi049026j; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; BLAKE RC, 1981, J BIOL CHEM, V256, P2127; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buddha MR, 2004, J BIOL CHEM, V279, P49567, DOI 10.1074/jbc.C400418200; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Denisov IG, 2002, J BIOL CHEM, V277, P42706, DOI 10.1074/jbc.M207949200; Denisov IG, 2002, METHOD ENZYMOL, V357, P103; Denisov IG, 2001, J BIOL CHEM, V276, P11648, DOI 10.1074/jbc.M010219200; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; GAMPP H, 1986, TALANTA, V33, P943, DOI 10.1016/0039-9140(86)80233-8; GAMPP H, 1985, TALANTA, V32, P1133, DOI 10.1016/0039-9140(85)80238-1; GAMPP H, 1985, TALANTA, V32, P257, DOI 10.1016/0039-9140(85)80077-1; GAMPP H, 1985, TALANTA, V32, P95, DOI 10.1016/0039-9140(85)80035-7; Golderer G, 2001, GENE DEV, V15, P1299, DOI 10.1101/gad.890501; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRINSTAFF MW, 1995, INORG CHEM, V34, P4896, DOI 10.1021/ic00123a026; Huang H, 2001, J AM CHEM SOC, V123, P2674, DOI 10.1021/ja005900u; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; Kers JA, 2004, NATURE, V429, P79, DOI 10.1038/nature02504; Klessig DF, 2000, P NATL ACAD SCI USA, V97, P8849, DOI 10.1073/pnas.97.16.8849; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAMBEIR AM, 1985, BIOCHIM BIOPHYS ACTA, V828, P144, DOI 10.1016/0167-4838(85)90050-0; LAMBEIR AM, 1985, EUR J BIOCHEM, V147, P93, DOI 10.1111/j.1432-1033.1985.tb08723.x; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li D, 2004, J BIOL CHEM, V279, P26489, DOI 10.1074/jbc.M400968200; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; Marchal S, 2004, J BIOL CHEM, V279, P19824, DOI 10.1074/jbc.M313587200; Midha S, 2005, BIOCHEM BIOPH RES CO, V336, P346, DOI 10.1016/j.bbrc.2005.08.083; Muller U, 1997, PROG NEUROBIOL, V51, P363, DOI 10.1016/S0301-0082(96)00067-6; Nagano S, 2005, J BIOL CHEM, V280, P22102, DOI 10.1074/jbc.M501732200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ninnemann H, 1996, PHOTOCHEM PHOTOBIOL, V64, P393, DOI 10.1111/j.1751-1097.1996.tb02477.x; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; POMPON D, 1984, J BIOL CHEM, V259, P5377; Roach MP, 1999, J AM CHEM SOC, V121, P12088, DOI 10.1021/ja9915504; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; SONO M, 1985, J BIOL CHEM, V260, P5530; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Spolitak T, 2005, J BIOL CHEM, V280, P20300, DOI 10.1074/jbc.M501761200; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Takami H, 2004, NUCLEIC ACIDS RES, V32, P6292, DOI 10.1093/nar/gkh970; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; TYSON CA, 1972, J BIOL CHEM, V247, P5777; Wang ZQ, 2004, J BIOL CHEM, V279, P19018, DOI 10.1074/jbc.M311663200; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; WEISS RF, 1970, DEEP-SEA RES, V17, P721, DOI 10.1016/0011-7471(70)90037-9	84	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9623	9632		10.1074/jbc.M510062200	http://dx.doi.org/10.1074/jbc.M510062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16407211	hybrid			2022-12-25	WOS:000236404700074
J	Branham, MAT; Mayorga, LS; Tomes, CN				Branham, MAT; Mayorga, LS; Tomes, CN			Calcium-induced acrosomal exocytosis requires cAMP acting through a protein kinase A-independent, Epac-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE ADENYLYL-CYCLASE; PANCREATIC BETA-CELLS; CA2+-INDUCED CA2+ RELEASE; HUMAN SPERM CAPACITATION; EXCHANGE FACTOR EPAC; MALE GERM-CELLS; CYCLIC-AMP; TYROSINE PHOSPHORYLATION; HUMAN SPERMATOZOA; REGULATED EXOCYTOSIS	Epac, a guanine nucleotide exchange factor for the small GTPase Rap, binds to and is activated by the second messenger cAMP. In sperm, there are a number of signaling pathways required to achieve egg-fertilizing ability that depend upon an intracellular rise of cAMP. Most of these processes were thought to be mediated by cAMP- dependent protein kinases. Here we report a new dependence for the cAMP- induced acrosome reaction involving Epac. The acrosome reaction is a specialized type of regulated exocytosis leading to a massive fusion between the outer acrosomal and the plasma membranes of sperm cells. Ca2+ is the archetypical trigger of regulated exocytosis, and we show here that its effects on acrosomal release are fully mediated by cAMP. Ca2+ failed to trigger acrosomal exocytosis when intracellular cAMP was depleted by an exogenously added phosphodiesterase or when Epac was sequestered by specific blocking antibodies. The nondiscriminating dibutyryl-cAMP and the Epac-selective 8-(p-chlorophenylthio)-2'-O-methyladenosine-3', 5'-cyclic monophosphate analogues triggered the acrosome reaction in the effective absence of extracellular Ca2+. This indicates that cAMP, via Epac activation, has the ability to drive the whole cascade of events necessary to bring exocytosis to completion, including tethering and docking of the acrosome to the plasma membrane, priming of the fusion machinery, mobilization of intravesicular Ca2+, and ultimately, bilayer mixing and fusion. cAMP- elicited exocytosis was sensitive to anti-alpha-SNAP, anti-NSF, and anti-Rab3A antibodies, to intra-acrosomal Ca2+ chelators, and to botulinum toxins but was resistant to cAMP- dependent protein kinase blockers. These experiments thus identify Epac in human sperm and evince its indispensable role downstream of Ca2+ in exocytosis.	Univ Nacl Cuyo, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, IHEM,Lab Biol Celular & Mol, RA-5500 Mendoza, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza	Tomes, CN (corresponding author), Univ Nacl Cuyo, Fac Ciencias Med, Consejo Nacl Invest Cient & Tecn, IHEM,Lab Biol Celular & Mol, CC 56, RA-5500 Mendoza, Argentina.	ctomes@fcm.uncu.edu.ar		Mayorga, Luis S/0000-0002-5995-0671				Aitken RJ, 1998, J CELL SCI, V111, P645; Aronoff DM, 2005, J IMMUNOL, V174, P595, DOI 10.4049/jimmunol.174.2.595; Berruti G, 2003, CELL MOL BIOL, V49, P381; BIELFELD P, 1994, FERTIL STERIL, V61, P536; Breitbart H, 1999, REV REPROD, V4, P151; Breitbart H, 2003, CELL MOL BIOL, V49, P321; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chin EC, 2004, J ENDOCRINOL, V183, P51, DOI 10.1677/joe.1.05550; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; Darszon A, 2005, INT REV CYTOL, V243, P79, DOI 10.1016/S0074-7696(05)43002-8; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; De Blas GA, 2005, PLOS BIOL, V3, P1801, DOI 10.1371/journal.pbio.0030323; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DEJONGE CJ, 1991, J EXP ZOOL, V258, P113, DOI 10.1002/jez.1402580113; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Fujimoto K, 2002, J BIOL CHEM, V277, P50497, DOI 10.1074/jbc.M210146200; Harrison DA, 2000, BIOL REPROD, V62, P811, DOI 10.1095/biolreprod62.3.811; Herrick SB, 2005, J CELL PHYSIOL, V202, P663, DOI 10.1002/jcp.20172; Hochbaum D, 2003, J BIOL CHEM, V278, P33738, DOI 10.1074/jbc.M305208200; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Jaiswal BS, 2003, P NATL ACAD SCI USA, V100, P10676, DOI 10.1073/pnas.1831008100; Kaneko M, 2004, J NEUROSCI, V24, P5202, DOI 10.1523/JNEUROSCI.0999-04.2004; Kang GX, 2005, J PHYSIOL-LONDON, V566, P173, DOI 10.1113/jphysiol.2005.087510; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; KATZ BM, 1989, INT J PEPT PROT RES, V33, P439; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kopperud R, 2003, FEBS LETT, V546, P121, DOI 10.1016/S0014-5793(03)00563-5; Kwon G, 2004, J BIOL CHEM, V279, P8938, DOI 10.1074/jbc.M310330200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Leclerc P, 1998, J ANDROL, V19, P434; Lefievre L, 2002, J ANDROL, V23, P709; Litvin TN, 2003, J BIOL CHEM, V278, P15922, DOI 10.1074/jbc.M212475200; Luconi M, 2005, BIOL REPROD, V72, P22, DOI 10.1095/biolreprod.104.032490; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; MENDOZA C, 1992, J REPROD FERTIL, V95, P755; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rehmann H, 2003, J BIOL CHEM, V278, P38548, DOI 10.1074/jbc.M306292200; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; Sakaba T, 2003, NATURE, V424, P775, DOI 10.1038/nature01859; Sakaba T, 2001, P NATL ACAD SCI USA, V98, P331, DOI 10.1073/pnas.021541098; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Sedej S, 2005, J PHYSIOL-LONDON, V567, P799, DOI 10.1113/jphysiol.2005.090381; Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005; Shibasaki T, 2004, J BIOL CHEM, V279, P7956, DOI 10.1074/jbc.M309068200; Shimomura H, 2004, ARCH BIOCHEM BIOPHYS, V431, P124, DOI 10.1016/j.abb.2004.07.021; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; Sollner TH, 2003, MOL MEMBR BIOL, V20, P209, DOI 10.1080/0968768031000104953; Steegborn C, 2005, NAT STRUCT MOL BIOL, V12, P32, DOI 10.1038/nsmb880; Sunahara Roger K, 2002, Mol Interv, V2, P168, DOI 10.1124/mi.2.3.168; Tardif S, 2004, MOL REPROD DEV, V69, P428, DOI 10.1002/mrd.20178; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Tomes CN, 1998, MOL HUM REPROD, V4, P17, DOI 10.1093/molehr/4.1.17; Tomes CN, 2005, MOL HUM REPROD, V11, P43, DOI 10.1093/molehr/gah126; Tomes CN, 2004, DEV BIOL, V265, P399, DOI 10.1016/j.ydbio.2003.09.032; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Ueno H, 2001, GENOMICS, V78, P91, DOI 10.1006/geno.2001.6641; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; Wuttke M S, 2001, JOP, V2, P154; Yanagimachi R., 1994, P189; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084; Yunes R, 2002, FEBS LETT, V525, P126, DOI 10.1016/S0014-5793(02)03102-2; Zhong N, 2005, J NEUROSCI, V25, P208, DOI 10.1523/JNEUROSCI.3703-04.2005; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	84	74	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8656	8666		10.1074/jbc.M508854200	http://dx.doi.org/10.1074/jbc.M508854200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407249	hybrid			2022-12-25	WOS:000236247100043
J	Sentman, ML; Granstrom, M; Jakobson, H; Reaume, A; Basu, S; Marklund, SL				Sentman, ML; Granstrom, M; Jakobson, H; Reaume, A; Basu, S; Marklund, SL			Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; LIPID-PEROXIDATION; OXIDATIVE STRESS; MUTANT MICE; NEONATAL LETHALITY; HYDROGEN-PEROXIDE; XANTHINE-OXIDASE; DEFICIENT MICE; NITRIC-OXIDE; PEROXYNITRITE	Mice lacking the secreted extracellular superoxide dismutase (EC-SOD) or the cytosolic copper- and zinc-containing SOD (CuZn-SOD) show relatively mild phenotypes. To explore the possibility that the isoenzymes have partly overlapping functions, single and double knockout mice were examined. The absence of EC-SOD was found to be without effect on the lifespan of mice, and the reduced lifespan of CuZn-SOD knockouts was not further shortened by EC-SOD deficiency. The urinary excretion of isoprostanes was increased in CuZn-SOD knockout mice, and plasma thiobarbituric acid-reactive substances levels were elevated in EC-SOD knockout mice. These oxidant stress markers showed potentiated increases in the absence of both isoenzymes. Other alterations were mainly found in CuZn-SOD knockout mice, such as halved glutathione peroxidase activity in the tissues examined and increased glutathione and iron in the liver. There were no changes in tissue content of the alternative superoxide scavenger ascorbate, but there was a 25% reduction in ascorbate in blood plasma in mice lacking CuZn-SOD. No increase was found in the urinary excretion of the terminal metabolites of NO, nitrite, and nitrate in any of the genotypes. In conclusion, apart from the increases in the global urinary and plasma oxidant stress markers, our phenotype studies revealed no other evidence that the copper- and zinc-containing SOD isoenzymes have overlapping roles.	Univ Umea Hosp, Dept Med Biosci, SE-90185 Umea, Sweden; Natl Def Res Estab, SE-90182 Umea, Sweden; Melior Discovery Inc, Malvern, PA 19355 USA; Uppsala Univ, Fac Med, Dept Geriatr, SE-75125 Uppsala, Sweden	Umea University; Uppsala University	Marklund, SL (corresponding author), Univ Umea Hosp, Dept Med Biosci, SE-90185 Umea, Sweden.	Stefan.Marklund@medbio.umu.se		Granstrom, Micael/0000-0003-4563-7403				Attieh ZK, 1999, J BIOL CHEM, V274, P1116, DOI 10.1074/jbc.274.2.1116; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Basu S, 1998, PROSTAG LEUKOTR ESS, V58, P319, DOI 10.1016/S0952-3278(98)90042-4; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BIEMOND P, 1986, BIOCHEM J, V239, P169, DOI 10.1042/bj2390169; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Copin JC, 2000, FREE RADICAL BIO MED, V28, P1571, DOI 10.1016/S0891-5849(00)00280-X; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; HALL MA, 1999, N AM ACTUARIAL J, V3, P34; HALLIWELL B, 1978, FEBS LETT, V92, P321, DOI 10.1016/0014-5793(78)80779-0; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Huang TT, 2002, METHOD ENZYMOL, V349, P191, DOI 10.1016/S0076-6879(02)49335-4; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1994, LAB INVEST, V70, P705; KOJIMA T, 1990, CHEM PHARM BULL, V38, P3414, DOI 10.1248/cpb.38.3414; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Landis GN, 2005, MECH AGEING DEV, V126, P365, DOI 10.1016/j.mad.2004.08.012; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Levy MA, 2001, AM J PHYSIOL-LUNG C, V281, pL172, DOI 10.1152/ajplung.2001.281.1.L172; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MARKLUND SL, 1981, CLIN CHIM ACTA, V116, P191, DOI 10.1016/0009-8981(81)90022-X; Marklund SL, 2002, METHOD ENZYMOL, V349, P74, DOI 10.1016/S0076-6879(02)49322-6; MARKLUND SL, 1982, CANCER RES, V42, P1955; Marklund SL, 1997, J NEUROCHEM, V69, P675; Marklund SL, 1985, HDB METHODS OXYGEN R, P249; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Missirlis F, 2003, J BIOL CHEM, V278, P47365, DOI 10.1074/jbc.M307700200; Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; Ookawara T, 2002, BIOCHEM BIOPH RES CO, V296, P54, DOI 10.1016/S0006-291X(02)00804-5; Oury TD, 1999, BRAIN RES, V850, P96, DOI 10.1016/S0006-8993(99)02103-4; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rohrdanz E, 2001, ARCH TOXICOL, V75, P150, DOI 10.1007/s002040000206; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Starzynski RR, 2005, J BIOL CHEM, V280, P4207, DOI 10.1074/jbc.M411055200; Stralin P, 2003, BBA-GEN SUBJECTS, V1619, P1, DOI 10.1016/S0304-4165(02)00419-1; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WINTERBOURN CC, 1987, J CLIN INVEST, V80, P1486, DOI 10.1172/JCI113230	51	113	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6904	6909		10.1074/jbc.M510764200	http://dx.doi.org/10.1074/jbc.M510764200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16377630	hybrid			2022-12-25	WOS:000236030900002
J	Zietkiewicz, S; Lewandowska, A; Stocki, P; Liberek, K				Zietkiewicz, S; Lewandowska, A; Stocki, P; Liberek, K			Hsp70 chaperone machine remodels protein aggregates at the initial step of Hsp70-Hsp100-dependent disaggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI PROTEINS; LAMBDA-DNA REPLICATION; ATP-BINDING-SITES; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL HSP78; CLPB; HSP104; SOLUBILIZATION; MECHANISM	Exposure to temperatures over a certain limit leads to massive protein aggregation in the cell. Disaggregation of such aggregates is largely dependent on the Hsp100 and Hsp70 chaperones. The exact role of the Hsp70 chaperone machine ( composed of DnaK, DnaJ, and GrpE) in the Hsp100-dependent process remains unknown. In this study we focused on the Hsp70 role at the initial step of the disaggregation process. Two different aggregated model substrates, green fluorescent protein (GFP) and firefly luciferase, were incubated with the Hsp70 machine resulting in efficient fragmentation of large aggregates into smaller ones. Our data suggest that the observed fragmentation is achieved first by extraction of polypeptides from aggregates in Hsp70 chaperone machine-dependent manner and not by direct fragmentation of large aggregates. In the absence of Hsp100 ( ClpB) these "extracted" polypeptides were not able to fold properly and promptly reassociated into new aggregates. The extracted GFP molecules were efficiently recognized and sequestered by a molecular trap, the mutant GroEL D87K, which binds stably to unfolded but not to native polypeptides. The binding of extracted GFP molecules to the GroEL trap prevented their reaggregation. We propose that the Hsp70 machine disentangles polypeptides from protein aggregates prior to Hsp100 action.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk	Liberek, K (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, Kladki 24, PL-80822 Gdansk, Poland.	liberek@biotech.univ.gda.pl	Liberek, Krzysztof/F-5812-2011; Lewandowska, Agnieszka/M-9281-2018; Ziętkiewicz, Szymon/L-5259-2014	Lewandowska, Agnieszka/0000-0001-6387-7318; Liberek, Krzysztof/0000-0002-7532-9279; Zietkiewicz, Szymon/0000-0002-3435-4603				Ben-Zvi A, 2004, J BIOL CHEM, V279, P37298, DOI 10.1074/jbc.M405627200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; Liu QL, 2003, SCIENCE, V300, P139, DOI 10.1126/science.1083379; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Schlieker C, 2004, FEBS LETT, V578, P351, DOI 10.1016/j.febslet.2004.11.051; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; Shorter J, 2005, NAT STRUCT MOL BIOL, V12, P4, DOI 10.1038/nsmb0105-4; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; WALL D, 1994, J BIOL CHEM, V269, P5446; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEIZBEZAHN J, 2003, J BIOL CHEM, V278, P32608; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zietkiewicz S, 2004, J BIOL CHEM, V279, P44376, DOI 10.1074/jbc.M402405200; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	43	76	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7022	7029		10.1074/jbc.M507893200	http://dx.doi.org/10.1074/jbc.M507893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415353	hybrid			2022-12-25	WOS:000236030900015
J	Stevens, JM; Uchida, T; Daltrop, O; Kitagawa, T; Ferguson, SJ				Stevens, JM; Uchida, T; Daltrop, O; Kitagawa, T; Ferguson, SJ			Dynamic Ligation properties of the Escherichia coli heme chaperone CcmE to non-covalently bound heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C MATURATION; RESONANCE RAMAN-SPECTRA; PROXIMAL HISTIDINE; PROTEIN CCME; ACTIVE-SITE; LIGAND; BIOGENESIS; MYOGLOBIN; COMPLEX; COOA	The cytochrome c maturation protein CcmE is an essential membrane-anchored heme chaperone involved in the post-translational covalent attachment of heme to c-type cytochromes in Gram-negative bacteria such as Escherichia coli. Previous in vitro studies have shown that CcmE can bind heme both covalently ( via a histidine residue) and non-covalently. In this work we present results on the latter form of heme binding to a soluble form of CcmE. Examination of a number of site-directed mutants of E. coli CcmE by resonance Raman spectroscopy has identified ligands of the heme iron and provided insight into the initial steps of heme binding by CcmE before it binds the heme covalently. The heme binding histidine (His-130) appears to ligate the heme iron in the ferric oxidation state, but two other residues ligate the iron in the ferrous form, thereby freeing His-130 to undergo covalent attachment to a heme vinyl group. It appears that the heme ligation in the non-covalent form is different from that in the holo-form, suggesting that a change in ligation could act as a trigger for the formation of the covalent bond and showing the dynamic and oxidation state-sensitive ligation properties of CcmE.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Oxford	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp; stuart.ferguson@bioch.ox.ac.uk	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329	Biotechnology and Biological Sciences Research Council [C20071] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahuja U, 2005, J BIOL CHEM, V280, P236, DOI 10.1074/jbc.M410912200; Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Allen JWA, 2005, BIOCHEM J, V389, P587, DOI 10.1042/BJ20041894; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; ANDERSSON LA, 1992, NEW J CHEM, V16, P569; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; ANZENBACHER P, 1989, BIOCHEM BIOPH RES CO, V162, P921, DOI 10.1016/0006-291X(89)90760-2; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; Enggist E, 2003, J BACTERIOL, V185, P3821, DOI 10.1128/JB.185.13.3821-3827.2003; Enggist E, 2002, STRUCTURE, V10, P1551, DOI 10.1016/S0969-2126(02)00885-7; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Harvat EM, 2005, J BIOL CHEM, V280, P36747, DOI 10.1074/jbc.M508355200; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Jayaraman V, 1996, BIOSPECTROSCOPY, V2, P311, DOI 10.1002/(SICI)1520-6343(1996)2:5<311::AID-BSPY4>3.3.CO;2-L; Lee DH, 2005, J AM CHEM SOC, V127, P3716, DOI 10.1021/ja044658e; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; Mowat CG, 2005, DALTON T, P3381, DOI 10.1039/b505184c; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; RAVA RP, 1985, BIOCHEMISTRY-US, V24, P1861, DOI 10.1021/bi00329a009; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; Stevens JM, 2003, J BIOL CHEM, V278, P20500, DOI 10.1074/jbc.M212925200; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uchida T, 2004, J BIOL CHEM, V279, P51981, DOI 10.1074/jbc.M408963200; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	42	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6144	6151		10.1074/jbc.M508765200	http://dx.doi.org/10.1074/jbc.M508765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373344	hybrid			2022-12-25	WOS:000236030800006
J	Matsuo, N; Tanaka, S; Gordon, MK; Koch, M; Yoshioka, H; Ramirez, F				Matsuo, N; Tanaka, S; Gordon, MK; Koch, M; Yoshioka, H; Ramirez, F			CREB-AP1 protein complexes regulate transcription of the collagen XXIV gene (Col24a1) in Osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE FIBRILLAR COLLAGEN; CHONDROCYTE-SPECIFIC ENHANCER; BONE-FORMATION; V COLLAGEN; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; PROMOTER; SOX9; SEQUENCE	Collagen XXIV is a newly discovered and poorly characterized member of the fibril-forming family of collagen molecules, which displays unique structural features of invertebrate fibrillar collagens and is expressed predominantly in bone tissue. Here we report the characterization of the proximal promoter of the mouse gene (Col24a1) and its regulation in osteoblastic cells. Using well characterized murine models of osteoblast differentiation, we found that the Col24a1 gene is activated sometime before onset of the late differentiation marker osteocalcin. Additional analyses revealed that Col24a1 produces equal amounts of two alternatively spliced products with different 5'-untranslated sequences that originate from distinct transcriptional start sites. Cell transfection experiments in combination with DNA binding assays demonstrated that Col24a1 promoter activity in ROS17/2.8 osteosarcoma cells is under the control of an upstream cis-acting element, which is shared by both transcripts and is recognized by specific combinations of c-Jun, CREB1, ATF1, and ATF2 dimers. Consistent with these results, overexpression of c-Jun, ATF1, ATF2, or CREB1 in transiently transfected osteoblastic cells stimulated transcription from reporter gene constructs driven by the Col24a1 promoter to different degrees. Moreover, chromatin immunoprecipitation experiments showed that these nuclear factors bind the same upstream sequence of the endogenous Col24a1 gene. Collectively these data provide new information about transcriptional control of collagen fibrillogenesis, in addition to implicating for the first time CREB-AP1 protein complexes in the regulation of collagen gene expression in osteoblasts.	Hosp Special Surg, Div Res, Lab Genet & Organogenesis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Oita Univ, Dept Anat Biol & Med, Oita 8795593, Japan; Rutgers State Univ, Ernest Mario Sch Pharm, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Univ Cologne, Inst Biochem 2, D-50931 Cologne, Germany; CEINGE Biotecnol Avanzate, I-80131 Naples, Italy	Cornell University; Oita University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Cologne; CEINGE Biotecnologie Avanzate	Ramirez, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, 89 French St, New Brunswick, NJ 08901 USA.	ramirefr@umdnj.edu	Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814	NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY009056, EY 09056] Funding Source: Medline; NIAMS NIH HHS [AR 38648] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; Aouacheria A, 2004, J BIOL CHEM, V279, P47711, DOI 10.1074/jbc.M408950200; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Chanut-Delalande H, 2004, MOL CELL BIOL, V24, P6049, DOI 10.1128/MCB.24.13.6049-6057.2004; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004-1343; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Long FX, 2001, DEVELOPMENT, V128, P541; Luvalle P, 2003, J BONE JOINT SURG AM, V85A, P133, DOI 10.2106/00004623-200300002-00018; MAJESKA RJ, 1982, J BIOL CHEM, V257, P3362; Matsuo N, 2003, J BIOL CHEM, V278, P32763, DOI 10.1074/jbc.M305599200; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Okazaki K, 2004, CLIN ORTHOP RELAT R, pS123, DOI 10.1097/01.blo.0000144478.51284.f3; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Ricard-Blum S, 2005, PATHOL BIOL, V53, P430, DOI 10.1016/j.patbio.2004.12.024; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sakamoto MK, 1998, J BIOCHEM-TOKYO, V123, P399; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; Tanaka S, 2004, J BIOL CHEM, V279, P56024, DOI 10.1074/jbc.M411406200; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40; Wenstrup RJ, 2004, J BIOL CHEM, V279, P53331, DOI 10.1074/jbc.M409622200; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	49	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5445	5452		10.1074/jbc.M509923200	http://dx.doi.org/10.1074/jbc.M509923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373341	hybrid			2022-12-25	WOS:000235568900016
J	Hsu, MC; Chang, HC; Hung, WC				Hsu, MC; Chang, HC; Hung, WC			HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; BREAST-CANCER; GENE-EXPRESSION; DOWN-REGULATION; PANCREATIC-CANCER; NEU PROTOONCOGENE; ACTIVATION; PROTEIN; PHOSPHORYLATION	Matrix metalloproteinase (MMP) inhibitory proteins may negatively regulate MMP activity to suppress tumor metastasis. In this study, we demonstrate that the HER-2/neu oncogene inhibits the expression of the MMP inhibitor RECK to promote cell invasion. RECK was inhibited via transcriptional repression in B104-1-1 cells, which express constitutively active HER-2/neu. Overexpression of HER-2/neu in NIH/3T3 or HaCaT cells also suppressed RECK expression. Deletion and mutation assays showed that HER-2/neu repressed RECK via the Sp1-binding site localized in the -82/-71 region from the translational start site. DNA affinity precipitation and chromatin immunoprecipitation assays indicated that binding of Sp1 and Sp3 to this consensus site was increased in B104-1-1 cells. We also found that HER-2/neu inhibited RECK via the ERK signaling pathway. Sp1 proteins phosphorylated at Thr(453) and Thr(739) by ERK bound preferentially to the RECK promoter, and this binding was reversed by HER-2/neu and ERK inhibitors. Furthermore, our data indicate that HER-2/neu obviously increased HDAC1 binding to the Sp1-binding site localized in the -72/-71 region of the RECK promoter. The histone deacetylase inhibitor trichostatin A reversed HER-2/neu-induced inhibition of RECK. HER-2/neu activation was associated with increased MMP-9 secretion and activation. Re-expression of RECK in HER-2/neu-overexpressing cells inhibited MMP-9 secretion and cell invasion. Taken together, our results suggest that HER-2/neu induces the binding of Sp proteins and HDAC1 to the RECK promoter to inhibit RECK expression and to promote cell invasion. Restoration of RECK provides a novel strategy for the inhibition of HER-2/neu-induced metastasis.	Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Fukuoka 804, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct, Tainan 701, Taiwan	National Sun Yat Sen University; Kaohsiung Medical University; National Cheng Kung University	Hung, WC (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung, Fukuoka 804, Taiwan.	hung1228@ms10.hinet.net	Hsu, MC/AAE-5310-2020; Hung, Wen-Chun/F-4846-2011					Alroy I, 1999, MOL CELL BIOL, V19, P1961; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Finkenzeller Gunter, 2004, Angiogenesis, V7, P59, DOI 10.1023/B:AGEN.0000037332.66411.f0; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; Howe LR, 2002, CANCER RES, V62, P5405; Huang YC, 2004, ONCOGENE, V23, P4856, DOI 10.1038/sj.onc.1207621; Hung MC, 1999, SEMIN ONCOL, V26, P51; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KING BL, 1992, AM J PATHOL, V140, P23; Konecny G, 2001, CLIN CANCER RES, V7, P2448; La Rocca G, 2004, BRIT J CANCER, V90, P1414, DOI 10.1038/sj.bjc.6601725; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li T, 2003, CIRC RES, V93, P1202, DOI 10.1161/01.RES.0000104085.76261.02; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Liu LT, 2003, CANCER RES, V63, P3069; Masui T, 2003, CLIN CANCER RES, V9, P1779; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; MITRA AB, 1994, CANCER RES, V54, P637; Nguyen DX, 2002, J VIROL, V76, P619, DOI 10.1128/JVI.76.2.619-632.2002; Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Pang RTK, 2004, MOL ENDOCRINOL, V18, P471, DOI 10.1210/me.2003-0245; Petit AMV, 1997, AM J PATHOL, V151, P1523; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SLEBOS RJC, 1989, BRIT J CANCER, V59, P76, DOI 10.1038/bjc.1989.14; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; VARLEY JM, 1987, ONCOGENE, V1, P423; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Wong WK, 2003, J BIOL CHEM, V278, P36227, DOI 10.1074/jbc.M305549200; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zhao SJ, 2003, CANCER RES, V63, P2624; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	46	97	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4718	4725		10.1074/jbc.M510937200	http://dx.doi.org/10.1074/jbc.M510937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377629	hybrid			2022-12-25	WOS:000235426200020
J	Myzak, MC; Dashwood, WM; Orner, GA; Ho, E; Dashwood, RH				Myzak, MC; Dashwood, WM; Orner, GA; Ho, E; Dashwood, RH			Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc(min) mice	FASEB JOURNAL			English	Article						chemoprevention; colorectal cancer; diet; gene regulation	CHAIN FATTY-ACIDS; INDUCE APOPTOSIS; COLON-CANCER; TRICHOSTATIN; EXPRESSION; P21(WAF1/CIP1); TRANSCRIPTION; ACETYLATION; BUTYRATE; ENZYMES	Sulforaphane (SFN) is an isothiocyanate from broccoli that induces phase 2 detoxification enzymes. We recently reported that SFN acts as a histone deacetylase ( HDAC) inhibitor in human colon cancer cells in vitro, and the present study sought to extend these findings in vivo. In mice treated with a single oral dose of 10 mu mol SFN, there was significant inhibition of HDAC activity in the colonic mucosa after 6 h, and immunoblots revealed a concomitant increase in acetylated histones H3 and H4, which returned to control levels by 48 h. Longer-term treatment with SFN in the diet resulted in levels of acetylated histones and p21(WAF1) in the ileum, colon, prostate, and peripheral blood mononuclear cells that were elevated compared with controls. Consistent with these findings, SFN suppressed tumor development in Apc(min) mice, and there was an increase in acetylated histones in the polyps, including acetylated histones specifically associated with the promoter region of the P21 and bax genes. These results provide the first evidence for HDAC inhibition by SFN in vivo and imply that such a mechanism might contribute to the cancer chemoprotective and therapeutic effects of SFN, alone or in combination with other HDAC inhibitors currently undergoing clinical trials.	Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA; Oregon State Univ, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University; Oregon State University	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst Sci & Med, Corvallis, OR 97331 USA.	Rod.Dashwood@oregonstate.edu	Orner, Gayle A./F-6876-2013; Dashwood, Roderick H/E-9090-2011; Dashwood, Roderick/AAF-2025-2020	Orner, Gayle A./0000-0002-4812-5297; 	NATIONAL CANCER INSTITUTE [P01CA090890, R01CA065525, R29CA065525, R21CA100608, R01CA107693, R01CA080176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA090890, P01 CA090890-01A20003, P01 CA090890-01A29001, CA-65525, R01 CA080176, CA-107693, P01 CA090890-05S1, CA-100608, CA-80176, P01 CA090890-05, R01 CA065525, R01 CA065525-08, R01 CA065525-09, R01 CA080176-05, CA-90890, R01 CA080176-04] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Acquavella J, 1999, CANCER EPIDEM BIOMAR, V8, P947; ACQUAVELLA J, 1999, CANCER EPIDEM BIOMAR, V7, P647; Ben-Dor A, 2005, MOL CANCER THER, V4, P177; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Dashwood RH, 2002, MUTAT RES-REV MUTAT, V511, P89, DOI 10.1016/S1383-5742(02)00005-4; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Eickhoff B, 2000, BIOL CHEM, V381, P107, DOI 10.1515/BC.2000.015; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Gottlicher M, 2004, ANN HEMATOL S1, V83, pS91; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; Kelly WK, 2003, CLIN CANCER RES, V9, P3578; Kobayashi H, 2004, INT J CANCER, V109, P207, DOI 10.1002/ijc.11697; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Lavelle D, 2001, AM J HEMATOL, V68, P170, DOI 10.1002/ajh.1174; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lipkin M, 1999, ANNU REV NUTR, V19, P545, DOI 10.1146/annurev.nutr.19.1.545; Mariadason JM, 2000, CANCER RES, V60, P4561; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; MYZAK MC, 2006, IN PRESS CURR DRUG T; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Reddy BS, 2000, CANCER EPIDEM BIOMAR, V9, P239; Remiszewski SW, 2002, J MED CHEM, V45, P753, DOI 10.1021/jm015568c; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sandor V, 2002, CLIN CANCER RES, V8, P718; Seow A, 2002, CARCINOGENESIS, V23, P2055, DOI 10.1093/carcin/23.12.2055; Woo SH, 2002, J MED CHEM, V45, P2877, DOI 10.1021/jm020154k; Yang K, 2003, CARCINOGENESIS, V24, P605, DOI 10.1093/carcin/24.3.605; Yasui W, 2003, ANN NY ACAD SCI, V983, P220, DOI 10.1111/j.1749-6632.2003.tb05977.x; Yoxall V, 2005, INT J CANCER, V117, P356, DOI 10.1002/ijc.21191; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440	39	263	269	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					506	+		10.1096/fj.05-4785fje	http://dx.doi.org/10.1096/fj.05-4785fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407454	Green Accepted			2022-12-25	WOS:000235996000022
J	Udagawa, T; Puder, M; Wood, M; Schaefer, BC; D'Amato, RJ				Udagawa, T; Puder, M; Wood, M; Schaefer, BC; D'Amato, RJ			Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells	FASEB JOURNAL			English	Article						tumor; stroma; cancer; Flk-1; VEGFR2; angiogenesis; endothelial cells; GFP	GENETIC-HETEROGENEITY; STEM-CELLS; IN-VIVO; ANGIOGENESIS; GROWTH; INDUCTION; ANGIOPOIETIN-2; MECHANISMS; PHENOTYPE; DORMANCY	The green fluorescence protein (GFP) from the UBI-GFP/BL6 transgenic line was bred into C57BL/6J-scid and C.B-17-scid mice for investigating host-tumor cell interactions. These mice express high levels of GFP under the control of the ubiquitin promoter in virtually all cells examined. In tumor tissue generated by implanting tumor cells in the GFP transgenic SCID mice, the tumor cells and tumor-associated murine host cells were clearly distinguished by GFP expression. A population of cells expressing the endothelial cell marker VEGFR-2/Flk-1, and the progenitor markers c-Kit and Sca-1, were incorporated into tumor tissue. The majority of the Flk-1-positive cells were hematopoietic-derived cells that coexpressed CD45. To investigate the contribution of bone marrow-derived cells to the formation of tumor vessels and stroma, tumor cells were implanted in nontransgenic SCID mice that received a bone marrow transplant from GFP-expressing SCID mice. Although GFP-positive cells were readily detected by histology in tumors taken from bone marrow transplanted animals, they were spatially isolated and lacked organization. In contrast, if tumors were implanted in nontransgenic SCID mice adjacent to a patch of transplanted GFP-expressing skin, these tumors recruited GFP-positive cells that organized into tumor vessels. The results demonstrate that hematopoietic-derived cells, including Flk-1(+)/CD45(+) cells, readily colonized the tumor stroma but were minimally incorporated in the tumor vasculature. The majority of the tumor vessels were instead recruited from tissue adjacent to the tumor. The expression of Flk-1 on nonendothelial, tumor-associated host cells raises the possibility that VEGF antagonists, such as Avastin, could inhibit tumor growth by a mechanism involving hematopoietic-derived CD45(+)/Flk-1(+) cells, in addition to direct suppression of endothelial cell function.-Udagawa, T., Puder, M., Wood, M., Schaefer, B. C., D'Amato, R. J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells.	Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Uniformed Services University of the Health Sciences - USA	Udagawa, T (corresponding author), Childrens Hosp, Vasc Biol Program, 1 Blackfan Cr, Boston, MA 02115 USA.	taturo.udagawa@childrens.harvard.edu		Schaefer, Brian C/0000-0001-8877-3507	NATIONAL CANCER INSTITUTE [K01CA087013] Funding Source: NIH RePORTER; NCI NIH HHS [KO1 CA087013-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Bavik C, 1996, P NATL ACAD SCI USA, V93, P3110, DOI 10.1073/pnas.93.7.3110; BOERRIGTER METI, 1995, MECH AGEING DEV, V82, P31, DOI 10.1016/0047-6374(95)01603-W; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hudson WA, 1998, LEUKEMIA, V12, P2029, DOI 10.1038/sj.leu.2401236; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Noonan FP, 2003, J INVEST DERMATOL, V121, P1175, DOI 10.1046/j.1523-1747.2003.12560.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336; Renz JF, 1996, J SURG RES, V65, P34, DOI 10.1006/jsre.1996.0340; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Schaefer BC, 2001, CELL IMMUNOL, V214, P110, DOI 10.1006/cimm.2001.1895; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; SURI C, 1996, CELL, V87, P1170; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang M, 2003, P NATL ACAD SCI USA, V100, P14259, DOI 10.1073/pnas.2436101100; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	32	62	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					95	102		10.1096/fj.04-3669com	http://dx.doi.org/10.1096/fj.04-3669com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394272				2022-12-25	WOS:000235996000049
J	Di Fulvio, M; Lehman, N; Lin, X; Lopez, I; Gomez-Cambronero, J				Di Fulvio, M.; Lehman, N.; Lin, X.; Lopez, I.; Gomez-Cambronero, J.			The elucidation of novel SH2 binding sites on PLD2	ONCOGENE			English	Article						PLD; Grb2; SOS; SH2 domains; cell signalling; cell proliferation; Ras/Erk pathway; site-directed mutagenesis	KINASE SIGNAL-TRANSDUCTION; RECEPTOR TYROSINE KINASES; COLONY-STIMULATING FACTOR; ADP-RIBOSYLATION FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-D; REGULATORY MECHANISM; CELL-PROLIFERATION; HUMAN NEUTROPHILS; PROTEIN GRB2	Our laboratory has recently reported that the enzyme phospholipase D2 (PLD2) exists as a ternary complex with PTP1b and the growth factor receptor bound protein 2 (Grb2). Here, we establish the mechanistic underpinnings of the PLD2/Grb2 association. We have identified residues Y-169 and Y-179 in the PLD2 protein as being essential for the Grb2 interaction. We present evidence indicating that Y-169 and Y179 are located within two consensus sites in PLD2 that mediate an SH2 interaction with Grb2. This was demonstrated with an SH2-deficient GSTGrb2 R86K mutant that failed to pull-down PLD2 in vitro. In order to elucidate the functions of the two neighboring tyrosines, we created a new class of deletion and point mutants in PLD2. Phenylalanine replacement of Y-169 (PLD2 Y169F)or Y-179 (PLD2 Y179F) reduced Grb2 binding while simultaneous mutation completely abolished it. The role of the two binding sites on PLD2 was found to be functionally nonequivalent: Y-169 serves to modulate the activity of the enzyme, whereas Y-179 regulates total tyrosine phosphorylation of the protein. Interestingly, binding of Grb2 to PLD2 occurs irrespectively of lipase activity, since Grb2 binds to catalytically inactive PLD2 mutants. Finally, PLD2 residues Y-169 and Y-179 are necessary for the recruitment of Sos, but only overexpression of the PLD2 Y179F mutant resulted in increased Ras activity, p44/42(Erk) phosphorylation and enhanced DNA synthesis. Since Y-169 remains able to modulate enzyme activity and is capable of binding to Grb2 in the PLD2 Y179F mutant, we propose that Y-169 is kept under negative regulation by Y-179. When this is released, Y-169 mediates cellular proliferation through the Ras/MAPK pathway.	Wright State Univ, Dept Physiol & Biophys, Sch Med, Dayton, OH 45435 USA; Univ Illinois, Dept Pharmacol, Chicago, IL USA	Wright State University Dayton; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gomez-Cambronero, J (corresponding author), Wright State Univ, Dept Physiol & Biophys, Sch Med, Dayton, OH 45435 USA.	julian.cambronero@wright.edu		Gomez-Cambronero, Julian/0000-0002-7581-9227	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056653, R01HL056653] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL056653-09, R29 HL056653, HL056653, R01 HL056653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Banno Y, 2005, J BIOL CHEM, V280, P16319, DOI 10.1074/jbc.M410903200; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Choi WS, 2004, MOL CELL BIOL, V24, P6980, DOI 10.1128/MCB.24.16.6980-6992.2004; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Di Fulvio M, 2000, J ENDOCRINOL, V166, P173, DOI 10.1677/joe.0.1660173; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Foster DA, 2003, MOL CANCER RES, V1, P789; Gomez-Cambronero J, 2003, J IMMUNOL, V171, P6846, DOI 10.4049/jimmunol.171.12.6846; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Horn J, 2005, BIOCHEM BIOPH RES CO, V332, P58, DOI 10.1016/j.bbrc.2005.04.093; Horn JM, 2001, BBA-MOL CELL BIOL L, V1530, P97, DOI 10.1016/S1388-1981(00)00172-4; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Liu MY, 2002, CANCER RES, V62, P6475; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3032	3040		10.1038/sj.onc.1209340	http://dx.doi.org/10.1038/sj.onc.1209340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407827	Green Accepted			2022-12-25	WOS:000237950800007
J	Han, YH; Cao, X; Lin, B; Lin, F; Kolluri, SK; Stebbins, J; Reed, JC; Dawson, MI; Zhang, XK				Han, Y-H; Cao, X.; Lin, B.; Lin, F.; Kolluri, S. K.; Stebbins, J.; Reed, J. C.; Dawson, M. I.; Zhang, X-k			Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt	ONCOGENE			English	Article						apoptosis; Nur77; JNK; Akt; AHPN; CD437	SYNTHETIC RETINOID CD437; CANCER-CELL-LINES; BREAST-CARCINOMA CELLS; ORPHAN RECEPTOR TR3; NGFI-B; PROSTATE-CANCER; APOPTOSIS INDUCTION; SIGNALING PATHWAY; BINDING DOMAIN; LEUKEMIA-CELLS	Proapoptotic nuclear receptor family member Nur77 translocates from the nucleus to the mitochondria, where it interacts with Bcl-2 to trigger apoptosis. Nur77 translocation is induced by certain apoptotic stimuli, including the synthetic retinoid-related 6-[3-(1-adamantyl)-4hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN)/CD437 class. In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3- Cl- AHPC) induces Nur77 nuclear export. Our results demonstrate that 3- Cl- AHPC effectively activated Jun N-terminal kinase (JNK), which phosphorylates Nur77. Inhibition of JNK activation by a JNK inhibitor suppressed 3-Cl-AHPC-induced Nur77 nuclear export and apoptosis. In addition, several JNK upstream activators, including the phorbol ester TPA, anisomycin and MAPK kinase kinase-1 (MEKK1), phosphorylated Nur77 and induced itsnuclear export. However, Nur77 phosphorylation by JNK, although essential, was not sufficient for inducing Nur77 nuclear export. Induction of Nur77 nuclear export by MEKK1 required a prolonged MEKK1 activation and was attenuated by Akt activation. Expression of constitutively active Akt prevented MEKK1-induced Nur77 nuclear export. Conversely, transfection of dominant-negative Akt or treatment with a phosphatidylinositol 3- kinase (PI3-K) inhibitor accelerated MEKK1-induced Nur77 nuclear export. Furthermore, mutation of an Akt phosphorylation residue Ser351 in Nur77 abolished the effect of Akt or the PI3-K inhibitor. Together, our results demonstrate that both activation of JNK and inhibition of Akt play a role in translocation of Nur77 from the nucleus to the cytoplasm.	Burke Med Res Inst, Ctr Canc, La Jolla, CA 92037 USA		Zhang, XK (corresponding author), Burke Med Res Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	xzhang@burnham.org			NATIONAL CANCER INSTITUTE [R01CA087000, R01CA109345] Funding Source: NIH RePORTER; NCI NIH HHS [CA109345, CA87000] Funding Source: Medline; NIGMS NIH HHS [GM60544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Boisvieux-Ulrich E, 2005, EXP CELL RES, V307, P76, DOI 10.1016/j.yexcr.2005.02.005; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Dawson MI, 1998, CANCER LETT, V133, P1, DOI 10.1016/S0304-3835(98)00147-5; Dawson MI, 2001, CANCER RES, V61, P4723; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Farhana L, 2004, ONCOGENE, V23, P1874, DOI 10.1038/sj.onc.1207311; Flaig R, 2005, J BIOL CHEM, V280, P19250, DOI 10.1074/jbc.M413175200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Gianni M, 1999, LEUKEMIA, V13, P739, DOI 10.1038/sj.leu.2401419; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jeong JH, 2003, ANN NY ACAD SCI, V1010, P171, DOI 10.1196/annals.1299.029; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Langdon SP, 1998, CANCER CHEMOTH PHARM, V42, P429, DOI 10.1007/s002800050841; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li XS, 1996, CANCER RES, V56, P5055; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liang JY, 1999, PROSTATE, V38, P228; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schadendorf D, 1995, Recent Results Cancer Res, V139, P183; SHAO ZM, 1995, ONCOGENE, V11, P493; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Wan XL, 2001, ANTICANCER RES, V21, P2657; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Widschwendter M, 1997, INT J CANCER, V71, P497; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WINGATE AD, 2005, BIOCH J         1013; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 2003, BLOOD, V102, P3743, DOI 10.1182/blood-2003-01-0108; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	74	110	116	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2974	2986		10.1038/sj.onc.1209358	http://dx.doi.org/10.1038/sj.onc.1209358			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16434970				2022-12-25	WOS:000237950800002
J	Galinier, A; Carriere, A; Fernandez, Y; Carpene, C; Andre, M; Caspar-Bauguil, S; Thouvenot, JP; Periquet, B; Penicaud, L; Casteilla, L				Galinier, A; Carriere, A; Fernandez, Y; Carpene, C; Andre, M; Caspar-Bauguil, S; Thouvenot, JP; Periquet, B; Penicaud, L; Casteilla, L			Adipose tissue proadipogenic redox changes in obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; INSULIN-RESISTANCE; GENE-EXPRESSION; PLASMA; BLOOD; MICE; SUPPLEMENTATION; DIFFERENTIATION; ANTIOXIDANTS; ADIPOCYTES	The role of inflammation and oxidative stress in the development of obesity and associated metabolic disorders is under debate. We investigated the redox metabolism in a non-diabetic obesity model, i.e. 11-week-old obese Zucker rats. Antioxidant enzyme activities, lipophilic antioxidant (alpha-tocopherol, coenzymes Q) and hydrophilic antioxidant ( glutathione, vitamin C) contents and their redox state (% oxidized form), were studied in inguinal white fat and compared with blood and liver. The adipose tissues of obese animals showed a specific higher content of hydrophilic molecules in a lower redox state than those of lean animals, which were associated with lower lipophilic molecule content and lipid peroxidation. Conversely and as expected, glutathione content decreased and its redox state increased in adipose tissues of rats subjected to lipowpolysaccharide-induced systemic oxidative stress. In these in vivo models, oxidative stress and obesity thus had opposite effects on adipose tissue redox state. Moreover, the increase in glutathione content and the decrease of its redox state by antioxidant treatment promoted in vitro the accumulation of triglycerides in preadipocytes. Taken together and contrary to the emergent view, our results suggest that obesity is associated with an intracellular reduced redox state that promotes on its own the development of a deleterious proadipogenic process.	Univ Toulouse 3, CNRS, UMR 5018, Inst Fed Rech 31,Inst Louis Bugnard, F-31432 Toulouse 4, France; Hop Purpan, Lab Biochim Gen & Nutr, F-31059 Toulouse 9, France; Inst Louis Bugnard, Unite 586, IFR 31, F-31432 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Casteilla, L (corresponding author), Univ Toulouse 3, CNRS, UMR 5018, Inst Fed Rech 31,Inst Louis Bugnard, BP 84225, F-31432 Toulouse 4, France.	casteil@toulouse.inserm.fr	Carpéné, Christian/S-3279-2019	Carriere, Audrey/0000-0002-4277-7905; Galinier, Anne/0000-0003-2454-5681; Casteilla, Louis/0000-0001-9647-3248; Caspar-Bauguil, Sylvie/0000-0003-2682-0704				Ben-Shaul V, 2001, TOXICOL LETT, V123, P1, DOI 10.1016/S0378-4274(01)00369-1; Carriere A, 2004, J BIOL CHEM, V279, P40462, DOI 10.1074/jbc.M407258200; Carriere A, 2003, FEBS LETT, V550, P163, DOI 10.1016/S0014-5793(03)00862-7; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; Deveaud C, 2005, BIOCHEM PHARMACOL, V70, P90, DOI 10.1016/j.bcp.2005.04.015; Douillet C, 1998, BIOL TRACE ELEM RES, V65, P221, DOI 10.1007/BF02789098; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1; FABREGAT I, 1987, BIOCHEM BIOPH RES CO, V146, P920, DOI 10.1016/0006-291X(87)90618-8; Faure P, 2004, EUR J CLIN INVEST, V34, P475, DOI 10.1111/j.1365-2362.2004.01362.x; Ford ES, 2003, DIABETES, V52, P2346, DOI 10.2337/diabetes.52.9.2346; Froyland L, 1996, LIPIDS, V31, P169, DOI 10.1007/BF02522617; Fujita A, 2005, DIABETES RES CLIN PR, V69, P113, DOI 10.1016/j.diabres.2004.11.016; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; Galinier A, 2004, FEBS LETT, V578, P53, DOI 10.1016/j.febslet.2004.10.067; GUNZLER WA, 1974, Z KLIN CHEM KLIN BIO, V12, P444; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; McClung JP, 2004, P NATL ACAD SCI USA, V101, P8852, DOI 10.1073/pnas.0308096101; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Molnar D, 2004, INT J OBESITY, V28, P1197, DOI 10.1038/sj.ijo.0802719; Morin N, 2001, J PHARMACOL EXP THER, V297, P563; Ogihara T, 2004, DIABETOLOGIA, V47, P794, DOI 10.1007/s00125-004-1391-x; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Prunet-Marcassus B, 1999, FEBS LETT, V464, P184, DOI 10.1016/S0014-5793(99)01710-X; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Reitman A, 2002, ISRAEL MED ASSOC J, V4, P590; Rosen ED, 2000, GENE DEV, V14, P1293; SPEEK AJ, 1984, J CHROMATOGR, V305, P53, DOI 10.1016/S0378-4347(00)83313-7; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; Tofovic SP, 2003, METH MOLEC MED, V86, P29; Touyz RM, 2004, HISTOCHEM CELL BIOL, V122, P339, DOI 10.1007/s00418-004-0696-7; Urakawa H, 2003, J CLIN ENDOCR METAB, V88, P4673, DOI 10.1210/jc.2003-030202; Visentin V, 2004, OBES RES, V12, P547, DOI 10.1038/oby.2004.62; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YAGI K, 1984, METHOD ENZYMOL, V105, P328; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829	37	79	83	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12682	12687		10.1074/jbc.M506949200	http://dx.doi.org/10.1074/jbc.M506949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16377639	hybrid			2022-12-25	WOS:000237134700059
J	Short, KM; Cox, TC				Short, KM; Cox, TC			Subclassification of the RBCC/TRIM superfamily reveals a novel motif necessary for microtubule binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; SYNDROME GENE-PRODUCT; RING FINGER PROTEIN; OPITZ-SYNDROME; MULIBREY NANISM; MID1; IDENTIFICATION; ENCODES; FAMILY; MUTATIONS	The biological significance of RBCC (N-terminal (R) under bar ING finger/ (B) under bar -box/(c) under bar oiled (c) under bar oil) proteins is increasingly being appreciated following demonstrated roles in disease pathogenesis, tumorigenesis, and retroviral protective activity. Found in all multicellular eukaryotes, RBCC proteins are involved in a vast array of intracellular functions; but as a general rule, they appear to function as part of large protein complexes and possess ubiquitin-protein isopeptide ligase activity. Those members characterized to date have diverse C-terminal domain compositions and equally diverse subcellular localizations and functions. Using a bioinformatics approach, we have identified some new RBCC proteins that help define a subfamily that shares an identical domain arrangement (MID1, MID2, TRIM9, TNL, TRIM36, and TRIFIC). Significantly, we show that all analyzed members of this subfamily associate with the microtubule cytoskeleton, suggesting that subcellular compartmentalization is determined by the unique domain architecture, which may in turn reflect basic functional similarities. We also report a new motif called the COS box, which is found within these proteins, the MURF family, and a distantly related non-RBCC microtubule-binding protein. Notably, we demonstrate that mutations in the COS box abolish microtubule binding ability, whereas its incorporation into a non-microtubule-binding RBCC protein redirects it to microtubule structures. Further bioinformatics investigation permitted subclassification of the entire human RBCC complement into nine subfamilies based on their varied C-terminal domain compositions. This classification schema may aid the understanding of the molecular function of members of each subgroup and their potential involvement in both basic cellular processes and human disease.	Monash Univ, Dept Anat & Cell Biol, Clayton, Vic 3800, Australia; Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	Monash University; University of Adelaide	Cox, TC (corresponding author), Monash Univ, Dept Anat & Cell Biol, Bldg 13C,Rm C180, Clayton, Vic 3800, Australia.	timothy.cox@med.monash.edu.au	Short, Kieran/O-4476-2019; Short, Kieran/A-2604-2012	Short, Kieran/0000-0001-9137-008X; Short, Kieran/0000-0001-9137-008X				Attwood TK, 2003, NUCLEIC ACIDS RES, V31, P400, DOI 10.1093/nar/gkg030; Balint I, 2004, GENE, V332, P45, DOI 10.1016/j.gene.2004.02.045; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; BENNER SA, 1994, PROTEIN ENG, V7, P1323, DOI 10.1093/protein/7.11.1323; Berti C, 2002, MECH DEVELOP, V113, P159, DOI 10.1016/S0925-4773(02)00013-8; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Cainarca S, 1999, HUM MOL GENET, V8, P1387, DOI 10.1093/hmg/8.8.1387; Carim-Todd L, 2001, BBA-GENE STRUCT EXPR, V1518, P200, DOI 10.1016/S0167-4781(01)00178-6; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Cox TC, 2000, HUM MOL GENET, V9, P2553, DOI 10.1093/hmg/9.17.2553; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FELSENSTEIN J, 2004, PHYLIP VERSION 3 62; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Hulo N, 2004, NUCLEIC ACIDS RES, V32, pD134, DOI 10.1093/nar/gkh044; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kallijarvi J, 2005, EXP CELL RES, V308, P146, DOI 10.1016/j.yexcr.2005.04.001; Kallijarvi J, 2002, AM J HUM GENET, V70, P1215, DOI 10.1086/340256; Kitamura K, 2003, J BIOL CHEM, V278, P44417, DOI 10.1074/jbc.M304306200; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; Manabe R, 2002, CURR BIOL, V12, P1946, DOI 10.1016/S0960-9822(02)01299-X; MORGAN K, 2005, CURRENT PROTOCOLS CE; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Perry J, 1999, GENOMICS, V62, P385, DOI 10.1006/geno.1999.6043; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rhodes DA, 2002, IMMUNOLOGY, V106, P246, DOI 10.1046/j.1365-2567.2002.01417.x; Schweiger S, 1999, P NATL ACAD SCI USA, V96, P2794, DOI 10.1073/pnas.96.6.2794; Short KM, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-1; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; Stein PA, 2002, J CELL SCI, V115, P3389; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Truong K, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-1; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Zapata JM, 2001, J BIOL CHEM, V276, P24242, DOI 10.1074/jbc.M100354200	43	223	235	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8970	8980		10.1074/jbc.M512755200	http://dx.doi.org/10.1074/jbc.M512755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16434393	hybrid			2022-12-25	WOS:000236247100077
J	Carta, L; Pereira, L; Arteaga-Solis, E; Lee-Arteaga, SY; Lenart, B; Starcher, B; Merkel, CA; Sukoyan, M; Kerkis, A; Hazeki, N; Keene, DR; Sakai, LY; Ramirez, F				Carta, L; Pereira, L; Arteaga-Solis, E; Lee-Arteaga, SY; Lenart, B; Starcher, B; Merkel, CA; Sukoyan, M; Kerkis, A; Hazeki, N; Keene, DR; Sakai, LY; Ramirez, F			Fibrillins 1 and 2 perform partially overlapping functions during aortic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; EXTRACELLULAR MICROFIBRILS; VASCULAR MORPHOGENESIS; LYSYL OXIDASE; EXPRESSION; ELASTIN; CYR61; MICE; PATHOGENESIS; FIBULIN-5	Fibrillin-rich microfibrils are extracellular assemblies that impart structural properties to the connective tissue. To elucidate the contribution of fibrillin-rich microfibrils to organogenesis, we have examined the vascular phenotype of a newly created strain of mice that completely lacks fibrillin-1 and the consequences of combined deficiency of fibrillins 1 and 2 on tissue formation. The results demonstrated that fibrillins 1 and 2 perform partially overlapping functions during aortic development. Fbn1(-/-) mice died soon after birth from ruptured aortic aneurysm, impaired pulmonary function, and/or diaphragmatic collapse. Analysis of the neonatal Fbn1(-/-) aorta documented a disorganized and poorly developed medial layer but normal levels of elastin cross-links. Transcriptional profiling revealed that aneurysm progression in Fbn1 null mice is accompanied by unproductive up-regulation of gene products normally involved in tissue repair and vascular integrity, such as plasminogen activator inhibitor-1, activin A, and cysteine-rich angiogenic protein 61. In contrast to Fbn1(-/-) mice, Fbn2 null mice had a well developed and morphologically normal aortic wall. However, virtually all Fbn1(-/-); Fbn2(-/-) embryos and about half of the Fbn1(+/-); Fbn2(-/-) embryos died in utero and displayed a significantly more severe vascular phenotype than Fbn1(-/-) mice. Consistent with a specialized function of fibrillin-2, electron microscopy visualized ultrastructurally different microfibrils in Fbn1 null compared with control cell cultures. Collectively, these data demonstrate that involvement of fibrillin-2 in the initial assembly of the aortic matrix overlaps in part with fibrillin-1 and that continued fibrillin-1 deposition is absolutely required for the maturation and function of the vessel during neonatal life.	CEINGE Biotecnol Avanzate, I-80131 Naples, Italy; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97239 USA; Univ Texas, Hlth Sci Ctr, Tyler, TX 75708 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ Sao Paulo, Inst Biociencias, Dept Genet & Biol Evolut, BR-05508900 Sao Paulo, Brazil; Cornell Univ, Hosp Special Surg, Weill Med Coll, Lab Genet & Organogenesis, New York, NY 10021 USA	CEINGE Biotecnologie Avanzate; Oregon Health & Science University; Oregon Health & Science University; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Universidade de Sao Paulo; Cornell University	Ramirez, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Inst Child Hlth, 89 French St, New Brunswick, NJ 08901 USA.	ramirefr@umdnj.edu	Merkel, Christian/K-7057-2012		NIAMS NIH HHS [R01 AR042044-13, R01 AR042044, P01 AR049698] Funding Source: Medline; NIGMS NIH HHS [F31 GM018511-04, F31 GM018511] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042044, P01AR049698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM018511] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Bonewald LF, 1999, CRIT REV EUKAR GENE, V9, P33, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.30; Brooke BS, 2003, TRENDS CELL BIOL, V13, P51, DOI 10.1016/S0962-8924(02)00007-7; Bunton TE, 2001, CIRC RES, V88, P37, DOI 10.1161/01.RES.88.1.37; Charbonneau Noe L, 2004, Birth Defects Res C Embryo Today, V72, P37, DOI 10.1002/bdrc.20000; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; DAVIS EC, 1994, J CELL SCI, V107, P727; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Faury G, 2001, PATHOL BIOL, V49, P310, DOI 10.1016/S0369-8114(01)00147-X; Gayraud B, 2000, J CELL BIOL, V150, P667, DOI 10.1083/jcb.150.3.667; Gelb BD, 2004, CURR OPIN CARDIOL, V19, P110, DOI 10.1097/00001573-200403000-00007; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Judge DP, 2004, J CLIN INVEST, V114, P172, DOI 10.1172/JCI200420641; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Kelleher CM, 2004, CURR TOP DEV BIOL, V62, P153; Kielty CM, 2002, J CELL SCI, V115, P2817; KUROO M, 1991, J BIOL CHEM, V266, P3768; Li DY, 1998, J CLIN INVEST, V102, P1783, DOI 10.1172/JCI4487; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Molloy CJ, 1999, J ENDOCRINOL, V161, P179, DOI 10.1677/joe.0.1610179; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Pyeritz RE, 2002, PRINCIPLES PRACTICE, P3977; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Spencer JA, 2005, P NATL ACAD SCI USA, V102, P2946, DOI 10.1073/pnas.0500058102; STARCHER B, 1995, CONNECT TISSUE RES, V31, P133, DOI 10.3109/03008209509028401; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	38	179	193	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8016	8023		10.1074/jbc.M511599200	http://dx.doi.org/10.1074/jbc.M511599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407178	Green Accepted, hybrid			2022-12-25	WOS:000236031000038
J	Hong, HD; Patel, DR; Tamm, LK; van den Berg, B				Hong, HD; Patel, DR; Tamm, LK; van den Berg, B			The outer membrane protein OmpW forms an eight-stranded beta-barrel with a hydrophobic channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEOMIC ANALYSIS; ENZYME PAGP; EXPRESSION; SEQUENCE; PORE; REPLACEMENT; DYNAMICS	Escherichia coli OmpW belongs to a family of small outer membrane proteins that are widespread in Gram-negative bacteria. Their functions are unknown, but recent data suggest that they may be involved in the protection of bacteria against various forms of environmental stress. To gain insight into the function of these proteins we have determined the crystal structure of E. coli OmpW to 2.7-angstrom resolution. The structure shows that OmpW forms an 8-stranded beta-barrel with a long and narrow hydrophobic channel that contains a bound n-dodecyl-N, N-dimethylamine-N-oxide detergent molecule. Single channel conductance experiments show that Omp W functions as an ion channel in planar lipid bilayers. The channel activity can be blocked by the addition of n-dodecyl-N, N-dimethylamine-N-oxide. Taken together, the data suggest that members of the Omp W family could be involved in the transport of small hydrophobic molecules across the bacterial outer membrane.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Virginia; University of Massachusetts System; University of Massachusetts Worcester	van den Berg, B (corresponding author), 373 Plantat St, Worcester, MA 01605 USA.	bert.vandenberg@umassmed.edu	Hong, Heedeok/E-9231-2018	Hong, Heedeok/0000-0003-0118-5193; van den Berg, Bert/0000-0003-1966-8804	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051329, R01GM074824] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 051329, GM 074824, R01 GM051329] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn VE, 2004, EMBO J, V23, P2931, DOI 10.1038/sj.emboj.7600320; Arora A, 2000, J BIOL CHEM, V275, P1594, DOI 10.1074/jbc.275.3.1594; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENZ R, 1988, EUR J BIOCHEM, V176, P699, DOI 10.1111/j.1432-1033.1988.tb14333.x; Bond PJ, 2002, BIOPHYS J, V83, P763, DOI 10.1016/S0006-3495(02)75207-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busch Wolfgang, 2003, Methods Mol Biol, V227, P21, DOI 10.1385/1-59259-387-9:21; Das M, 1998, FEMS IMMUNOL MED MIC, V22, P303, DOI 10.1111/j.1574-695X.1998.tb01219.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2002, PYMOL USERS MANUAL; EATON RW, 1994, J BACTERIOL, V176, P7757, DOI 10.1128/JB.176.24.7757-7762.1994; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hamilton JA, 2003, CURR OPIN LIPIDOL, V14, P263, DOI 10.1097/00041433-200306000-00006; Ho EM, 2004, CURR MICROBIOL, V49, P346, DOI 10.1007/s00284-004-4322-7; Hu WS, 2005, ANTIMICROB AGENTS CH, V49, P3955, DOI 10.1128/AAC.49.9.3955-3958.2005; Hwang PM, 2004, P NATL ACAD SCI USA, V101, P9618, DOI 10.1073/pnas.0402324101; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; JALAJAKUMARI MB, 1990, NUCLEIC ACIDS RES, V18, P2180, DOI 10.1093/nar/18.8.2180; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; MAIER C, 1988, J BIOL CHEM, V263, P2493; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Nandi B, 2005, MICROBIOL-SGM, V151, P2975, DOI 10.1099/mic.0.27995-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pilsl H, 1999, J BACTERIOL, V181, P3578, DOI 10.1128/JB.181.11.3578-3581.1999; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; Soderblom T, 2005, CELL MICROBIOL, V7, P779, DOI 10.1111/j.1462-5822.2005.00510.x; SUGAWARA E, 1992, J BIOL CHEM, V267, P2507; Tamm LK, 2003, FEBS LETT, V555, P139, DOI 10.1016/S0014-5793(03)01127-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van den Berg B, 2005, CURR OPIN STRUC BIOL, V15, P401, DOI 10.1016/j.sbi.2005.06.003; van den Berg B, 2004, SCIENCE, V304, P1506, DOI 10.1126/science.1097524; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; Vandeputte-Rutten L, 2003, J BIOL CHEM, V278, P24825, DOI 10.1074/jbc.M302803200; Xu CG, 2005, PROTEOMICS, V5, P3142, DOI 10.1002/pmic.200401128; Xu CX, 2004, RES MICROBIOL, V155, P835, DOI 10.1016/j.resmic.2004.07.001; Ye JQ, 2004, EMBO J, V23, P3187, DOI 10.1038/sj.emboj.7600330	42	160	174	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7568	7577		10.1074/jbc.M512365200	http://dx.doi.org/10.1074/jbc.M512365200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16414958	hybrid			2022-12-25	WOS:000236030900078
J	Kono, M; Dreier, JL; Ellis, JM; Allende, ML; Kalkofen, DN; Sanders, KM; Bielawski, J; Bielawska, A; Hannun, YA; Proia, RL				Kono, M; Dreier, JL; Ellis, JM; Allende, ML; Kalkofen, DN; Sanders, KM; Bielawski, J; Bielawska, A; Hannun, YA; Proia, RL			Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,2-DIMETHYLHYDRAZINE-TREATED CF1 MICE; ALKALINE SPHINGOMYELINASE ACTIVITY; HUMAN ACID CERAMIDASE; FULL-LENGTH CDNA; MOLECULAR-CLONING; GASTROINTESTINAL-TRACT; COLON-CANCER; CRYPT FOCI; METABOLISM; RAT	Complex sphingolipids are abundant as eukaryotic cell membrane components, whereas their metabolites, in particular ceramide, sphingosine, and sphingosine 1-phosphate, are involved in diverse cell signaling processes. In mammals, degradation of ceramide by ceramidase yields sphingosine, which is phosphorylated by the action of sphingosine kinase to generate sphingosine 1-phosphate. Therefore, ceramidases are key enzymes in the regulation of the cellular levels of ceramide, sphingosine, and sphingosine 1-phosphate. To explore the physiological functions of a neutral ceramidase with diverse cellular locations, we disrupted the Asah2 gene in mice. Asah2 null mice have a normal life span and do not show obvious abnormalities or major alterations in total ceramide levels in tissues. The Asah2-encoded neutral ceramidase is highly expressed in the small intestine along the brush border, suggesting that the neutral ceramidase may be involved in a pathway for the digestion of dietary sphingolipids. Indeed, Asah2 null mice were deficient in the intestinal degradation of ceramide. Thus, the results indicate that the Asah2-encoded neutral ceramidase is a key enzyme for the catabolism of dietary sphingolipids and regulates the levels of bioactive sphingolipid metabolites in the intestinal tract.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Medical University of South Carolina	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Kono, Mari/0000-0003-2447-4350; Stephanos, Kathleen/0000-0001-7170-0627; Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340, Z01DK056017, Z01DK056000] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [DK 59340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIELAWSKI J, 2006, IN PRESS METHODS; Choi MS, 2003, GENE, V315, P113, DOI 10.1016/S0378-1119(03)00721-2; DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615; Duan RD, 2003, J BIOL CHEM, V278, P38528, DOI 10.1074/jbc.M305437200; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu YJ, 1999, J CLIN INVEST, V103, P497, DOI 10.1172/JCI5542; Lundgren P, 2001, DIGEST DIS SCI, V46, P765, DOI 10.1023/A:1010792031910; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; MOSER HW, 2001, METABOLIC MOL BASES, V3, P3573; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; NILSSON A, 1968, BIOCHIM BIOPHYS ACTA, V164, P575, DOI 10.1016/0005-2760(68)90187-2; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V187, P113, DOI 10.1016/0005-2760(69)90138-6; Nilsson A, 1999, CHEM PHYS LIPIDS, V102, P97, DOI 10.1016/S0009-3084(99)00078-X; Okino N, 2002, BIOCHEM BIOPH RES CO, V299, P160, DOI 10.1016/S0006-291X(02)02540-8; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Schmelz EM, 2004, FRONT BIOSCI-LANDMRK, V9, P2632, DOI 10.2741/1422; Schmelz EM, 2000, J NUTR, V130, P522, DOI 10.1093/jn/130.3.522; SCHMELZ EM, 1994, J NUTR, V124, P702, DOI 10.1093/jn/124.5.702; Schmelz EM, 1996, CANCER RES, V56, P4936; Schmelz EM, 2001, CANCER RES, V61, P6723; Smith WL, 2002, J BIOL CHEM, V277, P25841, DOI 10.1074/jbc.R200011200; SULLARDS MC, 2001, SCI STKE, V67, P1; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Symolon H, 2004, J NUTR, V134, P1157, DOI 10.1093/jn/134.5.1157; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Vesper H, 1999, J NUTR, V129, P1239, DOI 10.1093/jn/129.7.1239; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; Yoshimura Y, 2004, J BIOL CHEM, V279, P44012, DOI 10.1074/jbc.M405598200; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215	43	111	115	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7324	7331		10.1074/jbc.M508382200	http://dx.doi.org/10.1074/jbc.M508382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16380386	hybrid			2022-12-25	WOS:000236030900051
J	Lu, XH; Gross, AW; Lodish, HF				Lu, XH; Gross, AW; Lodish, HF			Active conformation of the erythropoietin receptor - Random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; SIGNAL-TRANSDUCTION; INDEPENDENT ACTIVATION; ENDOPLASMIC-RETICULUM; PSEUDOKINASE DOMAIN; POINT MUTATION; LIGAND; JAK2; GENERATION; RESIDUES	In the absence of erythropoietin (Epo) cell surface Epo receptors (EpoR) are dimeric; dimerization is mediated mainly by the transmembrane domain. Binding of Epo changes the orientation of the two receptor subunits. This conformational change is transmitted through the juxtamembrane and transmembrane domains, leading to activation of JAK2 kinase and induction of proliferation and survival signals. To define the active EpoR conformation(s) we screened libraries of EpoRs with random mutations in the transmembrane domain and identified several point mutations that activate the EpoR in the absence of ligand, including changes of either of the first two transmembrane domain residues (Leu(226) and Ile(227)) to cysteine. Following this discovery, we performed cysteine-scanning mutagenesis in the EpoR juxtamembrane and transmembrane domains. Many mutants formed disulfide-linked receptor dimers, but only EpoR dimers linked by cysteines at positions 223, 226, or 227 activated EpoR signal transduction pathways and supported proliferation of Ba/F3 cells in the absence of cytokines. These data suggest that activation of dimeric EpoR by Epo binding is achieved by reorienting the EpoR transmembrane and the connected cytosolic domains and that certain disulfide-bonded dimers represent the activated dimeric conformation of the EpoR, constitutively activating downstream signaling. Based on our data and the previously determined structure of Epo bound to a dimer of the EpoR extracellular domain, we present a model of the active and inactive conformations of the Epo receptor.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu			NHLBI NIH HHS [P01 HL 32262, 5F32 HL 077036] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL077036, P01HL032262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe M, 2002, LEUKEMIA, V16, P1500, DOI 10.1038/sj.leu.2402554; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	29	75	80	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7002	7011		10.1074/jbc.M512638200	http://dx.doi.org/10.1074/jbc.M512638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16414957	hybrid			2022-12-25	WOS:000236030900013
J	Durham, JT; Brand, OM; Arnold, M; Reynolds, JG; Muthukumar, L; Weiler, H; Richardson, JA; Naya, FJ				Durham, JT; Brand, OM; Arnold, M; Reynolds, JG; Muthukumar, L; Weiler, H; Richardson, JA; Naya, FJ			Myospryn is a direct transcriptional target for MEF2A that encodes a striated muscle, alpha-actinin-interacting, costamere-localized protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER; DOMAIN; HEART; DIFFERENTIATION; REQUIREMENT; EXPRESSION; DEFICIENT; MUTATIONS; DYSBINDIN; FORM	The full repertoire of proteins that comprise the striated muscle Z-disc and peripheral structures, such as the costamere, have yet to be discovered. Recent studies suggest that this elaborate protein network, which acts as a structural and signaling center for striated muscle, harbors factors that function as mechanosensors to ensure coordinated contractile activity. Mutations in genes whose products reside in this region often result in skeletal and cardio myopathies, demonstrating the importance of this macromolecular complex in muscle structure and function. Here, we describe the characterization of a direct, downstream target gene for the MEF2A transcription factor encoding a large, muscle-specific protein that localizes to the costamere in striated muscle. This gene, called myospryn, was identified by microarray analysis as a transcript down-regulated in MEF2A knock-out mice. MEF2A knock-out mice develop cardiac failure during the perinatal period with mutant hearts exhibiting several cardiac abnormalities including myofibrillar disarray. Myospryn is the mouse ortholog of a partial human cDNA of unknown function named cardiomyopathy-associated gene 5 (CMYA5). Myospryn is expressed as a single, large transcript of similar to 12 kilobases in adult heart and skeletal muscle with an open reading frame of 3739 amino acids. This protein, belonging to the tripartite motif superfamily of proteins, contains a B-box coiled-coil ( BBC), two fibronectin type III (FN3) repeats, and SPRY domains and interacts with the sarcomeric Z-disc protein, alpha-actinin-2. Our findings demonstrate that myospryn functions directly downstream of MEF2A at the costamere in striated muscle potentially playing a role in myofibrillogenesis.	Boston Univ, Dept Biol, Cell & Mol Biol Program, Boston, MA 02215 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Med Coll Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA	Boston University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Medical College of Wisconsin; Versiti Blood Center of Wisconsin	Naya, FJ (corresponding author), Boston Univ, Dept Biol, Cell & Mol Biol Program, 24 Cummington St, Boston, MA 02215 USA.	fnaya@bu.edu	Arnold, Michael/GPW-8074-2022	Arnold, Michael/0000-0002-6921-3720	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073304] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73304] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Benson MA, 2001, J BIOL CHEM, V276, P24232, DOI 10.1074/jbc.M010418200; Benson MA, 2004, J BIOL CHEM, V279, P10450, DOI 10.1074/jbc.M312664200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Clark KA, 2002, ANNU REV CELL DEV BI, V18, P637, DOI 10.1146/annurev.cellbio.18.012502.105840; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; Ervasti JM, 2003, J BIOL CHEM, V278, P13591, DOI 10.1074/jbc.R200021200; GONZALEZ P, 2005, IN PRESS J MED GENET; Hauser MA, 2000, HUM MOL GENET, V9, P2141, DOI 10.1093/hmg/9.14.2141; Kajimoto K, 2005, CIRC J, V69, P1192, DOI 10.1253/circj.69.1192; Knoll R, 2002, CELL, V111, P943, DOI 10.1016/s0092-8674(02)01226-6; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Moreira ES, 2000, NAT GENET, V24, P163, DOI 10.1038/72822; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rybkin II, 2003, J BIOL CHEM, V278, P15927, DOI 10.1074/jbc.M213102200; Slack FJ, 1998, TRENDS BIOCHEM SCI, V23, P474, DOI 10.1016/S0968-0004(98)01299-7; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; Torok M, 2001, DIFFERENTIATION, V67, P63, DOI 10.1046/j.1432-0436.2001.067003063.x; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Weng L, 2005, J CLIN INVEST, V115, P1016, DOI 10.1172/JCI24186; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092; Zolk O, 2000, CIRCULATION, V101, P2674, DOI 10.1161/01.CIR.101.23.2674	30	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6841	6849		10.1074/jbc.M510499200	http://dx.doi.org/10.1074/jbc.M510499200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407236	hybrid			2022-12-25	WOS:000236030800082
J	Mishra, VK; Anantharamaiah, GM; Segrest, JP; Palgunachari, MN; Chaddha, M; Sham, SWS; Krishna, NR				Mishra, VK; Anantharamaiah, GM; Segrest, JP; Palgunachari, MN; Chaddha, M; Sham, SWS; Krishna, NR			Association of a model class a (apolipoprotein) amphipathic alpha helical peptide with lipid - High resolution NMR studies of peptide-lipid discoidal complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SECONDARY STRUCTURE; CHEMICAL-SHIFTS; MEMBRANE INTERACTIONS; BIOLOGICAL-ACTIVITY; DISTANCE GEOMETRY; AMINO-ACIDS; ATHEROSCLEROSIS; ANALOGS; LIPOPROTEINS	Class A amphipathic helical peptides have been shown to mimic apolipoprotein A-I, the major protein component of high density lipoproteins and have been shown to inhibit atherosclerosis in several dyslipidemic mouse models. Previously we reported the NMR structure of Ac-18A-NH2, the base-line model class A amphipathic helical peptide in a 50% (v/v) trifluoroethanol-d(3)/water mixture, a membrane-mimic environment (Mishra, V. K., Palgunachari, M. N., Anantharamaiah, G. M., Jones, M. K., Segrest, J. P., and Krishna, N. R. ( 2001) Peptides 22, 567 - 573). The peptide Ac-18A-NH2 forms discoidal nascent high density lipoprotein-like particles with 1,2-dimyristoyl-sn-glycero-3-phosphocholine. Because subtle structural changes in the peptide . lipid complexes have been shown to be responsible for their antiatherogenic properties, we undertook high resolution NMR studies to deduce detailed structure of recombinant peptide . 1,2-dimyristoyl-sn-glycero-3-phosphocholine complexes. The peptide adopts a well defined amphipathic alpha helical structure in association with the lipid at a 1: 1 peptide: lipid weight ratio. Nuclear Overhauser effect spectroscopy revealed a number of intermolecular close contacts between the aromatic residues in the hydrophobic face of the helix and the lipid acyl chain protons. The pattern of observed peptide-lipid nuclear Overhauser effects is consistent with a parallel orientation of the amphipathic alpha helix, with respect to the plane of the lipid bilayer, on the edge of the disc ( the belt model). Based on the results of chemical cross-linking and molecular modeling, we propose that peptide helices are arranged in a head to tail fashion to cover the edge of the disc. This arrangement of peptides is also consistent with the pK(a) values of the Lys residues determined previously. Taken together, these results provide for the first time a high resolution structural view of the peptide . lipid discoidal complexes formed by a class A amphipathic alpha helical peptide.	Univ Alabama Birmingham, Birmingham Med Ctr, Dept Med, Atherosclerosis Res Unit, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Birmingham Med Ctr, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Birmingham Med Ctr, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Anantharamaiah, GM (corresponding author), Univ Alabama Birmingham, Birmingham Med Ctr, Dept Med, Atherosclerosis Res Unit, D806,1808 7th Ave S, Birmingham, AL 35294 USA.	vmishra@uab.edu; ananth@uab.edu; NRKrishna@bmg.bhs.uab.edu	Mishra, Vinod/S-1151-2019	Mishra, Vinod/0000-0002-4527-1512	NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13148] Funding Source: Medline; NHLBI NIH HHS [P01 HL34343, P01 HL034343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; BASUS VJ, 1989, METHOD ENZYMOL, V177, P132; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; CHUNG BH, 1985, J BIOL CHEM, V260, P256; Datta G, 2004, J BIOL CHEM, V279, P26509, DOI 10.1074/jbc.M314276200; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; Epand RM, 2004, J BIOL CHEM, V279, P51404, DOI 10.1074/jbc.M408581200; Epand RM, 2004, BIOCHEMISTRY-US, V43, P5073, DOI 10.1021/bi049786u; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; Gurtovenko AA, 2004, BIOPHYS J, V86, P3461, DOI 10.1529/biophysj.103.038760; Hristova K, 1999, J MOL BIOL, V290, P99, DOI 10.1006/jmbi.1999.2840; HWANG TL, 1992, J AM CHEM SOC, V114, P3157, DOI 10.1021/ja00034a083; KUNTZ ID, 1991, J AM CHEM SOC, V113, P1406, DOI 10.1021/ja00004a050; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li L, 2004, J MOL BIOL, V343, P1293, DOI 10.1016/j.jmb.2004.09.017; LUNDKATZ S, 1995, BIOCHEMISTRY-US, V34, P9219, DOI 10.1021/bi00028a035; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; Mishra VK, 2001, PEPTIDES, V22, P567, DOI 10.1016/S0196-9781(01)00365-5; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKAI TT, 1993, BIOCHEMISTRY-US, V32, P5650, DOI 10.1021/bi00072a022; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Tangirala RK, 1999, CIRCULATION, V100, P1816, DOI 10.1161/01.CIR.100.17.1816; VENKATACHALAPATHI YV, 1993, PROTEINS, V15, P349, DOI 10.1002/prot.340150403; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042; Zhu HL, 2004, BIOCHEMISTRY-US, V43, P13156, DOI 10.1021/bi0487894	39	49	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6511	6519		10.1074/jbc.M511475200	http://dx.doi.org/10.1074/jbc.M511475200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407255	hybrid			2022-12-25	WOS:000236030800046
J	Panwar, SL; Moye-Rowley, WS				Panwar, SL; Moye-Rowley, WS			Long chain base tolerance in Saccharomyces cerevisiae is induced by retrograde signals from the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; MULTIDRUG-RESISTANCE; N-GLYCOSYLATION; TRANSCRIPTIONAL CONTROL; VACUOLAR DEGRADATION; YEAST SACCHAROMYCES; ALKALINE CERAMIDASE; GENE-PRODUCT; GENOME-WIDE; TRANSPORTER	Saccharomyces cerevisiae cells lacking their mitochondrial DNA (rho(0) cells) respond to this loss of genetic information by induction of a program of nuclear gene expression called the retrograde response. Expression of genes involved in multidrug resistance and sphingolipid biosynthesis is coordinately induced in rho(0) cells by the zinc cluster transcription factor Pdr3p. In this report, we identify a membrane protein involved in control of intracellular levels of a sphingolipid precursor as a transcriptional target of the Pdr3p-mediated retrograde response. These sphingolipid precursors are called long chain bases (LCBs) and increased LCB levels are growth inhibitory. This membrane protein has been designated Rsb1p and has previously been shown to act as a LCB transporter protein and to be a component of the endoplasmic reticulum. These earlier studies used an amino-terminal truncated form of Rsb1p. Here we employ a full-length form of Rsb1p and find that this protein is localized to the plasma membrane and is modified by N-linked glycosylation. Two glycosylation sites are present in the Rsb1p and both are required for normal LCB resistance. Mutational analysis of the RSB1 promoter revealed that two Pdr3p binding sites are present and both of these are required for normal retrograde induction of transcription. LCB tolerance is strongly increased in rho(0) cells but this increase is ablated in rho(0) rsb1 Delta cells. Together, these data indicate Pdr3p activation of RSB1 transcription is an important feature of the retrograde response allowing normal detoxification of an endogenous sphingolipid precursor.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 6-530 Bowen Sci Bldg, Iowa City, IA 52242 USA.	scott-moye-rowley@uiowa.edu	Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120				Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2002, FEBS LETT, V515, P25, DOI 10.1016/S0014-5793(02)02387-6; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Gerami-Nejad M, 2001, YEAST, V18, P859, DOI 10.1002/yea.738; Gilstring CF, 2000, J BIOL CHEM, V275, P31488, DOI 10.1074/jbc.M005047200; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Hallstrom TC, 2001, J BIOL CHEM, V276, P23674, DOI 10.1074/jbc.M101568200; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; Kihara A, 2004, MOL BIOL CELL, V15, P4949, DOI 10.1091/mbc.E04-06-0458; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; Kolaczkowski M, 2004, EUKARYOT CELL, V3, P880, DOI 10.1128/EC.3.4.880-892.2004; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Mandala SM, 1998, J BIOL CHEM, V273, P14942, DOI 10.1074/jbc.273.24.14942; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Marini AM, 2000, MOL MICROBIOL, V38, P552, DOI 10.1046/j.1365-2958.2000.02151.x; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Moye-Rowley WS, 2003, PROG NUCLEIC ACID RE, V73, P251, DOI 10.1016/S0079-6603(03)01008-0; Ogawa A, 1998, ANTIMICROB AGENTS CH, V42, P755, DOI 10.1128/AAC.42.4.755; Pohl A, 2005, BBA-MOL CELL BIOL L, V1733, P29, DOI 10.1016/j.bbalip.2004.12.007; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F, 1979, METHODS YEAST GENETI; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Tanaka K, 2004, J BIOL CHEM, V279, P14961, DOI 10.1074/jbc.M400197200; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Yan AX, 2005, J BIOL CHEM, V280, P3121, DOI 10.1074/jbc.R400036200; Zhang XT, 2001, J BIOL CHEM, V276, P47844, DOI 10.1074/jbc.M106285200; Zhang XT, 2005, J BIOL CHEM, V280, P2759, DOI 10.1074/jbc.M408333200	53	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6376	6384		10.1074/jbc.M512115200	http://dx.doi.org/10.1074/jbc.M512115200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407254	hybrid			2022-12-25	WOS:000236030800031
J	Anrather, J; Racchumi, G; Iadecola, C				Anrather, J; Racchumi, G; Iadecola, C			NF-kappa B regulates phagocytic NADPH oxidase by inducing the expression of gp91(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; MYELOID DIFFERENTIATION; PROMOTER ACTIVITY; NAD(P)H OXIDASE; GENE-EXPRESSION; MOLECULAR-BASIS; NITRIC-OXIDE	The superoxide-generating phagocytic NADPH oxidase is an important component of the innate immune response against microbial agents, and is involved in shaping the cellular response to a variety of physiological and pathological signals. One of the downstream targets of NADPH oxidase-derived radicals is the ubiquitous transcription factor NF-kappa B, which controls the expression of a large array of genes involved in immune function and cell survival. Here we show that NF-kappa B itself is a key factor in controlling NADPH oxidase expression and function. In monocytic and microglial cell lines, the expression of the NADPH oxidase subunit gp91(phox) was induced by lipopolysaccharide/interferon gamma treatment and was inhibited in cells constitutively expressing I kappa B alpha. Furthermore, inducible reactive oxygen species production was inhibited in I kappa B alpha overexpressing cells. gp91(phox) expression was very low in RelA(-/-) fibroblasts and could be induced by reconstituting these cells with p65/RelA. Thus, gp91(phox) expression is dependent on the presence of p65/RelA. We also found that gp91(phox) transcription is dependent on NF-kappa B and we identified two potential cis-acting elements in the murine gp91(phox) promoter that control NF-kappa B-dependent regulation. The findings raise the possibility of a positive feedback loop in which NF-kappa B activation by oxidative stress leads to further radical production via NADPH oxidase.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, Div Neurobiol, New York, NY 10021 USA	Cornell University	Anrather, J (corresponding author), 411 E 69th St KB410, New York, NY 10021 USA.	joa2006@med.cornell.edu	Iadecola, c/ABB-8377-2020	Iadecola, Costantino/0000-0001-9797-073X	NHLBI NIH HHS [HL 018974, HL 077308] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077308, P01HL018974] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ago T, 2005, STROKE, V36, P1040, DOI 10.1161/01.STR.0000163111.05825.0b; Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70; Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Aviram M, 1996, METABOLISM, V45, P1069, DOI 10.1016/S0026-0495(96)90005-0; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; Basile JR, 2003, MOL CANCER RES, V1, P262; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bei L, 2005, J BIOL CHEM, V280, P12359, DOI 10.1074/jbc.M408138200; Bengtsson SH, 2003, CLIN EXP PHARMACOL P, V30, P849, DOI 10.1046/j.1440-1681.2003.03929.x; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Brostjan C, 1997, J IMMUNOL, V158, P3836; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; Cathcart MK, 2004, ARTERIOSCL THROM VAS, V24, P23, DOI 10.1161/01.ATV.0000097769.47306.12; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; Chamseddine AH, 2003, AM J PHYSIOL-HEART C, V285, pH2284, DOI 10.1152/ajpheart.00459.2003; Clark RA, 2004, MECH AGEING DEV, V125, P799, DOI 10.1016/j.mad.2004.08.009; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Fan J, 2002, J BIOL CHEM, V277, P3404, DOI 10.1074/jbc.M110054200; Fujii Y, 2003, MICROBIOL IMMUNOL, V47, P803, DOI 10.1111/j.1348-0421.2003.tb03438.x; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; GREENBERG ME, 1997, IDENTIFICATION NEWLY; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; Kazama K, 2004, CIRC RES, V95, P1019, DOI 10.1161/01.RES.0000148637.85595.c5; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Li SL, 1997, J BIOL CHEM, V272, P17802, DOI 10.1074/jbc.272.28.17802; Li SL, 2001, J BIOL CHEM, V276, P39368, DOI 10.1074/jbc.M106111200; Li SL, 2002, BLOOD, V99, P4578, DOI 10.1182/blood.V99.12.4578; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MOST J, 1992, J IMMUNOL, V148, P1635; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park L, 2005, J NEUROSCI, V25, P1769, DOI 10.1523/JNEUROSCI.5207-04.2005; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Skalnik DG, 2002, GENE, V284, P1, DOI 10.1016/S0378-1119(02)00387-6; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085; Tammariello SP, 2000, J NEUROSCI, V20; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Xu P, 1996, GENOMICS, V34, P173, DOI 10.1006/geno.1996.0262	60	272	286	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5657	5667		10.1074/jbc.M506172200	http://dx.doi.org/10.1074/jbc.M506172200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407283	hybrid			2022-12-25	WOS:000235568900042
J	Kempe, DS; Lang, PA; Duranton, C; Akel, A; Lang, KS; Huber, SM; Wieder, T; Lang, F				Kempe, Daniela S.; Lang, Philipp A.; Duranton, Christophe; Akel, Ahmad; Lang, Karl S.; Huber, Stephan M.; Wieder, Thomas; Lang, Florian			Enhanced programmed cell death of iron-deficient erythrocytes	FASEB JOURNAL			English	Article									[Lang, Florian] Univ Tubingen, Inst Physiol, Dept Physiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Lang, F (corresponding author), Univ Tubingen, Inst Physiol, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	florian.lang@uni-tuebingen.de	Lang, Karl S/R-2505-2016; DURANTON, CHRISTOPHE/E-9582-2019	DURANTON, CHRISTOPHE/0000-0003-1127-2346; Huber, Stephan/0000-0002-9430-8334; Lang, Karl/0000-0001-9783-7605					0	211	214	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					368	370		10.1096/fj.05-4872fje	http://dx.doi.org/10.1096/fj.05-4872fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371427				2022-12-25	WOS:000207915000024
J	Sakai, K; Arao, T; Shimoyama, T; Murofushi, K; Sekijima, M; Kaji, N; Tamura, T; Saijo, N; Nishio, K				Sakai, Kazuko; Arao, Tokuzo; Shimoyama, Tatsu; Murofushi, Kimiko; Sekijima, Masaru; Kaji, Naoko; Tamura, Tomohide; Saijo, Nagahiro; Nishio, Kazuto			Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor	FASEB JOURNAL			English	Article									[Nishio, Kazuto] Natl Canc Ctr, Shien Lab, Chuo Ku, Tokyo 1040045, Japan; [Nishio, Kazuto] Natl Canc Ctr, Res Inst, Div Pharmacol, Tokyo 104, Japan; [Sakai, Kazuko; Murofushi, Kimiko] Ochanomizu Univ, Fac Sci, Dept Biol, Tokyo 112, Japan; [Sekijima, Masaru; Kaji, Naoko] Mitsubishi Chem Safety Inst Ltd, Ibaraki, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Ochanomizu University; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical Safety Institute	Nishio, K (corresponding author), Natl Canc Ctr, Shien Lab, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	knishio@gan2.res.ncc.go.jp							0	37	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					311	313		10.1096/fj.05-4034fje	http://dx.doi.org/10.1096/fj.05-4034fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16373402				2022-12-25	WOS:000207915000004
J	Kojro, E; Postina, R; Buro, C; Meiringer, C; Gehrig-Burger, K; Fahrenholz, F				Kojro, E; Postina, R; Buro, C; Meiringer, C; Gehrig-Burger, K; Fahrenholz, F			The neuropeptide PACAP promotes alpha-secretase pathway for processing Alzheimer amyloid precursor protein	FASEB JOURNAL			English	Article						PAC(1) recepter; GPCR; ADAM 10	CYCLASE-ACTIVATING POLYPEPTIDE; SIGNAL-REGULATED KINASE; NECROSIS-FACTOR-ALPHA; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; NEURITE OUTGROWTH; COUPLED RECEPTORS; RAT-BRAIN; CONVERTING-ENZYME; TYROSINE KINASE	The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) has neurotrophic as well as anti-apoptotic properties and is involved in learning and memory processes. Its specific G protein-coupled receptor PAC(1) is expressed in several central nervous system (CNS) regions, including the hippocampal formation. Here we examined the effect of PAC1 receptor activation on alpha-secretase cleavage of the amyloid precursor protein (APP) and the production of secreted APP (APPs alpha). Stimulation of endogenously expressed PAC1 receptors with PACAP in human neuroblastoma cells increased APPsa secretion, which was completely inhibited by the PAC1 receptor specific antagonist PACAP-(6-38). In HEK cells, stably overexpressing the functional PAC1 receptors PACAP- 27 and PACAP- 38 strongly stimulated alpha-secretase cleavage of APP. The PACAP-induced APPsa production was dose dependent and saturable. This increase of alpha-secretase activity was completely abolished by hydroxamate-based metalloproteinase inhibitors, including a preferential ADAM 10 inhibitor. By using several specific protein kinase inhibitors, we show that the MAP-kinase pathway [including extracellular-regulated kinase (ERK) 1 and ERK2] and phosphatidylinositol 3-kinase mediate the PACAP- induced alpha-secretase activation. Our findings provide evidence for a role of the neuropeptide PACAP in stimulation of the nonamyloidogenic pathway, which might be related to its neuroprotective properties.	Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany	Johannes Gutenberg University of Mainz	Kojro, E (corresponding author), Johannes Gutenberg Univ Mainz, Inst Biochem, D-55128 Mainz, Germany.	kojro@uni-mainz.de; bio.chemie@uni-mainz.de						Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BASILLE M, 1995, J NEUROCHEM, V65, P1318; Bhave SV, 2004, J NEUROCHEM, V88, P359, DOI 10.1046/j.1471-4159.2003.02167.x; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Caille I, 2004, DEVELOPMENT, V131, P2173, DOI 10.1242/dev.01103; Canet-Aviles RM, 2002, MOL BRAIN RES, V102, P62, DOI 10.1016/S0169-328X(02)00184-5; Cappai R, 1999, FEBS LETT, V442, P95, DOI 10.1016/S0014-5793(98)01635-4; CAUVIN A, 1991, REGUL PEPTIDES, V35, P161, DOI 10.1016/0167-0115(91)90478-Y; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; Crespo Piero, 2004, Methods Mol Biol, V250, P203; Dogrukol-Ak D, 2004, CURR PHARM DESIGN, V10, P1325, DOI 10.2174/1381612043384934; Efthimiopoulos S, 1996, J NEUROCHEM, V67, P872; Eggenberger M, 1999, NEUROPEPTIDES, V33, P107, DOI 10.1054/npep.1999.0004; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO Z, 1998, INORG CHIM ACTA, V1, P273; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Joo KM, 2004, J COMP NEUROL, V476, P388, DOI 10.1002/cne.20231; Kojro E, 2005, SUB CELL BIOCHEM, V38, P105; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lazarovici P, 1998, MOL PHARMACOL, V54, P547, DOI 10.1124/mol.54.3.547; Lee RKK, 1997, J NEUROCHEM, V68, P1830; Little KD, 2004, MOL BIOL CELL, V15, P2375, DOI 10.1091/mbc.E03-12-0886; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Moroo I, 1998, BRAIN RES, V795, P191, DOI 10.1016/S0006-8993(98)00291-1; Mucke L, 1996, ANN NY ACAD SCI, V777, P82, DOI 10.1111/j.1749-6632.1996.tb34405.x; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Nielsen KM, 2004, MOL CELL NEUROSCI, V25, P629, DOI 10.1016/j.mcn.2003.12.004; Nitsch RM, 2000, ANN NEUROL, V48, P913, DOI 10.1002/1531-8249(200012)48:6<913::AID-ANA12>3.3.CO;2-J; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; Parkin ET, 2002, BIOCHEMISTRY-US, V41, P4972, DOI 10.1021/bi015936e; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Petanceska SS, 1999, J NEUROCHEM, V73, P2316, DOI 10.1046/j.1471-4159.1999.0732316.x; Pisegna JR, 1996, J BIOL CHEM, V271, P17267, DOI 10.1074/jbc.271.29.17267; Postina R, 2004, J CLIN INVEST, V113, P1456, DOI 10.1172/JCI200420864; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Reglodi D, 2000, ANN NY ACAD SCI, V921, P119; ROBBERECHT P, 1992, MOL PHARMACOL, V42, P347; Sacchetti B, 2001, NEUROBIOL LEARN MEM, V76, P1, DOI 10.1006/nlme.2001.4014; Sakai Y, 2004, MOL BRAIN RES, V123, P18, DOI 10.1016/j.molbrainres.2003.12.013; Sanderson MP, 2005, J BIOL CHEM, V280, P1826, DOI 10.1074/jbc.M408804200; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SUDA K, 1991, J CLIN ENDOCR METAB, V72, P958, DOI 10.1210/jcem-72-5-958; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2000, PHARMACOL REV, V52, P269; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Xu HX, 1996, P NATL ACAD SCI USA, V93, P4081, DOI 10.1073/pnas.93.9.4081; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou CJ, 2001, PEPTIDES, V22, P1111, DOI 10.1016/S0196-9781(01)00437-5; Zimmermann M, 2004, J NEUROCHEM, V90, P1489, DOI 10.1111/j.1471-4159.2004.02680.x	64	92	99	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					512	+		10.1096/fj.05-4812fje	http://dx.doi.org/10.1096/fj.05-4812fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16401644				2022-12-25	WOS:000235996000033
J	Steelman, CA; Recknor, JC; Nettleton, D; Reecy, JM				Steelman, CA; Recknor, JC; Nettleton, D; Reecy, JM			Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy	FASEB JOURNAL			English	Article						microarray; Wnt4; satellite cells	SATELLITE CELL ACTIVATION; TGF-BETA; GENE-EXPRESSION; PROMOTES PROLIFERATION; FAMILY PROTEINS; DIFFERENTIATION; MYOGENESIS; PATHWAY; MYF5; MYOD	Myostatin is an inhibitor of skeletal muscle growth. Disruption of the Mstn gene in mice results in muscles that weigh two to three times those of controls, but precisely how myostatin signals to exert its effects on muscle is unclear. We used the Affymetrix GeneChip system to identify differences in gene expression between myostatin null and wild-type mice. The results indicated a switch in muscle fiber type, from slow to fast, in the absence of myostatin. They also indicated that myostatin may act upstream of Wnt pathway components. Notably, it repressed expression of Wnt4. Wnt4 was capable of stimulating satellite cell proliferation, while inhibition of Wnt signaling down-regulated satellite cell proliferation. This evidence points to a role for Wnt/calcium signaling in the growth and maintenance of postnatal skeletal muscle. This study offers new insight into potential downstream targets of myostatin, which will be beneficial for elucidation of the mechanism through which myostatin acts to inhibit muscle growth.	Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA; Iowa State Univ, Dept Stat, Ames, IA 50011 USA	Iowa State University; Iowa State University	Reecy, JM (corresponding author), Iowa State Univ, Dept Anim Sci, 2255 Kildee Hall, Ames, IA 50011 USA.	jreecy@iastate.edu		Nettleton, Dan/0000-0002-6045-1036; Reecy, James/0000-0003-4602-0990				Anakwe K, 2003, DEVELOPMENT, V130, P3503, DOI 10.1242/dev.00538; Armstrong DD, 2005, AM J PHYSIOL-CELL PH, V289, pC853, DOI 10.1152/ajpcell.00093.2005; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284; Bouley J, 2005, PROTEOMICS, V5, P490, DOI 10.1002/pmic.200400925; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Carlson CJ, 1999, AM J PHYSIOL-REG I, V277, pR601, DOI 10.1152/ajpregu.1999.277.2.R601; Carson JA, 2001, FASEB J, V15, P207, DOI 10.1096/fj.01-0544fje; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Chakravarthy MV, 2001, CELL MOL LIFE SCI, V58, P1150, DOI 10.1007/PL00000929; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Cooper RN, 1999, J CELL SCI, V112, P2895; Csete M, 2001, J CELL PHYSIOL, V189, P189, DOI 10.1002/jcp.10016; CULLEY G, 1807, OBSERVATIONS LIVESTO; De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Fan CM, 1997, DEV BIOL, V191, P160, DOI 10.1006/dbio.1997.8713; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Galli LM, 2004, DEV BIOL, V269, P489, DOI 10.1016/j.ydbio.2004.01.041; Girgenrath S, 2005, MUSCLE NERVE, V31, P34, DOI 10.1002/mus.20175; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Hanset R., 1986, Exploiting new technologies in animal breeding. Genetic developments., P71; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Kamanga-Sollo E, 2003, J CELL PHYSIOL, V197, P225, DOI 10.1002/jcp.10362; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Ladher RK, 2000, DEV BIOL, V218, P183, DOI 10.1006/dbio.1999.9586; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martyn JK, 2004, ANAT REC PART A, V281A, P1363, DOI 10.1002/ar.a.20140; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Ouko L, 2004, J BIOL CHEM, V279, P26707, DOI 10.1074/jbc.M402877200; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Philip B, 2005, CELL SIGNAL, V17, P365, DOI 10.1016/j.cellsig.2004.08.003; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Renzoni EA, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-24; Rios R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; ROBERTSON TA, 1993, NEUROPATH APPL NEURO, V19, P350, DOI 10.1111/j.1365-2990.1993.tb00451.x; Rochat A, 2004, MOL BIOL CELL, V15, P4544, DOI 10.1091/mbc.E03-11-0816; Sakamoto K, 2004, BIOCHEM BIOPH RES CO, V319, P419, DOI 10.1016/j.bbrc.2004.05.020; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; SCHULTZ E, 1985, MUSCLE NERVE, V8, P217, DOI 10.1002/mus.880080307; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Tajbakhsh S, 1996, NATURE, V384, P266, DOI 10.1038/384266a0; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wagner J, 2000, DEV BIOL, V228, P86, DOI 10.1006/dbio.2000.9921; Yoshino K, 2001, MECH DEVELOP, V102, P45, DOI 10.1016/S0925-4773(01)00282-9; Zhou SH, 2004, J BONE MINER RES, V19, P463, DOI 10.1359/JBMR.0301239; Zhu XY, 2004, CYTOKINE, V26, P262, DOI 10.1016/j.cyto.2004.03.007	73	98	107	2	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					580	+		10.1096/fj.05-5125fje	http://dx.doi.org/10.1096/fj.05-5125fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423875				2022-12-25	WOS:000235996000012
J	Horndasch, M; Lienkamp, S; Springer, E; Schmitt, A; Pavenstadt, H; Walz, G; Gloy, J				Horndasch, M.; Lienkamp, S.; Springer, E.; Schmitt, A.; Pavenstaedt, H.; Walz, G.; Gloy, J.			The C/EBP homologous protein CHOP (GADD153) is an inhibitor of Wnt/TCF signals	ONCOGENE			English	Article						C/EBP; CHOP; TCF; tumour cells; Wnt signalling	TRANSCRIPTION FACTORS C/EBP; BINDING-PROTEIN; BETA-CATENIN; UP-REGULATION; GROWTH ARREST; WNT; APOPTOSIS; PATHWAYS; EXPRESSION; KINASE	CHOP (GADD153) is a protein of the C/EBP family of transcriptional regulators, which dimerizes with other C/EBP members and changes their DNA-binding and transactivation properties. It induces growth arrest and apoptosis after endoplasmatic reticulum stress or DNA damage. CHOP is also expressed during early embryogenesis and upregulated in tumour tissues with defective Wnt signals. We report here that CHOP functions as a specific inhibitor of Wnt/T-cell factor (TCF) signalling. CHOP inhibits TCF-dependent transcription in human embryonic and colon cancer cell lines. Injection of CHOP mRNA into early Xenopus laevis embryos suppresses dorsal organizer formation and inhibits secondary axis formation and TCF-dependent transcription in response to Wnt-8, Dishevelled, beta-Catenin and TCF-VP16. In embryos and human cells, this inhibition depends on the N-terminal transactivation domain of CHOP, whereas the C-terminal dimerization domain is dispensable. CHOP binds to TCF factors, thereby preventing the binding of TCF to its DNA recognition site. Our findings demonstrate a novel function of CHOP as a Wnt repressor.	Univ Hosp Freiburg, Div Nephrol, Dept Med, Freiburg, Germany; UKM Munster, Div Nephrol & Hypertens, Dept Med, Munster, Germany	University of Freiburg; University of Munster	Gloy, J (corresponding author), Zentrum Klin Forsch, Breisacher Str 66, D-79106 Freiburg, Germany.	gloy@med1.ukl.uni-freiburg.de	Lienkamp, Soeren/AAH-6296-2020	Lienkamp, Soeren/0000-0003-2963-6865				BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Conn KJ, 2002, J NEUROSCI RES, V68, P755, DOI 10.1002/jnr.10252; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Fleming JV, 1997, MOL REPROD DEV, V48, P310, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;310::AID-MRD2&gt;3.0.CO;2-U; Fontanier-Razzaq NC, 1999, MOL REPROD DEV, V54, P326, DOI 10.1002/(SICI)1098-2795(199912)54:4&lt;326::AID-MRD2&gt;3.0.CO;2-3; Friedman AD, 1996, CANCER RES, V56, P3250; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Houston DW, 2002, DEVELOPMENT, V129, P4015; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pereira RC, 2004, ENDOCRINOLOGY, V145, P1952, DOI 10.1210/en.2003-0868; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Scott DW, 2004, CARCINOGENESIS, V25, P2155, DOI 10.1093/carcin/bgh239; Sokol SY, 1999, CURR OPIN GENET DEV, V9, P405, DOI 10.1016/S0959-437X(99)80061-6; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Talukder AH, 2002, ONCOGENE, V21, P4289, DOI 10.1038/sj.onc.1205529; Tang QQ, 2000, P NATL ACAD SCI USA, V97, P12446, DOI 10.1073/pnas.220425597; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Ubeda M, 2003, J BIOL CHEM, V278, P40514, DOI 10.1074/jbc.M306404200; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	46	42	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3397	3407		10.1038/sj.onc.1209380	http://dx.doi.org/10.1038/sj.onc.1209380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434966				2022-12-25	WOS:000238448100005
J	Mantoni, TS; Reid, G; Garrett, MD				Mantoni, T. S.; Reid, G.; Garrett, M. D.			Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner	ONCOGENE			English	Article						androgen receptor; genotoxic agents; p53; chemotherapeutics	PROSTATE-SPECIFIC ANTIGEN; RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; PIFITHRIN-ALPHA; HEAT-SHOCK; IN-VIVO; CANCER; PHOSPHORYLATION; CISPLATIN; CELLS	The androgen receptor (AR) is fundamental to androgen signalling within the prostate gland, and deregulation of its activity is frequently linked to the development of prostate cancer. Advanced prostate cancer is often treated with chemotherapy and most of these drugs exert their function by generating genotoxic stress such as DNA damage. We have investigated here the effects of genotoxic agents used in chemotherapeutic regimens on AR function and expression. We have discovered that endogenous AR activity in LNCaP cells is inhibited in response to the chemotherapeutic agents etoposide and cisplatin. This loss of AR activity is not caused by a change in cell cycle distribution, a change in subcellular localisation of the AR nor by induction of apoptosis. In addition, we found that inhibition of AR activity in response to genotoxic stress is independent of p53 function. Interestingly, our studies revealed that genotoxic stress inhibits the hormone-stimulated recruitment of AR to androgen response elements. Thus, we report for the first time a mechanism by which the AR activity is inhibited in response to different chemotherapeutic agents.	Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England; European Mol Biol Lab, Heidelberg, Germany	Cancer Research UK; University of London; Institute of Cancer Research - UK; European Molecular Biology Laboratory (EMBL)	Garrett, MD (corresponding author), Inst Canc Res, Haddow Labs, Canc Res UK Ctr Canc Therapeut, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	michelle.garrett@icr.ac.uk		Reid, George/0000-0002-0298-693X				Black BE, 2004, MOL ENDOCRINOL, V18, P834, DOI 10.1210/me.2003-0145; BRUCHOVSKY N, 1968, J BIOL CHEM, V243, P2012; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Denmeade SR, 2004, PROSTATE, V58, P211, DOI 10.1002/pros.10360; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Espinosa E, 2003, CANCER TREAT REV, V29, P515, DOI 10.1016/S0305-7372(03)00116-6; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Gregory CW, 2001, CANCER RES, V61, P2892; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hoshi Senji, 2003, Int J Clin Oncol, V8, P118, DOI 10.1007/s101470300021; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Linton KD, 2003, CANCER TREAT REV, V29, P151, DOI 10.1016/S0305-7372(03)00096-3; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Marcelli M, 2000, CANCER RES, V60, P944; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Parker CC, 2003, CANCER TREAT REV, V29, P161, DOI 10.1016/S0305-7372(03)00070-7; Pilat MJP, 1998, CANCER METAST REV, V17, P373, DOI 10.1023/A:1006166511344; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Rocha S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-9; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rosenhagen MC, 2003, MOL ENDOCRINOL, V17, P1991, DOI 10.1210/me.2003-0141; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Sciuto R, 2002, J NUCL MED, V43, P79; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Steineck G, 2002, ACTA ONCOL, V41, P668, DOI 10.1080/028418602321028292; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Vaishampayan U, 2004, AM J CLIN ONCOL-CANC, V27, P550, DOI 10.1097/01.coc.0000135922.12198.e4; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wong HY, 2004, BIOCHEM J, V383, P267, DOI 10.1042/BJ20040683; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137	49	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3139	3149		10.1038/sj.onc.1209347	http://dx.doi.org/10.1038/sj.onc.1209347			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16434973				2022-12-25	WOS:000237951000005
J	Nowak, E; Panjikar, S; Konarev, P; Svergun, DI; Tucker, PA				Nowak, E; Panjikar, S; Konarev, P; Svergun, DI; Tucker, PA			The structural basis of signal transduction for the response regulator PrrA from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; 2-COMPONENT SYSTEM; CRYSTAL-STRUCTURE; RECEIVER DOMAIN; ALPHA-SUBUNIT; DNA-BINDING; PHOB; TRANSCRIPTION; MODEL; PHOSPHORYLATION	The structure of the two-domain response regulator PrrA from Mycobacterium tuberculosis shows a compact structure in the crystal with a well defined interdomain interface. The interface, which does not include the interdomain linker, makes the recognition helix and the trans-activation loop of the effector domain inaccessible for interaction with DNA. Part of the interface involves hydrogen-bonding interactions of a tyrosine residue in the receiver domain that is believed to be involved in signal transduction, which, if disrupted, would destabilize the interdomain interface, allowing a more extended conformation of the molecule, which would in turn allow access to the recognition helix. In solution, there is evidence for an equilibrium between compact and extended forms of the protein that is far toward the compact form when the protein is inactivated but moves toward a more extended form when activated by the cognate sensor kinase PrrB.	DESY, European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Tucker, PA (corresponding author), DESY, European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	tucker@embl-hamburg.de	Panjikar, Santosh/D-2709-2012; Konarev, Petr V/W-1380-2017	Panjikar, Santosh/0000-0001-7429-3879; Svergun, Dmitri/0000-0003-0830-5696; Konarev, Petr/0000-0002-5606-1596				Appleby JL, 1998, J BACTERIOL, V180, P3563, DOI 10.1128/JB.180.14.3563-3569.1998; Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett JF, 1998, ANTIMICROB AGENTS CH, V42, P1529, DOI 10.1128/AAC.42.7.1529; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; Bent CJ, 2004, J BACTERIOL, V186, P2872, DOI 10.1128/JB.186.9.2872-2879.2004; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Birck C, 2003, J BACTERIOL, V185, P254, DOI 10.1128/JB.185.1.254-261.2003; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; BOULIN CJ, 1998, NUCL INSTRUM METH A, V269, P312; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buckler DR, 2002, STRUCTURE, V10, P153, DOI 10.1016/S0969-2126(01)00706-7; Djordjevic S, 1998, P NATL ACAD SCI USA, V95, P1381, DOI 10.1073/pnas.95.4.1381; Ellison DW, 2000, J BACTERIOL, V182, P6592, DOI 10.1128/JB.182.23.6592-6597.2000; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ewann F, 2004, MICROBIOL-SGM, V150, P241, DOI 10.1099/mic.0.26516-0; Ewann F, 2002, INFECT IMMUN, V70, P2256, DOI 10.1128/IAI.70.5.2256-2263.2002; Gardino AK, 2003, J MOL BIOL, V331, P245, DOI 10.1016/S0022-2836(03)00733-2; Gouet P, 1999, STRUCTURE, V7, P1517, DOI 10.1016/S0969-2126(00)88342-2; Graham JE, 1999, P NATL ACAD SCI USA, V96, P11554, DOI 10.1073/pnas.96.20.11554; Guillet V, 2002, J BIOL CHEM, V277, P42003, DOI 10.1074/jbc.M204789200; Guinier A., 1939, ANN PHYS-LEIPZIG, DOI DOI 10.1051/ANPHYS/193911120161; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaneko T, 2005, PROTEIN SCI, V14, P558, DOI 10.1110/ps.041170005; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Makino K, 1996, J MOL BIOL, V259, P15, DOI 10.1006/jmbi.1996.0298; MartinezHackert E, 1997, J MOL BIOL, V269, P301, DOI 10.1006/jmbi.1997.1065; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Morth JP, 2005, FEBS LETT, V579, P4145, DOI 10.1016/j.febslet.2005.06.043; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nowak E, 2006, STRUCTURE, V14, P275, DOI 10.1016/j.str.2005.10.006; Okamura H, 2000, J MOL BIOL, V295, P1225, DOI 10.1006/jmbi.1999.3379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Robinson VL, 2003, J BACTERIOL, V185, P4186, DOI 10.1128/JB.185.14.4186-4194.2003; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; SLAUCH JM, 1991, J BACTERIOL, V173, P7501, DOI 10.1128/jb.173.23.7501-7510.1991; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toro-Roman A, 2005, PROTEIN SCI, V14, P3077, DOI 10.1110/ps.051722805; Tyagi JS, 2004, CURR SCI INDIA, V86, P93; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Zahrt TC, 2001, P NATL ACAD SCI USA, V98, P12706, DOI 10.1073/pnas.221272198; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	60	63	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9659	9666		10.1074/jbc.M512004200	http://dx.doi.org/10.1074/jbc.M512004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16434396	hybrid			2022-12-25	WOS:000236404700078
J	Gonda, K; Wudel, J; Nelson, D; Katoku-Kikyo, N; Reed, P; Tamada, H; Kikyo, N				Gonda, K; Wudel, J; Nelson, D; Katoku-Kikyo, N; Reed, P; Tamada, H; Kikyo, N			Requirement of the protein B23 for nucleolar disassembly induced by the FRGY2a family proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I TRANSCRIPTION; MESSENGER-RNA; EMBRYONIC-DEVELOPMENT; NUCLEOPLASMIN FAMILY; NUCLEAR-LOCALIZATION; RIBOSOME BIOGENESIS; XENOPUS-LAEVIS; CELLS; P53; IDENTIFICATION	In Xenopus somatic cell nuclear cloning, the nucleoli of donor nuclei rapidly and almost completely disappear in egg cytoplasm. We previously showed that the germ cell-specific proteins FRGY2a and FRGY2b were responsible for this unusually drastic nucleolar disassembly. The nucleolar disassembly occurs without inhibition of pre-rRNA transcription, a well known trigger for nucleolar segregation, and the mechanism for the nucleolar disassembly by FRGY2a and FRGY2b remains largely unknown. In this study, we searched for FRGY2a-interacting proteins and investigated the functional consequences of their interactions through a series of experiments. We showed that during the nucleolar disassembly, FRGY2a localized to the nucleoli of isolated nuclei and was capable of disassembling purified nucleoli, suggesting a direct interaction between FRGY2a and nucleolar components. Using a His tag pull-down approach, we identified the abundant and multifunctional nucleolar protein B23 as a potential target of FRGY2a and its related human protein YB1. A specific interaction between FRGY2a/YB1 and B23 was confirmed by co-immunoprecipitation. Finally, B23 knockdown using short interfering RNA and a subsequent add-back experiment confirmed that B23 was necessary for nucleolar disassembly by YB1. We propose that FRGY2a and YB1 disassemble nucleoli by sequestering B23, which is associated with pre-ribosomes and other structurally important nucleolar components.	Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kikyo, N (corresponding author), Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Stem Cell Inst, MMC 716,420 Delaware St SE, Minneapolis, MN 55455 USA.	kikyo001@tc.umn.edu			NIGMS NIH HHS [R01 GM068027-03, R01 GM068027-01A1, R01 GM068027-02, R01 GM068027] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068027] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; CAIRNS C, 1995, NUCLEIC ACIDS RES, V23, P4583, DOI 10.1093/nar/23.22.4583; Chen DY, 2001, J CELL BIOL, V153, P169, DOI 10.1083/jcb.153.1.169; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; Gonda K, 2003, NAT CELL BIOL, V5, P205, DOI 10.1038/ncb939; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; GURDON JB, 1965, J MOL BIOL, V12, P27, DOI 10.1016/S0022-2836(65)80279-0; Hernandez-Verdun D, 2002, J CELL SCI, V115, P2265; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Leung AKL, 2003, CRIT REV EUKAR GENE, V13, P39, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i1.40; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Mekhail K, 2004, NAT CELL BIOL, V6, P642, DOI 10.1038/ncb1144; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Pinol-Roma S, 1999, MOL BIOL CELL, V10, P77, DOI 10.1091/mbc.10.1.77; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SCHMIDTZACHMANN MS, 1984, EXP CELL RES, V153, P327, DOI 10.1016/0014-4827(84)90604-9; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Simard R, 1970, Int Rev Cytol, V28, P169, DOI 10.1016/S0074-7696(08)62543-7; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Verheggen C, 1998, J CELL BIOL, V142, P1167, DOI 10.1083/jcb.142.5.1167; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Winokur ST, 1998, HUM MOL GENET, V7, P1947, DOI 10.1093/hmg/7.12.1947; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Yang JX, 2005, P NATL ACAD SCI USA, V102, P5755, DOI 10.1073/pnas.0408718102; Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; Zirwes RF, 1997, P NATL ACAD SCI USA, V94, P11387, DOI 10.1073/pnas.94.21.11387	41	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8153	8160		10.1074/jbc.M512890200	http://dx.doi.org/10.1074/jbc.M512890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415342	Green Accepted, hybrid			2022-12-25	WOS:000236031000053
J	Hakansson, P; Hofer, A; Thelander, L				Hakansson, P; Hofer, A; Thelander, L			Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT MOUSE; RENAL-FAILURE; SMALL-SUBUNIT; CYCLE; REPLICATION; EXPRESSION; PROTEIN; LOCALIZATION; INHIBITION; CHECKPOINT	Ribonucleotide reductase (RNR) provides the cell with a balanced supply of deoxyribonucleoside triphosphates ( dNTP) for DNA synthesis. In budding yeast DNA damage leads to an up-regulation of RNR activity and an increase in dNTP pools, which are essential for survival. Mammalian cells contain three non-identical subunits of RNR; that is, one homodimeric large subunit, R1, carrying the catalytic site and two variants of the homodimeric small subunit, R2 and the p53-inducible p53R2, each containing a tyrosyl free radical essential for catalysis. S-phase-specific DNA replication is supported by an RNR consisting of the R1 and R2 subunits. In contrast, DNA damage induces expression of the R1 and the p53R2 subunits. We now show that neither logarithmically growing nor G(o)/G(1)-synchronized mammalian cells show any major increase in their dNTP pools after DNA damage. However, non-dividing fibroblasts expressing the p53R2 protein, but not the R2 protein, have reduced dNTP levels if exposed to the RNR-specific inhibitor hydroxyurea, strongly indicating that there is ribonucleotide reduction in resting cells. The slow, 4-fold increase in p53R2 protein expression after DNA damage results in a less than 2-fold increase in the dNTP pools in G(o)/G(1) cells, where the pools are about 5% that of the size of the pools in S-phase cells. Our results emphasize the importance of the low constitutive levels of p53R2 in mammalian cells, which together with low levels of R1 protein may be essential for the supply of dNTPs for basal levels of DNA repair and mitochondrial DNA synthesis in G(o)/G(1) cells.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Hakansson, P (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	pelle.hakanson@medchem.umu.se		Hakansson, Pelle/0000-0003-0421-2433; Hofer, Anders/0000-0003-2890-2957				AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; Barzilai A, 2004, DNA REPAIR, V3, P1109, DOI 10.1016/j.dnarep.2004.03.002; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; DAVIS R, 1994, J BIOL CHEM, V269, P23171; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Filatov D, 1996, J BIOL CHEM, V271, P23698, DOI 10.1074/jbc.271.39.23698; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; Hakansson P, 2006, J BIOL CHEM, V281, P1778, DOI 10.1074/jbc.M511716200; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Imaizumi T, 1996, J DERMATOL SCI, V11, P134, DOI 10.1016/0923-1811(95)00431-9; Johansson E, 1998, J BIOL CHEM, V273, P29816, DOI 10.1074/jbc.273.45.29816; Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; Lembo D, 2000, J VIROL, V74, P11557, DOI 10.1128/JVI.74.24.11557-11565.2000; Lin ZP, 2004, J BIOL CHEM, V279, P27030, DOI 10.1074/jbc.M402056200; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; MANN GJ, 1988, CANCER RES, V48, P5151; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; NORDLUND P, 2006, IN PRESS ANN REV BIO; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; Powell DR, 2005, PEDIATR NEPHROL, V20, P432, DOI 10.1007/s00467-004-1696-5; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Sandrini MPB, 2005, TRENDS BIOCHEM SCI, V30, P225, DOI 10.1016/j.tibs.2005.03.003; SETO S, 1986, J IMMUNOL, V136, P2839; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; SPECTOR DL, 1998, CELLS LAB MANUAL, V1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	45	220	224	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7834	7841		10.1074/jbc.M512894200	http://dx.doi.org/10.1074/jbc.M512894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436374	hybrid			2022-12-25	WOS:000236031000017
J	Knapp, AM; Ramsey, JE; Wang, SX; Godburn, KE; Strauch, AR; Kelm, RJ				Knapp, AM; Ramsey, JE; Wang, SX; Godburn, KE; Strauch, AR; Kelm, RJ			Nucleoprotein interactions governing cell type-dependent repression of the mouse smooth muscle alpha-actin promoter by single-stranded DNA-binding proteins Pur alpha and Pur beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR TYPE-1; MYELIN BASIC-PROTEIN; CD43 GENE PROMOTER; MYOSIN HEAVY-CHAIN; MYOFIBROBLAST DIFFERENTIATION; TRANSCRIPTIONAL ACTIVITY; FUNCTIONAL INTERACTION; MCAT ENHANCER; NIH3T3 CELLS; IN-VITRO	Pur alpha and Pur beta are structurally related single-stranded DNA/RNA-binding proteins implicated in the control of cell growth and differentiation. The goal of this study was to determine whether Pur alpha and Pur beta function in a redundant, distinct, or collaborative manner to suppress smooth muscle alpha-actin gene expression in cell types relevant to wound repair and vascular remodeling. RNA interference-mediated loss-of-function analyses revealed that, although Pur beta was the dominant repressor, the combined action of endogenous Pur alpha and Pur beta was necessary to fully repress the full-length smooth muscle alpha-actin promoter in cultured fibroblasts but to a lesser extent in vascular smooth muscle cells. The activity of a minimal core enhancer containing a truncated 5' Pur repressor binding site was unaffected by knockdown of Pur alpha and/or Pur beta in fibroblasts. Conversely, gain-of-function studies indicated that Pur alpha or Pur beta could each independently repress core smooth muscle alpha-actin enhancer activity albeit in a cell type-dependent fashion. Biochemical analyses indicated that purified recombinant Pur alpha and Pur beta were essentially identical in terms of their binding affinity and specificity for GGN repeat-containing strands of several cis-elements comprising the core enhancer. However, Pur alpha and Pur beta exhibited more distinctive protein interaction profiles when evaluated for binding to enhancer-associated transcription factors in extracts from fibroblasts and vascular smooth muscle cells. These findings support the hypothesis that Pur alpha and Pur beta repress smooth muscle alpha-actin gene transcription by means of DNA strand-selective cis-element binding and cell type-dependent protein-protein interactions.	Univ Vermont, Coll Med, Dept Biochem, Cardiovasc Res Inst, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Med, Cardiovasc Res Inst, Burlington, VT 05405 USA; Ohio State Univ, Coll Med & Publ Hlth, Dorothy M Davis Heart & Lung Res Inst, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University of Vermont; University of Vermont; University System of Ohio; Ohio State University	Kelm, RJ (corresponding author), UVM, Colchester Res Facil, 208 S Pk Dr, Colchester, VT 05446 USA.	Robert.Kelm@uvm.edu			NHLBI NIH HHS [HL07594, HL 54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ban CG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh109; Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; Becker NA, 2000, J BIOL CHEM, V275, P15384, DOI 10.1074/jbc.M909687199; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; Bot I, 2003, CIRC RES, V93, P464, DOI 10.1161/01.RES.0000090993.01633.D4; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Chen YB, 2004, J CELL BIOCHEM, V92, P178, DOI 10.1002/jcb.20058; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; Da Silva N, 2002, BLOOD, V100, P3536, DOI 10.1182/blood.V100.10.3536; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; Darbinian N, 2001, J CELL BIOCHEM, V80, P589, DOI 10.1002/1097-4644(20010315)80:4<589::AID-JCB1013>3.0.CO;2-0; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; de Oliveira FMB, 2004, MOL BIOCHEM PARASIT, V135, P21, DOI 10.1016/j.molbiopara.2003.12.009; Desmouliere A, 2005, WOUND REPAIR REGEN, V13, P7, DOI 10.1111/j.1067-1927.2005.130102.x; Ding Y, 1997, NEUROCHEM INT, V31, P45, DOI 10.1016/S0197-0186(96)00127-1; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; Engelse MA, 2002, CIRC RES, V90, P1128, DOI 10.1161/01.RES.0000021044.53156.F5; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; GABBIANI G, 1984, J CLIN INVEST, V73, P148, DOI 10.1172/JCI111185; Gallia GL, 1998, J BIOL CHEM, V273, P32662, DOI 10.1074/jbc.273.49.32662; Gallia GL, 1999, J CELL BIOCHEM, V74, P334, DOI 10.1002/(SICI)1097-4644(19990901)74:3<334::AID-JCB3>3.0.CO;2-O; Gallia GL, 2001, J CELL BIOCHEM, V83, P355, DOI 10.1002/jcb.1247; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; Gaudreault I, 2004, NUCLEIC ACIDS RES, V32, P316, DOI 10.1093/nar/gkh170; Gupta M, 2003, J BIOL CHEM, V278, P44935, DOI 10.1074/jbc.M307696200; Hu YH, 2004, J CLIN INVEST, V113, P1258, DOI 10.1172/JCI200419628; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; Itoh S, 2002, CIRCULATION, V105, P2288, DOI 10.1161/01.CIR.0000015607.33345.1F; Johnson EM, 2003, ANTICANCER RES, V23, P2093; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Juliano RL, 2005, J CELL BIOL, V169, P847, DOI 10.1083/jcb.200501053; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kelm RJ, 2003, J BIOL CHEM, V278, P38749, DOI 10.1074/jbc.M306163200; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1999, J BIOL CHEM, V274, P38268, DOI 10.1074/jbc.274.53.38268; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Khalili K, 2003, MOL CELL BIOL, V23, P6857, DOI 10.1128/MCB.23.19.6857-6875.2003; Kolodgie FD, 2001, CURR OPIN CARDIOL, V16, P285, DOI 10.1097/00001573-200109000-00006; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; Li YM, 2001, BIOL PHARM BULL, V24, P231, DOI 10.1248/bpb.24.231; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Limesand SW, 2004, MOL ENDOCRINOL, V18, P447, DOI 10.1210/me.2003-0392; Liu H, 2005, BIOCHEM BIOPH RES CO, V328, P851, DOI 10.1016/j.bbrc.2005.01.038; Liu H, 2002, NUCLEIC ACIDS RES, V30, P2417, DOI 10.1093/nar/30.11.2417; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Melnikova IN, 2000, EUR J PHARMACOL, V393, P75, DOI 10.1016/S0014-2999(99)00884-5; Muralidharan V, 1997, J CELL BIOCHEM, V66, P524, DOI 10.1002/(SICI)1097-4644(19970915)66:4<524::AID-JCB11>3.0.CO;2-B; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Penberthy WT, 2004, DEV BIOL, V275, P225, DOI 10.1016/j.ydbio.2004.08.007; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sadakata T, 2000, MOL BRAIN RES, V77, P47, DOI 10.1016/S0169-328X(00)00039-5; Safak R, 1999, MOL CELL BIOL, V19, P2712; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Schildmeyer LA, 2000, FASEB J, V14, P2213, DOI 10.1096/fj.99-0927com; Schneider DJ, 1997, CIRCULATION, V96, P2868, DOI 10.1161/01.CIR.96.9.2868; Shelley CS, 2002, J IMMUNOL, V168, P3887, DOI 10.4049/jimmunol.168.8.3887; Shelley CS, 2001, BRIT J HAEMATOL, V115, P159, DOI 10.1046/j.1365-2141.2001.03066.x; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; Subramanian SV, 2004, MOL BIOL CELL, V15, P4532, DOI 10.1091/mbc.E04-04-0348; Subramanian SV, 2002, CARDIOVASC RES, V54, P539, DOI 10.1016/S0008-6363(02)00270-5; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Wang SX, 2005, J BIOL CHEM, V280, P6204, DOI 10.1074/jbc.M409506200; Wei Q, 2005, J BIOL CHEM, V280, P16284, DOI 10.1074/jbc.M500491200; Wilcox JN, 2001, ANN NY ACAD SCI, V947, P68; Wortman MJ, 2005, BBA-MOL CELL RES, V1743, P64, DOI 10.1016/j.bbamcr.2004.08.010; Yoshida T, 2005, CIRC RES, V96, P280, DOI 10.1161/01.RES.0000155951.62152.2e; Zeng LH, 2005, NEUROSCI RES, V51, P105, DOI 10.1016/j.neures.2004.09.009; Zhang AW, 2005, MOL BIOL CELL, V16, P4931, DOI 10.1091/mbc.E05-03-0216; Zhang QB, 2005, GENE, V348, P25, DOI 10.1016/j.gene.2004.12.050	77	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7907	7918		10.1074/jbc.M509682200	http://dx.doi.org/10.1074/jbc.M509682200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436378	hybrid			2022-12-25	WOS:000236031000026
J	Hattori, K; Uchino, S; Isosaka, T; Maekawa, M; Iyo, M; Sato, T; Kohsaka, S; Yagi, T; Yuasa, S				Hattori, K; Uchino, S; Isosaka, T; Maekawa, M; Iyo, M; Sato, T; Kohsaka, S; Yagi, T; Yuasa, S			Fyn is required for haloperidol-induced catalepsy in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTOR; PROTEIN-KINASE-C; ENHANCED TYROSINE PHOSPHORYLATION; INDUCED GENE-EXPRESSION; NMDA-RECEPTOR; ANTIPSYCHOTIC-DRUGS; DEFICIENT MICE; INCREASED FEARFULNESS; FOS PROTEIN; SRC-FAMILY	Fyn-mediated tyrosine phosphorylation of N-methyl-D-aspartate ( NMDA) receptor subunits has been implicated in various brain functions, including ethanol tolerance, learning, and seizure susceptibility. In this study, we explored the role of Fyn in haloperidol-induced catalepsy, an animal model of the extrapyramidal side effects of antipsychotics. Haloperidol induced catalepsy and muscle rigidity in the control mice, but these responses were significantly reduced in Fyn-deficient mice. Expression of the striatal dopamine D-2 receptor, the main site of haloperidol action, did not differ between the two genotypes. Fyn activation and enhanced tyrosine phosphorylation of the NMDA receptor NR2B subunit, as measured by Western blotting, were induced after haloperidol injection of the control mice, but both responses were significantly reduced in Fyn-deficient mice. Dopamine D2 receptor blockade was shown to increase both NR2B phosphorylation and the NMDA-induced calcium responses in control cultured striatal neurons but not in Fyn-deficient neurons. Based on these findings, we proposed a new molecular mechanism underlying haloperidol-induced catalepsy, in which the dopamine D2 receptor antagonist induces striatal Fyn activation and the subsequent tyrosine phosphorylation of NR2B alters striatal neuronal activity, thereby inducing the behavioral changes that are manifested as a cataleptic response.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo 1878502, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan; Osaka Univ, KOKORO Biol Grp, FBS, Suita, Osaka 5650871, Japan; Univ Grad Sch Med, Dept Psychiat, Chiba 2608670, Japan; Univ Grad Sch Med, Dept Anat & Dev Biol, Chiba 2608670, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan	National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Osaka University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Hattori, K (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo 1878502, Japan.	hattori@ncnp.go.jp						Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; Boulay D, 2000, EUR J PHARMACOL, V391, P63, DOI 10.1016/S0014-2999(99)00916-4; CEPEDA C, 1993, P NATL ACAD SCI USA, V90, P9576, DOI 10.1073/pnas.90.20.9576; Chartoff EH, 1999, J PHARMACOL EXP THER, V291, P531; Chase TN, 2004, PARKINSONISM RELAT D, V10, P305, DOI 10.1016/j.parkreldis.2004.02.012; Chen JF, 2001, P NATL ACAD SCI USA, V98, P1970, DOI 10.1073/pnas.98.4.1970; Cheung HH, 2001, J NEUROCHEM, V78, P524, DOI 10.1046/j.1471-4159.2001.00433.x; Crocker AD, 2001, PROG NEURO-PSYCHOPH, V25, P573, DOI 10.1016/S0278-5846(00)00176-7; De Souza IEJ, 1999, SYNAPSE, V32, P243, DOI 10.1002/(SICI)1098-2396(19990615)32:4<243::AID-SYN1>3.0.CO;2-O; DRAGUNOW M, 1990, NEUROSCIENCE, V37, P287, DOI 10.1016/0306-4522(90)90399-O; Dwivedi Y, 1999, J PHARMACOL EXP THER, V291, P688; Hironaka N, 2002, MOL BRAIN RES, V98, P102, DOI 10.1016/S0169-328X(01)00329-1; Kojima N, 1998, LEARN MEMORY, V5, P429; Kosinski CM, 1998, J COMP NEUROL, V390, P63; Kotecha SA, 2002, NEURON, V35, P1111, DOI 10.1016/S0896-6273(02)00859-0; Kulagowski JJ, 1996, J MED CHEM, V39, P1941, DOI 10.1021/jm9600712; Leveque JC, 2000, J NEUROSCI, V20, P4011; LorencKoci E, 1996, EXP BRAIN RES, V109, P268; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; Millan MJ, 2000, J PHARMACOL EXP THER, V293, P1063; MILLER AL, 1993, BIOL PSYCHIAT, V34, P178, DOI 10.1016/0006-3223(93)90389-U; Miyakawa T, 1996, MOL BRAIN RES, V37, P145; MIYAKAWA T, 1994, MOL BRAIN RES, V27, P179, DOI 10.1016/0169-328X(94)90201-1; Miyakawa T, 1997, SCIENCE, V278, P698, DOI 10.1126/science.278.5338.698; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; MOORE NA, 1993, EUR J PHARMACOL, V237, P1, DOI 10.1016/0014-2999(93)90085-V; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Oh JD, 1998, BRAIN RES, V813, P150, DOI 10.1016/S0006-8993(98)01049-X; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Saga Y, 1999, GENES CELLS, V4, P219, DOI 10.1046/j.1365-2443.1999.00253.x; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Svensson TH, 2000, BRAIN RES REV, V31, P320, DOI 10.1016/S0165-0173(99)00048-X; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Tsai GC, 2002, ANNU REV PHARMACOL, V42, P165, DOI 10.1146/annurev.pharmtox.42.082701.160735; Uchino S, 2001, FEBS LETT, V506, P117, DOI 10.1016/S0014-5793(01)02899-X; Viviani B, 2003, J NEUROSCI, V23, P8692; Wadenberg MLG, 2001, NEUROPSYCHOPHARMACOL, V25, P633, DOI 10.1016/S0893-133X(01)00261-5; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Watanabe M, 1998, EUR J NEUROSCI, V10, P478, DOI 10.1046/j.1460-9568.1998.00063.x; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAGI T, 1993, ONCOGENE, V8, P3343; Yaka R, 2003, J NEUROSCI, V23, P3623; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yanahashi S, 2004, BRAIN RES, V1011, P84, DOI 10.1016/j.brainres.2003.12.059; Yasunaga M, 1996, J CELL BIOL, V132, P91, DOI 10.1083/jcb.132.1.91; Yuasa S, 1996, ANAT EMBRYOL, V194, P223; ZIOLKOWSKA B, 1993, NEUROSCI LETT, V156, P39, DOI 10.1016/0304-3940(93)90434-M	51	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7129	7135		10.1074/jbc.M511608200	http://dx.doi.org/10.1074/jbc.M511608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407246	hybrid			2022-12-25	WOS:000236030900027
J	Weigert, C; Hennige, AM; Lehmann, R; Brodbeck, K; Baumgartner, F; Schauble, M; Haring, HU; Schleicher, ED				Weigert, C; Hennige, AM; Lehmann, R; Brodbeck, K; Baumgartner, F; Schauble, M; Haring, HU; Schleicher, ED			Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CIRCULATING INTERLEUKIN-6; INDUCED APOPTOSIS; IN-VIVO; PHOSPHORYLATION; PROTEIN; KINASE; EXERCISE; IRS-1; IL-6	The exercise-induced interleukin (IL)-6 production and secretion within skeletal muscle fibers has raised the question of a putative tissue-specific function of IL-6 in the energy metabolism of the muscle during and after the exercise. In the present study, we followed the hypothesis that IL-6 signaling may directly interact with insulin receptor substrate (IRS)-1, a keystone in the insulin signaling cascade. We showed that IL-6 induces a rapid recruitment of IRS-1 to the IL-6 receptor complex in cultured skeletal muscle cells. Moreover, IL-6 induced a rapid and transient phosphorylation of Ser-318 of IRS-1 in muscle cells and in muscle tissue, but not in the liver of IL-6-treated mice, probably via the IL-6-induced co-recruitment of protein kinase C-delta. This Ser-318 phosphorylation improved insulin-stimulated Akt phosphorylation and glucose uptake in myotubes since transfection with an IRS-1/Glu-318 mutant simulating a permanent phospho-Ser-318 modification increased Akt phosphorylation and glucose uptake. Noteworthily, two inhibitory mechanisms of IL-6 on insulin action, phosphorylation of the inhibitory Ser-307 residue of IRS-1 and induction of SOCS-3 expression, were only found in liver but not in muscle of IL-6-treated mice. Thus, the data provided evidence for a possible molecular mechanism of the physiological metabolic effects of IL-6 in skeletal muscle, thereby exerting short term beneficial effects on insulin action.	Univ Tubingen, Dept Internal Med, Div Endocrinol Metab Pathobiochem & Clin Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Weigert, C (corresponding author), Univ Tubingen, Dept Internal Med, Div Endocrinol Metab Pathobiochem & Clin Chem, Otfried Muller Str 10, D-72076 Tubingen, Germany.	caweiger@med.uni-tuebingen.de	Lehmann, Rainer/AAF-4281-2019	Lehmann, Rainer/0000-0003-1218-6810				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Beck A, 2003, J AM SOC MASS SPECTR, V14, P401, DOI 10.1016/S1044-0305(03)00122-3; Bruce CR, 2004, AM J PHYSIOL-ENDOC M, V287, pE616, DOI 10.1152/ajpendo.00150.2004; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Faldt J, 2004, ENDOCRINOLOGY, V145, P2680, DOI 10.1210/en.2003-1319; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Febbraio MA, 2004, DIABETES, V53, P1643, DOI 10.2337/diabetes.53.7.1643; Fernandez-Real JM, 2001, J CLIN ENDOCR METAB, V86, P1154, DOI 10.1210/jc.86.3.1154; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019; Hawley JA, 2004, DIABETES-METAB RES, V20, P383, DOI 10.1002/dmrr.505; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hennige AM, 2003, J CLIN INVEST, V112, P1521, DOI 10.1172/JCI200318581; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Klover PJ, 2003, DIABETES, V52, P2784, DOI 10.2337/diabetes.52.11.2784; Krutzfeldt J, 2000, DIABETES, V49, P992, DOI 10.2337/diabetes.49.6.992; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; Moeschel K, 2004, J BIOL CHEM, V279, P25157, DOI 10.1074/jbc.M402477200; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Mussig K, 2005, J BIOL CHEM, V280, P32693, DOI 10.1074/jbc.M506549200; Novotny-Diermayr V, 2002, J BIOL CHEM, V277, P49134, DOI 10.1074/jbc.M206727200; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Pedersen BK, 2003, J MUSCLE RES CELL M, V24, P113, DOI 10.1023/A:1026070911202; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Petersen EW, 2005, AM J PHYSIOL-ENDOC M, V288, pE155, DOI 10.1152/ajpendo.00257.2004; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Rosendal L, 2004, ACTA PHYSIOL SCAND, V182, P379, DOI 10.1111/j.1365-201X.2004.01356.x; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Sakamoto K, 2004, BIOCHEM BIOPH RES CO, V319, P419, DOI 10.1016/j.bbrc.2004.05.020; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Steensberg A, 2002, AM J PHYSIOL-ENDOC M, V283, pE1272, DOI 10.1152/ajpendo.00255.2002; Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687; Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weigert C, 2005, J BIOL CHEM, V280, P37393, DOI 10.1074/jbc.M506134200; Weigert C, 2005, AM J PHYSIOL-ENDOC M, V289, pE251, DOI 10.1152/ajpendo.00448.2004; Weigert C, 2004, J BIOL CHEM, V279, P23942, DOI 10.1074/jbc.M312692200; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Wojtaszewski JFP, 2003, ACTA PHYSIOL SCAND, V178, P321, DOI 10.1046/j.1365-201X.2003.01151.x; Wojtaszewski JFP, 2000, DIABETES, V49, P325, DOI 10.2337/diabetes.49.3.325	51	101	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7060	7067		10.1074/jbc.M509782200	http://dx.doi.org/10.1074/jbc.M509782200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16418171	hybrid			2022-12-25	WOS:000236030900019
J	Xie, LL; Boyle, D; Sanford, D; Scherer, PE; Pessin, JE; Mora, S				Xie, LL; Boyle, D; Sanford, D; Scherer, PE; Pessin, JE; Mora, S			Intracellular trafficking and secretion of adiponectin is dependent on GGA-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ADIPOSE-SPECIFIC PROTEIN; FATTY-ACID OXIDATION; EAR HOMOLOGY DOMAIN; INSULIN-RESISTANCE; BREFELDIN-A; GLOBULAR DOMAIN; GAMMA-ADAPTIN; VHS DOMAIN; GLUCOSE	Adiponectin (Acrp30) is an insulin-sensitizing hormone produced and secreted exclusively by adipose tissue. Confocal fluorescent microscopy demonstrated the colocalization of adiponectin with the Golgi membrane markers p115, beta-COP, and the trans-Golgi network marker, syntaxin 6. Treatment of cells with brefeldin A redistributed adiponectin to the endoplasmic reticulum where it colocalized with the chaperone protein BIP and inhibited secretion of adiponectin demonstrating a requirement for a functional Golgi apparatus for adiponectin release. Confocal fluorescent microscopy also demonstrated a colocalization of endogenous adiponectin with that of expressed GGA1myc (Golgi-localizing gamma-adaptin ear homology ARF-binding protein) but with no significant overlap between adiponectin and the GGA2myc or GGA3myc isoforms. Consistent with confocal fluorescent microscopy, transmission electron microscopy demonstrated the colocalization of GGA1 with adiponectin. Although GGA1 did not directly interact with the adiponectin protein, the adiponectin enriched membrane compartments of adipocyte were precipitated by a GST-GGA1 cargo binding domain (VHS) fusion protein but not with a GST-GGA2 VHS or GST-GGA3 VHS fusion proteins. Moreover, co-expression of adiponectin with a GGA1 dominant-interfering mutant (GGA1-VHS GAT domain) resulted in a marked inhibition of adiponectin secretion in both 3T3L1 adipocytes and HEK293 cells, whereas no inhibition was detected with the truncated mutants GGA2-VHSGAT or GGA3-VHSGAT. Moreover, co-expression of wild type GGA1 with adiponectin enhanced secretion of adiponectin. Interestingly, leptin secretion was unaffected by neither the wild type form or GGA1 mutant. Taken together these data demonstrate that the trafficking of adiponectin through its secretory pathway is dependent on GGA-coated vesicles.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Kansas State University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Mora, S (corresponding author), Kansas State Univ, Div Biol, 231 Ackert Hall, Manhattan, KS 66506 USA.	mora@ksu.edu	Mora, Silvia/Y-3131-2019; Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392; Mora, Silvia/0000-0002-8473-1497	NCRR NIH HHS [P20 RR 17708, P20 RR 017686] Funding Source: Medline; NIDDK NIH HHS [DK 55811, DK 63332] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708, P20RR017686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063332, R01DK055811] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Beltowski J, 2003, MED SCI MONITOR, V9, P55; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Boman AL, 2001, J CELL SCI, V114, P3413; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Fisher FM, 2002, HORM METAB RES, V34, P650, DOI 10.1055/s-2002-38246; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Guerre-Millo M, 2002, J ENDOCRINOL INVEST, V25, P855, DOI 10.1007/BF03344048; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Heilbronn LK, 2003, CURR PHARM DESIGN, V9, P1411, DOI 10.2174/1381612033454766; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Li LV, 2005, MOL ENDOCRINOL, V19, P2145, DOI 10.1210/me.2005-0032; Lihn AS, 2003, AM J PHYSIOL-ENDOC M, V284, pE443, DOI 10.1152/ajpendo.00358.2002; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SHAPIRO L, 1998, CURR BIOL, V276, P3628; Shuldiner AR, 2001, NEW ENGL J MED, V345, P1345, DOI 10.1056/NEJM200111013451814; Simon JP, 2000, METHODS, V20, P437, DOI 10.1006/meth.2000.0957; Statnick M A, 2000, Int J Exp Diabetes Res, V1, P81, DOI 10.1155/EDR.2000.81; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tschritter O, 2003, DIABETES, V52, P239, DOI 10.2337/diabetes.52.2.239; Ukkola O, 2002, J MOL MED, V80, P696, DOI 10.1007/s00109-002-0378-7; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Weiss R, 2003, J CLIN ENDOCR METAB, V88, P2014, DOI 10.1210/jc.2002-021711; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zhu GY, 2003, FEBS LETT, V537, P171, DOI 10.1016/S0014-5793(03)00095-4; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	57	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7253	7259		10.1074/jbc.M511313200	http://dx.doi.org/10.1074/jbc.M511313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407204	hybrid, Green Published			2022-12-25	WOS:000236030900043
J	Kurosu, H; Ogawa, Y; Miyoshi, M; Yamamoto, M; Nandi, A; Rosenblatt, KP; Baum, MG; Schiavi, S; Hu, CM; Moe, OW; Kuro-o, M				Kurosu, H; Ogawa, Y; Miyoshi, M; Yamamoto, M; Nandi, A; Rosenblatt, KP; Baum, MG; Schiavi, S; Hu, CM; Moe, OW; Kuro-o, M			Regulation of fibroblast growth factor-23 signaling by Klotho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT HYPOPHOSPHATEMIC RICKETS; BILE-ACID SYNTHESIS; HORMONE KLOTHO; PHOSPHATE; MICE; PROTEIN; FGF-23; FGF23; SUPPRESSION; HOMEOSTASIS	The aging suppressor gene Klotho encodes a single-pass transmembrane protein. Klotho-deficient mice exhibit a variety of aging-like phenotypes, many of which are similar to those observed in fibroblast growth factor-23 (FGF23)-deficient mice. To test the possibility that Klotho and FGF23 may function in a common signal transduction pathway(s), we investigated whether Klotho is involved in FGF signaling. Here we show that Klotho protein directly binds to multiple FGF receptors (FGFRs). The Klotho-FGFR complex binds to FGF23 with higher affinity than FGFR or Klotho alone. In addition, Klotho significantly enhanced the ability of FGF23 to induce phosphorylation of FGF receptor substrate and ERK in various types of cells. Thus, Klotho functions as a cofactor essential for activation of FGF signaling by FGF23.	Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Appl Genom, Dallas, TX 75390 USA	Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Sanofi-Aventis; Genzyme Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kuro-o, M (corresponding author), Univ Texas, SW Med Ctr Dallas, Genzyme Corp, Dept Pathol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	makoto.kuroo@utsouthwestern.edu	Ogawa, Yasushi/I-1140-2012; Ogawa, Yasushi/M-8900-2014	Ogawa, Yasushi/0000-0003-3553-9607	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025326, R01AG019712] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG025326-03, R01AG25326, R01 AG019712-05, R01 AG019712, R01AG19712, R01 AG025326] Funding Source: Medline; NIDDK NIH HHS [R01DK065842, R01 DK065842] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baum M, 2005, KIDNEY INT, V68, P1148, DOI 10.1111/j.1523-1755.2005.00506.x; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Ikushima M, 2006, BIOCHEM BIOPH RES CO, V339, P827, DOI 10.1016/j.bbrc.2005.11.094; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Ito S, 2005, J CLIN INVEST, V115, P2202, DOI 10.1172/JCI23076; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Liu SG, 2003, J BIOL CHEM, V278, P37419, DOI 10.1074/jbc.M304544200; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Quarles LD, 2003, AM J PHYSIOL-ENDOC M, V285, pE1, DOI 10.1152/ajpendo.00016.2003; Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200; Yamashita T, 2002, J BIOL CHEM, V277, P28265, DOI 10.1074/jbc.M202527200; Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105; Yoshida T, 2002, ENDOCRINOLOGY, V143, P683, DOI 10.1210/en.143.2.683; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Yu XJ, 2005, ENDOCRINOLOGY, V146, P4647, DOI 10.1210/en.2005-0670	24	988	1076	0	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6120	6123		10.1074/jbc.C500457200	http://dx.doi.org/10.1074/jbc.C500457200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16436388	Green Accepted, hybrid			2022-12-25	WOS:000236030800002
J	Li, YK; Gerbod-Giannone, MC; Seitz, H; Cui, DY; Thorp, E; Tall, AR; Matsushima, GK; Tabas, I				Li, YK; Gerbod-Giannone, MC; Seitz, H; Cui, DY; Thorp, E; Tall, AR; Matsushima, GK; Tabas, I			Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CELL-SURFACE CALRETICULIN; TYROSINE KINASE; IN-VITRO; ATHEROSCLEROTIC PLAQUE; ENDOPLASMIC-RETICULUM; LOADED MACROPHAGES; DEFICIENT MICE; CLEARANCE; BETA	Macrophage apoptosis and the ability of phagocytes to clear these apoptotic cells are important processes in advanced atherosclerosis. Phagocytic clearance not only disposes of dead cells but usually elicits an anti-inflammatory response. To study this process in a model of advanced lesional macrophage death, macrophages rendered apoptotic by free cholesterol loading (FC-AMs) were incubated briefly with fresh macrophages ("phagocytes"). FC-AMs were promptly ingested by the phagocytes, which was dependent upon actin polymerization and the phagocyte Mer receptor. Surprisingly, this brief exposure to FC-AMs triggered a modest proinflammatory response in the phagocytes: tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 beta were induced, whereas the levels of transforming growth factor-beta and IL-10 were not increased. This response required cell contact between the FC-AMs and phagocytes but not FC-AM ingestion. TNF-alpha and IL-1 beta induction required one or more proteins on the FC-AM surface and was dependent on signaling through extracellular signal-regulated kinase-1/2 mitogen-activated protein kinase and nuclear factor-kappa B in the phagocytes. TNF-alpha production was markedly greater when Mer-defective phagocytes were used, indicating that Mer attenuated the inflammatory response. Interestingly, a more typical anti-inflammatory response was elicited when phagocytes were exposed to macrophages rendered apoptotic by oxidized low density lipoprotein or UV radiation. Thus, the proinflammatory milieu of advanced atherosclerotic lesions may be promoted, or at least not dampened, by contact between FC-induced apoptotic macrophages and neighboring phagocytes prior to apoptotic cell ingestion.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Columbia University; Columbia University; Columbia University; University of North Carolina; University of North Carolina Chapel Hill	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Tall, Alan/AAT-8528-2021	Thorp, Edward/0000-0003-1387-7058	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075662, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54591, HL75662] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 2004, CARDIOVASC PATHOL, V13, P125, DOI 10.1016/S1054-8807(04)00004-3; Arai S, 2005, CELL METAB, V1, P201, DOI 10.1016/j.cmet.2005.02.002; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Caligiuri G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102; Camenisch TD, 1999, J IMMUNOL, V162, P3498; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 1998, J IMMUNOL, V161, P6250; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Fleetwood AJ, 2005, CRIT REV IMMUNOL, V25, P405, DOI 10.1615/CritRevImmunol.v25.i5.50; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Grainger DJ, 2004, J IMMUNOL, V173, P6366, DOI 10.4049/jimmunol.173.10.6366; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hinson RM, 1996, P NATL ACAD SCI USA, V93, P4885, DOI 10.1073/pnas.93.10.4885; Ishimoto Y, 2000, J BIOCHEM-TOKYO, V127, P411, DOI 10.1093/oxfordjournals.jbchem.a022622; Khan M, 2003, ATHEROSCLEROSIS, V171, P21, DOI 10.1016/j.atherosclerosis.2003.07.001; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; KRUTH HS, 1984, AM J PATHOL, V114, P201; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Li YK, 2005, J BIOL CHEM, V280, P21763, DOI 10.1074/jbc.M501759200; Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Libby P, 2001, AM J CARDIOL, V88, p3J, DOI [DOI 10.1016/S0002-9149(01)02145-2, 10.1016/S0002-9149(01)02145-2]; Liu J, 2005, ARTERIOSCL THROM VAS, V25, P174, DOI 10.1161/01.ATV.0000148548.47755.22; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Mahajan NP, 2003, J BIOL CHEM, V278, P42596, DOI 10.1074/jbc.M305817200; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; McDonald PP, 1999, J IMMUNOL, V163, P6164; Melaragno MG, 1999, TRENDS CARDIOVAS MED, V9, P250, DOI 10.1016/S1050-1738(00)00027-X; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Moreira MEC, 2004, AN ACAD BRAS CIENC, V76, P93, DOI 10.1590/S0001-37652004000100009; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; RAPP JH, 1983, J LIPID RES, V24, P1329; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROSS AC, 1984, J BIOL CHEM, V259, P815; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schaefer H E, 1981, Haematol Blood Transfus, V27, P137; Schrijvers DM, 2005, ARTERIOSCL THROM VAS, V25, P1256, DOI 10.1161/01.ATV.0000166517.18801.a7; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200	59	74	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6707	6717		10.1074/jbc.M510579200	http://dx.doi.org/10.1074/jbc.M510579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16380374	Green Published, hybrid			2022-12-25	WOS:000236030800068
J	Mattera, R; Tsai, YC; Weissman, AM; Bonifacino, JS				Mattera, R; Tsai, YC; Weissman, AM; Bonifacino, JS			The Rab5 guanine nucleotide exchange factor Rabex-5 binds ubiquitin (Ub) and functions as a Ub ligase through an atypical Ub-interacting motif and a zinc finger domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUE DOMAIN; RECEPTOR ENDOCYTOSIS; PROTEIN; COMPLEX; RABAPTIN-5; FAMILY; VPS9P; A20; IDENTIFICATION; RECOGNITION	Rabex-5, the mammalian orthologue of yeast Vps9p, is a guanine nucleotide exchange factor for Rab5. Rabex-5 forms a tight complex with Rabaptin-5, a multivalent adaptor protein that also binds to Rab4, Rab5, and to domains present in gamma-adaptins and the Golgi-localized, gamma-ear-containing, ARF-binding proteins ( GGAs). Rabaptin-5 augments the Rabex-5 exchange activity, thus generating GTP-bound, membrane-associated Rab5 that, in turn, binds Rabaptin-5 and stabilizes the Rabex-5 . Rabaptin-5 complex on endosomes. Although the Rabex-5 . Rabaptin-5 complex is critical to the regulation of endosomal fusion, the structural determinants of this interaction are unknown. Likewise, the possible binding and covalent attachment of ubiquitin to Rabex-5, two modifications that are critical to the function of yeast Vps9p in endosomal transport, have not been studied. In this study, we identify the 401 - 462 and 551 - 661 coiled-coils as the regions in Rabex-5 and Rabaptin-5, respectively, that interact with one another. We also demonstrate that Rabex-5 undergoes ubiquitination and binds ubiquitin, though not via its proposed C-terminal CUE-like domain. Instead, the N-terminal region of Rabex-5 ( residues 1 - 76), comprising an A20-like Cys(2)/ Cys(2) zinc finger and an adjacent alpha-helix, is important for ubiquitin binding and ubiquitination. Importantly, we demonstrate that the Rabex-5 zinc finger displays ubiquitin ligase (E3) activity. These observations extend our understanding of the regulation of Rabex-5 by Rabaptin-5. Moreover, the demonstration that Rabex-5 is a ubiquitin ligase that binds ubiquitin and undergoes ubiquitination indicates that its role in endosome fusion may be subject to additional regulation by ubiquitin-dependent modifications.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Prot Dynam & Signaling, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bonifacino, JS (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Rm 101, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010292, Z01BC010292] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Fujiwara K, 2004, J BIOL CHEM, V279, P4760, DOI 10.1074/jbc.M309448200; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Lippe R, 2001, MOL BIOL CELL, V12, P2219, DOI 10.1091/mbc.12.7.2219; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Mattera R, 2004, J BIOL CHEM, V279, P31409, DOI 10.1074/jbc.M402183200; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Shiba Y, 2004, J BIOL CHEM, V279, P7105, DOI 10.1074/jbc.M311702200; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhu GY, 2004, EMBO J, V23, P3909, DOI 10.1038/sj.emboj.7600411	35	91	93	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6874	6883		10.1074/jbc.M509939200	http://dx.doi.org/10.1074/jbc.M509939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407276	hybrid			2022-12-25	WOS:000236030800085
J	Swem, LR; Gong, X; Yu, CA; Bauer, CE				Swem, LR; Gong, X; Yu, CA; Bauer, CE			Identification of a ubiquinone-binding site that affects autophosphorylation of the sensor kinase RegB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; RHODOBACTER-SPHAEROIDES 2.4.1; CYTOCHROME-C REDUCTASE; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; DOMAIN; CAPSULATUS; EXPRESSION; PROTEIN; OXIDASE	Rhodobacter capsulatus regulates many metabolic processes in response to the level of environmental oxygen and the energy state of the cell. One of the key global redox regulators of the cell's metabolic physiology is the sensor kinase RegB that controls the synthesis of numerous energy generation and utilization processes. In this study, we have succeeded in purifying full-length RegB containing six transmembrane-spanning elements. Exogenous addition of excess oxidized coenzyme Q(1) is capable of inhibiting RegB autophosphorylation similar to 6-fold. However, the addition of reduced coenzyme Q(1) exhibits no inhibitory effect on kinase activity. A ubiquinone-binding site, as defined by azidoquinone photo affinity cross-linking, was determined to lie within a periplasmic loop between transmembrane helices 3 and 4 that contains a fully conserved heptapeptide sequence of GGXXNPF. Mutation of the phenylalanine in this heptapeptide renders RegB constitutively active in vivo, indicating that this domain is responsible for sensing the redox state of the ubiquinone pool and subsequently controlling RegB autophosphorylation.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Indiana University System; Indiana University Bloomington; Oklahoma State University System; Oklahoma State University - Stillwater	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	cbauer@bio.indiana.edu			NIGMS NIH HHS [R37 GM040941, R01 GM053940, R01 GM040941, GM53940, R01 GM030721, R37 GM040941-21, R37 GM030721, GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R37GM040941, R01GM053940, R01GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Bird TH, 1999, J BIOL CHEM, V274, P16343, DOI 10.1074/jbc.274.23.16343; Bock A, 2002, EUR J BIOCHEM, V269, P3479, DOI 10.1046/j.1432-1033.2002.03029.x; BOLTON JR, 1978, PHOTOSYNTHETIC BACTE, P419; BUGGY JJ, 1994, J BACTERIOL, V176, P6936, DOI 10.1128/JB.176.22.6936-6943.1994; DOYLE MP, 1989, J BIOL CHEM, V264, P1387; Dubbs JM, 2000, J BIOL CHEM, V275, P19224, DOI 10.1074/jbc.M002125200; Elsen S, 2000, J BACTERIOL, V182, P2831, DOI 10.1128/JB.182.10.2831-2837.2000; Elsen S, 2004, MICROBIOL MOL BIOL R, V68, P263, DOI 10.1128/MMBR.68.2.263-279.2004; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; HE DY, 1994, J BIOL CHEM, V269, P2292; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; MADIGAN MT, 1978, ARCH MICROBIOL, V117, P119, DOI 10.1007/BF00402298; Malpica R, 2004, P NATL ACAD SCI USA, V101, P13318, DOI 10.1073/pnas.0403064101; Oh JI, 2004, BIOCHEMISTRY-US, V43, P7915, DOI 10.1021/bi0496440; Oh JI, 2001, J BACTERIOL, V183, P6807, DOI 10.1128/JB.183.23.6807-6814.2001; Ouchane S, 1999, J BIOL CHEM, V274, P17290, DOI 10.1074/jbc.274.24.17290; Parson W. W., 1978, PHOTOSYNTHETIC BACTE, P455; Potter CA, 2002, J MOL BIOL, V320, P201, DOI 10.1016/S0022-2836(02)00424-2; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; Swem LR, 2003, EMBO J, V22, P4699, DOI 10.1093/emboj/cdg461; WELTER R, 1994, J BIOL CHEM, V269, P28834; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; YANG FD, 1986, J BIOL CHEM, V261, P4987; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; YU L, 1985, J BIOL CHEM, V260, P963; YU L, 1986, BIOCHIM BIOPHYS ACTA, V848, P305, DOI 10.1016/0005-2728(86)90204-5; YU L, 1987, J BIOL CHEM, V262, P1137	30	77	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6768	6775		10.1074/jbc.M509687200	http://dx.doi.org/10.1074/jbc.M509687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407278	hybrid, Green Accepted			2022-12-25	WOS:000236030800075
J	Kupke, T; Schwarz, W				Kupke, T; Schwarz, W			4 '-Phosphopantetheine biosynthesis in archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A BIOSYNTHESIS; BACTERIAL DFP FLAVOPROTEINS; MOLECULAR CHARACTERIZATION; PHOSPHOPANTOTHENOYLCYSTEINE SYNTHETASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; BINDING PROTEIN; 4'-PHOSPHOPANTOTHENOYLCYSTEINE; DECARBOXYLASE	Coenzyme A as the principal acyl carrier is required for many synthetic and degradative reactions in intermediary metabolism. It is synthesized in five steps from pantothenate, and recently the CoaA biosynthetic genes of eubacteria, plants, and human were all identified and cloned. In most bacteria, the so-called Dfp proteins catalyze the synthesis of the coenzyme A precursor 4'-phosphopantetheine. Dfp proteins are bifunctional enzymes catalyzing the synthesis of 4'-phosphopantothenoylcysteine (CoaB activity) and its decarboxylation to 4'-phosphopantetheine (CoaC activity). Here, we demonstrate the functional characterization of the CoaB and CoaC domains of an archaebacterial Dfp protein. Both domains of the Methanocaldococcus jannaschii Dfp protein were purified as His tag proteins, and their enzymatic activities were then identified and characterized by site-directed mutagenesis. Although the nucleotide binding motif II of the CoaB domain resembles that of eukaryotic enzymes, Methanocaldococcus CoaB is a CTP- and not an ATP-dependent enzyme, as shown by detection of the 4'-phosphopantothenoylCMP intermediate. The proposed 4'-phosphopantothenoylcysteine binding clamp of the Methanocaldococcus CoaC activity differs significantly from those of other characterized CoaC proteins. In particular, the active site cysteine residue, which otherwise is involved in the reduction of an aminoenethiol reaction intermediate, is not present. Moreover, the conserved Asn residue of the PXMNXXMW motif, which contacts the carboxyl group of 4'-phosphopantothenoylcysteine, is exchanged for His.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15,Verfugungsgebaude, D-72076 Tubingen, Germany.	Thomas.Kupke@t-online.de	Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; Blaesse M, 2003, ACTA CRYSTALLOGR D, V59, P1414, DOI 10.1107/S0907444903011831; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CORMACK B, 1991, CURRENT PROTOCOLS MO; Genschel U, 2004, MOL BIOL EVOL, V21, P1242, DOI 10.1093/molbev/msh119; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; Kupke T, 2004, EUR J BIOCHEM, V271, P163, DOI 10.1046/j.1432-1033.2003.03916.x; Kupke T, 2003, J BIOL CHEM, V278, P38229, DOI 10.1074/jbc.M306321200; Kupke T, 2002, J BIOL CHEM, V277, P36137, DOI 10.1074/jbc.M206188200; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Kupke T, 2001, J BIOL CHEM, V276, P27597, DOI 10.1074/jbc.M103342200; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Majer F, 2002, J BACTERIOL, V184, P1234, DOI 10.1128/JB.184.5.1234-1243.2002; Manoj N, 2003, STRUCTURE, V11, P927, DOI 10.1016/S0969-2126(03)00146-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stanitzek S, 2004, STRUCTURE, V12, P1977, DOI 10.1016/j.str.2004.08.007; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; Strauss E, 2004, BIOCHEMISTRY-US, V43, P15520, DOI 10.1021/bi048340a; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200	21	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5435	5444		10.1074/jbc.M510056200	http://dx.doi.org/10.1074/jbc.M510056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371361	hybrid			2022-12-25	WOS:000235568900015
J	Kaneki, H; Guo, R; Chen, D; Yao, ZQ; Schwarz, EM; Zhang, YE; Boyce, BF; Xing, LP				Kaneki, H; Guo, R; Chen, D; Yao, ZQ; Schwarz, EM; Zhang, YE; Boyce, BF; Xing, LP			Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; MURINE CLONAL OSTEOBLASTS; NF-KAPPA-B; FACTOR-ALPHA; SKELETAL-MUSCLE; BONE-FORMATION; TNF-ALPHA; MEDIATED DEGRADATION; TRANSGENIC MICE; CELL POLARITY	Tumor necrosis factor (TNF) plays an important role in the pathogenesis of inflammatory bone loss through stimulation of osteoclastic bone resorption and inhibition of osteoblastic bone formation. Compared with the well established role of TNF in osteoclastogenesis, mechanisms by which TNF inhibits osteoblast function have not been fully determined. Runx2 is an osteoblast-specific transcription factor whose steady-state protein levels are regulated by proteasomal degradation, mediated by the E3 ubiquitin ligases, Smurf1 and Smurf2. We hypothesized that TNF inhibits osteoblast function through Smurf-mediated Runx2 degradation. We treated C2C12 and 2T3 osteoblast precursor cell lines and primary osteoblasts with TNF and found that TNF, but not interleukin-1, significantly increased Smurf1 and Smurf2 expression. TNF increased the degradation of endogenous or transfected Runx2 protein, which was blocked by treating cells with a proteasomal inhibitor or by infecting cells with small interfering (si) RNA against Smurf1 or Smurf2. TNF inhibited the expression of bone morphogenetic protein and transforming growth factor-beta signaling reporter constructs, and the inhibition of each was blocked by Smurf1 siRNA and Smurf2 siRNA, respectively. Overexpression of Smurf1 and/or Smurf2 siRNAs prevented the inhibitory effect of TNF on Runx2 reporter. Consistent with these in vitro findings, bones from TNF transgenic mice or TNF-injected wild type mice had increased Smurf1 and decreased Runx2 protein levels. We propose that one of the mechanisms by which TNF inhibits bone formation in inflammatory bone disorders is by promoting Runx2 proteasomal degradation through up-regulation of Smurf1 and Smurf2 expression.	Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Dept Orthopaed, Ctr Musculoseletal Res, Rochester, NY 14642 USA; NCI, Ctr Canc Res, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xing, LP (corresponding author), Univ Rochester, Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	Lianping_xing@urmc.rochester.edu	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL CANCER INSTITUTE [Z01BC010419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051189, R01AR048697, R03AR048920, R01AR043510] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC011168-01] Funding Source: Medline; NIAMS NIH HHS [R01 AR051189, R03 AR048920-02, R01 AR043510, R01 AR048697, R03 AR048920, R01 AR051189-02, AR051189, AR48697, R01 AR051189-01, AR43510] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043-4666(03)00106-6; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; Datto M, 2005, CELL, V121, P2, DOI 10.1016/j.cell.2005.03.017; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Gilbert LC, 2005, AM J PHYSIOL-ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004; Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281-200005000-00006; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kitajima I, 1996, J BONE MINER RES, V11, P200; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Lam J, 2001, J BONE MINER RES, V16, pS150; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; LI YP, 1992, J IMMUNOL, V148, P788; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Nair SP, 2000, RHEUMATOLOGY, V39, P821, DOI 10.1093/rheumatology/39.8.821; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; TAICHMAN RS, 1992, INFLAMMATION, V16, P587, DOI 10.1007/BF00919342; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Tsuboi M, 1999, J LAB CLIN MED, V134, P222, DOI 10.1016/S0022-2143(99)90201-9; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang Y, 2004, CELL CYCLE, V3, P391; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	38	233	248	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4326	4333		10.1074/jbc.M509430200	http://dx.doi.org/10.1074/jbc.M509430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16373342	hybrid, Green Accepted			2022-12-25	WOS:000235275300067
J	Lemonnier, L; Trebak, M; Lievremont, JP; Bird, GS; Putney, JW				Lemonnier, L; Trebak, M; Lievremont, JP; Bird, GS; Putney, JW			Protection of TRPC7 cation channels from calcium inhibition by closely associated SERCA pumps	FASEB JOURNAL			English	Article						calcium channels; calcium signaling; ion channels; TRPC channels	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; CAPACITATIVE CA2+ ENTRY; TRANSIENT RECEPTOR; DROSOPHILA TRP; FUNCTIONAL-CHARACTERIZATION; TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; SIGNALING MECHANISM; MOLECULAR-CLONING; HUMAN HOMOLOG	Numerous studies have demonstrated that members of the transient receptor potential (TRP) superfamily of channels are involved in regulated Ca2+ entry. Additionally, most Ca2+-permeable channels are themselves regulated by Ca2+, often in complex ways. In the current study, we have investigated the regulation of TRPC7, a channel known to be potentially activated by both store-operated mechanisms and non-store-operated mechanisms involving diacylglycerols. Surprisingly, we found that activation of TRPC7 channels by diacylglycerol was blocked by the SERCA pump inhibitor thapsigargin. The structurally related channel, TRPC3, was similarly inhibited. This effect depended on extracellular calcium and on the driving force for Ca2+ entry. The inhibition is not due to calcium entry through store-operated channels but rather results from calcium entry through TRPC7 channels themselves. The effect of thapsigargin was prevented by inhibition of calmodulin and was mimicked by pharmacological disruption of the actin cytoskeleton. Our results suggest the presence of a novel mechanism involving negative regulation of TRPC channels by calcium entering through the channels. Under physiological conditions, this negative feedback by calcium is attenuated by the presence of closely associated SERCA pumps.	NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.	putney@niehs.nih.gov	Bird, Gary/AAI-8186-2021; Lemonnier, Loic/L-7289-2018; Trebak, Mohamed/E-7405-2014; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Lemonnier, Loic/0000-0001-6200-5382; Putney, James W/0000-0002-3379-4789	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boulay G, 2002, CELL CALCIUM, V32, P201, DOI 10.1016/S0143416002001550; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hovnanian A, 2004, BIOCHEM BIOPH RES CO, V322, P1237, DOI 10.1016/j.bbrc.2004.08.067; Lievremont JP, 2004, AM J PHYSIOL-CELL PH, V287, pC1709, DOI 10.1152/ajpcell.00350.2004; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Lucas P, 2003, NEURON, V40, P551, DOI 10.1016/S0896-6273(03)00675-5; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; Riccio A, 2002, J BIOL CHEM, V277, P12302, DOI 10.1074/jbc.M112313200; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Shi J, 2004, J PHYSIOL-LONDON, V561, P415, DOI 10.1113/jphysiol.2004.075051; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Vazquez G, 2004, J BIOL CHEM, V279, P40521, DOI 10.1074/jbc.M405280200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Xu SZ, 2001, CIRC RES, V88, P84, DOI 10.1161/01.RES.88.1.84; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	39	31	31	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					503	+		10.1096/fj.05-4714fje	http://dx.doi.org/10.1096/fj.05-4714fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16401641				2022-12-25	WOS:000235996000032
J	Taube, ME; Liu, XW; Fridman, R; Kim, HRC				Taube, M. E.; Liu, X-W; Fridman, R.; Kim, H-RC			TIMP-1 regulation of cell cycle in human breast epithelial cells via stabilization of p27(KIP1) protein	ONCOGENE			English	Article						TIMP-1; cell cycle; p27(KIP1); apoptosis	ERYTHROID-POTENTIATING ACTIVITY; TISSUE INHIBITOR; RETINOBLASTOMA PROTEIN; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; METALLOPROTEINASES-1 TIMP-1; BRANCHING MORPHOGENESIS; SIGNAL-TRANSDUCTION; LIVER FIBROSIS; MAMMARY-GLAND	Increasing evidence suggests that tissue inhibitor of metalloproteinases-1 (TIMP-1) can directly regulate cell growth and apoptosis independent of its matrix metalloproteinases (MMPs)-inhibitory activity. While TIMP-1's antiapoptotic activity has been well demonstrated, con. flicting data has been reported regarding TIMP-1's role in growth regulation. Here we show that TIMP-1 reduces the growth rate of human breast epithelial (MCF10A)cells by inducing cell cycle arrest at G(1). TIMP-1-mediated cell cycle arrest is associated with its downregulation of cyclin D-1 and upregulation of p27(KIP1), resulting in inhibition of cyclin-dependent kinase activity necessary for phosphorylation of the tumor suppressor retinoblastoma protein. We further show that TIMP-1 modulation of cyclin D1 and p27KIP1 is achieved through TIMP-1-mediated differential regulation of protein stability independent of growth factor signaling. We also show that TIMP-1-mediated differential regulation of cyclin D1 and p27KIP1 is independent of cell adhesion signaling. Whereas approximately 50% of MCF10A cells with reduced TIMP-1 expression underwent cell death following loss of cell adhesion (anoikis), TIMP-1 overexpressing cells remained viable with prominent cell cycle arrest without detectable cell death. Taken together, we propose that TIMP-1-mediated cell survival independent of cell adhesion is accompanied with cell cycle arrest in human breast epithelial cells, although cell cycle regulation may not be a prerequisite for TIMP-1 regulation of apoptosis in general.	Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 540 E Canfield Ave, Detroit, MI 48201 USA.	hrckim@med.wayne.edu			NCI NIH HHS [CA89113] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089113] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; AVALOS BR, 1988, BLOOD, V71, P1720; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DECLERCK YA, 1992, CANCER RES, V52, P701; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DULBECCO R, 1986, CANCER RES, V46, P2449; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Henriet P, 1999, APMIS, V107, P111, DOI 10.1111/j.1699-0463.1999.tb01533.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee SJ, 2003, BIOCHEM BIOPH RES CO, V312, P1196, DOI 10.1016/j.bbrc.2003.11.050; Lelievre S, 1996, RECENT PROG HORM RES, V51, P417; Li GY, 1999, CANCER RES, V59, P6267; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Liu XW, 2005, CANCER RES, V65, P898; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; McCarthy K, 1999, INT J CANCER, V84, P44, DOI 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.3.CO;2-G; Mohammed FF, 2005, HEPATOLOGY, V41, P857, DOI 10.1002/hep.20618; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Porter JF, 2004, BRIT J CANCER, V90, P463, DOI 10.1038/sj.bjc.6601533; Ree AH, 1997, CLIN CANCER RES, V3, P1623; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Schmidt J W, 1993, Semin Cell Biol, V4, P161, DOI 10.1006/scel.1993.1020; Schrohl AS, 2004, CLIN CANCER RES, V10, P2289, DOI 10.1158/1078-0432.CCR-03-0360; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Whitelock JM, 1996, J BIOL CHEM, V271, P10079, DOI 10.1074/jbc.271.17.10079; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; Yoshiji H, 2002, HEPATOLOGY, V36, P850, DOI 10.1053/jhep.2002.35625; Yoshiji H, 1996, INT J CANCER, V69, P131, DOI 10.1002/(SICI)1097-0215(19960422)69:2<131::AID-IJC11>3.0.CO;2-C	53	46	50	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3041	3048		10.1038/sj.onc.1209336	http://dx.doi.org/10.1038/sj.onc.1209336			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407831				2022-12-25	WOS:000237950800008
J	Kupzig, S; Deaconescu, D; Bouyoucef, D; Walker, SA; Liu, Q; Polte, CL; Daumke, O; Ishizaki, T; Lockyer, PJ; Wittinghofer, A; Cullen, PJ				Kupzig, S; Deaconescu, D; Bouyoucef, D; Walker, SA; Liu, Q; Polte, CL; Daumke, O; Ishizaki, T; Lockyer, PJ; Wittinghofer, A; Cullen, PJ			GAP1 family members constitute bifunctional Ras and Rap GTPase-activating proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,3,4,5-TETRAKISPHOSPHATE RECEPTORS GAP1(IP4BP); PLECKSTRIN HOMOLOGY DOMAIN; BINDING PROTEIN; ARGININE-FINGER; GENETIC SCREEN; KINASE-II; IDENTIFICATION; CALCIUM; SYNGAP; SPECTROSCOPY	GAP1(IP4BP) is a member of the GAP1 family of Ras GTPase-activating proteins ( Ras GAPs) that includes GAP1(m), CAPRI, and RASAL. Composed of a central Ras GAP domain, surrounded by amino-terminal C-2 domains and a carboxyl-terminal pleckstrin homology/Bruton's tyrosine kinase domain, GAP1(IP4BP) has previously been shown to possess an unexpected GAP activity on the Ras-related protein Rap, besides the predicted Ras GAP activity (Cullen, P. J., Hsuan, J. J., Truong, O., Letcher, A. J., Jackson, T. R., Dawson, A. P., and Irvine, R. F. ( 1995) Nature 376, 527 - 530). Here we have shown that GAP1IP4BP is indeed an efficient Ras/Rap GAP, having K(m)s of 213 and 42 mu M and estimated k(cat)s of 48 and 16 s(-1) for Ras and Rap, respectively. For this dual activity, regions outside the Ras GAP domain are required, as the isolated domain ( residues 291 - 569) retains a pronounced Ras GAP activity yet has very low activity toward Rap. Interestingly, mutagenesis of the RasGAP arginine finger, and surrounding residues important in Ras binding, inhibit both Ras and Rap GAP activity of GAP1(IP4BP). Although the precise details by which GAP1(IP4BP) can function as a Rap GAP remain to be determined, these data are consistent with Rap associating with GAP1(IP4BP) through the Ras-binding site within the Ras GAP domain. Finally, we have established that such dual Ras/Rap GAP activity is not restricted to GAP1(IP4BP). Although GAP1(m) appears to constitute a specific Ras GAP, CAPRI and RASAL display dual activity. For CAPRI, its Rap GAP activity is modulated upon its Ca2+-induced association with the plasma membrane.	Univ Bristol, Sch Med Sci, Dept Biochem, Henry Wellcome Integrated Signaling Labs, Bristol BS8 1TD, Avon, England; Max Planck Inst Mol Physiol, D-44202 Dortmund, Germany; Babraham Inst, Signaling Programme, Cambridge CB2 4AT, England	University of Bristol; Max Planck Society; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Henry Wellcome Integrated Signaling Labs, Bristol BS8 1TD, Avon, England.	Pete.Cullen@bris.ac.uk	Polte, Christian Lars/AAA-9490-2021	Polte, Christian Lars/0000-0001-7125-9747; Cullen, Peter/0000-0002-9070-8349; Walker, Simon/0000-0001-9185-4922	Wellcome Trust [072166] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Allen M, 1998, GENE, V218, P17, DOI 10.1016/S0378-1119(98)00394-1; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Bottomley JR, 1998, BIOCHEM BIOPH RES CO, V250, P143, DOI 10.1006/bbrc.1998.9179; Brinkmann T, 2002, J BIOL CHEM, V277, P12525, DOI 10.1074/jbc.M109176200; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Chakrabarti PP, 2004, J BIOL CHEM, V279, P46226, DOI 10.1074/jbc.M405603200; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Cozier GE, 2000, J BIOL CHEM, V275, P28261; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Daumke O, 2004, NATURE, V429, P197, DOI 10.1038/nature02505; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Fauchereau F, 2003, MOL CELL NEUROSCI, V23, P574, DOI 10.1016/S1044-7431(03)00078-2; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hattori M, 2003, J BIOCHEM, V134, P479, DOI 10.1093/jb/mvg180; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kolfschoten IGM, 2005, CELL, V121, P849, DOI 10.1016/j.cell.2005.04.017; Krapivinsky G, 2004, NEURON, V43, P563, DOI 10.1016/j.neuron.2004.08.003; Kupzig S, 2005, P NATL ACAD SCI USA, V102, P7577, DOI 10.1073/pnas.0409611102; Liu Q, 2005, J CELL BIOL, V170, P183, DOI 10.1083/jcb.200504167; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Moskwa P, 2005, J BIOL CHEM, V280, P6716, DOI 10.1074/jbc.M412563200; Oh JS, 2004, J BIOL CHEM, V279, P17980, DOI 10.1074/jbc.M314109200; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Zhang J, 2005, NAT IMMUNOL, V6, P911, DOI 10.1038/ni1232; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	46	57	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9891	9900		10.1074/jbc.M512802200	http://dx.doi.org/10.1074/jbc.M512802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16431904	Green Accepted, hybrid			2022-12-25	WOS:000236594300010
J	Kong, KY; Kedes, L				Kong, KY; Kedes, L			Leucine 135 of tropomodulin-1 regulates its association with tropomyosin, its cellular localization, and the integrity of sarcomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; CARDIAC MYOCYTES; SKELETAL-MUSCLE; POINTED ENDS; COILED-COIL; ACTIN; ISOFORM; CLONING; IDENTIFICATION; EXPRESSION	Tropomodulin-1 (Tmod-1) is a well defined actin-capping protein that interacts with tropomyosin (TM) at the pointed end of actin filaments. Previous studies by others have mapped its TM-binding domain to the amino terminus from amino acid 39 to 138. In this study, we have identified several amino acid residues on Tmod-1 that are important for its interaction with TM5 ( a nonmuscle TM isoform). Glutathione S-transferase affinity chromatography and immunoprecipitation assays reveal that Tmod sense mutations of either amino acid 134, 135, or 136 causes various degrees of loss of function of Tmod TM-binding ability. The reduction of TM-binding ability was relatively mild ( reduced similar to 20 - 40%) from the G136A Tmod mutant but more substantially ( reduced similar to 50 - 100%) from the I134D, L135E, and L135V Tmod mutants. In addition, mutation at any of these three sites dramatically alters the subcellular location of Tmod-1 when introduced into mammalian cells. Further analysis of these three mutants uncovered a previously unknown nuclear trafficking function of Tmod-1, and residues 134, 135, and 136 are located within a nuclear export signal motif. As a result, mutation on either residue 134 or residue 135 not only will cause a significant reduction of the Tmod-1 ability to bind to TM5 but also lead to predominant nuclear localization of Tmod-1 by crippling its nuclear export mechanism. The failure of the Tmod mutations to fully associate with TM5 when introduced into neonatal rat cardiomyocytes was also associated with an accelerated and severe fragmentation of sarcomeric structures compared with overexpression of wild type Tmod-1. The multiple losses of function of Tmod engendered by these missense mutations are most severe with the single substitution of residue 135.	Univ So Calif, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Kedes, L (corresponding author), Univ So Calif, Inst Med Genet, 2250 Alcazar St, Los Angeles, CA 90033 USA.	kedes@usc.edu			NATIONAL CANCER INSTITUTE [C06CA062528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR010600, C06RR014514] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012941] Funding Source: NIH RePORTER; NCI NIH HHS [C06 CA62528-01] Funding Source: Medline; NCRR NIH HHS [C06 RR014514-01, C06 RR10600-01] Funding Source: Medline; NHLBI NIH HHS [HL52771] Funding Source: Medline; NIDCR NIH HHS [DE12941] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLUCCIO LM, 1994, J CELL BIOL, V127, P1497, DOI 10.1083/jcb.127.6.1497; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Fischer RS, 2003, TRENDS CELL BIOL, V13, P593, DOI 10.1016/j.tcb.2003.09.007; Fowler VM, 2003, J BIOL CHEM, V278, P40000, DOI 10.1074/jbc.M306895200; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; Greenfield NJ, 2005, BIOPHYS J, V88, P372, DOI 10.1529/biophysj.104.051128; Greenfield NJ, 2002, BIOPHYS J, V82, P2580, DOI 10.1016/S0006-3495(02)75600-2; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; ITO M, 1995, DEV BIOL, V167, P317, DOI 10.1006/dbio.1995.1026; Kong KY, 2004, J BIOL CHEM, V279, P30856, DOI 10.1074/jbc.M302845200; Kostyukova AS, 2005, BIOCHEMISTRY-US, V44, P4905, DOI 10.1021/bi047468p; Kostyukova AS, 2004, J BIOL CHEM, V279, P5066, DOI 10.1074/jbc.M311186200; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; Sakoda T, 1999, J MOL CELL CARDIOL, V31, P2037, DOI 10.1006/jmcc.1999.1035; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SUNG LA, 1992, J BIOL CHEM, V267, P2616; Sussman MA, 1998, CIRC RES, V82, P94; SUSSMAN MA, 1994, CIRC RES, V75, P221, DOI 10.1161/01.RES.75.2.221; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; URSITTI JA, 1994, J CELL SCI, V107, P1633; Vera C, 2005, ARCH BIOCHEM BIOPHYS, V444, P130, DOI 10.1016/j.abb.2005.10.002; Watakabe A, 1996, J CELL SCI, V109, P2299; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627	29	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9589	9599		10.1074/jbc.M512064200	http://dx.doi.org/10.1074/jbc.M512064200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16434395	hybrid			2022-12-25	WOS:000236404700070
J	Nelson, SW; Yang, JS; Benkovic, SJ				Nelson, SW; Yang, JS; Benkovic, SJ			Site-directed mutations of T4 helicase loading protein (gp59) reveal multiple modes of DNA polymerase inhibition and the mechanism of unlocking by gp41 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPLICATION FORK; BINDING-PROTEIN; LEADING-STRAND; BACTERIOPHAGE-T4 PRIMOSOME; MEDIATOR PROTEINS; PRIMER SYNTHESIS; GENE-59 PROTEIN; SLIDING CLAMP; COMPLEX	The T4 helicase loading protein (gp59) interacts with amultitude of DNA replication proteins. In an effort to determine the functional consequences of these protein-protein interactions, point mutations were introduced into the gp59 protein. Mutations were chosen based on the available crystal structure and focused on hydrophobic residues with a high degree of solvent accessibility. Characterization of the mutant proteins revealed a single mutation, Y122A, which is defective in polymerase binding and has weakened affinity for the helicase. The interaction between single-stranded DNA-binding protein and Y122A is unaffected, as is the affinity of Y122A for DNA substrates. When standard concentrations of helicase are employed, Y122A is unable to productively load the helicase onto forked DNA substrates. As a result of the loss of polymerase binding, Y122A cannot inhibit the polymerase during nucleotide idling or prevent it from removing the primer strand of a D-loop. However, Y122A is capable of inhibiting strand displacement synthesis by polymerase. The retention of strand displacement inhibition by Y122A, even in the absence of a gp59-polymerase interaction, indicates that there are two modes of polymerase inhibition by gp59. Inhibition of the polymerase activity only requires gp59 to bind to the replication fork, whereas inhibition of the exonuclease activity requires an interaction between the polymerase and gp59. The inability of Y122A to interact with both the polymerase and the helicase suggests a mechanism for polymerase unlocking by the helicase based on a direct competition between the helicase and polymerase for an overlapping binding site on gp59.	Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, Wartik Lab 414, University Pk, PA 16802 USA.	sjb1@psu.edu			NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; Alley SC, 1999, J BIOL CHEM, V274, P24485, DOI 10.1074/jbc.274.35.24485; Alley SC, 2001, J BIOL CHEM, V276, P39340, DOI 10.1074/jbc.M104956200; Ando RA, 1998, J MOL BIOL, V283, P785, DOI 10.1006/jmbi.1998.2124; BARRY J, 1994, J BIOL CHEM, V269, P33049; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHA TA, 1989, J BIOL CHEM, V264, P12220; Chastain PD, 2003, J BIOL CHEM, V278, P21276, DOI 10.1074/jbc.M301573200; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, P NATL ACAD SCI USA, V93, P14456, DOI 10.1073/pnas.93.25.14456; Dudas KC, 2005, J BIOL CHEM, V280, P21561, DOI 10.1074/jbc.m502351200; HACKER KJ, 1994, J BIOL CHEM, V269, P24209; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Jones CE, 2004, J BIOL CHEM, V279, P25721, DOI 10.1074/jbc.M402128200; Jones CE, 2004, J BIOL CHEM, V279, P12067, DOI 10.1074/jbc.M313840200; Jones CE, 2000, J BIOL CHEM, V275, P27145; JONGENEEL CV, 1984, ADV EXP MED BIOL, V179, P17; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; Kadyrov FA, 2003, J BIOL CHEM, V278, P25247, DOI 10.1074/jbc.M302564200; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; Lefebvre SD, 1997, J MOL BIOL, V272, P312, DOI 10.1006/jmbi.1997.1264; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MANNIATIS T, 1994, MOL CLONING LAB MANU; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Morrical SW, 1996, J BIOL CHEM, V271, P20198, DOI 10.1074/jbc.271.33.20198; MOSIG G, 1995, FEMS MICROBIOL REV, V17, P83, DOI 10.1111/j.1574-6976.1995.tb00190.x; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; MUNN MM, 1991, J BIOL CHEM, V266, P20024; Neuvirth H, 2004, J MOL BIOL, V338, P181, DOI 10.1016/j.jmb.2004.02.040; Norcum MT, 2005, P NATL ACAD SCI USA, V102, P3623, DOI 10.1073/pnas.0500713102; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; SELICK HE, 1988, J BIOL CHEM, V263, P11336; Sexton DJ, 1997, CURR OPIN CHEM BIOL, V1, P316, DOI 10.1016/S1367-5931(97)80068-3; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Sun SY, 2003, J BIOL CHEM, V278, P3876, DOI 10.1074/jbc.M210497200; Valentine AM, 2001, BIOCHEMISTRY-US, V40, P15074, DOI 10.1021/bi0108554; Xi J, 2005, BIOCHEMISTRY-US, V44, P7747, DOI 10.1021/bi047296w; Xi J, 2005, BIOCHEMISTRY-US, V44, P2305, DOI 10.1021/bi0479508; Yang JS, 2005, J BIOL CHEM, V280, P25416, DOI 10.1074/jbc.M501847200; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; Zhang ZQ, 2005, P NATL ACAD SCI USA, V102, P3254, DOI 10.1073/pnas.0500327102	50	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8697	8706		10.1074/jbc.M512185200	http://dx.doi.org/10.1074/jbc.M512185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407253	hybrid			2022-12-25	WOS:000236247100047
J	Takekawa, H; Ina, C; Sato, R; Toma, K; Ogawa, H				Takekawa, H; Ina, C; Sato, R; Toma, K; Ogawa, H			Novel carbohydrate-binding activity of pancreatic trypsins to N-linked glycans of glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; PORCINE THYROGLOBULIN; SUGAR CHAINS; PROTEOLYTIC CLEAVAGE; AMINOPEPTIDASE-N; UNIT-A; GLYCOSYLATION; BOVINE; MOIETY; RAT	How glycosylation affects the reactivity of proteins to trypsin is not well understood. Bovine and porcine pancreatic trypsins were discovered to bind to alpha-Man, Neu5Ac alpha 2,6Gal beta 1,4Glc, and alpha-galactose sequences by binding studies with biotinylated sugar-polymers. Quantitative kinetic studies supported that phenylmethylsulfonyl fluoride (PMSF)-treated trypsin binds to glycolipid analogues possessing alpha- Man or alpha-NeuAc but not to those possessing beta-galactose or beta-GlcNAc residue. Enzyme-linked immunosorbent assay ( ELISA) showed that trypsin binds to six kinds of biotinylated glycoproteins possessing high mannose-type and complex-type N-glycans but not to bovine submaxillary mucin, which possesses only O-glycans. Further, the binding of trypsin to glycoproteins was differentially changed by treatments with sequential exoglycosidases, endoglycosidase H, or N-glycosidase F. Quantitative kinetic studies indicated that PMSF-treated trypsin binds with bovine thyroglobulin with the affinity constant of 10(10) M-1, which was the highest among the glycoproteins examined, and that alpha-galactosidase treatment decreased it to 10(5) M-1. PMSF-treated trypsin bound to other glycoproteins, including ovomucoid, a trypsin inhibitor, with the affinity constants of 10(8)- 10(5) mol(-1) and were markedly changed by glycosidase treatments in manners consistent with the sugar-binding specificities suggested by ELISA. Thus, the binding site for glycans was shown to be distinct from the catalytic site, allowing trypsin to function as an uncompetitive activator in the hydrolysis of a synthetic peptide substrate. Correspondingly the carbohydrate-binding activities of trypsin were unaffected by treatment with PMSF or soybean trypsin inhibitor. The results indicate the presence of an allosteric regulatory site on trypsin that sugar-specifically interacts with glycoproteins in addition to the proteolytic catalytic site.	Ochanomizu Univ, Grad Sch Humanities & Sci, Bunkyo Ku, Tokyo 1128610, Japan; Ochanomizu Univ, Glycosci Inst, Bunkyo Ku, Tokyo 1128610, Japan; Noguchi Inst, Itabashi Ku, Tokyo 1730003, Japan	Ochanomizu University; Ochanomizu University	Ogawa, H (corresponding author), Ochanomizu Univ, Grad Sch Humanities & Sci, Bunkyo Ku, Tokyo 1128610, Japan.	hogawa@cc.ocha.ac.jp						ABBOTT F, 1975, BIOCHEMISTRY-US, V14, P4935, DOI 10.1021/bi00693a024; Arnold U, 1998, J PROTEIN CHEM, V17, P397, DOI 10.1023/A:1022562316513; Ashida H, 2000, BIOSCI BIOTECH BIOCH, V64, P2266, DOI 10.1271/bbb.64.2266; Azefu Y, 2002, BIOORGAN MED CHEM, V10, P4013, DOI 10.1016/S0968-0896(02)00266-3; BERMAN E, 1987, MAGN RESON CHEM, V25, P784, DOI 10.1002/mrc.1260250910; Chen JM, 2000, PANCREAS, V21, P57, DOI 10.1097/00006676-200007000-00052; ERICKSON RH, 1983, BIOCHIM BIOPHYS ACTA, V743, P37, DOI 10.1016/0167-4838(83)90415-6; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FU DT, 1992, ANAL BIOCHEM, V206, P53, DOI 10.1016/S0003-2697(05)80010-7; GENTILE F, 1993, EUR J BIOCHEM, V218, P603, DOI 10.1111/j.1432-1033.1993.tb18414.x; GU JX, 1989, J BIOCHEM-TOKYO, V106, P66, DOI 10.1093/oxfordjournals.jbchem.a122821; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mann DA, 1998, J AM CHEM SOC, V120, P10575, DOI 10.1021/ja9818506; MARTH JD, 1999, ESSENTIALS GLYCOBIOL, P85; Matsushita H, 2002, J BIOL CHEM, V277, P4680, DOI 10.1074/jbc.M105877200; ORIOL R, 1994, TRANSPLANT INT, V7, P405, DOI 10.1111/j.1432-2277.1994.tb01259.x; PHILLIPS MA, 1992, CURR OPIN STRUC BIOL, V2, P713; PUSZTAI A, 1995, GLYCOCONJUGATE J, V12, P22, DOI 10.1007/BF00731865; Pusztai A, 1996, TRENDS GLYCOSCI GLYC, V8, P149, DOI 10.4052/tigg.8.149; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1993, HISTOCHEM J, V25, P687; Sato R, 2004, J CARBOHYD CHEM, V23, P375, DOI 10.1081/CAR-200039362; SCHWERT GW, 1955, BIOCHIM BIOPHYS ACTA, V16, P570, DOI 10.1016/0006-3002(55)90280-8; SHARON N, 1975, COMPLEX CARBOHYDRATE, P109; Shen H, 2001, PEDIATR RES, V49, P789, DOI 10.1203/00006450-200106000-00013; TAKASAKI S, 1986, BIOCHEMISTRY-US, V25, P5709, DOI 10.1021/bi00367a054; TAKASAKI S, 1991, BIOCHEMISTRY-US, V30, P9102, DOI 10.1021/bi00101a028; THALL A, 1990, BIOCHEMISTRY-US, V29, P3959, DOI 10.1021/bi00468a024; Toba SY, 2000, BIOCHEM BIOPH RES CO, V271, P281, DOI 10.1006/bbrc.2000.2618; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; TSUJI T, 1981, BIOCHEM J, V195, P691, DOI 10.1042/bj1950691; Uchibori-Iwaki H, 2000, GLYCOBIOLOGY, V10, P865, DOI 10.1093/glycob/10.9.865; Ueda H, 1999, FEBS LETT, V448, P75, DOI 10.1016/S0014-5793(99)00334-8; VANDIJK W, 1995, GLYCOCONJUGATE J, V12, P227, DOI 10.1007/BF00731324; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809	41	11	12	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8528	8538		10.1074/jbc.M513773200	http://dx.doi.org/10.1074/jbc.M513773200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16418164	Green Published, hybrid			2022-12-25	WOS:000236247100028
J	Abbasi, S; Lee, JD; Su, B; Chen, X; Alcon, JL; Yang, JH; Kellems, RE; Xia, Y				Abbasi, S; Lee, JD; Su, B; Chen, X; Alcon, JL; Yang, JH; Kellems, RE; Xia, Y			Protein kinase-mediated regulation of calcineurin through the phosphorylation of modulatory calcineurin-interacting protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CRITICAL REGION; CARDIAC-HYPERTROPHY; ELECTRICAL-STIMULATION; TARGETED INHIBITION; RECEPTOR ACTIVATION; GENE-EXPRESSION; GROWTH-FACTOR; C-JUN; FAMILY; PATHWAY	Calcineurin is a serine/threonine protein phosphatase that plays a critical role in many physiologic processes such as T-cell activation, skeletal myocyte differentiation, and cardiac hypertrophy. We previously showed that active MEKK3 is capable of stimulating calcineurin/ nuclear factor of activated T-cells ( NFAT) signaling in cardiac myocytes through phosphorylation of modulatory calcineurin-interacting protein 1 (MCIP1). However, the protein kinases that function downstream of MEKK3 to mediate MCIP1 phosphorylation and the mechanism of MCIP1-mediated calcineurin regulation have not been defined. Here, we show that MEK5 and big MAP kinase 1 (BMK1) function downstream of MEKK3 in a signaling cascade that induces calcineurin activity through phosphorylation of MCIP1. Genetic studies showed that BMK1-deficient mouse lung fibroblasts failed to mediate MCIP1 phosphorylation and activate calcineurin/ NFAT in response to angiotensin II, a potent NFAT activator. Conversely, restoring BMK1 to the deficient cells restored angiotensin II-mediated calcineurin/ NFAT activation. Thus, using BMK1-deficient mouse lung fibroblast cells, we provided the genetic evidence that BMK1 is required for angiotensin II-mediated calcineurin/ NFAT activation through MICP1 phosphorylation. Finally, we discovered that phosphorylated MCIP1 dissociates from calcineurin and binds with 14-3-3, thereby relieving its inhibitory effect on calcineurin activity. In summary, our findings reveal a previously unrecognized essential regulatory role of mitogen-activated protein kinase signaling in calcineurin activation through the reversible phosphorylation of a calcineurin-interacting protein, MCIP1.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston Med Sch, Houston, TX 77030 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Texas Childrens Hosp, Ctr Canc, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Pediat, Houston, TX 77030 USA; Cent S Univ, XiangYa Hosp, Dept Urol, Changsha 410078, Hunan, Peoples R China	University of Texas System; University of Texas Health Science Center Houston; Scripps Research Institute; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; Central South University	Xia, Y (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston Med Sch, 6431 Fannin St, Houston, TX 77030 USA.	Yang.Xia@uth.tmc.edu						Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Bueno OF, 2002, CARDIOVASC RES, V53, P806, DOI 10.1016/S0008-6363(01)00493-X; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hayashi M, 2004, J CLIN INVEST, V113, P1138, DOI 10.1172/JCI200419890; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hilioti Z, 2003, BIOCHEM BIOPH RES CO, V311, P1089, DOI 10.1016/S0006-291X(03)01515-8; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kato Y, 2000, IMMUNOL RES, V21, P233, DOI 10.1385/IR:21:2-3:233; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MFREY N, 2000, NAT MED, V6, P1221; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Ryeom S, 2003, NAT IMMUNOL, V4, P874, DOI 10.1038/ni966; SHAHRZAD A, 2005, J BIOL CHEM, V280, P36737; Thway TM, 2004, CIRCULATION, V110, P1612, DOI 10.1161/01.CIR.0000142855.68398.3A; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; van Rooij E, 2004, CIRC RES, V94, pE18, DOI 10.1161/01.RES.0000118597.54416.00; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Vega RB, 2002, J BIOL CHEM, V277, P30401, DOI 10.1074/jbc.M200123200; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Xia Y, 2002, J BIOL CHEM, V277, P24601, DOI 10.1074/jbc.M201369200; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769	52	60	62	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7717	7726		10.1074/jbc.M510775200	http://dx.doi.org/10.1074/jbc.M510775200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16415348	hybrid			2022-12-25	WOS:000236031000004
J	Bode, L; Murch, S; Freeze, HH				Bode, L; Murch, S; Freeze, HH			Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; BARRIER FUNCTION; TNF-ALPHA; FONTAN CIRCULATION; EPITHELIAL BARRIER; IFN-GAMMA; EXPRESSION; OPERATION; REVERSAL	Protein-losing enteropathy (PLE), the loss of plasma proteins through the intestine, is a symptom in ostensibly unrelated diseases. Emerging commonalities indicate that genetic insufficiencies predispose for PLE and environmental insults, e. g. viral infections and inflammation, trigger PLE onset. The specific loss of heparan sulfate (HS) from the basolateral surface of intestinal epithelial cells only during episodes of PLE suggests a possible mechanistic link. In the first tissue culture model of PLE using a monolayer of intestinal epithelial HT29 cells, we proved that HS loss directly causes protein leakage and amplifies the effects of the proinflammatory cytokine tumor necrosis factor alpha(TNF alpha). Here, we extend our in vitro model to assess the individual and combined effects of HS loss, interferon gamma (IFN gamma), TNF alpha, and increased pressure, and find that HS plays a central role in the patho-mechanisms underlying PLE. Increased pressure, mimicking venous hypertension seen in post-Fontan PLE patients, substantially increased protein leakage, but HS loss, IFN gamma, or TNF alpha alone had only minor effects. However, IFN gamma up-regulated TNFR1 expression and amplified TNF alpha-induced protein leakage. IFN gamma and TNF alpha compromised the integrity of the HT29 monolayer and made it more susceptible to increased pressure. HS loss itself compromises the integrity of the monolayer, amplifying the effects of pressure, but also amplifies the effects of both cytokines. In the absence of HS a combination of increased pressure, IFN gamma, and TNF alpha caused maximum protein leakage. Soluble heparin fully compensated for HS loss, providing a reasonable explanation for patient favorable response to heparin therapy.	Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, La Jolla, CA 92037 USA; Warwick Med Sch, Clin Sci Res Inst, Coventry CV2 2DX, W Midlands, England	Sanford Burnham Prebys Medical Discovery Institute; University of Warwick	Freeze, HH (corresponding author), Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hudson@burnham.org		Freeze, Hudson/0000-0001-6316-0501	NHLBI NIH HHS [R21 HL 078997] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL078997] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEEKEN WL, 1972, GASTROENTEROLOGY, V62, P207; Bode L, 2005, AM J PHYSIOL-GASTR L, V288, pG1015, DOI 10.1152/ajpgi.00461.2004; BODE L, 2005, IN PRESS BIOCH BIOPH; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Chakravortty D, 1999, MICROBIOL IMMUNOL, V43, P527, DOI 10.1111/j.1348-0421.1999.tb02438.x; Cheong JLY, 2004, ARCH DIS CHILD-FETAL, V89, pF367, DOI 10.1136/adc.2003.032821; Day RM, 2003, CYTOKINE, V21, P224, DOI 10.1016/S1043-4666(03)00091-7; Donnelly JP, 1997, J PEDIATR-US, V130, P474, DOI 10.1016/S0022-3476(97)70214-2; Fink Mitchell P, 2003, Curr Opin Crit Care, V9, P143, DOI 10.1097/00075198-200304000-00011; Fish SM, 1999, GUT, V45, P191, DOI 10.1136/gut.45.2.191; Fritchley SJ, 2000, CLIN EXP IMMUNOL, V120, P247, DOI 10.1046/j.1365-2249.2000.01178.x; Fujii T, 2003, J PEDIATR GASTR NUTR, V37, P577, DOI 10.1097/00005176-200311000-00014; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Harvima IT, 2004, J CELL BIOCHEM, V92, P372, DOI 10.1002/jcb.20068; Holmgren D, 2001, PEDIATR TRANSPLANT, V5, P135, DOI 10.1034/j.1399-3046.2001.005002135.x; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Kelly AM, 1998, MAYO CLIN PROC, V73, P777, DOI 10.4065/73.8.777; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; Lenz D, 2003, CRIT CARE, V7, P185, DOI 10.1186/cc2166; LORTAT-JACOB H, 1991, FEBS LETT, V280, P152, DOI 10.1016/0014-5793(91)80225-R; LORTAT-JACOB H, 1991, CELL MOL BIOL, V37, P253; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Marino BS, 2002, CURR OPIN PEDIATR, V14, P620, DOI 10.1097/00008480-200210000-00010; Mertens L, 1998, J THORAC CARDIOV SUR, V115, P1063, DOI 10.1016/S0022-5223(98)70406-4; Michell NP, 2001, EUR J GASTROEN HEPAT, V13, P449, DOI 10.1097/00042737-200104000-00026; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Murch SH, 1996, LANCET, V347, P1299, DOI 10.1016/S0140-6736(96)90941-1; MURCH SH, 1993, LANCET, V341, P711, DOI 10.1016/0140-6736(93)90485-Y; OSTROW A, 2004, IN PRESS J AM COLL C; Rychik Jack, 2002, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V5, P3, DOI 10.1053/pcsu.2002.31498; SALVESTRINI C, 2004, J PEDIAT GASTROENTER, V39, P278; Schmitz H, 1999, J CELL SCI, V112, P137; Shimizu T, 2003, J PEDIATR GASTR NUTR, V37, P504, DOI 10.1097/00005176-200310000-00019; Suenaert P, 2002, AM J GASTROENTEROL, V97, P2000; Thorne SA, 1998, EUR HEART J, V19, P514, DOI 10.1053/euhj.1997.0777; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; Tveit H, 2005, J BIOL CHEM, V280, P29596, DOI 10.1074/jbc.M503691200; Westphal V, 2000, AM J PATHOL, V157, P1917, DOI 10.1016/S0002-9440(10)64830-4; Youakim A, 1999, AM J PHYSIOL-GASTR L, V276, pG1279, DOI 10.1152/ajpgi.1999.276.5.G1279	39	52	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7809	7815		10.1074/jbc.M510722200	http://dx.doi.org/10.1074/jbc.M510722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434407	hybrid			2022-12-25	WOS:000236031000014
J	Lelj-Garolla, B; Mauk, AG				Lelj-Garolla, B; Mauk, AG			Self-association and chaperone activity of Hsp27 are thermally activated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SEDIMENTATION COEFFICIENT DISTRIBUTIONS; CRYSTAL-STRUCTURE; ANALYTICAL ULTRACENTRIFUGATION; ALPHA-CRYSTALLIN; CYTOCHROME-C; INDUCED OLIGOMERIZATION; REGULATED CHAPERONE; PROTECTIVE ACTIVITY; UNFOLDING PROTEINS	The small heat shock protein 27 (Hsp27) is an oligomeric, molecular chaperone in vitro. This chaperone activity and other physiological roles attributed to Hsp27 have been reported to depend on the state of self-association. In the present work, we have used sedimentation velocity experiments to demonstrate that the self-association of Hsp27 is independent of pH and ionic strength but increases significantly as the temperature is increased from 10 to 40 degrees C. The largest oligomers formed at 10 degrees C are similar to 8 - 12 mer, whereas at 40 degrees C oligomers as large as 22 - 30 mer are observed. Similarly, the chaperone activity of Hsp27 as indicated by its ability to inhibit dithiothreitol-induced insulin aggregation also increases with increased temperature, with a particularly sharp increase in activity as temperature is increased from 34 to 43 degrees C. Similar studies of an Hsp27 triple variant that mimics the behavior of the phosphorylated protein establish that this protein has greatly diminished chaperone activity that responds minimally to increased temperature. We conclude that Hsp27 can exploit a large number of oligomerization states and that the range of oligomer size and the magnitude of chaperone activity increase significantly as temperature is increased over the range that is relevant to the physiological heat shock response.	Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Mauk, AG (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mauk@interchange.ubc.ca		Lelj-Garolla, Barbara/0000-0002-6436-3850				Akhtar MW, 2004, J BIOL CHEM, V279, P55760, DOI 10.1074/jbc.M406333200; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; CANTOR CR, 1980, BIOPHYSICAL CHEM M 2; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chadli A, 1999, J BIOL CHEM, V274, P4133, DOI 10.1074/jbc.274.7.4133; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chowdary TK, 2004, BIOCHEM J, V381, P379, DOI 10.1042/BJ20031958; Dam J, 2005, BIOPHYS J, V89, P619, DOI 10.1529/biophysj.105.059568; Dam J, 2005, BIOPHYS J, V89, P651, DOI 10.1529/biophysj.105.059584; Dam J, 2004, METHOD ENZYMOL, V384, P185; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4559, DOI 10.1021/bi00692a001; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P19; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Lelj-Garolla B, 2005, J MOL BIOL, V345, P631, DOI 10.1016/j.jmb.2004.10.056; Lentze N, 2004, EUR J BIOCHEM, V271, P2494, DOI 10.1111/j.1432-1033.2004.04180.x; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN CS, 1995, BIOCHEMISTRY-US, V34, P5831, DOI 10.1021/bi00017a015; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2003, ANAL BIOCHEM, V320, P104, DOI 10.1016/S0003-2697(03)00289-6; Stromer T, 2004, J BIOL CHEM, V279, P11222, DOI 10.1074/jbc.M310149200; Stromer T, 2003, J BIOL CHEM, V278, P18015, DOI 10.1074/jbc.M301640200; Thorne ME, 2004, BIOCHEM BIOPH RES CO, V323, P1163, DOI 10.1016/j.bbrc.2004.08.215; Usui K, 2004, BIOCHEM BIOPH RES CO, V315, P113, DOI 10.1016/j.bbrc.2004.01.031; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vijayalakshmi J, 2001, STRUCTURE, V9, P367, DOI 10.1016/S0969-2126(01)00597-4; Wang XM, 1999, BIOCHEMISTRY-US, V38, P16876, DOI 10.1021/bi992005i	43	77	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8169	8174		10.1074/jbc.M512553200	http://dx.doi.org/10.1074/jbc.M512553200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16436384	hybrid			2022-12-25	WOS:000236031000055
J	Choi, SH; Hwang, SB				Choi, SH; Hwang, SB			Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TGF-BETA; NS5A PROTEIN; HEPATOCELLULAR-CARCINOMA; CELL-CYCLE; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR SUPPRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; LIVER FIBROSIS	Transforming growth factor-beta (TGF-beta) is implicated in the pathogenesis of liver disease. TGF-beta is involved both in liver regeneration and in the fibrotic and cirrhotic transformation with hepatitis viral infection. Hepatitis C virus (HCV) infection often leads to cirrhosis and hepatocellular carcinoma. HCV nonstructural 5A (NS5A) protein is a multifunctional protein that modulates cytokine-mediated signal transduction pathways. To elucidate the molecular mechanism of HCV pathogenesis, we examined the effect of NS5A protein on TGF-beta-stimulated signaling cascades. We show that NS5A protein inhibited the TGF-beta-mediated signaling pathway in hepatoma cell lines as determined by reporter gene assay. To further investigate the role of NS5A, we examined the protein/protein interaction between NS5A and TGF-beta signal transducers. Both in vitro and in vivo binding data showed that NS5A protein directly interacted with TGF-beta receptor I (T beta R-I) in hepatoma cell lines. This interaction was mapped to amino acids 148 - 238 of NS5A. We also found that NS5A protein co-localized with T beta R-I in the cytoplasm of Huh7 cells and inhibited TGF-beta-mediated nuclear translocation of Smad2. Furthermore, we demonstrate that NS5A protein abrogated the phosphorylation of Smad2 and the heterodimerization of Smad3 and Smad4. To further explore the relevance to viral infection, we examined the effect of the HCV subgenomic replicon on the TGF-beta signaling pathway. We show that the HCV subgenomic replicon also inhibited TGF-beta-induced signaling cascades. These results indicate that HCV NS5A modulates TGF-beta signaling through interaction with T beta R-I and that NS5A may be an important risk factor in HCV-associated liver pathogenesis.	Hallym Univ, Ilsong Inst Life Sci, Chunchon 200702, South Korea	Hallym University	Hwang, SB (corresponding author), Hallym Univ, Ilsong Inst Life Sci, 1 Ockcheon Dong, Chunchon 200702, South Korea.	sbhwang@hallym.ac.kr						AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CHO YG, 1993, MOL CELLS, V3, P195; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DI B, 1994, J CLIN GASTROENTEROL, V19, P222; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Ghosh AK, 2000, VIRUS RES, V67, P173, DOI 10.1016/S0168-1702(00)00141-6; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; JETTEN AM, 1986, EXP CELL RES, V167, P539, DOI 10.1016/0014-4827(86)90193-X; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee MN, 2002, J GEN VIROL, V83, P2145, DOI 10.1099/0022-1317-83-9-2145; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Majumder M, 2002, VIROLOGY, V294, P94, DOI 10.1006/viro.2001.1309; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki K, 2000, HEPATOLOGY, V32, P218, DOI 10.1053/jhep.2000.9145; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NEWMAN MJ, 1993, CANCER METAST REV, V12, P239, DOI 10.1007/BF00665956; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Park KJ, 2003, J BIOL CHEM, V278, P30711, DOI 10.1074/jbc.M209623200; Park KJ, 2002, J BIOL CHEM, V277, P13122, DOI 10.1074/jbc.M111599200; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; Ray S, 2003, J GASTROEN HEPATOL, V18, P393, DOI 10.1046/j.1440-1746.2003.02985.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Saltis J, 1996, MOL CELL ENDOCRINOL, V116, P227, DOI 10.1016/0303-7207(95)03721-7; Schuppan D, 2003, CELL DEATH DIFFER, V10, pS59, DOI 10.1038/sj.cdd.4401163; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Shimizu Ichiro, 2001, Current Drug Targets - Infectious Disorders, V1, P227, DOI 10.2174/1568005014606053; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Ueno T, 2001, INT J ONCOL, V18, P49; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	60	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7468	7478		10.1074/jbc.M512438200	http://dx.doi.org/10.1074/jbc.M512438200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407286	hybrid			2022-12-25	WOS:000236030900069
J	Christmas, P; Tolentino, K; Primo, V; Berry, KZ; Murphy, RC; Chen, M; Lee, DM; Soberman, RJ				Christmas, P; Tolentino, K; Primo, V; Berry, KZ; Murphy, RC; Chen, M; Lee, DM; Soberman, RJ			Cytochrome P-4504F18 is the leukotriene B-4 omega-1/omega-2 hydroxylase in mouse polymorphonuclear leukocytes - Identification as the functional orthologue of human polymorphonuclear leukocyte CYP4F3A in the down-regulation of responses to LTB4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DENDRITIC CELLS; ARACHIDONIC-ACID; B-4 RECEPTOR; 5-LIPOXYGENASE EXPRESSION; DIHYDRO METABOLITES; ALLOGRAFT-REJECTION; BIOLOGICAL-ACTIVITY; OMEGA-OXIDATION; HUMAN MONOCYTE	Leukotriene B-4 (LTB4) is a potent chemoattractant for polymorphonuclear leukocytes (PMN) and other cells. Human PMN inactivate LTB4 by omega-oxidation catalyzed by cytochrome P-450 (CYP) 4F3A. The contribution of the enzymatic inactivation of LTB4 by CYP4Fs to down-regulating functional responses of cells to LTB4 is unknown. To elucidate the role of CYP4F-mediated inactivation of LTB4 in terminating the responses of PMN to LTB4 and to identify a target for future genetic studies in mice, we have identified the enzyme that catalyzes the omega-1 and omega-2 oxidation of LTB4 in mouse myeloid cells as CYP4F18. As determined by mass spectrometry, this enzyme catalyzes the conversion of LTB4 to 19-OH LTB4 and to a lesser extent 18-OH LTB4. Inhibition of CYP4F18 resulted in a marked increase in calcium flux and a 220% increase in the chemotactic response of mouse PMN to LTB4. CYP4F18 expression was induced in bone marrow-derived dendritic cells by bacterial lipopolysaccharide, a ligand for TLR4, and by poly( I center dot C), a ligand for TLR3. However, when bone marrow-derived myeloid dendritic cells trafficked to popliteal lymph nodes from paw pads, the expression of CYP4F18 was down-regulated. The results identify CYP4F18 as a critical protein in the regulation of LTB4 metabolism and functional responses in mouse PMN and identify it as the functional orthologue of human PMN CYP4F3A.	Massachusetts Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Dept Med, Charlestown, MA 02129 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Brigham & Women's Hospital	Soberman, RJ (corresponding author), Massachusetts Gen Hosp E, Renal Unit, Bldg 149,Navy Yard,13th St, Charlestown, MA 02129 USA.	soberman@helix.mgh.harvard.edu			NHLBI NIH HHS [5R01 HL 025785, R01 HL 25785, 5R01 HL 068256-03] Funding Source: Medline; NIAID NIH HHS [R01 AI 059746-02] Funding Source: Medline; NIAMS NIH HHS [K08 AR 02214-04] Funding Source: Medline; NIDDK NIH HHS [R03 DK 067940, DK 59991] Funding Source: Medline; NIGMS NIH HHS [GM 61823] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068256, R01HL025785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK067940, K01DK059991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061823] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; Allen DL, 1996, J PHARMACOL EXP THER, V277, P341; Baumeister B, 1996, J CLIN GASTROENTEROL, V22, P117, DOI 10.1097/00004836-199603000-00009; Berry KAZ, 2003, J BIOL CHEM, V278, P24449, DOI 10.1074/jbc.M300856200; Boerr LAR, 1996, EUR J GASTROEN HEPAT, V8, P57, DOI 10.1097/00042737-199601000-00011; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Byrum RS, 1999, J IMMUNOL, V163, P6810; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2003, J BIOL CHEM, V278, P25133, DOI 10.1074/jbc.M302106200; Christmas P, 2001, J BIOL CHEM, V276, P38166; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000; Chuang SS, 2004, J BIOL CHEM, V279, P6305, DOI 10.1074/jbc.M311830200; Cui XM, 2001, J PHARMACOL EXP THER, V296, P542; DELPRETE A, 2006, KEYST S EIC INFL CHR; FOEGH ML, 1985, ADV PROSTAG THROMB L, V13, P209; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FRETLAND D, 1995, GUT, V37, P702, DOI 10.1136/gut.37.5.702; Gao JM, 2003, J BIOL CHEM, V278, P37902, DOI 10.1074/jbc.M306061200; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Gladue RP, 1996, J EXP MED, V183, P1893, DOI 10.1084/jem.183.4.1893; Goulet JL, 2001, J IMMUNOL, V167, P6631, DOI 10.4049/jimmunol.167.11.6631; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; KUMLIN M, 1990, BIOCHEM BIOPH RES CO, V170, P23, DOI 10.1016/0006-291X(90)91235-K; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lowell CA, 1998, P NATL ACAD SCI USA, V95, P7580, DOI 10.1073/pnas.95.13.7580; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; MIGLIORISI G, 1987, AM J PATHOL, V127, P157; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; MURPHY RC, 1993, HDB LIPID RES, V7, P131; NUMAO T, 1992, J IMMUNOL, V149, P3309; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Parmentier JH, 2001, J BIOL CHEM, V276, P15704, DOI 10.1074/jbc.M011473200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; POWELL WS, 1990, J BIOL CHEM, V265, P9131; POWELL WS, 1989, J BIOL CHEM, V264, P5364; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; RAHMAN MA, 1988, J CLIN INVEST, V81, P1945, DOI 10.1172/JCI113542; SCHMIDT C, 1995, EUR J GASTROEN HEPAT, V7, P865; SHAK S, 1985, J BIOL CHEM, V260, P3023; SHAK S, 1984, J BIOL CHEM, V259, P181; Soberman RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; Spanbroek R, 2000, BLOOD, V96, P3857, DOI 10.1182/blood.V96.12.3857.h8003857_3857_3865; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Struyf S, 1999, J IMMUNOL, V162, P4903; Subbarao K, 2004, ARTERIOSCL THROM VAS, V24, P369, DOI 10.1161/01.ATV.0000110503.16605.15; TERNOWITZ T, 1987, ACTA PATH MICRO IM C, V95, P47; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; Weringer EJ, 1999, TRANSPLANTATION, V67, P808, DOI 10.1097/00007890-199903270-00005; Wheelan P, 1996, J AM SOC MASS SPECTR, V7, P129, DOI 10.1016/1044-0305(95)00629-X; YARED A, 1991, J AM SOC NEPHROL, V2, P45; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOKOMIZO T, 2005, KEYST S BIOACT LIP L; [No title captured]	72	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7189	7196		10.1074/jbc.M513101200	http://dx.doi.org/10.1074/jbc.M513101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16380383	hybrid			2022-12-25	WOS:000236030900035
J	Otyepka, M; Bartova, I; Kriz, Z; Koca, J				Otyepka, M; Bartova, I; Kriz, Z; Koca, J			Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; PROTEIN-KINASE; MOLECULAR-DYNAMICS; STRUCTURAL BASIS; RECRUITMENT PEPTIDES; SUBSTRATE; SPECIFICITY; PHOSPHORYLATION; INHIBITION; SITE	A detailed analysis is presented of the dynamics of human CDK5 in complexes with the protein activator p25 and the purine-like inhibitor roscovitine. These and other findings related to the activation of CDK5 are critically reviewed from a molecular perspective. In addition, the results obtained on the behavior of CDK5 are compared with data on CDK2 to assess the differences and similarities between the two kinases in terms of (i) roscovitine binding, (ii) regulatory subunit association, (iii) conformational changes in the T-loop following CDK/regulatory subunit complex formation, and (iv) specificity in CDK/regulatory subunit recognition. An energy decomposition analysis, used for these purposes, revealed why the binding of p25 alone is sufficient to stabilize the extended active T-loop conformation of CDK5, whereas the equivalent conformational change in CDK2 requires both the binding of cyclin A and phosphorylation of the Thr(160) residue. The interaction energy of the CDK5 T-loop with p25 is about 26 kcal . mol(-1) greater than that of the CDK2T-loop with cyclin A. The binding pattern between CDK5 and p25 was compared with that of CDK2/cyclin A to find specific regions involved in CDK/regulatory subunit recognition. The analyses performed revealed that the alpha NT-helix of cyclin A interacts with the alpha 6-alpha 7 loop and the alpha 7 helix of CDK2, but these regions do not interact in the CDK5/p25 complex. Further differences between the CDK5/p25 and CDK2/cyclin A systems studied are discussed with respect to their specific functionality.	Palacky Univ, Dept Phys Chem, Olomouc 77146, Czech Republic; Palacky Univ, Ctr Biomol & Complex Mol Syst, Olomouc 77146, Czech Republic; Masaryk Univ, Fac Sci, Natl Ctr Biomol Res, Brno 62500, Czech Republic	Palacky University Olomouc; Palacky University Olomouc; Masaryk University Brno	Otyepka, M (corresponding author), Palacky Univ, Dept Phys Chem, Tr Svobody 26, Olomouc 77146, Czech Republic.	otyepka@aix.upol.cz; jkoca@chemi.muni.cz	Otyepka, Michal/D-1220-2017; Kriz, Zdenek/D-9929-2012; Koca, Jaroslav/E-4460-2012; Otyepka, Michal/A-5922-2008	Otyepka, Michal/0000-0002-1066-5677; Koca, Jaroslav/0000-0002-2780-4901; Otyepka, Michal/0000-0002-1066-5677				Ahn JS, 2005, CHEM BIOL, V12, P811, DOI 10.1016/j.chembiol.2005.05.011; Aimes RT, 2000, BIOCHEMISTRY-US, V39, P8325, DOI 10.1021/bi992800w; Barrett CP, 2005, J BIOL CHEM, V280, P13993, DOI 10.1074/jbc.M407371200; Bartova I, 2005, PROTEIN SCI, V14, P445, DOI 10.1110/ps.04959705; Bartova I, 2004, PROTEIN SCI, V13, P1449, DOI 10.1110/ps.03578504; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; Brown NR, 1999, NAT CELL BIOL, V1, P438, DOI 10.1038/15674; Cheng YH, 2005, J AM CHEM SOC, V127, P1553, DOI 10.1021/ja0464084; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; de Azevedo WF, 2002, BIOCHEM BIOPH RES CO, V297, P1154, DOI 10.1016/S0006-291X(02)02352-5; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; DUKE RE, 2003, PMEMD VERSION 3 01; Golsteyn RM, 2005, CANCER LETT, V217, P129, DOI 10.1016/j.canlet.2004.08.005; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Honda R, 2005, EMBO J, V24, P452, DOI 10.1038/sj.emboj.7600554; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jurecka P, 2004, J PHYS CHEM B, V108, P5466, DOI 10.1021/jp049956c; Kesavapany S, 2004, BBA-PROTEINS PROTEOM, V1697, P143, DOI 10.1016/j.bbapap.2003.11.020; Kriz Z, 2004, PROTEINS, V55, P258, DOI 10.1002/prot.20026; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mapelli M, 2005, J MED CHEM, V48, P671, DOI 10.1021/jm049323m; Mapelli M, 2003, NEUROSIGNALS, V12, P164, DOI 10.1159/000074617; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Muller-Dethlefs K, 2000, CHEM REV, V100, P143, DOI 10.1021/cr9900331; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Otyepka M, 2002, J BIOMOL STRUCT DYN, V20, P141, DOI 10.1080/07391102.2002.10506830; PEARLMAN DA, 1999, COMP PHYS COMMUN, V91, P1; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sakaue F, 2005, J BIOL CHEM, V280, P31522, DOI 10.1074/jbc.M504792200; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; Sharma P, 1999, J BIOL CHEM, V274, P9600, DOI 10.1074/jbc.274.14.9600; Smith DS, 2002, TRENDS CELL BIOL, V12, P28, DOI 10.1016/S0962-8924(01)02181-X; Smith DS, 2001, CELL GROWTH DIFFER, V12, P277; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Weishaupt JH, 2003, CELL TISSUE RES, V312, P1, DOI 10.1007/s00441-003-0703-7; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	51	41	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7271	7281		10.1074/jbc.M509699200	http://dx.doi.org/10.1074/jbc.M509699200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407256	hybrid			2022-12-25	WOS:000236030900045
J	Vincent, P; Priceputu, E; Kay, D; Saksela, K; Jolicoeur, P; Hanna, Z				Vincent, P; Priceputu, E; Kay, D; Saksela, K; Jolicoeur, P; Hanna, Z			Activation of p21-activated kinase 2 and its association with Nef are conserved in murine cells but are not sufficient to induce an AIDS-like disease in CD4C/HIV transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 NEF; SIMIAN-IMMUNODEFICIENCY-VIRUS; CELLULAR SERINE/THREONINE KINASE; CD4 DOWN-REGULATION; LONG-TERM SURVIVOR; PAK-RELATED KINASE; P85 BETA-PIX; HIV-1 NEF; T-CELLS; PROTEIN-KINASE	A well conserved feature of human immunodeficiency virus, type 1 (HIV-1) and simian immunodeficiency virus (SIV) Nef is the interaction with and activation of the human p21-activated kinase 2 (PAK2). The conservation of this interaction in other species and its significance for Nef pathogenesis in vivo are poorly documented. In the present study, we measured these parameters in Nef-expressing thymocytes, macrophages, and dendritic cells of a transgenic (Tg) mouse model of AIDS (CD4C/HIV). We found that Nef binds to and activates PAK2, but not PAK1 and - 3, in these three cell subsets. Nef associates with only a small fraction of PAK2. The Nef-PAK2 complex also comprises beta-PIX-COOL. The impact of the Nef-PAK2 association on disease development was also analyzed in Tg mice expressing 10 different Nef mutant alleles. CD4C/HIV Tg mice expressing Nef alleles defective in Nef-PAK2 association (P69A, P72A/P75A, R105A/R106A, Delta 56 - 66, or G2A (myristoylation site)) failed to develop disease of the non-lymphoid organs ( kidneys and lungs). Among these, only Tg mice expressing Nef(P69A) and Nef(G2A) showed some depletion of CD4(+) T cells, although a down-regulation of the CD4 surface protein was documented in all these Tg lines, except those expressing Nef Delta 56-66. Among other Tg mice expressing Nef mutants having conserved the Nef-PAK2 association (RD35AA, D174K, P147A/P150A, Delta 8-17, and Delta 25-65), only Tg mice expressing Nef(Delta 8-17) develop kidney and lung diseases, but all showed partial CD4(+) T cell depletion despite some being defective for CD4 down-regulation ( RD35AA and D174K). Therefore, Nef can activate murine PAK2 and associate with a small fraction of it, as inhuman cells. Such activation and binding of PAK2 is clearly not sufficient but may be required to induce amultiorgan AIDS-like disease in Tg mice.	Clin Res Inst Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada; Univ Helsinki, Haartman Inst, Dept Virol, FIN-0014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-0014 Helsinki, Finland; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, FIN-33014 Tampere, Finland; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital; Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Dept Mol Biol, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	jolicop@ircm.qc.ca; hannaz@ircm.umontreal.ca		Saksela, Kalle/0000-0003-0827-122X				Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000; Arora VK, 2000, J VIROL, V74, P11081, DOI 10.1128/JVI.74.23.11081-11087.2000; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bell I, 1998, J GEN VIROL, V79, P2717, DOI 10.1099/0022-1317-79-11-2717; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown A, 1999, J VIROL, V73, P9899, DOI 10.1128/JVI.73.12.9899-9907.1999; Carl S, 2000, J VIROL, V74, P4155, DOI 10.1128/JVI.74.9.4155-4164.2000; Cheng H, 1999, VIROLOGY, V264, P5, DOI 10.1006/viro.1999.9937; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cullen BR, 1996, CURR BIOL, V6, P1557, DOI 10.1016/S0960-9822(02)70770-7; CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Foster JL, 2001, J VIROL, V75, P1672, DOI 10.1128/JVI.75.4.1672-1680.2001; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Geffin R, 2000, AIDS RES HUM RETROV, V16, P1855, DOI 10.1089/08892220050195810; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; Guatelli JC, 1997, RES VIROLOGY, V148, P34, DOI 10.1016/S0923-2516(97)81910-3; Hanna Z, 2004, VIROLOGY, V327, P273, DOI 10.1016/j.virol.2004.06.028; Hanna Z, 2001, J VIROL, V75, P9378, DOI 10.1128/JVI.75.19.9378-9392.2001; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; HANNA Z, 2006, IN PRESS VIROLOGY; Harris M, 1996, J GEN VIROL, V77, P2379, DOI 10.1099/0022-1317-77-10-2379; Harris M, 1999, CURR BIOL, V9, pR459, DOI 10.1016/S0960-9822(99)80282-6; Hua J, 1997, VIROLOGY, V231, P231, DOI 10.1006/viro.1997.8517; HUANG M, 1995, J VIROL, V69, P60, DOI 10.1128/JVI.69.1.60-68.1995; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Keppler OT, 2005, J VIROL, V79, P1655, DOI 10.1128/JVI.79.3.1655-1665.2005; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Khan IH, 1998, J VIROL, V72, P5820, DOI 10.1128/JVI.72.7.5820-5830.1998; Kirchhoff F, 2004, J VIROL, V78, P6864, DOI 10.1128/JVI.78.13.6864-6874.2004; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004; Lafrate AJ, 2000, J VIROL, V74, P9836, DOI 10.1128/JVI.74.21.9836-9844.2000; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Lang SM, 1997, NAT MED, V3, P860, DOI 10.1038/nm0897-860; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LeGall S, 1997, RES VIROLOGY, V148, P43, DOI 10.1016/S0923-2516(97)81912-7; Liu LX, 2000, J VIROL, V74, P5310, DOI 10.1128/JVI.74.11.5310-5319.2000; Luo TC, 1997, J VIROL, V71, P9524, DOI 10.1128/JVI.71.12.9524-9530.1997; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; Manninen A, 1998, VIROLOGY, V250, P273, DOI 10.1006/viro.1998.9381; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; Marsh JW, 1999, ARCH BIOCHEM BIOPHYS, V365, P192, DOI 10.1006/abbi.1999.1208; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Peter F, 1998, IMMUNITY, V9, P433, DOI 10.1016/S1074-7613(00)80626-3; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Priceputu E, 2005, J VIROL, V79, P6377, DOI 10.1128/JVI.79.10.6377-6391.2005; Pulkkinen K, 2004, J VIROL, V78, P12773, DOI 10.1128/JVI.78.23.12773-12780.2004; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998; Sawai ET, 1997, RES VIROLOGY, V148, P47, DOI 10.1016/S0923-2516(97)81913-9; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; Sawai ET, 2000, J VIROL, V74, P2038, DOI 10.1128/JVI.74.4.2038-2045.2000; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Simard MC, 2002, J VIROL, V76, P3981, DOI 10.1128/JVI.76.8.3981-3995.2002; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Skowronski J, 1999, COLD SPRING HARB SYM, V64, P453, DOI 10.1101/sqb.1999.64.453; Stoddart CA, 2003, J VIROL, V77, P2124, DOI 10.1128/JVI.77.3.2124-2133.2003; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; Weng XD, 2004, J VIROL, V78, P5244, DOI 10.1128/JVI.78.10.5244-5257.2004; Wiskerchen M, 1996, VIROLOGY, V224, P292, DOI 10.1006/viro.1996.0531; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32	93	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6940	6954		10.1074/jbc.M512710200	http://dx.doi.org/10.1074/jbc.M512710200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407193	hybrid			2022-12-25	WOS:000236030900006
J	Wood, TC; Salavagionne, OE; Mukherjee, B; Wang, LW; Klumpp, AF; Thomae, BA; Eckloff, BW; Schaid, DJ; Wieben, ED; Weinshilboum, RM				Wood, TC; Salavagionne, OE; Mukherjee, B; Wang, LW; Klumpp, AF; Thomae, BA; Eckloff, BW; Schaid, DJ; Wieben, ED; Weinshilboum, RM			Human arsenic methyltransferase (AS3MT) pharmacogenetics - Gene resequencing and functional genomics studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOMETHYLARSONOUS ACID MMA(III); PROTEASOMAL DEGRADATION; ENZYMATIC METHYLATION; ASSOCIATION; TOXICITY; SEQUENCE; LIVER; RAT; INHIBITION; HAPLOTYPES	Arsenic contaminates ground water worldwide. Methylation is an important reaction in the biotransformation of arsenic. We set out to study the pharmacogenetics of human arsenic methyltransferase (AS3MT, previously CYT19). After cloning the human AS3MT cDNA, we annotated the human gene and resequenced its 5'-flanking region, exons, and splice junctions using 60 DNA samples from African-American ( AA) and 60 samples from Caucasian-American(CA) subjects. We observed 26 single nucleotide polymorphisms ( SNPs), including 3 non-synonymous cSNPs, as well as a variable number of tandem repeats in exon 1 within an area encoding the cDNA 5'-untranslated region. The nonsynonymous cSNPs included T860C (M287T) with frequencies of 10.8 and 10% in AA and CA subjects, respectively, as well as C517T (A173W) in one AA and C917T (T306I) in one CA sample. Haplotype analysis showed that Ile(306) was linked to Thr(287), so this double variant allozyme was also studied functionally. After expression in COS-1 cells and correction for transfection efficiency, the Trp(173) allozyme displayed 31%, Thr(287) 350%, Ile(306) 4.8%, and Thr(287)/ Ile(306) 6.2% of the activity of the wild type (WT) allozyme, with 20, 190, 4.4, and 7.9% of the level of WT immunoreactive protein, respectively. Apparent Km values for S-adenosyl-L-methionine were 4.6, 3.1, and 11 mu M for WT, Trp(173), and Thr(287) allozymes, with K-m values for sodium arsenite with the same allozymes of 11.8, 8.9, and 4.5 mu M. The Ile(306) and Thr(287)/Ile(306) allozymes expressed too little activity for inclusion in the substrate kinetic studies. Expression of reporter gene constructs for the 5'-flanking region and the variable number of tandem repeats in the 5'-untranslated region demonstrated cell line-dependent variation in reporter gene expression, with shorter repeats associated with increased transcription in HepG2 cells. These results raise the possibility that inherited variation in AS3MT may contribute to variation in arsenic metabolism and, perhaps, arsenic-dependent carcinogenesis in humans.	Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Weinshilboum, RM (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	weinshilboum.richard@mayo.edu			NIGMS NIH HHS [R01 GM 35720, R01 GM 28157, U01 GM 61388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061388, R01GM028157, R01GM035720] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abernathy C.O., 1997, ARSENIC EXPOSURE HLT; Brodde OE, 2005, PHARMACOGENET GENOM, V15, P267, DOI 10.1097/01213011-200505000-00001; Chadwick RB, 1996, BIOTECHNIQUES, V20, P676; Chen CJ, 2005, TOXICOL APPL PHARM, V206, P198, DOI 10.1016/j.taap.2004.10.023; Chouchane S, 2001, CHEM RES TOXICOL, V14, P517, DOI 10.1021/tx000123x; CLELAND WW, 1963, NATURE, V198, P463, DOI 10.1038/198463a0; CRECELIUS EA, 1977, ENVIRON HEALTH PERSP, V19, P147, DOI 10.2307/3428467; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Fullerton SM, 2000, AM J HUM GENET, V67, P881, DOI 10.1086/303070; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hart TR, 2000, MOD LANG REV, V95, P107, DOI 10.2307/3736374; HENDRICK PW, 2000, GENETICS POPULATIONS, P396; Ji Y, 2005, J NEUROCHEM, V95, P1766, DOI 10.1111/j.1471-4159.2005.03453.x; Jones KD, 2003, J HAZARD MATER, V103, P93, DOI 10.1016/S0304-3894(03)00227-9; Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007; Li JX, 2005, TOXICOL APPL PHARM, V204, P164, DOI 10.1016/j.taap.2004.12.002; Lin S, 1999, CHEM RES TOXICOL, V12, P924, DOI 10.1021/tx9900775; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; Lin S, 2001, CHEM RES TOXICOL, V14, P305, DOI 10.1021/tx0001878; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Petrick JS, 2000, TOXICOL APPL PHARM, V163, P203, DOI 10.1006/taap.1999.8872; Petrick JS, 2001, CHEM RES TOXICOL, V14, P651, DOI 10.1021/tx000264z; Preuss CV, 1998, MOL PHARMACOL, V53, P708, DOI 10.1124/mol.53.4.708; Raftogianis RB, 1997, BIOCHEM BIOPH RES CO, V239, P298, DOI 10.1006/bbrc.1997.7466; Salavaggione OE, 2005, PHARMACOGENET GENOM, V15, P801, DOI 10.1097/01.fpc.0000174788.69991.6b; Sanz MA, 2005, HAEMATOLOGICA, V90, P1231; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Shield AJ, 2004, MOL PSYCHIATR, V9, P151, DOI 10.1038/sj.mp.4001386; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Simeonova PP, 2004, TOXICOL APPL PHARM, V198, P444, DOI 10.1016/j.taap.2003.10.018; Sirulnik L Andres, 2005, Clin Adv Hematol Oncol, V3, P391; SIRULNIK LA, 2005, CLIN ADV HEMATOL ONC, V3, P429; SMITH TJ, 1977, ENVIRON HEALTH PERSP, V19, P89, DOI 10.2307/3428456; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Styblo M, 1997, CHEM RES TOXICOL, V10, P27, DOI 10.1021/tx960139g; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; Tai HL, 1999, PHARMACOGENETICS, V9, P641, DOI 10.1097/01213011-199910000-00011; TAJIMA F, 1989, GENETICS, V123, P585; Tchounwou PB, 2004, MOL CELL BIOCHEM, V255, P47, DOI 10.1023/B:MCBI.0000007260.32981.b9; Thomae BA, 2003, J NEUROCHEM, V87, P809, DOI 10.1046/j.1471-4159.2003.02027.x; Wang LW, 2003, PHARMACOGENETICS, V13, P555, DOI 10.1097/00008571-200309000-00004; Weinshilboum R, 2004, CLIN PHARMACOL THER, V75, P253, DOI 10.1016/j.clpt.2003.12.002; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; Wulff M, 1996, ACTA ONCOL, V35, P179, DOI 10.3109/02841869609098499; Yoshida T, 2004, TOXICOL APPL PHARM, V198, P243, DOI 10.1016/j.taap.2003.10.022; ZAKHARYAN R, 1995, CHEM RES TOXICOL, V8, P1029, DOI 10.1021/tx00050a006; Zakharyan RA, 1999, TOXICOL APPL PHARM, V158, P9, DOI 10.1006/taap.1999.8687	49	111	118	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7364	7373		10.1074/jbc.M512227200	http://dx.doi.org/10.1074/jbc.M512227200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407288	hybrid			2022-12-25	WOS:000236030900056
J	Kalabis, J; Rosenberg, I; Podolsky, DK				Kalabis, J; Rosenberg, I; Podolsky, DK			Vangl1 protein acts as a downstream effector of intestinal trefoil factor (ITF)/TFF3 signaling and regulates wound healing of intestinal epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; DISCS-LARGE; GENE; STRABISMUS; PEPTIDES; POLARITY; IDENTIFICATION; MIGRATION; FAMILY; PHOSPHORYLATION	The intestinal trefoil factor (ITF/TFF3) protects intestinal epithelia from a range of insults and contributes to mucosal repair. However, the signaling events that mediate healing responses are only partially understood. To identify ITF signaling pathways, proteins that were Ser/Thr phosphorylated in response to ITF stimulation were immunoprecipitated from human colon carcinoma cell lines and identified by mass spectrometry. We demonstrated that Van Gogh-like protein 1 ( also designated Vang-like 1 or Vangl1), a protein with four transmembrane domains, was Ser/Thr phosphorylated in response to ITF stimulation. Vangl1 was present in normal human colon and all intestinal epithelial cell lines (IEC) tested. In transfected IEC, FLAG-Vangl1 was mostly present in the Nonidet P-40 soluble fraction as detected by Western blotting, corresponding to the localization of endogenous protein in cytoplasmic vesicular structures by confocal microscopy with rabbit polyclonal antihuman Vangl1 antibody (alpha-Vangl1). Vangl1 cell membrane association increased with differentiation, as demonstrated by co-localization with E-cadherin in differentiated IEC. Increased Vangl1 phosphorylation after stimulation with ITF corresponded to decreased cell membrane association with E-cadherin. Functionally, Vangl1 overexpression enhanced ITF unstimulated and stimulated wound closure of IEC, whereas siRNA directed against Vangl1 inhibited the migratory response to ITF. Vangl1 protein may serve as an effector mediating the ITF healing response of the intestinal mucosa.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Podolsky, DK (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 55 Fruit St, Boston, MA 02114 USA.	dpodolsky@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK046906] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30DK043351, R01DK046906] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chan VYW, 2005, REGUL PEPTIDES, V127, P87, DOI 10.1016/j.regpep.2004.10.016; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Iizuka-Kogo A, 2005, HISTOCHEM CELL BIOL, V123, P67, DOI 10.1007/s00418-004-0729-2; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275; Lee OK, 2003, NAT CELL BIOL, V5, P987, DOI 10.1038/ncb1055; Liu D, 1997, LAB INVEST, V77, P557; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Muskett FW, 2003, BIOCHEMISTRY-US, V42, P15139, DOI 10.1021/bi030182k; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; Schmoranzer J, 2003, J CELL SCI, V116, P4513, DOI 10.1242/jcs.00748; SEFTON B, 1997, CURRENT PROTOCOLS MO; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Wolff T, 1998, DEVELOPMENT, V125, P1149; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	34	36	39	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6434	6441		10.1074/jbc.M512905200	http://dx.doi.org/10.1074/jbc.M512905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16410243	hybrid			2022-12-25	WOS:000236030800037
J	Ramos, CRR; Oliveira, CLP; Torriani, IL; Oliveira, CC				Ramos, CRR; Oliveira, CLP; Torriani, IL; Oliveira, CC			The Pyrococcus exosome complex - Structural and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXAMERIC RING STRUCTURE; SMALL-ANGLE SCATTERING; X-RAY-SCATTERING; POLYNUCLEOTIDE PHOSPHORYLASE; RNA-BINDING; RIBOSOMAL-RNA; BIOLOGICAL MACROMOLECULES; ARCHAEAL EXOSOME; YEAST EXOSOME; KH DOMAINS	The exosome is a conserved eukaryotic enzymatic complex that plays an essential role in many pathways of RNA processing and degradation. Here, we describe the structural characterization of the predicted archaeal exosome in solution using small angle x-ray scattering. The structure model calculated from the small angle x-ray scattering pattern provides an indication of the existence of a disk-shaped structure, corresponding to the "RNases PH ring" complex formed by the proteins aRrp41 and aRrp42. The RNases PH ring complex corresponds to the core of the exosome, binds RNA, and has phosphorolytic and polymerization activities. Three additional molecules of the RNA-binding protein aRrp4 are attached to the core as extended and flexible arms that may direct the substrates to the active sites of the exosome. In the presence of aRrp4, the activity of the core complex is enhanced, suggesting a regulatory role for this protein. The results shown here also indicate the participation of the exosome in RNA metabolism in Archaea, as was established in Eukarya.	Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, Brazil; Brazilian Synchrotron Light Lab, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Phys, BR-13084971 Campinas, SP, Brazil	Universidade de Sao Paulo; Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas	Oliveira, CC (corresponding author), Univ Sao Paulo, Inst Chem, Dept Biochem, Av Prof Lineu Prestes 748, BR-05508900 Sao Paulo, Brazil.	ccoliv@iq.usp.br	Oliveira, Cristiano L P/B-4403-2008; Oliveira, Carla C/F-2323-2011; Ramos, Celso R. R./H-6349-2015; Torriani, Iris L/E-5686-2010	Oliveira, Cristiano L P/0000-0002-3426-6507; Oliveira, Carla C/0000-0002-1098-9241; Ramos, Celso R. R./0000-0002-5760-8661; 				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; Cantor C. R, 1980, BIOPHYSICAL CHEM 2, P591; Cavalcanti LP, 2004, REV SCI INSTRUM, V75, P4541, DOI 10.1063/1.1804956; Chekanova JA, 2000, J BIOL CHEM, V275, P33158, DOI 10.1074/jbc.M005493200; Chekanova JA, 2002, NUCLEIC ACIDS RES, V30, P695, DOI 10.1093/nar/30.3.695; Choi JM, 2004, J BIOL CHEM, V279, P755, DOI 10.1074/jbc.M309628200; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Estevez AM, 2003, J BIOL CHEM, V278, P34943, DOI 10.1074/jbc.M305333200; Evguenieva-Hackenberg E, 2003, EMBO REP, V4, P889, DOI 10.1038/sj.embor.embor929; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P422; Harlow LS, 2004, PROTEIN SCI, V13, P668, DOI 10.1110/ps.03477004; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; KLEE CB, 1969, J BIOL CHEM, V244, P2558; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lorentzen E, 2005, NAT STRUCT MOL BIOL, V12, P575, DOI 10.1038/nsmb952; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Oliveira CC, 2002, NUCLEIC ACIDS RES, V30, P4186, DOI 10.1093/nar/gkf545; OLIVEIRA CLP, 2003, 012003 LAB NAC LUZ S; Raijmakers R, 2004, EUR J CELL BIOL, V83, P175, DOI 10.1078/0171-9335-00385; Raijmakers R, 2002, J MOL BIOL, V323, P653, DOI 10.1016/S0022-2836(02)00947-6; Ramos CRR, 2004, BRAZ J MED BIOL RES, V37, P1103, DOI 10.1590/S0100-879X2004000800001; Regonesi ME, 2004, NUCLEIC ACIDS RES, V32, P1006, DOI 10.1093/nar/gkh268; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Stickney LM, 2005, J BACTERIOL, V187, P7214, DOI 10.1128/JB.187.21.7214-7221.2005; SULEWSKI M, 1989, BIOCHEMISTRY-US, V28, P5855, DOI 10.1021/bi00440a023; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Worbs M, 2001, MOL CELL, V7, P1177, DOI 10.1016/S1097-2765(01)00262-3; [No title captured]	42	31	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6751	6759		10.1074/jbc.M512495200	http://dx.doi.org/10.1074/jbc.M512495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407194	hybrid			2022-12-25	WOS:000236030800073
J	Solda, T; Garbi, N; Hammerling, GJ; Molinari, M				Solda, T; Garbi, N; Hammerling, GJ; Molinari, M			Consequences of ERp57 deletion on oxidative folding of obligate and facultative clients of the calnexin cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; PROTEIN DISULFIDE-ISOMERASE; DEPENDENT REDUCTASE ERP57; PEPTIDE-LOADING COMPLEX; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; INFLUENZA HEMAGGLUTININ; GLYCOPROTEIN-SYNTHESIS; REDUCED RIBONUCLEASE; OXIDOREDUCTASE ERP57	Members of the protein-disulfide isomerase superfamily catalyze the formation of intra- and intermolecular disulfide bonds, a rate-limiting step of protein folding in the endoplasmic reticulum ( ER). Here we compared maturation of one obligate and two facultative calnexin substrates in cells with and without ERp57, the calnexin-associated, glycoprotein-specific oxidoreductase. ERp57 deletion did not prevent the formation of disulfide bonds during co-translational translocation of nascent glycopolypeptides in the ER. It affected, however, the post-translational phases of oxidative influenza virus hemagglutinin ( HA) folding, resulting in significant loss of folding efficiency for this obligate calnexin substrate. Without ERp57, HA also showed reduced capacity to recover from an artificially induced aberrant conformation, thus revealing a crucial role of ERp57 during post-translational reshuffling to the native set of HA disulfides. ERp57 deletion did not affect maturation of the model facultative calnexin substrates E1 and p62 ( and of most cellular proteins, as shown by lack of induction of ER stress). ERp72 was identified as one of the ER-resident oxidoreductases associating with the orphan ERp57 substrates to maintain their folding competence.	Inst Biomed Res, CH-6500 Bellinzona, Switzerland; DKFZ, German Canc Res Ctr, D-69120 Heidelberg, Germany	Universita della Svizzera Italiana; Helmholtz Association; German Cancer Research Center (DKFZ)	Molinari, M (corresponding author), Inst Biomed Res, CH-6500 Bellinzona, Switzerland.	maurizio.molinari@irb.unisi.ch	Garbi, Natalio/H-7666-2014; Garbi, Natalio/B-9147-2009; Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829				ANFINSEN C, 1961, J BIOL CHEM, V236, P1361; Antoniou AN, 2003, ANTIOXID REDOX SIGN, V5, P375, DOI 10.1089/152308603768295104; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; Cresswell P, 2000, TRAFFIC, V1, P301, DOI 10.1034/j.1600-0854.2000.010402.x; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Denzel A, 2002, MOL CELL BIOL, V22, P7398, DOI 10.1128/MCB.22.21.7398-7404.2002; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Elliott T, 2005, IMMUNOL REV, V207, P89, DOI 10.1111/j.0105-2896.2005.00311.x; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Garbi N, 2006, NAT IMMUNOL, V7, P93, DOI 10.1038/ni1288; Garbi N, 2005, IMMUNOL REV, V207, P77, DOI 10.1111/j.0105-2896.2005.00303.x; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Jessop CE, 2004, J BIOL CHEM, V279, P55341, DOI 10.1074/jbc.M411409200; Jessop CE, 2004, BIOCHEM SOC T, V32, P655, DOI 10.1042/BST0320655; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Leach MR, 2002, J BIOL CHEM, V277, P29686, DOI 10.1074/jbc.M202405200; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2005, MOL CELL, V20, P503, DOI 10.1016/j.molcel.2005.09.027; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 2002, METHOD ENZYMOL, V348, P35, DOI 10.1016/S0076-6879(02)48623-5; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Pieren M, 2005, J BIOL CHEM, V280, P28265, DOI 10.1074/jbc.M501020200; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; Solda T, 2005, BIOL PROCED ONLINE, V7, P136, DOI 10.1251/bpo111; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; VENETIANER P, 1963, BIOCHIM BIOPHYS ACTA, V67, P166; WAECHTER CJ, 1976, ANNU REV BIOCHEM, V45, P95, DOI 10.1146/annurev.bi.45.070176.000523; WHITE FH, 1961, J BIOL CHEM, V236, P1353; Wilkinson B, 2004, BBA-PROTEINS PROTEOM, V1699, P35, DOI 10.1016/j.bbapap.2004.02.017; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	49	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6219	6226		10.1074/jbc.M513595200	http://dx.doi.org/10.1074/jbc.M513595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407314	hybrid			2022-12-25	WOS:000236030800014
J	Peter, GJ; During, L; Ahmed, A				Peter, GJ; During, L; Ahmed, A			Carbon catabolite repression regulates amino acid permeases in Saccharomyces cerevisiae via the TOR signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPTAKE SYSTEMS; BUDDING YEAST; GENE; NITROGEN; EXPRESSION; PRODUCT	We have identified carbon catabolite repression (CCR) as a regulator of amino acid permeases in Saccharomyces cerevisiae, elucidated the permeases regulated by CCR, and identified the mechanisms involved in amino acid permease regulation by CCR. Transport of L-arginine and L-leucine was increased by similar to 10-25-fold in yeast grown in carbon sources alternate to glucose, indicating regulation by CCR. In wild type yeast the uptake (pmol/10(6) cells/ h), in glucose versus galactose medium, of L-[C-14] arginine was (0.24 +/- 0.04 versus 6.11 +/- 0.42) and L-[C-14] leucine was (0.30 +/- 0.02 versus 3.60 +/- 0.50). The increase in amino acid uptake was maintained when galactose was replaced with glycerol. Deletion of gap1 Delta and agp1 Delta from the wild type strain did not alter CCR induced increase in L- leucine uptake; however, deletion of further amino acid permeases reduced the increase in L- leucine uptake in the following manner: 36% (gnp1 Delta), 62% (bap2 Delta), 83% (Delta(bap2tat1)). Direct immunofluorescence showed large increases in the expression of Gnp1 and Bap2 proteins when grown in galactose compared with glucose medium. By extending the functional genomic approach to include major nutritional transducers of CCR in yeast, we concluded that SNF/MIG, GCN, or PSK pathways were not involved in the regulation of amino acid permeases by CCR. Strikingly, the deletion of TOR1, which regulates cellular response to changes in nitrogen availability, from the wild type strain abolished the CCR-induced amino acid uptake. Our results provide novel insights into the regulation of yeast amino acid permeases and signaling mechanisms involved in this regulation.	UCL, Inst Urol & Nephrol, London W1W 7EY, England; Carlsberg Res Lab, DK-2500 Copenhagen, Denmark	University of London; University College London	Ahmed, A (corresponding author), UCL, Inst Urol & Nephrol, 67 Riding House St, London W1W 7EY, England.	aamir.ahmed@ucl.ac.uk		Ahmed, Aamir/0000-0001-7405-5336	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ahmed A, 1999, CELL, V99, P283, DOI 10.1016/S0092-8674(00)81659-1; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Caspary F, 1997, MOL GEN GENET, V255, P619, DOI 10.1007/s004380050536; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P4455, DOI 10.1128/MCB.11.9.4455; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Cutler NS, 2001, MOL BIOL CELL, V12, P4103, DOI 10.1091/mbc.12.12.4103; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; During-Olsen L, 1999, CURR GENET, V35, P609, DOI 10.1007/s002940050459; Forsberg H, 2001, MOL MICROBIOL, V42, P215, DOI 10.1046/j.1365-2958.2001.02627.x; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1982, EUR J BIOCHEM, V121, P643, DOI 10.1111/j.1432-1033.1982.tb05834.x; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Horak J, 1997, BBA-REV BIOMEMBRANES, V1331, P41, DOI 10.1016/S0304-4157(96)00015-9; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; KRATZER S, 1995, GENE, V161, P75, DOI 10.1016/0378-1119(95)00289-I; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Rutter J, 2002, CELL, V111, P17, DOI 10.1016/S0092-8674(02)00974-1; SCHOLER A, 1994, MOL CELL BIOL, V14, P3613, DOI 10.1128/MCB.14.6.3613; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; Wilson WA, 2002, CELL, V111, P155, DOI 10.1016/S0092-8674(02)01043-7; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	31	27	27	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5546	5552		10.1074/jbc.M513842200	http://dx.doi.org/10.1074/jbc.M513842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407266	hybrid			2022-12-25	WOS:000235568900029
J	Flaherty, DM; Monick, MM; Hinde, SL				Flaherty, DM; Monick, MM; Hinde, SL			Human alveolar macrophages are deficient in PTEN - The role of endogenous oxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-SUPPRESSOR PTEN; ACETYL-L-CYSTEINE; AP-1 DNA-BINDING; PROTEIN-KINASE-B; TRANSCRIPTION FACTOR; REDOX REGULATION; CELL-SURVIVAL; ACTIVATION; APOPTOSIS	Human alveolar macrophages play a critical role in host defense and in the development of inflammation and fibrosis in the lung. Unlike their precursor cells, blood monocytes, alveolar macrophages are long-lived and tend to be resistant to apoptotic stimuli. In this study, we examined the role of differentiation in altering baseline phosphatidylinositol ( PI) 3-kinase/Akt activity. We found that differentiation increased activity of pro-survival PI3-kinase/Akt while decreasing amounts of the negative PI3-kinase regulator, PTEN. PTEN is a lipid phosphatase with activity against phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3), the major bioactive product of PI 3-kinase. Examining in vivo differentiation of alveolar macrophages ( by comparing blood monocytes to alveolar macrophages from single donors), we found that differentiation resulted in increased baseline reactive oxygen species ( ROS) in the alveolar macrophages. This led to a deficiency in PTEN, increased activity of Akt, and prolonged survival of alveolar macrophages. These data support the hypothesis that alterations in ROS levels contribute to macrophage homeostasis by altering the balance between PI 3-kinase/Akt and the phosphatase, PTEN.	Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa	Flaherty, DM (corresponding author), Div Pulm Crit Care & Occupat Med, 100 Eckstein Med Res Bldg, Iowa City, IA 52242 USA.	dawn-flaherty@uiowa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077431, P50HL060316, K08HL004428] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-04428, HL-60316, HL-077431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carter AB, 2004, AM J RESP CELL MOL, V31, P43, DOI 10.1165/rcmb.2003-0377OC; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Fernandez PC, 1999, BIOL CHEM, V380, P1383, DOI 10.1515/BC.1999.178; Flaherty DM, 2001, AM J RESP CELL MOL, V25, P254, DOI 10.1165/ajrcmb.25.2.4446; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Han H, 2001, J BIOL CHEM, V276, P26357, DOI 10.1074/jbc.M011136200; Kaul N, 1996, FREE RADICAL BIO MED, V21, P401, DOI 10.1016/0891-5849(96)00178-5; Kim H, 2000, FREE RADICAL BIO MED, V29, P674, DOI 10.1016/S0891-5849(00)00368-3; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Qanungo S, 2004, J BIOL CHEM, V279, P50455, DOI 10.1074/jbc.M406749200; Rasheed BKA, 1997, CANCER RES, V57, P4187; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; THOMAS ED, 1976, SCIENCE, V192, P1016, DOI 10.1126/science.775638; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yamada KM, 2001, J CELL SCI, V114, P2375; Zhang Jiyan, 2003, Hematol J, V4, P277, DOI 10.1038/sj.thj.6200252	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5058	5064		10.1074/jbc.M508997200	http://dx.doi.org/10.1074/jbc.M508997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371363	hybrid			2022-12-25	WOS:000235426200060
J	Stafforini, DM; Sheller, JR; Blackwell, TS; Sapirstein, A; Yull, FE; McIntyre, TM; Bonventre, JV; Prescott, SM; Roberts, LJ				Stafforini, DM; Sheller, JR; Blackwell, TS; Sapirstein, A; Yull, FE; McIntyre, TM; Bonventre, JV; Prescott, SM; Roberts, LJ			Release of free F-2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NEOINTIMA FORMATION; LIPID-PEROXIDATION; OXIDANT STRESS; ATHEROSCLEROTIC LESIONS; OXIDATIVE MODIFICATION; PAF-ACETYLHYDROLASE; GENE-TRANSFER; CELL-DEATH; IN-VIVO	F-2-isoprostanes are produced in vivo by nonenzymatic peroxidation of arachidonic acid esterified in phospholipids. Increased urinary and plasma F-2-isoprostane levels are associated with a number of human diseases. These metabolites are regarded as excellent markers of oxidant stress in vivo. Isoprostanes are initially generated in situ, i.e. when the arachidonate precursor is esterified in phospholipids, and they are subsequently released in free form. Although the mechanism(s) responsible for the release of free isoprostanes after in situ generation in membrane phospholipids is, for the most part, unknown, this process is likely mediated by phospholipase A(2) activity(ies). Here we reported that human plasma contains an enzymatic activity that catalyzes this reaction. The activity associates with high density and low density lipoprotein and comigrates with platelet-activating factor (PAF) acetylhydrolase on KBr density gradients. Plasma samples from subjects deficient in PAF acetylhydrolase do not release F-2-isoprostanes from esterified precursors. The intracellular PAF acetylhydrolase II, which shares homology to the plasma enzyme, also catalyzes this reaction. We found that both the intracellular and plasma PAF acetylhydrolases have high affinity for esterified F-2-isoprostanes. However, the rate of esterified F-2-isoprostane hydrolysis is much slower compared with the rate of hydrolysis of other substrates utilized by these enzymes. Studies using PAF acetylhydrolase transgenic mice indicated that these animals have a higher capacity to release F-2-isoprostanes compared with nontransgenic littermates. Our results suggested that PAF acetylhydrolases play key roles in the hydrolysis of F-2- isoprostanes esterified on phospholipids in vivo.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Vanderbilt University; Vanderbilt University; Harvard University; Harvard Medical School; Cleveland Clinic Foundation	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu			NHLBI NIH HHS [HL44513, HL061419, HL35828] Funding Source: Medline; NIDDK NIH HHS [DK38452, DK26657] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061419, R01HL035828, R01HL044513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed Z, 2002, BIOCHEM BIOPH RES CO, V290, P391, DOI 10.1006/bbrc.2001.6150; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; AMES BN, 1960, J BIOL CHEM, V235, P769; Arakawa H, 2005, CIRCULATION, V111, P3302, DOI 10.1161/CIRCULATIONAHA.104.476242; Cao Y, 1998, J BIOL CHEM, V273, P4012, DOI 10.1074/jbc.273.7.4012; Connelly PW, 2005, FREE RADICAL BIO MED, V38, P164, DOI 10.1016/j.freeradbiomed.2004.10.010; Cracowski JL, 2004, CHEM PHYS LIPIDS, V128, P75, DOI 10.1016/j.chemphyslip.2003.10.006; Crankshaw DJ, 2003, MOL CELL BIOCHEM, V253, P125, DOI 10.1023/A:1026052123843; FitzGerald GA, 1997, THROMB HAEMOSTASIS, V78, P280; GOPAUL NK, 1994, BIOCHEM BIOPH RES CO, V200, P338, DOI 10.1006/bbrc.1994.1453; GOPAUL NK, 1994, FEBS LETT, V348, P297, DOI 10.1016/0014-5793(94)00628-8; Hakkinen T, 1999, ARTERIOSCL THROM VAS, V19, P2909, DOI 10.1161/01.ATV.19.12.2909; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HATTORI M, 1993, J BIOL CHEM, V268, P18748; Ho YS, 2002, ARCH TOXICOL, V76, P484, DOI 10.1007/s00204-002-0373-3; Hou X, 2004, FREE RADICAL BIO MED, V36, P163, DOI 10.1016/j.freeradbiomed.2003.10.024; Itabe H, 2000, ANAL BIOCHEM, V285, P151, DOI 10.1006/abio.2000.4751; Kruse S, 2000, AM J HUM GENET, V66, P1522, DOI 10.1086/302901; Leach CA, 2001, FARMACO, V56, P45, DOI 10.1016/S0014-827X(01)01011-4; LIU M, 1994, P NATL ACAD SCI USA, V91, P6035, DOI 10.1073/pnas.91.13.6035; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MOORE KP, 1995, CIRC RES, V77, P335, DOI 10.1161/01.RES.77.2.335; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Morrow JD, 2005, ARTERIOSCL THROM VAS, V25, P279, DOI 10.1161/01.ATV.0000152605.64964.c0; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Musiek ES, 2005, J BIOL CHEM, V280, P35562, DOI 10.1074/jbc.M504785200; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Pratico D, 2004, CHEM PHYS LIPIDS, V128, P165, DOI 10.1016/j.chemphyslip.2003.09.012; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Quarck R, 2001, CIRCULATION, V103, P2495; Reilly MP, 1998, CIRCULATION, V98, P2822, DOI 10.1161/01.CIR.98.25.2822; Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P808, DOI 10.1007/s00018-002-8469-8; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Shimokata K, 2004, ATHEROSCLEROSIS, V172, P167, DOI 10.1016/j.atherosclerosis.2003.09.019; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1992, T ASSOC AM PHYSICIAN, V105, P44; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; Turunen P, 2005, ATHEROSCLEROSIS, V179, P27, DOI 10.1016/j.atherosclerosis.2004.10.025; Wu XQ, 2004, J BIOL CHEM, V279, P36158, DOI 10.1074/jbc.M402454200; Yamada Y, 2000, ATHEROSCLEROSIS, V150, P209, DOI 10.1016/S0021-9150(99)00385-8; Zalewski A, 2005, ARTERIOSCL THROM VAS, V25, P923, DOI 10.1161/01.ATV.0000160551.21962.a7	53	171	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4616	4623		10.1074/jbc.M507340200	http://dx.doi.org/10.1074/jbc.M507340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371369	hybrid			2022-12-25	WOS:000235426200009
J	Tang, W; Tu, YP; Nayak, SK; Woodson, J; Jehl, M; Ross, EM				Tang, W; Tu, YP; Nayak, SK; Woodson, J; Jehl, M; Ross, EM			G beta gamma inhibits G alpha GTPase-activating proteins by inhibition of G alpha-GTP binding during stimulation by receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE C-BETA; CRYSTAL-STRUCTURE; REGULATORY COMPONENT; MEDIATED ACTIVATION; ADENYLATE-CYCLASE; COUPLED RECEPTORS; SIGNALING RGS; K+ CHANNEL; IDENTIFICATION	G beta gamma subunits modulate several distinct molecular events involved with G protein signaling. In addition to regulating several effector proteins, G beta gamma subunits help anchor G alpha subunits to the plasma membrane, promote interaction of G alpha with receptors, stabilize the binding of GDP to G alpha to suppress spurious activation, and provide membrane contact points for G protein-coupled receptor kinases. G beta gamma subunits have also been shown to inhibit the activities of GTPase-activating proteins (GAPs), both phospholipase C (PLC)-beta s and RGS proteins, when assayed in solution under single turnover conditions. We show here that G beta gamma subunits inhibit G protein GAP activity during receptor-stimulated, steady-state GTPase turnover. GDP/GTP exchange catalyzed by receptor requires G beta gamma in amounts approximately equimolar to G alpha, but GAP inhibition was observed with superstoichiometric G beta gamma. The potency of inhibition varied with the GAP and the G alpha subunit, but half-maximal inhibition of the GAP activity of PLC-beta 1 was observed with 5-10 nM G beta gamma, which is at or below the concentrations of G beta gamma needed for regulation of physiologically relevant effector proteins. The kinetics of GAP inhibition of both receptor-stimulated GTPase activity and single turnover, solution-based GAP assays suggested a competitive mechanism in which G beta gamma competes with GAPs for binding to the activated, GTP-bound G alpha subunit. An N-terminal truncation mutant of PLC-beta 1 that cannot be directly regulated by G beta gamma-remained sensitive to inhibition of its GAP activity, suggesting that the G beta gamma binding site relevant for GAP inhibition is on the G alpha subunit rather than on the GAP. Using fluorescence resonance energy transfer between cyan or yellow fluorescent protein-labeled G protein subunits and Alexa532-labeled RGS4, we found that G beta gamma directly competes with RGS4 for high-affinity binding to G alpha(i)-GDP-AlF4.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Elliott.Ross@UTSouthwestern.edu			NIGMS NIH HHS [GM30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Chidiac P, 1999, BIOCHEM PHARMACOL, V58, P39, DOI 10.1016/S0006-2952(99)00080-5; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ilkaeva O, 2002, J BIOL CHEM, V277, P4294, DOI 10.1074/jbc.M109612200; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PARKER EM, 1991, J BIOL CHEM, V266, P519; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; WU DQ, 1993, J BIOL CHEM, V268, P3704	49	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4746	4753		10.1074/jbc.M510573200	http://dx.doi.org/10.1074/jbc.M510573200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16407201	hybrid			2022-12-25	WOS:000235426200024
J	Tussie-Luna, MI; Rozo, L; Roy, AL				Tussie-Luna, M. I.; Rozo, L.; Roy, A. L.			Pro-proliferative function of the long isoform of PML-RAR alpha involved in acute promyelocytic leukemia	ONCOGENE			English	Article						APL; PML-RAR alpha; c-fos; transcription; chromatin	RETINOIC ACID RECEPTOR; PML/RAR-ALPHA; FUSION PROTEINS; CELL DIFFERENTIATION; HISTONE DEACETYLASE; GENE; ACTIVATION; PHOSPHORYLATION; TRANSLOCATION; ACETYLATION	The promyelocytic leukemia (PML) gene codes for a tumor suppressor protein that is associated with distinct subnuclear macromolecular structures called the PML bodies. The PML gene is frequently involved in the t(15; 17) chromosomal translocation of acute promyelocytic leukemia (APL). The translocation results in a fusion gene product, PML-RAR alpha, in which the PML gene fuses to the retinoic acid receptor alpha (RAR alpha) gene. PML-RAR alpha has been shown to promote transcriptional repression of genes involved in myeloid terminal differentiation and to disrupt the architecture of PML bodies, a phenotype reversed by treatment with all trans retinoic acid (ATRA). However, there are several alternatively spliced isoforms of PML-RAR alpha. Here, we addressed the differences between the short and the long isoforms of PML-RAR alpha (L and S) since both are associated with APL. We demonstrate that PML-RAR alpha L, but not PML-RAR alpha S, can directly promote cell growth by transcriptionally activating the pro-proliferative gene, c-fos, in response to mitogenic stimulation. The activity of the PML-RAR alpha L is completely sensitive to ATRA. We further show that this activation is not via direct recruitment of the protein to the c-fos promoter but indirectly by altering the chromosomal environment of the c-fos gene, thereby rendering it more accessible to the signal induced transcriptional activators. Our results suggest that in addition to antagonizing the PML-tumor suppressor or the PML-pro-apoptotic activity, PML-RAR alpha proteins can also directly promote cell growth by activating c-fos.	Tufts Univ, Dept Pathol, Sch Med, Boston, MA 02111 USA; Tufts Univ, Program Immunol, Sch Med, Boston, MA 02111 USA; Tufts Univ, Genet Program, Sch Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Dept Pathol, Sch Med, 150 Harrison Ave, Boston, MA 02111 USA.	ananda.roy@tufts.edu		Tussie-Luna, Maria Isabel/0000-0002-5033-408X	NIAID NIH HHS [AI056240] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI056240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duprez E, 2004, CELL CYCLE, V3, P389; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Insinga A, 2005, CELL CYCLE, V4, P67, DOI 10.4161/cc.4.1.1400; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Jurcic JG, 2001, BLOOD, V98, P2651, DOI 10.1182/blood.V98.9.2651; Kane JR, 1996, LEUKEMIA, V10, P1296; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lunghi P, 2005, LEUKEMIA, V19, P234, DOI 10.1038/sj.leu.2403585; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Meani N, 2005, ONCOGENE, V24, P3358, DOI 10.1038/sj.onc.1208498; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Segalla S, 2003, MOL CELL BIOL, V23, P8795, DOI 10.1128/MCB.23.23.8795-8808.2003; Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407; Sucic M, 2002, J HEMATOTH STEM CELL, V11, P941, DOI 10.1089/152581602321080600; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	54	11	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3375	3386		10.1038/sj.onc.1209388	http://dx.doi.org/10.1038/sj.onc.1209388			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434964				2022-12-25	WOS:000238448100003
J	Tan, M; Li, P; Sun, M; Yin, G; Yu, D				Tan, M.; Li, P.; Sun, M.; Yin, G.; Yu, D.			Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCa and Src inhibitors	ONCOGENE			English	Article						breast cancer; invasion; metastasis; Src; PKC alpha; ErbB2	PROTEIN-KINASE-C; TUMOR PROGRESSION; FAMILY KINASES; EXPRESSION; OVEREXPRESSION; METASTASIS; THERAPY; PHOSPHORYLATION; TRANSFORMATION; INVASIVENESS	Although ErbB2 is known to enhance breast cancer metastasis, the signaling events responsible for this remain elusive. alpha-Isozyme of protein kinase C (PKC alpha), which is involved in cancer development and progression, has been suggested to be activated by ErbB2 without direct evidence. In addition, the roles of PKC alpha in ErbB2-mediated cancer cell malignancy have not been clearly identifed. In this study, we investigated whether ErbB2 can activate PKC alpha and determined what role PKCa plays in ErbB2-mediated breast cancer cell invasion. We expressed wild-type and mutant ErbB2 with altered signaling capacities in MDA-MB-435 breast cancer cells and revealed that overexpression or activation of ErbB2 in MDA-MB-435 cells upregulated and activated PKC alpha and that downregulation of ErbB2by small-interfering RNA decreased the expression and activity of PKC alpha in BT474 breast cancer cells. These in vitro results were supported by data from breast cancer patient samples. In 150 breast cancer tumor samples, ErbB2-overexpressing tumors showed significantly higher positive rates of PKCa membrane immunohistochemistry staining than that of ErbB2-low-expressing tumors. Mechanistically, we found that PKC alpha is co-immunoprecipitated with Src and PKC alpha expression and activity can be decreased by Src inhibitor PP2 and by the expression of a dominantnegative mutant of Src. Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is reduced by either the PKC alpha inhibitor Go6976 or the Src inhibitor PP2, and the combination of Go6976 with PP2 is superior to either agent alone in suppressing uPAR expression and cell invasion. These results demonstrate that PKC alpha is critical for ErbB2-mediated cancer cell invasion and provide valuable insights for current and future PKC alpha and Src inhibitor clinical trials.	Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Unit 107, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dyu@mdanderson.org	Tan, Ming/ABD-5847-2021; Yin, Guosheng/D-3214-2009	Tan, Ming/0000-0003-2007-9898; Yu, Dihua/0000-0001-6231-9381; Yin, Guosheng/0000-0003-3276-1392	NATIONAL CANCER INSTITUTE [R01CA112567, R01CA109570, P30CA016672, P01CA099031, R01CA060488] Funding Source: NIH RePORTER; NCI NIH HHS [1R01-CA109570, R01-CA112567, P01-CA099031, P30-CA16672, 2R01-CA60488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; de Bono JS, 2003, BREAST CANCER RES, V5, P154, DOI 10.1186/bcr597; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; GUM R, 1995, ANTICANCER RES, V15, P1167; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Johnson MD, 1999, EXP CELL RES, V247, P105, DOI 10.1006/excr.1998.4336; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Lahn M, 2004, ONCOLOGY-BASEL, V67, P1, DOI 10.1159/000080279; Longo M, 2004, BONE, V34, P100, DOI 10.1016/j.bone.2003.09.007; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; Michie AM, 2005, IMMUNOL LETT, V96, P155, DOI 10.1016/j.imlet.2004.08.013; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Morse-Gaudio M, 1998, INT J ONCOL, V12, P1349; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Palka HL, 1997, J CELL SCI, V110, P2359; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Sidenius N, 2003, CANCER METAST REV, V22, P205, DOI 10.1023/A:1023099415940; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tan M, 1999, CANCER RES, V59, P1620; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan M, 1997, CANCER RES, V57, P1199; VADERGREER P, 1994, ANN REV CELL BIOL, V10, P251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359; Zhou XY, 2004, CLIN CANCER RES, V10, P6779, DOI 10.1158/1078-0432.CCR-04-0112	39	74	75	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3286	3295		10.1038/sj.onc.1209361	http://dx.doi.org/10.1038/sj.onc.1209361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407820				2022-12-25	WOS:000237951200007
J	Ehtesham, M; Winston, JA; Kabos, P; Thompson, RC				Ehtesham, M; Winston, JA; Kabos, P; Thompson, RC			CXCR4 expression mediates glioma cell invasiveness	ONCOGENE			English	Article						chemokine; CXCR4; invasion; glioma; brain tumor	BREAST-CANCER METASTASIS; NF-KAPPA-B; TUMOR-GROWTH; CHEMOKINE RECEPTOR; MALIGNANT GLIOMA; INVASION; MIGRATION; BRAIN; METALLOPROTEINASE; ANGIOGENESIS	Glioblastoma multiforme is a highly invasive tumor bearing a dismal prognosis. Experimental strategies that focus on the specific biological cues governing the invasive capacity of these tumors may hold significant therapeutic promise. In this context, we describe the in vitro and in vivo association of the cell surface chemokine receptor, CXCR4, with the development of an invasive phenotype in malignant glioblastoma. We demonstrate that invasive populations of glioma cells overexpress CXCR4 at the message and protein levels, and that this expression ranges from 25- to 89-fold higher than that found in noninvasive tumor cells. Furthermore, neutralization of CXCR4 significantly impairs the in vitro invasive capacity of malignant glial cells. In addition, glioma cells secrete CXCL12 and demonstrate robust invasive capacity toward a CXCL12 gradient in vitro. These findings underscore the importance of CXCR4 as a potential therapeutic target for the treatment of invasive glioblastoma.	Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ So Calif, Dept Med, Los Angeles, CA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Southern California	Ehtesham, M (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, T-4224 Med Ctr N, Nashville, TN 37232 USA.	moneeb.ehtesham@vanderbilt.edu			NINDS NIH HHS [NS051557] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051557] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barbero S, 2003, CANCER RES, V63, P1969; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Belperio JA, 2004, CHEST, V125, p156S, DOI 10.1378/chest.125.5_suppl.156S; COLEMAN MT, 1980, CANCER LETT, V8, P255, DOI 10.1016/0304-3835(80)90011-7; Ehtesham M, 2003, J IMMUNOTHER, V26, P107, DOI 10.1097/00002371-200303000-00003; Ehtesham M, 2002, CANCER GENE THER, V9, P925, DOI 10.1038/sj.cgt.7700516; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; Liang ZX, 2005, CANCER RES, V65, P967; Mori T, 2004, MOL CANCER THER, V3, P29; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Woo JH, 2003, CANCER RES, V63, P3430; Yu JS, 2001, CANCER RES, V61, P842; Zeelenberg IS, 2003, CANCER RES, V63, P3833; ZHANG J, 2005, CARCINOGENESIS; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	26	153	164	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2006	25	19					2801	2806		10.1038/sj.onc.1209302	http://dx.doi.org/10.1038/sj.onc.1209302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407848				2022-12-25	WOS:000237272900011
J	Deka, RK; Brautigam, CA; Yang, XFF; Blevins, JS; Machius, M; Tomchick, DR; Norgard, MV				Deka, RK; Brautigam, CA; Yang, XFF; Blevins, JS; Machius, M; Tomchick, DR; Norgard, MV			The PnrA (Tp0319; TmpC) lipoprotein represents a new family of bacterial purine nucleoside receptor encoded within an ATP-binding cassette (ABC)-like operon in Treponema pallidum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; OUTER-MEMBRANE PROTEIN; X-RAY STRUCTURE; ESCHERICHIA-COLI; SYPHILIS SPIROCHETE; SUBSP PALLIDUM; PERIPLASMIC LYSINE; PORIN ACTIVITY; LIGAND; CRYSTALLOGRAPHY	Treponema pallidum, the bacterial agent of syphilis, cannot be cultivated in vitro. This constraint has severely impeded the study of the membrane biology of this complex human pathogen. A structure-to-function approach thus was adopted as a means of discerning the likely function of Tp0319, a 35-kDa cytoplasmic membrane-associated lipoprotein of T. pallidum formerly designated as TmpC. A 1.7-angstrom crystal structure showed that recombinant Tp0319 (rTp0319) consists of two alpha/beta domains, linked by three crossovers, with a deep cleft between them akin to ATP-binding cassette (ABC) receptors. In the cleft, a molecule of inosine was bound. Isothermal titration calorimetry demonstrated that rTp0319 specifically binds purine nucleosides (dissociation constant (K-d) similar to 10(-7) M). This predilection for purine nucleosides by rTp0319 is consistent with its likely role as a receptor component of a cytoplasmic membrane-associated transporter system. Reverse transcription-PCR analysis of RNA isolated from rabbit tissue-extracted T. pallidum additionally showed that tp0319 is transcriptionally linked to four other downstream open reading frames, thereby supporting the existence of an ABC-like operon (tp0319-0323). We herein thus re-name tp0319 as purine nucleoside receptor A (pnrA), with its operonic partners tp0320-0323 designated as pnrB-E, respectively. Our study not only infers that PnrA transports purine nucleosides essential for the survival of T. pallidum within its obligate human host, but to our knowledge, this is the first description of an ABC-type nucleoside transport system in any bacterium. PnrA has been grouped with a functionally uncharacterized protein family (HBG016869), thereby implying that other members of the family may have similar nucleoside-binding function(s).	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University-Purdue University Indianapolis	Norgard, MV (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	michael.norgard@utsouthwestern.edu	Yang, X. Frank/F-3266-2010; Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643; Brautigam, Chad/0000-0001-6563-1338	NIAID NIH HHS [AI-56305] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER PS, 1994, INFECT IMMUN, V62, P1381, DOI 10.1128/IAI.62.4.1381-1391.1994; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; Blanco DR, 1996, J BACTERIOL, V178, P6685, DOI 10.1128/jb.178.23.6685-6692.1996; BLANCO DR, 1995, J BACTERIOL, V177, P3556, DOI 10.1128/jb.177.12.3556-3562.1995; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; COX DL, 1992, INFECT IMMUN, V60, P1076, DOI 10.1128/IAI.60.3.1076-1083.1992; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Deka RK, 2004, J BIOL CHEM, V279, P55644, DOI 10.1074/jbc.M409263200; Deka RK, 2004, J BACTERIOL, V186, P2303, DOI 10.1128/JB.186.8.2303-2308.2004; FALKOW S, 1988, REV INFECT DIS, V10, pS274; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Haake DA, 2000, MICROBIOL-SGM, V146, P1491, DOI 10.1099/00221287-146-7-1491; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; Hazlett KRO, 2005, J BACTERIOL, V187, P6499, DOI 10.1128/JB.187.18.6499-6508.2005; HERSHFIELD MS, 1976, J BIOL CHEM, V251, P7348; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MAO B, 1982, J BIOL CHEM, V257, P1131; MCFALL E, 1960, J BIOL CHEM, V235, P2103; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Munch-Petersen A, 1983, METABOLISM NUCLEOTID, P259; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; NORRIS SJ, 1993, MICROBIOL REV, V57, P750, DOI 10.1128/MMBR.57.3.750-779.1993; Ochsner UA, 1999, J BACTERIOL, V181, P1099, DOI 10.1128/JB.181.4.1099-1109.1999; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P26323; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; Porcella SF, 1996, GENE, V177, P115, DOI 10.1016/0378-1119(96)00286-7; RADOLF JD, 1989, P NATL ACAD SCI USA, V86, P2051, DOI 10.1073/pnas.86.6.2051; RADOLF JD, 1995, INFECT IMMUN, V63, P4244, DOI 10.1128/IAI.63.11.4244-4252.1995; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1995, MOL MICROBIOL, V16, P1067, DOI 10.1111/j.1365-2958.1995.tb02332.x; Radolf Justin D., 1994, Trends in Microbiology, V2, P307, DOI 10.1016/0966-842X(94)90446-4; Ren QH, 2004, NUCLEIC ACIDS RES, V32, pD284, DOI 10.1093/nar/gkh016; ROBERTSON SM, 1982, INFECT IMMUN, V36, P1076, DOI 10.1128/IAI.36.3.1076-1085.1982; SCHOULS LM, 1991, INFECT IMMUN, V59, P3536, DOI 10.1128/IAI.59.10.3536-3546.1991; SCHOULS LM, 1989, MICROB PATHOGENESIS, V7, P175, DOI 10.1016/0882-4010(89)90053-3; SELL S, 1983, INT REV EXP PATHOL, V24, P203; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TURNER TB, 1957, BIOLOGY TREPONEMATOS, P31; WALKER EM, 1989, J BACTERIOL, V171, P5005, DOI 10.1128/jb.171.9.5005-5011.1989; WEIGEL LM, 1992, INFECT IMMUN, V60, P1568, DOI 10.1128/IAI.60.4.1568-1576.1992; Ye JQ, 2004, EMBO J, V23, P3187, DOI 10.1038/sj.emboj.7600330; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	59	50	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8072	8081		10.1074/jbc.M511405200	http://dx.doi.org/10.1074/jbc.M511405200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418175	hybrid			2022-12-25	WOS:000236031000044
J	Liu, Q; Chen, BJ; Gaier, E; Joshi, J; Wang, ZW				Liu, Q; Chen, BJ; Gaier, E; Joshi, J; Wang, ZW			Low conductance gap junctions mediate specific electrical coupling in body-wall muscle cells of Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCARIS-LUMBRICOIDES; C-ELEGANS; SOMATIC MUSCULATURE; ACTION-POTENTIALS; NEMATODE ASCARIS; GENETIC-ANALYSIS; MAMMALIAN BRAIN; SPINAL-CORD; NERVE CORD; SYNAPSES	Invertebrate innexins and their mammalian homologues, the pannexins, are gap junction proteins. Although a large number of such proteins have been identified, few of the gap junctions that they form have been characterized to provide combined information of biophysical properties, coupling pattern, and molecular compositions. We adapted the dual whole cell voltage clamp technique to in situ analysis of electrical coupling in Caenorhabditis elegans body-wall muscle. We found that body-wall muscle cells were electrically coupled in a highly organized and specific pattern. The coupling was characterized by small ( 350 pS or less) junctional conductance (G(j)), which showed a bell-shaped relationship with junctional potential (V-j) but was independent of membrane potential (V-m). Injection of currents comparable to the junctional current (I-j) into body-wall muscle cells caused significant depolarization, suggesting important functional relevance. The innexin UNC-9 appeared to be a key component of the gap junctions. Both Myc- and green fluorescent protein-tagged UNC-9 was localized to muscle intercellular junctions. G(j) was greatly inhibited in unc-9(fc16), a putative null mutant. Specific inhibition of UNC-9 function in muscle cells reduced locomotion velocity. Despite UNC-9 expression in both motor neurons and body-wall muscle cells, analyses of miniature and evoked postsynaptic currents in the unc-9 mutant showed normal neuromuscular transmission. These analyses provide a relatively detailed description of innexin-based gap junctions in a native tissue and suggest that innexin-based small conductance gap junctions can play an important role in processes such as locomotion.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	University of Connecticut	Wang, ZW (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	zwwang@uchc.edu		Liu, Qiang/0000-0002-9232-1420	NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH070739] Funding Source: NIH RePORTER; NIMH NIH HHS [MH070739] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AVERY L, 1993, GENETICS, V133, P897; Bao L, 2004, FEBS LETT, V572, P65, DOI 10.1016/j.febslet.2004.07.009; Baranova A, 2004, GENOMICS, V83, P706, DOI 10.1016/j.ygeno.2003.09.025; Barnes TM, 1997, J NEUROCHEM, V69, P2251; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BODMER R, 1988, J NEUROSCI, V8, P1656; BOSWELL MV, 1990, FASEB J, V4, P2506, DOI 10.1096/fasebj.4.8.2335273; BRENNER S, 1974, GENETICS, V77, P71; BRINK PR, 1988, BIOPHYS J, V53, P795, DOI 10.1016/S0006-3495(88)83159-X; Bruzzone R, 2003, P NATL ACAD SCI USA, V100, P13644, DOI 10.1073/pnas.2233464100; Bukauskas FF, 2004, BBA-BIOMEMBRANES, V1662, P42, DOI 10.1016/j.bbamem.2004.01.008; BUKAUSKAS FF, 1994, BIOPHYS J, V67, P613, DOI 10.1016/S0006-3495(94)80521-1; Bukauskas FF, 1997, J PHYSIOL-LONDON, V499, P701, DOI 10.1113/jphysiol.1997.sp021962; CHALFIE M, 2000, NEMATODE CAENORHABID, V20, pRC113; Chang Q, 1999, J NEUROSCI, V19, P10813, DOI 10.1523/JNEUROSCI.19-24-10813.1999; Connors BW, 2004, ANNU REV NEUROSCI, V27, P393, DOI 10.1146/annurev.neuro.26.041002.131128; De-Miguel FF, 2001, J EXP BIOL, V204, P3241; DEBELL JT, 1963, J CELL COMPAR PHYSL, V62, P159, DOI 10.1002/jcp.1030620206; DELCASTILLO J, 1989, Q J EXP PHYSIOL CMS, V74, P1071, DOI 10.1113/expphysiol.1989.sp003334; DELCASTILLO J, 1967, J EXP BIOL, V46, P263; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; Dixon SJ, 2005, DEVELOPMENT, V132, P3079, DOI 10.1242/dev.01883; Dykes IM, 2004, J NEUROSCI, V24, P886, DOI 10.1523/JNEUROSCI.3676-03.2004; Harris AL, 2001, Q REV BIOPHYS, V34, P325, DOI 10.1017/S0033583501003705; Hecht RM, 1996, GENOME, V39, P459, DOI 10.1139/g96-058; Hidaka S, 2004, J NEUROSCI, V24, P10553, DOI 10.1523/JNEUROSCI.3319-04.2004; Jospin M, 2002, J CELL BIOL, V159, P337, DOI 10.1083/jcb.200203055; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Landesman Y, 1999, J CELL SCI, V112, P2391; LeBeau FEN, 2005, TRENDS NEUROSCI, V28, P552, DOI 10.1016/j.tins.2005.08.005; Li SL, 2003, MOL BIOL CELL, V14, P2630, DOI 10.1091/mbc.E02-11-0716; Li W, 2004, NAT NEUROSCI, V7, P751, DOI 10.1038/nn1275; Liu Q, 2005, J NEUROSCI, V25, P6745, DOI 10.1523/JNEUROSCI.1730-05.2005; Mello C, 1995, METHOD CELL BIOL, V48, P451; Nolan MF, 1999, J PHYSIOL-LONDON, V519, P753, DOI 10.1111/j.1469-7793.1999.0753n.x; Nonet ML, 1997, J NEUROSCI, V17, P8061; OKKEMA PG, 1993, GENETICS, V135, P385; Pakhotin P, 2005, MOL CELL NEUROSCI, V28, P79, DOI 10.1016/j.mcn.2004.08.014; Panchin Y, 2000, CURR BIOL, V10, pR473, DOI 10.1016/S0960-9822(00)00576-5; Panchin YV, 2005, J EXP BIOL, V208, P1415, DOI 10.1242/jeb.01547; Phelan P, 1998, NATURE, V391, P181, DOI 10.1038/34426; Phelan P, 2001, BIOESSAYS, V23, P388, DOI 10.1002/bies.1057; Phelan P, 1996, J NEUROSCI, V16, P1101; Rekling JC, 2000, J NEUROSCI, V20, part. no.; SEDENSKY MM, 1987, SCIENCE, V236, P952, DOI 10.1126/science.3576211; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Starich T, 2001, CELL COMMUN ADHES, V8, P311, DOI 10.3109/15419060109080744; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; Starich TA, 2003, DEV BIOL, V256, P403, DOI 10.1016/S0012-1606(02)00116-1; STARICH TA, 1993, GENETICS, V133, P527; STRETTON AOW, 1976, J EXP BIOL, V64, P773; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Tavernarakis N, 2000, NAT GENET, V24, P180, DOI 10.1038/72850; Tresch MC, 2000, NAT NEUROSCI, V3, P593, DOI 10.1038/75768; Vandecasteele M, 2005, J NEUROSCI, V25, P291, DOI 10.1523/JNEUROSCI.4167-04.2005; Venance L, 2004, J PHYSIOL-LONDON, V559, P215, DOI 10.1113/jphysiol.2004.065672; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; Wang ZW, 2001, NEURON, V32, P867, DOI 10.1016/S0896-6273(01)00522-0; Waterston R., 1988, NEMATODE C ELEGANS, P281; WEISBLAT DA, 1976, J COMP PHYSIOL, V107, P293, DOI 10.1007/BF00656739; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; White TW, 1999, ANNU REV PHYSIOL, V61, P283, DOI 10.1146/annurev.physiol.61.1.283; Winston WM, 2002, SCIENCE, V295, P2456, DOI 10.1126/science.1068836; Yuan A, 2000, NAT NEUROSCI, V3, P771, DOI 10.1038/77670	69	54	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7881	7889		10.1074/jbc.M512382200	http://dx.doi.org/10.1074/jbc.M512382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434400	hybrid			2022-12-25	WOS:000236031000023
J	Mok, H; Mlodnicka, AE; Hentze, MW; Muckenthaler, M; Schumacher, A				Mok, H; Mlodnicka, AE; Hentze, MW; Muckenthaler, M; Schumacher, A			The molecular circuitry regulating the switch between iron deficiency and overload in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; POLYCYTHEMIA MICE; FERROPORTIN; METABOLISM; HEMOCHROMATOSIS; HEPCIDIN; HOMEOSTASIS; MUTATIONS; LIVER; INFLAMMATION	Recent positional cloning of the radiation-induced polycythaemia (Pcm) mutation revealed a 58-bp microdeletion in the promoter region of ferroportin 1 (Fpn1), the sole cellular iron exporter identified to date. Here we report a molecular definition of the regulatory mechanisms governing the dynamic changes in iron balance in Pcm heterozygous mice between 3 and 12 weeks of age. Hepatic and/or duodenal response patterns of iron metabolism genes, such as Trfr, cybrd1, and Slc11a2, explained the transition from early postnatal iron deficiency to iron overload by 12 weeks of age. A significant delay in developmental up-regulation of hepcidin (Hamp), the pivotal hormonal regulator of iron homeostasis, correlated with high levels of Fpn1 expression in hepatic Kupffer cells and duodenal epithelial cells at 7 weeks of age. Conversely, upon up-regulation of Hamp expression at 12 weeks of age, Fpn1 expression decreased, indicative of a Hamp-mediated homeostatic loop. Hamp regulation due to iron did not appear dependent on transcription-level changes of the murine homolog of Hemojuvelin (Rgmc). Aged cohorts of Pcm mice exhibited low levels of Fpn1 expression in the context of an iron-deficient erythropoiesis and profound iron sequestration in reticuloendothelial macrophages, duodenum, and other tissues. Thus, similar to the anemia of chronic disease, these findings demonstrate decreased iron bioavailability due to sustained down-regulation of Fpn1 levels by Hamp. We conclude that regulatory alleles, such as Pcm, with highly dynamic changes in iron balance are ideally suited to interrogate the genetic circuitry regulating iron metabolism.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Med Sci Training Program, Houston, TX 77030 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Heidelberg, Dept Pediat Oncol Hematol & Immunol, D-69120 Heidelberg, Germany	Baylor College of Medicine; Baylor College of Medicine; European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg	Schumacher, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,S-803, Houston, TX 77030 USA.	armins@bcm.tmc.edu	Hentze, Matthias W/V-3980-2017	Hentze, Matthias W/0000-0002-4023-7876; Muckenthaler, Martina/0000-0002-3778-510X				Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; Adams PC, 2003, BLOOD CELL MOL DIS, V31, P256, DOI 10.1016/S1079-9796(03)00136-0; Bridle KR, 2003, LANCET, V361, P669, DOI 10.1016/S0140-6736(03)12602-5; Celec P, 2005, J MOL MED-JMM, V83, P521, DOI 10.1007/s00109-005-0668-y; De Domenico I, 2005, P NATL ACAD SCI USA, V102, P8955, DOI 10.1073/pnas.0503804102; Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003; Drakesmith H, 2005, BLOOD, V106, P1092, DOI 10.1182/blood-2005-02-0561; Dupic F, 2002, GUT, V51, P648, DOI 10.1136/gut.51.5.648; Frazer DM, 2003, BLOOD CELL MOL DIS, V30, P288, DOI 10.1016/S1079-9796(03)00039-1; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; Knutson M, 2003, CRIT REV BIOCHEM MOL, V38, P61, DOI 10.1080/713609210; Knutson MD, 2003, BLOOD, V102, P4191, DOI 10.1182/blood-2003-04-1250; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; Latunde-Dada GO, 2004, BBA-MOL BASIS DIS, V1690, P169, DOI 10.1016/j.bbadis.2004.06.011; Liu XB, 2005, BLOOD CELL MOL DIS, V35, P33, DOI 10.1016/j.bcmd.2005.04.005; Liu XB, 2002, BLOOD CELL MOL DIS, V29, P315, DOI 10.1006/bcmd.2002.0572; Martini LA, 2002, J NUTR, V132, P693, DOI 10.1093/jn/132.4.693; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Mok H, 2004, DEVELOPMENT, V131, P4871, DOI 10.1242/dev.01342; Mok H, 2004, DEVELOPMENT, V131, P1859, DOI 10.1242/dev.01081; Muckenthaler M, 2003, NAT GENET, V34, P102, DOI 10.1038/ng1152; Muckenthaler M, 2003, BLOOD, V101, P3690, DOI 10.1182/blood-2002-07-2140; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Pietrangelo A, 2004, BLOOD CELL MOL DIS, V32, P131, DOI 10.1016/j.bcmd.2003.08.003; Ponka P, 2004, ANN NY ACAD SCI, V1012, P267, DOI 10.1196/annals.1306.022; Richter A, 2002, BIOTECHNIQUES, V33, P620, DOI 10.2144/02333rr05_11834a; Schimanski LM, 2005, BLOOD, V105, P4096, DOI 10.1182/blood-2004-11-4502; Viatte L, 2005, BLOOD, V105, P4861, DOI 10.1182/blood-2004-12-4608; Zoller H, 2002, BLOOD CELL MOL DIS, V29, P488, DOI 10.1006/bcmd.2002.0587	31	13	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7946	7951		10.1074/jbc.M509857200	http://dx.doi.org/10.1074/jbc.M509857200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418170	hybrid			2022-12-25	WOS:000236031000030
J	Reinboth, B; Thomas, J; Hanssen, E; Gibson, MA				Reinboth, B; Thomas, J; Hanssen, E; Gibson, MA			beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; 5Q31-LINKED CORNEAL DYSTROPHIES; MATRIX PROTEIN BETA-IG-H3; RGD-CAP BETA-IG-H3; CELL-ADHESION; IN-VITRO; EXTRACELLULAR-MATRIX; TERMINAL REGION; MICROFIBRILS; IDENTIFICATION	Recombinant human beta ig-h3 was found to bind I-125-labeled small leucine-rich proteoglycans (SLRPs), biglycan, and decorin, in co-immunoprecipitation experiments. In each instance the binding could be blocked by an excess of the unlabeled proteoglycan, confirming the specificity of the interaction. Scatchard analysis showed that biglycan bound beta ig-h3 more avidly than decorin with K-d values estimated as 5.88 x 10(-8) and 1.02 x 10(-7) M, respectively. In reciprocal blocking experiments both proteoglycans inhibited the others binding to beta ig-h3 indicating that they may share the same binding site or that the two binding sites are in close proximity on the beta ig-h3 molecule. Since beta ig-h3 and the SLRPs are known to be associated with the amino-terminal region of collagen VI in tissue microfibrils, the effects of including collagen VI in the incubations were investigated. Co-immunoprecipitation of I-125-labeled biglycan incubated with equimolar mixtures of beta ig-h3 and pepsin-collagen VI was increased 6-fold over beta ig-h3 alone and 3-fold over collagen VI alone. Similar increases were also observed for decorin. The findings indicate that beta ig-h3 participates in a ternary complex with collagen VI and SLRPs. Static light scattering techniques were used to show that beta ig-h3 rapidly forms very high molecular weight complexes with both native and pepsin-collagen VI, either alone or with the SLRPs. Indeed beta ig-h3 was shown to form a complex with collagen VI and biglycan, which appeared to be much more extensive than that formed by beta ig-h3 with collagen VI and decorin or those formed between the collagen and beta ig-h3, biglycan, or decorin alone. Biglycan core protein was shown to inhibit the extent of complexing of beta ig-h3 with native and pepsin-collagen VI suggesting that the glycosaminoglycan side chains of the proteoglycan were important for the formation of the large ternary complexes. Further studies showed that the direct interaction between beta ig-h3 and biglycan and between biglycan and collagen VI were also important for the formation of these complexes. The globular domains of collagen VI also appeared to have an influence on the interaction of the three components. Overall the results indicate that beta ig-h3 can differentially modulate the aggregation of collagen VI with biglycan and decorin. Thus this interplay is likely to be important in tissues such as cornea where such complexes are considered to occur.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Phys, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	mark.gibson@adelaide.edu.au	Thomas, John C/D-1259-2011; Hanssen, Eric/A-7217-2013	Thomas, John C/0000-0001-8966-5014; Hanssen, Eric/0000-0002-4064-1844				Aitkenhead M, 2002, MICROVASC RES, V63, P159, DOI 10.1006/mvre.2001.2380; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; Clout N, 2003, MOL VIS, V9, P440; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; Ferguson JW, 2003, MECH DEVELOP, V120, P851, DOI 10.1016/S0925-4773(03)00165-5; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; Hanssen E, 2003, J BIOL CHEM, V278, P24334, DOI 10.1074/jbc.M303455200; Hashimoto K, 1997, BBA-MOL CELL RES, V1355, P303, DOI 10.1016/S0167-4889(96)00147-4; Hirano K, 1996, CURR EYE RES, V15, P965, DOI 10.3109/02713689609017642; Isogai Z, 2003, J BIOL CHEM, V278, P2750, DOI 10.1074/jbc.M209256200; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kitahama S, 2000, BONE, V27, P61, DOI 10.1016/S8756-3282(00)00292-1; Lampe AK, 2005, J MED GENET, V42, P673, DOI 10.1136/jmg.2002.002311; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Oh JE, 2005, J BIOL CHEM, V280, P21629, DOI 10.1074/jbc.m412293200; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Ohno S, 2002, BBA-GEN SUBJECTS, V1572, P114, DOI 10.1016/S0304-4165(02)00286-6; Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Streeten BW, 1999, ARCH OPHTHALMOL-CHIC, V117, P67; Thapa N, 2005, BONE, V36, P232, DOI 10.1016/j.bone.2004.08.007; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; Wiberg C, 2003, J BIOL CHEM, V278, P37698, DOI 10.1074/jbc.M304638200; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200	39	71	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7816	7824		10.1074/jbc.M511316200	http://dx.doi.org/10.1074/jbc.M511316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16434404	hybrid			2022-12-25	WOS:000236031000015
J	Stathopulos, PB; Rumfeldt, JAO; Karbassi, F; Siddall, CA; Lepock, JR; Meiering, EM				Stathopulos, PB; Rumfeldt, JAO; Karbassi, F; Siddall, CA; Lepock, JR; Meiering, EM			Calorimetric analysis of thermodynamic stability and aggregation for apo and holo amyotrophic lateral sclerosisassociated Gly-93 mutants of superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; HANDED HELICAL CONFORMATION; HEAT-CAPACITY; CU,ZN-SUPEROXIDE DISMUTASE; GUANIDINIUM CHLORIDE; RECOMBINANT HUMAN; GENE-MUTATIONS; FREE CYSTEINES; SURFACE-AREAS; SCLEROSIS	Differential scanning calorimetry was used to measure changes in thermodynamic stability and aggregation for glycine 93 mutants of human copper, zinc-superoxide dismutase ( SOD). Glycine 93 is a conserved residue at position i + 3 of a tight turn and has been found to be a mutational hot spot in familial amyotrophic lateral sclerosis (fALS). The fALS-associated mutations, G93A, G93S, G93R, G93D, and G93V, were made in a pseudo wild-type background containing no free cysteines, which prevented the formation of aberrant disulfide bonds upon thermal unfolding, and enabled quantitative thermodynamic analysis of the effects of the mutations. Thermal unfolding was highly reversible for all the SODs in both the fully metallated ( holo) and metal-free (apo) forms. The data for all the holo-SODs and for the apo-pseudo-wild-type SOD were well fit by a 2-state unfolding model for native dimer (N-2) to two unfolded monomers (2U), N-2 <-> 2U. The holo- and apo-forms of the mutants are significantly destabilized ( by 1.5 - 3.5 kcal mol(-1) monomer) relative to the corresponding forms of pseudo wild-type, with the relative stabilities being correlated with statistical preferences for amino acids in this structural context. Although van't Hoff (Delta H-vH) to calorimetric (Delta H-cal) enthalpy ratios are close to unity for all the holo-SODs and for apo-pseudo-wild-type, consistent with a 2-state transition, Delta H-vH is considerably larger than Delta H-cal for all the apo-mutants. This suggests that the mutations cause apo-SOD to have an increased propensity to misfold or aggregate, which may be linked to increased toxic mutant SOD aggregation in fALS.	Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Waterloo; University of Waterloo; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Meiering, EM (corresponding author), Univ Waterloo, Dept Chem, 200 Univ Ave, Waterloo, ON N2L 3G1, Canada.	meiering@uwaterloo.ca		Stathopulos, Peter B./0000-0002-0536-6656				Andersen PM, 2003, AMYOTROPH LATERAL SC, V4, P62, DOI 10.1080/14660820310011700; Assfalg M, 2003, J MOL BIOL, V330, P145, DOI 10.1016/S0022-2836(03)00533-3; BANNISTER WH, 1991, FREE RADICAL RES COM, V12-3, P349, DOI 10.3109/10715769109145804; Barrera FN, 2002, BIOCHEMISTRY-US, V41, P5743, DOI 10.1021/bi0159478; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cooper A, 2000, PROTEIN LIGAND INTER; Creamer TP, 1995, BIOCHEMISTRY-US, V34, P16245, DOI 10.1021/bi00050a003; Crow JP, 1997, J NEUROCHEM, V69, P1936; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; di Patti MCB, 2002, METHOD ENZYMOL, V349, P49; DiDonato M, 2003, J MOL BIOL, V332, P601, DOI 10.1016/S0022-2836(03)00889-1; Durr E, 2000, BIOCHEMISTRY-US, V39, P4472, DOI 10.1021/bi992948f; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Freire E, 1995, Methods Mol Biol, V40, P191; Furukawa Y, 2005, J BIOL CHEM, V280, P17266, DOI 10.1074/jbc.M500482200; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GOMEZ J, 1995, PROTEINS, V22, P404, DOI 10.1002/prot.340220410; Gregersen N, 2005, MOL BIOTECHNOL, V31, P141, DOI 10.1385/MB:31:2:141; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; Hosler BA, 1996, NEUROMUSCULAR DISORD, V6, P361, DOI 10.1016/0960-8966(96)00353-7; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Iwai K, 2002, J NEUROL NEUROSUR PS, V72, P819, DOI 10.1136/jnnp.72.6.819; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Juneja T, 1997, NEUROLOGY, V48, P55, DOI 10.1212/WNL.48.1.55; Khare SD, 2004, P NATL ACAD SCI USA, V101, P15094, DOI 10.1073/pnas.0406650101; KIMURA S, 1992, J BIOL CHEM, V267, P22014; KLIBANOV AM, 1987, PROTEIN ENG, P213; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; LEPOCK JR, 1985, ARCH BIOCHEM BIOPHYS, V241, P243, DOI 10.1016/0003-9861(85)90380-7; LEPOCK JR, 1992, BIOCHEMISTRY-US, V31, P12706, DOI 10.1021/bi00165a023; Lindberg MJ, 2005, P NATL ACAD SCI USA, V102, P9754, DOI 10.1073/pnas.0501957102; Lindberg MJ, 2004, P NATL ACAD SCI USA, V101, P15893, DOI 10.1073/pnas.0403979101; Liu CS, 2001, BIOCHEMISTRY-US, V40, P3817, DOI 10.1021/bi002609i; Liu YF, 1996, BIOCHEMISTRY-US, V35, P3059, DOI 10.1021/bi952198j; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; Masumoto K, 2000, PROTEIN ENG, V13, P691, DOI 10.1093/protein/13.10.691; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; McCrary BS, 1996, J MOL BIOL, V264, P784, DOI 10.1006/jmbi.1996.0677; MCREE DE, 1990, J BIOL CHEM, V265, P14234; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; ORRELL R, 1995, NATURE, V374, P504, DOI 10.1038/374504a0; Orrell RW, 1999, J NEUROL SCI, V169, P56, DOI 10.1016/S0022-510X(99)00216-6; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Radunovic A, 1999, AMYOTROPH LATERAL SC, V1, P45; Ramos CHI, 2005, PROTEIN PEPTIDE LETT, V12, P213, DOI 10.2174/0929866053587156; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rumfeldt JAO, 2006, J MOL BIOL, V355, P106, DOI 10.1016/j.jmb.2005.10.042; Shipp EL, 2003, BIOCHEMISTRY-US, V42, P1890, DOI 10.1021/bi026704y; Stathopulos PB, 2003, P NATL ACAD SCI USA, V100, P7021, DOI 10.1073/pnas.1237797100; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; SVENSSON AKE, 2004, FASEB M PROT MISF AM, P12; Takano K, 2001, PROTEINS, V44, P233, DOI 10.1002/prot.1088; Takano K, 2001, PROTEINS, V45, P274, DOI 10.1002/prot.1147; TAMURA A, 1994, BIOCHEMISTRY-US, V33, P14512, DOI 10.1021/bi00252a018; Taylor JR., 1982, INTRO ERROR ANAL, V2nd edition; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; WENISCH E, 1994, ELECTROPHORESIS, V15, P647, DOI 10.1002/elps.1150150191; Wittung-Stafshede P, 2002, ACCOUNTS CHEM RES, V35, P201, DOI 10.1021/ar010106e	74	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6184	6193		10.1074/jbc.M509496200	http://dx.doi.org/10.1074/jbc.M509496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407238	hybrid			2022-12-25	WOS:000236030800010
J	Spengler, ML; Brattain, MG				Spengler, ML; Brattain, MG			Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; SUMO-1 MODIFICATION; GROWTH-FACTOR; UBIQUITIN; PROTEINS; GLYCOSYLATION; TRICHOSTATIN; EXPRESSION; REPRESSION; MECHANISM	Sp1 is a ubiquitously expressed transcription factor that binds GC-rich cis elements. Many posttranslational modifications have been implicated in the regulation of Sp1 activity. We now provide evidence for a novel mechanism of Sp1 regulation involving the small ubiquitin-like modifier (SUMO-1). Western blot analysis revealed a high molecular mass Sp1 of 125 kDa that is stabilized by a selective SUMO hydrolase inhibitor and destabilized by a specific SUMO-1 hydrolase. The covalent modification of Sp1 by endogenous SUMO-1 and SUMO-1 that has been fused to green fluorescent protein was demonstrated using transient transfection assays. A high probability sumoylation consensus motif, (VKIE18)-I-16, is located within the N-terminal negative regulatory domain of Sp1. Either arginine substitution for lysine 16 ( Sp1(K16R)) or alanine substitution for glutamic acid 18 ( Sp1(E18A)), abrogated Sp1 sumoylation. In vitro SUMO-1 covalently bound affinity-purified GST-Sp1, but not GST-Sp1(K16R). In vivo Sp1 was determined to be N- terminally cleaved, while Sp1( K16R) could not be cleaved indicating that sumoylation and cleavage are coupled through the key regulatory lysine 16. This coupling was evident by the demonstration of an inverse relationship between cellular SUMO-modified Sp1 and N- terminally cleaved Sp1. Compared with Sp1, sumoylation-deficient Sp1( E18A) exhibited enhanced cleavage and was a better transcriptional activator, while constitutively SUMO-1-modified Sp1 was deficient in proteolytic processing and repressed Sp1 transcriptional activity. The repressive effect of sumoylation on Sp1 activity is emphasized through the use of a GAL4 based transactivation assay. A model is proposed defining a mechanism by which sumoylation preserves the integrity of a negative regulatory domain thereby allowing for the inhibition of Sp-dependent transcription.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton Sts, Buffalo, NY 14263 USA.	Michael.Brattain@roswellpark.org			NCI NIH HHS [CA 72001, CA 38173, F32 CA 86500-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA038173, R01CA072001, F32CA086500, R01CA038173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lee JA, 2005, J BIOL CHEM, V280, P28061, DOI 10.1074/jbc.M414134200; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Spengler ML, 2005, CELL SIGNAL, V17, P153, DOI 10.1016/j.cellsig.2004.06.007; Spengler ML, 2002, J VIROL, V76, P2990, DOI 10.1128/JVI.76.6.2990-2996.2002; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	37	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5567	5574		10.1074/jbc.M600035200	http://dx.doi.org/10.1074/jbc.M600035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407261	hybrid			2022-12-25	WOS:000235568900032
J	Yoshida, K; Liu, HS; Miki, Y				Yoshida, K; Liu, HS; Miki, Y			Protein kinase C delta regulates Ser(46) phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; PROTEOLYTIC ACTIVATION; P53-DEPENDENT APOPTOSIS; CASPASE-3; STRESS; CELLS; RADIATION; RAD9; P21	The p53 tumor suppressor is activated in the cellular response to genotoxic stress. Transactivation of p53 target genes dictates cell cycle arrest and DNA repair or induction of apoptosis; however, a molecular mechanism responsible for these distinct functions remains unclear. Recent studies revealed that phosphorylation of p53 on Ser(46) was associated with induction of p53AIP1 expression, resulting in the commitment of the cell fate into apoptotic cell death. Moreover, upon exposure to genotoxic stress, p53DINP1 was expressed and recruited a kinase(s) to p53 that specifically phosphorylated Ser46. Here, we show that the pro-apoptotic kinase, protein kinase C delta(PKC delta), is involved in phosphorylation of p53 on Ser46. PKC delta-mediated phosphorylation is required for the interaction of PKC delta with p53. The results also demonstrate that p53DINP1 associates with PKC delta upon exposure to genotoxic agents. Consistent with these results, PKC delta potentiates p53-dependent apoptosis by Ser46 phosphorylation in response to genotoxic stress. These findings indicate that PKC delta regulates p53 to induce apoptotic cell death in the cellular response to DNA damage.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Yoshida, K (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	yos.mgen@mri.tmd.ac.jp						Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Johnson CL, 2002, MOL CANCER THER, V1, P861; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Leitges M, 2001, J CLIN INVEST, V108, P1505; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Voss OH, 2005, J BIOL CHEM, V280, P17371, DOI 10.1074/jbc.M412449200; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2005, CELL CYCLE, V4, P777, DOI 10.4161/cc.4.6.1746; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	34	130	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5734	5740		10.1074/jbc.M512074200	http://dx.doi.org/10.1074/jbc.M512074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377624	hybrid			2022-12-25	WOS:000235568900051
J	Yu, WM; Daino, H; Chen, J; Bunting, KD; Qu, CK				Yu, WM; Daino, H; Chen, J; Bunting, KD; Qu, CK			Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUVENILE MYELOMONOCYTIC LEUKEMIA; HEMATOPOIETIC-CELL DEVELOPMENT; COLONY-STIMULATING FACTOR; TYROSINE-PHOSPHATASE; PTPN11 MUTATIONS; NOONAN-SYNDROME; SH2 DOMAINS; MOUSE MODEL; RECEPTOR; NF1	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3. However, the molecular mechanisms by which gain-of-function (GOF) mutations of SHP-2 induce hematopoietic malignancies are not fully understood. Our previous studies have shown that SHP-2 plays an essential role in IL-3 signal transduction in both catalytic-dependent and - independent manners and that overexpression (5-6-fold) of wild type (WT) SHP-2 attenuates IL-3-mediated hematopoietic cell function through accelerated dephosphorylation of STAT5. These results raised the possibility that SHP-2-associated leukemias are not solely attributed to the increased catalytic activity of GOF mutant SHP-2. GOF mutant SHP-2 must have gained additional capacities. To test this possibility, we investigated effects of a GOF mutation of SHP- 2 ( SHP- 2 E76K) on hematopoietic cell function and IL-3 signal transduction by comparing with those of overexpressed WT SHP-2. Our results showed that SHP- 2 E76K mutation caused myeloproliferative disease in mice, while overexpression of WT SHP- 2 decreased hematopoietic potential of the transduced cells in recipient animals. The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP- 2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways. In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP- 2 E76K was dampened. Furthermore, catalytically inactive SHP- 2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway. Taken together, these studies suggest that in addition to the elevated catalytic activity, fundamental changes in physical and functional interactions between GOF mutant SHP- 2 and signaling partners also play an important role in SHP- 2-related leukemigenesis.	Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Qu, CK (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cxq6@case.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 68212] Funding Source: Medline; NIDDK NIH HHS [R01 DK059380] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Arico M, 1997, BLOOD, V90, P479, DOI 10.1182/blood.V90.2.479.479_479_488; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Chen J, 2004, ONCOGENE, V23, P3659, DOI 10.1038/sj.onc.1207471; Cichowski K, 2003, GENE DEV, V17, P449, DOI 10.1101/gad.1054703; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Emanuel PD, 1996, MOL MED TODAY, V2, P468, DOI 10.1016/1357-4310(96)10044-7; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Okuda K, 1999, ANN NY ACAD SCI, V872, P305, DOI 10.1111/j.1749-6632.1999.tb08474.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Schubbert S, 2005, BLOOD, V106, P311, DOI 10.1182/blood-2004-11-4207; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Zhang YY, 1998, J EXP MED, V187, P1893, DOI 10.1084/jem.187.11.1893	33	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5426	5434		10.1074/jbc.M507622200	http://dx.doi.org/10.1074/jbc.M507622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371368	hybrid			2022-12-25	WOS:000235568900014
J	Liu, JB; Chen, QH; Huang, W; Horak, KM; Zheng, HQ; Mestril, R; Wang, XJ				Liu, Jinbao; Chen, Quanhai; Huang, Wei; Horak, Kathleen M.; Zheng, Hanqiao; Mestril, Ruben; Wang, Xuejun			Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts	FASEB JOURNAL			English	Article									[Liu, Jinbao; Chen, Quanhai; Huang, Wei; Horak, Kathleen M.; Zheng, Hanqiao; Wang, Xuejun] Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, Sioux Falls, SD 57105 USA; [Liu, Jinbao; Chen, Quanhai; Huang, Wei; Horak, Kathleen M.; Zheng, Hanqiao; Wang, Xuejun] Sioux Valley Hosp & Hlth Syst, Sioux Falls, SD USA; [Liu, Jinbao] Guangzhou Med Coll, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China; [Huang, Wei] Nanjing Med Univ, Cardiovasc Res Inst, Nanjing, Jiangsu, Peoples R China; [Mestril, Ruben] Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA	University of South Dakota; Guangzhou Medical University; Nanjing Medical University; Loyola University Chicago	Wang, XJ (corresponding author), Univ S Dakota, Sch Med, Cardiovasc Res Inst, S Dakota Hlth Res Fdn, 1100 E 21st St,Suite 700, Sioux Falls, SD 57105 USA.	xwang@usd.edu	Wang, Xuejun/AAT-9490-2021; Wang, Xuejun/K-8874-2013	Wang, Xuejun/0000-0001-9267-1343; Wang, Xuejun/0000-0001-9267-1343; Mestril, Ruben/0000-0003-3631-2236	NHLBI NIH HHS [R01 HL072166, R01-HL-72166] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072166] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	112	115	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					362	364		10.1096/fj.05-4869fje	http://dx.doi.org/10.1096/fj.05-4869fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371426				2022-12-25	WOS:000207915000022
J	Fineschi, S; Reith, W; Guerne, PA; Dayer, JM; Chizzolini, C				Fineschi, S; Reith, W; Guerne, PA; Dayer, JM; Chizzolini, C			Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts	FASEB JOURNAL			English	Article						fibrosis; proteasome inhibition; c-Jun	GROWTH-FACTOR-BETA; COL1A2 PROMOTER ACTIVITY; SYSTEMIC-SCLEROSIS; TGF-BETA; MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; PROCOLLAGEN GENE; PHORBOL ESTER; EXPRESSION; INDUCTION	Tissue fibrosis results when dysregulation of extracellular matrix (ECM) turnover favors deposition of collagen and other ECM proteins over degradation. Fibrosis may then lead to organ dysfunction and pathology as observed in systemic sclerosis (SSc). In the present study, we investigated the antifibrotic properties of proteasome blockade. A dose- and time-dependent reduction in type-I collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) production was observed in normal fibroblasts exposed to proteasome inhibitors ( PI). In the same culture conditions, metalloproteinase- 1 (MMP-1) protein and the collagenolytic activity on type I collagen was increased. The steady-state mRNA levels of COL1A1, TIMP-1, and MMP-1 paralleled protein levels. These effects were dominant over the profibrotic properties of TGF-beta and were observed with fibroblasts generated from normal and SSc skin. PI decreased type I collagen mRNA levels with kinetics similar to those observed with DRB, a specific RNA polymerase II inhibitor, thus indicating transcriptional inhibition. Of interest, PI induced c-Jun phosphorylation and c-Jun nuclear accumulation. The specific N-terminal Jun-kinase inhibitor SP-600125 selectively abrogated c-Jun phosphorylation and, in a dose- dependent fashion, the up-regulated synthesis of MMP-1 induced by PI. Finally, PI did not affect fibroblast viability. Thus, the coordinated down-regulation of collagen and TIMP-1 and up-regulation of MMP-1 renders proteasome blockade an attractive strategy for treating conditions as SSc, characterized by excessive fibrosis.	Geneva Univ Hosp, Geneva Sch Med, Dept Internal Med, CH-1211 Geneva 14, Switzerland; Geneva Univ Hosp, Geneva Sch Med, Dept Pathol & Immunol, CH-1211 Geneva 14, Switzerland	University of Geneva	Chizzolini, C (corresponding author), Geneva Univ Hosp, Geneva Sch Med, Dept Internal Med, CH-1211 Geneva 14, Switzerland.	chizzolini@medecine.unige.ch	Chizzolini, Carlo/V-4847-2019					Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chizzolini C, 2003, ARTHRITIS RHEUM-US, V48, P2593, DOI 10.1002/art.11129; Chizzolini C, 1998, ARTHRITIS RHEUM-US, V41, P2039; Chizzolini C, 1999, SPRINGER SEMIN IMMUN, V21, P431, DOI 10.1007/BF00870304; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Eckes B, 1999, SPRINGER SEMIN IMMUN, V21, P415, DOI 10.1007/BF00870303; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Hitraya EG, 1996, ARTHRITIS RHEUM-US, V39, P1347, DOI 10.1002/art.1780390812; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Jimenez SA, 2004, ANN INTERN MED, V140, P37, DOI 10.7326/0003-4819-140-1-200401060-00010; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Li DQ, 2004, INVEST OPHTH VIS SCI, V45, P4302, DOI 10.1167/iovs.04-0299; MACKAY AR, 1992, INVAS METAST, V12, P168; McGaha TL, 2002, ARTHRITIS RHEUM, V46, P2748, DOI 10.1002/art.10549; Medsger Jr T. A., 2001, ARTHRITIS ALLIED CON, P1590; Meiners S, 2004, HYPERTENSION, V44, P471, DOI 10.1161/01.HYP.0000142772.71367.65; Mori Y, 2003, ARTHRITIS RHEUM-US, V48, P1964, DOI 10.1002/art.11157; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Sakai T, 2001, J BONE MINER RES, V16, P1272, DOI 10.1359/jbmr.2001.16.7.1272; SLACK JL, 1995, J CELL BIOCHEM, V58, P380, DOI 10.1002/jcb.240580311; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Tashiro K, 2003, INT J MOL MED, V12, P587; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vergeer WP, 2000, ARCH BIOCHEM BIOPHYS, V377, P69, DOI 10.1006/abbi.2000.1760; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Wendling J, 2003, MOL PHARMACOL, V64, P707, DOI 10.1124/mol.64.3.707; White S.C., 2002, J INT DEV, V14, P725, DOI DOI 10.1002/JID.919; Wu HM, 2002, FEBS LETT, V526, P101, DOI 10.1016/S0014-5793(02)03151-4; Yang Y, 2004, CANCER SCI, V95, P176, DOI 10.1111/j.1349-7006.2004.tb03200.x; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zhang F, 2003, EXP CELL RES, V291, P275, DOI 10.1016/j.yexcr.2003.07.007	48	51	55	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					562	+		10.1096/fj.05-4870fje	http://dx.doi.org/10.1096/fj.05-4870fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16410344				2022-12-25	WOS:000235996000019
J	Mingorance, A; Sole, M; Muneton, V; Martinez, A; Nieto-Sampedro, M; Soriano, E; del Rio, JA				Mingorance, A; Sole, M; Muneton, V; Martinez, A; Nieto-Sampedro, M; Soriano, E; del Rio, JA			Regeneration of lesioned entorhino-hippocampal axons in vitro by combined degradation of inhibitory proteoglycans and blockade of Nogo-66/NgR signaling	FASEB JOURNAL			English	Article						organotypic cultures; perforant path lesion; chondroitin sulfate; axotomy	MYELIN-ASSOCIATED GLYCOPROTEIN; SPINAL-CORD-INJURY; CHONDROITIN SULFATE PROTEOGLYCANS; RECEPTOR FAMILY-MEMBER; CAJAL-RETZIUS CELLS; NOGO RECEPTOR; NEURITE OUTGROWTH; PATHWAY; CNS; REORGANIZATION	Damaged axons do not regenerate after axotomy in the adult mammalian central nervous system (CNS). This may be due to local inhibitory factors at the site of injury, such as overexpression of chondroitin sulfate (CS) proteoglycans (CSPG), and the presence of myelin-associated inhibitors (MAI). To overcome CSPG- or myelin-induced inhibition, strategies based on extrinsic and intrinsic treatments have been developed. For example, NEP1-40 is a synthetic peptide that promotes axonal regeneration by blocking Nogo-66/NgR interaction and chondroitinase ABC (ChABC), which degrades CS, thereby also promoting axon regrowth. Here, we examined whether the combination of these complementary strategies facilitates regeneration of the lesioned entorhino-hippocampal pathway (EHP) in slice cultures. In this model, overexpressed CSPG and MAI impaired axon regrowth, which mimics regeneration failure in vivo. Both CS cleavage with ChABC and NEP1-40 strongly facilitated the regrowth of entorhinal axons after axotomy, permitting the re-establishment of synaptic contacts with target cells. However, the combined treatment did not improve the regeneration induced by ChABC alone, and the delayed treatment of ChABC, but not NEP1-40, had a less pronounced effect on axonal regrowth compared with acute treatment. These results provide insight into the development of new assays and strategies to enhance axon regeneration in injured cortical connections.	Univ Barcelona, IRB PCB, Dept Cell Biol, Dev & Regenerat CNS, E-08028 Barcelona, Spain; CSIC, Inst Cajal, Regenerat CNS Unit, E-28002 Madrid, Spain; Natl Hosp Parapleg, Toledo, OH USA	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	del Rio, JA (corresponding author), Univ Barcelona, IRB PCB, Dept Cell Biol, Dev & Regenerat CNS, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	jario@pcb.ub.es	Del Rio Fernandez, Jose A/AAD-1121-2020; Mingorance-Le Meur, Ana/A-7147-2008; del rio, jose antonio/L-9232-2014; Soriano, Eduardo/AAB-3216-2019	del rio, jose antonio/0000-0002-5214-4909; Soriano, Eduardo/0000-0002-3204-9285; Mingorance, Ana/0000-0002-6213-6160; Martinez, Albert/0000-0003-0831-9916				Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; Bechmann I, 2000, ANN NY ACAD SCI, V911, P192; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CASTELLANO B, 1991, J HISTOCHEM CYTOCHEM, V39, P561, DOI 10.1177/39.5.1707903; del Rio JA, 2002, EUR J NEUROSCI, V15, P1881, DOI 10.1046/j.1460-9568.2002.02027.x; Deller T, 2000, ANN NY ACAD SCI, V911, P207; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Hasegawa Y, 2004, J NEUROSCI, V24, P6826, DOI 10.1523/JNEUROSCI.1856-04.2004; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Ji BX, 2005, EUR J NEUROSCI, V22, P587, DOI 10.1111/j.1460-9568.2005.04241.x; Laabs T, 2005, CURR OPIN NEUROBIOL, V15, P116, DOI 10.1016/j.conb.2005.01.014; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Li SX, 2003, J NEUROSCI, V23, P4219; Li WW, 2004, J BIOL CHEM, V279, P43780, DOI 10.1074/jbc.M401803200; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Mingorance A, 2005, MOL CELL NEUROSCI, V29, P471, DOI 10.1016/j.mcn.2005.03.016; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; Nieto-Sampedro M, 1999, ADV EXP MED BIOL, V468, P207; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Prang P, 2001, EXP NEUROL, V169, P135, DOI 10.1006/exnr.2001.7648; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Schweigreiter R, 2004, MOL CELL NEUROSCI, V27, P163, DOI 10.1016/j.mcn.2004.06.004; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Steinmetz MP, 2005, J NEUROSCI, V25, P8066, DOI 10.1523/JNEUROSCI.2111-05.2005; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	33	35	39	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					491	+		10.1096/fj.05-5121fje	http://dx.doi.org/10.1096/fj.05-5121fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407455				2022-12-25	WOS:000235996000024
J	Qiu, W; Schonleben, F; Thaker, HM; Goggins, M; Su, GH				Qiu, W.; Schoenleben, F.; Thaker, H. M.; Goggins, M.; Su, G. H.			A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma	ONCOGENE			English	Article						HNSCC; PJS; STK11; LKB1; genetic mutation; tumor-suppressor gene	PEUTZ-JEGHERS-SYNDROME; SYNDROME KINASE LKB1; SOMATIC MUTATIONS; LKB1/STK11 GENE; TUMORS; POLYPOSIS; EXPRESSION; CANCER; RISK; LUNG	To investigate whether genetic alteration of the STK11 ( serine/ threonine kinase 11)/ LKB1 tumor- suppressor gene is involved in the carcinogenesis of head and neck squamous cell carcinoma ( HNSCC), the entire encoding exons and flanking intronic sequences of the STK11/ LKB1 gene were analysed with direct genomic sequencing of 15 HNSCC specimens. A novel missense mutation with presumed loss of heterozygosity ( LOH) and 10 polymorphisms were identified in these samples. The novel mutation of STK11/ LKB1 at nucleotide position 613 G -> A, which causes the amino- acid substitution from alanine to threonine at residue 205 within the catalytic kinase domain, was identified in cell line RPMI 2650. To further determine whether this point mutation affects the gene function, constructs of the wild type and A205T mutant of the STK11/ LKB1 gene expression vectors were created and transfected into RPMI 2650 cells. Our results showed that the reintroduction of the wild- type but not the mutant STK11/ LKB1 construct into RPMI 2650 cells induced suppression of the cell growth. The mutation also affected the kinase activity of the Stk11/ Lkb1 protein. This led us to conclude that the A205T point mutation of the STK11/ LKB1 gene produces functionally inactive proteins. This is the first described mutation of the STK11/ LKB1 gene in HNSCC. While the mutation frequency of the STK11/ LKB1 gene in HNSCC remains to be determined in future studies, our data strongly suggests that STK11/ LKB1 is involved in the carcinogenesis of HNSCC.	Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Columbia University; Columbia University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Su, GH (corresponding author), Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, 1130 St Nicholas Ave,ICRC 10-04, New York, NY 10032 USA.	gs2157@columbia.edu	Su, Gloria/AAJ-1457-2020	Su, Gloria/0000-0002-5158-6019	NATIONAL CANCER INSTITUTE [R01CA109525, K01CA095434] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA095434, CA95434, R01 CA109525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avizienyte E, 1998, CANCER RES, V58, P2087; Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Boudeau J, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9112; Chen RW, 1999, J MED GENET, V36, P943; Ghaffar H, 2003, CLIN CANCER RES, V9, P2998; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Jordanova A, 1997, HUM MUTAT, V10, P65, DOI 10.1002/(SICI)1098-1004(1997)10:1<65::AID-HUMU9>3.3.CO;2-9; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Launonen V, 2005, HUM MUTAT, V26, P291, DOI 10.1002/humu.20222; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Nakau M, 2002, CANCER RES, V62, P4549; Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Rowan A, 2000, J PATHOL, V192, P203; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Spicer J, 2003, ONCOGENE, V22, P4752, DOI 10.1038/sj.onc.1206669; Su GH, 1999, AM J PATHOL, V154, P1835, DOI 10.1016/S0002-9440(10)65440-5; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Westerman AM, 1999, HUM MUTAT, V13, P476, DOI 10.1002/(SICI)1098-1004(1999)13:6<476::AID-HUMU7>3.3.CO;2-U; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074	34	30	30	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2937	2942		10.1038/sj.onc.1209325	http://dx.doi.org/10.1038/sj.onc.1209325			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407837	Green Accepted			2022-12-25	WOS:000237448200012
J	Chen, E; Lim, MS; Rosic-Kablar, S; Liu, J; Jolicoeur, P; Dube, ID; Hough, MR				Chen, E; Lim, MS; Rosic-Kablar, S; Liu, J; Jolicoeur, P; Dube, ID; Hough, MR			Dysregulated expression of mitotic regulators is associated with B-cell lymphomagenesis in HOX11-transgenic mice	ONCOGENE			English	Article						HOX11; homeobox; aneuploidy; insertional mutagenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; INSERTIONAL MUTAGENESIS; DISEASE GENES; IDENTIFICATION; HOX11; IMMUNODEFICIENCY; VIRUS; INDUCTION; PATHWAY	Dysregulated expression of the homeobox gene, HOX11 is a frequent etiologic event in T-cell acute lymphoblastic leukemias. HOX11-transgenic mice ( IgH mu-HOX11(Tg))-expressing HOX11 in the B-cell compartment develop B-cell lymphomas with extended latency. The latency suggests that additional genetic events are required prior to the onset of malignant lymphoma. We report the identification of 17 HOX11 collaborating genes, revealed through their propensity to be targeted in a proviral insertional mutagenesis screen. Seven integrations disrupted genes in mitotic spindle checkpoint control, suggesting that cells with elevated HOX11 expression are especially sensitive to dysregulation of chromosome segregation during mitosis. IgH mu-HOX11(Tg) primary B-lymphocyte cultures exposed to the aneugenic agents, colchicine and colcemid, exhibited increased incidences of chromosome missegregation as assessed by cytokinesis-block micronucleus assays. Additionally, IgH mu-HOX11(Tg) cultures were shown to exhibit aberrant bypass of spindle checkpoint arrest, as assessed by the increased presence of cycling cells determined by assessment of DNA content and by BrdU immunolabelling. Western immunoblotting revealed elevated expression of the mitotic effector molecules, cyclin A, cyclin B1 and cdc20 in IgH mu-HOX11(Tg) cultures. Moreover, spontaneously arising lymphoid neoplasms in IgH mu-HOX11(Tg) mice frequently exhibit aberrant expression of mitotic regulators, concomitant with increased development of micronuclei, abnormal mitotic checkpoint control and increased incidences of abnormal karyotypes when expanded in culture. Collectively, these findings indicate that abnormal regulation of spindle checkpoint control as a result of HOX11 overexpression leads to a heightened predisposition for development of aneuploidy, contributing to oncogenesis.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada; Univ Utah, Dept Pathol, Salt Lake City, UT USA; McGill Univ, Clin Res Inst Montreal, Montreal, PQ, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; Utah System of Higher Education; University of Utah; Institut de Recherche Clinique de Montreal (IRCM); McGill University; Universite de Montreal	Hough, MR (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Mol & Cellular Biol, 2075 Bayview Ave,Room S232, Toronto, ON M4N 3M5, Canada.	margaret.hough@sw.ca	Liu, Ju/Q-6319-2016; Hough, Margaret/AAA-1026-2019	Liu, Ju/0000-0001-9932-2613; Hough, Margaret/0000-0001-8539-6398; Chen, Edwin/0000-0003-0742-9734; Lim, Megan/0000-0002-0415-2867				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Asnafi V, 2005, BLOOD, V105, P3072, DOI 10.1182/blood-2004-09-3666; Asnafi V, 2004, BLOOD, V104, P4173, DOI 10.1182/blood-2003-11-3944; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; Bourner RDP, 1998, MUTAT RES-FUND MOL M, V404, P191, DOI 10.1016/S0027-5107(98)00113-4; Casabianca A, 2003, J VIROL METHODS, V110, P81, DOI 10.1016/S0166-0934(03)00104-6; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; DUBE ID, 1986, BLOOD, V67, P1181; DUBE ID, 1991, BLOOD, V78, P2996; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Ferrando AA, 2004, LANCET, V363, P535, DOI 10.1016/S0140-6736(04)15542-6; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; HUANG M, 1995, J VIROL, V69, P4069, DOI 10.1128/JVI.69.7.4069-4078.1995; HUANG M, 1989, SCIENCE, V246, P1614, DOI 10.1126/science.2480643; HUANG M, 1991, J VIROL, V65, P6562, DOI 10.1128/JVI.65.12.6562-6571.1991; HUANG M, 1992, J VIROL, V66, P2398, DOI 10.1128/JVI.66.4.2398-2406.1992; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Iwasaki M, 2005, BLOOD, V105, P784, DOI 10.1182/blood-2004-04-1508; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kees UR, 2003, LEUKEMIA, V17, P887, DOI 10.1038/sj.leu.2402892; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; LICHTY BD, 1995, LEUKEMIA LYMPHOMA, V16, P209, DOI 10.3109/10428199509049759; Mauvieux L, 2002, LEUKEMIA, V16, P2417, DOI 10.1038/sj.leu.2402709; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Muehlbauer PA, 2005, MUTAT RES-GEN TOX EN, V585, P156, DOI 10.1016/j.mrgentox.2005.05.002; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Rosic-Kablar S, 2000, P NATL ACAD SCI USA, V97, P13300, DOI 10.1073/pnas.240221297; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142	36	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2575	2587		10.1038/sj.onc.1209285	http://dx.doi.org/10.1038/sj.onc.1209285			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16407851				2022-12-25	WOS:000237099400002
J	Greenall, A; Williams, ES; Martin, KA; Palmer, JM; Gray, J; Liu, C; Whitehall, SK				Greenall, A; Williams, ES; Martin, KA; Palmer, JM; Gray, J; Liu, C; Whitehall, SK			Hip3 interacts with the HIRA proteins Hip1 and Slm9 and is required for transcriptional silencing and accurate chromosome segregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY FACTOR-I; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; AFFINITY PURIFICATION; LYSINE-9 METHYLATION; RNA INTERFERENCE; REGULATORY GENES; HISTONE GENES; HUMAN HOMOLOG; EXPRESSION	The fission yeast HIRA proteins Hip1 and Slm9 are members of an evolutionarily conserved family of histone chaperones that are implicated in nucleosome assembly. Here we have used single-step affinity purification and mass spectrometry to identify factors that interact with both Hip1 and Slm9. This analysis identified Hip3, a previously uncharacterized 187-kDa protein, with similarity to S. cerevisiae Hir3. Consistent with this, cells disrupted for hip3(+) exhibit a range of growth defects that are similar to those associated with loss of Hip1 and Slm9. These include temperature sensitivity, a cell cycle delay, and synthetic lethality with cdc25-22. Furthermore, genetic analysis also indicates that disruption of hip3(+) is epistatic with mutation of hip1(+) and slm9(+). Mutation of hip3(+) alleviates transcriptional silencing at several heterochromatic loci, including in the outer (otr) centromeric repeats, indicating that Hip3 is required for the integrity of pericentric heterochromatin. As a result, loss of Hip3 function leads to high levels of minichromosome loss and an increased frequency of lagging chromosomes during mitosis. Importantly, the function of Hip1, Slm9, and Hip3 is not restricted to constitutive heterochromatic loci, since these proteins also repress the expression of a number of genes, including the Tf2 retrotransposons.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	Newcastle University - UK; University of Sussex	Whitehall, SK (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	S.K.Whitehall@ncl.ac.uk	Liu, Cong/GOE-5572-2022	Liu, Cong/0000-0001-5192-6784; Gray, Joseph/0000-0003-2338-0301				ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Blackwell C, 2004, MOL CELL BIOL, V24, P4309, DOI 10.1128/MCB.24.10.4309-4320.2004; Bowen NJ, 2003, GENOME RES, V13, P1984, DOI 10.1101/gr.1191603; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; Craven RA, 1998, GENE, V221, P59, DOI 10.1016/S0378-1119(98)00434-X; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Ekwall K, 1999, GENETICS, V153, P1153; Formosa T, 2002, GENETICS, V162, P1557; Gunjan A, 2005, BIOCHIMIE, V87, P625, DOI 10.1016/j.biochi.2005.02.008; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; Hansen KR, 2005, MOL CELL BIOL, V25, P590, DOI 10.1128/MCB.25.2.590-601.2005; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Huang Y, 2002, NUCLEIC ACIDS RES, V30, P1465, DOI 10.1093/nar/30.7.1465; Kanoh J, 2000, GENETICS, V155, P623; Kaufman PD, 1998, MOL CELL BIOL, V18, P4793, DOI 10.1128/MCB.18.8.4793; Kirov N, 1998, GENE, V212, P323, DOI 10.1016/S0378-1119(98)00143-7; Kniola B, 2001, MOL BIOL CELL, V12, P2767, DOI 10.1091/mbc.12.9.2767; LAMOUR V, 1995, HUM MOL GENET, V4, P791, DOI 10.1093/hmg/4.5.791; Lippman Z, 2003, PLOS BIOL, V1, P420, DOI 10.1371/journal.pbio.0000067; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; NIWA O, 1989, EMBO J, V8, P3045, DOI 10.1002/j.1460-2075.1989.tb08455.x; Partridge JF, 2000, GENE DEV, V14, P783; Pidoux AL, 2004, CHROMOSOME RES, V12, P521, DOI 10.1023/B:CHRO.0000036586.81775.8b; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Prochasson P, 2005, GENE DEV, V19, P2534, DOI 10.1101/gad.1341105; Provost P, 2002, P NATL ACAD SCI USA, V99, P16648, DOI 10.1073/pnas.212633199; Qian ZJ, 1998, MOL CELL BIOL, V18, P4783, DOI 10.1128/MCB.18.8.4783; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Roberts C, 1997, HUM MOL GENET, V6, P237, DOI 10.1093/hmg/6.2.237; Scamps C, 1996, BBA-GENE STRUCT EXPR, V1306, P5, DOI 10.1016/0167-4781(96)00010-3; Sharp JA, 2002, GENE DEV, V16, P85, DOI 10.1101/gad.925302; Spector MS, 1997, MOL CELL BIOL, V17, P545, DOI 10.1128/MCB.17.2.545; SPECTOR MS, 1993, GENETICS, V135, P25; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Thon G, 2000, GENETICS, V155, P551; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Walsh EP, 2002, BIOCHEMISTRY-US, V41, P2409, DOI 10.1021/bi015815e; XU HX, 1992, MOL CELL BIOL, V12, P5249, DOI 10.1128/MCB.12.11.5249; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	50	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8732	8739		10.1074/jbc.M512170200	http://dx.doi.org/10.1074/jbc.M512170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16428807	hybrid			2022-12-25	WOS:000236247100051
J	Oh, CS; Martin, CE				Oh, CS; Martin, CE			Candida albicans Spt23p controls the expression of the Ole1p Delta 9 fatty acid desaturase and regulates unsaturated fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HETEROLOGOUS EXPRESSION; ENDOPLASMIC-RETICULUM; MORTIERELLA FUNGUS; MEMBRANE-PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; TRANSCRIPTION; YEAST; ACTIVATION	In Saccharomyces cerevisiae the endoplasmic reticulum membrane proteins scSpt23p and scMga2p control the formation of unsaturated fatty acids by a mechanism that involves their release from the membrane by ubiquitin-mediated proteolysis. The resulting soluble polypeptides act as transcription activators that specifically control the expression of scOLE1, a gene that encodes scOle1p, a Delta 9 fatty acid desaturase that forms cis-monounsaturated fatty acids (9Z-16: 1 and 9Z-18: 1) from saturated fatty acyl-CoA precursors. ScOle1p is the only long chain fatty acid desaturase in Saccharomyces and its membrane and storage lipids contain only saturated fatty acids and the monounsaturated products of that enzyme. Most other fungi, however, express multiple endoplasmic reticulum desaturases, including enzymes that form both mono- and polyunsaturated fatty acids. These typically include Delta 12 and Delta 15 enzymes that form the polyunsaturated species, 9Z, 12Z-18: 2, and 9Z, 12Z, 15Z-18: 3, which are the most abundant fatty acids in membrane and storage lipids. An analysis of genomic DNA sequences shows that Candida albicans has a single homologue of the Saccharomyces scSPT23 and scMGA2 genes that we designate here as caSPT23. This study describes the characterization of the caSPT23 gene product and shows that it can repair the unsaturated fatty acid auxotrophy when it is expressed in a Saccharomyces scspt23 Delta; sc-mga2 Delta strain. In addition we show caSPT23 is essential for the expression of one of the two Delta 9 desaturase homologues in Candida and potentially other functions associated with fatty acid metabolism.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Martin, CE (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.	martin@biology.rutgers.edu			NIGMS NIH HHS [GM 45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Backen AC, 2000, YEAST, V16, P1121, DOI 10.1002/1097-0061(20000915)16:12&lt;1121::AID-YEA614&gt;3.0.CO;2-U; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; Brown A J, 2000, Contrib Microbiol, V5, P112; Chellappa R, 2001, J BIOL CHEM, V276, P43548, DOI 10.1074/jbc.M107845200; Choi JY, 1996, J BIOL CHEM, V271, P3581; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEBER A, 1992, J BACTERIOL, V174, P6992, DOI 10.1128/JB.174.21.6992-6996.1992; Gola S, 2003, YEAST, V20, P1339, DOI 10.1002/yea.1044; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Kandasamy P, 2004, J BIOL CHEM, V279, P36586, DOI 10.1074/jbc.M401557200; Krishnamurthy S, 2004, MICROBIOL-SGM, V150, P1991, DOI 10.1099/mic.0.27029-0; LAEMMLI UK, 1970, J MOL BIOL, V49, P99, DOI 10.1016/0022-2836(70)90379-7; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Michaelson LV, 1998, J BIOL CHEM, V273, P19055, DOI 10.1074/jbc.273.30.19055; PUGH EL, 1977, J BIOL CHEM, V252, P68; PUGH EL, 1975, BIOCHIM BIOPHYS ACTA, V380, P442, DOI 10.1016/0005-2760(75)90112-5; Sakuradani E, 1999, GENE, V238, P445, DOI 10.1016/S0378-1119(99)00359-5; Sakuradani E, 1999, EUR J BIOCHEM, V261, P812, DOI 10.1046/j.1432-1327.1999.00333.x; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; Sudbery P, 2004, TRENDS MICROBIOL, V12, P317, DOI 10.1016/j.tim.2004.05.008; Tocher DR, 1998, PROG LIPID RES, V37, P73, DOI 10.1016/S0163-7827(98)00005-8; Toke DA, 1996, J BIOL CHEM, V271, P18413, DOI 10.1074/jbc.271.31.18413; Vemula M, 2003, J BIOL CHEM, V278, P45269, DOI 10.1074/jbc.M308812200; Wilson RB, 2000, YEAST, V16, P65, DOI 10.1002/(SICI)1097-0061(20000115)16:1&lt;65::AID-YEA508&gt;3.0.CO;2-M; Wilson RB, 1999, J BACTERIOL, V181, P1868, DOI 10.1128/JB.181.6.1868-1874.1999; Zhang SR, 1999, GENETICS, V151, P473	31	17	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7030	7039		10.1074/jbc.M510746200	http://dx.doi.org/10.1074/jbc.M510746200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415349	hybrid			2022-12-25	WOS:000236030900016
J	Zihni, C; Mitsopoulos, C; Tavares, IA; Ridley, AJ; Morris, JDH				Zihni, C; Mitsopoulos, C; Tavares, IA; Ridley, AJ; Morris, JDH			Prostate-derived sterile 20-like kinase 2 (PSK2) regulates apoptotic morphology via C-jun N-terminal kinase and Rho kinase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED ACTIVATION; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; ROCK-I; MEMBRANE; PATHWAY; CLEAVAGE; JNK; INDUCTION; SUBFAMILY	We have reported previously that human prostate-derived sterile 20-like kinase (PSK) 1 alters actin cytoskeletal organization and binds to microtubules, regulating their organization and stability. We have shown a structurally related protein kinase PSK2, which lacks amicrotubule-binding site, activated c-Jun N-terminal kinase (JNK), and induced apoptotic morphological changes that include cell contraction, membrane blebbing, and apoptotic body formation. Apoptotic stimuli increased the catalytic activity of endogenous PSK2 and JNK, and dominant negative JNK or a physiological inhibitor of JNK blocked these apoptotic morphological responses to PSK2, demonstrating a requirement for JNK. PSK2 also stimulated the cleavage of Rho kinase-1 (ROCK-I), and the activity of ROCK-I was required for PSK2 to induce cell contraction and membrane blebbing. The activation of caspases was also needed for the induction of membrane blebbing by PSK2, which was itself a substrate for caspase 3. PSK2 therefore regulates apoptotic morphology associated with the execution phase of apoptosis, which involves dynamic reorganization of the actin cytoskeleton, via downstream targets that include JNK and ROCK-I. Our findings suggest that PSKs form a subgroup of sterile 20 (STE20)-like kinases that regulate different cytoskeletal processes.	Kings Coll London, KCL Sch Med & Dent, Rayne Inst, London SE5 9NU, England; Ludwig Inst Canc Res, Univ Coll London Branch, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), Kings Coll London, KCL Sch Med & Dent, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Mitsopoulos, Costas/0000-0002-9116-5921; Ridley, Anne/0000-0001-8186-5708; Morris, Jonathan/0000-0002-3211-1798				Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; Mitsopoulos C, 2003, J BIOL CHEM, V278, P18085, DOI 10.1074/jbc.M213064200; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Schwab BL, 1998, EXP CELL RES, V238, P415, DOI 10.1006/excr.1997.3850; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yustein JT, 2003, ONCOGENE, V22, P6129, DOI 10.1038/sj.onc.1206605; Zhou TJ, 2004, STRUCTURE, V12, P1891, DOI 10.1016/j.str.2004.07.021	41	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7317	7323		10.1074/jbc.M513769200	http://dx.doi.org/10.1074/jbc.M513769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407310	hybrid			2022-12-25	WOS:000236030900050
J	Deregowski, V; Gazzerro, E; Priest, L; Rydziel, S; Canalis, E				Deregowski, V; Gazzerro, E; Priest, L; Rydziel, S; Canalis, E			Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-DIFFERENTIATION; PROTEOLYTIC RELEASE; TUMOR-SUPPRESSOR; PROGENITOR CELLS; WNT FAMILY; EXPRESSION; ACTIVATION; SCLEROSTIN; APOPTOSIS	Notch proteins are transmembrane receptors that control cell-fate decisions. Upon ligand binding, Notch receptors undergo proteolytic cleavage leading to the release of their intracellular domain ( NICD). Overexpression of NICD impairs osteoblastogenesis, but the mechanisms are not understood. We examined consequences of the constitutive activation of Notch 1 in ST-2 cells. Notch opposed the effects of bone morphogenetic protein (BMP)-2 and Wnt 3a on alkaline phosphatase activity (APA). BMP-2 induced the phosphorylation of Smad 1/5/8 and the transactivation of a BMP/Smad-responsive construct ( 12 x SBE-Oc-pGL3), but the effect was not modified by Notch. BMP-2 had minimal effects on the phosphorylation of the mitogen-activated protein kinases ERK, p38, and JNK, in the absence or presence of NICD. Notch overexpression decreased the transactivating effect of Wnt 3a, cytoplasmic beta-catenin levels, and Wnt-dependent gene expression. Transfection of a mutant beta-catenin expression construct, or the use of a glycogen synthase kinase 3 beta inhibitor to stabilize beta-catenin, partially blocked the inhibitory effect of NICD on Wnt signaling and on APA. HES-1 or Groucho1/TLE1 RNA interference enhanced basal and induced Wnt/beta-catenin signaling opposing NICD effects, but only HES-1 silencing enhanced Wnt 3a effects on APA. In conclusion, NICD overexpression prevents BMP-2 and Wnt biological effects by suppressing Wnt but not BMP signaling. HES-1 appears to mediate effects of Notch on osteoblastogenesis.	St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Farmington, CT 06030 USA	Saint Francis Hospital & Medical Center; University of Connecticut	Canalis, E (corresponding author), St Francis Hosp & Med Ctr, Dept Res, 114 Woodland St, Hartford, CT 06105 USA.	ecanalis@stfranciscare.org			NIAMS NIH HHS [AR21707] Funding Source: Medline; NIDDK NIH HHS [DK45227] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR021707, R37AR021707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045227] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Bianco P, 2000, J CLIN INVEST, V105, P1663, DOI 10.1172/JCI10413; Boden SD, 1997, ENDOCRINOLOGY, V138, P2820, DOI 10.1210/en.138.7.2820; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Dale TC, 1998, BIOCHEM J, V329, P209; DANIELS DL, 2005, NAT STRUCT MOL BIOL; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; Egan SE, 1998, CURR TOP MICROBIOL, V228, P273; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004-0766; Ghosh-Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345; Gumbiner BM, 1998, CURR OPIN GENET DEV, V8, P430, DOI 10.1016/S0959-437X(98)80114-7; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; HUGHES FJ, 1995, ENDOCRINOLOGY, V136, P2671, DOI 10.1210/en.136.6.2671; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200; Lindsell CE, 1996, MOL CELL NEUROSCI, V8, P14, DOI 10.1006/mcne.1996.0040; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; MILLER JR, 2001, GENOME BIOL; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, P2089, DOI 10.1093/nar/30.9.2089; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nobta M, 2005, J BIOL CHEM, V280, P15842, DOI 10.1074/jbc.M412891200; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Nohe A, 2003, J CELL SCI, V116, P3277, DOI 10.1242/jcs.00519; Noll E, 2000, DEV BIOL, V227, P450, DOI 10.1006/dbio.2000.9925; NYE JS, 1994, DEVELOPMENT, V120, P2421; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; OWEN M, 1988, CIBA F SYMP, V136, P42; Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756-3282(02)00687-7; Pereira RMR, 2002, J CELL BIOCHEM, V85, P252, DOI 10.1002/jcb.10125; Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756-3282(01)00422-7; Rawadi G, 2003, J BONE MINER RES, V18, P1842, DOI 10.1359/jbmr.2003.18.10.1842; Reddi H, 1995, Adv Dent Res, V9, P13; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; Ross DA, 2004, MOL CELL BIOL, V24, P3505, DOI 10.1128/MCB.24.8.3505-3513.2004; Schnabel M, 2002, INT J MOL MED, V9, P229; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003-0463; Semenov M, 2005, J BIOL CHEM, V280, P26770, DOI 10.1074/jbc.M504308200; Shindo K, 2003, EXP CELL RES, V290, P370, DOI 10.1016/S0014-4827(03)00349-5; Smith E, 2005, J BIOL CHEM, V280, P2388, DOI 10.1074/jbc.M406294200; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; Tamaki K, 1998, J CELL PHYSIOL, V177, P355, DOI 10.1002/(SICI)1097-4652(199811)177:2<355::AID-JCP17>3.0.CO;2-8; Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wang FS, 2005, ENDOCRINOLOGY, V146, P2415, DOI 10.1210/en.2004-1050; Wesley CS, 1999, MOL CELL BIOL, V19, P5743; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Winkler DG, 2005, J BIOL CHEM, V280, P2498, DOI 10.1074/jbc.M400524200; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	73	169	185	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6203	6210		10.1074/jbc.M508370200	http://dx.doi.org/10.1074/jbc.M508370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407293	hybrid			2022-12-25	WOS:000236030800012
J	Grau, S; Richards, PJ; Kerr, B; Hughes, C; Caterson, B; Williams, AS; Junker, U; Jones, SA; Clausen, T; Ehrmann, M				Grau, S; Richards, PJ; Kerr, B; Hughes, C; Caterson, B; Williams, AS; Junker, U; Jones, SA; Clausen, T; Ehrmann, M			The role of human HtrA1 in arthritic disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTICULAR-CARTILAGE; SERINE-PROTEASE; SYNOVIAL-FLUID; FIBRONECTIN FRAGMENTS; MATRIX METALLOPROTEINASES; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; EXPRESSION; IDENTIFICATION	Human HtrA1 belongs to a widely conserved family of serine proteases involved in various aspects of protein quality control and cell fate. Although HtrA1 has been implicated in the pathology of several diseases, its precise biological functions remain to be established. Through identification of potential HtrA1 targets, studies presented herein propose that within the context of arthritis pathology HtrA1 contributes to cartilage degradation. Elevated synovial HtrA1 levels were detected in fluids obtained from rheumatoid and osteoarthritis patients, with synovial fibroblasts identified as a major source of secreted HtrA1. Mass spectrometry analysis of potential HtrA1 substrates within synovial fluids identified fibronectin as a candidate target, and treatment of fibronectin with recombinant HtrA1 led to the generation of fibronectin-degradation products that may be involved in cartilage catabolism. Consistently, treatment of synovial fibroblasts with HtrA1 or HtrA1-generated fibronectin fragments resulted in the specific induction of matrix metalloprotease 1 and matrix metalloprotease 3 expression, suggesting that HtrA1 contributes to the destruction of extracellular matrix through both direct and indirect mechanisms.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Cardiff Univ, Rheumatol Res Lab, Cardiff CF14 4XN, S Glam, Wales; Novartis Pharmaceut, CH-4002 Basel, Switzerland; Inst Mol Pathol, A-1030 Vienna, Austria	Cardiff University; Cardiff University; Novartis; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Ehrmann, M (corresponding author), Cardiff Univ, Sch Biosci, Biosci-2, Cardiff CF10 3US, S Glam, Wales.	ehrmann@cf.ac.uk	Caterson, Bruce/A-8085-2010; Ehrmann, Michael/A-7307-2012; Hughes, Clare E/A-4526-2010; Jones, Simon Arnett/Q-7017-2018	Ehrmann, Michael/0000-0002-1927-260X; Hughes, Clare/0000-0003-4726-5877; Kerr, Briedgeen/0000-0002-8504-7953; Caterson, Bruce/0000-0001-6016-0661; Clausen, Tim/0000-0003-1582-6924; Jones, Simon Arnett/0000-0001-7297-9711				Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BurtonWurster N, 1997, MATRIX BIOL, V15, P441, DOI 10.1016/S0945-053X(97)90018-4; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; CLEMMENSEN I, 1982, HISTOCHEMISTRY, V76, P51, DOI 10.1007/BF00493284; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; GLANT TT, 1985, HISTOCHEMISTRY, V82, P149, DOI 10.1007/BF00708199; GRIFFITHS AM, 1989, CLIN CHIM ACTA, V184, P133, DOI 10.1016/0009-8981(89)90283-0; Harnasch M, 2004, MOL MEMBR BIOL, V21, P373, DOI 10.1080/09687860400008429; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; Homandberg GA, 2001, OSTEOARTHR CARTILAGE, V9, P673, DOI 10.1053/joca.2001.0419; Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kageyama Y, 2000, CLIN RHEUMATOL, V19, P14, DOI 10.1007/s100670050004; LOHMANDER LS, 1993, ARTHRITIS RHEUM-US, V36, P181, DOI 10.1002/art.1780360207; Mort JS, 2001, ARTHRITIS RES, V3, P337, DOI 10.1186/ar325; Muller-Ladner U, 2002, ANN RHEUM DIS, V61, P957, DOI 10.1136/ard.61.11.957; Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572; Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435; Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569; Richards PJ, 1999, RHEUMATOLOGY, V38, P984, DOI 10.1093/rheumatology/38.10.984; Roughley PJ, 2001, ARTHRITIS RES, V3, P342, DOI 10.1186/ar326; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Shridhar V, 2002, CANCER RES, V62, P262; SMITH RL, 1999, FRONT BIOSCI, V4, P704; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257; Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975; Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015; VANDELOOSDRECHT AA, 1991, J IMMUNOL METHODS, V141, P15, DOI 10.1016/0022-1759(91)90205-T; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; WACHTFOGEL YT, 1988, J CLIN INVEST, V81, P1310, DOI 10.1172/JCI113456; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; XIE DL, 1993, BLOOD, V81, P186; XIE DL, 1993, ARCH BIOCHEM BIOPHYS, V307, P110, DOI 10.1006/abbi.1993.1568; Yoshihara Y, 2000, ANN RHEUM DIS, V59, P455, DOI 10.1136/ard.59.6.455; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	42	217	231	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6124	6129		10.1074/jbc.M500361200	http://dx.doi.org/10.1074/jbc.M500361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377621	Green Accepted, hybrid			2022-12-25	WOS:000236030800003
J	Teer, JK; Machida, YJ; Labit, H; Novac, O; Hyrien, O; Marheineke, K; Zannis-Hadjopoulos, M; Dutta, A				Teer, JK; Machida, YJ; Labit, H; Novac, O; Hyrien, O; Marheineke, K; Zannis-Hadjopoulos, M; Dutta, A			Proliferating human cells hypomorphic for origin recognition complex 2 and pre-replicative complex formation have a defect in p53 activation and Cdk2 kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; EUKARYOTIC DNA-REPLICATION; CYCLIN-E; CHECKPOINT PATHWAY; SACCHAROMYCES-CEREVISIAE; ECTOPIC EXPRESSION; G(1)/S TRANSITION; DAMAGE CHECKPOINT; CDC6 PROTEIN; PHOSPHORYLATION	The Origin Recognition Complex (ORC) is a critical component of replication initiation. We have previously reported generation of an Orc2 hypomorph cell line (Delta/-) that expresses very low levels of Orc2 but is viable. We have shown here that Chk2 is phosphorylated, suggesting that DNA damage checkpoint pathways are activated. p53 was inactivated during the derivation of the Orc2 hypomorphic cell lines, accounting for their survival despite active Chk2. These cells also show a defect in the G(1) to S-phase transition. Cdk2 kinase activation in G(1) is decreased due to decreased Cyclin E levels, preventing progression into S-phase. Molecular combing of bromodeoxyuridine-labeled DNA revealed that once the Orc2 hypomorphic cells enter S-phase, fork density and fork progression are approximately comparable with wild type cells. Therefore, the low level of Orc2 hinders normal cell cycle progression by delaying the activation of G(1) cyclin-dependent kinases. The results suggest that hypomorphic mutations in initiation factor genes may be particularly deleterious in cancers with mutant p53 or increased activity of Cyclin E/Cdk2.	Univ Virginia, Dept Biochem, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA; Ecole Normale Super, F-75230 Paris, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	University of Virginia; Harvard University; Harvard Medical School; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); McGill University; McGill University	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016; Marheineke, Kathrin/C-1797-2008; Machida, Yuichi/AAO-3533-2021; Hyrien, Olivier/R-5108-2017	Machida, Yuichi/0000-0003-1414-0568; Hyrien, Olivier/0000-0001-8879-675X; Marheineke, Kathrin/0000-0002-1514-0167; Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA060499-13, R01 CA60499, R01 CA089406, R01 CA060499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089406, R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bunz F, 2002, CANCER RES, V62, P1129; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KATO J, 1993, GENE DEV, V7, P331; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Marheineke K, 2004, J BIOL CHEM, V279, P28071, DOI 10.1074/jbc.M401574200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	60	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6253	6260		10.1074/jbc.M507150200	http://dx.doi.org/10.1074/jbc.M507150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407251	hybrid			2022-12-25	WOS:000236030800018
J	Zhou, WX; Lepesheva, GI; Waterman, MR; Nes, WD				Zhou, WX; Lepesheva, GI; Waterman, MR; Nes, WD			Mechanistic analysis of a multiple product sterol methyltransferase implicated in ergosterol biosynthesis in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; METHYL TRANSFERASE; ACTIVE-SITE; ENZYME; (S)-ADENOSYL-L-METHIONINE; PURIFICATION; AZASTEROLS; INHIBITORS; ANALOGS; C-25	Sterol methyltransferase (SMT) plays a key role in sterol biosynthesis in different pathogenic organisms by setting the pattern of the side chain structure of the final product. This catalyst, absent in humans, provides critical pathway-specific enzymatic steps in the production of ergosterol in fungi or phytosterols in plants. The new SMT gene was isolated from Trypanosoma brucei genomic DNA and cloned into an Escherichia coli expression system. The recombinant SMT was purified to homogeneity to give a band at 40.0 kDa upon SDS-PAGE and showed a tetrameric subunit organization by gel chromatography. It has a pH optimum of 7.5, an apparent k(cat) value of 0.01 s(-1), and a K-m of 47 +/- 4 mu M for zymosterol. The products of the reaction were a mixture of C24-monoalkylated sterols, ergosta-8,24 ( 25)-dienol, ergosta-8,25 ( 27)-dienol, and ergosta-8,24 ( 28)-dienol ( fecosterol), and an unusual double C24-alkylated sterol, 24,24-dimethyl ergosta-8,25 ( 27)- dienol, typically found in plants. Inhibitory profile studies with 25-azalanosterol (K-i value of 39 nM) or 24( R, S), 25- epiminolanosterol (K-i value of 49 nM), ergosterol (K-i value of 27 mu M) and 26,27-dehydrozymosterol (K-i and k(inact) values of 29 mu M and 0.26 min(-1), respectively) and data showing zymosterol as the preferred acceptor strongly suggest that the protozoan SMT has an active site topography combining properties of the SMT1 from plants and yeast ( 37 - 47% identity). The enzymatic activation of this and other SMTs reveals that the catalytic requirements for the C-methyl reaction are remarkably versatile, whereas the inhibition studies provide a powerful approach to rational design of new anti-sleeping sickness chemotherapeutic drugs.	Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Texas Tech University System; Texas Tech University; Vanderbilt University	Nes, WD (corresponding author), Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.	wdavid.nes@ttu.edu	Zhou, Wenxu/T-6917-2019					AKIHISA T, 1990, J CHEM SOC PERK T 1, P2213, DOI 10.1039/p19900002213; Arigoni D., 1978, CIBA FDN S, P243; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON H, 1972, COMP BIOCHEM PHYSIOL, V41, P1, DOI 10.1016/0305-0491(72)90002-8; FONTENEAU P, 1977, PLANT SCI LETT, V10, P147, DOI 10.1016/0304-4211(77)90122-5; Fujimoto Y, 1997, CHEM COMMUN, P681, DOI 10.1039/a700492c; GOAD LJ, 1974, LIPIDS, V9, P582, DOI 10.1007/BF02532508; Guo DA, 1996, TETRAHEDRON LETT, V37, P6823, DOI 10.1016/0040-4039(96)01534-1; Hannaert V, 2003, P NATL ACAD SCI USA, V100, P1067, DOI 10.1073/pnas.0335769100; Joubert BM, 2001, ORG LETT, V3, P1957, DOI 10.1021/ol0160506; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KALINOWSKA M, 1990, PHYTOCHEMISTRY, V29, P3427, DOI 10.1016/0031-9422(90)85251-A; Kanagasabai R, 2004, LIPIDS, V39, P737, DOI 10.1007/s11745-004-1290-7; Lepesheva GI, 2004, BIOCHEMISTRY-US, V43, P10789, DOI 10.1021/bi048967t; Lorente SO, 2004, ANTIMICROB AGENTS CH, V48, P2937, DOI 10.1128/AAC.48.8.2937-2950.2004; LOW P, 1991, J BIOL CHEM, V266, P19250; Magaraci F, 2003, J MED CHEM, V46, P4714, DOI 10.1021/jm021114j; Mangla AT, 2000, BIOORGAN MED CHEM, V8, P925, DOI 10.1016/S0968-0896(00)00040-7; Nes WD, 2005, BIOCHEM SOC T, V33, P1189, DOI 10.1042/BST0331189; Nes WD, 2004, BIOCHEMISTRY-US, V43, P569, DOI 10.1021/bi035257z; Nes WD, 2003, PHYTOCHEMISTRY, V64, P75, DOI 10.1016/S0031-9422(03)00349-2; Nes WD, 2003, J BIOL CHEM, V278, P34505, DOI 10.1074/jbc.M303359200; Nes WD, 2002, J BIOL CHEM, V277, P42549, DOI 10.1074/jbc.M204223200; NES WD, 1990, P NATL ACAD SCI USA, V87, P7565, DOI 10.1073/pnas.87.19.7565; Nes WD, 2000, BBA-MOL CELL BIOL L, V1529, P63, DOI 10.1016/S1388-1981(00)00138-4; NES WD, 1991, J BIOL CHEM, V266, P15202; Nes WD, 1998, ARCH BIOCHEM BIOPHYS, V353, P297, DOI 10.1006/abbi.1998.0665; Nes WD, 1999, J ORG CHEM, V64, P1535, DOI 10.1021/jo9819943; NES WR, 1980, LIPIDS EVOLUTION, P157; Pourshafie M, 2004, ANTIMICROB AGENTS CH, V48, P2409, DOI 10.1128/AAC.48.7.2409-2414.2004; RAHIER A, 1984, J BIOL CHEM, V259, P5215; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Zhou WX, 2004, MOLECULES, V9, P185, DOI 10.3390/90400185; Zhou WX, 2003, ARCH BIOCHEM BIOPHYS, V420, P18, DOI 10.1016/j.abb.2003.08.029	35	44	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6290	6296		10.1074/jbc.M511749200	http://dx.doi.org/10.1074/jbc.M511749200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16414960	hybrid			2022-12-25	WOS:000236030800022
J	Meme, W; Calvo, CF; Froger, N; Ezan, P; Amigou, E; Koulakoff, A; Giaume, C				Meme, W; Calvo, CF; Froger, N; Ezan, P; Amigou, E; Koulakoff, A; Giaume, C			Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid	FASEB JOURNAL			English	Article						glial cells; inflammation; Cx43; brain macrophages	CALCIUM-WAVE-PROPAGATION; ALZHEIMERS-DISEASE; IMMUNE FUNCTION; NITRIC-OXIDE; TNF-ALPHA; COMMUNICATION; EXPRESSION; INTERLEUKIN-1-BETA; NEUROTOXICITY; AMPLIFICATION	Brain inflammation is characterized by a reactive gliosis involving the activation of astrocytes and microglia. This process, common to many brain injuries and diseases, underlies important phenotypic changes in these two glial cell types. One characteristic feature of astrocytes is their high level of intercellular communication mediated by gap junctions. Previously, we have reported that astrocyte gap junctional communication (AGJC) and the expression of connexin 43 (Cx43), the main constitutive protein of gap junctions, are inhibited in microglia (MG)-astrocyte cocultures. Here, we report that bacterial lipopolysaccharide activation of microglia increases their inhibitory effect on Cx43 expression and AGJC. This inhibition is mimicked by treating astrocyte cultures with conditioned medium harvested from activated microglia. Interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) were identified as being the main factors responsible for this conditioned medium-mediated activity. Interestingly, an inflammatory response characterized by MG activation and reactive astrocytes occurs in Alzheimer's disease, at sites of beta-amyloid (A beta) deposits. We found that this peptide potentiates the inhibitory effect of a conditioned medium diluted at a concentration that is not effective per se. This potentiation is prevented by treating astrocytes with specific blockers of IL-1 beta and TNF-alpha activities. Thus, the suppression of communication between astrocytes, induced by activated MG could contribute to the proposed role of reactive gliosis in this neurodegenerative disease.	Coll France, INSERM, U587, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Giaume, C (corresponding author), Coll France, INSERM, U587, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	christian.giaume@college-de-france.fr		KOULAKOFF, Annette/0000-0002-3143-2215				Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Blanc EM, 1998, J NEUROCHEM, V70, P958; Calvo CF, 2000, EUR J NEUROSCI, V12, P2676, DOI 10.1046/j.1460-9568.2000.00145.x; Chandross KJ, 1998, GLIA, V24, P21, DOI 10.1002/(SICI)1098-1136(199809)24:1<21::AID-GLIA3>3.0.CO;2-3; CHANSON M, 2005, BIOCHIM BIOPHYS ACTA, V1771, P197; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Cotrina ML, 1998, J NEUROSCI, V18, P2520; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Duffy HS, 2000, J NEUROSCI, V20; Faustmann PM, 2003, GLIA, V42, P101, DOI 10.1002/glia.10141; Gasic-Milenkovic J, 2003, EUR J NEUROSCI, V17, P813, DOI 10.1046/j.1460-9568.2003.02506.x; Giaume C, 2004, GLIAL NEURONAL SIGNALING, P323; Giaume C, 1996, TRENDS NEUROSCI, V19, P319, DOI 10.1016/0166-2236(96)10046-1; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haughey NJ, 2003, NEUROMOL MED, V3, P173, DOI 10.1385/NMM:3:3:173; Hinkerohe D, 2005, GLIA, V52, P85, DOI 10.1002/glia.20223; John GR, 2005, GLIA, V49, P161, DOI 10.1002/glia.20109; John GR, 1999, P NATL ACAD SCI USA, V96, P11613, DOI 10.1073/pnas.96.20.11613; Kielian T, 2004, NEUROCHEM INT, V45, P429, DOI 10.1016/j.neuint.2003.09.010; Kirchhoff F, 2001, EUR ARCH PSY CLIN N, V251, P159, DOI 10.1007/s004060170036; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; Medina JM, 1999, ADV EXP MED BIOL, V468, P361; Meme W, 2004, NEUROSCIENCE, V126, P95, DOI 10.1016/j.neuroscience.2004.03.031; Nagy JI, 1996, BRAIN RES, V717, P173, DOI 10.1016/0006-8993(95)01526-4; Nakase T, 2004, BBA-BIOMEMBRANES, V1662, P149, DOI 10.1016/j.bbamem.2004.01.009; Nakase T, 2003, STROKE, V34, P1987, DOI 10.1161/01.STR.0000079814.72027.34; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; Rapoport SI, 1999, EUR ARCH PSY CLIN N, V249, P46; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rouach N, 2002, BIOL CELL, V94, P457, DOI 10.1016/S0248-4900(02)00016-3; Rouach N, 2002, EUR J NEUROSCI, V15, P403, DOI 10.1046/j.0953-816x.2001.01868.x; Rouach N, 2000, J CELL BIOL, V149, P1513, DOI 10.1083/jcb.149.7.1513; Scemes E, 2000, MOL NEUROBIOL, V22, P167, DOI 10.1385/MN:22:1-3:167; Schubert P, 2001, MECH AGEING DEV, V123, P47, DOI 10.1016/S0047-6374(01)00343-8; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Vega C, 2002, GLIA, V39, P10, DOI 10.1002/glia.10080; Zhang W, 1999, CANCER RES, V59, P1994; Zvalova D, 2004, GLIA, V46, P323, DOI 10.1002/glia.10334	44	153	159	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					494	+		10.1096/fj.05-4297fje	http://dx.doi.org/10.1096/fj.05-4297fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423877				2022-12-25	WOS:000235996000010
J	Shank-Calvo, JA; Draheim, K; Bhasin, M; Kelliher, MA				Shank-Calvo, J. A.; Draheim, K.; Bhasin, M.; Kelliher, M. A.			P16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice	ONCOGENE			English	Article						T-cell leukemia; Tal1/scl; p16(Ink4a); p19(Arf)	ACUTE LYMPHOBLASTIC-LEUKEMIA; ONCOGENIC TRANSCRIPTION FACTORS; LOOP-HELIX PROTEINS; T-CELL; C-MYC; TUMOR SUPPRESSION; MTS1 P16(INK4A); TRANSGENIC MICE; INK4A LOCUS; EXPRESSION	Analysis of the INK4A/ARF locus in human T-ALL patients revealed frequent deletions in exon 2, the exon common to both p16(INK4A) and p14(ARF). Other studies have described selective deletion of exon 1 ss of p14ARF or methylation of the p16INK4A promoter. Therefore, it is unclear from these studies whether loss of p16INK4A and/or p14ARF contributes to the development of T-ALL. To elucidate the relative contribution of the ink4a/arf locus to T-cell leukemogenesis, we mated our tal1 transgenic mice to ink4a/arf-/-, p16(ink4a)-/-,and p19(arf)-/- mice and generated tal1/ink4a/arf+/-, tal1/p16(ink4a)+/-, and tal1/p19(arf) +/- mice. Each of these mice developed T-cell leukemia rapidly, indicating that loss of either p16(ink4a) or p19(arf) cooperates with Tal1 to induce leukemia in mice. Preleukemic studies reveal that Tal1 expression stimulates entry into the cell cycle and thymocyte apoptosis in vivo. Interestingly, mice expressing a DNA-binding mutant of Tal1 do not exhibit increases in S phase cells. The S phase induction is accompanied by an increase in thymocyte apoptosis in tal1 transgenic mice. Whereas apoptosis is reduced to wild-type levels in tal1/ink4a/arf-/- mice, S phase induction remains unaffected. Thus, Tal1 stimulates cell cycle entry independent of the ink4a/arf locus, but its ability to induce apoptosis is Ink4a/Arf-dependent.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01650 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA USA; Dana Faber Canc Inst, Immunobiol Lab, Boston, MA USA; Dana Faber Canc Inst, Dept Med Oncol, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01650 USA.	michelle.kelliher@umassmed.edu		Bhasin, Manoj/0000-0001-5172-420X	NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER; NCI NIH HHS [CA096899] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batova A, 1997, CANCER RES, V57, P832; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; CAYUELA JM, 1995, BLOOD, V85, P854, DOI 10.1182/blood.V85.3.854a.bloodjournal853854a; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Condorelli GL, 1996, CANCER RES, V56, P5113; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ferrando AA, 2004, BLOOD, V103, P1909, DOI 10.1182/blood-2003-07-2577; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Harrison CJ, 2001, BEST PRACT RES CL HA, V14, P593, DOI 10.1053/beha.2001.0156; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kees UR, 1997, BLOOD, V89, P4161, DOI 10.1182/blood.V89.11.4161; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; O'Neil J, 2005, BLOOD; Pagliuca A, 2000, CANCER RES, V60, P1376; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Valtieri M, 1998, CANCER RES, V58, P562; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Zhou MX, 1997, PEDIATR HEMAT ONCOL, V14, P141, DOI 10.3109/08880019709030900; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3023	3031		10.1038/sj.onc.1209326	http://dx.doi.org/10.1038/sj.onc.1209326			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407836				2022-12-25	WOS:000237950800006
J	Enk, CD; Jacob-Hirsch, J; Gal, H; Verbovetski, I; Amariglio, N; Mevorach, D; Ingber, A; Givol, D; Rechavi, G; Hochberg, M				Enk, CD; Jacob-Hirsch, J; Gal, H; Verbovetski, I; Amariglio, N; Mevorach, D; Ingber, A; Givol, D; Rechavi, G; Hochberg, M			The UVB-induced gene expression profile of human epidermis in vivo is different from that of cultured keratinocytes	ONCOGENE			English	Article						UVB; epidermis; p53; in vivo; in vitro; microarrays	CELL CARCINOMA ANTIGENS; MATRIX METALLOPROTEINASES; FUNCTIONAL GENOMICS; CYCLE CHECKPOINT; DNA MICROARRAYS; MESSENGER-RNA; P53 PROTEIN; ULTRAVIOLET; SKIN; APOPTOSIS	In order to obtain a comprehensive picture of the molecular events regulating cutaneous photodamage of intact human epidermis, suction blister roofs obtained after a single dose of in vivo ultraviolet ( UV) B exposure were used for microarray profiling. We found a changed expression of 619 genes. Half of the UVB-regulated genes had returned to pre-exposure baseline levels at 72 h, underscoring the transient character of the molecular cutaneous UVB response. Of special interest was our finding that several of the central p53 target genes remained unaffected following UVB exposure in spite of p53 protein accumulation. We next compared the in vivo expression profiles of epidermal sheets to that of cultured human epidermal keratinocytes exposed to UVB in vitro. We found 1931 genes that differed in their expression profiles between the two groups. The expression pro. le in intact epidemis was geared mainly towards DNA repair, whereas cultured keratinocytes responded predominantly by activating genes associated with cell-cycle arrest and apoptosis. These differences in expression profiles might reflect differences between mature differentiating keratinocytes in the suprabasal epidermal layers versus exponentially proliferating keratinocytes in cell culture. Our findings show that extreme care should be taken when extrapolating from findings based on keratinocyte cultures to changes in intact epidermis.	Hebrew Univ Jerusalem, Dept Dermatol, Hadassah Med Ctr, IL-91010 Jerusalem, Israel; Safra Childrens Hosp, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Lab Cellular Mol Immunol, Hadassah Med Ctr, Dept Med, IL-91010 Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center	Enk, CD (corresponding author), Hebrew Univ Jerusalem, Dept Dermatol, Hadassah Med Ctr, POB 12000, IL-91010 Jerusalem, Israel.	enk@md.huji.ac.il						Abts HF, 1999, J MOL BIOL, V293, P29, DOI 10.1006/jmbi.1999.3159; Alowami Salem, 2003, BMC Dermatol, V3, P1, DOI 10.1186/1471-5945-3-1; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BAADSGAARD O, 1991, ARCH DERMATOL, V127, P99, DOI 10.1001/archderm.127.1.99; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Becker B, 2001, J INVEST DERMATOL, V116, P983, DOI 10.1046/j.1523-1747.2001.01347.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Boni R, 1997, J CUTAN PATHOL, V24, P76, DOI 10.1111/j.1600-0560.1997.tb01100.x; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Broome AM, 2003, J HISTOCHEM CYTOCHEM, V51, P675, DOI 10.1177/002215540305100513; BROWN DW, 1993, BIOCHEMISTRY-US, V32, P10527, DOI 10.1021/bi00091a001; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; Chaturvedi V, 2004, J INVEST DERMATOL, V123, P1200, DOI 10.1111/j.0022-202X.2004.23514.x; Courtois SJ, 1997, EXP CELL RES, V233, P135, DOI 10.1006/excr.1997.3537; CROMBACH G, 1989, CANCER, V63, P1337, DOI 10.1002/1097-0142(19890401)63:7<1337::AID-CNCR2820630719>3.0.CO;2-J; Dazard JE, 2003, ONCOGENE, V22, P2993, DOI 10.1038/sj.onc.1206537; Decraene D, 2004, J INVEST DERMATOL, V122, pA140; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DUK JM, 1989, CANCER, V64, P1652, DOI 10.1002/1097-0142(19891015)64:8<1652::AID-CNCR2820640816>3.0.CO;2-M; EL DW, 1993, CELL, V75, P817; Enk CD, 2004, PHOTODERMATOL PHOTO, V20, P129, DOI 10.1111/j.1600-0781.2004.00097.x; ENK CD, 1994, ARCH DERMATOL RES, V287, P72, DOI 10.1007/BF00370722; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Gibbs S, 1998, CELL TISSUE RES, V292, P107, DOI 10.1007/s004410051040; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Grimbaldeston MA, 2003, J INVEST DERMATOL, V121, P1168, DOI 10.1046/j.1523-1747.2003.12561.x; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HALL PA, 1993, ONCOGENE, V8, P203; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Horiuchi Yasuhiro, 1994, Journal of Dermatology (Tokyo), V21, P67; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Joos L, 2003, SWISS MED WKLY, V133, P31; Kahari VM, 1997, EXP DERMATOL, V6, P199, DOI 10.1111/j.1600-0625.1997.tb00164.x; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato H, 1996, ANTICANCER RES, V16, P2149; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Lahmann C, 2001, PHOTOCHEM PHOTOBIOL, V73, P657, DOI 10.1562/0031-8655(2001)073<0657:IOMFMM>2.0.CO;2; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee JH, 2002, PHOTODERMATOL PHOTO, V18, P253, DOI 10.1034/j.1600-0781.2002.02755.x; Lee KM, 2005, BRIT J DERMATOL, V152, P52, DOI 10.1111/J.1365-2133.2005.06412.X; Li DL, 2001, FASEB J, V15, P2533, DOI 10.1096/fj.01-0172fje; Li G, 1998, BRIT J DERMATOL, V139, P3; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Liu XQ, 2000, BIOCHEMISTRY-US, V39, P557, DOI 10.1021/bi991771m; Maelandsmo GM, 1997, INT J CANCER, V74, P464, DOI 10.1002/(SICI)1097-0215(19970822)74:4<464::AID-IJC19>3.0.CO;2-9; Marionnet C, 2003, J INVEST DERMATOL, V121, P1447, DOI 10.1111/j.1523-1747.2003.12629.x; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Murakami T, 2001, J DERMATOL SCI, V27, P121, DOI 10.1016/S0923-1811(01)00124-4; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977; Pfundt R, 2000, ARCH DERMATOL RES, V292, P180, DOI 10.1007/s004030050475; Pisarchik A, 2004, GENE, V341, P199, DOI 10.1016/j.gene.2004.06.046; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; SCHARFFETTER K, 1991, ARCH DERMATOL RES, V283, P506, DOI 10.1007/BF00371923; Sellheyer K, 2004, J AM ACAD DERMATOL, V51, P681, DOI 10.1016/j.jaad.2004.03.038; Sesto A, 2002, P NATL ACAD SCI USA, V99, P2965, DOI 10.1073/pnas.052678999; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sudel KM, 2003, PHOTOCHEM PHOTOBIOL, V78, P355, DOI 10.1562/0031-8655(2003)078<0355:TCOMMA>2.0.CO;2; Suminami Y, 2000, BRIT J CANCER, V82, P981, DOI 10.1054/bjoc.1999.1028; Takao J, 2002, PHOTODERMATOL PHOTO, V18, P5, DOI 10.1034/j.1600-0781.2002.180102.x; Takeda A, 2002, J INVEST DERMATOL, V118, P147, DOI 10.1046/j.0022-202x.2001.01610.x; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanaka N, 2000, BRIT J DERMATOL, V143, P728, DOI 10.1046/j.1365-2133.2000.03766.x; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Tran SEF, 2004, TRENDS BIOCHEM SCI, V29, P601, DOI 10.1016/j.tibs.2004.09.009; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Welss T, 2003, BIOCHEMISTRY-US, V42, P7381, DOI 10.1021/bi027307q; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; Zhang T, 2002, J INVEST DERMATOL, V119, P1196, DOI 10.1046/j.1523-1747.2002.19520.x; Zhao RB, 2000, GENE DEV, V14, P981	81	72	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2601	2614		10.1038/sj.onc.1209292	http://dx.doi.org/10.1038/sj.onc.1209292			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16434974				2022-12-25	WOS:000237099400004
J	Michos, A; Gryllos, I; Hakansson, A; Srivastava, A; Kokkotou, E; Wessels, MR				Michos, A; Gryllos, I; Hakansson, A; Srivastava, A; Kokkotou, E; Wessels, MR			Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the group A streptococcal toxin, NAD-glycohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOLYSIN-MEDIATED TRANSLOCATION; HYALURONIC-ACID CAPSULE; CYCLIC ADP-RIBOSE; HEMOLYTIC STREPTOCOCCI; III SECRETION; IDENTIFICATION; PYOGENES; KERATINOCYTES; PURIFICATION; PATHOGENESIS	Streptolysin O (SLO) is a cholesterol-dependent cytolysin produced by the important human pathogen, group A Streptococcus ( Streptococcus pyogenes or GAS). In addition to its cytolytic activity, SLO mediates the translocation of GAS NAD-glycohydrolase ( NADase) into human epithelial cells in vitro. Production of both NADase and SLO is associated with augmented host cell injury beyond that produced by SLO alone, but the mechanism of enhanced cytotoxicity is not known. We have now shown that expression of NADase together with SLO dramatically enhanced the lytic activity of GAS culture supernatants for erythrocytes but had no effect on SLO-mediated poration of synthetic cholesterol-rich liposomes. This result revealed a previously unknown contribution of NADase to the cytolytic activity associated with GAS production of SLO. Purified recombinant SLO bound NADase in vitro, supporting a specific, physical interaction of the two proteins. Exposure of human keratinocytes to wild-type GAS, but not to a NADase-deficient mutant strain, resulted in profound depletion of cellular NAD(+) and ATP. Furthermore, expression of recombinant GASNADase in yeast, in the absence of SLO, induced growth arrest, depletion of NAD(+) and ATP, and cell death. These findings have provided evidence that the augmentation of SLO-mediated cytotoxicity by NADase is a consequence of depletion of host cell energy stores through the enzymatic action of NADase. Together, the results have provided mechanistic insight into the cytotoxic effects of a unique bipartite bacterial toxin.	Childrens Hosp, Div Infect Dis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Wessels, MR (corresponding author), Childrens Hosp, Div Infect Dis, 300 Longwood Ave, Boston, MA 02215 USA.	michael.wessels@childrens.harvard.edu	Hakansson, Anders/H-8190-2014; Hakansson, Anders P/AAX-1225-2020; Michos, Athanasios/H-2389-2012	Hakansson, Anders/0000-0002-2834-6009; Hakansson, Anders P/0000-0002-2834-6009; Michos, Athanasios/0000-0003-1745-1118	NIAID NIH HHS [AI30040, AI29952] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029952] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALOUF JE, 1973, BIOCHIMIE, V55, P1187, DOI 10.1016/S0300-9084(74)80322-6; ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; Alouf JE, 2000, METH MOL B, V145, P1; AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Bricker AL, 2005, INFECT IMMUN, V73, P6562, DOI 10.1128/IAI.73.10.6562-6566.2005; Bricker AL, 2002, MOL MICROBIOL, V44, P257, DOI 10.1046/j.1365-2958.2002.02876.x; Chaussee MS, 2001, INFECT IMMUN, V69, P822, DOI 10.1128/IAI.69.2.822-831.2001; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Everse K E, 1980, Methods Enzymol, V66, P137; Fischetti VA, 2000, GRAM-POSITIVE PATHOGENS, P11; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Gryllos I, 2003, P NATL ACAD SCI USA, V100, P4227, DOI 10.1073/pnas.0636231100; Guse AH, 2004, CURR MOL MED, V4, P239, DOI 10.2174/1566524043360771; Hakansson A, 2005, P NATL ACAD SCI USA, V102, P5192, DOI 10.1073/pnas.0408721102; HALPERN BN, 1968, BRIT J PHARMACOL, V32, P441, DOI 10.1111/j.1476-5381.1968.tb00445.x; KARASAWA T, 1995, FEMS MICROBIOL LETT, V130, P201; KARASAWA T, 1995, FEMS MICROBIOL LETT, V128, P289, DOI 10.1016/0378-1097(95)00120-T; KIM UH, 1993, ARCH BIOCHEM BIOPHYS, V305, P147, DOI 10.1006/abbi.1993.1404; Kimoto H, 2005, BBA-GENE STRUCT EXPR, V1681, P134, DOI 10.1016/j.bbaexp.2004.10.011; Kristian T, 2004, BRAIN RES PROTOC, V13, P176, DOI 10.1016/j.brainresprot.2004.05.001; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lee VT, 1999, IMMUNOL REV, V168, P241, DOI 10.1111/j.1600-065X.1999.tb01296.x; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Levin JC, 1998, MOL MICROBIOL, V30, P209, DOI 10.1046/j.1365-2958.1998.01057.x; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; Meehl MA, 2004, MOL MICROBIOL, V52, P1665, DOI 10.1111/j.1365-2958.2004.04082.x; Meehl MA, 2005, PLOS PATHOG, V1, P362, DOI 10.1371/journal.ppat.0010035; Millard PJ, 1997, APPL ENVIRON MICROB, V63, P2897, DOI 10.1128/AEM.63.7.2897-2905.1997; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Palmer M, 2001, TOXICON, V39, P1681, DOI 10.1016/S0041-0101(01)00155-6; Ruiz N, 1998, MOL MICROBIOL, V27, P337, DOI 10.1046/j.1365-2958.1998.00681.x; Sambrook J, 2001, MOL CLONING LAB MANU; Savic DJ, 2002, INFECT IMMUN, V70, P2730, DOI 10.1128/IAI.70.5.2730-2733.2002; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; Stevens DL, 2000, J INFECT DIS, V182, P1117, DOI 10.1086/315850; Sumby P, 2005, J INFECT DIS, V192, P771, DOI 10.1086/432514; Ziegler M, 1997, Rev Physiol Biochem Pharmacol, V131, P89; Zitzer A, 2001, J BIOL CHEM, V276, P14628, DOI 10.1074/jbc.M100241200	40	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8216	8223		10.1074/jbc.M511674200	http://dx.doi.org/10.1074/jbc.M511674200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431917	hybrid			2022-12-25	WOS:000236031000061
J	Wu, PL; Lee, SC; Chuang, CC; Mori, S; Akakura, N; Wu, WG; Takada, Y				Wu, PL; Lee, SC; Chuang, CC; Mori, S; Akakura, N; Wu, WG; Takada, Y			Non-cytotoxic cobra cardiotoxin A5 binds to alpha v beta 3 integrin and inhibits bone resorption - Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSIDE-OUT ACTIVATION; PHOSPHOLIPASE A(2); STRUCTURAL REQUIREMENTS; DOMAIN; VENOM; MECHANISM; LIGAND; CELLS; ALPHA(V)BETA(3); ECHISTATIN	Severe tissue necrosis with a retarded wound healing process is a major symptom of a cobra snakebite. Cardiotoxins (CTXs) are major components of cobra venoms that belong to the Ly-6 protein family and are implicated in tissue damage. The interaction of the major CTX from Taiwan cobra, i.e. CTX A3, with sulfatides in the cell membrane has recently been shown to induce pore formation and cell internalization and to be responsible for cytotoxicity in cardiomyocytes (Wang, C.-H., Liu, J.-H., Lee, S.-C., Hsiao, C.-D., and Wu, W.-g. (2006) J. Biol. Chem. 281, 656-667). We show here that one of the non-cytotoxic CTXs, i.e. CTX A5 or cardiotoxin-like basic polypeptide, from Taiwan cobra specifically bound to alpha v beta 3 integrin and inhibited bone resorption activity. We found that both membrane-bound and recombinant soluble alpha v beta 3 integrins bound specifically to CTX A5 in a dose-dependent manner. Surface plasmon resonance analysis showed that human soluble alpha v beta 3 bound to CTX A5 with an apparent affinity of similar to 0.3 mu M. Calf pulmonary artery endothelial cells, which constitutively express alpha v beta 3, showed a CTX A5 binding profile similar to that of membrane-bound and soluble alpha v beta 3 integrins, suggesting that endothelial cells are a potential target for CTX action. We tested whether CTXA5 inhibits osteoclast differentiation and bone resorption, a process known to be involved in alpha v beta 3 binding and inhibited by RGD-containing peptides. We demonstrate that CTXA5 inhibited both activities at a micromolar range by binding to murine alpha v beta 3 integrin in osteoclasts and that CTX A5 co-localized with beta 3 integrin. Finally, after comparing the integrin binding affinity among CTX homologs, we propose that the amino acid residues near the two loops of CTXA5 are involved in integrin binding. These results identify CTXA5 as a non-RGD integrin-binding protein with therapeutic potential as an integrin antagonist.	Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 30043, Taiwan; Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA	National Tsing Hua University; University of California System; University of California Davis	Wu, WG (corresponding author), Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 30043, Taiwan.	wgwu@life.nthu.edu.tw; ytakada@ucdavis.edu		takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adermann K, 1999, PROTEIN SCI, V8, P810, DOI 10.1110/ps.8.4.810; Ariyoshi W, 2005, J BIOL CHEM, V280, P18967, DOI 10.1074/jbc.M412740200; Bazan-Socha S, 2004, BIOCHEMISTRY-US, V43, P1639, DOI 10.1021/bi035853t; Boilard E, 2003, BLOOD, V102, P2901, DOI 10.1182/blood-2002-12-3702; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Calvete JJ, 2000, BIOCHEM J, V345, P573, DOI 10.1042/0264-6021:3450573; Chattopadhyay Anindya, 2004, Indian Journal of Pediatrics, V71, P397, DOI 10.1007/BF02725623; Chen TS, 2005, BIOCHEMISTRY-US, V44, P7414, DOI 10.1021/bi050172e; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Eble JA, 2003, J BIOL CHEM, V278, P26488, DOI 10.1074/jbc.M301860200; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; EVANS RA, 1979, MINER ELECTROL METAB, V2, P179; Forouhar F, 2003, J BIOL CHEM, V278, P21980, DOI 10.1074/jbc.M208650200; Gentzsch C, 2003, CALCIFIED TISSUE INT, V72, P698, DOI 10.1007/s00223-002-2020-7; GRZESIAK JJ, 1995, J CLIN INVEST, V95, P227, DOI 10.1172/JCI117644; Guan JL, 2004, SCIENCE, V303, P773, DOI 10.1126/science.1094376; Hirata A, 2003, AM J PATHOL, V163, P203, DOI 10.1016/S0002-9440(10)63644-9; Horton MA, 2001, P NUTR SOC, V60, P275; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; Hung DZ, 2003, TOXICON, V41, P409, DOI 10.1016/S0041-0101(02)00336-7; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lee SC, 2005, J BIOL CHEM, V280, P9567, DOI 10.1074/jbc.M412398200; Liau MY, 1997, J TOXICOL-TOXIN REV, V16, P163; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; Medved L, 1997, BIOCHEMISTRY-US, V36, P4685, DOI 10.1021/bi962795l; Miller WH, 2000, DRUG DISCOV TODAY, V5, P397, DOI 10.1016/S1359-6446(00)01545-2; Murakami M, 2004, BIOL PHARM BULL, V27, P1158, DOI 10.1248/bpb.27.1158; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SMITH JW, 1994, J BIOL CHEM, V269, P960; Sue SC, 2001, BIOCHEMISTRY-US, V40, P10436, DOI 10.1021/bi010847n; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tarui T, 2003, J BIOL CHEM, V278, P29863, DOI 10.1074/jbc.M304694200; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Vaananen K, 2005, ADV DRUG DELIVER REV, V57, P959, DOI 10.1016/j.addr.2004.12.018; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Vyas KA, 1998, BIOCHEMISTRY-US, V37, P4527, DOI 10.1021/bi972637+; Wang CH, 2006, J BIOL CHEM, V281, P656, DOI 10.1074/jbc.M507880200; Wang CH, 2005, TOXICON, V46, P430, DOI 10.1016/j.toxicon.2005.06.012; Wang CH, 2005, FEBS LETT, V579, P3169, DOI 10.1016/j.febslet.2005.05.006; Wierzbicka-Patynowski I, 1999, J BIOL CHEM, V274, P37809, DOI 10.1074/jbc.274.53.37809; Wu WG, 1998, TRENDS CARDIOVAS MED, V8, P270, DOI 10.1016/S1050-1738(98)00019-X; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yamamoto M, 1998, ENDOCRINOLOGY, V139, P1411, DOI 10.1210/en.139.3.1411; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	55	49	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7937	7945		10.1074/jbc.M513035200	http://dx.doi.org/10.1074/jbc.M513035200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407244	hybrid			2022-12-25	WOS:000236031000029
J	Zufferey, R; Ben Mamoun, C				Zufferey, R; Ben Mamoun, C			Leishmania major expresses a single dihydroxyacetone phosphate acyltransferase localized in the glycosome, important for rapid growth and survival at high cell density and essential for virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LIVER; YEAST SACCHAROMYCES-CEREVISIAE; PROTOZOAN PARASITE LEISHMANIA; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; INITIAL STEP; GLYCEROLIPID BIOSYNTHESIS; DONOVANI PROMASTIGOTES; VISCERAL LEISHMANIASIS; TERMINAL EXTENSION; TRYPANOSOMA-BRUCEI	Despite major advances in the understanding of pathogenesis of the human protozoan parasite Leishmania major, little is known about the enzymes and the primary precursors involved in the initial steps of synthesis of its major glycerolipids including those involved in virulence. We have previously demonstrated that the initial step of acylation of the precursor glycerol 3-phosphate is not essential for the synthesis of ester and ether phospholipids in this parasite. Here we show that Leishmania expresses a single acyltransferase with high specificity for the precursor dihydroxyacetone phosphate and shows the best activity in the presence of palmitoyl-CoA. We have identified and characterized the LmDAT gene encoding this activity. LmDAT complements the lethality resulting from the loss of both dihydroxyacetone phosphate and glycerol-3-phosphate acyltransferase activities in yeast. Recombinant LmDAT exhibits biochemical properties similar to those of the native enzyme of the promastigote stage parasites. We show that LmDAT is a glycosomal enzyme and its loss in a Delta lmdat/Delta lmdat null mutant results in complete abrogation of the parasite dihydroxyacetone phosphate acyltransferase activity. Furthermore, lack of LmDAT causes a major alteration in parasite division during the logarithmic phase of growth, an accelerated cell death during stationary phase, and loss of virulence. Together, our results demonstrate that LmDAT is the only dihydroxyacetone phosphate acyltransferase of the L. major localized in the peroxisome, important for growth and survival and essential for virulence.	Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	Choukri@up.uchc.edu						Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; Barth PG, 1996, AM J MED GENET, V62, P164, DOI 10.1002/(SICI)1096-8628(19960315)62:2<164::AID-AJMG9>3.0.CO;2-W; BATES EJ, 1979, BIOCHEM J, V182, P751, DOI 10.1042/bj1820751; BEACH DH, 1979, J PARASITOL, V65, P203, DOI 10.2307/3280147; Biermann J, 1999, EUR J BIOCHEM, V261, P492, DOI 10.1046/j.1432-1327.1999.00295.x; CHAUDHURI G, 1987, INDIAN J MED RES, V85, P140; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Croft SL, 2003, MOL BIOCHEM PARASIT, V126, P165, DOI 10.1016/S0166-6851(02)00283-9; Dasgupta A, 2002, MED SCI MONITOR, V8, pCR341; de Vet ECJM, 2000, J BIOL CHEM, V275, P6276, DOI 10.1074/jbc.275.9.6276; DECLERCQ PE, 1984, J BIOL CHEM, V259, P9064; Descoteaux A, 2002, MICROBES INFECT, V4, P975, DOI 10.1016/S1286-4579(02)01624-6; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; HAJRA AK, 1968, J BIOL CHEM, V243, P3458; Hajra AK, 1995, PROG LIPID RES, V34, P343, DOI 10.1016/0163-7827(95)00013-5; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; Helfert S, 2001, BIOCHEM J, V357, P117, DOI 10.1042/0264-6021:3570117; Ilg T, 2001, MED MICROBIOL IMMUN, V190, P13, DOI 10.1007/s004300100071; Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403; JONES CL, 1983, ARCH BIOCHEM BIOPHYS, V226, P155, DOI 10.1016/0003-9861(83)90280-1; LABELLE EF, 1972, J BIOL CHEM, V247, P5825; Lewin TM, 2004, J BIOL CHEM, V279, P13488, DOI 10.1074/jbc.M314032200; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; Liu DL, 2005, J LIPID RES, V46, P727, DOI 10.1194/jlr.M400364-JLR200; Matlashewski G, 2001, MED MICROBIOL IMMUN, V190, P37, DOI 10.1007/s004300100076; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; MOSER HW, 1993, ADV HUM GENET, V21, P1; Murata N, 1997, BBA-LIPID LIPID MET, V1348, P10, DOI 10.1016/S0005-2760(97)00115-X; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Ofman R, 1998, HUM MOL GENET, V7, P847, DOI 10.1093/hmg/7.5.847; OFMAN R, 1994, BBA-PROTEIN STRUCT M, V1206, P27, DOI 10.1016/0167-4838(94)90068-X; OPPERDOES FR, 1977, FEBS LETT, V80, P360, DOI 10.1016/0014-5793(77)80476-6; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; Santiago TC, 2004, J BIOL CHEM, V279, P9222, DOI 10.1074/jbc.M310502200; Schimanski B, 2003, MOL BIOCHEM PARASIT, V126, P193, DOI 10.1016/S0166-6851(02)00273-6; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0; Thai TP, 1997, FEBS LETT, V420, P205, DOI 10.1016/S0014-5793(97)01495-6; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; WEBBER KO, 1993, ARCH BIOCHEM BIOPHYS, V300, P88, DOI 10.1006/abbi.1993.1013; Williams RAM, 2003, J BIOL CHEM, V278, P1480, DOI 10.1074/jbc.M209395200; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zhang K, 2003, EMBO J, V22, P6016, DOI 10.1093/emboj/cdg584; Zheng ZF, 2003, PLANT CELL, V15, P1872, DOI 10.1105/tpc.012427; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200; Zufferey R, 2005, MOL MICROBIOL, V56, P800, DOI 10.1111/j.1365-2958.2005.04579.x; Zufferey R, 2003, J BIOL CHEM, V278, P44708, DOI 10.1074/jbc.M308063200	55	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7952	7959		10.1074/jbc.M512911200	http://dx.doi.org/10.1074/jbc.M512911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16423830	hybrid			2022-12-25	WOS:000236031000031
J	Makareeva, E; Cabral, WA; Marini, JC; Leikin, S				Makareeva, E; Cabral, WA; Marini, JC; Leikin, S			Molecular mechanism of alpha 1(I)-osteogenesis Imperfecta/Ehlers-Danlos syndrome - Unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-VII; OSTEOGENESIS-IMPERFECTA; THERMAL-STABILITY; PROCOLLAGEN; PROTEINASE; MUTATIONS; DEFECT; CHAIN; TEMPERATURE; PROPEPTIDE	We demonstrate that 85 N-terminal amino acids of the alpha 1(I) chain participate in a highly stable folding domain, acting as the stabilizing anchor for the amino end of the type I collagen triple helix. This anchor region is bordered by amicrounfolding region, 15 amino acids in each chain, which include no proline or hydroxyproline residues and contain a chymotrypsin cleavage site. Glycine substitutions and amino acid deletions within the N-anchor domain induce its reversible unfolding above 34 degrees C. The overall triple helix denaturation temperature is reduced by 5 - 6 degrees C, similar to complete N-anchor removal. N-propeptide partially restores the stability of mutant procollagen but not sufficiently to prevent N-anchor unfolding and a conformational change at the N-propeptide cleavage site. The ensuing failure of N-proteinase to cleave at the misfolded site leads to incorporation of pN-collagen into fibrils. Similar, but weaker, effects are caused by G88E substitution in the adjacent triplet, which appears to alter N-anchor structure as well. As in Ehlers-Danlos syndrome (EDS) VIIA/B, fibrils containing pN-collagen are thinner and weaker causing EDS-like laxity of large and small joints and paraspinal ligaments. However, distinct structural consequences of N-anchor destabilization result in a distinct alpha 1( I)osteogenesis imperfecta (OI)/EDS phenotype.	NICHD, Sect Phys Biochem, NIH, Bethesda, MD 20892 USA; NICHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Leikin, S (corresponding author), NICHD, Sect Phys Biochem, NIH, Bldg 9,Rm 1E-127, Bethesda, MD 20892 USA.	leikins@mail.nih.gov	Leikin, Sergey/A-5518-2008; Makareeva, Elena/F-5183-2011	Leikin, Sergey/0000-0001-7095-0739; Makareeva, Elena/0000-0002-5815-0760	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000256, ZIAHD000408] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000408, Z01HD000256] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arnold WV, 1998, J BIOL CHEM, V273, P31822, DOI 10.1074/jbc.273.48.31822; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; Beighton P, 1998, AM J MED GENET, V77, P31, DOI 10.1002/(SICI)1096-8628(19980428)77:1<31::AID-AJMG8>3.3.CO;2-P; Byers P, 2002, CONNECTIVE TISSUE IT, P385, DOI DOI 10.1002/0471221929.CH8; Cabral WA, 2005, J BIOL CHEM, V280, P19259, DOI 10.1074/jbc.M414698200; Cabral WA, 2003, J BIOL CHEM, V278, P10006, DOI 10.1074/jbc.M212523200; DAVIS JM, 1993, J BIOL CHEM, V268, P25965; Di Lullo GA, 2002, J BIOL CHEM, V277, P4223, DOI 10.1074/jbc.M110709200; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; EYRE DR, 1985, J BIOL CHEM, V260, P1322; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; Kuznetsova NV, 2003, J MOL BIOL, V331, P191, DOI 10.1016/S0022-2836(03)00715-0; Leikina E, 2002, P NATL ACAD SCI USA, V99, P1314, DOI 10.1073/pnas.032307099; Marini JC, 2004, NELSON TXB PEDIAT, P2336; NESTLER FHM, 1983, BIOPOLYMERS, V22, P1747, DOI 10.1002/bip.360220710; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2005, BIOCHEMISTRY-US, V44, P1414, DOI 10.1021/bi048216r; PRIVALOV PL, 1979, J MOL BIOL, V127, P203, DOI 10.1016/0022-2836(79)90240-7; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raff ML, 2000, HUM GENET, V106, P19, DOI 10.1007/s004390051004; SIPPOLA M, 1984, J BIOL CHEM, V259, P4094; Steinmann B., 2002, CONNECTIVE TISSUE IT, P431, DOI DOI 10.1002/0471221929.CH9; VEIS A, 1982, CONNECT TISSUE RES, V10, P11, DOI 10.3109/03008208209034402	26	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6463	6470		10.1074/jbc.M511830200	http://dx.doi.org/10.1074/jbc.M511830200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407265	hybrid			2022-12-25	WOS:000236030800041
J	Pei, ZT; Jia, ZZ; Watkins, PA				Pei, ZT; Jia, ZZ; Watkins, PA			The second member of the human and murine "bubblegum" family is a testis- and brainstem-specific acyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSPORT; X-LINKED ADRENOLEUKODYSTROPHY; COENZYME-A SYNTHETASE; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; BETA-OXIDATION; RAT-LIVER; EXPRESSION; CLONING; IDENTIFICATION	Acyl-CoA synthetases that activate fatty acids to their CoA derivatives play a central role in fatty acid metabolism. ACSBG1, an acyl-CoA synthetase originally identified in the fruit fly mutant bubblegum, was hypothesized to contribute to the biochemical pathology of X-linked adrenoleukodystrophy. We looked for homologous proteins and identified ACSBG2 in humans, mice, and rats. Human ACSBG1 and ACSBG2 amino acid sequences are 50% identical. ACSBG2 expression was confined to the testis and brainstem. Immunohistochemistry and in situ hybridization studies further localized ACSBG2 expression to testicular Sertoli cells and large motoneurons in the medulla oblongata and cervical spinal cord. Full-length cDNA encoding human and mouse ACSBG2 was cloned. In transfected COS-1 cells, both human and murine ACSBG2 were detected as 75- to 80-kDa proteins by Western blot. Cells overexpressing ACSBG2 had increased ability to activate oleic acid (C18: 1 omega 9) and linoleic acid (C18:2 omega 6) but not other fatty acid substrates tested. Within a highly conserved motif known to be important for catalysis, human ACSBG2 contains a histidine residue where all other known acyl-CoA synthetases, including mouse and rat ACSBG2, contain an arginine. This substitution resulted in a shift of the human ACSBG2 pH optimum to a more acidic pH. Mutation of this histidine to arginine improved catalytic function at neutral pH by shifting the pH profile without affecting substrate specificity. Although the role of ACSBG2 in testicular and neuronal lipid metabolism remains unclear, the limited tissue expression pattern and limited substrate specificity rule out a likely role for this enzyme in X-linked adrenoleukodystrophy pathology.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	watkins@kennedykrieger.org		Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD10981, HD24061] Funding Source: Medline; NINDS NIH HHS [NS37355] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; Fraisl P, 2004, BIOCHEM J, V377, P85, DOI 10.1042/BJ20031062; Gabelli SB, 2004, STRUCTURE, V12, P927, DOI 10.1016/j.str.2004.03.028; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; Gulick AM, 2003, BIOCHEMISTRY-US, V42, P2866, DOI 10.1021/bi0271603; Hall AM, 2005, J BIOL CHEM, V280, P11948, DOI 10.1074/jbc.M412629200; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Hisanaga Y, 2004, J BIOL CHEM, V279, P31717, DOI 10.1074/jbc.M400100200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jia ZZ, 2004, MOL GENET METAB, V83, P117, DOI 10.1016/j.ymgme.2004.06.015; Jogl G, 2004, BIOCHEMISTRY-US, V43, P1425, DOI 10.1021/bi035911a; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E400002-JLR200; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moriya-Sato A, 2000, BIOCHEM BIOPH RES CO, V279, P62, DOI 10.1006/bbrc.2000.3897; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; OMURA S, 1986, J ANTIBIOT, V39, P1211, DOI 10.7164/antibiotics.39.1211; Pei ZT, 2003, J BIOL CHEM, V278, P47070, DOI 10.1074/jbc.M310075200; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Tang PZ, 2001, P NATL ACAD SCI USA, V98, P6581, DOI 10.1073/pnas.121046998; Van Horn CG, 2005, BIOCHEMISTRY-US, V44, P1635, DOI 10.1021/bi047721l; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; WATKINS PA, 1995, AM J HUM GENET, V57, P292; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Zheng Y, 2005, ASIAN J ANDROL, V7, P21, DOI 10.1111/j.1745-7262.2005.00014.x; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	35	35	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6632	6641		10.1074/jbc.M511558200	http://dx.doi.org/10.1074/jbc.M511558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16371355	hybrid			2022-12-25	WOS:000236030800060
J	Payandeh, J; Fujihashi, M; Gillon, W; Pai, EF				Payandeh, J; Fujihashi, M; Gillon, W; Pai, EF			The crystal structure of (S)-3-O-geranylgeranylglyceryl phosphate synthase reveals an ancient fold for an ancient enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHER LIPIDS; THERMOACIDOPHILIC ARCHAEON; PROTEIN STRUCTURES; BIOSYNTHESIS; EVOLUTION; MECHANISM; BACTERIA; MODEL; PRENYLTRANSFERASES; PYROPHOSPHATE	We report crystal structures of the citrate and sn-glycerol-1-phosphate (G1P) complexes of (S)-3-O-geranylgeranylglyceryl phosphate synthase from Archaeoglobus fulgidus (AfGGGPS) at 1.55 and 2.0 angstrom resolution, respectively. AfGGGPS is an enzyme that performs the committed step in archaeal lipid biosynthesis, and it presents the first triose phosphate isomerase (TIM)-barrel structure with a prenyltransferase function. Our studies provide insight into the catalytic mechanism of AfGGGPS and demonstrate how it selects for the sn-G1P isomer. The replacement of "Helix 3" by a "strand" in AfGGGPS, a novel modification to the canonical TIM-barrel fold, suggests a model of enzyme adaptation that involves a "greasy slide" and a "swinging door." We propose functions for the homologous PcrB proteins, which are conserved in a subset of pathogenic bacteria, as either prenyltransferases or being involved in lipoteichoic acid biosynthesis. Sequence and structural comparisons lead us to postulate an early evolutionary history for AfGGGPS, which may highlight its role in the emergence of Archaea.	Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Biochem, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Princess Margaret Hosp, Div Canc Genom & Proteom, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Pai, EF (corresponding author), MaRS Ctr, Div Canc Genom & Proteom, Ontario Canc Inst, Toronto Med Discovery Tower,101 Coll St,Rm 5-358, Toronto, ON M5G 1L7, Canada.	pai@hera.med.toronto.ca	Pai, Emil F/D-2526-2013; Pai, Emil/R-8908-2019	Pai, Emil/0000-0002-1162-7242	NIGMS NIH HHS [GM 008003] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn VE, 2004, EMBO J, V23, P2931, DOI 10.1038/sj.emboj.7600320; Barona-Gomez F, 2003, EMBO REP, V4, P296, DOI 10.1038/sj.embor.embor771; Boucher Y, 2004, MOL MICROBIOL, V52, P515, DOI 10.1111/j.1365-2958.2004.03992.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang SY, 2003, J BIOL CHEM, V278, P29298, DOI 10.1074/jbc.M302687200; CHEN AJ, 1993, J BIOL CHEM, V268, P21701; CHRISTOPHER JA, 1997, SPOCK STRUCTURAL PRO; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; FISCHER W, 1988, ADV MICROB PHYSIOL, V29, P233, DOI 10.1016/S0065-2911(08)60349-5; Gaspar JA, 2005, PROTEIN SCI, V14, P216, DOI 10.1110/ps.041068605; Gattinger A, 2002, FEMS MICROBIOL LETT, V213, P133, DOI 10.1111/j.1574-6968.2002.tb11297.x; GOLDFINE H, 1988, TRENDS BIOCHEM SCI, V13, P217, DOI 10.1016/0968-0004(88)90087-4; Griffith OH, 1999, BBA-MOL CELL BIOL L, V1441, P237, DOI 10.1016/S1388-1981(99)00153-5; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; Hemmi H, 2004, J BIOL CHEM, V279, P50197, DOI 10.1074/jbc.M409207200; Hocker B, 2004, P NATL ACAD SCI USA, V101, P16448, DOI 10.1073/pnas.0405832101; Hocker B, 2001, NAT STRUCT BIOL, V8, P32; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan IK, 2005, NATURE, V433, P633, DOI 10.1038/nature03306; KATES M, 1978, Progress in the Chemistry of Fats and Other Lipids, V15, P301; KOGA Y, 1993, MICROBIOL REV, V57, P164, DOI 10.1128/MMBR.57.1.164-182.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzuyama T, 2005, NATURE, V435, P983, DOI 10.1038/nature03668; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leopoldseder S, 2004, J MOL BIOL, V337, P871, DOI 10.1016/j.jmb.2004.01.062; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mesecar AD, 2000, NATURE, V403, P614, DOI 10.1038/35001144; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; Nemoto N, 2003, J BIOCHEM, V133, P651, DOI 10.1093/jb/mvg083; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALTAUF F, 1994, CHEM PHYS LIPIDS, V74, P101, DOI 10.1016/0009-3084(94)90054-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; POULTER CD, 1978, J BIOL CHEM, V253, P7227; Soderberg T, 2001, BIOCHEMISTRY-US, V40, P14847, DOI 10.1021/bi0111799; Sundaresan V, 2002, PROTEIN SCI, V11, P1330, DOI 10.1110/ps.3280102; Taylor JS, 2003, EMBO J, V22, P5963, DOI 10.1093/emboj/cdg571; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Van Gelder P, 2001, PROTEIN ENG, V14, P943, DOI 10.1093/protein/14.11.943; Vega MC, 2003, CURR OPIN CHEM BIOL, V7, P694, DOI 10.1016/j.cbpa.2003.10.004; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; ZHANG DL, 1993, J AM CHEM SOC, V115, P1270, DOI 10.1021/ja00057a008	51	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6070	6078		10.1074/jbc.M509377200	http://dx.doi.org/10.1074/jbc.M509377200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377641	hybrid			2022-12-25	WOS:000235568900088
J	Ponchon, L; Boulanger, P; Labesse, G; Letellier, L				Ponchon, L; Boulanger, P; Labesse, G; Letellier, L			The endonuclease domain of bacteriophage terminases belongs to the resolvase/integrase/ribonuclease H superfamily - A bioinformatics analysis validated by a functional study on bacteriophage T5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA TERMINASE; LARGE SUBUNIT; ATPASE CENTER; DNA; PROTEIN; SEQUENCE; RECOGNITION; MUTATIONS; ENZYME; PURIFICATION	Bacteriophage terminases are essential molecular motors involved in the encapsidation of viral DNA. They are hetero- multimers whose large subunit encodes both ATPase and endonuclease activities. Although the ATPase domain is well characterized from sequence and functional analysis, the C- terminal region remains poorly defined. We describe sequence- structure comparisons of the endonuclease region of various bacteriophages that revealed new sequence similarities shared by this region and the Holliday junction resolvase RuvC and to a lesser extent the HIV integrase and the ribonuclease H. Extensive sequence comparison and motif refinement led to a common signature of terminases and resolvases with three conserved acidic residues engaged in catalytic activity. Sequence analyses were validated by in vivo and in vitro functional assays showing that the nuclease activity of the endonuclease domain of bacteriophage T5 terminase was abolished by mutation of any of the three predicted catalytic aspartates. Overall, these data suggest that the endonuclease domains of terminases operate autonomously and that they adopt a fold similar to that of resolvases and share the same divalent cation- dependent enzymatic mechanism.	Univ Paris Sud, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France; Univ Montpellier I, CNRS, UMR5048, INSERM,U554,Ctr Biochim Struct, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Letellier, L (corresponding author), Univ Paris Sud, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, Batiment 430, F-91405 Orsay, France.	lucienne.letellier@biomemb.u-psud.fr		Labesse, Gilles/0000-0002-6861-3300; ponchon, Luc/0000-0002-4094-4853				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Catalano CE, 2000, CELL MOL LIFE SCI, V57, P128, DOI 10.1007/s000180050503; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; Dhar A, 2005, J MOL BIOL, V347, P71, DOI 10.1016/j.jmb.2004.12.041; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; DROGE A, 2005, BACTERIOPHAGE SPP1 D, P89; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; EVERETT RD, 1981, J GEN VIROL, V52, P25, DOI 10.1099/0022-1317-52-1-25; Feiss Michael, 2005, P5; Gual A, 2000, J BIOL CHEM, V275, P35311, DOI 10.1074/jbc.M004309200; Hwang Y, 1996, BIOCHEMISTRY-US, V35, P2796, DOI 10.1021/bi952322z; Hwang Y, 1996, J MOL BIOL, V261, P524, DOI 10.1006/jmbi.1996.0480; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kanamaru S, 2004, J BIOL CHEM, V279, P40795, DOI 10.1074/jbc.M403647200; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; Maluf NK, 2005, J MOL BIOL, V347, P523, DOI 10.1016/j.jmb.2005.01.016; MCCORQUODALE JD, 1988, VIRUSES, V1, P439; Mitchell MS, 2004, VIROLOGY, V321, P217, DOI 10.1016/j.virol.2003.11.006; Mitchell MS, 2002, NUCLEIC ACIDS RES, V30, P4009, DOI 10.1093/nar/gkf524; MORITA M, 1995, VIROLOGY, V211, P516, DOI 10.1006/viro.1995.1433; Nishino T, 2002, ONCOGENE, V21, P9022, DOI 10.1038/sj.onc.1206135; Nowotny M, 2005, CELL, V121, P1005, DOI 10.1016/j.cell.2005.04.024; PARRIS W, 1994, J BIOL CHEM, V269, P13564; Ponchon L, 2005, BBA-GEN SUBJECTS, V1724, P255, DOI 10.1016/j.bbagen.2005.04.016; Przech AJ, 2003, J VIROL, V77, P9613, DOI 10.1128/JVI.77.17.9613-9621.2003; Rao Venigalla B., 2005, P40; Rentas FJ, 2003, J MOL BIOL, V334, P37, DOI 10.1016/j.jmb.2003.09.028; RHOADES M, 1972, J MOL BIOL, V69, P187, DOI 10.1016/0022-2836(72)90224-0; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Wang JB, 2005, VIROLOGY, V332, P45, DOI 10.1016/j.virol.2004.10.049; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	47	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5829	5836		10.1074/jbc.M511817200	http://dx.doi.org/10.1074/jbc.M511817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377618	hybrid			2022-12-25	WOS:000235568900062
J	Saladino, R; Crestini, C; Ciciriello, F; Di Mauro, E; Costanzo, G				Saladino, R; Crestini, C; Ciciriello, F; Di Mauro, E; Costanzo, G			Origin of informational polymers - Differential stability of phosphoester bonds in ribomonomers and ribooligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMAMIDE; PHOSPHORYLATION; DEGRADATION; ENZYMES; XENDOU; LIFE	We have measured the stabilities of the bonds that are critical for determining the half- life of ribonucleotides and the beta-glycosidic and 3'- and 5'- phosphoester bonds. Stabilities were measured under a wide range of temperatures and water/ formamide ratios. The stability of phosphodiester bonds in oligoribonucleotides was determined in the same environments. The comparison of bond stabilities in the monomer versus the polymer forms of the ribo compounds revealed that physico- chemical conditions exist in which polymerization is thermodynamically favored. These conditions were compared with those determining a similar behavior for 2 '- deoxyribonucleosides, deoxyribonucleotides, and deoxyribooligonucleotides and were shown to profoundly differ. The implications of these facts on the origin of informational polymers are discussed.	Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Tuscia, Dipartimento Agrobiol & Agrochim, I-01100 Viterbo, Italy; CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy	Sapienza University Rome; Tuscia University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Di Mauro, E (corresponding author), Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Fdn Ist Pasteur Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	ernesto.dimauro@uniroma1.it	Ciciriello, Fabiana/AAA-8065-2020; Crestini, Claudia/O-6781-2015	Ciciriello, Fabiana/0000-0003-1493-9767; Crestini, Claudia/0000-0001-9903-2675				Achenbach JC, 2004, CURR PHARM BIOTECHNO, V5, P321, DOI 10.2174/1389201043376751; Atkins J.F, 1999, RNA WORLD; BALES TC, 1990, J MOL BIOL, V213, P931; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; Breaker RR, 1997, NAT BIOTECHNOL, V15, P427, DOI 10.1038/nbt0597-427; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; Breaker RR, 2000, SCIENCE, V290, P2095, DOI 10.1126/science.290.5499.2095; DARWIN F, 1988, LIFE LETT C DARWIN, V3, P18; DIEKMANN S, 1989, EMBO J, V8, P1; Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a; Emilsson GM, 2002, CELL MOL LIFE SCI, V59, P596, DOI 10.1007/s00018-002-8452-4; GARRETT ER, 1966, J ORG CHEM, V31, P189; Gioia U, 2005, J BIOL CHEM, V280, P18996, DOI 10.1074/jbc.M501160200; Halvorson H. O., 1980, ORIGINS LIFE EVOL B, P31; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; JARVINEN P, 1991, J ORG CHEM, V56, P5396, DOI 10.1021/jo00018a037; Joyce GF, 2004, ANNU REV BIOCHEM, V73, P791, DOI 10.1146/annurev.biochem.73.011303.073717; Kochetkov N.K., 1972, ORGANIC CHEM NUCLE B, P425; Laneve P, 2003, J BIOL CHEM, V278, P13026, DOI 10.1074/jbc.M211937200; Millar TJ, 2004, ASTROPHYS SPACE SC L, V305, P17; MORROW JR, 1995, J CHEM SOC CHEM COMM, P2431, DOI 10.1039/c39950002431; Peracchi A, 2005, CHEMBIOCHEM, V6, P1316, DOI 10.1002/cbic.200500098; Saladino R, 2005, J BIOL CHEM, V280, P35658, DOI 10.1074/jbc.M504537200; Saladino R, 2005, CHEMBIOCHEM, V6, P1368, DOI 10.1002/cbic.200500035; Saladino R, 2004, CHEMBIOCHEM, V5, P1558, DOI 10.1002/cbic.200400119; Saladino R, 2003, CHEMBIOCHEM, V4, P514, DOI 10.1002/cbic.200300567; Saladino R, 2001, BIOORGAN MED CHEM, V9, P1249, DOI 10.1016/S0968-0896(00)00340-0; SCHOFFSTALL AM, 1988, ORIGINS LIFE EVOL B, V18, P389, DOI 10.1007/BF01808217; SCHOFFSTALL AM, 1976, ORIGINS LIFE EVOL B, V7, P399, DOI 10.1007/BF00927935; SCHOFFSTALL AM, 1982, ORIGINS LIFE EVOL B, V12, P143, DOI 10.1007/BF00927141; Travers A., 1993, DNA PROTEIN INTERACT	31	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5790	5796		10.1074/jbc.M512545200	http://dx.doi.org/10.1074/jbc.M512545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407319	hybrid			2022-12-25	WOS:000235568900057
J	Jonas, WB; Ives, JA; Rollwagen, F; Denman, DW; Hintz, K; Hammer, M; Crawford, C; Henry, K				Jonas, WB; Ives, JA; Rollwagen, F; Denman, DW; Hintz, K; Hammer, M; Crawford, C; Henry, K			Can specific biological signals be digitized?	FASEB JOURNAL			English	Article						social management of science; controversial science claims; electromagnetic signals; digital biology; thrombin; fibrinogen; coagulation	HUMAN BASOPHIL DEGRANULATION; DILUTE ANTISERUM; IGE; INHIBITION; ACTIVATION; HISTAMINE	At the request of the United States Defense Advanced Research Projects Agency, we attempted to replicate the data of Professor Jacques Benveniste that digital signals recorded on a computer disc produce specific biological effects. The hypothesis was that a digitized thrombin inhibitor signal would inhibit the fibrinogen-thrombin coagulation pathway. Because of the controversies associated with previous research of Prof. Benveniste, we developed a system for the management of social controversy in science that incorporated an expert in social communication and conflict management. The social management approach was an adaptation of interactional communication theory, for management of areas that interfere with the conduct of good science. This process allowed us to successfully complete a coordinated effort by a multidisciplinary team, including Prof. Benveniste, a hematologist, engineer, skeptic, statistician, neuroscientist and conflict management expert. Our team found no replicable effects from digital signals. Jonas, W. B., Ives, J. A., Rollwagen, F., Denman, D. W., Hintz K., Hammer, M., Crawford, C., Henry, K. Can specific biological signals be digitized?	Samueli Inst Informat Biol, Alexandria, VA 22314 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed Army Inst Res, Washington, DC USA; Univ Maryland, College Pk, MD 20742 USA; George Mason Univ, Fairfax, VA 22030 USA; American Univ, Washington, DC 20016 USA; Def Advance Res Projects Agcy, Arlington, VA USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University System of Maryland; University of Maryland College Park; George Mason University; American University; United States Department of Defense; Defense Advanced Research Projects Agency (DARPA)	Jonas, WB (corresponding author), 1700 Diagonal Rd,Suite 400, Alexandria, VA 22314 USA.	wjonas@siib.org						[Anonymous], 1967, PRAGMATICS HUMAN COM; Belon P, 1999, INFLAMM RES, V48, pS17; Benveniste J, 1999, FASEB J, V13, pA163; Brown V, 2001, INFLAMM RES, V50, pS47; Cissna K.N.L., 1981, RIGOR IMAGINATION ES, P253; COLES P, 1988, NATURE, V334, P372, DOI 10.1038/334372a0; DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0; DESTEPHEN RS, 1988, SMALL GROUP BEHAV, V19, P227, DOI 10.1177/104649648801900204; HAMMER M, 1997, PRACTICE OUTCOMES MO; HAMMER M, 1996, BURZYNSKI ANTINEOPLA; HAMMER M, 1996, MANAGEMENT DISPUTE J; Hammer M. R., 1997, DYNAMIC PROCESSES CR, P9; Hammer Mitchell R, 2004, Integr Cancer Ther, V3, P59, DOI 10.1177/1534735404263448; HIRST SJ, 1993, NATURE, V366, P525, DOI 10.1038/366525a0; Janis, 1989, CRUCIAL DECISIONS; Janis I. L, 1982, GROUPTHINK, V2nd; MADDOX J, 1988, NATURE, V334, P287, DOI 10.1038/334287a0; OVELGONNE JH, 1992, EXPERIENTIA, V48, P504, DOI 10.1007/BF01928175; Rogan R. G., 2002, LAW ENFORCEMENT COMM, P229; SCHIFF M, 1994, MEMORY WATER; STENT GS, 1972, SCI AM, V227, P84, DOI 10.1038/scientificamerican1272-84; Thomas Y, 2000, MED HYPOTHESES, V54, P33, DOI 10.1054/mehy.1999.0891; URESCH J, 1951, COMMUNICATION SOCIAL; Walleczek J., 2000, SELF ORG BIOL DYNAMI; 1988, NATURE LONDON, V333, P787	25	27	29	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					23	28		10.1096/fj.05-3815hyp	http://dx.doi.org/10.1096/fj.05-3815hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394263				2022-12-25	WOS:000235996000040
J	Alabert, C; Rogers, L; Kahn, L; Niellez, S; Fafet, P; Cerulis, S; Blanchard, JM; Hipskind, RA; Vignais, ML				Alabert, C.; Rogers, L.; Kahn, L.; Niellez, S.; Fafet, P.; Cerulis, S.; Blanchard, J. M.; Hipskind, R. A.; Vignais, M. -L.			Cell type-dependent control of NF-Y activity by TGF-beta	ONCOGENE			English	Article						TGF-beta; NF-Y; MAPK	CCAAT-BINDING-FACTOR; CYCLIN-A EXPRESSION; P38 MAP KINASE; TRANSCRIPTION FACTOR; INDEPENDENT PATHWAYS; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-TRANSCRIPTION; B-SUBUNIT; CBF/NF-Y	Transforming growth factor b (TGF-beta) is a pluripotent cytokine that regulates cell growth and differentiation in a cell type-dependent fashion. TGF-beta exerts its effects through the activation of several signaling pathways. One involves membrane proximal events that lead to nuclear translocation of members of the Smad family of transcriptional regulators. TGF-beta can also activate MAPK cascades. Here, we show that TGF-beta induces nuclear translocation of the NF-YA subunit of the transcription factor NF-Y by a process that requires activation of the ERK cascade. This results in increased binding of endogenous NF-Y to chromatin and TGF-beta-dependent transcriptional regulation of the NF-Y target gene cyclin A2. Interestingly, the kinetics of NF-YA relocalization differs between epithelial cells and fibroblasts. NIH3T3 fibroblasts show an elevated basal level of phosphorylated p38 and delayed nuclear accumulation of NF-YA after TGF-beta treatment. In contrast, MDCK cells show low basal p38 activation, higher basal ERK phosphorylation and more rapid localization of NF-YA after induction. Thus, NF-Y activation by TGF-beta 1 involves ERK1/2 and potentially an interplay between MAPK pathways, thereby opening the possibility for finely tuned transcriptional regulation.	CNRS, Inst Mol Genet, UMR5535, IFR122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Vignais, ML (corresponding author), CNRS, Inst Mol Genet, UMR5535, IFR122, 1919 Route Mende, F-34293 Montpellier 5, France.	vignais@igmm.cnrs.fr	Vignais, Marie Luce/D-5144-2017	Vignais, Marie Luce/0000-0002-0183-5953				Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; Bhattacharya A, 2003, CANCER RES, V63, P8167; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; de Caestecker M, 2004, CYTOKINE GROWTH F R, V15, P1, DOI 10.1016/j.cytogfr.2003.10.004; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Frontini M, 2004, CELL CYCLE, V3, P217; Hall JP, 2002, J CELL BIOCHEM, V86, P1, DOI 10.1002/jcb.10187; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Huet X, 1996, MOL CELL BIOL, V16, P3789; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kahle J, 2005, MOL CELL BIOL, V25, P5339, DOI 10.1128/MCB.25.13.5339-5354.2005; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Testa A, 2005, J BIOL CHEM, V280, P13606, DOI 10.1074/jbc.M414039200; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200	51	21	21	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3387	3396		10.1038/sj.onc.1209385	http://dx.doi.org/10.1038/sj.onc.1209385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434965	Green Published			2022-12-25	WOS:000238448100004
J	Siegmund, SV; Seki, E; Osawa, Y; Uchinami, H; Cravatt, BF; Schwabe, RF				Siegmund, SV; Seki, E; Osawa, Y; Uchinami, H; Cravatt, BF; Schwabe, RF			Fatty acid amide hydrolase determines anandamide-induced cell death in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID ANANDAMIDE; HEPATIC STELLATE CELLS; TUMOR-NECROSIS-FACTOR; N-TERMINAL KINASE; MOLECULAR CHARACTERIZATION; ENDOCANNABINOID SYSTEM; GLUTATHIONE DEPLETION; KAPPA-B; RECEPTORS; APOPTOSIS	The endocannabinoid anandamide ( AEA) induces cell death in many cell types, but determinants of AEA-induced cell death remain unknown. In this study, we investigated the role of the AEA-degrading enzyme fatty acid amide hydrolase ( FAAH) in AEA-induced cell death in the liver. Primary hepatocytes expressed high levels of FAAH and were completely resistant to AEA-induced cell death, whereas primary hepatic stellate cells (HSCs) expressed low levels of FAAH and were highly sensitive to AEA-induced cell death. Hepatocytes that were pretreated with the FAAH inhibitor URB597 or isolated from FAAH(-/-) mice displayed increased AEA-induced reactive oxygen species (ROS) formation and were susceptible to AEA-mediated death. Conversely, overexpression of FAAH in HSCs prevented AEA-induced death. Since FAAH inhibition conferred only partial AEA sensitivity in hepatocytes, we analyzed additional factors that might regulate AEA-induced death. Hepatocytes contained significantly higher levels of glutathione (GSH) than HSCs. Glutathione depletion by DL-buthionine-(S, R)-sulfoximine rendered hepatocytes susceptible to AEA-mediated ROS production and cell death, whereas GSH ethyl ester prevented ROS production and cell death in HSCs. FAAH inhibition and GSH depletion had additive effects on AEA-mediated hepatocyte cell death resulting in almost 70% death after 24 h at 50 mu M AEA and lowering the threshold for cell death to 500 nM. Following bile duct ligation, FAAH(-/-) mice displayed increased hepatocellular injury, suggesting that FAAH protects hepatocytes from AEA-induced cell death in vivo. In conclusion, FAAH and GSH are determinants of AEA-mediated cell death in the liver.	Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, Dept Chem, La Jolla, CA 92037 USA	Columbia University; Scripps Research Institute; Scripps Research Institute	Schwabe, RF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, P&S 9-460,630 W 168th St, New York, NY 10032 USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021; Seki, Ekihiro/K-2481-2016	Seki, Ekihiro/0000-0002-9472-6085				Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Begg M, 2005, PHARMACOL THERAPEUT, V106, P133, DOI 10.1016/j.pharmthera.2004.11.005; Berdyshev EV, 2001, BIOCHEM J, V360, P67, DOI 10.1042/0264-6021:3600067; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; Cravatt BF, 2004, P NATL ACAD SCI USA, V101, P10821, DOI 10.1073/pnas.0401292101; Derkinderen P, 2003, J NEUROSCI, V23, P2371; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Fegley D, 2004, P NATL ACAD SCI USA, V101, P8756, DOI 10.1073/pnas.0400997101; Femandez-Checa JC, 2005, TOXICOL APPL PHARM, V204, P263, DOI 10.1016/j.taap.2004.10.001; Fernandez-Rodriguez CM, 2004, LIVER INT, V24, P477, DOI 10.1111/j.1478-3231.2004.0945.x; Fischer R, 2002, GASTROENTEROLOGY, V123, P845, DOI 10.1053/gast.2002.35384; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Kathuria S, 2003, NAT MED, V9, P76, DOI 10.1038/nm803; KRAHENBUHL S, 1995, HEPATOLOGY, V22, P607, DOI 10.1016/0270-9139(95)90586-3; Ligresti A, 2004, BIOCHEM J, V380, P265, DOI 10.1042/BJ20031812; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2003, CELL DEATH DIFFER, V10, P946, DOI 10.1038/sj.cdd.4401284; Maccarrone M, 2003, ENDOCRINOLOGY, V144, P20, DOI 10.1210/en.2002-220544; McKallip RJ, 2002, BLOOD, V100, P627, DOI 10.1182/blood-2002-01-0098; Movsesyan VA, 2004, CELL DEATH DIFFER, V11, P1121, DOI 10.1038/sj.cdd.4401442; Nagai H, 2002, HEPATOLOGY, V36, P55, DOI 10.1053/jhep.2002.33995; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pacher P, 2005, AM J PHYSIOL-HEART C, V289, pH533, DOI 10.1152/ajpheart.00107.2005; Patricelli MP, 2001, BIOCHEMISTRY-US, V40, P6107, DOI 10.1021/bi002578r; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Sarker KP, 2003, J NEUROCHEM, V85, P50, DOI 10.1046/j.1471-4159.2003.01663.x; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Schwabe RF, 2004, FASEB J, V18, P720, DOI 10.1096/fj.03-0771fje; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Schwabe RF, 2001, HEPATOLOGY, V33, P81, DOI 10.1053/jhep.2001.20799; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198	42	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10431	10438		10.1074/jbc.M509706200	http://dx.doi.org/10.1074/jbc.M509706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16418162	hybrid			2022-12-25	WOS:000236594300072
J	Freie, AB; Ferrato, F; Carriere, F; Lowe, ME				Freie, AB; Ferrato, F; Carriere, F; Lowe, ME			Val-407 and Ile-408 in the beta 5 '-loop of pancreatic lipase mediate lipase-colipase interactions in the presence of bile salt micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; BINDING; COMPLEX; PURIFICATION; PROCOLIPASE; ACTIVATION; TAURODEOXYCHOLATE; SUBSTRATE; RESIDUES; ABSENCE	In a previous study, we demonstrated that the beta 5'-loop in the C-terminal domain of human pancreatic triglyceride lipase (hPTL) makes a major contribution in the function of hPTL (Chahinian et al. ( 2002) Biochemistry 41, 13725 - 13735). In the present study, we characterized the contribution of three residues in the beta 5'-loop, Val-407, Ile-408, and Leu-412, to the function of hPTL. By substituting charged residues, aspartate or lysine, in these positions, we altered the hydrophilic to lipophilic ratio of the beta 5'-loop. Each of the mutants was expressed, purified, and characterized for activity and binding with both monolayers and emulsions and for binding to colipase. Experiments with monolayers and with emulsions suggested that the interaction of hPTL with a phospholipid monolayer differs from the interaction of the hPTL-colipase complex with a dicaprin monolayer or a triglyceride emulsion (i.e. neutral lipids). Val-407, Ile-408, and Leu-412 make major contributions to interactions with monolayers, whereas only Val-407 and Ile-408 appear essential for activity on triglyceride emulsions in the presence of bile salt micelles. In solutions of taurodeoxycholate at micellar concentrations, a major effect of the beta 5'-loop mutations is to change the interaction between hPTL and colipase. These observations support a major contribution of residues in the beta 5'-loop in the function of hPTL and suggest that a third partner, bile salt micelles or the lipid interface or both, influence the binding of colipase and hPTL through interactions with the beta 5'-loop.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; CNRS, Lab Enzymol Interfaciale & Physiol Lipolyse, F-13402 Marseille 20, France; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Gastroenterol, Pittsburgh, PA 15213 USA	Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lowe, ME (corresponding author), Childrens Hosp Pittsburgh, Dept Gastroenterol, 3705 5th Ave, Pittsburgh, PA 15213 USA.	mark.lowe@chp.edu	Carrière, Frédéric/E-8408-2010	Carrière, Frédéric/0000-0003-4848-9418	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033060] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33060, R01 HD033060] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ayvazian L, 2001, J BIOL CHEM, V276, P14014, DOI 10.1074/jbc.M010328200; Bezzine S, 1998, BIOCHEMISTRY-US, V37, P11846, DOI 10.1021/bi973136r; Bezzine S, 1999, BIOCHEMISTRY-US, V38, P5499, DOI 10.1021/bi982601x; BORGSTROM B, 1975, J LIPID RES, V16, P287; BORGSTROM B, 1975, J LIPID RES, V16, P411; Chahinian H, 2002, BIOCHEMISTRY-US, V41, P13725, DOI 10.1021/bi0257944; Cordle RA, 1998, PROTEIN EXPRES PURIF, V13, P30, DOI 10.1006/prep.1998.0873; Cordle RA, 1998, J LIPID RES, V39, P1759; Crandall WV, 2001, J BIOL CHEM, V276, P12505, DOI 10.1074/jbc.M009986200; DONNER J, 1976, BIOCHEMISTRY-US, V15, P5413, DOI 10.1021/bi00669a031; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LAIRON D, 1978, BIOCHEMISTRY-US, V17, P5263, DOI 10.1021/bi00617a028; LAIRON D, 1980, BIOCHIM BIOPHYS ACTA, V618, P119, DOI 10.1016/0005-2760(80)90059-4; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; MOMSEN WE, 1976, J BIOL CHEM, V251, P384; PATTON JS, 1978, J BIOL CHEM, V253, P4195; PATTON JS, 1978, BIOCHIM BIOPHYS ACTA, V529, P67, DOI 10.1016/0005-2760(78)90104-2; PATTON JS, 1978, FEBS LETT, V86, P179, DOI 10.1016/0014-5793(78)80558-4; Pignol D, 2000, J BIOL CHEM, V275, P4220, DOI 10.1074/jbc.275.6.4220; Ransac S, 1997, METHOD ENZYMOL, V286, P263; Reissner KJ, 2003, CELL MOL LIFE SCI, V60, P1281, DOI 10.1007/s00018-003-2287-5; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Sambrook J, 2001, MOL CLONING LAB MANU; SARI H, 1975, BIOCHIMIE, V57, P1045, DOI 10.1016/S0300-9084(75)80360-9; SARI H, 1975, EUR J BIOCHEM, V58, P561, DOI 10.1111/j.1432-1033.1975.tb02406.x; Strandberg E, 2003, FEBS LETT, V544, P69, DOI 10.1016/S0014-5793(03)00475-7; van Tilbeurgh H, 1999, BBA-MOL CELL BIOL L, V1441, P173, DOI 10.1016/S1388-1981(99)00149-3; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1993, J MOL BIOL, V229, P552, DOI 10.1006/jmbi.1993.1054; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yang YQ, 1998, PROTEIN EXPRES PURIF, V13, P36, DOI 10.1006/prep.1998.0874	32	22	24	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7793	7800		10.1074/jbc.M512984200	http://dx.doi.org/10.1074/jbc.M512984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431912	hybrid, Green Accepted			2022-12-25	WOS:000236031000012
J	Yang, ML; Hsu, CT; Ting, CY; Liu, LF; Hwang, JL				Yang, ML; Hsu, CT; Ting, CY; Liu, LF; Hwang, JL			Assembly of a polymeric chain of SUMO1 on human topoisomerase I in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; DNA-REPAIR; PROTEIN SUMO-1; NUCLEAR; ACTIVATION; COMPLEX; SIGNAL; YEAST; MONOUBIQUITIN; CAMPTOTHECIN	Human ( h) DNA topoisomerase I has been identified as a major SUMO1 target in camptothecin-treated cells. In response to TOP1-mediated DNA damage induced by camptothecin, multiple SUMO1 molecules are conjugated to the N-terminal domain of a single TOP1 molecule. To investigate the molecular mechanism of SUMO1 conjugation to TOP1, an in vitro system using purified SAE1/2, Ubc9, SUMO1, and TOP1 peptides was developed. Consistent with results from in vivo studies, multiple SUMO1 molecules were found to be conjugated to the N-terminal domain of a single TOP1 molecule. Systematic analysis has identified a single major SUMO1 conjugation site located between amino acid residues 110 and 125 that contains a single lysine residue at 117 (Lys-117). Using a short peptide spanning this region, we showed that a poly-SUMO1 chain was assembled in this peptide at Lys-117. Interestingly, a Ubc9-poly-SUMO1 intermediate had accumulated to a high level when the sumoylation assay was performed in the absence of hTOP1 substrate, suggesting a possibility that the poly-SUMO1 chain is formed on Ubc9 first and then transferred en bloc onto hTOP1. This is the first definitive demonstration of the assembly of a poly-SUMO1 chain on protein substrate. These results offer new insight into hTOP1 polysumoylation in response to TOP1-mediated DNA damage and may have general implications in protein polysumoylation.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Hwang, JL (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	jaulangh@imb.sinica.edu.tw	Ting, chun-yuan/F-6448-2013	Ting, chun-yuan/0000-0002-2302-4203; Liu, Leroy/0000-0001-9396-763X	NCI NIH HHS [CA39662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen TY, 2000, APPL MICROBIOL BIOT, V53, P558, DOI 10.1007/s002530051657; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haluska P, 1998, ADV ENZYME REGUL, V38, P253, DOI 10.1016/S0065-2571(97)00008-3; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mayer RJ, 1998, FOLD DES, V3, pR97, DOI 10.1016/S1359-0278(98)00047-9; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	47	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8264	8274		10.1074/jbc.M510364200	http://dx.doi.org/10.1074/jbc.M510364200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16428803	hybrid			2022-12-25	WOS:000236031000066
J	Bois, PRJ; O'Hara, BP; Nietlispach, D; Kirkpatrick, J; Izard, T				Bois, PRJ; O'Hara, BP; Nietlispach, D; Kirkpatrick, J; Izard, T			The vinculin binding sites of talin and alpha-actinin are sufficient to activate vinculin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ASSOCIATION; CRYSTAL-STRUCTURE; CYTOSKELETAL PROTEINS; STRUCTURAL BASIS; FOCAL ADHESIONS; CELL-ADHESION; TAIL DOMAINS; HEAD; DYNAMICS; FORCE	Vinculin regulates both cell-cell and cell-matrix junctions and anchors adhesion complexes to the actin cytoskeleton through its interactions with the vinculin binding sites of alpha-actinin or talin. Activation of vinculin requires a severing of the intramolecular interactions between its N- and C-terminal domains, which is necessary for vinculin to bind to F-actin; yet how this occurs in cells is not resolved. We tested the hypothesis that talin and alpha-actinin activate vinculin through their vinculin binding sites. Indeed, we show that these vinculin binding sites have a high affinity for full-length vinculin, are sufficient to sever the head-tail interactions of vinculin, and they induce conformational changes that allow vinculin to bind to F-actin. Finally, microinjection of these vinculin binding sites specifically targets vinculin in cells, disrupting its interactions with talin and alpha-actinin and disassembling focal adhesions. In their native ( inactive) states the vinculin binding sites of talin and alpha-actinin are buried within helical bundles present in their central rod domains. Collectively, these results support a model where the engagement of adhesion receptors first activates talin or alpha-actinin, by provoking structural changes that allow their vinculin binding sites to swing out, which are then sufficient to bind to and activate vinculin.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Cell Adhes Lab, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Cambridge	Izard, T (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, Cell Adhes Lab, 332 N Lauderdale St, Memphis, TN 38105 USA.	tina.izard@stjude.org		Nietlispach, Daniel/0000-0003-4364-9291	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 071596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann SM, 2002, STRUCTURE, V10, P1085, DOI 10.1016/S0969-2126(02)00808-0; Bailly M, 2003, TRENDS CELL BIOL, V13, P163, DOI 10.1016/S0962-8924(03)00030-8; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; Bois PRJ, 2005, MOL CELL BIOL, V25, P6112, DOI 10.1128/MCB.25.14.6112-6122.2005; Borgon RA, 2004, STRUCTURE, V12, P1189, DOI 10.1016/j.str.2004.05.009; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Chandrasekar I, 2005, J CELL SCI, V118, P1461, DOI 10.1242/jcs.01734; Chen H, 2005, J CELL BIOL, V169, P459, DOI 10.1083/jcb.200410100; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Katsumi A, 2004, J BIOL CHEM, V279, P12001, DOI 10.1074/jbc.R300038200; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; MANGEAT P, 1984, J CELL BIOL, V99, pS95, DOI 10.1083/jcb.99.1.95s; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Pokutta S, 2002, CURR OPIN STRUC BIOL, V12, P255, DOI 10.1016/S0959-440X(02)00318-4; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; Propato A, 2001, NAT MED, V7, P807, DOI 10.1038/89930; Rudiger M, 1998, BIOESSAYS, V20, P733; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; STEENBERGEN C, 1987, CIRC RES, V60, P478, DOI 10.1161/01.RES.60.4.478; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; von Wichert G, 2003, EMBO J, V22, P5023, DOI 10.1093/emboj/cdg492; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Weis WI, 2004, NATURE, V430, P513, DOI 10.1038/430513a; Winkler J, 1996, J STRUCT BIOL, V116, P270, DOI 10.1006/jsbi.1996.0042; WOOD CK, 1994, J CELL SCI, V107, P709; Xu WM, 1998, DEVELOPMENT, V125, P327; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zamir E, 2001, J CELL SCI, V114, P3583	55	103	104	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7228	7236		10.1074/jbc.M510397200	http://dx.doi.org/10.1074/jbc.M510397200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407299	hybrid			2022-12-25	WOS:000236030900040
J	Chen, ZQ; Dong, JS; Ishimura, A; Daar, I; Hinnebusch, AG; Dean, M				Chen, ZQ; Dong, JS; Ishimura, A; Daar, I; Hinnebusch, AG; Dean, M			The essential vertebrate ABCE1 protein interacts with eukaryotic initiation factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNASE-L INHIBITOR; 2-5A-DEPENDENT RNASE; SEQUENCE ALIGNMENT; XENOPUS-OOCYTES; TRANSLATION; INTERFERON; PATHWAY; CELLS; BIOGENESIS; EVOLUTION	The ABCE1 gene is a member of the ATP-binding cassette (ABC) multigene family and is composed of two nucleotide binding domains and an N-terminal Fe-S binding domain. The ABCE1 gene encodes a protein originally identified for its inhibition of ribonuclease L, a nuclease induced by interferon in mammalian cells. The protein is also required for the assembly of the HIV and SIV gag polypeptides. However, ABCE1 is one of the most highly conserved proteins and is found in one or two copies in all characterized eukaryotes and archaea. Yeast ABCE1/RLI1 is essential to cell division and interacts with translation initiation factors in the assembly of the pre-initiation complex. We show here that the human ABCE1 protein is essential for in vitro and in vivo translation of mRNA and that it binds to eIF2 alpha and eIF5. Inhibition of the Xenopus ABCE1 arrests growth at the gastrula stage of development, consistent with a block in translation. The human ABCE1 gene contains 16 introns, and the extremely high degree of amino acid identity allows the evolution of its introns to be examined throughout eukaryotes. The demonstration that ABCE1 plays a role in vertebrate translation initiation extends the known functions of this highly conserved protein. Translation is a highly regulated process important to development and pathologies such as cancer, making ABCE1 a potential target for therapeutics. The evolutionary analysis supports a model in which an ancestral eukaryote had large number of introns and that many of these introns were lost in non-vertebrate lineages.	NCI, Lab Genom Divers, Ctr Canc Res, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, SAIC Frederick Inc, NIH, Frederick, MD 21702 USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; NCI, Lab Prot Dynam & Signaling, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dean, M (corresponding author), NCI, Lab Genom Divers, Ctr Canc Res, NIH, Frederick, MD 21702 USA.	dean@ncifcrf.gov	Dean, Michael C/G-8172-2012; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; Daar, Ira/0000-0003-2657-526X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01 CO 12400] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC005725] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Clemens M, 1984, TRANSCRIPTION TRANSL, P231; Coelho CMA, 2005, GENETICS, V171, P597, DOI 10.1534/genetics.105.045021; Dean M, 2005, ANNU REV GENOM HUM G, V6, P123, DOI 10.1146/annurev.genom.6.080604.162122; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Dooher JE, 2004, J VIROL, V78, P1645, DOI 10.1128/JVI.78.4.1645-1656.2004; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Gorchakov R, 2005, J VIROL, V79, P9397, DOI 10.1128/JVI.79.15.9397-9409.2005; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Martinand C, 1999, J VIROL, V73, P290, DOI 10.1128/JVI.73.1.290-296.1999; Monnier A, 2001, NUCLEIC ACIDS RES, V29, P1453, DOI 10.1093/nar/29.7.1453; Mood K, 2004, CELL SIGNAL, V16, P631, DOI 10.1016/j.cellsig.2003.10.005; Roy SW, 2005, P NATL ACAD SCI USA, V102, P5773, DOI 10.1073/pnas.0500383102; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zimmerman C, 2002, NATURE, V415, P88, DOI 10.1038/415088a	24	118	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7452	7457		10.1074/jbc.M510603200	http://dx.doi.org/10.1074/jbc.M510603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16421098	hybrid			2022-12-25	WOS:000236030900067
J	Meller, R; Cameron, JA; Torrey, DJ; Clayton, CE; Ordonez, AN; Henshall, DC; Minami, M; Schindler, CK; Saugstad, JA; Simon, RP				Meller, R; Cameron, JA; Torrey, DJ; Clayton, CE; Ordonez, AN; Henshall, DC; Minami, M; Schindler, CK; Saugstad, JA; Simon, RP			Rapid degradation of Bim by the ubiquitin-proteasome pathway mediates short-term ischemic tolerance in cultured neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; GLOBAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE-C; HIPPOCAMPAL SLICES; CELL-DEATH; APOPTOSIS; ACTIVATION; EXPRESSION; INDUCTION; ADENOSINE	A previous exposure to a non-harmful ischemic insult ( preconditioning) protects the brain against subsequent harmful ischemia ( ischemic tolerance). In contrast to delayed gene-mediated ischemic tolerance, little is known about the molecular mechanisms that regulate rapid ischemic tolerance, which occurs within 1 h following preconditioning. Here we have investigated the degradation of the pro-apoptotic Bcl-2 family member Bim as a mechanism of rapid ischemic tolerance. Bim protein levels were reduced 1 h following preconditioning and occurred concurrent with an increase in Bim ubiquitination. Ubiquitinated proteins are degraded by the proteasome, and inhibition of the proteasome with MG132 ( a proteasome inhibitor) prevented Bim degradation and blocked rapid ischemic tolerance. Inhibition of p42/p44 mitogen-activated protein kinase activation by U0126 reduced Bim ubiquitination and Bim degradation and blocked rapid ischemic tolerance. Finally, inhibition of Bim expression using antisense oligonucleotides also reduced cell death following ischemic challenge. Our results suggest that following preconditioning ischemia, Bim is rapidly degraded by the ubiquitin-proteasome system, resulting in rapid ischemic tolerance. This suggests that the rapid degradation of cell death-promoting proteins by the ubiquitin-proteasome pathway may represent a novel therapeutic strategy to reduce cell damage following neuropathological insults, e. g. stroke.	Legacy Res, Legacy Clin Res & Technol Ctr, Robert S Dow Neurobiol Labs, Portland, OR 97232 USA; Royal Coll Surgeons Ireland, Dublin 2, Ireland	Royal College of Surgeons - Ireland	Meller, R (corresponding author), Legacy Res, Legacy Clin Res & Technol Ctr, Robert S Dow Neurobiol Labs, 1225 NE 2nd Ave, Portland, OR 97232 USA.	rmeller@downeurobiology.org	Minami, Manabu/H-8540-2016; Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024728, R21NS050669] Funding Source: NIH RePORTER; NINDS NIH HHS [R42 NS065515, NS 050669, R01 NS024728, NS 24728, R21 NS050669] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Baker JE, 1997, J MOL CELL CARDIOL, V29, P845, DOI 10.1006/jmcc.1996.0361; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BISWAS SC, 2002, J BIOL CHEM, V17, P17; Bossenmeyer-Pourie C, 1998, MOL BRAIN RES, V58, P237, DOI 10.1016/S0169-328X(98)00123-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; Dave KR, 2001, J CEREBR BLOOD F MET, V21, P1401, DOI 10.1097/00004647-200112000-00004; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Harris CA, 2001, J BIOL CHEM, V276, P37754; Ishida T, 1997, SHOCK, V8, P86, DOI 10.1097/00024382-199708000-00003; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; LEY R, 2003, J BIOL CHEM; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Meller R, 2005, J CEREBR BLOOD F MET, V25, P234, DOI 10.1038/sj.jcbfm.9600024; Meller R, 2005, J CEREBR BLOOD F MET, V25, P217, DOI 10.1038/sj.jcbfm.9600022; Meller R, 2002, NEUROSCI LETT, V324, P33, DOI 10.1016/S0304-3940(02)00166-0; Miura T, 1996, EXS, V76, P365; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Nakamura M, 2002, J CEREBR BLOOD F MET, V22, P161, DOI 10.1097/00004647-200202000-00004; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ogawa T, 1996, J AM COLL CARDIOL, V27, P225, DOI 10.1016/0735-1097(95)00412-2; Perez-Pinzon MA, 1999, NEUROSCIENCE, V89, P453, DOI 10.1016/S0306-4522(98)00560-0; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Qi SH, 2001, NEUROSCI LETT, V315, P133, DOI 10.1016/S0304-3940(01)02368-0; Reshef A, 2000, ADV EXP MED BIOL, V486, P217; Reshef A, 1997, NEUROSCI LETT, V238, P37, DOI 10.1016/S0304-3940(97)00841-0; Reshef A, 1998, NEUROSCI LETT, V250, P111, DOI 10.1016/S0304-3940(98)00458-3; Reshef A, 1996, BRAIN RES, V741, P252, DOI 10.1016/S0006-8993(96)00939-0; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Shimizu S, 2001, J CEREBR BLOOD F MET, V21, P233, DOI 10.1097/00004647-200103000-00007; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Strasser A, 2000, ANN NY ACAD SCI, V917, P541; Tauskela JS, 1999, BRAIN RES, V827, P143, DOI 10.1016/S0006-8993(99)01322-0; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235	51	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7429	7436		10.1074/jbc.M512138200	http://dx.doi.org/10.1074/jbc.M512138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16431916	Green Accepted, hybrid			2022-12-25	WOS:000236030900064
J	Patel, B; Gingras, AR; Bobkov, AA; Fujimoto, LM; Zhang, M; Liddington, RC; Mazzeo, D; Emsley, J; Roberts, GCK; Barsukov, IL; Critchley, DR				Patel, B; Gingras, AR; Bobkov, AA; Fujimoto, LM; Zhang, M; Liddington, RC; Mazzeo, D; Emsley, J; Roberts, GCK; Barsukov, IL; Critchley, DR			The activity of the vinculin binding sites in talin is influenced by the stability of the helical bundles that make up the talin rod	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETAL PROTEINS TALIN; EMBRYONIC STEM-CELLS; F-ACTIN-BINDING; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; FERM DOMAIN; INTEGRIN ACTIVATION; PLASMA-MEMBRANE; FOCAL ADHESIONS; KINASE	The talin rod contains similar to 11 vinculin binding sites (VBSs), each defined by hydrophobic residues in a series of amphipathic helices that are normally buried within the helical bundles that make up the rod. Consistent with this, talin failed to compete for binding of the vinculin Vd1 domain to an immobilized talin polypeptide containing a constitutively active VBS. However, talin did bind to GST- Vd1 in pull-down assays, and isothermal titration calorimetry measurements indicate a K-d of similar to 9 mu M. Interestingly, Vd1 binding exposed a trypsin cleavage site in the talin rod between residues 898 and 899, indicating that there are one or more active VBSs in the N-terminal part of the talin rod. This region comprises a five helix bundle ( residues 482 - 655) followed by a seven-helix bundle ( 656 - 889) and contains five VBSs ( helices 4, 6, 9, 11, and 12). The single VBS within 482 - 655 is cryptic at room temperature. In contrast, talin 482 - 889 binds Vd1 with high affinity (K-d similar to 0.14 mu M), indicating that one or more of the four VBSs within 656 - 889 are active, and this likely represents the vinculin binding region in intact talin. In support of this, hemagglutinin-tagged talin 482 - 889 localized efficiently to focal adhesions, whereas 482 - 655 did not. Differential scanning calorimetry showed a strong negative correlation between Vd1 binding and helical bundle stability, and a 755 - 889 mutant with a more stable fold bound Vd1 much less well than wild type. We conclude that the stability of the helical bundles that make up the talin rod is an important factor determining the activity of the individual VBSs.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Burnham Inst, La Jolla, CA 92037 USA; Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England	University of Leicester; Sanford Burnham Prebys Medical Discovery Institute; University of Nottingham	Critchley, DR (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	drc@le.ac.uk	emsley, jonas/A-8509-2016; Gingras, Alexandre R/E-1867-2011	emsley, jonas/0000-0002-8949-8030; Gingras, Alexandre R/0000-0002-5373-0176; Roberts, Gordon/0000-0001-6200-1373	NIGMS NIH HHS [5U54 GM 64346] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; Bakolitsa C, 2004, NATURE, V430, P583, DOI 10.1038/nature02610; Barsukov IL, 2003, J BIOL CHEM, V278, P31202, DOI 10.1074/jbc.M303850200; Bass MD, 1999, BIOCHEM J, V341, P257, DOI 10.1042/0264-6021:3410257; Bass MD, 2002, BIOCHEM J, V362, P761, DOI 10.1042/0264-6021:3620761; BELKIN AM, 1986, FEBS LETT, V200, P32, DOI 10.1016/0014-5793(86)80505-1; Bellissent-Waydelich A, 1999, J HISTOCHEM CYTOCHEM, V47, P1357, DOI 10.1177/002215549904701102; Bolton SJ, 1997, CELL MOTIL CYTOSKEL, V36, P363; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; BURRIDGE K, 1983, J CELL BIOL, V97, P359, DOI 10.1083/jcb.97.2.359; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; Cram EJ, 2003, J CELL SCI, V116, P3871, DOI 10.1242/jcs.00705; Critchley DR, 2004, BIOCHEM SOC T, V32, P831, DOI 10.1042/BST0320831; de Pereda JM, 2005, J BIOL CHEM, V280, P8381, DOI 10.1074/jbc.M413180200; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; FERNANDEZ JLR, 1992, CELL MOTIL CYTOSKEL, V22, P127, DOI 10.1002/cm.970220206; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Fillingham I, 2005, STRUCTURE, V13, P65, DOI 10.1016/j.str.2004.11.006; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Giannone G, 2003, J CELL BIOL, V163, P409, DOI 10.1083/jcb.200302001; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Gingras AR, 2005, J BIOL CHEM, V280, P37217, DOI 10.1074/jbc.M508060200; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; Hemmings L, 1996, J CELL SCI, V109, P2715; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; Izard T, 2004, J BIOL CHEM, V279, P27667, DOI 10.1074/jbc.M403076200; Izard T, 2004, NATURE, V427, P171, DOI 10.1038/nature02281; Jiang GY, 2003, NATURE, V424, P334, DOI 10.1038/nature01805; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Lee HS, 2004, J MOL BIOL, V343, P771, DOI 10.1016/j.jmb.2004.08.069; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCLACHLAN AD, 1994, J MOL BIOL, V235, P1278, DOI 10.1006/jmbi.1994.1081; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Monkley SJ, 2000, DEV DYNAM, V219, P560, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1079>3.0.CO;2-Y; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Morgan JR, 2004, J CELL BIOL, V167, P43, DOI 10.1083/jcb.200406020; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; OTEY CA, 1993, J BIOL CHEM, V268, P21193; Papagrigoriou E, 2004, EMBO J, V23, P2942, DOI 10.1038/sj.emboj.7600285; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Schmidt JM, 1999, ARCH BIOCHEM BIOPHYS, V366, P139, DOI 10.1006/abbi.1999.1204; SEALOCK R, 1986, EXP CELL RES, V163, P143, DOI 10.1016/0014-4827(86)90566-5; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; TIDBALL JG, 1986, J CELL BIOL, V103, P1465, DOI 10.1083/jcb.103.4.1465; Torgler CN, 2004, DEV CELL, V6, P357, DOI 10.1016/S1534-5807(04)00055-3; Tremuth L, 2004, J BIOL CHEM, V279, P22258, DOI 10.1074/jbc.M400947200; VOLBERG T, 1986, J MUSCLE RES CELL M, V7, P375; VOLBERG T, 1995, J CELL SCI, V108, P2253; Winkler J, 1997, EUR J BIOCHEM, V243, P430, DOI 10.1111/j.1432-1033.1997.0430a.x; Xu WM, 1998, DEVELOPMENT, V125, P327; Xu WM, 1998, J CELL SCI, V111, P1535; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	68	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7458	7467		10.1074/jbc.M508058200	http://dx.doi.org/10.1074/jbc.M508058200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407302	Green Submitted, hybrid			2022-12-25	WOS:000236030900068
J	Boucher, MJ; Selander, L; Carlsson, L; Edlund, H				Boucher, MJ; Selander, L; Carlsson, L; Edlund, H			Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; RECEPTOR-RELATED PROTEIN-5; DNA-BINDING ACTIVITY; OXIDATIVE STRESS; FACTOR PDX-1; C-JUN; MEDIATED SUPPRESSION; UPSTREAM FACTOR-1; DIABETES-MELLITUS; PROMOTER ACTIVITY	The transcription factor IPF1/PDX1 plays a crucial role in both pancreas development and maintenance of beta-cell function. Targeted disruption of this transcription factor in beta-cells leads to diabetes, whereas reduced expression levels affect insulin expression and secretion. Therefore, it is essential to determine molecular mechanisms underlying the regulation of this key transcription factor on mRNA levels and, most importantly, on protein levels. Here we show that a minor portion of IPF1/PDX1 is phosphorylated on serine 61 and/or serine 66 in pancreatic beta-cells. This phosphorylated form of IPF1/PDX1 preferentially accumulates following proteasome inhibition, an effect that is prevented by inhibition of glycogen synthase kinase 3 (GSK3) activity. Oxidative stress, which is associated with the diabetic state, (i) increases IPF1/PDX1 Ser(61) and/or Ser(66) phosphorylation and (ii) increases the degradation rate and decreases the half-life of IPF-1/PDX-1 protein. In addition, we provide evidence that GSK3 activity participates in oxidative stress-induced effects on beta-cells. Thus, this current study uncovers a new mechanism that might contribute to diminished levels of IPF1/ PDX1 protein and beta-cell dysfunction during the progression of diabetes.	Umea Univ, Umea Ctr Mol Med, SE-90187 Umea, Sweden	Umea University	Boucher, MJ (corresponding author), Umea Univ, Umea Ctr Mol Med, SE-90187 Umea, Sweden.	marie-josee.boucher@ucmm.umu.se; helena.edlund@ucmm.umu.se		Boucher, Marie-Josee/0000-0002-7615-3121; Edlund, Helena/0000-0002-3553-7348				Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ahren B, 1997, METABOLISM, V46, P97, DOI 10.1016/S0026-0495(97)90175-X; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; Cockburn BN, 2004, J CLIN ENDOCR METAB, V89, P971, DOI 10.1210/jc.2003-031282; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Elbein SC, 2004, DIABETES CARE, V27, P1968, DOI 10.2337/diacare.27.8.1968; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Engler TA, 2005, BIOORG MED CHEM LETT, V15, P899, DOI 10.1016/j.bmcl.2004.12.063; Fernandez-Alvarez J, 2004, DIABETOLOGIA, V47, P470, DOI 10.1007/s00125-004-1332-8; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hansen L, 2000, J CLIN ENDOCR METAB, V85, P1323, DOI 10.1210/jc.85.3.1323; Harada Y, 2005, J BIOL CHEM, V280, P31714, DOI 10.1074/jbc.M506225200; Harmon JS, 2005, J BIOL CHEM, V280, P11107, DOI 10.1074/jbc.M410345200; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Henriksen EJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE892, DOI 10.1152/ajpendo.00346.2002; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Kim AJ, 2005, J CELL SCI, V118, P89, DOI 10.1242/jcs.01562; Kishi A, 2003, AM J PHYSIOL-ENDOC M, V284, pE830, DOI 10.1152/ajpendo.00390.2002; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Lebrun P, 2005, J BIOL CHEM, V280, P38203, DOI 10.1074/jbc.M504842200; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Quelo I, 2004, BIOCHEMISTRY-US, V43, P2906, DOI 10.1021/bi036256+; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Redmon JB, 1996, J CLIN INVEST, V98, P2786, DOI 10.1172/JCI119105; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sayo Y, 2000, EUR J BIOCHEM, V267, P971, DOI 10.1046/j.1432-1327.2000.01080.x; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Stanojevic V, 2005, MOL CELL ENDOCRINOL, V237, P67, DOI 10.1016/j.mce.2005.03.003; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Thomas MK, 1999, MOL CELL BIOL, V19, P8492; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wagman AS, 2004, CURR PHARM DESIGN, V10, P1105, DOI 10.2174/1381612043452668; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	66	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6395	6403		10.1074/jbc.M511597200	http://dx.doi.org/10.1074/jbc.M511597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407209	hybrid			2022-12-25	WOS:000236030800033
J	Gang, L; Kang, YJ; Han, JH; Herschman, HR; Stefani, E; Wang, YB				Gang, L; Kang, YJ; Han, JH; Herschman, HR; Stefani, E; Wang, YB			TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENCODED FLUORESCENT REPORTER; CARDIAC MYOCYTES; CYCLOOXYGENASE-2 EXPRESSION; INDEPENDENT ACTIVATION; LIVING CELLS; IN-VITRO; STRESS; HEART; PATHWAYS	Stress-activated mitogen-activated protein (MAP) kinase p38 mediates stress signaling in mammalian cells via threonine and tyrosine phosphorylation in its conserved TGY motif by upstream MAP kinase kinases (MKKs). In addition, p38 MAP kinase can also be activated by an MKK-independent mechanism involving TAB-1 (TAK-1-binding protein)-mediated autophosphorylation. Although TAB-1-mediated p38 activation has been implicated in ischemic heart, the biological consequences and downstream signaling of TAB-1-mediated p38 activation in cardiomyocytes is largely unknown. We show here that TAB-1 expression leads to a significant induction of p38 autophosphorylation and consequent kinase activation in cultured neonatal cardiomyocytes. In contrast to MKK3-induced p38 kinase downstream effects, TAB-1-induced p38 kinase activation does not induce expression of pro-inflammatory genes, cardiac marker gene expression, or changes in cellular morphology. Rather, TAB-1 binds to p38 and prevents p38 nuclear localization. Furthermore, TAB-1 disrupts p38 interaction with MKK3 and redirects p38 localization in the cytosol. Consequently, TAB-1 expression antagonizes the downstream activity of p38 kinase induced by MKK3 and attenuates interleukin-1 beta-induced inflammatory gene induction in cardiomyocytes. These data suggest that TAB-1 can mediate MKK-independent p38 kinase activation while negatively modulating MKK-dependent p38 function. Our study not only redefines the functional role of TAB-1 in p38 kinase-mediated signaling pathways but also provides the first evidence that intracellular localization of p38 kinase and complex interaction dictates its downstream effects. These results suggest a previously unknown mechanism for stress-MAP kinase regulation in mammalian cells.	Univ Calif Los Angeles, Dept Anesthesiol & Med, Div Mol Med, CSH,David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Pharmacol & Biol Chem, Div Mol Med, CSH,David Geffen Sch Med, Los Angeles, CA 90095 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Scripps Research Institute	Wang, YB (corresponding author), Univ Calif Los Angeles, Dept Anesthesiol & Med, Div Mol Med, CSH,David Geffen Sch Med, BH-569, Los Angeles, CA 90095 USA.	yibinwang@mednet.ucla.edu	Han, J/G-4671-2010	Wang, Yibin/0000-0003-0852-0767	NCI NIH HHS [R01 CA 84572] Funding Source: Medline; NHLBI NIH HHS [HL 62311, HL 08111] Funding Source: Medline; NIAID NIH HHS [AI 41637] Funding Source: Medline; NIGMS NIH HHS [GM 037696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogoyevitch MA, 2000, CARDIOVASC RES, V45, P826, DOI 10.1016/S0008-6363(99)00386-7; Chen CA, 2004, BBA-PROTEINS PROTEOM, V1697, P39, DOI 10.1016/j.bbapap.2003.11.012; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Degousee N, 2003, CIRC RES, V92, P757, DOI 10.1161/01.RES.0000067929.01404.03; Dinarello CA, 2001, BLOOD PURIFICAT, V19, P314, DOI 10.1159/000046960; Force T, 1999, GENE EXPRESSION, V7, P337; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Herschman HR, 1999, ADV EXP MED BIOL, V469, P3; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Komatsu Y, 2002, MECH DEVELOP, V119, P239, DOI 10.1016/S0925-4773(02)00391-X; Kunkel MT, 2005, J BIOL CHEM, V280, P5581, DOI 10.1074/jbc.M411534200; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10; Li MX, 2005, CIRCULATION, V111, P2494, DOI 10.1161/01.CIR.0000165117.71483.0C; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Liao P, 2002, CIRC RES, V90, P190, DOI 10.1161/hh0202.104220; Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Morrison DK, 2001, J CELL SCI, V114, P1609; Ohkusu-Tsukada K, 2004, MOL CELL BIOL, V24, P6957, DOI 10.1128/MCB.24.16.6957-6966.2004; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Schuette R, 2000, AM J PHYSIOL-HEART C, V279, pH719, DOI 10.1152/ajpheart.2000.279.2.H719; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sugden PH, 2001, ANN MED, V33, P611; Tanno M, 2003, CIRC RES, V93, P254, DOI 10.1161/01.RES.0000083490.43943.85; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	39	61	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6087	6095		10.1074/jbc.M507610200	http://dx.doi.org/10.1074/jbc.M507610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407200	hybrid			2022-12-25	WOS:000235568900090
J	Kim, E; Yamashita, M; Nakanishi, T; Park, KE; Kimura, M; Kashiwabara, S; Baba, T				Kim, E; Yamashita, M; Nakanishi, T; Park, KE; Kimura, M; Kashiwabara, S; Baba, T			Mouse sperm lacking ADAM1b/ADAM2 fertilin can fuse with the egg plasma membrane and effect fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEASE-DISINTEGRINS; MAMMALIAN FERTILIZATION; POLY(A) POLYMERASE; ANCHORED PROTEIN; EPIDIDYMAL SPERM; GENE FAMILY; MALE-MICE; SURFACE; FUSION; CALMEGIN	Fertilin, a heterodimeric protein complex composed of alpha (ADAM1) and beta (ADAM2) subunits on the sperm surface, is believed to mediate adhesion and fusion between the sperm and egg plasma membranes. Here we have shown that mutant male mice lacking ADAM1b are fertile and that the loss of ADAM1b results in no significant defect in sperm functions such as migration from the uterus into oviduct, binding to egg zona pellucida, and fusion with zona pellucida-free eggs. ADAM1b-deficient epididymal sperm showed a severe reduction of ADAM2 on the cell surface, despite the normal presence of ADAM2 in testicular germ cells. The appearance of ADAM1b and ADAM2 on the sperm surface depended on formation and abundance of ADAM1b/ADAM2 fertilin in testicular germ cells. These results suggest that mouse ADAM1b/ADAM2 fertilin may play a crucial role not in the sperm/ egg fusion but in the appearance of these two ADAMs on the sperm surface.	Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Baba, T (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba Sci City, Tsukuba, Ibaraki 3058572, Japan.	acroman@sakura.cc.tsukuba.ac.jp						Baba D, 2002, J BIOL CHEM, V277, P30310, DOI 10.1074/jbc.M204596200; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Cho CH, 1998, SCIENCE, V281, P1857, DOI 10.1126/science.281.5384.1857; Evans JP, 2002, HUM REPROD UPDATE, V8, P297, DOI 10.1093/humupd/8.4.297; He ZY, 2003, DEV BIOL, V254, P226, DOI 10.1016/S0012-1606(02)00043-X; Honda A, 2002, J BIOL CHEM, V277, P16976, DOI 10.1074/jbc.M112470200; Ikawa M, 2001, DEV BIOL, V240, P254, DOI 10.1006/dbio.2001.0462; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Kashiwabara S, 2002, SCIENCE, V298, P1999, DOI 10.1126/science.1074632; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; Kim E, 2004, J REPROD DEVELOP, V50, P571, DOI 10.1262/jrd.50.571; Kim E, 2003, BIOCHEM BIOPH RES CO, V304, P313, DOI 10.1016/S0006-291X(03)00588-6; KIM T, 2006, BIOL REPROD; Kondoh G, 2005, NAT MED, V11, P160, DOI 10.1038/nm1179; Nakanishi T, 2004, BIOL REPROD, V71, P959, DOI 10.1095/biolreprod.104.028647; Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200; Nishimura H, 2002, GENE, V291, P67, DOI 10.1016/S0378-1119(02)00540-1; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shamsadin R, 1999, BIOL REPROD, V61, P1445, DOI 10.1095/biolreprod61.6.1445; Stein KK, 2005, BIOL REPROD, V73, P1032, DOI 10.1095/biolreprod.105.040972; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yamagata K, 2002, DEV BIOL, V250, P348, DOI 10.1006/dbio.2002.0803; YAMAGIMACHI R, 1994, PHYSL REPROD, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]	32	61	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5634	5639		10.1074/jbc.M510558200	http://dx.doi.org/10.1074/jbc.M510558200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407235	hybrid			2022-12-25	WOS:000235568900039
J	Matsukawa, A; Kudoh, S; Sano, G; Maeda, T; Ito, T; Lukacs, NW; Hogaboam, CM; Kunkel, SL; Lira, SA				Matsukawa, Akihiro; Kudoh, Shinji; Sano, Gen-ichiro; Maeda, Takako; Ito, Takaaki; Lukacs, Nicholas W.; Hogaboam, Cory M.; Kunkel, Steven L.; Lira, Sergio A.			Absence of CC chemokine receptor 8 enhances innate immunity during septic peritonitis	FASEB JOURNAL			English	Article									[Matsukawa, Akihiro; Kudoh, Shinji; Maeda, Takako; Ito, Takaaki] Kumamoto Univ, Grad Sch Med Sci, Dept Pathol & Expt Med, Kumamoto 8608556, Japan; [Lukacs, Nicholas W.; Hogaboam, Cory M.; Kunkel, Steven L.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; [Sano, Gen-ichiro; Lira, Sergio A.] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY USA	Kumamoto University; University of Michigan System; University of Michigan; Icahn School of Medicine at Mount Sinai	Matsukawa, A (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Pathol & Expt Med, 1-1-1 Honjo, Kumamoto 8608556, Japan.	matsu@kaiju.medic.kumamoto-u.ac.jp	hogaboam, cory/M-3578-2014; Hogaboam, Cory M./AAI-1433-2021; Lukacs, Nicholas W/ABH-5583-2020	Hogaboam, Cory M./0000-0003-3366-4850; Matsukawa, Akihiro/0000-0002-5081-6089	NHLBI NIH HHS [P50-HL074024, R01-HL031237] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL074024, R01HL031237] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))			0	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					302	304		10.1096/fj.04-1728fje	http://dx.doi.org/10.1096/fj.04-1728fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16384913	Green Published			2022-12-25	WOS:000207915000001
J	Serbest, G; Horwitz, J; Jost, M; Barbee, K				Serbest, Gulyeter; Horwitz, Joel; Jost, Monika; Barbee, Kenneth			Mechanisms of cell death and neuroprotection by poloxamer 188 after mechanical trauma	FASEB JOURNAL			English	Article									[Serbest, Gulyeter; Barbee, Kenneth] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Jost, Monika] Drexel Univ, Coll Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	Drexel University; Drexel University	Barbee, K (corresponding author), Sch Biomed Engn, 3141 Chestnut St, Philadelphia, PA 19104 USA.	barbee@drexel.edu	Barbee, Kenneth/F-4333-2014						0	74	80	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					308	310		10.1096/fj.05-4024fje	http://dx.doi.org/10.1096/fj.05-4024fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371428				2022-12-25	WOS:000207915000003
J	Clavreul, N; Adachi, T; Pimental, DR; Ido, Y; Schoneich, C; Cohen, RA				Clavreul, N; Adachi, T; Pimental, DR; Ido, Y; Schoneich, C; Cohen, RA			S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells	FASEB JOURNAL			English	Article						glutathione; oxidized low-density lipoproteins; thiol	GUANINE-NUCLEOTIDE EXCHANGE; NITRIC-OXIDE; OXIDATIVE MODIFICATION; HYDROGEN-PEROXIDE; STRUCTURAL BASIS; RAS; PROTEINS; P21(RAS); IDENTIFICATION; NITROSYLATION	The highly reactive species, peroxynitrite, is produced in endothelial cells in pathological states in which the production of superoxide anion and NO is increased. Here, we show that peroxynitrite added exogenously or generated endogenously in response to exposure to an NO donor or oxidized low-density lipoproteins (oxLDL) increases p21ras activity in bovine aortic endothelial cells. The activation is not dependent on upstream elements but rather is due to direct targeting of p21ras by reversible S-glutathiolation of cysteine thiols as demonstrated by biotin-labeling techniques. The time course of p21ras S-glutathiolation following peroxynitrite corresponds to the increase in its Raf-1 binding activity and translocation to the membrane. Moreover, p21ras S-glutathiolation and activation can be reversed by dithiothreitol, confirming the importance of a disulfide bond. S-glutathiolation also promoted guanine nucleotide exchange of recombinant p21ras. In addition, the oxidant-induced activation of Mek/Erk and PI3 kinase/Akt was abrogated by dominant-negative and Cys-118p21ras mutants, and the latter also prevented S-glutathiolation of p21ras. These results indicate that peroxynitrite arising from NO donors or pathological stimuli such as oxLDL triggers direct S-glutathiolation of p21ras Cys-118, which increases p21ras activity and mediates downstream signaling.	Boston Univ, Med Ctr, Dept Med, Vasc Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Myocardial Biol Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Diabet & Metab Unit, Boston, MA 02118 USA; Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Tokyo 108, Japan; Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66045 USA	Boston University; Boston University; Boston University; Keio University; University of Kansas	Cohen, RA (corresponding author), Boston Univ, Med Ctr, Dept Med, Vasc Biol Unit, Boston, MA 02118 USA.	racohen@bu.edu		Ido, Yasuo/0000-0002-3036-9971; /0000-0002-1070-6408	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081587, P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012993, R01AG027080] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL-81587, HL-68758, N01-HV-28178] Funding Source: Medline; NIA NIH HHS [AG-27080, P01 AG 12993] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi T, 2004, NAT MED, V10, P1200, DOI 10.1038/nm1119; Adachi T, 2004, J BIOL CHEM, V279, P29857, DOI 10.1074/jbc.M313320200; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Go YM, 2001, AM J PHYSIOL-HEART C, V281, pH2705, DOI 10.1152/ajpheart.2001.281.6.H2705; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Heo J, 2005, J BIOL CHEM, V280, P12438, DOI 10.1074/jbc.M414282200; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kuster GM, 2005, CIRCULATION, V111, P1192, DOI 10.1161/01.CIR.0000157148.59308.F5; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Moellering DR, 2002, BIOCHEM J, V362, P51, DOI 10.1042/0264-6021:3620051; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; SCHONEICH C, 1995, METHOD ENZYMOL, V251, P45, DOI 10.1016/0076-6879(95)51109-1; Stepp DW, 2002, AM J PHYSIOL-HEART C, V283, pH750, DOI 10.1152/ajpheart.00029.2002; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Yang Y, 2005, P NATL ACAD SCI USA, V102, P117, DOI 10.1073/pnas.0405989102; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zmijewski JW, 2005, AM J PHYSIOL-HEART C, V289, pH852, DOI 10.1152/ajpheart.00015.2005; Zou MH, 2002, DIABETES, V51, P198, DOI 10.2337/diabetes.51.1.198; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	35	114	115	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					518	+		10.1096/fj.05-4875fje	http://dx.doi.org/10.1096/fj.05-4875fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16415107				2022-12-25	WOS:000235996000017
J	Grossin, L; Cournil-Henrionnet, C; Pinzano, A; Gaborit, N; Dumas, D; Etienne, S; Stoltz, JF; Terlain, B; Netter, P; Mir, LM; Gillet, P				Grossin, L; Cournil-Henrionnet, C; Pinzano, A; Gaborit, N; Dumas, D; Etienne, S; Stoltz, JF; Terlain, B; Netter, P; Mir, LM; Gillet, P			Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis	FASEB JOURNAL			English	Article						gene delivery; patellar cartilage; apoptosis; MIA	NITRIC-OXIDE SYNTHASE; HEAT-SHOCK PROTEINS; ARTICULAR-CARTILAGE; INDUCED APOPTOSIS; ANIMAL-MODELS; DOSE-RESPONSE; CELL-DEATH; VIVO; EXPRESSION; CASPASE-3	Osteoarthritis is characterized by a gradual degradation of extracellular matrix, resulting from an excess of chondrocyte cell death, mainly due to an increase in apoptotis. Recent studies have revealed the essential role of HSP70 in protecting cells from stressful stimuli. Therefore, overexpressing HSP70 in chondrocytes could represent a good strategy to prevent extracellular matrix destruction. To this end, we have developed a vector carrying HSP70/GFP, and transduced chondrocytes were thus more resistant to cell death induced by mono-iodoacetate (MIA). To overcome the barrier-effect of matrix, we investigated the efficacy of plasmid delivery by electroporation (EP) in rat patellar cartilage. Two days after EP, 50% of patellar chondrocytes were HSP/GFP+. After 3 months, long-term expression of transgene was only depicted in the deep layer (20-30% positive cells). HSP70 overexpression inhibited the natural endochondral ossification in the deep layer, thus leading to a lesser decrease in chondrocyte distribution. Moreover, overexpression of HSP70, after a preventive EP transfer in rat patella, was sufficient to decrease the severity of osteoarthritis-induced lesions, as demonstrated histologically and biochemically. In conclusion, intracellular overexpression of HSP70, through EP delivery, could protect chondrocytes from cellular injuries and thus might be a novel chondroprotective modality in rat OA.-Grossin, L., Cournil-Henrionnet, C., Pinzano, A., Gaborit, N., Dumas, D., Etienne, S., Stoltz, J. F., Terlain, B., Netter, P., Mir, L. M., Gillet, P. Gene transfer with HSP 70 in rat chondrocytes confers cytoprotection in vitro and during experimental osteoarthritis.	Univ Nancy 1, Fac Med Vandoeuvre Nancy, CNRS, UMR 7561, F-54505 Vandoeuvre Les Nancy, France; Inst Gustave Roussy, CNRS, UMR 8121, Villejuif, France; Univ Nancy 1, Fac Med Vandoeuvre Nancy, CNRS, UMR 7563,LEMTA, F-54505 Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Lorraine	Gillet, P (corresponding author), Univ Nancy 1, Fac Med Vandoeuvre Nancy, CNRS, UMR 7561, Ave Foret Haye,BP184, F-54505 Vandoeuvre Les Nancy, France.	Pierre.Gillet@medecine.uhp-nancy.fr	Gaborit, Nadège A/O-7825-2017; Dumas, Dominique DD/A-5633-2012; PINZANO, Astrid/ABD-5162-2020; MIR, Lluis M/AAJ-9110-2020	PINZANO, Astrid/0000-0002-3867-2676; Cournil, Christel/0000-0002-4827-4276; Christel, HENRIONNET/0000-0001-7484-0377; GILLET, Pierre/0000-0002-0598-7508; GROSSIN, Laurent/0000-0001-6761-0936				Aigner T, 2002, J PATHOL, V198, P1, DOI 10.1002/path.1172; Aigner T, 2002, ARTHRITIS RHEUM-US, V46, P1986, DOI 10.1002/art.10554; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bloquel C, 2004, J GENE MED, V6, pS11, DOI 10.1002/jgm.508; BOILEAU C, 2002, FUNDAM CLIN PHARM S1, V16, pA47; Bove SE, 2003, OSTEOARTHR CARTILAGE, V11, P821, DOI 10.1016/S1063-4584(03)00163-8; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Dumond H, 2004, OSTEOARTHR CARTILAGE, V12, P284, DOI 10.1016/j.joca.2003.11.008; Galois L, 2004, OSTEOARTHR CARTILAGE, V12, P779, DOI 10.1016/j.joca.2004.06.008; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Grogan SP, 2002, J PATHOL, V198, P5, DOI 10.1002/path.1169; Grossin L, 2004, BIORHEOLOGY, V41, P521; Grossin L, 2003, FASEB J, V17, P829, DOI 10.1096/fj.02-0518com; GROSSIN L, 2003, ARTHRITIS RES THE S3, V5, P53; Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917; Gutmann B, 2002, NEUROTOX RES, V4, P59, DOI 10.1080/10298420290007637; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1266, DOI 10.1002/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Janusz MJ, 2001, OSTEOARTHR CARTILAGE, V9, P751, DOI 10.1053/joca.2001.0472; Jouzeau JY, 2000, JOINT BONE SPINE, V67, P565, DOI 10.1016/S1297-319X(00)00214-1; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; Kouri-Floras JB, 2002, ULTRASTRUCT PATHOL, V26, P33, DOI 10.1080/01913120252934314; Kuhn K, 2004, OSTEOARTHR CARTILAGE, V12, P1, DOI 10.1016/j.joca.2003.09.015; Lee SW, 2004, ARTHRITIS RHEUM-US, V50, P534, DOI 10.1002/art.20052; Loeuille D, 1997, J RHEUMATOL, V24, P133; Malemud CJ, 2003, CELLS TISSUES ORGANS, V174, P34, DOI 10.1159/000070573; Malhotra R, 1999, J BIOL CHEM, V274, P12567, DOI 10.1074/jbc.274.18.12567; MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623-197153030-00009; Matsuo M, 2001, ACTA MED OKAYAMA, V55, P333; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Nuttall ME, 2000, J ORTHOPAED RES, V18, P356, DOI 10.1002/jor.1100180306; Okubo S, 2001, CIRCULATION, V103, P877, DOI 10.1161/01.CIR.103.6.877; Pelletier JP, 2003, CLIN EXP RHEUMATOL, V21, P171; Pelletier JP, 2000, ARTHRITIS RHEUM-US, V43, P1290, DOI 10.1002/1529-0131(200006)43:6<1290::AID-ANR11>3.0.CO;2-R; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saied A, 1997, J BONE MINER RES, V12, P1378, DOI 10.1359/jbmr.1997.12.9.1378; Sharif M, 2004, ARTHRITIS RHEUM-US, V50, P507, DOI 10.1002/art.20020; Sironen RK, 2002, BBA-MOL CELL RES, V1591, P45, DOI 10.1016/S0167-4889(02)00247-1; Sperling O, 2003, NEUROSCI LETT, V351, P137, DOI 10.1016/S0304-3940(03)00858-9; Suzuki K, 1997, J CLIN INVEST, V99, P1645, DOI 10.1172/JCI119327; Takahashi K, 1997, OSTEOARTHR CARTILAGE, V5, P321, DOI 10.1016/S1063-4584(97)80036-2; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Terauchi R, 2003, ARTHRITIS RHEUM-US, V48, P1562, DOI 10.1002/art.11040; Tiffee JC, 2000, TISSUE CELL, V32, P141, DOI 10.1054/tice.2000.0097; van den Berg WB, 2001, CURR OPIN RHEUMATOL, V13, P452, DOI 10.1097/00002281-200109000-00019; Weiss YG, 2002, J CLIN INVEST, V110, P801, DOI 10.1172/JCI200215888	47	49	53	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					65	75		10.1096/fj.04-2889com	http://dx.doi.org/10.1096/fj.04-2889com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394269				2022-12-25	WOS:000235996000046
J	Jin, LM; Liu, TY; Lagoda, GA; Champion, HC; Bivalacqua, TJ; Burnett, AL				Jin, LM; Liu, TY; Lagoda, GA; Champion, HC; Bivalacqua, TJ; Burnett, AL			Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction	FASEB JOURNAL			English	Article						erection; corpus cavernosum; smooth muscle; myosin light chain phosphatase	NITRIC-OXIDE SYNTHASE; GENE-TRANSFER; MYOSIN PHOSPHATASE; SIGNALING PATHWAY; SMOOTH-MUSCLE; PHOSPHORYLATION; INHIBITION; PROTEIN; PHYSIOLOGY; VASOCONSTRICTION	Epidemiologic studies have shown that aging accounts significantly for the prevalence of erectile dysfunction (ED). The pathophysiology of ED during aging and its underlying molecular mechanisms are largely unknown. We hypothesized that increased RhoA/Rho-kinase signaling is a major factor in the pathogenesis of age-associated ED and the mechanism involves increased penile smooth muscle contractility through inhibition of myosin light chain phosphatase. Male Fischer 344 young (4 month old) and aged (20-22 month old) rats underwent erectile function testing in vivo by measuring intracavernosal pressure (ICP) and mean arterial blood pressure (MAP) upon electrical stimulation of the cavernous nerve. The data demonstrated that erectile function was significantly lower in aged rats than that in young rats at all voltages tested (P < 0.05). Western blot analysis results showed that there were no significant changes in protein expressions of RhoA, Rho-kinase-alpha and -beta isoforms, and myosin light chain phosphatase target subunit (MYPT1); however, membrane-bound RhoA and phosphorylated MYPT1 were increased in aged rat penes by 95 +/- 15 and 56 +/- 8% (P < 0.05), respectively, indicating enhanced RhoA and Rho-kinase activity. Inhibition of Rho-kinase with Y27632 maximally increased ICP/MAP to 0.72 +/- 0.05 in aged rats vs. 0.47 +/- 0.06 in young rats (P < 0.05). Gene transfer of adeno-associated virus (AAV) encoding dominant negative RhoA (T19NRhoA) to penes of aged and young rats for 7 days markedly improved erectile function in aged rats when compared with that in young rats (P < 0.05). These observations were also supported by Rho-kinase activity assay results showing that basal Rho-kinase activity in aged rat penes receiving AAV vehicle treatment was twofold greater than that in young rat penes receiving AAV vehicle treatment, while it was reduced to a level similar to that in young rat penes after gene therapy of T19NRhoA (P < 0.05). Taken together, these data suggest that impaired erectile function during the aging process involves increased RhoA/Rho-kinase signaling, and this pathway may be exploited for the treatment of age-associated ED.	Johns Hopkins Univ, Dept Urol, Baltimore, MD 21287 USA	Johns Hopkins University	Burnett, AL (corresponding author), Johns Hopkins Univ, Dept Urol, 600 N Wolfe St, Baltimore, MD 21287 USA.	aburnett@jhmi.edu			NIDDK NIH HHS [DK-67223, DK-02568] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067223, K08DK002568] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON KE, 1995, PHYSIOL REV, V75, P191, DOI 10.1152/physrev.1995.75.1.191; Aytac IA, 1999, BJU INT, V84, P50; Bivalacqua TJ, 2000, INT J IMPOT RES, V12, pS8, DOI 10.1038/sj.ijir.3900556; Bivalacqua TJ, 2004, P NATL ACAD SCI USA, V101, P9121, DOI 10.1073/pnas.0400520101; Bivalacqua TJ, 2003, J ANDROL, V24, pS17; BURNETT AL, 1995, BIOL REPROD, V52, P485, DOI 10.1095/biolreprod52.3.485; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; Carrier S, 1997, J UROLOGY, V157, P1088, DOI 10.1016/S0022-5347(01)65147-4; Champion HC, 1999, P NATL ACAD SCI USA, V96, P11648, DOI 10.1073/pnas.96.20.11648; Chang S, 2003, INT J IMPOT RES, V15, P53, DOI 10.1038/sj.ijir.3900947; Chitaley K, 2002, BIOCHEM BIOPH RES CO, V298, P427, DOI 10.1016/S0006-291X(02)02458-0; Chitaley K, 2001, NAT MED, V7, P119, DOI 10.1038/83258; Eto M, 2001, J BIOL CHEM, V276, P29072, DOI 10.1074/jbc.M103206200; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; GIVALACQUA TJ, 2003, AM J PHYSIOL-HEART C, V284, pH1408; Gonzalez-Cadavid NF, 2004, EXP GERONTOL, V39, P1705, DOI 10.1016/j.exger.2004.06.022; Jin LM, 2004, AM J PHYSIOL-HEART C, V287, pH1495, DOI 10.1152/ajpheart.01006.2003; Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1; Jones R W A, 2002, Expert Opin Pharmacother, V3, P889; Magee TR, 2002, BIOL REPROD, V67, P20, DOI 10.1093/biolreprod/67.1.20; Miao LY, 2001, MECH AGEING DEV, V122, P1757, DOI 10.1016/S0047-6374(01)00297-4; Mills TM, 2002, EUR J PHARMACOL, V439, P173, DOI 10.1016/S0014-2999(02)01408-5; Mills TM, 2001, J APPL PHYSIOL, V91, P1269, DOI 10.1152/jappl.2001.91.3.1269; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Musicki B, 2005, J SEX MED, V2, P347, DOI 10.1111/j.1743-6109.2005.20349.x; Rajasekaran M, 2005, J ANDROL, V26, P182; Rajasekaran M, 2002, J ANDROL, V23, P393; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Seko T, 2003, CIRC RES, V92, P411, DOI 10.1161/01.RES.0000059987.90200.44; SNYDER RO, 1996, VECTORS GENE THERAPY; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Wingard CJ, 2003, AM J PHYSIOL-REG I, V285, pR1145, DOI 10.1152/ajpregu.00329.2003	35	79	90	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					536	+		10.1096/fj.05-4232fje	http://dx.doi.org/10.1096/fj.05-4232fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16396994				2022-12-25	WOS:000235996000034
J	Matsumoto, SC; Labovsky, V; Roncoroni, M; Guida, MAC; Gimenez, L; Mitelman, J; Gori, H; Jurgelevicius, R; Grillo, A; Manfredi, P; Levin, MJ; Paveto, C				Matsumoto, SC; Labovsky, V; Roncoroni, M; Guida, MAC; Gimenez, L; Mitelman, J; Gori, H; Jurgelevicius, R; Grillo, A; Manfredi, P; Levin, MJ; Paveto, C			Retinal dysfunction in patients with chronic Chagas' disease is associated to anti-Trypanosoma cruzi antibodies that crossreact with rhodopsin	FASEB JOURNAL			English	Article						electroretinography; rod dysfunction	IDIOPATHIC DILATED CARDIOMYOPATHY; HUMAN BETA-1-ADRENERGIC RECEPTOR; RIBOSOMAL P2-BETA PROTEIN; HEART-DISEASE; MONOCLONAL-ANTIBODY; AMERICAN TRYPANOSOMIASIS; AUTOIMMUNITY HYPOTHESIS; ADRENERGIC-RECEPTOR; P PROTEINS; EPITOPE	To investigate retinal involvement in chronic Chagas' disease, we performed electroretinography and retinal fluorescein angiography studies in chagasic patients. Our results demonstrated a dissociated electrophysiological response characterized by both an abnormal reduction of the electroretinographic b-wave amplitude and a delayed latency, under the dark-adaptated condition. These alterations are compatible with a selective dysfunction of the rods. Antibodies raised against Trypanosoma cruzi that also interact with beta 1-adrenergic receptor blocked light stimulation of cGMP-phosphodiesterase in bovine rod membranes. The specificity from the antibody-rhodopsin interaction was confirmed by Western blot analysis and antigenic competition experiments. Our results suggest an immunomediated rhodopsin blockade. T. cruzi infection probably induces an autoimmune response against rhodopsin in the chronic phase of Chagas' disease through a molecular mimicry mechanism similar to that described previously on cardiac human beta 1-adrenergic and M2-cholinergic receptors, all related to the same subfamily of G-protein-coupled receptors.	Univ Buenos Aires, CONICET, Inst Invest Ingn Genet & Biol Mol, RA-1428 Buenos Aires, DF, Argentina; Hosp Dr Teodoro Alvarez, Dept Neurol, RA-1406 Buenos Aires, DF, Argentina; Hosp Dr Teodoro Alvarez, Dept Ophthalmol, RA-1406 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Paveto, C (corresponding author), Univ Buenos Aires, CONICET, Inst Invest Ingn Genet & Biol Mol, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	cpaveto@dna.uba.ar						ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Bergami PL, 2001, FASEB J, V15, P2602, DOI 10.1096/fj.01-0132com; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cha KW, 2000, P NATL ACAD SCI USA, V97, P3016, DOI 10.1073/pnas.97.7.3016; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Elies R, 1998, EUR J BIOCHEM, V251, P659, DOI 10.1046/j.1432-1327.1998.2510659.x; Engman DM, 2002, ACTA TROP, V81, P123, DOI 10.1016/S0001-706X(01)00202-9; FARBER DB, 1976, J CYCLIC NUCL PROT, V2, P139; FERRARI I, 1995, J EXP MED, V182, P59, DOI 10.1084/jem.182.1.59; Freedman NJ, 2004, J CLIN INVEST, V113, P1379, DOI 10.1172/JCI200421748; Frohlich SJ, 1998, OPHTHALMOLOGE, V95, P168, DOI 10.1007/s003470050257; Frohlich SJ, 1997, OPHTHALMOLOGE, V94, P206, DOI 10.1007/s003470050103; Galfre G, 1981, Methods Enzymol, V73, P3; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Kaplan D, 1997, P NATL ACAD SCI USA, V94, P10301, DOI 10.1073/pnas.94.19.10301; KHORANA HG, 1992, J BIOL CHEM, V267, P1; Kierszenbaum F, 1999, CLIN MICROBIOL REV, V12, P210, DOI 10.1128/CMR.12.2.210; Kierszenbaum F, 2003, FEMS IMMUNOL MED MIC, V37, P1, DOI 10.1016/S0928-8244(03)00097-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb TD, 1996, P NATL ACAD SCI USA, V93, P566, DOI 10.1073/pnas.93.2.566; LEVIN MJ, 1993, PARASITOL TODAY, V9, P381, DOI 10.1016/0169-4758(93)90088-W; LONDESBOROUGH J, 1976, ANAL BIOCHEM, V71, P623, DOI 10.1016/S0003-2697(76)80037-1; Lugones H, 1994, ENFERMEDAD DE CHAGAS, P209; Mahler E, 2004, CLIN EXP IMMUNOL, V136, P527, DOI 10.1111/j.1365-2249.2004.02480.x; Mahler E, 2001, EUR J IMMUNOL, V31, P2210, DOI 10.1002/1521-4141(200107)31:7&lt;2210::AID-IMMU2210&gt;3.0.CO;2-J; MARMOR MF, 1995, DOC OPHTHALMOL, V89, P199, DOI 10.1007/BF01203373; Masuda MO, 1998, FASEB J, V12, P1551, DOI 10.1096/fasebj.12.14.1551; MATSUMOTO SC, 2001, CLIN NEUROPHYSIOL, V112, pS31; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; MESRI EA, 1990, J CLIN MICROBIOL, V28, P1219, DOI 10.1128/JCM.28.6.1219-1224.1990; MIMOUN G, 1991, INT OPHTHALMOL, V15, P4; Mobini R, 2000, HYBRIDOMA, V19, P135, DOI 10.1089/02724570050031176; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PERLMAN I, 1983, BRIT J OPHTHALMOL, V67, P443, DOI 10.1136/bjo.67.7.443; ROMANO C, 1995, INVEST OPHTH VIS SCI, V36, P1968; ROMANO C, 1992, INVEST OPHTH VIS SCI, V4, P396; ROSENBAUM MB, 1994, J CARDIOVASC ELECTR, V5, P367, DOI 10.1111/j.1540-8167.1994.tb01174.x; ROSENBAUM MB, 1964, PROG CARDIOVASC DIS, V7, P199, DOI 10.1016/S0033-0620(64)80020-7; Sakmar TP, 2002, CURR OPIN CELL BIOL, V14, P189, DOI 10.1016/S0955-0674(02)00306-X; SICHI H, 1969, J BIOL CHEM, V244, P178; Sterin-Borda L, 2000, ANN NY ACAD SCI, V917, P273; Stryer L, 1996, P NATL ACAD SCI USA, V93, P557, DOI 10.1073/pnas.93.2.557; Terakita A, 2000, P NATL ACAD SCI USA, V97, P14263, DOI 10.1073/pnas.260349597; Tornow RP, 1998, ACTA ANAT, V162, P163; Trabanino RJ, 2004, BIOPHYS J, V86, P1904, DOI 10.1016/S0006-3495(04)74256-3; Tsukamoto H, 2005, P NATL ACAD SCI USA, V102, P6303, DOI 10.1073/pnas.0500378102; WITT PL, 1984, J GEN PHYSIOL, V84, P51	52	5	5	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					550	+		10.1096/fj.05-4654fje	http://dx.doi.org/10.1096/fj.05-4654fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16423878				2022-12-25	WOS:000235996000011
J	He, LS; Wu, XL; Siegel, R; Lipsky, PE				He, LS; Wu, XL; Siegel, R; Lipsky, PE			TRAF6 regulates cell fate decisions by inducing caspase 8-dependent apoptosis and the activation of NF-kappa B.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; RECEPTOR-ASSOCIATED KINASE; LIVING CELLS; INTERLEUKIN-1 RECEPTOR; PROTEASOME INHIBITORS; CASPASE ACTIVITY; FLOW-CYTOMETRY; PROTEIN; DEATH; MEDIATE	Tumor necrosis factor receptor-associated factor 6 (TRAF6) functions as an adaptor, positively regulating the NF-kappa B pathway. Here we report a new function of human TRAF6, the direct stimulation of apoptosis. The mechanism of apoptosis induction results from the capacity of human TRAF6 to interact and activate caspase 8. Both the C-terminal TRAF domain of human TRAF6, which directly interacts with the death effector domain of pro-caspase 8, and the N-terminal RING domain, which is required for activation of caspase 8, are necessary for the induction of apoptosis. The role of endogenous TRAF6 in regulating apoptosis was confirmed by extinguishing TRAF6 expression with specific small-hairpin RNA that resulted in diminished spontaneous apoptosis and resistance to induced apoptosis. In contrast to the human molecule, murine TRAF6 displayed less ability to induce apoptosis and a greater capacity to stimulate NF-kappa B activity. Human and murine TRAF6 are similar except in the region between zinc finger 5 and the TRAF domains. Reciprocal transfer of this connecting region completely exchanged the ability of human and murine TRAF6 to induce apoptosis and activate NF-kappa B. Unique regions of TRAF6 therefore play an important role in determining cell fate.	NIAMS, Flow Cytometry Sect, Off Sci & Technol, NIH, Bethesda, MD 20892 USA; NIAMS, Autoimmun Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	He, LS (corresponding author), NIAMS, Flow Cytometry Sect, Off Sci & Technol, NIH, Bethesda, MD 20892 USA.	Liusheng.He@Stjude.org	Siegel, Richard/C-7592-2009	Siegel, Richard/0000-0001-5953-9893	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041133, Z01AR041128, ZIAAR041133] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; He LS, 1999, RADIAT RES, V151, P283, DOI 10.2307/3579940; He LS, 2004, J BIOL CHEM, V279, P55855, DOI 10.1074/jbc.M407284200; He LS, 2004, AM J PATHOL, V164, P1901, DOI 10.1016/S0002-9440(10)63751-0; He LS, 2003, CYTOM PART A, V55A, P71, DOI 10.1002/cyto.a.10073; He LS, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni057; Hostager BS, 2003, J BIOL CHEM, V278, P45382, DOI 10.1074/jbc.M306708200; Hug H, 1999, BIOCHEMISTRY-US, V38, P13906, DOI 10.1021/bi9913395; Hull C, 2002, J IMMUNOL, V169, P2611, DOI 10.4049/jimmunol.169.5.2611; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lomaga MA, 2000, J NEUROSCI, V20, P7384; Matsumura T, 2003, IMMUNOLOGY, V109, P127, DOI 10.1046/j.1365-2567.2003.01627.x; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schleicher U, 2000, J IMMUNOL METHODS, V246, P165, DOI 10.1016/S0022-1759(00)00298-2; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; van Rheenen J, 2004, BIOPHYS J, V86, P2517, DOI 10.1016/S0006-3495(04)74307-6; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Werneburg BG, 2001, J BIOL CHEM, V276, P43334, DOI 10.1074/jbc.M104994200; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200; Xu Q, 2004, J BIOL CHEM, V279, P25511, DOI 10.1074/jbc.M311256200; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; You SA, 1999, INT J ONCOL, V15, P625; Zapata Juan M, 2002, Sci STKE, V2002, ppe27	40	30	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					11235	11249		10.1074/jbc.M508779200	http://dx.doi.org/10.1074/jbc.M508779200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16436380	hybrid			2022-12-25	WOS:000236822200067
J	Lopez-Alonso, JP; Bruix, M; Font, J; Ribo, M; Vilanova, M; Rico, M; Gotte, G; Libonati, M; Gonzalez, C; Laurents, DV				Lopez-Alonso, JP; Bruix, M; Font, J; Ribo, M; Vilanova, M; Rico, M; Gotte, G; Libonati, M; Gonzalez, C; Laurents, DV			Formation, structure, and dissociation of the ribonuclease S three-dimensional domain-swapped dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	7th International Meeting on Ribonucleases	JUN, 2005	Stara Lesna, SLOVAKIA				RNASE-A; CRYSTAL-STRUCTURE; HYDROGEN-EXCHANGE; PROTEIN; OLIGOMERIZATION; MECHANISM; RESOLUTION; PRESSURE; FIBRILS; STATE	Post-translational events, such as proteolysis, are believed to play essential roles in amyloid formation in vivo. Ribonuclease A forms oligomers by the three-dimensional domain-swapping mechanism. Here, we demonstrate the ability of ribonuclease S, a proteolytically cleaved form of ribonuclease A, to oligomerize efficiently. This unexpected capacity has been investigated to study the effect of proteolysis on oligomerization and amyloid formation. The yield of the RNase S dimer was found to be significantly higher than that of RNase A dimers, which suggests that proteolysis can activate oligomerization via the three-dimensional domain-swapping mechanism. Characterization by chromatography, enzymatic assays, and NMR spectroscopy indicate that the structure of the RNase S dimer is similar to that of the RNase A C-dimer. The RNase S dimer dissociates much more readily than the RNase A C-dimer does. By measuring the dissociation rate as a function of temperature, the activation enthalpy and entropy for RNase S dimer dissociation were found to resemble those for the release of the small fragment (S-peptide) from monomeric RNase S. Excess S-peptide strongly slows RNase S dimer dissociation. These results strongly suggest that S-peptide release is the rate-limiting step of RNase S dimer dissociation.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Girona, Fac Ciencies, Dept Biol, Lab Engn Prot, E-17071 Girona, Catalunya, Spain; Univ Verona, Fac Med & Chirurg, Sez Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Universitat de Girona; University of Verona	Laurents, DV (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	dlaurents@iqfr.csic.es	Sadurni, Josep Font/A-2499-2010; Laurents, Douglas V/E-7527-2015; López-Alonso, Jorge Pedro/U-5551-2018; Ribó, Marc/M-4514-2013; Vilanova, Maria/ABG-5767-2020; Ribó, Marc/R-5704-2019; Gonzalez, Carlos/A-4734-2013; Vilanova, Maria/D-9525-2011; Bruix, Marta/H-4161-2011	Sadurni, Josep Font/0000-0001-5284-1344; Laurents, Douglas V/0000-0002-4187-165X; López-Alonso, Jorge Pedro/0000-0003-2081-2607; Ribó, Marc/0000-0001-6944-6383; Vilanova, Maria/0000-0003-0523-815X; Ribó, Marc/0000-0001-6944-6383; Gonzalez, Carlos/0000-0001-8796-1282; Vilanova, Maria/0000-0003-0523-815X; Bruix, Marta/0000-0002-0096-3558; Gotte, Giovanni/0000-0003-3179-7158				BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Catanzano F, 1996, BIOCHEMISTRY-US, V35, P13378, DOI 10.1021/bi960855h; Chakshusmathi G, 1999, P NATL ACAD SCI USA, V96, P7899, DOI 10.1073/pnas.96.14.7899; COHEN JS, 1973, J BIOL CHEM, V248, P4305; CRESTFIELD AM, 1962, ARCH BIOCHEM BIOPHYS, P217; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Goldberg JM, 1998, BIOCHEMISTRY-US, V37, P2556, DOI 10.1021/bi972403q; Gomez-Pinto I, 2004, J BIOL CHEM, V279, P24552, DOI 10.1074/jbc.M311751200; Gotte G, 2004, J BIOL CHEM, V279, P36670, DOI 10.1074/jbc.M404780200; Gotte G, 2003, J BIOL CHEM, V278, P10763, DOI 10.1074/jbc.M213146200; Gotte G, 2003, J BIOL CHEM, V278, P46241, DOI 10.1074/jbc.M308470200; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; Graziano G, 1996, BIOCHEMISTRY-US, V35, P13386, DOI 10.1021/bi960856+; Guo M, 2005, FEBS LETT, V579, P3574, DOI 10.1016/j.febslet.2005.05.036; Houry WA, 1996, BIOCHEMISTRY-US, V35, P11734, DOI 10.1021/bi961085c; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Janowski R, 2001, NAT STRUCT BIOL, V8, P316, DOI 10.1038/86188; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KUNITZ M, 1946, J BIOL CHEM, V164, P563; Libonati M, 2004, BIOCHEM J, V380, P311, DOI 10.1042/BJ20031922; Libonati M, 2001, METHOD ENZYMOL, V341, P234, DOI 10.1016/S0076-6879(01)41155-4; LIN MC, 1972, J BIOL CHEM, V247, P4768; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Nadig G, 1996, PROTEIN SCI, V5, P2104, DOI 10.1002/pro.5560051017; Nakano S, 2003, J AM CHEM SOC, V125, P8728, DOI 10.1021/ja034659r; Neira JL, 1999, J MOL BIOL, V285, P627, DOI 10.1006/jmbi.1998.2365; Nenci A, 2001, PROTEIN SCI, V10, P2017, DOI 10.1110/ps.14101; PACE CN, 1980, J BIOL CHEM, V255, P3862; Park C, 2000, PROTEIN SCI, V9, P2026, DOI 10.1110/ps.9.10.2026; Ribo M, 2001, METHOD ENZYMOL, V341, P221, DOI 10.1016/S0076-6879(01)41154-2; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; Rousseau F, 2003, STRUCTURE, V11, P243, DOI 10.1016/S0969-2126(03)00029-7; Sambashivan S, 2005, NATURE, V437, P266, DOI 10.1038/nature03916; SANTORO J, 1993, J MOL BIOL, V229, P722, DOI 10.1006/jmbi.1993.1075; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; Sorrentino S, 2000, FEBS LETT, V466, P35, DOI 10.1016/S0014-5793(99)01742-1; Tamura A, 1997, J MOL BIOL, V273, P1048, DOI 10.1006/jmbi.1997.1368; Torrent J, 1999, BIOCHEMISTRY-US, V38, P15952, DOI 10.1021/bi991460b; Torrent J, 2001, PROTEIN SCI, V10, P725, DOI 10.1110/ps.43001; UNGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WYCKOFF HW, 1970, J BIOL CHEM, V245, P305	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9400	9406		10.1074/jbc.M510491200	http://dx.doi.org/10.1074/jbc.M510491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	027HB	16415350	Green Published, hybrid			2022-12-25	WOS:000236404700049
J	Myers, JS; Cortez, D				Myers, JS; Cortez, D			Rapid activation of ATR by ionizing radiation requires ATM and Mre11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DAMAGE-INDUCED PHOSPHORYLATION; DOUBLE-STRAND BREAKS; DNA-DAMAGE; BINDING; COMPLEX; KINASE; CHK1; RECOGNITION; HELICASE	The ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases are crucial regulatory proteins in genotoxic stress response pathways that pause the cell cycle to permit DNA repair. Here we show that Chk1 phosphorylation in response to hydroxyurea and ultraviolet radiation is ATR-dependent and ATM- and Mre11-independent. In contrast, Chk1 phosphorylation in response to ionizing radiation (IR) is dependent on ATR, ATM, and Mre11. The ATR and ATM/Mre11 pathways are generally thought to be separate with ATM activation occurring early and ATR activation occurring as a late response to double strand breaks. However, we demonstrate that ATR is activated rapidly by IR, and ATM and Mre11 enhance ATR signaling. ATR-ATR-interacting protein recruitment to double strand breaks is less efficient in the absence of ATM and Mre11. Furthermore, IR-induced replication protein A foci formation is defective in ATM- and Mre11-deficient cells. Thus, ATM and Mre11 may stimulate the ATR signaling pathway by converting DNA damage generated by IR into structures that recruit and activate ATR.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Cortez, D (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.	david.cortez@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA102729, K01CA093701, T32CA009582, T32CA093240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA093240, R01CA102729, T32CA093240, K01 CA093701, R01 CA102729, T32CA009582, T32 CA009582] Funding Source: Medline; NIEHS NIH HHS [P30 ES000267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Ball HL, 2005, MOL BIOL CELL, V16, P2372, DOI 10.1091/mbc.e04-11-1006; Block WD, 2004, NUCLEIC ACIDS RES, V32, P997, DOI 10.1093/nar/gkh265; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; CANMAN CE, 1994, CANCER RES, V54, P5054; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 2005, GENE DEV, V19, P1007, DOI 10.1101/gad.1316905; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kim SM, 2005, J BIOL CHEM, V280, P38355, DOI 10.1074/jbc.M508673200; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wang HY, 2001, CANCER RES, V61, P8554; Wang Y, 2000, GENE DEV, V14, P927; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhong H, 2005, HUM MOL GENET, V14, P2685, DOI 10.1093/hmg/ddi302; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	38	236	243	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9346	9350		10.1074/jbc.M513265200	http://dx.doi.org/10.1074/jbc.M513265200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16431910	hybrid, Green Accepted			2022-12-25	WOS:000236404700043
J	Forment, JV; Flipphi, M; Ramon, D; Ventura, L; MacCabe, AP				Forment, JV; Flipphi, M; Ramon, D; Ventura, L; MacCabe, AP			Identification of the mstE gene encoding a glucose-inducible, low affinity glucose transporter in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; EXOFACIAL LIGAND-BINDING; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; SUGAR-TRANSPORT; HEXOSE TRANSPORTER; MOLECULAR-GENETICS; PROTEIN; EXPRESSION; GLUT1	The mstE gene encoding a low affinity glucose transporter active during the germination of Aspergillus nidulans conidia on glucose medium has been identified. mstE expression also occurs in hyphae, is induced in the presence of other repressing carbon sources besides glucose, and is dependent on the function of the transcriptional repressor CreA. The expression of MstE and its subcellular distribution have been studied using a MstE- sGFP fusion protein. Concordant with data on mstE expression, MstE- sGFP is synthesized in the presence of repressing carbon sources, and fluorescence at the periphery of conidia and hyphae is consistent with MstE location in the plasma membrane. Deletion of mstE has no morphological phenotype but results in the absence of low affinity glucose uptake kinetics, the latter being substituted by a high affinity system.	Consejo Super Invest Cient, Inst Agroquim & Tecnol Alimentos, Valencia 46100, Spain; Univ Valencia, Fac Farm, Dept Med Prevent & Salud Publ Bromatol Toxicol &, Valencia 46100, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); University of Valencia	MacCabe, AP (corresponding author), Consejo Super Invest Cient, Inst Agroquim & Tecnol Alimentos, Apartado Correos 73, Valencia 46100, Spain.	andrew@iata.csic.es	Forment, Josep/J-3678-2015; MacCabe, Andrew P/H-4522-2012	Forment, Josep/0000-0002-7797-2583; MacCabe, Andrew P/0000-0003-4918-7761				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARST HN, 1973, MOL GEN GENET, V126, P111, DOI 10.1007/BF00330988; ARST HN, 1990, MOL MICROBIOL, V4, P851, DOI 10.1111/j.1365-2958.1990.tb00656.x; Attwood TK, 2003, NUCLEIC ACIDS RES, V31, P400, DOI 10.1093/nar/gkg030; BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; Black M., 1990, PHYSL BIOCH PLANT CE, P4; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Boles E, 2002, TRANSMEMBRANE TRANSP, P19; CELENZA JL, 1988, P NATL ACAD SCI USA, V85, P2130, DOI 10.1073/pnas.85.7.2130; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; de Vries RP, 2001, MICROBIOL MOL BIOL R, V65, P497, DOI 10.1128/MMBR.65.4.497-522.2001; Delgado-Jarana J, 2003, EUKARYOT CELL, V2, P708, DOI 10.1128/EC.2.4.708-717.2003; dEnfert C, 1997, FUNGAL GENET BIOL, V21, P163, DOI 10.1006/fgbi.1997.0975; Fischer-Parton S, 2000, J MICROSC-OXFORD, V198, P246, DOI 10.1046/j.1365-2818.2000.00708.x; Flipphi M, 2004, MYCOTA, V3, P403; Flipphi M, 2003, J BIOL CHEM, V278, P11849, DOI 10.1074/jbc.M209443200; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; GOFFRINI P, 1990, NUCLEIC ACIDS RES, V18, P5294, DOI 10.1093/nar/18.17.5294; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; Heiland S, 2000, J BACTERIOL, V182, P2153, DOI 10.1128/JB.182.8.2153-2162.2000; Karos M, 1999, MOL GEN GENET, V260, P510, DOI 10.1007/s004380050924; Kasahara M, 1997, J BIOL CHEM, V272, P16721, DOI 10.1074/jbc.272.27.16721; Kelly JM, 2004, MYCOTA, V3, P385; KO CH, 1993, MOL CELL BIOL, V13, P638, DOI 10.1128/MCB.13.1.638; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kurtov D, 1999, MOL GEN GENET, V262, P115, DOI 10.1007/s004380051065; LAGUNAS R, 1993, FEMS MICROBIOL LETT, V104, P229, DOI 10.1016/0378-1097(93)90598-V; Lee WJ, 2002, APPL MICROBIOL BIOT, V60, P186, DOI 10.1007/s00253-002-1085-6; MacCabe AP, 2003, MICROBIOL-SGM, V149, P2129, DOI 10.1099/mic.0.26349-0; Madi L, 1997, GENETICS, V146, P499; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MARK CG, 1971, BIOCHIM BIOPHYS ACTA, V249, P216, DOI 10.1016/0005-2736(71)90098-8; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Nehls U, 1998, MOL PLANT MICROBE IN, V11, P167, DOI 10.1094/MPMI.1998.11.3.167; NEIGEBORN L, 1984, GENETICS, V108, P845; NELISSEN B, 1997, FEMS MICROBIOL REV, V21, P114; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PUNT PJ, 1988, GENE, V69, P49, DOI 10.1016/0378-1119(88)90377-0; Sambrook J, 2001, MOL CLONING LAB MANU; SCARBOROUGH GA, 1970, J BIOL CHEM, V245, P3985; SCARBOROUGH GA, 1970, J BIOL CHEM, V245, P1694; SCHNEIDER RP, 1971, J BACTERIOL, V106, P487, DOI 10.1128/JB.106.2.487-492.1971; SPECHT CA, 1982, ANAL BIOCHEM, V119, P158, DOI 10.1016/0003-2697(82)90680-7; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; Toews MW, 2004, CURR GENET, V45, P383, DOI 10.1007/s00294-004-0495-7; Valdez-Taubas J, 2004, FUNGAL GENET BIOL, V41, P42, DOI 10.1016/j.fgb.2003.09.003; vanKuyk PA, 2004, BIOCHEM J, V379, P375, DOI 10.1042/BJ20030624; Voegele RT, 2001, P NATL ACAD SCI USA, V98, P8133, DOI 10.1073/pnas.131186798; Wei HJ, 2004, FUNGAL GENET BIOL, V41, P148, DOI 10.1016/j.fgb.2003.10.006; WEUSTHUIS RA, 1994, MICROBIOL REV, V58, P616, DOI 10.1128/MMBR.58.4.616-630.1994; Wieczorke R, 1999, FEBS LETT, V464, P123, DOI 10.1016/S0014-5793(99)01698-1	55	35	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8339	8346		10.1074/jbc.M508198200	http://dx.doi.org/10.1074/jbc.M508198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16418173	hybrid			2022-12-25	WOS:000236247100007
J	Chang, KJ; Lin, G; Men, LC; Wang, CC				Chang, KJ; Lin, G; Men, LC; Wang, CC			Redundancy of non-AUG initiators - A clever mechanism to enhance the efficiency of translation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; GENE ENCODES; MITOCHONDRIAL; CODON; PROTEIN; SELECTION; THALIANA; FEATURES; REGION	It was recently shown that ALA1, the only alanyl-tRNA synthetase gene in Saccharomyces cerevisiae, uses two successive ACG triplets as the translation initiators for its mitochondrial form. Evidence presented here argues that the second ACG triplet not only acts as a remedial initiation site for scanning ribosomes that skip the first ACG, but also enhances the activity of the preceding initiator by providing a preferable "A" at its relative position +4. Therefore, ALA1 constructs with redundant ACG initiators exhibit stronger complementing activity and express a higher level of protein than do those with a single ACG initiator. A similar scenario is seen when a single or redundant ACG triplets are placed in the positions of the first and second AUG initiators of VAS1, which serve as the start sites of the mitochondrial and cytoplasmic forms of valyl-tRNA synthetase, respectively. Cumulatively, the results suggest that this feature of redundancy of non-AUG initiators in a single mRNA per se may represent a novel paradigm for improving the efficiency of a poor or otherwise nonproductive initiation event.	Natl Cent Univ, Dept Life Sci, Jungli 32001, Taiwan; ROCAEC, Inst Nucl Energy Res, Taoyuan 32546, Taiwan	National Central University; Institute of Nuclear Energy Research - Taiwan	Wang, CC (corresponding author), Natl Cent Univ, Dept Life Sci, Jungli 32001, Taiwan.	dukewang@cc.ncu.edu.tw	Chang, Kuang-Jung/J-2193-2012					Abramczyk D, 2003, YEAST, V20, P1045, DOI 10.1002/yea.1020; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; CHATTON B, 1988, J BIOL CHEM, V263, P52; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; CLEMENTS JM, 1988, MOL CELL BIOL, V8, P4533, DOI 10.1128/MCB.8.10.4533; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MARECHALDROUARD L, 1993, ANN REV CELL BIOL, V8, P115; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Nett JH, 2001, EUR J BIOCHEM, V268, P5209, DOI 10.1046/j.0014-2956.2001.02454.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pelchat M, 1999, BIOCHEM CELL BIOL, V77, P343, DOI 10.1139/bcb-77-4-343; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SHERMAN F, 1980, CELL, V20, P215, DOI 10.1016/0092-8674(80)90249-4; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; Tang HL, 2004, J BIOL CHEM, V279, P49656, DOI 10.1074/jbc.M408081200; Turner RJ, 2000, J BIOL CHEM, V275, P27681; Unbehaun A, 2004, GENE DEV, V18, P3078, DOI 10.1101/gad.1255704; Wang CC, 2003, BIOCHEMISTRY-US, V42, P1646, DOI 10.1021/bi025964c; WOLFE CL, 1994, J BIOL CHEM, V269, P13361; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x	35	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7775	7783		10.1074/jbc.M511265200	http://dx.doi.org/10.1074/jbc.M511265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431919	hybrid			2022-12-25	WOS:000236031000010
J	Fernandez-Saiz, V; Moro, F; Arizmendi, JM; Acebron, SP; Muga, A				Fernandez-Saiz, V; Moro, F; Arizmendi, JM; Acebron, SP; Muga, A			Ionic contacts at DnaK substrate binding domain involved in the allosteric regulation of lid dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE DNAK; PEPTIDE-BINDING; INTERDOMAIN COMMUNICATION; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; PROTEIN; ATPASE; HSP70; GRPE; COMPLEX	To gain further insight into the interactions involved in the allosteric transition of DnaK we have characterized wild-type (wt) protein and three mutants in which ionic interactions at the interface between the two subdomains of the substrate binding domain, and within the lid subdomain have been disrupted. Our data show that ionic contacts, most likely forming an electrically charged network, between the N-terminal region of helix B and an inner loop of the beta-sandwich are involved in maintaining the position of the lid relative to the beta-subdomain in the ADP state but not in the ATP state of the protein. Disruption of the ionic interactions between the C-terminal region of helix B and the outer loops of the beta-sandwich, known as the latch, does not have the same conformational consequences but results equally in an inactive protein. This indicates that a variety of mechanisms can inactivate this complex allosteric machine. Our results identify the ionic contacts at the subdomain and interdomain interfaces that are part of the hinge region involved in the ATP-induced allosteric displacement of the lid away from the peptide binding site. These interactions also stabilize peptide-Hsp70 complexes at physiological (37 degrees C) and stress (42 degrees C) temperatures, a requirement for productive substrate (re) folding.	Univ Basque Country, Euskal Herriko Unibertsitatea, Consejo Super Invest Cient, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Fac Ciencias, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Muga, A (corresponding author), Univ Basque Country, Euskal Herriko Unibertsitatea, Consejo Super Invest Cient, Unidad Biofis, Aptdo 644, E-48080 Bilbao, Spain.	gbpmuvia@lg.ehu.es	Fernandez, Vanesa/ABD-6688-2021; Muga, Arturo/N-1174-2014; Moro Pérez, Fernando/P-3891-2015	Muga, Arturo/0000-0003-0345-6882; Moro Pérez, Fernando/0000-0002-3568-3388; Arizmendi, Jesus M/0000-0002-1412-4042; Fernandez-Saiz, Vanesa/0000-0002-7139-8680				Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Buczynski G, 2001, J BIOL CHEM, V276, P27231, DOI 10.1074/jbc.M100237200; Chang TC, 2001, ARCH BIOCHEM BIOPHYS, V386, P30, DOI 10.1006/abbi.2000.2176; Cupp-Vickery JR, 2004, J MOL BIOL, V342, P1265, DOI 10.1016/j.jmb.2004.07.025; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Ha JH, 1997, J BIOL CHEM, V272, P27796, DOI 10.1074/jbc.272.44.27796; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hu SM, 2002, ARCH BIOCHEM BIOPHYS, V407, P135, DOI 10.1016/S0003-9861(02)00515-5; Jiang JW, 2005, MOL CELL, V20, P513, DOI 10.1016/j.molcel.2005.09.028; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; Larsen MR, 2002, PROTEOMICS, V2, P1277, DOI 10.1002/1615-9861(200209)2:9<1277::AID-PROT1277>3.0.CO;2-P; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Mehl AF, 2001, BIOCHEM BIOPH RES CO, V282, P562, DOI 10.1006/bbrc.2001.4567; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Moro F, 2005, FEBS J, V272, P3184, DOI 10.1111/j.1742-4658.2005.04737.x; Moro F, 2004, J BIOL CHEM, V279, P19600, DOI 10.1074/jbc.M400921200; Moro F, 2003, FEBS LETT, V533, P119, DOI 10.1016/S0014-5793(02)03752-3; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Revington M, 2005, J MOL BIOL, V349, P163, DOI 10.1016/j.jmb.2005.03.033; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Slepenkov SV, 2002, BIOCHEMISTRY-US, V41, P12224, DOI 10.1021/bi0263208; Stevens SY, 2003, PROTEIN SCI, V12, P2588, DOI 10.1110/ps.03269103; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Zhang YB, 2004, P NATL ACAD SCI USA, V101, P10272, DOI 10.1073/pnas.0401313101; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	40	36	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7479	7488		10.1074/jbc.M512744200	http://dx.doi.org/10.1074/jbc.M512744200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16415343	hybrid			2022-12-25	WOS:000236030900070
J	Hamburgh, ME; Curr, KA; Monaghan, M; Rao, VR; Tripathi, S; Preston, BD; Sarafianos, S; Arnold, E; Darden, T; Prasad, VR				Hamburgh, ME; Curr, KA; Monaghan, M; Rao, VR; Tripathi, S; Preston, BD; Sarafianos, S; Arnold, E; Darden, T; Prasad, VR			Structural determinants of slippage-mediated mutations by human immunodeficiency virus type 1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE ANALOG SENSITIVITY; POLYMERASE FIDELITY; ERROR SPECIFICITY; CRYSTAL-STRUCTURE; GLU-89 RESIDUE; MINOR-GROOVE; HIV-1 RT; DNA; MUTANT; RESISTANCE	Single-base deletions at nucleotide runs or - 1 frameshifting by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) result from template slippage during polymerization. In crystal structures of HIV-1 RT complexed with DNA-DNA template-primer, the palm subdomain in the template cleft contacts the template backbone near the proposed site of slippage via the Glu(89) side chain. We investigated the role of Glu(89) in frameshifting by perturbing this interaction. Substitutions with Asp, Gly, Ala, Val, Ser, Thr, Asn, or Lys were created in recombinant HIV RT, and frameshift frequencies of the resulting mutant RTs were measured. All substitutions led to reduced -1 frameshifting by HIV-1 RT (2-40-fold). Interestingly, the suppression of -1 frameshifting frequently coincided with an enhancement of -1 frameshifting (3-47-fold) suggesting that Glu(89) can influence the slippage of both strands. Glu(89) substitutions also led to reduced rates of dNTP mis-incorporation that paralleled reductions in -1 frameshifting, suggesting a common structural mechanism for both classes of RT error. Our results reveal a major influence of Glu(89) on slippage-mediated errors and dNTP incorporation fidelity. The crystal structure of HIV-1 RT reveals a salt bridge between Glu(89) and Lys(154), which may facilitate -1 frameshifting; this concept is supported by the observed reduction in -1 frameshifting for K154A and K154R mutants.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27707 USA	Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Washington; University of Washington Seattle; Rutgers State University New Brunswick; Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Prasad, VR (corresponding author), 1300 Morris Pk Ave,Rm GB 401, Bronx, NY 10461 USA.	prasad@aecom.yu.edu	Prasad, Vinayaka R./A-1029-2011	Sarafianos, Stefan G/0000-0002-5840-154X; Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030861, R01AI030861, R21AI030861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES043010, Z01ES090601] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI030861, AI 30861] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07461] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Curr K, 2006, J GEN VIROL, V87, P419, DOI 10.1099/vir.0.81458-0; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; Fisher TS, 2002, J BIOL CHEM, V277, P22345, DOI 10.1074/jbc.M200282200; GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P1390, DOI 10.1128/AAC.37.6.1390; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KEW Y, 1994, J BIOL CHEM, V269, P15331; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; Lavigne M, 1999, J MOL BIOL, V285, P977, DOI 10.1006/jmbi.1998.2367; Mansky LM, 2003, J VIROL, V77, P2071, DOI 10.1128/JVI.77.3.2071-2080.2003; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Natrajan G, 2003, NUCLEIC ACIDS RES, V31, P4814, DOI 10.1093/nar/gkg677; Newstein MC, 2001, J INFECT DIS, V184, P1262, DOI 10.1086/324079; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PRASAD VR, 1989, J BIOL CHEM, V264, P16689; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Quan YD, 1998, J BIOL CHEM, V273, P21918, DOI 10.1074/jbc.273.34.21918; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Shahs FS, 2000, J BIOL CHEM, V275, P27037; Sharma B, 2003, NUCLEIC ACIDS RES, V31, P5167, DOI 10.1093/nar/gkg708; SONG QG, 1992, J VIROL, V66, P7568, DOI 10.1128/JVI.66.12.7568-7571.1992; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282	40	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7421	7428		10.1074/jbc.M511380200	http://dx.doi.org/10.1074/jbc.M511380200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16423828	hybrid			2022-12-25	WOS:000236030900063
J	Crawley, SW; de la Roche, MA; Lee, SF; Li, ZH; Chitayat, S; Smith, SP; Cote, GP				Crawley, SW; de la Roche, MA; Lee, SF; Li, ZH; Chitayat, S; Smith, SP; Cote, GP			Identification and characterization of an 8-kDa light chain associated with Dictyostelium discoideum MyoB, a class I myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; FLUORESCENT PROTEIN; CORTICAL TENSION; DOMAINS; CALMODULIN; SEQUENCE; AFFINITY; MOTILITY; MUTANTS; ISOFORM	Dictyostelium discoideum MyoB is a single-headed class I myosin. Analysis of purified MyoB by SDS-PAGE indicated the presence of an similar to 9-kDa light chain. A tryptic digest of MyoB yielded a partial sequence for the light chain that exactly matched a sequence in a 73-amino acid, 8,296-Da protein (dictyBase number DDB0188713). This protein, termed MlcB, contains two EF-hand motifs and shares similar to 30% sequence identity with the N- and C-terminal lobes of calmodulin. FLAG-MlcB expressed in Dictyostelium co-immunoprecipitated with MyoB but not with the related class I myosins MyoC and MyoD. Recombinant MlcB bound Ca2+ with a K-d value of 0.2 mu M and underwent a Ca2+-induced change in conformation that increased alpha-helical content and surface hydrophobicity. Mutational analysis showed that the first EF-hand was responsible for Ca2+ binding. In the presence and absence of Ca2+ MlcB was a monomer in solution and bound to a MyoB IQ motif peptide with a K-d value of similar to 0.5 mu M. A MyoB head-neck construct with a Ser to Glu mutation at the TEDS site bound MlcB and displayed an actin-activated Mg2+ ATPase activity that was insensitive to Ca2+. We conclude that MlcB represents a novel type of small myosin light chain that binds to IQ motifs in a manner comparable with a single lobe of a typical four-EF-hand protein.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Cote, GP (corresponding author), Queens Univ, Dept Biochem, Rm 617,Botterell Hall, Kingston, ON K7L 3N6, Canada.	coteg@post.queensu.ca		Smith, Steven/0000-0003-2710-4400				Bahler M, 2002, FEBS LETT, V513, P107, DOI 10.1016/S0014-5793(01)03239-2; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Dai JW, 1999, BIOPHYS J, V77, P1168, DOI 10.1016/S0006-3495(99)76968-7; De La Roche MA, 2003, BIOCHEM J, V374, P697, DOI 10.1042/BJ20030656; de la Roche MA, 2001, BBA-GEN SUBJECTS, V1525, P245, DOI 10.1016/S0304-4165(01)00110-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Falk DL, 2003, J CELL SCI, V116, P3985, DOI 10.1242/jcs.00696; Fischer M, 2004, FEBS LETT, V577, P227, DOI 10.1016/j.febslet.2004.09.084; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; Gillespie PG, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-31; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jung G, 2001, J CELL BIOL, V153, P1479, DOI 10.1083/jcb.153.7.1479; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1993, J BIOL CHEM, V268, P14981; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Korn ED, 2000, P NATL ACAD SCI USA, V97, P12559, DOI 10.1073/pnas.230441597; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1993, J BIOL CHEM, V268, P20923; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; LYNCH TJ, 1991, METHOD ENZYMOL, V196, P12; MANSTEIN DJ, 1995, J MUSCLE RES CELL M, V16, P325, DOI 10.1007/BF00121141; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; Martin SR, 2002, PROTEIN SCI, V11, P2909, DOI 10.1110/ps.0210402; MARUTA H, 1979, J BIOL CHEM, V254, P3624; McCormack E, 2003, NEW PHYTOL, V159, P585, DOI 10.1046/j.1469-8137.2003.00845.x; Morita YS, 1996, EUR J CELL BIOL, V71, P371; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; Neuhaus EM, 2000, J CELL BIOL, V150, P1013, DOI 10.1083/jcb.150.5.1013; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; Osherov N, 2000, CELL MOTIL CYTOSKEL, V47, P163, DOI 10.1002/1097-0169(200011)47:3<163::AID-CM1>3.0.CO;2-U; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Schwarz EC, 2000, J CELL SCI, V113, P621; SLUPSKY CM, 1995, PROTEIN SCI, V4, P1279, DOI 10.1002/pro.5560040704; Smith SP, 1998, BIOCHEM CELL BIOL, V76, P324, DOI 10.1139/bcb-76-2-3-324; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Terrak M, 2003, EMBO J, V22, P362, DOI 10.1093/emboj/cdg058; Vargas M, 1997, MOL BIOCHEM PARASIT, V86, P61, DOI 10.1016/S0166-6851(97)90006-2; Wang ZY, 1997, J MUSCLE RES CELL M, V18, P395, DOI 10.1023/A:1018686428955; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; Yamaguchi K, 1999, J BIOL CHEM, V274, P3610, DOI 10.1074/jbc.274.6.3610	47	14	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6307	6315		10.1074/jbc.M508670200	http://dx.doi.org/10.1074/jbc.M508670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16415352	hybrid			2022-12-25	WOS:000236030800024
J	Mezhybovska, M; Wikstrom, K; Ohd, JF; Sjolander, A				Mezhybovska, M; Wikstrom, K; Ohd, JF; Sjolander, A			The inflammatory mediator leukotriene D-4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; ADENOCARCINOMA CELLS; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CYSLT(1) RECEPTOR; C-MYC; PATHWAY; ACTIVATION; SURVIVAL; PROTEIN	Increased levels of the inflammatory mediator leukotriene D-4 (LTD4) are present at sites of inflammatory bowel disease, and such areas also exhibit an increased risk for subsequent cancer development. It is known that LTD4 affects the expression of many proteins that influence survival and proliferation of intestinal epithelial cells. We demonstrate here that after LTD4 exposure, beta-catenin translocates to the nucleus where it signals activation of the TCF/LEF family of transcription factors. These events are mediated via a phosphatidylinositol 3-kinase-dependent phosphorylation of the inhibitory Ser-9 residue of glycogen synthase kinase 3 beta. We also show that in the presence of LTD4, free beta-catenin translocates to the mitochondria where it associates with the cell survival protein Bcl-2. We hypothesize that LTD4 may enhance cell survival via activation of beta-catenin signaling, in particular, by promoting the association of beta-catenin with Bcl-2 in the mitochondria. Similar to Wnt-1 signaling, LTD4 signals an increased level of free beta-catenin and elevated TCF/LEF promotor activity. This work in intestinal epithelial cells further lends credence to the idea that inflammatory signaling pathways are intrinsically linked with potential oncogenic signals involved in cell survival and apoptosis.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Sjolander, A (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, SE-20502 Malmo, Sweden.	anita.sjolander@med.lu.se						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cellerino A, 2000, CELL TISSUE RES, V301, P53, DOI 10.1007/s004410000178; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cullen DA, 2004, NEUROSCI LETT, V354, P54, DOI 10.1016/j.neulet.2003.09.074; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Diks SH, 2003, J BIOL CHEM, V278, P52491, DOI 10.1074/jbc.M310712200; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Hawkey CJ, 1997, GASTROENTEROLOGY, V112, P718, DOI 10.1053/gast.1997.v112.pm9041232; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; HENLE G, 1957, J IMMUNOL, V79, P54; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Howe LR, 2001, ENDOCR-RELAT CANCER, V8, P97, DOI 10.1677/erc.0.0080097; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lynch KR, 1999, NATURE, V399, P789; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nialbon C. C., 2005, SCI STKE, V2005, ppe35; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; Nielsen CK, 2005, CANCER RES, V65, P732; Nielsen CK, 2005, EXP CELL RES, V302, P31, DOI 10.1016/j.yexcr.2004.08.042; NIELSEN OH, 1991, PROSTAG LEUKOTR ESS, V42, P181, DOI 10.1016/0952-3278(91)90155-X; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park JR, 1996, J CELL BIOCHEM, V60, P12, DOI 10.1002/(SICI)1097-4644(19960101)60:1<12::AID-JCB3>3.0.CO;2-6; Paruchuri S, 2005, J BIOL CHEM, V280, P13538, DOI 10.1074/jbc.M409811200; Paruchuri S, 2003, J BIOL CHEM, V278, P45577, DOI 10.1074/jbc.M302881200; Paruchuri S, 2002, J CELL SCI, V115, P1883; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Samuelsson B, 1979, Harvey Lect, V75, P1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Takahashi M, 1998, CANCER RES, V58, P42; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wikstrom K, 2003, BIOCHEM BIOPH RES CO, V302, P330, DOI 10.1016/S0006-291X(03)00187-6; Wkstrom K, 2003, BIOCHEM J, V371, P115; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	57	48	49	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6776	6784		10.1074/jbc.M509999200	http://dx.doi.org/10.1074/jbc.M509999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407243	hybrid			2022-12-25	WOS:000236030800076
J	Park, YH; Lee, BR; Seok, YJ; Peterkofsky, A				Park, YH; Lee, BR; Seok, YJ; Peterkofsky, A			In vitro reconstitution of catabolite repression in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; PHOSPHORYL TRANSFER COMPLEX; ADENYLATE-CYCLASE ACTIVITY; CYTOPLASMIC DOMAIN; ENZYME IIA(GLC); PROTEIN; EXPRESSION; MONOPHOSPHATE; PURIFICATION; IIA(GLUCOSE)	A widely accepted model for catabolite repression posits that phospho-IIA(Glc) of the bacterial phosphotransferase system activates adenylyl cyclase (AC) activity. For many years, attempts to observe such regulatory properties of AC in vitro have been unsuccessful. To further study the regulation, AC was produced fused to the transmembrane segments of the serine chemoreceptor Tsr. Cells harboring Tsr-AC and normal AC, expressed from the cya promoter on a low copy number vector, exhibit similar behavior with respect to elevation of cAMP levels resulting from deletion of crp, expressing the catabolite regulatory protein. Membrane-bound Tsr-AC exhibits activity comparable with the native form of AC. Tsr-AC binds IIA(Glc) specifically, regardless of its phosphorylation state, but not the two general phosphotransferase system proteins, enzyme I and HPr; IIA(Glc) binding is localized to the C-terminal region of AC. Binding to membranes of either dephospho- or phospho-IIA(Glc) has no effect on AC activity. However, in the presence of an Escherichia coli extract, P-IIA(Glc), but not IIA(Glc), stimulates AC activity. Based on these findings of a direct interaction of IIAGlc with AC, but activity regulation only in the presence of E. coli extract, a revised model for AC activity regulation is proposed.	Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; Seowon Univ, Dept Biol, Chongju City 361742, South Korea; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Seoul National University (SNU); Seoul National University (SNU); Seowon University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Seok, YJ (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 50,Rm 2316,MSC-8017, Bethesda, MD 20814 USA.	yjseok@plaza.snu.ac.kr; peterkofsky@nih.gov		Seok, Yeong-Jae/0000-0003-0379-3619	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ACKERMAN RS, 1974, J BACTERIOL, V119, P357, DOI 10.1128/JB.119.2.357-362.1974; [Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200; CRASNIER M, 1990, J GEN MICROBIOL, V136, P1825, DOI 10.1099/00221287-136-9-1825; DANIEL J, 1984, J BACTERIOL, V157, P940, DOI 10.1128/JB.157.3.940-941.1984; DEROBERTIS EM, 1973, BIOCHEM BIOPH RES CO, V55, P758, DOI 10.1016/0006-291X(73)91209-6; HARWOOD JP, 1975, J BIOL CHEM, V250, P4656; Higuchi R., 1989, PCR TECHNOLOGY, P61; Koo BM, 2004, J BIOL CHEM, V279, P31613, DOI 10.1074/jbc.M405048200; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LIBERMAN E, 1986, BIOCHEM BIOPH RES CO, V141, P1138, DOI 10.1016/S0006-291X(86)80162-0; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; Miller J. H., 1972, EXPT MOL GENETICS, P433; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; NIELSEN LD, 1973, J BACTERIOL, V116, P857, DOI 10.1128/JB.116.2.857-866.1973; Nosworthy NJ, 1998, BIOCHEMISTRY-US, V37, P6718, DOI 10.1021/bi980126x; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; Pettigrew DW, 1998, BIOCHEMISTRY-US, V37, P4875, DOI 10.1021/bi971634u; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; POTTER K, 1974, BIOCHEM BIOPH RES CO, V57, P379, DOI 10.1016/0006-291X(74)90941-3; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; REDDY P, 1995, ANAL BIOCHEM, V231, P282, DOI 10.1006/abio.1995.9998; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; REDDY P, 1985, P NATL ACAD SCI USA, V82, P8300, DOI 10.1073/pnas.82.24.8300; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; ROY A, 1983, J MOL BIOL, V165, P197, DOI 10.1016/S0022-2836(83)80251-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sondej M, 2002, BIOCHEMISTRY-US, V41, P5556, DOI 10.1021/bi011990j; Takahashi H, 1998, MOL GEN GENET, V259, P317, DOI 10.1007/s004380050818; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; YANG JK, 1983, J BIOL CHEM, V258, P3750	33	90	95	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6448	6454		10.1074/jbc.M512672200	http://dx.doi.org/10.1074/jbc.M512672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407219	hybrid			2022-12-25	WOS:000236030800039
J	Chen, YM; Ferrar, TS; Lohmeir-Vogel, E; Morrice, N; Mizuno, Y; Berenger, B; Ng, KKS; Muench, DG; Moorhead, GBG				Chen, YM; Ferrar, TS; Lohmeir-Vogel, E; Morrice, N; Mizuno, Y; Berenger, B; Ng, KKS; Muench, DG; Moorhead, GBG			The PII signal transduction protein of Arabidopsis thaliana forms an arginine-regulated complex with plastid N-acetyl glutamate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-II PROTEIN; PUTATIVE NITROGEN SENSOR; GLNB GENE-PRODUCT; PHOSPHORYLATION; NITRATE; CARBON; PURIFICATION; EXPRESSION	The PII proteins are key mediators of the cellular response to carbon and nitrogen status and are found in all domains of life. In eukaryotes, PII has only been identified in red algae and plants, and in these organisms, PII localizes to the plastid. PII proteins perform their role by assessing cellular carbon, nitrogen, and energy status and conferring this information to other proteins through protein-protein interaction. We have used affinity chromatography and mass spectrometry to identify the PII-binding proteins of Arabidopsis thaliana. The major PII-interacting protein is the chloroplast-localized enzyme N-acetyl glutamate kinase, which catalyzes the key regulatory step in the pathway to arginine biosynthesis. The interaction of PII with N-acetyl glutamate kinase was confirmed through pull-down, gel filtration, and isothermal titration calorimetry experiments, and binding was shown to be enhanced in the presence of the downstream product, arginine. Enzyme kinetic analysis showed that PII increases N-acetyl glutamate kinase activity slightly, but the primary function of binding is to relieve inhibition of enzyme activity by the pathway product, arginine. Knowing the identity of PII-binding proteins across a spectrum of photosynthetic and non-photosynthetic organisms provides a framework for a more complete understanding of the function of this highly conserved signaling protein.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Calgary; University of Dundee	Moorhead, GBG (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	moorhead@ucalgary.ca	Ferrar, Tony S/M-6782-2015; Berenger, Byron/M-4761-2019	Ferrar, Tony S/0000-0002-4606-1613; Berenger, Byron/0000-0001-9062-6346; Ng, Kenneth K.S./0000-0001-7280-8445				Aldehni MF, 2003, J BACTERIOL, V185, P2582, DOI 10.1128/JB.185.8.2582-2591.2003; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Burillo S, 2004, J BACTERIOL, V186, P3346, DOI 10.1128/JB.186.11.3346-3354.2004; Coruzzi GM, 2003, ARABIDOPSIS BOOK; Fernandez-Murga ML, 2004, J BACTERIOL, V186, P6142, DOI 10.1128/JB.186.18.6142-6149.2004; Ferraris S, 2005, 5 INT FOR AL SHIPS, P1; Forchhammer K, 2004, FEMS MICROBIOL REV, V28, P319, DOI 10.1016/j.femsre.2003.11.001; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; Hanson TE, 1998, MICROBIOL-SGM, V144, P1537, DOI 10.1099/00221287-144-6-1537; Heinrich A, 2004, MOL MICROBIOL, V52, P1303, DOI 10.1111/j.1365-2958.2004.04058.x; Hisbergues M, 1999, FEBS LETT, V463, P216, DOI 10.1016/S0014-5793(99)01624-5; Hsieh MH, 1998, P NATL ACAD SCI USA, V95, P13965, DOI 10.1073/pnas.95.23.13965; Lee HM, 2000, EUR J BIOCHEM, V267, P591, DOI 10.1046/j.1432-1327.2000.01043.x; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Magasanik B, 2000, TRENDS MICROBIOL, V8, P447, DOI 10.1016/S0966-842X(00)01849-7; Maheswaran M, 2004, J BIOL CHEM, V279, P55202, DOI 10.1074/jbc.M410971200; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; MOFFATT B, 2002, ARABIDOPSIS BOOK; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Moorhead GBG, 2003, PLANT PHYSIOL, V133, P492, DOI 10.1104/pp.103.025627; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; Ninfa AJ, 2005, CURR OPIN MICROBIOL, V8, P168, DOI 10.1016/j.mib.2005.02.011; Palinska KA, 2002, MICROBIOL-SGM, V148, P2405, DOI 10.1099/00221287-148-8-2405; Paz-Yepes J, 2003, FEBS LETT, V543, P42, DOI 10.1016/S0014-5793(03)00384-3; Smith CS, 2004, BBA-PROTEINS PROTEOM, V1699, P145, DOI 10.1016/j.bbapap.2004.02.009; Smith CS, 2003, PLANT J, V33, P353, DOI 10.1046/j.1365-313X.2003.01634.x; Smith CS, 2002, PROTEIN EXPRES PURIF, V25, P342, DOI 10.1016/S1046-5928(02)00018-9; Sugiyama K, 2004, PLANT CELL PHYSIOL, V45, P1768, DOI 10.1093/pcp/pch199; Templeton GW, 2005, EMBO REP, V6, P723, DOI 10.1038/sj.embor.7400479; Tran HT, 2004, MOL CELL PROTEOMICS, V3, P257, DOI 10.1074/mcp.M300115-MCP200	30	84	92	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5726	5733		10.1074/jbc.M510945200	http://dx.doi.org/10.1074/jbc.M510945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377628	hybrid			2022-12-25	WOS:000235568900050
J	Dresbach, T; Torres, V; Wittenmayer, N; Altrock, WD; Zamorano, P; Zuschratter, W; Nawrotzki, R; Ziv, NE; Garner, CC; Gundelfinger, ED				Dresbach, T; Torres, V; Wittenmayer, N; Altrock, WD; Zamorano, P; Zuschratter, W; Nawrotzki, R; Ziv, NE; Garner, CC; Gundelfinger, ED			Assembly of active zone precursor vesicles - Obligatory trafficking of presynaptic cytomatrix proteins bassoon and piccolo via a trans-Golgi compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MECHANISMS; BREFELDIN-A; NEUROTRANSMITTER RELEASE; FUNCTIONAL INTERACTION; SYNAPSES; FAMILY; RIM1; SYNAPTOGENESIS; INVOLVEMENT; MEMBRANES	\Neurotransmitter release from presynaptic nerve terminals is restricted to specialized areas of the plasma membrane, so-called active zones. Active zones are characterized by a network of cytoplasmic scaffolding proteins involved in active zone generation and synaptic transmission. To analyze the modes of biogenesis of this cytomatrix, we asked how Bassoon and Piccolo, two prototypic active zone cytomatrix molecules, are delivered to nascent synapses. Although these proteins may be transported via vesicles, little is known about the importance of a vesicular pathway and about molecular determinants of cytomatrix molecule trafficking. We found that Bassoon and Piccolo co-localize with markers of the trans-Golgi network in cultured neurons. Impairing vesicle exit from the Golgi complex, either using brefeldin A, recombinant proteins, or a low temperature block, prevented transport of Bassoon out of the soma. Deleting a newly identified Golgi-binding region of Bassoon impaired subcellular targeting of recombinant Bassoon. Overexpressing this region to specifically block Golgi binding of the endogenous protein reduced the concentration of Bassoon at synapses. These results suggest that, during the period of bulk synaptogenesis, a primordial cytomatrix assembles in a trans-Golgi compartment. They further indicate that transport via Golgi-derived vesicles is essential for delivery of cytomatrix proteins to the synapse. Paradigmatically this establishes Golgi transit as an obligatory step for subcellular trafficking of distinct cytoplasmic scaffolding proteins.	Heidelberg Univ, Inst Anat & Cell Biol, D-69120 Heidelberg, Germany; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; Technion Israel Inst Technol, Fac Med, Dept Physiol, IL-31096 Haifa, Israel	Ruprecht Karls University Heidelberg; Leibniz Institut fur Neurobiologie (LIN); Stanford University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Gundelfinger, ED (corresponding author), Heidelberg Univ, Inst Anat & Cell Biol, Neuenheimer Feld 307, D-69120 Heidelberg, Germany.	gundelfinger@ifn-magdeburg.de	Ziv, Noam/ABA-6551-2020; Torres, Viviana/AAC-3329-2019	Ziv, Noam/0000-0001-9197-326X; Torres, Viviana/0000-0002-1220-7709; Garner, Craig/0000-0003-1970-5417	NIA NIH HHS [AG 12978-02, AG 06569-09] Funding Source: Medline; NICHD NIH HHS [P30 HD 38985-03, P50 HD 32901] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD038985] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG012978] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Bresler T, 2004, J NEUROSCI, V24, P1507, DOI 10.1523/JNEUROSCI.3819-03.2004; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Dick O, 2003, NEURON, V37, P775, DOI 10.1016/S0896-6273(03)00086-2; Dieck ST, 2005, J CELL BIOL, V168, P825, DOI 10.1083/jcb.200408157; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Dresbach T, 2003, MOL CELL NEUROSCI, V23, P279, DOI 10.1016/S1044-7431(03)00015-0; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; Garner CC, 2002, TRENDS NEUROSCI, V25, P243, DOI 10.1016/S0166-2236(02)02152-5; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jareb M, 1997, J NEUROSCI, V17, P8955; Kanaani J, 2004, J CELL SCI, V117, P2001, DOI 10.1242/jcs.01030; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Polishchuk RS, 2004, CELL MOL LIFE SCI, V61, P146, DOI 10.1007/s00018-003-3353-8; Righter K, 1999, J COMP NEUROL, V408, P437, DOI 10.1002/(SICI)1096-9861(19990607)408:3<437::AID-CNE9>3.0.CO;2-5; Roos J, 2000, NAT NEUROSCI, V3, P415, DOI 10.1038/74773; Rosenmund C, 2003, CURR OPIN NEUROBIOL, V13, P509, DOI 10.1016/j.conb.2003.09.011; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shapira M, 2003, NEURON, V38, P237, DOI 10.1016/S0896-6273(03)00207-1; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Spang A, 2002, CURR OPIN CELL BIOL, V14, P423, DOI 10.1016/S0955-0674(02)00346-0; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Takao-Rikitsu E, 2004, J CELL BIOL, V164, P301, DOI 10.1083/jcb.200307101; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Ziv NE, 2004, NAT REV NEUROSCI, V5, P385, DOI 10.1038/nrn1370	40	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6038	6047		10.1074/jbc.M508784200	http://dx.doi.org/10.1074/jbc.M508784200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373352	hybrid			2022-12-25	WOS:000235568900085
J	Hernandez-Gonzalez, EO; Sosnik, J; Edwards, J; Acevedo, JJ; Mendoza-Lujambio, I; Lopez-Gonzalez, I; Demarco, I; Wertheimer, E; Darszon, A; Visconti, PE				Hernandez-Gonzalez, EO; Sosnik, J; Edwards, J; Acevedo, JJ; Mendoza-Lujambio, I; Lopez-Gonzalez, I; Demarco, I; Wertheimer, E; Darszon, A; Visconti, PE			Sodium and epithelial sodium channels participate in the regulation of the capacitation-associated hyperpolarization in mouse sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PROTEIN-TYROSINE PHOSPHORYLATION; MEDIATED SIGNAL-TRANSDUCTION; SPERMATOGENIC CELLS; NA+ CHANNEL; FUNCTIONAL EXPRESSION; CA2+ CHANNELS; ION CHANNELS; ACROSOME REACTION; MAMMALIAN SPERM	In a process called capacitation, mammalian sperm gain the ability to fertilize after residing in the female tract. During capacitation the mouse sperm plasma membrane potential (E-m) hyperpolarizes. However, the mechanisms that regulate sperm E-m are not well understood. Here we show that sperm hyperpolarize when external Na+ is replaced by N-methyl-glucamine. Readdition of external Na+ restores a more depolarized E-m by a process that is inhibited by amiloride or by its more potent derivative 5-(N-ethyl-N-isopropyl)amiloride hydrochloride. These findings indicate that under resting conditions an electrogenic Na+ transporter, possibly involving an amiloride sensitive Na+ channel, may contribute to the sperm resting E-m. Consistent with this proposal, patch clamp recordings from spermatogenic cells reveal an amiloride-sensitive inward Na+ current whose characteristics match those of the epithelial Na+ channel ( ENaC) family of epithelial Na+ channels. Indeed, ENaC-alpha and -delta mRNAs were detected by reverse transcription-PCR in extracts of isolated elongated spermatids, and ENaC-alpha and -delta proteins were found on immunoblots of sperm membrane preparations. Immunostaining indicated localization of ENaC-alpha to the flagellar midpiece and of ENaC-delta to the acrosome. Incubations known to produce capacitation in vitro or induction of capacitation by cell-permeant cAMP analogs decreased the depolarizing response to the addition of external Na+. These results suggest that increases in cAMP content occurring during capacitation may inhibit ENaCs to produce a required hyperpolarization of the sperm membrane.	Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Dev Genet & Mol Physiol, Cuernavaca 62210, Morelos, Mexico; Univ Massachusetts, Dept Vet & Anim Sci, Paige Labs, Amherst, MA 01003 USA; Inst Politecn Nacl, Ctr Res & Adv Studies, Dept Cell Biol, Mexico City 07300, DF, Mexico; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Autonoma Morelos, Sch Med, Dept Physiol & Pathophysiol, Cuernavaca 62210, Morelos, Mexico; Inst Politecn Nacl, Natl Med & Homeopathy Sch, Mol Biomed Postgrad Program, Mexico City 07320, DF, Mexico	Universidad Nacional Autonoma de Mexico; University of Massachusetts System; University of Massachusetts Amherst; Instituto Politecnico Nacional - Mexico; University of Virginia; Universidad Autonoma del Estado de Morelos; Instituto Politecnico Nacional - Mexico	Darszon, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Dev Genet & Mol Physiol, Ave Univ 2001 Col Chamilpa, Cuernavaca 62210, Morelos, Mexico.	darszon@ibt.unam.mx	Hernández-González, Enrique/AAU-8526-2020; Sosnik, Julian/A-8310-2010; Mendoza-Lujambio, Irene/AAD-6955-2022	Sosnik, Julian/0000-0002-0528-9929; Mendoza-Lujambio, Irene/0000-0002-0677-9946; Darszon, Alberto/0000-0002-2502-0505; Lopez-Gonzalez, Ignacio/0000-0002-1536-0258; Acevedo, Juan Jose/0000-0001-8306-1690	FIC NIH HHS [R03 TW 006121] Funding Source: Medline; NICHD NIH HHS [HD 44044, HD 38082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD038082, R01HD044044] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW006121] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Arnoult C, 1998, MOL PHARMACOL, V53, P1104; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Blanco G, 2003, ANN NY ACAD SCI, V986, P536, DOI 10.1111/j.1749-6632.2003.tb07245.x; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Castellano LE, 2003, FEBS LETT, V541, P69, DOI 10.1016/S0014-5793(03)00305-3; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Delmas P, 2004, FASEB J, V18, P740, DOI 10.1096/fj.03-0319fje; Demarco IA, 2003, J BIOL CHEM, V278, P7001, DOI 10.1074/jbc.M206284200; ESPINOSA F, 1995, FEBS LETT, V372, P119, DOI 10.1016/0014-5793(95)00962-9; Ficarro S, 2003, J BIOL CHEM, V278, P11579, DOI 10.1074/jbc.M202325200; Florman HM, 1998, BIOL REPROD, V59, P12, DOI 10.1095/biolreprod59.1.12; Gamper N, 2000, PFLUG ARCH EUR J PHY, V441, P281, DOI 10.1007/s004240000410; Gong XD, 2001, MOL HUM REPROD, V7, P705, DOI 10.1093/molehr/7.8.705; Gonzalez-Martinez MT, 2003, J BIOL CHEM, V278, P36304, DOI 10.1074/jbc.M304479200; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hernandez-Gonzalez EO, 2000, CELL MOTIL CYTOSKEL, V46, P43, DOI 10.1002/(SICI)1097-0169(200005)46:1&lt;43::AID-CM5&gt;3.0.CO;2-1; Inagaki A, 2004, AM J PHYSIOL-CELL PH, V286, pC380, DOI 10.1152/ajpcell.00373.2003; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Ji HL, 2004, J BIOL CHEM, V279, P26939, DOI 10.1074/jbc.M401143200; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; KALAB P, 1994, J BIOL CHEM, V269, P3810; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kierszenbaum AL, 2004, MOL REPROD DEV, V67, P385, DOI 10.1002/mrd.20042; Konig J, 2001, EMBO REP, V2, P1047, DOI 10.1093/embo-reports/kve232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; Lopez-Gonzalez I, 2001, DEV BIOL, V236, P210, DOI 10.1006/dbio.2001.0314; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; MOORE GD, 1994, DEVELOPMENT, V120, P3313; Munoz-Garay C, 2001, DEV BIOL, V234, P261, DOI 10.1006/dbio.2001.0196; Narahashi T, 2002, MINI-REV MED CHEM, V2, P419, DOI 10.2174/1389557023405927; Patrat C, 2000, BIOL CELL, V92, P255, DOI 10.1016/S0248-4900(00)01072-8; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Schreiber R, 2003, J MEMBRANE BIOL, V192, P101, DOI 10.1007/s00232-002-1067-8; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Trevino CL, 2004, FEBS LETT, V563, P87, DOI 10.1016/S0014-5793(04)00257-1; Trevino CL, 2001, FEBS LETT, V509, P119, DOI 10.1016/S0014-5793(01)03134-9; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Visconti PE, 1999, DEV BIOL, V214, P429, DOI 10.1006/dbio.1999.9428; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; Wright SH, 2004, ADV PHYSIOL EDUC, V28, P139, DOI 10.1152/advan.00029.2004; Yamamura H, 2004, J BIOL CHEM, V279, P12529, DOI 10.1074/jbc.M400274200; Yanagimachi R., 1994, P189; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; ZENG Y, 1995, DEV BIOL, V171, P554, DOI 10.1006/dbio.1995.1304	60	99	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5623	5633		10.1074/jbc.M508172200	http://dx.doi.org/10.1074/jbc.M508172200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407190	hybrid			2022-12-25	WOS:000235568900038
J	Korber, P; Barbaric, S; Luckenbach, T; Schmid, A; Schermer, UJ; Blaschke, D; Horz, W				Korber, P; Barbaric, S; Luckenbach, T; Schmid, A; Schermer, UJ; Blaschke, D; Horz, W			The histone chaperone Asf1 increases the rate of histone eviction at the yeast PHO5 and PHO8 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-SYNTHESIS; IN-VIVO; TRANSCRIPTIONAL REGULATION; NUCLEOSOME DISRUPTION; CHROMATIN TRANSITION; ASSEMBLY PATHWAYS; ACTIVATION; INDUCTION; BINDING	Eukaryotic gene expression starts off from a largely obstructive chromatin substrate that has to be rendered accessible by regulated mechanisms of chromatin remodeling. The yeast PHO5 promoter is a well known example for the contribution of positioned nucleosomes to gene repression and for extensive chromatin remodeling in the course of gene induction. Recently, the mechanism of this remodeling process was shown to lead to the disassembly of promoter nucleosomes and the eviction of the constituent histones in trans. This finding called for a histone acceptor in trans and thus made histone chaperones likely to be involved in this process. In this study we have shown that the histone chaperone Asf1 increases the rate of histone eviction at the PHO5 promoter. In the absence of Asf1 histone eviction is delayed, but the final outcome of the chromatin transition is not affected. The same is true for the coregulated PHO8 promoter where induction also leads to histone eviction and where the rate of histone loss is reduced in asf1 strains as well, although less severely. Importantly, the final extent of chromatin remodeling is not affected. We have also presented evidence that Asf1 and the SWI/SNF chromatin remodeling complex work in distinct parallel but functionally overlapping pathways, i.e. they both contribute toward the same outcome without being mutually strictly dependent.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Univ Zagreb, Fac Food Technol & Biotechnol, Biochem Lab, Zagreb 10000, Croatia	University of Munich; University of Zagreb	Korber, P (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	pkorber@lmu.de	Korber, Philipp/AAN-7633-2021	Korber, Philipp/0000-0001-7526-6549				Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; Barbaric S, 2001, EMBO J, V20, P4944, DOI 10.1093/emboj/20.17.4944; Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Boeger H, 2003, MOL CELL, V11, P1587, DOI 10.1016/S1097-2765(03)00231-4; Dhasarathy A, 2005, MOL CELL BIOL, V25, P2698, DOI 10.1128/MCB.25.7.2698-2707.2005; ERTINGER G, 1998, THESIS U MUNCHEN GER; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Gregory PD, 1999, METH MOL B, V119, P417; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Huang SD, 2005, GENETICS, V169, P1859, DOI 10.1534/genetics.104.038695; Ito T, 1996, MOL CELL BIOL, V16, P3112; KANEKO Y, 1989, MOL GEN GENET, V220, P133, DOI 10.1007/BF00260867; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Loyola A, 2001, GENE DEV, V15, P2837; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Munsterkotter M, 2000, J BIOL CHEM, V275, P22678, DOI 10.1074/jbc.M001409200; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neef DW, 2003, MOL CELL BIOL, V23, P3788, DOI 10.1128/MCB.23.11.3788-3797.2003; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; OSLEY MA, 1987, MOL CELL BIOL, V7, P4204, DOI 10.1128/MCB.7.12.4204; Ray-Gallet D, 2004, METHOD ENZYMOL, V375, P117; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Richmond E, 1996, NUCLEIC ACIDS RES, V24, P3685, DOI 10.1093/nar/24.19.3685; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; Sharp JA, 2005, GENETICS, V171, P885, DOI 10.1534/genetics.105.044719; Shen XT, 2003, MOL CELL, V12, P147, DOI 10.1016/S1097-2765(03)00264-8; Springer M, 2003, PLOS BIOL, V1, P261, DOI 10.1371/journal.pbio.0000028; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Sutton A, 2001, GENETICS, V158, P587; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SVAREN J, 1995, METH MOL G, V6, P153; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Verreault A, 2000, GENE DEV, V14, P1430	49	89	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5539	5545		10.1074/jbc.M513340200	http://dx.doi.org/10.1074/jbc.M513340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407267	hybrid			2022-12-25	WOS:000235568900028
J	Maeda, S; Sugita, C; Sugita, M; Omata, T				Maeda, S; Sugita, C; Sugita, M; Omata, T			Latent nitrate transport activity of a novel sulfate permease-like protein of the cyanobacterium Synechococcus elongatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRITE REDUCTASE; GENE; IDENTIFICATION; CLONING; SYSTEM; EXPRESSION; ASSIMILATION; MUTAGENESIS; PCC-7942	The Synechococcus elongatus mutant lacking the nrtABCD gene cluster (NA3) is defective in active nitrate transport and requires high nitrate concentrations (> 30 mM) for sustained growth. Prolonged incubation of NA3 in medium containing 2 mM nitrate led to isolation of a pseudorevertant (NA3R) capable of transport of millimolar concentrations of nitrate, from which three mutants with improved affinity for nitrate were obtained. We identified three genes responsible for the latent transport activity for nitrate: ltnA, which encodes a response regulator with no effector domain; ltnB, which encodes a hybrid histidine kinase with two receiver domains; and ltnT, which encodes a sulfate permease-like protein with a putative cyclic nucleoside monophosphate (cNMP)-binding domain. Missense mutations of the high affinity derivatives of NA3R were found in ltnT, verifying that LtnT acts as the transporter. Overexpression of truncated LtnT lacking the cNMP-binding domain (but not full-length LtnT) conferred nitrate transport activity on NA3, suggesting that the cNMP-binding domain inhibits transport under normal conditions. A nonsense mutation in ltnB that resulted in elimination of the receiver domains of the encoded protein was responsible for expression of nitrate transport activity in NA3R. Expression of LtnB derivatives lacking the receiver domains also conferred low affinity nitrate transport activity on NA3. The phosphoryl group of the histidine kinase domain of LtnB was transferred to Asp(52) of LtnA in vitro. Overexpression of LtnA (but not LtnA(D52E)) led to manifestation of the latent nitrate transport activity in NA3, indicating involvement of phosphorylated LtnA in activation of the novel transporter.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Mol Plant Physiol, Chikusa Ku, Aichi 4648601, Japan; Nagoya Univ, Ctr Gene Res, Aichi 4648601, Japan	Nagoya University; Nagoya University	Maeda, S (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Mol Plant Physiol, Chikusa Ku, Aichi 4648601, Japan.	maeda@agr.nagoya-u.ac.jp						AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; ANDRIESSE X, 1990, INORGANIC NITROGEN P, P303; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; DZELZKALNS VA, 1984, NUCLEIC ACIDS RES, V12, P8917, DOI 10.1093/nar/12.23.8917; Forde BG, 2000, BBA-BIOMEMBRANES, V1465, P219, DOI 10.1016/S0005-2736(00)00140-1; GREEN LS, 1989, P NATL ACAD SCI USA, V86, P1949, DOI 10.1073/pnas.86.6.1949; Guerrero M. G., 1987, The Cyanobacteria., P163; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUHLEMEIER CJ, 1983, PLASMID, V10, P156, DOI 10.1016/0147-619X(83)90068-9; KUHLEMEIER CJ, 1984, J BACTERIOL, V159, P36, DOI 10.1128/JB.159.1.36-41.1984; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUQUE I, 1993, PLANT MOL BIOL, V21, P1201, DOI 10.1007/BF00023618; MacKinney G, 1941, J BIOL CHEM, V140, P315; Maeda S, 1998, J BACTERIOL, V180, P4080, DOI 10.1128/JB.180.16.4080-4088.1998; Maeda SI, 1997, J BIOL CHEM, V272, P3036, DOI 10.1074/jbc.272.5.3036; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; OMATA T, 1995, PLANT CELL PHYSIOL, V36, P207, DOI 10.1093/oxfordjournals.pcp.a078751; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; Price GD, 2004, P NATL ACAD SCI USA, V101, P18228, DOI 10.1073/pnas.0405211101; SILVERMAN M, 1977, J BACTERIOL, V130, P1317, DOI 10.1128/JB.130.3.1317-1325.1977; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; SUZUKI I, 1993, PLANT CELL PHYSIOL, V34, P1311; Suzuki I, 1996, J BACTERIOL, V178, P2688, DOI 10.1128/jb.178.9.2688-2694.1996; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WILLIAMS JGK, 1983, GENE, V24, P37, DOI 10.1016/0378-1119(83)90129-4; Yoshihara S, 2000, PLANT CELL PHYSIOL, V41, P1299, DOI 10.1093/pcp/pce010; Yoshimura H, 2000, J BIOL CHEM, V275, P6241, DOI 10.1074/jbc.275.9.6241	33	9	10	2	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5869	5876		10.1074/jbc.M513196200	http://dx.doi.org/10.1074/jbc.M513196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407232	hybrid			2022-12-25	WOS:000235568900067
J	Sun, MX; Oakes, JL; Ananthanarayanan, SK; Hawley, KH; Tsien, RY; Adams, SR; Yengo, CM				Sun, MX; Oakes, JL; Ananthanarayanan, SK; Hawley, KH; Tsien, RY; Adams, SR; Yengo, CM			Dynamics of the upper 50-kDa domain of myosin V examined with fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; F-ACTIN; BINDING; MECHANISM; MOVEMENT; RELEASE; COMPLEX; CLEFT; MOTOR	The upper 50-kDa region of myosin may be critical for coupling between the nucleotide- and actin-binding regions. We introduced a tetracysteine motif in the upper 50-kDa domain ( residues 292 297) of myosin V containing a single IQ domain (MV 1IQ), allowing us to label this site with the fluorescein biarscenical hairpin-binding dye (FlAsH) (MV1IQ FlAsH). The enzymatic properties of MV 1IQ FlAsH were similar to those of unlabeled MV 1IQ except for a 3-fold reduced ADP-release rate. MV1IQ FlAsH was also capable of moving actin filaments in the in vitro motility assay. To examine rotation of the upper 50-kDa region, we determined the difference in the degree of energy transfer from N-methylanthraniloyl ( mant)-labeled nucleotides to FlAsH in both steady-state and transient kinetic experiments. The energy transfer efficiency was higher with mant-ATP (0.65 +/- 0.02) compared with mant-ADP (0.55 +/- 0.02) in the absence of actin. Stopped- flow measurements suggested that the energy transfer efficiency decreased with phosphate release (0.04 s(-1)) in the absence of actin. In contrast, upon mixing MV 1IQ FlAsH in the ADP.P-i state with actin, a decrease in the energy transfer signal was observed at a rate of 13 s(-1), similar to the ADP release rate. Our results demonstrate there was no change in the energy transfer signal upon actin-activated phosphate release and suggest that actin binding alters the dynamics of the upper 50-kDa region, which may be critical for the ability of myosin to bind tightly to both ADP and actin.	Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of North Carolina; University of North Carolina Charlotte; University of California System; University of California San Diego	Yengo, CM (corresponding author), Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA.	cmyengo@email.uncc.edu						Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Conibear PB, 2004, BIOCHEMISTRY-US, V43, P15404, DOI 10.1021/bi048338j; Conibear PB, 2003, NAT STRUCT BIOL, V10, P831, DOI 10.1038/nsb986; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Holmes KC, 2004, PHILOS T ROY SOC B, V359, P1819, DOI 10.1098/rstb.2004.1566; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Ignatova Z, 2004, P NATL ACAD SCI USA, V101, P523, DOI 10.1073/pnas.0304533101; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lawson JD, 2004, BIOPHYS J, V86, P3794, DOI 10.1529/biophysj.103.037390; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Robia SL, 2005, BIOCHEMISTRY-US, V44, P4302, DOI 10.1021/bi0478446; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; Sellers J. R., 1999, MYOSINS; Takagi Y, 2004, PHILOS T R SOC B, V359, P1913, DOI 10.1098/rstb.2004.1561; Tiago T, 2004, BIOCHEMISTRY-US, V43, P5551, DOI 10.1021/bi049910+; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	35	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5711	5717		10.1074/jbc.M508103200	http://dx.doi.org/10.1074/jbc.M508103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377637	hybrid			2022-12-25	WOS:000235568900048
J	Wee, G; Koo, DB; Song, BS; Kim, JS; Kang, MJ; Moon, SJ; Kang, YK; Lee, KK; Han, YM				Wee, G; Koo, DB; Song, BS; Kim, JS; Kang, MJ; Moon, SJ; Kang, YK; Lee, KK; Han, YM			Inheritable histone H4 acetylation of somatic chromatins in cloned embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; IN-VITRO; NUCLEAR TRANSFER; DNA METHYLATION; IMPRINTED GENES; MOUSE; CELL; ABERRANT; H1	A viable cloned animal indicates that epigenetic status of the differentiated cell nucleus is reprogrammed to an embryonic totipotent state. However, molecular events regarding epigenetic reprogramming of the somatic chromatin are poorly understood. Here we provide new insight that somatic chromatins are refractory to reprogramming of histone acetylation during early development. A low level of acetylated histone H4-lysine 5 (AcH4K5) of the somatic chromatin was sustained at the pronuclear stage. Unlike in vitro fertilized (IVF) embryos, the AcH4K5 level remarkably reduced at the 8-cell stage in cloned bovine embryos. The AcH4K5 status of somatic chromatins transmitted to cloned and even recloned embryos. Differences of AcH4K5 signal intensity were more distinguishable in the metaphase chromosomes between IVF and cloned embryos. Two imprinted genes, Ndn and Xist, were aberrantly expressed in cloned embryos as compared with IVF embryos, which is partly associated with the AcH4K5 signal intensity. Our findings suggest that abnormal epigenetic reprogramming in cloned embryos may be because of a memory mechanism, the epigenetic status itself of somatic chromatins.	KRIBB, Lab Dev & Differentiat, Taejon 305806, South Korea; Chonnam Natl Univ, Dept Anim Sci, Kwangju 500757, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chonnam National University	Han, YM (corresponding author), 52 Eoeun Dong, Taejon 305806, South Korea.	ymhan@kribb.re.kr	Han, Yong-Mahn/C-1652-2011					Adenot PG, 1997, DEVELOPMENT, V124, P4615; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; BAVISTER BD, 1977, BIOL REPROD, V16, P228, DOI 10.1095/biolreprod16.2.228; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Bordignon V, 1999, BIOL REPROD, V61, P22, DOI 10.1095/biolreprod61.1.22; BOUNIOL C, 1995, EXP CELL RES, V218, P57, DOI 10.1006/excr.1995.1130; Bourc'his D, 2001, CURR BIOL, V11, P1542, DOI 10.1016/S0960-9822(01)00480-8; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Clarke HJ, 1997, J CELL SCI, V110, P477; Dean W, 2001, P NATL ACAD SCI USA, V98, P13734, DOI 10.1073/pnas.241522698; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Gao SR, 2004, DEV BIOL, V266, P62, DOI 10.1016/j.ydbio.2003.10.003; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hu JF, 2000, ENDOCRINOLOGY, V141, P4428, DOI 10.1210/en.141.12.4428; Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399; Hyttel P, 1996, J REPROD FERTIL, V108, P263, DOI 10.1530/jrf.0.1080263; Inoue K, 2002, SCIENCE, V295, P297, DOI 10.1126/science.295.5553.297; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kang YK, 2001, NAT GENET, V28, P173, DOI 10.1038/88903; Kang YK, 2003, CURR OPIN CELL BIOL, V15, P290, DOI 10.1016/S0955-0674(03)00031-0; Kang YK, 2002, EMBO J, V21, P1092, DOI 10.1093/emboj/21.5.1092; Kim JM, 2003, J CELL BIOL, V162, P37, DOI 10.1083/jcb.200303047; KOPECNY V, 1989, Molecular Reproduction and Development, V1, P79; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LATHAM KE, 1991, DEVELOPMENT, V112, P921; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Memili E, 1998, MOL REPROD DEV, V51, P36, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;36::AID-MRD4&gt;3.0.CO;2-X; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Ohgane J, 2001, GENESIS, V30, P45, DOI 10.1002/gene.1031; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Peippo JP, 2002, MOL HUM REPROD, V8, P923, DOI 10.1093/molehr/8.10.923; Pfister-Genskow M, 2005, BIOL REPROD, V72, P546, DOI 10.1095/biolreprod.104.031799; Ruddock NT, 2004, BIOL REPROD, V70, P1131, DOI 10.1095/biolreprod.103.022236; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Svensson K, 1998, DEVELOPMENT, V125, P61; Teranishi T, 2004, DEV BIOL, V266, P76, DOI 10.1016/j.ydbio.2003.10.004; THOMPSON EM, 1995, DEVELOPMENT, V121, P3425; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Viuff D, 1996, MOL REPROD DEV, V43, P171, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;171::AID-MRD6&gt;3.0.CO;2-O; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WORRAD DM, 1995, DEVELOPMENT, V121, P2949; Wrenzycki C, 2001, BIOL REPROD, V65, P309, DOI 10.1095/biolreprod65.1.309; Xue F, 2002, NAT GENET, V31, P216, DOI 10.1038/ng900; Yang L, 2005, MOL REPROD DEV, V71, P431, DOI 10.1002/mrd.20311; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155; Zhang KL, 2002, MOL CELL PROTEOMICS, V1, P500, DOI 10.1074/mcp.M200031-MCP200	55	103	119	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6048	6057		10.1074/jbc.M511340200	http://dx.doi.org/10.1074/jbc.M511340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371357	hybrid			2022-12-25	WOS:000235568900086
J	Shen, H; Schuster, R; Stringer, KF; Waltz, SE; Lentsch, AB				Shen, H; Schuster, R; Stringer, KF; Waltz, SE; Lentsch, AB			The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth	FASEB JOURNAL			English	Article						cancer; angiogenesis; African-American; endothelial cell	IN-VITRO; ANTIGEN; CANCER; CELLS; RECEPTOR; INTERLEUKIN-8; ANGIOGENESIS; EXPRESSION; BINDING; MOTIF	The Duffy antigen/receptor for chemokines (DARC) is a promiscuous chemokine receptor that binds to members of the CXC chemokine family possessing angiogenic properties. The DARC is expressed on erythrocytes and endothelial cells and is required for Plasmodium vivax infection of erythrocytes. Approximately 70% of African-Americans lack erythrocyte expression of the DARC as a genetic mechanism of protection against malaria infection. African-American men have a 60% greater incidence of prostate cancer and a 2-fold higher mortality rate than Caucasian men. Using a transgenic model of prostate cancer with DARC-deficient mice, we tested the hypothesis that lack of DARC expression on erythrocytes contributes to enhanced prostate tumor growth. In vitro, erythrocytes from wild-type mice but not DARC-deficient mice cleared angiogenic chemokines produced by prostate cancer cells and reduced endothelial cell chemotaxis. In vivo, tumors from DARC-deficient mice had higher intra-tumor concentrations of angiogenic chemokines, increased tumor vessel density, and greatly augmented prostate tumor growth. The data suggest that the DARC functions to clear angiogenic CXC chemokines from the prostate tumor microcirculation and that the lack of erythroid DARC, as occurs in the majority of African-Americans, may be a contributing factor to the increased mortality to prostate cancer in this population.-Shen, H., Schuster, R., Stringer, K. F., Waltz, S. E., Lentsch, A. B. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lentsch, AB (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	alex.lentsch@uc.edu		Waltz, Susan/0000-0003-3572-4642				Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Addison CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-28; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; Dawson TC, 2000, BLOOD, V96, P1681, DOI 10.1182/blood.V96.5.1681.h8001681a_1681_1684; Du JG, 2002, J LEUKOCYTE BIOL, V71, P141; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; Kashiwazaki M, 2003, INT IMMUNOL, V15, P1219, DOI 10.1093/intimm/dxg121; Lee JS, 2003, J IMMUNOL, V170, P5244, DOI 10.4049/jimmunol.170.10.5244; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Ries LAG, 2004, SEER CANC STAT REV; Shen H, 2004, AM J PHYSIOL-CELL PH, V286, pC840, DOI 10.1152/ajpcell.00335.2003; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5	20	98	109	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					59	64		10.1096/fj.05-4764com	http://dx.doi.org/10.1096/fj.05-4764com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16394268				2022-12-25	WOS:000235996000045
J	Chan, IH; Privalsky, ML				Chan, I. H.; Privalsky, M. L.			Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs	ONCOGENE			English	Article						nuclear hormone receptors; dominant-negatives; hepatocellular carcinoma; DNA recognition; c-Jun; AP-1	DOMINANT-NEGATIVE ACTIVITY; RETINOIC ACID RECEPTORS; HUMAN HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; V-ERBA; TRANSCRIPTIONAL ACTIVATION; RESISTANCE; COREPRESSOR; GENE; EXPRESSION	Aberrant thyroid hormone receptors (TRs) are found in over 70% of the human hepatocellular carcinomas (HCCs) analysed. To better understand the role(s) of these TR mutants in this neoplasia, we analysed a panel of HCC mutant receptors for their molecular properties. Virtually all HCC-associated TR mutants tested retained the ability to repress target genes in the absence of T3, yet were impaired in T3-driven gene activation and functioned as dominant-negative inhibitors of wild-type TR activity. Intriguingly, the HCC TRa1 mutants exerted dominant-negative interference at all T3 concentrations tested, whereas the HCC TR beta 1 mutants were dominant-negatives only at low and intermediate T3 concentrations, reverting to transcriptional activators at higher hormone levels. The relative affinity for the SMRT versus N-CoR corepressors was detectably altered for several of the HCC mutant TRs, suggesting changes in corepressor preference and recruitment compared to wild type. Several of the TR alpha HCC mutations also altered the DNA recognition properties of the encoded receptors, indicating that these HCC TR mutants may regulate a distinct set of target genes from those regulated by wild-type TRs. Finally, whereas wild-type TRs interfere with c-Jun/AP-1 function in a T3-dependent fashion and suppress anchorage-independent growth when ectopically expressed in HepG2 cells, at least certain of the HCC mutants did not exert these inhibitory properties. These alterations in transcriptional regulation and DNA recognition appear likely to contribute to oncogenesis by reprogramming the differentiation and proliferative properties of the hepatocytes in which the mutant TRs are expressed.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu	Chan, Ivan/B-7922-2010	Chan, Ivan/0000-0003-2834-2574	NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA53394, R37 CA053394, R37 CA053394-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572; Apriletti JW, 1998, CLIN EXP PHARMACOL P, V25, pS2, DOI 10.1111/j.1440-1681.1998.tb02293.x; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; Cheng SY, 2003, MOL CELL ENDOCRINOL, V213, P23, DOI 10.1016/j.mce.2003.10.051; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Farboud B, 2004, MOL ENDOCRINOL, V18, P2839, DOI 10.1210/me.2004-0236; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Garcia-Silva S, 2004, MOL CELL BIOL, V24, P7514, DOI 10.1128/MCB.24.17.7514-7523.2004; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HuberGieseke T, 1997, ONCOLOGY, V54, P214; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Jonas BA, 2004, J BIOL CHEM, V279, P54676, DOI 10.1074/jbc.M410128200; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; Kamiya Y, 2003, ENDOCRINOLOGY, V144, P4144, DOI 10.1210/en.2003-0239; Kamiya Y, 2002, CARCINOGENESIS, V23, P25, DOI 10.1093/carcin/23.1.25; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Koenig RJ, 1998, THYROID, V8, P703, DOI 10.1089/thy.1998.8.703; Kopp P, 1996, P SOC EXP BIOL MED, V211, P49; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Lee JW, 2002, CANCER LETT, V184, P149, DOI 10.1016/S0304-3835(02)00206-9; Lee MO, 2002, BIOL PHARM BULL, V25, P1298, DOI 10.1248/bpb.25.1298; Lee S, 2005, MOL ENDOCRINOL, V19, P863, DOI 10.1210/me.2004-0210; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Lin KH, 1997, ENDOCRINOLOGY, V138, P5308, DOI 10.1210/en.138.12.5308; Lin KH, 2001, ENDOCRINOLOGY, V142, P653, DOI 10.1210/en.142.2.653; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Liu Y, 1998, ENDOCRINOLOGY, V139, P4197, DOI 10.1210/en.139.10.4197; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsushita A, 2000, J ENDOCRINOL, V167, P493, DOI 10.1677/joe.0.1670493; Moehren U, 2004, ESSAYS BIOCHEM, V40, P89, DOI 10.1042/bse0400089; Murata Y, 1998, Nagoya J Med Sci, V61, P103; Nagaya T, 1998, BIOCHEM BIOPH RES CO, V247, P620, DOI 10.1006/bbrc.1998.8854; Nagaya T, 1998, ENDOCR J, V45, P709, DOI 10.1507/endocrj.45.709; Ordentlich P, 2001, CURR TOP MICROBIOL, V254, P101; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Privalsky ML, 2000, MOL CELL ENDOCRINOL, V159, P109, DOI 10.1016/S0303-7207(99)00201-4; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SCHMIDT EDL, 1993, BIOCHEM BIOPH RES CO, V192, P151, DOI 10.1006/bbrc.1993.1394; SHARIF M, 1992, ONCOGENE, V7, P953; SISLEY K, 1993, MELANOMA RES, V3, P457, DOI 10.1097/00008390-199311000-00009; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; Tagami T, 1998, ENDOCRINOLOGY, V139, P640, DOI 10.1210/en.139.2.640; Tenbaum S, 1997, INT J BIOCHEM CELL B, V29, P1325, DOI 10.1016/S1357-2725(97)00087-3; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wang CS, 2002, CANCER LETT, V175, P121, DOI 10.1016/S0304-3835(01)00722-4; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Winter WE, 2001, ANN CLIN LAB SCI, V31, P221; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Yen PM, 2003, J ENDOCRINOL INVEST, V26, P780, DOI 10.1007/BF03347365; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	72	49	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3576	3588		10.1038/sj.onc.1209389	http://dx.doi.org/10.1038/sj.onc.1209389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434963	Green Accepted			2022-12-25	WOS:000238448200010
J	Vasilcanu, D; Weng, WH; Girnita, A; Lui, WO; Vasilcanu, R; Axelson, M; Larsson, O; Larsson, C; Girnita, L				Vasilcanu, D.; Weng, W-H; Girnita, A.; Lui, W-O; Vasilcanu, R.; Axelson, M.; Larsson, O.; Larsson, C.; Girnita, L.			The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection	ONCOGENE			English	Article						IGF-1 receptor; drug resistance; PPP	TYROSINE KINASE-ACTIVITY; SINGLE-CHAIN ANTIBODY; BREAST-CANCER CELLS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; IGF-I; ANTITUMOR-ACTIVITY; CYCLOLIGNAN PPP; MULTIDRUG-RESISTANCE; MOLECULAR-MECHANISMS; MULTIPLE-MYELOMA	The cyclolignan PPP was recently demonstrated to inhibit the activity of insulin-like growth factor-1 receptor (IGF-1R), without affecting the highly homologous insulin receptor. In addition, PPP caused complete regression of xenografts derived from various types of cancer. These data highlight the use of this compound in cancer treatment. However, a general concern with antitumor agents is development of resistance. In light of this problem, we aimed to investigate whether malignant cells may develop serious resistance to PPP. After trying to select 10 malignant cell lines, with documented IGF-1R expression and apoptotic responsiveness to PPP treatment (IC(50)s less than 0.1 mu M), only two survived an 80-week selection but could only tolerate maximal PPP doses of 0.2 and 0.5 mu M, respectively. Any further increase in the PPP dose resulted in massive cell death. These two cell lines were demonstrated not to acquire any essential alteration in responsiveness to PPP regarding IGF-1-induced IGF-1R phosphorylation. Neither did they exhibit any increase in expression of the multidrug resistance proteins MDR1 or MRP1. Consistently, they did not exhibit decreased sensitivity to conventional cytostatic drugs. Rather, the sensitivity was increased. During the first half of the selection period, both cell lines responded with a temporary and moderate increase in IGF-1R expression, which appeared to be because of an increased transcription of the IGF-1R gene. This increase in IGF-1R might be necessary to make cells competent for further selection but only up to a PPP concentration of 0.2 and 0.5 mu M. In conclusion, malignant cells develop no or remarkably weak resistance to the IGF-1R inhibitor PPP.	Karolinska Univ Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Univ Hosp, Dept Pathol & Oncol, CCK R8-04, SE-17176 Stockholm, Sweden.	olllar@ki.se	Girnita, Leonard/A-4168-2008; Weng, Wen Hui/AAV-7260-2021; Lui, Weng-Onn/X-5957-2019; Girnita, Ada/AAC-4518-2020; Lui, Weng-Onn/G-6703-2013	Girnita, Leonard/0000-0003-0280-9500; Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Ahlen J, 2005, CLIN CANCER RES, V11, P206; Alexia C, 2004, BIOCHEM PHARMACOL, V68, P1003, DOI 10.1016/j.bcp.2004.05.029; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; DAmbrosio C, 1996, CANCER RES, V56, P4013; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; GIRNITA A, 2005, IN PRESS CLIN CANC R; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; HIRSCHERNST KI, 1995, BIOCHEM BIOPH RES CO, V215, P179, DOI 10.1006/bbrc.1995.2450; Jerome L, 2003, ENDOCR-RELAT CANCER, V10, P561, DOI 10.1677/erc.0.0100561; Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799; Kanter-Lewensohn L, 2000, MOL CELL ENDOCRINOL, V165, P131, DOI 10.1016/S0303-7207(00)00253-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Le Roith D, 1999, ISR MED ASSOC J, V1, P25; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Peggs K, 2004, CLIN EXP MED, V4, P1, DOI 10.1007/s10238-004-0032-5; Reinmuth N, 2002, CLIN CANCER RES, V8, P3259; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; Sachdev D, 2003, CANCER RES, V63, P627; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VANWYK JJ, 1985, J CLIN ENDOCR METAB, V61, P639; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Yang K, 2002, ONCOGENE, V21, P4181, DOI 10.1038/sj.onc.1205569; Ye JJ, 2003, HORM METAB RES, V35, P836; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	59	37	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3186	3195		10.1038/sj.onc.1209339	http://dx.doi.org/10.1038/sj.onc.1209339			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407828				2022-12-25	WOS:000237951000009
J	Soria, G; Podhajcer, O; Prives, C; Gottifredi, V				Soria, G.; Podhajcer, O.; Prives, C.; Gottifredi, V.			P21(Cip1/WAF1) downregulation is required for efficient PCNA ubiquitination after UV irradiation	ONCOGENE			English	Article						p21; PCNA; ubiquitination; proteolysis; DNA repair	CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; KINASE INHIBITOR P21; DOUBLE-STRAND BREAK; DNA-DAMAGE; REPLICATION ARREST; POLYMERASE SWITCH; IN-VITRO; S-PHASE; DEGRADATION	p21(Cip1/WAF1) is a known inhibitor of the short- gap. filling activity of proliferating cell nuclear antigen ( PCNA) during DNA repair. In agreement, p21 degradation after UV irradiation promotes PCNA- dependent repair. Recent reports have identified ubiquitination of PCNA as a relevant feature for PCNA- dependent DNA repair. Here, we show that PCNA ubiquitination in human cells is notably augmented after UV irradiation and other genotoxic treatments such as hydroxyurea, aphidicolin and methylmethane sulfonate. Intriguingly, those DNA damaging agents also promoted downregulation of p21. While ubiquitination of PCNA was not affected by deficient nucleotide excision repair ( NER) and was observed in both proliferating and arrested cells, stable p21 expression caused a significant reduction in UV-induced ubiquitinated PCNA. Surprisingly, the negative regulation of PCNA ubiquitination by p21 does not depend on the direct interaction with PCNA but requires the cyclin dependent kinase binding domain of p21. Taken together, our data suggest that p21 downregulation plays a role in efficient PCNA ubiquitination after UV irradiation.	Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Leloir Institute; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Columbia University	Gottifredi, V (corresponding author), Fdn Inst Leloir, RA-1405 Buenos Aires, DF, Argentina.	vgottifredi@leloir.org.ar	Gottifredi, Vanesa/AAI-1788-2019	Gottifredi, Vanesa/0000-0001-9656-5951; podhajcer, osvaldo/0000-0002-6512-8553	NCI NIH HHS [CA058316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058316, R37CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carr AM, 2003, SCIENCE, V300, P1512, DOI 10.1126/science.1085689; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Chuang LC, 2005, J BIOL CHEM, V280, P35299, DOI 10.1074/jbc.M506429200; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Frouin I, 2005, NUCLEIC ACIDS RES, V33, P5354, DOI 10.1093/nar/gki845; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gottifredi V, 2004, J BIOL CHEM, V279, P5802, DOI 10.1074/jbc.M310373200; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kuhne C, 2003, NUCLEIC ACIDS RES, V31, P7227, DOI 10.1093/nar/gkg937; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; McDonald E, 1996, CANCER RES, V56, P2250; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Nikiforov A, 2004, BIOCHEM BIOPH RES CO, V323, P831, DOI 10.1016/j.bbrc.2004.08.165; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Pickart CM, 2002, NATURE, V419, P120, DOI 10.1038/419120a; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Solomon DA, 2004, J CELL BIOL, V166, P455, DOI 10.1083/jcb.200312048; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Watanabe K, 2004, EMBO J, V23, P3886, DOI 10.1038/sj.emboj.7600383	51	87	90	12	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2829	2838		10.1038/sj.onc.1209315	http://dx.doi.org/10.1038/sj.onc.1209315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407842				2022-12-25	WOS:000237448200001
J	Cheong, N; Madesh, M; Gonzales, LW; Zhao, M; Yu, K; Ballard, PL; Shuman, H				Cheong, N; Madesh, M; Gonzales, LW; Zhao, M; Yu, K; Ballard, PL; Shuman, H			Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMELLAR BODY MEMBRANE; LYSOSOME-RELATED ORGANELLES; II CELLS; TANGIER-DISEASE; PULMONARY SURFACTANT; MISSENSE MUTATIONS; QUALITY-CONTROL; IN-VITRO; PROTEIN; BODIES	Members of the ATP binding cassette (ABC) protein superfamily actively transport a wide range of substrates across cell and intracellular membranes. Mutations in ABCA3, a member of the ABCA subfamily with unknown function, lead to fatal respiratory distress syndrome (RDS) in the newborn. Using cultured human lung cells, we found that recombinant wild-type hABCA3 localized to membranes of both lysosomes and lamellar bodies, which are the intracellular storage organelles for surfactant. In contrast, hABCA3 with mutations linked to RDS failed to target to lysosomes and remained in the endoplasmic reticulum as unprocessed forms. Treatment of those cells with the chemical chaperone sodium 4-phenylbutyrate could partially restore trafficking of mutant ABCA3 to lamellar body-like structures. Expression of recombinant ABCA3 in non-lung human embryonic kidney 293 cells induced formation of lamellar body-like vesicles that contained lipids. Small interfering RNA knockdown of endogenous hABCA3 in differentiating human fetal lung alveolar type II cells resulted in abnormal, lamellar bodies comparable with those observed in vivo with mutant ABCA3. Silencing of ABCA3 expression also reduced vesicular uptake of surfactant lipids phosphatidylcholine, sphingomyelin, and cholesterol but not phosphatidylethanolamine. We conclude that ABCA3 is required for lysosomal loading of phosphatidylcholine and conversion of lysosomes to lamellar body-like structures.	Univ Penn, Dept Physiol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Canc Biol, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Div Neonatol, Sch Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Shuman, H (corresponding author), Univ Penn, Dept Physiol, Sch Med, B400 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.	shuman@mail.med.upenn.edu						Akasaki K, 2004, ARCH BIOCHEM BIOPHYS, V425, P147, DOI 10.1016/j.abb.2004.02.042; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; CHINOY MR, 1994, AM J PHYSIOL, V266, pL713, DOI 10.1152/ajplung.1994.266.6.L713; Choo-Kang LR, 2001, AM J PHYSIOL-LUNG C, V281, pL58, DOI 10.1152/ajplung.2001.281.1.L58; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; DOBBS LG, 1989, ANNU REV MED, V40, P431; Foster CD, 2003, AM J RESP CELL MOL, V29, P259, DOI 10.1165/rcmb.2002-0149OC; GIBSON KF, 1991, AM J RESP CELL MOL, V4, P504, DOI 10.1165/ajrcmb/4.6.504; Gonzales LW, 2002, AM J PHYSIOL-LUNG C, V283, pL940, DOI 10.1152/ajplung.00127.2002; Guo ZG, 2002, J HUM GENET, V47, P325, DOI 10.1007/s100380200044; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HOOK GER, 1982, J BIOL CHEM, V257, P9211; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Lim M, 2004, AM J RESP CELL MOL, V31, P351, DOI 10.1165/rcmb.2002-0086OC; Liu XL, 2004, J AM SOC NEPHROL, V15, P1731, DOI 10.1097/01.ASN.0000129826.28932.FD; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079; MULLER WJ, 1995, AM J PHYSIOL-LUNG C, V269, pL11, DOI 10.1152/ajplung.1995.269.1.L11; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Nagata K, 2004, BIOCHEM BIOPH RES CO, V324, P262, DOI 10.1016/j.bbrc.2004.09.043; Nishibori Y, 2004, KIDNEY INT, V66, P1755, DOI 10.1111/j.1523-1755.2004.00898.x; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Peelman F, 2003, J MOL BIOL, V325, P259, DOI 10.1016/S0022-2836(02)01105-1; Powell K, 2002, ADV DRUG DELIVER REV, V54, P1395, DOI 10.1016/S0169-409X(02)00148-5; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; Schaller-Bals S, 2000, AM J PHYSIOL-LUNG C, V279, pL631, DOI 10.1152/ajplung.2000.279.4.L631; SCHMITZ G, 1991, J LIPID RES, V32, P1539; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; SHULENIN S, 2004, NEW ENGL J MED, V350, P10; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; WASANO K, 1994, HISTOCHEMISTRY, V102, P329, DOI 10.1007/BF00268903; Weaver TE, 2002, SEMIN CELL DEV BIOL, V13, P263, DOI 10.1016/S1084952102000551; Welch WJ, 2004, SEMIN CELL DEV BIOL, V15, P31, DOI 10.1016/j.semcdb.2003.12.011; Wiszniewski W, 2005, HUM MOL GENET, V14, P2769, DOI 10.1093/hmg/ddi310; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	43	145	152	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9791	9800		10.1074/jbc.M507515200	http://dx.doi.org/10.1074/jbc.M507515200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16415354	hybrid			2022-12-25	WOS:000236404700092
J	Matsuo, Y; Morimoto, T; Kuwano, M; Loh, PC; Oshima, T; Ogasawara, N				Matsuo, Y; Morimoto, T; Kuwano, M; Loh, PC; Oshima, T; Ogasawara, N			The GTP-binding protein YlqF participates in the late step of 50 S ribosomal subunit assembly in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CROSS-LINKING; RNA HELICASE; 50S; ERA; RECONSTITUTION; IDENTIFICATION; OBG; OVEREXPRESSION; SUPPRESSION	Bacillus subtilis YlqF belongs to the Era/Obg subfamily of small GTP-binding proteins and is essential for bacterial growth. Here we report that YlqF participates in the late step of 50 S ribosomal subunit assembly. YlqF was co-fractionated with the 50 S subunit, depending on the presence of noncleavable GTP analog. Moreover, the GTPase activity of YlqF was stimulated specifically by the 50 S subunit in vitro. Dimethyl sulfate footprinting analysis disclosed that YlqF binds to a unique position in 23 S rRNA. Yeast two-hybrid data revealed interactions between YlqF and the B. subtilis L25 protein (Ctc). The interaction was confirmed by the pull-down assay of the purified proteins. Specifically, YlqF is positioned around the A-site and P-site on the 50 S subunit. Proteome analysis of the abnormal 50 S subunits that accumulated in YlqF-depleted cells showed that L16 and L27 proteins, located near the YlqF-binding domain, are missing. Our results collectively indicate that YlqF will organize the late step of 50 S ribosomal subunit assembly.	Nara Inst Sci & Technol, Grad Sch Informat Sci, Dept Bioinformat & Genom, Nara 6300101, Japan	Nara Institute of Science & Technology	Ogasawara, N (corresponding author), Nara Inst Sci & Technol, Grad Sch Informat Sci, Dept Bioinformat & Genom, 8916-5 Takayama, Nara 6300101, Japan.	nogasawa@bs.naist.jp	Ogasawara, Naotake/B-7971-2011; Loh, Pek Chin/S-9048-2017	Loh, Pek Chin/0000-0003-4865-0523				Arigoni F, 1998, NAT BIOTECHNOL, V16, P851, DOI 10.1038/nbt0998-851; Bongiorni C, 2005, J BACTERIOL, V187, P4353, DOI 10.1128/JB.187.13.4353-4361.2005; Caldon CE, 2001, MOL MICROBIOL, V41, P289, DOI 10.1046/j.1365-2958.2001.02536.x; Charollais J, 2004, NUCLEIC ACIDS RES, V32, P2751, DOI 10.1093/nar/gkh603; Charollais J, 2003, MOL MICROBIOL, V48, P1253, DOI 10.1046/j.1365-2958.2003.03513.x; Czyz A, 2005, ACTA BIOCHIM POL, V52, P35; Daigle DM, 2004, J BACTERIOL, V186, P1381, DOI 10.1128/JB.186.5.1381-1387.2004; DAMMEL CS, 1995, GENE DEV, V9, P626, DOI 10.1101/gad.9.5.626; DOHME F, 1976, J MOL BIOL, V107, P585, DOI 10.1016/S0022-2836(76)80085-X; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; HAMPL H, 1981, J BIOL CHEM, V256, P2284; Hang JQ, 2003, EUR J BIOCHEM, V270, P4164, DOI 10.1046/j.1432-1033.2003.03813.x; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HEROLD M, 1987, J BIOL CHEM, V262, P8826; Himeno H, 2004, NUCLEIC ACIDS RES, V32, P5303, DOI 10.1093/nar/gkh861; Inoue K, 2003, MOL MICROBIOL, V48, P1005, DOI 10.1046/j.1365-2958.2003.03475.x; James P, 1996, GENETICS, V144, P1425; KAZEMIE M, 1976, EUR J BIOCHEM, V67, P373, DOI 10.1111/j.1432-1033.1976.tb10701.x; KAZEMIE M, 1975, EUR J BIOCHEM, V58, P501, DOI 10.1111/j.1432-1033.1975.tb02398.x; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; LERNER CG, 1991, MOL MICROBIOL, V5, P951, DOI 10.1111/j.1365-2958.1991.tb00770.x; Lin B, 2004, J BACTERIOL, V186, P481, DOI 10.1128/JB.186.2.481-489.2004; LOTTI M, 1987, MOL GEN GENET, V210, P498, DOI 10.1007/BF00327203; Lu M, 2000, P NATL ACAD SCI USA, V97, P2023, DOI 10.1073/pnas.97.5.2023; Meier TI, 1999, J BACTERIOL, V181, P5242, DOI 10.1128/JB.181.17.5242-5249.1999; MICHELINE FR, 2003, GENE, V313, P17; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P21; MOORE VG, 1975, P NATL ACAD SCI USA, V72, P844, DOI 10.1073/pnas.72.3.844; Morimoto T, 2002, MICROBIOL-SGM, V148, P3539, DOI 10.1099/00221287-148-11-3539; Nanamiya H, 2004, MOL MICROBIOL, V52, P273, DOI 10.1111/j.1365-2958.2003.03972.x; Nishimura M, 2004, J MOL BIOL, V344, P1369, DOI 10.1016/j.jmb.2004.10.011; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; Sayed A, 1999, BIOCHEM BIOPH RES CO, V264, P51, DOI 10.1006/bbrc.1999.1471; Schmalisch M, 2002, J MOL MICROB BIOTECH, V4, P495; Scott JM, 2000, J BACTERIOL, V182, P2771, DOI 10.1128/JB.182.10.2771-2777.2000; Sharma H, 2005, INT ORTHOP, V29, P319, DOI 10.1007/s00264-005-0673-3; SRIVASTAVA AK, 1990, ANNU REV MICROBIOL, V44, P105, DOI 10.1146/annurev.mi.44.100190.000541; Takahashi N, 2003, MASS SPECTROM REV, V22, P287, DOI 10.1002/mas.10057; TATE WP, 1983, J BIOL CHEM, V258, P2810; TERAOKA H, 1978, FEBS LETT, V88, P223, DOI 10.1016/0014-5793(78)80179-3; TRAUB P, 1968, P NATL ACAD SCI USA, V59, P777, DOI 10.1073/pnas.59.3.777; Uchiumi T, 1999, J BIOL CHEM, V274, P681, DOI 10.1074/jbc.274.2.681; Uicker WC, 2006, MOL MICROBIOL, V59, P528, DOI 10.1111/j.1365-2958.2005.04948.x; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; WALLECZEK J, 1989, BIOCHEMISTRY-US, V28, P4099, DOI 10.1021/bi00435a071; Wilson DN, 2005, EMBO J, V24, P251, DOI 10.1038/sj.emboj.7600525; Wout P, 2004, J BACTERIOL, V186, P5249, DOI 10.1128/JB.186.16.5249-5257.2004; Wower IK, 1998, J BIOL CHEM, V273, P19847, DOI 10.1074/jbc.273.31.19847; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4; Zalacain M, 2003, J MOL MICROB BIOTECH, V6, P109, DOI 10.1159/000076741	51	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8110	8117		10.1074/jbc.M512556200	http://dx.doi.org/10.1074/jbc.M512556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16431913	hybrid			2022-12-25	WOS:000236031000048
J	Lafleur, MA; Mercuri, FA; Ruangpanit, N; Seiki, M; Sato, H; Thompson, EW				Lafleur, MA; Mercuri, FA; Ruangpanit, N; Seiki, M; Sato, H; Thompson, EW			Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A; CELL-SURFACE; MMP-2 ACTIVATION; METASTATIC PROGRESSION; MESSENGER-RNA; CANCER; INVASION; EXPRESSION; PROTEOLYSIS; PROGELATINASE	Type I collagen (Col I)-stimulated matrix metalloproteinase- 2 (MMP-2) activation via membrane type 1 MMP (MT1-MMP) involves both a transcriptional increase in MT1-MMP expression and a nontranscriptional response mediated by preexisting MT1-MMP. In order to identify which MT1-MMP domains were required for the nontranscriptional response, MCF-7 cells that lack endogenous MT1-MMP were transfected with either wild type or domain mutant MT1-MMP constructs. We observed that mutant constructs lacking the MT1-MMP cytoplasmic tail were able to activate MMP-2 in response to Col I but not a construct lacking the MT1-MMP hemopexin domain. Col I did not alter total MT1-MMP protein levels; nor did it appear to directly induce MT1-MMP oligomerization. Col I did, however, redistribute preexisting MT1-MMP to the cell periphery compared with unstimulated cells that displayed a more diffuse staining pattern. In addition, Col I blocked the internalization of MT1-MMP in a dynamin-dependent manner via clathrin-coated pit-mediated endocytosis. This mechanism of impaired internalization is different from that reported for concanavalin A, since it is not mediated by the cytoplasmic tail of MT1-MMP but rather by the hemopexin domain. In summary, upon Col I binding to its cell surface receptor, MT1-MMP internalization via clathrin-coated pit-mediated endocytosis is impaired through interactions with the hemopexin domain, thereby regulating its function and ability to activate MMP-2.	St Vincents Inst Med Res, VBCRC Invas & Metastasis Grp, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Surg, Fitzroy, Vic 3065, Australia; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Tokyo 1088639, Japan; Kanazawa Univ, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne; University of Tokyo; Kanazawa University	Thompson, EW (corresponding author), St Vincents Inst Med Res, VBCRC Invas & Metastasis Grp, 9 Princes St, Fitzroy, Vic 3065, Australia.	rik@medstv.unimelb.edu.au	Seiki, Motoharu/K-9443-2015; Thompson, Erik W/A-1425-2009; SATO, Hiroshi/D-8454-2015; Thompson, Erik/GPK-2067-2022	Thompson, Erik W/0000-0002-9723-4924; Thompson, Erik/0000-0002-9723-4924; Lafleur, Marc/0000-0002-8776-9773; Mercuri, Francesca/0000-0003-1026-2672				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Benmerah A, 1999, J CELL SCI, V112, P1303; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao H, 2000, J CELL SCI, V113, P1993; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1998, CANCER RES, V58, P5529; Gingras D, 2000, BBA-MOL CELL RES, V1497, P341, DOI 10.1016/S0167-4889(00)00071-9; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Henley JR, 1999, FASEB J, V13, pS243, DOI 10.1096/fasebj.13.9002.S243; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lafleur Marc A, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403006628; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; NOEL AC, 1994, INT J CANCER, V56, P331, DOI 10.1002/ijc.2910560306; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Ruangpanit N, 2001, MATRIX BIOL, V20, P193, DOI 10.1016/S0945-053X(01)00135-4; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Takino T, 2003, BIOCHEM BIOPH RES CO, V304, P160, DOI 10.1016/S0006-291X(03)00544-8; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Wang P, 2004, J BIOL CHEM, V279, P51148, DOI 10.1074/jbc.M409074200; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; YU M, 1995, CANCER RES, V55, P3272; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	55	46	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6826	6840		10.1074/jbc.M513084200	http://dx.doi.org/10.1074/jbc.M513084200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407177	Green Published, hybrid			2022-12-25	WOS:000236030800081
J	Li, XF; Kiedrowski, L; Tremblay, F; Fernandez, FR; Perizzolo, M; Winkfein, RJ; Turner, RW; Bains, JS; Rancourt, DE; Lytton, J				Li, XF; Kiedrowski, L; Tremblay, F; Fernandez, FR; Perizzolo, M; Winkfein, RJ; Turner, RW; Bains, JS; Rancourt, DE; Lytton, J			Importance of K+-dependent Na+/Ca2+-exchanger 2, NCKX2, in motor learning and memory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; LONG-TERM POTENTIATION; NA+/CA2+ EXCHANGERS; EXTRACELLULAR POTASSIUM; MICE LACKING; CA2+ CLEARANCE; RETINAL CONE; ROD; HOMEOSTASIS; RECEPTORS	Plasma membrane Na+/Ca2+-exchangers play a predominant role in Ca2+ extrusion in brain. Neurons express several different Na+/Ca2+-exchangers belonging to both the K+-independent NCX family and the K+-dependent NCKX family. The unique contributions of each of these proteins to neuronal Ca2+ homeostasis and/or physiology remain largely unexplored. To address this question, we generated mice in which the gene encoding the abundant neuronal K+-dependent Na+/Ca2+-exchanger protein, NCKX2, was knocked out. Analysis of these animals revealed a significant reduction in Ca2+ flux in cortical neurons, a profound loss of long term potentiation and an increase in long term depression at hippocampal Schaffer/CA1 synapses, and clear deficits in specific tests of motor learning and spatial working memory. Surprisingly, there was no obvious loss of photoreceptor function in cones, where expression of the NCKX2 protein had been reported previously. These data emphasize the critical and non-redundant role of NCKX2 in the local control of neuronal [Ca2+] that is essential for the development of synaptic plasticity associated with learning and memory.	Univ Calgary, Hlth Sci Ctr, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB T2N 4N1, Canada; Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Illinois, Inst Psychiat, Dept Psychiat, Chicago, IL 60612 USA; Univ Illinois, Inst Psychiat, Dept Pharmacol, Chicago, IL 60612 USA; Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3J 3G9, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; Libin Cardiovascular Institute Of Alberta; University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Dalhousie University	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Hotchkiss Brain Inst, Rm 2518,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Bains, Jaideep/0000-0002-3634-6463; Lytton, Jonathan/0000-0003-4770-2512; Tremblay, Francois/0000-0001-7780-8719	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037390] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37390] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; Ausubel F.M., 1998, CURRENT PROTOCOLS MO; BALLYK BA, 1992, J NEUROSCI RES, V33, P598, DOI 10.1002/jnr.490330412; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Biel M, 1999, P NATL ACAD SCI USA, V96, P7553, DOI 10.1073/pnas.96.13.7553; BLANKS JC, 1983, J COMP NEUROL, V221, P31, DOI 10.1002/cne.902210103; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Cai X, 2004, NEURON, V44, P351, DOI 10.1016/j.neuron.2004.09.026; Cai XJ, 2004, MOL BIOL EVOL, V21, P1692, DOI 10.1093/molbev/msh177; Cai XJ, 2002, J BIOL CHEM, V277, P48923, DOI 10.1074/jbc.M208818200; Chandrasekera CP, 2003, J BIOL CHEM, V278, P12482, DOI 10.1074/jbc.M212745200; Choi DW, 2005, NATURE, V433, P696, DOI 10.1038/433696a; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; Czyz A, 2002, J NEUROCHEM, V83, P1321, DOI 10.1046/j.1471-4159.2002.01227.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dong H, 2001, J BIOL CHEM, V276, P25919, DOI 10.1074/jbc.M103401200; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; HUANG YY, 1987, NEUROSCIENCE, V22, P9, DOI 10.1016/0306-4522(87)90193-X; Imahashi K, 2005, CIRC RES, V97, P916, DOI 10.1161/01.RES.0000187456.06162.cb; Jeon D, 2003, NEURON, V38, P965, DOI 10.1016/S0896-6273(03)00334-9; Kiedrowski L, 2002, ANN NY ACAD SCI, V976, P413; Kiedrowski L, 2004, NEUROREPORT, V15, P2113, DOI 10.1097/00001756-200409150-00023; Kiedrowski L, 2004, J NEUROCHEM, V90, P117, DOI 10.1111/j.1471-4159.2004.02462.x; Kim MH, 2005, J NEUROSCI, V25, P6057, DOI 10.1523/JNEUROSCI.0454-05.2005; Kim MH, 2003, J NEUROSCI, V23, P11673; Korenbrot JI, 2002, ADV EXP MED BIOL, V514, P179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SH, 2002, J NEUROSCI, V22, P6891; Lees-Miller JP, 2003, MOL CELL BIOL, V23, P1856, DOI 10.1128/MCB.23.6.1856-1862.2003; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; LI ZP, 1994, J BIOL CHEM, V269, P17434; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Lytton J, 2002, ANN NY ACAD SCI, V976, P382; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Marth JD, 1996, J CLIN INVEST, V97, P1999, DOI 10.1172/JCI118634; Medina JF, 2002, NAT REV NEUROSCI, V3, P122, DOI 10.1038/nrn728; Nakanishi S, 2005, TRENDS NEUROSCI, V28, P93, DOI 10.1016/j.tins.2004.12.004; Ngo-Anh TJ, 2005, NAT NEUROSCI, V8, P642, DOI 10.1038/nn1449; Papa M, 2003, J COMP NEUROL, V461, P31, DOI 10.1002/cne.10665; Pignataro G, 2004, NEUROPHARMACOLOGY, V46, P439, DOI 10.1016/j.neuropharm.2003.09.015; POOLOS NP, 1990, BRAIN RES, V508, P7, DOI 10.1016/0006-8993(90)91110-3; Poolos NP, 1999, J NEUROSCI, V19, P5205; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Prinsen CFM, 2002, ADV EXP MED BIOL, V514, P237; Quednau BD, 2004, PFLUG ARCH EUR J PHY, V447, P543, DOI 10.1007/s00424-003-1065-4; Reisel D, 2002, NAT NEUROSCI, V5, P868, DOI 10.1038/nn910; REUTER H, 1995, NEURON, V15, P1077, DOI 10.1016/0896-6273(95)90096-9; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; SALVATERRA PM, 1980, NEUROCHEM RES, V5, P181, DOI 10.1007/BF00964331; Schnetkamp PPM, 2004, PFLUG ARCH EUR J PHY, V447, P683, DOI 10.1007/s00424-003-1069-0; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; Sharon D, 2002, INVEST OPHTH VIS SCI, V43, P1971; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; STRINGER JL, 1988, EXP NEUROL, V101, P147, DOI 10.1016/0014-4886(88)90071-4; Szel A, 1996, MICROSC RES TECHNIQ, V35, P445; Tremblay F, 2002, VISION RES, V42, P1715, DOI 10.1016/S0042-6989(02)00113-X; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Tsuzuki T, 1998, NUCLEIC ACIDS RES, V26, P988, DOI 10.1093/nar/26.4.988; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; Whishaw IQ, 1999, MODERN TECHNIQUES NE, P1243, DOI 10.1007/978-3-642-58552-4_44; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333	64	65	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6273	6282		10.1074/jbc.M512137200	http://dx.doi.org/10.1074/jbc.M512137200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407245	Green Published, hybrid			2022-12-25	WOS:000236030800020
J	Smith, BO; Picken, NC; Westrop, GW; Bromek, K; Mottram, JC; Coombs, GH				Smith, BO; Picken, NC; Westrop, GW; Bromek, K; Mottram, JC; Coombs, GH			The structure of Leishmania mexicana ICP provides evidence for convergent evolution of cysteine peptidase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; N-TERMINAL REGION; PROTEASE INHIBITOR; TRYPANOSOMA-CRUZI; STEFIN-A; CHAGASIN; PROTEINASES; BINDING; DIFFERENTIATION; IDENTIFICATION	Clan CA, family C1 cysteine peptidases ( CPs) are important virulence factors and drug targets in parasites that cause neglected diseases. Natural CP inhibitors of the I42 family, known as ICP, occur in some protozoa and bacterial pathogens but are absent from metazoa. They are active against both parasite and mammalian CPs, despite having no sequence similarity with other classes of CP inhibitor. Recent data suggest that Leishmania mexicana ICP plays an important role in host- parasite interactions. We have now solved the structure of ICP from L. mexicana by NMR and shown that it adopts a type of immunoglobulin- like fold not previously reported in lower eukaryotes or bacteria. The structure places three loops containing highly conserved residues at one end of the molecule, one loop being highly mobile. Interaction studies with CPs confirm the importance of these loops for the interaction between ICP and CPs and suggest the mechanism of inhibition. Structure- guided mutagenesis of ICP has revealed that residues in the mobile loop are critical for CP inhibition. Data- driven docking models support the importance of the loops in the ICP- CP interaction. This study provides structural evidence for the convergent evolution from an immunoglobulin fold of CP inhibitors with a cystatin- like mechanism.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immunol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Wellcome Ctr Mol Parasitol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Smith, BO (corresponding author), Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	b.smith@bio.gla.ac.uk	Smith, Brian/AAJ-9393-2020; Smith, Brian O/J-1899-2015	Smith, Brian/0000-0003-3363-4168; Smith, Brian O/0000-0003-3363-4168; Mottram, Jeremy/0000-0001-5574-3766; Westrop, Gareth/0000-0002-8011-6219	Medical Research Council [G0000508] Funding Source: Medline; Wellcome Trust [074875, 074875/2/04/2] Funding Source: Medline; MRC [G0000508] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alves LC, 2001, MOL BIOCHEM PARASIT, V116, P1, DOI 10.1016/S0166-6851(01)00290-0; Besteiro S, 2004, MOL MICROBIOL, V54, P1224, DOI 10.1111/j.1365-2958.2004.04355.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Bozic D, 2004, J BIOL CHEM, V279, P44812, DOI 10.1074/jbc.C400353200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR 3 1; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jenko S, 2003, J MOL BIOL, V326, P875, DOI 10.1016/S0022-2836(02)01432-8; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Markley JL, 1998, PURE APPL CHEM, V70, P117, DOI 10.1351/pac199870010117; MARTIN JR, 1994, EUR J BIOCHEM, V225, P1181, DOI 10.1111/j.1432-1033.1994.1181b.x; Monteiro ACS, 2001, J CELL SCI, V114, P3933; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Pol E, 2003, BBA-PROTEINS PROTEOM, V1645, P105, DOI 10.1016/S1570-9639(02)00526-5; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825; Riekenberg S, 2005, FEBS LETT, V579, P1573, DOI 10.1016/j.febslet.2005.01.067; Rigden DJ, 2002, PROTEIN SCI, V11, P1971, DOI 10.1110/ps.0207202; Rigden DJ, 2001, FEBS LETT, V504, P41, DOI 10.1016/S0014-5793(01)02753-3; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Sanderson SJ, 2003, FEBS LETT, V542, P12, DOI 10.1016/S0014-5793(03)00327-2; Sanderson SJ, 2000, BIOCHEM J, V347, P383, DOI 10.1042/0264-6021:3470383; Santos CC, 2005, J CELL SCI, V118, P901, DOI 10.1242/jcs.01677; SMITH BO, 2005, IN PRESS J BIOMOL NM; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449	36	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5821	5828		10.1074/jbc.M510868200	http://dx.doi.org/10.1074/jbc.M510868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407198	Green Accepted, hybrid			2022-12-25	WOS:000235568900061
J	Embry, MR; Billiard, SM; Di Giulio, RT				Embry, MR; Billiard, SM; Di Giulio, RT			Lack of p53 induction in fish cells by model chemotherapeutics	ONCOGENE			English	Article						PLHC-1; rainbow trout; p53; chemotherapeutics; protein induction; apoptosis	FLOUNDER PLATICHTHYS-FLESUS; TUMOR-SUPPRESSOR PROTEIN; EUROPEAN FLOUNDER; DNA-DAMAGE; WILD-TYPE; MUTATION ANALYSIS; EPITHELIAL-CELLS; PRIMARY CULTURES; GENE; APOPTOSIS	Although p53 has been extensively studied in mammalian models, relatively little is known about its specific function in lower vertebrates. It has long been assumed that p53 pathways characterized in mammals apply to other vertebrates as well. Fish provide a useful model for the study of environmental carcinogenesis, and populations of fish inhabiting highly polluted environments provide information on the etiology of pollutant-mediated cancer. In this study, we investigated p53 protein and apoptosis induction in PLHC-1 ( desert topminnow hepatocellular carcinoma), RTL-W1 ( rainbow trout normal liver), and primary rainbow trout hepatocytes exposed to model chemotherapeutics. All of the chemicals used in these studies have been demonstrated to increase p53 protein levels and induce apoptosis in mammalian cell lines. In contrast, PLHC-1 p53 protein was not induced in response to any model mammalian p53 inducers following 24 h exposures. Additionally, both trout cell types demonstrated this same lack of p53 induction upon exposure to model chemotherapeutic drugs. PLHC-1 cells demonstrated an induction of apoptosis as measured by caspase-3 activation following exposure to all of the chemotherapeutics tested. Our results suggest that fish p53 may be activated differently from that of their mammalian counterparts, and that important differences may exist between phyla in the function and regulation of p53 as well as other mechanisms involved in environmental carcinogenesis.	Duke Univ, Ecotoxicol Lab, Nicholas Sch Environm & Earth Sci, Integrated Toxicol Program, Durham, NC USA	Duke University	Embry, MR (corresponding author), US EPA, Off Pollut Prevent & Tox Subst, Off Pesticide Programs, 1200 Penn Ave,NW,NW Mail Code 7507C, Washington, DC 20460 USA.	embry.michelle@epa.gov			NIEHS NIH HHS [ES07031, ES10356] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031, P42ES010356] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Cachot J, 2004, GENE, V324, P97, DOI 10.1016/j.gene.2003.09.052; Cachot J, 2000, MUTAT RES-GEN TOX EN, V464, P279, DOI 10.1016/S1383-5718(99)00205-3; Cachot J, 1998, COMP BIOCHEM PHYS C, V120, P351, DOI 10.1016/S0742-8413(98)00039-5; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Franklin TM, 2000, MAR ENVIRON RES, V50, P251, DOI 10.1016/S0141-1136(00)00091-X; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; FRITSCHE M, 1993, ONCOGENE, V8, P307; HIGHTOWER LE, 1988, J EXP ZOOL, V248, P290, DOI 10.1002/jez.1402480307; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Houser S, 2001, BIOCHEM BIOPH RES CO, V289, P998, DOI 10.1006/bbrc.2001.6073; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; Kazianis S, 1998, GENE, V212, P31, DOI 10.1016/S0378-1119(98)00144-9; Krause MK, 1997, GENE, V189, P101, DOI 10.1016/S0378-1119(96)00841-4; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; LEE LEJ, 1993, CELL BIOL TOXICOL, V9, P279, DOI 10.1007/BF00755606; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marechal V, 1997, PATHOL BIOL, V45, P824; Matsubara H, 1999, INT J ONCOL, V14, P1081; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Okamura M, 2004, ANTICANCER RES, V24, P655; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PART P, 1993, J EXP BIOL, V175, P219; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Sandbacka M, 2000, COMP BIOCHEM PHYS C, V127, P307, DOI 10.1016/S0742-8413(00)00156-0; Schlenk D, 1998, AQUAT TOXICOL, V43, P121, DOI 10.1016/S0166-445X(98)00050-2; Sekelsky JJ, 2000, J CELL BIOL, V150, pF31, DOI 10.1083/jcb.150.2.F31; Sueiro RA, 2000, MUTAT RES-GEN TOX EN, V468, P63, DOI 10.1016/S1383-5718(00)00040-1; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	44	28	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2004	2010		10.1038/sj.onc.1209238	http://dx.doi.org/10.1038/sj.onc.1209238			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434976				2022-12-25	WOS:000236359700003
J	Perez-Vilar, J; Mabolo, R; McVaugh, CT; Bertozzi, CR; Boucher, RC				Perez-Vilar, J; Mabolo, R; McVaugh, CT; Bertozzi, CR; Boucher, RC			Mucin granule intraluminal organization in living mucous/goblet cells - Roles of protein post-translational modifications and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; O-GLYCOSYLATION; ION-EXCHANGE; MUC5AC MUCIN; RELEASE; EXOCYTOSIS; KINETICS; PEPTIDE; PATHWAY; CA2+	Recent studies suggest that the mucin granule lumen consists of a matrix meshwork embedded in a fluid phase. Secretory products can both diffuse, although very slowly, through the meshwork pores and interact noncovalently with the matrix. Using a green fluorescent protein-mucin fusion protein (SHGFP-MUC5AC/CK) as a FRAP (fluorescence recovery after photobleaching) probe, we have assessed in living mucous cells the relative importance of different protein post-translational modifications on the intragranular organization. Long term inhibition of mucin-type O-glycosylation, sialylation, or sulfation altered SHGFP-MUC5AC/CK characteristic diffusion time (t(1/2)), whereas all but sulfation diminished its mobile fraction. Reduction of protein disulfide bonds with tris(hydroxypropyl) phosphine resulted in virtually complete immobilization of the SHGFP-MUC5AC/CK intragranular pool. However, when activity of the vacuolar H+-ATPase was also inhibited, disulfide reduction decreased SHGFP-MUC5AC/CKt(1/2) while diminishing its intraluminal concentration. Similar FRAP profiles were observed in granules that remained in the cells after the addition of amucin secretagogue. Taken together these results suggest that: (a) the relative content of O-glycans and intragranular anionic groups is crucial for protein diffusion through the intragranular meshwork; (b) protein-protein, rather than carbohydrate-mediated, interactions are responsible for binding of SHGFP-MUC5AC/CK to the immobile fraction, although the degree of matrix O-glycosylation and sialylation affects such interactions; (c) intragranular organization does not depend on covalent multimerization of mucins or the presence of native disulfide bonds in the intragranular mucin/proteins, but rather on specific protein-mediated interactions that are important during the early stages of mucin matrix condensation; (d) alterations of the intragranular matrix precede granule discharge, which can be partial and, accordingly, does not necessarily involve the disappearance of the granule.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Howard Hughes Med Inst, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Perez-Vilar, J (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, CB7248, Chapel Hill, NC 27599 USA.	juan_vilar@med.unc.edu			NCI NIH HHS [P50 CA89520] Funding Source: Medline; NIDDK NIH HHS [DK63030] Funding Source: Medline; NIGMS NIH HHS [GM66047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK063030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brockhausen I, 2003, BIOCHEM SOC T, V31, P318, DOI 10.1042/BST0310318; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chin WC, 2004, PLANT CELL PHYSIOL, V45, P535, DOI 10.1093/pcp/pch062; Day R, 2003, TRENDS ENDOCRIN MET, V14, P10, DOI 10.1016/S1043-2760(02)00011-5; DEKKER J, 1989, J BIOL CHEM, V264, P10431; Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7; Drose S, 1997, J EXP BIOL, V200, P1; Espinosa M, 2002, HUM REPROD, V17, P1964, DOI 10.1093/humrep/17.8.1964; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; Halm DR, 2000, AM J PHYSIOL-CELL PH, V278, pC212, DOI 10.1152/ajpcell.2000.278.1.C212; Han WP, 1999, J NEUROSCI, V19, P900; Hang HC, 2004, CHEM BIOL, V11, P337, DOI 10.1016/j.chembiol.2004.02.023; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Kelly ML, 2004, CELL BIOL INT, V28, P709, DOI 10.1016/j.cellbi.2004.07.005; Kepes F, 2005, INT REV CYTOL, V242, P55; Kitamura H, 1996, EUR J CANCER, V32A, P1788, DOI 10.1016/0959-8049(96)00168-2; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Lee KY, 2002, J BIOL CHEM, V277, P49341, DOI 10.1074/jbc.M209618200; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; LOHMANDER LS, 1979, J BIOL CHEM, V254, P551; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; Molist A, 1998, EUR J BIOCHEM, V254, P371, DOI 10.1046/j.1432-1327.1998.2540371.x; NEUTRA MR, 1984, CIBA F SYMP, V109, P20, DOI 10.1002/9780470720905.ch3; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; Palfrey HC, 2003, CURR BIOL, V13, pR397, DOI 10.1016/S0960-9822(03)00320-8; Perez-Vilar J, 2004, FREE RADICAL BIO MED, V37, P1564, DOI 10.1016/j.freeradbiomed.2004.07.027; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 2005, J HISTOCHEM CYTOCHEM, V53, P1305, DOI 10.1369/jhc.5B6713.2005; Perez-Vilar J, 2005, J BIOL CHEM, V280, P16868, DOI 10.1074/jbc.M413289200; Perez-Vilar J, 2004, GLYCOBIOLOGY, V14, P325, DOI 10.1093/glycob/cwh041; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; PHILLIPS TE, 1995, IN VITRO CELL DEV-AN, V31, P421, DOI 10.1007/BF02634251; Pollack GH, 2003, ADV COLLOID INTERFAC, V103, P173, DOI 10.1016/S0001-8686(02)00095-7; PUCHELLE E, 1991, BIOL CELL, V72, P159, DOI 10.1016/0248-4900(91)90090-A; Quesada I, 2003, BIOPHYS J, V85, P963, DOI 10.1016/S0006-3495(03)74535-4; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; Sheehan JK, 2004, J BIOL CHEM, V279, P15698, DOI 10.1074/jbc.M313241200; Sheehan JK, 2000, BIOCHEM J, V347, P37, DOI 10.1042/0264-6021:3470037; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Snapp E.L., 2003, CURRENT PROTOCOLS CE; SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183, DOI 10.1152/ajpcell.1991.260.2.C183; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TANAKA T, 1979, J CHEM PHYS, V70, P1214, DOI 10.1063/1.437602; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; THORNTON DJ, 1995, ANAL BIOCHEM, V227, P162, DOI 10.1006/abio.1995.1266; Tian E, 2004, J BIOL CHEM, V279, P50382, DOI 10.1074/jbc.M406397200; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VERDUGO P, 1984, CIBA F SYMP, V109, P212, DOI 10.1002/9780470720905.ch15; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Wickstrom C, 2001, J BIOL CHEM, V276, P47116, DOI 10.1074/jbc.M106593200	63	25	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4844	4855		10.1074/jbc.M510520200	http://dx.doi.org/10.1074/jbc.M510520200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377632	hybrid			2022-12-25	WOS:000235426200035
J	Ritz, BW; Lelkes, PI; Gardner, EM				Ritz, Barry W.; Lelkes, Peter I.; Gardner, Elizabeth M.			Functional recovery of peripheral blood mononuclear cells in modeled microgravity	FASEB JOURNAL			English	Article									[Ritz, Barry W.; Gardner, Elizabeth M.] Drexel Univ, Dept Biosci & Biotechnol, Philadelphia, PA 19104 USA; [Lelkes, Peter I.] Drexel Univ, Coll Med, Dept Biomed Engn, Philadelphia, PA 19104 USA	Drexel University; Drexel University	Ritz, BW (corresponding author), Drexel Univ, Dept Biosci & Biotechnol, 3141 Chestnut St,210 Stratton Hall, Philadelphia, PA 19104 USA.	bwr24@drexel.edu	Lelkes, Peter/HGA-2907-2022; Lelkes, Peter I/S-1751-2019						0	15	20	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2006	20	2					305	307		10.1096/fj.04-3122fje	http://dx.doi.org/10.1096/fj.04-3122fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16371429				2022-12-25	WOS:000207915000002
J	Watanabe, S; Umehara, H; Murayama, K; Okabe, M; Kimura, T; Nakano, T				Watanabe, S; Umehara, H; Murayama, K; Okabe, M; Kimura, T; Nakano, T			Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells	ONCOGENE			English	Article						Akt; ES cells; pluripotency; stem cell system	SELF-RENEWAL; ES CELLS; PROTEIN; MAINTENANCE; STAT3; DIFFERENTIATION; EXPRESSION; PATHWAY; PROLIFERATION; SUPPRESSION	Embryonic stem (ES) cells can self-renew indefinitely without losing their differentiation ability to any cell types. Phosphoinositide-3 kinase (PI3K)/Akt signaling plays a pivotal role in various stem cell systems, including the formation of embryonic germ (EG) cells from primordial germ cells and self-renewal of neural stem cells. Here, we show that myristoylated, active form of Akt (myr-Akt) maintained the undifferentiated phenotypes in mouse ES cells without the addition of leukemia inhibitory factor (LIF). The effects of myr-Akt were reversible, because LIF dependence and pluripotent differentiation activity were restored by the deletion of myr-Akt. In addition, myr-Akt-Mer fusion protein, whose enzymatic activity is controlled by 4-hydroxy-tamoxifen, also maintained the pluripotency of not only mouse but also cynomolgus monkey ES cells. These results clearly demonstrate that Akt signaling sufficiently maintains pluripotency in mouse and primate ES cells, and support the notion that PI3K/Akt signaling axis regulates 'stemness' in a broad spectrum of stem cell systems.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University	Kimura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Pathol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tkimura@patho.med.osaka-u.ac.jp; tnakano@patho.med.osaka-u.ac.jp	; Okabe, Masaru/B-6917-2015	Kimura, Tohru/0000-0001-9227-0996; Okabe, Masaru/0000-0002-0803-9044				Ben-Shushan E, 1998, MOL CELL BIOL, V18, P1866, DOI 10.1128/MCB.18.4.1866; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; Furuya M, 2003, GENESIS, V37, P180, DOI 10.1002/gene.10246; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim SJ, 2005, FEBS LETT, V579, P534, DOI 10.1016/j.febslet.2004.12.024; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kimura T, 2003, MOL CELL BIOL, V23, P1304, DOI 10.1128/MCB.23.4.1304-1315.2003; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nagata M, 2003, J GENE MED, V5, P921, DOI 10.1002/jgm.431; Nakano T, 1996, SCIENCE, V272, P722, DOI 10.1126/science.272.5262.722; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Suemori H, 2003, METHOD ENZYMOL, V365, P419; Sumi T, 2004, STEM CELLS, V22, P861, DOI 10.1634/stemcells.22-5-861; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	42	252	268	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2697	2707		10.1038/sj.onc.1209307	http://dx.doi.org/10.1038/sj.onc.1209307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407845	Bronze			2022-12-25	WOS:000237272900001
J	Salvatorelli, E; Guarnieri, S; Menna, P; Liberi, G; Calafiore, AM; Mariggio, MA; Mordente, A; Gianni, L; Minotti, G				Salvatorelli, E; Guarnieri, S; Menna, P; Liberi, G; Calafiore, AM; Mariggio, MA; Mordente, A; Gianni, L; Minotti, G			Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart - Relative importance of vesicular sequestration and impaired efficiency of electron addition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR OXIDATIVE STRESS; DOXORUBICIN-MEDIATED APOPTOSIS; SECONDARY ALCOHOL METABOLITE; IRON REGULATORY PROTEIN-1; HUMAN MYOCARDIUM; BREAST-CANCER; INDUCED CARDIOTOXICITY; CYTOSOLIC FRACTIONS; CARBONYL REDUCTASE; RADICAL FORMATION	One-electron quinone reduction and two-electron carbonyl reduction convert the anticancer anthracycline doxorubicin to reactive oxygen species(ROS) or a secondary alcohol metabolite that contributes to inducing a severe form of cardiotoxicity. The closely related analogue epirubicin induces less cardiotoxicity, but the determinants of its different behavior have not been elucidated. We developed a translational model of the human heart and characterized whether epirubicin exhibited a defective conversion to ROS and secondary alcohol metabolites. Small myocardial samples from cardiac surgery patients were reconstituted in plasma that contained clinically relevant concentrations of doxorubicin or epirubicin. In this model only doxorubicin formed ROS, as detected by fluorescent probes or aconitase inactivation. Experiments with cell-free systems and confocal laser scanning microscopy studies of H9c2 cardiomyocytes suggested that epirubicin could not form ROS because of its protonation-dependent sequestration in cytoplasmic acidic organelles and the consequent limited localization to mitochondrial one-electron quinone reductases. Accordingly, blocking the protonation-sequestration mechanism with the vacuolar H+-ATPase inhibitor bafilomycin A1 relocalized epirubicin to mitochondria and increased its conversion to ROS in human myocardial samples. Epirubicin also formed similar to 60% less alcohol metabolites than doxorubicin, but this was caused primarily by its higher K-m and lower V-max values for two-electron carbonyl reduction by aldo/keto-reductases of human cardiac cytosol. Thus, vesicular sequestration and impaired efficiency of electron addition have separate roles in determining a defective bioactivation of epirubicin to ROS or secondary alcohol metabolites in the human heart. These results uncover the molecular determinants of the reduced cardiotoxicity of epirubicin and serve mechanism-based guidelines to improving antitumor therapies.	Univ G DAnnunzio, Sch Med, Ctr Excellence Aging, I-66013 Chieti, Italy; Univ G DAnnunzio, Sch Med, Dept Cardiac Surg, I-66013 Chieti, Italy; European Hosp, Unit Cardiac Surg, I-00148 Rome, Italy; Univ Sacred Heart, Sch Med, Inst Biochem & Clin Biochem, I-00168 Rome, Italy; Ist Nazl Tumori, Med Oncol Unit, I-20133 Milan, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Fondazione IRCCS Istituto Nazionale Tumori Milan	Minotti, G (corresponding author), Univ G DAnnunzio, Sch Med, CeSI, Rm 412,Via Vestini, I-66013 Chieti, Italy.	gminotti@unich.it	Mordente, Alvaro/AAB-7290-2019; Mariggiò, Maria Addolorata/T-9047-2017; Guarnieri, Simone/AAA-5921-2020	Mariggiò, Maria Addolorata/0000-0001-5306-7143; GIANNI, LUCA/0000-0002-2372-9625; Mariggio, Maria Addolorata/0000-0002-3508-8706; Minotti, Giorgio/0000-0002-5678-6175; MORDENTE, Alvaro/0000-0003-3260-9796; MENNA, Pierantonio/0000-0002-7755-818X; Guarnieri, Simone/0000-0002-2916-2965; Salvatorelli, Emanuela/0000-0001-9805-4100				Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; BONADONNA G, 1993, ANN ONCOL, V4, P359, DOI 10.1093/oxfordjournals.annonc.a058514; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Charlier HA, 2005, MOL PHARMACOL, V67, P1505, DOI 10.1124/mol.104.005728; Corna G, 2004, J BIOL CHEM, V279, P13738, DOI 10.1074/jbc.M310106200; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; DOROSHOW JH, 1995, ACS SYM SER, V574, P259; EWER MS, 2000, CANC MED, P2324; Finlay GJ, 2000, CANCER CHEMOTH PHARM, V45, P417, DOI 10.1007/s002800051011; Forrest GL, 2000, CHEM-BIOL INTERACT, V129, P21, DOI 10.1016/S0009-2797(00)00196-4; Gambliel HA, 2002, BIOCHEM BIOPH RES CO, V291, P433, DOI 10.1006/bbrc.2002.6380; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gianni L, 1997, J CLIN ONCOL, V15, P1906, DOI 10.1200/JCO.1997.15.5.1906; Gille L, 1997, FREE RADICAL BIO MED, V23, P775, DOI 10.1016/S0891-5849(97)00025-7; Giraud MN, 2005, J APPL PHYSIOL, V99, P313, DOI 10.1152/japplphysiol.00609.2004; Gong YP, 2003, J BIOL CHEM, V278, P50234, DOI 10.1074/jbc.M306606200; Grasselli G, 2001, J CLIN ONCOL, V19, P2222, DOI 10.1200/JCO.2001.19.8.2222; GREGORY J, 2002, 07510 MP, P1; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hurwitz SJ, 1997, BLOOD, V89, P3745, DOI 10.1182/blood.V89.10.3745.3745_3745_3754; Innocenti F, 2001, DRUG METAB DISPOS, V29, P686; Kalivendi SV, 2005, BIOCHEM J, V389, P527, DOI 10.1042/BJ20050285; Kang YJ, 2002, CHEM RES TOXICOL, V15, P1, DOI 10.1021/tx015532n; Kluza J, 2004, ONCOGENE, V23, P7018, DOI 10.1038/sj.onc.1207936; Kotamraju S, 2004, METHOD ENZYMOL, V378, P362; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; L'Ecuyer T, 2004, AM J PHYSIOL-HEART C, V286, pH2057, DOI 10.1152/ajpheart.00778.2003; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; MAESSEN PA, 1987, CANCER CHEMOTH PHARM, V20, P85, DOI 10.1007/BF00252968; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Menna P, 2002, CHEM RES TOXICOL, V15, P1179, DOI 10.1021/tx020055+; Minotti G, 1998, FASEB J, V12, P541, DOI 10.1096/fasebj.12.7.541; Minotti G, 2004, METHOD ENZYMOL, V378, P340; Minotti G, 2001, CLIN CANCER RES, V7, P1511; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; Minotti G, 2000, CHEM RES TOXICOL, V13, P1336, DOI 10.1021/tx000143z; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; MUSHLIN PS, 1993, BRIT J PHARMACOL, V110, P975, DOI 10.1111/j.1476-5381.1993.tb13909.x; Olson LE, 2003, CANCER RES, V63, P6602; OLSON RD, 1988, P NATL ACAD SCI USA, V85, P3585, DOI 10.1073/pnas.85.10.3585; OLSSON JM, 1991, CANCER RES, V51, P3774; OPPERMANN UCT, 1991, BIOCHEM PHARMACOL, V42, P189; Ouar Z, 2003, BIOCHEM J, V370, P185, DOI 10.1042/BJ20021411; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Raghunand N, 2000, DRUG RESIST UPDATE, V3, P39, DOI 10.1054/drup.2000.0119; Ramachandran A, 2002, P NATL ACAD SCI USA, V99, P6643, DOI 10.1073/pnas.102019899; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; Siebert GA, 2004, J PHARMACOL EXP THER, V308, P228, DOI 10.1124/jpet.103.056770; Singal P, 2000, MOL CELL BIOCHEM, V207, P77, DOI 10.1023/A:1007094214460; Wagner BA, 2005, ARCH BIOCHEM BIOPHYS, V440, P181, DOI 10.1016/j.abb.2005.06.015; Wielinga PR, 2000, EUR J BIOCHEM, V267, P649, DOI 10.1046/j.1432-1327.2000.01030.x; Yokogawa K, 2002, METHOD FIND EXP CLIN, V24, P81, DOI 10.1358/mf.2002.24.2.677131	58	85	87	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	2006	281	16					10990	11001		10.1074/jbc.M508343200	http://dx.doi.org/10.1074/jbc.M508343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	033BV	16423826	hybrid			2022-12-25	WOS:000236822200040
J	Padilla-Lopez, S; Pearce, DA				Padilla-Lopez, S; Pearce, DA			Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity to regulate pH imbalance in the vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEINS; NEURONAL CEROID-LIPOFUSCINOSES; BATTEN-DISEASE; H+-ATPASE; YEAST MODEL; TRANSPORT-SYSTEMS; MEMBRANE-VESICLES; NA+/H+ EXCHANGER; SUBUNIT-C; HOMEOSTASIS	The vacuolar H+-ATPase (V-ATPase) along with ion channels and transporters maintains vacuolar pH. V-ATPase ATP hydrolysis is coupled with proton transport and establishes an electrochemical gradient between the cytosol and vacuolar lumen for coupled transport of metabolites. Btn1p, the yeast homolog to human CLN3 that is defective in Batten disease, localizes to the vacuole. We previously reported that Btn1p is required for vacuolar pH maintenance and ATP-dependent vacuolar arginine transport. We report that extracellular pH alters both V-ATPase activity and proton transport into the vacuole of wild-type Saccharomyces cerevisiae. V-ATPase activity is modulated through the assembly and disassembly of the V-0 and V-1 V-ATPase subunits located in the vacuolar membrane and on the cytosolic side of the vacuolar membrane, respectively. V-ATPase assembly is increased in yeast cells grown in high extracellular pH. In addition, at elevated extracellular pH, S. cerevisiae lacking BTN1 (btn1-Delta), have decreased V-ATPase activity while proton transport into the vacuole remains similar to that for wild type. Thus, coupling of V-ATPase activity and proton transport in btn1-Delta is altered. We show that down-regulation of V-ATPase activity compensates the vacuolar pH imbalance for btn1-Delta at early growth phases. We therefore propose that Btn1p is required for tight regulation of vacuolar pH to maintain the vacuolar luminal content and optimal activity of this organelle and that disruption in Btn1p function leads to a modulation of V-ATPase activity to maintain cellular pH homeostasis and vacuolar luminal content.	Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Pearce, DA (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Aging & Dev Biol, Aab Inst Biomed Sci, Box 645, Rochester, NY 14642 USA.	David_Pearce@urmc.rochester.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036610] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 036610] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali R, 2004, J BIOL CHEM, V279, P4498, DOI 10.1074/jbc.M307446200; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BANERJEE P, 1992, AM J MED GENET, V42, P549, DOI 10.1002/ajmg.1320420426; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Brett CL, 2005, MOL BIOL CELL, V16, P1396, DOI 10.1091/mbc.E04-11-0999; Camarasa C, 1996, YEAST, V12, P1301, DOI 10.1002/(SICI)1097-0061(199610)12:13<1301::AID-YEA18>3.0.CO;2-A; Chattopadhyay S, 2000, J BACTERIOL, V182, P6418, DOI 10.1128/JB.182.22.6418-6423.2000; Chattopadhyay S, 2003, BIOCHEM BIOPH RES CO, V302, P534, DOI 10.1016/S0006-291X(03)00209-2; Chattopadhyay S, 2002, EUKARYOT CELL, V1, P606, DOI 10.1128/EC.1.4.606-612.2002; Croopnick JB, 1998, BIOCHEM BIOPH RES CO, V250, P335, DOI 10.1006/bbrc.1998.9272; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forster C, 2000, J BIOL CHEM, V275, P38245, DOI 10.1074/jbc.M006650200; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gaxiola RA, 1998, P NATL ACAD SCI USA, V95, P4046, DOI 10.1073/pnas.95.7.4046; GOEBEL HH, 1995, J CHILD NEUROL, V10, P424, DOI 10.1177/088307389501000602; Graham LA, 2000, J EXP BIOL, V203, P61; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HALL NA, 1991, BIOCHEM J, V275, P269, DOI 10.1042/bj2750269; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; Hirata T, 2002, J BIOCHEM, V131, P261, DOI 10.1093/oxfordjournals.jbchem.a003097; Jezek P, 2004, PHYSIOL RES, V53, pS199; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Kim Y, 2005, EUKARYOT CELL, V4, P281, DOI 10.1128/EC.4.2.281-288.2005; Kim Y, 2003, P NATL ACAD SCI USA, V100, P15458, DOI 10.1073/pnas.2136651100; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BIOCHEM SOC T, V29, P806; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Klingenberg M, 1999, J BIOENERG BIOMEMBR, V31, P419, DOI 10.1023/A:1005440221914; KOENIG H, 1964, J NEUROCHEM, V11, P729, DOI 10.1111/j.1471-4159.1964.tb06118.x; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Mole SE, 1998, NEUROBIOL DIS, V5, P287, DOI 10.1006/nbdi.1998.0209; Nass R, 1999, MICROBIOL-SGM, V145, P3221, DOI 10.1099/00221287-145-11-3221; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OKOROKOV LA, 1985, FEBS LETT, V192, P303, DOI 10.1016/0014-5793(85)80130-7; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; Pearce DA, 1998, P NATL ACAD SCI USA, V95, P6915, DOI 10.1073/pnas.95.12.6915; Pearce DA, 1997, YEAST, V13, P691, DOI 10.1002/(SICI)1097-0061(19970630)13:8<691::AID-YEA123>3.0.CO;2-D; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Pearce DA, 1999, P NATL ACAD SCI USA, V96, P11341, DOI 10.1073/pnas.96.20.11341; Plant PJ, 1999, J BIOL CHEM, V274, P37270, DOI 10.1074/jbc.274.52.37270; Russnak R, 2001, J BIOL CHEM, V276, P23849, DOI 10.1074/jbc.M008028200; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; Shimazu M, 2005, J BIOL CHEM, V280, P4851, DOI 10.1074/jbc.M412617200; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Tomitori H, 2001, BIOCHEM J, V353, P681, DOI 10.1042/0264-6021:3530681; Uemura T, 2004, BIOCHEM BIOPH RES CO, V315, P1082, DOI 10.1016/j.bbrc.2004.01.162; Weimer JM, 2002, NEUROMOL MED, V1, P111, DOI 10.1385/NMM:1:2:111	55	65	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10273	10280		10.1074/jbc.M510625200	http://dx.doi.org/10.1074/jbc.M510625200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16423829	hybrid			2022-12-25	WOS:000236594300055
J	Mendez-Ortiz, MM; Hyodo, M; Hayakawa, Y; Membrillo-Hernandez, J				Mendez-Ortiz, MM; Hyodo, M; Hayakawa, Y; Membrillo-Hernandez, J			Genome-wide transcriptional profile of Escherichia coli in response to high levels of the second messenger 3 ',5 '-cyclic diguanylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC DI-GMP; DIRECT OXYGEN SENSOR; BIOFILM FORMATION; ACETOBACTER-XYLINUM; CELLULOSE SYNTHESIS; ALLOSTERIC CONTROL; REGULATORY SYSTEM; RCS PHOSPHORELAY; PROTEIN DOMAIN; EAL DOMAINS	Cyclic diguanylic acid(c-di-GMP; cGpGp) is a global second messenger controlling motility and adhesion in bacterial cells. Intracellular concentrations of c-di-GMP depend on two opposite activities: diguanylate cyclase, recently assigned to the widespread GGDEF domain, and c-di-GMP-specific phosphodiesterase, associated with proteins harboring the EAL domain. To date, little is known about the targets of c-di-GMP in the cell or if it affects transcriptional regulation of certain genes. In order to expand our knowledge of the effect of this molecule on the bacterial metabolism, here we report on the Escherichia coli transcriptional profile under high levels of c-di-GMP. We show that an important number of genes encoding cell surface and membrane-bound proteins are altered in their transcriptional activity. On the other hand, genes encoding several transcriptional factors, such as Fur, RcsA, SoxS, and ZraR, are up-regulated, and others, such as GadE, GadX, GcvA, and MetR, are down-regulated. Transcription of motility and cell division genes were altered, and consistent with this was the physiological analysis of cells overexpressing yddV, a diguanylate cyclase; these cells displayed an abnormal cell division process when high levels of c-di-GMP were present. We also show evidence that the diguanylate cyclase gene yddV is co-transcribed with dos, a heme base oxygen sensor with c-di-GMP-specific phosphodiesterase activity. A Delta dos::kan mutation rendered the cells unable to divide properly, suggesting that dos and yddV may be part of a fine-tuning mechanism for regulating the intracellular levels of c-di-GMP.	Univ Nacl Autonoma Mexico, Dept Biol Mol & Biotecnol, Inst Invest Biomed, Lab Microbiol Genet Mol, Mexico City 04510, DF, Mexico; Nagoya Univ, Grad Sch Informat Sci Human Informat, Nagoya, Aichi 4648601, Japan; Nagoya Univ, CREST JST, Nagoya, Aichi 4648601, Japan	Universidad Nacional Autonoma de Mexico; Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Membrillo-Hernandez, J (corresponding author), Univ Nacl Autonoma Mexico, Dept Biol Mol & Biotecnol, Inst Invest Biomed, Lab Microbiol Genet Mol, POB 70-228, Mexico City 04510, DF, Mexico.	jmh@biomedicas.unam.mx	Hyodo, Mamoru/D-5496-2012; Membrillo-Hernández, Jorge/AAN-4996-2021	Hyodo, Mamoru/0000-0002-1766-3949; Membrillo-Hernández, Jorge/0000-0001-7650-8116				AMIKAM D, 1989, J BACTERIOL, V171, P6649, DOI 10.1128/jb.171.12.6649-6655.1989; AMIKAM D, 1995, BIOCHEM J, V311, P921, DOI 10.1042/bj3110921; Ausmees N, 2001, FEMS MICROBIOL LETT, V204, P163, DOI 10.1111/j.1574-6968.2001.tb10880.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Chaveroche MK, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e97; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Corona-Izquierdo FP, 2002, FEMS MICROBIOL LETT, V211, P105, DOI 10.1016/S0378-1097(02)00672-9; D'Argenio DA, 2004, MICROBIOL-SGM, V150, P2497, DOI 10.1099/mic.0.27099-0; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Francez-Charlot A, 2003, MOL MICROBIOL, V49, P823, DOI 10.1046/j.1365-2958.2003.03601.x; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Galperin MY, 2004, ENVIRON MICROBIOL, V6, P552, DOI 10.1111/j.1462-2920.2004.00633.x; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; Hayakawa Y, 2003, TETRAHEDRON, V59, P6465, DOI 10.1016/S0040-4020(03)01045-7; Hommais F, 2004, MICROBIOL-SGM, V150, P61, DOI 10.1099/mic.0.26659-0; Jenal U, 2004, CURR OPIN MICROBIOL, V7, P185, DOI 10.1016/j.mib.2004.02.007; Karaolis DKR, 2005, ANTIMICROB AGENTS CH, V49, P1029, DOI 10.1128/AAC.49.3.1029-1038.2005; Kirillina O, 2004, MOL MICROBIOL, V54, P75, DOI 10.1111/j.1365-2958.2004.04253.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Leonhartsberger S, 2001, J MOL BIOL, V307, P93, DOI 10.1006/jmbi.2000.4451; Majdalani N, 2005, ANNU REV MICROBIOL, V59, P379, DOI 10.1146/annurev.micro.59.050405.101230; Majdalani N, 2005, J BACTERIOL, V187, P6770, DOI 10.1128/JB.187.19.6770-6778.2005; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; McHugh JP, 2003, J BIOL CHEM, V278, P29478, DOI 10.1074/jbc.M303381200; O'Toole GA, 1999, METHOD ENZYMOL, V310, P91; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Romling U, 2005, MOL MICROBIOL, V57, P629, DOI 10.1111/j.1365-2958.2005.04697.x; Rosenow C, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.22.e112; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; ROSS P, 1990, J BIOL CHEM, V265, P18933; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Solano C, 2002, MOL MICROBIOL, V43, P793, DOI 10.1046/j.1365-2958.2002.02802.x; Takeda S, 2001, MOL MICROBIOL, V40, P440, DOI 10.1046/j.1365-2958.2001.02393.x; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; Wehland M, 2000, J BIOL CHEM, V275, P7013, DOI 10.1074/jbc.275.10.7013; Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7; WINANS SC, 1985, J BACTERIOL, V161, P1219, DOI 10.1128/JB.161.3.1219-1221.1985; Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x	45	89	92	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8090	8099		10.1074/jbc.M510701200	http://dx.doi.org/10.1074/jbc.M510701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16418169	hybrid			2022-12-25	WOS:000236031000046
J	Kassavetis, GA; Steiner, DF				Kassavetis, GA; Steiner, DF			Nhp6 is a transcriptional initiation fidelity factor for RNA polymerase III transcription in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; START-SITE; MUTATIONAL ANALYSIS; GENE-TRANSCRIPTION; YEAST TFIIIB; DNA; COMPLEXES; UPSTREAM; ORGANIZATION	The binding of the RNA polymerase III (pol III) transcription factor TFIIIC to the box A intragenic promoter element of tRNA genes specifies the placement of TFIIIB on upstream-lying DNA. In turn, TFIIIB recruits pol III to the promoter and specifies transcription initiating 17 - 19 base pairs upstream of boxA. The resolution of the pol III transcription apparatus into recombinant TFIIIB, highly purified TFIIIC, and pol III is accompanied by a loss of precision in specifying where transcription initiation occurs due to heterogeneous placement of TFIIIB. In this paper we show that Nhp6a, an abundant high mobility group B ( HMGB) family, non-sequence-specific DNA-binding protein in Saccharomyces cerevisiae restores transcriptional initiation fidelity to this highly purified in vitro system. Restoration of initiation fidelity requires the presence of Nhp6a prior to TFIIIB-DNA complex formation. Chemical nuclease footprinting of TFIIIC- and TFIIIB-TFIIIC-DNA complexes reveals that Nhp6a markedly alters the TFIIIC footprint over box A and reduces the size of the TFIIIB footprint on upstream DNA sequence. Analyses of unprocessed tRNAs from yeast lacking Nhp6a and its closely related paralogue Nhp6b demonstrate that Nhp6 is required for transcriptional initiation fidelity of some but not all tRNA genes, in vivo.	Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kassavetis, GA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gak@biomail.ucsd.edu						Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; Andrau JC, 2001, EUR J BIOCHEM, V268, P5167, DOI 10.1046/j.0014-2956.2001.02445.x; Bachman N, 2004, GENOME RES, V14, P1232, DOI 10.1101/gr.2052904; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; DIECI G, 1993, J BIOL CHEM, V268, P11199; Eriksson P, 2004, MOL CELL BIOL, V24, P6419, DOI 10.1128/MCB.24.14.6419-6429.2004; FABRIZIO P, 1987, P NATL ACAD SCI USA, V84, P8763, DOI 10.1073/pnas.84.24.8763; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; FRUSCOLONI P, 1995, NUCLEIC ACIDS RES, V23, P2914, DOI 10.1093/nar/23.15.2914; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Giuliodori S, 2003, J MOL BIOL, V333, P1, DOI 10.1016/j.jmb.2003.08.016; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Huet J, 1996, METHOD ENZYMOL, V273, P249; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; Kassavetis GA, 2005, P NATL ACAD SCI USA, V102, P15406, DOI 10.1073/pnas.0507653102; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Kufel J, 2003, RNA, V9, P202, DOI 10.1261/rna.2145103; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; Martin MP, 2001, MOL CELL BIOL, V21, P6429, DOI 10.1128/MCB.21.19.6429-6439.2001; Masse JE, 2002, J MOL BIOL, V323, P263, DOI 10.1016/S0022-2836(02)00938-5; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NICHOLS M, 1989, J BIOL CHEM, V264, P17084; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; Persinger J, 1999, MOL CELL BIOL, V19, P5218; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; WHITE RJ, 2002, RNA POLYM 3 TRANSCRI; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1; Zecherle GN, 1996, MOL CELL BIOL, V16, P5801; Ziehler WA, 2000, BIOCHEMISTRY-US, V39, P9909, DOI 10.1021/bi000603n	47	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7445	7451		10.1074/jbc.M512810200	http://dx.doi.org/10.1074/jbc.M512810200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407207	hybrid			2022-12-25	WOS:000236030900066
J	Shah, M; Patel, K; Mukhopadhyay, S; Xu, F; Guo, G; Sehgal, PB				Shah, M; Patel, K; Mukhopadhyay, S; Xu, F; Guo, G; Sehgal, PB			Membrane-associated STAT3 and PY-STAT3 in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING ENDOSOME HYPOTHESIS; RESONANCE ENERGY-TRANSFER; PLASMA-MEMBRANE; CYTOSOLIC COMPLEXES; CLATHRIN EXCHANGE; PROTEIN; GROWTH; ACTIVATION; TRANSPORT; INTERNALIZATION	Signal transduction from the plasma membrane to the nucleus by STAT proteins is widely represented as exclusively a soluble cytosolic process. Using cell-fractionation methods, we observed that similar to 5% of cytoplasmic STAT3 was constitutively associated with the purified early endosome (EE) fraction in human Hep3B liver cells. By 15 - 30 min after interleukin-6 (IL-6) treatment, up to two-thirds of cytoplasmic Tyr-phosphorylated STAT3 can be associated with the purified early endosome fraction (Rab-5-, EEA1-, transferrin receptor-, and clathrin-positive fraction). Electron microscopy, immunofluorescence, and detergent dissection approaches confirmed the association of STAT3 and PY-STAT3 with early endosomes. STAT3 was constitutively associated with clathrin heavy chain in membrane and in the 1- to 2-MDa cytosolic complexes. The membrane association was dynamic in that, within 15 min of treatment with the vicinal-thiol cross-linker phenylarsine oxide, there was a dramatic increase in bulk STAT3 association with sedimentable membranes. The functional contribution of PY-STAT3 association with the endocytic pathway was evaluated in transient transfection assays using IL-6-inducible STAT3-reporter-luciferase constructs and selective regulators of this pathway. STAT3-transcriptional activation was inhibited by expression constructs for dominant negative dynamin K44A, epsin 2a, amphiphysin A1, and clathrin light chain but enhanced by that for the active dynamin species MxA. Taken together, these studies emphasize the contribution of the endocytic pathway to productive IL-6/ STAT3 signaling.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Sehgal, PB (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Rm 201,Basic Sci Bldg, Valhalla, NY 10595 USA.	pravin_sehgal@nymc.edu		Mukhopadhyay, Somshuvra/0000-0002-3420-7830	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073301] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 73301] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Beattie EC, 1996, COLD SPRING HARB SYM, V61, P389; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; HOLTZMAN E, 1966, J MOL BIOL, V17, P131, DOI 10.1016/S0022-2836(66)80099-2; Howe CL, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742-4682-2-43; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; JHUN BH, 1991, J BIOL CHEM, V266, P22260; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; KALEF E, 1994, METHOD ENZYMOL, V233, P395; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Kojima H, 2005, P NATL ACAD SCI USA, V102, P4524, DOI 10.1073/pnas.0500679102; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; MANDERS EMM, 1992, J CELL SCI, V103, P857; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Ota N, 2004, NAT IMMUNOL, V5, P208, DOI 10.1038/ni1032; Parker MS, 2002, EUR J PHARMACOL, V452, P279, DOI 10.1016/S0014-2999(02)02339-7; PENMAN S, 1966, J MOL BIOL, V17, P117, DOI 10.1016/S0022-2836(66)80098-0; Rayala SK, 2006, J BIOL CHEM, V281, P4395, DOI 10.1074/jbc.M510368200; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Saxena S, 2005, MOL CELL NEUROSCI, V28, P571, DOI 10.1016/j.mcn.2004.11.011; Schroder M, 2004, J LEUKOCYTE BIOL, V75, P792, DOI 10.1189/jlb.1003496; Scoles DR, 2002, HUM MOL GENET, V11, P3179, DOI 10.1093/hmg/11.25.3179; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Sehgal PB, 2003, ACTA BIOCHIM POL, V50, P583; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Sehgal PB, 2003, SIGNAL TRANSDUCERS A, P1; Shah M, 2005, AM J PHYSIOL-CELL PH, V288, pC850, DOI 10.1152/ajpcell.00327.2004; Shah M, 2002, J BIOL CHEM, V277, P45662, DOI 10.1074/jbc.M205935200; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Thiel S, 2000, FEBS LETT, V470, P15, DOI 10.1016/S0014-5793(00)01276-X; Thiel S, 1998, FEBS LETT, V441, P231, DOI 10.1016/S0014-5793(98)01559-2; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; Watanabe K, 2004, BIOCHEM BIOPH RES CO, V324, P1264, DOI 10.1016/j.bbrc.2004.09.187; Wu XF, 2003, MOL BIOL CELL, V14, P516, DOI 10.1091/mbc.E02-06-0353; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Yeung YG, 2003, MOL CELL PROTEOMICS, V2, P1143, DOI 10.1074/mcp.R300009-MCP200; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102	60	66	67	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7302	7308		10.1074/jbc.M508527200	http://dx.doi.org/10.1074/jbc.M508527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407171	hybrid			2022-12-25	WOS:000236030900048
J	Tian, XJ; Feig, LA				Tian, XJ; Feig, LA			Age-dependent participation of Ras-GRF proteins in coupling calcium-permeable AMPA glutamate receptors to Ras/Erk signaling in cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SYNAPTIC PLASTICITY; PYRAMIDAL NEURONS; COMPLEX-FORMATION; MAP KINASE; TRAFFICKING; SPECIFICITY; ACTIVATION; CREB; PHOSPHORYLATION	alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors (AMPARs) are ligand-gated sodium channels. Through their ability to mediate the majority of rapid excitatory transmission in the central nervous system, these neurotransmitter receptors have been shown to influence synaptic plasticity. Some of these receptors are also calcium-permeable (CP), and they also have been implicated in regulating synaptic plasticity, particularly in interneurons where their concentration is highest. However, the biochemical pathways emanating from CP-AMPARs that mediate these effects have not been well characterized. In this paper, we show that CP-AMPARs are the predominant AMPAR class responsible for activating the Ras/Erk kinase signaling cascade and the cAMP-response element-binding protein (CREB) transcription factor in the cortex of mature mice. Activation of Ras and Erk, but not CREB, occurs through the calcium/calmodulin regulated Ras-GRF1 and Ras-GRF2 exchange factors, which form AMPA-induced complexes with CP-AMPARs but not calcium-impermeable (CI) AMPARs in vivo. Furthermore, we show that CP-AMPARs are also the major AMPAR type to activate Ras/Erk signaling in pubescent mice; however, at this developmental stage Ras-GRF (guanine nucleotide-releasing factor) proteins are not involved. Finally, in neonatal animals CI-AMPARs, but not CP-AMPARs, are the predominant AMPAR type that activates Ras-Erk signaling and CREB in cortical neurons. This occurs indirectly through activation of L-type voltage-dependent calcium channels, an event that is also Ras-GRF-independent. Thus, Ras/Erk signaling and CREB activity induced by AMPARs occur through age-dependent mechanisms that likely make unique developmentally dependent contributions to synaptic function.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA	Tufts University; Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.	larry.feig@tufts.edu			NCI NIH HHS [R01 CA 47391] Funding Source: Medline; NIDDK NIH HHS [P3 DK 3498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Connolly BA, 2005, MOL CELL BIOL, V25, P4602, DOI 10.1128/MCB.25.11.4602-4614.2005; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Goldberg JH, 2003, NEURON, V40, P807, DOI 10.1016/S0896-6273(03)00714-1; HOLLMANN M, 1994, RENAL PHYSIOL BIOCH, V17, P182; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; Kumar SS, 2002, J NEUROSCI, V22, P3005, DOI 10.1523/JNEUROSCI.22-08-03005.2002; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; Malenka RC, 2003, ANN NY ACAD SCI, V1003, P1, DOI 10.1196/annals.1300.001; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Ogoshi F, 2003, J NEUROSCI, V23, P10521; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tian XJ, 2004, EMBO J, V23, P1567, DOI 10.1038/sj.emboj.7600151; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	26	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7578	7582		10.1074/jbc.M512060200	http://dx.doi.org/10.1074/jbc.M512060200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407208	hybrid			2022-12-25	WOS:000236030900079
J	Wang, DM; Masutani, H; Oka, S; Tanaka, T; Yamaguchi-Iwai, Y; Nakamura, H; Yodoi, J				Wang, DM; Masutani, H; Oka, S; Tanaka, T; Yamaguchi-Iwai, Y; Nakamura, H; Yodoi, J			Control of mitochondrial outer membrane permeabilization and Bcl-xL levels by thioredoxin 2 in DT40 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; DEPENDENT APOPTOSIS; CASPASE ACTIVATION; DEATH; TRANSITION; PROTEINS; INVOLVEMENT; EXPRESSION; RELEASE; GLUTAREDOXIN-2	Mitochondria play a central role in the initiation of apoptosis, which is regulated by various factors such as ATP synthesis, reactive oxygen species, redox status, and outer membrane permeabilization. Disruption of chicken thioredoxin 2 (Trx2), a mitochondrial redox-regulating protein, results in apoptosis in DT40 cells. To investigate the mechanism of this apoptosis, we prepared transfectants expressing control (DT40-TRX2-/-), human thioredoxin 2 (TRX2) (DT40-hTRX2), or redox-inactive TRX2 (DT40-hTRX2CS) in conditional Trx2-deficient DT40 cells containing a tetracycline-repressible Trx2 gene. Production of ATP was not significantly changed by down-regulation of Trx2 expression. The generation of reactive oxygen species was enhanced by the down-regulation of Trx2 expression in DT40-TRX2-/-. Unexpectedly, the change was blocked in both DT40-hTRX2 and DT40-hTRX2CS cells. The down-regulation of Trx2 expression caused the release of cytochrome c and apoptosis-inducing factor on day 3, and apoptosis on day 5. These changes were also suppressed in both DT40-hTRX2 and DT40-hTRX2CS cells, suggesting that TRX2 regulates mitochondrial outer membrane permeabilization and apoptosis by redox-active site cysteine-independent mechanisms. The downregulation of Trx2 expression caused a decrease in the protein level of Bcl-xL on day 3, whereas the protein level of Bcl-2 did not change until day 4, and the mRNA level of Bcl-xL was unchanged. The decrease in Bcl-xL was not blocked by a caspase 3 inhibitor but blocked in both DT40-hTRX2 and DT40-hTRX2CS. These findings indicate a link between the redox active site cysteine-independent action of TRX2 and the level of Bcl-xL in the regulation of apoptosis.	Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Kyoto Univ Hosp, Translat Res Ctr, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	hmasutan@virus.kyoto-u.ac.jp	Masutani, Hiroshi/B-5114-2014	Masutani, Hiroshi/0000-0001-7633-2827				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brichese L, 2002, EXP CELL RES, V278, P101, DOI 10.1006/excr.2002.5563; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen Y, 2002, J BIOL CHEM, V277, P33242, DOI 10.1074/jbc.M202026200; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eguchi Y, 1997, CANCER RES, V57, P1835; Granot Z, 2003, MOL ENDOCRINOL, V17, P2461, DOI 10.1210/me.2003-0074; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hasegawa J, 1996, CANCER RES, V56, P1713; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Lillig CH, 2005, P NATL ACAD SCI USA, V102, P8168, DOI 10.1073/pnas.0500735102; Lillig CH, 2004, P NATL ACAD SCI USA, V101, P13227, DOI 10.1073/pnas.0401896101; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Masutani H, 2005, CELL DEATH DIFFER, V12, P991, DOI 10.1038/sj.cdd.4401625; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nonn L, 2003, MOL CANCER RES, V1, P682; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Ueda S, 1998, J IMMUNOL, V161, P6689; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	41	40	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7384	7391		10.1074/jbc.M509876200	http://dx.doi.org/10.1074/jbc.M509876200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407224	hybrid, Green Submitted			2022-12-25	WOS:000236030900058
J	Wills, NM; Moore, B; Hammer, A; Gesteland, RF; Atkins, JF				Wills, NM; Moore, B; Hammer, A; Gesteland, RF; Atkins, JF			A functional-1 ribosomal frameshift signal in the human paraneoplastic Ma3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MAMMARY-TUMOR VIRUS; RNA PSEUDOKNOT; MESSENGER-RNA; MUTATIONAL ANALYSIS; STIMULATORY SIGNAL; SARS CORONAVIRUS; RECODING SIGNALS; HIV-1; SITE	A bioinformatics approach to finding new cases of -1 frameshifting in the expression of human genes revealed a classical retrovirus-like heptanucleotide shift site followed by a potential structural stimulator in the paraneoplastic antigen Ma3 and Ma5 genes. Analysis of the sequence 3' of the shift site demonstrated that an RNA pseudoknot in Ma3 is important for promoting efficient -1 frameshifting. Ma3 is a member of a family of six genes in humans whose protein products contain homology to retroviral Gag proteins. The -1 frameshift site and pseudoknot structure are conserved in other mammals, but there are some sequence differences. Although the functions of the Ma genes are unknown, the serious neurological effects of ectopic expression in tumor cells indicate their importance in the brain.	Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Coll Cork, Biosci Inst, Cork, Ireland	Utah System of Higher Education; University of Utah; University College Cork	Atkins, JF (corresponding author), Univ Utah, Dept Human Genet, 15 N 2030 E,Bldg 533,Rm 7410, Salt Lake City, UT 84112 USA.	john.atkins@genetics.utah.edu		Atkins, John/0000-0001-7933-0165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048152, R01GM071853] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 71853, GM 48152] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Atkins JF, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P369; Baranov PV, 2005, VIROLOGY, V332, P498, DOI 10.1016/j.virol.2004.11.038; Baranov PV, 2004, RNA, V10, P221, DOI 10.1261/rna.5122604; Bertrand C, 2002, RNA, V8, P16, DOI 10.1017/S1355838202012086; Bidou L, 1997, RNA, V3, P1153; Brandt J, 2005, CYTOGENET GENOME RES, V110, P307, DOI 10.1159/000084963; BRIERLEY I, 1991, J MOL BIOL, V220, P889, DOI 10.1016/0022-2836(91)90361-9; Brierley I, 2001, COLD SPRING HARB SYM, V66, P233, DOI 10.1101/sqb.2001.66.233; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; CHEN XY, 1995, EMBO J, V14, P842, DOI 10.1002/j.1460-2075.1995.tb07062.x; Dulude D, 2002, NUCLEIC ACIDS RES, V30, P5094, DOI 10.1093/nar/gkf657; Gao X, 2005, TRENDS GENET, V21, P133, DOI 10.1016/j.tig.2005.01.006; Gao X, 2003, RNA, V9, P1422, DOI 10.1261/rna.5105503; Gaudin C, 2005, J MOL BIOL, V349, P1024, DOI 10.1016/j.jmb.2005.04.045; Grentzmann G, 1998, RNA, V4, P479; Griffiths A, 2003, J VIROL, V77, P4703, DOI 10.1128/JVI.77.8.4703-4709.2003; HATFIELD DL, 1992, ADV VIRUS RES, V41, P193, DOI 10.1016/S0065-3527(08)60037-8; HEROLD J, 1993, NUCLEIC ACIDS RES, V21, P5838; Hung M, 1998, J VIROL, V72, P4819, DOI 10.1128/JVI.72.6.4819-4824.1998; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; Kang HS, 1997, NUCLEIC ACIDS RES, V25, P1943, DOI 10.1093/nar/25.10.1943; Kim YG, 2001, NUCLEIC ACIDS RES, V29, P1125, DOI 10.1093/nar/29.5.1125; Kinzy TG, 2002, VIROLOGY, V300, P60, DOI 10.1006/viro.2002.1567; Larsen B, 1997, J MOL BIOL, V271, P47, DOI 10.1006/jmbi.1997.1162; Licznar P, 2003, EMBO J, V22, P4770, DOI 10.1093/emboj/cdg465; Manktelow E, 2005, NUCLEIC ACIDS RES, V33, P1553, DOI 10.1093/nar/gki299; MARCZINKE B, 1994, J VIROL, V68, P5588, DOI 10.1128/JVI.68.9.5588-5595.1994; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Napthine S, 1999, J MOL BIOL, V288, P305, DOI 10.1006/jmbi.1999.2688; Ono R, 2006, NAT GENET, V38, P101, DOI 10.1038/ng1699; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pallan PS, 2005, BIOCHEMISTRY-US, V44, P11315, DOI 10.1021/bi051061i; Pardue ML, 2003, ANNU REV GENET, V37, P485, DOI 10.1146/annurev.genet.38.072902.093115; Plant EP, 2005, PLOS BIOL, V3, P1012, DOI 10.1371/journal.pbio.0030172; Rettberg CC, 1999, J MOL BIOL, V286, P1365, DOI 10.1006/jmbi.1999.2546; Rosenfeld MR, 2001, ANN NEUROL, V50, P339, DOI 10.1002/ana.1288; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; Shigemoto K, 2001, NUCLEIC ACIDS RES, V29, P4079, DOI 10.1093/nar/29.19.4079; Sonnhammer ELL, 1998, NUCLEIC ACIDS RES, V26, P320, DOI 10.1093/nar/26.1.320; Stahl G, 2001, COLD SPRING HARB SYM, V66, P249, DOI 10.1101/sqb.2001.66.249; Staple DW, 2005, J MOL BIOL, V349, P1011, DOI 10.1016/j.jmb.2005.03.038; Su MC, 2005, NUCLEIC ACIDS RES, V33, P4265, DOI 10.1093/nar/gki731; Takyar S, 2005, CELL, V120, P49, DOI 10.1016/j.cell.2004.11.042; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toulouse A, 2005, HUM MOL GENET, V14, P2649, DOI 10.1093/hmg/ddi299; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; Yu ET, 2005, J MOL BIOL, V345, P69, DOI 10.1016/j.jmb.2004.10.014; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	53	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7082	7088		10.1074/jbc.M511629200	http://dx.doi.org/10.1074/jbc.M511629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407312	hybrid			2022-12-25	WOS:000236030900022
J	Fritz, A; Brayer, KJ; McCormick, N; Adams, DG; Wadzinski, BE; Vaillancourt, RR				Fritz, A; Brayer, KJ; McCormick, N; Adams, DG; Wadzinski, BE; Vaillancourt, RR			Phosphorylation of serine 526 is required for MEKK3 activity, and association with 14-3-3 blocks dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; STRUCTURAL BASIS; CELLS; P38; TRANSFORMATION; PATHWAYS; BINDING; CLONING; DOMAIN	MAPK/ERK kinase kinase 3 (MEKK3) is a mitogen-activated protein kinase kinase kinase (MAP3K) that functions upstream of the MAP kinases and I kappa B kinase. Phosphorylation is believed to be a critical component for MEKK3-dependent signal transduction, but little is known about the phosphorylation sites of this MAP3K. To address this question, point mutations were introduced in the activation loop (T-loop), substituting alanine for serine or threonine, and the mutants were transfected into HEK293 Epstein-Barr virus nuclear antigen cells. MEKK3-dependent activation of an NF-kappa B reporter gene as well as ERK, JNK, and p38 MAP kinases correlated with a requirement for serine at position 526. Constitutively active mutants of MEKK3, consisting of S526D and S526E, were capable of activating a NF-kappa B luciferase reporter gene as well as ERK and MEK, suggesting that a negative charge at Ser(526) was necessary for MEKK3 activity and implicating Ser(526) as a phosphorylation site. An antibody was developed that specifically recognized phospho-Ser(526) of MEKK3 but did not recognize the S526A point mutant. The catalytically inactive (K391M) mutant of MEKK3 was not phosphorylated at Ser(526), indicating that phosphorylation of Ser(526) occurs via autophosphorylation. Endogenous MEKK3 was phosphorylated on Ser(526) in response to osmotic stress. In addition, phosphorylation of Ser(526) was required for MKK6 phosphorylation in vitro, whereas dephosphorylation of Ser(526) was mediated by protein phosphatase 2A and sensitive to okadaic acid and sodium fluoride. Finally, the association between MEKK3 and 14-3-3 was dependent on Ser(526) and prevented dephosphorylation of Ser(526). In summary, Ser(526) of MEKK3 is an autophosphorylation site within the T-loop that is regulated by PP2A and 14-3-3 proteins.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	University of Arizona; Vanderbilt University	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, 1703 E Mabel St, Tucson, AZ 85721 USA.	vaillancourt@pharmacy.arizona.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004940, R01ES012007, P30ES006694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062265, R01GM051366, R56GM051366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019710] Funding Source: NIH RePORTER; NIA NIH HHS [AG19710] Funding Source: Medline; NIEHS NIH HHS [P30 ES06694, ES12007, P42 ES04940] Funding Source: Medline; NIGMS NIH HHS [GM62265, GM51366] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams DG, 2002, ARCH BIOCHEM BIOPHYS, V407, P103, DOI 10.1016/S0003-9861(02)00464-2; Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Blonska M, 2004, MOL CELL BIOL, V24, P10757, DOI 10.1128/MCB.24.24.10757-10765.2004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Derbyshire ZE, 2005, MOL CELL BIOCHEM, V271, P77, DOI 10.1007/s11010-005-5386-9; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; HARLOW E, 1988, ANTIBODIES LAB MANUA, P551; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Lee TH, 2003, MOL CELL BIOL, V23, P8377, DOI 10.1128/MCB.23.22.8377-8385.2003; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nho CW, 2004, J BIOL CHEM, V279, P26019, DOI 10.1074/jbc.M309022200; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Samanta AK, 2004, J BIOL CHEM, V279, P7576, DOI 10.1074/jbc.M311659200; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe Michael B, 2004, Biochem J, V379, pe1, DOI 10.1042/BJ20040284; Yang J, 2004, J MOL BIOL, V336, P473, DOI 10.1016/j.jmb.2003.11.044; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	35	42	44	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6236	6245		10.1074/jbc.M509249200	http://dx.doi.org/10.1074/jbc.M509249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407301	hybrid			2022-12-25	WOS:000236030800016
J	Vinolo, E; Sebban, H; Chaffotte, A; Israel, A; Courtois, G; Veron, M; Agou, F				Vinolo, E; Sebban, H; Chaffotte, A; Israel, A; Courtois, G; Veron, M; Agou, F			A point mutation in NEMO associated with anhidrotic ectodermal dysplasia with immunodeficiency pathology results in destabilization of the oligomer and reduces lipopolysaccharide- and tumor necrosis factor-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; HELICAL COILED-COILS; GAMMA IKK-GAMMA; KINASE COMPLEX; ZINC-FINGER; HYDROPHOBIC INTERACTIONS; TYROSINATE FLUORESCENCE; INCONTINENTIA PIGMENTI; CIRCULAR-DICHROISM; ALPHA	The NEMO (NF-kappa B essential modulator) protein plays a crucial role in the canonical NF-kappa B pathway as the regulatory component of the IKK (I kappa B kinase) complex. The human disease anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) has been recently linked to mutations in NEMO. We investigated the effect of an alanine to glycine substitution found in the NEMO polypeptide of an EDA-ID patient. This pathogenic mutation is located within the minimal oligomerization domain of the protein, which is required for the IKK activation in response to diverse stimuli. The mutation does not dramatically change the native-like state of the trimer, but temperature-induced unfolding studied by circular dichroism showed that it leads to an important loss in the oligomer stability. Furthermore, fluorescence studies showed that the tyrosine located in the adjacent zinc finger domain, which is possibly required for NEMO ubiquitination, exhibits an alteration in its spectral properties. This is probably due to a conformational change of this domain, providing evidence for a close interaction between the oligomerization domain and the zinc finger. In addition, functional complementation assays using NEMO-deficient pre-B and T lymphocytes showed that the pathogenic mutation reduced TNF-alpha and LPS-induced NF-kappa B activation by altering the assembly of the IKK complex. Altogether, our findings provide understanding as to how a single point mutation in NEMO leads to the observed EDA-ID phenotype in relation to the NEMO-dependent mechanism of IKK activation.	Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2185, Unite Repliement & Modelisat Prot, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2582, Unite Signalisat Mol & Activat Cellulaire, F-75724 Paris 15, France; Hop St Louis, INSERM, U697, F-75475 Paris 10, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Agou, F (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	fagou@pasteur.fr	, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Aradhya S, 2001, HUM MOL GENET, V10, P2171, DOI 10.1093/hmg/10.19.2171; Boice JA, 1996, BIOCHEMISTRY-US, V35, P14480, DOI 10.1021/bi961831d; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; Courtois G, 2005, CELL MOL LIFE SCI, V62, P1682, DOI 10.1007/s00018-005-5031-5; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dragan AI, 2002, J MOL BIOL, V321, P891, DOI 10.1016/S0022-2836(02)00699-X; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Fusco F, 2004, HUM MOL GENET, V13, P1763, DOI 10.1093/hmg/ddh192; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Harding S. E., 1992, ANAL ULTRACENTRIFUGA; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HENNESSEY JP, 1982, ANAL BIOCHEM, V125, P177, DOI 10.1016/0003-2697(82)90400-6; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; JASANOFF A, 1992, J MOL BIOL, V225, P1035, DOI 10.1016/0022-2836(92)90103-Q; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; Kohsaka T, 1999, HUM MUTAT, V14, P466, DOI 10.1002/(SICI)1098-1004(199912)14:6<466::AID-HUMU4>3.3.CO;2-Y; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Lachenmann MJ, 2002, J MOL BIOL, V316, P969, DOI 10.1006/jmbi.2001.5335; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Muller KM, 2000, METHOD ENZYMOL, V328, P261; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; PUNDAK S, 1984, BIOCHEMISTRY-US, V23, P1549, DOI 10.1021/bi00302a032; Receveur V, 2000, PROTEINS, V38, P226, DOI 10.1002/(SICI)1097-0134(20000201)38:2<226::AID-PROT10>3.0.CO;2-H; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; Smahi A, 2000, NATURE, V405, P466; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SZABO AG, 1978, FEBS LETT, V94, P249, DOI 10.1016/0014-5793(78)80948-X; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2004, J IMMUNOL, V172, P2446, DOI 10.4049/jimmunol.172.4.2446; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	60	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6334	6348		10.1074/jbc.M510118200	http://dx.doi.org/10.1074/jbc.M510118200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16379012	hybrid			2022-12-25	WOS:000236030800027
J	Barends, TRM; Polderman-Tijmes, JJ; Jekel, PA; Williams, C; Wybenga, G; Janssen, DB; Dijkstra, BW				Barends, TRM; Polderman-Tijmes, JJ; Jekel, PA; Williams, C; Wybenga, G; Janssen, DB; Dijkstra, BW			Acetobacter turbidans alpha-amino acid ester hydrolase - How a single mutation improves an antibiotic-producing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL DIPEPTIDYL AMINOPEPTIDASE; ACYL TRANSFER; SUBSTRATE-SPECIFICITY; PENICILLIN ACYLASE; XANTHOMONAS-CITRI; IDENTIFICATION; RESIDUES; SEQUENCE; KINETICS; PROGRAM	The alpha- amino acid ester hydrolase ( AEH) from Acetobacter turbidans is a bacterial enzyme catalyzing the hydrolysis and synthesis of beta- lactam antibiotics. The crystal structures of the native enzyme, both unliganded and in complex with the hydrolysis product D- phenylglycine are reported, as well as the structures of an inactive mutant ( S205A) complexed with the substrate ampicillin, and an active site mutant ( Y206A) with an increased tendency to catalyze antibiotic production rather than hydrolysis. The structure of the native enzyme shows an acyl binding pocket, in which D- phenylglycine binds, and an additional space that is large enough to accommodate the beta- lactam moiety of an antibiotic. In the S205A mutant, ampicillin binds in this pocket in a non- productive manner, making extensive contacts with the side chain of Tyr(112), which also participates in oxyanion hole formation. In the Y206A mutant, the Tyr(112) side chain has moved with its hydroxyl group toward the catalytic serine. Because this changes the properties of the beta- lactam binding site, this could explain the increased beta- lactam transferase activity of this mutant.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Biochem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.w.dijkstra@rug.nl	Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586				Alkema WBL, 2002, EUR J BIOCHEM, V269, P2093, DOI 10.1046/j.1432-1033.2002.02857.x; ALKEMA WBL, 2002, THESIS U GRONINGIN G, P142; Barends TRM, 2003, ACTA CRYSTALLOGR D, V59, P2237, DOI 10.1107/S0907444903020729; Barends TRM, 2003, J BIOL CHEM, V278, P23076, DOI 10.1074/jbc.M302246200; BLINKOVSKY AM, 1993, ENZYME MICROB TECH, V15, P965, DOI 10.1016/0141-0229(93)90173-Y; Bruggink A, 1998, ORG PROCESS RES DEV, V2, P128, DOI 10.1021/op9700643; CHICH JF, 1992, FEBS LETT, V314, P139, DOI 10.1016/0014-5793(92)80960-O; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Fernandez-Lafuente R, 2001, J MOL CATAL B-ENZYM, V11, P633, DOI 10.1016/S1381-1177(00)00065-5; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; KATO K, 1980, AGR BIOL CHEM TOKYO, V44, P1083, DOI 10.1080/00021369.1980.10864077; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen NA, 2002, NAT STRUCT BIOL, V9, P17, DOI 10.1038/nsb742; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAM DH, 1985, BIOTECHNOL BIOENG, V27, P953, DOI 10.1002/bit.260270705; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polderman-Tijmes JJ, 2002, J BIOL CHEM, V277, P28474, DOI 10.1074/jbc.M204143200; Polderman-Tijmes JJ, 2002, APPL ENVIRON MICROB, V68, P211, DOI 10.1128/AEM.68.1.211-218.2002; Rigolet P, 2002, STRUCTURE, V10, P1383, DOI 10.1016/S0969-2126(02)00851-1; SINGER PT, 1993, SCIENCE, V261, P621, DOI 10.1126/science.261.5121.621; TAKAHASHI T, 1972, J AM CHEM SOC, V94, P4035, DOI 10.1021/ja00766a076; TAKAHASHI T, 1974, BIOCHEM J, V137, P497, DOI 10.1042/bj1370497; Topf M, 2002, PROTEINS, V47, P357, DOI 10.1002/prot.10097; Turner JM, 2002, BIOCHEMISTRY-US, V41, P12297, DOI 10.1021/bi026131p; Van der Laan J-M, 2002, WO Patent, Patent No. [W002086111, C12N15/55, C12N9/18, (IPC1-7): C 12N9/00.2002, 02086111]; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Youshko MI, 2002, BBA-PROTEINS PROTEOM, V1599, P134, DOI 10.1016/S1570-9639(02)00413-2	32	21	26	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5804	5810		10.1074/jbc.M511187200	http://dx.doi.org/10.1074/jbc.M511187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377627	hybrid, Green Published			2022-12-25	WOS:000235568900059
J	Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Kurumizaka, H; Yokoyama, S				Enomoto, R; Kinebuchi, T; Sato, M; Yagi, H; Kurumizaka, H; Yokoyama, S			Stimulation of DNA strand exchange by the human TBPIP/Hop2-Mnd1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST RAD51 PROTEIN; RECA PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; BRANCH MIGRATION; FISSION YEAST; HOMOLOGOUS RECOMBINATION; CHROMOSOME SYNAPSIS; MOLECULAR-CLONING	In Saccharomyces cerevisiae, the Hop2 protein forms a complex with the Mnd1 protein and is required for the alignment of homologous chromosomes during meiosis, probably through extensive homology matching between them. The Rad51 and Dmc1 proteins, the eukaryotic RecA orthologs, promote strand exchange and may function in the extensive matching of homology within paired DNA molecules. In the present study, we purified the human TBPIP/ Hop2-Mnd1 complex and found that it significantly stimulates the Dmc1- and Rad51-mediated strand exchange. The human Hop2-Mnd1 complex preferentially binds to a three-stranded DNA branch, which mimics the strand-exchange intermediate. These findings are consistent with genetic data, which showed that the Hop2 and Mnd1 proteins are required for homology matching between homologous chromosomes. Therefore, the human TBPIP/ Hop2-Mnd1 complex may ensure proper pairing between homologous chromosomes through its stimulation of strand exchange during meiosis.	RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Fukui, Fac Med Sci, Dept Morphol & Physiol Sci, Div Cell Biol & Neurosci, Matsuoka, Fukui 9101193, Japan; Japan Sci & Technol Agcy, SORST, Kawaguchi, Saitama 3320012, Japan; Waseda Univ, Grad Sch Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; RIKEN, Harima Inst SPring8, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan	RIKEN; University of Fukui; Japan Science & Technology Agency (JST); Waseda University; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo	Kurumizaka, H (corresponding author), RIKEN, Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	kurumizaka@waseda.jp; yokoyama@biochem.s.u-tokyo.ac.jp	Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yagi, Hideshi/0000-0002-8506-8965; Kurumizaka, Hitoshi/0000-0001-7412-3722				Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Chen YK, 2004, P NATL ACAD SCI USA, V101, P10572, DOI 10.1073/pnas.0404195101; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; Enomoto R, 2004, J BIOL CHEM, V279, P35263, DOI 10.1074/jbc.M402481200; Gerton JL, 2002, P NATL ACAD SCI USA, V99, P6895, DOI 10.1073/pnas.102167899; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hong ERL, 2001, J BIOL CHEM, V276, P41906, DOI 10.1074/jbc.M105563200; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; Ijichi H, 2000, GENE, V248, P99, DOI 10.1016/S0378-1119(00)00141-4; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Kato A, 2004, P NATL ACAD SCI USA, V101, P13554, DOI 10.1073/pnas.0403659101; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Maeshima K, 1996, GENES CELLS, V1, P1057, DOI 10.1046/j.1365-2443.1996.d01-224.x; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Nabeshima K, 2001, EMBO J, V20, P3871, DOI 10.1093/emboj/20.14.3871; Petukhova GV, 2005, NAT STRUCT MOL BIOL, V12, P449, DOI 10.1038/nsmb923; Petukhova GV, 2003, DEV CELL, V5, P927, DOI 10.1016/S1534-5807(03)00369-1; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Saito TT, 2004, NUCLEIC ACIDS RES, V32, P3325, DOI 10.1093/nar/gkh654; Schommer C, 2003, PLANT J, V36, P1, DOI 10.1046/j.1365-313X.2003.01850.x; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V239, P176, DOI 10.1006/bbrc.1997.7447; Tanaka Y, 2004, METHODS, V33, P3, DOI 10.1016/j.ymeth.2003.10.024; Tracy RB, 1997, GENE DEV, V11, P3423, DOI 10.1101/gad.11.24.3423; Tsubouchi H, 2002, MOL CELL BIOL, V22, P3078, DOI 10.1128/MCB.22.9.3078-3088.2002	40	39	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5575	5581		10.1074/jbc.M506506200	http://dx.doi.org/10.1074/jbc.M506506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407260	hybrid			2022-12-25	WOS:000235568900033
J	He, Y; Zhang, W; Zhang, R; Zhang, HF; Min, W				He, Y; Zhang, W; Zhang, R; Zhang, HF; Min, W			SOCS1 inhibits tumor necrosis factor-induced activation of ASK1-JNK inflammatory signaling by mediating ASK1 degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; NF-KAPPA-B; ASK1-MEDIATED APOPTOSIS; FACTOR-ALPHA; INDEPENDENT MANNER; OXIDATIVE STRESS; CYTOKINE; RECEPTOR; PROTEINS; KINASE	We have previously shown that ASK1 undergoes ubiquitination and degradation in resting endothelial cells (EC) and that proinflammatory cytokine tumor necrosis factor (TNF) induces deubiquitination and stabilization, leading to ASK1 activation. However, the mechanism for the regulation of ASK1 stability is not known. In the present study, we have shown that SOCS1, a member of suppressor of cytokine signaling, induces ASK1 degradation. SOCS1 was constitutively expressed in EC and formed a labile complex with ASK1 that can be stabilized by proteasomal inhibitors. The phosphotyrosine-binding SH2 domain of SOCS1 was critical for its association with ASK1. Thus a SOCS1 mutant defective in phosphotyrosine binding failed to bind to and induce ASK1 degradation. Phosphotyrosine of ASK1 was induced in response to growth factors, and TNF induced dephosphorylation and dissociation of ASK1 from SOCS1. ASK1 with a mutation at Tyr-718 diminished the binding to SOCS1, suggesting that the phosphotyrosine-718 of ASK1 is critical for SOCS1 binding. Moreover, ASK1 expression and activity were up-regulated in SOCS1-deficient mice and derived EC, resulting in enhanced TNF-induced activation of JNK, expression of proinflammatory molecules, and apoptotic responses. We concluded that SOCS1 functions as a negative regulator in TNF-induced inflammation in EC, in part, by inducing ASK1 degradation.	Yale Univ, Sch Med, Boyer Ctr Mol Med,Dept Pathol, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06510 USA; Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou S1008, Peoples R China	Yale University; Sun Yat Sen University	Min, W (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med,Dept Pathol, Interdepartmental Program Vasc Biol & Transplanta, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu			NHLBI NIH HHS [1R01 HL 65978-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Chong MMW, 2002, J BIOL CHEM, V277, P27945, DOI 10.1074/jbc.M110214200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Sepulveda P, 1999, EMBO J, V18, P904; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Galvan V, 2003, J BIOL CHEM, V278, P13325, DOI 10.1074/jbc.M211398200; Ilangumaran S, 2003, IMMUNOL REV, V192, P196, DOI 10.1034/j.1600-065X.2003.00020.x; Karmann K, 1996, J EXP MED, V184, P173, DOI 10.1084/jem.184.1.173; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lim YC, 2003, AM J PATHOL, V162, P1591, DOI 10.1016/S0002-9440(10)64293-9; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Liu YM, 2001, J CLIN INVEST, V107, P917, DOI 10.1172/JCI11947; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Min W, 1997, J IMMUNOL, V159, P3508; Mooney RA, 2001, J BIOL CHEM, V276, P25889, DOI 10.1074/jbc.M010579200; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; RUI L, 2002, J BIOL CHEM, V12, P12; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2004, CIRC RES, V94, P1483, DOI 10.1161/01.RES.0000130525.37646.a7; Zhang R, 2005, ONCOGENE, V24, P3954, DOI 10.1038/sj.onc.1208548; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	36	83	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5559	5566		10.1074/jbc.M512338200	http://dx.doi.org/10.1074/jbc.M512338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407264	hybrid			2022-12-25	WOS:000235568900031
J	Ignatiuk, A; Quickfall, JP; Hawrysh, AD; Chamberlain, MD; Anderson, DH				Ignatiuk, A; Quickfall, JP; Hawrysh, AD; Chamberlain, MD; Anderson, DH			The smaller isoforms of ankyrin 3 bind to the p85 subunit of phosphatidylinositol 3 '-kinase and enhance platelet-derived growth factor receptor down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF-BETA-RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; P85-ALPHA SUBUNIT; RAB PROTEINS; GENE FAMILY; SH2 DOMAINS; INTERNALIZATION; ENDOSOMES; 3-KINASE	The Src homology 2 (SH2) domains of the p85 subunit of phosphatidylinositol 3'-kinase have been shown to bind to the tyrosine-phosphorylated platelet-derived growth factor receptor (PDGFR). Previously, we have demonstrated that p85 SH2 domains can also bind to the serine/threonine kinase A-Raf via a unique phosphorylation-independent interaction. In this report, we describe a new phosphotyrosine-independent p85 SH2-binding protein, ankyrin 3 (Ank3). In general, ankyrins serve a structural role by binding to both integral membrane proteins at the plasma membrane and spectrin/fodrin proteins of the cytoskeleton. However, smaller isoforms of Ank3 lack the membrane domain and are localized to late endosomes and lysosomes. We found that p85 binds directly to these smaller 120- and 105-kDa Ank3 isoforms. Both the spectrin domain and the regulatory domain of Ank3 are involved in binding to p85. At least two domains of p85 can bind to Ank3, and the interaction involving the p85 C-SH2 domain was found to be phosphotyrosine-independent. Overexpression of the 120- or 105-kDa Ank3 proteins resulted in significantly enhanced PDGFR degradation and a reduced ability to proliferate in response to PDGF. Ank3 overexpression also differentially regulated signaling pathways downstream from the PDGFR. Chloroquine, an inhibitor of lysosomal-mediated degradation pathways, blocked the ability of Ank3 to enhance PDGFR degradation. Immunofluorescence experiments demonstrated that both small Ank3 isoforms colocalized with the lysosomal-associated membrane protein and with p85 and the PDGFR. These results suggest that Ank3 plays an important role in lysosomal-mediated receptor down-regulation, likely through a p85-Ank3 interaction.	Saskatoon Canc Agcy, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 535, Canada; Univ Saskatchewan, Dept Oncol, Saskatoon, SK S7N 535, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Anderson, DH (corresponding author), Saskatoon Canc Agcy, Canc Res Unit, Hlth Res Div, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	deborah.anderson@scf.sk.ca	Chamberlain, Michael/A-9107-2016; Chamberlain, Michael Dean/AAX-1670-2021	Chamberlain, Michael/0000-0003-1813-8545; Chamberlain, Michael Dean/0000-0003-1813-8545				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Anderson DH, 1998, ONCOGENE, V16, P2321, DOI 10.1038/sj.onc.1201780; Armstrong J, 2000, INT J BIOCHEM CELL B, V32, P303, DOI 10.1016/S1357-2725(99)00112-0; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Chamberlain MD, 2004, J BIOL CHEM, V279, P48607, DOI 10.1074/jbc.M409769200; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Fang Y, 2002, BIOCHEM BIOPH RES CO, V290, P1267, DOI 10.1006/bbrc.2002.6347; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; IINO T, 1986, J GEN VIROL, V67, P1373, DOI 10.1099/0022-1317-67-7-1373; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; King TR, 2000, J BIOL CHEM, V275, P36450, DOI 10.1074/jbc.M004720200; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; Sorkin A, 2000, J CELL SCI, V113, P4375; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Stenmark H, 2001, GENOME BIOL, V2; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5956	5964		10.1074/jbc.M510032200	http://dx.doi.org/10.1074/jbc.M510032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377635	hybrid			2022-12-25	WOS:000235568900076
J	Newton, DA; Rao, KMK; Dluhy, RA; Baatz, JE				Newton, DA; Rao, KMK; Dluhy, RA; Baatz, JE			Hemoglobin is expressed by alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GLOBIN GENE; SURFACTANT PROTEINS; PRIMARY CULTURE; LUNG; HEMORPHINS; PHENOTYPE; LINES; DIFFERENTIATION; COMPONENTS	Hemoglobin gene expression in non-erythroid cells has been previously reported in activated macrophages from adult mice and lens cells, and recent studies indicate that alveolar epithelial cells can be derived from hematopoietic stem cells. Our laboratory has now produced strong evidence that hemoglobin is expressed by alveolar type II (ATII) cells and Clara cells, the primary producers of pulmonary surfactant. ATII cells are also closely involved in innate immunity within the lung and are stem cells that differentiate into alveolar type I cells. Reverse transcriptase-PCR was used to measure the expression of transcripts from the alpha- and beta-globin gene clusters in several human and rodent pulmonary epithelial cells. Surprisingly, the two major globin mRNAs characteristic of adult erythroid precursor cells were clearly expressed in human A549 and H441 cell lines, mouse MLE-15 cells, and primary ATII cells isolated from normal rat and mouse lungs. DNA sequencing verified that these PCR products were indeed the result of specific amplification of globin gene cDNAs. These alveolar epithelial cells also expressed the corresponding hemoglobin protein subunits as determined by Western blotting, and tandem mass spectrometry sequencing was used to verify the presence of both alpha- and beta-globin polypeptides in rat primary ATII cells. The function of hemoglobin expression by cells of the pulmonary epithelium will be determined by future studies, but this novel finding could potentially have important implications for the physiology and pathology of the lung.	Med Univ S Carolina, Dept Pediat, Div Neonatol, Charleston, SC 29425 USA; NIOSH, Morgantown, WV 26505 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Medical University of South Carolina; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University System of Georgia; University of Georgia	Baatz, JE (corresponding author), 171 Ashley Ave, Charleston, SC 29425 USA.	baatzje@musc.edu			NHLBI NIH HHS [HL 66066] Funding Source: Medline; NIBIB NIH HHS [EB 001956] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001956] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Acierno Paula M, 2003, J Transl Med, V1, P3, DOI 10.1186/1479-5876-1-3; Baatz JE, 2001, PROTEIN EXPRES PURIF, V23, P180, DOI 10.1006/prep.2001.1492; Ballard PL, 2000, CONT ENDOCRINOL, P1; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Bhandari V, 2002, LUNG, V180, P301, DOI 10.1007/s00408-002-0102-y; Bishop AE, 2004, CELL PROLIFERAT, V37, P89, DOI 10.1111/j.1365-2184.2004.00302.x; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOROK Z, 1994, IN VITRO CELL DEV-AN, V30A, P99; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; BROWER M, 1986, CANCER RES, V46, P798; Cao A, 2002, PEDIATR RES, V51, P415, DOI 10.1203/00006450-200204000-00003; Chen JJ, 2000, COLD SPRING HARBOR M, V39, P529; Cheung P, 1997, J VIROL, V71, P1784, DOI 10.1128/JVI.71.3.1784-1793.1997; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Duethman D, 2000, PEPTIDES, V21, P137, DOI 10.1016/S0196-9781(99)00186-2; Fruitier I, 1999, FEBS LETT, V447, P81, DOI 10.1016/S0014-5793(99)00271-9; Fruitier-Arnaudin I, 2002, PEPTIDES, V23, P1465, DOI 10.1016/S0196-9781(02)00083-9; Fuchs S, 2003, CELL TISSUE RES, V311, P31, DOI 10.1007/s00441-002-0653-5; Glovanella B C, 1976, J Natl Cancer Inst, V56, P1131; Gross SS, 1999, P NATL ACAD SCI USA, V96, P9967, DOI 10.1073/pnas.96.18.9967; GROUDINE M, 1975, P NATL ACAD SCI USA, V72, P4464, DOI 10.1073/pnas.72.11.4464; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; Hardison R. C., 2001, DISORDERS HEMOGLOBIN, P95; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hardison RC, 2001, HEMOGLOBIN, V25, P183, DOI 10.1081/HEM-100104027; HSU SL, 1988, NATURE, V331, P94, DOI 10.1038/331094a0; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Isakson BE, 2001, AM J PHYSIOL-CELL PH, V281, pC1291, DOI 10.1152/ajpcell.2001.281.4.C1291; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Kao YJ, 2001, AM J RESP CRIT CARE, V163, P532, DOI 10.1164/ajrccm.163.2.9912068; KIM JH, 1989, NUCLEIC ACIDS RES, V17, P5687, DOI 10.1093/nar/17.14.5687; Kotton DN, 2001, DEVELOPMENT, V128, P5181; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Lammerich HP, 2003, BRIT J PHARMACOL, V138, P1431, DOI 10.1038/sj.bjp.0705177; Liang TS, 2001, J IMMUNOL, V167, P6609, DOI 10.4049/jimmunol.167.11.6609; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; Liu LM, 1999, P NATL ACAD SCI USA, V96, P6643, DOI 10.1073/pnas.96.12.6643; Mallory G B Jr, 2001, Paediatr Respir Rev, V2, P151; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nyberg F, 1997, BIOPOLYMERS, V43, P147; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poynter SE, 2003, CRIT CARE CLIN, V19, P459, DOI 10.1016/S0749-0704(03)00011-3; Rao KMK, 2004, ENVIRON HEALTH PERSP, V112, P1679, DOI 10.1289/ehp.7295; Rice WR, 2002, AM J PHYSIOL-LUNG C, V283, pL256, DOI 10.1152/ajplung.00302.2001; Rioli V, 2003, J BIOL CHEM, V278, P8547, DOI 10.1074/jbc.M212030200; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; Salinas D, 2003, AM J PHYSIOL-LUNG C, V285, pL1153, DOI 10.1152/ajplung.00084.2003; SANNES PL, 1991, EXP LUNG RES, V17, P639, DOI 10.3109/01902149109062871; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Stamatoyannopoulos G, 2005, EXP HEMATOL, V33, P259, DOI 10.1016/j.exphem.2004.11.007; Sun P, 2003, EXP LUNG RES, V29, P303, DOI 10.1080/01902140303787; Vinogradov SN, 2005, P NATL ACAD SCI USA, V102, P11385, DOI 10.1073/pnas.0502103102; VOLLOCH V, 1987, EXP CELL RES, V173, P38, DOI 10.1016/0014-4827(87)90329-6; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Williams MC, 2003, ANNU REV PHYSIOL, V65, P669, DOI 10.1146/annurev.physiol.65.092101.142446; Wride MA, 2003, MOL VIS, V9, P360; Wright JR, 2003, J CLIN INVEST, V111, P1453, DOI 10.1172/JCI200318650	62	119	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5668	5676		10.1074/jbc.M509314200	http://dx.doi.org/10.1074/jbc.M509314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407281	hybrid			2022-12-25	WOS:000235568900043
J	Suram, S; Brown, GD; Ghosh, M; Gordon, S; Loper, R; Taylor, PR; Akira, S; Uematsu, S; Williams, DL; Leslie, CC				Suram, S; Brown, GD; Ghosh, M; Gordon, S; Loper, R; Taylor, PR; Akira, S; Uematsu, S; Williams, DL; Leslie, CC			Regulation of cytosolic phospholipase A(2) activation and cyclooxygenase 2 expression in macrophages by the beta-glucan receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; ARACHIDONIC-ACID RELEASE; TOLL-LIKE RECEPTOR-2; ALTERNATIVE COMPLEMENT PATHWAY; PATTERN-RECOGNITION RECEPTORS; CELL-WALL COMPONENTS; BINDING LECTIN SITE; MANNOSE RECEPTOR; HUMAN-MONOCYTES; SACCHAROMYCES-CEREVISIAE	Phagocytosis of non-opsonized microorganisms bymacrophages initiates innate immune responses for host defense against infection. Cytosolic phospholipase A(2) is activated during phagocytosis, releasing arachidonic acid for production of eicosanoids, which initiate acute inflammation. Our objective was to identify pattern recognition receptors that stimulate arachidonic acid release and cyclooxygenase 2 (COX2) expression in macrophages by pathogenic yeast and yeast cell walls. Zymosan- and Candida albicans-stimulated arachidonic acid release from resident mouse peritoneal macrophages was blocked by soluble glucan phosphate. In RAW264.7 cells arachidonic acid release, COX2 expression, and prostaglandin production were enhanced by overexpressing the beta-glucan receptor, dectin-1, but not dectin-1 lacking the cytoplasmic tail. Pure particulate (1, 3)-beta-D-glucan stimulated arachidonic acid release and COX2 expression, which were augmented in a Toll-like receptor 2 (TLR2)-dependent manner by macrophage-activating lipopeptide-2. However, arachidonic acid release and leukotriene C-4 production stimulated by zymosan and C. albicans were TLR2-independent, whereas COX2 expression and prostaglandin production were partially blunted in TLR2(-/-) macrophages. Inhibition of Syk tyrosine kinase blocked arachidonic acid release and COX2 expression in response to zymosan, C. albicans, and particulate (1, 3)-beta-D-glucan. The results suggest that cytosolic phospholipase A(2) activation triggered by the beta-glucan component of yeast is dependent on the immunoreceptor tyrosine-based activation motif-like domain of dectin-1 and activation of Syk kinase, whereas both TLR2 and Syk kinase regulate COX2 expression.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 565, Japan; E Tennessee State Univ, James H Quillen Coll Med, Dept Surg, Johnson City, TN 37614 USA; Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	National Jewish Health; University of Cape Town; University of Oxford; Osaka University; East Tennessee State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org	Akira, Shizuo/C-3134-2009; brown, gordon/B-4249-2012	brown, gordon/0000-0002-0287-5383; Taylor, Philip/0000-0003-0163-1421	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053522] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61378, P01 HL034303, R01 HL061378, HL 34303] Funding Source: Medline; NIAID NIH HHS [AI 45829] Funding Source: Medline; NIGMS NIH HHS [GM 53522] Funding Source: Medline; Wellcome Trust [70579] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Aderem A, 2003, J INFECT DIS, V187, pS340, DOI 10.1086/374747; ADEREM AA, 1986, J EXP MED, V164, P165, DOI 10.1084/jem.164.1.165; ADEREM AA, 1985, J EXP MED, V161, P617, DOI 10.1084/jem.161.3.617; BONNEY RJ, 1985, FED PROC, V44, P2933; BONNEY RJ, 1978, BIOCHEM J, V176, P433, DOI 10.1042/bj1760433; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Byrum RS, 1999, J IMMUNOL, V163, P6810; CASTRO M, 1993, AM J RESP CELL MOL, V9, P73, DOI 10.1165/ajrcmb/9.1.73; CASTRO M, 1994, INFECT IMMUN, V62, P3138, DOI 10.1128/IAI.62.8.3138-3145.1994; CHAKRAVARTI B, 1986, J IMMUNOL, V137, P880; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; CZOP JK, 1985, J IMMUNOL, V134, P2588; DAUM T, 1992, FEBS LETT, V309, P119, DOI 10.1016/0014-5793(92)81077-Y; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; ENSLEY HE, 1994, CARBOHYD RES, V258, P307, DOI 10.1016/0008-6215(94)84098-9; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FELS AOS, 1986, J EXP MED, V163, P752, DOI 10.1084/jem.163.3.752; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Ghomashchi F, 1999, BBA-BIOMEMBRANES, V1420, P45, DOI 10.1016/S0005-2736(99)00056-5; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Herre J, 2004, MOL IMMUNOL, V40, P869, DOI 10.1016/j.molimm.2003.10.007; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; HUMES JL, 1980, J IMMUNOL, V124, P2110; Jansen MJJM, 1997, SHOCK, V8, P261, DOI 10.1097/00024382-199710000-00005; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Kolaczkowska E, 2002, INFLAMMATION, V26, P61, DOI 10.1023/A:1014837110735; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Lee SJ, 2003, INFECT IMMUN, V71, P437, DOI 10.1128/IAI.71.1.437-445.2003; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIM LK, 1985, MOL IMMUNOL, V22, P1365, DOI 10.1016/0161-5890(85)90058-6; LUNDY SR, 1990, J IMMUNOL, V144, P2671; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Mukhopadhyay S, 2004, IMMUNOLOGY, V112, P521, DOI 10.1111/j.1365-2567.2004.01941.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511; Panini SR, 2001, J LIPID RES, V42, P1678; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAO TS, 1994, J PHARMACOL EXP THER, V269, P917; Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031; Rice PJ, 2002, J LEUKOCYTE BIOL, V72, P140; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; SCOTT WA, 1980, J EXP MED, V152, P324, DOI 10.1084/jem.152.2.324; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; STEIN M, 1991, EUR J IMMUNOL, V21, P431, DOI 10.1002/eji.1830210227; Swain SD, 2003, INFECT IMMUN, V71, P6213, DOI 10.1128/IAI.71.11.6213-6221.2003; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Taylor PR, 2004, J IMMUNOL, V172, P1157, DOI 10.4049/jimmunol.172.2.1157; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Thornton BP, 1996, J IMMUNOL, V156, P1235; TRIPP CS, 1986, P NATL ACAD SCI USA, V83, P9655, DOI 10.1073/pnas.83.24.9655; TSUNAWAKI S, 1986, J BIOL CHEM, V261, P1563; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Underhill DM, 2004, MICROBES INFECT, V6, P1368, DOI 10.1016/j.micinf.2004.08.016; Underhill DM, 2003, J ENDOTOXIN RES, V9, P176, DOI 10.1179/096805103125001586; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020; Viriyakosol S., 2005, INFECT IMMUN, V73, P1553; WILLIAMS DL, 1991, CARBOHYD RES, V219, P203, DOI 10.1016/0008-6215(91)89052-H; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; Willment JA, 2003, J IMMUNOL, V171, P4569, DOI 10.4049/jimmunol.171.9.4569; Xia Y, 1999, J IMMUNOL, V162, P2281; Young SH, 2001, J BIOL CHEM, V276, P20781, DOI 10.1074/jbc.M101111200; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	89	95	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5506	5514		10.1074/jbc.M509824200	http://dx.doi.org/10.1074/jbc.M509824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407295	hybrid, Green Published			2022-12-25	WOS:000235568900024
J	Drees, JC; Chitteni-Pattu, S; McCaslin, DR; Inman, RB; Cox, MM				Drees, JC; Chitteni-Pattu, S; McCaslin, DR; Inman, RB; Cox, MM			Inhibition of RecA protein function by the RdgC protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENETIC-RECOMBINATION; COPROTEASE ACTIVITIES; BINDING-PROTEIN; ATP HYDROLYSIS; C-TERMINUS; IN-VITRO; FILAMENT; EXCHANGE; REPAIR	The Escherichia coli RdgC protein is a potential negative regulator of RecA function. RdgC inhibits RecA protein-promoted DNA strand exchange, ATPase activity, and RecA-dependent LexA cleavage. The primary mechanism of RdgC inhibition appears to involve a simple competition for DNA binding sites, especially on duplex DNA. The capacity of RecA to compete with RdgC is improved by the DinI protein. RdgC protein can inhibit DNA strand exchange catalyzed by RecA nucleoprotein filaments formed on single-stranded DNA by binding to the homologous duplex DNA and thereby blocking access to that DNA by the RecA nucleoprotein filaments. RdgC protein binds to single-stranded and double-stranded DNA, and the protein can be visualized on DNA using electron microscopy. RdgC protein exists in solution as a mixture of oligomeric states in equilibrium, most likely as monomers, dimers, and tetramers. This concentration-dependent change of state appears to affect its mode of binding to DNA and its capacity to inhibit RecA. The various species differ in their capacity to inhibit RecA function.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Cox JM, 2005, PLOS BIOL, V3, P231, DOI 10.1371/journal.pbio.0030052; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Drees JC, 2004, J BIOL CHEM, V279, P52991, DOI 10.1074/jbc.M409050200; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; HOWARDFLANDERS P, 1987, DNA REPLICATION RECO, P609; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Moore T, 2004, J BACTERIOL, V186, P870, DOI 10.1128/JB.186.3.870-874.2004; Moore T, 2003, EMBO J, V22, P735, DOI 10.1093/emboj/cdg048; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Ryder L, 1996, GENETICS, V143, P1101; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; Tessmer I, 2005, J MOL BIOL, V350, P254, DOI 10.1016/j.jmb.2005.04.043; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256; Yu VPCC, 2000, GENE DEV, V14, P1400; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L	45	36	37	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4708	4717		10.1074/jbc.M513592200	http://dx.doi.org/10.1074/jbc.M513592200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377615	hybrid			2022-12-25	WOS:000235426200019
J	Patel, VA; Longacre, A; Hsiao, K; Fan, HL; Meng, F; Mitchell, JE; Rauch, J; Ucker, DS; Levine, JS				Patel, VA; Longacre, A; Hsiao, K; Fan, HL; Meng, F; Mitchell, JE; Rauch, J; Ucker, DS; Levine, JS			Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells - Implications for the delayed clearance model of autoimmunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; IMPAIRED UPTAKE; PRONE MICE; MACROPHAGES; PHAGOCYTOSIS; DYSREGULATION; DISEASE; KINASE; TRANSDUCTION; INFLAMMATION	Current models of autoimmunity suggest that delayed clearance of apoptotic cells leads to the presentation of apoptotic antigens in the context of inflammatory signals, with resultant autoimmunity. These models implicitly assume that, in contrast to early apoptotic cells (that retain membrane integrity), late apoptotic cells (with compromised membranes) act like necrotic cells (which also lack intact membranes), possibly because of the release of proinflammatory intracellular contents. We showed previously that early apoptotic and necrotic cells induce distinct mitogen-activated protein kinase modules in macrophages with which they interact. Exposure to apoptotic cells led to nearly complete inhibition of both basal and macrophage colony-stimulating factor-induced ERK1/2 by macrophages. In contrast, necrotic cells induced ERK1/2. We show here that apoptotic cells also strongly induced both c-Jun N-terminal kinase and p38, whereas necrotic cells had no detectable effect on c-Jun N-terminal kinase and p38. We also compared the signaling events induced in macrophages by exposure to early apoptotic cells, late apoptotic cells, and necrotic cells. The signaling events induced by late apoptotic cells were identical to and just as potent as those induced by early apoptotic cells. Thus, apoptotic cells are functionally equivalent throughout the cell death process, irrespective of membrane integrity. Moreover, the effects of both early and late apoptotic cells on signaling were dominant over those of necrotic cells. These data show that apoptotic cells do not become proinflammatory upon the loss of membrane integrity and are inconsistent with the notion that delayed clearance alone can lead to autoimmunity.	Univ Illinois, Dept Med, Div Nephrol, Coll Med, Chicago, IL 60612 USA; Promega Corp, Madison, WI 53711 USA; McGill Univ, Ctr Hlth, Dept Med, Div Rheumatol, Montreal, PQ H3G 1A4, Canada; Univ Illinois, Dept Immunol & Microbiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Promega Corporation; McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Levine, JS (corresponding author), Univ Illinois, Dept Med, Div Nephrol, Coll Med, MC793,820 S Wood St, Chicago, IL 60612 USA.	jslevine@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL069722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG024234] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [42391] Funding Source: Medline; NHLBI NIH HHS [HL69722] Funding Source: Medline; NIA NIH HHS [AG024234, R21 AG024234] Funding Source: Medline; NIDDK NIH HHS [DK59793, R01 DK059793] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert ML, 2004, NAT REV IMMUNOL, V4, P223, DOI 10.1038/nri11308; Barker RN, 2002, CLIN EXP IMMUNOL, V127, P220, DOI 10.1046/j.1365-2249.2002.01774.x; Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K; Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Cvetanovic M, 2004, J IMMUNOL, V172, P880, DOI 10.4049/jimmunol.172.2.880; Devitt A, 2004, J CELL BIOL, V167, P1161, DOI 10.1083/jcb.200410057; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Fan HL, 2006, J LEUKOCYTE BIOL, V79, P155, DOI 10.1189/jlb.0705408; Fan HL, 2004, J IMMUNOL, V172, P4834, DOI 10.4049/jimmunol.172.8.4834; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gaipl US, 2005, AUTOIMMUN REV, V4, P189, DOI 10.1016/j.autrev.2004.10.007; Giles KM, 2001, J IMMUNOL, V167, P976, DOI 10.4049/jimmunol.167.2.976; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H; Hugues S, 2002, IMMUNITY, V16, P169, DOI 10.1016/S1074-7613(02)00273-X; Koh JS, 2000, J IMMUNOL, V165, P4190, DOI 10.4049/jimmunol.165.8.4190; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEVINE JS, 1993, EUR J IMMUNOL, V23, P2951, DOI 10.1002/eji.1830231134; Longacre A, 2004, J LEUKOCYTE BIOL, V76, P971, DOI 10.1189/jlb.0604346; MAJNO G, 1995, AM J PATHOL, V146, P3; Mitchell DA, 2002, J IMMUNOL, V168, P2538, DOI 10.4049/jimmunol.168.5.2538; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sinha D, 2005, AM J PHYSIOL-RENAL, V288, pF703, DOI 10.1152/ajprenal.00189.2004; Skoberne M, 2005, CURR TOP MICROBIOL, V289, P259; Stuart LM, 2005, J IMMUNOL, V174, P3220, DOI 10.4049/jimmunol.174.6.3220; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wu XW, 2001, ARTHRITIS RHEUM, V44, P2642, DOI 10.1002/1529-0131(200111)44:11<2642::AID-ART444>3.0.CO;2-8	32	116	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4663	4670		10.1074/jbc.M508342200	http://dx.doi.org/10.1074/jbc.M508342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377620	Green Accepted, hybrid			2022-12-25	WOS:000235426200014
J	Inoue, K; Takano, H; Shimada, A; Wada, E; Yanagisawa, R; Sakurai, M; Satoh, M; Yoshikawa, T				Inoue, K; Takano, H; Shimada, A; Wada, E; Yanagisawa, R; Sakurai, M; Satoh, M; Yoshikawa, T			Role of metallothionein in coagulatory disturbance and systemic inflammation induced by lipopolysaccharide in mice	FASEB JOURNAL			English	Article						MT; endothelial damage; systemic inflammatory response syndrome; cytokine	TUMOR-NECROSIS-FACTOR; PROTECTIVE ROLE; ACUTE-PHASE; ENDOTOXIN; INTERLEUKIN-6; EXPRESSION; INDUCTION; BIOLOGY; DEATH; GAMMA	Although metallothionein (MT) can be induced by inflammatory mediators, its roles in coagulatory disturbance during inflammation are poorly defined. We determined whether MT protects against coagulatory and fibrinolytic disturbance and systemic inflammation induced by intraperitoneal administration of lipopolysaccharide (LPS) in MT-I/II null (-/-) and wild-type (WT) mice. As compared with WT mice, MT (-/-) mice revealed significant prolongation of prothrombin and activated partial thromboplastin time, a significant increase in the levels of fibrinogen and fibrinogen/fibrin degradation products, and a significant decrease in activated protein C, after LPS treatment. LPS induced inflammatory organ damages in the lung, kidney, and liver in both genotypes of mice. The damages, including neutrophil infiltration, were more prominent in MT (-/-) mice than in WT mice after LPS treatment. In both genotypes of mice, LPS enhanced protein expression of interleukin (IL)-1 beta, IL-6, granulocyte/macrophage-colony-stimulating factor, macrophage inflammatory protein (MIP)-1 alpha, MIP-2, macrophage chemoattractant protein-1, and keratinocyte chemoattractant in the lung, kidney, and liver and circulatory levels of IL-1 beta, IL-6, MIP-2, and KC. In overall trends, however, the levels of these proinflammatory proteins were greater in MT (-/-) mice than in WT mice after LPS challenge. Our results suggest that MT protects against coagulatory and fibrinolytic disturbance and multiple organ damages induced by LPS, at least partly, via the inhibition of the expression of proinflammatory proteins.	Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan; Tottori Univ, Fac Agr, Dept Vet Pathol, Tottori 680, Japan; Gifu Pharmaceut Univ, Dept Hyg, Gifu, Japan	National Institute for Environmental Studies - Japan; Kyoto Prefectural University of Medicine; Tottori University; Gifu Pharmaceutical University	Takano, H (corresponding author), Natl Inst Environm Studies, Environm Hlth Sci Div, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.	htakano@nies.go.jp						Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; Badamchian M, 2003, INT IMMUNOPHARMACOL, V3, P1225, DOI 10.1016/S1567-5769(03)00024-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHESTERMAN CN, 1988, BLOOD REV, V2, P88, DOI 10.1016/0268-960X(88)90029-X; Cuzzocrea S, 1999, J IMMUNOL, V163, P5094; De la Fuente M, 2001, FREE RADICAL RES, V35, P73, DOI 10.1080/10715760100300611; DE SK, 1990, J BIOL CHEM, V265, P15267; GANDO S, 1995, INTENS CARE MED, V21, P636, DOI 10.1007/BF01711540; Hambleton Julie, 2002, Hematology Am Soc Hematol Educ Program, P335; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Heremans H, 2000, AM J RESP CRIT CARE, V161, P110, DOI 10.1164/ajrccm.161.1.9902089; Inoue K, 2004, THROMB HAEMOSTASIS, V91, P1194, DOI 10.1160/TH03-09-0595; Jirillo E, 2002, J ENDOTOXIN RES, V8, P319, DOI 10.1179/096805102125000641; Joyce DE, 2004, CRIT CARE MED, V32, pS280, DOI 10.1097/01.CCM.0000128037.72072.22; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Kimura T, 2001, BIOCHEM BIOPH RES CO, V280, P358, DOI 10.1006/bbrc.2000.4085; Klaassen Curtis D., 1998, Journal of Toxicological Sciences, V23, P97; LAZO JS, 1995, ANNU REV PHARMACOL, V35, P635; Lip GYH, 1997, CARDIOVASC RES, V34, P255, DOI 10.1016/S0008-6363(97)00039-4; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MIN KS, 1991, TOXICOL APPL PHARM, V111, P152, DOI 10.1016/0041-008X(91)90144-4; NABEL EG, 1991, AM J CARDIOL, V68, pC6; Nath R, 2000, TOXICOLOGY, V155, P17, DOI 10.1016/S0300-483X(00)00273-0; NISHIMURA H, 1990, J HISTOCHEM CYTOCHEM, V38, P927, DOI 10.1177/38.7.2355174; Penkowa M, 2003, GLIA, V42, P287, DOI 10.1002/glia.10208; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; PUTT FA, 1972, MANUAL HISTOPATHOLOG, P94; Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021; Rofe AM, 1996, BIOCHEM J, V314, P793, DOI 10.1042/bj3140793; SATO M, 1992, RES COMMUN CHEM PATH, V75, P159; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Takano H, 2004, THORAX, V59, P1057, DOI 10.1136/thx.2004.024232; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; Takano H, 2002, AM J RESP CRIT CARE, V165, P1329, DOI 10.1164/rccm.2108122; Takano H, 2000, LAB INVEST, V80, P371, DOI 10.1038/labinvest.3780041; Tohyama C, 1981, Fundam Appl Toxicol, V1, P1; Waelput W, 2001, J EXP MED, V194, P1617, DOI 10.1084/jem.194.11.1617; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Yamaguchi K, 2000, SHOCK, V14, P535, DOI 10.1097/00024382-200014050-00007; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	41	42	42	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2005	19	14					533	+		10.1096/fj.05-3864fje	http://dx.doi.org/10.1096/fj.05-3864fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	999QR	16387980				2022-12-25	WOS:000234405500013
J	Cerda, SR; Mustafi, R; Little, H; Cohen, G; Khare, S; Moore, C; Majumder, P; Bissonnette, M				Cerda, S. R.; Mustafi, R.; Little, H.; Cohen, G.; Khare, S.; Moore, C.; Majumder, P.; Bissonnette, M.			Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators	ONCOGENE			English	Review						pKC; cyclins; p21(Waf1); Bcl-2; Bax; colon cancer cells	COLON-CANCER CELLS; PKC-DELTA; INDUCED APOPTOSIS; BREAST-CANCER; UP-REGULATION; 1,25-DIHYDROXYVITAMIN D-3; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; TRANSFORMED PHENOTYPE; ACTIVATION MECHANISMS	PKC-delta is a serine/threonine kinase that mediates diverse signal transduction pathways. We previously demonstrated that overexpression of PKC-delta slowed the G1 progression of Caco-2 colon cancer cells, accelerated apoptosis, and induced cellular differentiation. In this study, we further characterized the PKC-delta dependent signaling pathways involved in these tumor suppressor actions in Caco-2 cells overexpressing PKC-delta using a Zn2+ inducible expression vector. Consistent with a G1 arrest, increased expression of PKC-delta caused rapid and significant downregulation of cyclin D1 and cyclin E proteins (50% decreases, P < 0.05), while mRNA levels remained unchanged. The PKC agonist, phorbol 12-myristate 13-acetate (TPA, 100 nM, 4 h), induced two-fold higher protein and mRNA levels of p21(Waf1), a cyclin-dependent kinase (cdk) inhibitor in PKC-delta transfectants compared with empty vector (EV) transfected cells, whereas the PKC-delta specific inhibitor rottlerin (3 mu M) or knockdown of this isoenzyme with specific siRNA oligonucleotides blocked p21(Waf1) expression. Concomitantly, compared to EV control cells, PKC-delta upregulation decreased cyclin D1 and cyclin E proteins co-immunoprecipitating with cdk6 and cdk2, respectively. In addition, overexpression of PKC-delta increased binding of cdk inhibitor p27(Kip1) to cdk4. These alterations in cyclin-cdks and their inhibitors are predicted to decrease G1 cyclin kinase activity. As an independent confirmation of the direct role PKC-delta plays in cell growth and cell cycle regulation, we knocked down PKC-delta using specific siRNA oligonucleotides. PKC-delta specific siRNA oligonucleotides, but not irrelevant control oligonucleotides, inhibited PKC-delta protein by more than 80% in Caco-2 cells. Moreover, PKC-delta knockdown enhanced cell proliferation (similar to 1.4-2-fold, P < 0.05) and concomitantly increased cyclin D1 and cyclin E expression (similar to 1.7-fold, P < 0.05). This was a specific effect, as nontargeted PKC-zeta was not changed by PKC-delta siRNA oligonucleotides. Consistent with accelerated apoptosis in PKC-delta transfectants, compared to EV cells, PKC-delta upregulation increased proapoptotic regulator Bax two-fold at mRNA and protein levels, while antiapoptotic Bcl-2 protein was decreased by 50% at a post-transcriptional level. PKC-delta specific siRNA oligonucleotides inhibited Bax protein expression by more than 50%, indicating that PKC-delta regulates apoptosis through Bax. Taken together, these results elucidate two critical mechanisms regulated by PKC-delta that inhibit cell cycle progression and enhance apoptosis in colon cancer cells. We postulate these antiproliferative pathways mediate an important tumor suppressor function for PKC-delta in colonic carcinogenesis.	Univ Chicago, Dept Med, Div Gastroenterol, Chicago, IL 60637 USA; Loyola Univ, Med Ctr, Dept Med, Div Gastroenterol, Maywood, IL 60153 USA	University of Chicago; Loyola University Chicago	Cerda, SR (corresponding author), Univ Chicago, Dept Med, Div Gastroenterol, MC 4076,5841 S Maryland Ave, Chicago, IL 60637 USA.	scerda@medicine.bsd.uchicago.edu		Cerda, Sandra/0000-0002-7779-6110	NCI NIH HHS [2R01CA36745] Funding Source: Medline; NIDDK NIH HHS [P30DK42086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; Acevedo-Duncan M, 2002, CELL PROLIFERAT, V35, P23, DOI 10.1046/j.1365-2184.2002.00220.x; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Andre F, 1999, GASTROENTEROLOGY, V116, P64, DOI 10.1016/S0016-5085(99)70230-1; Arber N, 1997, CANCER RES, V57, P1569; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Arita Y, 1998, EXP CELL RES, V242, P381, DOI 10.1006/excr.1997.3911; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Assert R, 1999, INT J CANCER, V80, P47, DOI 10.1002/(SICI)1097-0215(19990105)80:1<47::AID-IJC10>3.3.CO;2-A; Atten MJ, 2005, INVEST NEW DRUG, V23, P111, DOI 10.1007/s10637-005-5855-8; Avazeri N, 2004, J CELL SCI, V117, P4969, DOI 10.1242/jcs.01375; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Banan A, 2002, J PHARMACOL EXP THER, V303, P17, DOI 10.1124/jpet.102.037218; Barrett CM, 2002, MOL CANCER THER, V1, P469; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; Besson A, 2000, MOL CELL BIOL, V20, P4580, DOI 10.1128/MCB.20.13.4580-4590.2000; Black JD, 2001, GASTROENTEROLOGY, V120, P1868, DOI 10.1053/gast.2001.25287; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOSARI S, 1995, HUM PATHOL, V26, P534, DOI 10.1016/0046-8177(95)90250-3; Brasitus TA, 1998, GASTROENTEROLOGY, V115, P225, DOI 10.1016/S0016-5085(98)70387-7; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; BRONNER MP, 1995, AM J PATHOL, V146, P20; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Clark JA, 2004, J BIOL CHEM, V279, P9233, DOI 10.1074/jbc.M312268200; CRAVEN PA, 1992, CANCER RES, V52, P2216; CRAVEN PA, 1994, DIGEST DIS SCI, V39, P481, DOI 10.1007/BF02088331; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, P261; DAVIDSON LA, 1994, ARCH BIOCHEM BIOPHYS, V312, P547, DOI 10.1006/abbi.1994.1344; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Di Mari JF, 2005, GASTROENTEROLOGY, V128, P2131, DOI 10.1053/j.gastro.2004.09.078; Ding QM, 1998, AM J PHYSIOL-CELL PH, V275, pC1193, DOI 10.1152/ajpcell.1998.275.5.C1193; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Fima E, 2001, ONCOGENE, V20, P6794, DOI 10.1038/sj.onc.1204885; Fishman DD, 1998, INT J ONCOL, V12, P181; Frey MR, 2000, J CELL BIOL, V151, P763, DOI 10.1083/jcb.151.4.763; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Gavrielides MV, 2004, CURR DRUG TARGETS, V5, P431, DOI 10.2174/1389450043345380; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Goerke A, 2002, J BIOL CHEM, V277, P32054, DOI 10.1074/jbc.M203734200; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; Graham MA, 2000, INVEST OPHTH VIS SCI, V41, P4124; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev; Jang SJ, 1999, EUR J SURG ONCOL, V25, P157, DOI 10.1053/ejso.1998.0619; Jones SM, 2001, FEBS LETT, V490, P110, DOI 10.1016/S0014-5793(01)02113-5; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KahlRainer P, 1996, GASTROENTEROLOGY, V110, P1753, DOI 10.1053/gast.1996.v110.pm8964400; Khare S, 1999, AM J PHYSIOL-GASTR L, V276, pG993, DOI 10.1152/ajpgi.1999.276.4.G993; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kitamura K, 2003, GENES CELLS, V8, P311, DOI 10.1046/j.1365-2443.2003.00635.x; Klein IK, 2000, CANCER RES, V60, P2077; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; La Porta CAM, 2002, MELANOMA RES, V12, P297, DOI 10.1097/00008390-200208000-00001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YJ, 2002, CELL GROWTH DIFFER, V13, P237; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Lewis AE, 2005, CELL SIGNAL, V17, P253, DOI 10.1016/j.cellsig.2004.07.005; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Lin SY, 2002, MOL CARCINOGEN, V35, P21, DOI 10.1002/mc.10070; LIPKIN M, 1971, CANCER-AM CANCER SOC, V28, P38, DOI 10.1002/1097-0142(197107)28:1<38::AID-CNCR2820280108>3.0.CO;2-W; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Mandal M, 2001, GASTROENTEROLOGY, V120, P71, DOI 10.1053/gast.2001.20897; McCracken MA, 2003, MOL CANCER THER, V2, P273; MCGARRITY TJ, 1994, DIGEST DIS SCI, V39, P458, DOI 10.1007/BF02088328; McMillan L, 2003, BRIT J CANCER, V88, P748, DOI 10.1038/sj.bjc.6600793; Meyer E, 2005, CANCER RES, V65, P4261, DOI 10.1158/0008-5472.CAN-04-2908; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Moss SF, 1996, GASTROENTEROLOGY, V111, P1425, DOI 10.1016/S0016-5085(96)70003-3; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Ogura E, 1999, ONCOL REP, V6, P365; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Perletti G, 2004, J CELL MOL MED, V8, P563, DOI 10.1111/j.1582-4934.2004.tb00481.x; Perletti G, 2005, INT J CANCER, V113, P42, DOI 10.1002/ijc.20535; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; PINTO M, 1983, BIOL CELL, V47, P323; Polyak K, 1996, AM J PATHOL, V149, P381; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Qiao L, 1996, CANCER LETT, V107, P83, DOI 10.1016/0304-3835(96)04346-7; Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sauma S, 1996, CELL GROWTH DIFFER, V7, P587; Savickiene J, 1999, CELL DEATH DIFFER, V6, P698, DOI 10.1038/sj.cdd.4400541; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Scaglione-Sewell BA, 2000, ENDOCRINOLOGY, V141, P3931, DOI 10.1210/en.141.11.3931; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Seki T, 2005, GENES CELLS, V10, P225, DOI 10.1111/j.1365-2443.2005.00830.x; Shanmugam M, 2001, CANCER LETT, V172, P43, DOI 10.1016/S0304-3835(01)00602-4; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Srivastava J, 2002, BIOCHEM J, V368, P349, DOI 10.1042/BJ20020737; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tillman DM, 2003, CANCER RES, V63, P5118; Toyoda M, 1998, BIOCHEM BIOPH RES CO, V250, P430, DOI 10.1006/bbrc.1998.9332; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG765, DOI 10.1152/ajpgi.2000.278.5.G765; Verstovsek G, 1998, GASTROENTEROLOGY, V115, P75, DOI 10.1016/S0016-5085(98)70367-1; Villalba M, 1998, NEUROREPORT, V9, P2381, DOI 10.1097/00001756-199807130-00042; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; WALI RK, 1995, CANCER RES, V55, P5257; Wang QD, 2006, INT J CANCER, V118, P326, DOI 10.1002/ijc.21373; Wang QD, 2003, J BIOL CHEM, V278, P51091, DOI 10.1074/jbc.M306541200; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Watters D, 1998, BIOCHEM PHARMACOL, V55, P1691, DOI 10.1016/S0006-2952(97)00680-1; Weinstein I B, 1991, Princess Takamatsu Symp, V22, P277; Weller SG, 1999, GASTROENTEROLOGY, V117, P848, DOI 10.1016/S0016-5085(99)70343-4; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; Yin LH, 2005, J BIOL CHEM, V280, P5533, DOI 10.1074/jbc.M405266200; Yokoyama G, 2005, BIOCHEM BIOPH RES CO, V327, P720, DOI 10.1016/j.bbrc.2004.12.070; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zeng YX, 1996, ONCOGENE, V12, P1557; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3	152	45	48	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3123	3138		10.1038/sj.onc.1209360	http://dx.doi.org/10.1038/sj.onc.1209360			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16434969				2022-12-25	WOS:000237951000004
J	Li, D; Hayden, EY; Panda, K; Stuehr, DJ; Deng, HT; Rousseau, DL; Yeh, SR				Li, D; Hayden, EY; Panda, K; Stuehr, DJ; Deng, HT; Rousseau, DL; Yeh, SR			Regulation of the monomer-dimer equilibrium in inducible nitric-oxide synthase by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; SOLUBLE GUANYLATE-CYCLASE; NO SYNTHASE; DIMERIZATION INHIBITORS; REACTION-MECHANISM; ELECTRON-TRANSFER; ESCHERICHIA-COLI; CARBON-MONOXIDE; S-NITROSOTHIOL; ZN2+ RELEASE	The oxygenase domain of inducible nitric-oxide synthase exists as a functional tight homodimer in the presence of the substrate L-arginine and the cofactor tetrahydrobiopterin (H4B). In the absence of H4B, the enzyme is a mixture of monomer and loose dimer. We show that exposure of H4B-free enzyme to NO induces dissociation of the loose dimer into monomers in a reaction that follows single exponential decay kinetics with a lifetime of similar to 300 min. It is followed by a faster autoreduction reaction of the heme iron with a lifetime of similar to 30 min and the concurrent breakage of the proximal iron - thiolate bond, forming a five-coordinate NO-bound ferrous species. Mass spectrometry revealed that the NO-induced monomerization is associated with intramolecular disulfide bond formation between Cys(104) and Cys(109), located in the zinc-binding motif. The regulatory effect of NO as a dimer inhibitor is discussed in the context of the structure/function relationships of this enzyme.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Rockefeller Univ, Proteom Resource Ctr, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Cleveland Clinic Foundation; Rockefeller University	Rousseau, DL (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ullman 325,1300 Morris Pk Ave, Bronx, NY 10461 USA.	rousseau@aecom.yu.edu; syeh@aecom.yu.edu	; Panda, Koustubh/E-5273-2017	Yeh, Syun-Ru/0000-0002-9858-386X; Hayden, Eric/0000-0001-6977-5056; Panda, Koustubh/0000-0002-4783-2221	NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491, R01GM054806] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NHLBI NIH HHS [HL65465] Funding Source: Medline; NIGMS NIH HHS [GM54806, GM07288, GM08572, GM51491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andrew CR, 2001, BIOCHEMISTRY-US, V40, P4115, DOI 10.1021/bi0023652; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Binet MRB, 2002, FEMS MICROBIOL LETT, V213, P121, DOI 10.1016/S0378-1097(02)00803-0; Blasko E, 2002, J BIOL CHEM, V277, P295, DOI 10.1074/jbc.M105691200; Boffi A, 2002, BIOPHYS CHEM, V98, P209, DOI 10.1016/S0301-4622(02)00094-7; Chen YS, 2002, BIOCHEMISTRY-US, V41, P4618, DOI 10.1021/bi011877t; CHIEN JCW, 1969, J AM CHEM SOC, V91, P2166, DOI 10.1021/ja01036a085; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Deinum G, 1996, BIOCHEMISTRY-US, V35, P1540; EHRENBERG A, 1960, ACTA CHEM SCAND, V14, P1684, DOI 10.3891/acta.chem.scand.14-1684; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gautier C, 2004, J BIOL CHEM, V279, P4358, DOI 10.1074/jbc.M305048200; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; Hoshino M, 1996, J AM CHEM SOC, V118, P5702, DOI 10.1021/ja953311w; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Karow DS, 2004, BIOCHEMISTRY-US, V43, P10203, DOI 10.1021/bi049374l; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Kolodziejski PJ, 2004, P NATL ACAD SCI USA, V101, P18141, DOI 10.1073/pnas.0406711102; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Lawson DM, 2000, EMBO J, V19, P5661, DOI 10.1093/emboj/19.21.5661; Li D, 2004, J BIOL CHEM, V279, P26489, DOI 10.1074/jbc.M400968200; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; LukatRodgers GS, 1997, BIOCHEMISTRY-US, V36, P4178, DOI 10.1021/bi9628230; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1993, ADV EXP MED BIOL, V338, P281; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; Miller RT, 1999, J BIOL CHEM, V274, P14537, DOI 10.1074/jbc.274.21.14537; Mitchell DA, 2005, BIOCHEMISTRY-US, V44, P4636, DOI 10.1021/bi0474463; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Spahl DU, 2003, P NATL ACAD SCI USA, V100, P13952, DOI 10.1073/pnas.2335190100; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Voegtle HL, 2003, BIOCHEMISTRY-US, V42, P2475, DOI 10.1021/bi0271502; Vogel KM, 1999, J BIOL INORG CHEM, V4, P804, DOI 10.1007/s007750050354; Walker FA, 2005, J INORG BIOCHEM, V99, P216, DOI 10.1016/j.jinorgbio.2004.10.009; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; Weichsel A, 2005, P NATL ACAD SCI USA, V102, P594, DOI 10.1073/pnas.0406549102	58	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8197	8204		10.1074/jbc.M507328200	http://dx.doi.org/10.1074/jbc.M507328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421101	hybrid			2022-12-25	WOS:000236031000059
J	Moshnikova, A; Frye, J; Shay, JW; Minna, JD; Khokhlatchev, AV				Moshnikova, A; Frye, J; Shay, JW; Minna, JD; Khokhlatchev, AV			The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLAND PROMOTER HYPERMETHYLATION; K-RAS; EPIGENETIC INACTIVATION; BINDING-PROTEIN; CELL-LINES; RASSF1A; GENE; ASSOCIATION; EFFECTOR; IDENTIFICATION	NORE1A is a growth and tumor suppressor that is inactivated in a variety of cancers. NORE1A has been shown to bind to the active Ras oncogene product. However, the mechanism of NORE1A-induced growth arrest and tumor suppression remains unknown. Using anchorage-independent growth assays, we mapped the NORE1A effector domain ( the minimal region of the protein responsible for its growth-suppressive effects) to the fragment containing the central and Ras association domains of NORE1A ( amino acids 191 - 363). Expression of the NORE1A effector domain in A549 lung adenocarcinoma cells resulted in the selective inhibition of signal transduction through the ERK pathway. The full-length NORE1A ( 416 amino acids) and its fragments capable of growth suppression were localized to centrosomes and microtubules in normal and transformed human cells in a Ras-independent manner. A mutant that was deficient in binding to centrosomes and microtubules was also deficient in inducing cell cycle arrest. This suggests that cytoskeletal localization is required for growth-suppressive effects of NORE1A. Ras binding function was required for growth-suppressive effects of the full-length NORE1A but not for the growth-suppressive effects of the effector domain. Our studies suggest that association of NORE1A with cytoskeletal elements is essential for NORE1A-induced growth suppression and that the ERK pathway is a target for NORE1A growth-suppressive activities.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Virginia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Khokhlatchev, AV (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, 415 Lane Rd, Charlottesville, VA 22908 USA.	ak9k@virginia.edu	Shay, Jerry W/F-7878-2011		NATIONAL CANCER INSTITUTE [P50CA070907, R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA70907, CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Aoyama Y, 2004, ONCOGENE, V23, P3426, DOI 10.1038/sj.onc.1207486; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chow LSN, 2004, ONCOL REP, V12, P781; Cifone M A, 1982, Cancer Metastasis Rev, V1, P335, DOI 10.1007/BF00124216; Comincini S, 2001, MAMM GENOME, V12, P150, DOI 10.1007/s003350010239; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hull J, 2004, HUM GENET, V114, P272, DOI 10.1007/s00439-003-1038-x; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Levy P, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-20; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; PERGOLIZZI RG, 1993, CANCER INVEST, V11, P25, DOI 10.3109/07357909309020257; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Sambrook J, 2001, MOL CLONING LAB MANU; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339	40	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8143	8152		10.1074/jbc.M511837200	http://dx.doi.org/10.1074/jbc.M511837200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16421102	hybrid			2022-12-25	WOS:000236031000052
J	Gaultier, A; Salicioni, AM; Arandjelovic, S; Gonias, SL				Gaultier, A; Salicioni, AM; Arandjelovic, S; Gonias, SL			Regulation of the composition of the extracellular matrix by low density lipoprotein receptor-related protein-1 - Activities based on regulation of mRNA expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIUM-DERIVED FACTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; UROKINASE RECEPTOR; ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; GENE FAMILY; HUMAN-SKIN; IN-VITRO; COLLAGEN	Low density lipoprotein receptor-related protein-1 (LRP-1) is a catabolic receptor for extracellular matrix (ECM) structural proteins and for proteins that bind to ECM. LRP-1 also is implicated in integrin maturation. In this study, we applied a proteomics strategy to identify novel proteins involved in ECM modeling that are regulated by LRP-1. We show that LRP-1 deficiency in murine embryonic fibroblasts (MEFs) is associated with increased levels of type III collagen and pigment epithelium-derived factor, which accumulate in the substratum surrounding cells. The collagen receptor, uPAR-AP/ Endo-180, is also increased in LRP-1-deficient MEFs. Human LRP-1 reversed the changes in protein expression associated with LRP-1 deficiency; however, the endocytic activity of LRP-1 was not involved. Instead, regulation occurred at the mRNA level. Inhibition of c-Jun amino-terminal kinase (JNK) blocked type III collagen expression in LRP-1-deficient MEFs, suggesting regulation of JNK activity as a mechanism by which LRP-1 controls mRNA expression. The ability of LRP-1 to regulate expression of the factors identified here suggests a role for LRP-1 in determining blood vessel structure and in angiogenesis.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of California System; University of California San Diego; University of Massachusetts System; University of Massachusetts Amherst	Gonias, SL (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu	Salicioni, Ana Maria/ABD-8384-2021	Salicioni, Ana Maria/0000-0002-8951-3587	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 60551] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arandjelovic S, 2005, ARCH BIOCHEM BIOPHYS, V438, P29, DOI 10.1016/j.abb.2005.03.019; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; Bock HH, 2003, J BIOL CHEM, V278, P38772, DOI 10.1074/jbc.M306416200; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; COTTAPEREIRA G, 1980, J CELL PHYSIOL, V102, P183, DOI 10.1002/jcp.1041020209; Curino AC, 2005, J CELL BIOL, V169, P977, DOI 10.1083/jcb.200411153; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Engelholm LH, 2003, J CELL BIOL, V160, P1009, DOI 10.1083/jcb.200211091; EPSTEIN EH, 1974, J BIOL CHEM, V249, P3225; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FOUSER L, 1991, J BIOL CHEM, V266, P18345; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; GERSTENFELD L, 1984, J BIOL CHEM, V259, P9158; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Green KA, 2005, BIOESSAYS, V27, P894, DOI 10.1002/bies.20281; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hosomichi J, 2005, BIOCHEM BIOPH RES CO, V335, P756, DOI 10.1016/j.bbrc.2005.07.140; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Kanda S, 2005, J CELL SCI, V118, P961, DOI 10.1242/jcs.01686; KONTUSAARI S, 1990, AM J HUM GENET, V47, P112; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li YH, 2003, FEBS LETT, V555, P346, DOI 10.1016/S0014-5793(03)01272-9; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Meyer C, 2002, J BIOL CHEM, V277, P45400, DOI 10.1074/jbc.M208339200; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; Ranganathan S, 2004, J BIOL CHEM, V279, P40536, DOI 10.1074/jbc.M407592200; Salicioni AM, 2004, J BIOL CHEM, V279, P10005, DOI 10.1074/jbc.M306625200; Salicioni AM, 2002, J BIOL CHEM, V277, P16160, DOI 10.1074/jbc.M201401200; Sheikh H, 2000, J CELL SCI, V113, P1021; Spijkers PPEM, 2005, BLOOD, V105, P170, DOI 10.1182/blood-2004-02-0498; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANIWAKI T, 1995, J NEUROCHEM, V64, P2509; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wu LH, 2004, J CELL BIOCHEM, V93, P1169, DOI 10.1002/jcb.20288; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje	59	28	28	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7332	7340		10.1074/jbc.M511857200	http://dx.doi.org/10.1074/jbc.M511857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407289	hybrid			2022-12-25	WOS:000236030900052
J	Ridge, KD; Abdulaev, NG; Zhang, C; Ngo, T; Brabazon, DM; Marino, JP				Ridge, KD; Abdulaev, NG; Zhang, C; Ngo, T; Brabazon, DM; Marino, JP			Conformational changes associated with receptor-stimulated guanine nucleotide exchange in a heterotrimeric G-protein alpha-subunit - NMR analysis of GTP gamma S-bound states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; STRUCTURAL-CHANGES; BINDING-SITE; TRANSDUCIN BINDING; SYNTHETIC PEPTIDES; CARBOXYL-TERMINUS; BOVINE RHODOPSIN; ADP-RIBOSYLATION; ACTIVATION; LIGHT	Solution NMR studies of a N-15-labeled G-protein alpha-subunit (G(alpha)) chimera (N-15-ChiT)-reconstituted heterotrimer have shown previously that G-protein beta gamma-subunit (G(beta gamma)) association induces a "preactivated" conformation that likely facilitates interaction with the agonist-activated form of a G-protein-coupled receptor (R*) and guanine nucleotide exchange (Abdulaev, N. G., Ngo, T., Zhang, C., Dinh, A., Brabazon, D. M., Ridge, K. D., and Marino, J.P. (2005) J. Biol. Chem. 280, 38071-38080). Here we demonstrated that the N-15-ChiT-reconstituted heterotrimer can form functional complexes under NMR experimental conditions with light-activated, detergent-solubilized rhodopsin (R*), as well as a soluble mimic of R*. NMR methods were used to track R*-triggered guanine nucleotide exchange and release of guanosine 5'-O-3-thiotriphosphate (GTP gamma S)/Mg2+-bound ChiT. A heteronuclear single quantum correlation (HSQC) spectrum of R*-generated GTP gamma S/Mg2+-bound ChiT revealed (HN)-H-1, N-15 chemical shift changes relative to GDP/Mg2+-bound ChiT that were similar, but not identical, to those observed for the GDP center dot AlF4-/Mg2+-bound state. Line widths observed for R*-generated GTP gamma S/Mg2+-bound N-15-ChiT, however, indicated that it is more conformationally dynamic relative to the GDP/Mg2+- and GDP center dot AlF4-/Mg-2(+)-bound states. The increased dynamics appeared to be correlated with G(beta gamma) and R* interactions because they are not observed for GTP gamma S/Mg2+-bound ChiT generated independently of R*. In contrast to R*, a soluble mimic that does not catalytically interact with G-protein (Abdulaev, N. G., Ngo, T., Chen, R., Lu, Z., and Ridge, K. D. (2000) J. Biol. Chem. 275, 39354-39363) is found to form a stable complex with the GTP gamma S/Mg2+-exchanged heterotrimer. The HSQC spectrum of N-15-ChiT in this complex displays a unique chemical shift pattern that nonetheless shares similarities with the heterotrimer and GTP gamma S/Mg2+-bound ChiT. Overall, these results demonstrated that R*-induced changes in G(alpha) can be followed by NMR and that guanine nucleotide exchange can be uncoupled from heterotrimer dissociation.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA; Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Natl Inst Stand & Technol, Rockville, MD 20850 USA; Loyola Coll, Dept Chem, Baltimore, MD 21210 USA	University of Texas System; University of Texas Health Science Center Houston; National Institute of Standards & Technology (NIST) - USA; Loyola University Maryland	Ridge, KD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Ctr Membrane Biol, Houston, TX 77030 USA.	Kevin.D.Ridge@uth.tmc.edu; john.marino@nist.gov			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015744] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013286] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P77, DOI 10.1002/352760510X.ch4; Abdulaev NG, 2005, J BIOL CHEM, V280, P38071, DOI 10.1074/jbc.M505259200; Abdulaev NG, 2005, J BIOMOL NMR, V32, P31, DOI 10.1007/s10858-005-3340-5; Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Abdulaev NG, 2000, J BIOL CHEM, V275, P39354, DOI 10.1074/jbc.M005642200; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Alves ID, 2005, BIOPHYS J, V88, P198, DOI 10.1529/biophj.104.046722; Anderson LL, 2005, J BIOL CHEM, V280, P31019, DOI 10.1074/jbc.M503690200; Arimoto R, 2001, BIOPHYS J, V81, P3285, DOI 10.1016/S0006-3495(01)75962-0; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BLAZYNSKI C, 1984, VISION RES, V24, P459, DOI 10.1016/0042-6989(84)90043-9; BLAZYNSKI C, 1981, VISION RES, V21, P833, DOI 10.1016/0042-6989(81)90183-8; Bohm A, 1997, CURR OPIN BIOTECH, V8, P480, DOI 10.1016/S0958-1669(97)80072-9; Brabazon DM, 2003, BIOCHEMISTRY-US, V42, P302, DOI 10.1021/bi0268899; CAI K, 2001, P NATL ACAD SCI USA, V98, P4819; Cherfils J, 2003, TRENDS BIOCHEM SCI, V28, P13, DOI 10.1016/S0968-0004(02)00006-3; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Herrmann R, 2004, J BIOL CHEM, V279, P24283, DOI 10.1074/jbc.M311166200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Janz JM, 2004, J BIOL CHEM, V279, P29767, DOI 10.1074/jbc.M402567200; KATADA T, 1984, J BIOL CHEM, V259, P3578; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Koenig BW, 2000, J BIOMOL NMR, V16, P121, DOI 10.1023/A:1008378523816; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Lundstrom K, 2005, TRENDS BIOTECHNOL, V23, P103, DOI 10.1016/j.tibtech.2004.12.006; Marin EP, 2002, BIOCHEMISTRY-US, V41, P6988, DOI 10.1021/bi025514k; Marin EP, 2001, J BIOL CHEM, V276, P27400, DOI 10.1074/jbc.C100198200; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Medkova M, 2002, BIOCHEMISTRY-US, V41, P9962, DOI 10.1021/bi0255726; MITTAL R, 1994, BIOCHEMISTRY-US, V33, P10178, DOI 10.1021/bi00199a046; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PELLICONE C, 1985, BIOCHEM BIOPH RES CO, V127, P816, DOI 10.1016/S0006-291X(85)80016-4; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Ruan B, 2004, BIOCHEMISTRY-US, V43, P14539, DOI 10.1021/bi048177j; Salamon Z, 1996, BIOPHYS J, V71, P283, DOI 10.1016/S0006-3495(96)79224-X; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; VANDOP C, 1984, J BIOL CHEM, V259, P23; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEST RE, 1985, J BIOL CHEM, V260, P4428; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379	77	33	33	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7635	7648		10.1074/jbc.M509851200	http://dx.doi.org/10.1074/jbc.M509851200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407225	hybrid			2022-12-25	WOS:000236030900085
J	Irvin, JD; Pugh, BF				Irvin, JD; Pugh, BF			Genome-wide transcriptional dependence on TAF1 functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; EXPRESSION PATTERNS; GENE DISRUPTION; SAGA COMPLEXES; BOX-BINDING; YEAST; TAF(II)S; IDENTIFICATION; ACTIVATORS	Transcription factor IID ( TFIID) plays a central role in regulating the expression of most eukaryotic genes. Of the 14 TBP-associated factor (TAF) subunits that compose TFIID, TAF1 is one of the largest and most functionally diverse. Yeast TAF1 can be divided into four regions including a putative histone acetyltransferase domain and TBP, TAF, and promoter binding domains. Establishing the importance of each region in gene expression through deletion analysis has been hampered by the cellular requirement of TAF1 for viability. To circumvent this limitation we introduced galactose-inducible deletion derivatives of previously defined functional regions of TAF1 into a temperature-sensitive taf1(ts2) yeast strain. After galactose induction of the TAF1 mutants and temperature-induced elimination of the resident Taf1(ts2) protein, we examined the properties and phenotypes of the mutants, including their impact on genome-wide transcription. Virtually all TAF1-dependent genes, which comprise similar to 90% of the yeast genome, displayed a strong dependence upon all regions of TAF1 that were tested. This finding might reflect the need for each region of TAF1 to stabilize TAF1 against degradation or may indicate that all TAF1-dependent genes require the many activities of TAF1. Paradoxically, deletion of the region of TAF1 that is important for promoter binding interfered with the expression of many genes that are normally TFIID-independent/ SAGA (Spt-Ada-Gcn5-acetyltransferase)- dominated, suggesting that this region normally prevents TAF1 ( TFIID) from interfering with the expression of SAGA-regulated genes.	Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Ctr Gene Regulat, 452 N Frear Lab, University Pk, PA 16802 USA.	bfp2@psu.edu		Irvin, Jordan/0000-0001-8504-5985	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059055, GM059055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Brachmann CB, 1998, YEAST, V14, P115; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURANT M, 2003, IN PRESS MOL CELL BI; Durso RJ, 2001, MOL CELL BIOL, V21, P7331, DOI 10.1128/MCB.21.21.7331-7344.2001; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kirchner J, 2001, MOL CELL BIOL, V21, P6668, DOI 10.1128/MCB.21.19.6668-6680.2001; Kirschner DB, 2002, MOL CELL BIOL, V22, P3178, DOI 10.1128/MCB.22.9.3178-3193.2002; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; Mencia M, 2001, MOL CELL BIOL, V21, P1145, DOI 10.1128/MCB.21.4.1145-1154.2001; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Ruzzi M, 1997, YEAST, V13, P365, DOI 10.1002/(SICI)1097-0061(19970330)13:4<365::AID-YEA78>3.0.CO;2-F; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Shen WC, 2003, EMBO J, V22, P3395, DOI 10.1093/emboj/cdg336; Singh MV, 2004, MOL CELL BIOL, V24, P4929, DOI 10.1128/MCB.24.11.4929-4942.2004; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Zanton SJ, 2004, P NATL ACAD SCI USA, V101, P16843, DOI 10.1073/pnas.0404988101	39	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6404	6412		10.1074/jbc.M513776200	http://dx.doi.org/10.1074/jbc.M513776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407318	hybrid			2022-12-25	WOS:000236030800034
J	Tu, Z; Prajapati, S; Park, KJ; Kelly, NJ; Yamamoto, Y; Gaynor, RB				Tu, Z; Prajapati, S; Park, KJ; Kelly, NJ; Yamamoto, Y; Gaynor, RB			IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BREAST-CANCER CELLS; GENE-EXPRESSION; KINASE-ALPHA; FAMILY-MEMBERS; DIFFERENTIAL REGULATION; RETINOBLASTOMA PROTEIN; LIVER DEGENERATION; DEPENDENT KINASES; MICE LACKING	The I kappa B kinase (IKK) complex consists of the catalytic subunits IKK alpha and IKK beta and a regulatory subunit, IKK gamma/NEMO. Even though IKK alpha and IKK beta share significant sequence similarity, they have distinct biological roles. It has been demonstrated that IKKs are involved in regulating the proliferation of both normal and tumor cells, although the mechanisms by which they function in this process remain to be better defined. In this study, we demonstrate that IKK alpha, but not IKK beta, is important for estrogen-induced cell cycle progression by regulating the transcription of the E2F1 gene as well as other E2F1-responsive genes, including thymidine kinase 1, proliferating cell nuclear antigen, cyclin E, and cdc25A. The role of IKK alpha in regulating E2F1 was not the result of reduced levels of cyclin D1, as overexpression of this gene could not overcome the effects of IKK alpha knock-down. Furthermore, estrogen treatment increased the association of endogenous IKK alpha and E2F1, and this interaction occurred on promoters bound by E2F1. IKK alpha also potentiated the ability of p300/CBP-associated factor to acetylate E2F1. Taken together, these data suggest a novel mechanism by which IKK alpha can influence estrogen-mediated cell cycle progression through its regulation of E2F1.	Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Yamamoto, Y (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.	yamamoto_yumi@lilly.com; gaynor_richard@lilly.com						Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Altucci L, 1996, ONCOGENE, V12, P2315; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cress WD, 1996, MOL CELL BIOL, V16, P2119; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008; Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Krutzfeldt M, 2005, MOL CELL, V18, P213, DOI 10.1016/j.molcel.2005.03.009; Kwak YT, 2005, J BIOL CHEM, V280, P33945, DOI 10.1074/jbc.M506206200; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ngwenya S, 2003, ENDOCRINOLOGY, V144, P1675, DOI 10.1210/en.2002-0009; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Ren H, 2002, J IMMUNOL, V168, P3721, DOI 10.4049/jimmunol.168.8.3721; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6699	6706		10.1074/jbc.M512439200	http://dx.doi.org/10.1074/jbc.M512439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407216	hybrid			2022-12-25	WOS:000236030800067
J	Arnold, M; Nath, A; Wohlwend, D; Kehlenbach, RH				Arnold, M; Nath, A; Wohlwend, D; Kehlenbach, RH			Transportin is a major nuclear import receptor for c-Fos - A novel mode of cargo interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; LOCALIZATION SIGNAL; FACTOR P97; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; PORE COMPLEX; BETA; BINDING; ALPHA; EXPORT	c-Fos, a component of the transcription factor AP-1, is rapidly imported into the nucleus after translation. We established an in vitro system using digitonin-permeabilized cells to analyze nuclear import of c-Fos in detail. Two import receptors of the importin beta superfamily, importin beta itself and transportin, promote import of c-Fos in vitro. Under conditions where importin beta-dependent transport was blocked, c-Fos still accumulated in the nucleus in the presence of cytosol. Inhibition of the transportin-dependent pathway, in contrast, abolished import of c-Fos. Furthermore, c-Fos mutants that interact with transportin but not with importin beta were efficiently imported in the presence of cytosol. Hence, transportin appears to be the predominant import receptor for c-Fos. A detailed biochemical characterization revealed that the interaction of transportin with c-Fos is distinct from the interaction with its established import cargoes, the M9 sequence of heterogeneous nuclear ribonucleoprotein A1 or the nuclear localization sequence of some basic proteins. Likewise, the binding sites on importin beta for its classic import cargo and for c-Fos can be separated. In summary, c-Fos employs a novel mode of receptor-cargo interaction. Hence, transportin may be as versatile as importin beta in recognizing different nuclear import cargoes.	Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	University of Gottingen; University of Gottingen	Kehlenbach, RH (corresponding author), Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	rkehlen@gwdg.de		Kehlenbach, Ralph/0000-0003-4920-9916				ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Baake M, 2001, EUR J CELL BIOL, V80, P669, DOI 10.1078/0171-9335-00208; Bednenko J, 2003, J CELL BIOL, V162, P391, DOI 10.1083/jcb.200303085; Campos MAS, 1999, CELL BIOL INT, V23, P81, DOI 10.1006/cbir.1998.0323; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Cingolani G, 2000, FEBS LETT, V484, P291, DOI 10.1016/S0014-5793(00)02154-2; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; Dean KA, 2001, J CELL SCI, V114, P3479; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Fridell RA, 1997, J CELL SCI, V110, P1325; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Higashi N, 2004, GENES CELLS, V9, P233, DOI 10.1111/j.1356-9597.2004.00715.x; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee SJ, 2003, SCIENCE, V302, P1571, DOI 10.1126/science.1088372; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Ng KW, 1997, EMBO J, V16, P2072, DOI 10.1093/emboj/16.8.2072; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Tanos T, 2005, J BIOL CHEM, V280, P18842, DOI 10.1074/jbc.M500620200; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; TRATNER I, 1991, ONCOGENE, V6, P2049; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Yamasaki H, 2005, GENES CELLS, V10, P455, DOI 10.1111/j.1365-2443.2005.00850.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	52	27	28	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5492	5499		10.1074/jbc.M513281200	http://dx.doi.org/10.1074/jbc.M513281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407315	hybrid			2022-12-25	WOS:000235568900022
J	Grimsley, CM; Lu, MJ; Haney, LB; Kinchen, JM; Ravichandran, KS				Grimsley, CM; Lu, MJ; Haney, LB; Kinchen, JM; Ravichandran, KS			Characterization of a novel interaction between ELMO1 and ERM proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN BINDING; CELL-ADHESION; EZRIN/RADIXIN/MOESIN PROTEINS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; CULTURED-CELLS; ACTIVATES RAC1; THREONINE 558; IN-VITRO; EZRIN	ERMs are closely related proteins involved in cell migration, cell adhesion, maintenance of cell shape, and formation of microvilli through their ability to cross-link the plasma membrane with the actin cytoskeleton. ELMO proteins are also known to regulate actin cytoskeleton reorganization through activation of the small GTP-binding protein Rac via the ELMO-Dock180 complex. Here we showed that ERM proteins associate directly with ELMO1 as purified recombinant proteins in vitro and at endogenous levels in intact cells. We mapped ERM binding on ELMO1 to the N-terminal 280 amino acids, which overlaps with the region required for binding to the GTPase RhoG, but is distinct from the C-terminal Dock180 binding region. Consistent with this, ELMO1 could simultaneously bind both radixin and Dock180, although radixin did not alter Rac activation via the Dock180-ELMO complex. Most interestingly, radixin binding did not affect ELMO binding to active RhoG and a trimeric complex of active RhoG-ELMO-radixin could be detected. Moreover, the three proteins colocalized at the plasma membrane. Finally, in contrast to most other ERM-binding proteins, ELMO1 binding occurred independently of the state of radixin C-terminal phosphorylation, suggesting an ELMO1 interaction with both the active and inactive forms of ERM proteins and implying a possible role of ELMO in localizing or retaining ERM proteins in certain cellular sites. Together these data suggest that ELMO1-mediated cytoskeletal changes may be coordinated with ERM protein cross-linking activity during dynamic cellular functions.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Ravichandran, KS (corresponding author), Univ Virginia, Carter Immunol Ctr, MR4 Rm 4072D,Box 801386,Lane Rd, Charlottesville, VA 22908 USA.	Ravi@virginia.edu	Lu, Mingjian/AGK-0751-2022; Lu, Mingjian/AAO-6179-2021; Kinchen, Jason/ABC-5663-2021	Lu, Mingjian/0000-0001-9328-4935; Kinchen, Jason/0000-0001-8430-2265	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064709] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 064709] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blangy A, 2000, J CELL SCI, V113, P729; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cao XW, 2005, J BIOL CHEM, V280, P13584, DOI 10.1074/jbc.M411941200; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DeBakker CD, 2004, CURR BIOL, V14, P2208, DOI 10.1016/j.cub.2004.12.029; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; FRANCK Z, 1993, J CELL SCI, V105, P219; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gobel V, 2004, DEV CELL, V6, P865, DOI 10.1016/j.devcel.2004.05.018; Granes F, 2000, J CELL SCI, V113, P1267; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hayashi K, 1999, J CELL SCI, V112, P1149; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Ishikawa H, 2001, J MOL BIOL, V310, P973, DOI 10.1006/jmbi.2001.4818; Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Kitajiri S, 2004, J CELL BIOL, V166, P559, DOI 10.1083/jcb.200402007; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; Manchanda N, 2005, J BIOL CHEM, V280, P12517, DOI 10.1074/jbc.C400583200; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SATO N, 1992, J CELL SCI, V103, P131; SCHWARTZALBIEZ R, 1995, EUR J CELL BIOL, V67, P189; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 2002, J CELL SCI, V115, P2569; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	56	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5928	5937		10.1074/jbc.M510647200	http://dx.doi.org/10.1074/jbc.M510647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377631	hybrid			2022-12-25	WOS:000235568900073
J	Krementsova, EB; Hodges, AR; Lu, HL; Trybus, KM				Krementsova, EB; Hodges, AR; Lu, HL; Trybus, KM			Processivity of chimeric class V myosins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEAK BINDING; ACTIN; MOTOR; COORDINATION; MECHANISM; MOVEMENT; KINETICS; DOMAIN	Unconventional myosin V takes many 36-nm steps along an actin filament before it dissociates, thus ensuring its ability to move cargo intracellularly over long distances. In the present study we assessed the structural features that affect processive run length by analyzing the properties of chimeras of mouse myosin V and a non-processive class V myosin from yeast (Myo4p) (Reck-Peterson, S. L., Tyska, M. J., Novick, P. J., and Mooseker, M. S. (2001) J. Cell Biol. 153, 1121-1126). Surprisingly a chimera containing the yeast motor domain on the neck and rod of mouse myosin V (Y-MD) showed longer run lengths than mouse wild type at low salt. Run lengths of mouse myosin V showed little salt dependence, whereas those of Y-MD decreased steeply with ionic strength, similar to a chimera containing yeast loop 2 in the mouse myosin V backbone. Loop 2 binds to acidic patches on actin in the weak binding states of the cycle (Volkmann, N., Liu, H., Hazelwood, L., Krementsova, E. B., Lowey, S., Trybus, K. M., and Hanein, D. (2005) Mol. Cell 19, 595-605). Constructs containing yeast loop 2, which has no net charge compared with +6 for wild type, showed a higher K-m for actin in steady-state ATPase assays. The results imply that a positively charged loop 2 and a high affinity for actin are important to maintain processivity near physiologic ionic strength.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu	lu, hailong/C-7754-2009		NHLBI NIH HHS [HL 38113] Funding Source: Medline; NIAMS NIH HHS [AR 47906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047906] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Buss F, 2004, ANNU REV CELL DEV BI, V20, P649, DOI 10.1146/annurev.cellbio.20.012103.094243; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 2001, MECH MOTOR PROTEINS, P95; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Purcell TJ, 2005, P NATL ACAD SCI USA, V102, P13873, DOI 10.1073/pnas.0506441102; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Toth J, 2005, J BIOL CHEM, V280, P30594, DOI 10.1074/jbc.M505209200; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2005, NAT CELL BIOL, V7, P861, DOI 10.1038/ncb1287; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Volkmann N, 2005, MOL CELL, V19, P595, DOI 10.1016/j.molcel.2005.07.015; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	26	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6079	6086		10.1074/jbc.M510041200	http://dx.doi.org/10.1074/jbc.M510041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377634	hybrid			2022-12-25	WOS:000235568900089
J	LeBlanc, SE; Jang, SW; Ward, RM; Wrabetz, L; Svaren, J				LeBlanc, SE; Jang, SW; Ward, RM; Wrabetz, L; Svaren, J			Direct regulation of myelin protein zero expression by the Egr2 transactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELL DIFFERENTIATION; PERIPHERAL NERVOUS-SYSTEM; TRANSCRIPTION FACTOR SOX10; GENE-EXPRESSION; NEURAL CREST; NGFI-A; INHERITED NEUROPATHIES; AXONAL REGULATION; NAB PROTEINS; GLYCOPROTEIN	During myelination of the peripheral nervous system, the myelin protein zero (Mpz) gene is induced to produce the most abundant protein component (P-0) of mature myelin. Although the basal embryonic expression of Mpz in Schwann cells has been attributed to regulation by Sox10, the molecular mechanism for the profound up-regulation of this gene during myelination has not been established. In this study, we have identified a highly conserved element within the first intron of the Mpz gene, which contains binding sites for the early growth response 2 (Egr2/Krox20) transcription factor, a critical regulator of peripheral nerve myelination. Egr2 can transactivate the intron element, and the induction is blocked by two known repressors of Egr2 activity. Using chromatin immunoprecipitation assays, we find that Egr2 binds in vivo to the intron element, but not to the Mpz promoter. Known inducers of Mpz expression such as forskolin and insulin-like growth factor-1 also activate the element in an Egr2-dependent manner. In addition, we found that Egr2 can act synergistically with Sox10 to activate this intron element, suggesting a model in which cooperative interactions between Egr2 and Sox10 mediate a large increase in Mpz expression to the high levels found in myelinating Schwann cells.	Univ Wisconsin, Sch Vet Med, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Grad Program Cellular & Mol Biol, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA; San Raffaele Sci Inst, Dipartimento Ric Biol & Technol, I-20132 Milan, Italy	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Svaren, J (corresponding author), Univ Wisconsin, Sch Vet Med, Mol & Cellular Pharmacol Program, 2015 Linden Dr, Madison, WI 53706 USA.	jpsvaren@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	NICHD NIH HHS [R01 HD041590, P30 HD 03352, HD 41590] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08688] Funding Source: Medline; NINDS NIH HHS [NS 045630, NS 055256, NS 043560] Funding Source: Medline; Telethon [GGP030074] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045630, R01NS055256, R01NS043560] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BHATTACHARYYA A, 1991, NEURON, V7, P831, DOI 10.1016/0896-6273(91)90285-8; Blanchard AD, 1996, J NEUROSCI RES, V46, P630, DOI 10.1002/(SICI)1097-4547(19961201)46:5<630::AID-JNR11>3.0.CO;2-0; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Brown AM, 1997, J BIOL CHEM, V272, P28939, DOI 10.1074/jbc.272.46.28939; Cheng HL, 1999, ENDOCRINOLOGY, V140, P4478, DOI 10.1210/en.140.10.4478; Colosimo A, 1999, BIOTECHNIQUES, V26, P870, DOI 10.2144/99265bm15; Denarier E, 2005, J NEUROSCI, V25, P11210, DOI 10.1523/JNEUROSCI.2596-05.2005; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; Feltri ML, 1999, EUR J NEUROSCI, V11, P1577, DOI 10.1046/j.1460-9568.1999.00568.x; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; FRANZ T, 1993, DEV BRAIN RES, V72, P99, DOI 10.1016/0165-3806(93)90163-5; Ghislain J, 2002, DEVELOPMENT, V129, P155; Ghislain J, 2003, DEVELOPMENT, V130, P941, DOI 10.1242/dev.00318; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; Hai M, 2002, J NEUROSCI RES, V69, P497, DOI 10.1002/jnr.10327; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; KNIGHT RM, 1993, J NEUROSCI RES, V35, P38, DOI 10.1002/jnr.490350106; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Le N, 2005, NAT NEUROSCI, V8, P932, DOI 10.1038/nn1490; Le N, 2005, P NATL ACAD SCI USA, V102, P2596, DOI 10.1073/pnas.0407836102; LeBlanc SE, 2005, J NEUROCHEM, V93, P737, DOI 10.1111/j.1471-4159.2005.03056.x; Lee MJ, 1997, MOL CELL NEUROSCI, V8, P336, DOI 10.1006/mcne.1996.0589; Lee SL, 1996, MOL CELL BIOL, V16, P4566; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, DEVELOPMENT, V102, P499; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Mandemakers W, 2000, EMBO J, V19, P2992, DOI 10.1093/emboj/19.12.2992; Maurel P, 2000, J NEUROSCI, V20, P4635, DOI 10.1523/JNEUROSCI.20-12-04635.2000; Maycox PR, 1997, MOL CELL NEUROSCI, V8, P405, DOI 10.1006/mcne.1997.0600; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nagarajan R, 2002, P NATL ACAD SCI USA, V99, P8998, DOI 10.1073/pnas.132080999; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Ogata T, 2004, J NEUROSCI, V24, P6724, DOI 10.1523/JNEUROSCI.5520-03.2004; Parkinson DB, 2003, MOL CELL NEUROSCI, V23, P13, DOI 10.1016/S1044-7431(03)00024-1; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Shy ME, 2005, PERIPHERAL NEUROPATH, P1681; Slutsky SG, 2003, J BIOL CHEM, V278, P8960, DOI 10.1074/jbc.M210569200; STAHL N, 1990, MOL BRAIN RES, V8, P209, DOI 10.1016/0169-328X(90)90018-9; Stewart HJS, 1996, EUR J NEUROSCI, V8, P553, DOI 10.1111/j.1460-9568.1996.tb01240.x; Suter U, 2003, NAT REV NEUROSCI, V4, P714, DOI 10.1038/nrn1196; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Takeda Yasuo, 2001, Keio Journal of Medicine, V50, P240; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; Taveggia C, 2004, J NEUROCHEM, V91, P813, DOI 10.1111/j.1471-4159.2004.02745.x; TODA K, 1994, J NEUROCHEM, V63, P1646; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Verheijen MHG, 2003, GENE DEV, V17, P2450, DOI 10.1101/gad.1116203; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Wegner M, 2000, GLIA, V31, P1, DOI 10.1002/(SICI)1098-1136(200007)31:1<1::AID-GLIA10>3.0.CO;2-V; Wight PA, 2004, CELL MOL LIFE SCI, V61, P810, DOI 10.1007/s00018-003-3309-z; WRABETZ L, 2004, MYELIN BIOL DISORDER, P905; ZHANG SM, 1995, J NEUROSCI RES, V40, P241, DOI 10.1002/jnr.490400213; Zorick TS, 1999, DEVELOPMENT, V126, P1397; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	64	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5453	5460		10.1074/jbc.M512159200	http://dx.doi.org/10.1074/jbc.M512159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373334	hybrid			2022-12-25	WOS:000235568900017
J	Hu, J; Xiong, Y				Hu, J; Xiong, Y			An evolutionarily conserved function of proliferating cell nuclear antigen for Cdt1 degradation by the Cul4-Ddb1 ubiquitin ligase in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE REPLICATION; GENOME STABILITY; GEMININ BINDING; FISSION YEAST; INHIBITION; CHECKPOINT; KINASE; PHASE; PCNA; PROTEOLYSIS	The DNA replication licensing factor Cdt1 is degraded by the ubiquitin-proteasome pathway during S phase of the cell cycle, to ensure one round of DNA replication during each cell division and in response to DNA damage to halt DNA replication. Constitutive expression of Cdt1 causes DNA re-replication and is associated with the development of a subset of human non-small cell-lung carcinomas. In mammalian cells, DNA damage-induced Cdt1 degradation is catalyzed by the Cul4-Ddb1-Roc1 E3 ubiquitin ligase. We report here that overexpression of the proliferating cell nuclear antigen (PCNA) inhibitory domain from the CDK inhibitors p21 and p57, but not the CDK-cyclin inhibitory domain, blocked Cdt1 degradation in cultured mammalian cells after UV irradiation. In vivo soluble Cdt1 and PCNA co-elute by gel filtration and associate with each other physically. Silencing PCNA in cultured mammalian cells or repression of pcn1 expression in fission yeast blocked Cdt1 degradation in response to DNA damage. Unexpectedly, deletion of Ddb1 in fission yeast cells also accumulated Cdt1 in the absence of DNA damage. We suggest that the Cul4-Ddb1 ligase evolved to ubiquitinate Cdt1 during normal cell growth as well as in response to DNA damage and a separate E3 ligase, possibly SCFSkp2, evolved to either share or take over the function of Cdt1 ubiquitination during normal cell growth and that PCNA is involved in mediating Cdt1 degradation by the Cul4-Ddb1 ligase in response to DNA damage.	Univ N Carolina, Lineberger Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27516 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27516 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Canc Ctr, Dept Biochem & Biophys, 22-012, Chapel Hill, NC 27516 USA.	yxiong@email.unc.edu	, Proteomics Core UNC/AFQ-7201-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067113] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067113] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias EE, 2005, GENE DEV, V19, P114, DOI 10.1101/gad.1255805; Arroyo MP, 1999, METHODS, V18, P335, DOI 10.1006/meth.1999.0795; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bondar T, 2004, J BIOL CHEM, V279, P9937, DOI 10.1074/jbc.M312570200; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Holmberg C, 2005, GENE DEV, V19, P853, DOI 10.1101/gad.329905; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; Kondo T, 2004, J BIOL CHEM, V279, P27315, DOI 10.1074/jbc.M314023200; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	27	97	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3753	3756		10.1074/jbc.C500464200	http://dx.doi.org/10.1074/jbc.C500464200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16407242	hybrid, Green Published			2022-12-25	WOS:000235275300002
J	Buning, J; Hundorfean, G; Schmitz, M; Zimmer, KP; Strobel, S; Gebert, A; Ludwig, D				Buening, Juergen; Hundorfean, Gheorghe; Schmitz, Martina; Zimmer, Klaus-Peter; Strobel, Stephan; Gebert, Andreas; Ludwig, Diether			Antigen targeting to MHC class II-enriched late endosomes in colonic epithelial cells: trafficking of luminal antigens studied in vivo in Crohn's colitis patients	FASEB JOURNAL			English	Article									[Buening, Juergen; Hundorfean, Gheorghe; Ludwig, Diether] Univ Klinikum Schleswig Holstein, Med Klin 1, D-23538 Lubeck, Germany; [Buening, Juergen; Gebert, Andreas] Univ Lubeck, Inst Anat, Lubeck, Germany; [Schmitz, Martina; Zimmer, Klaus-Peter] Univ Klinikum Munster, Klin & Poliklin Kinderheilkunde, Munster, Germany; [Strobel, Stephan] Univ Plymouth, Peninsula Med Sch, Plymouth PL4 8AA, Devon, England; [Strobel, Stephan] Univ Exeter, Peninsula Med Sch, Plymouth, Devon, England	University of Kiel; Schleswig Holstein University Hospital; University of Lubeck; University of Munster; University of Plymouth; University of Exeter; University of Plymouth	Buning, J (corresponding author), Univ Klinikum Schleswig Holstein, Med Klin 1, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	buening@anat.uni-luebeck.de	Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020						0	20	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2006	20	2					359	361		10.1096/fj.05-4807fje	http://dx.doi.org/10.1096/fj.05-4807fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V17CJ	16373401				2022-12-25	WOS:000207915000021
J	Sayeed, I; Parvez, S; Winkler-Stuck, K; Seitz, G; Trieu, I; Wallesch, CW; Schonfeld, P; Siemen, D				Sayeed, I; Parvez, S; Winkler-Stuck, K; Seitz, G; Trieu, I; Wallesch, CW; Schonfeld, P; Siemen, D			Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole	FASEB JOURNAL			English	Article						cyclosporin A; mitochondrion; dopamine agonist; single channel; neuroprotection	DEPENDENT ANION CHANNEL; CELL-DEATH; BRAIN MITOCHONDRIA; RESPIRATORY-CHAIN; SKELETAL-MUSCLE; INHIBITION; DOPAMINE; REPERFUSION; MODULATION; MEMBRANE	The dopamine-D2-agonist pramipexole (PPX) was tested for blocking mitochondrial permeability transition ( PT) in order to give a possible explanation for its neuroprotective effect seen in PPX-treated Parkinson's disease patients. Patch-clamp techniques for studying single-channel currents in the inner mitochondrial membrane and large-amplitude swelling of energized mitochondria were used to study PPX action on the permeability transition pore (PTP), a key player in the mitochondrial route of the apoptotic cascade. Identity of the PTP was proven by measuring the concentration-response relation for cyclosporin A-blockade (IC50= 26 nM). PPX inhibits the PTP reversibly with an IC50 of 500 nM, which is close to the values determined earlier as plasma concentrations after PPX medication in patients. Interaction of PPX with the PTP is further supported by demonstrating that it abolished Ca2+-triggered swelling in functionally intact mitochondria. Blockade of the PTP by PPX was attenuated by increasing concentrations of inorganic phosphate and by acidification. We suggest that PPX could exert part of its neuroprotective effect by inhibition of the PTP and thus, probably, blocking of the mitochondrial pathway of the apoptosis cascade.	Univ Magdeburg, Dept Neurol, D-39120 Magdeburg, Germany; Univ Magdeburg, Dept Biochem, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Siemen, D (corresponding author), Univ Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany.	detlef.siemen@medizin.unimagdeburg.de	Parvez, Suhel/E-6778-2010	Parvez, Suhel/0000-0002-6318-6506				Abramova NA, 2002, J NEUROSCI RES, V67, P494, DOI 10.1002/jnr.10127; Anderson DW, 2001, BRAIN RES, V905, P44, DOI 10.1016/S0006-8993(01)02466-0; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Brecht HM, 1998, AKTUEL NEUROL, V25, pS310, DOI 10.1055/s-2007-1017756; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Cassarino DS, 1998, J NEUROCHEM, V71, P295; Cesura AM, 2003, J BIOL CHEM, V278, P49812, DOI 10.1074/jbc.M304748200; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; de Lau LML, 2004, NEUROLOGY, V63, P1240, DOI 10.1212/01.WNL.0000140706.52798.BE; Di Lisa F, 2003, BASIC RES CARDIOL, V98, P235, DOI 10.1007/s00395-003-0415-x; Fiskum G, 2003, ANN NY ACAD SCI, V991, P111; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Gu M, 2004, J NEUROCHEM, V91, P1075, DOI 10.1111/j.1471-4159.2004.02804.x; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hansson MJ, 2004, J NEUROCHEM, V89, P715, DOI 10.1111/j.1471-4159.2004.02400.x; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Holloway RG, 2004, ARCH NEUROL-CHICAGO, V61, P1044; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Joyce JN, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-22; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; Kitamura Y, 1998, MOL PHARMACOL, V54, P1046, DOI 10.1124/mol.54.6.1046; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Le WD, 2000, J NEURAL TRANSM, V107, P1165, DOI 10.1007/s007020070030; Loupatatzis C, 2002, CELL PHYSIOL BIOCHEM, V12, P269, DOI 10.1159/000067897; Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Michel P.-P., 2002, Rev Neurol (Paris), V158, P24; Pavlov E, 2005, BIOPHYS J, V88, P2614, DOI 10.1529/biophysj.104.057281; Schaper A, 2002, WORLD TODAY, V58, P18; SCHAPIRA AH, 2004, JAMA-J AM MED ASSOC, V291, P2430; Schluter T, 2000, FEBS LETT, V481, P42, DOI 10.1016/S0014-5793(00)01923-2; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tatton WG, 1998, ANN NEUROL, V44, pS134, DOI 10.1002/ana.410440720; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Winkler-Stuck K, 2005, J NEURAL TRANSM, V112, P499, DOI 10.1007/s00702-004-0195-y; Wright CE, 1997, J CLIN PHARMACOL, V37, P520, DOI 10.1002/j.1552-4604.1997.tb04330.x; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zou LL, 1999, LIFE SCI, V64, P1275, DOI 10.1016/S0024-3205(99)00062-4; Zou LL, 2000, NEUROSCI LETT, V281, P167, DOI 10.1016/S0304-3940(00)00853-3	50	55	69	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2006	20	1					556	+		10.1096/fj.05-4748fje	http://dx.doi.org/10.1096/fj.05-4748fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	021PU	16407457				2022-12-25	WOS:000235996000021
J	Ridgeway, AG; McMenamin, J; Leder, P				Ridgeway, A. G.; McMenamin, J.; Leder, P.			P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells	ONCOGENE			English	Article						oncogene; tumor suppressor; teratomas; metastasis; breast cancer	WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS-COLI; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; P53-DEFICIENT MICE; PROGENITOR CELLS; DOWN-REGULATION; CYCLIN D1; TUMORIGENESIS; CANCER	beta-catenin, an oncogene, and P53, a tumor suppressor, are common targets of mutation in human cancers. It has been observed that P53 is often inactivated in tumors involving b-catenin activation. In an attempt to model this situation in vivo, we crossed the previously characterized MMTV-Delta N-beta- catenin mouse with the P53 knockout mouse. Female multiparous mice that carry the MMTV-Delta N-beta-catenin transgene and that are heterozygous for P53 (Tg(Delta N-beta Cat)/+, P53 +/-) display an increased tumor burden (2.05 vs 1.31 tumors/animal), with a generally more advanced pathology, and increased metastatic rate (39 vs 0%) relative to transgenic female mice that are wild type for P53 (Tg(Delta N-beta Cat)/ +, P53 +/+). These differences were not due to complete loss of P53 as only one of 21 tumors demonstrated loss of heterozygosity at the P53 locus. Furthermore, no mutations were present in tumors retaining a single wild-type allele. Tg(Delta N-beta Cat)/ +, P53 -/- male mice developed testicular teratomas and survived an average of 65 days, whereas non-Tg(Delta N-beta Cat), P53 -/- males survived an average of 84 days. Sixty-two percent of Tg(Delta N-beta Cat), P53 -/- mice developed testicular teratomas, whereas only 10% of the non-Tg(Delta N-beta Cat), P53 -/- mice developed these tumors. These results indicate that the level of P53 and the tissue of origin are important factors in determining outcome of cancer caused by oncogene activation.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, NRB 356B,77 Ave Louis Pasteur, Boston, MA 02115 USA.	leder@genetics.med.harvard.edu						Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; Honecker F, 2004, J PATHOL, V204, P167, DOI 10.1002/path.1614; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KOZMA S, 1980, J GEN VIROL, V51, P327, DOI 10.1099/0022-1317-51-2-327; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Polakis P, 2000, GENE DEV, V14, P1837; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Smalley MJ, 2001, J MAMMARY GLAND BIOL, V6, P37, DOI 10.1023/A:1009564431268; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yin YZ, 1998, DEV BIOL, V204, P165, DOI 10.1006/dbio.1998.9074	51	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3518	3527		10.1038/sj.onc.1209391	http://dx.doi.org/10.1038/sj.onc.1209391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434961				2022-12-25	WOS:000238448200004
J	Ying, MY; Xu, R; Wu, XH; Zhu, HX; Zhuang, Y; Han, M; Xu, T				Ying, MY; Xu, R; Wu, XH; Zhu, HX; Zhuang, Y; Han, M; Xu, T			Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; BULBAR MUSCULAR-ATROPHY; CREB-BINDING PROTEIN; HUNTINGTONS-DISEASE; EXPANDED POLYGLUTAMINE; REPRESSES TRANSCRIPTION; MICE; DEACETYLASE; REPEATS; PATHOGENESIS	Dentatorubral-pallidoluysian atrophy ( DRPLA) is a progressive neurodegenerative disease caused by polyglutamine expansion within the Atrophin-1 protein. To study the mechanism of this disease and to test potential therapeutic methods, we established Atro-118Q transgenic mice, which express in neurons a mutant human Atrophin-1 protein that contains an expanded stretch of 118 glutamines. Consistent with the results from previous studies on transgenic mice that expressed mutant Atrophin-1 with 65 glutamines, Atro-118Q mice exhibited several neurodegenerative phenotypes that are commonly seen in DRPLA patients, including ataxia, tremors, and other motor defects. Overexpression of wild-type human Atrophin-1 could not rescue the motor and survival defects in Atro-118Q mice, indicating that the mutant protein with polyglutamine expansion does not simply function in a dominant negative manner. Biochemical analysis of Atro-118Q mice revealed hypoacetylation of histone H3 in brain tissues and thus suggested that global gene repression is an underlying mechanism for neurodegeneration in this mouse model. We further show that intraperitoneal administration of sodium butyrate, a histone deacetylase inhibitor, ameliorated the histone acetylation defects, significantly improved motor performance, and extended the average life span of Atro-118Q mice. These results support the hypothesis that transcription deregulation plays an important role in the pathogenesis of polyglutamine expansion diseases and suggest that reversion of transcription repression with small molecules such as sodium butyrate is a feasible approach to treating DRPLA symptoms.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Fudan Univ, Inst Dev Biol & Mol Med, Morgan Tan Int Ctr Life Sci, Shanghai 200433, Peoples R China; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Howard Hughes Medical Institute; Yale University; Yale University; Fudan University; Duke University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Xu, T (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 295 Congress Ave,BCMM236, New Haven, CT 06510 USA.	tian.xu@yale.edu		zhuang, yuan/0000-0002-2964-3654				Adachi H, 2003, J NEUROSCI, V23, P2203; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Becher MW, 1997, MOVEMENT DISORD, V12, P519, DOI 10.1002/mds.870120408; Bodai L, 2003, CURR MED CHEM, V10, P2577, DOI 10.2174/0929867033456530; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P53; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Lalonde R, 1996, NEUROBIOL LEARN MEM, V65, P113, DOI 10.1006/nlme.1996.0013; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1927, DOI 10.1093/hmg/11.17.1927; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAGY A, 2002, MANIPULATING MOUSE E, P289; NAITO H, 1982, NEUROLOGY, V32, P798, DOI 10.1212/WNL.32.8.798; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; ONODERA O, 1995, AM J HUM GENET, V57, P1050; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ross CA, 1998, PROG BRAIN RES, V117, P397; Ross CA, 1997, BRAIN PATHOL, V7, P1003, DOI 10.1111/j.1750-3639.1997.tb00898.x; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sakata T, 1993, Rinsho Shinkeigaku, V33, P777; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; Sato T, 1999, HUM MOL GENET, V8, P99, DOI 10.1093/hmg/8.1.99; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Schilling G, 2001, NEUROBIOL DIS, V8, P405, DOI 10.1006/nbdi.2001.0385; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Takahashi H, 1999, Rinsho Shinkeigaku, V39, P1279; Takeda S, 1992, No To Shinkei, V44, P111; UYAMA E, 1995, J NEUROL SCI, V130, P146, DOI 10.1016/0022-510X(95)00019-X; VAN LC, 1996, GENE EXPRESSION, V5, P245; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Yanagisawa H, 2000, HUM MOL GENET, V9, P1433, DOI 10.1093/hmg/9.9.1433; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4; Zoltewicz JS, 2004, DEVELOPMENT, V131, P3, DOI 10.1242/dev.00908	51	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12580	12586		10.1074/jbc.M511677200	http://dx.doi.org/10.1074/jbc.M511677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16407196	hybrid			2022-12-25	WOS:000237134700047
J	Kim, HJ; Chakravarti, N; Oridate, N; Choe, C; Claret, FX; Lotan, R				Kim, HJ; Chakravarti, N; Oridate, N; Choe, C; Claret, FX; Lotan, R			N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells	ONCOGENE			English	Article						4HPR; apoptosis; ROS; MAPK; HNSCC	N-TERMINAL KINASE; MITOCHONDRIAL-MEMBRANE DEPOLARIZATION; FENRETINIDE-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASES; PROSTATE-CANCER CELLS; MEK-ERK PATHWAY; PROTEIN-KINASE; C-JUN; OXIDATIVE STRESS; CYTOCHROME-C	N-(4-hydroxyphenyl) retinamide (4HPR), a synthetic retinoid effective in cancer chemoprevention and therapy, is thought to act via apoptosis induction resulting from increased reactive oxygen species (ROS) generation. As ROS can activate MAP kinases and protein kinase C (PKC), we examined the role of such enzymes in 4HPR-induced apoptosis in HNSCC UMSCC22B cells. 4HPR increased ROS level within 1 h and induced activation of caspase 3 and PARP cleavage within 24 h. Activation of MKK3/6 and MKK4, JNK, p38 and ERK was detected between 6 and 12 h, increased up to 24 h and preceded apoptosis. 4HPR-induced activation of these kinases was abrogated by the antioxidants BHA and vitamin C. SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis. Suppression of JNK1 and JNK2 using siRNA decreased, whereas overexpression of wild type-JNK1 enhanced 4HPR-induced apoptosis. PD169316, a p38, inhibitor suppressed phosphorylation of Hsp27 and apoptosis. PD98059, an MEK1/2 inhibitor, also suppressed ERK1/2 activation and apoptosis induced by 4HPR. Likewise, PKC inhibitor GF109203X suppressed ERK and p38 phosphorylation and PARP cleavage. These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlotan@mdanderson.org	Claret, Francois X/R-2104-2016; Oridate, Nobuhiko/G-5365-2012; Oridate, Nobuhiko/ABC-4116-2020; Chakravarti, Nitin/F-7964-2011	Claret, Francois X/0000-0003-4629-6495; Oridate, Nobuhiko/0000-0002-6968-3028; Chakravarti, Nitin/0000-0002-6619-953X	NCI NIH HHS [P30 CA16672-30, P50 CA97007, R01 CA090853, P50 CA097007, P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhatt NY, 2002, J IMMUNOL, V169, P6427, DOI 10.4049/jimmunol.169.11.6427; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Carvalho H, 2004, J CELL BIOCHEM, V92, P502, DOI 10.1002/jcb.20070; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 2000, INT J ONCOL, V16, P651; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Garaventa A, 2003, CLIN CANCER RES, V9, P2032; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hail N, 2001, J BIOL CHEM, V276, P45614, DOI 10.1074/jbc.M106559200; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Kim HJ, 2004, CANCER RES, V64, P2439, DOI 10.1158/0008-5472.CAN-03-2643; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee YJ, 2003, EXP CELL RES, V291, P251, DOI 10.1016/S0014-4827(03)00391-4; Liao YF, 2005, LIFE SCI, V77, P707, DOI 10.1016/j.lfs.2005.01.010; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Lovat PE, 2000, EXP CELL RES, V260, P50, DOI 10.1006/excr.2000.4988; Lovat PE, 2002, CANCER RES, V62, P5158; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Malone W, 2003, EXPERT OPIN INV DRUG, V12, P1829, DOI 10.1517/eoid.12.11.1829.21882; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Poot M, 2002, EXP CELL RES, V279, P128, DOI 10.1006/excr.2002.5582; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; Reynolds CP, 2004, PEDIATR TRANSPLANT, V8, P56, DOI 10.1111/j.1398-2265.2004.00216.x; Robertson JD, 2002, TOXICOLOGY, V181, P491, DOI 10.1016/S0300-483X(02)00464-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; Shimada K, 2003, MOL CARCINOGEN, V36, P115, DOI 10.1002/mc.10107; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sun SY, 1999, CANCER RES, V59, P2493; Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tamura Y, 2004, FEBS LETT, V569, P249, DOI 10.1016/j.febslet.2004.06.003; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Traore K, 2005, LEUKEMIA RES, V29, P863, DOI 10.1016/j.leukres.2004.12.011; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ulukaya E, 2003, CELL DEATH DIFFER, V10, P856, DOI 10.1038/sj.cdd.4401242; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Won YK, 2005, CARCINOGENESIS, V26, P2149, DOI 10.1093/carcin/bgi194; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Xiao D, 2002, CANCER RES, V62, P3615; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001; Yu WP, 2003, CANCER RES, V63, P2483; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC	67	66	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2785	2794		10.1038/sj.onc.1209303	http://dx.doi.org/10.1038/sj.onc.1209303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16407847	Green Accepted			2022-12-25	WOS:000237272900009
J	DeLisser, HM; Helmke, BP; Cao, GY; Egan, PM; Taichman, D; Fehrenbach, M; Zaman, A; Cui, Z; Mohan, GS; Baldwin, HS; Davies, PF; Savani, RC				DeLisser, HM; Helmke, BP; Cao, GY; Egan, PM; Taichman, D; Fehrenbach, M; Zaman, A; Cui, Z; Mohan, GS; Baldwin, HS; Davies, PF; Savani, RC			Loss of PECAM-1 function impairs alveolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; PLATELET; THALIDOMIDE; INHIBITION; EXPRESSION; MIGRATION; SURVIVAL	The final stage of lung development in humans and rodents occurs principally after birth and involves the partitioning of the large primary saccules into smaller air spaces by the inward protrusion of septae derived from the walls of the saccules. Several observations in animal models implicate angiogenesis as critical to this process of alveolarization, but all anti-angiogenic treatments examined to date have resulted in endothelial cell (EC) death. We therefore targeted the function of platelet endothelial cell adhesion molecule, (PECAM-1), an EC surface molecule that promotes EC migration and has been implicated in in vivo angiogenesis. Administration of an anti-PECAM-1 antibody that inhibits EC migration, but not proliferation or survival in vitro, disrupted normal alveolar septation in neonatal rat pups without reducing EC content. Three-dimensional reconstruction of lungs showed that pups treated with a blocking PECAM-1 antibody had remodeling of more proximal branches resulting in large tubular airways. Subsequent studies in PECAM-1-null mice confirmed that the absence of PECAM-1 impaired murine alveolarization, without affecting EC content, proliferation, or survival. Further, cell migration was reduced in lung endothelial cells isolated from these mice. These data suggest that the loss of PECAM-1 function compromises postnatal lung development and provide evidence that inhibition of EC function, in contrast to a loss of viable EC, inhibits alveolarization.	Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Dept Pediat,Div Neonatol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Med,Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Cardiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Savani, RC (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Dept Pediat,Div Neonatol, 3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rsavani@mail.med.upenn.edu	DeLisser, Horace/AFM-1942-2022; Rashmin C. Savani, MBChB/AAG-2041-2021; Mohan, Gopi/AAP-5976-2020	Rashmin C. Savani, MBChB/0000-0002-9533-5422; 	NHLBI NIH HHS [HL62868, HL62472, HL075930, HL10058] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062868, R01HL075930, R01HL062472, F32HL010058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albelda SM, 2004, AM J RESP CELL MOL, V31, P246, DOI 10.1165/rcmb.2003-0404OC; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Bowden RA, 2002, CIRC RES, V90, P562, DOI 10.1161/01.RES.0000013835.53611.97; BURRI PH, 1997, LUNG GROWTH DEV, P1035; Cao GY, 2002, AM J PHYSIOL-CELL PH, V282, pC1181, DOI 10.1152/ajpcell.00524.2001; Carrithers M, 2005, AM J PATHOL, V166, P185, DOI 10.1016/S0002-9440(10)62243-2; COALSON JJ, 2000, LUNG BIOL HEALTH DIS, V137, P85; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; COONEY TP, 1982, THORAX, V37, P572, DOI 10.1136/thx.37.8.572; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DeLisser HM, 1997, AM J PATHOL, V151, P671; deMello DE, 1997, AM J RESP CELL MOL, V16, P568, DOI 10.1165/ajrcmb.16.5.9160839; Duncan GS, 1999, J IMMUNOL, V162, P3022; Gao CJ, 2003, BLOOD, V102, P169, DOI 10.1182/blood-2003-01-0003; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Gratzinger D, 2003, FASEB J, V17, P1458, DOI 10.1096/fj.02-1040com; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Ilan N, 2003, CURR OPIN CELL BIOL, V15, P515, DOI 10.1016/S0955-0674(03)00100-5; Jackson DE, 2003, FEBS LETT, V540, P7, DOI 10.1016/S0014-5793(03)00224-2; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Maas M, 2005, AM J PHYSIOL-HEART C, V288, pH159, DOI 10.1152/ajpheart.00500.2004; Maniscalco WM, 2002, AM J PHYSIOL-LUNG C, V282, pL811, DOI 10.1152/ajplung.00325.2001; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; MASSARO D, 1986, ANNU REV PHYSIOL, V58, P73; Massaro GD, 1997, NAT MED, V3, P675, DOI 10.1038/nm0697-675; Massaro GD, 2000, AM J PHYSIOL-LUNG C, V278, pL955, DOI 10.1152/ajplung.2000.278.5.L955; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Nakada MT, 2000, J IMMUNOL, V164, P452, DOI 10.4049/jimmunol.164.1.452; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; O'Brien CD, 2004, AM J PHYSIOL-CELL PH, V287, pC1103, DOI 10.1152/ajpcell.00573.2003; Schachtner SK, 2000, AM J RESP CELL MOL, V22, P157, DOI 10.1165/ajrcmb.22.2.3766; Schenkel AR, 2004, J IMMUNOL, V173, P6403, DOI 10.4049/jimmunol.173.10.6403; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Thompson RD, 2001, BLOOD, V97, P1854, DOI 10.1182/blood.V97.6.1854; Zhou Z, 1999, Angiogenesis, V3, P181, DOI 10.1023/A:1009092107382	43	73	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8724	8731		10.1074/jbc.M511798200	http://dx.doi.org/10.1074/jbc.M511798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16377626	hybrid			2022-12-25	WOS:000236247100050
J	Machide, M; Hashigasako, A; Matsumoto, K; Nakamura, T				Machide, M; Hashigasako, A; Matsumoto, K; Nakamura, T			Contact inhibition of hepatocyte growth regulated by functional association of the c-Met/hepatocyte growth factor receptor and LAR protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON-ANTIGEN; MATURE RAT HEPATOCYTES; PRIMARY CULTURE; MOLECULAR-CLONING; RECIPROCAL MODULATION; SUSTAINED ACTIVATION; LIVER-REGENERATION; SIGNALING PATHWAY; CELL-MIGRATION; G(1) PHASE	Contact inhibition, the inhibition of cell proliferation by tight cell-cell contact is a fundamental characteristic of normal cells. Using primary cultured hepatocytes, we investigated the mechanisms of contact inhibition that decrease the mitogenic activity of hepatocyte growth factor (HGF), focusing on the regulation of c-Met/HGF-receptor activation. In hepatocytes cultured at a sparse cell density, HGF stimulation induced prolonged c-Met tyrosine phosphorylation for over 5 h and a marked mitogenic response. In contrast, HGF stimulation induced transient c-Met tyrosine phosphorylation in <3 h and failed to induce mitogenic response in hepatocytes cultured at a confluent cell density. Treatment of the confluent cells with HGF plus orthovanadate, a broad spectrum protein-tyrosine phosphatase inhibitor, however, prolonged c-Met tyrosine phosphorylation for over 5 h and permitted the subsequent mitogenic response. The mitogenic response to HGF was associated with the duration of c-Met tyrosine phosphorylation even in the sparse cells. We found that the activity and expression of the protein-tyrosine phosphatase LAR increased following HGF stimulation specifically in confluent hepatocytes and not in sparse hepatocytes. LAR and c-Met were associated, and purified LAR dephosphorylated tyrosine-phosphorylated c-Met in in vitro phosphatase reactions. Furthermore, antisense oligonucleotides specific for LAR mRNA suppressed the expression of LAR, allowed prolonged c-Met tyrosine phosphorylation, and led to acquisition of a mitogenic response in hepatocytes even under the confluent condition. Thus functional association of LAR and c-Met underlies the inhibition of c-Met-mediated mitogenic signaling through the dephosphorylation of c-Met, which specifically occurs under the confluent condition.	Osaka Univ, Dept Biochem & Mol Biol, Grad Sch Med, Div Mol Regenerat Med, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Dept Biochem & Mol Biol, Grad Sch Med, Div Mol Regenerat Med, 2-2-B7 Yamadaoka, Suita, Osaka 5650871, Japan.	Nakamura@onbich.med.osaka-u.ac.jp	Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; ABERCROMBIE M, 1979, NATURE, V281, P259, DOI 10.1038/281259a0; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; FISHER HW, 1967, SCIENCE, V155, P581, DOI 10.1126/science.155.3762.581; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Honkaniemi J, 1998, MOL BRAIN RES, V60, P1, DOI 10.1016/S0169-328X(98)00151-X; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1993, J BIOCHEM-TOKYO, V114, P96, DOI 10.1093/oxfordjournals.jbchem.a124147; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1983, P NATL ACAD SCI-BIOL, V80, P7229, DOI 10.1073/pnas.80.23.7229; NAKAMURA T, 1984, J BIOL CHEM, V259, P8056; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OGRADY P, 1994, J BIOL CHEM, V269, P25193; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Stoker M, 1967, Curr Top Dev Biol, V2, P107; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; Symons JR, 2002, BIOCHEM J, V365, P513, DOI 10.1042/BJ20020381; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039	42	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8765	8772		10.1074/jbc.M512298200	http://dx.doi.org/10.1074/jbc.M512298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16415345	hybrid			2022-12-25	WOS:000236247100055
J	Ji, HL; Su, XF; Kedar, S; Li, J; Barbry, P; Smith, PR; Matalon, S; Benos, DJ				Ji, HL; Su, XF; Kedar, S; Li, J; Barbry, P; Smith, PR; Matalon, S; Benos, DJ			delta-subunit confers novel biophysical features to alpha beta gamma-human epithelial sodium channel (ENaC) via a physical interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ CHANNEL; MOLECULAR CHARACTERIZATION; SELF-INHIBITION; ION-TRANSPORT; A549 CELLS; EXPRESSION; LUNG; CONDUCTANCE; CLONING; STOICHIOMETRY	Native amiloride-sensitive Na+ channels exhibit a variety of biophysical properties, including variable sensitivities to amiloride, different ion selectivities, and diverse unitary conductances. The molecular basis of these differences has not been elucidated. We tested the hypothesis that co-expression of delta-epithelial sodium channel ( ENaC) underlies, at least in part, the multiplicity of amiloride-sensitive Na+ conductances in epithelial cells. For example, the delta-subunit may form multimeric channels with alpha beta gamma-ENaC. Reverse transcription-PCR revealed that delta-ENaC is co-expressed with alpha beta gamma-subunits in cultured human lung (H441 and A549), pancreatic (CFPAC), and colonic epithelial cells (Caco-2). Indirect immunofluorescence microscopy revealed that delta-ENaC is co-expressed with alpha-, beta-, and gamma-ENaC in H441 cells at the protein level. Measurement of current-voltage relationships revealed that the cation selectivity ratios for Na+/Li+/ K+/Cs+/Ca2+/Mg2+, the apparent dissociation constant (K-i) for amiloride, and unitary conductances for delta alpha beta gamma-ENaC differed from those of both alpha beta gamma- and alpha beta gamma-ENaC ( n = 6). The contribution of the delta subunit to P-Li/P-Na ratio and unitary Na+ conductance under bi-ionic conditions depended on the injected cRNA concentration. In addition, the EC50 for proton activation, mean open and closed times, and the self-inhibition time of delta alpha beta gamma-ENaC differed from those of alpha beta gamma- and delta beta gamma-ENaC. Co-immunoprecipitation of delta-ENaC with alpha- and gamma-subunits in H441 and transfected COS-7 cells suggests an interaction among these proteins. We, therefore, concluded that the interactions of delta-ENaC with other subunits could account for heterogeneity of native epithelial channels.	Univ Alabama, Dept Anesthesiol, Birmingham, AL 35205 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35205 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR411, F-06560 Sophia Antipolis, France	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Benos, DJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,704 MCLM, Birmingham, AL 35294 USA.	benos@physiology.uab.edu	JI, HONGLONG/N-7822-2014; Barbry, Pascal/O-5021-2016	JI, HONGLONG/0000-0002-3228-7144; Barbry, Pascal/0000-0001-9632-6483	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075540, R01HL051173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R01DK056596, R56DK037206] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51173, HL075540] Funding Source: Medline; NIDDK NIH HHS [DK56596, DK37206] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babini E, 2003, J BIOL CHEM, V278, P28418, DOI 10.1074/jbc.M301315200; Becchetti A, 2002, AM J PHYSIOL-RENAL, V283, pF1030, DOI 10.1152/ajprenal.00011.2002; Benos DJ, 1996, KIDNEY INT, V49, P1632, DOI 10.1038/ki.1996.237; Berdiev BK, 2004, AM J PHYSIOL-RENAL, V286, pF1100, DOI 10.1152/ajprenal.00344.2003; Biasio W, 2004, J BIOL CHEM, V279, P5429, DOI 10.1074/jbc.M311155200; Bremner HR, 2002, AM J PHYSIOL-LUNG C, V282, pL124, DOI 10.1152/ajplung.2002.282.1.L124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chraibi A, 2002, J GEN PHYSIOL, V120, P133, DOI 10.1085/jgp.20028612; Clunes MT, 2004, J PHYSIOL-LONDON, V557, P809, DOI 10.1113/jphysiol.2004.061143; Cotton CU, 1998, PANCREAS, V17, P247, DOI 10.1097/00006676-199810000-00004; Fu J, 2001, J PHYSIOL-LONDON, V536, P459, DOI 10.1111/j.1469-7793.2001.0459c.xd; Fukuda M, 2000, JPN J PHYSIOL, V50, P215, DOI 10.2170/jjphysiol.50.215; Fyfe GK, 1998, J GEN PHYSIOL, V112, P423, DOI 10.1085/jgp.112.4.423; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Hardiman KA, 2004, AM J RESP CELL MOL, V30, P720, DOI 10.1165/rcmb.2003-0325OC; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Ji HL, 2004, J BIOL CHEM, V279, P26939, DOI 10.1074/jbc.M401143200; Ji HL, 2004, J BIOL CHEM, V279, P8428, DOI 10.1074/jbc.M312012200; Ji HL, 2001, AM J PHYSIOL-CELL PH, V281, pC64, DOI 10.1152/ajpcell.2001.281.1.C64; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lazrak A, 2000, AM J PHYSIOL-CELL PH, V279, pC762, DOI 10.1152/ajpcell.2000.279.3.C762; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Lazrak A, 2000, AM J PHYSIOL-LUNG C, V278, pL848, DOI 10.1152/ajplung.2000.278.4.L848; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Novak I, 2002, BBA-BIOMEMBRANES, V1566, P162, DOI 10.1016/S0005-2736(02)00598-9; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Ramminger SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL411, DOI 10.1152/ajplung.00407.2003; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Staruschenko A, 2005, BIOPHYS J, V88, P3966, DOI 10.1529/biophysj.104.056804; Staruschenko A, 2004, J BIOL CHEM, V279, P27729, DOI 10.1074/jbc.M404169200; Tucker JK, 1998, AM J PHYSIOL-CELL PH, V274, pC1081, DOI 10.1152/ajpcell.1998.274.4.C1081; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wodopia R, 2000, AM J PHYSIOL-LUNG C, V279, pL1110, DOI 10.1152/ajplung.2000.279.6.L1110; YUE G, 1993, AM J PHYSIOL, V265, pC630, DOI 10.1152/ajpcell.1993.265.3.C630; Zhao WC, 2003, WORLD J GASTROENTERO, V9, P2505	44	80	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8233	8241		10.1074/jbc.M512293200	http://dx.doi.org/10.1074/jbc.M512293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16423824	hybrid			2022-12-25	WOS:000236031000063
J	Costet, P; Cariou, B; Lambert, G; Lalanne, F; Lardeux, B; Jarnoux, AL; Grefhorst, A; Stels, B; Krempf, M				Costet, P; Cariou, B; Lambert, G; Lalanne, F; Lardeux, B; Jarnoux, AL; Grefhorst, A; Stels, B; Krempf, M			Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-X-RECEPTOR; LIPOGENIC GENE-EXPRESSION; LEUCINE ZIPPER PROTEIN; FATTY-ACID SYNTHESIS; TRANSGENIC MICE; CULTURED-CELLS; DOMINANT HYPERCHOLESTEROLEMIA; TRANSCRIPTION FACTOR; APOLIPOPROTEIN-B; LDL CHOLESTEROL	Familial autosomal dominant hypercholesterolemia is associated with high risk for cardiovascular accidents and is related to mutations in the low density lipoprotein receptor or its ligand apolipoprotein B ( apoB). Mutations in a third gene, proprotein convertase subtilisin kexin 9 (PCSK9), were recently associated to this disease. PCSK9 acts as a natural inhibitor of the low density lipoprotein receptor pathway, and both genes are regulated by depletion of cholesterol cell content and statins, via sterol regulatory element-binding protein ( SREBP). Here we investigated the regulation of PCSK9 gene expression during nutritional changes. We showed that PCSK9 mRNA quantity is decreased by 73% in mice after 24 h of fasting, leading to a 2-fold decrease in protein level. In contrast PCSK9 expression was restored upon high carbohydrate refeeding. PCSK9 mRNA increased by 4-5-fold in presence of insulin in rodent primary hepatocytes, whereas glucose had no effect. Moreover, insulin up-regulated hepatic PCSK9 expression in vivo during a hyperinsulinemic-euglycemic clamp in mice. Adenoviral mediated overexpression of a dominant or negative form of SREBP-1c confirmed the implication of this transcription factor in insulin-mediated stimulation of PCSK9 expression. Liver X receptor agonist T0901317 also regulated PCSK9 expression via this same pathway ( a 2-fold increase in PCSK9 mRNA of primary hepatocytes cultured for 24 h in presence of 1 mu M T0901317). As our last investigation, we isolated PCSK9 proximal promoter and verified the functionality of a SREBP-1c responsive element located from 335 bp to 355 bp upstream of the ATG. Together, these results show that PCSK9 expression is regulated by nutritional status and insulinemia.	CHU Hotel Dieu, INSERM, U539, F-44093 Nantes, France; Univ Lille 2, Fac Pharm, Pasteur Inst Lille, F-59019 Lille, France; Univ Lille 2, INSERM, U545, F-59019 Lille, France; Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, NL-9700 RB Groningen, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; University of Groningen	Costet, P (corresponding author), CHU Hotel Dieu, INSERM, U539, 3eme Etage Nord,1 Pl Alexis Ricordeau, F-44093 Nantes, France.	philippe.costet@univ-nantes.fr	costet, philippe/A-5314-2010; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503; Krempf, Michel/0000-0002-4353-9511; Lambert, Gilles/0000-0001-5632-0685; Cariou, Bertrand/0000-0002-1580-8040				Attie AD, 2005, CELL METAB, V1, P290, DOI 10.1016/j.cmet.2005.04.006; Avramoglu RK, 2004, REV ENDOCR METAB DIS, V5, P293, DOI 10.1023/B:REMD.0000045100.66675.92; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; BALAVOINE S, 1993, J CELL PHYSIOL, V156, P56, DOI 10.1002/jcp.1041560109; Benjannet S, 2004, J BIOL CHEM, V279, P48865, DOI 10.1074/jbc.M409699200; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Brunham LR, 2005, CLIN GENET, V67, P476, DOI 10.1111/j.1399-0004.2005.0453a.x; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Commerford SR, 2004, AM J PHYSIOL-REG I, V287, pR218, DOI 10.1152/ajpregu.00377.2003; Costet P, 2003, MOL CELL BIOL, V23, P7756, DOI 10.1128/MCB.23.21.7756-7766.2003; Dentin R, 2004, J BIOL CHEM, V279, P20314, DOI 10.1074/jbc.M312475200; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Dubuc G, 2004, ARTERIOSCL THROM VAS, V24, P1454, DOI 10.1161/01.ATV.0000134621.14315.43; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fromes Y, 1999, GENE THER, V6, P683, DOI 10.1038/sj.gt.3300853; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; KRAEMER FB, 1994, AM J PHYSIOL, V266, pE26, DOI 10.1152/ajpendo.1994.266.1.E26; Lalanne F, 2005, J LIPID RES, V46, P1312, DOI 10.1194/jlr.M400396-JLR200; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Maxwell KN, 2003, J LIPID RES, V44, P2109, DOI 10.1194/jlr.M300203-JLR200; Ness GC, 1996, ARCH BIOCHEM BIOPHYS, V325, P242, DOI 10.1006/abbi.1996.0030; Ouguerram K, 2004, ARTERIOSCL THROM VAS, V24, P1448, DOI 10.1161/01.ATV.0000133684.77013.88; Park SW, 2004, J BIOL CHEM, V279, P50630, DOI 10.1074/jbc.M410077200; Rader DJ, 2003, J CLIN INVEST, V111, P1795, DOI 10.1172/JCI200318925; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Sun XM, 2005, HUM MOL GENET, V14, P1161, DOI 10.1093/hmg/ddi128; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	54	238	286	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6211	6218		10.1074/jbc.M508582200	http://dx.doi.org/10.1074/jbc.M508582200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407292	hybrid			2022-12-25	WOS:000236030800013
J	Kontaridis, MI; Swanson, KD; David, FS; Barford, D; Neel, BG				Kontaridis, MI; Swanson, KD; David, FS; Barford, D; Neel, BG			PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; NOONAN-SYNDROME; CRYSTAL-STRUCTURE; LEUKEMIA; MUTANTS; HEART; GENE; DIFFERENTIATION; LEUKEMOGENESIS; VALVULOGENESIS	Multiple lentigines/LEOPARD syndrome (LS) is a rare, autosomal dominant disorder characterized by Lentigines, Electrocardiogram abnormalities, Ocular hypertelorism, Pulmonic valvular stenosis, Abnormalities of genitalia, Retardation of growth, and Deafness. Like the more common Noonan syndrome (NS), LS is caused by germ line missense mutations in PTPN11, encoding the protein-tyrosine phosphatase Shp2. Enzymologic, structural, cell biological, and mouse genetic studies indicate that NS is caused by gain-of-function PTPN11 mutations. Because NS and LS share several features, LS has been viewed as an NS variant. We examined a panel of LS mutants, including the two most common alleles. Surprisingly, we found that in marked contrast to NS, LS mutants are catalytically defective and act as dominant negative mutations that interfere with growth factor/Erk-mitogen-activated protein kinase-mediated signaling. Molecular modeling and biochemical studies suggest that LS mutations contort the Shp2 catalytic domain and result in open, inactive forms of Shp2. Our results establish that the pathogenesis of LS and NS is distinct and suggest that these disorders should be distinguished by mutational analysis rather than clinical presentation.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Canc Biol Program, 330 Brookline Ave, Boston, MA 02215 USA.	bneel@bidmc.harvard.edu	Kontaridis, Maria/AAN-9781-2021	Kontaridis, Maria/0000-0002-6121-0533; David, Frank/0000-0002-8025-4427	PHS HHS [R37 49152] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLANSON JE, 1985, AM J MED GENET, V21, P507, DOI 10.1002/ajmg.1320210313; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Armstrong EJ, 2004, CIRC RES, V95, P459, DOI 10.1161/01.RES.0000141146.95728.da; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Digilio MC, 2002, AM J HUM GENET, V71, P389, DOI 10.1086/341528; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; GORLIN RJ, 1969, AM J DIS CHILD, V117, P652, DOI 10.1001/archpedi.1969.02100030654006; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Keren B, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.021451; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Krenz M, 2005, CIRC RES, V97, P813, DOI 10.1161/01.RES.0000186194.06514.b0; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Legius E, 2002, J MED GENET, V39, P571, DOI 10.1136/jmg.39.8.571; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Merks JHM, 2005, AM J MED GENET A, V134A, P132, DOI 10.1002/ajmg.a.30603; MOHI MG, 2005, CANCER CELL, V7, P1; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Niihori T, 2005, J HUM GENET, V50, P192, DOI 10.1007/s10038-005-0239-7; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Sarkozy A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013466; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	42	225	235	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6785	6792		10.1074/jbc.M513068200	http://dx.doi.org/10.1074/jbc.M513068200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377799	hybrid			2022-12-25	WOS:000236030800077
J	Cunningham, P; Afzal-Ahmed, I; Naftalin, RJ				Cunningham, P; Afzal-Ahmed, I; Naftalin, RJ			Docking studies show that D-glucose and quercetin slide through the transporter GLUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUGAR-TRANSPORT; ISOLATED RAT ADIPOCYTES; DEHYDROASCORBIC ACID; ESCHERICHIA-COLI; BINDING-SITE; 3-DIMENSIONAL STRUCTURE; LACTOSE PERMEASE; MEMBRANE; MODEL; FLAVONOIDS	On a three- dimensional templated model of GLUT1 ( Protein Data Bank code 1SUK), a molecular recognition program, AUTODOCK 3, reveals nine hexose- binding clusters spanning the entire " hydrophilic" channel. Five of these cluster sites are within 3 - 5 angstrom of 10 glucose transporter deficiency syndrome missense mutations. Another three sites are within 8 angstrom of two other missense mutations. D- Glucose binds to five sites in the external channel opening, with increasing affinity toward the pore center and then passes via a narrow channel into an internal vestibule containing four lower affinity sites. An external site, not adjacent to any mutation, also binding phloretin but recognizing neither D- fructose nor L- glucose, may be the main threading site for glucose uptake. Glucose exit from human erythrocytes is inhibited by quercetin ( K-i = 2.4 mu M) but not anionic quercetin- semiquinone. Quercetin influx is retarded by extracellular D- glucose ( 50 mM) but not by phloretin and accelerated by intracellular D- glucose. Quercetin docking sites are absent from the external opening but fill the entire pore center. In the inner vestibule, Glu(254) and Lys(256) hydrogen- bond quercetin ( K-i = 10 mu M) but not quercetin- semiquinone. Consistent with the kinetics, this site also binds D- glucose, so quercetin displacement by glucose could accelerate quercetin influx, whereas quercetin binding here will competitively inhibit glucose efflux. beta- D- Hexoses dock twice as frequently as their alpha- anomers to the 23 aromatic residues in the transport pathway, suggesting that endocyclic hexose hydrogens, as with maltosaccharides in maltoporins, form pi- bonds with aromatic rings and slide between sites instead of being translocated via a single alternating site.	Kings Coll London, Dept Physiol, London SE1 1UL, England; Kings Coll London, London SE1 9NH, England	University of London; King's College London; University of London; King's College London	Naftalin, RJ (corresponding author), Kings Coll London, Dept Physiol, Guys Campus, London SE1 1UL, England.	richard.naftalin@kcl.ac.uk	Naftalin, Richard J/F-1112-2010	Naftalin, Richard/0000-0001-8783-390X				Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Afzal I, 2002, BIOCHEM J, V365, P707, DOI 10.1042/BJ20011624; BAKER GF, 1973, J PHYSIOL-LONDON, V231, P143, DOI 10.1113/jphysiol.1973.sp010225; BAKER GF, 1979, BIOCHIM BIOPHYS ACTA, V550, P474, DOI 10.1016/0005-2736(79)90150-0; Barrett MP, 1999, CURR OPIN CELL BIOL, V11, P496, DOI 10.1016/S0955-0674(99)80072-6; Blodgett DM, 2005, BIOCHEMISTRY-US, V44, P2650, DOI 10.1021/bi048247m; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; Cohen NR, 1996, BIOCHEM J, V315, P971, DOI 10.1042/bj3150971; Corchado JC, 2004, J AM CHEM SOC, V126, P7311, DOI 10.1021/ja0398767; Dutzler R, 2002, STRUCTURE, V10, P1273, DOI 10.1016/S0969-2126(02)00811-0; Fernandez MD, 2005, J AM CHEM SOC, V127, P7379, DOI 10.1021/ja051020+; Galati G, 2002, TOXICOLOGY, V177, P91, DOI 10.1016/S0300-483X(02)00198-1; GECK P, 1971, BIOCHIM BIOPHYS ACTA, V241, P462, DOI 10.1016/0005-2736(71)90045-9; Heard KS, 2000, BIOCHEMISTRY-US, V39, P3005, DOI 10.1021/bi991931u; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; JANOSHAZI A, 1993, J MEMBRANE BIOL, V132, P167; Kasahara T, 2000, FEBS LETT, V471, P103, DOI 10.1016/S0014-5793(00)01371-5; Klepper J, 2005, BIOCHEMISTRY-US, V44, P12621, DOI 10.1021/bi051079t; LEFEVRE PG, 1962, AM J PHYSIOL, V203, P286, DOI 10.1152/ajplegacy.1962.203.2.286; Levine KB, 1998, BIOCHEMISTRY-US, V37, P12221, DOI 10.1021/bi980585y; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; Martin HJ, 2003, CHEM-BIOL INTERACT, V146, P225, DOI 10.1016/j.cbi.2003.06.001; Metodiewa D, 1999, FREE RADICAL BIO MED, V26, P107, DOI 10.1016/S0891-5849(98)00167-1; MIWA I, 1988, BIOCHEM INT, V16, P111; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mueckler M, 2004, J BIOL CHEM, V279, P46876, DOI 10.1074/jbc.M408632200; Naftalin RJ, 2003, BRIT J PHARMACOL, V140, P487, DOI 10.1038/sj.bjp.0705460; NAFTALIN RJ, 1994, BBA-BIOMEMBRANES, V1191, P65, DOI 10.1016/0005-2736(94)90234-8; Naftalin RJ, 2002, J MEMBRANE BIOL, V186, P113, DOI 10.1007/s00232-001-0140-z; Naftalin RJ, 1997, BBA-BIOMEMBRANES, V1328, P13, DOI 10.1016/S0005-2736(97)00062-X; Park JB, 2000, J NUTR, V130, P1297, DOI 10.1093/jn/130.5.1297; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; SALTER DW, 1978, J MEMBRANE BIOL, V40, P67, DOI 10.1007/BF01909739; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; Song J, 2002, J BIOL CHEM, V277, P15252, DOI 10.1074/jbc.M110496200; Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703; Sujatha MS, 2005, BIOCHEMISTRY-US, V44, P8554, DOI 10.1021/bi050298b; Uldry M, 2002, FEBS LETT, V524, P199, DOI 10.1016/S0014-5793(02)03058-2; Van Gelder P, 2002, J BACTERIOL, V184, P2994, DOI 10.1128/JB.184.11.2994-2999.2002; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang D, 2005, ANN NEUROL, V57, P111, DOI 10.1002/ana.20331	46	87	89	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5797	5803		10.1074/jbc.M509422200	http://dx.doi.org/10.1074/jbc.M509422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407180	hybrid			2022-12-25	WOS:000235568900058
J	Kreiner, L; Lee, A				Kreiner, L; Lee, A			Endogenous and exogenous Ca2+ buffers differentially modulate Ca2+-dependent inactivation of Ca(V)2.1 Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; PURKINJE-CELLS; P-TYPE; CA2+/CALMODULIN-DEPENDENT FACILITATION; SYNAPTIC-TRANSMISSION; FOREBRAIN NEURONS; PARVALBUMIN; CALMODULIN; CALBINDIN-D-28K; CURRENTS	Voltage-gated Ca2+ channels undergo a negative feedback regulation by Ca2+ ions, Ca2+-dependent inactivation, which is important for restricting Ca2+ signals in nerve and muscle. Although the molecular details underlying Ca2+-dependent inactivation have been characterized, little is known about how this process might be modulated in excitable cells. Based on previous findings that Ca2+-dependent inactivation of Ca(v)2.1 (P/Q-type) Ca2+ channels is suppressed by strong cytoplasmic Ca2+ buffering, we investigated how factors that regulate cellular Ca2+ levels affect inactivation of Ca(v)2.1 Ca2+ currents in transfected 293T cells. We found that inactivation of Ca(v)2.1 Ca2+ currents increased exponentially with current amplitude with low intracellular concentrations of the slow buffer EGTA (0.5 mM), but not with high concentrations of the fast Ca2+ buffer BAPTA ( 10 mM). However, when the concentration of BAPTA was reduced to 0.5 mM, inactivation of Ca2+ currents was significantly greater than with an equivalent concentration of EGTA, indicating the importance of buffer kinetics in modulating Ca2+-dependent inactivation of Ca(v)2.1. Cotransfection of Ca(v)2.1 with the EF-hand Ca2+-binding proteins, parvalbumin and calbindin, significantly altered the relationship between Ca2+ current amplitude and inactivation in ways that were unexpected from behavior as passive Ca2+ buffers. We conclude that Ca2+-dependent inactivation of Ca(v)2.1 depends on a subplasmalemmal Ca2+ microdomain that is affected by the amplitude of the Ca2+ current and differentially modulated by distinct Ca2+ buffers.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University; Emory University	Lee, A (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5123 Rollins Res Bldg,1510 Clifton Rd, Atlanta, GA 30322 USA.	alee@pharm.emory.edu		Lee, Amy/0000-0001-8021-0443	NINDS NIH HHS [NS044922, F31NS049757] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS049757, R01NS044922] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bodding M, 1999, PFLUG ARCH EUR J PHY, V439, P27, DOI 10.1007/s004240051124; Borst JGG, 1998, J PHYSIOL-LONDON, V513, P149, DOI 10.1111/j.1469-7793.1998.149by.x; BREHM P, 1978, SCIENCE, V202, P1203, DOI 10.1126/science.103199; Cavelier P, 2002, J PHYSIOL-LONDON, V540, P57, DOI 10.1113/jphysiol.2001.013294; Chaudhuri D, 2005, J NEUROSCI, V25, P8282, DOI 10.1523/JNEUROSCI.2253-05.2005; Chaudhuri D, 2004, J NEUROSCI, V24, P6334, DOI 10.1523/JNEUROSCI.1712-04.2004; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Cuttle MF, 1998, J PHYSIOL-LONDON, V512, P723, DOI 10.1111/j.1469-7793.1998.723bd.x; Dargan SL, 2003, J PHYSIOL-LONDON, V553, P775, DOI 10.1113/jphysiol.2003.054247; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Ferreira G, 1997, J GEN PHYSIOL, V109, P449, DOI 10.1085/jgp.109.4.449; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; GILLIS JM, 1982, J MUSCLE RES CELL M, V3, P377, DOI 10.1007/BF00712090; Hackney CM, 2005, J NEUROSCI, V25, P7867, DOI 10.1523/JNEUROSCI.1196-05.2005; HAIECH J, 1979, BIOCHEMISTRY-US, V18, P2752, DOI 10.1021/bi00580a010; Hartley DM, 1996, MOL BRAIN RES, V40, P285, DOI 10.1016/0169-328X(96)00066-6; HOU TT, 1991, J PHYSIOL-LONDON, V441, P285, DOI 10.1113/jphysiol.1991.sp018752; John LM, 2001, J PHYSIOL-LONDON, V535, P3, DOI 10.1111/j.1469-7793.2001.t01-2-00003.x; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; KADOWAKI K, 1993, NEUROSCI LETT, V153, P80, DOI 10.1016/0304-3940(93)90082-V; KOSAKA T, 1993, EXP BRAIN RES, V93, P483; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee SH, 2000, J PHYSIOL-LONDON, V525, P419, DOI 10.1111/j.1469-7793.2000.t01-2-00419.x; Lee SH, 2000, J PHYSIOL-LONDON, V525, P405, DOI 10.1111/j.1469-7793.2000.t01-3-00405.x; LI ZH, 1995, J PHYSIOL-LONDON, V488, P601, DOI 10.1113/jphysiol.1995.sp020993; Li-Smerin YY, 2001, J PHYSIOL-LONDON, V533, P729, DOI 10.1111/j.1469-7793.2001.t01-1-00729.x; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; Lutz W, 2003, BIOCHEM BIOPH RES CO, V303, P1186, DOI 10.1016/S0006-291X(03)00499-6; Maetzler W, 2004, EXP NEUROL, V186, P78, DOI 10.1016/j.expneurol.2003.10.014; Meuth SG, 2005, PFLUG ARCH EUR J PHY, V450, P111, DOI 10.1007/s00424-004-1377-z; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; Miyazaki T, 2004, J NEUROSCI, V24, P1734, DOI 10.1523/JNEUROSCI.4208-03.2004; Muller A, 2005, J NEUROSCI, V25, P558, DOI 10.1523/JNEUROSCI.3799-04.2005; Nagerl UV, 2000, BIOPHYS J, V79, P3009, DOI 10.1016/S0006-3495(00)76537-4; Nagerl UV, 2000, J NEUROSCI, V20, P1831; PAULS TL, 1993, J BIOL CHEM, V268, P20897; PAULS TL, 1994, BIOCHEMISTRY-US, V33, P10393, DOI 10.1021/bi00200a021; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PLOGMANN D, 1993, BRAIN RES, V600, P273, DOI 10.1016/0006-8993(93)91383-4; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rousset M, 2004, J BIOL CHEM, V279, P14619, DOI 10.1074/jbc.M313284200; Schmidt H, 2005, P NATL ACAD SCI USA, V102, P5850, DOI 10.1073/pnas.0407855102; Schmidt H, 2003, J PHYSIOL-LONDON, V551, P13, DOI 10.1113/jphysiol.2002.035824; Schmidt H, 2003, BIOPHYS J, V84, P2599, DOI 10.1016/S0006-3495(03)75065-6; Schwaller B, 1999, AM J PHYSIOL-CELL PH, V276, pC395, DOI 10.1152/ajpcell.1999.276.2.C395; Soong TW, 2002, J NEUROSCI, V22, P10142; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; Stout AK, 1996, J PHYSIOL-LONDON, V492, P641, DOI 10.1113/jphysiol.1996.sp021334; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Van den Bosch L, 2002, EXP NEUROL, V174, P150, DOI 10.1006/exnr.2001.7858; Wheeler DB, 1996, J NEUROSCI, V16, P2226; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	59	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4691	4698		10.1074/jbc.M511971200	http://dx.doi.org/10.1074/jbc.M511971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373336	hybrid			2022-12-25	WOS:000235426200017
J	Ku, MC; Howard, S; Ni, WH; Lagna, G; Hata, A				Ku, MC; Howard, S; Ni, WH; Lagna, G; Hata, A			OAZ regulates bone morphogenetic protein signaling through Smad6 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE; PATHWAY; TARGET; OSTEOBLAST; DIFFERENTIATION; NEUROGENESIS; ANGIOGENESIS; RESISTANCE; INHIBITOR; MUTATIONS	The intensity and duration of activation of a signal transduction system are important determinants of the specificity of the cellular response to the stimulus. It is unclear how different cells can generate a signal of varying intensity and duration in response to the same cytokine. We investigated the role of the transcriptional activator and Smad1/4 cofactor OAZ in regulating bone morphogenetic protein (BMP) signaling. We demonstrate that upon BMP4 stimulation, an OAZ-Smad1/4 complex binds to and activates the gene encoding Smad6, a specific inhibitor of the BMP pathway. Removal of endogenous OAZ from pluripotent embryonal carcinoma cells prevents the induction of Smad6 by BMP4 and extends the period of detection of phosphorylated Smad1 after BMP stimulation. Conversely, in cells that do not normally express OAZ, such as myoblasts and smooth muscle cells, forced OAZ expression leads to faster and higher Smad6 induction in response to BMP4, decrease of Smad1 phosphorylation, and attenuation of BMP-mediated responses. Our results demonstrate that OAZ can alter the intensity and duration of the BMP stimulus through Smad6 and indicate that the tissue-specific expression of OAZ is a critical determinant of the cellular response to the BMP signal.	Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Hata, A (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	akiko.hata@tufts.edu						Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L., 2001, GENOME BIOL, V2, p3010.3011, DOI [DOI 10.1186/GB-2001-2-8-REVIEWS3010, 10.1186/gb-2001-2-8-reviews3010]; BONBUBNOFF A, 2005, DEV BIOL, V281, P210; Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388; Chang H, 1999, DEVELOPMENT, V126, P1631; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Eddahibi S, 2002, EUR RESPIR J, V20, P1559, DOI 10.1183/09031936.02.00081302; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hentges KE, 2005, ONCOGENE, V24, P1220, DOI 10.1038/sj.onc.1208243; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Horiki M, 2004, J CELL BIOL, V165, P433, DOI 10.1083/jcb.200311015; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Ku MC, 2005, MOL CELL BIOL, V25, P7144, DOI 10.1128/MCB.25.16.7144-7157.2005; Ku MC, 2003, BIOCHEM BIOPH RES CO, V311, P702, DOI 10.1016/j.bbrc.2003.10.053; Ladher R, 1996, DEVELOPMENT, V122, P2385; Lechleider RJ, 2001, DEV BIOL, V240, P157, DOI 10.1006/dbio.2001.0469; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Mandegar M, 2004, CARDIOL CLIN, V22, P417, DOI 10.1016/j.ccl.2004.04.005; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Naeije R, 2004, Bull Mem Acad R Med Belg, V159, P219; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Seki K, 2004, J BIOL CHEM, V279, P18544, DOI 10.1074/jbc.M311592200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; von Bubnoff N, 2005, CELL CYCLE, V4, P400, DOI 10.4161/cc.4.3.1560; Warming S, 2004, ONCOGENE, V23, P2727, DOI 10.1038/sj.onc.1207452; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Yang X, 1999, DEVELOPMENT, V126, P1571; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang S, 2003, AM J PHYSIOL-LUNG C, V285, pL740, DOI 10.1152/ajplung.00284.2002; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	49	33	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5277	5287		10.1074/jbc.M510004200	http://dx.doi.org/10.1074/jbc.M510004200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373339	hybrid			2022-12-25	WOS:000235426200082
